<SUBMISSION>
<ACCESSION-NUMBER>0000950134-08-010232
<TYPE>S-1/A
<PUBLIC-DOCUMENT-COUNT>12
<FILING-DATE>20080527
<DATE-OF-FILING-DATE-CHANGE>20080527
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>FLUIDIGM CORP
<CIK>0001162194
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>S-1/A
<ACT>33
<FILE-NUMBER>333-150227
<FILM-NUMBER>08859365
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>7100 SHORELINE CT
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
<PHONE>6502666000
</BUSINESS-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>f39432a1sv1za.htm
<DESCRIPTION>AMENDMENT TO FORM S-1
<TEXT>
<HTML>
<HEAD>
<TITLE>sv1za</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> As filed with the Securities and Exchange Commission on
    May&#160;27, 2008</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> Registration
    <FONT style="white-space: nowrap">No.&#160;333-150227</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>
    <CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=128 iwidth=540 length=0 --></B>
</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt">UNITED STATES SECURITIES AND
    EXCHANGE COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">AMENDMENT NO. 1 TO</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt">
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT></FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">REGISTRATION
    STATEMENT</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">UNDER</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">THE SECURITIES ACT OF
    1933</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 24pt">FLUIDIGM CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Exact name of Registrant as
    specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Delaware</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>3826</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>77-0513190</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(Primary Standard Industrial<BR>
    Classification Code Number)<BR>
    </FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification Number)</FONT></I><FONT style="font-size: 8pt">
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>



<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>7000 Shoreline Court, Suite 100</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>South San&#160;Francisco, CA 94080</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(650) 266-6000</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Address, including zip code,
    and telephone number,<BR>
    including area code, of Registrant&#146;s principal executive
    offices)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Gajus V. Worthington</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>President and Chief Executive Officer</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>7000 Shoreline Court, Suite&#160;100</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>South San&#160;Francisco, CA 94080</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="white-space: nowrap">(650)&#160;266-6000</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Name, address, including zip
    code, and telephone number,<BR>
    including area code, of agent for service)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Copies to:</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="center" valign="top">
    <B>David J. Segre<BR>
    Robert F. Kornegay<BR>
    Asaf H. Kharal<BR>
    Wilson Sonsini Goodrich &#038; Rosati P.C.<BR>
    650 Page&#160;Mill Road<BR>
    Palo Alto, CA 94304<BR>
    Telephone:
    <FONT style="white-space: nowrap">(650)&#160;493-9300</FONT><BR>
    Telecopy:
    <FONT style="white-space: nowrap">(650)&#160;493-6811</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>William M. Smith<BR>
    Vice President, Legal Affairs<BR>
    and General Counsel<BR>
    7000 Shoreline Court, Suite 100<BR>
    South San&#160;Francisco, CA 94080<BR>
    Telephone: (650) 266-6000<BR>
    Telecopy: (650) 871-7152</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>Charles K. Ruck<BR>
    B. Shayne Kennedy<BR>
    Latham &#038; Watkins LLP<BR>
    650 Town Center Drive,
    20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>&#160;Floor<BR>
    Costa Mesa, CA 92626<BR>
    Telephone: (714) 540-1235<BR>
    Telecopy: (714) 755-8290</B>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Approximate date of commencement of proposed sale to the
    public:</B>&#160;&#160;As soon as practicable after the
    effective date of this Registration Statement.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any of the securities being registered on this Form are to be
    offered on a delayed or continuous basis pursuant to
    Rule&#160;415 under the Securities Act, as amended, check the
    following
    box.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is filed to register additional securities for an
    offering pursuant to Rule&#160;462(b) under the Securities Act,
    please check the following box and list the Securities Act
    registration statement number of the earlier effective
    registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(c) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(d) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Indicate by check mark whether the registrant is a large
    accelerated filer, an accelerated filer, a non-accelerated
    filer, or a smaller reporting company. See the definitions of
    &#147;large accelerated filer,&#148; &#147;accelerated
    filer&#148; and &#147;smaller reporting company&#148; in Ruler
    <FONT style="white-space: nowrap">12b-2</FONT> of the
    Exchange Act. (Check one):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="24%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="center" valign="top">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Large accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Non-accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Smaller reporting
    company&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="5" align="center" valign="top">
    (Do not check if a smaller reporting company)
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>The Registrant hereby amends this Registration Statement on
    such date or dates as may be necessary to delay its effective
    date until the Registrant shall file a further amendment that
    specifically states that this Registration Statement shall
    thereafter become effective in accordance with Section&#160;8(a)
    of the Securities Act of 1933, as amended, or until the
    Registration Statement shall become effective on such date as
    the Securities and Exchange Commission, acting pursuant to such
    Section&#160;8(a), may determine.</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<TABLE style="color: #FF0000" width="100%" border="1" cellpadding="5"><TR><TD style=text-align:justify>
<FONT style="font-size: 9pt; font-family: Arial, Helvetica; color: #F93F26">The
information in this preliminary prospectus is not complete and
may be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange
Commission is declared effective. This preliminary prospectus is
not an offer to sell these securities and is not soliciting an
offer to buy these securities in any state where the offer or
sale is not permitted.<BR>
</FONT>
</TD></TR></TABLE>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 12pt; color: #F93F26">PROSPECTUS
    (Subject to Completion)</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 11pt; color: #F93F26"> Issued May 27,
    2008</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 18pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares</FONT></I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a1f3943216.gif" alt="(FLUIDIGM LOGO)"><FONT style="font-size: 18pt">
    </FONT>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 12pt">COMMON STOCK</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Fluidigm Corporation is
    offering&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of its common stock. This is our initial public offering, and no
    public market currently exists for our shares. We anticipate
    that the initial public offering price will be between
    $&#160;&#160;&#160;&#160;&#160; and
    $&#160;&#160;&#160;&#160;&#160; per share.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have applied to list our common stock on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 12pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Investing in our common stock involves risks. See
    &#147;Risk Factors&#148; beginning on page&#160;7.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>PRICE
    <FONT style="font-size: 12pt">$&#160;&#160;&#160;&#160;&#160;</FONT>
    A SHARE</I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="64%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Underwriting<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Proceeds to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Price to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Discounts and<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Fluidigm<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Public</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Commissions</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Corporation</I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Per Share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have granted the underwriters the right to purchase up to an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock to cover over-allotments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Securities and Exchange Commission and state securities
    regulators have not approved or disapproved these securities or
    determined if this prospectus is truthful or complete. Any
    representation to the contrary is a criminal offense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Morgan Stanley&#160;&#038; Co. Incorporated expects to deliver
    the shares to purchasers
    on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 18pt; font-variant: SMALL-CAPS">MORGAN
    STANLEY</FONT></I>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 18pt; font-variant: SMALL-CAPS">UBS
    INVESTMENT BANK</FONT></I>
</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 18pt; font-variant: SMALL-CAPS">LEERINK
    SWANN</FONT></I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008
    </FONT>
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a1f3943218.gif" alt="(GRAPHIC)">
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="89%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Page</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'>Prospectus Summary</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'>Risk Factors</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'>Special Note Regarding Forward-Looking
    Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'>Use of Proceeds</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#105'>Dividend Policy</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'>Capitalization</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#107'>Dilution</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#108'>Selected Consolidated Financial Data</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#109'>Management&#146;s Discussion and Analysis of
    Financial Condition and Results of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#110'>Business</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#111'>Management</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    74
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#112'>Certain Relationships and Related Party
    Transactions</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#113'>Principal Stockholders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#114'>Description of Capital Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    108
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#115'>Shares Eligible For Future Sale</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    113
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#120'>Material U.S. Federal Income and Estate Tax
    Consequences to Non-U.S. Holders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    115
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#121'>Underwriters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#116'>Legal Matters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#117'>Experts</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#118'>Where You Can Find Additional Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#119'>Index to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a1exv3w2.htm">EXHIBIT 3.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a1exv10w2.htm">EXHIBIT 10.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a1exv10w13.htm">EXHIBIT 10.13</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a1exv10w18.htm">EXHIBIT 10.18</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a1exv23w1.htm">EXHIBIT 23.1</A></FONT></TD></TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=96 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should rely only on the information contained in this
    prospectus and in any free writing prospectus prepared by or on
    behalf of us. We have not, and the underwriters have not,
    authorized anyone to provide you with information different
    from, or in addition to, that contained in this prospectus or
    any related free writing prospectus. This prospectus is an offer
    to sell only the shares offered hereby but only under
    circumstances and in jurisdictions where it is lawful to do so.
    The information contained in this prospectus is current only as
    of its date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Through and
    including,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008 (the 25th&#160;day after the date of this prospectus), all
    dealers effecting transactions in these securities, whether or
    not participating in this offering, may be required to deliver a
    prospectus. This is in addition to a dealer&#146;s obligation to
    deliver a prospectus when acting as an underwriter and with
    respect to an unsold allotment or subscription</B>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For investors outside the United States: Neither we nor any of
    the underwriters have done anything that would permit this
    offering or possession or distribution of this prospectus in any
    jurisdiction where action for that purpose is required, other
    than the United States. You are required to inform yourselves
    about and to observe any restrictions relating to this offering
    and the distribution of this prospectus.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<A name='101'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROSPECTUS
    SUMMARY</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>This summary highlights information contained in greater
    detail elsewhere in this prospectus. This summary may not
    contain all the information that you should consider before
    investing in our common stock. You should read the entire
    prospectus carefully, including &#147;Risk Factors&#148;
    beginning on page&#160;7 and our consolidated financial
    statements and related notes included elsewhere in this
    prospectus, before making an investment decision. Unless
    otherwise indicated, the terms &#147;Fluidigm,&#148;
    &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to
    Fluidigm Corporation.</I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in the life science industry. Our Integrated Fluidic Circuits,
    or IFCs, address critical industry needs by providing very
    large-scale integration of essential laboratory functions on a
    single microfabricated device. IFCs can measure, combine,
    diffuse, fold, mix, separate or pump nanoliter volumes of fluids
    with precise control and reproducibility. Based on their
    similarities to the integrated circuit that revolutionized the
    microelectronics industry, we often refer to our IFCs as
    &#147;integrated circuits for biology.&#148; These devices
    enable our customers to perform thousands of sophisticated
    biochemical reactions and measurements in parallel on samples
    smaller than the content of a single cell, while reducing the
    consumption of expensive laboratory chemicals. Particularly for
    large-scale experimentation, our IFC systems increase
    throughput, decrease costs and enhance sensitivity compared to
    conventional laboratory systems.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems, consisting of
    instrumentation, software and single-use IFCs, for a wide range
    of life science applications. Researchers and clinicians have
    successfully employed our products in achieving breakthroughs
    across diverse scientific disciplines such as genetic variation,
    cellular function and structural biology. These advances include
    using our systems to help detect life-threatening mutations in
    patients&#146; cancer cells, discover indicators of
    susceptibility to cancer, manage some of the world&#146;s most
    valuable fisheries, analyze the genetic composition of
    individual stem cells, identify fetal chromosomal abnormalities
    from maternal blood samples, analyze the aggressiveness of the
    avian flu virus and assess the quality of agricultural seed
    products. We believe that the flexible architecture of our IFC
    technology will lead to the development of IFC systems for a
    wide variety of additional markets and applications, including
    molecular diagnostics.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our success and continued growth prospects are
    attributable to the following:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Disruptive Technology.</I>&#160;&#160;We believe we have
    achieved an unprecedented level of miniaturization in
    microfluidics, allowing us to integrate the components required
    to automate a broad range of life science applications in an
    area less than half the size of a credit card. Our IFCs deliver
    orders of magnitude improvements in cost and labor efficiencies,
    while being easily incorporated into existing laboratory
    workflows and allowing the use of broadly accepted chemistries.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Proven Customer Adoption.</I>&#160;&#160;We have sold our
    IFCs to over 100 customers. These customers include many leading
    biotechnology and pharmaceutical companies, academic
    institutions and life science laboratories worldwide.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Broad Application in the Life Science
    Market.</I>&#160;&#160;We have developed and commercialized IFCs
    for several significant life science research applications and
    believe that the inherent flexibility of our technology will
    enable the development of IFCs for a wide variety of additional
    markets and applications.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Strong Research and Development Capabilities and Intellectual
    Property Position.</I>&#160;&#160;We have and will continue to
    invest substantially in research and development to increase the
    density, throughput and functionality of our IFCs. We have
    developed an extensive portfolio of intellectual property,
    including more than 80 issued U.S.&#160;patents and 240 patent
    applications pending worldwide either owned by or licensed to us.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Efficient Manufacturing and Process
    Development.</I>&#160;&#160;Our sophisticated manufacturing
    process, which combines standard semiconductor methods with
    proprietary techniques, enables us to produce large quantities
    of IFCs to stringent quality standards. We have established our
    manufacturing facility in
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 6%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     Singapore because of the availability of a skilled workforce,
    an extensive supplier and partner network, lower operating costs
    and significant government support.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Target Markets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The life science industry is currently facing challenges similar
    to those faced by the information technology industry when
    computational power was constrained by the inherent limitations
    of the vacuum tube. Life science research efforts, ranging from
    large-scale initiatives, such as the Human Genome Project, to
    more traditional academic and commercial research projects, are
    continuing to reveal the complex biological and chemical
    processes that are fundamental to living organisms. Developing
    and applying this knowledge increasingly requires performing
    experimentation on a scale and with a precision that can be
    achieved only through automation. However, the most common forms
    of life science automation rely on cumbersome robotic systems
    that are slow, expensive and labor intensive and, we believe,
    fundamentally constrain life science research. In much the same
    way that integrated circuits overcame the limitations of early
    computers by placing an increasing number of transistors on a
    single silicon chip, our IFCs are designed to overcome many of
    the limitations of conventional laboratory systems by
    integrating an increasing number of fluidic components on a
    single microfabricated IFC.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Currently, researchers and clinicians use our IFCs to perform
    large-scale experimentation in the fields of genomics and
    proteomics. Genomics is the in-depth study of the genetic makeup
    of microorganisms, plants, animals and people, including
    analyzing variations in genes and gene activity. Proteomics is
    the large-scale study of the structure and function of proteins.
    Our IFC systems support the following types of genomic and
    proteomic studies:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Genotyping: </I>determining the specific genetic traits of an
    individual or individuals;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Gene expression analysis: </I>measuring the activity of genes.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Protein crystallization:</I> determining the
    three-dimensional structure of proteins.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Digital PCR:</I> quantifying scarce genetic sequences in a
    biological sample.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to Strategic Directions International, in 2005 the
    principal segments of the genomic analysis market, gene
    expression and genotyping, accounted for $4.9&#160;billion
    worldwide in expenditures and are expected to grow annually by
    8% through 2010. We believe that our products may further be
    developed for use in molecular diagnostics. Molecular
    diagnostics is a rapidly growing market that seeks to apply
    information learned from genomic and proteomic analysis to
    clinical practice in diagnosing, monitoring and treating disease.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Fluidigm Solution</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems are designed to overcome many of the limitations
    of conventional laboratory systems by enabling researchers and
    clinicians to rapidly perform a large number of experiments at
    one time and in nanoliter volumes, significantly increasing
    throughput, reducing reagent costs, conserving patient samples
    and reducing workflow complexity.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Topaz IFC system in the first
    quarter of 2003 and our Biomark IFC system in the fourth quarter
    of 2006. Our first IFC, the 1.96 Dynamic Array for our Topaz
    system, was introduced in the first quarter of 2003 and allowed
    researchers to test a single sample against 96 different
    reagents. In May 2008, we introduced the 96.96 Dynamic Array IFC
    for our Biomark system. This IFC is based on a matrix
    architecture that allows a researcher to test each of 96
    different samples against each of 96 different reagents in
    parallel, and thus perform 9,216 individual experiments
    simultaneously.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The advantages of our IFC systems over conventional laboratory
    systems include:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Complexity.</I>&#160;&#160;Loading our IFC requires
    orders of magnitude fewer liquid handling steps than
    conventional systems for the same experiment.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Improved Throughput.</I>&#160;&#160;Our most advanced IFCs
    can conduct up to 24 times more experiments than a conventional
    system can perform in a single run.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Nanoliter Precision.</I>&#160;&#160;Our IFC systems allow
    researchers to dispense samples and reagents in nanoliter, or
    billionths of a liter, volumes, which supports high sensitivity
    techniques.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Reagent and Sample Requirements.</I>&#160;&#160;Our
    systems operate on volumes of reagents and samples that are
    typically less than 1% of the volumes required by conventional
    systems.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Decreased Capital Cost.</I>&#160;&#160;For high volume users,
    the cost of purchasing one BioMark system is much lower than the
    cost of purchasing the number of conventional systems required
    to provide the same throughput.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Ease of Adoption.</I>&#160;&#160;Our IFCs systems support
    widely-used chemistries and are compatible with standard
    laboratory equipment, allowing researchers to easily incorporate
    our products into their laboratory workflow and processes.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that our IFC systems also offer significant
    advantages over other high-throughput methods for large scale
    experimentation. These alternative approaches have one or more
    limitations, such as lack of flexibility, poor data quality,
    complex and slow workflows or high running costs. Our IFC
    systems are not designed for smaller scale research initiatives
    where complexity and workflow issues may be less pressing and
    conventional systems may be more economical. As life science
    research continues to evolve and is commercialized, we believe
    that there will be increasing demand for life science automation
    solutions that enable experimentation on the scale supported by
    our IFC systems.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Affecting Us</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is subject to numerous risks, as more fully
    described in the section entitled &#147;Risk Factors&#148;
    immediately following this prospectus summary, including the
    following:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We have incurred significant losses since our inception, had an
    accumulated deficit of $140.4&#160;million as of March&#160;29,
    2008 and expect to incur losses for the foreseeable future.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    If our products fail to achieve and sustain market acceptance,
    our revenue will be adversely affected.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our sales cycle for the BioMark and Topaz systems is lengthy and
    unpredictable, which makes it difficult for us to forecast
    revenue and could cause significant quarterly fluctuations in
    revenue and other operating results.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We receive a substantial portion of our revenues from a limited
    number of customers and other entities, and the loss of, or a
    significant reduction in, orders or grants from one or more of
    our major customers or grantors would adversely affect our
    operations and financial condition.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The life science industry is highly competitive and subject to
    rapid technological change, and we may not be able to
    successfully compete.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We have limited experience in producing our products, and we may
    experience development or manufacturing problems or delays that
    could limit the growth of our revenue or increase our losses.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We are dependent on single source suppliers for some of the
    components and materials used in our systems, and the loss of
    any of these suppliers could harm our business.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our ability to protect our intellectual property and proprietary
    technology through patents and other means is uncertain, and we
    are dependent on certain licensed-in technology. In addition,
    future third-party claims of intellectual property infringement
    could adversely affect our operations and financial condition.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Corporate
    History and Information</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were incorporated in California in May 1999 as Mycometrix
    Corporation, changed our name to Fluidigm Corporation in April
    2001 and reincorporated in Delaware in July 2007. Our principal
    executive offices are located at 7000 Shoreline Court,
    Suite&#160;100, South San&#160;Francisco, California 94080. Our
    telephone number is
    <FONT style="white-space: nowrap">(650)&#160;266-6000.</FONT>
    Our website address is www.fluidigm.com. Information contained
    on our website is not incorporated by reference into this
    prospectus, and should not be considered to be part of this
    prospectus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;Fluidigm,&#148; the Fluidigm logo, &#147;Topaz,&#148;
    &#147;BioMark,&#148; &#147;AutoInspeX,&#148; &#147;MSL&#148; and
    &#147;NanoFlex&#148; are trademarks or registered trademarks of
    Fluidigm. Other service marks, trademarks and trade names
    referred to in this prospectus are the property of their
    respective owners.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
  </DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">THE
    OFFERING</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
    Common stock offered by us</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Common stock to be outstanding after this offering</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Use of proceeds</TD>
    <TD></TD>
    <TD valign="bottom">
    We intend to use the net proceeds from this offering to expand
    our sales force, support the commercialization of our products,
    continue research and development, expand our facilities and
    manufacturing operations and for working capital and other
    general corporate purposes. We may also use a portion of the net
    proceeds to acquire other businesses, products or technologies.
    However, we do not have agreements or commitments for any
    specific acquisitions at this time. See &#147;Use of
    Proceeds.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Proposed NASDAQ Global Market symbol</TD>
    <TD></TD>
    <TD valign="bottom">
    FLDM</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The number of shares of our common stock to be outstanding
    following this offering is based on 66,638,462&#160;shares of
    our common stock outstanding as of March&#160;29, 2008, but
    excludes:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    8,103,050&#160;shares of common stock issuable upon exercise of
    options outstanding as of March&#160;29, 2008 at a weighted
    average exercise price of $0.93 per share;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    598,720&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of March&#160;29, 2008 at a weighted
    average exercise price of $2.97 per share, after conversion from
    preferred stock;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for future issuance under our
    stock-based compensation plans,
    including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for issuance under our 2008 Equity
    Incentive Plan, which will become effective on the date of this
    prospectus, and any future automatic increase in shares reserved
    for issuance under such plan; and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1,503,945 shares of our Series&#160;E preferred stock issued
    upon the conversion of principal and accrued interest on a
    convertible promissory note held by Biomedical Sciences
    Investment Fund Pte Ltd  on April&#160;30, 2008.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, this prospectus reflects and assumes
    the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a&#160;&#160;-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    reverse split of our outstanding common stock and convertible
    preferred stock, to be effected prior to the completion of this
    offering;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the conversion of all outstanding shares of our convertible
    preferred stock into an aggregate of 56,670,894&#160;shares of
    common stock upon the closing of this offering;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the filing of our amended and restated certificate of
    incorporation immediately prior to the effectiveness of this
    offering;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    no exercise by the underwriters of their over-allotment option.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    CONSOLIDATED FINANCIAL DATA</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have derived the summary consolidated statement of operations
    data for the years ended December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007 and the
    consolidated balance sheet data as of December&#160;29, 2007
    from our audited consolidated financial statements included
    elsewhere in this prospectus. We have derived the summary
    consolidated statement of operations data for the three months
    ended March&#160;31, 2007 and March&#160;29, 2008 and the
    consolidated balance sheet data as of March&#160;29, 2008 from
    our unaudited consolidated financial statements included
    elsewhere in this prospectus. Our historical results are not
    necessarily indicative of the results that may be expected in
    the future. The following summary consolidated financial data
    should be read in conjunction with &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#148; and our consolidated financial statements and
    related notes, included elsewhere in this prospectus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="64%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="font-size: 1pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Consolidated Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    527
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cost and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    847
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,473
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,280
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,037
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,510
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,523
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,227
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (505
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss before provision for income taxes and cumulative effect of
    change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,334
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,589
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Shares used in computing net loss per share of common stock,
    basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Pro forma net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Shares used in computing pro forma net loss per share of common
    stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Please see Note&#160;2 to our
    audited consolidated financial statements for an explanation of
    the method used to calculate basic and diluted net loss per
    common share and pro forma net loss per common share.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of March&#160;29, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro
    Forma<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As
    Adjusted<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(in thousands)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated Balance Sheet Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash and cash equivalents and available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    31,235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total long-term debt and convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,742
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (136,921
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The pro forma balance sheet data in
    the table above reflects (i)&#160;the automatic conversion
    principal and accrued interest of a convertible promissory note
    held by Biomedical Sciences Investment Fund Pte Ltd into
    1,503,945&#160;shares of our common stock, which conversion
    occurred on April&#160;30, 2008, (ii)&#160;the conversion of all
    outstanding shares of convertible preferred stock into common
    stock and (iii)&#160;the reclassification of the convertible
    preferred stock warrant liabilities to additional
    <FONT style="white-space: nowrap">paid-in-capital,</FONT>
    each effective upon the closing of this offering.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The pro forma as adjusted balance
    sheet data in the table above also reflects the sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock in this offering and the application of the
    net proceeds at an initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us.
    </FONT></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">A $1.00 increase (decrease) in the
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, would
    increase (decrease) each of cash, cash equivalents and
    available-for-sale securities, working capital, total assets and
    total stockholders&#146; equity by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that the
    number of shares offered by us, as set forth on the cover page
    of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions payable by us.
    Each increase of 1.0&#160;million shares in the number of shares
    offered by us would increase each of cash, cash equivalents,
    available-for-sale securities, working capital, total assets and
    total stockholders&#146; equity by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. Similarly, each
    decrease of 1.0&#160;million shares in the number of shares
    offered by us would decrease each of cash, cash equivalents,
    available-for-sale securities, working capital, total assets and
    total stockholders&#146; equity by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. The pro forma as
    adjusted information discussed above is illustrative only and
    will adjust based on the actual public offering price and other
    terms of this offering determined at pricing.
    </FONT></TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Investing in our common stock involves a high degree of risk.
    You should consider carefully the risks and uncertainties
    described below, together with all of the other information in
    this prospectus, including our consolidated financial statements
    and related notes, before deciding whether to purchase shares of
    our common stock. If any of the following risks is realized, our
    business, financial condition, results of operations and
    prospects could be materially and adversely affected. In that
    event, the price of our common stock could decline and you could
    lose part or all of your investment.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to our Business and Strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have incurred losses since inception, and we expect to
    continue to incur substantial losses for the foreseeable
    future.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have a limited operating history and have incurred
    significant losses in each fiscal year since our inception,
    including net losses of $16.4&#160;million, $23.6&#160;million,
    $25.5&#160;million and $6.6&#160;million during 2005, 2006, 2007
    and the three months ended March&#160;29, 2008. As of
    March&#160;29, 2008, we had an accumulated deficit of
    $140.4&#160;million. These losses have resulted principally from
    costs incurred in our research and development programs and from
    our selling, general and administrative expenses. We expect to
    continue to incur operating and net losses and negative cash
    flow from operations, which may increase, for the foreseeable
    future due in part to anticipated increases in expenses for
    research and product development and expansion of our sales and
    marketing capabilities. Additionally, following this offering,
    we expect that our selling, general and administrative expenses
    will increase due to the additional operational and reporting
    costs associated with being a public company. We anticipate that
    our business will generate operating losses until we
    successfully implement our commercial development strategy and
    generate significant additional revenues to support our level of
    operating expenses. Because of the numerous risks and
    uncertainties associated with our commercialization efforts and
    future product development, we are unable to predict when we
    will become profitable, and we may never become profitable. Even
    if we do achieve profitability, we may not be able to sustain or
    increase our profitability.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If our products fail to achieve and sustain sufficient
    market acceptance, our revenue will be adversely
    affected.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends, in part, on our ability to develop and
    market products that are recognized and accepted as reliable,
    enabling and cost effective. Most of our potential customers
    already use expensive research systems in their laboratories and
    may be reluctant to replace those systems. Market acceptance of
    our instrument systems will depend on many factors, including
    our ability to convince potential customers that our systems are
    an attractive alternative to existing technologies. Compared to
    other technologies, our Integrated Fluidic Circuit, or IFC,
    technology is new and unproven, and most potential customers
    have limited knowledge of, or experience with, our products.
    Prior to adopting our technology, potential customers generally
    need to devote significant effort to testing and validating our
    systems and benchmarking them against their current systems and
    performance requirements. Any failure of our systems to meet
    these customer benchmarks could result in customers choosing to
    retain their existing systems or to purchase systems other than
    ours.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, many customers intend to publish the results of
    their experiments in scientific and medical journals. Therefore,
    it is important that our systems be perceived as accurate and
    reliable by the scientific and medical research community as a
    whole. Many factors influence the perception of a system
    including its use by leading research groups and the publication
    of their results in well regarded journals. A significant part
    of our sales and marketing efforts have been directed at
    convincing industry leaders of the advantages of our systems and
    encouraging such leaders to publish or present the results of
    their evaluation of our system. If we are unable to induce
    leading researchers to use our system or if such researchers are
    unable to achieve and publish or present significant
    experimental results using our system, acceptance and adoption
    of our systems will be slowed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our sales cycle is lengthy and unpredictable, which makes
    it difficult for us to forecast revenue and could cause
    significant quarterly fluctuations in revenue and other
    operating results.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The sales cycles for our instrument systems is lengthy, which
    makes it difficult for us to accurately forecast revenues in a
    given period, and may cause revenue and operating results to
    vary significantly from period to period.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Due in part to the high up-front cost associated with our
    systems, potential customers for our instrument systems
    typically need to commit significant time and resources to
    evaluate our technology and their decision to purchase our
    instruments may be further limited by budgetary constraints and
    several layers of internal review and approval, which are beyond
    our control. Even after initial approval by appropriate decision
    makers, the negotiation and documentation processes for a
    purchase can be lengthy. As a result of these factors, our sales
    cycle has varied widely and, in certain instances has been
    longer than 12&#160;months. The complexity and variability of
    our sales cycle has made it difficult for us to accurately
    project quarterly revenues, and we have frequently failed to
    meet our internal quarterly projections. Moreover, we do not
    recognize revenue on sales of our systems until the system has
    been delivered to the customer and, in many instances, installed
    and our other revenue recognition criteria have been met. This
    further complicates our ability to project quarterly revenue as
    we may have entered into a sale agreement with a customer for a
    system but cannot predict when that customer will take delivery
    of the system and when we will be able to recognize the revenue.
    We expect that our sales will continue to fluctuate on a
    quarterly basis and that our financial results for some periods
    may be below those projected by securities analysts. Such
    fluctuations could have a material adverse effect on our
    business and on the price of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our sales efforts require significant time and effort and
    could hinder our ability to increase sales.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Before purchasing one of our systems, customers typically
    require input from one or more scientific evaluators as well as
    a review by personnel with finance or operational expertise. As
    a result, during our sales effort, we must identify all persons
    involved in the purchasing decision and devote a sufficient
    amount of time to presenting our systems to those individuals.
    The newness and complexity of our products often requires us to
    spend substantial time and effort assisting potential customers
    in evaluating our instruments including providing demonstrations
    and benchmarking our products against other available
    technologies. This process can be costly and time consuming. We
    expect that our sales process will become less burdensome as our
    products become more widely known and used. However, if this
    change does not occur, we will not be able to expand our sales
    effort as quickly as anticipated and our sales will be adversely
    affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our future success is dependent upon our ability to expand
    our customer base and introduce new applications.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our customer base is primarily composed of pharmaceutical and
    biotechnology companies, academic institutions and life science
    laboratories that perform large-scale experimentation for life
    science research purposes. Our success will depend in part upon
    our ability to increase our market share amongst these
    customers, attract life science research customers who do not
    currently perform large-scale experimentation, attract customers
    outside the life science research market and market new
    applications to existing and new customers as we develop such
    applications. Attracting new customers and introducing new
    applications requires substantial time and expense. For example,
    it may be difficult to identify, engage and market to customers
    who do not currently perform large-scale experimentation or are
    unfamiliar with our current applications. In addition, certain
    new applications that we are considering developing are not
    practical to perform with conventional techniques. Any failure
    to expand our existing customer base or launch new applications
    would adversely affect our ability to increase our revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our inability to develop new systems and enhance the
    capabilities of our IFC systems to keep pace with rapidly
    changing technology and customer requirements could adversely
    affect our business.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends on our ability to develop new applications
    for our IFC technology in existing and new markets, while
    improving the performance and cost effectiveness of our systems.
    New technologies, techniques or products could emerge that might
    offer better combinations of price and performance than our
    current or future product lines and systems. Existing markets
    for our products, including gene expression analysis,
    genotyping, digital polymerase chain reaction, or PCR, and
    proteomics, as well as potential markets for our products such
    as molecular diagnostics, are characterized by rapid
    technological change and innovation. It is critical to our
    success for us to anticipate changes in technology and customer
    requirements and to successfully introduce new, enhanced and
    competitive technology to meet our customers&#146; and
    prospective customers&#146; needs on a timely basis. While we
    have planned substantial improvements to the BioMark system,
    including enhancing the capabilities of our IFCs, we may not be
    able to successfully implement these improvements. Even if we
    successfully implement some or all of these planned
    improvements, we could incur substantial development costs in
    doing so. We may not have adequate resources available to
    develop new technologies or be able to successfully introduce
    new applications of,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    or enhancements to, our systems. We cannot guarantee that we
    will be able to maintain technological advantages over emerging
    technologies in the future. If we fail to keep pace with
    emerging technologies, demand for our systems will not grow and
    may decline, and our business, revenue, financial condition and
    operating results could suffer materially.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have limited resources for marketing, selling and
    distributing our products and we may not be able to develop a
    direct sales and marketing force or distribution capabilities
    that can meet our customers&#146; needs.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have limited marketing, sales and distribution resources and
    capabilities. We sell our products primarily through our own
    sales force and through distributors in certain territories. Our
    first product line, the Topaz system for protein
    crystallization, was introduced for commercial sale in 2002. Our
    BioMark system was introduced for commercial sale in 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our future sales will depend in large part on our ability to
    develop and expand our direct sales force and to increase the
    scope of our marketing efforts. Our products are technically
    complex and used for highly specialized applications. As a
    result, we believe it is necessary to develop a direct sales
    force that includes people with specific scientific backgrounds
    and expertise and a marketing group with technical
    sophistication. Competition for such employees is intense. We
    may not be able to attract and retain personnel or be able to
    build an efficient and effective sales and marketing force,
    which could negatively impact sales of our products, and reduce
    our revenues and profitability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we may seek to enlist one or more parties to assist
    with sales, distribution and customer support globally or in
    certain regions of the world. If we do seek to enter into such
    arrangements, we may not be successful in attracting desirable
    sales and distribution partners, or we may not be able to enter
    into such arrangements on favorable terms. If our sales and
    marketing efforts, or those of any third-party sales and
    distribution partners, are not successful, our technologies and
    products may not gain market acceptance, which would materially
    impact our business operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>The life science industry is highly competitive and
    subject to rapid technological change, and we may not be able to
    successfully compete.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The markets for our products are characterized by rapidly
    changing technology, evolving industry standards, changes in
    customer needs, emerging competition, new product introductions
    and strong price competition. We compete with both established
    and development stage life science companies that design,
    manufacture and market instruments for gene expression analysis,
    genotyping, other nucleic acid detection and additional
    applications using well established laboratory techniques, as
    well as newer technologies such as bead encoded arrays,
    microfluidics, nanotechnology, next-generation DNA sequencing
    and inkjet and photolithographic arrays. Most of our current
    competitors have significantly greater name recognition, greater
    financial and human resources, broader product lines and product
    packages, larger sales forces, large existing installed bases,
    substantial intellectual property portfolios and greater
    experience in research and development, manufacturing and
    marketing than we do. For example, companies such as Affymetrix,
    Applied Biosystems, BioTrove, Illumina, Roche Diagnostics and
    Sequenom have products that compete in certain segments of the
    market in which we sell our BioMark system.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Competitors may be able to respond more quickly and effectively
    than we can to new or changing opportunities, technologies,
    standards or customer requirements. In light of these
    advantages, even if our technology is more effective than the
    product or service offerings of our competitors, current or
    potential customers might accept competitive products and
    services in lieu of purchasing our technology. We anticipate
    that we will face increased competition in the future as
    existing companies and competitors develop new or improved
    products and as new companies enter the market with new
    technologies. We may not be able to compete effectively against
    these organizations. Increased competition is likely to result
    in pricing pressures, which could harm our sales, profitability
    or market share. Our failure to compete effectively could
    materially and adversely affect our business, financial
    condition and results of operations.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We receive a substantial portion of our revenue from a
    limited number of customers and other entities, and the loss of,
    or a significant reduction in, orders or grants from one or more
    of our major customers or grantors would adversely affect our
    operations and financial condition.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive a substantial portion of our revenue from a limited
    number of customers and grantors. We received an aggregate of
    approximately 30%, 44%, 24% and 16% of our total revenue from
    our top three customers in 2005, 2006, 2007 and the three months
    ended March&#160;29, 2008. Grant revenue from the Singapore
    Economic Development Board, or EDB, represented 0%, 14%, 24% and
    16% of our total revenue in 2005, 2006 and 2007 and the three
    months ended March&#160;29, 2008. We anticipate that we will
    continue to be dependent on a limited number of customers and
    grantors for a significant portion of our revenue in the near
    future and in some cases the portion of our revenue attributable
    to certain customers or grantors may increase in the future.
    However, we may not be able to maintain or increase sales to our
    top customers or grants from our top grantors for a variety of
    reasons, including the following:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our agreements with our customers and grantors do not require
    them to purchase a minimum quantity of our products or make a
    minimum amount of grants in any year;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our customers can stop using our products with limited notice to
    us and suffer little or no payment penalty;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our grants are subject to the achievement of milestones that we
    may not meet;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    many of our customers have pre-existing or concurrent
    relationships with our current or potential competitors that may
    affect the customers&#146; decisions to purchase our products.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the past, we have relied in significant part on our strategic
    relationships with customers that are technology leaders in our
    target markets. We intend to pursue the expansion of such
    relationships and the formation of new strategic relationships
    but we cannot assure you that we will be able to do so. These
    relationships often require us to develop new products that may
    involve significant technological challenges. Our customers
    frequently place considerable pressure on us to meet their tight
    development schedules. Our grantors frequently condition their
    present and future grants on our compliance with certain
    development, hiring and local investment milestones.
    Accordingly, we may have to devote a substantial amount of our
    resources to our strategic relationships, which could detract
    from or delay our completion of other important development
    projects. Delays in development could impair our relationships
    with our strategic customers and grantors and negatively impact
    sales of the products under development or future grant
    activity. The loss of a key customer or grantor, a reduction in
    sales to any key customer, a reduction in grants from a key
    grantor, or our inability to attract new significant customers
    could seriously impact our revenue and materially and adversely
    affect our results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our business depends on research and development spending
    levels of pharmaceutical and biotechnology companies and
    academic, clinical and governmental research institutions and
    any reduction in such spending could limit our ability to sell
    our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect that our revenue in the foreseeable future will be
    derived primarily from sales of instruments and IFCs to academic
    institutions, biotechnology and pharmaceutical companies and
    life science laboratories worldwide. Our success will depend
    upon their demand for and use of our products. Accordingly, the
    spending policies of these customers could have a significant
    effect on the demand for our technology. These policies may be
    based on a wide variety of factors, including the resources
    available to make purchases, the spending priorities among
    various types of equipment, policies regarding spending during
    recessionary periods and changes in the political climate. In
    addition, academic, governmental and other research institutions
    that fund research and development activities may be subject to
    stringent budgetary constraints that could result in spending
    reductions, reduced allocations or budget cutbacks, which could
    jeopardize the ability of these customers to purchase our
    system. Our operating results may fluctuate substantially due to
    reductions and delays in research and development expenditures
    by these customers. For example, reductions in capital
    expenditures by these customers may result in lower than
    expected system sales and, similarly, reductions in operating
    expenditures by these customers could result in lower than
    expected sales of IFCs. These reductions and delays may result
    from factors that are not within our control, such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in economic conditions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in government programs that provide funding to research
    institutions and companies;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in the regulatory environment affecting life science
    companies and life science research;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market-driven pressures on companies to consolidate operations
    and reduce costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    mergers and acquisitions in the life science industry;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    other factors affecting research and development spending.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any decrease in our customers&#146; budgets or expenditures or
    in the size, scope or frequency of capital or operating
    expenditures as a result of the foregoing or other factors could
    materially adversely affect our operations or financial
    condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we cannot provide quality technical support, we could
    lose customers and our operating results could suffer.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The placement of our products at new customer sites, the
    introduction of our technology into our customers&#146; existing
    systems and ongoing customer support can be complex.
    Accordingly, we need highly trained technical support personnel.
    Hiring technical support personnel is very competitive in our
    industry due to the limited number of people available with the
    necessary biochemistry background and ability to understand our
    systems at a technical level. We are currently expanding our
    technical support staff and will need to increase it further to
    support expected new customers as well as the expanding needs of
    existing customers. If we are unable to attract, train or retain
    the number of highly qualified technical services personnel that
    our business needs, our business and prospects will suffer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>To use our products, customers typically need to purchase
    specialized reagents. Any interruption in the availability of
    these reagents for use in our products could limit our ability
    to market our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products must be used in conjunction with one or more
    reagents designed to produce or facilitate the particular
    biological or chemical reaction desired by the user. Many of
    these reagents are highly specialized and available to the user
    only from a single supplier or a limited number of suppliers.
    Our customers typically purchase these reagents directly from
    the suppliers and we have no control over the supply of those
    materials. In addition, our products are designed to work with
    these reagents as they are currently formulated. We have no
    control of the formulation of these reagents and the performance
    of our products might be adversely affected if the formulation
    of these reagents was changed. If one or more of these reagents
    were to become unavailable or were reformulated, our ability to
    market and sell our products could be materially and adversely
    affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the use of a reagent for a particular process may
    be covered by one or more patents relating to the reagent
    itself, the use of the reagent for the particular process, the
    performance of that process or the equipment required to perform
    the process. Typically, reagent suppliers, who are either the
    patent holders or their authorized licensees, sell the reagents
    along with a license or covenant not to sue with respect to such
    patents. The license accompanying the sale of a reagent often
    purports to restrict the purposes for which the reagent may be
    used. If a patent holder or authorized licensee were to assert
    against us or our customers that the license or covenant
    relating to a reagent precluded its use with our systems, our
    ability to sell and market our products could be materially and
    adversely affected. For example, the current applications of our
    BioMark system, which represented 41% of our product revenue in
    2007, involve real-time polymerase chain reaction, or PCR,
    reactions. The primary producers of reagents for PCR reactions
    are Applied Biosystems and Roche Diagnostics, who are our direct
    competitors, and their licensees. These PCR reagents are sold
    pursuant to limited licenses or covenants not to sue with
    respect to patents held by these companies. We do not have any
    contractual relationship with Roche Diagnostics or Applied
    Biosystems regarding these PCR reagents, and we cannot assure
    you that these reagents will continue to be available to our
    customers for use with our systems, or that these patent holders
    will not seek to enforce their patents against us, our
    customers, or suppliers.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We are dependent on single source suppliers for some of
    the components and materials used in our systems, and the loss
    of any of these suppliers could harm our business.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on single source suppliers for certain components and
    materials used in our systems. Of these single source suppliers,
    the loss of any of the following would require significant time
    and effort to locate and qualify an alternative source of supply:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    An essential component of our BioMark system is a specialized
    thermal cycler that is available from a limited number of
    suppliers. We purchase this thermal cycler from one supplier,
    Eppendorf AG, which customizes it to our specifications pursuant
    to a supply agreement.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our IFCs are fabricated using a specialized polymer that is
    available from a limited number of sources. In the past we have
    encountered quality issues that have reduced our manufacturing
    yield or required the use of additional manufacturing processes.
    We do not have a long term contract with our current sole
    supplier.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The plastic carriers that hold the core components of our IFCs
    need to be produced to specifications and tolerances that few
    manufacturers are able to meet. We have experienced quality
    issues in the past and, as a result, have recently switched
    suppliers. We do not have a long term contract with either of
    our current sole suppliers for particular carriers.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The reader for our BioMark system requires specialized high
    resolution camera lenses that are available from a limited
    number of sources. We do not have a long term contract with our
    current sole supplier.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our reliance on these suppliers also subjects us to other risks
    that could harm our business, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may be subject to increased component costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we are not a major customer of many of our suppliers, and these
    suppliers may therefore give other customers&#146; needs higher
    priority than ours;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may not be able to obtain adequate supply in a timely manner
    or on commercially reasonable terms;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our suppliers may make errors in manufacturing components that
    could negatively affect the efficacy of our systems or cause
    delays in shipment of our systems;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our suppliers may encounter financial hardships unrelated to our
    demand for components, which could inhibit their ability to
    fulfill our orders and meet our requirements.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have in the past experienced supply problems with some of our
    suppliers, such as manufacturing errors, and may again
    experience problems in the future. We may not be able to quickly
    establish additional or replacement suppliers, particularly for
    our single source components. Any interruption or delay in the
    supply of components or materials, or our inability to obtain
    components or materials from alternate sources at acceptable
    prices in a timely manner, could impair our ability to meet the
    demand of our customers and cause them to cancel orders or
    switch to competitive products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have limited experience in producing our products, and
    we may experience development or manufacturing problems or
    delays that could limit the growth of our revenue or increase
    our losses.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have limited experience manufacturing and assembling our
    products in commercial quantities and we may encounter
    unforeseen situations that would result in delays or shortfalls.
    In addition, our production processes and assembly methods may
    have to change to accommodate any significant future expansion
    of our manufacturing capacity. If we are unable to keep up with
    demand for our products, our revenue could be impaired, market
    acceptance for our products could be adversely affected and our
    customers might instead purchase our competitors&#146; products.
    Our inability to successfully manufacture our products would
    have a material adverse effect on our operating results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We first produced the IFCs used in our current Topaz system in
    June 2002 at our facility in South San&#160;Francisco. We have
    since moved our commercial production of IFCs to our facility in
    Singapore, which first produced commercial IFCs for our Topaz
    systems in October 2006 and first produced commercial IFCs for
    our BioMark
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     system in December 2007. Production of the elastomeric block
    that is at the core of our IFCs is a complex process requiring
    advanced clean rooms, sophisticated equipment and strict
    adherence to procedures. Any contamination of the clean room,
    equipment malfunction or failure to strictly follow procedures
    can significantly reduce our yield in one or more batches. Such
    a drop in yield can greatly increase our cost to manufacture our
    IFCs or, in more severe cases, require us to halt the
    manufacture of IFCs until the problem is resolved. Identifying
    and resolving the cause of a drop in yield can require
    substantial time and resources. We have had significant yield
    problems in the past and cannot assure you that these types of
    yield issues will not occur again. Sustained yield problems
    would have a material adverse affect on our business, financial
    condition and results of operations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, developing an IFC for a new application typically
    requires developing a specific production process for that type
    of IFC. While all of our IFCs are produced using the same basic
    processes, significant variations are required to ensure
    adequate yield of any particular type of IFC. Developing such a
    process can be very time consuming, and any unexpected
    difficulty in doing so can delay the introduction of a product.
    For example, in the second quarter of 2006, our ability to
    conduct demonstrations for potential customers for our BioMark
    system was impaired because we were unable to produce sufficient
    quantities of that IFC. Though these production problems were
    resolved, the delay in conducting customer demonstrations
    resulted in the loss and delay of orders from potential
    customers. We cannot assure you that we will not face similar
    difficulties in developing new processes in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we are unable to recruit and retain key executives and
    scientists, we may be unable to achieve our goals.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our performance is substantially dependent on the performance of
    our senior management and key scientific and technical
    personnel, particularly Gajus V. Worthington, our President and
    Chief Executive Officer. We do not maintain fixed term
    employment contracts with any of our employees. The loss of the
    services of any member of our senior management or our
    scientific or technical staff might significantly delay or
    prevent the development of our products or achievement of other
    business objectives by diverting management&#146;s attention to
    transition matters and identification of suitable replacements,
    if any, and could have a material adverse effect on our
    business. We do not maintain significant key man life insurance
    on any of our employees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, our research and product development efforts could
    be delayed or curtailed if we are unable to attract, train and
    retain highly skilled employees, particularly, senior scientists
    and engineers. To expand our research and product development
    efforts we need additional people skilled in areas such as
    molecular and cellular biology, assay development and
    manufacturing. Competition for these people is intense. Because
    of the complex and technical nature of our system and the
    dynamic market in which we compete, any failure to attract and
    retain a sufficient number of qualified employees could
    materially harm our ability to develop and commercialize our
    technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be unable to manage our anticipated growth
    effectively.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The rapid growth of our business has placed a significant strain
    on our managerial, operational and financial resources and
    systems. We have increased the number of our employees from 78
    at December&#160;31, 2005 to 137 at March&#160;29, 2008. In
    addition, since October 2006 we have commenced manufacturing
    operations in Singapore and opened sales offices in Europe and
    Japan. To execute our anticipated growth successfully, we must
    continue to attract and retain qualified personnel and manage
    and train them effectively. We must also upgrade our internal
    business processes and capabilities to create the scalability
    that a growing business demands.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our primary commercial manufacturing facility located
    in Singapore is sufficient to meet our short-term manufacturing
    needs. However, the current lease for our manufacturing facility
    in Singapore expires in October&#160;2008. In order to meet the
    long-term demand for our IFC systems, we believe that we will
    need to add to our existing manufacturing space in Singapore or
    move all of our manufacturing facilities to a new location in
    Singapore. Such a move will involve significant expense in
    connection with the establishment of new clean rooms, the
    movement and installation of key manufacturing equipment and
    modifications to our manufacturing process and we cannot assure
    you that such a move would not delay or otherwise adversely
    affect our manufacturing activities.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Further, our anticipated growth will place additional strain on
    our suppliers and manufacturing facilities, resulting in an
    increased need for us to carefully monitor quality assurance.
    Any failure by us to manage our growth effectively could have an
    adverse effect on our ability to achieve our development and
    commercialization goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our research and product development efforts may not
    result in commercially viable products within the timeline
    anticipated, if at all.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is dependent on the improvement of our existing
    products, our development of new products to serve existing
    markets and our development of new products to create new
    markets and applications that were previously not practical with
    existing systems. We intend to devote significant personnel and
    financial resources to research and development activities
    designed to advance the capabilities of our IFC technology. Our
    IFC technology is new and complex and the behavior of fluids and
    surrounding compounds in a nanoscale environment is difficult to
    predict in advance. Though we have developed design rules for
    the implementation of our IFC technology, these are frequently
    revised to reflect new insights we have gained about the
    technology. In addition, we have discovered that biological or
    chemical reactions sometimes behave differently when implemented
    on IFCs rather than in a standard laboratory environment. As a
    result, significant research and development efforts may be
    required to transfer even well-understood reactions to our
    technology. In the past, product development projects have been
    significantly delayed when we encountered unanticipated
    difficulties in implementing a process on our IFCs. We may have
    similar delays in the future, and we may not obtain any benefits
    from our research and development activities. Any delay or
    failure by us to develop new products or enhance existing
    products would have a substantial adverse effect on our business
    and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our products, although not currently regulated, could in
    the future be subject to regulation by the U.S. Food and Drug
    Administration or other regulatory agencies.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products are currently labeled and sold for research
    purposes only and are not subject to U.S.&#160;Food and Drug
    Administration, or FDA, clearance or approval. However, in the
    future, certain of our products or related applications could be
    subject to the FDA&#146;s regulation, the FDA&#146;s regulatory
    jurisdiction could be expanded to include our products, or both.
    For example, if we wished to label and market our products for
    use in performing clinical diagnostics, FDA clearance or
    approval would be required. Even where a product is exempted
    from FDA clearance or approval, the FDA may impose restrictions
    on how and to whom we can market and sell our products.
    Obtaining FDA approval can be expensive and uncertain, generally
    takes several years to obtain and requires detailed and
    comprehensive scientific and clinical data. Notwithstanding the
    expense, these efforts may never result in FDA approval or
    clearance. Even if we were to obtain regulatory approval or
    clearance, it may not be for the uses we believe are important
    or commercially attractive. As a result, these regulations and
    restrictions could materially and adversely affect our business,
    financial condition and results of operations. Similar laws and
    regulations are also in effect in many foreign countries that
    could affect our ability to market certain products. The number
    and scope of these requirements are increasing. We may not be
    able to obtain regulatory approvals in such countries or may
    incur significant costs in obtaining or maintaining our foreign
    regulatory approvals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our future capital needs are uncertain and we may need to
    raise additional funds in the future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the net proceeds from this offering, together
    with our existing cash and cash equivalents, available for sale
    securities balances and cash receipts generated from sales of
    our products, will be sufficient to meet our anticipated cash
    requirements for at least the next 18&#160;months. However, we
    may need to raise substantial additional capital to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    expand the commercialization of our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fund our operations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    continue our research and development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    defend, in litigation or otherwise, any claims that we infringe
    third-party patents or violate other intellectual property
    rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    commercialize new products;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    acquire companies and in-license products or intellectual
    property.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our future funding requirements will depend on many factors,
    including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market acceptance of our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of our research and development activities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of filing and prosecuting patent applications;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of defending, in litigation or otherwise, any claims
    that we infringe third-party patents or violate other
    intellectual property rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of regulatory clearances or approvals, if
    any;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of establishing additional sales, marketing
    and distribution capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of establishing additional technical support
    capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the effect of competing technological and market
    developments;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the extent to which we acquire or invest in businesses, products
    and technologies, although we currently have no commitments or
    agreements relating to any of these types of transactions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we require additional funds in the future, such funds
    may not be available on acceptable terms, or at all.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may require additional funds in the future and we may not be
    able to obtain such funds on acceptable terms, or at all. If we
    raise additional funds by issuing equity securities, our
    stockholders may experience dilution. Debt financing, if
    available, may involve covenants restricting our operations or
    our ability to incur additional debt. Any debt or additional
    equity financing that we raise may contain terms that are not
    favorable to us or our stockholders. If we raise additional
    funds through collaboration and licensing arrangements with
    third parties, it may be necessary to relinquish some rights to
    our technologies or our products, or grant licenses on terms
    that are not favorable to us. If we are unable to raise adequate
    funds, we may have to liquidate some or all of our assets, or
    delay, reduce the scope of or eliminate some or all of our
    development programs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we do not have, or are not able to obtain, sufficient funds,
    we may have to delay development or commercialization of our
    products or license to third parties the rights to commercialize
    products or technologies that we would otherwise seek to
    commercialize. We also may have to reduce marketing, customer
    support or other resources devoted to our products or cease
    operations. Any of these factors could harm our operating
    results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our products could have unknown defects or errors, which
    may give rise to claims against us and adversely affect market
    adoption of our systems.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems utilize novel and complex technology applied on
    a nanoliter scale and such systems may develop or contain
    undetected defects or errors. We cannot assure you that material
    performance problems, defects or errors will not arise, and as
    we increase the density and integration of our IFCs, these risks
    may increase. While we do not provide express warranties that
    our IFCs will meet performance expectations or be free from
    defects, we have done so in the past, and expect to in the
    future in response to customer concerns in order to preserve
    customer relationships and help foster continued adoption and
    use of our systems. We typically do provide warranties relating
    to other parts of our IFC systems. The costs incurred in
    correcting any defects or errors may be substantial and could
    adversely affect our operating margins.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In manufacturing our products, we depend upon third parties for
    the supply of various components. Many of these components
    require a significant degree of technical expertise to produce.
    If our suppliers fail to produce components to specification, or
    if the suppliers, or we, use defective materials or workmanship
    in the manufacturing process, the reliability and performance of
    our products will be compromised.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our products contain defects, we may experience:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a failure to achieve market acceptance or expansion of our
    product sales;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    loss of customer orders and delay in order fulfillment;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    damage to our brand reputation;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increased cost of our warranty program due to product repair or
    replacement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    product recalls or replacements;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    inability to attract new customers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    diversion of resources from our manufacturing and research and
    development departments into our service department;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    legal claims against us, including product liability claims,
    which could be costly and time consuming to defend and result in
    substantial damages.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The occurrence of any one or more of the foregoing could
    negatively affect our business, financial condition and results
    of operations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We generate a substantial portion of our revenues
    internationally and are subject to various risks relating to
    such international activities which could adversely affect our
    international sales and operating performance.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, 2006, 2007 and the three months ended
    March&#160;29, 2008, approximately 28%, 40%, 52% and 49% of our
    total revenue was attributable to revenues generated outside of
    North America. We believe that a significant percentage of our
    future revenue will come from international sources as we expand
    our overseas operations and develop opportunities in additional
    international areas. Our international business may be adversely
    affected by changing economic, political and regulatory
    conditions in foreign countries. Because the majority of our
    product sales are currently denominated in U.S.&#160;dollars, if
    the value of the U.S.&#160;dollar increases relative to foreign
    currencies, our products could become more costly to the
    international consumer and therefore less competitive in
    international markets, which could affect our financial
    performance. In addition, if the value of the U.S.&#160;dollar
    decreases relative to the Singapore dollar, it would become more
    costly in U.S.&#160;dollars for us to manufacture our products
    in Singapore. Furthermore, fluctuations in exchange rates could
    reduce our revenue, particularly with respect to grant revenue
    under agreements in Singapore, and affect demand for our
    products. Engaging in international business inherently involves
    a number of other difficulties and risks, including:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    required compliance with existing and changing foreign
    regulatory requirements and laws;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    export or import restrictions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    laws and business practices favoring local companies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    longer payment cycles and difficulties in enforcing agreements
    and collecting receivables through certain foreign legal systems;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    political and economic instability;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    potentially adverse tax consequences, tariffs, customs charges,
    bureaucratic requirements and other trade barriers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties and costs of staffing and managing foreign
    operations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties protecting or procuring intellectual property
    rights.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If one or more of these risks occurs, it could require us to
    dedicate significant resources to remedy, and if we are
    unsuccessful in finding a solution, our financial results will
    suffer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We use hazardous chemicals and biological materials in our
    business. Any claims relating to improper handling, storage or
    disposal of these materials could be time consuming and
    costly.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development and manufacturing processes involve
    the controlled use of hazardous materials, including flammables,
    toxics, corrosives and biologics. Our operations produce
    hazardous biological and chemical waste products. We cannot
    eliminate the risk of accidental contamination or discharge and
    any resultant injury from these materials. In addition, our IFC
    systems involve the use of pressurized systems and may involve
    the use of hazardous materials, which could result in injury. We
    may be sued for any injury or contamination that results from
    our use or the use by third parties of these materials. We do
    not currently maintain separate environmental liability
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     coverage and any such contamination or discharge could result
    in significant cost to us in penalties, damages and suspension
    of our operations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If our facilities become inoperable, we will be unable to
    continue manufacturing our products and as a result, our
    business will be harmed until we are able to secure a new
    facility.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We manufacture and assemble our IFCs for commercial sale at our
    facility in Singapore and assemble our instrument platforms at
    our facilities in Singapore and South San&#160;Francisco,
    California. No other manufacturing or assembly facilities are
    currently available to us. Our facilities and the equipment we
    use to manufacture our products would be costly to replace and
    could require substantial lead time to repair or replace. The
    facilities may be harmed or rendered inoperable by natural or
    man-made disasters, including earthquakes, flooding and power
    outages, which may render it difficult or impossible for us to
    perform our research, development and manufacturing for some
    period of time. The inability to perform our research,
    development and manufacturing activities, combined with our
    limited inventory of reserve raw materials and manufactured
    supplies, may result in the loss of customers or harm our
    reputation, and we may be unable to reestablish relationships
    with those customers in the future. Although we possess
    insurance for damage to our property and the disruption of our
    business, this insurance may not be sufficient to cover all of
    our potential losses and may not continue to be available to us
    on acceptable terms, or at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we fail to maintain effective internal control over
    financial reporting in the future, the accuracy and timing of
    our financial reporting may be adversely affected.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the audit of our consolidated financial
    statements for the years ended December&#160;31, 2005 and 2006
    we, together with our independent registered public accounting
    firm identified material weaknesses in our internal control over
    financial reporting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The material weaknesses related to our financial statement close
    process, revenue recognition and accrual processes and inventory
    costing, cost of sales, purchases cut-off and stock-based
    compensation. These material weaknesses resulted in the
    recording of numerous audit adjustments over the two year period
    ending December&#160;31, 2006. Since the date of our independent
    registered public accounting firm&#146;s reports on our
    consolidated financial statements for the years ended
    December&#160;31, 2005 and 2006 and through the date of this
    prospectus, we have taken steps intended to remediate these
    material weaknesses, primarily through the hiring of additional
    accounting and finance personnel with technical accounting and
    financial reporting experience. In addition, we have implemented
    procedures and controls in the financial statement close process
    designed to improve the accuracy and timeliness in financial
    accounting and reporting.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April and May 2008, we reviewed our internal control over
    financial reporting and concluded that we had certain
    significant deficiencies. A significant deficiency is defined as
    a deficiency, or combination of deficiencies, in internal
    control over financial reporting that is less severe than a
    material weakness, yet important enough to merit attention by
    those responsible for oversight of a company&#146;s financial
    reporting. The significant deficiencies identified by us related
    to: our controls for the consolidation and elimination entries
    relating to intercompany transfer pricing and elimination of
    intercompany profits embedded in deferred costs of our Japanese
    subsidiary; our controls for applying SFAS&#160;123R to option
    grants with non-standard vesting terms and validation of stock
    compensation expenses calculated by our option tracking
    software; and our controls and procedures for the valuation of
    inventory.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not know the specific time frame that we will require to
    remediate the significant deficiencies identified. In addition,
    we expect to incur some incremental costs associated with this
    remediation. If we fail to enhance our internal control over
    financial reporting to meet the demands that will be placed upon
    us as a public company, including the requirements of the
    Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, we may be
    unable to report our financial results accurately and prevent
    fraud. While we expect to remediate the significant
    deficiencies, we cannot assure you that we will be able to do so
    in a timely manner, which could impair our ability to accurately
    and timely report our financial position, results of operations
    or cash flows.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     No material weaknesses in internal control over financial
    reporting were identified in our April 2008 review. However, our
    management and independent registered public accounting firm did
    not perform an evaluation of our internal control over financial
    reporting during any period in accordance with the provisions of
    Section&#160;404 of the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sarbanes-Oxley Act. Had we and our independent registered public
    accounting firm performed an evaluation of our internal control
    over financial reporting in accordance with the provisions of
    Section&#160;404 of the Sarbanes-Oxley Act, additional control
    deficiencies may have been identified by management or our
    independent registered public accounting firm.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We will incur significant increased costs as a result of
    operating as a public company, and our management will be
    required to devote substantial time to new compliance
    initiatives.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have never operated as a public company. As a public company,
    we will incur significant legal, accounting and other expenses
    that we did not incur as a private company. In addition, the
    Sarbanes-Oxley Act, as well as new rules subsequently
    implemented by the Securities and Exchange Commission and the
    NASDAQ Global Market, have imposed various new requirements on
    public companies, including requiring changes in corporate
    governance practices. Our management and other personnel will
    need to devote a substantial amount of time to these new
    compliance initiatives. Moreover, these rules and regulations
    will increase our legal and financial compliance costs and will
    make some activities more time-consuming and costly. For
    example, we expect these new rules and regulations to make it
    more difficult and more expensive for us to obtain director and
    officer liability insurance and we may be required to incur
    substantial costs to maintain the same or similar coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the Sarbanes-Oxley Act requires, among other
    things, that we maintain effective internal control over
    financial reporting and disclosure controls and procedures. In
    particular, commencing in 2009, we must perform system and
    process evaluation and testing of our internal control over
    financial reporting to allow management to report on the
    effectiveness of our internal control over financial reporting,
    as required by Section&#160;404 of the Sarbanes-Oxley Act. Our
    testing, or the subsequent testing by our independent registered
    public accounting firm, may reveal deficiencies in our internal
    control over financial reporting that are deemed to be material
    weaknesses. Our compliance with Section&#160;404 will require
    that we incur substantial accounting expense and expend
    significant management time on compliance-related issues. We
    currently do not have an internal audit group and we will
    evaluate the need to hire additional accounting and financial
    staff with appropriate public company experience and technical
    accounting knowledge. Moreover, if we are not able to comply
    with the requirements of Section&#160;404 in a timely manner, or
    if we or our independent registered public accounting firm
    identifies deficiencies in our internal control over financial
    reporting that are deemed to be material weaknesses, the market
    price of our stock could decline and we could be subject to
    sanctions or investigations by the NASDAQ Global Market, the
    Securities and Exchange Commission or other regulatory
    authorities, which would require additional financial and
    management resources.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Some of our programs are partially supported by government
    grants, which may be reduced, withdrawn, delayed or
    reclaimed.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have received and may continue to receive funds under
    research and economic development programs funded by the
    governments of Singapore and the United States. Funding by these
    governments may be significantly reduced or eliminated in the
    future for a number of reasons. For example, some
    U.S.&#160;programs are subject to a yearly appropriations
    process in Congress. Similarly, our grants from the Singapore
    government are part of an official policy to develop a life
    science industry in Singapore; that policy could change or the
    role of grants in it could be reduced or eliminated at any time.
    In addition, we may not receive funds under existing or future
    grants because of budgeting constraints of the agency
    administering the program. A restriction on the government
    funding available to us would reduce the resources that we would
    be able to devote to existing and future research and
    development efforts. Such a reduction could delay the
    introduction of new products and hurt our competitive position.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our agreements with the Singapore Economic Development Board, or
    EDB, provide that our continued eligibility for reimbursements
    is subject to our operation of increasing levels of research,
    development and manufacturing in Singapore, including the use of
    local service providers, the hiring of personnel in Singapore,
    the incurrence of research and development expenses in
    Singapore, our receipt of new investment in our company and our
    achievement of certain milestones relating to the development of
    our products. These agreements further provide EDB with the
    right to demand repayment of a portion of past grants in the
    event that it concludes that we have not met our obligations
    under the applicable agreements. Based on correspondence with
    EDB, we believe that we have satisfied the conditions applicable
    to our EDB grant revenue through March&#160;29, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our ability to use net operating losses to offset future
    taxable income may be subject to certain limitations.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Section&#160;382 of the Internal Revenue Code,
    a corporation that undergoes an &#147;ownership change&#148; is
    subject to limitations on its ability to utilize its pre-change
    net operating losses or NOLs to offset future taxable income.
    Our existing NOLs may be subject to limitations arising from
    previous ownership changes, and if we undergo an ownership
    change in connection with or after this offering, our ability to
    utilize NOLs could be further limited by Section&#160;382 of the
    Internal Revenue Code. Future changes in our stock ownership,
    some of which are outside of our control, could result in an
    ownership change under Section&#160;382 of the Internal Revenue
    Code. We may not be able to utilize a material portion of the
    NOLs reflected on our balance sheet and for this reason, we have
    fully reserved against the value of our NOLs on our balance
    sheet.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Intellectual Property</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our ability to protect our intellectual property and
    proprietary technology through patents and other means is
    uncertain.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our ability to
    protect our intellectual property and proprietary technologies.
    We rely on patent protection, where appropriate and available,
    as well as a combination of copyright, trade secret and
    trademark laws, and nondisclosure, confidentiality and other
    contractual restrictions to protect our proprietary technology.
    However, these legal means afford only limited protection and
    may not adequately protect our rights or permit us to gain or
    keep any competitive advantage. Our pending U.S.&#160;and
    foreign patent applications may not issue as patents or may not
    issue in a form that will be advantageous to us. Any patents we
    have obtained or do obtain may be subject to re-examination,
    reissue, opposition or other administrative proceeding, or may
    be challenged in litigation, and such challenges could result in
    a determination that the patent is invalid or unenforceable. In
    addition, competitors may be able to design alternative methods
    or devices that avoid infringement of our patents. To the extent
    our intellectual property, including licensed intellectual
    property, offers inadequate protection, or is found to be
    invalid or unenforceable, we are exposed to a greater risk of
    direct competition. If our intellectual property does not
    provide adequate protection against our competitors&#146;
    products, our competitive position could be adversely affected,
    as could our business. Both the patent application process and
    the process of managing patent disputes can be time consuming
    and expensive. Furthermore, the laws of some foreign countries
    may not protect our intellectual property rights to the same
    extent as do the laws of the United States.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The patent positions of life science companies can be highly
    uncertain and involve complex legal and factual questions for
    which important legal principles remain unresolved. No
    consistent policy regarding the breadth of claims allowed in
    such companies&#146; patents has emerged to date in the United
    States. The laws of some
    <FONT style="white-space: nowrap">non-U.S.&#160;countries</FONT>
    do not protect intellectual property rights to the same extent
    as the laws of the United States, and many companies have
    encountered significant problems in protecting and defending
    such rights in foreign jurisdictions. The legal systems of
    certain countries, particularly certain developing countries, do
    not favor the enforcement of patents and other intellectual
    property protection, particularly those relating to
    biotechnology, which could make it difficult for us to stop the
    infringement of our patents. Proceedings to enforce our patent
    rights in foreign jurisdictions could result in substantial cost
    and divert our efforts and attention from other aspects of our
    business. Changes in either the patent laws or in
    interpretations of patent laws in the United States or other
    countries may diminish the value of our intellectual property.
    We cannot predict the breadth of claims that may be allowed or
    enforced in our patents or in third-party patents. For example:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We might not have been the first to make the inventions covered
    by each of our pending patent applications.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We might not have been the first to file patent applications for
    these inventions.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Others may independently develop similar or alternative products
    and technologies or duplicate any of our products and
    technologies.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    It is possible that none of our pending patent applications will
    result in issued patents, and even if they issue as patents,
    they may not provide a basis for commercially viable products,
    or may not provide us with any competitive advantages, or may be
    challenged and invalidated by third parties.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We may not develop additional proprietary products and
    technologies that are patentable.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The patents of others may have an adverse effect on our business.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We apply for patents covering our products and technologies and
    uses thereof, as we deem appropriate. However, we may fail to
    apply for patents on important products and technologies in a
    timely fashion or at all.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to pursuing patents on our technology, we take steps
    to protect our intellectual property and proprietary technology
    by entering into confidentiality agreements and intellectual
    property assignment agreements with our employees, consultants,
    corporate partners and, when needed, our advisors. Such
    agreements may not be enforceable or may not provide meaningful
    protection for our trade secrets or other proprietary
    information in the event of unauthorized use or disclosure or
    other breaches of the agreements, and we may not be able to
    prevent such unauthorized disclosure. Monitoring unauthorized
    disclosure is difficult, and we do not know whether the steps we
    have taken to prevent such disclosure are, or will be, adequate.
    If we were to enforce a claim that a third party had illegally
    obtained and was using our trade secrets, it would be expensive
    and time consuming, and the outcome would be unpredictable. In
    addition, courts outside the United States may be less willing
    to protect trade secrets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We depend on certain technologies that are licensed to us.
    We do not control these technologies and any loss of our rights
    to them could prevent us from selling our products.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on licenses in order to be able to use various
    proprietary technologies that are material to our business,
    including our core integrated fluidic circuit and multi-layer
    soft lithography technologies. We do not own the patents that
    underlie these licenses. Our rights to use these technologies
    and employ the inventions claimed in the licensed patents are
    subject to the negotiation of, continuation of and compliance
    with the terms of those licenses. In some cases, we do not
    control the prosecution, maintenance, or filing of the patents
    to which we hold licenses, or the enforcement of these patents
    against third parties. Some of our patents and patent
    applications were either acquired from another company who
    acquired those patents and patent applications from yet another
    company, or are licensed from a third party. Thus, these patents
    and patent applications are not written by us or our attorneys,
    and we did not have control over the drafting and prosecution.
    The former patent owners and our licensors might not have given
    the same attention to the drafting and prosecution of these
    patents and applications as we would have if we had been the
    owners of the patents and applications and had control over the
    drafting and prosecution. We cannot be certain that drafting
    <FONT style="white-space: nowrap">and/or</FONT>
    prosecution of the licensed patents and patent applications by
    the licensors have been or will be conducted in compliance with
    applicable laws and regulations or will result in valid and
    enforceable patents and other intellectual property rights.
    Enforcement of our licensed patents or defense or any claims
    asserting the invalidity of these patents is often subject to
    the control or cooperation of our licensors. Certain of our
    licenses contain provisions that allow the licensor to terminate
    the license upon specific conditions. Our rights under the
    licenses are subject to our continued compliance with the terms
    of the license, including the payment of royalties due under the
    license. Because of the complexity of our products and the
    patents we have licensed, determining the scope of the license
    and related royalty obligation can be difficult and can lead to
    disputes between us and the licensor. An unfavorable resolution
    of such a dispute could lead to an increase in the royalties
    payable pursuant to the license. If a licensor believed we were
    not paying the royalties due under the license or were otherwise
    not in compliance with the terms of the license, the licensor
    might attempt to revoke the license. If such an attempt were
    successful, we might be barred from producing and selling some
    or all of our products.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are subject to certain U.S.&#160;government regulations
    because we have licensed technologies that were developed with
    U.S.&#160;government grants. These licenses provide that
    products embodying the technologies will be manufactured
    substantially in the United States. If this domestic
    manufacturing requirement is not met, the government agency that
    funded the relevant grant is entitled to exercise specified
    rights, referred to as march-in rights, which if exercised would
    allow the government agency to require the licensors or us to
    grant a non-exclusive, partially exclusive or exclusive license
    in any field of use to a third party designated by such agency.
    The federal regulations allow the funding government agency to
    grant, at the request of the licensors of such technology, a
    waiver of the domestic manufacturing requirement. Most of our
    products, including all of our commercial IFCs, incorporate
    technologies that were developed with U.S.&#160;government
    grants and are currently manufactured in Singapore. We are
    assisting the licensors of these technologies with the analysis
    of both the domestic manufacturing requirement and the
    preparation of any associated waiver requests. If it were to be
    determined that we are in violation of the domestic
    manufacturing requirement and a waiver of such requirement was
    either not requested or
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     not granted, then the U.S.&#160;government could exercise its
    march-in rights. In such event, our sales and manufacturing
    could be materially disrupted, and our business, operations and
    financial condition could suffer materially.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be involved in lawsuits to protect or enforce our
    patents and proprietary rights and to determine the scope,
    coverage and validity of others&#146; proprietary rights.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Litigation may be necessary to enforce our patent and
    proprietary rights
    <FONT style="white-space: nowrap">and/or</FONT> to
    determine the scope, coverage and validity of others&#146;
    proprietary rights. Litigation on these matters has been
    prevalent in our industry and we expect that this will continue.
    To determine the priority of inventions, we may have to initiate
    and participate in interference and re-examination proceedings
    declared by the U.S.&#160;Patent and Trademark Office that could
    result in substantial legal fees and could substantially affect
    the scope of our patent protection. Also, our intellectual
    property may be subject to significant administrative and
    litigation proceedings such as invalidity, unenforceability and
    opposition proceedings against our patents. The outcome of any
    litigation or interference proceeding might not be favorable to
    us, and we might not be able to obtain licenses to technology
    that we require. Even if such licenses are obtainable, they may
    not be available at a reasonable cost. In addition, if we resort
    to legal proceedings to enforce our intellectual property rights
    or to determine the validity, scope and coverage of the
    intellectual property or other proprietary rights of others, the
    proceedings could be burdensome and expensive, even if we were
    to prevail. Any litigation that may be necessary in the future
    could result in substantial costs and diversion of resources and
    could have a material adverse effect on our business, operating
    results or financial condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Litigation, other proceedings or third party claims of
    intellectual property infringement could require us to spend
    significant time and money and could prevent us from selling our
    products or services or impact our stock price.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our
    non-infringement of the patents or proprietary rights of third
    parties. Third parties have asserted and may assert in the
    future that we are employing their proprietary technology
    without authorization. Competitors may assert that our products
    infringe their intellectual property rights as part of a
    business strategy to impede our successful entry into those
    markets. For example, numerous significant intellectual property
    issues have been litigated between existing and new participants
    in the PCR market, including litigation initiated by Applied
    Biosystems, Inc., one of our competitors. In addition, our
    competitors and others may have patents or may in the future
    obtain patents and claim that use of our products infringes
    these patents. We could incur substantial costs and divert the
    attention of our management and technical personnel in defending
    against any of these claims. Parties making claims against us
    may be able to obtain injunctive or other relief, which could
    block our ability to develop, commercialize and sell products,
    and could result in the award of substantial damages against us.
    In the event of a successful claim of infringement against us,
    we may be required to pay damages and obtain one or more
    licenses from third parties, or be prohibited from selling
    certain products. We may not be able to obtain these licenses at
    a reasonable cost, if at all. We could therefore incur
    substantial costs related to royalty payments for licenses
    obtained from third parties, which could negatively affect our
    gross margins. In addition, we could encounter delays in product
    introductions while we attempt to develop alternative methods or
    products to avoid infringing third-party patents or proprietary
    rights. Defense of any lawsuit or failure to obtain any of these
    licenses on favorable terms could prevent us from
    commercializing products, and the prohibition of sale of any of
    our products could materially affect our ability to grow and
    gain market acceptance for our products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Furthermore, because of the substantial amount of discovery
    required in connection with intellectual property litigation,
    there is a risk that some of our confidential information could
    be compromised by disclosure during this type of litigation. In
    addition, during the course of this kind of litigation, there
    could be public announcements of the results of hearings,
    motions or other interim proceedings or developments. If
    securities analysts or investors perceive these results to be
    negative, it could have a substantial adverse effect on the
    price of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be subject to damages resulting from claims that we
    or our employees have wrongfully used or disclosed alleged trade
    secrets of our employees&#146; former employers.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Many of our employees were previously employed at universities
    or other life science companies, including our competitors or
    potential competitors. Although no claims against us are
    currently pending, we may be subject to claims that these
    employees or we have inadvertently or otherwise used or
    disclosed trade secrets or other
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    proprietary information of their former employers. Litigation
    may be necessary to defend against these claims. If we fail in
    defending such claims, in addition to paying monetary damages,
    we may lose valuable intellectual property rights or personnel.
    A loss of key research personnel or their work product could
    hamper or prevent our ability to commercialize certain potential
    products, which could severely harm our business. Even if we are
    successful in defending against these claims, litigation could
    result in substantial costs and be a distraction to management.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Our Common Stock and this Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We expect that our stock price will fluctuate
    significantly, and you may not be able to resell your shares at
    or above the initial public offering price.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for
    shares of our common stock. We cannot predict the extent to
    which investor interest in our company will lead to the
    development of an active trading market on the NASDAQ Global
    Market or otherwise or how liquid that market might become. If
    an active trading market does not develop, you may have
    difficulty selling any of our shares of common stock that you
    buy. We and the underwriters will determine the initial public
    offering price of our common stock through negotiation. This
    price will not necessarily reflect the price at which investors
    in the market will be willing to buy and sell our shares
    following this offering. In addition, the trading price of our
    common stock following this offering may be highly volatile and
    could be subject to wide fluctuations in response to various
    factors, some of which are beyond our control. These factors
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    actual or anticipated quarterly variation in our results of
    operations or the results of our competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announcements by us or our competitors of new commercial
    products, significant contracts, commercial relationships or
    capital commitments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    issuance of new or changed securities analysts&#146; reports or
    recommendations for our stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    developments or disputes concerning our intellectual property or
    other proprietary rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    commencement of, or our involvement in, litigation;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market conditions in the life science sector;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any major change in our Board or management;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    general economic conditions and slow or negative growth of our
    markets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The trading market for our common stock will rely in part on the
    research and reports that equity research analysts publish about
    us and our business. We do not control these analysts or the
    content and opinions included in their reports. Securities
    analysts may elect not to provide research coverage of our
    common stock after the completion of this offering, and such
    lack of research coverage may adversely affect the market price
    of our common stock. The price of our stock could decline if one
    or more equity research analysts downgrade our stock or if those
    analysts issue other unfavorable commentary or cease publishing
    reports about us or our business. If one or more equity research
    analysts ceases coverage of our company, we could lose
    visibility in the market, which in turn could cause our stock
    price to decline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Purchasers in this offering will experience immediate and
    substantial dilution in the book value of their
    investment.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial public offering price of our common stock is
    substantially higher than the net tangible book value per share
    of our common stock immediately after this offering. Therefore,
    if you purchase our common stock in this offering, you will
    incur an immediate dilution of $&#160;&#160;&#160;&#160;&#160;
    in net tangible book value per share from the price you paid,
    based on an assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the mid-point of the
    range set forth on the cover page of this prospectus. In
    addition, new investors who purchase shares in this offering
    will contribute approximately&#160;&#160;&#160;&#160;&#160;% of
    the total amount of equity capital raised by us through the date
    of this offering, but will only own
    approximately&#160;&#160;&#160;&#160;&#160;% of the outstanding
    share capital and approximately&#160;&#160;&#160;&#160;&#160;%
    of the voting rights. The exercise of outstanding options and
    warrants will result in further dilution. For a further
    description of the dilution that you will experience immediately
    after this offering, see &#147;Dilution.&#148;
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Future sales of shares by existing stockholders could
    cause our stock price to decline.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our existing stockholders sell, or indicate an intention to
    sell, substantial amounts of our common stock in the public
    market after the
    <FONT style="white-space: nowrap">lock-up</FONT> and
    other legal restrictions on resale discussed in this prospectus
    lapse, the trading price of our common stock could decline.
    Based on shares outstanding as of April&#160;30, 2008, upon
    completion of this offering, we will have outstanding a total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock, assuming no exercise of the underwriters&#146;
    over-allotment option. Of these shares, only
    the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock sold in this offering by us will be freely
    tradable, without restriction, in the public market immediately
    after the offering. Each of our directors and officers, and
    certain of our stockholders, have entered into
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements with the underwriters that restrict their ability to
    sell or transfer their shares. The
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements pertaining to this offering will expire 180&#160;days
    from the date of this prospectus, although they may be extended
    for up to an additional 34&#160;days under certain
    circumstances. Our underwriters, however, may, in their sole
    discretion, permit our officers, directors and other current
    stockholders who are subject to the contractual
    <FONT style="white-space: nowrap">lock-up</FONT> to
    sell shares prior to the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements. After the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements expire, based on shares outstanding as of
    April&#160;30, 2008, up to an additional 68,101,494&#160;shares
    of common stock will be eligible for sale in the public
    market,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    of which are held by directors, executive officers and other
    affiliates and will be subject to volume limitations under
    Rule&#160;144 under the Securities Act and various vesting
    agreements. In
    addition,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock that are subject to outstanding options as of
    April&#160;30, 2008 will become eligible for sale in the public
    market to the extent permitted by the provisions of various
    vesting agreements, the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements and Rules&#160;144 and 701 under the Securities Act.
    If these additional shares are sold, or if it is perceived that
    they will be sold, in the public market, the trading price of
    our common stock could decline.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our directors and executive officers will continue to have
    substantial control over us after this offering and could limit
    your ability to influence the outcome of key transactions,
    including changes of control.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers, directors and their affiliates will
    beneficially own or control
    approximately&#160;&#160;&#160;&#160;&#160;% of the outstanding
    shares of our common stock, following the completion of this
    offering. Accordingly, these executive officers, directors and
    their affiliates, acting as a group, will have substantial
    influence over the outcome of corporate actions requiring
    stockholder approval, including the election of directors, any
    merger, consolidation or sale of all or substantially all of our
    assets or any other significant corporate transactions. These
    stockholders may also delay or prevent a change of control of
    us, even if such a change of control would benefit our other
    stockholders. The significant concentration of stock ownership
    may adversely affect the trading price of our common stock due
    to investors&#146; perception that conflicts of interest may
    exist or arise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Anti-takeover provisions in our charter documents and
    under Delaware law could make an acquisition of us, which may be
    beneficial to our stockholders, more difficult and may prevent
    attempts by our stockholders to replace or remove our current
    management and limit the market price of our common
    stock.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Provisions in our certificate of incorporation and bylaws, as
    amended and restated upon the closing of this offering, may have
    the effect of delaying or preventing a change of control or
    changes in our management. Our amended and restated certificate
    of incorporation and amended and restated bylaws to become
    effective upon completion of this offering include provisions
    that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    authorize our Board of Directors to issue, without further
    action by the stockholders, up to 20,000,000&#160;shares of
    undesignated preferred stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require that any action to be taken by our stockholders be
    effected at a duly called annual or special meeting and not by
    written consent;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that special meetings of our stockholders can be called
    only by our Board of Directors, the Chairman of the Board, the
    Chief Executive Officer or the President;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish an advance notice procedure for stockholder approvals
    to be brought before an annual meeting of our stockholders,
    including proposed nominations of persons for election to our
    Board of Directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish that our Board of Directors is divided into three
    classes, Class&#160;I, Class&#160;II and Class&#160;III, with
    each class serving staggered terms;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that our directors may be removed only for cause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that vacancies on our Board of Directors may be filled
    only by a majority of directors then in office, even though less
    than a quorum;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that no stockholder is permitted to cumulate votes at
    any election of directors;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require a super-majority of votes to amend certain of the
    above-mentioned provisions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These provisions may frustrate or prevent any attempts by our
    stockholders to replace or remove our current management by
    making it more difficult for stockholders to replace members of
    our Board of Directors, which is responsible for appointing the
    members of our management. In addition, because we are
    incorporated in Delaware, we are governed by the provisions of
    Section&#160;203 of the Delaware General Corporation Law, which
    limits the ability of stockholders owning in excess of 15% of
    our outstanding voting stock to merge or combine with us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have broad discretion in the use of the net proceeds
    from this offering and may not use them effectively.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will have broad discretion in the application of the net
    proceeds from this offering and could spend the proceeds in ways
    that do not improve our results of operations or enhance the
    value of our common stock. Our failure to apply these funds
    effectively could have a material adverse effect on our
    business, delay the development of our product candidates and
    cause the price of our common stock to decline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have never paid dividends on our capital stock, and we
    do not anticipate paying any cash dividends in the foreseeable
    future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have paid no cash dividends on any of our classes of capital
    stock to date, have contractual restrictions against paying cash
    dividends and currently intend to retain our future earnings to
    fund the development and growth of our business. As a result,
    capital appreciation, if any, of our common stock will be your
    sole source of gain for the foreseeable future.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='103'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SPECIAL
    NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus includes forward-looking statements that relate
    to future events or our future financial performance and involve
    known and unknown risks, uncertainties and other factors that
    may cause our actual results, levels of activity, performance or
    achievements to differ materially from any future results,
    levels of activity, performance or achievements expressed or
    implied by these forward-looking statements. Words such as, but
    not limited to, &#147;believe,&#148; &#147;expect,&#148;
    &#147;anticipate,&#148; &#147;estimate,&#148;
    &#147;intend,&#148; &#147;plan,&#148; &#147;targets,&#148;
    &#147;likely,&#148; &#147;will,&#148; &#147;would,&#148;
    &#147;could,&#148; and similar expressions or phrases, or the
    negative of those expressions or phrases identify
    forward-looking statements. Although we believe that we have a
    reasonable basis for each forward-looking statement contained in
    this prospectus, we caution you that these statements are based
    on our projections of the future that are subject to known and
    unknown risks and uncertainties and other factors that may cause
    our actual results, level of activity, performance or
    achievements expressed or implied by these forward-looking
    statements, to differ. The sections in this prospectus entitled
    &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    and &#147;Business,&#148; as well as other sections in this
    prospectus, discuss some of the factors that could contribute to
    these differences.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other unknown or unpredictable factors also could harm our
    results. Consequently, actual results or developments
    anticipated by us may not be realized or, even if substantially
    realized, may not have the expected consequences to, or effects
    on, us. Given these uncertainties, prospective investors are
    cautioned not to place undue reliance on such forward-looking
    statements. Except as required by law, we undertake no
    obligation to update or revise publicly any of the
    forward-looking statements after the date of this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus contains market data that we obtained from
    industry sources. These sources do not guarantee the accuracy or
    completeness of the information. Although we believe that the
    industry sources are reliable, we have not independently
    verified the information. The market data include projections
    that are based on a number of projections. While we believe
    these assumptions to be reasonable and sound as of the date of
    this prospectus, if these assumptions turn out to be incorrect,
    actual results may differ from the projections based on these
    assumptions.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='104'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">USE OF
    PROCEEDS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate that the net proceeds from the sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock that we are selling in this offering will be
    $&#160;&#160;&#160;&#160;&#160;&#160;million, based on an
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses. A $1.00 increase (decrease) in the
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share would increase
    (decrease) the net proceeds to us by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, after deducting
    estimated underwriting discounts and commissions and estimated
    offering expenses, assuming that the number of shares offered by
    us, as set forth on the cover page of this prospectus, remains
    the same. We may also increase or decrease the number of shares
    we are offering. An increase of 1.0&#160;million shares in the
    number of shares offered by us would increase the net proceeds
    to us by $&#160;&#160;&#160;&#160;&#160;&#160;million.
    Similarly, a decrease of 1.0&#160;million shares in the number
    of shares offered by us would decrease the net proceeds to us by
    $&#160;&#160;&#160;&#160;&#160;&#160;million. If the
    underwriters&#146; over-allotment option is exercised in full,
    we estimate that we will receive net proceeds of
    $&#160;&#160;&#160;&#160;&#160;&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Of the net proceeds that we will receive from this offering, we
    expect to use approximately:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $&#160;&#160;&#160;&#160;&#160;&#160;million for sales and
    marketing initiatives, including significantly expanding our
    sales force, to support the ongoing commercialization of our
    products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $&#160;&#160;&#160;&#160;&#160; for research and product
    development activities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $&#160;&#160;&#160;&#160;&#160;&#160;million to expand our
    facilities and manufacturing operations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the balance for working capital and other general corporate
    purposes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may also use a portion of our net proceeds to acquire and
    invest in complementary products, technologies or businesses;
    however, we currently have no agreements or commitments to
    complete any such transaction and are not involved in
    negotiations to do so. Pending these uses, we intend to invest
    our net proceeds from this offering primarily in
    investment-grade, interest-bearing instruments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of the date of this prospectus, we cannot specify with
    certainty all of the particular uses for the net proceeds to be
    received upon the completion of this offering. The amount and
    timing of our expenditures will depend on several factors,
    including cash flows from our operations and the anticipated
    growth of our business. Accordingly, our management will have
    broad discretion in the application of the net proceeds and
    investors will be relying on the judgment of our management
    regarding the application of the proceeds from this offering. We
    reserve the right to change the use of these proceeds as a
    result of certain contingencies such as the results of our
    commercialization efforts, competitive developments,
    opportunities to acquire products, technologies or businesses
    and other factors.
</DIV>
<A name='105'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DIVIDEND
    POLICY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have never declared or paid any cash dividends on our capital
    stock. We currently intend to retain all future earnings for the
    operation and expansion of our business and, therefore, we do
    not anticipate declaring or paying cash dividends in the
    foreseeable future. The payment of dividends will be at the
    discretion of our Board of Directors and will depend on our
    results of operations, capital requirements, financial
    condition, prospects, contractual arrangements, any limitations
    on payment of dividends present in our current and future debt
    agreements, and other factors that our Board of Directors may
    deem relevant. In addition, we are subject to several covenants
    under our debt arrangements that place restrictions on our
    ability to pay dividends.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='106'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CAPITALIZATION</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our capitalization as of
    March&#160;29, 2008:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on an actual basis;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma basis to give effect to (1)&#160;the conversion
    of principal and accrued interest on a convertible promissory
    note held by Biomedical Sciences Investment Fund Pte Ltd into
    1,503,945&#160;shares of our Series&#160;E preferred stock on
    April&#160;30, 2008, (2) the conversion of all outstanding
    shares of convertible preferred stock into common stock and
    (3)&#160;the reclassification of the convertible preferred stock
    warrant liabilities to additional
    <FONT style="white-space: nowrap">paid-in-capital,</FONT>
    each effective upon the closing of this offering;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma as adjusted basis to also give effect to the pro
    forma conversions and reclassifications described above and the
    sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock in this offering and the application of the
    net proceeds at the assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should read this table together with &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#148; and our consolidated financial statements and
    related notes included elsewhere in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="66%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of March&#160;29, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>as
    Adjusted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(unaudited)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt, net of current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock issuable in series, $0.001&#160;par
    value: 61,798&#160;shares authorized, 56,671&#160;shares issued
    and outstanding (actual); no shares authorized, issued or
    outstanding (pro forma and pro forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stockholders&#146; equity (deficit):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Common stock, $0.001&#160;par value: 87,386&#160;shares
    authorized, 9,928&#160;shares issued and outstanding
    (actual);&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    issued and outstanding (pro
    forma);&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    issued and outstanding (pro forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Preferred stock, $0.001 par value: no shares authorized, no
    shares issued
    (actual);&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized, no shares issued (pro forma and pro forma as
    adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in
    capital<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,824
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (344
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (140,411
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total stockholders&#146; equity
    (deficit)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (136,921
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
    capitalization<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">A $1.00 increase (decrease) in the
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, would
    increase (decrease) each of additional paid-in capital, total
    stockholders&#146; equity and total capitalization by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that the
    number of shares offered by us, as set forth on the cover page
    of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions payable by us.
    Each increase of 1.0&#160;million shares in the number of shares
    offered by us, together with a $1.00 increase in the assumed
    offering price of $&#160;&#160;&#160;&#160;&#160; per share,
    would increase additional paid-in capital, total
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">stockholders&#146; equity and total
    capitalization by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. Similarly, each
    decrease of 1.0&#160;million shares in the number of shares
    offered by us, together with a $1.00 decrease in the assumed
    offering price of $&#160;&#160;&#160;&#160;&#160; per share,
    would decrease additional paid-in capital, total
    stockholders&#146; equity and total capitalization by
    approximately $&#160;&#160;&#160;&#160;&#160;&#160;million. The
    pro forma as adjusted information discussed above is
    illustrative only and will adjust based on the actual public
    offering price and terms of this offering determined at pricing.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table above excludes the following shares:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    8,103,050&#160;shares of common stock issuable upon exercise of
    options outstanding as of March&#160;29, 2008 at a weighted
    average exercise price of $0.93&#160;per share;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    598,720&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of March&#160;29, 2008 at a weighted
    average exercise price of $2.97&#160;per share, after conversion
    from preferred stock;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for future issuance under our
    stock-based compensation plans,
    including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for issuance under our 2008 Equity
    Incentive Plan, and any future increase in shares reserved for
    issuance under such plan, each of which will become effective on
    the date of this prospectus; and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    27,084&#160;shares of common stock that were legally issued and
    outstanding but were not included in stockholders&#146; deficit
    as of March&#160;29, 2008 pursuant to accounting principles
    generally accepted in the United States, as these shares were
    subject to a right of repurchase by us.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='107'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DILUTION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you invest in our common stock, your interest will be diluted
    to the extent of the difference between the initial public
    offering price per share of our common stock and the pro forma
    as adjusted net tangible book value per share of our common
    stock immediately after this offering. Net tangible book value
    dilution per share to new investors represents the difference
    between the amount per share paid by purchasers of shares of
    common stock in this offering and the pro forma as adjusted net
    tangible book value per share of common stock immediately after
    completion of this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net tangible book value per share is determined by dividing our
    total tangible assets less our total liabilities by the number
    of shares of common stock outstanding. Our historical net
    tangible book value (deficit) as of March&#160;29, 2008, was
    $25.2&#160;million, or $2.53 per share. Our pro forma net
    tangible book value as of March&#160;29, 2008 was
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or
    $&#160;&#160;&#160;&#160;&#160; per share, based on the total
    number of shares of our common stock outstanding as of
    March&#160;29, 2008, after giving effect to (1)&#160;the
    conversion of an outstanding convertible promissory note into
    1,503,945&#160;shares of common stock, (2)&#160;the conversion
    of all outstanding shares of our convertible preferred stock
    into common stock and (3)&#160;the reclassification of the
    convertible preferred stock warrant liabilities to additional
    <FONT style="white-space: nowrap">paid-in-capital,</FONT>
    each effective upon the closing of this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After giving effect to our sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock in this offering at an assumed initial public
    offering price of $&#160;&#160;&#160;&#160;&#160; per share, the
    midpoint of the range set forth on the cover page of this
    prospectus, and after deducting the estimated underwriting
    discounts and commissions and estimated offering expenses, our
    pro forma as adjusted net tangible book value as of
    March&#160;29, 2008 would have been
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or
    $&#160;&#160;&#160;&#160;&#160; per share. This represents an
    immediate increase in net tangible book value of
    $&#160;&#160;&#160;&#160;&#160; per share to existing
    stockholders and an immediate dilution in net tangible book
    value of $&#160;&#160;&#160;&#160;&#160; per share to purchasers
    of common stock in this offering, as illustrated in the
    following table:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Assumed initial public offering price per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Historical net tangible book value per share as of
    March&#160;29, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.53
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Pro forma as adjusted net tangible book value per share as of
    March&#160;29, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in pro forma as adjusted net tangible book value per
    share attributable to new investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma as adjusted net tangible book value per share after
    this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma dilution per share to new investors in this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each $1.00 increase (decrease) in the assumed public offering
    price of $&#160;&#160;&#160;&#160;&#160; per share, the
    mid-point of the range set forth on the cover of this
    prospectus, would increase (decrease) our pro forma as adjusted
    net tangible book value by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or approximately
    $&#160;&#160;&#160;&#160;&#160; per share, and the pro forma
    dilution per share to investors in this offering by
    approximately $&#160;&#160;&#160;&#160;&#160; per share,
    assuming that the number of shares offered by us, as set forth
    on the cover page of this prospectus, remains the same and after
    deducting estimated underwriting discounts and commissions. We
    may also increase or decrease the number of shares we are
    offering. An increase of 1.0&#160;million shares in the number
    of shares offered by us, together with a $1.00 increase in the
    assumed offering price of $&#160;&#160;&#160;&#160;&#160; per
    share, would result in a pro forma as adjusted net tangible book
    value of approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or
    $&#160;&#160;&#160;&#160;&#160; per share, and the pro forma
    dilution per share to investors in this offering would be
    $&#160;&#160;&#160;&#160;&#160; per share. Similarly, a decrease
    of 1.0&#160;million shares in the number of shares offered by
    us, together with a $1.00 decrease in the assumed public
    offering price of $&#160;&#160;&#160;&#160;&#160; per share,
    would result in an pro forma as adjusted net tangible book value
    of approximately $&#160;&#160;&#160;&#160;&#160;&#160;million,
    or $&#160;&#160;&#160;&#160;&#160; per share, and the pro forma
    dilution per share to investors in this offering would be
    $&#160;&#160;&#160;&#160;&#160; per share. The pro forma as
    adjusted information discussed above is illustrative only and
    will adjust based on the actual public offering price and other
    terms of this offering determined at pricing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the underwriters&#146; over-allotment option is exercised in
    full, the pro forma as adjusted net tangible book value per
    share after this offering would be
    $&#160;&#160;&#160;&#160;&#160; per share, the increase in pro
    forma as adjusted net tangible book value per share to existing
    stockholders would be $&#160;&#160;&#160;&#160;&#160; per share
    and the dilution to new investors purchasing shares in this
    offering would be $&#160;&#160;&#160;&#160;&#160; per share.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents on a pro forma as adjusted basis as
    of March&#160;29, 2008, after giving effect to the automatic
    conversion of all outstanding shares of convertible preferred
    stock into common stock, the differences between the existing
    stockholders and the purchasers of shares in this offering with
    respect to the number of shares purchased from us, the total
    consideration paid and the average price paid per share, and
    before deducting estimated underwriting discounts and
    commissions and estimated offering expenses payable by us (in
    thousands, except per share amounts and percentages):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares Purchased</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total Consideration</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Number</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percent</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percent</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Per Share</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Existing stockholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    New investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Totals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Each $1.00 increase (decrease) in
    the assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share would increase
    (decrease) the total consideration paid to us by new investors
    and total consideration paid to us by all stockholder by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that the
    number of shares offered by us, as set forth on the cover page
    of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions payable by us.
    An increase of 1.0&#160;million shares in the number of shares
    offered by us would increase the total consideration paid to us
    by new investors and total consideration paid to us by all
    stockholder by $&#160;&#160;&#160;&#160;&#160;&#160;million.
    Similarly, a decrease of 1.0&#160;million shares in the number
    of shares offered by us would decrease the total consideration
    paid to us by new investors and total consideration paid to us
    by all stockholder by
    $&#160;&#160;&#160;&#160;&#160;&#160;million.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the underwriters exercise their over-allotment option in
    full, our existing stockholders would
    own&#160;&#160;&#160;&#160;&#160;% and our new investors would
    own&#160;&#160;&#160;&#160;&#160;% of the total number of shares
    of our common stock outstanding after this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table above excludes the following shares:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    8,103,050&#160;shares of common stock issuable upon exercise of
    options outstanding as of March&#160;29, 2008 at a weighted
    average exercise price of $0.93 per share;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    598,720&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of March&#160;29, 2008 at a weighted
    average exercise price of $2.97 per share;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for future issuance under our
    stock-based compensation plans,
    including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for issuance under our 2008 Equity
    Incentive Plan, which will become effective on the date of this
    prospectus; and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    27,084&#160;shares of common stock that were legally issued and
    outstanding but were not included in stockholders&#146; deficit
    as of March&#160;29, 2008 pursuant to accounting principles
    generally accepted in the United States, as these shares were
    subject to a right of repurchase by us.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assuming the exercise in full of the outstanding options and
    warrants, pro forma net tangible book value before this offering
    at March&#160;29, 2008 would be $&#160;&#160;&#160;&#160;&#160;
    per share, and after giving effect to the sale of shares in this
    offering, there would be immediate dilution of
    $&#160;&#160;&#160;&#160;&#160; per share to new investors in
    this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective upon the closing of this offering, an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock will be reserved for future issuance under
    our benefit plans. To the extent that any of these options or
    warrants are exercised, new options are issued under our benefit
    plans or we issue additional shares of common stock in the
    future, there will be further dilution to investors
    participating in this offering.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='108'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SELECTED
    CONSOLIDATED FINANCIAL DATA</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following selected consolidated financial data should be
    read in conjunction with &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    and our consolidated financial statements and related notes
    included elsewhere in this prospectus. We have derived the
    selected consolidated statement of operations data for the years
    ended December&#160;31, 2005, December&#160;31, 2006 and
    December&#160;29, 2007 and the selected consolidated balance
    sheet data as of December&#160;31, 2006 and December&#160;29,
    2007 from our audited consolidated financial statements included
    elsewhere in this prospectus. We have derived the summary
    consolidated statement of operations data for the three months
    ended March&#160;31, 2007 and March&#160;29, 2008 and the
    consolidated balance sheet data as of March&#160;29, 2008 from
    our unaudited consolidated financial statements included
    elsewhere in this prospectus. We have derived the selected
    consolidated statement of operations data for the years ended
    December&#160;31, 2003 and 2004 and the selected consolidated
    balance sheet data as of December&#160;31, 2003, 2004 and 2005
    from our audited consolidated financial statements not included
    in this prospectus. Our historical results are not necessarily
    indicative of the results to be expected for any future period.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2003</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2004</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Consolidated Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,603
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    366
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    527
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,039
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Costs and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    847
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,608
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,473
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,280
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,690
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,037
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,266
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,621
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,510
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,523
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (305
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,227
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (505
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Loss before provision for income taxes and cumulative of change
    in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,334
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,523
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.23
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.98
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Shares used in computing net loss per share of common stock,
    basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Please see Note&#160;2 to our
    audited consolidated financial statements for an explanation of
    the method used to calculate basic and diluted net loss per
    share.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2003</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2004</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Consolidated Balance Sheet Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,874
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,518
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    40,363
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    31,235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,590
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,610
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total long-term debt and convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,910
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,742
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    814
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total stockholder&#146;s deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49,812
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,471
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (83,154
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (136,921
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='109'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT&#146;S
    DISCUSSION AND ANALYSIS OF<BR>
    FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The following discussion and analysis of the financial
    condition and results of our operations should be read in
    conjunction with the consolidated financial statements and
    related notes included elsewhere in this prospectus. This
    discussion contains forward-looking statements that involve
    risks and uncertainties. Our actual results could differ
    materially from those discussed below. Factors that could cause
    or contribute to such differences include, but are not limited
    to, those identified below, and those discussed in the section
    titled &#147;Risk Factors&#148; included elsewhere in this
    prospectus.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in the life science industry. Our Integrated Fluidic Circuits,
    or IFCs, enable the simultaneous performance of thousands of
    biochemical measurements in extremely minute volumes. We created
    this &#147;integrated circuit for biology&#148; by achieving
    unprecedented miniaturization, integration and automation of
    sophisticated liquid handling processes on a single
    microfabricated device. Particularly in large-scale
    experimentation, our IFC systems, consisting of instrumentation,
    software and single-use IFCs, increase throughput, decrease
    costs and enhance sensitivity compared to conventional
    laboratory systems. We have sold our IFCs to over 100 customers,
    including many leading biotechnology and pharmaceutical
    companies, academic institutions, and life science laboratories
    worldwide.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems for a wide range of life
    science applications, including our BioMark system for gene
    expression analysis, genotyping and digital PCR, and our Topaz
    system for protein crystallization. Researchers and clinicians
    have successfully employed our products to help achieve
    breakthroughs in the fields of genetic variation, cellular
    function and structural biology. We believe that the broad
    applicability of our IFC technology will lead to the development
    of IFC systems for a wide variety of additional markets and
    applications, including molecular diagnostics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were founded in 1999. In the first quarter of 2003, we
    introduced our first product line, the Topaz system for protein
    crystallization based on our first generation Topaz IFC. In
    subsequent years, we enhanced the capability of the Topaz system
    by introducing IFCs with increased throughput. Prior to 2007,
    Topaz system products accounted for substantially all of our
    product revenue. In the fourth quarter of 2006, we announced the
    commercial availability of our BioMark system. We currently sell
    two types of single-use IFCs for use with the BioMark system,
    the Dynamic Array for gene expression and genotyping and the
    Digital Array for digital PCR.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have incurred significant losses since our inception,
    including net losses of $16.4&#160;million, $23.6&#160;million,
    $25.5&#160;million and $6.6&#160;million in 2005, 2006, 2007 and
    the three months ended March&#160;29, 2008. As of March&#160;29,
    2008, we had an accumulated deficit of $140.4&#160;million. We
    sell our IFC systems around the world. For 2007 and the three
    months ended March&#160;29, 2008, customers in North America
    accounted for approximately 48% and 51% of our product revenue
    while European customers accounted for 10% and 12% and Asian
    customers accounted for 37% and 31%. We distribute our systems
    through our direct field sales and support organizations located
    in North America, Europe and Asia and through distributors or
    sales agents in several European countries. Our manufacturing
    operations are located in Singapore and South
    San&#160;Francisco. Our facility in Singapore fabricates all of
    our IFCs for commercial sale and some IFCs for our own research
    and development purposes and assembles certain elements of our
    BioMark and Topaz instrumentation. Our South San&#160;Francisco
    facility also assembles certain elements of our BioMark and
    Topaz instrumentation and fabricates IFCs for our own research
    and development purposes.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since 2002, we have received significant revenue from research
    and development agreements and government grants. The most
    significant of these arrangements have been with entities
    associated with the government of Singapore that have helped
    support our establishment of manufacturing facilities in
    Singapore and our research and development activities there. Our
    grant agreements with the Singapore Economic Development Board,
    or EDB, provide that we are eligible to receive reimbursement
    from EDB for a portion of the expenses we incur in Singapore
    during the term of such agreements, including expenses relating
    to our local employees, equipment purchases, materials and
    software, professional service fees and costs. We submit
    reimbursement requests for qualifying
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     expenditures on a quarterly basis. Reimbursement requests are
    subject to review by EDB. Our continued eligibility for such
    reimbursements is subject to our meeting targets for increasing
    levels of research, development and manufacturing activity in
    Singapore, including the use of local service providers, the
    hiring of personnel in Singapore, the incurrence of research and
    development expenses in Singapore, our receipt of new equity
    investment and our achievement of
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    targets relating to new product development or completion of
    specific manufacturing process objectives. Together these
    agreements provide for funding eligibility through 2011, subject
    to our compliance with the requirements of the agreements. In
    addition, we have entered into collaboration and license
    arrangements with other parties that generally provide us with
    up-front and periodic milestone fees or fees based on
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rates for time incurred by our research staff.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fiscal
    Year Presentation</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the year ended December&#160;29, 2007, we adopted a 52 or
    53&#160;week year convention for our fiscal years and,
    therefore, our 2007 fiscal year ended on December&#160;29, 2007
    and the first three-month periods of 2007 and 2008 ended on
    March&#160;31, 2007 and March&#160;29, 2008. Future fiscal years
    will end on the last Saturday in December of each year. Prior to
    the adoption of this method, we reported our fiscal years on a
    calendar basis. The fiscal years discussed in this
    management&#146;s discussion and analysis of financial condition
    and results of operations ended on December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Critical
    Accounting Policies, Significant Judgments and
    Estimates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our consolidated financial statements and the related notes
    included elsewhere in this prospectus are prepared in accordance
    with accounting principles generally accepted in the United
    States. The preparation of these consolidated financial
    statements requires us to make estimates and assumptions that
    affect the reported amounts of assets, liabilities, revenues,
    costs and expenses and related disclosures. We base our
    estimates on historical experience and on various other
    assumptions that we believe to be reasonable under the
    circumstances. Changes in the accounting estimates are
    reasonably likely to occur from period to period. Accordingly,
    actual results could differ significantly from the estimates
    made by our management. We evaluate our estimates and
    assumptions on an ongoing basis. To the extent that there are
    material differences between these estimates and actual results,
    our future financial statement presentation, financial
    condition, results of operations and cash flows will be affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following critical accounting policies
    involve a greater degree of judgment and complexity than our
    other accounting policies. Accordingly, these are the policies
    we believe are the most critical to understanding and evaluating
    our consolidated financial condition and results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generate revenue from sales of our products and services,
    collaboration agreements and government grants. Our products
    consist of single-use IFCs, various instruments and software
    related to our BioMark and Topaz systems. Our services include
    system installation, training and customer support services. We
    also have entered into a number of research and development
    contracts and have received government grants to conduct
    research and development activities.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We record revenue in accordance with the guidelines established
    by the Securities and Exchange Commission, or SEC, Staff
    Accounting Bulletin&#160;No.&#160;104, <I>Revenue
    Recognition</I>, or SAB&#160;104. In addition, we have concluded
    that software included with certain of our instruments is
    essential to their functionality. We apply AICPA Statement of
    Position
    <FONT style="white-space: nowrap">97-2,</FONT>
    <I>Software Revenue Recognition</I>, or
    <FONT style="white-space: nowrap">SOP&#160;97-2.</FONT>
    If the arrangement includes IFCs, we use the separation criteria
    in EITF Issue
    <FONT style="white-space: nowrap">No.&#160;00-21,</FONT>
    <I>Revenue Arrangements with Multiple Deliverables, </I>to
    separate revenues related to IFCs, which are non-software
    related deliverables, from software related deliverables.
    Revenue is recognized when all of the following criteria are
    met: persuasive evidence of an arrangement exists, delivery has
    occurred or services rendered, the price to the buyer is fixed
    or determinable and collectibility is reasonably assured. The
    evaluation of these revenue recognition criteria requires
    significant management judgment. For instance, we use judgment
    to assess collectibility based on factors such as the
    customer&#146;s creditworthiness and past collection history, if
    applicable. If we determine that collection of a payment is not
    reasonably assured, revenue recognition is deferred until the
    time collection becomes reasonably assured, which is generally
    upon receipt of payment. We also use
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     judgment to assess whether a price is fixed or determinable by
    reviewing contractual terms and conditions related to payment
    terms.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, and thereafter, no right of return existed for our
    products. In prior years, if an agreement included a right of
    return, the related revenue was deferred until the right had
    lapsed. Historically, we have not experienced any significant
    returns of our products. Also, accruals are provided for
    estimated warranty expenses at the time that the associated
    revenue is recognized. We use judgment to estimate these
    accruals and, if we were to experience an increase in warranty
    claims or if costs of servicing our products under warranty were
    greater than our estimates, our gross margins could be adversely
    affected in future periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Some of our sales contracts which include items such as our
    BioMark instrument systems or our Topaz readers involve the
    delivery or performance of multiple products and services within
    contractually binding arrangements. Significant contract
    interpretation is sometimes required to determine the
    appropriate accounting, including whether the deliverables
    specified in a multiple element arrangement should be treated as
    separate units of accounting for revenue recognition purposes,
    and, if so, how the price should be allocated among the
    elements, when to recognize revenue for each element, and the
    period over which revenue should be recognized. We use judgment
    to evaluate whether a delivered item has value on a stand-alone
    basis prior to delivery of the remaining items by determining
    whether we have made separate sales of such items or whether the
    undelivered items are essential to the functionality of the
    delivered items. Further, we use judgment to evaluate whether
    there is vendor-specific objective evidence, or VSOE, of fair
    value of the undelivered items, determined by reference to
    stand-alone sales of such items. We recognize revenue for
    delivered elements only when we determine that the fair values
    of undelivered elements are known. For a multiple element
    arrangement that includes both IFCs and instruments we separate
    these elements into separate units of accounting as we consider
    these elements to have standalone value to the customer. We
    recognize revenue for the IFCs under SAB&#160;104 and the
    instruments under SAB&#160;104 or
    <FONT style="white-space: nowrap">SOP&#160;97-2,</FONT>
    as applicable. If the fair value of any undelivered item related
    to instruments and software included in a multiple element
    arrangement cannot be objectively determined, revenue will be
    deferred until all items are delivered, or until fair value can
    objectively be determined for any remaining undelivered items.
    However, if the only such undelivered element is post-contract
    customer support services, such as maintenance agreements, the
    entire revenue is recognized ratably over the service period.
    Recognition of revenue from these arrangements generally begins
    upon installation of the instruments as installation is deemed
    essential to the functionality of the instruments. The
    corresponding costs of products sold related to multiple element
    arrangements are also deferred and amortized over the same
    period.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our deferred revenue balance increased by $1.6&#160;million
    during 2007 and decreased by $0.1&#160;million during the three
    months ended March&#160;29, 2008. The increase during 2007 was
    primarily due to the increase in sales of our BioMark instrument
    systems, all of which included maintenance agreements. Although
    there was a slight decrease in deferred revenue during the three
    months ended March&#160;29, 2008, we expect our deferred revenue
    balance to continue to increase until we are able to establish
    VSOE of the fair value of the post-contract customer support. We
    expect to establish VSOE for post-contract customer support as
    we enter into renewal agreements for maintenance with our
    customers upon the expiration of the initial agreements;
    however, we are not able to estimate when that will occur.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Changes in judgments and estimates regarding application of
    these revenue recognition guidelines as well as changes in facts
    and circumstances including the establishment of VSOE of fair
    value could result in a change in the timing or amount of
    revenue recognized in future periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue from the sales of our products that are not part of a
    multiple element arrangement is recognized when no significant
    obligations remain undelivered and collection of the receivables
    is reasonably assured, which is generally upon shipment of the
    product and transfer of title to the customer.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into collaboration research and development
    arrangements that generally provide us with up-front and
    periodic milestone fees or fees based on
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rates for time incurred by our research staff. Revenue is
    recognized either ratably over the term of the agreement or as
    time is incurred on the project. Revenue from government grants
    is for reimbursement of research and development expenses and is
    recognized in the period in which the related costs are
    incurred, provided that the conditions under which the
    government grants are awarded have been substantially met and
    only perfunctory obligations remain outstanding.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock-Based
    Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2006, we accounted for our stock
    options granted to employees using the intrinsic value method
    prescribed by Accounting Principles Board Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees</I>, or APB 25, and
    related interpretations as permitted by Statement of Financial
    Accounting Standards, or SFAS&#160;No.&#160;123, <I>Accounting
    for Stock-Based Compensation</I>, or SFAS&#160;123, and
    SFAS&#160;No.&#160;148, <I>Accounting for Stock-Based
    Compensation&#160;&#151; Transaction and Disclosure</I>, or
    SFAS&#160;148. Accordingly, any compensation cost relating to
    stock options was recorded on the date of the grant in
    stockholders&#146; equity as deferred compensation and was
    thereafter amortized to expense over the vesting period of the
    grant, which was generally four years. We amortized deferred
    stock-based compensation using the multiple option method as
    prescribed by FASB Interpretation No.&#160;28, <I>Accounting for
    Stock Appreciation Rights and Other Variable Stock Option or
    Award Plans</I>, or FIN&#160;28, over the option vesting period
    using an accelerated amortization schedule.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, we adopted the fair value
    recognition provisions of SFAS&#160;No.&#160;123 (revised 2004),
    <I>Share-Based Payment</I>, or SFAS&#160;123(R), which requires
    companies to measure the cost of employee services received in
    exchange for an award of equity instruments, including stock
    options, based on the grant date fair value of the award. The
    fair value is estimated using the Black-Scholes option-pricing
    model. The resulting cost is recognized over the period during
    which an employee is required to provide service in exchange for
    the award, usually the vesting period.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted SFAS&#160;123(R) using the prospective-transition
    method as all prior grants were measured using the minimum value
    method for the pro forma disclosures previously required by
    SFAS&#160;123. The prospective-transition method requires us to
    continue to apply APB 25 in future periods to equity awards
    outstanding at the date of our adoption of SFAS&#160;123(R) on
    January&#160;1, 2006. Under the prospective-transition method,
    any compensation costs that will be recognized from
    January&#160;1, 2006 will include only: (a)&#160;compensation
    cost for all stock-based awards granted prior to, but not yet
    vested as of, December&#160;31, 2005, based on the intrinsic
    value method in accordance with the provisions of ABP 25; and
    (b)&#160;compensation cost for all stock-based awards granted or
    modified subsequent to December&#160;31, 2005, net of estimated
    forfeitures, based on the grant date fair value estimated in
    accordance with the provisions of SFAS&#160;123(R). We amortize
    the fair value of stock-based compensation under
    SFAS&#160;123(R) on a straight-line basis. In accordance with
    the prospective-transition method as prescribed under
    SFAS&#160;123(R), results for prior periods are not restated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for stock options issued to nonemployees in
    accordance with the provisions of SFAS 123(R) and EITF Issue No.
    96-18, <I>Accounting for Equity Instruments That Are Issued to
    Other Than Employees for Acquiring, or in Conjunction with
    Selling, Goods or Services,</I> or EITF
    <FONT style="white-space: nowrap">96-18.</FONT> In
    accordance with SFAS 123(R) and EITF
    <FONT style="white-space: nowrap">96-18,</FONT> stock
    options issued to nonemployees are accounted for at their
    estimated fair value determined using the Black-Scholes
    option-pricing model. The fair value of the options granted to
    nonemployees is remeasured as they vest, and the resulting
    increase in value, if any, is recognized as expense during the
    period the related services are rendered.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We use the Black-Scholes option-pricing model to calculate the
    fair value of our options on the grant date. This model requires
    inputs such as expected term, expected volatility and risk-free
    interest rate. Further, the forfeiture rate also affects the
    amount of aggregate compensation. These inputs are subjective
    and generally require significant judgment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our expected volatility is derived from the historical
    volatilities of several unrelated public companies within the
    life science industry because we have little information on the
    volatility of the price of our common stock since we have no
    trading history. When making the selections of our industry peer
    companies to be used in the volatility calculation, we also
    considered the stage of development, size and financial leverage
    of potential comparable companies. Our historical volatility is
    weighted based on certain qualitative factors and combined to
    produce a single volatility factor. The risk-free interest rate
    is based on the U.S.&#160;Treasury yield in effect at the time
    of grant for zero coupon U.S.&#160;Treasury notes with
    maturities approximately equal to each grant&#146;s expected
    life. Given our limited history to accurately estimate the
    expected lives for the various employee groups, we used the
    &#145;simplified&#146; method as provided by Staff Accounting
    Bulletin&#160;No.&#160;107, <I>Share Based Payment</I>. The
    &#145;simplified&#146; method is calculated as the average of
    the
    <FONT style="white-space: nowrap">time-to-vesting</FONT>
    and the contractual life of the options.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beginning on January&#160;1, 2006 upon the adoption of
    SFAS&#160;123(R), the fair value of each new option awarded was
    estimated on the grant date for the periods below using the
    Black-Scholes option-pricing model with the following
    weighted-average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="17%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Three Months Ended<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>March&#160;29,&#160;2008</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    72.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    54.7%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.1&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5.9 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.4%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.0%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If in the future we determine that another method is more
    reasonable, or if another method for calculating these input
    assumptions is prescribed by authoritative guidance, and,
    therefore, should be used to estimate expected volatility or
    expected life, the fair value calculated for our stock options
    could change significantly. Higher volatility and longer
    expected lives result in an increase to stock-based compensation
    expense determined at the date of grant. Stock-based
    compensation expense affects our cost of revenue, sales and
    marketing expense, research and development expense, and general
    and administrative expense.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate our forfeiture rate based on an analysis of our
    actual forfeitures and will continue to evaluate the
    appropriateness of the forfeiture rate based on actual
    forfeiture experience, analysis of employee turnover behavior
    and other factors. Quarterly changes in the estimated forfeiture
    rate can have a significant effect on reported stock-based
    compensation expense, as the cumulative effect of adjusting the
    rate for all expense amortization is recognized in the period
    the forfeiture estimate is changed. If a revised forfeiture rate
    is higher than the previously estimated forfeiture rate, an
    adjustment is made that will result in a decrease to the
    stock-based compensation expense recognized in the consolidated
    financial statements. If a revised forfeiture rate is lower than
    the previously estimated forfeiture rate, an adjustment is made
    that will result in an increase to the stock-based compensation
    expense recognized in the consolidated financial statements. The
    effect of forfeiture adjustments during 2006, 2007 and the three
    months ended March&#160;29, 2008 was insignificant. We will
    continue to use judgment in evaluating the expected term,
    volatility and forfeiture rate related to our own stock-based
    compensation on a prospective basis and incorporating these
    factors into the Black-Scholes option-pricing model.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Also required for the fair value calculation of the options is
    the fair value of the underlying common stock. We have
    historically granted stock options with exercise prices no less
    than the fair market value of our common stock as determined at
    the date of grant by our Board of Directors with input from
    management. The following table summarizes, by grant date, the
    number of stock options granted since January&#160;1, 2007 and
    the associated per share exercise price, which equaled the fair
    value of our common stock for each of these grants.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Per Share of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Grant Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Granted</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May&#160;8, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,613,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September&#160;20, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;28, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    328,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    February&#160;7, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    723,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Given the absence of an active market for our common stock prior
    to this offering, our Board of Directors determined the fair
    value of our common stock for our grants of stock options. Our
    Board of Directors determined the estimated fair value of our
    common stock based in part on an analysis of relevant metrics,
    including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the prices of our convertible preferred stock sold to outside
    investors in arms-length transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights, preferences and privileges of our convertible
    preferred stock relative to those of our common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights of freestanding warrants and other similar
    instruments related to shares that are redeemable;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our operating and financial performance;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of key personnel;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the introduction of new products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our stage of development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that the option grants involve illiquid securities in a
    private company;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risks inherent in the development and expansion of our
    products and services;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the likelihood of achieving a liquidity event, such as an
    initial public offering or sale of our company given prevailing
    market conditions.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From January&#160;2007 through March&#160;2008, our Board of
    Directors performed contemporaneous valuations of our common
    stock for each grant of stock options during this period.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The valuations were prepared using the market approach and the
    income approach to estimate our aggregate enterprise value at
    each valuation date. The market approach measures the value of a
    company through the analysis of recent sales of comparable
    companies. Consideration is given to the financial condition and
    operating performance of the company being valued relative to
    those of publicly traded companies operating in the same or
    similar lines of business. When choosing the comparable
    companies to be used for the market approach, we focused on
    companies in the life science industry. Some of the specific
    criteria used to select comparable companies within this
    industry include the business description, business size,
    projected growth, financial condition and historical earnings.
    The income approach measures the value of a company as the
    present value of its future economic benefits by applying an
    appropriate risk-adjusted discount rate to expected cash flows,
    based on forecasted revenue and costs. We prepared a financial
    forecast for each valuation report to be used in the computation
    of the enterprise value for both the market approach and the
    income approach. The financial forecasts took into account our
    past experience and future expectations. The risks associated
    with achieving these forecasts were assessed in selecting the
    appropriate discount rate. There is inherent uncertainty in
    these estimates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In assessing the fair value of our common stock, our Board of
    Directors applied an equal weighting to the value indications
    presented by the income approach and market approach. In order
    to arrive at the estimated fair value of our common stock, the
    indicated enterprise value of our company calculated at each
    valuation date was allocated to the shares of convertible
    preferred stock and the warrants to purchase these shares, and
    shares of common stock and the options to purchase these shares
    using an option-pricing methodology. The option-pricing method
    treats common stock and preferred stock as call options on the
    total equity value of a company, with exercise prices based on
    the value thresholds at which the allocation among the various
    holders of a company&#146;s securities changes. Under this
    method, the common stock has value only if the funds available
    for distribution to stockholders exceed the value of the
    liquidation preference at the time of a liquidity event, such as
    a strategic sale, merger or initial public offering, assuming
    the enterprise has funds available to make a liquidation
    preference meaningful and collectable by the holders of
    preferred stock. The common stock is modeled as a call option on
    the underlying equity value at a predetermined exercise price.
    In the model, the exercise price is based on a comparison with
    the total equity value rather than, as in the case of a regular
    call option, a comparison with a per share stock price. Thus,
    common stock is considered to be a call option with a claim on
    the enterprise at an exercise price equal to the remaining value
    immediately after the preferred stock is liquidated. The
    option-pricing method uses the Black-Scholes option-pricing
    model to price the call options. This model defines the
    securities&#146; fair values as functions of the current fair
    value of a company and uses assumptions such as the anticipated
    timing of a potential liquidity event and the estimated
    volatility of the equity securities. The anticipated timing of a
    liquidity event utilized in these valuations was based on
    then-current plans and estimates of our Board of Directors and
    management regarding a liquidity event. Estimates of the
    volatility of our stock were based on available information on
    the volatility of capital stock of comparable publicly traded
    companies. This approach is consistent with the methods outlined
    in the AICPA Practice Guide, <I>Valuation of
    Privately-Held-Company Equity Securities Issued as
    Compensation</I>. Also, we considered the fact that our
    stockholders cannot freely trade our common stock in the public
    markets. Therefore, the estimated fair value of our common stock
    at each grant date reflected a non-marketability discount.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There is inherent uncertainty in these estimates and if we had
    made different assumptions than those described above, the
    amount of our stock-based compensation expense, net loss and net
    loss per share amounts could have been significantly different.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors performed a contemporaneous valuation in
    order to determine the fair value of our common stock for the
    grant of options on May&#160;8, 2007 which indicated a fair
    value of $1.36 per share for our common stock. Our Board of
    Directors performed a second contemporaneous valuation in order
    to update the determination of the fair value of our common
    stock for the grant of options on September&#160;20, 2007 which
    indicated a fair value of $1.38 per share for our common stock.
    The increase in the fair value between the contemporaneous
    valuation performed for the grant of options on May&#160;8, 2007
    and the date of this contemporaneous valuation was minimal,
    however, it relates mostly to a slight decrease in the
    non-marketability discount rate and the time to a liquidity
    event. Our Board of Directors performed another contemporaneous
    valuation in order to update the determination of the fair value
    of our common stock for the grant of options on
    December&#160;28, 2007 which indicated a fair value of $2.40 per
    share for our common stock. The increase in the fair value
    between the contemporaneous valuation performed for the grant of
    options on September&#160;20, 2007 and December&#160;28, 2007
    valuation relates mostly to the decrease in the
    non-marketability discount rate, the risk-adjusted discount and
    the time to a liquidity event.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We recorded stock-based compensation of $5,000,
    $0.1&#160;million, $0.7&#160;million and $0.2&#160;million
    during 2005, 2006, 2007 and the three months ended
    March&#160;29, 2008. Included in these amounts was employee
    stock-based compensation of $0, $0.1 million, $0.5&#160;million
    and $0.2&#160;million, and nonemployee stock-based compensation
    of $5,000, $59,000, $0.2&#160;million and $50,000 during 2005,
    2006, 2007 and the three months ended March&#160;29, 2008. In
    future periods, stock-based compensation expense is expected to
    increase as a result of our existing unrecognized stock-based
    compensation and as we issue additional stock-based awards to
    continue to attract and retain employees and nonemployee
    directors. Additionally, SFAS&#160;123(R) requires that we
    recognize compensation expense only for the portion of stock
    options that are expected to vest. If the actual rate of
    forfeitures differs from that estimated by management, we may be
    required to record adjustments to stock-based compensation
    expense in future periods. As of December&#160;29, 2007 and
    March&#160;29, 2008, we had $1.7&#160;million and $2.5 million
    of unrecognized stock-based compensation costs related to stock
    options granted under our 1999 Stock Option Plan, which is
    expected to be recognized over an average period of 2.9 and
    2.6&#160;years.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for Income Taxes</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant management judgment is required in determining our
    provision for income taxes, our deferred tax assets and
    liabilities and any valuation allowance recorded against our net
    deferred tax assets. We have recorded a full valuation allowance
    on our net deferred tax assets as of December&#160;31, 2006,
    December&#160;29, 2007 and March&#160;29, 2008 due to
    uncertainties related to our ability to utilize our deferred tax
    assets in the foreseeable future. These deferred tax assets
    primarily consist of certain net operating loss carryforwards
    and research and development tax credits.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted FASB Interpretation No.&#160;48, <I>Accounting for
    Uncertainties in Income Taxes&#160;&#151; an interpretation of
    FASB Statement No.&#160;109</I>, or FIN&#160;48, effective
    January&#160;1, 2007. FIN&#160;48 requires us to recognize the
    financial statement effects of a tax position when it is more
    likely than not, based on the technical merits, that the
    position will be sustained upon examination. Upon adoption, the
    Company recorded a charge of $75,000 as a cumulative effect of a
    change in accounting principle in the accumulated deficit during
    2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Inventory
    Valuation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We record adjustments to inventory for potentially excess,
    obsolete or impaired goods in order to state inventory at net
    realizable value. The business environment in which we operate
    is subject to rapid changes in technology and customer demand.
    We regularly review inventory for excess and obsolete products
    and components, taking into account product life cycle and
    development plans, product expiration and quality issues,
    historical experience and our current inventory levels. If
    actual market conditions are less favorable than anticipated,
    additional inventory adjustments could be required.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Warrants
    to Purchase Convertible Preferred Stock</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for freestanding warrants related to shares that are
    redeemable in accordance with FASB Staff Position
    <FONT style="white-space: nowrap">No.&#160;150-5,</FONT>
    <I>Issuer&#146;s Accounting Under FASB Statement No.&#160;150
    for Freestanding Warrants and Other Similar Instruments on
    Shares&#160;That Are Redeemable</I>, or
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    an interpretation of SFAS&#160;No.&#160;150, <I>Accounting for
    Certain Financial Instruments with Characteristics of Both
    Liabilities and Equity</I>. Under
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    freestanding warrants to purchase shares of our convertible
    preferred stock are classified as liabilities on the
    consolidated balance sheets at fair value because the warrants
    may conditionally obligate us to transfer assets at some point
    in the future. The warrants are subject to remeasurement at each
    balance sheet date, and any change in fair value will be
    recognized as a component of other income (expense), net in the
    consolidated statements of operations. We estimated the fair
    value of these warrants at the respective balance sheet dates
    using the Black-Scholes option-pricing model. A number of our
    assumptions used in the
    <FONT style="white-space: nowrap">Black-Scholes</FONT>
    <FONT style="white-space: nowrap">option-pricing</FONT>
    model, especially the market value and the expected volatility,
    are highly judgmental and could differ materially in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will continue to record adjustments to the fair value of the
    warrants until they are exercised, expire or, upon the closing
    of this offering, become warrants to purchase shares of our
    common stock, wherein the warrants will no longer be subject to
    <FONT style="white-space: nowrap">FSP&#160;150-5.</FONT>
    At that time, the then-current aggregate fair value of these
    warrants will be reclassified from current liabilities to
    additional paid-in capital, a component of stockholders&#146;
    equity, and we will cease to record any related periodic fair
    value adjustments. Upon the closing of this offering, the
    preferred stock warrants will be converted into common stock
    warrants with the same exercise prices and expiration dates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Results
    of Operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our revenue by source for each
    period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="52%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    527
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generate revenue from sales of our products, collaboration
    agreements and government grants. Our products consist of
    single-use IFCs, various instruments, software and service
    related to our BioMark and Topaz systems. We also have entered
    into a number of research and development contracts and have
    received government grants to conduct research and development
    activities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Total
    Revenue</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our total revenue increased $0.9&#160;million, or 60%, for the
    three months ended March&#160;29, 2008 compared to the three
    months ended March&#160;31, 2007. Total revenue increased
    $0.9&#160;million, or 14%, for 2007 as compared to 2006, and
    decreased by $1.3&#160;million, or 17%, for 2006 as compared to
    2005. Total revenue from our five largest customers comprised
    48%, 56%, 47% and 40% of revenue in 2005, 2006, 2007 and the
    three months ended March&#160;29, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As we expand our business through Europe and Asia, we expect our
    sales from outside of North America to increase as a percentage
    of our revenue. The following table presents our revenue by
    geography based on the billing address of our customers for each
    period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="27%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>March&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>March&#160;29, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    United States
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,807
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    672
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    470
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Japan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    732
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Europe
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    735
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    318
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    289
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Product
    Revenue</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We derive product revenue from sales to biotechnology and
    pharmaceutical companies, academic institutions and life science
    laboratories worldwide. These sales are generally made through
    direct sales personnel to customers in North America, Asia and
    most of Europe and through distributors in parts of Europe and
    Asia.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Product revenue increased $1.1&#160;million, or 150%, for the
    three months ended March&#160;29, 2008 compared to the three
    months ended March&#160;31, 2007. The increase relates mostly to
    the increase in sales of our BioMark instrument systems and
    related IFC&#146;s in the amount of $1.0&#160;million, as we
    sold five BioMark instrument systems for the three months ended
    March&#160;29, 2008 compared to one BioMark instrument system
    for the three months ended March&#160;31, 2007. Topaz instrument
    systems and related IFC&#146;s increased $0.1&#160;million for
    the three months ended March&#160;29, 2008 compared to the three
    months ended March&#160;31, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Product revenue for 2007 increased by $0.4&#160;million, or 12%,
    compared to 2006. Revenues from our BioMark instrument systems
    and related IFCs which were introduced in late 2006 increased by
    $1.2&#160;million, as we sold 14 BioMark instrument systems
    during 2007 compared to three BioMark instrument systems during
    2006. This increase, however, was mostly offset by a decrease of
    $1.1&#160;million related to a decrease in the sales of our
    Topaz IFCs. The unit sales of our Topaz instrument systems
    remained constant as we sold 10 Topaz instrument systems during
    both 2006 and 2007. In addition, our deferred revenue balance
    increased from $1.8&#160;million at December&#160;31, 2006 to
    $3.4&#160;million at December&#160;29, 2007 as we sold more
    BioMark instrument systems as part of multiple element
    arrangements for which we did not have VSOE on post-contract
    support. We recognized $1.0&#160;million of the deferred revenue
    balance at December&#160;31, 2006 during 2007. We expect the
    current portion of our deferred revenue balance as of
    December&#160;29, 2007 in the amount of $2.6&#160;million will
    be recognized as revenue during 2008. Product revenue for 2006
    decreased by $2.1&#160;million, or 35%, when compared to 2005.
    The decrease was primarily due to a decrease in the sales of our
    Topaz instrument systems as we sold 10 Topaz instrument systems
    during 2006 compared to 16 Topaz instrument systems during 2005;
    however, sales of our Topaz IFCs remained relatively consistent
    with 2005.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The increase in sales of our BioMark instrument systems in 2007
    and the concurrent decrease in sales of our Topaz systems
    reflect the refocusing of our product development and sales and
    marketing efforts, beginning in 2005, to focus on the larger
    markets served by our BioMark instrument systems. Since then, we
    have reduced new Topaz product introductions. We will continue
    to manufacture and sell our Topaz instrument systems and IFCs
    and we expect unit sales of Topaz instrument systems and IFCs in
    2008 and future periods to be consistent with or slightly lower
    than the 2006 and 2007 levels. We expect unit sales of our
    BioMark instrument systems and IFCs to increase in 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive payments from third parties under research and
    development contracts. Fixed-fee research and development
    contracts generally provide us with up-front and periodic
    milestone-based fees. Variable-fee research and development
    contracts generally provide us with fees based on an
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rate for time incurred by our research staff.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Collaboration revenue decreased $0.1&#160;million, or 70%, for
    the three months ended March&#160;29, 2008 compared to the three
    months ended March&#160;31, 2007. The decrease relates to the
    completion of one of our development agreements in the first
    quarter of 2007. Collaboration revenue for 2007 decreased by
    $0.9&#160;million, or 67%, compared to 2006. This decrease was
    primarily due to the completion of one of our collaboration
    agreements during 2006 that accounted for $1.0&#160;million of
    our 2006 collaboration revenue. Collaboration revenue for 2006
    decreased by $0.2&#160;million, or 12%, compared to 2005. The
    decrease was primarily due to the termination of one of our
    collaboration agreements in December 2005. We expect
    collaboration revenue to continue to decrease as we complete our
    current collaboration agreements, most of which are likely to
    terminate during 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grant
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive payments in the form of grants from certain
    government entities. Government grants are agreements that
    generally provide us reimbursement for specified research and
    development activities over a contractually defined period.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Grant revenue decreased $62,000, or 11%, for the three months
    ended March&#160;29, 2008 compared to the three months ended
    March&#160;31, 2007. The decrease relates to the reduction in
    activity for the National Institutes of Health, or NIH, grant
    agreement that will terminate in June&#160;2008. Grant revenue
    for 2007 increased by $1.3&#160;million, or 122%, when compared
    to 2006, and our grant revenue for 2006 increased by
    $1.0&#160;million when compared to 2005. These increases were
    primarily due to the addition of a grant from the NIH, which was
    entered into in June 2006, and research grants from EDB, which
    were entered into in October 2005 and February 2007. We
    recognized revenue from the 2005 EDB research grant in the
    amount of $0.9&#160;million during 2006 and $1.1&#160;million
    during 2007. In addition, we recognized revenue in the amount of
    $0.6&#160;million during 2007 from the 2007 EDB research grant.
    Also, we recognized revenue from the NIH grant in the amount of
    $0.2&#160;million during 2006 and $0.6&#160;million during 2007.
    Although the NIH grant is scheduled to terminate in June 2008,
    we expect grant revenue from the EDB research grants to increase
    in 2008 and remain at such levels through 2011, therefore, we
    expect our total grant revenue in 2008 through 2011 to be
    consistent with 2007 levels.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our agreements with EDB provide that grants extended to us in
    the past and future grants are subject to our operation of
    increasing levels of research, development and manufacturing in
    Singapore, including the use of local service providers, the
    hiring of personnel in Singapore, the incurrence of research and
    development expenses in Singapore, our receipt of new investment
    in our company and our achievement of certain milestones
    relating to the development of our products. These agreements
    further provide EDB with the right to demand repayment of a
    portion past grants in the event that it concludes that we have
    not met our obligations under the applicable agreements. Based
    on correspondence with EDB, we believe we have satisfied the
    conditions applicable to our EDB grant revenue through
    March&#160;29, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cost of
    Product Revenue and Gross Margin</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our cost of revenue and gross
    margin for each period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="52%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    847
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gross margin
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14
</TD>
<TD nowrap align="left" valign="bottom">
    )%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of product revenue includes manufacturing costs incurred in
    the production process, including component materials, assembly
    labor and overhead, testing, installation, warranty, packaging
    and delivery costs. In addition, cost of product revenue
    includes royalty expenses for licensed technologies included in
    our products, provisions for warranties and stock-based
    compensation expense. Costs related to collaboration and
    government grant revenue are included in research and
    development expense.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of product revenue increased $0.5&#160;million, or 56%, for
    the three months ended March&#160;29, 2008 compared to the three
    months ended March&#160;31, 2007. The increase related to the
    increase of product revenue from both higher instrument and IFC
    sales. Cost of product revenue in the first three months of 2007
    was adversely affected by
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     <FONT style="white-space: nowrap">start-up</FONT>
    costs for our new Singapore manufacturing facility and
    underutilized capacity as we transitioned manufacturing from the
    United States to Singapore. Cost of product revenue for 2007
    increased $0.7&#160;million, or 27%, compared to 2006, primarily
    driven by higher instrument sales, start-up costs for our new
    Singapore manufacturing facility and underutilized capacity as
    we transitioned manufacturing from the United States to
    Singapore. Additionally we wrote-off obsolete raw materials in
    2007 in the amount of $0.2&#160;million, which decreased our
    gross margin by 5&#160;percentage points. Cost of product
    revenue for 2006 decreased by $2.0&#160;million, or 42%, when
    compared to 2005, primarily driven by a decrease in sales of our
    Topaz instruments during 2006. We expect our unit costs to
    decline in future periods as a result of our ongoing efforts to
    automate our manufacturing processes and expected increases in
    production volumes and yields. However, improvement in unit
    costs may be offset by increasing price competition, which could
    cause our gross margins to fluctuate from
    <FONT style="white-space: nowrap">year-to-year</FONT>
    and
    <FONT style="white-space: nowrap">quarter-to-quarter.</FONT>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operating
    Expenses</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our operating expenses for each
    period presented (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,473
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,280
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total operating expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    27,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Research and development expense is the largest component of our
    operating expenses and consists primarily of personnel costs,
    independent contractor costs, prototype expenses and other
    allocated facilities and information technology expenses. We
    have made substantial investments in research and development
    since our inception. Our research and development efforts have
    focused primarily on the tasks required to optimize our
    technologies and to support commercialization of the products
    and services derived from these technologies.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Research and development expense decreased $0.2&#160;million, or
    6%, for the three months ended March&#160;29, 2008 compared to
    the three months ended March&#160;31, 2007. The decrease relates
    to a decrease of $0.3&#160;million in supply expenses, a
    decrease of $0.2&#160;million in license expenses offset by a
    $0.2&#160;million increase in headcount costs due to increased
    research and development headcount. Research and development
    expense decreased in 2007 by $1.2&#160;million, or 8%, compared
    to 2006, primarily due to decreased research and development
    license costs of $0.3&#160;million, decreased supply costs of
    $0.3&#160;million due to more efficient development activities
    and decreased compensation costs of $0.2&#160;million due to a
    decrease in our average compensation rates. Research and
    development expense for 2006 increased by $4.1&#160;million, or
    36%, compared to 2005, primarily due to increased compensation
    costs of $2.1&#160;million due mostly to a significant increase
    in research and development headcount and $0.1&#160;million
    related to the adoption of SFAS&#160;123(R) during 2006,
    $0.7&#160;million attributable to increased contractor expenses,
    $0.6&#160;million in increased licenses and royalties, and
    $0.3&#160;million attributable to increased supply expenses. We
    believe that our continued investment in research and
    development is essential to a long-term competitive position and
    expect these expenses, including stock-based compensation, to
    increase in future periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Selling,
    General and Administrative</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Selling, general and administrative expense consists primarily
    of personnel costs for our sales and marketing, business
    development, finance, legal, human resources and general
    management, as well as professional services, such as legal and
    accounting services.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Selling, general and administrative expense increased
    $1.7&#160;million, or 62%, for the three months ended
    March&#160;29, 2008 compared to the three months ended
    March&#160;31, 2007. The increase relates to a $0.8&#160;million
    increase for accounting and consulting services, a
    $0.4&#160;million increase in compensation costs due to
    increased head count, a $0.1&#160;million increase in
    advertising and promotions and a $0.1&#160;million increase in
    facilities allocation. Selling,
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     general and administrative expense for 2007 increased by
    $3.2&#160;million, or 33%, compared to 2006, primarily due to
    increased compensation costs of $1.7&#160;million due mostly to
    an increase in headcount and a $0.5&#160;million increase in
    stock-based compensation over 2006, an increase of
    $1.4&#160;million in spending primarily for accounting and legal
    services, $0.3&#160;million resulting from increased advertising
    and promotions, and $0.2&#160;million attributable to increased
    supplies for customer demonstrations. However, this increase was
    partially offset by a decrease of $0.4&#160;million due to fewer
    patent filings. Selling, general administrative expense for 2006
    increased by $1.7&#160;million, or 22%, compared to 2005,
    primarily due to increased compensation costs of
    $1.1&#160;million due to an increase in headcount,
    $0.4&#160;million due to the filing of additional patents,
    $0.1&#160;million from increased advertising and promotions, and
    $0.1&#160;million attributable to increased supplies for
    customer demonstrations. We expect selling, general and
    administrative expense, including stock-based compensation, to
    significantly increase in 2008 and future periods as we continue
    to grow our sales, technical support, marketing and
    administrative headcount, support increased product sales,
    broaden our customer base and incur additional costs to support
    the growth in our business.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Interest
    Income and Expense</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive interest income from our cash and cash equivalents
    and our
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    security balances held with certain financial institutions.
    Conversely, we incur interest expense from our long-term debt
    and convertible promissory notes and the amortization of our
    debt discounts related to these items. The following table
    presents our interest income and expense for each period
    presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="51%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,227
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (505
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interest income increased $0.1&#160;million, or 37%, for the
    three months ended March&#160;29, 2008 compared to the three
    months ended March&#160;31, 2007 due to higher average cash and
    available-for-sale securities balances. Interest income for 2007
    increased by $0.6&#160;million compared to 2006. The increase in
    interest income was due to higher cash and available-for-sale
    securities balances during 2007 as compared to 2006. Interest
    income for 2006 increased by $0.2&#160;million compared to 2005.
    The increase in interest income was also primarily due to higher
    cash and available-for-sale securities balances during 2006 as
    compared to 2005. We expect interest income to increase as we
    invest a portion of the net proceeds from this offering in
    available-for-sale securities.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interest expense decreased $0.7&#160;million, or 59%, for the
    three months ended March&#160;29, 2008 compared to the three
    months ended March&#160;31, 2007 due to lower average debt
    balance due to conversion of the $10&#160;million promissory
    notes in March&#160;2007. Interest expense for 2007 increased by
    $0.5&#160;million compared to 2006. The increase was primarily
    due to higher debt balances during 2007 as compared to 2006
    primarily due to the $5.0&#160;million convertible promissory
    note issued in March 2007. Interest expense for 2006 increased
    by $1.4&#160;million compared to 2005. The increase was
    primarily due to higher debt balances from the
    $13.0&#160;million Loan and Security agreement that was fully
    drawn by December 2005. We expect interest expense to increase
    if we draw on the $10.0&#160;million credit line which is
    available up to July&#160;1, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cumulative
    Effect of Change in Accounting Principle</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon adoption of
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    on July&#160;1, 2005, we reclassified the fair value of warrants
    to purchase shares of our convertible preferred stock from
    stockholders&#146; equity to liabilities and recorded a
    cumulative effect of a change in accounting principle in the
    amount of $0.6&#160;million during 2005 in the statement of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidity
    and Capital Resources</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Sources
    of Liquidity</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of March&#160;29, 2008, we had $29.2&#160;million of cash and
    cash equivalents and $2.0&#160;million of available-for-sale
    securities. As of March&#160;29, 2008, our working capital was
    $29.9&#160;million, and we had an accumulated deficit of
    $140.4&#160;million. Since our inception, we have principally
    funded our operations through issuances of convertible
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     preferred stock, which have provided us with aggregate net
    proceeds of $162.1&#160;million. We have also received
    significant funding in the form of loans and convertible note
    purchase agreements that have provided us with aggregate net
    proceeds of $36.6&#160;million, of which $20.0&#160;million was
    provided by companies affiliated with EDB.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have received funding in the form of grants from government
    entities, the most significant of which have been associated
    with two grant agreements with EDB that have helped support the
    establishment and operation of our Singapore manufacturing,
    research and development facilities in October 2005. As of
    March&#160;29, 2008, we had received approximately
    $3.1&#160;million from these grant agreements, from a possible
    total amount of approximately $9.9&#160;million. In the event
    that we do not receive grant funding from EDB in the future, we
    do not believe that our liquidity would be materially affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into multiple convertible note purchase
    agreements with Biomedical Sciences Investment Fund&#160;Pte.
    Ltd., or BMSIF,  an investment arm of EDB, pursuant to which we
    issued convertible notes and received proceeds in the amount of
    $20.0&#160;million through March&#160;29, 2008. As of
    March&#160;29, 2008, the outstanding principal and accrued
    interest balance of our convertible note purchase agreements
    with BMSIF was $5.2&#160;million, net of unamortized debt
    discounts of $0.4&#160;million, all of which was converted into
    shares of our Series&#160;E preferred stock in April&#160;2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In November 2002, we entered into a master security agreement
    with a lender under which we borrowed $3.6&#160;million to be
    used for purchases of capital equipment, software and tenant
    improvements. The outstanding principal and accrued interest
    balance for this loan was paid in February 2008. Upon full
    payment of the debt in February 2008, restricted cash in the
    amount of $0.5&#160;million was released by the lender.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2005, we entered into a loan and security agreement
    with a lender under which we borrowed $13.0&#160;million to be
    used for general corporate purposes. We are currently making
    equal monthly payments of $0.3&#160;million towards the loan
    which is to be paid off in February 2010. The loan is subject to
    prepayment penalties if paid off prior to 2010. As of
    March&#160;29, 2008, the outstanding principal and accrued
    interest balance for this loan and security agreement was
    $7.6&#160;million, net of unamortized debt discounts of $25,000.
    In February 2008, this loan and security agreement was amended
    to provide us with an additional credit line in the amount of
    $10.0&#160;million that we can draw upon until July&#160;1, 2008
    for general corporate purposes. Amounts drawn down under this
    additional line of credit plus accrued interest will be repaid
    in installments through June 2011 and outstanding amounts will
    accrue interest at the rate of 11.5% per year. As of
    March&#160;29, 2008, we had not drawn down any amounts on the
    additional line of credit.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The loan and security agreement contains customary covenants
    that, among other things, require us to deliver both annual
    audited and periodic unaudited financial statements by specified
    dates and maintain collateral on company premises and restrict
    our ability, without the consent of the lender, to incur
    additional debt, pay dividends or make certain other
    distributions, or payments in respect of our capital stock,
    engage in transactions with affiliates or engage in the sale,
    lease or license of our assets outside of the ordinary course of
    business. As of March&#160;29, 2008, we were in compliance with
    the above covenants with the exception of the timely delivery of
    our audited financial statements for 2007. In this instance, we
    obtained a waiver from the lender and subsequently complied with
    the covenant. We are currently unaware of any circumstances that
    would prevent us from complying with these covenants in the
    future.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Used in Operating Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We derive cash flows from operations primarily from cash
    collected from the sale of our products and related services,
    collaboration agreements and grants from certain government
    entities. Our cash flows from operating activities are also
    significantly influenced by our use of cash for operating
    expenses to support the growth of our business. We have
    historically experienced negative cash flows from operating
    activities as we have expanded our business and built our
    infrastructure domestically and internationally and we expect
    this trend to continue for the foreseeable future as our
    business grows and we continue to expand into new markets.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $7.5&#160;million for
    the three months ended March&#160;29, 2008. Net cash used by
    operating activities primarily consisted of a net loss of
    $6.6&#160;million and changes in our working capital amounts in
    the amount of $1.8&#160;million, which were partially offset by
    non-cash expense items such as depreciation
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     and amortization of our property and equipment in the amount of
    $0.4&#160;million, amortization of our debt discounts in the
    amount of $0.3&#160;million, stock-based compensation in the
    amount of $0.2&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     Net cash used by operating activities was $21.8&#160;million
    during 2007. Net cash used by operating activities primarily
    consisted of a net loss of $25.5&#160;million, which was
    partially offset by non-cash expense items such as depreciation
    and amortization of our property and equipment in the amount of
    $1.6&#160;million, amortization of debt discounts in the amount
    of $0.5&#160;million, stock-based compensation in the amount of
    $0.7&#160;million, and changes in our working capital accounts
    in the amount of $0.5&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $22.3&#160;million
    during 2006. Net cash used by operating activities primarily
    consisted of a net loss of $23.6&#160;million and changes in our
    working capital accounts in the amount of $1.2&#160;million. The
    cash used by operating activities for these items was partially
    offset by non-cash expense items such as depreciation and
    amortization of our property and equipment in the amount of
    $1.4&#160;million, amortization of our debt discounts in the
    amount of $0.1&#160;million, stock-based compensation in the
    amount of $0.1&#160;million, and the issuance of convertible
    preferred stock under a license agreement in the amount of
    $0.6&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $14.3&#160;million
    during 2005. Net cash used by operating activities primarily
    consisted of a net loss of $16.4&#160;million. The cash used by
    operating activities was partially offset by non-cash expense
    items such as depreciation and amortization of our property and
    equipment in the amount of $1.3&#160;million and increases in
    our working capital accounts in the amount of $1.4&#160;million.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Used in Investing Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, our primary investing activities have consisted of
    capital expenditures for laboratory, manufacturing and computer
    equipment and software to support our expanding infrastructure
    and work force; restricted cash related to leased space and
    lending agreements; and purchases, sales and maturities of our
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities. We expect to continue to expand our manufacturing
    capability, primarily in Singapore, and expect to incur
    additional costs for capital expenditures related to these
    efforts in 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generated $4.7&#160;million of cash in investing activities
    for the three months ended March&#160;29,&#160;2008 primarily
    from maturities of available-for-sale securities in the amount
    of $3.0&#160;million, sales of available-for-sale securities in
    the amount of $2.3&#160;million and a reduction of restricted
    cash of $0.5&#160;million, partially offset by purchases of
    available-for-sale securities in the amount of $1.0&#160;million
    and purchases of capital equipment of $0.1&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We used $6.7&#160;million of cash in investing activities during
    2007, primarily for purchases of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $6.3&#160;million and
    $1.0&#160;million for capital expenditures related to purchases
    of equipment, including $0.4&#160;million for our Singapore
    manufacturing facility, partially offset by maturities of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $0.5&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We used $2.9&#160;million of cash in investing activities during
    2006, primarily for capital expenditures in the amount of
    $2.9&#160;million related to purchases of equipment, including
    $1.3&#160;million for our Singapore manufacturing facility.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, investing activities provided cash of
    $6.8&#160;million. This cash was generated primarily from sales
    and maturities of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $8.9&#160;million, partially offset
    by purchases of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $0.5&#160;million and capital
    expenditures in the amount of $1.7&#160;million. Our capital
    expenditures during 2005 consisted of $1.0&#160;million related
    to purchases of manufacturing equipment for our Singapore
    facility, which began operations during the year.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Provided by Financing Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, we have principally funded our operations through
    issuances of convertible preferred stock.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the three months ended March&#160;29, 2008, we used
    $1.8&#160;million of cash from financing activities primarily
    due to repayment of long-term debt. During 2007, we generated
    $37.6&#160;million of cash from financing activities primarily
    due to $35.9&#160;million of net proceeds from sales of our
    Series&#160;E preferred stock and $5.0&#160;million of proceeds
    from the issuance of convertible promissory notes, partially
    offset by repayments of our long-term debt in the amount of
    $3.5&#160;million. During 2006, we generated approximately
    $31.1&#160;million of cash from financing
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     activities primarily due to $22.0&#160;million of net proceeds
    from sales of our Series&#160;E preferred stock and
    $13.0&#160;million of proceeds from the issuance of convertible
    promissory notes, partially offset by repayments of our
    long-term debt in the amount of $4.0&#160;million. During 2005,
    we generated approximately $23.0&#160;million of cash from
    financing activities, primarily due to $10.0&#160;million of net
    proceeds from sales of our Series&#160;D preferred stock and
    $14.7&#160;million of net proceeds from the issuance of
    long-term debt, partially offset by repayments of our long-term
    debt in the amount of $1.7&#160;million.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Capital
    Resources</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our existing cash and cash equivalents,
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities, amounts available under current credit lines and the
    net proceeds from this offering, will be sufficient to meet our
    working capital and capital expenditure needs for at least the
    next 18&#160;months. However, we may need to raise substantial
    additional capital to expand the commercialization of our
    products, fund our operations, continue our research and
    development, defend, in litigation or otherwise, any claims that
    we infringe third-party patents or violate other intellectual
    property rights, commercialize new products and acquire
    companies and in-license products or intellectual property. Our
    future funding requirements will depend on many factors,
    including market acceptance of our products, the cost of our
    research and development activities, the cost of filing and
    prosecuting patent applications, the cost of defending, in
    litigation or otherwise, any claims that we infringe third-party
    patents or violate other intellectual property rights, the cost
    and timing of regulatory clearances or approvals, if any, the
    cost and timing of establishing additional sales, marketing and
    distribution capabilities, the cost and timing of establishing
    additional technical support capabilities, the effect of
    competing technological and market developments, and the extent
    to which we acquire or invest in businesses, products and
    technologies, although we currently have no commitments or
    agreements relating to any of these types of transactions. We
    currently expect to use the proceeds from this offering to
    expand our sales force, to support the ongoing commercialization
    of our products, for research and product development
    activities, to expand our facilities and manufacturing
    operations, and for working capital and other general corporate
    purposes. As of the date of this prospectus, we cannot predict
    with certainty all of the particular uses for the proceeds from
    this offering or the amounts that we will actually spend on the
    uses set forth above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may require additional funds in the future and we may not be
    able to obtain such funds on acceptable terms, or at all. If we
    raise additional funds by issuing equity securities, our
    stockholders may experience dilution. Debt financing, if
    available, may involve covenants restricting our operations or
    our ability to incur additional debt. Any debt or additional
    equity financing that we raise may contain terms that are not
    favorable to us or our stockholders. If we raise additional
    funds through collaboration and licensing arrangements with
    third parties, it may be necessary to relinquish some rights to
    our technologies or our products, or grant licenses on terms
    that are not favorable to us. If we are unable to raise adequate
    funds, we may have to liquidate some or all of our assets, or
    delay, reduce the scope of or eliminate some or all of our
    development programs. If we do not have, or are not able to
    obtain, sufficient funds, we may have to delay development or
    commercialization of our products or license to third parties
    the rights to commercialize products or technologies that we
    would otherwise seek to commercialize. We also may have to
    reduce marketing, customer support or other resources devoted to
    our products or cease operations. Any of these factors could
    harm our operating results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Off-Balance
    Sheet Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since our inception, we have not had any off-balance sheet
    arrangements as defined in Item&#160;303(a)(4) of the Securities
    and Exchange Commission&#146;s
    <FONT style="white-space: nowrap">Regulation&#160;S-K.</FONT>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contractual
    Obligations and Commitments</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summarizes our contractual obligations as of
    December&#160;29, 2007 (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Payments Due by Period</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Less Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1&#160;Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1-3&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>3-5&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Thereafter</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,782
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Purchase obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our operating lease obligations relate to leases for our current
    headquarters and leases for office space for our foreign
    subsidiaries. Principal and interest on our convertible
    promissory notes are convertible into shares of our
    Series&#160;E preferred stock at the lender&#146;s election, at
    any time, or upon our election upon the achievement of certain
    milestones or automatically upon the completion of this
    offering. Purchase obligations consist of contractual and
    legally binding commitments to purchase goods. We have entered
    into several patent license agreements in which we are obligated
    to pay annual license maintenance fees, non-refundable license
    issuance fees and royalties as a percentage of sales for the
    sale or sublicense of products using the licensed technology.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into several license and patent agreements.
    Under these agreements, we pay annual license maintenance fees,
    nonrefundable license issuance fees, and royalties as a
    percentage of net sales for the sale or sublicense of products
    using the licensed technology. If we elect to maintain these
    license agreements, we will pay aggregate annual fees of
    $315,000 in 2008 and $270,000 per year until 2027. Future
    payments related to these license agreements have not been
    included in the contractual obligations table above as the
    period of time over which the future license payments will be
    required to be made, and the amount of such payments are
    indeterminable.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;7, 2003 we entered into a Master Closing Agreement
    with Oculus Pharmaceuticals, Inc. and the UAB Research
    Foundation, or UAB, related to certain intellectual property and
    technology rights licensed by us from UAB. Pursuant to the
    agreement, we are obligated to issue UAB shares of our common
    stock with a value equal to $1,500,000 upon the achievement of a
    certain milestone and based upon the fair market value of our
    common stock at the time the milestone is achieved. We currently
    do not anticipate achieving this milestone in the foreseeable
    future and do not anticipate issuing these shares.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our manufacturing operations in Singapore, which commenced in
    October 2005, have been supported by grants from EDB, which
    provide partial reimbursement of qualifying costs arising from
    research and development projects relating to our manufacturing
    process. To remain eligible for future reimbursement, we are
    required to maintain a significant and increasing manufacturing
    and research and development presence in Singapore. Under our
    current grant agreements with EDB, we expect our spending
    related to these grant agreements to increase in order to
    maintain our manufacturing facility in Singapore. Future
    expenditures related to these grant agreements have not been
    included in the contractual obligations table above as the
    amounts of future expenditures, if any, and the timing of when
    they will be incurred are still indeterminable.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subsequent to our year ended December&#160;29, 2007, the
    remaining outstanding principal and accrued interest balance for
    a master security agreement in the amount of $1.1&#160;million
    was paid in February 2008. The loan was originally scheduled to
    be repaid in monthly installments though July 2009 and,
    accordingly, was reflected in the table above as such. Also, the
    convertible promissory notes noted in the table above were
    converted into shares of our Series&#160;E preferred stock
    during April 2008 in accordance with the convertible note
    purchase agreements with BMSIF.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2006, the FASB issued SFAS&#160;No.&#160;157,
    <I>Fair Value Measurement</I>, or SFAS&#160;157, which defines
    and establishes a framework for measuring the fair value of
    assets and liabilities when required or permitted by other
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     standards within generally accepted accounting principles in
    the United States but does not require any new fair value
    measurements. SFAS&#160;157 also expands disclosures about fair
    value measurements. SFAS&#160;157 is effective for all financial
    statements issued for fiscal years beginning after
    November&#160;15, 2007. However, in February 2008 the FASB
    issued FSP
    <FONT style="white-space: nowrap">No.&#160;157-2,</FONT>
    or
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    which delays the effective date of SFAS&#160;157 in accordance
    with the provisions in
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    as of January&#160;1, 2008. The adoption of SFAS&#160;157 did
    not have a significant impact on our consolidated financial
    statements and the resulting fair values calculated in
    accordance with SFAS&#160;157 were not significantly different
    than the fair values that would have been calculated in
    accordance with the previous guidance.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, the FASB issued SFAS&#160;No.&#160;159, <I>The
    Fair Value Option for Financial Assets and Financial
    Liabilities</I>, or SFAS&#160;159, including an amendment of
    SFAS&#160;No.&#160;115, <I>Accounting for Certain Investments in
    Debt and Equity Securities</I>, which allows an entity to choose
    to measure certain financial instruments and liabilities at fair
    value. Subsequent measurements for the financial instruments and
    liabilities an entity elects to measure at fair value will be
    recognized in earnings. SFAS&#160;159 also establishes
    additional disclosure requirements. SFAS&#160;159 is effective
    for fiscal years beginning after November&#160;15, 2007. The
    adoption of SFAS&#160;159 did not have a significant impact on
    our consolidated financial statements.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-1,</FONT>
    <I>Accounting for Collaborative Agreements</I>, or
    <FONT style="white-space: nowrap">EITF&#160;07-1,</FONT>
    which addresses the accounting for participants in collaborative
    agreements, defined as contractual arrangements that involve a
    joint operating activity, that are conducted without the
    creation of a separate legal entity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    requires participants in a collaborative agreement to make
    separate disclosures for each period a statement of operations
    is presented regarding the nature and purpose of the agreement,
    the rights and obligations under the agreement, the accounting
    policy for the agreement, and the classification of and amounts
    arising from the agreement between participants. These
    arrangements involve two or more parties who are both active
    participants in the activity and that are exposed to significant
    risks and rewards dependent on the commercial success of the
    activity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    provides that a company should report the effects of adoption as
    a change in accounting principle through retrospective
    application to all periods and requires specific additional
    disclosures.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2008. We are currently assessing the
    impact the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    will have on our consolidated financial statements.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-3,</FONT>
    <I>Accounting for Nonrefundable Advance Payments for Goods or
    Services to Be Used in Future Research and Development
    Activities</I>, or
    <FONT style="white-space: nowrap">EITF&#160;07-3.</FONT>
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    provides clarification surrounding the accounting for
    nonrefundable research and development advance payments, whereby
    such payments should be recorded as an asset when the advance
    payment is made and recognized as an expense when the research
    and development activities are performed.
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2007. We adopted
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    as of December&#160;30, 2007. The adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    did not have a significant impact on our consolidated financial
    statements.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Quantitative
    and Qualitative Disclosures about Market Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Market risk represents the risk of loss that may impact our
    financial position due to adverse changes in financial market
    prices and rates. Our market risk exposure is primarily a result
    of fluctuations in foreign currency exchange rates and interest
    rates. We do not hold or issue financial instruments for trading
    purposes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency Exchange Risk</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As we expand internationally our results of operations and cash
    flows will become increasingly subject to fluctuations due to
    changes in foreign currency exchange rates. Our revenue is
    generally denominated in the local currency of the contracting
    party. Historically, the substantial majority of our revenue has
    been denominated in U.S.&#160;dollars. Our expenses are
    generally denominated in the currencies in which our operations
    are located, which is primarily in the United States, with a
    portion of expenses incurred in Singapore where our other
    manufacturing facility is located. Our results of operations and
    cash flows are, therefore, subject to fluctuations due to
    changes in foreign currency exchange rates. Fluctuations in
    currency exchange rates could harm our business in the future.
    However, the effect of a 10% adverse change in exchange rates on
    foreign denominated receivables and payables as
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008 would not have been material. To date, we
    have not entered into any foreign currency hedging contracts
    although we may do so in the future.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Interest
    Rate Sensitivity</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We had cash and cash equivalents of $25.0&#160;million,
    $34.1&#160;million and $29.2&#160;million and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities of $0.5&#160;million, $6.3&#160;million and
    $2.0&#160;million as of December&#160;31, 2006,
    December&#160;29, 2007 and March&#160;29, 2008. These amounts
    were held primarily in cash on deposit with banks, money market
    funds, commercial paper, corporate notes or notes from
    government-sponsored agencies, which are short-term. Cash and
    cash equivalents and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities are held for working capital purposes and restricted
    cash amounts are held as letters of credit for collateral for a
    security agreement with a lender and for our facility lease
    agreements. Due to the short-term nature of these investments,
    we believe that we do not have any material exposure to changes
    in the fair value of our investment portfolio as a result of
    changes in interest rates. Declines in interest rates, however,
    will reduce future investment income. If overall interest rates
    had decreased by 10% during 2007 or the three months ended
    March&#160;29, 2008, our interest income would not have been
    materially affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, the principal amount of our long-term debt
    outstanding was $12.8&#160;million, $9.4&#160;million
    $7.6&#160;million and the principal amount of our convertible
    promissory notes outstanding was $13.1&#160;million,
    $5.0&#160;million and $5.2&#160;million. The interest rates on
    our long-term debt and convertible promissory notes are largely
    fixed, however, a small portion of our long-term debt
    outstanding has interest rates that are variable and adjust
    periodically based on the prime rate. If overall interest rates
    had increased by 10% during 2007 or the three months ended
    March&#160;29, 2008, our interest expense would not have been
    materially affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have material exposure to market risk with respect to
    investments as our investments consist primarily of highly
    liquid securities that approximate their fair values due to
    their short period of time to maturity. We do not use derivative
    financial instruments for speculative or trading purposes,
    however, we may adopt specific hedging strategies in the future.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Controls
    and Procedures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, in connection with the audit of our
    consolidated financial statements for 2005 and 2006, we
    determined that we had material weaknesses relating to our
    financial statement close and accrual process and revenue
    recognition and inventory costing, cost of sales, purchases
    cut-off and stock-based compensation. A material weakness is
    defined as a deficiency, or combination of deficiencies, in
    internal control over financial reporting, such that there is a
    reasonable possibility that a material misstatement of the
    company&#146;s annual or interim financial statements will not
    be prevented or detected on a timely basis by the company&#146;s
    internal controls. These material weaknesses were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have a sufficient number of personnel in the
    accounting and finance department with sufficient proficiency
    and technical accounting expertise;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have effective controls in place or designed to
    evaluate the accounting implications of our business
    transactions during 2005 and 2006 and to determine if such
    matters had been properly accounted for in a timely
    manner;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we had not designed or maintained effective operating controls
    over the financial statement close and reporting process in
    order to ensure the accurate and timely preparation of our
    financial statements in accordance with generally accepted
    accounting principles.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These material weaknesses resulted in the recording of numerous
    audit adjustments for 2005 and 2006. We have taken steps
    intended to remediate these material weaknesses through:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of additional accounting and finance personnel with
    technical accounting and financial reporting experience,
    including Vikram Jog, our new Chief Financial Officer, who
    joined us in February 2008;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the engagement of a consulting firm to provide further
    accounting expertise to complement the skills of our existing
    team;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the engagement of an accounting firm to advise us on local and
    international tax planning and compliance;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of an experienced finance manager for Fluidigm
    Singapore Pte. Ltd., who is expected to start in May 2008;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increased scheduled communication and coordination among our
    finance teams in the United States and our foreign subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhanced coordination among, and training of, accounting, sales,
    technical support and legal personnel on transactional issues;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhancements to our financial statement close process and
    financial close calendar to help enable processes and procedures
    to be completed on a timely basis;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    installation of common accounting software and systems in our
    U.S. and Singapore offices.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April and May 2008, following the audit of our consolidated
    financial statements for 2007 and the review of our financial
    statements for the three months ended March&#160;29, 2008, we
    reviewed our internal control over financial reporting and
    concluded that we had certain significant deficiencies, none of
    which were determined to be material weaknesses. A significant
    deficiency is defined as a deficiency, or combination of
    deficiencies, in internal control over financial reporting that
    is less severe than a material weakness, yet important enough to
    merit attention by those responsible for oversight of a
    company&#146;s financial reporting. These significant
    deficiencies were as follows:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have sufficient controls in place to review
    consolidation and elimination entries relating to intercompany
    transfer pricing to detect and eliminate intercompany profits
    embedded in deferred costs of our Japanese subsidiary;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have effective controls in place designed to apply
    SFAS&#160;123R to option grants with a variety of vesting terms
    and to validate stock compensation expenses calculated by our
    option tracking software;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have sufficient controls in place to review the
    valuation of our inventory.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not know the specific time frame needed to remediate the
    significant deficiencies identified. In addition, we expect to
    incur some incremental costs associated with this remediation.
    If we fail to enhance our internal control over financial
    reporting to meet the demands that will be placed upon us as a
    public company, including the requirements of the Sarbanes-Oxley
    Act, we may be unable to report our financial results
    accurately. The actions we plan to take are subject to continued
    management review supported by confirmation and testing, as well
    as audit committee oversight. While we expect to remediate these
    significant deficiencies, we cannot assure you that we will be
    able to do so in a timely manner, which could impair our ability
    to report our financial position, results of operations or cash
    flows accurately and timely.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='110'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">BUSINESS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in the life science industry. Our Integrated Fluidic Circuits,
    or IFCs, integrate a diverse set of critical liquid handling
    functions on a nanoliter scale. Our IFCs can meter, combine,
    diffuse, fold, mix, separate or pump nanoliter volumes of
    fluids, with precise control and reproducibility, many thousands
    of times&#160;&#151; all in parallel on a single chip. This
    technology enables our customers to perform thousands of
    sophisticated biochemical measurements on samples smaller than
    the content of a single cell, with minute volumes of reagents,
    in half the area of a credit card. We achieved this
    &#147;integrated circuit for biology&#148; by miniaturizing and
    integrating liquid handling components on a single
    microfabricated device. Through innovations in material science
    and manufacturing, our IFC architectures are highly flexible,
    and can be designed to support a wide range of applications and
    assay types. For large-scale experimentation, our IFC systems,
    consisting of instrumentation, software and single-use IFCs,
    increase throughput, decrease costs and enhance sensitivity
    compared to conventional laboratory systems. We have sold our
    IFCs to over 100 customers, including many leading biotechnology
    and pharmaceutical companies, academic institutions and life
    science laboratories worldwide.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems for a wide range of life
    science applications, including our BioMark system for gene
    expression analysis, genotyping and digital PCR, and our Topaz
    system for protein crystallization. Researchers and clinicians
    have successfully employed our products in achieving
    breakthroughs across diverse scientific disciplines such as
    genetic variation, cellular function and structural biology.
    These advances include using our systems to help detect
    life-threatening mutations in patients&#146; cancer cells,
    discover indicators of susceptibility to cancer, manage some of
    the world&#146;s most valuable fisheries, analyze the genetic
    composition of individual stem cells, identify fetal chromosomal
    abnormalities from maternal blood samples, analyze the
    aggressiveness of the avian flu virus and assess the quality of
    agricultural seed products. We believe that the flexible
    architecture of our IFC technology will lead to the development
    of IFC systems for a wide variety of additional markets and
    applications, including molecular diagnostics.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a1f3943217.gif" alt="(IFC FIGURE)">
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Schematic of our 96.96 Dynamic Array IFC including an
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    enlarged section showing four of the IFC&#146;s 9,216 test
    chambers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The life science industry is currently facing challenges similar
    to those faced by the information technology industry when
    computational power was constrained by the inherent limitations
    of the vacuum tube. Life science research efforts, ranging from
    large-scale initiatives, such as the Human Genome Project, to
    more traditional academic and commercial research projects, are
    continuing to reveal the complex biological and chemical
    processes that are fundamental to living organisms. Automated,
    high-precision and large-scale experimentation is increasingly
    necessary to develop and apply this knowledge. However, the most
    common forms of life science automation rely on cumbersome
    robotic systems that are slow, expensive and labor-intensive
    and, we believe,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    fundamentally constrain the pace and productivity of life
    science research. In much the same way that integrated circuits
    overcame the limitations of early computers by placing an
    increasing number of transistors on a single silicon chip, our
    IFCs overcome many of the limitations of conventional laboratory
    systems by integrating an increasing number of fluidic
    components on a single microfabricated IFC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that much of analytical biology and chemistry can be
    performed more efficiently and more economically in nanoliter,
    or one billionth of a liter, volumes than in conventional
    microliter volume platforms. Moreover, we believe that these
    advantages can be further enhanced through high levels of
    integration. Our IFC systems overcome many of the limitations of
    conventional methods by integrating on a single device the
    ability to perform thousands of experiments at one time and in
    nanoliter volumes. Our IFCs consist of an elastomeric, or
    rubber-like, core bonded to a specialized hard plastic input
    frame. The input frame is compatible with standard laboratory
    workflow equipment and facilitates loading the IFC with samples
    and reagents. Each IFC contains an extensive network of
    microfluidic components, such as valves, channels, pumps, mixers
    and other components that deliver samples and reagents to
    thousands of nanoliter chambers across the IFC where individual
    tests can be performed. This high level of nanofluidic
    integration significantly reduces the time and complexity of
    large-scale experimentation and the volume of costly reagents
    and scarce patient samples required. In addition, our IFC
    systems enable users to address problems that would be difficult
    or impractical to solve using conventional life science tools.
    We believe that our ongoing research efforts to increase the
    density and degree of miniaturization of our IFCs will result in
    further such benefits to our customers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Target Markets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Biotechnology and pharmaceutical companies, academic
    institutions and life science laboratories collectively spent
    approximately $35&#160;billion in 2007 for analytical and life
    science instruments, according to Strategic Directions
    International, or SDI. Growth in the life science equipment and
    supplies industry has been driven in part by increased demand
    for tools that allow researchers to discover how fundamental
    functional elements of biology such as nucleic acids, proteins,
    carbohydrates and cells interact within living organisms. This
    research often entails analyzing or identifying numerous such
    elements across large sample populations. Conducting and
    commercializing this research requires equipment that reliably
    performs experimentation with precision, on a large scale and at
    an affordable cost. The need for equipment with these
    capabilities is particularly evident in the areas of genomics,
    proteomics and molecular diagnostics, which comprise our initial
    target markets.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Genomics</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Genomics is the analysis of nucleic acids, including DNA and
    RNA, the fundamental building blocks of life. The entire DNA
    content of an organism is known as its genome and is commonly
    organized into functional units known as genes. Analysis of
    variations in genomes, genes and gene activity in and between
    organisms can provide tremendous insight into its health and
    functioning. The worldwide demand for genomic analysis
    instruments and supplies was approximately $4.9&#160;billion in
    2005, according to SDI. Of this total, SDI estimated that 56%,
    or about $2.7&#160;billion, was spent on gene expression
    analysis, and 20%, or about $1.0&#160;billion, was spent on
    genotyping. In a 2006 report, SDI projected that the markets for
    gene expression analysis and genotyping would grow approximately
    8% per year from 2005 to 2010.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Gene expression and genotyping today are studied through a
    combination of various technology platforms that characterize
    gene function and genetic variation. Gene expression and
    genotyping are commonly performed using a technique known as
    polymerase chain reaction, or PCR, and often with a chemistry
    branded as TaqMan, which is proprietary to Roche Molecular
    Systems, Inc. and is widely used in the industry. The PCR method
    is used to replicate a strand of DNA or RNA into millions of
    copies to facilitate detection in a sample. Real-time
    quantitative PCR, or real-time qPCR, is a more advanced form of
    PCR that makes it possible to identify the number of copies of
    DNA present in a sample at a certain time. According to Frost
    and Sullivan, the U.S.&#160;market for real-time qPCR was
    approximately $741&#160;million in 2007, growing at
    approximately 11% per year from 2005 to 2012. Based on our
    estimates, we believe the global market for real-time qPCR was
    approximately $1.7&#160;billion in 2007. Gene expression,
    genotyping and digital PCR are three powerful forms of genomic
    analysis.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Gene Expression Analysis.</I>&#160;&#160;One of the ways
    genes control cellular activity is through a process known as
    gene expression, when a cell transcribes a section of a
    gene&#146;s DNA to create another nucleic acid sequence, known
    as messenger RNA. This messenger RNA may then be translated by
    the cell into a protein. Messenger RNA can be detected and
    quantified by performing real-time qPCR tests, or assays. Gene
    expression analysis typically entails determining which genes
    are active by measuring messenger RNA levels in a blood or
    tissue sample. These results can be correlated with disease
    activity and clinical outcomes. As multiple genes are involved
    in most biological processes, gene expression analysis usually
    requires assaying the expression levels of many genes
    simultaneously across many samples. We estimate that
    approximately 80% of the market for real-time qPCR involves gene
    expression analysis.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Genotyping.</I>&#160;&#160;Genotyping involves the analysis
    of variations across individual genomes. These variations often
    take the form of single nucleotide changes, known as single
    nucleotide polymorphisms, or SNPs, that can determine the
    characteristics or health of the individual. In SNP genotyping
    studies, the DNA sequences of a group of individuals are
    analyzed to determine patterns of SNPs. Statistical analysis is
    then performed to determine whether a SNP or group of SNPs can
    be associated with a particular characteristic, such as
    propensity for a disease. We estimate that approximately 20% of
    the market for real-time qPCR involves genotyping analysis. We
    believe this percentage share of the real-time qPCR market is
    growing based on technological innovations allowing increasing
    amounts of genetic content to be analyzed more quickly and cost
    effectively.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Digital PCR.</I>&#160;&#160;Digital PCR is a technique that
    allows researchers to detect nucleic acid sequences that are
    present in a patient sample in concentrations that are too low
    to be detected by conventional methods. Digital PCR typically
    relies on standard PCR techniques, but increases their
    sensitivity by dividing a sample into hundreds or thousands of
    smaller samples and performing a PCR assay on each such sample.
    The ability to actually count the presence or absence of
    amplification in this assay format provides quantitative
    measurement capabilities known as absolute quantification.
    Digital PCR has the potential to enable early detection of
    diseases and other conditions, thereby improving prospects for
    effective treatment. In addition, this technique enhances the
    precision of single molecule assays and copy number variation.
    While the digital PCR market is currently nascent, we believe it
    has the potential to grow significantly as researchers learn how
    to apply this technique to a broader range of research
    applications and associated diseases.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Proteomics</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Proteomics is the large-scale study of the function and
    structure of proteins. Proteins are produced by all living
    organisms and directly affect cellular function, the overall
    health of an organism and, in the case of pathogens, how the
    organism interacts with its host. Developing drugs to treat a
    disease often involves identifying molecules that are able to
    interfere with the activity of a particular protein in the
    pathway for that disease. One approach to finding such molecules
    is to first determine the structure of the protein and then look
    for molecules that bind to the structure and interfere with the
    activity of the protein. A technique known as protein
    crystallization is typically used to determine protein
    structures. Crystallizing a protein can be a time-consuming and
    labor-intensive process because different proteins will
    crystallize in the presence of different reagents and under
    different conditions. As samples of particular proteins are
    often scarce and expensive, researchers usually conduct only a
    limited number of experiments, none of which might provide a
    crystallized protein.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Molecular
    Diagnostics</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Molecular diagnostic tests are used in clinical practice to
    diagnose, classify or monitor a disease; determine a
    patient&#146;s susceptibility to a disease; or monitor a
    patient&#146;s response to therapy by detecting one or more
    biomarkers, such as nucleic acids or proteins, in a blood,
    tissue or other type of patient sample. The advancement of
    molecular diagnostics is being driven by researchers performing
    large-scale experiments analyzing the prevalence of SNPs,
    variations in gene expression levels and patterns of protein
    production. SNPs, gene expression levels and proteins often
    directly cause or control diseases. Molecular diagnostic tests
    based on measuring these biomarkers have the potential to be
    much more accurate, discriminating and robust than conventional
    diagnostics. According to Frost and Sullivan, the
    U.S.&#160;market for molecular diagnostics was estimated at
    $2.0&#160;billion in 2007, growing at a compound annual growth
    rate of 17% from 2005 to 2012.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Limitations of Existing Laboratory Systems</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Scientists increasingly seek to identify and measure a large
    number of characteristics across large populations. The most
    common existing methods of large-scale experimentation require a
    workflow that is complex, labor-intensive and expensive. In this
    workflow, biological samples and chemical compounds, usually in
    solution, are generally dispensed or pipetted into standard
    microwell plates, which usually consist of 96 or 384&#160;wells
    each in a standardized format. The plates may then be moved to
    another station where reagents can be applied to the sample or
    compound to create a single assay in each microwell. The
    microwell plates may be moved again to attain ideal reaction
    temperatures or other conditions. The plates are then generally
    moved into a reader to detect the results of the experiment in
    each well. This process of dispensing materials and conveying
    the plates may include robotically performed steps but generally
    also requires a significant manual labor component. To
    accomplish these steps on a large scale typically requires the
    use of large laboratories equipped with many types of equipment,
    robotics, conveyor systems and personnel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conventional microwell plate workflows have a number of
    characteristics that inherently limit their effectiveness as
    tools for large scale experimentation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Complex Workflow.</I>&#160;&#160;Pipetting stations may have
    to perform hundreds of thousands of pipetting steps using
    hundreds of microwell plates in order to conduct a single set of
    experiments. These microwell plates must typically be moved
    among several work stations to complete and measure the results
    of each assay. Maintaining and overseeing complex workflows
    involving large numbers of microwell plates requires ongoing
    attention from trained technicians.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Limited Throughput.</I>&#160;&#160;Due to the large number of
    pipetting steps, microwell plates and process steps involved in
    a conventional microwell workflow, these systems are often
    unable to perform large-scale experiments in a timely and
    cost-effective manner.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Limited Low Volume Capabilities.</I>&#160;&#160;Conventional
    systems are typically unable to dispense samples and reagents in
    quantities small enough to conduct certain high sensitivity, low
    volume techniques, such as digital PCR.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Large Sample Requirements and Significant Running
    Costs.</I>&#160;&#160;Biological samples are often available in
    only very small quantities. As a result, the sample amount that
    needs to be placed in each well often limits the number of
    experiments that can be performed. In addition, reagents can be
    expensive to purchase or produce, and consuming them in
    microliter or larger quantities results in significant and
    sometimes prohibitive costs.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>High Capital Cost.</I>&#160;&#160;Because of the limited
    throughput of conventional systems, multiple pipetting stations,
    plate handlers and readers may be required to meet the demands
    of large-scale experimentation, resulting in high capital
    equipment costs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other methods of large-scale experimentation, including
    microarrays, pre-formatted arrays, bead arrays and mass
    spectrometer analysis, have been developed to address some of
    the limitations of conventional microwell plate systems.
    However, each of these high throughput methods has one or more
    limitations that reduce its utility for large-scale
    experimentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Microarrays, pre-formatted arrays and bead arrays all lack
    flexibility because researchers must specify the assays they
    wish to perform at the time the products are ordered. This in
    turn limits researchers&#146; ability to refine their assay
    panel during the course of a study. In addition, if researchers
    wish to use assay panels other than a manufacturer&#146;s
    standard panels, it may take weeks for a customized product to
    be produced, and the cost may be significant. Furthermore, it is
    often difficult or impossible to convert existing validated
    assays for use with these technologies or with mass spectrometry
    analysis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The quality of the data produced by microarrays, pre-formatted
    arrays and mass spectrometer analysis is insufficient for
    certain research activities. For genotyping studies, data
    quality is typically measured by a call rate, which is the
    percentage of time that a method provides a reading with respect
    to a particular SNP. Both pre-formatted arrays and mass
    spectrometer analysis generally have call rates lower than
    conventional microwell plate systems. For gene expression
    studies, it is often important to measure expression levels over
    a broad dynamic range to capture all or most of the variation
    typically found among subjects. None of microarrays,
    pre-formatted arrays,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     bead arrays or mass spectrometer analysis routinely measure
    gene expression levels over as broad a dynamic range as
    conventional microwell plates.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The workflow for bead arrays and mass spectrometer analysis is
    complex, time consuming and expensive. For example, standard
    protocols often require multiple complex operations to be
    performed over several days by skilled technicians.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These methods can also be very expensive for certain types of
    large-scale experimentation. For example, a single microarray or
    bead array is capable of analyzing thousands of genes from a
    single sample and these devices have been successfully used for
    surveying the genome to discover basic patterns of gene
    expression and genotyping. These surveys or &#147;association
    studies&#148; are commonly performed on tens or hundreds of
    samples and are intended to identify a subset of genes for
    further study. However, for validation studies, which typically
    require the analysis of thousands or tens of thousands of
    samples, the high per sample cost of microarrays and bead arrays
    often make them uneconomical. Similarly, the high initial setup
    costs for mass spectrometry analysis generally make it
    economical only for very large-scale studies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A number of companies have attempted to develop more universal
    <FONT style="white-space: nowrap">&#147;lab-on-a-chip&#148;</FONT>
    solutions which could perform large numbers of complex
    biochemical operations on a single device. These chips typically
    incorporate a variety of micron-level features, such as channels
    and wells, but lack robust methods of fluid control such as
    valves. As a result, the products have been unable to support
    the complex fluidic manipulation required by large-scale
    experimentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The limitations of existing technologies become even more acute
    when clinicians attempt to translate scientific research into
    molecular diagnostics. Given the commercial nature of their
    operations, clinical laboratories need systems that can test
    large numbers of patient samples at low cost and with minimal
    labor requirements. Moreover, many of the most promising
    research studies rely on measuring each sample across tens or
    even hundreds of SNPs, gene expression levels or protein
    concentrations to diagnose or classify a disease. We believe
    that using standard microwell plate technology to make multiple
    measurements on a large number of samples is often too complex
    and expensive for most clinical laboratories. As a result, the
    molecular diagnostic tests adopted by clinical laboratories have
    generally been relatively simple or have required specialized
    machines to perform. Diagnostic approaches that require
    measuring large numbers of SNPs, gene expression levels or
    protein concentrations are generally not available or are
    available only from a diagnostic laboratory that specializes in
    the particular test.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To achieve and exploit breakthroughs in genomics, proteomics and
    molecular diagnostics, research and clinical laboratories need
    robust systems that deliver increased throughput and simpler
    workflows with decreased costs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Fluidigm Solution</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems are designed to overcome many of the limitations
    of conventional methods by empowering researchers and clinicians
    to rapidly perform a large number of experiments at one time and
    in nanoliter volumes, significantly increasing throughput,
    reducing costs associated with reagents and patient samples and
    reducing the time and number of steps involved. Our IFCs deliver
    these advantages through integration of sophisticated nanoliter
    fluid handling in an easy-to-use format. We believe the
    advantages of our IFC systems can be applied to a wide variety
    of applications across many fields using standard chemistries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For each application, we provide a complete IFC system
    consisting of specially designed single-use IFCs,
    instrumentation, software and support services. Our IFC systems
    are designed to be easily incorporated into our customers&#146;
    laboratory environments and analysis workflow. For example, our
    IFCs are the same size and shape as standard 384 microwell
    plates, which facilitate the loading and handling of our IFCs by
    standard laboratory equipment. Each IFC includes an elastomeric,
    or rubber-like, core that contains an extensive network of
    microfluidic components, such as valves, channels, pumps, mixers
    and other components that deliver samples and reagents to
    thousands of nanoliter volume chambers where individual assays
    can be performed. In much the same way that semiconductor
    technology has enabled tremendous computational power to be
    placed onto a single silicon chip, the integration of large
    numbers of miniaturized components on our IFCs enables
    sophisticated fluid handling at high throughput and low cost.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our BioMark 48.48 Dynamic Array IFC allows users to individually
    assay 48 samples against 48 primer-probe sets, generating 2,304
    separate real-time qPCR reactions on a single device. In May
    2008, we launched our 96.96 Dynamic Array IFC, which is
    configured to run 96 samples against 96 primer-probe sets,
    generating 9,216 separate reactions.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table compares the performance of one conventional
    384 microwell plate to that of one of our 48.48 Dynamic Array
    IFCs and one of our 96.96 Dynamic Array IFCs for a genotyping
    study involving 1,000 samples and 96 SNPs:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fluidigm 48.48<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fluidigm 96.96<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>384 Microwell<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Dynamic Array<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Dynamic Array<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Plate (5 &#181;l/well)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>IFC</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>IFC</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Runs for Study
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    250
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    42
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    11
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total reaction volume
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    480 ml
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    20 ml
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10 ml
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pipetting Steps
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    192,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4,032
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    2,112
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The advantages of our IFC systems over existing microwell-based
    systems include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Complexity.</I>&#160;&#160;Loading our IFC requires
    orders of magnitude fewer pipetting steps than
    384&#160;microwell plates for the same experiment, which reduces
    the time, cost and potential for error.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Improved Throughput.</I>&#160;&#160;A single IFC based on our
    96.96 format can conduct 9,216 real-time qPCR or other assays,
    or 24 times more assays than a single 384 microwell plate. The
    improved throughput reduces the time and cost associated with
    complex experiments and expands the number and range of
    experiments that may be conducted.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Nanoliter Precision.</I>&#160;&#160;Our IFC systems allow
    users to dispense samples and reagents in microliter volumes
    which are automatically combined and mixed in nanoliter and
    sub-nanoliter volumes. In addition to cost and workflow
    benefits, this capability makes it practical for users to
    conduct certain high sensitivity, low volume techniques, such as
    digital PCR and single cell analysis.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Sample and Reagent
    Requirements.</I>&#160;&#160;Obtaining patient samples for
    assays can also be costly, and in many cases the amount of those
    samples is finite. Our systems typically require between 0.5%
    and 1.0% of the amount of sample and reagent per reaction as
    conventional systems, allowing scarce samples and costly
    reagents to be conserved or tested more extensively.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Decreased Capital Cost.</I>&#160;&#160;A single BioMark
    system has the same throughput as the combined throughput of
    multiple conventional systems. As a result, for high volume
    users, the cost of purchasing one BioMark system can be much
    lower than the cost of purchasing the number of competing
    systems and associated robotic equipment required to provide the
    same throughput, even though our BioMark system may cost more on
    a per unit basis.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Compatibility with Existing
    Infrastructure.</I>&#160;&#160;Our IFCs incorporate plastic
    input frames that are the same size as standard microwell plates
    and are designed to work with the most commonly used laboratory
    systems, including existing robotic pipetting systems, bar code
    readers, plate handling systems and other equipment. Our IFCs
    are also designed to work with standard real-time qPCR
    techniques and TaqMan chemistries. As a result, we believe users
    are able to quickly introduce our systems into their
    laboratories and achieve results equal to or better than they
    were obtaining with conventional systems.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems also have significant advantages over other
    high-throughput approaches. For example, our BioMark system can
    detect gene expression levels over a much broader dynamic range
    than microarrays, pre-formatted arrays, bead arrays or mass
    spectrometry analysis. For genotyping, our BioMark system has a
    call rate equal to or better than conventional microwell-based
    systems. Also, our IFC systems provide researchers with needed
    flexibility in assay selection and study design. Unlike
    microarrays, bead arrays and pre-formatted arrays, our IFCs are
    not limited to detecting certain predetermined genetic markers.
    Instead, users can perform experiments with our IFCs using
    assays from their existing libraries, purchased from a wide
    variety of commercial sources or
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    developed in their own laboratories. Finally, the efficient
    workflow of our IFC systems enables users to complete an IFC run
    in less than three hours.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other high throughput approaches have advantages over
    conventional microwell plate systems that are similar to the
    advantages of our IFC systems. For example, microarrays,
    pre-formatted arrays, bead arrays and mass spectrometry analysis
    all reduce complexity and increase throughput as compared to
    conventional approaches when used for large scale
    experimentation, and, in many instances, are more cost-effective
    than conventional approaches. In addition, pre-formatted arrays
    significantly reduce sample and reagent consumption as compared
    to microwell plates. Also, microarrays and bead arrays have call
    rates for genotyping that are comparable to those obtained with
    our systems or with microwell plate systems. Because these
    systems are designed to detect thousands of genetic markers,
    they are often chosen by researchers to perform very large-scale
    association or survey studies over conventional microwell plate
    systems or our systems.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems address the needs of researchers and clinicians
    who perform large-scale experimentation in the areas of
    genomics, proteomics and molecular diagnostics. In particular,
    for validation studies or projects of a similar scale, our IFC
    systems substantially reduce cost, simplify workflow and
    increase throughput as compared to conventional microwell plate
    systems. Nevertheless, researchers and clinicians may be slow to
    adopt our IFC systems as they are based on technology that,
    compared to conventional technology, is new and not yet
    well-established in the industry. Moreover, many of the existing
    laboratories have already made substantial capital investments
    in their existing systems and may be hesitant to abandon that
    investment. While we believe our systems provide significant
    cost-savings, the initial price of our systems and the price of
    our IFCs is higher than conventional systems and standard
    384&#160;microwell plates. Our IFC systems are less well suited
    for smaller scale research initiatives where complexity and
    workflow issues may be less pressing and conventional systems
    may be more economical. As life science research continues to
    evolve and is commercialized, we believe that there will be
    increasing demand for life science automation solutions that
    enable experimentation on the scale supported by our IFC systems.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Applications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC technology has the potential to be applied to a vast
    range of research and commercial applications. We have
    commercialized IFC systems for life science research
    applications such as gene expression analysis, genotyping,
    digital PCR and protein crystallization. We believe that these
    applications are relevant to markets beyond life science
    research, such as the development of molecular diagnostics, and
    that IFC systems can be developed for numerous other life
    science applications. We and our academic collaborators have
    developed non-commercial IFCs for a wide variety of applications
    in the areas of genomics, proteomics, cellular biology and
    synthetic chemistry. As illustrated by the examples below,
    researchers have been able to utilize the advantages of our IFC
    systems in their laboratories to achieve significant research
    successes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Current
    Commercial Applications</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gene Expression Analysis.</I>&#160;&#160;Researchers may
    conduct gene expression studies to measure the activity of tens
    or hundreds of genes across hundreds or thousands of
    individuals. For these validation studies, it is often important
    to know the expression level of a gene, not merely whether the
    gene is &#147;on&#148; or &#147;off,&#148; as often either high
    or low activity level is associated with a particular
    characteristic or disease state. Our IFC systems have been used
    to deliver high throughput and precise measurements in gene
    expression analysis applications. For example, researchers at
    Myriad Genetics have identified panels of genes that could be
    used to predict cancer progression or select treatment options.
    However, the cost and complexity of high-throughput real-time
    qPCR using conventional microwell plates significantly limited
    researchers&#146; ability to perform the appropriate assays. In
    response, Myriad Genetics adopted our BioMark system which,
    together with our Dynamic Array IFCs, has allowed them to
    significantly reduce their pipetting workload, and therefore
    pursue research projects that may have been prohibitively
    cumbersome without our system.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Genotyping.</I>&#160;&#160;Researchers performing genotyping
    studies may begin by surveying the genomes of relatively few
    individuals looking for tens of thousands or even hundreds of
    thousands of SNPs. Analysis of these studies will often reveal
    that a relatively small number of SNPs appear to be correlated
    with the characteristic of interest. In
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    order to validate this analysis, researchers may conduct
    additional studies involving hundreds or even thousands of
    individuals focused on tens or hundreds of SNPs. For example,
    the National Cancer Institute&#146;s Core Genotyping Facility,
    or the CGF, collaborates with researchers at other government
    research centers and academic institutions with the goal of
    developing screens to identify individuals susceptible to
    particular forms of cancer and guiding the development of
    targeted therapeutics. One of the CGF&#146;s primary
    responsibilities in these collaborations is conducting the
    large-scale experiments necessary to accurately interrogate
    hundreds of SNPs on many patient samples. In a typical
    association study, the CGF runs 30 to 300 assays on 1,000 to
    10,000&#160;patient samples. Such large-scale studies are
    difficult and expensive to perform with conventional microwell
    plate technology. Using our BioMark system, the CGF continues to
    perform the same assays previously developed in its existing
    library of over 5,000 assays.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Genotyping analysis is also used in situations where research
    has already identified particular genetic profiles of interest
    and there is a need to test a group of subjects to determine
    which profile they fit. For example, the Alaska Department of
    Fish and Game uses our BioMark system to perform genotyping
    analysis to determine the region of origin of salmon caught in
    commercial or sport fisheries. By analyzing a large number of
    salmon, the department can gain an understanding of the effects
    that fisheries have on populations of salmon and thereby manage
    the resource more effectively. The department has developed
    panels for three species which range from 40 to 60 SNPs, and its
    throughput approaches 100,000 samples per year.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Digital PCR.</I>&#160;&#160;The widespread use of genetic
    testing in high-risk pregnancies has created strong interest in
    rapid and accurate molecular diagnostics for certain common
    chromosomal abnormalities. However, conventional methods have
    limitations related to speed, precision and the risks associated
    with sampling a significant amount of material from the fetus
    during an invasive procedure such as amniocentesis or chorionic
    villi sampling. Digital PCR has been identified as a technique
    for highly sensitive and precise nucleic acid measurement, but
    performing it with conventional laboratory equipment is so
    cumbersome that it has not been widely adopted. In an article
    published by Analytical Chemistry in August 2007, researchers at
    the laboratory of Professor Stephen Quake, our
    <FONT style="white-space: nowrap">co-founder,</FONT>
    at Stanford University demonstrated that digital PCR can be used
    for accurate measurement of trisomy&#160;21, or Down syndrome.
    Using our Digital Array IFC and DNA from human cell lines,
    Dr.&#160;Quake&#146;s laboratory was able to precisely measure
    the number of copies of a DNA sequence from this chromosome and
    at the same time measure the number of copies of a DNA sequence
    from another chromosome whose copy number does not vary. For
    trisomy 21, the ratio of these markers is significantly higher
    than normal. Similar work in pre-natal genetic testing is being
    pursued using our IFCs by other customers at leading academic
    institutions. We believe that with further clinical validation
    and development, such research could be developed into a
    diagnostic test that would require significantly less material
    from the fetus and provide results much more rapidly than
    current methods. We also believe that digital PCR will enable
    such diagnostics to ultimately be used in a non-invasive
    fashion, thus further reducing risk to the fetus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cancer researchers have identified a particular mutation in
    chronic myeloid leukemia cells that render those cells resistant
    to the drug Gleevec. Gleevec is typically used as the initial
    treatment for this type of leukemia and is often able to put the
    disease into remission for months or years. However, a
    significant proportion of these leukemia patients eventually
    develop mutated leukemia cells that are resistant to Gleevec.
    These mutated cells are initially very scarce and undetectable
    using conventional systems, but they eventually multiply and
    cause the patient to become symptomatic again. Researchers at
    the Fred Hutchinson Cancer Research Center have used our Digital
    Array IFC in their laboratory to test patient samples and have
    been able to detect these mutated cells earlier than with
    conventional techniques. With additional validation and
    demonstration of clinical relevance, we believe a test based on
    digital PCR could be a useful tool for monitoring patients who
    are diagnosed with chronic myeloid leukemia.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Protein Crystallization.</I>&#160;&#160;In order to determine
    how a particular protein interacts with other components of a
    disease pathway, researchers often attempt to determine its
    structure using protein crystallization. Because most proteins
    will crystallize only under very precise conditions that are
    specific to the particular protein, protein crystallization
    involves performing numerous assays to determine the conditions
    under which the protein crystallizes. As described in the April
    2006 issue of the journal <I>Science, </I>researchers at the
    Wilson lab of Scripps Research Institute in La Jolla, California
    used our Topaz system to understand how the H5N1 avian flu virus
    can infect humans. Researchers at the Wilson lab had prepared a
    small sample of the protein that the virus uses to attach
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     itself to cells in the respiratory tract. With the Topaz
    system, they were able to quickly screen a few microliters of
    the sample across a wide variety of different conditions and
    determine the optimum conditions for protein crystallization.
    Using this information, they were able to grow larger crystals
    using standard crystallization techniques. Subsequent analysis
    of the structure of the crystallized protein revealed why the
    current form of the avian H5N1 virus has not yet acquired the
    ability to readily infect humans compared to other flu viruses.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Potential
    Future Applications</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Molecular Diagnostics.</I>&#160;&#160;Life science research
    is revealing an increasing number of diseases and conditions
    that can be diagnosed, evaluated and monitored by measuring
    panels of gene expression levels, SNPs, proteins or other
    biomarkers. Validating these research findings and translating
    them into clinically available tests often requires life science
    automation systems that are able to efficiently measure multiple
    biomarkers in a large number of patient samples. Our existing
    IFC systems are able to measure certain nucleic acid biomarkers
    that are commonly used in these tests, and we expect that we
    will be able to develop IFC systems to measure other relevant
    biomarkers. As described above, researchers have used our IFC
    systems to detect clinically relevant biomarkers, such as drug
    resistant leukemia cells and fetal chromosomal abnormalities. We
    believe that the high throughput, flexibility and simplified
    workflow of our IFC systems could make them an attractive
    solution for validating and commercializing a wide range of
    molecular diagnostic tests being developed by researchers. In
    addition, we believe that our IFC systems&#146; ability to
    measure gene expression levels across a broad range and to
    detect nucleic acid sequences present in very low concentrations
    will support the development and commercialization of molecular
    diagnostic tests that would not be practical with conventional
    systems. Our IFC systems have not been cleared or approved by
    the U.S.&#160;Food and Drug Administration, or FDA, for use in
    any molecular diagnostic tests and we cannot currently market
    them for the purpose of performing molecular diagnostic tests.
    We do not have any current plans to develop products that are
    regulated by the FDA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Applications.</I>&#160;&#160;We believe that the
    inherent design flexibility of our core technology allows us to
    build IFC systems that can provide significant benefits in a
    wide range of fields and industries. For example, the
    architecture of our Dynamic Array is flexible and supports the
    development of IFCs that create matrixed combinations of a
    variable number of samples versus a variable number of reagents.
    In addition, our IFC technology utilizes a variety of
    microfluidic components, such as pumps, mixers and separation
    columns, that allow the implementation of sophisticated
    biochemical processes on our IFCs. While we have not commenced
    commercial development of IFC systems for these fields, we have
    developed IFCs for internal research purposes in such diverse
    fields as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    immunoassays, which can measure levels of protein expression and
    other molecules in a highly-parallel, multiplexed format;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    high-throughput drug screening, including the analysis of
    molecules that inhibit protein-protein and protein-nucleic acid
    interactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    chemical synthesis, including production of radio-labeled sugars
    which in combination with advanced medical imaging can help
    diagnose and monitor cancer;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    pharmacogenomics, an emerging field that analyzes how variations
    in human genomes affect the performance and toxicity of
    therapeutic agents;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    systems biology, an effort to understand the collective behavior
    of genes as they collaborate in networks;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    synthetic biology, an emerging field aimed at engineering
    biological systems to build novel biological functions, systems
    and perhaps organisms; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cellular assays, including stem cells and regenerative medicine,
    where our IFCs have been used to isolate, cultivate and analyze
    single cells.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Strategy</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to become a global leader in providing automated
    bio-analytical research and molecular diagnostic systems. Our
    business strategy consists of the following elements:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Establish our IFC Technology as the Leading Solution for a
    Broad Range of Life Science Applications.</I>&#160;&#160;Our
    initial sales and marketing efforts have been focused on
    establishing our IFC systems as leading solutions for high
    throughput life science research applications. We intend to
    leverage the market awareness and acceptance created by our
    initial product offerings to market new products and
    applications to life science researchers and to sell new and
    existing applications to customers in other markets, such as
    molecular diagnostics and applied genomics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Continue to Increase the Throughput and Efficiency of Our
    IFCs.</I>&#160;&#160;A primary focus of our research and
    development efforts is the development of IFCs with increased
    component density and, therefore, the ability to conduct an
    increased number of experiments on a single IFC. Increasing
    density provides value to our customers by increasing
    throughput, enhancing efficiency, reducing labor costs and
    reducing reagent and sample volumes. We expect that these
    increased capacity IFCs will allow us to deliver additional
    capabilities and cost savings, and further improve our
    competitive position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Expand Recurring IFC Revenue Stream Through Product
    Innovation and System Sales.</I>&#160;&#160;We intend to drive
    revenue growth by increasing the number of installed IFC
    systems, improving the cost per test of our IFCs and developing
    IFCs and systems for additional applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Provide Superior Customer Service.</I>&#160;&#160;We have a
    global sales force and support organization that offers
    technical solutions and customer support through direct
    relationships with our current and potential customers. Through
    the direct connection with our customers, we are able to better
    understand their needs and apprise them of new product offerings
    and technological advances in our current IFC systems, related
    instrumentation and software, while maintaining a consistent
    marketing message and high level of customer service.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Enhance IFC Manufacturing Efficiency.</I>&#160;&#160;We
    intend to enhance our manufacturing efficiency through
    improvements in our existing processes, development of new IFC
    designs and implementation of new manufacturing methods in order
    to improve our manufacturing yields and reduce our manufacturing
    costs. We believe that these improvements will enable us to
    deliver additional value to our customers and to maintain or
    enhance our advantages over competing systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Continue to Develop our Technology and Intellectual Property
    Position.</I>&#160;&#160;Our products are based on a set of
    related proprietary technologies that we have either developed
    internally or licensed from third parties. We intend to continue
    making significant investments in research and development to
    further expand and deepen our technological base. At the same
    time, we intend to maintain and strengthen our intellectual
    property position through the continued filing and prosecution
    of patents in the United States and internationally and through
    the in-licensing of third party intellectual property as
    appropriate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Products</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently market two IFC systems, the BioMark system for
    real-time qPCR and the Topaz system for protein crystallization.
    Each system consists of single-use IFCs, loaders that control
    the IFCs, readers that detect reactions on the IFCs and software
    for analyzing, annotating and archiving the data produced by the
    readers.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    BioMark System for Real-Time qPCR</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The BioMark system allows users to perform gene expression
    analysis, genotyping and digital PCR using standard TaqMan
    chemistry.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Dynamic Array IFCs</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our BioMark 48.48 Dynamic Array IFC is based on matrix
    architecture that allows users to individually assay 48 samples
    against 48 primer-probe sets, generating 2,304 real-time qPCR
    reactions on a single device. One version
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    of this IFC is optimized to perform gene expression analysis and
    another is optimized for genotyping, each assay in volumes of
    10&#160;nanoliters or less.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Dynamic Arrays in the fourth
    quarter of 2006 and, as of March&#160;29, 2008, 23 customers
    have purchased Dynamic Array IFCs for use in applications, such
    as SNP association follow-up studies and single stem-cell gene
    expression profiling. In May 2008, we launched our&#160;96.96
    Dynamic Array IFC, which is configured to run 96 samples against
    96 primer-probe sets, generating 9,216 reactions.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Digital Array IFCs</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The BioMark 12.765 Digital Array IFC is based on partitioning
    architecture that allows users to divide 12&#160;separate
    samples into 765 smaller samples and perform a real-time qPCR
    assay against each sample in less than 10&#160;nanoliter
    volumes. This IFC can be used for digital PCR and to precisely
    quantify the amount of a particular nucleic acid sequence
    present in a sample. We have been selling Digital Array IFCs
    since March 2007 and, as of March&#160;29, 2008, 14 customers
    have purchased Digital Array IFCs for use in applications, such
    as characterizing unculturable bacteria and cancer detection.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Instrumentation and Software</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our NanoFlex IFC Controller for the BioMark system fully
    automates the setup of IFCs for real-time qPCR-based experiments
    and includes software for implementing and tracking experiments.
    The instrumentation for our BioMark system controls the
    real-time qPCR process and detects the fluorescent signals
    generated using a white light source, emission and excitation
    filters, precision lenses, a licensed thermal cycler and a
    digital camera. We also offer various software packages that
    provide data analysis following data collection. Our analysis
    software shows data as color-coded maps of every position on the
    IFC, as amplification curves and as numeric tabular data.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Topaz System for Protein Crystallization</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Topaz system allows users to screen protein samples against
    a set of reagents in order to determine the optimum conditions
    for crystallizing a protein. The Topaz system includes IFCs
    similar to our Dynamic Array architecture that have been
    optimized for highly efficient protein crystallization screening.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Topaz
    Screening IFCs and Reagents</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1.96, 4.96 and 8.96 Screening IFCs for our Topaz system
    allow users to test 96 different reagents or reagent
    concentrations against one, four or eight different protein
    samples. We estimate that our screening IFCs require only
    1%&#160;the amount of sample used in standard microwell plate
    technologies, which is important because protein samples are
    often extremely scarce or difficult to prepare. The 4.96 and
    8.96 IFCs provide greater fluid handling efficiency by enabling
    the parallel processing of different samples containing a
    particular protein or different constructs of the same protein
    on a single IFC. This parallel processing saves pipetting steps
    and allows the user to determine the best sample or construct to
    use when scaling up production of a protein to generate
    diffraction-quality crystals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also re-sell third party reagents that we have tested with
    our Topaz system. Though our customers may purchase or make
    their own reagents for use with our system, we recommend that
    they use reagents that we have validated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Topaz systems in the first
    quarter of 2003 and, as of March&#160;29, 2008, 75 customers
    have purchased Topaz IFCs for use in applications such as
    functional studies and structure-based drug design.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Topaz
    Instrumentation and Software</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The NanoFlex IFC controller for the Topaz system fully automates
    the setup of diffusion-based protein crystallization experiments
    and includes software for tracking experiments.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Topaz AutoInspeX II workstation automates the scanning of
    Topaz IFCs and the identification of reaction chambers where
    crystallization has occurred. The AutoInspeX II incorporates
    high-end optical performance and a full suite of software for
    analyzing and archiving crystallization results. The
    sophisticated instrumentation and software included in our Topaz
    system enables users to automatically image and accurately score
    crystals as small as 10 microns by 20 microns.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Sales and
    Marketing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We distribute our systems through our direct field sales and
    support organizations located in North America, Europe and Asia
    and through distributors or sales agents in several European
    countries. Our global sales force is able to apprise our current
    and potential customers of new product offerings and
    technological advances in our current IFC systems, related
    instrumentation and software to help drive revenue growth. As
    our primary point of contact in the marketplace, our sales force
    ensures a consistent marketing message and high level of
    customer service, while enhancing our understanding of customer
    needs. As of December&#160;29, 2007, we had 24 people employed
    in sales, sales support and marketing, including 9 sales
    representatives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our sales and marketing efforts are targeted at laboratory
    directors and principal investigators at leading companies and
    institutions who need reliable, high throughput life science
    automation solutions to conduct large-scale experimentation. We
    seek to increase awareness of our products among our target
    customers through participation in tradeshows and academic
    conferences including sponsoring scientific lectures by
    prominent users of our systems. Because our systems are
    relatively new and require a capital investment, the sales
    process typically involves numerous interactions and
    demonstrations with multiple people within an organization. In
    addition, potential customers will often wish to conduct
    in-depth evaluations of the system including running identical
    sets of samples and reagents on both our system and competing
    systems. As a result of these factors and the budget cycles of
    our customers, our sales cycle, the time from initial contact
    with a customer to our receipt of a purchase order, can often be
    12&#160;months or longer.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Customers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have sold our BioMark and Topaz systems to a wide variety of
    biotechnology and pharmaceutical companies and to academic,
    governmental and clinical research institutions. As of
    March&#160;29, 2008, 75 of our Topaz systems have been installed
    at customer sites and 20 of our BioMark systems have been
    installed at customer sites. The following is a list of our
    representative customers in each of the listed markets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="19%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="40%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Customer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Market</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Application</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    MedImmune
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Pharmaceutical drug development&#160;&#151; real-time qPCR for
    gene expression profiling in research and clinical trials
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Myriad Genetics
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Cancer and diagnostics research&#160;&#151; real-time qPCR for
    differential gene expression in cancer studies
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Merck &#038; Co.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Gene expression profiling for pharmaceutical drug development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alaska Department of Fish and Game
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Genotyping
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Government wild-life resource management&#160;&#151; SNP
    genotyping for identification of salmon species
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    National Cancer Institute
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Genotyping
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Academic basic research; clinical diagnostics
    research&#160;&#151; genotyping for cancer research
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Chinese University of Hong Kong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Digital PCR
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Academic basic research; clinical diagnostics
    research&#160;&#151; digital PCR for early cancer detection
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vertex Pharmaceuticals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Protein crystallization
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Pharmaceutical drug discovery
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Revenue Concentration.</I>&#160;&#160;We receive a
    substantial portion of our revenue from a limited number of
    customers and grantors. For the year ended December&#160;29,
    2007, the Singapore Economic Development Board, or EDB,
    accounted for 24% of our total revenue. For the year ended
    December&#160;31, 2006, CTI Molecular Imaging accounted for 16%
    of our total revenue, Kikotech Co., Ltd. accounted for 14% of
    our total revenue and EDB accounted for 14% of our total
    revenue. For the year ended December&#160;31, 2005, Kikotech
    accounted for 16% of our total revenue and a collaboration
    agreement accounted for 14% of our total revenue. We anticipate
    that we will continue to be dependent on a limited number of
    customers and grantors for a significant portion of our revenue
    in the near future. The loss of any of these customers could
    have a material adverse effect on our results of operations and
    cash flows.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Competition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We compete with both established and development stage life
    science companies that design, manufacture and market
    instruments for gene expression analysis, genotyping, other
    nucleic acid detection and additional applications using
    established laboratory techniques. For example, companies such
    as Affymetrix, Applied Biosystems, BioTrove, Illumina, Roche
    Diagnostics and Sequenom have products for gene expression
    <FONT style="white-space: nowrap">and/or</FONT>
    genotyping that compete in certain segments of the market in
    which we sell our BioMark system. In addition, a number of other
    companies and academic groups are in the process of developing
    novel technologies for genetic analysis, many of which have also
    received grants from the National Human Genome Research
    Institute, a branch of the National Institutes of Health.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The high-throughput life science platforms industry is highly
    competitive and expected to grow more competitive with the
    increasing knowledge gained from molecular biology
    experimentation. Many of our competitors are either
    publicly-traded or are divisions of publicly-traded companies
    and enjoy several competitive advantages over us, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    significantly greater name recognition;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    greater financial and human resources;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    broader product lines and product packages;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    larger sales forces;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    larger and more geographically dispersed customer support
    organization;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    substantial intellectual property portfolios;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    established customer bases and relationships;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    greater experience in research and development, manufacturing
    and marketing.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the principal competitive factors in our markets
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cost of capital equipment and supplies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    ease of use;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    accuracy and reproducibility of results;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compatibility with existing laboratory processes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to successfully compete with existing products and
    future technologies, we will need to demonstrate to potential
    customers that the cost savings and performance of our
    technologies and products, as well as our customer support
    capabilities, are superior to those of our competitors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Technology</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products are based on a tiered set of related proprietary
    technologies that we have either developed internally or
    licensed from third parties.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Multi-Layer
    Soft Lithography</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFCs are manufactured using a technology known as
    multi-layer soft lithography, or MSL. With MSL, we are able to
    use standard semiconductor manufacturing techniques, along with
    certain proprietary processes, to create complex integrated
    microfluidic devices.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Using MSL technology, we are able to create valves, chambers,
    channels and other fluidic components on our IFCs at high
    density. We combine these components in complex arrangements
    that allow nanoliter quantities of fluids to be precisely
    directed to specific positions within the IFC. Unlike most prior
    microfluidic technologies, our IFCs do not rely on electricity,
    magnetism or similar approaches to control fluid movement.
    Rather, our IFCs control fluid flow with valves. The most
    important components on our IFCs are our NanoFlex valves, which
    are created by the intersection of two channels. When the valve
    is open, fluid is able to flow through the lower channel. When
    the upper or &#147;control&#148; channel is pressurized, the
    material separating the two channels is deflected into the lower
    channel, closing the valve and stopping fluid flow. If pressure
    is removed from the control channel, the channels return to
    their original form, and the valve is again open. The
    elastomeric properties of IFC cores allow our NanoFlex valves to
    form a reliable seal and cycle through millions of openings and
    closings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The elastomer we currently use for our commercial products is a
    form of silicone rubber known as polydimethylsiloxane, or PDMS,
    but we have researched other materials with different properties
    for specific purposes. PDMS is transparent, which allows fluid
    movement to be easily monitored with a variety of existing
    optical technologies, such as bright field or phase contrast
    microscopy. In addition, the gas permeability of PDMS allows the
    reliable metering of fluids with near picoliter precision by
    eliminating the bubble problems encountered by most other
    microfluidic technologies. In essence, we are able to pump
    fluids into closed reaction chambers at sufficient pressure to
    drive any air out of the chamber directly through the chamber
    walls. PDMS also supports an environment that is favorable to
    maintaining cell cultures.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have developed commercial manufacturing processes to
    fabricate valves, channels and chambers with dimensions in the
    10 to 100 micron range, at high density and with high
    reliability. For research purposes, we have created devices with
    both substantially smaller and larger features. Though our
    manufacturing is based on standard semiconductor manufacturing
    technologies and techniques, we have also developed novel
    processes for mold fabrication that enable mass production of
    high density IFCs with nanoliter volume features.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Integrated
    Fluidic Circuits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFCs incorporate several different types of technology that
    together enable us to use MSL to rapidly design and deploy new
    microfluidic applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Microfluidic Components.</I>&#160;&#160;The first level of
    our IFC technology is a library of components that perform basic
    microfluidic functions. We have proven designs for numerous
    elements, such as pumps, mixers, separation columns, control
    logic and reaction chambers. These are readily integrated to
    create circuits capable of performing a wide range of
    biochemical reactions. Even when it is necessary to integrate
    multiple elements to perform a particularly complex reaction,
    the area taken up on a circuit for a single reaction is small
    compared to a typical overall circuit size of three centimeters
    by three centimeters. As a result, we are routinely able to
    develop IFCs that perform thousands of reactions per square
    centimeter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Architectures.</I>&#160;&#160;The second level of our IFC
    technology comprises the architectures we have designed to
    exploit our ability to conduct thousands of reactions on a
    single IFC. The first of these is the Dynamic Array, a matrix
    architecture that allows multiple different samples and multiple
    different reagents to be loaded onto a single IFC and then
    combined so that there is an isolated reaction between each
    sample and each reagent. The primary advantage of this
    architecture is that each sample and reagent has to be pipetted
    only once per IFC rather than once per reaction, as is the case
    with plate-based technologies. For example, a single 48.48
    Dynamic Array IFC can perform a total of 2,304 unique reactions
    between 48 samples and 48 reagents with only 96 pipetting steps.
    With conventional microwell plate-based technologies, the same
    experiment would require about 4,608 pipetting steps and at
    least six conventional microwell plates. Our Digital Array
    architecture provides similar benefits with respect to pipetting
    steps and fluid handling. The Digital Array architecture allows
    a sample to be split into hundreds or thousands of smaller
    samples. Separate reactions can then be conducted on each of the
    smaller samples.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interface and Handling Frames.</I>&#160;&#160;The third level
    of our IFC technology involves the interaction of our IFCs with
    the actual laboratory environment. The elastomeric blocks at the
    center of our IFCs sit in specially designed frames that are
    able to deliver samples and reagents to the block. These frames
    are the same size as standard 384&#160;microwell plates and have
    sample and reagent input ports laid out in a standard
    384&#160;microwell plate format. As a result, our IFCs can be
    loaded with standard laboratory pipetting robots and can be used
    with standard plate handling equipment.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Technological Advances.</I>&#160;&#160;In the second quarter
    of 2002, we sold the first prototype of our 1.48 IFC for our
    Topaz system, which featured 22 valves capable of 2.5 assays per
    square centimeter. In the second quarter of 2006, we introduced
    our 12.765&#160;Digital Array IFC, with over 1,000 valves
    capable of more than 1,000 assays per square centimeter, a
    46-fold increase in valve density and a 400-fold increase in
    assay capability. The chart below illustrates the timing of a
    number of our technological advances. We introduced our
    96.96&#160;Dynamic Array IFC in May 2008, which again increased
    the number of valves and assays per square centimeter relative
    to the 48.48&#160;Dynamic Array. In the semiconductor industry,
    Moore&#146;s Law describes the principle that the shrinking of
    features has allowed for a doubling of transistors on a chip
    approximately every 18&#160;months. Based on manufacturing
    processes borrowed from those in the semiconductor industry,
    Fluidigm has similarly achieved significant gains in the density
    and productivity of our IFCs.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a1f3943222.gif" alt="(BAR GRAPH)">
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Software
    and Instrumentation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have developed instrumentation technology to load samples and
    reagents on to the IFC and to control and monitor reactions
    within our IFCs. Our NanoFlex controller consists of commercial
    pneumatic components and both custom and commercial electronics.
    It uses precise control of multiple pressures to independently
    move fluid through up to four IFCs simultaneously and can be
    configured for use with either our BioMark or Topaz systems. Our
    Topaz Auto-InspeX II workstation consists of a commercial
    microscope, illumination source, stage and camera system in a
    single package. Our BioMark system consists of a commercial
    thermal cycler packaged with a sophisticated fluorescence
    detection system. All of these instruments are designed to be
    easily introduced into standard automated lab environments.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have developed specialized software packages to manage and
    analyze the unusually large amounts of data produced by our
    systems. Our BioMark gene expression analysis software
    automatically identifies individual real-time qPCR reactions
    from fluorescent images and generates amplification threshold
    crossing values allowing researchers to readily perform complete
    normalized comparative gene expression analysis across large
    numbers of samples and assays. Similarly, the BioMark genotyping
    analysis software automatically clusters fluorescent intensities
    from individual genotype reactions and makes genotype calls
    across individual and multiple IFC runs. Our Topaz system
    software incorporates sophisticated image processing and
    analysis functionality that enables the
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    automatic detection and classification of protein crystals. Most
    of our software development uses Microsoft.NET tools to
    facilitate interaction with typical laboratory information
    management systems.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Manufacturing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our manufacturing operations are located in Singapore and South
    San&#160;Francisco. Our Singapore facility fabricates all of our
    IFCs for commercial sale. IFCs for research and development
    purposes are fabricated at both locations. We manufacture
    instrument systems at both locations, with certain instruments
    assembled in Singapore and others in South San&#160;Francisco.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Singapore facility commenced operations in October 2005 and
    established full process capability for its first product, the
    Topaz Screening IFC, in June 2006 and for its first Dynamic
    Array, the 48.48 Dynamic Array in October 2006. Our Singapore
    facility has been producing components for our Topaz system
    since October 2006 and components for our BioMark system since
    December 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We established our manufacturing facility in Singapore to take
    advantage of the skilled workforce, supplier and partner
    network, lower operating costs and government support available
    there. Our IFC manufacturing process includes photolithography
    and fabrication technologies that are very similar to those used
    in the fabrication of semiconductor chips. As a result, we are
    able to hire from a pool of skilled manpower created by the
    existing semiconductor industry in Singapore. Similarly, the
    Singapore semiconductor industry has created a broad network of
    potential suppliers and partners for our manufacturing
    operations. We are able to locally source a large proportion of
    the raw materials required in our processes and have been able
    to collaborate with local engineering companies to develop
    enabling technologies for IFC fabrication. We have made
    significant improvements in yields through process improvements
    at our Singapore facility and IFC production increased
    three-fold in 2007 compared to 2006.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our manufacturing operations in Singapore have been supported by
    grants from the Singapore Economic Development Board, or EDB,
    which provide partial reimbursement of qualifying costs arising
    from research and development projects relating to our
    manufacturing process. Our arrangements with EDB require us to
    maintain a significant and increasing manufacturing and research
    and development presence in Singapore.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our South San&#160;Francisco facility began producing Topaz
    systems in 2002. In 2005, our South San Francisco facility began
    assembling instrumentation for our BioMark system.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect that our existing manufacturing capacity for
    instrumentation and IFCs is sufficient to meet our needs for at
    least the next two years. However, we are considering developing
    additional capacity in order to ensure that all or most of our
    products are produced by at least two different facilities. We
    believe that having dual sources for our products would help
    mitigate the potential impact of a production disruption at any
    one of our facilities and that such redundancy may be required
    by our customers in the future. We have not determined the
    timing or location of any additional manufacturing capacity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on a limited number of suppliers for certain components
    and materials used in our systems. While we are in the process
    of qualifying additional sources of supply, we cannot predict
    how long that qualification process will last. If we were to
    lose one or more of our limited source suppliers, it would take
    significant time and effort to qualify alternative suppliers.
    Key components in our products that are supplied by sole or
    limited source suppliers include a thermal cycler customized to
    our specifications, a specialized polymer from which our IFC
    cores are fabricated, the plastic carrier that holds the IFC
    core in certain of our products and the specialized high
    resolution camera lenses used in the reader for our BioMark
    system. We are neither a major customer of our suppliers, nor do
    we have long term supply contracts with most of these suppliers.
    These suppliers may therefore give other customers&#146; needs
    higher priority than ours, and we may not be able to obtain
    adequate supply in a timely manner or on commercially reasonable
    terms.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into a supply agreement with Eppendorf AG to
    provide to us a thermal cycler customized to our specifications.
    Pursuant to this agreement, we have agreed to purchase from
    Eppendorf at least a specified minimum number of units each year
    in exchange for volume discounts. We have also agreed, during
    the term of the agreement, not to manufacture or sell a product,
    in stand-alone form, or compete in any way directly or
    indirectly with the customized thermal cycler provided by
    Eppedorf in stand-alone form. Eppendorf has agreed to refrain
    from providing a similarly customized unit to any person or
    entity until two years after the agreement has terminated.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    67
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     Either party may terminate the agreement with good reason,
    which includes a failure to timely deliver conforming units,
    subject to a cure period. Eppendorf may terminate the agreement
    if we purchase fewer than 75% of the specified minimum units for
    each of two consecutive years. After April&#160;1, 2010, either
    party may terminate the supply agreement upon six months prior
    written notice.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have assembled experienced research and development teams at
    our South San&#160;Francisco and Singapore locations with the
    scientific, engineering, software and process talent that we
    believe is required to grow our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">New
    Product and Application Development</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The largest component of our current research and development
    effort is in the areas of new product and new application
    development. In particular, we are focused on extending and
    supporting the BioMark and Topaz product lines by developing new
    DNA-based applications, improving the introduction of these
    products into existing workflows of our customers and increasing
    the functionality of the products. For example, the addition of
    multi-color analysis allows Digital Array users to analyze as
    many as 36,720 real-time qPCR assays in parallel on a single
    Digital Array.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are also developing new product lines that leverage our
    investment in our Dynamic Array and Digital Array architectures.
    As an example, we have demonstrated Dynamic Array formats that
    can implement over 1,000 immunoassays in parallel. We also
    invest in extending the reach of existing chip designs through
    new chemistries. From time to time, we collaborate with other
    life science companies, universities and government labs on the
    development of prototype IFCs for particular purposes. For
    example, there have been a variety of publications by
    independent researchers demonstrating the use of MSL for
    applications such as immunoassays based on surface-plasma
    resonance, cell culturing and complementary DNA library
    synthesis from single cells.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Process
    Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The second component of our research and development effort is
    process development. We frequently develop new manufacturing
    processes and test methods to support new IFC designs, drive
    down manufacturing cost and increase manufacturing throughput.
    We also invest in manufacturing automation, process changes and
    design modifications in order to improve yield and lower costs
    on existing IFCs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">New
    Technology Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have active research and development efforts to increase the
    density of components on our IFCs and to lower the materials
    cost of our current production methods. We are evaluating new
    materials that can increase the functionality of existing
    products and that would allow our IFCs to be used for a wider
    variety of biological and chemical reactions. Over the longer
    term, we are seeking ways to transfer functionality from
    instrumentation to IFCs to support development of field-based
    and point-of-care applications.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development expenses were $11.4&#160;million,
    $15.6&#160;million, $14.4&#160;million and $3.3&#160;million in
    2005, 2006, 2007 and the three months ended March&#160;29, 2008.
    As of December&#160;29, 2007, 68 of our employees were engaged
    in research and development activities.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Scientific
    Advisory Board</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We maintain a scientific advisory board, consisting of members
    with experience and expertise in the field of microfluidic
    systems and their application, who provide us with consulting
    services. The scientific advisory board generally does not meet
    as a group but instead, at our request, the individual members
    advise us on matters related to their areas of expertise. We
    have entered into agreements with each of our advisors, other
    than Stephen Quake, that require them spend between 6 and
    12&#160;days each year advising us and provide for stock option
    grants to the advisor.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     Dr.&#160;Quake serves as chair of the Scientific Advisory Board
    pursuant to a broader consulting agreement with us. Our
    scientific advisory board consists of the following members:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stephen Quake, Ph.D.</I> is a co-founder of Fluidigm and the
    chair of our scientific advisory board. He is a co-chair of the
    bioengineering department at Stanford University and an
    investigator of the Howard Hughes Medical Institute.
    Dr.&#160;Quake received a B.S. in Physics and a M.S. in
    Mathematics from Stanford University and a Ph.D. in Physics from
    Oxford University. Dr. Quake has been a member of our scientific
    advisory board since June 1999.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Frances H. Arnold, Ph.D.</I> is the Dick and Barbara
    Dickinson Professor of chemical engineering and biochemistry at
    the California Institute of Technology. She is a member of the
    National Academy of Engineering and a fellow at the American
    Institute for Medical and Biological Engineering.
    Dr.&#160;Arnold received a B.S. in Mechanical and Aerospace
    Engineering from Princeton University and a Ph.D. in Chemical
    Engineering from the University of California, Berkeley. Dr.
    Arnold has been a member of our scientific advisory board since
    August 1999.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>James M. Berger, Ph.D.</I> is a Professor of Biochemistry and
    Molecular Biology at the University of California, Berkeley and
    a member of the Physical Biosciences Division, Lawrence Berkeley
    National Laboratory. Dr.&#160;Berger received a B.S. in
    Biochemistry from the University of Utah and a Ph.D. in
    Biochemistry from Harvard University. Dr. Berger has been a
    member of our scientific advisory board since June 2002.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Carl Hansen, Ph.D.</I> is an Assistant Professor in the
    Department of Physics and Astronomy at the University of British
    Columbia. Dr.&#160;Hansen received a Ph.D. and M.S. in Applied
    Physics from the California Institute of Technology and a B.S.
    in Engineering Physics/Electrical Engineering/Honors Math from
    the University of British Columbia. Dr.&#160;Hansen has been a
    member of our Scientific Advisory Board since May 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Frank McCormick, Ph.D.</I> is the David A. Wood Distinguished
    Professor of Tumor Biology and the E. Dixon Heise Distinguished
    Professor in Oncology at the University of California,
    San&#160;Francisco, or UCSF. He is also the director of
    UCSF&#146;s Comprehensive Cancer Center. He is a member of the
    Institute of Medicine and a fellow of The Royal Society.
    Dr.&#160;McCormick received a B.Sc. in Biochemistry from the
    University of Birmingham and a Ph.D. in Biochemistry from the
    University of Cambridge. Dr. McCormick has been a member of our
    scientific advisory board since November 2006.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Howard M. Shapiro,&#160;M.D.</I> is a lecturer on Pathology
    at Harvard Medical School, a visiting scientist at the
    Rosenstiel Basic Medical Sciences Research Center at Brandeis
    University and a research associate in Medicine and Pathology at
    Beth Israel Hospital. Dr.&#160;Shapiro received a B.A. from
    Harvard College and an M.D. from New York University School of
    Medicine. Dr.&#160;Shapiro has been a member of our scientific
    advisory board since December 1999.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Richard N. Zare,&#160;Ph.D.</I> is the Marguerite Blake
    Wilbur Professor of Natural Science and chair of the chemistry
    department at Stanford University. He is a member of the
    National Academy of Sciences, the American Academy of Arts and
    Sciences and the recipient of the National Medal of Science.
    Dr.&#160;Zare received a B.S. in Chemistry and Physics and a
    Ph.D. in Chemical Physics from Harvard University. Dr.&#160;Zare
    has been a member of our scientific advisory board since
    December 2000.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Intellectual
    Property Strategy and Position</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm&#146;s core technology originated at the California
    Institute of Technology, or Caltech, in the laboratory of
    Professor Stephen Quake, who is a co-founder of Fluidigm.
    Dr.&#160;Quake, his students and their collaborators pioneered
    the application of multilayer soft lithography in the field of
    microfluidics. In particular, Dr.&#160;Quake&#146;s laboratory
    developed technologies that enabled the production of
    specialized valves and pumps capable of controlling fluid flow
    at nanoliter volumes. In a series of transactions, we
    exclusively licensed from Caltech the relevant patent filings
    relating to these developments.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    69
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our license agreement with Caltech provides us with an
    exclusive, worldwide license to certain patents and related
    intellectual property, as well as the right to prosecute
    licensed patent filings worldwide at our expense and to initiate
    any infringement proceedings. Caltech retains the right to use
    the licensed materials for noncommercial educational and
    research purposes, as well as any rights necessary to comply
    with the statutory rights of the U.S.&#160;government. We have
    issued shares of our common stock to Caltech and, in addition to
    an annual license fee, we agreed to pay to Caltech royalties
    based on sales revenues of licensed products on a
    <FONT style="white-space: nowrap">country-by-country</FONT>
    basis. The license agreement will terminate as to each country
    and licensed product upon expiration of the last-to-expire
    patent covering licensed products in each country.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also have co-exclusive licenses to patents and patent
    applications owned by Harvard University, a non-exclusive,
    field-limited license to patents and patent applications
    controlled by Gyros AB and additional patent licenses from other
    academic institutions and companies.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our license agreements with Harvard University allow us to grant
    sublicenses of our rights in limited situations, and Harvard
    retains the right to use and to grant to others non-exclusive
    licenses to use the patented subject matter for academic
    research purposes. We have issued shares of our common stock to
    Harvard and, in addition to an annual license fee, we agreed to
    pay to Harvard royalties based on sales revenues of licensed
    products on a
    <FONT style="white-space: nowrap">country-by-country</FONT>
    basis. Harvard is responsible for filing and maintaining all
    licensed patents, but we must reimburse Harvard for our share of
    its related patent prosecution expenses. We have the right to
    prosecute any infringement of our licensed patent rights. The
    license agreement will terminate with the last-to-expire of the
    licensed patents.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our license agreement with Gyros AB grants us a non-exclusive,
    field-limited license to specified patents and patent
    applications filings in exchange for an upfront fee plus annual
    royalty payments based on net revenues of licensed products
    above an annual license fee. Gyros has the right to terminate if
    we assign our interest to a third party competitor of Gyros or
    if we come under common control of such a third party.
    Otherwise, the license will terminate at the expiration of the
    last-to-expire of the licensed patents.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our license agreement with The UAB Research Foundation grants us
    an exclusive worldwide license, including the right to
    sublicense, under certain intellectual property rights. Such
    license grant is subject to prior existing license grants, plus
    the reservation of rights to UAB for internal research, academic
    and educational purposes
    <FONT style="white-space: nowrap">and/or</FONT> for
    performance of services for other institutions and to fulfill
    obligations to the U.S.&#160;government. We prosecute and
    maintain the patent rights licensed under this agreement. The
    license agreement will terminate at the expiration of the
    last-to-expire of the licensed patents.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our patent strategy is to seek broad patent protection on new
    developments in microfluidic technology and then later file
    patent applications covering new implementations of the
    technology and new microfluidic circuit architectures utilizing
    the technology. As these technologies are implemented and
    tested, we file new patent applications covering scientific
    methodology enabled by our technology. Additionally, where
    appropriate, we file new patent applications covering
    instrumentation and software that are used in conjunction with
    our IFCs.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of March&#160;29, 2008, we own or have licensed 81 issued US
    patents and 62 issued international patents.  There are
    240&#160;pending patent applications, including 116 in the
    United States, 118 international applications and 6 applications
    filed under the Patent Cooperation Treaty. The issued patents we
    have licensed from Caltech expire between 2019 and 2024, and the
    issued patents owned by us expire between 2018 and 2025.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The patent positions of companies like ours are generally
    uncertain and involve complex legal and factual questions. Our
    patents may not enable us to obtain or keep any competitive
    advantage. Our pending U.S.&#160;and foreign patent applications
    may not issue as patents or may not issue in a form that will be
    advantageous to us. Any patents we have obtained or do obtain
    may be challenged by re-examination, opposition or other
    administrative proceeding, or may be challenged in litigation,
    and such challenges could result in a determination that the
    patent is invalid. In addition, competitors may be able to
    design alternative methods or devices that avoid infringement of
    our patents. To the extent our intellectual property protection
    offers inadequate protection, or is found to be invalid, we are
    exposed to a greater risk of direct competition. If our
    intellectual property does not provide adequate protection
    against our competitors&#146; products, our competitive position
    could be adversely affected, as could our business. Both
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    70
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the patent application process and the process of managing
    patent disputes can be time consuming and expensive.
    Furthermore, the laws of some foreign countries may not protect
    our intellectual property rights to the same extent as do the
    laws of the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to pursuing patents on our technology, we have taken
    steps to protect our intellectual property and proprietary
    technology by entering into confidentiality agreements and
    intellectual property assignment agreements with our employees,
    consultants, corporate partners and, when needed, our advisors.
    Such agreements may not be enforceable or may not provide
    meaningful protection for our trade secrets or other proprietary
    information in the event of unauthorized use or disclosure or
    other breaches of the agreements, and we may not be able to
    prevent such unauthorized disclosure. Monitoring unauthorized
    disclosure is difficult, and we do not know whether the steps we
    have taken to prevent such disclosure are, or will be, adequate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our
    non-infringement of the patents or proprietary rights of third
    parties. Third parties have asserted and may assert in the
    future that we are employing their proprietary technology
    without authorization. Competitors may assert that our products
    infringe their intellectual property rights as part of a
    business strategy to impede our successful entry into those
    markets. In addition, our competitors and others may have
    patents or may in the future obtain patents and claim that use
    of our products infringes these patents. We could incur
    substantial costs and divert the attention of our management and
    technical personnel in defending against any of these claims.
    Parties making claims against us may be able to obtain
    injunctive or other relief, which could block our ability to
    develop, commercialize and sell products, and could result in
    the award of substantial damages against us. In the event of a
    successful claim of infringement against us, we may be required
    to pay damages and obtain one or more licenses from third
    parties, or be prohibited from selling certain products. We may
    not be able to obtain these licenses at a reasonable cost, if at
    all.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Government
    Regulation</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Federal Food, Drug and Cosmetic Act, or FFDCA, defines
    medical devices to mean, among other things, &#147;an
    instrument, apparatus . . . in&#160;vitro reagent, or other
    similar or related article . . . intended for use in the
    diagnosis of disease or other conditions . . ..&#148; This broad
    definition includes in&#160;vitro diagnostic products, or IVDs.
    Our products are currently labeled and sold for research
    purposes only, and we sell them to pharmaceutical and
    biotechnology companies, academic institutions and life sciences
    laboratories. Because our products are not intended for use in
    clinical practice, they do not fit the definition of a medical
    device under the FFDCA and thus are not subject to regulation by
    the U.S.&#160;Food and Drug Administration, or FDA. However, in
    the future, certain of our products or related applications
    could be subject to the FDA&#146;s regulation, the FDA&#146;s
    regulatory jurisdiction could be expanded to include our
    products, or both. For example, if we wished to label and market
    our products for use in performing clinical diagnostics, they
    would be considered medical devices and FDA clearance or
    approval would be required.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless an exemption applies, each medical device we wish to
    commercially distribute in the United States would require
    either prior 510(k) clearance or prior pre-market approval from
    the FDA. The FDA classifies medical devices into one of three
    classes. Devices deemed to pose lower risk to the patient are
    placed in either class&#160;I or II, which, unless an exemption
    applies, requires the manufacturer to submit a pre-market
    notification requesting FDA clearance for commercial
    distribution pursuant to Section&#160;510k of the FFDCA. This
    process, known as 510(k) clearance, requires that the
    manufacturer demonstrate that the device is substantially
    equivalent to a previously cleared 510(k) device or a
    <FONT style="white-space: nowrap">&#147;pre-amendment&#148;</FONT>
    class&#160;III device for which pre-market approval
    applications, or PMAs, have not been required by the FDA. This
    process typically takes from four to twelve months, although it
    can take longer. Most class&#160;I devices are exempted from
    this requirement. Devices deemed by FDA to pose the greatest
    risk, such as life-sustaining, life-supporting or implantable
    devices, or those deemed not substantially equivalent to a
    legally marketed predicate device, are placed in class&#160;III.
    Class&#160;III devices typically require PMA approval. To obtain
    PMA approval, an applicant must demonstrate the safety and
    effectiveness of the device based, in part, on data obtained in
    clinical studies. PMA reviews generally last between one and two
    years, although they can take longer. Both the 510(k) and the
    PMA processes can be expensive and lengthy and may not result in
    clearance or approval. If we are required to submit our products
    for pre-market review by FDA, we may be required to cease
    marketing while we obtain premarket clearance or approval from
    FDA. There would be no assurance that we could ever obtain such
    clearance or approval.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    71
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Changes to a device which have received PMA approval typically
    require a new PMA or PMA supplement. Changes to a device that
    receives 510(k) clearance, that could significantly affect its
    safety or effectiveness, or that would constitute a major change
    in its intended use, require a new 510(k) clearance or possibly
    PMA approval. The FDA requires each manufacturer to make this
    determination initially, but the FDA can review any of these
    decisions. If the FDA disagreed with our determination not to
    seek a new 510(k) clearance, the FDA could require us to seek a
    new 510(k) clearance or pre-market approval. The FDA also could
    require us to cease manufacturing
    <FONT style="white-space: nowrap">and/or</FONT>
    recall the modified device until 510(k) clearance or pre-market
    approval was obtained. Also, in these circumstances, we could be
    subject to warning letters, significant regulatory fines or
    penalties, seizure or injunctive action, or criminal prosecution.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, if our products become subject to regulation as a
    medical device, we would become subject to additional FDA
    requirements, and we could be subject to unannounced inspections
    by FDA and other governmental authorities, which could increase
    our costs of doing business. Specifically, manufacturers of
    medical devices must comply with various requirements of the
    FFDCA and its implementing regulations, including:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the Quality System Regulations, labeling regulations,
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    medical device reporting, or MDR, regulations,
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    correction and removal regulations,&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    post-market surveillance regulations, which include restrictions
    on marketing and promotion.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We would need to continue to invest significant time and other
    resources to ensure ongoing compliance with FDA quality system
    regulations and other post-market regulatory requirements.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our failure to comply with applicable FDA regulatory
    requirements, or our failure to timely and adequately respond to
    inspectional observations, could result in enforcement action by
    the FDA, which may include the following sanctions:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fines, injunctions and civil penalties;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recall or seizure or our products;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    operating restrictions, partial suspension or total shutdown of
    production;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in clearance or approval, or failure to obtain approval
    or clearance of future product candidates or product
    modifications;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    restrictions on labeling and promotion;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    warning letters, fines, or injunctions;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    withdrawal of previously granted clearances or
    approvals;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    criminal prosecution.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    International sales of medical devices are subject to foreign
    government regulations, which vary substantially from country to
    country. The primary regulatory environment in Europe is that of
    the European Union (EU), which includes most of the major
    countries in Europe. Currently, 27 countries make up the EU.
    Other countries, such as Switzerland, have voluntarily adopted
    laws and regulations that mirror those of the EU with respect to
    medical devices. The EU has adopted numerous directives and
    standards regulating the design, manufacture, clinical trials,
    labeling and adverse event reporting for medical devices.
    Devices that comply with the requirements of a relevant
    directive will be entitled to bear the CE conformity marking,
    indicating that the device conforms to the essential
    requirements of the applicable directives and, accordingly, can
    be commercially distributed throughout Europe.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Outside of the EU, regulatory approval needs to be sought on a
    <FONT style="white-space: nowrap">country-by-country</FONT>
    basis in order to market medical devices. Although there is a
    trend towards harmonization of quality system standards,
    regulations in each country may vary substantially which can
    affect timelines of introduction.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    72
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employees</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, we had 131&#160;employees, of
    which 68 work in research and development, 18 work in general
    and administrative, 21 work in manufacturing and 24 work in
    sales and marketing. None of our employees are represented by a
    labor union or are the subject of a collective bargaining
    agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property
    and Environmental Matters</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We lease approximately 35,000&#160;square feet of office and
    laboratory space at our headquarters in South
    San&#160;Francisco, California under leases and subleases that
    expire in March 2011, and 13,000&#160;square feet of
    manufacturing and office space at our facility in Singapore
    under a lease that expires in September 2008. In addition, we
    lease office space in Tokyo and Osaka, Japan. We are in
    negotiations to extend and expand our lease relating to our
    Singapore facility and we believe that our existing office,
    laboratory and manufacturing space, together with additional
    space and facilities available on commercially reasonable terms,
    will be sufficient to meet our needs for at least the next two
    years.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development and manufacturing processes involve
    the controlled use of hazardous materials, including flammables,
    toxics, corrosives and biologics. Our research and manufacturing
    operations produce hazardous biological and chemical waste
    products. We seek to comply with applicable laws regarding the
    handling and disposal of such materials. Given the small volume
    of such materials used or generated at our facilities, we do not
    expect our compliance efforts to have a material effect on our
    capital expenditures, earnings and competitive position.
    However, we cannot eliminate the risk of accidental
    contamination or discharge and any resultant injury from these
    materials. We do not currently maintain separate environmental
    liability coverage and any such contamination or discharge could
    result in significant cost to us in penalties, damages and
    suspension of our operations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Legal
    Proceedings</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not engaged in any material legal proceedings.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    73
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='111'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers and Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers and directors, and their ages and
    positions as of March&#160;29, 2008, are as set forth below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="51%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Age</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    38
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    President, Chief Executive Officer and Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vikram Jog
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    51
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Chief Financial Officer
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    53
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Executive Vice President, Research and Development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    57
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Legal Affairs and General Counsel, Secretary
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    49
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Worldwide Manufacturing and Managing Director of
    Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel
    Colella<SUP style="font-size: 85%; vertical-align: text-top">(2),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    68
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael W. Hunkapiller,
    Ph.D<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    59
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones,
    Ph.D.<SUP style="font-size: 85%; vertical-align: text-top">(1),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    53
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(1),(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    55
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A.
    Young<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    75
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Audit Committee
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Compensation Committee
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Nominating and
    Governance Committee
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gajus V. Worthington </I>is a Co-Founder of Fluidigm and has
    served as our President and Chief Executive Officer and a
    Director since our inception in June 1999. From May 1994 to
    April 1999, Mr.&#160;Worthington held various staff and
    management positions at Actel Corporation, a public
    semiconductor corporation. Mr.&#160;Worthington received a B.S.
    in Physics and an M.S. in Electrical Engineering from Stanford
    University.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vikram Jog </I>has served as our Chief Financial Officer
    since February 2008. From April 2005 to February 2008,
    Mr.&#160;Jog served as Chief Financial Officer for XDx, Inc., a
    molecular diagnostics company. From March 2003 to April 2005,
    Mr.&#160;Jog was a Vice President of Applera Corporation, a life
    science company, and Vice President of Finance for its related
    businesses, Celera Genomics and Celera Diagnostics. From April
    2001 to March 2003, Mr.&#160;Jog was Vice President of Finance
    for Celera Diagnostics and Corporate Controller of Applera
    Corporation. Mr.&#160;Jog received a Bachelor of Commerce degree
    from Delhi University and an M.B.A. from Temple University.
    Mr.&#160;Jog is a member of the American Institute of Certified
    Public Accountants.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Robert C. Jones </I>has served as our Executive Vice
    President, Research and Development since August 2005. From
    August 1984 to July 2005, Mr.&#160;Jones held various managerial
    and research and development positions at Applied Biosystems, a
    laboratory equipment and supplies manufacturer that is a
    division of Applera Corporation, including: Senior Vice
    President Research and Development from April 2001 to August
    2005, Vice President and General Manager Informatics Division
    from 1998 to 2001,&#160;and Vice President PCR Business Unit
    from 1994 to 1998. Mr.&#160;Jones received a BSEE and an MSEE in
    Computer Engineering from the University of Washington.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>William M. Smith </I>has served as our Vice President, Legal
    Affairs and General Counsel as well as our Secretary since May
    2000 and served as a Director from May 2000 to April 2008.
    Mr.&#160;Smith served as a partner at the law firm of Townsend
    and Townsend and Crew, LLP from 1985 through April 2008.
    Mr.&#160;Smith received a J.D. and an M.P.A. from the University
    of Southern California and a B.A. in Biology from the University
    of California, San&#160;Diego.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mai Chan (Grace) Yow </I>has served as our Vice President,
    Worldwide Manufacturing, and Managing Director, Fluidigm
    Singapore Pte. Ltd., our Singapore subsidiary, since March 2006.
    From June 2005 to March 2006,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ms.&#160;Yow served as General Manager of Fluidigm Singapore
    Pte. Ltd. From August 2004 to May 2005, Ms.&#160;Yow served as
    Vice President Engineering (Asia) for Kulicke and Soffa, a
    public semiconductor equipment manufacturer. From March 1991 to
    July 2004, Ms.&#160;Yow served as Director, Assembly Operations,
    Plant Facilities and EHS, for National Semiconductor Singapore,
    a semiconductor fabrication subsidiary of National Semiconductor
    Corporation. Ms.&#160;Yow received a BE in Electronic
    Engineering from Curtin University, a Certificate in Management
    Studies from the Singapore Institute of Management and a Diploma
    in Electrical Engineering from Singapore Polytechnic.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board of
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Samuel Colella </I>has served as a member of our Board of
    Directors since July 2000. Mr.&#160;Colella is a managing
    director of Versant Ventures, a healthcare venture capital firm
    he co-founded in 1999, and has been a general partner of
    Institutional Venture Partners since 1984. Mr.&#160;Colella is a
    member of the Board of Directors of Alexza Pharmaceuticals,
    Inc., Genomic Health, Inc. and Jazz Pharmaceuticals, Inc.
    Mr.&#160;Colella received a B.S. in business and engineering
    from the University of Pittsburgh and an M.B.A. from Stanford
    University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Michael Hunkapiller, Ph.D. </I>has served as a member of our
    Board of Directors since August 2005. He has been a Partner at
    Alloy Ventures, a venture capital firm, since February 2004.
    From July 1983 to August 2004, he served in various managerial
    and research and development positions at Applied Biosystems,
    most recently as President, from March 1997 to August 2004. He
    received a B.S. in Chemistry from Oklahoma Baptist University
    and a Ph.D. in Chemical Biology from Caltech.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Elaine V. Jones,&#160;Ph.D.</I> has been a member of our
    Board of Directors since October 2001. Since August 2003, she
    has been a general partner of EuclidSR Associates, L.P., which
    is the general partner of EuclidSR Partners, L.P., a venture
    capital fund that focuses on life sciences and information
    technology companies, and also a general partner of EuclidSR
    Biotechnology Associates, L.P., which is the general partner of
    Euclid Biotechnology Partners, L.P., a venture capital fund that
    focuses on the life sciences. Dr.&#160;Jones was an investment
    manager from June 1999 to September 2001, and was a Vice
    President from September 2001 to August 2003, for S.R. One,
    Limited, a venture capital subsidiary of SmithKline Beecham.
    Dr.&#160;Jones received a B.S. in Biology from Juniata College
    and received a Ph.D. in Microbiology from the University of
    Pittsburgh.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Kenneth J. Nussbacher </I>has been a member of our Board of
    Directors since July 2003. Since 2000, Mr. Nussbacher has served
    as an Affymetrix Fellow, a non-executive employee position, at
    Affymetrix, Inc., a biotechnology company. From 1995 to 2000,
    Mr.&#160;Nussbacher was Executive Vice President of Affymetrix,
    Inc. and from 1995 to 1997, he was also Chief Financial Officer
    of Affymetrix. Prior to joining Affymetrix, Mr.&#160;Nussbacher
    was Executive Vice President for business and legal affairs of
    Affymax Technologies N.V. He received a B.S. from Cooper Union
    and a J.D. from Duke University. Mr.&#160;Nussbacher is also a
    member of the Board of Directors of Xenoport, a
    biopharmaceutical company.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gajus V. Worthington </I>is a Co-Founder of Fluidigm
    Corporation and has served as our President and Chief Executive
    Officer and a Director since our inception in June 1999.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>John A. Young </I>has been a member of our Board of Directors
    since March 2001. Mr.&#160;Young retired as President and Chief
    Executive Officer of Hewlett-Packard Company, a diversified
    electronics manufacturer, in October 1992, where he had served
    as President and Chief Executive Officer since 1978.
    Mr.&#160;Young received a B.S. in Electrical Engineering from
    Oregon State University and an M.B.A. from Stanford University.
    Mr.&#160;Young serves as a director of Affymetrix, Inc.,
    Vermillion, Inc., a molecular diagnostics company, Perlegen
    Sciences, Inc., a drug development company, and Nanosys, Inc., a
    nanotechnology company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board
    Composition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors is currently composed of six members,
    five of whom are independent within the meaning of the
    independent director guidelines of the NASDAQ Stock Market LLC.
    Immediately prior to this offering, our Board of Directors will
    be divided into three staggered classes of directors. At each
    annual meeting of stockholders, a class of directors will be
    elected for a three-year term to succeed the same class whose
    terms are then expiring. The terms of the directors will expire
    upon the election and qualification of successor directors at
    the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Annual Meeting of Stockholders to be held during the years 2009
    for the Class&#160;I directors, 2010 for the Class&#160;II
    directors and 2011 for the Class&#160;III directors.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;I directors will be Elaine Jones and Michael
    Hunkapiller.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;II directors will be Samuel Colella and Kenneth
    Nussbacher.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;III directors will be John Young and Gajus
    Worthington.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    provide that the number of our directors, which is currently six
    members, shall be fixed from time to time by a resolution of the
    majority of our Board of Directors. Each officer serves at the
    discretion of the Board of Directors and holds office until his
    successor is duly elected and qualified or until his or her
    earlier resignation or removal. There are no family
    relationships among any of our directors or executive officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The division of our Board of Directors into three classes with
    staggered three-year terms may delay or prevent a change of our
    management or a change of control. See &#147;Description of
    Capital Stock&#160;&#151; Anti-Takeover Effects of Delaware Law
    and Our Certificate of Incorporation and Bylaws&#148; for a
    discussion of other anti-takeover provisions found in our
    certificate of incorporation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board
    Committees</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board has an audit committee, a compensation committee and a
    nominating and governance committee, each of which has the
    composition and the responsibilities described below.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Audit Committee.</I>&#160;&#160;Our audit committee oversees
    our corporate accounting and financial reporting process and
    assists the Board in monitoring our financial systems and our
    legal and regulatory compliance. Our audit committee will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    oversee the work of our independent auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approve the hiring, discharging and compensation of our
    independent auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approve engagements of the independent auditors to render any
    audit or permissible non-audit services;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review the qualifications and independence of the independent
    auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    monitor the rotation of partners of the independent auditors on
    our engagement team as required by law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review our financial statements and review our critical
    accounting policies and estimates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review the adequacy and effectiveness of our internal
    controls;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and discuss with management and the independent auditors
    the results of our annual audit, our quarterly financial
    statements, and our publicly filed reports.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our audit committee are Elaine Jones and Kenneth
    Nussbacher. Mr. Nussbacher is our acting audit committee
    chairman. We are currently conducting a search for an additional
    audit committee member who we expect to serve as chairman and as
    financial expert under the rules of the Securities and Exchange
    Commission, or SEC, implementing Section&#160;407 of the
    Sarbanes Oxley Act of 2002. We expect that, prior to the
    completion of this offering, that the composition of our audit
    committee will meet the requirements for independence under the
    current requirements of the NASDAQ Stock Market LLC and SEC
    rules and regulations. We believe that the functioning of our
    audit committee complies with the applicable requirements of the
    NASDAQ Stock Market LLC and SEC rules and regulations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Compensation Committee.</I>&#160;&#160;Our compensation
    committee oversees our corporate compensation programs. The
    compensation committee will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and recommend policy relating to compensation and
    benefits of our officers and employees;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and approve corporate goals and objectives relevant to
    compensation of our Chief Executive Officer and other senior
    officers;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    76
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evaluate the performance of our officers in light of established
    goals and objectives;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommend compensation of our officers based on its
    evaluations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    administer the issuance of stock options and other awards under
    our stock plans;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our compensation committee are Samuel Colella,
    Michael Hunkapiller and Kenneth Nussbacher. Mr.&#160;Colella is
    the chairman of our compensation committee. Our Board of
    Directors has determined that each member of our compensation
    committee is independent within the meaning of the independent
    director guidelines of the NASDAQ Stock Market LLC. We believe
    that the composition of our compensation committee meets the
    requirements for independence under, and the functioning of our
    compensation committee complies with, any applicable
    requirements of the NASDAQ Stock Market LLC and SEC rules and
    regulations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Nominating and Governance Committee.</I>&#160;&#160;Our
    nominating and governance committee oversees and assists our
    Board of Directors in reviewing and recommending nominees for
    election as directors. The nominating and governance committee
    will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evaluate and make recommendations regarding the organization and
    governance of the Board and its committees;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    assess the performance of members of the Board and make
    recommendations regarding committee and chair assignments;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommend desired qualifications for Board membership and
    conduct searches for potential Board members;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and make recommendations with regard to our corporate
    governance guidelines.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our nominating and governance committee are
    Elaine Jones, John Young and Samuel Colella. Ms.&#160;Jones is
    the chairman of our nominating and governance committee. Our
    Board of Directors has determined that each member of our
    compensation committee is independent within the meaning of the
    independent director guidelines of the NASDAQ Stock Market LLC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors may from time to time establish other
    committees.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Director
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information concerning
    compensation paid or accrued for services rendered to us by
    members of our Board of Directors for the fiscal year ended
    December&#160;29, 2007. The table excludes Mr.&#160;Worthington
    and Mr.&#160;Smith, who are Named Executive Officers and did not
    receive any compensation from us in their roles as directors in
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fees Earned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Paid in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Cash&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce
    Burrows<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel D. Colella
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hingge
    Hsu<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Hunkapiller
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    S. Edward
    Torres<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth J.
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    72,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    112,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A. Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    compensation expense recognized by us for financial statement
    reporting purposes in fiscal 2007 related to grants of stock
    options in 2007, calculated in accordance with Financial
    Accounting Standards Board Statement of Financial Accounting
    Standards No.&#160;123 (Revised 2004) (&#147;SFAS
    No.&#160;123(R)&#148;) without regard to estimated forfeitures.
    See Note&#160;2 of Notes to Consolidated Financial Statements
    for a discussion of valuation assumptions made in determining
    the grant date fair value and compensation expense of our stock
    options.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">For his service as a director,
    Mr.&#160;Nussbacher was granted an option to purchase 100,000
    shares of common stock on December&#160;28, 2007 at an exercise
    price of $2.40, with a grant date fair value of $143,151,
    computed in accordance with SFAS&#160;123(R).
    Mr.&#160;Nussbacher was paid fees of $40,000 for services
    rendered pursuant to a consulting agreement with us. This
    consulting agreement was terminated on April&#160;14, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Resigned from the Board of
    Directors on or prior to April 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate number of shares subject to stock options
    outstanding at December&#160;29, 2007 for each director is as
    follows:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="69%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="14%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Aggregate Number of Stock Options<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding as of December&#160;29, 2007&#160;(#)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce Burrows
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel D. Colella
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hingge Hsu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Hunkapiller
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth J. Nussbacher
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    S. Edward Torres
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A. Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our directors do not currently receive any cash compensation for
    their services as members of our Board of Directors or any
    committee of our Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon consummation of our initial public offering, non-employee
    directors will receive an annual retainer of $20,000. The
    chairman of the audit committee will be paid an additional
    annual retainer of $15,000. The chairman of the compensation
    committee will be paid an additional annual retainer of $10,000.
    The chairman of the nominating and governance committee will be
    paid an additional annual retainer of $5,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our outside director equity compensation policy was adopted by
    our Board of Directors on January&#160;29, 2008 and will become
    effective immediately upon the completion of this offering. The
    policy is intended to formalize the granting of equity
    compensation to our non-employee directors under the 2008 Equity
    Incentive Plan. Non-employee directors may receive all types of
    awards under the 2008 Equity Incentive Plan, except for
    incentive stock options, including discretionary awards not
    covered by the policy. The policy provides for automatic and
    nondiscretionary grants of nonstatutory stock options subject to
    the terms and conditions of the policy and the 2008 Equity
    Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the policy, each non-employee director, who first becomes
    a non-employee director following the effective date of the
    first registration statement filed by us and declared effective
    with respect to any class of our securities, will be
    automatically granted a stock option to purchase
    40,000&#160;shares of our common stock on the date such person
    first becomes a non-employee director. A director who is an
    employee and who ceases to be an employee, but who remains a
    director will not receive such an initial award.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, each non-employee director will be automatically
    granted an annual stock option to purchase 10,000&#160;shares of
    our common stock on the date of each annual meeting beginning on
    the date of the first annual meeting that is held at least
    six&#160;months after such non-employee director received his or
    her initial award. In connection with the closing of this
    initial public offering, each non-employee director serving on
    our Board at the time of this offering will be automatically
    granted an option to purchase 10,000&#160;shares of our common
    stock at the price per share at which such common stock is sold
    in this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of all stock options granted pursuant to the
    policy will be equal to the fair market value of our common
    stock on the date of grant. The term of all stock options will
    be 10&#160;years. Subject to the adjustment provisions of the
    2008 Equity Incentive Plan, initial awards will vest as to 25%
    of the shares subject to such awards each anniversary of the
    date of grant, provided such non-employee director continues to
    serve as a director through each such date. Subject to the
    adjustment provisions of the 2008 Equity Incentive Plan, the
    annual awards, including such awards granted in connection with
    this offering, will vest monthly over a twelve month period
    following the date of grant, provided such non-employee director
    continues to serve as a director through such date.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The administrator of the 2008 Equity Incentive Plan in its
    discretion may change or otherwise revise the terms of awards
    granted under the outside director equity compensation policy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a &#147;change in control,&#148; as defined in
    our 2008 Equity Incentive Plan, with respect to awards granted
    under the 2008 Equity Incentive Plan to non-employee directors,
    the participant non-employee director will fully vest in and
    have the right to exercise awards as to all shares underlying
    such awards and all restrictions on awards will lapse, and all
    performance goals or other vesting criteria will be deemed
    achieved at 100% of target level and all other terms and
    conditions met.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Code of
    Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to the completion of this offering, we expect to adopt a
    code of business conduct and ethics that is applicable to all of
    our employees, officers and directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Interlocks and Insider Participation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of the members of our compensation committee is an officer
    or employee of our company. None of our executive officers
    currently serves, or in the past year has served, as a member of
    the Board of Directors or compensation committee of any entity
    that has one or more executive officers serving on our Board of
    Directors or compensation committee.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Discussion and Analysis</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We seek to have a compensation program that supports a team
    ethic among our management, fairly rewards executives for
    corporate performance and provides incentives for executives to
    meet or exceed our short and long term goals. The primary
    components of our compensation program are base salary, an
    annual incentive bonus plan, option awards and change of control
    arrangements. In addition, we provide our executive officers a
    variety of benefits that are available generally to all salaried
    employees. The compensation committee of our Board of Directors
    is responsible for evaluating the compensation of our executive
    officers and making recommendations to the Board of Directors.
    The independent members of the Board of Directors have final
    approval authority with respect to executive compensation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Objectives
    and Principles of Our Executive Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The primary goal of our executive compensation program is to
    ensure that we hire and retain talented and experienced
    executives that are motivated toward achieving or exceeding our
    short-term and long-term corporate goals. As a starting point,
    we believe that it is critical that our executive officers work
    together as a team and look beyond departmental lines to achieve
    overall corporate goals rather than focusing on individual
    departmental objectives. Our compensation philosophy is team
    oriented and our success dependent on what our management team
    can accomplish together. Therefore, we seek to provide the
    executive officers listed in the Summary Compensation table
    below, or our &#147;named executive officers,&#148; with
    comparable levels of base salary, bonuses and equity awards that
    are based largely on overall company performance.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For our fiscal year 2007, our named executive officers were
    Gajus Worthington, President and Chief Executive Officer,
    Richard DeLateur, our former Chief Financial Officer, Michael
    Lucero, our former Executive Vice President, Sales and
    Marketing, William Smith, Vice President, Legal Affairs and
    General Counsel, Robert Jones, our Executive Vice President,
    Research and Development, Grace Yow, Vice President, Worldwide
    Manufacturing and Managing Director, Fluidigm Singapore.
    Mr.&#160;DeLateur resigned as our Chief Financial Officer
    effective February&#160;29, 2008 and Mr.&#160;Lucero resigned as
    our Executive Vice President, Sales and Marketing on
    March&#160;14, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    79
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While the compensation level of Mr.&#160;Worthington, our Chief
    Executive Officer, is marginally higher than our other executive
    officers, his compensation has historically been based on our
    team-based compensation philosophy rather than on CEO
    compensation levels reported in market surveys of other
    companies in the life science industry.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We strongly believe that executive compensation should be
    directly linked to our performance. Our compensation program is
    designed so that a significant portion of the potential
    compensation of all of our executive officers is contingent on
    the achievement of our business objectives. In rewarding
    performance, we seek to reward both short and long term
    performance. We expect our executive leadership to manage our
    company so that we achieve our annual goals while at the same
    time positioning us to achieve our longer term strategic
    objectives. Short term elements of compensation include annual
    salary reviews, stock option awards and incentive bonuses that
    are tied closely to achieving our corporate and, to a lesser
    extent, on achieving individual performance objectives. Long
    term elements have historically been limited to stock options
    with multi-year vesting designed to retain executives and align
    their long term interests with those of our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that hiring and retaining well performing executives
    is important to our ongoing success. While we review generally
    available surveys on executive compensation to confirm that our
    compensation decisions do not result in compensation levels that
    are dramatically different from other companies in our industry,
    the compensation committee has not in the past attempted to
    benchmark our executive compensation against any particular
    indices or salary surveys. While occasional review of market
    surveys is considered helpful, the compensation committee has
    historically placed substantially greater weight on internal
    considerations than on position-specific pay differences found
    in the market.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as described below, neither the Board of Directors nor
    the compensation committee has adopted any formal or informal
    policies or guidelines for allocating compensation between cash
    and non-cash compensation, among different forms of non-cash
    compensation or with respect to long and short term performance.
    The determination of the Board of Directors or compensation
    committee as to the appropriate use and weight of each component
    of executive compensation is subjective, based on their view of
    the relative importance of each component in meeting our overall
    objectives and factors relevant to the individual executive.
    Historically, our Board of Directors has focused significantly
    on the affordability of our compensation arrangements. As a
    result, when weighting forms of compensation, the Board of
    Directors and the compensation committee have historically
    placed greater emphasis on non-cash equity incentive
    compensation together with base salary. In 2006, the Board of
    Directors determined that our business was of sufficient
    maturity to permit us to establish a cash bonus plan.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a publicly held company, we expect to periodically engage the
    services of a compensation consultant to assist us in further
    aligning our compensation philosophy with our corporate
    objectives. In particular, in order to attract and retain key
    executives, we may be required to modify individual executive
    compensation levels to remain competitive in the market for such
    positions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Compensation
    Process and Compensation Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2007 and January 2008, the compensation committee consisted
    of Messrs.&#160;Colella and Nussbacher and Ms.&#160;Jones. Since
    January&#160;29, 2008, the compensation committee has consisted
    of Messrs.&#160;Colella, Nussbacher and Hunkapiller, each of
    whom is an independent director under the rules of the NASDAQ
    Stock Market LLC and a &#147;non-employee director&#148; for
    purposes of
    <FONT style="white-space: nowrap">Rule&#160;16b-3</FONT>
    under the Securities Exchange Act of 1934, as amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee makes recommendations to the Board
    regarding compensation structure, goals and individual
    compensation levels, which recommendations are considered for
    approval by the independent members of the Board. The
    compensation committee makes its compensation recommendations
    based on input from Mr.&#160;Worthington, our Chief Executive
    Officer, the judgment of its members based on their tenure and
    experience in our industry, and, starting with compensation
    levels for 2007, the advice of Compensia, Inc., an independent
    compensation consultant hired by the compensation committee in
    April 2007. The compensation committee has the responsibility of
    formulating, evaluating and recommending to the Board of
    Directors the compensation of our executive officers.
    Historically, our annual compensation review process has been
    initiated by Mr.&#160;Worthington who performs a review of the
    performance of each executive officer in the prior year and
    formulates proposals regarding the elements of compensation,
    corporate and individual goals and compensation levels for our
    executive officers, other than himself.
    Mr.&#160;Worthington&#146;s proposals for compensation
    structure, goals
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and individual compensation levels are typically based on
    discussions with and directions from members of the compensation
    committee. Mr.&#160;Worthington does not prepare proposals or
    advise the compensation committee on his own compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Compensation levels and mix for Mr.&#160;Worthington, our Chief
    Executive Officer, are recommended by the compensation committee
    based on the committee&#146;s assessment of our overall
    corporate performance and Mr.&#160;Worthington&#146;s
    contribution to that performance. Mr.&#160;Worthington does not
    participate in compensation committee or Board deliberations
    regarding his own compensation. As with other members of our
    executive team, the compensation committee determines
    Mr.&#160;Worthington&#146;s compensation based on our
    achievement of corporate objectives and compensation levels of
    other members of our executive team, rather than attempting to
    tie Mr.&#160;Worthington&#146;s compensation to a specific
    percentile of CEO compensation reported in market compensation
    surveys.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to any limitations or guidelines that may be adopted by
    the Board of Directors in the future, the compensation committee
    does have the authority to approve the grant of stock options or
    stock purchase rights to individuals eligible for such grants,
    including officers and directors. The compensation committee met
    three times during 2007 and we expect that it will meet at least
    quarterly during 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee has the authority under its charter
    to engage the services of outside advisors, experts and others
    for assistance. In April 2007, the compensation committee
    engaged Compensia, Inc., an outside consulting firm, to advise
    it on developing a principles based executive compensation
    strategy to help transition us from a privately held to a
    publicly held company and on matters relating to our equity
    compensation plans as a whole. Compensia reviewed our proposed
    2007 compensation philosophy and compensation levels and
    provided advice regarding the suitability of our executive
    compensation structure for a company at our stage of development
    and the impact the structure was likely to have on executive
    performance and our ability to attract executive talent.
    Compensia did not prepare a formal report or recommend specific
    compensation levels. In 2008, we expect the compensation
    committee will engage an outside consulting firm to review more
    broadly our compensation practices and provide specific
    recommendations on executive compensation levels.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After setting compensation levels for our executive officers for
    2007, but before making its recommendations to the Board, the
    compensation committee reviewed the 2006 Radford Biotechnology
    Survey by Aon Consulting and the 2006 Executive Compensation
    Survey for pre-IPO life science companies by Top Five Data
    Services, Inc. to confirm that the proposed mix and levels of
    compensation for our executive officers was not outside of the
    ranges reported for senior executive officers in general. The
    compensation committee did not benchmark or tie compensation
    levels for our executive officers to any particular compensation
    level provided by the companies included in these surveys.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Corporate
    and Individual Performance Goals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2007 Corporate Goals.</I>&#160;&#160;Our corporate and
    individual performance goals for each year are formulated by the
    Board of Directors with input from the compensation committee
    and our Chief Executive Officer. For 2007, two corporate goals
    were established. The first related to our selling a certain
    number of IFC systems and reaching certain revenue targets,
    whether through system sales or collaboration agreements. The
    second goal related to our equity fund raising activity. The
    compensation committee believed attaining these goals would take
    a high level of executive performance and that such goals would
    be very challenging given the initial lack of market awareness
    of our products in 2007. The committee did not assign weights to
    these goals, except to treat them as equally important.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2007 Individual Goals.</I>&#160;&#160;Individual goals for
    2007 were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>2007 Individual Goals</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus Worthington, Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving target levels of sales of our IFC systems and
    achieving target revenues, whether through system sales or
    collaboration agreements.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Raising target levels of equity financing.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur, former Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Preparing our finance organization for an initial public
    offering and public company status.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Michael Lucero, former Executive Vice President,
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Launching our BioMark product and developing a
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    Sales and Marketing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    strategy for new market penetration.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William Smith, Vice President, Legal Affairs and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Maintaining and advancing our intellectual property
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
     position with respect to existing and new products.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Robert Jones, Executive Vice President, Research
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Deliver commercial genotyping applications, digital
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    array applications and finish feasibility phase of additional
    products.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow, Vice President, Worldwide
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving specified IFC manufacturing yields and
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Manufacturing and Managing Director of
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    output levels.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2008 Corporate Goals.</I>&#160;&#160;For 2008, the Board,
    with the participation of the compensation committee and members
    of management, reassessed our corporate goals in light of the
    maturation of our business and commercialization of our
    products. Following this reassessment, the Board approved
    corporate goals that include achieving specified levels of
    product sales and product gross margins, completing an initial
    public offering and keeping expenses and cash outlays within the
    budget approved by the Board of Directors. The Board believes
    that the goals are attainable with a very high level of
    executive performance. The target sales level represents
    significant growth from 2007 levels and will be achieved only if
    we are able to increase market awareness of our products and
    expand our customer base. The targeted gross margin will require
    significant contributions from both our manufacturing and
    research and development groups. Given the uncertainty in global
    financial markets, our ability to complete an initial public
    offering was also uncertain at the time these corporate goals
    were established. Achieving our overall corporate goals while
    staying within our proposed budget will require strong fiscal
    discipline.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2008 Individual Goals.</I>&#160;&#160;The goals for our
    individual executives in 2008 are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008 Individual Goals</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus Worthington, Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving specified levels of product sales and product gross
    margins, completing an initial public offering and keeping
    expenses and cash outlays within the budget approved by the
    Board of Directors.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vikram Jog, Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Ensuring accurate revenue recognition during each quarter,
    closing our books in an accurate and timely manner, completing
    our 2005, 2006 and 2007 audits and ensuring compliance with
    applicable financial and disclosure regulations of the
    Securities and Exchange Commission.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    William Smith, Vice President, Legal Affairs and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Maintaining our intellectual property position and
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    supporting our initial public offering.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert Jones, Executive Vice President, Research
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Completing market-ready 96.96 BioMark IFC, loaders
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    and readers for 96.96 and certain future applications.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Mai Chan (Grace) Yow, Vice President, Worldwide
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving overall IFC yields sufficient to achieve our
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    Manufacturing and Managing Director of
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
     gross margin goals, achieving specified yields on our
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    new 96.96 Dynamic Array IFC, maintaining or improving 2007
    quality levels for our IFC systems and ensuring on-time
    manufacture and delivery of IFCs and IFC systems.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Elements
    of Executive Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive compensation program consists of four main
    elements: base salary, an annual incentive bonus plan, option
    awards and change of control arrangements. The following is a
    discussion of each element.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Base Salary.</I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to 2007, the Board and the compensation committee
    established base salaries based on a number of factors including
    the scope of responsibility of each individual and a desire to
    encourage a team ethic. In 2007, the compensation committee and
    the Board concluded that our company and its stockholders would
    be better served by placing greater emphasis on creating a team
    ethic among our executive officers and that a team ethic would
    be better supported if all executive officers received
    approximately the same salary. Therefore, in May 2007, the
    compensation committee recommended and the Board approved a
    raise in the base annual salaries of Richard DeLateur, Michael
    Lucero, William Smith and Robert Jones to $265,000 effective
    February&#160;1, 2007, which represented a 20% increase for
    Mr.&#160;DeLateur, a 2.5% increase for Mr.&#160;Lucero, a 16%
    increase for Mr.&#160;Smith and a 6% increase for
    Mr.&#160;Jones, based on their salaries for 2006. This salary
    increase was based upon the compensation committee&#146;s
    assessment of the life science industry in the
    San&#160;Francisco Bay Area gathered from the active involvement
    of committee members as investors in such industry and the
    committee&#146;s conclusion that competition for executives in
    our industry was increasing. Ms.&#160;Yow&#146;s salary was set
    at S$307,224, or US$200,000 using the exchange rate at the time
    such salary was set, to reflect the lower cost of living in
    Singapore where she is based. At the same time, the compensation
    committee also recommended that Mr.&#160;Worthington&#146;s
    salary be increased by 5% to $283,920 based on the factors
    described above. However, Mr.&#160;Worthington requested that
    this salary increase be deferred until his performance during
    2007 could be assessed. In December 2007, the compensation
    committee reviewed Mr.&#160;Worthington&#146;s overall
    performance during the year. In particular, it noted that
    Mr.&#160;Worthington had fully met his individual goal for
    equity financing as we had raised more money than had been
    targeted and had partially met his individual goal for revenue,
    as we had strong sales performance although the target revenue
    level was not achieved. The compensation committee therefore
    recommended and the Board approved the 5% raise that had been
    originally proposed for Mr.&#160;Worthington. The raise was made
    retroactive to February&#160;15, 2007 so that it would be
    effective as of the same date as the raises for all the other
    executive officers.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee reviewed 2008 base
    salaries in light of general market conditions in the
    San&#160;Francisco Bay Area life science industry. The
    compensation committee concluded that competition for executive
    talent remained strong as a result of the solid economic
    performance of the industry and the region overall, the
    continued high level of investment by venture capital firms in
    new and existing life science companies and the specialized
    skills and experiences required to manage life science
    companies. The compensation committee&#146;s assessment of
    general market conditions in the life science industry, and the
    life science industry in the San&#160;Francisco Bay Area in
    particular, was based on the experience of the committee members
    who were and are actively involved in venture capital investing
    in such industry and area. The compensation committee did not
    rely on any formal compensation survey data in making its
    assessment. The compensation committee therefore recommended and
    the Board approved a 4.0% raise for all executive officers other
    than Messrs.&#160;DeLateur and Lucero, who were expected to be
    leaving Fluidigm in early 2008. This 4.0% raise was applied to
    Ms.&#160;Yow&#146;s salary in Singapore dollars, resulting in an
    increase of S$12,289. As a result, the 2008 base salary for
    Mr.&#160;Smith and Mr.&#160;Jones was increased to $275,600, the
    2008 base salary for Ms.&#160;Yow was increased to S$319,513, or
    US$232,002 on the date of the increase, and the 2008 salary for
    Mr.&#160;Worthington was increased to $294,840. These salary
    increases became effective on February&#160;1, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, we entered into an offer letter with Vikram
    Jog, our Chief Financial Officer that provides for him to
    receive a base salary of $278,000 per year and a signing bonus
    of $20,000. The Board approved this departure from our standard
    base salary and bonus practice for executive officers based on
    several factors, including his unique qualifications, the need
    to induce him to leave his existing employment, his base salary
    at his previous employer and our need to fill the position as
    soon as possible.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Incentive Bonus Plan.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2007, the compensation committee and the Board established a
    bonus structure for all named executive officers that provided
    for performance bonuses of up to 35% of base salary. 80% of the
    performance bonus was payable based upon our reaching our
    corporate goals described above, with each corporate goal
    receiving equal weighting and the remaining 20% payable to each
    executive based on the executive&#146;s attainment of his or her
    individual performance goals described above. Payment of
    performance bonuses was allocated among corporate and individual
    goals in this manner in recognition of our compensation
    philosophy in which the compensation committee sought to
    incentivize executive officers to look beyond their individual
    departmental goals and work with other executive officers to
    achieve our overall corporate goals. The compensation committee
    and Board concluded that the corporate goals portion of the
    bonus would not be payable if the goals were less than 80%
    attained, based on the average percentage completion of all such
    goals, and would be paid in full if the goals were 100%
    attained. The compensation committee retained discretion to
    determine the portion of the bonus that would be paid if the
    corporate goals were achieved at a level between 80% and 100%.
    The compensation committee also retained the discretion to
    change the bonus structure and the bonus payment amounts as it
    considered appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee concluded that the
    first 2007 corporate goal described above had been partially met
    and the second 2007 corporate goal had been fully met, but that
    taken together the 80% threshold had not been attained. As a
    result, no 2007 bonuses were paid to our executive officers with
    respect to achievement of corporate goals.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee also considered the achievement of
    2007 individual performance goals in January 2008 and concluded
    that Mr.&#160;Smith had achieved his goals by maintaining and
    advancing our intellectual property position with respect to
    existing and new products. The Board awarded Mr.&#160;Smith 100%
    of his individual performance bonus of $18,550. The compensation
    committee concluded that Mr.&#160;Jones achieved his 2007
    individual goals of delivering a commercial genotyping
    application and digital array applications and awarded him his
    maximum individual performance bonus of $18,550. The
    compensation committee concluded that Ms.&#160;Yow had achieved
    her 2007 individual goals by achieving specified IFC
    manufacturing yields and output levels in 2007 and the Board
    awarded Ms.&#160;Yow 100% of her individual performance bonus of
    $14,000. The compensation committee concluded that
    Mr.&#160;Worthington had partially achieved his 2007 individual
    performance goals of achieving target levels of IFC system sales
    and revenue and raising target levels of equity financing, and
    the Board awarded Mr.&#160;Worthington a partial bonus of
    $14,175. No other individual performance bonuses were awarded to
    our named executive officers for 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2008, the compensation committee and Board have approved the
    same bonus structure and potential bonus percentages as for 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In making recommendations regarding and approving compensation
    with respect to 2007, the compensation committee and the Board
    have not exercised their discretion to either award compensation
    absent attainment of relevant performance goals or to reduce the
    size of an award or payout following the attainment of relevant
    performance goals. We intend for the bonus plan to provide a
    significant portion of an executive&#146;s potential
    compensation. It is designed to help ensure that executives are
    focused on our near-term performance and on working together to
    achieve key corporate objectives. We expect that corporate and
    individual goals will be reviewed each year and adjusted to
    reflect changes in our stage of development, competitive
    position and corporate objectives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Option Awards.</I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We grant options to new executives upon the commencement of
    their employment and on an annual basis make additional grants
    to existing executives based on our overall corporate
    performance, individual performance and the executives&#146;
    existing option grants and equity holdings. We believe that
    option awards are an effective means of aligning the interests
    of executives and stockholders, rewarding executives for our
    achieving success over the long term and providing executives an
    incentive to remain with us. Most option grants to our named
    executive officers provide the holder with the right to exercise
    the option and purchase shares prior to vesting, subject to our
    right to repurchase unvested shares pursuant to the terms of our
    restricted stock purchase agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, the compensation committee redesigned our option
    granting policy in light of the shift in our compensation
    philosophy toward team-based compensation. The compensation
    committee concluded that the number of shares that vest each
    year for each executive should be relatively consistent and
    should be comparable to the number of shares that vest for other
    executives. The committee determined that each executive should
    vest in approximately 70,000&#160;shares per year over a four
    year period. For each executive, the exact number of shares that
    vest in any year would be subject to adjustment either upward or
    downward by up to 35,000&#160;shares based on the
    executive&#146;s performance relative to the corporate goals and
    his or her individual performance goals. The compensation
    committee&#146;s selection of 70,000&#160;shares as the target
    number of shares to vest annually for each executive officer was
    based on the committee&#146;s determination that such number of
    shares would provide meaningful compensation to our executive
    officers. The committee did not rely on compensation surveys or
    other third party sources in arriving at the 70,000 annual
    vesting target. In addition to this annual vesting target and
    the possible adjustment of actual vesting amounts by up to
    35,000, the compensation committee retained the authority to
    approve additional option grants to executive officers who
    demonstrated exceptional performance in a given year.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of our adoption of this new approach to equity
    compensation, our grants in 2007 were primarily intended to
    regularize each executive&#146;s vesting schedules to
    approximately 70,000 per year. As a result, certain executives
    received option grants where shares were immediately vested
    while others received grants where the vesting occurs largely
    three or four years from the grant of the date. The number of
    shares vesting for each such officer in 2007 were
    68,332&#160;shares for Mr.&#160;Worthington, 187,499&#160;shares
    for Mr.&#160;DeLateur, 104,083&#160;shares for Mr.&#160;Lucero,
    68,750 for Mr.&#160;Smith, 91,667 for Mr.&#160;Jones and 97,500
    for Ms.&#160;Yow. Variations in the number of shares vested in
    2007 for these officers was the result of vesting under options
    granted prior to 2007 rather than intentional variation in 2007
    grants on the part of the compensation committee. In the future,
    once the vesting of existing options are normalized at
    approximately 70,000&#160;shares per year, we intend for
    executives to receive additional grants that vest only in the
    fourth year following the date of their grant. We also expect to
    reconsider the target share amount each year and may in the
    future consider granting restricted stock as a form of equity
    compensation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2008, the compensation committee did not alter the target
    amount of annual vesting for any executive. To give effect to
    this target annual vesting rate, the committee recommended and
    the Board approved grants of options to purchase
    70,000&#160;shares each to Mr.&#160;Jones, Mr.&#160;Smith,
    Mr.&#160;Worthington and Ms.&#160;Yow. These options vest fully
    on December&#160;31, 2011, subject to continued service through
    the vesting date. In addition, the compensation committee
    recommended that additional discretionary option grants be made
    to Mr.&#160;Jones, Mr.&#160;Smith, Mr.&#160;Worthington and
    Ms.&#160;Yow for their exceptional performance in 2007.
    Mr.&#160;Jones, Mr.&#160;Smith and Mr.&#160;Worthington received
    a fully-vested option to purchase 70,000&#160;shares and
    Ms.&#160;Yow received a fully-vested option to purchase
    40,000&#160;shares. These grants were issued separately from the
    annual grants and were not considered an adjustment to the
    annual grants. Accordingly, the 35,000&#160;share adjustment
    limit for annual grants did not apply.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed above, the compensation committee retains the
    discretion to grant additional options to executive officers as
    a reward for exceptional performance. In addition, the committee
    may decide to grant options that vest upon the achievement of
    certain performance goals. Finally, the committee is exploring
    the desirability of other forms of equity based compensation
    including restricted stock grants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the Board approved amendments to our 1999 Stock
    Option Plan to permit the use of performance based vesting in
    connection with equity grants under the plan. The amendment
    provided the Board and compensation committee with the ability
    to grant options or other equity awards under the plan that vest
    upon the achievement of specified milestones or goals. These
    amendments were made to enhance the ability of the Board and
    compensation committee to closely align equity compensation with
    the achievement of corporate or individual goals.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board adopted our 2008 Equity Incentive Plan in January 2008
    and we expect our stockholders will approve it prior to the
    completion of this offering. Subject to stockholder approval,
    the 2008 Equity Incentive Plan is effective upon its adoption by
    our Board, but is not expected to be utilized until after the
    completion of this offering. Our 2008 Equity Incentive Plan
    provides for the grant of incentive stock options, within the
    meaning of Section&#160;422 of the Internal Revenue Code, to our
    employees and any parent and subsidiary corporations&#146;
    employees, and for the grant of nonstatutory stock options,
    restricted stock, restricted stock units, stock appreciation
    rights, performance units and performance shares to our
    employees, directors and consultants and our parent and
    subsidiary corporations&#146; employees and consultants. Our
    Board and compensation committee are evaluating the costs and
    benefits of the various forms of equity compensation issuable
    under the 2008 plan and may elect to use restricted stock,
    restricted stock units, stock appreciation rights, performance
    units and performance shares in the future to further align the
    interests of our management and stockholders and to manage the
    financial statement impact of such forms of equity compensation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee participated in the
    negotiation of a compensation package for Vikram Jog, our Chief
    Financial Officer, in which the compensation committee agreed to
    grant Mr.&#160;Jog compensation that exceeded our standard
    compensation package for the named executive officers. As
    indicated above, the compensation committee approved this
    package based on Mr.&#160;Jog&#146;s unique qualifications, our
    need to fill this position and the need to induce Mr.&#160;Jog
    to leave his then current employer. In February 2008, the
    compensation committee approved the grant of the following
    options to Mr.&#160;Jog in February 2008 under our 1999 Stock
    Option Plan:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="11%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>Accelerated Vesting if<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Shares</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Standard Vesting</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Milestones Met</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Performance Milestones</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    500,000
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    25% on first anniversary<BR>
    of the vesting commencement date, and 1/48 per month thereafter
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    n/a
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    50,000&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% on December&#160;31, 2011
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% upon achievement<BR>
    of Milestones prior to December 31, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    (1) Revenue recognition - no material changes upon quarterly
    reviews and annual audit;<BR>
    (2) Accurate and timely closing of books and reporting
    (timeliness as required by investors and SEC);<BR>
    (3) SEC and Sarbanes-Oxley compliance, as needed; and<BR>
    (4) Produce audited financial statements for 2005, 2006 and 2007
    (and the first quarter of 2008, if necessary) to enable the
    filing of a Form S-1 registration statement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    50,000&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    25% on first anniversary<BR>
    of the vesting  commencement date and 1/48 per month thereafter
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% upon achievement<BR>
    of Milestones prior to December 31, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    (1) Achievement of target revenues;<BR>
    (2) Achievement of target margins for 2008;<BR>
    (3) Completion of an initial public offering in 2008; and<BR>
    (4) Compliance with 2008 budget for expenses and cash outflows.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In light of the performance based option grants made to
    Mr.&#160;Jog and our team-based approach to executive
    compensation, the compensation committee recommended to the
    Board, and the Board approved similar grants for all other named
    executive officers other than Mr.&#160;Worthington. Thus,
    Mr.&#160;Jones, Mr.&#160;Smith and Ms.&#160;Yow each received
    two additional options to purchase 50,000&#160;shares on
    April&#160;24, 2008. The first option becomes fully vested on
    the earlier of December&#160;11, 2011 or, with respect to each
    officer, December&#160;31, 2008 if that officer meets his or her
    individual goals for 2008. The second option vest with respects
    25% of the shares subject to the option on February&#160;1, 2009
    and 1/48th&#160;of the shares each month thereafter; provided
    that the option becomes fully vested on December&#160;31, 2008
    if the corporate goals for 2008 are achieved.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Employment and Severance Agreements.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, we entered into Employment and Severance
    Agreements with each of our named executive officers that
    provide for specified payments and benefits if the
    officer&#146;s employment is terminated without cause, or if the
    officer&#146;s employment is terminated without cause or for
    good reason within 12&#160;months following a change of control.
    The terms of these agreements are described under
    &#147;Potential Payments Upon Termination or Change of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Control.&#148; We adopted these arrangements because we
    recognize that we will from time to time consider the
    possibility of an acquisition by another company or other change
    of control transaction and that such consideration can be a
    distraction to our executive officers and can cause such
    officers to consider alternative employment opportunities.
    Accordingly, the Board concluded that it is in the best
    interests of our company and its stockholders to provide
    executives with certain severance benefits upon termination of
    employment without cause or for good reason following a change
    of control. Our Board determined to provide such executives with
    certain severance benefits upon their termination of employment
    without cause outside of the change of control context in order
    to provide executives with enhanced financial security and
    incentive to remain with our company. In addition, we believe
    that providing for acceleration of options if an officer is
    terminated following a change of control transaction aligns the
    executive officer&#146;s interest more closely with those of
    other stockholders when evaluating the transaction rather than
    putting the officer at risk of losing the benefits of those
    equity incentives.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In determining the amount of cash payments, benefits coverage
    and acceleration of vesting to be provided to officers upon
    termination prior to a change of control or within
    12&#160;months following a change of control, our Board
    considered the following factors:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the expected time required for an officer to find comparable
    employment following a termination event;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    feedback received from potential candidates for officer
    positions at our company as to the level of severance payments
    and benefits they would require to leave other employment and
    join our company;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the context of a change of control, the amount of vesting
    acceleration that would align the officer&#146;s interests more
    closely with the interests of stockholders when considering a
    potential change of control transaction;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the period of time following a change of control during which
    management positions are evaluated and subject to a heightened
    risk of elimination.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, all outstanding options granted to our employees
    will become fully vested upon a change of control if the options
    are not assumed by the acquiring company.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the resignation of Mr.&#160;Lucero, our
    former Vice President of Sales and Marketing, on March&#160;22,
    2008, we entered into a Settlement Agreement and General Release
    of Claims with Mr.&#160;Lucero that provided for mutual releases
    of us and Mr.&#160;Lucero, our continued payment of
    Mr.&#160;Lucero&#146;s salary and health insurance premiums
    through July 2008 and payment of an additional $90,000 to
    Mr.&#160;Lucero. The amount and timing of payments to
    Mr.&#160;Lucero under this agreement were the result of
    negotiations between us and Mr.&#160;Lucero, with the
    involvement of the compensation committee. The compensation
    committee concluded that this agreement was in the best
    interests of our company in reaching an amicable separation with
    Mr.&#160;Lucero.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with Mr.&#160;DeLateur&#146;s resignation, we
    entered into a consulting agreement dated February&#160;29,
    2008. Under the consulting agreement, we agreed to pay
    Mr.&#160;DeLateur $200 per hour for performing various
    consulting services, provided that Mr.&#160;DeLateur work no
    more than five hours per week without our written authorization.
    We entered into this arrangement to ensure that
    Mr.&#160;DeLateur would be available as needed to ensure an
    orderly transition to our new Chief Financial Officer,
    Mr.&#160;Jog.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Benefits.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Executive officers are eligible to participate in all of our
    employee benefit plans, such as medical, dental, vision, group
    life, disability, and accidental death and dismemberment
    insurance and our 401(k) plan, in each case on the same basis as
    other employees, subject to applicable law. We also provide
    vacation and other paid holidays to all employees, including our
    executive officers, which we believe are comparable to those
    provided at peer companies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">CEO
    Loan and Stock Repurchase</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;20, 2004, we entered into an Employee Loan
    Agreement, Secured Promissory Note and Stock Pledge Agreement
    with Mr.&#160;Worthington pursuant to which we loaned
    Mr.&#160;Worthington $250,000 at an interest rate of 3.52% per
    annum. The loan was secured by the pledge of 833,334&#160;shares
    of our common stock held by
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     Mr.&#160;Worthington. On April&#160;10, 2008,
    Mr.&#160;Worthington repaid the loan in full in accordance with
    Section&#160;2.2(d) of the note by exchanging shares of our
    common stock held by Mr.&#160;Worthington to us at the fair
    market value of such stock, which was determined by the Board of
    Directors to be $3.19 per share. The note and
    Mr.&#160;Worthington&#146;s loan were repaid in full and
    cancelled in exchange for 90,913&#160;shares of our common stock
    which Mr.&#160;Worthington transferred to us pursuant to the
    terms of a repurchase agreement dated April&#160;10, 2008. This
    loan repayment and share cancellation transaction were approved
    by the Board based on its determination that we received full
    and fair consideration for the cancellation of the loan and that
    the cancellation of the loan was in the best interests of our
    company and its stockholders.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    and Tax Considerations</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section 162(m) of the Internal Revenue Code of 1986, as amended,
    or the Code, places a limit of $1,000,000 on the amount of
    compensation that we may deduct as a business expense in any
    year with respect to our Chief Executive Officer and certain of
    our highly paid executive officers. We can, however, preserve
    the deductibility of certain performance-based compensation in
    excess of $1,000,000 if the conditions of Code
    Section&#160;162(m) are met. Under applicable tax guidance for
    newly-public companies, the deduction limitation generally will
    not apply to compensation paid pursuant to any plan or agreement
    that existed before the company became publicly held. In
    addition, compensation provided by newly-public companies
    through the first stockholder meeting to elect directors after
    the close of the third calendar year following the year in which
    the initial public offering occurs, or earlier upon the
    occurrence of certain events (e.g., a material modification of
    the plan or agreement under which the compensation is granted),
    will not be included in for purposes of the Code
    Section&#160;162(m) limit provided the arrangement is adequately
    described in this prospectus. Accordingly, we believe that
    deductibility of all income recognized by executives pursuant to
    equity compensation granted by us prior to this offering, as
    well as any equity compensation granted by us under the 2008
    Equity Incentive Plan following this offering through the
    expiration of the reliance period, will not be limited by Code
    Section&#160;162(m). While the compensation committee cannot
    predict how the deductibility limit may impact our compensation
    program in future years, the compensation committee intends to
    maintain an approach to executive compensation that strongly
    links pay to performance. While the compensation committee has
    not adopted a formal policy regarding tax deductibility of
    compensation paid to our executive officers, the compensation
    committee intends to consider tax deductibility under
    Section&#160;162(m) as a factor in compensation decisions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Code Section 409A imposes additional taxes on certain
    non-qualified deferred compensation arrangements that do not
    comply with its requirements. These requirements regulate an
    individual&#146;s election to defer compensation and the
    individual&#146;s selection of the timing and form of
    distribution of the deferred compensation. Code
    Section&#160;409A generally also provides that distributions of
    deferred compensation only can be made on or following the
    occurrence of certain events (i.e., the individual&#146;s
    separation from service, a predetermined date, a change in
    control, or the individual&#146;s death or disability). For
    certain executives, Code Section&#160;409A requires that such
    individual&#146;s distribution commence no earlier than six
    (6)&#160;months after such officer&#146;s separation from
    service. We have and will continue to endeavor to structure our
    compensation arrangements to comply with Code Section&#160;409A
    so as to avoid the adverse tax consequences associated therewith.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents information concerning the total
    compensation of our Chief Executive Officer, Chief Financial
    Officer and our four other most highly compensated officers
    during the last fiscal year (the &#147;Named Executive
    Officers&#148;) for services rendered to us in all capacities
    for the fiscal year ended December&#160;29, 2007:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    283,357
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    33,631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,175
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    331,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    President and Chief<BR>
    Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard A.
    DeLateur<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    71,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    312,759
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Former Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    247,502
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    270,315
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    Executive Vice President<BR>
    Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Y.
    Lucero<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    264,517
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    278,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Former Executive Vice President,<BR>
    Sales and Marketing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    261,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,590
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    317,123
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    Vice President, Legal<BR>
    Affairs and General<BR>
    Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    204,214
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    84,310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    302,524
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President, Worldwide<BR>
    Manufacturing and Managing Director of Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    expense recognized for financial statement reporting purposes
    for fiscal 2007 calculated in accordance with
    SFAS&#160;No.&#160;123(R) without regard for estimated
    forfeitures. See Note&#160;2 of Notes to Consolidated Financial
    Statements for a discussion of assumptions made in determining
    the grant date fair value and compensation expense of our stock
    options.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;DeLateur resigned
    effective February&#160;29, 2008. From August&#160;16, 2007 to
    December&#160;31, 2007, Mr.&#160;DeLateur worked for us on a
    <FONT style="white-space: nowrap">part-time</FONT>
    basis. Currently Mr.&#160;DeLateur serves as a consultant. See
    &#147;Employment Agreements and Offer Letters.&#148;
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Lucero resigned effective
    March&#160;22, 2008. See &#147;Employment and Severance
    Agreements.&#147;
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts in this column
    represent total
    <FONT style="white-space: nowrap">performance-based</FONT>
    bonuses earned for service rendered during fiscal 2007 under our
    incentive bonus plan. Under our incentive bonus plan, each
    executive was eligible to receive a cash bonus of up to 35% of
    his or her base salary based on achievement of certain corporate
    goals and certain individual performance goals. Please see
    &#147;Incentive Bonus Plan&#148; under &#147;Compensation
    Discussion and Analysis&#148; above for additional information
    regarding our fiscal 2007 cash bonuses.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grants
    of Plan-Based Awards</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents information concerning grants of
    plan-based awards to each of the Named Executive Officers during
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Grants of
    Plan-Based Awards</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payouts Under<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Grant Date<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fair Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Base Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Target<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($/Sh)<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Awards<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    131,533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    99,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    115,668
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    69,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Y. Lucero
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    101,114
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    165,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">10,000 of the shares subject to
    this grant were vested as of the grant date, 10,000&#160;shares
    vested on February&#160;1, 2008, 65,000&#160;shares vest on
    February&#160;1, 2009, and 70,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">70,000 of the shares subject to
    this grant were vested as of the grant date and
    70,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">All of the shares subject to this
    grant vest on February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">10,000 of the shares subject to
    this grant vested on February&#160;1, 2008, 38,000&#160;shares
    vest on February&#160;1, 2009, and 70,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">50,000 of the shares subject to
    this grant were vested as of the grant date, 50,000&#160;shares
    vested on February&#160;1, 2008, 40,000&#160;shares vest on
    February&#160;1, 2009, and 59,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">10,000 of the shares subject to
    this grant vest on February&#160;1, 2009 and 70,000&#160;shares
    vest on February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    grant date fair value of stock options granted in fiscal 2007,
    calculated in accordance with SFAS&#160;No.&#160;123(R) without
    regard to estimated forfeitures. See Note&#160;2 of Notes to
    Consolidated Financial Statements for a discussion of
    assumptions made in determining the grant date fair value of our
    stock options.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our shares of common stock were not
    publicly traded during the 2007 fiscal year; our board of
    directors in good faith determined the fair market value on the
    date of grant.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents certain information concerning
    equity awards held by the Named Executive Officers at the end of
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="54%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Unexercisable</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
     0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/20/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(22)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/03/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(23)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Y. Lucero
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/04/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    180,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    04/18/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    07/15/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(10)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(11)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/14/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(12)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(13)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/04/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    175,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(14)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    07/15/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(15)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    04/18/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(16)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(17)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/14/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(18)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(19)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/03/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(20)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    09/27/2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(21)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Unless otherwise noted, all option
    grants may be exercised pursuant to a restricted stock purchase
    agreement prior to vesting; any shares purchased prior to
    vesting are subject to a right of repurchase in our favor in the
    event the individual ceases to provide services for any reason
    which right lapses in accordance with the vesting schedule of
    the option.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">10,000 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    10,000&#160;shares vested on February&#160;1, 2008,
    65,000&#160;shares vest on February&#160;1, 2009, and 70,000
    vest on February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;21, 2005 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">70,000 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    and 70,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This option may not be exercised
    prior to vesting.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;4, 2001 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    April&#160;19, 2004 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    July&#160;16, 2003 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;15, 2006 vest over 4&#160;years. 1.67% of the shares
    vest each month for the first two years and 2.5% of the shares
    vest each month in the final two years.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. All of the shares subject to this grant vest
    on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;4, 2001 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    July&#160;16, 2003 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    April&#160;19, 2004 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(17)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;15, 2006 vest over 4&#160;years. 1.67% of the shares
    vest each month for the first two years and 2.5% of the shares
    vest each month in the final two years.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(18)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. 10,000 of the shares subject to this grant
    vested on February&#160;1, 2008, 38,000&#160;shares vest on
    February&#160;1, 2009, and 70,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(19)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;3, 2005 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(20)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    September&#160;27, 2006. These stock options vest over
    4&#160;years in monthly increments. During the first two years,
    1.67% of the shares vest each month and during the final two
    years, 2.5% of the shares vest each month.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(21)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">50,000 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    50,000&#160;shares vested on February&#160;1, 2008,
    40,000&#160;shares vest on February&#160;1, 2009, and
    59,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(22)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This option was granted on
    August&#160;3, 2005 and vests over 4&#160;years. Twenty-five
    percent of the shares vest one year after grant and 2.083% of
    the shares vest each month thereafter.
    </FONT></TD>
</TR>



<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(23)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. 10,000 of the shares subject to this grant
    vest on February&#160;1, 2009, and 70,000&#160;shares subject to
    this grant vest on February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreements and Offer Letters</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Richard A DeLateur.</I>&#160;&#160;We entered into a
    consulting agreement dated February&#160;29, 2008 with Richard
    A. DeLateur, our former Chief Financial Officer. Under the
    consulting agreement, we agreed to pay Mr.&#160;DeLateur $200
    per hour for performing various consulting services, provided
    that Mr.&#160;DeLateur shall work no more than five hours per
    week without our written authorization. The consulting agreement
    terminated on May&#160;17, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Michael Y. Lucero.</I>&#160;&#160;We entered into to a
    Settlement Agreement and General Release of Claims effective
    March&#160;30, 2008 with Michael Y. Lucero, our former Executive
    Vice President of Sales and Marketing. Under the settlement
    agreement, we agreed, in exchange for a general release of all
    claims and other customary terms and conditions, (i)&#160;to pay
    Mr.&#160;Lucero on each pay day through July&#160;15, 2008 an
    amount equal to what he would have received on that pay day
    based on an annual base salary of $265,000 and (ii)&#160;to
    reimburse Mr.&#160;Lucero for costs of coverage under the
    Consolidated Omnibus Budget Reconciliation Act of 1985, or
    COBRA, that are incurred during April, May, June and July of
    2008, in an amount no greater than the amount we contributed on
    Mr.&#160;Lucero&#146;s behalf for February 2008. We also agreed
    to make a one time payment to Mr.&#160;Lucero of $90,000.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vikram Jog.</I>&#160;&#160;We are a party to an offer letter
    dated January&#160;29, 2008, with Vikram Jog, our Chief
    Financial Officer. Under the offer letter, we employ
    Mr.&#160;Jog on an at-will basis for no specified term and
    agreed to pay Mr.&#160;Jog an annual base salary of $278,000,
    which continues to be his base salary. We also agreed to pay
    Mr.&#160;Jog a signing bonus of $20,000 pursuant to his offer
    letter. Pursuant to the offer letter, we granted Mr.&#160;Jog an
    initial options to purchase a total of 600,000&#160;shares of
    our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Potential
    Payments Upon Termination or Change of Control</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, we entered into employment and severance
    agreements with Gajus V. Worthington, William M. Smith, Mai Chan
    (Grace) Yow, Robert C. Jones and Vikram Jog, which require us to
    make payments if the named executive officer&#146;s employment
    with us is terminated in certain circumstances.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    93
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with our
    named executive officers, a &#147;change of control&#148; is
    defined as the occurrence of the following events:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any &#147;person,&#148; as such term is used in
    Sections&#160;13(d) and 14(d) of the Securities Exchange Act of
    1934, as amended, is or becomes the &#147;beneficial
    owner,&#148; as such term is defined in
    <FONT style="white-space: nowrap">Rule&#160;13d-3</FONT>
    under said Act, directly or indirectly, of our securities
    representing 50% or more of the total voting power represented
    by our then outstanding voting securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a change in the composition of our Board occurring within a
    two-year period, as a result of which fewer than a majority of
    our directors are &#147;incumbent directors,&#148; which term is
    defined as either (i)&#160;our directors as of the execution
    date of the relevant agreement or (ii)&#160;directors who are
    elected, or nominated for election, to our Board with the
    affirmative votes of at least a majority of the incumbent
    directors at the time of such election or nomination (but will
    not include an individual whose election or nomination is in
    connection with an actual or threatened proxy contest relating
    to the election of our directors);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the date of the consummation of our merger or consolidation with
    any other corporation that has been approved by the our
    stockholders, other than a merger or consolidation that would
    result in our voting securities outstanding immediately prior
    thereto continuing to represent (either by remaining outstanding
    or by being converted into voting securities of the surviving
    entity) more than 50% of the total voting power represented by
    our voting securities or such surviving entity outstanding
    immediately after such merger or consolidation, or our
    stockholders approve a plan of our complete liquidation;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the date of the consummation of the sale or disposition by us of
    all or substantially all of our assets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with our
    named executive officers, &#147;cause&#148; is defined as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an act of dishonesty in connection with a named executive
    officer&#146;s responsibilities as an employee;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a conviction of, or plea of <I>nolo contendere </I>to, a felony
    or any crime involving fraud, embezzlement or any other act of
    moral turpitude;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    gross misconduct;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an unauthorized use or disclosure of any of our proprietary
    information or of any other party to whom he or she owes an
    obligation of nondisclosure as a result of his or her
    relationship with us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a willful breach of any obligations under any written agreement
    or covenant with us;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a named executive officer&#146;s continued failure to perform
    his or her employment duties after he or she has received a
    written demand of performance from us and has failed to cure
    such non-performance to our satisfaction within 10 business days
    after receiving such notice.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with Gajus
    V. Worthington, William M. Smith, Robert C. Jones and Vikram
    Jog, &#147;good reason&#148; means the occurrence of one or more
    of the following events effected without the named executive
    officer&#146;s prior consent, provided that he or she terminates
    his or her employment within one year thereafter:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the assignment to the named executive officer of any duties or a
    reduction of the named executive officer&#146;s duties, either
    of which significantly reduces his or her responsibilities;
    provided that the continuance of his or her responsibilities at
    the subsidiary or divisional level following a change of
    control, rather than at the parent, combined or surviving
    company level following such change of control shall not be
    deemed &#147;good reason&#148; within the meaning of this clause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material reduction of the named executive officer&#146;s base
    salary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the relocation of the named executive officer to a facility or a
    location greater than 50&#160;miles from his or her present
    location;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material breach by us of any material provision of the
    employment and severance agreement.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    94
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, no act or omission by us shall constitute &#147;good
    reason&#148; if we fully cure that act or omission within
    30&#160;days of receiving notice of receiving notice from the
    named executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreement with Mai Chan
    (Grace) Yow, &#147;good reason&#148; means the occurrence of one
    or more of the following events effected without her consent,
    provided that she terminates her employment within one year
    thereafter:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the assignment to Ms.&#160;Yow of any duties or a reduction of
    her duties, either of which significantly reduces her
    responsibilities; provided that the continuance of her
    responsibilities at the subsidiary or divisional level following
    a change of control, rather than at the parent, combined or
    surviving company level following such change of control shall
    not be deemed &#147;good reason&#148; within the meaning of this
    clause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material reduction of Ms.&#160;Yow&#146;s base salary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the relocation of Ms.&#160;Yow to a facility or a location
    outside the country of Singapore;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material breach by us of any material provision of the
    employment and severance agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, no act or omission by us shall constitute &#147;good
    reason&#148; if we fully cure that act or omission within
    30&#160;days of receiving notice of receiving notice from the
    named executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment and severance agreements provide that in the
    event the named executive officer&#146;s employment is
    terminated by us or our successor without &#147;cause&#148;
    prior to a &#147;change of control&#148; or after 12&#160;months
    following a &#147;change of control&#148; and the named
    executive officer executes a standard release of claims with us,
    the named executive officer is entitled to receive, in addition
    to such officer&#146;s salary payable through the date of
    termination of employment and any other benefits earned and owed
    through the date of termination, the following cash payments:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount, payable in accordance with our customary payroll
    practices, equal to six&#160;months of the named executive
    officer&#146;s base salary in effect immediately prior to the
    time of termination;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of costs and expenses incurred by the executive
    officer and his or her eligible dependents for coverage under
    group health plans, policies or arrangements sponsored by us for
    a period of up to six&#160;months, provided that such coverage
    is timely elected under COBRA or similar applicable state
    statute.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment and severance agreements further provide that in
    the event the named executive officer&#146;s employment is
    terminated by (i)&#160;us or our successor without
    &#147;cause&#148; and within 12&#160;months following a
    &#147;change of control&#148; or (ii)&#160;by the executive
    officer for &#147;good reason&#148; and within 12&#160;months
    following a &#147;change of control&#148;, and in each case the
    named executive officer executes a standard release of claims
    with us, the executive officer is entitled to receive, in
    addition to such officer&#146;s salary payable through the date
    of termination of employment and any other benefits earned and
    owed through the date of termination, the following cash
    payments and benefits:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount, payable in a lump sum, equal to the greater of
    (i)&#160;six&#160;months of the named executive officer&#146;s
    base salary in effect immediately prior to the change in control
    or (ii)&#160;six&#160;months of the named executive&#146;s
    officer&#146;s base salary in effect immediately prior to the
    time of termination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all outstanding unvested stock options, equity appreciation
    rights or similar equity awards then held by the named executive
    officer as of the date of termination will immediately vest and
    become exercisable as to all shares underlying such options;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any shares of restricted stock, restricted stock units and
    similar equity awards then held by the named executive officer
    will immediately vest and any of our rights of repurchase or
    reacquisition with respect to such shares will lapse as to all
    shares;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of costs and expenses incurred by the executive
    officer and his or her eligible dependents for coverage under
    group health plans, policies or arrangements sponsored by us for
    a period of up to six months, provided that such coverage is
    timely elected under COBRA or similar applicable state statute.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table describes the payments and benefits that
    each of our named executive officers would be entitled to
    receive pursuant to the employment and severance agreements,
    assuming that each of the following
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    triggers occurred in December&#160;29, 2007: their employment
    was terminated without &#147;cause&#148; prior to or after
    12&#160;months following a &#147;change of control&#148; and
    (ii) their employment was terminated without &#147;cause&#148;
    or for &#147;good reason&#148; within 12&#160;months following a
    &#147;change of control&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Employment Terminated without Cause Prior<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Employment Terminated within 12 Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>to or After 12 Months Following Change of Control</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Following Change of
    Control<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Severance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Health Care<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Severance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Health Care<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payments<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Benefits<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Acceleration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payments<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Benefits<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    President and Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President, Legal Affairs and General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    106,130
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    106,130
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    Vice President, Worldwide Manufacturing and Managing Director of
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Executive Vice President, Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Vikram Jog
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    139,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    139,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Includes involuntary termination
    other than for cause, death or disability, and voluntary
    termination for good reason.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts shown in this column
    are equal to 6&#160;months of the named executive officer&#146;s
    base salary as of December&#160;29, 2007.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts shown in this column
    are equal to the spread value between (i)&#160;the unvested
    portion of all outstanding stock options, equity appreciation
    rights or similar equity awards held by the named executive
    officer on December&#160;29, 2007 and (ii)&#160;the initial
    public offering price of our common stock, which we have assumed
    to be the midpoint of the price range set forth on the cover
    page of this prospectus.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts shown in this column
    are equal to the cost of covering the named executive officer
    and his or her eligible dependents coverage under our benefit
    plans for a period of six months, assuming that such coverage is
    timely elected under COBRA.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amount shown has been converted
    from Singapore dollars to U.S. dollars based on the interbank
    exchange rate for December&#160;29, 2007 of 1&#160;Singapore
    dollar = 0.6909 U.S. dollars.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the benefits described above, our 2008 Equity
    Incentive Plan and 1999 Stock Option Plan provide for full
    acceleration of all outstanding options in the event of a change
    of control of our company where the successor company does not
    assume our outstanding options and other awards in connection
    with such acquisition transaction. We estimate the value of this
    benefit for each named executive officer to be equal to the
    amount listed above in the column labeled &#147;Equity
    Acceleration.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Benefit Plans</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">2008
    Equity Incentive Plan.</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors adopted our 2008 Equity Incentive Plan on
    January&#160;29, 2008, and we expect our stockholders will
    approve it prior to the completion of this offer. Subject to
    stockholder approval, the 2008 Equity Incentive Plan is
    effective upon its adoption by our Board of Directors, but is
    not expected to be utilized until after the completion of this
    offering. Our 2008 Equity Incentive Plan provides for the grant
    of incentive stock options, within the meaning of
    Section&#160;422 of the Internal Revenue Code, to our employees
    and any parent and subsidiary corporations&#146; employees, and
    for the grant of nonstatutory stock options, restricted stock,
    restricted stock units, stock appreciation rights, performance
    units and performance shares to our employees, directors and
    consultants and our parent and subsidiary corporations&#146;
    employees and consultants.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock are reserved for issuance pursuant to the
    2008 Equity Incentive Plan, of which no options are issued and
    outstanding. In addition, the shares reserved for issuance under
    our 2008 Equity Incentive Plan will also include (a)&#160;those
    shares reserved but unissued under the 1999 Stock Option
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Plan as of the effective date of the first registration
    statement filed by us and declared effective with respect to any
    class of our securities and (b)&#160;shares returned to the 1999
    Stock Option Plan as the result of expiration or termination of
    options (provided that the maximum number of shares that may be
    added to the 2008 Equity Incentive Plan pursuant to (a)&#160;and
    (b)&#160;is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares).
    The number of shares available for issuance under the 2008
    Equity Incentive Plan will also include an annual increase on
    the first day of each fiscal year beginning
    in&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    equal to the lesser of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    4% of the outstanding shares of common stock as of the last day
    of our immediately preceding fiscal year;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    such other amount as our Board of Directors may determine.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors or a committee appointed by our Board
    administers our 2008 Equity Incentive Plan. Our compensation
    committee will administer our 2008 Equity Incentive Plan after
    the completion of the offering. In the case of options intended
    to qualify as &#147;performance-based compensation&#148; within
    the meaning of Section&#160;162(m) of the Internal Revenue Code,
    the committee will consist of two or more &#147;outside
    directors&#148; within the meaning of Section&#160;162(m).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the provisions of our 2008 Equity Incentive Plan, the
    administrator has the power to determine the terms of the
    awards, including the exercise price, the number of shares
    subject to each such award, the exercisability of the awards and
    the form of consideration, if any, payable upon exercise. The
    administrator also has the authority to amend existing awards to
    reduce their exercise price, to allow participants the
    opportunity to transfer outstanding awards to a financial
    institution or other person or entity selected by the
    administrator and to institute an exchange program by which
    outstanding awards may be surrendered in exchange for awards
    with a higher or lower exercise price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of options granted under our 2008 Equity
    Incentive Plan must at least be equal to the fair market value
    of our common stock on the date of grant. The term of an
    incentive stock option may not exceed 10&#160;years, except that
    with respect to any participant who owns 10% of the voting power
    of all classes of our outstanding stock, the term must not
    exceed 5&#160;years and the exercise price must equal at least
    110% of the fair market value on the grant date. Subject to the
    provisions of our 2008 Equity Incentive Plan, the administrator
    determines the term of all other options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the termination of service of an employee, director or
    consultant, he or she may exercise his or her option for the
    period of time stated in his or her option agreement. Generally,
    if termination is due to death or disability, the option will
    remain exercisable for 12&#160;months. In all other cases, the
    option will generally remain exercisable for three months
    following the termination of service. However, in no event may
    an option be exercised later than the expiration of its term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stock appreciation rights may be granted under our 2008 Equity
    Incentive Plan. Stock appreciation rights allow the recipient to
    receive the appreciation in the fair market value of our common
    stock between the exercise date and the date of grant. Subject
    to the provisions of our 2008 Equity Incentive Plan, the
    administrator determines the terms of stock appreciation rights,
    including when such rights become exercisable and whether to pay
    any increased appreciation in cash or with shares of our common
    stock, or a combination thereof, except that the per share
    exercise price for the shares to be issued pursuant to the
    exercise of a stock appreciation right will be no less than 100%
    of the fair market value per share on the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Restricted stock may be granted under our 2008 Equity Incentive
    Plan. Restricted stock awards are grants of shares of our common
    stock that vest in accordance with terms and conditions
    established by the administrator. The administrator will
    determine the number of shares of restricted stock granted to
    any employee, director or consultant. The administrator may
    impose whatever conditions to vesting it determines to be
    appropriate (for example, the administrator may set restrictions
    based on the achievement of specific performance goals or
    continued service to us); provided, however, that the
    administrator, in its sole discretion, may accelerate the time
    at which any restrictions will lapse or be removed. Shares of
    restricted stock that do not vest are subject to our right of
    repurchase or forfeiture.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Restricted stock units may be granted under our 2008 Equity
    Incentive Plan. Restricted stock units are bookkeeping entries
    representing an amount equal to the fair market value of one
    share of our common stock. The administrator determines the
    terms and conditions of restricted stock units including the
    vesting criteria (which may include accomplishing specified
    performance criteria or continued service to us) and the form
    and timing of payment. Notwithstanding the foregoing, the
    administrator, in its sole discretion may accelerate the time at
    which any restrictions will lapse or be removed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Performance units and performance shares may be granted under
    our 2008 Equity Incentive Plan. Performance units and
    performance shares are awards that will result in a payment to a
    participant only if performance goals established by the
    administrator are achieved or the awards otherwise vest. The
    administrator will establish organizational or individual
    performance goals in its discretion, which, depending on the
    extent to which they are met, will determine the number
    <FONT style="white-space: nowrap">and/or</FONT> the
    value of performance units and performance shares to be paid out
    to participants. After the grant of a performance unit or
    performance share, the administrator, in its sole discretion,
    may reduce or waive any performance objectives or other vesting
    provisions for such performance units or performance shares.
    Performance units shall have an initial dollar value established
    by the administrator prior to the grant date. Performance shares
    shall have an initial value equal to the fair market value of
    our common stock on the grant date. The administrator, in its
    sole discretion, may pay earned performance units or performance
    shares in the form of cash, in shares or in some combination
    thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 2008 Equity Incentive Plan provides that all non-employee
    directors will be eligible to receive all types of awards
    (except for incentive stock options) under the 2008 Equity
    Incentive Plan. Please see the description of our Outside
    Director Equity Compensation Policy below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the administrator provides otherwise, our 2008 Equity
    Incentive Plan generally does not allow for the transfer of
    awards and only the recipient of an award may exercise an award
    during his or her lifetime.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 2008 Equity Incentive Plan provides that in the event of a
    merger or &#147;change in control,&#148; as defined in the 2008
    Equity Incentive Plan, each outstanding award will be treated as
    the administrator determines, including that the successor
    corporation or its parent or subsidiary will assume or
    substitute an equivalent award for each outstanding award. The
    administrator is not required to treat all awards similarly. If
    there is no assumption or substitution of outstanding awards,
    the awards will fully vest, all restrictions will lapse, all
    performance goals or other vesting criteria will be deemed
    achieved at 100% of target levels and the awards will become
    fully exercisable. The administrator will provide notice to the
    recipient that he or she has the right to exercise the option
    and stock appreciation right as to all of the shares subject to
    the award, all restrictions on restricted stock will lapse, and
    all performance goals or other vesting requirements
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">1999
    Stock Option Plan, as amended</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1999 Stock Option Plan was adopted by our Board of Directors
    and approved by our stockholders on May&#160;12, 1999. Our 1999
    Stock Option Plan was most recently amended on April&#160;24,
    2008. Our 1999 Stock Option Plan provides for the grant of
    incentive stock options, within the meaning of Section&#160;422
    of the Internal Revenue Code, to our employees and any parent
    and subsidiary corporations&#146; employees, and for the grant
    of nonstatutory stock options to our employees, directors and
    consultants and our parent and subsidiary corporations&#146;
    employees and consultants. Our Board of Directors has decided
    not to grant any additional options under our 1999 Stock Option
    Plan following the completion of this offering. However, our
    1999 Stock Option Plan will continue to govern the terms and
    conditions of the outstanding stock options previously granted
    thereunder.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the provisions of our 1999 Stock Option Plan, the
    maximum aggregate number of shares which may be subject to
    option and sold under our 1999 Stock Option Plan is
    14,800,000&#160;shares. As of December&#160;29, 2007, options to
    purchase 7,467,230&#160;shares of our common stock were
    outstanding and 1,197,154&#160;shares were available for future
    grant under the 1999 Stock Option Plan.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our compensation committee appointed by our Board of Directors
    currently administers our 1999 Stock Option Plan. Under our 1999
    Stock Option Plan, the administrator has the power to determine
    the terms of the stock options, including the employees,
    directors and consultants who will receive stock options, the
    number of shares subject to each stock option, the vesting
    schedule, any vesting acceleration, and the exercisability of
    stock options.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    98
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The administrator also has the authority to initiate an option
    exchange program whereby stock options are exchanged for stock
    options with a lower exercise price. The administrator may also
    reduce the exercise price of any option to the then current fair
    market value if the fair market value of our common stock has
    declined since the date the option was granted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of options granted under our 1999 Stock
    Option Plan must at least be equal to the fair market value of
    our common stock on the date of grant. The term of an incentive
    stock option may not exceed 10&#160;years, except that with
    respect to any optionee who owns 10% of the voting power of all
    classes of our outstanding stock as of the grant date, the term
    must not exceed 5&#160;years and the exercise price must equal
    at least 110% of the fair market value on the grant date.
    Subject to the provisions of our 1999 Stock Option Plan, the
    administrator determines the terms of all other options in its
    discretion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the termination of service of an employee, director or
    consultant, he or she may exercise his or her option for the
    period of time stated in his or her option agreement. Generally,
    if termination is due to death or disability, the option will
    remain exercisable for 12&#160;months. In all other cases, the
    option will generally remain exercisable for three months
    following the termination of service. In some cases, options
    issued to consultants pursuant to our 1999 Stock Option Plan
    provide that they may be exercised at anytime prior to the
    expiration of the ten year term of the option. However, in no
    event may an option be exercised later than the expiration of
    its term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the administrator provides otherwise, our 1999 Stock
    Option Plan generally does not allow for the transfer of awards
    and only the recipient of an award may exercise an award during
    his or her lifetime.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1999 Stock Option Plan provides that in the event of a
    merger of our company or a sale of substantially all of our
    assets, each outstanding stock option will be assumed or an
    equivalent option or right substituted by the successor
    corporation. If there is no assumption or substitution of
    outstanding options (or portions thereof), the options (or
    portions thereof) will fully vest and become fully exercisable.
    In such case, the administrator will provide notice to the
    optionee that he or she has the right to exercise the option as
    to all of the shares subject to the option for a period of at
    least 15&#160;days. The option will terminate upon the
    expiration of the period of time the administrator provides in
    the notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors has the authority to amend, suspend or
    terminate the 1999 Stock Option Plan provided such action does
    not impair the rights of any optionee without his or her written
    consent.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Retirement
    Plans</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>401(k) Plan.</I>&#160;&#160;We maintain a tax-qualified
    retirement plan that provides eligible employees with an
    opportunity to save for retirement on a tax advantaged basis.
    Eligible employees are able to participate in the 401(k) plan as
    of the first&#160;day of the month on or following the date they
    begin employment and participants are able to defer up to 60% of
    their eligible compensation subject to applicable annual
    Internal Revenue Code limits. All participants&#146; interests
    in their deferrals are 100% vested when contributed. The 401(k)
    plan permits us to make matching contributions and profit
    sharing contributions to eligible participants, although we have
    not made any such contributions to date. Pre-tax contributions
    are allocated to each participant&#146;s individual account and
    are then invested in selected investment alternatives according
    to the participants&#146; directions. The 401(k) plan is
    intended to qualify under Sections&#160;401(a) and 501(a) of the
    Internal Revenue Code. As a tax-qualified retirement plan,
    contributions to the 401(k) plan and earnings on those
    contributions are not taxable to the employees until distributed
    from the 401(k) plan and all contributions are deductible by us
    when made.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Limitation
    on Liability and Indemnification Matters</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    that will become effective upon the completion of this offering
    contain provisions that limit the personal liability of our
    directors for monetary damages to the fullest extent permitted
    by Delaware law. Consequently, our directors will not be
    personally liable to us or our stockholders for monetary damages
    for any breach of fiduciary duties as directors, except
    liability for:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any breach of the director&#146;s duty of loyalty to us or our
    stockholders;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any act or omission not in good faith or that involves
    intentional misconduct or a knowing violation of law;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    99
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    unlawful payments of dividends or unlawful stock repurchases or
    redemptions as provided in Section&#160;174 of the Delaware
    General Corporation Law;&#160;or
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any transaction from which the director derived an improper
    personal benefit.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation that will
    become effective upon the completion of this offering, provides
    that we indemnify our directors to the fullest extent permitted
    by Delaware law. In addition, our amended and restated bylaws,
    that will become effective upon the completion of this offering,
    provides that we indemnify our directors and officers to the
    fullest extent permitted by Delaware law. Our amended and
    restated bylaws, that will become effective upon the completion
    of this offering, also provide that we shall advance expenses
    incurred by a director or officer in advance of the final
    disposition of any action or proceeding, and permit us to secure
    insurance on behalf of any officer, director, employee or other
    agent for any liability arising out of his or her actions in
    that capacity, regardless of whether we would otherwise be
    permitted to indemnify him or her under the provisions of
    Delaware law. We have entered and expect to continue to enter
    into agreements to indemnify our directors, executive officers
    and other employees as determined by the Board of Directors.
    With certain exceptions, these agreements provide for
    indemnification for related expenses including, among others,
    attorneys&#146; fees, judgments, fines and settlement amounts
    incurred by any of these individuals in any action or
    proceeding. We believe that these bylaw provisions and
    indemnification agreements are necessary to attract and retain
    qualified persons as directors and officers. We also maintain
    directors&#146; and officers&#146; liability insurance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The limitation of liability and indemnification provisions in
    our amended and restated certificate of incorporation and
    bylaws, that will become effective upon the completion of this
    offering, may discourage stockholders from bringing a lawsuit
    against our directors for breach of their fiduciary duty of
    care. They may also reduce the likelihood of derivative
    litigation against our directors and officers, even though an
    action, if successful, might benefit us and other stockholders.
    Further, a stockholder&#146;s investment may be adversely
    affected to the extent that we pay the costs of settlement and
    damage awards against directors and officers. At present, there
    is no pending litigation or proceeding involving any of our
    directors, officers or employees for which indemnification is
    sought, and we are not aware of any threatened litigation that
    may result in claims for indemnification.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    100
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='112'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the director and executive compensation
    arrangements discussed above in &#147;Management,&#148; we have
    been a party to the following transactions since January&#160;1,
    2005, in which the amount involved exceeded or will exceed
    $120,000, and in which any director, executive officer or holder
    of more than 5% of any class of our voting stock, or any member
    of the immediate family of or entities affiliated with any of
    them, had or will have a material interest.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Sales of
    Series&#160;E Preferred Stock</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table below summarizes purchases of shares of our
    Series&#160;E preferred stock since January&#160;1, 2005, by our
    directors, executive officers, holders of more than 5% of any
    class of our voting securities, or any member of the immediate
    family of or any entities affiliated with any of the foregoing
    persons. In connection with these sales, we granted the
    purchasers certain registration rights with respect to their
    securities. See &#147;Description of Capital Stock&#160;&#151;
    Registration Rights.&#148; Each outstanding share of our
    preferred stock will be converted automatically into one share
    of our common stock upon the completion of this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Series E<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Preferred<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Purchasers</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Alloy
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    645,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce
    Burrows<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,579,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with EuclidSR
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    211,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    847,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Biomedical Sciences Investment Fund&#160;Pte
    Ltd<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,458,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16,049,815
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with InterWest
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Lehman Brothers Holdings,
    Inc.<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    159,749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    638,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lilly
    Ventures<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    359,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Versant
    Ventures<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,064,476
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    38,474,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,120&#160;shares
    purchased by Alloy Partners 2002, L.P., 78,505&#160;shares
    purchased by Alloy Ventures 2002, L.P. and 80,625&#160;shares
    purchased by Alloy Ventures 2005, L.P. Michael Hunkapiller, an
    affiliate of Alloy Ventures, is a member of our Board of
    Directors.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Bruce Burrows served as member of
    our Board of Directors from January&#160;3, 2000 to
    January&#160;15, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 105,875&#160;shares
    purchased EuclidSR Biotechnology Partners, L.P. and
    105,875&#160;shares purchased by EuclidSR Partners, L.P. Elaine
    Jones, an affiliate of Euclid SR Partners, is a member of our
    Board of Directors.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of shares issued to
    Biomedical Sciences Investment Fund&#160;Pte Ltd in connection
    with the conversion of convertible promissory notes.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,285&#160;shares
    purchased by InterWest Investors VII, L.P. and
    47,715&#160;shares purchased by InterWest Partners VII, L.P.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 39,937&#160;shares
    purchased by Lehman Brothers Healthcare Venture Capital L.P.,
    8,932&#160;shares purchased by Lehman Brothers Offshore
    Partnership Account 2000/2001, L.P., 76,440&#160;shares
    purchased by Lehman Brothers P.A., LLC, and 34,440 purchased by
    Lehman Brothers Partnership Account 2001/2001, L.P. Hingge Hsu,
    an affiliate of Lehman Brothers Holdings, Inc., served as a
    member of our Board of Directors at the time of the financing.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Ed Torres, an affiliate of Lilly
    Ventures, served as a member of our Board of Directors at the
    time of the financing.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 5,000&#160;shares
    purchased by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;1-A,</FONT>
    L.P., 10,500&#160;shares purchased by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;1-B,</FONT>
    L.P., 4,500&#160;shares purchased by Versant Side Fund&#160;I,
    L.P. and 230,000&#160;shares purchased by Versant Venture
    Capital&#160;I, L.P. Sam Colella, an affiliate of Versant
    Ventures, is a member of our Board of Directors.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Transactions
    with the Singapore Government</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Convertible
    Note Financings</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;18, 2003, we entered into a convertible note
    purchase agreement (as amended December&#160;17, 2004)&#160;with
    Biomedical Sciences Investment Fund&#160;Pte Ltd, or BMSIF, an
    investment arm of the Singapore Economic Development Board, or
    EDB. Upon execution of the agreement, BMSIF purchased a
    convertible promissory note in the principal amount of
    $2,000,000 at an interest rate equal to 8% per annum. The
    principal and
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    101
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     interest on this note was convertible into our Series&#160;D
    preferred stock at a price of $2.80 per share, which was equal
    to the per share purchase price of our Series&#160;D preferred
    stock sold to other investors in December 2003. This note was
    converted into 823,635&#160;shares of our Series&#160;D
    preferred stock on December&#160;15, 2005. Additionally, the
    agreement provided for the issuance of up to two additional
    convertible promissory notes, each in the principal amount of
    $1,500,000, or a single additional convertible promissory note
    in the principal amount of $3,000,000, and all at an interest
    rate of 8% per annum. Pursuant to the terms of the agreement, on
    June&#160;20, 2006 we issued a single note in the principal
    amount of $3,000,000 to BMSIF. The principal and interest on
    this note was also convertible into our Series&#160;D preferred
    stock at a price of $2.80 per share. This note was converted
    into 1,157,142&#160;shares of our Series&#160;D preferred stock
    on July&#160;2, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;7, 2006, we entered into a second convertible
    note purchase agreement with BMSIF pursuant to which BMSIF
    purchased three convertible promissory notes each in the
    principal amount of $5&#160;million, for an aggregate principal
    amount of $15,000,000, and each at an interest rate equal to 8%
    per annum. The principal and interest on these notes was
    convertible into our Series&#160;E preferred stock at a price of
    $3.60 per share, which represented a 10% discount on the $4.00
    per share price at which our Series&#160;E preferred stock was
    sold to other investors in our Series&#160;E preferred stock
    financing which occurred between June 2006 and December 2007.
    The first note was issued on August&#160;7, 2006 and was
    converted into 1,460,730&#160;shares of our Series&#160;E
    preferred stock on March&#160;31, 2007. The second note was
    issued on November&#160;20, 2006 and was converted into
    1,493,607&#160;shares of our Series&#160;E preferred stock on
    March&#160;31, 2007. The last note was issued on April&#160;19,
    2007 and was converted into 1,503,945&#160;shares of our
    Series&#160;E preferred stock on April&#160;30, 2008. Each such
    conversion was completed following the agreement of the parties
    that the required milestones had been met to the parties
    satisfaction or waived.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Government
    Reimbursement Grants</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2005, Fluidigm Singapore entered into a letter
    agreement providing for up to S$10&#160;million (approximately
    US$7.2&#160;million using March&#160;29, 2008 exchange rates) in
    grants from the Singapore Economic Development Board, or EDB.
    The grants are payable only as reimbursement for a portion of
    the expenses incurred in Singapore from August&#160;1, 2005
    through July&#160;31, 2010 in connection with the establishment
    and operation of a research, development and manufacturing
    center for IFCs in Singapore. Eligible expenses include expenses
    relating to human resources, equipment, materials and software
    purchases, and professional service fees. Fluidigm Singapore is
    required to submit reimbursement requests for qualifying
    expenditures on a quarterly basis along with reports regarding
    its compliance with the reimbursement conditions through the end
    of the applicable quarter.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;11, 2006, Fluidigm Singapore and EDB entered
    into a supplement to the October 2005 letter agreement. This
    supplement was entered into to create a process whereby Fluidigm
    Singapore and EDB would agree on new quarterly development
    targets at the start of each year, Fluidigm Singapore would
    submit to EDB a progress report and evidence of the achievement
    of targets on a quarterly basis and the parties would resolve
    any disagreements regarding the satisfaction of targets using an
    established procedure and the parties would be entitled to
    obtain a third party audit of our reimbursement requests on a
    semi-annual rather than an annual basis.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm Singapore&#146;s continued eligibility for such
    reimbursement grants is subject to its compliance with
    increasing levels of research, development and manufacturing
    activity in Singapore, including employment of specified numbers
    of research scientists and engineers, its incurrence of
    specified levels of research and development expenses in
    Singapore over the course of each calendar year, its use of
    local service providers, its manufacture in Singapore of the
    products developed in Singapore and its achievement of certain
    targets relating to new product development or completion of
    specific manufacturing process objectives. These required levels
    of research, development and manufacturing activity in Singapore
    and the associated increases from one year to the next are the
    result of negotiations between the parties and are generally
    consistent with our business strategy for our Singapore
    operations. All ownership rights in the intellectual property
    developed by Fluidigm Singapore remain with Fluidigm Singapore
    and no such rights are conveyed to EDB under the agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On February&#160;12, 2007, Fluidigm Singapore entered into a
    second letter agreement with EDB which provided for up to an
    additional S$3.7&#160;million (approximately US$2.7&#160;million
    using March&#160;29, 2008 exchange rates) in reimbursement
    grants. The terms and conditions of this letter agreement are
    substantially the same as the October 2005 letter agreement,
    with the exception of the size of the potential grant, the term
    of the agreement and the
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    102
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     specific levels of research, development and manufacturing
    activity required to maintain eligibility for such grants. The
    primary focus of this grant agreement was the ongoing
    development and manufacture in Singapore of instrumentation to
    be used with our IFCs. This letter agreement applies to eligible
    expenses incurred by Fluidigm Singapore in Singapore from
    June&#160;1, 2006 through May&#160;31, 2011.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;27, 2008, Fluidigm Singapore entered into amended
    and restated versions of our October 2005 and February 2007
    letter agreements with EDB. The purpose of these amendments was
    to consolidate and streamline the original agreements to
    eliminate sub-categories of eligible expenditures and rely on
    more general descriptions of the eligible expenditures that the
    parties had been applying in practice, to consolidate certain
    administrative terms and conditions of the reimbursement grants,
    and to remove various forms attached to the original letter
    agreements that had changed over time or were not part of the
    ongoing agreement between the parties. The January 2006
    supplement to the October 2005 letter agreement remains in
    effect.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Loan to
    Gajus Worthington</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;20, 2004, we entered into an Employee Loan
    Agreement, Secured Promissory Note and Stock Pledge Agreement
    with Mr.&#160;Worthington pursuant to which we loaned
    Mr.&#160;Worthington $250,000 at an interest rate of 3.52% per
    annum and the principal and interest were not due and payable
    until 7&#160;years after the date of the loan or upon the
    earlier occurrence of certain events. The loan was secured by
    the pledge of 833,334&#160;shares of our common stock held by
    Mr.&#160;Worthington and was otherwise non-recourse. The loan
    was extended to Mr.&#160;Worthington to assist him in purchasing
    a home for his personal residence in Northern California. On
    April&#160;10, 2008, Mr.&#160;Worthington repaid the loan in
    full in accordance with Section&#160;2.2(d) of the note by
    selling shares of our common stock held by Mr.&#160;Worthington
    to us at the fair market value of such stock on the date of such
    sale, which was determined by the Board of Directors to be $3.19
    per share. The note and Mr.&#160;Worthington&#146;s loan were
    repaid in full and cancelled in exchange for 90,913&#160;shares
    of our common stock which Mr.&#160;Worthington transferred to us
    pursuant to the terms of a repurchase agreement dated
    April&#160;10, 2008. This loan repayment and share cancellation
    transaction was approved by the Board based on its determination
    that we received full and fair consideration for the
    cancellation of the loan and that the cancellation of the loan
    was in the best interests of our company and its stockholders.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consulting
    Agreement with Stephen Quake</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In May 2006, we entered into an agreement with Stephen Quake
    pursuant to which we have agreed to pay Dr.&#160;Quake $8,333
    per month for providing various consulting services to us
    including serving on our Scientific Advisory Board. The
    agreement has a term of 10&#160;years and is terminable by us
    only for cause. At approximately the same time, we repurchased
    from Dr.&#160;Quake approximately 124,000&#160;shares of our
    common stock for aggregate consideration of $69,425.
    Dr.&#160;Quake served as a director of Fluidigm from its
    inception until December 2005 and, at the time of these
    transactions, was the holder of more than 5% of our outstanding
    common stock.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Engagement
    of Townsend and Townsend and Crew LLP</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since before 2005, the law firm of Townsend and Townsend and
    Crew LLP, or Townsend, has served as our primary outside patent
    counsel. William Smith, our Vice President, Legal Affairs and
    General Counsel as well as our Secretary since May 2000 and a
    director from May 2000 until April&#160;7, 2008, was a partner
    at Townsend from 1985 to April&#160;1, 2008. Amounts paid to
    Townsend for services and direct patent fees were $880,000,
    $960,000 and $576,000 for 2005, 2006 and 2007. Accrued amounts
    payable to Townsend were $174,000 and $257,000 as of
    December&#160;31, 2006 and December&#160;29, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of our preferred stock and our co-founders are entitled
    to certain registration rights with respect to the common stock
    issued or issuable upon conversion of the preferred stock. See
    &#147;Registration Rights&#148; under &#147;Description of
    Capital Stock&#148; below for additional information.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    103
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Option Grants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain stock option grants to our directors and executive
    officers and related option grant policies are described above
    in this prospectus under the caption &#147;Management.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Arrangements and Indemnification Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into employment arrangements with certain of our
    executive officers. See &#147;Management&#160;&#151; Employment
    Agreements and Offer Letters&#148; above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have also entered into indemnification agreements with each
    of our directors and executive officers. The indemnification
    agreements and our certificate of incorporation and bylaws
    require us to indemnify our directors and executive officers to
    the fullest extent permitted by Delaware law. See
    &#147;Management&#160;&#151; Limitations on Liability and
    Indemnification Matters&#148; above.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Related
    Party Transaction Policy</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have adopted a formal policy that our executive officers,
    directors, holders of more than 5% of any class of our voting
    securities, and any member of the immediate family of and any
    entity affiliated with any of the foregoing persons, are not
    permitted to enter into a related party transaction with us
    without the prior consent of our audit committee, or other
    independent members of our Board in the case it is inappropriate
    for our audit committee to review such transaction due to a
    conflict of interest. Any request for us to enter into a
    transaction with an executive officer, director, principal
    stockholder, or any of their immediate family members or
    affiliates, in which the amount involved exceeds $120,000 must
    first be presented to our audit committee for review,
    consideration and approval. In approving or rejecting any such
    proposal, our audit committee is to consider the relevant facts
    and circumstances available and deemed relevant to the audit
    committee, including, but not limited to, whether the
    transaction is on terms no less favorable than terms generally
    available to an unaffiliated third party under the same or
    similar circumstances and the extent of the related party&#146;s
    interest in the transaction. All of the transactions described
    above were entered into prior to the adoption of this policy.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    104
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='113'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PRINCIPAL
    STOCKHOLDERS</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth certain information with respect
    to the beneficial ownership of our common stock at
    April&#160;30, 2008, as adjusted to reflect the sale of common
    stock offered by us in this offering, for:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each person who we know beneficially owns more than five percent
    of our common stock;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our named executive officers;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all of our directors and executive officers as a group.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have determined beneficial ownership in accordance with SEC
    rules. Except as indicated by the footnotes below, we believe,
    based on the information furnished to us, that the persons and
    entities named in the table below have sole voting and
    investment power with respect to all shares of common stock that
    they beneficially own, subject to applicable community property
    laws.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Applicable percentage ownership is based on
    68,101,494&#160;shares of common stock outstanding at
    April&#160;30, 2008. For purposes of the table below, we have
    assumed
    that&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock will be outstanding upon completion of this
    offering, based upon an assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share. In computing the
    number of shares of common stock beneficially owned by a person
    and the percentage ownership of that person, we deemed to be
    outstanding all shares of common stock subject to options,
    warrants or other convertible securities held by that person or
    entity that are currently exercisable or exercisable within
    60&#160;days of April&#160;30, 2008. We did not deem these
    shares outstanding, however, for the purpose of computing the
    percentage ownership of any other person. Beneficial ownership
    representing less than one percent is denoted with an
    &#147;*.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, the address of each beneficial owner
    listed in the table below is
    <FONT style="white-space: nowrap">c/o&#160;Fluidigm</FONT>
    Corporation, 7000 Shoreline Court, Suite&#160;100, South
    San&#160;Francisco, California 94080.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="58%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Beneficial Ownership<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Beneficial Ownership<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Prior to the Offering</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>After the Offering</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name of Beneficial Owner</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>5% Stockholders:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Alloy
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,732,679
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.48
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with EuclidSR
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,898,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.19
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with the Singapore
    government<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,008,967
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.23
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Fidelity
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,250,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.18
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with InterWest
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,776,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.55
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Lehman
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,693,907
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.42
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    SMALLCAP World Fund,
    Inc.<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,378,695
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.43
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Versant
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,879,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.63
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Bruce Burrows
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,647,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.36
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Directors and Named Executive Officers:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Gajus V.
    Worthington<SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,386,087
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.13
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Richard
    DeLateur<SUP style="font-size: 85%; vertical-align: text-top">(10)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    324,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Robert C.
    Jones<SUP style="font-size: 85%; vertical-align: text-top">(11)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    690,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.00
</TD>
<TD nowrap align="left" valign="bottom">
    %*
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Michael Y.
    Lucero<SUP style="font-size: 85%; vertical-align: text-top">(12)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    718,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.04
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    William M.
    Smith<SUP style="font-size: 85%; vertical-align: text-top">(13)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,117,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.62
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mai Chan (Grace)
    Yow<SUP style="font-size: 85%; vertical-align: text-top">(14)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    307,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Samuel
    Colella<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,879,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.63
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Michael
    Hunkapiller<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,732,679
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.48
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Elaine V.
    Jones<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,898,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.19
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Kenneth
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(15)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    137,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    John
    Young<SUP style="font-size: 85%; vertical-align: text-top">(16)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All directors and executive officers as a group (10&#160;persons)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,199,742
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28.39
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(footnotes appear on following
    page)</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(*)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Less than one percent.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 1,866,340&#160;shares
    held of record by Alloy Ventures 2005, L.P.,
    1817,272&#160;shares held of record by Alloy Ventures 2002,
    L.P., and 49,067&#160;shares held of record by Alloy Partners
    2002, L.P. Michael Hunkapiller, a member of our Board of
    Directors, is a Managing Member of
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    105
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"> Alloy Ventures 2005, LLC, the
    General Partner of Alloy Ventures 2005, L.P. Alloy Ventures
    2002, LLC is the General Partner of Alloy Ventures 2002, L.P.
    and Alloy Partners 2002, L.P. The Managing Members of Alloy
    Ventures 2002, LLC are Craig C. Taylor, John F. Shoch, Douglas
    E. Kelly, Daniel I. Rubin and Tony Di Bona. Each of the Managing
    Members of Alloy Ventures 2002, LLC is also a Managing Member of
    Alloy Ventures 2005, LLC. The individuals listed herein may be
    deemed to have shared voting and dispositive power over the
    shares which are or may be deemed to be beneficially owned by
    Alloy Ventures 2005, L.P., Alloy Ventures 2002, L.P. and Alloy
    Partners 2002, L.P. Each Managing Member disclaims beneficial
    ownership of the shares except to extent of their pecuniary
    interest therein. The address of the entities affiliated with
    Alloy Ventures is 400 Hamilton Avenue, Fourth Floor, Palo Alto,
    CA 94301.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,449,498&#160;shares
    held of record by EuclidSR Partners, L.P. and
    2,449,498&#160;shares held of record by EuclidSR Biotechnology
    Partners, L.P. Elaine V. Jones, a member of our Board of
    Directors shares voting and investment power with Graham D.S.
    Anderson, Raymond J. Whitaker, Milton J. Pappas and Stephen K.
    Reidy, each of whom are General Partners of EuclidSR Associates,
    L.P., the General Partner of EuclidSR Partners and EuclidSR
    Biotechnology Associates, L.P., the General Partner of EuclidSR
    Biotechnology Partners. Each General Partner of EuclidSR
    Associates, L.P. and EuclidSR Biotechnology Associates, L.P.
    disclaims beneficial ownership of the shares except to the
    extent of their pecuniary interest therein. The address of the
    entities affiliated with EuclidSR Associates, L.P. and EuclidSR
    Biotechnology Associates, L.P. is 45 Rockefeller Plaza, Suite
    3240, New York, NY 10111.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 6,729,828&#160;shares
    held of record by Biomedical Sciences Investment Fund Pte Ltd
    which includes 1,503,945&#160;shares issued upon conversion of a
    convertible promissory note, and 775,194&#160;shares held of
    record by Singapore Bio-Innovations Pte Ltd, EDB Investments Pte
    Ltd, or EDB Investments, the parent entity of Biomedical
    Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations
    Pte Ltd and the Economic Development Board of Singapore, or EDB,
    the ultimate parent entity of EDB Investments, may be deemed to
    have voting and dispositive power over the shares owned
    beneficially and of record by Biomedical Sciences Investment
    Fund&#160;Pte Ltd and Singapore Bio-Innovations Pte Ltd. The
    address associated with entities affiliated with EDB is 20
    Biopolis Way, #09-01 Centros, Singapore 138668.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 481,170&#160;shares
    held of record by Fidelity Contrafund: Fidelity New Advisor New
    Insights Fund, 4,389,865&#160;shares held of record by Fidelity
    Contrafund: Fidelity Contrafund and 1,378,965&#160;shares held
    of record by Variable Insurance Products Fund&#160;II:
    Contrafund Portfolio. Each of these entities is a registered
    investment fund (each, a &#147;Fund&#148;) advised by Fidelity
    Management&#160;&#038; Research Company (&#147;FMR Co.&#148;), a
    registered investment adviser under the Investment Advisers Act
    of 1940, as amended. The address of FMR Co., a wholly-owned
    subsidiary of FMR Corp. and an investment adviser registered
    under Section&#160;203 of the Investment Advisers Act of 1940 is
    82&#160;Devonshire Street, Boston Massachusetts 02109. Edward C.
    Johnson 3d, FMR Corp., through its control of FMR Co., and each
    Fund has sole power to dispose of the securities owned by such
    Fund. Neither FMR Corp. nor Edward C. Johnson 3d, Chairman of
    FMR Corp., has sole power to vote or direct the voting of the
    shares owned directly by each Fund, which power resides with
    each Fund&#146;s Board of Trustees. Each Fund is an affiliate of
    a broker-dealer. Each Fund purchased the securities in the
    ordinary course of business and, at the time of the purchase of
    the securities to be resold, no Fund had any agreements or
    understandings, directly or indirectly, with any person to
    distribute the securities. No Fund intends to sell, transfer,
    assign, pledge or hypothecate or otherwise enter into any
    hedging, short sale, derivative, put or call transaction that
    would result in the effective economic disposition of the
    securities through an affiliated broker-dealer.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 172,602&#160;shares
    held of record by InterWest Investors VII, L.P. and
    3,604,283&#160;shares held of record by InterWest Partners VII,
    L.P. InterWest Management Partners VII, L.L.C. has sole voting
    and investment control over the shares owned by InterWest
    Partners VII, L.P. and InterWest Investors VII, L.P. Harvey B.
    Cash, Philip T. Gianos, W. Scott Hedrick, W. Stephen Holmes,
    Gilbert H. Kliman, Thomas L. Rosch and Arnold L. Oronsky, each
    Managing Directors of InterWest Management Partners VII, LLC,
    have shared voting and investment control over the shares owned
    by InterWest Partners VII, L.P. and InterWest Investors VII,
    L.P. Stephen C. Bowsher, Alan W. Crites, Rodney A. Ferguson and
    Karen A. Wilson are Members of InterWest Management Partners
    VII, L.L.C. All Managing Directors and Members disclaim
    beneficial ownership of the shares owned by InterWest Partners
    VII, LP and InterWest Investor VII, LP except to the extent of
    their pro rata partnership interests in such shares. The address
    of the entities affiliated with InterWest is 2710 Sand Hill
    Road, Second Floor, Menlo Park, CA 94025.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 923,476&#160;shares
    held of record by Lehman Brothers Healthcare Venture Capital,
    L.P., 206,536&#160;shares held of record by Lehman Brothers
    Offshore Partnership Account 2000/2001, L.P.,
    1,767,535&#160;shares held of record by Lehman Brothers P.A.,
    LLC and 796,360&#160;shares held of record by Lehman Brothers
    Partnership Account 2000/2001, L.P. Hingge Hsu, a former member
    of our Board of Directors, was formerly employed by Lehman
    Brothers Inc., and now serves as a consultant of Lehman Brothers
    Inc. In each of the limited partnerships referenced above,
    Lehman Brothers Inc. controls the general partner of the fund.
    In the limited liability company, Lehman Brothers Inc. controls
    the manager of that fund. In all instances, the general partner
    or the manager has voting and dispositive control of the shares
    held by that particular fund, and thus may be attributed to
    Lehman Brothers Inc.. In all four funds listed above, Lehman
    Brothers Holdings Inc. ultimately controls the manager and the
    general partners of the funds. Employees of Lehman Brothers
    Inc., a subsidiary of Lehman Brothers Holdings Inc. manages each
    of the funds. No one person controls Lehman Brothers Holdings
    Inc. The address of the entities affiliated with Lehman Brothers
    Inc.  is 399 Park Avenue,
    11<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>
    Floor, New York, NY 10022.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 4,378,695&#160;shares
    held of record by SMALLCAP World Fund, Inc, or SMALLCAP.
    SMALLCAP is an investment company registered under the
    Investment Company Act of 1940. Capital Research and Management
    Company, or CRMC, an investment adviser registered under the
    Investment Advisers Act of 1940, is the investment adviser to
    SMALLCAP. In that capacity, CRMC may be deemed to be the
    beneficial owner of the shares held by SMALLCAP. CRMC, however,
    disclaims such beneficial ownership. The address of the SMALLCAP
    is The Capital Group Companies, 333, South Hope Street, Los
    Angeles, California 90071.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 5,378,019&#160;shares
    held of record by Versant Venture Capital&#160;I, L.P.,
    98,662&#160;shares held of record by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-A,</FONT>
    L.P., 291,146&#160;shares held of record by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-B,</FONT>
    L.P. and 112,153&#160;shares held of record by Versant Side
    Fund&#160;I, L.P. Voting and investment power over the shares
    directly held by Versant Venture Capital&#160;I, L.P., Versant
    Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-A,</FONT>
    L.P., Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-B,</FONT>
    L.P., and Versant Side Fund&#160;I, L.P. is held by Versant
    Ventures&#160;I, LLC, their sole General Partner. Samuel D.
    Colella, a member of our Board of Directors is a Managing Member
    of Versant Ventures&#160;I, LLC but he disclaims beneficial
    ownership of these shares, except to the extent of his pecuniary
    interest in such shares. The individual Managing Members of
    Versant Ventures&#160;I, LLC are Brian G. Atwood, Samuel D.
    Colella, Ross A. Jaffe, William J. Link, Barbara N. Lubash,
    Donald B. Milder, and Rebecca B. Robertson, all of whom share
    voting and dispositive control. Each respective individual
    General Partner disclaims beneficial ownership of these shares,
    except to
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    106
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">the extent of their pecuniary
    interest in such shares. The address of the entities affiliated
    with Versant Ventures is 3000 Sand Hill Road, Building Four,
    Suite&#160;210, Menlo Park, CA 94025.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,341,087&#160;shares
    held of record by Gajus Worthington and Jami A. Worthington as
    TTEES of the Worthington Family Trust dtd 3-6-07 and options to
    purchase 495,000&#160;shares of Common Stock that are
    exercisable within 60&#160;days of April&#160;30, 2008, of which
    254,999&#160;shares are vested as of June&#160;29, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 140,000&#160;shares
    held of record by Richard A. DeLateur and options to purchase
    184,582&#160;shares of common stock that are vested and
    exercisable no later than May&#160;29, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    690,000&#160;shares of common stock that are exercisable within
    60&#160;days of April&#160;30, 2008 of which 323,332&#160;shares
    are vested as of February&#160;27, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    718,500&#160;shares of common stock that are vested and
    exercisable no later than June&#160;14, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 300,000&#160;shares
    held of record by William M. Smith and options to purchase
    817,000&#160;shares of common stock that are exercisable within
    60&#160;days of April&#160;30, 2008, of which 771,500 are vested
    as of June&#160;29, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    307,500&#160;shares of common stock that are exercisable within
    60&#160;days of April&#160;30, 2008, of which 270,000 are vested
    as of June&#160;29, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    137,500&#160;shares of common stock that are exercisable within
    60&#160;days of April&#160;30, 2008, all of which are vested as
    of June&#160;29, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Young disclaims beneficial
    ownership of 270,000&#160;shares as all of the shares were
    subsequently transferred to his children, Diana Young, Gregory
    Young and John Peter Young. As of February&#160;27, 2008
    29,167&#160;shares of common stock are subject to a right of
    repurchase at cost. The right of repurchase lapses at a rate of
    approximately 2,083&#160;shares of common stock per month.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    107
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='114'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF CAPITAL STOCK</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">General</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of the rights of our common stock and
    preferred stock and of certain provisions of our restated
    certificate of incorporation and bylaws, as they will be in
    effect upon the completion of this offering. For more detailed
    information, please see our restated certificate of
    incorporation and bylaws, which are filed as exhibits to the
    registration statement of which this prospectus is part.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately following the completion of this offering, our
    authorized capital stock will consist of
    320,000,000&#160;shares, all with a par value of $0.001 per
    share, of which:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    300,000,000&#160;shares are designated as common stock;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    20,000,000&#160;shares are designated as preferred stock.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of April&#160;30, 2008, we had outstanding
    68,101,494&#160;shares of common stock held of record by 248
    stockholders, assuming the automatic conversion of all
    outstanding shares of our preferred stock on a one-for-one basis
    into 58,174,839&#160;shares of common stock. In addition, as of
    April&#160;30, 2008, 9,395,448&#160;shares of our common stock
    were subject to outstanding options and 598,720&#160;shares of
    our capital stock were subject to outstanding warrants. If not
    exercised, 41,284&#160;shares subject to a warrant to purchase
    preferred stock expired on May&#160;14, 2008. No options will
    expire prior to the completion of this offering. For more
    information on our capitalization, see
    &#147;Capitalization&#148; above.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Common
    Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The holders of our common stock are entitled to one vote per
    share on all matters to be voted on by our stockholders. Subject
    to preferences that may be applicable to any outstanding shares
    of preferred stock, holders of common stock are entitled to
    receive ratably such dividends as may be declared by our Board
    of Directors out of funds legally available for that purpose. In
    the event of our liquidation, dissolution or winding up, the
    holders of common stock are entitled to share ratably in all
    assets remaining after the payment of liabilities, subject to
    the prior distribution rights of preferred stock then
    outstanding. Holders of common stock have no preemptive,
    conversion or subscription rights. There are no redemption or
    sinking fund provisions applicable to the common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Preferred
    Stock</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately after the completion of this offering, no shares of
    preferred stock will be outstanding (assuming the automatic
    conversion of all outstanding shares of our preferred stock on a
    one-for-one basis into 58,174,839&#160;shares of common stock
    immediately prior to the completion of this offering). Though we
    currently have no plans to issue any shares of preferred stock,
    upon the closing of this offering and the filing of our restated
    certificate of incorporation, our Board of Directors will have
    the authority, without further action by our stockholders, to
    designate and issue up to 20,000,000&#160;shares of preferred
    stock in one or more series. Our Board of Directors may also
    designate the rights, preferences and privileges of the holders
    of each such series of preferred stock, any or all of which may
    be greater than or senior to those granted to the holders of
    common stock. Though the actual effect of any such issuance on
    the rights of the holders of common stock will not be known
    until our Board of Directors determines the specific rights of
    the holders of preferred stock, the potential effects of such an
    issuance include:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    diluting the voting power of the holders of common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reducing the likelihood that holders of common stock will
    receive dividend payments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reducing the likelihood that holders of common stock will
    receive payments in the event of our liquidation, dissolution,
    or winding up;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delaying, deterring or preventing a
    <FONT style="white-space: nowrap">change-in-control</FONT>
    or other corporate takeover.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    108
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Warrants</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of April&#160;30, 2008, we had outstanding warrants to
    purchase an aggregate of 598,720&#160;shares of our preferred
    stock, all of which will be converted into warrants to purchase
    an equal number of shares of our common stock at exercise prices
    ranging from $1.78 per share to $4.00 per share. These warrants
    will expire at various times between May 2008 and February 2015.
    In the event of a distribution of dividends, a stock split, a
    reorganization, a reclassification, a consolidation, or a
    similar event, each warrant provides for adjustment of the
    exercise price and the number of shares issuable upon exercise.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Potential
    Increase in Warrant Shares</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, we amended a loan and security agreement with
    Lighthouse Capital Partners&#160;V, L.P., or Lighthouse. The
    amendment provided us with an additional credit line of
    $10,000,000 which can be drawn upon until July&#160;1, 2008 for
    general corporate purposes. In connection with the amendment, we
    issued a warrant to purchase 100,000&#160;shares of our
    Series&#160;E preferred stock at a purchase price of $4.00,
    which is reflected in the aggregate number of outstanding
    warrants discussed above. The number of shares of Series&#160;E
    preferred stock subject to the warrant may be increased by up to
    200,000 additional shares of Series&#160;E preferred stock at
    the same exercise price, depending on the aggregate amount of
    funds loaned to us pursuant to the amendment. Series E preferred
    stock is convertible into common stock on a one to one basis. As
    of April&#160;30, 2008, we had not borrowed any amounts under
    the credit facility. The potential increase in the number of
    shares underlying this warrant is not reflected in the number of
    shares of common stock outstanding or the number of shares
    subject to issuance upon exercise of outstanding warrants in
    this prospectus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Potential
    Issuance of Common Stock</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;7, 2003, we entered into a Master Closing
    Agreement with Oculus Pharmaceuticals, Inc. and The UAB Research
    Foundation, or UAB, related to certain intellectual property and
    technology rights licensed by us from UAB. Pursuant to the
    agreement, we are obligated to issue UAB shares of our common
    stock with a value equal to approximately $1,500,000 upon the
    achievement of a certain milestone and based upon the fair
    market value of our common stock at the time the milestone is
    achieved. We currently do not anticipate achieving this
    milestone in the foreseeable future and do not anticipate
    issuing these shares. The potential issuance discussed above is
    not reflected in the number of shares of common stock
    outstanding in this prospectus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of April&#160;30, 2008, the holders of an aggregate of
    63,541,524&#160;shares of our common stock, which includes
    58,174,839&#160;shares of common stock issued on conversion of
    outstanding preferred stock and 598,720&#160;shares of common
    stock issuable upon the exercise of warrants and conversion of
    preferred stock underlying such warrants, are entitled to the
    following rights with respect to the registration of such shares
    for public resale under the Securities Act, pursuant to an
    investor rights agreement by and among us and certain of our
    stockholders. In addition, the aggregate number above includes
    an additional 4,767,965&#160;shares of common stock entitled to
    the rights described below, in the section titled
    &#147;Piggyback Registration Rights.&#148; We refer to these
    shares collectively as &#147;registrable securities.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registration of shares of common stock as a result of the
    following rights being exercised would enable the holders to
    trade these shares without restriction under the Securities Act
    when the applicable registration statement is declared
    effective. Ordinarily, we will be required to pay all expenses,
    other than underwriting discounts and commissions, related to
    any registration effected pursuant to the exercise of these
    registration rights.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registration rights terminate upon the earlier of five years
    after completion of this offering, or, with respect to the
    registration rights of an individual holder, when the holder of
    one percent or less of our outstanding common stock can sell all
    of such holder&#146;s registrable securities in any three-month
    period without registration, in compliance with Rule&#160;144 of
    the Securities Act or another similar exemption.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    109
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Demand
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after this offering the holders of at least a
    majority of the registrable securities request in writing that
    we effect a registration that has a reasonably anticipated
    aggregate price to the public in excess of $20,000,000, we may
    be required to register their shares. At most, we are obligated
    to effect two registrations for the holders of registrable
    securities in response to these demand registration rights.
    Depending on certain conditions, however, we may defer such
    registration for up to 90&#160;days. If the holders requesting
    registration intend to distribute their shares by means of an
    underwriting, the managing underwriter of such offering will
    have the right to limit the number of shares to be underwritten
    for reasons related to the marketing of the shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Piggyback
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after this offering we propose to register any
    shares of our common stock under the Securities Act, subject to
    certain exceptions, the holders of registrable securities will
    be entitled to notice of the registration and to include their
    shares of registrable securities in the registration. If our
    proposed registration involves an underwriting, the managing
    underwriter of such offering will have the right to limit the
    number of shares to be underwritten for reasons related to the
    marketing of the shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after we become entitled under the Securities Act
    to register our shares on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    a holder of registrable securities requests in writing that we
    register their shares for public resale on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    and the reasonably anticipated price to the public of the
    offering exceeds $2,000,000, we will be required to use our best
    efforts to effect such registration; provided, however, that if
    such registration would be seriously detrimental to us or our
    stockholders, we may defer the registration for up to
    90&#160;days.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the provisions of our amended and restated certificate of
    incorporation to become effective upon completion of this
    offering, holders of our common stock are entitled to one vote
    for each share of common stock held by such holder on any matter
    submitted to a vote at a meeting of stockholders. In addition,
    our amended and restated certificate of incorporation provides
    that certain corporate actions require the approval of our
    stockholders. These actions, and the vote required, are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the removal of a director requires the vote of a majority of the
    voting power of our issued and outstanding capital stock
    entitled to vote in the election of directors;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amendment of provisions of our amended and restated
    certificate of incorporation relating to blank check preferred
    stock, the classification of our directors, the removal of
    directors, the filling of vacancies on our Board of Directors,
    cumulative voting, annual and special meetings of our
    stockholders and the amendment of certain provisions of our
    restated certificate of incorporation require the vote of 66
    2/3% of our then outstanding voting securities.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Anti
    Takeover Effects of Delaware Law and Our Certificate of
    Incorporation and Bylaws</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain provisions of Delaware law and our restated certificate
    of incorporation and bylaws that will become effective upon
    completion of this offering contain provisions that could have
    the effect of delaying, deferring or discouraging another party
    from acquiring control of us. These provisions, which are
    summarized below, are expected to discourage certain types of
    coercive takeover practices and inadequate takeover bids. These
    provisions are also designed in part to encourage anyone seeking
    to acquire control of us to first negotiate with our Board of
    Directors. We believe that the advantages gained by protecting
    our ability to negotiate with any unsolicited and potentially
    unfriendly acquirer outweigh the disadvantages of discouraging
    such proposals, including those priced above the then-current
    market value of our common stock, because, among other reasons,
    the negotiation of such proposals could improve their terms.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    110
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Certificate
    of Incorporation and Bylaws</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    to become effective upon completion of this offering include
    provisions that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    authorize our Board of Directors to issue, without further
    action by the stockholders, up to 20,000,000&#160;shares of
    undesignated preferred stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require that any action to be taken by our stockholders be
    effected at a duly called annual or special meeting and not by
    written consent;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that special meetings of our stockholders can be called
    only by our Board of Directors, the Chairman of the Board, the
    Chief Executive Officer or the President;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish an advance notice procedure for stockholder approvals
    to be brought before an annual meeting of our stockholders,
    including proposed nominations of persons for election to our
    Board of Directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that directors may be removed only for cause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that vacancies on our Board of Directors may be filled
    only by a majority of directors then in office, even though less
    than a quorum;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish that our Board of Directors is divided into three
    classes, Class&#160;I, Class&#160;II, and Class&#160;III, with
    each class serving staggered terms;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that no stockholder is permitted to cumulate votes at
    any election of the Board of Directors;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require a super-majority of votes to amend certain of the
    above-mentioned provisions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Delaware
    Anti-Takeover Statute</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are subject to the provisions of Section&#160;203 of the
    Delaware General Corporation Law regulating corporate takeovers.
    In general, Section&#160;203 prohibits a publicly-held Delaware
    corporation from engaging, under certain circumstances, in a
    business combination with an interested stockholder for a period
    of three years following the date the person became an
    interested stockholder unless:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the date of the transaction, the Board of Directors of
    the corporation approved either the business combination or the
    transaction which resulted in the stockholder becoming an
    interested stockholder;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    upon completion of the transaction that resulted in the
    stockholder becoming an interested stockholder, the interested
    stockholder owned at least 85% of the voting stock of the
    corporation outstanding at the time the transaction commenced,
    excluding for purposes of determining the voting stock
    outstanding, but not for determining the outstanding voting
    stock owned by the interested stockholder, (1)&#160;shares owned
    by persons who are directors and also officers, and
    (2)&#160;shares owned by employee stock plans in which employee
    participants do not have the right to determine confidentially
    whether shares held subject to the plan will be tendered in a
    tender or exchange offer;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at or subsequent to the date of the transaction, the business
    combination is approved by the Board of Directors of the
    corporation and authorized at an annual or special meeting of
    stockholders, and not by written consent, by the affirmative
    vote of at least
    66<FONT style="vertical-align: text-top; font-size: 70%;">2</FONT>/<FONT style="font-size: 70%;">3</FONT>%
    of the outstanding voting stock which is not owned by the
    interested stockholder.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, a business combination includes a merger, asset or
    stock sale, or other transaction resulting in a financial
    benefit to the interested stockholder. An interested stockholder
    is a person who, together with affiliates and associates, owns
    or, within three years prior to the determination of interested
    stockholder status, did own 15% or more of a corporation&#146;s
    outstanding voting stock. We expect the existence of this
    provision to have an anti-takeover effect with respect to
    transactions our Board of Directors does not approve in advance.
    We also anticipate that Section&#160;203&#160;may discourage
    business combinations or other attempts that might result in a
    premium over the market price for the shares of common stock
    held by our stockholders.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    111
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The provisions of Delaware law and our restated certificate of
    incorporation and bylaws to become effective upon completion of
    this offering could have the effect of discouraging others from
    attempting hostile takeovers and, as a consequence, they may
    also inhibit temporary fluctuations in the market price of our
    common stock that often result from actual or rumored hostile
    takeover attempts. These provisions may also have the effect of
    preventing changes in our management. It is possible that these
    provisions could make it more difficult to accomplish
    transactions that stockholders may otherwise deem to be in their
    best interests.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Transfer
    Agent and Registrar</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The transfer agent and registrar for our common stock is
    Computershare Trust Company, N.A. The transfer agent&#146;s
    address is 250&#160;Royall Street, Canton, MA 02021, and its
    telephone number is (781) 575-2900.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">NASDAQ
    Global Market Listing</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied to have our common stock listed on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    112
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='115'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SHARES
    ELIGIBLE FOR FUTURE SALE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Before this offering, there has not been a public market for
    shares of our common stock. Future sales of substantial amounts
    of shares of our common stock, including shares issued upon the
    exercise of outstanding options, in the public market after this
    offering, or the possibility of these sales occurring, could
    cause the prevailing market price for our common stock to fall
    or impair our ability to raise equity capital in the future.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the completion of this offering, a total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock will be outstanding, assuming that there are no
    exercises of options or warrants after April&#160;30, 2008. Of
    these shares,
    all&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock sold in this offering by us, plus any shares
    sold upon exercise of the underwriters&#146; over-allotment
    option, will be freely tradable in the public market without
    restriction or further registration under the Securities Act,
    unless these shares are held by &#147;affiliates,&#148; as that
    term is defined in Rule&#160;144 under the Securities Act.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The remaining 68,101,494&#160;shares of common stock will be
    &#147;restricted securities,&#148; as that term is defined in
    Rule&#160;144 under the Securities Act. These restricted
    securities are eligible for public sale only if they are
    registered under the Securities Act or if they qualify for an
    exemption from registration under Rules&#160;144 or 701 under
    the Securities Act, which are summarized below.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the lock up agreements described below and the
    provisions of Rules&#160;144 and 701 under the Securities Act,
    these restricted securities will be available for sale in the
    public market as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    On the date of this prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Between 90 and 180&#160;days after the date of this prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    At various times beginning more than 180&#160;days after the
    date of this prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,101,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, of the 9,395,448&#160;shares of our common stock
    that were subject to stock options outstanding as of
    April&#160;30, 2008, options to purchase 4,384,570&#160;shares
    of common stock were vested as of April&#160;30, 2008 and will
    be eligible for sale 180&#160;days following the effective date
    of this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;144</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;144 as currently in effect, once we
    have been subject to public company reporting requirements for
    at least 90&#160;days, a person who is not deemed to have been
    one of our affiliates for purposes of the Securities Act at any
    time during the 90&#160;days preceding a sale and who has
    beneficially owned the shares proposed to be sold for at least
    six months, including the holding period of any prior owner
    other than our affiliates, is entitled to sell those shares
    without complying with the manner of sale, volume limitation or
    notice provisions of Rule&#160;144, subject to compliance with
    the public information requirements of Rule&#160;144. If such a
    person has beneficially owned the shares proposed to be sold for
    at least one year, including the holding period of any prior
    owner other than our affiliates, then that person is entitled to
    sell those shares without complying with any of the requirements
    of Rule&#160;144.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;144, as currently in effect, our
    affiliates or persons selling shares on behalf of our affiliates
    are entitled to sell upon expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements described above, within any three-month period
    beginning 90&#160;days after the date of this prospectus, a
    number of shares that does not exceed the greater of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1% of the number of shares of common stock then outstanding,
    which will equal
    approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    immediately after this offering;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the average weekly trading volume of the common stock during the
    four calendar weeks preceding the filing of a notice on
    Form&#160;144 with respect to that sale.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sales under Rule&#160;144 by our affiliates or persons selling
    shares on behalf of our affiliates are also subject to certain
    manner of sale provisions and notice requirements and to the
    availability of current public information about us.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    113
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;701</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;701 as currently in effect, any of
    our employees, consultants or advisors who purchase shares from
    us in connection with a compensatory stock or option plan or
    other written agreement in a transaction before the effective
    date of this offering that was completed in reliance on
    Rule&#160;701 and complied with the requirements of
    Rule&#160;701 will, subject to the lock up restrictions
    described below, be eligible to resell such shares 90&#160;days
    after the effective date of this offering in reliance on
    Rule&#160;144, but without compliance with certain restrictions,
    including the holding period, contained in Rule&#160;144.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Lock Up
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and all of our directors and officers, as well as the other
    holders of substantially all shares of common stock outstanding
    immediately prior to this offering, have agreed that, without
    the prior written consent of Morgan Stanley&#160;&#038; Co.
    Incorporated on behalf of the underwriters, we and they will
    not, during the period ending 180&#160;days after the date of
    this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend or
    otherwise transfer or dispose of, directly or indirectly, any
    shares of our common stock or any securities convertible into or
    exercisable or exchangeable for shares of our common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of our common stock,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any transaction described above is to be settled by
    delivery of shares of our common stock or such other securities,
    in cash or otherwise. This agreement is subject to certain
    exceptions, and is also subject to extension for up to an
    additional days, as set forth in &#147;Underwriters.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, the holders of
    63,541,524&#160;shares of common stock or their transferees will
    be entitled to various rights with respect to the registration
    of these shares under the Securities Act. Registration of these
    shares under the Securities Act would result in these shares
    becoming fully tradable without restriction under the Securities
    Act immediately upon the effectiveness of the registration,
    except for shares purchased by affiliates. See &#147;Description
    of Capital Stock&#160;&#151; Registration Rights&#148; for
    additional information.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Statements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to file a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    under the Securities Act covering all of the shares of common
    stock subject to options outstanding or reserved for issuance
    under our stock plans. We expect to file this registration
    statement as soon as practicable after this offering. In
    addition, we intend to file a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    under the Securities Act for the resale of shares of common
    stock issued upon the exercise of options that were not granted
    under Rule&#160;701. We expect to file this registration
    statement as soon as practicable after this offering. However,
    none of the shares registered on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    will be eligible for resale until the expiration of the lock up
    agreements to which they are subject.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    114
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='120'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MATERIAL
    U. S. FEDERAL INCOME AND ESTATE TAX<BR>
    CONSEQUENCES TO NON-U. S. HOLDERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a general discussion of certain material United
    States federal income and estate tax considerations with respect
    to the acquisition, ownership and disposition of shares of our
    common stock applicable to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders.</FONT>
    In general, a
    <FONT style="white-space: nowrap">&#147;non-U.S.&#160;holder&#148;</FONT>
    is any holder other than:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an individual who is a citizen or resident of the United States
    for United States federal income tax purposes;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a corporation (or other entity treated as a corporation for
    United States federal income tax purposes) created or organized
    in or under the laws of the United States, any state thereof or
    the District of Columbia;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an estate, the income of which is includible in gross income for
    United States federal income tax purposes regardless of its
    source;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trust if (a)&#160;a court within the United States is able to
    exercise primary supervision over the administration of the
    trust and one or more United States persons have the authority
    to control all substantial decisions of the trust or (b)&#160;it
    has a valid election in effect under applicable Treasury
    regulations to be treated as a United&#160;States person.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion is based on current provisions of the Internal
    Revenue Code, final, temporary or proposed Treasury regulations
    promulgated thereunder, judicial opinions, published positions
    of the Internal Revenue Service and all other applicable
    authorities, all of which are subject to change (possibly with
    retroactive effect). We assume in this discussion that a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    holds shares of our common stock as a capital asset (generally
    property held for investment).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion does not address all aspects of United States
    federal income and estate taxation that may be important to a
    particular
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    in light of that
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    individual circumstances, nor does it address any aspects of
    United States state or local taxes or
    <FONT style="white-space: nowrap">non-U.S.&#160;taxes.</FONT>
    This discussion also does not consider any specific facts or
    circumstances that may apply to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    subject to special treatment under the United&#160;States
    federal income tax laws, including, without limitation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    banks, insurance companies or other financial institutions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    partnerships or other pass-through entities or persons that hold
    shares of our common stock through such entities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    tax-exempt organizations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    tax-qualified retirement plans;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    dealers in securities or currencies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    traders in securities that elect to use a mark-to-market method
    of accounting for their securities holdings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    United States expatriates;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    persons that will hold common stock as a position in a hedging
    transaction, &#147;straddle&#148; or &#147;conversion
    transaction&#148; for tax purposes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accordingly, we urge prospective investors to consult with their
    own tax advisors regarding the United States federal, state and
    local income and
    <FONT style="white-space: nowrap">non-U.S.&#160;income</FONT>
    and other tax considerations of acquiring, holding and disposing
    of shares of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If a partnership or other pass-through entity holds shares of
    our common stock, the tax treatment of a partner in such
    partnership or an owner of such other pass-through entity will
    generally depend upon the status of such partner or other owner
    and the activities of such partnership or other entity. Any
    partnership or other pass-through entity that holds shares of
    our common stock or any partner in such partnership or owner of
    such other entity should consult its own tax advisors.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    115
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we make cash or other property distributions on our common
    stock, such distributions will constitute dividends for United
    States federal income tax purposes to the extent paid from our
    current or accumulated earnings and profits, as determined under
    United States federal income tax principles. To the extent those
    distributions exceed both our current and our accumulated
    earnings and profits, such excess will constitute a return of
    capital and will first reduce the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    adjusted tax basis in our common stock, but not below zero. Any
    remaining excess will be treated as gain from the sale or other
    disposition of shares of our common stock (as described under
    &#147;&#151;&#160;Gain on Sale or Other Disposition of Common
    Stock&#148; below).
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, dividends we pay, if any, to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to United States withholding tax at a rate of
    30% of the gross amount. The withholding tax might not apply or
    might apply at a reduced rate under the terms of an applicable
    income tax treaty between the United States and the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    country of residence. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    must demonstrate its entitlement to treaty benefits by
    certifying, among other things, its nonresident status. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    generally can meet this certification requirement by providing
    an Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8BEN</FONT>
    or appropriate substitute form to us or our paying agent. Also,
    special rules apply if the dividends are effectively connected
    with a trade or business carried on by the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United States and, if a treaty applies, are
    attributable to a permanent establishment of the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United States. Dividends effectively connected with
    this United States trade or business, and, if a treaty applies,
    attributable to such a permanent establishment of a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder,</FONT>
    generally will not be subject to United States withholding tax
    if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    files certain forms, including Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8ECI</FONT>
    (or any successor form), with the payor of the dividend, and
    generally will be subject to United States federal income tax on
    a net income basis, in the same manner as if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    were a resident of the United States. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    that is a corporation may be subject to an additional
    &#147;branch profits tax&#148; at a rate of 30% (or a reduced
    rate as may be specified by an applicable income tax treaty) on
    the repatriation from the United States of its &#147;effectively
    connected earnings and profits,&#148; subject to certain
    adjustments. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of shares of our common stock eligible for a reduced rate of
    United States withholding tax pursuant to an income tax treaty
    may obtain a refund of any excess amounts withheld by timely
    filing an appropriate claim for refund with the Internal Revenue
    Service.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Gain on
    Sale or Other Disposition of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will not be subject to United States federal income tax on any
    gain realized upon the sale or other disposition of the
    holder&#146;s shares of our common stock unless:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the gain is effectively connected with a trade or business
    carried on by the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United&#160;States and, if required by an applicable
    income tax treaty as a condition to subjecting a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    to United States income tax on a net basis, the gain is
    attributable to a permanent establishment of the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    maintained in the United States, in which case a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to United States federal income tax on any gain
    realized upon the sale or other disposition on a net income
    basis, in the same manner as if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    were a resident of the United States. Furthermore, the branch
    profits tax discussed above may also apply if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is a corporation;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is an individual and is present in the United States for
    183&#160;days or more in the taxable year of disposition and
    certain other tests are met, in which case a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to a flat 30% tax on any gain realized upon the
    sale or other disposition, which tax may be offset by United
    States source capital losses (even though the individual is not
    considered a resident of the United States);&#160;or
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we are or have been a United States real property holding
    corporation (a USRPHC) for United States federal income tax
    purposes at any time within the shorter of the five-year period
    preceding the disposition and the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    holding period. We do not believe that we are or have been a
    USRPHC, and we do not anticipate becoming a USRPHC. If we have
    been in the past or were to become a USRPHC at any time during
    this period, generally gains realized upon a disposition of
    shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    that did not directly or indirectly own more than 5% of our
    common stock during this period would not be subject to United
    States federal income tax, provided that our common stock is
    &#147;regularly traded on an established securities market&#148;
    (within the meaning of Section&#160;897(c)(3) of the Internal
    Revenue Code). Our common stock will be treated as regularly
    traded on an established securities market during any period in
    which it is listed on a registered national securities exchange
    or any over-the-counter market.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    116
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    States Federal Estate Tax</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares of our common stock that are owned or treated as owned by
    an individual who is not a citizen or resident (as defined for
    United States federal estate tax purposes) of the United States
    at the time of death will be includible in the individual&#146;s
    gross estate for United States federal estate tax purposes,
    unless an applicable estate tax treaty provides otherwise, and
    therefore may be subject to United States federal estate tax.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Backup
    Withholding, Information Reporting and Other Reporting
    Requirements</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, we must report annually to the Internal Revenue
    Service and to each
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    the amount of dividends paid to, and the tax withheld with
    respect to, each
    <FONT style="white-space: nowrap">non-U.S.&#160;holder.</FONT>
    These reporting requirements apply regardless of whether
    withholding was reduced or eliminated by an applicable tax
    treaty. Copies of this information also may be made available
    under the provisions of a specific treaty or agreement with the
    tax authorities in the country in which the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    resides or is established.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    United States backup withholding tax is imposed (at a current
    rate of 28%) on certain payments to persons that fail to furnish
    the information required under the United States information
    reporting requirements. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of shares of our common stock will be subject to this backup
    withholding tax on dividends we pay unless the holder certifies,
    under penalties of perjury, among other things, its status as a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and we or our paying agent do not have actual knowledge or
    reason to know the holder is a United States person) or
    otherwise establishes an exemption.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Treasury regulations, the payment of proceeds from the
    disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a United States office of a broker generally
    will be subject to information reporting and backup withholding
    unless the beneficial owner certifies, under penalties of
    perjury, among other things, its status as a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and we or our paying agent do not have actual knowledge or
    reason to know the holder is a United States person) or
    otherwise establishes an exemption. The payment of proceeds from
    the disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a
    <FONT style="white-space: nowrap">non-U.S.&#160;office</FONT>
    of a broker generally will not be subject to backup withholding
    and information reporting, except as noted below. In the case of
    proceeds from a disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a
    <FONT style="white-space: nowrap">non-U.S.&#160;office</FONT>
    of a broker that is:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a United States person;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a &#147;controlled foreign corporation&#148; for United States
    federal income tax purposes;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a foreign person 50% or more of whose gross income from certain
    periods is effectively connected with a United States trade or
    business;&#160;or
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a foreign partnership if at any time during its tax year
    (a)&#160;one or more of its partners are United States persons
    who, in the aggregate, hold more than 50% of the income or
    capital interests of the partnership or (b)&#160;the foreign
    partnership is engaged in a United States trade or business;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    information reporting (but not backup withholding) will apply
    unless the broker has documentary evidence in its files that the
    owner is a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    and certain other conditions are satisfied, or the beneficial
    owner otherwise establishes an exemption (and the broker has no
    actual knowledge or reason to know to the contrary).
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Backup withholding is not an additional tax. Any amounts
    withheld under the backup withholding rules from a payment to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    may generally be refunded or credited against the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    United States federal income tax liability, if any, provided
    that the required information is furnished to the Internal
    Revenue Service in a timely manner.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    EACH PROSPECTIVE HOLDER OF SHARES OF OUR COMMON STOCK SHOULD
    CONSULT HIS, HER OR ITS OWN TAX ADVISOR WITH RESPECT TO THE
    UNITED STATES FEDERAL, STATE AND LOCAL TAX CONSEQUENCES AND
    <FONT style="white-space: nowrap">NON-U.S.&#160;TAX</FONT>
    CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF
    OUR COMMON STOCK.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    117
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='121'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNDERWRITERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the terms and subject to the conditions contained in an
    underwriting agreement dated the date of this prospectus, the
    underwriters named below, for whom Morgan Stanley&#160;&#038;
    Co. Incorporated is acting as the representative, have severally
    agreed to purchase, and we have agreed to sell to them,
    severally, the number of shares indicated in the table below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="90%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Morgan Stanley&#160;&#038; Co. Incorporated
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    UBS Securities LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leerink Swann LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters are offering the shares of common stock subject
    to their acceptance of the shares from us and subject to prior
    sale. The underwriting agreement provides that the obligations
    of the several underwriters to pay for and accept delivery of
    the shares of common stock offered by this prospectus are
    subject to the approval of certain legal matters by their
    counsel and to certain other conditions. The underwriters are
    obligated to take and pay for all of the shares of common stock
    offered by this prospectus if any such shares are taken.
    However, the underwriters are not required to take or pay for
    the shares covered by the underwriters&#146; over-allotment
    option described below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters initially propose to offer part of the shares
    of common stock directly to the public at the offering price
    listed on the cover page of this prospectus and part to certain
    dealers at a price that represents a concession not in excess of
    $&#160;&#160;  per share under the public offering price. After
    the initial offering of the shares of common stock, the offering
    price and other selling terms may from time to time be varied by
    the representative.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have granted to the underwriters an option, exercisable for
    30&#160;days from the date of this prospectus, to purchase up to
    an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional
    shares of common stock at the public offering price set forth on
    the cover page of this prospectus, less underwriting discounts
    and commissions. The underwriters may exercise this option
    solely for the purpose of covering over-allotments, if any, made
    in connection with the offering of the shares of common stock
    offered by this prospectus. To the extent the option is
    exercised, each underwriter will become obligated, subject to
    certain conditions, to purchase approximately the same
    percentage of the additional shares of common stock as the
    number listed next to the underwriter&#146;s name in the
    preceding table bears to the total number of shares of common
    stock listed next to the names of all underwriters in the
    preceding table.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table shows the per share and total public
    offering price, underwriting discounts and commissions and
    proceeds before expenses to us. These amounts are shown assuming
    both no exercise and full exercise of the underwriters&#146;
    option to purchase up to an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>No exercise</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Full Exercise</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Public offering price
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Underwriting discounts and commissions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Proceeds, before expenses, to us
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The estimated offering expenses payable by us, exclusive of the
    underwriting discounts and commissions are approximately
    $&#160;&#160;&#160;&#160;&#160; .
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters have informed us that they do not intend sales
    to discretionary accounts to exceed five percent of the total
    number of shares of common stock offered by them.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied to have the common stock listed on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    118
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and all directors, officers and substantially all of our
    other security holders have agreed that, without the prior
    written consent of Morgan Stanley&#160;&#038; Co. Incorporated
    on behalf of the underwriters, we and they will not, during the
    period ending 180&#160;days after the date of this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend, or
    otherwise transfer or dispose of directly or indirectly, any
    shares of common stock or any securities convertible into or
    exercisable or exchangeable for common stock;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of the common stock; or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in our case only, file or cause to be filed a registration
    statement, including any amendments with respect to the
    registration statement of any shares of common stock or
    securities convertible, exercisable or exchangeable into our
    common stock or any other securities of the company (other than
    any registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8),</FONT>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any such transaction described above is to be settled by
    delivery of common stock or such other securities, in cash or
    otherwise. In addition, each such person agrees that, without
    the prior written consent of Morgan Stanley&#160;&#038; Co.
    Incorporated on behalf of the underwriters, they will not,
    during the period ending 180&#160;days after the date of this
    prospectus, make any demand for, or exercise any right with
    respect to, the registration of any shares of common stock or
    any security convertible into or exercisable or exchangeable for
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to certain restrictions, the restrictions described in
    the immediately preceding paragraph do not apply to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the sale of shares to the underwriters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transactions relating to shares of common stock or other
    securities acquired in open market transactions after the
    completion of this offering, provided that no filing under
    Section&#160;16(a) of the Securities Exchange Act of 1934, as
    amended, shall be required or shall be voluntarily made in
    connection with subsequent sales of common stock or other
    securities acquired in such open market transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise of any options to acquire common stock or
    conversion of any convertible security into common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of shares of common stock or any security convertible
    into common stock as a bona fide gift;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    distributions of shares of common stock or any security
    convertible into common stock to limited partners, members or
    stockholders of the transferor;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of shares of common stock or any security convertible
    into common stock by will or intestacy to the transferor&#146;s
    immediate family or to a trust, the beneficiaries of which are
    members of the transferor&#146;s immediate family;&#160;or
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the establishment of a trading plan pursuant to
    <FONT style="white-space: nowrap">Rule&#160;10b5-1</FONT>
    under the Exchange Act for the transfer of shares of common
    stock, provided that such plan does not provide for the transfer
    of common stock during the restricted period.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The <FONT style="white-space: nowrap">180-day</FONT>
    restricted period described in the preceding paragraph will be
    extended if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    during the last 17&#160;days of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period, we issue a release regarding earnings or
    regarding material news or events relating to us;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the expiration of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period, we announce that we will release earnings
    results during the
    <FONT style="white-space: nowrap">16-day</FONT>
    period beginning on the last day of the
    <FONT style="white-space: nowrap">180-day</FONT>
    period,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    in which case, the restrictions described in the preceding
    paragraph will continue to apply until the expiration of the
    <FONT style="white-space: nowrap">18-day</FONT>
    period beginning on the issuance of the earnings release or the
    occurrence of the material news or material event, unless such
    extension is waived, in writing, by Morgan Stanley&#160;&#038;
    Co. Incorporated on behalf of the underwriters.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    119
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to facilitate the offering of the common stock, the
    underwriters may engage in transactions that stabilize, maintain
    or otherwise affect the price of the common stock. Specifically,
    the underwriters may sell more shares than they are obligated to
    purchase under the underwriting agreement, creating a short
    position. A short sale is covered if the short position is no
    greater than the number of shares available for purchase by the
    underwriters under the over-allotment option. The underwriters
    can close out a covered short sale by exercising the
    over-allotment option or purchasing shares in the open market.
    In determining the source of shares to close out a covered short
    sale, the underwriters will consider, among other things, the
    open market price of shares compared to the price available
    under the over-allotment option. The underwriters may also sell
    shares in excess of the over-allotment option, creating a naked
    short position. The underwriters must close out any naked short
    position by purchasing shares in the open market. A naked short
    position is more likely to be created if the underwriters are
    concerned that there may be downward pressure on the price of
    the common stock in the open market after pricing that could
    adversely affect investors who purchase in the offering. As an
    additional means of facilitating the offering, the underwriters
    may bid for, and purchase, shares of common stock in the open
    market. Finally, the underwriting syndicate may reclaim selling
    concessions allowed to an underwriter or a dealer for
    distributing the common stock in the offering, if the syndicate
    repurchases previously distributed common stock to cover
    syndicate short positions or to stabilize the price of the
    common stock. These activities may raise or maintain the market
    price of the common stock above independent market levels or
    prevent or retard a decline in the market price of the common
    stock. The underwriters are not required to engage in these
    activities, and may end any of these activities at any time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and the underwriters have agreed to indemnify each other
    against certain liabilities, including liabilities under the
    Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A prospectus in electronic format may be made available on
    websites maintained by one or more underwriters participating in
    this offering. Other than the prospectus in electronic format,
    the information on the underwriters&#146; websites is not part
    of this prospectus. The underwriters may agree to allocate a
    number of shares of common stock to underwriters for sale to
    their online brokerage account holders. Internet distributions
    will be allocated by Morgan Stanley&#160;&#038; Co. Incorporated
    to underwriters that may make Internet distributions on the same
    basis as other allocations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">European
    Economic Area</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In relation to each Member State of the European Economic Area
    which has implemented the Prospectus Directive, each underwriter
    has represented and agreed that with effect from and including
    the date on which the Prospectus Directive is implemented in
    that Member State it has not made and will not make an offer of
    the common stock to the public in that Member State, except that
    it may, with effect from and including such date, make an offer
    of the common stock to the public in that Member State:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time to legal entities which are authorized or regulated
    to operate in the financial markets or, if not so authorized or
    regulated, whose corporate purpose is solely to invest in
    securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time to any legal entity which has two or more of
    (1)&#160;an average of at least 250&#160;employees during the
    last financial year; (2)&#160;a total balance sheet of more than
    &#128;43,000,000 and (3)&#160;an annual net turnover of more
    than &#128;50,000,000, as shown in its last annual or
    consolidated accounts;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time in any other circumstances which do not require the
    publication by us of a prospectus pursuant to Article&#160;3 of
    the Prospectus Directive.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the purposes of the above, the expression an &#147;offer of
    the common stock to the public&#148; in relation to any shares
    of common stock in any Member State means the communication in
    any form and by any means of sufficient information on the terms
    of the offer and the common stock to be offered so as to enable
    an investor to decide to purchase or subscribe shares of common
    stock, as the same may be varied in that Member State by any
    measure implementing the Prospectus Directive in that Member
    State, and the expression Prospectus Directive means Directive
    2003/71/EC and includes any relevant implementing measure in
    that Member State.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    120
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    Kingdom</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each underwriter has represented and agreed that it has only
    communicated or caused to be communicated and will only
    communicate or cause to be communicated an invitation or
    inducement to engage in investment activity (within the meaning
    of Section&#160;21 of the Financial Services and Markets Act
    2000)&#160;in connection with the issue or sale of shares of
    common stock in circumstances in which Section&#160;21(1) of
    such Act does not apply to us and it has complied and will
    comply with all applicable provisions of such Act with respect
    to anything done by it in relation to any shares of common stock
    in, from or otherwise involving the United Kingdom.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Relationships</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2007, we sold shares of our Series&#160;E preferred
    stock in a private placement transaction. Leerink Swann LLC
    acted as the placement agent in the October 2007 offering and
    received a fee of $1,000,000 for services rendered. Entities
    affiliated with Leerink Swann LLC also participated in the
    October 2007 offering and purchased an aggregate of
    141,250&#160;shares of our Series&#160;E preferred stock for an
    aggregate purchase price of $565,000. One or more of the
    underwriters may in the future provide investment banking
    services to us for which they would receive customary
    compensation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of the Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for our
    common stock. The initial public offering price will be
    determined by negotiations between us and the underwriters.
    Among the factors to be considered in determining the initial
    public offering price are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our future prospects and those of our industry in general;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our sales, earnings and certain other financial and operating
    information in recent periods;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the price-earnings ratios, price-sales ratios and market prices
    of securities and certain financial and operating information of
    companies engaged in activities similar to ours.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An active trading market for the shares may not develop. It is
    also possible that after the offering the shares will not trade
    in the public market at or above the initial public offering
    price.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    121
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='116'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The validity of the shares of common stock offered hereby will
    be passed upon for us by Wilson Sonsini Goodrich&#160;&#038;
    Rosati, Professional Corporation, Palo Alto, California.
    Latham&#160;&#038; Watkins LLP, Costa Mesa, California is acting
    as counsel to the underwriters. Members of Wilson Sonsini
    Goodrich &#038; Rosati, Professional Corporation and investment
    funds associated with that firm hold 160,956 shares of our
    common stock.
</DIV>
<A name='117'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ernst &#038; Young LLP, independent registered public accounting
    firm, has audited our consolidated financial statements at
    December&#160;31, 2006 and December&#160;29, 2007, and for each
    of the three years in the period ended December&#160;29, 2007,
    as set forth in their report. We have included our consolidated
    financial statements in the prospectus and elsewhere in the
    registration statement in reliance on Ernst &#038; Young
    LLP&#146;s report, given on their authority as experts in
    accounting and auditing.
</DIV>
<A name='118'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">WHERE YOU
    CAN FIND ADDITIONAL INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have filed with the SEC a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT>
    under the Securities Act with respect to the shares of common
    stock offered hereby. This prospectus, which constitutes a part
    of the registration statement, does not contain all of the
    information set forth in the registration statement or the
    exhibits and schedules filed therewith. For further information
    about us and the common stock offered hereby, we refer you to
    the registration statement and the exhibits and schedules filed
    thereto. Statements contained in this prospectus regarding the
    contents of any contract or any other document that is filed as
    an exhibit to the registration statement are not necessarily
    complete, and each such statement is qualified in all respects
    by reference to the full text of such contract or other document
    filed as an exhibit to the registration statement. Upon
    completion of this offering, we will be required to file
    periodic reports, proxy statements, and other information with
    the SEC pursuant to the Securities Exchange Act of 1934. You may
    read and copy this information at the Public Reference Room of
    the SEC, 100 F. Street, N.E., Room&#160;1580,
    Washington,&#160;D.C. 20549. You may obtain information on the
    operation of the public reference rooms by calling the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330.</FONT>
    The SEC also maintains an Internet website that contains
    reports, proxy statements and other information about issuers,
    like us, that file electronically with the SEC. The address of
    that site is www.sec.gov.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to provide our stockholders with annual reports
    containing financial statements that have been audited by an
    independent registered public accounting firm, and to file with
    the SEC quarterly reports containing unaudited financial data
    for the first three quarters of each year.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    122
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='119'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#300'>Report of Independent Registered Public
    Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#301'>Consolidated Balance Sheets</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-3
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#302'>Consolidated Statements of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-4
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#303'>Consolidated Statements of Convertible Preferred
    Stock and Stockholders&#146; Equity (Deficit)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#304'>Consolidated Statements of Cash Flows</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#305'>Notes to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-8
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='300'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Report of
    Independent Registered Public Accounting Firm</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors and Stockholders<BR>
    Fluidigm Corporation
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have audited the accompanying consolidated balance sheets of
    Fluidigm Corporation as of December&#160;31, 2006 and
    December&#160;29, 2007, and the related consolidated statements
    of operations, convertible preferred stock and
    stockholders&#146; equity (deficit), and cash flows for each of
    the three fiscal years in the period ended December&#160;29,
    2007. These financial statements are the responsibility of the
    Company&#146;s management. Our responsibility is to express an
    opinion on these financial statements based on our audits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audit to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement. We were not engaged to perform an
    audit of the Company&#146;s internal control over financial
    reporting. Our audits included consideration of internal control
    over financial reporting as a basis for designing audit
    procedures that are appropriate in the circumstances, but not
    for the purpose of expressing an opinion on the effectiveness of
    the Company&#146;s internal control over financial reporting.
    Accordingly, we express no such opinion. An audit also includes
    examining, on a test basis, evidence supporting the amounts and
    disclosures in the financial statements, assessing the
    accounting principles used and significant estimates made by
    management, and evaluating the overall financial statement
    presentation. We believe that our audits provide a reasonable
    basis for our opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our opinion, the financial statements referred to above
    present fairly, in all material respects, the consolidated
    financial position of Fluidigm Corporation at December&#160;31,
    2006 and December&#160;29, 2007, and the consolidated results of
    its operations and its cash flows for each of the three fiscal
    years in the period ended December&#160;29, 2007, in conformity
    with U.S.&#160;generally accepted accounting principles.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed in Note&#160;2 to the consolidated financial
    statements, Fluidigm Corporation changed its method of
    accounting for preferred stock warrants as of July&#160;1, 2005,
    its method of accounting for stock-based compensation as of
    January&#160;1, 2006, and its method of accounting for uncertain
    tax positions as of January&#160;1, 2007.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Ernst&#160;&#038;
    Young LLP</DIV>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Palo Alto, California
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    April 12, 2008
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='301'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Balance Sheets</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="13" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Assets</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Current assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,286
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accounts receivable (net of allowances of $3, $0 and $0;
    includes accounts receivable from EDB of $272, $679 and $466,
    respectively (Note&#160;3))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,521
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,457
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Prepaid expenses and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    768
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,329
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Property and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    688
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    47,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="13">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="13" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Liabilities, Convertible Preferred Stock and
    Stockholders&#146; Equity (Deficit)</B>
</DIV>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Current liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accrued compensation and related benefits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Other accrued liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Deferred revenue, current portion (includes deferred revenue
    from EDB of $227, $276 and $260, respectively (Note&#160;3))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,628
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Long-term debt, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,476
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,834
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,414
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred revenue, net of current portion (includes deferred
    revenue from EDB of $493, $359 and $306, respectively
    (Note&#160;3))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    762
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term debt, net of current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Convertible promissory notes from BMSIF
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Commitments and contingencies (Note&#160;6)&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Convertible preferred stock issuable in series, $0.001&#160;par
    value: 52,438, 61,798 and 61,798&#160;shares authorized, 43,284,
    56,671 and 56,671&#160;shares issued and outstanding as of
    December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, respectively; aggregate liquidation
    preference of $165,169 as of March&#160;29, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Stockholders&#146; equity (deficit):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Common stock, $0.001&#160;par value: 77,857, 87,386 and
    87,386&#160;shares authorized, 9,498, 9,901 and
    9,928&#160;shares issued and outstanding as of December&#160;31,
    2006, December&#160;29, 2007 and March&#160;29, 2008,
    respectively
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,824
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (344
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (108,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (140,411
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (136,921
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities, convertible preferred stock and
    stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    47,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='302'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Statements of Operations</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="46%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Grant revenue (includes revenue from EDB of $0, $879, $1,758,
    $463 and $401, respectively (Note&#160;3))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    527
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Costs and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    847
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,473
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,280
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,037
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,510
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,523
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest expense (includes interest to BMSIF of $160, $445,
    $1,286, $806 and $152)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,227
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (505
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loss before provision for income taxes and cumulative effect of
    change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,334
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,589
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock before cumulative effect of
    change in accounting principle, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.89
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle, basic and
    diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shares used in computing net loss per share of common stock,
    basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 100%; margin-left: 0%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='303'><B>Consolidated Statements of Convertible
    Preferred Stock and Stockholders&#146; Equity (Deficit)</B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-In<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stockholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income (Loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of January&#160;1, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,845
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    76,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,870
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (68,334
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (65,471
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    170
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock for cash
    at $2.80 per share, net of issuance costs of $11
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of convertible preferred stock warrants in connection
    with financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock upon
    conversion of promissory note at $2.80 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    833
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Reclassification of convertible preferred stock warrants to
    liabilities upon adoption of FSP
    <FONT style="white-space: nowrap">150-5</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,473
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,473
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Unrealized gain on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,349
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of December&#160;31, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,179
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (84,719
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (83,154
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Repurchase of common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (124
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock at $2.80
    per share upon exercise of warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    268
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;E convertible preferred stock for cash
    at $4.00 per share, net of issuance costs of $133
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,535
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock at $2.80
    per share under license agreement, net of issuance costs of $3
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    214
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Beneficial conversion feature for convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (36
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (36
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Unrealized loss on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,590
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of December&#160;31, 2006
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (108,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    297
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    146
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;E convertible preferred stock for cash
    at $4.00 per share, net of issuance costs of $1,189
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,276
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;D convertible preferred stock upon
    conversion of promissory note at $2.80 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;E convertible preferred stock upon
    conversion of promissory notes at $3.60 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,954
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Beneficial conversion feature for convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Unrealized loss on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,569
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Balance as of December&#160;29, 2007 (carried forward)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,901
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> Consolidated Statements of Convertible Preferred Stock and
    Stockholders&#146; Equity (Deficit)&#160;&#151; (Continued)</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-In<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stockholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income (Loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of December&#160;29, 2007 (brought forward)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,901
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
    (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Stock-based compensation expense (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Foreign currency translation adjustment (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (226
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (226
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Unrealized gain on available-for-sale securities (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Net loss (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Total comprehensive loss (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of March&#160;29, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,824
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (344
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (140,411
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (136,921
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='304'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Statements of Cash Flows</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Operating activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Adjustments to reconcile net loss to net cash used in operating
    activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,309
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,379
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,643
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    426
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    416
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign exchange gain
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (242
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Adjustment to fair value of convertible preferred stock warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Loss on retirement of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    .&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of debt discount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    136
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Issuance of convertible preferred stock under license agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (637
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Changes in assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (287
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (400
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (407
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (562
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (955
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,460
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (431
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (899
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Prepaid expenses and other assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (78
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,552
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (231
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (821
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (575
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (306
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    187
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,202
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    212
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (70
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (320
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash used in operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,292
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,306
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,759
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,664
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,777
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Investing activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Purchases of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,990
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,273
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Maturities of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,249
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Sales of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Purchase of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,656
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,932
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (973
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (94
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash provided by (used in) investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,943
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,740
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Financing activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,651
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Repayment of long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,745
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,503
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (857
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,776
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from exercise of stock options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from issuance of convertible preferred stock, net of
    issuance costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from issuance of convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Repurchase of common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash provided by (used in) financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,762
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Effect of exchange rate changes on cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net increase (decrease) in cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,059
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,518
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,846
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents as of beginning of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents as of end of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Supplemental disclosures of cash flow information</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash paid for interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    560
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    363
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Conversion of convertible promissory notes into convertible
    preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cashless net exercise of convertible preferred stock warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Issuance of warrants in connection with long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Issuance of convertible preferred stock under license agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='305'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial Statements</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Description
    of Business</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm Corporation (the Company) was incorporated in the state
    of California on May&#160;19, 1999, to commercialize
    microfluidic technology initially developed at the California
    Institute of Technology (Caltech). In July 2007, the Company was
    reincorporated in Delaware. The Company&#146;s headquarters are
    located in South San&#160;Francisco, California.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company develops, manufactures and markets proprietary
    Integrated Fluidic Circuit systems that significantly improve
    the productivity of life science research. The Company&#146;s
    Integrated Fluidic Circuits, or IFCs, enable the simultaneous
    performance of thousands of biochemical measurements in
    extremely minute volumes. The Company created this
    &#147;integrated circuit for biology&#148; by achieving
    unprecedented miniaturization, integration and automation of
    sophisticated liquid handling processes on a single
    microfabricated device. The Company&#146;s customers include
    many leading biotechnology and pharmaceutical companies,
    academic institutions, and life science laboratories worldwide.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has incurred significant net losses since inception.
    As of March&#160;29, 2008, the Company had an accumulated
    deficit of approximately $140.4&#160;million and cash, cash
    equivalents and available-for-sale securities of approximately
    $31.2&#160;million. The Company expects to incur significant
    expenses to fund operations to develop new products and to
    support existing product sales. Failure to generate sufficient
    revenues, achieve planned gross margins, control operating
    costs, or to raise sufficient additional funds may require the
    Company to modify, delay, or abandon some of its future
    expansion or expenditures, which could have a material adverse
    effect on the Company&#146;s business, operating results,
    financial condition, and ability to achieve its intended
    business objectives.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    of Significant Accounting Policies</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Basis of
    Presentation and Consolidation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements of the Company have been
    prepared in conformity with U.S.&#160;generally accepted
    accounting principles and include the accounts of the Company
    and its wholly owned subsidiaries. The Company has wholly owned
    subsidiaries in Singapore, the Netherlands, Japan, and France.
    All subsidiaries, except for Singapore, use their local currency
    as their functional currency. The Singapore subsidiary uses the
    U.S.&#160;dollar as its functional currency. All intercompany
    transactions and balances have been eliminated in consolidation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Fiscal
    Year</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2007, the Company adopted a 52 or 53&#160;week year
    convention for its fiscal years and, therefore, the 2007 fiscal
    year ended on December&#160;29, 2007 and the first quarterly
    periods of 2007 and 2008 ended on March&#160;31, 2007 and
    March&#160;29, 2008. Future fiscal years will end on the last
    Saturday in December of each respective year. Prior to 2007, the
    Company used a calendar year. The fiscal years presented in
    these consolidated financial statements ended on
    December&#160;31, 2005, December&#160;31, 2006 and
    December&#160;29, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Unaudited
    Interim Financial Information</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying interim consolidated balance sheet as of
    March&#160;29, 2008, the interim consolidated statements of
    operations and cash flows for the three months ended
    March&#160;31, 2007 and March&#160;29, 2008 and the interim
    consolidated statements of convertible preferred stock and
    stockholders&#146; equity (deficit) for the three months ended
    March&#160;29, 2008 are unaudited. The unaudited interim
    consolidated financial statements have been prepared on the same
    basis as the annual consolidated financial statements and, in
    the opinion of management, reflect all adjustments, which
    include only normal recurring adjustments, necessary to present
    fairly the Company&#146;s financial position as of
    March&#160;29, 2008 and its results of operations and its cash
    flows for the three months ended March&#160;31, 2007 and
    March&#160;29, 2008. The financial data and the other financial
    information disclosed in these notes to the consolidated
    financial statements related to the three months periods are
    unaudited. The results of operations
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    for the three months ended March&#160;29, 2008 are not
    necessarily indicative of the results to be expected for 2008 or
    any other interim period or for any other future year.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Use of
    Estimates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preparation of consolidated financial statements requires
    management to make estimates and assumptions that affect the
    amounts reported in the consolidated financial statements and
    accompanying notes. The Company regularly assesses these
    estimates which affect the fair value of undelivered elements
    for revenue recognition purposes, the valuation of accounts
    receivable, the valuation of inventories, accrued liabilities,
    the fair value of the Company&#146;s convertible preferred stock
    and common stock, warrants, stock-based compensation, beneficial
    conversion features, and valuation allowances associated with
    deferred tax assets. The Company bases its estimates on
    historical experience and on various other assumptions believed
    to be reasonable, the results of which form the basis for making
    judgments about the carrying values of assets and liabilities.
    Actual results could differ materially from these estimates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assets and liabilities of
    <FONT style="white-space: nowrap">non-U.S.&#160;subsidiaries</FONT>
    that use the local currency as their functional currency are
    translated into U.S.&#160;dollars at exchange rates in effect at
    the balance sheet date, with the resulting translation
    adjustments recorded to a separate component of accumulated
    other comprehensive income (loss) within stockholders&#146;
    equity. Income and expense accounts are translated at average
    exchange rates during the year. Foreign currency transaction
    gains and losses for
    <FONT style="white-space: nowrap">non-U.S.&#160;subsidiaries</FONT>
    that use the U.S.&#160;dollar as their functional currency are
    recognized in other income (expense), net. The Company had net
    foreign currency transaction losses of $27,000 and $70,000
    during 2005 and 2006, respectively, and net foreign currency
    transaction gains of $72,000, $23,000 and $308,000 during 2007
    and the three months ended March&#160;31, 2007 and
    March&#160;29, 2008, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cash and
    Cash Equivalents</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company considers all highly liquid financial instruments
    with maturities at the time of purchase of three months or less
    to be cash equivalents. Cash and cash equivalents consist of
    cash on deposit with banks, money market funds, commercial
    paper, corporate notes, and notes from government-sponsored
    agencies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Available-for-Sale
    Securities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Available-for-sale securities are comprised of corporate notes
    and notes from government-sponsored agencies. Investments
    classified as &#147;available-for-sale&#148; and are recorded at
    estimated fair value, as determined by quoted market rates, on
    the consolidated balance sheets with any unrealized gains and
    losses reported in stockholders&#146; equity as a component of
    accumulated other comprehensive income (loss). Realized gains
    and losses and declines in the fair value of available-for-sale
    securities below their cost that are deemed to be &#147;other
    than temporary&#148; are reflected in interest income. No
    &#147;other than temporary&#148; unrealized losses have been
    incurred to date and realized gains and losses were immaterial
    during the years presented. The cost of securities sold is based
    on the specific-identification method.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Restricted
    Cash</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company had restricted cash balances of $900,000, $881,000
    and $381,000 as of December&#160;31, 2006, December&#160;29,
    2007 and March&#160;29, 2008, respectively. Included in
    restricted cash is cash amounts that collateralize the
    Company&#146;s standby letters of credit issued under operating
    lease agreements for office facilities that it currently
    occupies.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, the respective carrying values of the
    Company&#146;s financial instruments, including accounts
    receivable, restricted cash, and accounts payable, approximated
    their fair values due to their short period of time to maturity
    or repayment. Based on borrowing rates currently available to
    the Company for loans with similar terms, the carrying value of
    long-term debt and convertible promissory notes approximated
    their fair values.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;No.&#160;157, <I>Fair Value Measurement</I>
    (SFAS&#160;157), clarifies that fair value is an exit price,
    representing the amount that would be received to sell an asset
    or paid to transfer a liability in an orderly transaction
    between market participants. As such, fair value is a
    market-based measurement that should be determined based on
    assumptions that market participants would use in pricing an
    asset or liability. As a basis for considering such assumptions,
    SFAS&#160;157 establishes a three-tier value hierarchy, which
    prioritizes the inputs used in measuring fair value as follows:
    (Level I) observable inputs such as quoted prices in active
    markets; (Level II) inputs other than the quoted prices in
    active markets that are observable either directly or
    indirectly; and (Level III) unobservable inputs in which there
    is little or no market data, which requires the Company to
    develop its own assumptions. This hierarchy requires the Company
    to use observable market data, when available, and to minimize
    the use of unobservable inputs when determining fair value. On a
    recurring basis, the Company measures its cash equivalents and
    available-for-sale securities at fair value.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of the Company&#146;s cash equivalents and
    available-for-sale securities are classified within Level I or
    Level II of the fair value hierarchy because they are valued
    using quoted market prices, market prices for similar
    securities, or alternative pricing sources with reasonable
    levels of price transparency. Instruments valued based on quoted
    market prices in active markets, i.e. level I, include the
    Company&#146;s money market funds. Instruments valued based on
    other observable inputs, i.e. level II, include notes from
    government-sponsored agencies, corporate notes and commercial
    paper.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Accounts
    Receivable</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Trade accounts receivable are recorded at net invoice value. The
    Company considers receivables past due based on the contractual
    payment terms. The Company reviews its exposure to accounts
    receivable and reserves specific amounts if collectibility is no
    longer reasonably assured based on historical experience and
    specific customer collection issues. The Company reevaluates
    such reserves on a regular basis and adjusts its reserves as
    needed. Write-offs of accounts receivable were insignificant
    during 2005, 2006, 2007 and the three months ended
    March&#160;31, 2007 and March&#160;29, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Concentrations
    of Credit Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Financial instruments that potentially subject the Company to
    credit risk consist of cash, cash equivalents,
    available-for-sale securities, and accounts receivable. The
    Company maintains cash, cash equivalents, and available-for-sale
    securities with major financial institutions. The Company&#146;s
    cash, cash equivalents, and available-for-sale securities
    consist of deposits held with banks, commercial paper, money
    market funds, and other highly liquid investments that, at
    times, exceed federally insured limits. The Company performs
    periodic evaluations of its investments and the relative credit
    standing of these financial institutions and limits the amount
    of credit exposure with any one institution.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company does not require collateral to support credit sales.
    To reduce credit risk, the Company performs periodic credit
    evaluations of its customers. The Company has had no credit
    losses to date. Customers with revenues of 10% or greater of
    total revenues for 2005, 2006, 2007 and the three months ended
    March&#160;29, 2008 are as follows:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="16" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage of Total Revenue</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Three Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Three Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Customers:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    A
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    24%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    B
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents less than 10% of total revenues.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s products include components that are
    currently available from a single source or a limited number of
    sources. The Company believes that other vendors would be able
    to provide similar components; however, the qualification of
    such vendors may require
    <FONT style="white-space: nowrap">start-up</FONT>
    time. In order to mitigate any adverse impacts from a disruption
    of supply, the Company attempts to maintain an adequate supply
    of critical limited-sourced components.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Inventories</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Inventories are stated at the lower of cost (which approximates
    actual cost on a
    <FONT style="white-space: nowrap">first-in,</FONT>
    first-out method) or market. Inventories include raw materials,
    <FONT style="white-space: nowrap">work-in-process,</FONT>
    and finished goods that may be used in the research and
    development process, and such items are expensed when they are
    designated for use in research and development. Provisions for
    slow moving, excess, and obsolete inventories are recorded based
    on product life cycle, development plans, product expiration,
    and quality issues.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property
    and Equipment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property and equipment, including leasehold improvements, are
    stated at cost less accumulated depreciation, which is
    calculated using the straight-line method over the estimated
    useful lives of the assets, which range from three to five
    years. Leasehold improvements are amortized using the
    straight-line method over the estimated useful lives of the
    assets or the remaining term of the lease, whichever is shorter.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;No.&#160;144, <I>Accounting for the
    Impairment or Disposal of Long-Lived Assets</I>, if indicators
    of impairment exist, the Company assesses the recoverability of
    the affected long-lived assets by determining whether the
    carrying value of such assets can be recovered through
    undiscounted future operating cash flows. If impairment is
    indicated, the Company measures the future discounted cash flows
    associated with the use of the asset and adjusts the value of
    the asset accordingly. While the Company&#146;s current and
    historical operating and cash flow losses are indicators of
    impairment, the Company believes the future cash flows to be
    received from the long-lived assets recorded as of
    March&#160;29, 2008 will exceed the assets&#146; carrying value,
    and, accordingly, the Company has not recognized any impairment
    losses through March&#160;29, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Reserve
    for Product Warranties</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company generally provides a one-year warranty on
    instruments. The Company reviews its exposure to estimated
    warranty expenses associated with instrument sales and
    establishes an accrual based on historical product failure rates
    and actual warranty costs incurred. This expense is recorded as
    a component of cost of product revenue in the consolidated
    statements of operations. Warranty accruals and expenses were
    immaterial for all periods presented.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company generates revenue from sales of its products and
    services. The Company&#146;s products consist of single-use
    IFCs, various instruments, software, and reagents. The
    Company&#146;s services include instrument installation,
    training, and customer support services. The Company has also
    entered into a number of research and development agreements and
    received government grants to conduct research and development
    activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company records revenue in accordance with the guidelines
    established by the Securities and Exchange Commission (SEC)
    Staff Accounting Bulletin&#160;No.&#160;104, <I>Revenue
    Recognition </I>(SAB&#160;104). In addition, the Company has
    concluded that pursuant to AICPA Statement of Position
    <FONT style="white-space: nowrap">97-2,</FONT>
    <I>Software Revenue Recognition
    </I><FONT style="white-space: nowrap">(SOP&#160;97-2),</FONT>
    software included with certain of its instruments is more than
    incidental to their functionality. Accordingly, the Company
    applies
    <FONT style="white-space: nowrap">SOP&#160;97-2</FONT>
    to sales of such instruments and related deliverables. Revenue
    is recognized when all of the following criteria are met:
    persuasive evidence of an arrangement exists, delivery has
    occurred or services rendered, the seller&#146;s price to the
    buyer is fixed or determinable, and collectibility is reasonably
    assured.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Product
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sells instruments in arrangements that may include
    related installation and training, customer support services and
    software and may also include single-use IFCs. If the
    arrangement includes IFCs, the Company uses the separation
    criteria in EITF Issue
    <FONT style="white-space: nowrap">No.&#160;00-21,</FONT>
    <I>Revenue Arrangements with Multiple Deliverables</I>, to
    separate revenues related to IFCs, which are non-software
    related deliverables, from software related deliverables. IFC
    revenue is recognized upon delivery. Revenue from software
    related deliverables is recognized in accordance with
    <FONT style="white-space: nowrap">SOP&#160;97-2</FONT>
    and related pronouncements. Under
    <FONT style="white-space: nowrap">SOP&#160;97-2,</FONT>
    the Company recognizes revenue for delivered elements only when
    it determines that undelivered elements are not essential to the
    functionality of the delivered elements and the vendor-specific
    objective evidence (VSOE) of fair values of undelivered elements
    are known. Installation is deemed essential to the functionality
    of certain instruments; for those instruments recognition of
    revenue begins after installation has been completed. Fair value
    of undelivered elements is established by reference to VSOE
    which is based on stand-alone sales of such elements. If any
    undelivered element does not have VSOE of fair value, revenue is
    deferred until all of such elements are delivered, or until VSOE
    of fair value can objectively be determined for any remaining
    undelivered elements. However, if the only undelivered element
    is post-contract customer support services, such as those
    included in the Company&#146;s maintenance agreements, revenue
    on the software related deliverables is recognized ratably over
    the service period. When revenues are deferred, the
    corresponding costs of products sold are also deferred in other
    assets in the consolidated financial statements and recognized
    over the same period. If VSOE of fair value exists for all
    undelivered elements, but does not exist for the delivered
    elements in the arrangement, revenue is allocated to the
    undelivered elements based on their VSOE of fair values, with
    the residual amount allocated to the delivered elements and
    recognized upon their delivery.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, 2006, 2007 and the three months ended
    March&#160;29, 2008, the Company did not have VSOE of fair value
    for software support services. Therefore, revenue and the
    corresponding costs of software-related deliverables is deferred
    and recognized over the customer support period ranging from one
    to three years. All revenue from these arrangements has been
    classified as product revenue in the statements of operations,
    as the amount attributed to services was immaterial.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007 and thereafter, no right of return has existed for the
    Company&#146;s products. In prior years, if there was a right of
    return, the entire revenue from the arrangement was deferred
    until the right had lapsed. The Company has not experienced any
    significant returns of its products. Accruals are provided for
    anticipated warranty expenses at the time the associated revenue
    is recognized. Amounts received in advance of when revenue
    recognition criteria are met are recorded as deferred revenue on
    the consolidated balance sheets.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sells its products to third-party resellers located
    in certain international markets. From time to time, these
    arrangements may be subject to contingencies such as completion
    of the instrument delivery to or
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    installation at the end customer. The Company recognizes revenue
    on sales of products to the resellers if all revenue recognition
    criteria have been met and any contingency provisions related to
    the sale have been satisfied.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Revenue</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has entered into agreements with third parties,
    including government entities, to provide research and
    development services. Fixed-fee research and development
    agreements generally provide the Company with up-front and
    periodic milestone fees. Variable-fee research and development
    agreements generally provide the Company with fees based upon
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rates for time incurred by research staff. Under
    <FONT style="white-space: nowrap">EITF&#160;00-21,</FONT>
    the Company evaluates whether these arrangements contain
    multiple units of accounting by evaluating whether delivered
    elements have value on a stand-alone basis and whether there is
    objective and reliable evidence of fair value of the undelivered
    items. During 2005, 2006, 2007 and the three months ended
    March&#160;29, 2008, the Company concluded that these
    arrangements consisted of a single unit of accounting, namely,
    research and development services. Accordingly, the Company
    recognizes the fees under these arrangements over the period the
    Company performs these services. Costs associated with the
    research and development agreements are included in research and
    development expense.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grant
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Government grants provide the Company with cost reimbursement
    for certain types of research and development activities
    performed over a contractually defined period. Revenue from
    government grants is recognized during the period during which
    the related costs are incurred, provided that the conditions
    under which the government grants were provided have been met
    and the Company has only perfunctory obligations outstanding.
    Amounts received in advance of when revenue recognition criteria
    are met are recorded as deferred revenue on the consolidated
    balance sheets. Costs associated with the grants are included in
    research and development expense.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Shipping
    and Handling Costs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shipping and handling costs incurred for product shipments are
    included within cost of product revenue in the consolidated
    statements of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company expenses research and development expenditures in
    the period incurred. Research and development expense consists
    of personnel costs, independent contractor costs, prototype
    expenses, and allocated facilities and information technology
    expenses. These costs include direct and research-related
    overhead expenses.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Advertising
    Costs</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company expenses advertising costs as incurred. The Company
    incurred advertising costs of $237,000, $324,000, $701,000,
    $221,000 and $228,000 during 2005, 2006, 2007 and the three
    months ended March&#160;31, 2007 and March&#160;29, 2008,
    respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company uses the liability method to account for income
    taxes, whereby deferred income taxes reflect the impact of
    temporary differences for items recognized for financial
    reporting purposes over different periods than for income tax
    purposes. Valuation allowances are provided when the expected
    realization of deferred tax assets does not meet a &#147;more
    likely than not&#148; criterion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company adopted Financial Accounting Standards Board (FASB)
    Interpretation No.&#160;48, <I>Accounting for Uncertainties in
    Income Taxes&#160;&#151; an interpretation of FASB Statement
    No.&#160;109 </I>(FIN&#160;48), effective January&#160;1, 2007.
    FIN&#160;48 requires that the Company recognize the financial
    statement effects of a tax position when it is more likely
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    than not, based on the technical merits, that the position will
    be sustained upon examination. Upon adoption, the Company
    recorded a charge of $75,000 as a cumulative effect of a change
    in accounting principle in the accumulated deficit during 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock-Based
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2006, the Company accounted for its
    employee stock option plans using the intrinsic value method
    prescribed by Accounting Principles Board Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees </I>(APB 25), which
    required the Company to recognize the difference between the
    exercise price of an employee option and the fair value of the
    underlying common stock as of the grant date. The resulting
    stock-based compensation expense, if any, was recorded on the
    date of the grant in stockholders&#146; equity as deferred
    compensation and amortized to expense over the vesting period of
    the grant, which was generally four years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2004, the FASB issued SFAS&#160;No.&#160;123
    (revised 2004), <I>Share-Based Payment </I>(SFAS&#160;123(R)),
    that addresses the accounting for stock-based payment
    transactions in which a company receives services in exchange
    for equity instruments, including stock options. The Company
    adopted SFAS&#160;123(R) beginning January&#160;1, 2006 using
    the prospective-transition method, as options granted prior to
    January&#160;1, 2006 were measured using the minimum value
    method for the pro forma disclosures previously required by
    SFAS&#160;No.&#160;123, <I>Accounting for Stock-Based
    Compensation </I>(SFAS&#160;123). Under the
    prospective-transition method, the Company continues to apply
    APB 25 to employee equity awards outstanding at the date of the
    Company&#146;s adoption of SFAS&#160;123(R). Any compensation
    costs recognized from January&#160;1, 2006 onward consists of:
    (a)&#160;compensation cost for all stock-based awards granted
    prior to, but not vested as of, December&#160;31, 2005 based on
    the intrinsic value determined in accordance with the provisions
    of APB 25; and (b)&#160;compensation cost for all stock-based
    awards granted or modified subsequent to December&#160;31, 2005,
    net of estimated forfeitures, based on the grant date fair value
    estimated in accordance with the provisions of SFAS&#160;123(R).
    The Company recognizes stock-based compensation expense on a
    straight-line basis over the vesting period of the respective
    grants. In accordance with the prospective-transition method,
    results for prior periods have not been restated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company applies SFAS&#160;123(R) and EITF Issue
    <FONT style="white-space: nowrap">No.&#160;96-18,</FONT>
    <I>Accounting for Equity Instruments That Are Issued to Other
    Than Employees for Acquiring, or in Conjunction with Selling,
    Goods or Services
    </I><FONT style="white-space: nowrap">(EITF&#160;96-18),</FONT>
    to options and other stock-based awards issued to nonemployees.
    In accordance with SFAS&#160;123(R) and
    <FONT style="white-space: nowrap">EITF&#160;96-18,</FONT>
    the Company uses the Black-Scholes option-pricing model to
    measure the fair value of the options at the measurement dates.
    The nonemployee options are subject to periodic reevaluation
    over their vesting terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Comprehensive
    Loss</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Comprehensive loss is comprised of net loss and other
    comprehensive income (loss). Other comprehensive income (loss)
    includes unrealized holding gains and losses on the
    Company&#146;s available-for-sale securities and foreign
    currency translation adjustments. Total comprehensive loss for
    all periods presented has been disclosed in the consolidated
    statements of convertible preferred stock and stockholders&#146;
    equity (deficit).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accumulated other comprehensive income (loss) consists of the
    following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Unrealized gain (loss) on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (123
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (349
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (344
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Preferred Stock Warrants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Freestanding warrants related to shares that may be redeemable
    are accounted for in accordance with FASB Staff Position (FSP)
    <FONT style="white-space: nowrap">No.&#160;150-5,</FONT>
    <I>Issuer&#146;s Accounting Under FASB Statement No.&#160;150
    for Freestanding Warrants and Other Similar Instruments on
    Shares That Are Redeemable
    </I><FONT style="white-space: nowrap">(FSP&#160;150-5),</FONT>
    an interpretation of SFAS&#160;No.&#160;150, <I>Accounting for
    Certain Financial Instruments with Characteristics of Both
    Liabilities and Equity</I>. Under
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    freestanding warrants to purchase the Company&#146;s convertible
    preferred stock are classified as liabilities on the
    consolidated balance sheets and carried at fair value because
    the warrants may conditionally obligate the Company to transfer
    assets at some point in the future. The warrants are subject to
    remeasurement at each balance sheet date, and any change in fair
    value is recognized as a component of other income (expense),
    net in the consolidated statements of operations. The Company
    will continue to adjust the liability for changes in fair value
    until the earlier of the exercise or expiration of the warrants,
    the completion of a deemed liquidation event, conversion of
    preferred stock into common stock, or until the convertible
    preferred stockholders can no longer trigger a deemed
    liquidation event. At that time, the convertible preferred stock
    warrant liabilities will be reclassified to convertible
    preferred stock or additional paid-in capital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    is effective for all periods beginning after June&#160;30, 2005,
    and accordingly, it was adopted by the Company on July&#160;1,
    2005. Upon adoption, the Company reclassified the fair value of
    its warrants to purchase shares of its convertible preferred
    stock as of the adoption date from additional paid-in capital to
    liabilities and recorded a gain of $637,000 as the cumulative
    effect of a change in an accounting principle in the
    consolidated statement of operations during 2005.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Net Loss
    per Share of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s basic net loss per share of common stock is
    calculated by dividing the net loss by the weighted-average
    number of shares of common stock outstanding for the period. The
    weighted-average number of shares of common stock excludes those
    shares subject to repurchase related to stock options that were
    exercised prior to vesting as they are not deemed to be issued
    for accounting purposes until they vest. The diluted net loss
    per share of common stock is computed by dividing the net loss
    by the weighted-average number of common stock equivalents
    outstanding for the period determined using the treasury-stock
    method. For purposes of this calculation, convertible preferred
    stock, options to purchase common stock, common stock subject to
    repurchase, warrants to purchase convertible preferred stock,
    and shares of convertible preferred stock subject to conversion
    of the Company&#146;s convertible promissory notes are
    considered to be common stock equivalents but have been excluded
    from the calculation of diluted net loss per share of common
    stock as their effect is anti-dilutive.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth the computation of net loss per
    share of common stock (in thousands, except per share amounts):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>March&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>March&#160;29, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Historical</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Numerator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    23,553
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,355
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,613
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denominator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shares used in computing net loss per share of common stock,
    basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock before cumulative effect of
    change in accounting principle, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.89
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle, basic and
    diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following outstanding shares of common stock equivalents
    were excluded from the computation of diluted net loss per share
    of common stock for the periods presented because including them
    would have been anti-dilutive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited))</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,654
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options to purchase common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Common stock subject to repurchase
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Warrants to purchase convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,211
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    704
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    704
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    599
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible promissory notes convertible into shares of
    convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,952
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,466
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,504
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2006, the FASB issued SFAS&#160;No.&#160;157, which
    establishes a framework for measuring the fair value of assets
    and liabilities when required or permitted by other standards
    within generally accepted accounting principles in the United
    States but does not require any new fair value measurements.
    SFAS&#160;157 also expands disclosures about fair value
    measurements. SFAS&#160;157 is effective for all financial
    statements issued for fiscal years beginning after
    November&#160;15, 2007. However, in February 2008 the FASB
    issued FSP
    <FONT style="white-space: nowrap">No.&#160;157-2</FONT>
    <FONT style="white-space: nowrap">(FSP&#160;157-2)</FONT>
    which allows companies to delay the effective date of
    SFAS&#160;157 for all nonfinancial assets and liabilities,
    except those that are recognized or disclosed at fair value in
    the financial statements on a recurring basis, until fiscal
    years beginning after November&#160;15, 2008. Generally, the
    provisions of this statement should be applied prospectively as
    of the beginning of the fiscal year in which this statement is
    initially applied. The Company adopted SFAS&#160;157 in
    accordance with the provisions in
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    as of December&#160;30, 2007. The adoption of SFAS&#160;157 did
    not have a significant impact on the Company&#146;s consolidated
    financial statements.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, the FASB issued SFAS&#160;No.&#160;159, <I>The
    Fair Value Option for Financial Assets and Financial Liabilities
    </I>(SFAS&#160;159), including an amendment of
    SFAS&#160;No.&#160;115, A<I>ccounting for Certain Investments in
    Debt and Equity Securities</I>, which allows an entity to choose
    to measure certain financial instruments and liabilities at fair
    value. Subsequent measurements for the financial instruments and
    liabilities an entity elects to measure at fair value will be
    recognized in earnings. SFAS&#160;159 also establishes
    additional disclosure requirements. SFAS&#160;159 is effective
    for fiscal years beginning after November&#160;15, 2007. The
    Company adopted SFAS&#160;159 as of December&#160;30, 2007 but
    chose not to measure the financial instruments and liabilities
    permitted by the standard to be measured at fair value.
    Therefore, the adoption of SFAS&#160;159 did not have a
    significant impact on the Company&#146;s consolidated financial
    statements.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-1,</FONT>
    <I>Accounting for Collaborative Agreements
    </I><FONT style="white-space: nowrap">(EITF&#160;07-1),</FONT>
    which addresses the accounting for participants in collaborative
    agreements, defined as contractual arrangements that involve a
    joint operating activity, that are conducted without the
    creation of a separate legal entity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    requires participants in a collaborative agreement to make
    separate disclosures for each period a statement of operations
    is presented regarding the nature and purpose of the agreement,
    the rights and obligations under the agreement, the accounting
    policy for the agreement, and the classification of and amounts
    arising from the agreement between participants. These
    arrangements involve two or more parties who are both active
    participants in the activity and are exposed to significant
    risks and rewards dependent on the commercial success of the
    activity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    provides that a company should report the effects of adoption as
    a change in accounting principle through retrospective
    application to all periods and requires specific additional
    disclosures.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2008. The Company is currently assessing
    the impact of the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    on the Company&#146;s consolidated financial statements.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-3,</FONT>
    <I>Accounting for Nonrefundable Advance Payments for Goods or
    Services to Be Used in Future Research and Development
    Activities
    </I><FONT style="white-space: nowrap">(EITF&#160;07-3).</FONT>
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    provides clarification surrounding the accounting for
    nonrefundable research and development advance payments, whereby
    such payments should be recorded as an asset when the advance
    payment is made and recognized as an expense when the research
    and development activities are performed.
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2007. The Company adopted EITF 07-3 as
    of December&#160;30, 2007. The adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    did not impact the Company&#146;s consolidated financial
    statements.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">License,
    Development, Collaboration and Grant Agreements</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">License
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2003, the Company entered into a license agreement to
    obtain an exclusive worldwide license for certain technology
    regarding nanovolume crystallization arrays. The Company may, in
    its sole discretion, cancel the license agreement with a
    <FONT style="white-space: nowrap">30-day</FONT>
    notice; otherwise, the license terminates at the end of the life
    of the last patent
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    to expire. Under the terms of the agreement, the Company is
    obligated to issue up to $2,100,000 of shares of the
    Company&#146;s common or convertible preferred stock if the
    Company achieves certain milestones. As a result of achieving
    one of these milestones during 2006, the Company issued
    214,285&#160;shares of Series&#160;D convertible preferred stock
    at $2.80 per share for an aggregate value of $597,000, net of
    issuance costs. During 2003, the Company also entered into a
    separate research sponsorship agreement under which the Company
    agreed to pay a total of $900,000 over 5&#160;years in 20
    quarterly installments of $45,000 to sponsor certain research.
    As of March&#160;29, 2008, the entire $900,000 had been paid.
    Following the final $45,000 payment, which was paid during the
    three months ended March&#160;29, 2008, the agreement terminated.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2003, the Company entered into a license agreement
    to obtain a nonexclusive worldwide license for certain
    technology regarding submicroliter protein crystallization. The
    Company may, in its sole discretion, cancel the agreement with a
    <FONT style="white-space: nowrap">30-day</FONT>
    notice; otherwise, the license terminates at the end of the life
    of the last licensed patent to expire. Pursuant to the
    agreement, the Company made four payments for annual
    nonrefundable license fees, each in the amount of $250,000,
    beginning in January 2004 with subsequent payments made in
    January 2005, 2006 and 2007. Also pursuant to the agreement, the
    Company began making quarterly payments in the amount of $25,000
    starting in the first quarter of 2007. These quarterly payments,
    which are scheduled to continue until the agreement is
    terminated, could increase in future periods if the Company
    meets certain sales volumes. The annual nonrefundable license
    fee payments were recorded as expense during the year in which
    they were paid.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Development
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2004, the Company entered into a development agreement
    to evaluate two application areas of interest. Under the
    agreement, the Company performed research and development
    services, manufactured prototypes, and licensed certain
    nonexclusive rights. In addition, the Company issued a fully
    vested warrant to purchase 507,407&#160;shares of Series&#160;D
    convertible preferred stock at $2.80 per share (see
    Note&#160;8). As consideration, the Company received payments
    totaling $1,500,000 during 2004 and 2005. The Company determined
    that the license, research and development services, and
    prototypes should be accounted for as a combined unit of
    accounting and recognized the revenues ratably over the
    <FONT style="white-space: nowrap">12-month</FONT>
    project period. The fair value of the warrant issued was
    estimated to be $750,000, as determined using the Black-Scholes
    option-pricing model, and was recognized as a reduction to the
    collaboration revenue. The Company recognized collaboration
    revenue of $366,000 and $384,000 related to this agreement
    during 2004 and 2005, respectively. The agreement terminated
    during 2005.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2005, the Company entered into another development
    agreement to develop another application area of interest. Under
    the agreement, the Company performed research and development
    services and manufactured prototype instruments. The agreement
    provided for payments to the Company in the amount of $942,000,
    to be paid in installments over the
    <FONT style="white-space: nowrap">30-month</FONT>
    life of the agreement. The Company determined that the research
    and development services and the manufacturing of prototype
    instruments should be accounted for as a combined unit of
    accounting and revenue was therefore recognized ratably over the
    estimated project period. The Company recognized revenue of
    $94,000, $377,000, $377,000, $94,000 and $94,000 related to this
    agreement during 2005, 2006, 2007 and the three months ended
    March&#160;31, 2007 and March&#160;29, 2008, respectively. The
    agreement terminated during the three months ended
    March&#160;29, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2005, the Company entered into a collaborative
    agreement to develop and commercialize radiopharmaceutical
    manufacturing products for use in the positron emission
    tomography field. As consideration, the Company received an
    up-front fee of $1,000,000, which the Company deferred and
    recognized over the obligation period of approximately two
    years, with $458,000 and $542,000 recognized as revenue during
    2005 and 2006, respectively. Also, the Company recognized
    additional revenue of $635,000 and $500,000 during 2005 and
    2006, respectively, related to payments for research and
    development activities under the agreement based on
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rates for time incurred by the research staff. The agreement
    terminated on December&#160;31, 2006.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Grants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">National
    Institutes of Health</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2006, the Company was awarded a government grant from
    the National Institutes of Health (NIH) in the amount of
    $1,048,000 to be earned over a two-year period. Under the grant,
    the Company performs research and development activities to
    design a diffraction capable Topaz screening chip. The agreement
    provides for quarterly reimbursement of the eligible research
    and development expenses, including salaries, equipment,
    scientific consumables, and certain third-party costs. The grant
    revenue is recognized as the related services are performed and
    costs associated with this grant are reported as research and
    development expense in the period incurred. The Company
    recognized revenue of $184,000, $606,000, $6,000, and $116,000
    during 2006 and 2007 and the three months ended March&#160;31,
    2007 and March&#160;29, 2008,  respectively, under this grant.
    This agreement terminates in June 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Singapore
    Economic Development Board</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2005, Fluidigm Singapore, a wholly owned subsidiary
    of the Company, entered into a letter agreement providing for up
    to S$10&#160;million (approximately US$7.2&#160;million using
    March&#160;29, 2008 exchange rates) in grants from the Singapore
    Economic Development Board, or EDB. The grants are payable only
    as reimbursement for a portion of the expenses Fluidigm
    Singapore incurs in Singapore from August&#160;1, 2005 through
    July&#160;31, 2010 in connection with the establishment and
    operation of a research, development and manufacturing center
    for IFCs in Singapore. Eligible expenses include expenses
    relating to human resources, equipment, materials and software
    purchases, and professional service fees. Fluidigm Singapore is
    required to submit reimbursement requests for qualifying
    expenditures on a quarterly basis along with reports regarding
    its compliance with the reimbursement conditions, as described
    below, through the end of the applicable quarter.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2006. Fluidigm Singapore and EDB entered into a
    supplement to the October&#160;2005 letter agreement. This
    supplement was entered into to create a process whereby Fluidigm
    Singapore and EDB would agree on new quarterly development
    targets at the start of each year, Fluidigm Singapore would
    submit to EDB a progress report and evidence of the achievement
    of targets on a quarterly basis and the parties would resolve
    any disagreements regarding the satisfaction of targets using an
    established procedure and the parties would be entitled to
    obtain a third party audit of the reimbursement requests on a
    semi-annual rather than an annual basis.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm Singapore&#146;s continued eligibility for such
    reimbursement grants is subject to its compliance with the
    following conditions: increasing levels of research; its
    development and manufacturing activity in Singapore, including
    employment of specified numbers of research scientists and
    engineers; its incurrence of specified levels of research and
    development expenses in Singapore over the course of each
    calendar year; its use of local service providers; its
    manufacture in Singapore of the products developed in Singapore
    and its achievement of certain targets relating to new product
    development or completion of specific manufacturing process
    objectives. These required levels of research, development and
    manufacturing activity in Singapore and the associated increases
    from one year to the next are the result of negotiations between
    the parties and are generally consistent with Company&#146;s
    business strategy for its Singapore operations. All ownership
    rights in the intellectual property developed by Fluidigm
    Singapore remain with Fluidigm Singapore and no such rights are
    conveyed to EDB under the agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, Fluidigm Singapore entered into a second
    letter agreement with EDB which provided for up to an additional
    S$3.7&#160;million (approximately US$2.7&#160;million using
    March&#160;29, 2008 exchange rates) in reimbursement grants. The
    terms and conditions of this letter agreement are substantially
    the same as the October&#160;2005 letter agreement, with the
    exception of the size of the potential grant, the term of the
    agreement and the specific levels of research, development and
    manufacturing activities required to maintain eligibility for
    such grants. The primary focus of this letter agreement is the
    ongoing development and manufacture in Singapore of certain
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    instrumentation. This letter agreement applies to eligible
    expenses incurred by Fluidigm Singapore in Singapore from
    June&#160;1, 2006 through May&#160;31, 2011.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company recognized revenue of $879,000,  $1,758,000,
    $463,000 and $401,000 related to EDB grants during 2006, 2007
    and the three months ended March&#160;31, 2007 and
    March&#160;29, 2008, respectively. As of December&#160;31, 2006,
    December&#160;29, 2007 and March&#160;29, 2008, the Company had
    deferred revenue of $720,000, $635,000 and $566,000,
    respectively, related to equipment reimbursements under the EDB
    grants, which is being recognized ratably over the estimated
    useful life of the equipment of four years. As of
    December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, the Company had accounts receivable from
    EDB in the amounts of $272,000, $679,000 and $466,000,
    respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Balance
    Sheet Data</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cash
    Equivalents and Available-for-Sale Securities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following are summaries of cash equivalents and
    available-for-sale securities (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Amortized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unrealized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unrealized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Cost</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Gain</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Loss</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Fair Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of December&#160;31, 2006:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Commercial paper
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Corporate notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of December&#160;29, 2007:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Commercial paper
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Corporate notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Notes from government-sponsored agencies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,283
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,985
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,286
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of March&#160;29, 2008 (unaudited):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    27,499
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    27,499
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Notes from government-sponsored agencies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    27,499
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, the contractual maturities of the
    Company&#146;s available-for-sale securities were less than one
    year.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Inventories</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Inventories consist of the following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Raw materials
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    803
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,551
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">Work-in-process</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    645
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Finished goods and demonstration units
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,457
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property
    and Equipment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property and equipment consists of the following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Computer equipment and software
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lab and manufacturing equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Office furniture and fixtures
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    372
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    372
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less accumulated depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,885
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,177
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,593
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">Construction-in-progress</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation and amortization expense was $1,309,000,
    $1,379,000, $1,643,000, $426,000 and $416,000 for 2005, 2006,
    2007 and the three months ended March&#160;31, 2007 and
    March&#160;29, 2008, respectively. During 2005, 2006, 2007 and
    the three months ended March&#160;31, 2007 and March&#160;29,
    2008, the Company recognized a loss on retirement of property
    and equipment of $0, $111,000, $20,000, $0 and $0, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Long-Term
    Debt</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In November 2002, the Company entered into a master security
    agreement with a lender. Per the terms of the agreement, the
    Company could draw up to $4,000,000 for purchases of capital
    equipment, software, and tenant improvements. A second master
    security agreement entered into in March 2004 increased the
    amount of the allowable draw for the Company to $11,000,000. The
    draw down period expired on December&#160;31, 2005, at which
    time the Company had drawn down $3,584,000 under the agreement.
    The loan, which was secured by the underlying equipment and a
    letter of credit, carried an interest rate between 8.0% and
    10.5% per annum, and each draw under the agreement was to be
    repaid in 42 varying monthly installments, which was originally
    scheduled to end on July&#160;1, 2009. In connection with the
    execution of the second agreement in 2004, the Company issued a
    warrant to purchase 37,500&#160;shares of Series&#160;D
    convertible preferred stock at $2.80 per share (see
    Note&#160;8)&#160;which was recorded on the consolidated balance
    sheet at fair value of $90,000 as a debt discount that was
    amortized to interest expense over two years. As of
    December&#160;31, 2006 and December&#160;29, 2007, the
    outstanding principal balance of this loan was $2,267,000 and
    $1,130,000, respectively. In February 2008, prior to the due
    date, the Company paid off the outstanding principal and accrued
    interest balance and paid a prepayment fee in the amount of
    $41,000 to the lender. Accordingly, the entire outstanding
    principal balance for this loan as of December&#160;29, 2007 was
    classified as
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    a current liability on the consolidated balance sheet. Upon full
    payment of this debt, restricted cash in the amount of $500,000
    was released by the lender and thus has been classified as a
    current asset as of December&#160;29, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2005, the Company entered into a loan and security
    agreement with another lender. Under this agreement the Company
    borrowed $13,000,000 during 2005 for general corporate purposes.
    This loan is secured by the Company&#146;s assets except for
    intellectual property; however, the security interest does
    include proceeds from sales of the intellectual property. The
    loan was originally scheduled to be repaid by 2009; however, the
    agreement was amended in August 2006 to extend the final
    repayment date to February&#160;1, 2010. The agreement carried a
    variable interest rate of prime plus 2.5% through March 2006.
    Thereafter, the agreement carried a fixed interest rate of 10.0%
    through July 2006 and a fixed interest rate of 9.75% following
    the amendment to the agreement in August 2006. In August 2006,
    the Company began making monthly payments in the amount of
    $310,000 for principal and interest under the agreement. The
    agreement also requires payment of fees in March 2009 in the
    amount of $1,612,500. The fees are accreted as interest expense
    over the term of the loan. The agreement restricts the
    Company&#146;s ability to pay dividends. The Company is subject
    to a prepayment fee in the amount of 1% of the outstanding
    principal amount being prepaid if paid during 2008 or 2009. In
    connection with the execution of this loan and security
    agreement, the Company issued a warrant to purchase
    185,714&#160;shares of Series&#160;D convertible preferred stock
    at $2.80 per share (see Note&#160;8)&#160;which was recorded on
    the consolidated balance sheet at fair value of $54,000 as a
    debt discount. In connection with the final draw down of this
    loan, the Company issued another warrant to purchase
    185,714&#160;shares of Series&#160;D convertible preferred stock
    at $2.80 per share (see Note&#160;8)&#160;which was recorded on
    the consolidated balance sheet at fair value of $50,000 as a
    debt discount. The debt discounts are amortized to interest
    expense over the life of the agreement. As of December&#160;31,
    2006, December&#160;29, 2007 and March&#160;29, 2008, the
    outstanding principal balance of this loan was $10,570,000,
    $8,232,000 and $7,592,000, respectively, net of the unamortized
    debt discounts of $58,000, $31,000 and $25,000, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, the Company amended this loan and security
    agreement to provide the Company with an additional credit line
    in the amount of $10,000,000 that the Company can draw upon
    until July&#160;1, 2008 for general corporate purposes. In
    connection with the amendment of this loan and security
    agreement, the Company issued a warrant to purchase
    100,000&#160;shares of Series E convertible preferred stock at
    $4.00&#160;per share (see Note&#160;8). The warrant was recorded
    on the consolidated balance sheet as a deferred charge at a fair
    value of $111,000 and will be amortized to interest expense over
    the period of the availability of the funds. As of
    March&#160;29, 2008, the Company had not utilized any of this
    facility. If the Company does borrow from this credit line, the
    borrowing will bear interest at 11.5%&#160;per annum and will be
    repaid in installments through June&#160;2011. In addition, the
    Company could be required to issue additional warrants to
    purchase up to 200,000&#160;shares of Series E convertible
    preferred stock at $4.00&#160;per share depending on the amounts
    of draws on the facility, if any.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The amortization of the debt discounts for the Company&#146;s
    long-term debt agreements was recorded as interest expense in
    the consolidated statements of operations in the amounts of
    $9,000, $37,000, $27,000, $7,000 and $6,000 during 2005, 2006,
    2007 and the three months ended March&#160;31, 2007 and
    March&#160;29, 2008, respectively. As of March&#160;29, 2008,
    the Company was either in compliance with all loan covenants or
    had obtained waivers from the respective lenders.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table does not include principal payments for the
    master security agreement with a principal balance of $1,130,000
    as of December&#160;29, 2007 that was paid off in February 2008.
    The scheduled principal payments of the Company&#146;s other
    long-term debt as of December&#160;29, 2007 are as follows (in
    thousands):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    609
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total principal payments due in future periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: debt discounts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Commitments
    and Contingencies</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operating
    Leases</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company leases its headquarters in South San&#160;Francisco,
    California, under multiple noncancelable lease agreements that
    expire in February 2011. These agreements include renewal
    options which provide the Company with the ability to extend the
    lease terms for an additional three years. The Company also
    leases office and manufacturing space under noncancelable leases
    in Singapore that expire in September 2008. The Company&#146;s
    other operating leases are for office space in the Netherlands,
    Japan, and France and are on a month-to-month basis. As of
    December&#160;29, 2007, future minimum lease payments under
    noncancelable operating leases were as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,374
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total minimum payments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s lease payments are recognized as an expense
    on a straight-line basis over the life of the lease. Rental
    expense under operating leases for 2005, 2006, 2007 and the
    three months ended March&#160;31, 2007 and March&#160;29, 2008
    totaled $1,468,000, $1,494,000, $1,574,000, $354,000 and
    $367,000, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contingencies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company is party to various claims arising in the ordinary
    course of business. These claims relate to intellectual property
    rights and employment matters. While there is no assurance that
    an adverse determination of any of such matters will not occur,
    management does not believe, based upon information known to it,
    that a potential resolution of any of these matters will have a
    material adverse effect upon the Company&#146;s financial
    position, results of operations, or cash flows.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Indemnifications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From time to time, the Company has entered into indemnification
    provisions under certain of its agreements with other companies
    in the ordinary course of business, typically with business
    partners, customers, and suppliers. Pursuant to these
    agreements, the Company may indemnify, hold harmless, and agree
    to reimburse the indemnified
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    parties on a case by case basis for losses suffered or incurred
    by the indemnified parties in connection with any patent or
    other intellectual property infringement claim by any
    third-party with respect to its products. The term of these
    indemnification provisions is generally perpetual from the time
    of the execution of the agreement. The maximum potential amount
    of future payments the Company could be required to make under
    these indemnification provisions is typically not limited to a
    specific amount. In addition, the Company has entered into
    indemnification agreements with its officers and directors. The
    Company has not incurred material costs to defend lawsuits or
    settle claims related to these indemnification provisions. As of
    March&#160;29, 2008, the Company had not accrued a liability for
    these indemnification provisions because the likelihood of
    incurring a payment obligation was remote.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Promissory Notes</FONT></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2003, the Company entered into a convertible note
    purchase agreement with the Biomedical Sciences Investment
    Fund&#160;Pte Ltd or BMSIF, an investment arm of EDB. Under this
    agreement BMSIF agreed to provide a $2,000,000 credit facility
    to be used for general corporate purposes. In December 2003, the
    Company issued a $2,000,000 convertible promissory note to
    BMSIF. The note, which was unsecured, carried an interest rate
    of 8% per year. Per the agreement, principal and interest were
    convertible into the Company&#146;s Series&#160;D convertible
    preferred stock at $2.80 per share at the lender&#146;s
    election, at any time, or upon the election of the Company upon
    the achievement of certain milestones by the Company. In June
    2005, the agreement was amended to allow the Company to issue
    additional convertible promissory notes in the amount of
    $3,000,000 if the Company achieved certain milestones. In
    December 2005, upon the successful completion of specified
    milestones, the $2,000,000 convertible promissory note and
    interest of $331,000 converted into 832,635&#160;shares of
    Series&#160;D convertible preferred stock at $2.80 per share as
    settlement of the outstanding balance on the date of the
    conversion. In June 2006, the Company issued a $3,000,000
    convertible promissory note, which was also unsecured, that
    carried an interest rate of 8% per year. Principal and interest
    are also convertible into the Company&#146;s Series&#160;D
    convertible preferred stock at $2.80 per share at the
    lender&#146;s election, at any time, or upon the election of the
    Company upon the achievement of certain milestones by the
    Company or upon the completion of an initial public offering in
    which the convertible preferred stock has converted into common
    stock. As of December&#160;31, 2006, the outstanding principal
    and accrued interest balance for the convertible promissory note
    was $3,128,000. In July 2007, upon the successful completion of
    specified milestones, the principal balance in the amount of
    $3,000,000 for the convertible promissory note and accrued
    interest of $240,000 converted into 1,157,142&#160;shares of
    Series&#160;D convertible preferred stock at $2.80 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2006, the Company entered into another convertible
    note purchase agreement with BMSIF. Under this agreement, BMSIF
    agreed to provide a $15,000,000 credit facility, to be issued in
    three separate $5,000,000 tranches, and to be used for general
    corporate purposes. The Company issued two $5,000,000
    convertible promissory notes against equal amounts of borrowings
    under this facility, each unsecured and carrying an interest
    rate of 8% per year, in August and November 2006. In March 2007,
    BMSIF exercised the conversion provision of the convertible note
    purchase agreement and the Company issued 2,954,337&#160;shares
    of Series&#160;E convertible preferred stock at $3.60 per share
    as settlement of the outstanding principal and accrued interest
    balance on the date of the conversion in the amount of
    $10,636,000. Upon conversion of these convertible promissory
    notes, the Company issued the third and final $5,000,000
    convertible promissory note against an equal amount of borrowing
    under this facility with an interest rate of 8% per year in
    April 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For these convertible note purchase agreements in which the
    repayment was in the form of Series&#160;E convertible preferred
    stock, the conversion price of $3.60 per share was a discount to
    the estimated fair values of $3.71 and $4.00 per share for the
    Series&#160;E convertible preferred stock at the times of the
    borrowings. The intrinsic value of the embedded beneficial
    conversion option associated with each borrowing of convertible
    promissory notes under the arrangement was measured as the
    difference between the conversion price and the fair value of
    Series&#160;E convertible preferred stock on the commitment date
    and the resulting debt discount is being amortized to interest
    expense over
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the two year contractual term of the debt. Upon conversion of
    the notes to convertible preferred stock, any remaining
    unamortized debt discount was immediately recognized as interest
    expense.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2006 and 2007, the Company recognized debt discounts of
    $306,000 and $485,000, respectively, related to the beneficial
    conversion feature of the notes. Amortization of the debt
    discounts for the convertible note purchase agreements was
    recorded as interest expense in the consolidated statements of
    operations in the amount of $43,000, $468,000, $0 and $52,000
    during 2006, 2007 and the three months ended March&#160;31, 2007
    and March&#160;29, 2008, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, the outstanding principal and accrued
    interest balance for the convertible note purchase agreements
    with BMSIF was $9,944,000,  $4,997,000 and $5,150,000,
    respectively, net of the unamortized debt discounts of $263,000,
    $280,000 and $228,000, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Preferred Stock Warrant Liabilities</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company issued warrants to purchase 1,211,203&#160;shares of
    the Company&#146;s convertible preferred stock at various times
    between 2001 and 2005. The Company did not issue any warrants to
    purchase convertible preferred stock during 2006 or 2007. The
    convertible preferred stock warrants are generally exercisable
    immediately and can only be exercised for cash or net share
    settled. Changes in the fair value of the underlying stock do
    not affect the settlement amounts of the warrants, therefore,
    the maximum amount of shares to be issued upon the settlement of
    these warrants is noted in the table below. As of
    December&#160;29, 2007, the following warrants were issued and
    outstanding:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="29%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Warrant to Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Reason for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Issue Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Expiration</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May 2001
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    41,284
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) May 14, 2008
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    17,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 27, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    November 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    31,008
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) December 16, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September 2003
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Collaboration agreement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    200,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    December 31, 2007
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2004
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    37,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 18, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 29, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 29, 2012
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    698,720
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2007, warrants to purchase 5,076&#160;shares of
    Series&#160;C convertible preferred stock expired. Upon
    expiration, the related warrant liability was eliminated and
    reflected as other income (expense), net. During 2006, warrants,
    issued in connection with a collaboration agreement (see
    Note&#160;3), to purchase 507,407&#160;shares of the
    Series&#160;D convertible preferred stock were exercised
    utilizing a cashless exercise option that allowed the holder to
    receive 267,857&#160;shares of convertible preferred stock. The
    fair value of the warrants and the shares of convertible
    preferred stock issued upon the cashless exercise was $729,000
    on the exercise date, calculated as the fair value of the shares
    of convertible preferred stock issued.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of March&#160;29, 2008, the following warrants were issued
    and outstanding (unaudited):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="29%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Warrant to Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Reason for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Issue Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Expiration</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May 2001
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    41,284
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) May&#160;14, 2008
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    17,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;27, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    November 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    31,008
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) December&#160;16, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2004
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    37,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;18, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;29, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;29, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    February 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series E
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    100,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    4.00
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) February&#160;15, 2015
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    598,720
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the three months ended March&#160;29, 2008, the Company
    issued a warrant to purchase 100,000&#160;shares of
    Series&#160;E convertible preferred stock in connection with the
    amendment of a loan and security agreement (see Note&#160;5).
    Warrants to purchase 200,000&#160;shares of the Company&#146;s
    Series C convertible preferred stock expired unexercised on
    December&#160;31, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of the warrants to purchase
    convertible preferred stock outstanding and their fair values as
    of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares as of</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Fair Value as of</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Warrants to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Purchase</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    294,868
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    289,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    61,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    101,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    194,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    407,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    584,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series E
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    166,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    703,796
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    698,720
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    598,720
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    223,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    468,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    851,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The fair values of the outstanding convertible preferred stock
    warrants were measured using the Black-Scholes option-pricing
    model with the following weighted-average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="9%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.6%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    49.7%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    50.0%
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life (equals the remaining contractual term)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.7 years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    2.8 years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.3 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.2%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    2.2%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A decrease in fair value of the convertible preferred stock
    warrant liabilities in the amount of $72,000 and $16,000 during
    2005 and the three months ended March&#160;31, 2007, and
    increases in fair value in the amounts of $138,000, $245,000 and
    $272,000 during 2006, 2007 and the three months ended
    March&#160;29, 2008, respectively, were recognized as other
    income (expense), net in the consolidated statements of
    operations. Upon adoption of
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    on July&#160;1, 2005, the Company recorded a gain of $637,000 as
    a cumulative effect of a change in accounting principle in the
    consolidated statement of operations during 2005.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Preferred Stock</FONT></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007, and
    March&#160;29, 2008 (unaudited) convertible preferred stock was
    comprised of the following (in thousands):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="33%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;29, 2007 and March&#160;29, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Liquidation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;A
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;B
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,794
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,353
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;E
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,535
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,110
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71,060
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,438
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    165,169
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s convertible preferred stock had been
    classified as temporary equity on the consolidated balance sheet
    instead of in stockholders&#146; equity (deficit) in accordance
    with EITF Abstracts Topic
    <FONT style="white-space: nowrap">No.&#160;D-98,</FONT>
    <I>Classification and Measurement of Redeemable Securities</I>.
    Upon certain change in control events that are outside of the
    control of the Company, including liquidation, sale or transfer
    of control of the Company, holders of the convertible preferred
    stock can cause its redemption. Accordingly, these shares are
    considered contingently
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    redeemable. The Company has not adjusted the carrying values of
    the convertible preferred stock to their redemption values since
    it is uncertain whether or when a redemption event will occur.
    Subsequent adjustments to increase the carrying values to the
    redemption values would be made if it becomes probable that such
    redemption will occur. The significant rights, privileges, and
    preferences of the convertible preferred stock are as follows:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Conversion</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each share of convertible preferred stock is convertible, at any
    time at the option of the holder, into common stock based upon a
    conversion rate of one share of common stock for each share of
    convertible preferred stock regardless of the series.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conversion is automatic upon: (i)&#160;the closing of an
    underwritten initial public offering of the Company&#146;s
    common stock at an offering price of not less that $5.69 per
    share (appropriately adjusted for any stock splits, stock
    dividends, recapitalization, or similar events) and with
    aggregate gross proceeds of not less than $25,000,000,
    (ii)&#160;the closing of an underwritten initial public offering
    of the Company&#146;s common stock at an offering price of less
    than $5.69 per share (appropriately adjusted for any stock
    splits, stock dividends, recapitalization, or similar events) or
    with aggregate gross proceeds of less than $25,000,000 and
    written consent of the holders of two-thirds of all shares of
    convertible preferred stock voting together for such automatic
    conversion, or (iii)&#160;the written consent of the holders of
    two-thirds of all shares of convertible preferred stock voting
    together, except that the written consent of the holders of
    greater than two-thirds of all shares of Series&#160;E
    convertible preferred stock voting separately is required for
    Series&#160;E convertible preferred stock to convert if such
    conversion is not in connection with the closing of an
    underwritten initial public offering of the Company&#146;s
    common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of Series&#160;A, B, C, D, and E convertible preferred
    stock are entitled to noncumulative dividends of $0.11, $0.18,
    $0.26, $0.30, and $0.43 per share, respectively, if and when
    declared by the Board of Directors (adjusted for any stock
    splits, stock dividends, recapitalization, or similar events)
    and subject to the preferences described below. Holders of
    Series&#160;D and E convertible preferred stock shall be
    entitled to receive dividends, when and if declared, in
    preference and priority to any declaration or payment of
    dividends to holders of Series&#160;A, B, or C convertible
    preferred stock or common stock, other than for dividends
    payable in only common stock. Payments of any dividends to the
    holders of Series&#160;D and E convertible preferred stock shall
    be on a pro rata, pari passu basis in proportion to the entitled
    dividend rates for these respective series, as applicable.
    Holders of Series&#160;C convertible preferred stock shall be
    entitled to receive dividends, when and if declared, in
    preference and priority to any declaration or payment of
    dividends to holders of Series&#160;A and B convertible
    preferred stock or common stock, other than for dividends
    payable in only common stock. Holders of Series&#160;A and B
    convertible preferred stock shall be entitled to receive
    dividends, when and if declared, in preference and priority to
    any declaration or payment of dividends to holders of common
    stock, other than for dividends payable in only common stock.
    Payments of any dividends to the holders of Series&#160;A and B
    convertible preferred stock shall be on a pro rata, pari passu
    basis in proportion to the entitled dividend rates for these
    respective series, as applicable. No dividends have been
    declared or paid through March&#160;29, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidation
    Preferences</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a liquidation, dissolution, or winding up of the
    Company, holders of Series&#160;E convertible preferred stock
    shall be entitled to receive a liquidation preference of $4.00
    per share, together with any declared but unpaid dividends,
    prior to any payment or distribution to holders of Series A, B,
    C, or D convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;E convertible
    preferred stock, holders of Series&#160;D convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $2.80 per share, together with any declared but unpaid
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    dividends, prior to any payment or distribution to holders of
    Series A, B, or C convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;D convertible
    preferred stock, holders of Series&#160;C convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $2.58 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series A or B convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;C convertible
    preferred stock, holders of Series&#160;B convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $1.78 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series&#160;A convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;B convertible
    preferred stock, holders of Series&#160;A convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $1.10 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the payment to the holders of convertible preferred stock
    or their respective liquidation preferences, the entire
    remaining assets of the Company shall be distributed on a pro
    rata basis to the holders of common stock. A change of control
    or a sale, transfer, or lease of all or substantially all of the
    assets of the Company is considered to be a liquidation event.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of convertible preferred stock are entitled to the
    number of votes they would have upon conversion of their
    convertible preferred stock into common stock on the applicable
    record date. So long as 2,000,000&#160;shares of Series&#160;D
    convertible preferred stock remain outstanding, the holders of
    Series&#160;D convertible preferred stock are entitled to elect
    two members to the Company&#146;s Board of Directors, and so
    long as 2,000,000&#160;shares of Series&#160;C convertible
    preferred stock remain outstanding, the holders of Series&#160;C
    convertible preferred stock are entitled to elect three members
    to the Board of Directors. The holders of Series&#160;A, B, and
    E convertible preferred stock and the holders of common stock,
    voting together as a single class, are entitled to elect any
    additional members to the Board of Directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Option Activity</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">1999
    Stock Option Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On May&#160;12, 1999, the Board of Directors adopted the 1999
    Stock Option Plan (the Stock Plan) under which incentive stock
    options and nonstatutory stock options may be granted to
    employees, officers, and directors of, or consultants to, the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options granted under the Stock Plan expire no later than ten
    years from the date of grant. The exercise price of each
    incentive stock option granted to an employee shall be at least
    110% of the fair market value of the underlying common stock on
    the date of grant if, on the grant date, the employee owns stock
    representing more than 10% of the voting power of all classes of
    the Company&#146;s capital stock; otherwise, the exercise price
    shall be at least 100% of the fair market value of the
    underlying common stock on the date of grant. The exercise price
    for each nonstatutory stock option granted to a service provider
    shall be at least 110% of the fair market value of the
    underlying common stock on the date of grant if, on the grant
    date, the service provider owns stock representing more than 10%
    of the voting power of all classes of the Company&#146;s capital
    stock; otherwise, the exercise price shall be at least 85% of
    the fair market value of the underlying common stock on the date
    of grant. The fair market value of the underlying common stock
    shall be determined by the Board of Directors until such time as
    the Company&#146;s common stock is listed on any established
    stock exchange or national market system. Options may be granted
    with different vesting terms from time to time, but the vesting
    terms may not exceed five years from the date of grant.
    Generally,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    outstanding options are immediately exercisable and vest at a
    rate of 25% on the first anniversary of the option grant date
    and
    <FONT style="vertical-align: text-top; font-size: 70%;">1</FONT>/<FONT style="font-size: 70%;">48</FONT>
    of the total grant each month thereafter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, the Stock Plan is the
    Company&#146;s only stock-based compensation plan and a total of
    12,800,000&#160;shares of common stock have been authorized for
    issuance under the Stock Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Activity under the Stock Plan is as follows (in thousands,
    except per share amounts):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Available for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price per<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Share</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of January&#160;1, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional shares authorized
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,559
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,559
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    153
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (153
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.47
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of December&#160;31, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,216
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (443
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    817
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (817
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of December&#160;31, 2006
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional shares authorized
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,042
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.53
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (264
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.49
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options granted (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (724
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options exercised (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options canceled (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of March&#160;29, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    540
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.93
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercised during 2005, 2006, 2007 and the three months
    ended March&#160;29, 2008  exclude options that are exercised
    prior to vesting. These shares generally vest over a four-year
    period. Unvested shares, which amount to 65,000, 33,334 and
    27,084 as of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, respectively, are subject to a repurchase
    option held by the Company at the original exercise price and
    are not deemed to be issued for accounting purposes until those
    shares vest.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, the Company adopted the
    provisions of SFAS&#160;123(R). The fair value of each new
    option awarded was estimated on the grant date using the
    Black-Scholes option-pricing model using the following
    weighted-average assumptions. No options were granted during the
    three months ended March&#160;31, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Three Months<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Ended March&#160;29,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    72.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    54.7%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.1&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5.9 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.4%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.0%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted-average fair value of options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $0.55
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $0.92
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $1.31
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Expected volatility is derived from historical volatilities of
    several unrelated public companies within the biomedical
    instrument and system industry. Each company&#146;s historical
    volatility is weighted based on certain qualitative factors and
    combined to produce a single volatility factor used by the
    Company. The risk-free interest rate is based on the
    U.S.&#160;Treasury yield curve in effect at the time of grant
    for zero coupon U.S.&#160;Treasury notes with maturities
    approximately equal to the option&#146;s expected life. Given
    the limited history to accurately estimate expected lives of
    options granted to the various employee groups, the Company used
    the &#147;simplified&#148; method as provided by the SEC Staff
    Accounting Bulletin&#160;No.&#160;107, <I>Share Based Payment
    </I>(SAB&#160;107). The &#147;simplified&#148; method is
    calculated as the average of the time-to-vesting and the
    contractual life of the options. The Company estimates its
    forfeiture rate based on an analysis of its actual forfeitures
    and will continue to evaluate the adequacy of the forfeiture
    rate based on actual forfeiture experience, analysis of employee
    turnover behavior, and other factors. The impact from a
    forfeiture rate adjustment will be recognized in full in the
    period of adjustment, and if the actual number of future
    forfeitures differs from that estimated by the Company, the
    Company may be required to record adjustments to stock-based
    compensation expense in future periods. Adjustments to the
    forfeiture rates have not had a significant impact on any of the
    periods presented. Each of these inputs is subjective and
    generally requires significant judgment to determine.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The absence of an active market for the Company&#146;s common
    stock required the Company&#146;s Board of Directors, with input
    from management, to estimate the fair value of the common stock
    for purposes of granting options and for determining stock-based
    compensation expense for the periods presented. In response to
    these requirements, the Company&#146;s Board of Directors
    estimated the fair value of the common stock at each meeting at
    which options were granted based on factors such as the price of
    the most recent convertible preferred stock sales to investors,
    the preferences held by the convertible preferred stock classes
    in favor of common stock, the valuations of comparable
    companies, the hiring of key personnel, the status of the
    Company&#146;s development and sales efforts, revenue growth and
    additional objective, and subjective factors relating to the
    Company&#146;s business. The Company has historically granted
    stock options at not less than the fair value of the underlying
    common stock as determined at the time of grant by the
    Company&#146;s Board of Directors.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Information regarding the Company&#146;s stock option grants
    during 2007 and the three months ended March&#160;29, 2008,
    including the grant date; the number of stock options issued
    with each grant; and the exercise price, which equals the grant
    date fair value of the underlying common stock for each grant of
    stock options, is summarized as follows (in thousands, except
    per share amounts):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>per Share of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Grant Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Granted</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May&#160;8, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,613
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September&#160;20, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;28, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    February&#160;7, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additional information regarding the Company&#146;s stock
    options outstanding and exercisable as of December&#160;29, 2007
    is summarized in the following table:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Subject<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exercise Price</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>to Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $0.15
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.30
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,651
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.56
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.83
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.36
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,587
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.38
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    217
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,539
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Certain options under the Stock
    Plan may be exercised prior to vesting but are subject to
    repurchase at the original exercise price in the event the
    optionees&#146; employment is terminated.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercisable as of December&#160;29, 2007 had a
    weighted-average remaining contractual life of 7.4&#160;years, a
    weighted-average exercise price per share of $0.74, and an
    aggregate intrinsic value of $3,662,000.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additional information regarding the Company&#146;s stock
    options outstanding and exercisable as of March&#160;29, 2008 is
    summarized in the following table (unaudited):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Subject<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exercise Price</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>to Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $0.15
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.30
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,628
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,628
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.56
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,062
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.83
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    977
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    870
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.36
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,307
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.38
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,259
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Certain options under the Stock
    Plan may be exercised prior to vesting but are subject to
    repurchase at the original exercise price in the event the
    optionees&#146; employment is terminated.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercisable as of March&#160;29, 2008 had a
    weighted-average remaining contractual life of 7.4 years, a
    weighted-average exercise price per share of $0.91, and an
    aggregate intrinsic value of $16,565,000.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options outstanding that have vested and are expected to vest as
    of December&#160;29, 2007 are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Intrinsic<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vested
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,307
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,097
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,049
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total vested and expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,356
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The aggregate intrinsic value was
    calculated as the difference between the exercise price of the
    underlying options and the fair value of the Company&#146;s
    common stock in the amount of $2.40&#160;per share as of
    December&#160;29, 2007.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options outstanding that have vested and are expected to vest as
    of March&#160;29, 2008 are summarized as follows (unaudited):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Intrinsic<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vested
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,598
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.57
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.43
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,315
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total vested and expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,986
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.93
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,695
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The total intrinsic value of options exercised during 2006, 2007
    and the three months ended March&#160;29, 2008 was $167,000,
    $259,000 and $39,000, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There were no stock-based compensation tax benefits during 2005,
    2006, 2007 or the three months ended March&#160;29, 2008.
    Capitalized stock-based compensation costs were insignificant
    during 2005, 2006, 2007 and the three months ended
    March&#160;29, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company recognized stock-based compensation expense of
    $5,000, $145,000, $708,000, $122,000 and $218,000 during 2005,
    2006, 2007 and the three months ended March&#160;31, 2007 and
    March&#160;29, 2008. Included in these amounts was employee
    stock-based compensation expense of $0, $86,000, $526,000,
    $64,000 and $168,000  and nonemployee stock-based compensation
    expense of $5,000, $59,000, $182,000, $58,000 and $50,000 during
    2005, 2006, 2007 and the three months ended March&#160;31, 2007
    and March&#160;29, 2008, respectively. As of December&#160;29,
    2007 and March&#160;29, 2008, there was $1,698,000 and
    $2,474,000 of total unrecognized compensation costs related to
    stock-based compensation arrangements granted under the Stock
    Plan, which is expected to be recognized over an average period
    of 2.9&#160;and 2.6 years, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Options Granted to Nonemployees</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company accounts for options granted to nonemployees under
    the fair value method in accordance with SFAS&#160;123(R) and
    <FONT style="white-space: nowrap">EITF&#160;96-18.</FONT>
    The fair value of these options was estimated using the
    Black-Scholes option-pricing model with the following
    assumptions for 2005, 2006 and 2007 and the three months ended
    March&#160;31, 2007 and March&#160;29, 2008: risk-free interest
    rates of 3.5% to 5.0%, dividend yield of 0%, expected volatility
    of 54.7% to 82.9%, and an expected life of the options equal to
    the remaining contractual terms of one to ten years. In
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    accordance with
    <FONT style="white-space: nowrap">EITF&#160;96-18,</FONT>
    options granted to nonemployees are remeasured at each
    accounting period-end until the award is vested.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company granted options to nonemployees to purchase 17,050,
    88,250 and 236,000 shares of common stock during 2005, 2006 and
    2007, respectively. No such options were granted during the
    three months ended March&#160;31, 2007 and March&#160;29, 2008.
    As of December&#160;29, 2007 and March&#160;29, 2008, there were
    127,085 and 112,453&#160;shares, respectively, subject to
    unvested options held by nonemployees with a weighted-average
    exercise price of $1.63 and $2.12, respectively, and an average
    remaining vesting period of 2.7&#160;years for both periods.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Shares
    Reserved for Issuance</FONT></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007 and March&#160;29, 2008, the
    Company has reserved shares of common stock for future issuance
    as follows (in thousands):
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options outstanding
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options available for grant
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    540
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of outstanding convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of convertible preferred stock upon exercise of
    warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    599
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The above table does not include shares of common stock reserved
    for potential conversions of the convertible promissory notes
    (see Note&#160;7)&#160;into shares of convertible preferred
    stock. The only outstanding convertible promissory note as of
    December&#160;29, 2007 and March&#160;29, 2008 was converted in
    April&#160;2008, at which time the Company issued
    1,503,945&#160;shares of Series&#160;E convertible preferred
    stock.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">12.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s net loss before the provision for income
    taxes is as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Domestic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,181
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (21,816
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,372
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    International
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,737
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,079
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss before provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant components of the Company&#146;s provision for
    income taxes are as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Federal
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    State
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total current provision
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Federal
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    State
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total deferred provision
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reconciliation of the benefits for income taxes at the statutory
    rate to the provision for income taxes is as follows:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax benefit at federal statutory rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    State income taxes (net of federal benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Change in valuation allowance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effective tax rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.4
</TD>
<TD nowrap align="left" valign="bottom">
    )%
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant components of the Company&#146;s deferred tax assets
    and liabilities are as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Reserves and accruals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Tax credit carryforwards
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,936
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net operating loss carryforwards
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Valuation allowance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43,177
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52,747
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Recognition of deferred tax assets is appropriate when
    realization of these assets is more likely than not. The Company
    has incurred losses since its inception; accordingly, the net
    deferred tax assets have been fully offset by a valuation
    allowance. The valuation allowance increased by $5,954,000,
    $8,534,000 and $9,570,000 during 2005, 2006 and 2007,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, the Company had net operating loss
    carryforwards for federal income tax purposes of $121,531,000
    which expire in the years 2019 through 2026 and federal research
    and development tax credits of $2,749,000 which expire in the
    years 2008 through 2016. As of December&#160;29, 2007, the
    Company had net operating
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    loss carryforwards for state income tax purposes of $119,340,000
    which expire in the years 2012 through 2016 and state research
    and development tax credits of $2,722,000 which do not expire.
    As of December&#160;29, 2007, the Company had foreign net
    operating loss carryforwards of $4,768,000. A significant
    portion of the foreign net operating losses relate to activity
    in Singapore that has an indefinite carryforward period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Utilization of the net operating loss carryforwards and credits
    may be subject to a substantial annual limitation due to the
    ownership change limitations provided by the Internal Revenue
    Code of 1986, as amended, and similar state provisions. The
    annual limitation may result in the expiration of net operating
    losses and credits before utilization. If an ownership change
    has occurred at different dates or in addition to the dates
    preliminarily identified, the utilization of net operation loss
    and credit carryforwards could be significantly reduced.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has not provided for U.S. federal and state income
    taxes on all of the non U.S. subsidiaries&#146; undistributed
    earnings as of December&#160;29, 2007, because such earnings are
    intended to be indefinitely reinvested under APB&#160;23. Upon
    distribution of those earnings in the form of dividends or
    otherwise, the Company would be subject to applicable U.S.
    federal and state income taxes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Uncertain
    Tax Positions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2007, the Company adopted the
    provisions of FIN&#160;48. As a result, the Company recorded a
    liability for net unrecognized tax benefits of $75,000, and
    recognized a cumulative effect of a change in accounting
    principle that resulted in a charge to the accumulated deficit.
    The liability for unrecognized tax benefits is classified as
    non-current.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate changes in the balance of the Company&#146;s gross
    unrecognized tax benefits during 2007 were as follows (in
    thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Increases in balances related to tax provisions taken during
    current periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accrued interest and penalties related to unrecognized tax
    benefits are classified as income tax expense and were
    immaterial. As of December&#160;29, 2007, unrecognized tax
    benefits of $162,000, if recognized, would affect the
    Company&#146;s effective tax rate. The remaining unrecognized
    tax benefits were netted against deferred tax assets with a full
    valuation allowance, and if recognized, would not affect the
    Company&#146;s effective tax rate. The Company does not
    anticipate that the amount of existing unrecognized tax benefits
    will significantly increase or decrease within the next
    12&#160;months. The Company files income tax returns in the
    United States, various states and certain foreign jurisdictions.
    The tax years 1999 through 2007 remain open in most
    jurisdictions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Benefit Plans</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sponsors a 401(k) plan that stipulates that eligible
    employees can elect to contribute to the plan, subject to
    certain limitations, up to the lesser of 60% of eligible
    compensation or the maximum amount allowed by the IRS on a
    pretax basis annually. The Company has not made contributions to
    this plan since its inception.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Related-Party
    Transactions</FONT></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed further in Note&#160;7, the Company has entered
    into multiple Convertible Note Purchase Agreements with BMSIF,
    an investment arm of EDB, pursuant to which the Company issued
    convertible notes and received proceeds in the amount of
    $20.0&#160;million. Principal and interest on the notes is
    convertible into shares of Series&#160;E convertible preferred
    stock at the lender&#146;s election, at any time, and
    automatically convert upon the achievement of certain targets or
    upon the completion of an initial public offering in which the
    convertible preferred stock has converted into common stock.
    Through March&#160;29, 2008, $15.0&#160;million of these notes
    had been converted to shares of Series&#160;E convertible
    preferred stock.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    BMSIF and its related companies held 7,505,022&#160;shares of
    the Company&#146;s common stock as of March&#160;29, 2008, which
    constitutes 9.7% of the outstanding shares on a fully diluted
    basis. In addition, the Company&#146;s manufacturing operations
    in Singapore, which commenced operations in October 2005, have
    been supported by grants from EDB which provide partial
    reimbursement of qualifying costs arising from research and
    development projects relating to the Company&#146;s
    manufacturing process. These agreements are discussed further in
    Note&#160;3.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2004, the Company loaned an officer of the Company
    $250,000 in connection with the purchase of a new home, which is
    secured by 833,334&#160;shares of the Company&#146;s common
    stock held by the officer. The loan carried an interest rate of
    3.52% per annum. The outstanding balance of this loan, including
    accrued interest, was $277,000, $287,000 and $290,000 as of
    December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, respectively. On April&#160;10, 2008, the
    principal amount of this note and all accrued interest was
    settled with 90,913&#160;shares held by the officer at fair
    value of the common stock, which was determined by the Board of
    Directors to be $3.19 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Stephen Quake, who is a professor of bioengineering at
    Stanford University, is one of the Company&#146;s founding
    stockholders and as such held 2,326,000&#160;shares of common
    stock as of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008. In June 2006, the Company repurchased
    124,000&#160;shares of the Company&#146;s common stock held by
    Dr.&#160;Quake for $0.56 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Quake also serves as a consultant to the Company and is
    a member of the Company&#146;s Scientific Advisory Board. The
    Company paid consulting fees of $45,000, $97,000, $67,000,
    $25,000 and $50,000 to Dr.&#160;Quake during 2005, 2006, 2007
    and the three months ended March&#160;31, 2007 and
    March&#160;29, 2008, respectively, and accrued amounts payable
    to Dr.&#160;Quake related to these payments were $0, $33,000 and
    $8,000 as of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, respectively. The Company recognized
    $205,000, $241,000, $15,000, $0 and $19,000 in revenue related
    to products and services sold to Stanford University during
    2005, 2006, 2007 and the three months ended March&#160;31, 2007
    and March&#160;29, 2008, respectively, and had accounts
    receivable balances related to these sales of $0, $11,000 and
    $15,000 as of December&#160;31, 2006, December&#160;29, 2007 and
    March&#160;29, 2008, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s general counsel was  also a member of a law
    firm whose services are utilized by the Company. On
    April&#160;1, 2008, the Company&#146;s general counsel resigned
    his position from such law firm. Amounts paid to the law firm
    for services and direct patent fees were $880,000, $960,000,
    $576,000, $208,000 and $180,000 for 2005, 2006, 2007 and the
    three months ended March&#160;31, 2007 and March&#160;29, 2008,
    respectively, and accrued amounts payable to the law firm were
    $174,000, $257,000 and $175,000 as of December&#160;31, 2006,
    December&#160;29, 2007 and March&#160;29, 2008, respectively.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Information
    about Geographic Areas</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;No.&#160;131, <I>Disclosures about Segments of an
    Enterprise and Related Information</I>, establishes standards
    for reporting information about operating segments. Operating
    segments are defined as components of an enterprise about which
    separate financial information is available that is evaluated
    regularly by a company&#146;s chief operating decision maker, or
    decision making group, in deciding how to allocate resources and
    in assessing performance. The chief operating decision maker for
    the Company is the Chief Executive Officer. The Chief Executive
    Officer reviews financial information presented on a
    consolidated basis, accompanied by information about revenue by
    geographic region, for purposes of allocating resources and
    evaluating financial performance. The Company has one business
    activity and there are no segment managers who are held
    accountable for operations, operating results or plans for
    levels or components below the consolidated unit level.
    Accordingly, the Company has determined that it has a single
    reporting segment and operating unit structure which is the
    development, manufacturing and commercialization of IFCs and
    complementary laboratory instruments.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue by geography is based on the billing address of the
    customer. The following tables set forth revenue and long-lived
    assets by geographic area (in thousands):
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="52%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March 31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March 29,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    United States
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,807
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    672
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    470
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Japan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    732
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Europe
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    735
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    318
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    289
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Long-lived
    Assets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    United States
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,818
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,824
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Japan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Europe
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">16.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Subsequent
    Events (Unaudited)</FONT></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, the Company&#146;s Board of Directors approved
    the filing of a registration statement with the Securities and
    Exchange Commission for an initial public offering of the
    Company&#146;s common stock.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     In April&#160;2008, BMSIF exercised the conversion provision
    for the third and final convertible promissory note and the
    Company issued 1,503,945&#160;shares of Series E convertible
    preferred stock at $3.60&#160;per share as settlement of the
    outstanding principal and accrued interest balance on the date
    of the conversion in the amount of $5,414,000.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a1f3943219.gif" alt="(DYNAMIC ARRAY SCHEMATIC GRAPHIC)">
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a1f3943220.gif" alt="(CIRCUITS &#38; SYSTEMS GRAPHIC)">
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a1f3943216.gif" alt="(FLUIDIGM LOGO)">
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;II<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INFORMATION
    NOT REQUIRED IN PROSPECTUS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;13.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Other
    Expenses of Issuance and Distribution.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth all expenses to be paid by the
    registrant, other than estimated underwriting discounts and
    commissions, in connection with this offering. All amounts shown
    are estimates except for the SEC registration fee, the NASD
    filing fee and the NASDAQ Global Market listing fee.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SEC registration fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NASD filing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NASDAQ Global Market listing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Printing and engraving
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounting fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Blue sky fees and expenses (including legal fees)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Transfer agent and registrar fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Miscellaneous
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    To be provided by amendment.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;14.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Indemnification
    of Directors and Officers.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section&#160;145 of the Delaware General Corporation Law
    authorizes a corporation&#146;s board of directors to grant, and
    authorizes a court to award, indemnity to officers, directors
    and other corporate agents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As permitted by Section&#160;102(b)(7) of the Delaware General
    Corporation Law, the registrant&#146;s certificate of
    incorporation includes provisions that eliminate the personal
    liability of its directors and officers for monetary damages for
    breach of their fiduciary duty as directors and officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, as permitted by Section&#160;145 of the Delaware
    General Corporation Law, the bylaws of the registrant provide
    that:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant shall indemnify its directors and officers for
    serving the registrant in those capacities or for serving other
    business enterprises at the registrant&#146;s request, to the
    fullest extent permitted by Delaware law. Delaware law provides
    that a corporation may indemnify such person if such person
    acted in good faith and in a manner such person reasonably
    believed to be in or not opposed to the best interests of the
    registrant and, with respect to any criminal proceeding, had no
    reasonable cause to believe such person&#146;s conduct was
    unlawful.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant may, in its discretion, indemnify employees and
    agents in those circumstances where indemnification is not
    required by law.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant is required to advance expenses, as incurred, to
    its directors and officers in connection with defending a
    proceeding, except that such director or officer shall undertake
    to repay such advances if it is ultimately determined that such
    person is not entitled to indemnification.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant will not be obligated pursuant to the bylaws to
    indemnify a person with respect to proceedings initiated by that
    person, except with respect to proceedings authorized by the
    registrant&#146;s Board of Directors or brought to enforce a
    right to indemnification.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The rights conferred in the bylaws are not exclusive, and the
    registrant is authorized to enter into indemnification
    agreements with its directors, officers, employees and agents
    and to obtain insurance to indemnify such persons.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant may not retroactively amend the bylaw provisions
    to reduce its indemnification obligations to directors,
    officers, employees and agents.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registrant&#146;s policy is to enter into separate
    indemnification agreements with each of its directors and
    officers that provide the maximum indemnity allowed to directors
    and executive officers by Section&#160;145 of the Delaware
    General Corporation Law and also provides for certain additional
    procedural protections. The registrant also maintains directors
    and officers insurance to insure such persons against certain
    liabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These indemnification provisions and the indemnification
    agreements entered into between the registrant and its officers
    and directors may be sufficiently broad to permit
    indemnification of the registrant&#146;s officers and directors
    for liabilities (including reimbursement of expenses incurred)
    arising under the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriting agreement filed as Exhibit&#160;1.1 to this
    registration statement provides for indemnification by the
    underwriters of the registrant and its officers and directors
    for certain liabilities arising under the Securities Act and
    otherwise.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;15.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Sales of Unregistered Securities.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the three years prior to the filing of this registration
    statement, the registrant has issued the following unregistered
    securities:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;From March 2005 through July&#160;17, 2007, Fluidigm
    Corporation, a California corporation, issued and sold an
    aggregate of 470,965&#160;shares of its common stock upon the
    exercise of options issued to certain employees, directors and
    consultants under the registrant&#146;s 1999 Stock Option Plan,
    as amended, at exercise prices ranging from $0.30 to $0.83, for
    aggregate consideration of $188,442. From July&#160;18, 2007
    through May&#160;22,&#160;2008, the registrant issued and sold
    an aggregate of 250,720&#160;shares of its common stock upon the
    exercise of options issued to certain employees, directors and
    consultants under the registrant&#146;s 1999 Stock Option Plan,
    as amended, at exercise prices ranging from $0.30 to $1.36 per
    share, for aggregate consideration of $123,346.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;From March 2005 through July&#160;17, 2007, Fluidigm
    Corporation, a California corporation, granted to certain of its
    employees, directors and consultants under the registrant&#146;s
    1999 Stock Option Plan, as amended, options to purchase an
    aggregate of 3,986,044&#160;shares of its common stock at
    exercise prices ranging from $0.30 to $1.36 per share. From
    July&#160;18, 2007 through May&#160;22, 2008, the registrant
    granted to certain of its employees, directors and consultants
    under the registrant&#146;s 1999 Stock Option Plan, as amended,
    options to purchase an aggregate of 452,200&#160;shares of the
    registrant&#146;s common stock at exercise prices ranging from
    $1.38 to $2.40 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;In March 2005, Fluidigm Corporation, a California
    corporation, pursuant to a loan and security agreement, issued
    and sold a warrant to purchase 371,428&#160;shares of its
    Series&#160;D Preferred Stock to one accredited investor at an
    exercise price of $2.80 per share. In connection with the
    registrant&#146;s reincorporation into the State of Delaware on
    July&#160;18, 2007, the warrant was converted into a warrant to
    purchase an equal number of shares of the registrant&#146;s
    Series&#160;D Preferred Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;In November 2005, Fluidigm Corporation, a California
    corporation, issued and sold 70,000&#160;shares of its common
    stock to one accredited investor at an issuance price of $0.56
    per share for aggregate monetary consideration of $39,200, which
    amount was deemed paid by the transfer of certain rights granted
    to registrant pursuant to the terms of a licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;In December 2005, Fluidigm Corporation, a California
    corporation, issued 832,635&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor in connection with
    the conversion of a convertible promissory note at a conversion
    price per share of $2.80.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (f)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued to one accredited investor a convertible
    promissory notes in an aggregate principal amount of $3,000,000
    convertible into shares of its Series&#160;D Preferred Stock. In
    July 2007, the notes were converted into 1,157,142&#160;shares
    of Series&#160;D Preferred Stock at a conversion price per share
    of $2.80.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (g)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued 214,285&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor at an issuance price
    of $2.80 per share, for aggregate monetary consideration of
    $599,998, which amount was deemed paid by the transfer of
    certain rights granted to registrant pursuant to the terms of a
    licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (h)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued 267,858&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor in connection with
    the exercise of a warrant to purchase shares of its
    Series&#160;D Preferred Stock at an exercise price per share of
    $2.80.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;From August 2006 through April 2007, Fluidigm
    Corporation, a California corporation, issued three convertible
    promissory notes to one accredited investor in an aggregate
    principal amount of $15,000,000, all of which were convertible
    into shares of its Series&#160;E Preferred Stock. In March 2007,
    two of the notes were converted into an aggregate of
    2,954,337&#160;shares of the Series&#160;E Preferred Stock of
    Fluidigm Corporation, a California corporation. In connection
    with the registrant&#146;s reincorporation into the State of
    Delaware on July&#160;18, 2007, the remaining outstanding
    convertible promissory note was made convertible into shares of
    the registrant&#146;s Series&#160;E Preferred Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (j)&#160;In March 2007, Fluidigm Corporation, a California
    corporation, issued 100,000&#160;shares of its common stock to
    one accredited investor at an issuance price of $0.83 per share,
    for aggregate monetary consideration of $83,000, which amount
    was deemed paid by the transfer of certain rights granted to
    registrant pursuant to the terms of a licensing agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (k)&#160;In May 2007, Fluidigm Corporation, a California
    corporation, granted to seven of its employees and directors
    under the registrant&#146;s 1999 Stock Option Plan, as amended,
    options to purchase an aggregate of 767,000&#160;shares of its
    common stock at an exercise price of $1.36 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (l)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    9,695,998&#160;shares of common stock to a total of 128
    stockholders in exchange for the outstanding shares of common
    stock Fluidigm Corporation, a California corporation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (m)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    2,727,273&#160;shares of the registrant&#146;s Series&#160;A
    Preferred Stock to a total of 41 investors in exchange for the
    outstanding shares of Series&#160;A Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (n)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    6,460,675&#160;shares of the registrant&#146;s Series&#160;B
    Preferred Stock to a total of 35 investors in exchange for the
    outstanding shares of Series&#160;B Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (o)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    16,364,832&#160;shares of the registrant&#146;s Series&#160;C
    Preferred Stock to a total of 62 investors in exchange for the
    outstanding shares of Series&#160;C Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (p)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    12,196,191&#160;shares of the registrant&#146;s Series&#160;D
    Preferred Stock to a total of 52 investors in exchange for the
    outstanding shares of Series&#160;D Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (q)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    8,969,836&#160;shares of the registrant&#146;s Series&#160;E
    Preferred Stock to a total of 35 investors in exchange for the
    outstanding shares of Series&#160;E Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (r)&#160;From October 2007 through December 2007, the registrant
    issued and sold an aggregate of 8,794,945&#160;shares of
    Series&#160;E Preferred Stock to a total of seven investors at
    $4.00 per share, for aggregate proceeds of $35,179,780.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (s)&#160;In December 2007, the registrant issued
    6,000&#160;shares of its common stock to one accredited investor
    at an issuance price of $1.36 per share for aggregate monetary
    consideration of $8,160, which amount was deemed paid by the
    transfer of certain rights granted to registrant pursuant to the
    terms of a licensing agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (t)&#160;In December 2007, the registrant granted to one of its
    directors under the registrant&#146;s 1999 Stock Option Plan, as
    amended, options to purchase an aggregate of 100,000&#160;shares
    of the registrant&#146;s common stock at an exercise price of
    $2.40 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (u)&#160;In February 2008, the registrant issued a warrant to
    purchase 100,000&#160;shares of the registrant&#146;s
    Series&#160;E Preferred Stock to one accredited investor at an
    exercise price of $4.00 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (v)&#160;In February 2008, the registrant granted to one of its
    executive officers under the registrant&#146;s 1999 Stock Option
    Plan, as amended, options to purchase an aggregate of
    600,000&#160;shares of the registrant&#146;s common stock at an
    exercise price of $2.40 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (w)&#160;In April 2008, the registrant granted to six of its
    employees and directors under the registrant&#146;s 1999 Stock
    Option Plan, as amended, options to purchase an aggregate of
    1,090,000&#160;shares of its common stock at an exercise price
    of $3.19 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of the foregoing transactions involved any underwriters,
    underwriting discounts or commissions, or any public offering,
    and the registrant believes that each transaction was exempt
    from the registration requirements of the Securities Act in
    reliance on the following exemptions:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs
    (a)&#160;and (b), Rule&#160;701 promulgated under the Securities
    Act as transactions pursuant to a compensatory benefit plan
    approved by the registrant&#146;s Board of Directors;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs (1)
    through (q), Rule&#160;145(a)(2) promulgated under the
    Securities Act as transactions pursuant to a plan or agreement
    for statutory merger or similar plan or acquisition in which
    securities of the registrant were exchanged for the securities
    of Fluidigm Corporation, a California corporation, the sole
    purpose of which was to change the registrant&#146;s domicile
    solely within the United States, and a Permit granted pursuant
    to Section 25121 of the California Corporations Code;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs
    (c)&#160;through (k) and paragraphs (r) through (w),
    Section&#160;4(2) of the Securities Act, or Rule&#160;506 of
    Regulation&#160;D promulgated thereunder, as transactions by an
    issuer not involving a public offering. Each recipient of the
    securities in this transaction represented his or her intention
    to acquire the securities for investment only and not with a
    view to, or for resale in connection with, any distribution
    thereof, and appropriate legends were affixed to the share
    certificates issued in each such transaction. In each case, the
    recipient received adequate information about the registrant or
    had adequate access, through his or her relationship with the
    registrant, to information about the registrant.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;16.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Exhibits
    and Financial Statement Schedules.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I>Exhibits.</I>&#160;&#160;The following exhibits are
    included herein or incorporated herein by reference:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certificate of Incorporation of the Registrant, as currently in
    effect.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Restated Certificate of Incorporation of the Registrant,
    to be in effect upon the completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Bylaws of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Amended and Restated Bylaws of the Registrant, to be in
    effect upon completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;E Preferred Stock Purchase Agreement dated
    June&#160;13, 2006 through October&#160;26, 2007 between the
    Registrant and the Purchasers set forth therein, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Eighth Amended and Restated Investor Rights Agreement between
    the Registrant and certain holders of the Registrant&#146;s
    common stock named therein, including amendments No.&#160;1 and
    No.&#160;2.
</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Loan and Security Agreement No.&#160;4561 between the Registrant
    and Lighthouse Capital Partners&#160;V, L.P. dated
    March&#160;29, 2005, including amendments Nos. 1 through 4.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preferred Stock Purchase Warrant issued to Lighthouse Capital
    Partners&#160;V, L.P. effective March&#160;29, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4B<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Negative Pledge Agreement by and between the Registrant and
    Lighthouse Capital Partners&#160;V, L.P. dated March&#160;29,
    2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Note Purchase Agreement by and between Biomedical
    Sciences Investment Fund&#160;Pte Ltd and the Registrant dated
    August&#160;7, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Promissory Note issued to Biomedical Sciences
    Investment Fund&#160;Pte Ltd dated April&#160;19, 2007, as
    amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between the Registrant and its
    directors and officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Plan of the Registrant, as amended April&#160;24,
    2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 1999 Stock Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3A<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated License Agreement by and between
    California Institute of Technology and the Registrant effective
    as of May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Addendum, effective as of March&#160;29, 2007, to Second
    Amended and Restated License Agreement by and between California
    Institute of Technology and the Registrant effective as of
    May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Co-Exclusive License Agreement between
    President and Fellows of Harvard College and the Registrant
    effective as of October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Patent License Agreement by and between Gyros AB and the
    Registrant dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 dated January&#160;9, 2005 to Patent
    License Agreement by and between Gyros AB and the Registrant
    dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Master Closing Agreement by and between UAB Research Foundation,
    Oculus Pharmaceuticals, Inc. and the Registrant dated
    March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement by and between UAB Research Foundation and the
    Registrant dated March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    October&#160;7, 2005), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Supplement Dated January&#160;11, 2006 to Letter Agreement
    Relating to Application for Incentives under the Research
    Incentive Scheme for Companies (RISC), dated October&#160;7,
    2005 between Singapore Economic Development Board and Fluidigm
    Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .11<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    February&#160;12, 2007), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Employment and Severance Agreement between the
    Registrant and each of its executive officers.
</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .14<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consulting Agreement by and between the Registrant and Richard
    DeLateur dated February&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employee Loan Agreement with Gajus Worthington dated
    January&#160;20, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Repurchase Agreement between the Registrant and Gajus V.
    Worthington dated April&#160;10, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Offer Letter to Vikram Jog dated January&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .17<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Settlement Agreement and General Release of all Claims by and
    between Michael Ybarra Lucero and the Registrant dated
    March&#160;20, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .18<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Letter Agreement between President and Fellows of Harvard
    College and the Registrant dated December&#160;22, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    List of subsidiaries of Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation (included in Exhibit&#160;5.1).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    24
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Power of Attorney.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">To be filed by amendment.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Confidential treatment has been
    requested with respect to certain portions of this exhibit.
    Omitted portions have been filed separately with the Securities
    and Exchange Commission.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Previously filed.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I>Financial Statement Schedules.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All schedules have been omitted because the information required
    to be presented in them is not applicable or is shown in the
    consolidated financial statements or related notes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;17.&#160;&#160;<I>Undertakings.</I></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes to provide to the
    underwriters at the closing specified in the underwriting
    agreement certificates in such denominations and registered in
    such names as required by the underwriters to permit prompt
    delivery to each purchaser.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act of 1933&#160;may be permitted to directors,
    officers and controlling persons of the registrant pursuant to
    the foregoing provisions, or otherwise, the registrant has been
    advised that in the opinion of the Securities and Exchange
    Commission such indemnification is against public policy as
    expressed in the Act and is, therefore, unenforceable. In the
    event that a claim for indemnification against such liabilities
    (other than the payment by the registrant of expenses incurred
    or paid by a director, officer or controlling person of the
    registrant in the successful defense of any action, suit or
    proceeding) is asserted by such director, officer or controlling
    person in connection with the securities being registered, the
    registrant will, unless in the opinion of its counsel the matter
    has been settled by controlling precedent, submit to a court of
    appropriate jurisdiction the question whether such
    indemnification by it is against public policy as expressed in
    the Act and will be governed by the final adjudication of such
    issue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;For purposes of determining any liability under the
    Securities Act of 1933, the information omitted from the form of
    prospectus filed as part of this registration statement in
    reliance upon Rule&#160;430A and contained in a form of
    prospectus filed by the registrant pursuant to
    Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities
    Act shall be deemed to be part of this registration statement as
    of the time it was declared effective.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;For the purpose of determining any liability under the
    Securities Act of 1933, each post effective amendment that
    contains a form of prospectus shall be deemed to be a new
    registration statement relating to the securities offered
    therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;For the purpose of determining liability under the
    Securities Act of 1933 to any purchaser, if the registrant is
    subject to Rule&#160;430C, each prospectus filed pursuant to
    Rule&#160;424(b) as part of a registration statement relating to
    an offering, other than registration statements relying on
    Rule&#160;430B or other than prospectuses filed in reliance on
    Rule 430A, shall be deemed to be part of and included in the
    registration statement as of the date it is first used after
    effectiveness; provided, however, that no statement made in a
    registration statement or prospectus that is part of the
    registration statement or made in a document incorporated or
    deemed incorporated by reference into the registration statement
    or prospectus that is part of the registration statement will,
    as to a purchaser with a time of contract of sale prior to such
    first use, supersede or modify any statement that was made in
    the registration statement or prospectus that was part of the
    registration statement or made in any such document immediately
    prior to such date of first use.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;For the purpose of determining liability of the
    registrant under the Securities Act of 1933 to any purchaser to
    the initial distribution of the securities, the undersigned
    registrant undertakes that in a primary offering of securities
    of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell
    the securities to the purchaser, if the securities are offered
    or sold to such purchaser by means of any of the following
    communications, the undersigned registrant will be a seller to
    the purchasers and will be considered to offer or sell such
    securities to such purchaser:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;Any preliminary prospectus or prospectus of the
    undersigned registrant relating to the offering required to be
    filed pursuant to Rule&#160;424;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;Any free writing prospectus relating to the offering
    prepared by or on behalf of the undersigned registrant or used
    or referred to by the undersigned registrant;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;The portion of any other free writing prospectus
    relating to the offering containing material information about
    the undersigned registrant or its securities provided by or on
    behalf of the undersigned registrant;&#160;and
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;Any other communication that is an offer in the
    offering made by the undersigned registrant to the purchaser.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURES</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, the
    Registrant has duly caused this Amendment No.&#160;1 to the
    registration statement to be signed on its behalf by the
    undersigned, thereunto duly authorized, in the City of Palo
    Alto, State of California, on the 27th day of May 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>FLUIDIGM CORPORATION</B>
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="center">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Gajus V. Worthington
</DIV>

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>President and Chief Executive Officer</I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, this
    Amendment No. 1 to the registration statement has been signed by
    the following persons in the capacities indicated on the 27 day
    of May 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="38%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="37%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Signature</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Title</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Date</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Gajus
    V. Worthington
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    President, Chief Executive Officer and Director (Principal
    Executive Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    May&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Vikram
    Jog</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Vikram
    Jog
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Chief Financial Officer (Principal Accounting and Financial
    Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    May&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Samuel
    Colella
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    May&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Michael
    W. Hunkapiller
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    May&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Elaine
    V. Jones
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    May&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Kenneth
    Nussbacher
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    May&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->John
    A. Young
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    May&#160;27, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    *By:
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=208 iwidth=174 length=0 -->Gajus
    V. Worthington<BR>
    Attorney-in-Fact
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    *By:
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Vikram
    Jog</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=208 iwidth=174 length=0 -->Vikram
    Jog<BR>
    Attorney-in-Fact
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXHIBIT&#160;INDEX</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certificate of Incorporation of the Registrant, as currently in
    effect.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Restated Certificate of Incorporation of the Registrant,
    to be in effect upon the completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Bylaws of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Amended and Restated Bylaws of the Registrant, to be in
    effect upon completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;E Preferred Stock Purchase Agreement dated
    June&#160;13, 2006 through October&#160;26, 2007 between the
    Registrant and the Purchasers set forth therein, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Eighth Amended and Restated Investor Rights Agreement between
    the Registrant and certain holders of the Registrant&#146;s
    common stock named therein, including amendments No.&#160;1 and
    No.&#160;2.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Loan and Security Agreement No.&#160;4561 between the Registrant
    and Lighthouse Capital Partners&#160;V, L.P. dated
    March&#160;29, 2005, including amendments Nos. 1 through 4.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preferred Stock Purchase Warrant issued to Lighthouse Capital
    Partners&#160;V, L.P. effective March&#160;29, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4B<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Negative Pledge Agreement by and between the Registrant and
    Lighthouse Capital Partners&#160;V, L.P. dated March&#160;29,
    2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Note Purchase Agreement by and between Biomedical
    Sciences Investment Fund&#160;Pte Ltd and the Registrant dated
    August&#160;7, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Promissory Note issued to Biomedical Sciences
    Investment Fund&#160;Pte Ltd dated April&#160;19, 2007, as
    amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between the Registrant and its
    directors and officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Plan of the Registrant, as amended April&#160;24,
    2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 1999 Stock Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3A<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated License Agreement by and between
    California Institute of Technology and the Registrant effective
    as of May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Addendum, effective as of March&#160;29, 2007, to Second
    Amended and Restated License Agreement by and between California
    Institute of Technology and the Registrant effective as of
    May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Co-Exclusive License Agreement between
    President and Fellows of Harvard College and the Registrant
    effective as of October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Patent License Agreement by and between Gyros AB and the
    Registrant dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 dated January&#160;9, 2005 to Patent
    License Agreement by and between Gyros AB and the Registrant
    dated January&#160;9, 2003.
</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Master Closing Agreement by and between UAB Research Foundation,
    Oculus Pharmaceuticals, Inc. and the Registrant dated
    March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement by and between UAB Research Foundation and the
    Registrant dated March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    October&#160;7, 2005), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Supplement Dated January&#160;11, 2006 to Letter Agreement
    Relating to Application for Incentives under the Research
    Incentive Scheme for Companies (RISC), dated October&#160;7,
    2005 between Singapore Economic Development Board and Fluidigm
    Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .11<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    February&#160;12, 2007), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Employment and Severance Agreement between the
    Registrant and each of its executive officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .14<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consulting Agreement by and between the Registrant and Richard
    DeLateur dated February&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employee Loan Agreement with Gajus Worthington dated
    January&#160;20, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Repurchase Agreement between the Registrant and Gajus V.
    Worthington dated April&#160;10, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Offer Letter to Vikram Jog dated January&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .17<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Settlement Agreement and General Release of all Claims by and
    between Michael Ybarra Lucero and the Registrant dated
    March&#160;20, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .18<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Letter Agreement between President and Fellows of Harvard
    College and the Registrant dated December&#160;22, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    List of subsidiaries of Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation (included in Exhibit&#160;5.1).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    24
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Power of Attorney.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">To be filed by amendment.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Confidential treatment has been
    requested with respect to certain portions of this exhibit.
    Omitted portions have been filed separately with the Securities
    and Exchange Commission.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Previously filed.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>f39432a1exv3w2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv3w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;3.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CERTIFICATE OF INCORPORATION OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fluidigm Corporation, a corporation organized and existing under the laws of the State of
Delaware (the &#147;<B>Corporation</B>&#148;), certifies that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;The name of the Corporation is Fluidigm Corporation. The Corporation&#146;s original Certificate
of Incorporation was filed with the Secretary of State of the State of Delaware on March&nbsp;29, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;This Amended and Restated Certificate of Incorporation was duly adopted in accordance with
Sections&nbsp;242 and 245 of the General Corporation Law of the State of Delaware, and has been duly
approved by the written consent of the stockholders of the Corporation in accordance with Section
228 of the General Corporation Law of the State of Delaware.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;The text of the Certificate of Incorporation is amended and restated to read as set forth
in <U>Exhibit&nbsp;A</U> attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Fluidigm Corporation has caused this Amended and Restated Certificate of
Incorporation to be signed by Gajus V. Worthington, a duly authorized officer of the Corporation,
on &#95;&#95;&#95;&#95;&#95; &#95;&#95;, 2008.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Gajus V. Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ARTICLE I</B>

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The name of the corporation is Fluidigm Corporation (the &#147;<B>Corporation</B>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The address of the Corporation&#146;s registered office in the State of Delaware is 1209 Orange
Street, City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent
at such address is The Corporation Trust Company.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The nature of the business or purposes to be conducted or promoted by the Corporation is to
engage in any lawful act or activity for which corporations may be organized under the Delaware
General Corporation Law (&#147;<B>DGCL</B>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. This Corporation is authorized to issue two classes of stock, to be designated,
respectively, Common Stock and Preferred Stock. The total number of shares of stock that the
Corporation shall have authority to issue is three hundred twenty million (320,000,000) shares, of
which three hundred million (300,000,000) shares are Common Stock, $0.001 par value, and twenty
million (20,000,000) shares are Preferred Stock, $0.001 par value.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. Each share of Common Stock shall entitle the holder thereof to one (1)&nbsp;vote on any
matter submitted to a vote at a meeting of stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3. The Preferred Stock may be issued from time to time in one or more series pursuant
to a resolution or resolutions providing for such issue duly adopted by the Board of Directors
(authority to do so being hereby expressly vested in the Board of Directors). The Board of
Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or
resolutions the designations, powers, preferences and rights, and the qualifications, limitations
or restrictions thereof, of any wholly unissued series of Preferred Stock, including without
limitation authority to fix by resolution or resolutions the dividend rights, dividend rate,
conversion rights, voting rights, rights and terms of redemption (including sinking fund
provisions), redemption price or prices, and liquidation preferences of any such series, and the
number of shares constituting any such series and the designation thereof, or any of the foregoing.
The Board of Directors is further authorized to increase (but not above the total number of
authorized shares of the class) or decrease (but not below the number of shares of any such series
then outstanding) the number of shares of any series, the number of which was fixed by it,
subsequent to the issuance of shares of such series then outstanding, subject to the powers,
preferences and rights, and the qualifications, limitations and restrictions thereof stated in this
Amended and Restated Certificate of Incorporation or the resolution of the Board of Directors
originally fixing the number of shares of such series. If the number of
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shares of any series is so decreased, then the Corporation shall take all such steps as are
necessary to cause the shares constituting such decrease to resume the status which they had prior
to the adoption of the resolution originally fixing the number of shares of such series.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4. Except as otherwise required by law, holders of Common Stock shall not be entitled
to vote on any amendment to this Amended and Restated Certificate of Incorporation (including any
certificate of designation filed with respect to any series of Preferred Stock) that relates solely
to the terms of one or more outstanding series of Preferred Stock if the holders of such affected
series are entitled, either separately or together as a class with the holders of one or more other
such series, to vote thereon by law or pursuant to this Amended and Restated Certificate of
Incorporation (including any certificate of designation filed with respect to any series of
Preferred Stock).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. The number of directors that constitutes the entire Board of Directors of the
Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. At each
annual meeting of stockholders, directors of the Corporation shall be elected to hold office until
the expiration of the term for which they are elected and until their successors have been duly
elected and qualified or until their earlier resignation or removal; except that if any such
meeting shall not be so held, such election shall take place at a stockholders&#146; meeting called and
held in accordance with the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. The directors of the Corporation shall be divided into three classes as nearly
equal in size as is practicable, hereby designated Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Directors shall
be assigned to each class in accordance with a resolution or resolutions adopted by the Board of
Directors. At the first annual meeting of stockholders following the date hereof, the term of
office of the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term
of three years. At the second annual meeting of stockholders following the date hereof, the term of
office of the Class&nbsp;II directors shall expire and Class&nbsp;II directors shall be elected for a full
term of three years. At the third annual meeting of stockholders following the date hereof, the
term of office of the Class&nbsp;III directors shall expire and Class&nbsp;III directors shall be elected for
a full term of three years. At each succeeding annual meeting of stockholders, directors shall be
elected for a full term of three years to succeed the directors of the class whose terms expire at
such annual meeting. If the number of directors is changed, any newly created directorships or
decrease in directorships shall be so apportioned among the classes as to make all classes as
nearly equal in number as is practicable, provided that no decrease in the number of directors
constituting the Board of Directors shall shorten the term of any incumbent director.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. Any director or the entire Board of Directors may be removed from office at any
time, but only for cause, and only by the affirmative vote of the holders of at least a majority of
the voting power of the issued and outstanding capital stock of the Corporation entitled to vote in
the election of directors.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. Except as otherwise provided for or fixed by or pursuant to the provisions of
Article&nbsp;IV hereof in relation to the rights of the holders of Preferred Stock to elect directors
under specified circumstances, newly created directorships resulting from any increase in the
number of directors, created in accordance with the Bylaws of the Corporation, and any vacancies on
the Board of Directors resulting from death, resignation, disqualification, removal or other cause
shall be filled only by the affirmative vote of a majority of the remaining directors then in
office, even though less than a quorum of the Board of Directors, or by a sole remaining director,
and not by the stockholders. A person so elected by the Board of Directors to fill a vacancy or
newly created directorship shall hold office until the next election of the class for which such
director shall have been chosen until his or her successor shall have been duly elected and
qualified, or until such director&#146;s earlier death, resignation or removal. No decrease in the
number of directors constituting the Board of Directors shall shorten the term of any incumbent
director.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. The Corporation is to have perpetual existence.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. The business and affairs of the Corporation shall be managed by or under the
direction of the Board of Directors. In addition to the powers and authority expressly conferred
upon them by statute or by this Amended and Restated Certificate of Incorporation or the Bylaws of
the Corporation, the directors are hereby empowered to exercise all such powers and do all such
acts and things as may be exercised or done by the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3. In furtherance and not in limitation of the powers conferred by statute, the Board
of Directors is expressly authorized to adopt, alter, amend or repeal the Bylaws of the
Corporation. The affirmative vote of at least a majority of the Board of Directors then in office
shall be required in order for the Board of Directors to adopt, amend, alter or repeal the
Corporation&#146;s Bylaws. The Corporation&#146;s Bylaws may also be adopted, amended, altered or repealed by
the stockholders of the Corporation. Notwithstanding the above or any other provision of this
Amended and Restated Certificate of Incorporation, the Bylaws of the Corporation may not be
amended, altered or repealed except in accordance with Article&nbsp;XI of the Bylaws. No Bylaw hereafter
legally adopted, amended, altered or repealed shall invalidate any prior act of the directors or
officers of the Corporation that would have been valid if such Bylaw had not been adopted, amended,
altered or repealed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4. The election of directors need not be by written ballot unless the Bylaws of the
Corporation shall so provide.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5. No stockholder will be permitted to cumulate votes at any election of directors.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. Any action required or permitted to be taken by the stockholders of the Corporation
must be effected at a duly called annual or special meeting of stockholders of the Corporation and
may not be effected by any consent in writing by such stockholders.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. Special meetings of stockholders of the Corporation may be called only by the
Chairperson of the Board of Directors, the Chief Executive Officer, the President or the Board of
Directors acting pursuant to a resolution adopted by a majority of the Board of Directors, and any
power of stockholders to call a special meeting of stockholders is specifically denied. Only such
business shall be considered at a special meeting of stockholders as shall have been stated in the
notice for such meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3. Advance notice of stockholder nominations for the election of directors and of
business to be brought by stockholders before any meeting of the stockholders of the Corporation
shall be given in the manner and to the extent provided in the Bylaws of the Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1. To the fullest extent permitted by the DGCL as the same exists or as may hereafter
be amended, a director of the Corporation shall not be personally liable to the Corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director. If the DGCL is
amended to authorize corporate action further eliminating or limiting the personal liability of
directors, then the liability of a director of the Corporation shall be eliminated or limited to
the fullest extent permitted by the DGCL, as so amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2. The Corporation may indemnify to the fullest extent permitted by law any person
made or threatened to be made a party to an action or proceeding, whether criminal, civil,
administrative or investigative, by reason of the fact that he, she, his or her testator or
intestate is or was a director, officer, employee or agent of the Corporation or any predecessor of
the Corporation or serves or served at any other enterprise as a director, officer, employee or
agent at the request of the Corporation or any predecessor of the Corporation or serves or served
at any other enterprise as a director, officer, employee or agent at the request of the Corporation
or any predecessor to the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3. Neither any amendment nor repeal of any Section of this Article&nbsp;IX, nor the
adoption of any provision of this Amended and Restated Certificate of Incorporation or the Bylaws
of the Corporation inconsistent with this Article&nbsp;IX, shall eliminate or reduce the effect of this
Article&nbsp;IX in respect of any matter occurring, or any cause of action, suit, claim or proceeding
accruing or arising or that, but for this Article&nbsp;IX, would accrue or arise, prior to such
amendment, repeal or adoption of an inconsistent provision.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE X</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings of stockholders may be held within or outside of the State of Delaware, as the Bylaws
may provide. The books of the Corporation may be kept (subject to any provision contained in the
statutes) outside of the State of Delaware at such place or places as may be designated from time
to time by the Board of Directors or in the Bylaws of the Corporation.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XI</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporation reserves the right to amend or repeal any provision contained in this Amended
and Restated Certificate of Incorporation in the manner prescribed by the laws of the State of
Delaware and all rights conferred upon stockholders are granted subject to this reservation;
<I>provided</I>, <I>however</I>, that notwithstanding any other provision of this Amended and Restated
Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote or
no vote, the Board of Directors acting pursuant to a resolution adopted by a majority of the Board
of Directors and the affirmative vote of sixty-six and two-thirds percent (66 2/3%) of the then
outstanding voting securities of the Corporation, voting together as a single class, shall be
required for the amendment, repeal or modification of the provisions of Section&nbsp;3 of Article&nbsp;IV,
Section&nbsp;2 of Article&nbsp;V, Article&nbsp;VI, Section&nbsp;5 of Article&nbsp;VII, Article&nbsp;VIII or Article&nbsp;XI of this
Amended and Restated Certificate of Incorporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">***
</DIV>



<P align="right" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>f39432a1exv10w2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN<BR>
(as amended April&nbsp;24, 2007, January&nbsp;29, 2008, April&nbsp;24, 2008)</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Purposes&nbsp;of&nbsp;the&nbsp;Plan</U>. The purposes of this Stock Option Plan are to attract and
retain the best available personnel for positions of substantial responsibility, to provide
additional incentive to Employees, Directors and Consultants and to promote the success of the
Company&#146;s business. Options granted under the Plan may be Incentive Stock Options or Nonstatutory
Stock Options, as determined by the Administrator at the time of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Definitions</U>. As used herein, the following definitions shall apply:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) &#147;<U>Administrator</U>&#148; means the Board or any of its Committees as shall be administering
the Plan in accordance with Section&nbsp;4 hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &#147;<U>Applicable Laws</U>&#148; means the requirements relating to the administration of stock
option plans under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any
stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable
laws of any other country or jurisdiction where Options are granted under the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) &#147;<U>Board</U>&#148; means the Board of Directors of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) &#147;<U>Committee</U>&#148; means a committee of Directors appointed by the Board in accordance
with Section&nbsp;4 hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) &#147;<U>Common Stock</U>&#148; means the Common Stock of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) &#147;<U>Company</U>&#148; means Fluidigm Corporation, a Delaware corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) &#147;<U>Consultant</U>&#148; means any person who is engaged by the Company or any Parent or
Subsidiary to render consulting or advisory services to such entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) &#147;<U>Director</U>&#148; means a member of the Board of Directors of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) &#147;<U>Disability</U>&#148; means total and permanent disability as defined in Section&nbsp;22(e)(3)
of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) &#147;<U>Employee</U>&#148; means any person, including Officers and Directors, employed by the
Company or any Parent or Subsidiary of the Company. A Service Provider shall not cease to be an
Employee in the case of (i)&nbsp;any leave of absence approved by the Company or (ii)&nbsp;transfers between
locations of the Company or between the Company, its Parent, any Subsidiary, or any successor. For
purposes of Incentive Stock Options, no such leave may exceed three (3)&nbsp;months, unless reemployment
upon expiration of such leave is guaranteed by statute or contract. If
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reemployment upon expiration of a leave of absence approved by the Company is not so
guaranteed, then six (6)&nbsp;months following the first day of such leave any Incentive Stock Option
held by the Optionee shall cease to be treated as an Incentive Stock Option and shall be treated
for tax purposes as a Nonstatutory Stock Option. Neither service as a Director nor payment of a
director&#146;s fee by the Company shall be sufficient to constitute &#147;employment&#148; by the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) &#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) &#147;<U>Fair Market Value</U>&#148; means, as of any date, the value of Common Stock determined as
follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If the Common Stock is listed on any established stock exchange or a national market
system, including without limitation the Nasdaq National Market or The Nasdaq SmallCap Market of
The Nasdaq Stock Market, its Fair Market Value shall be the closing sales price for such stock (or
the closing bid, if no sales were reported) as quoted on such exchange or system for the last
market trading day prior to the time of determination, as reported in <I>The Wall Street Journal </I>or
such other source as the Administrator deems reliable;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;If the Common Stock is regularly quoted by a recognized securities dealer but selling
prices are not reported, its Fair Market Value shall be the mean between the high bid and low asked
prices for the Common Stock on the last market trading day prior to the day of determination; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;In the absence of an established market for the Common Stock, the Fair Market Value
thereof shall be determined in good faith by the Administrator.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) &#147;<U>Incentive Stock Option</U>&#148; means an Option intended to qualify as an incentive stock
option within the meaning of Section&nbsp;422 of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) &#147;<U>Nonstatutory Stock Option</U>&#148; means an Option not intended to qualify as an
Incentive Stock Option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) &#147;<U>Officer</U>&#148; means a person who is an officer of the Company within the meaning of
Section&nbsp;16 of the Exchange Act and the rules and regulations promulgated thereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) &#147;<U>Option</U>&#148; means a stock option granted pursuant to the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) &#147;<U>Option Agreement</U>&#148; means a written or electronic agreement between the Company and
an Optionee evidencing the terms and conditions of an individual Option grant. The Option
Agreement is subject to the terms and conditions of the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) &#147;<U>Option Exchange Program</U>&#148; means a program whereby outstanding Options are
exchanged for Options with a lower exercise price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) &#147;<U>Optioned&nbsp;Stock</U>&#148; means the Common Stock subject to an Option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) &#147;<U>Optionee</U>&#148; means the holder of an outstanding Option granted under the Plan.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) &#147;<U>Parent</U>&#148; means a &#147;parent corporation,&#148; whether now or hereafter existing, as
defined in Section&nbsp;424(e) of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) &#147;<U>Plan</U>&#148; means this 1999 Stock Option Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) &#147;<U>Service Provider</U>&#148; means an Employee, Director or Consultant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) &#147;<U>Share</U>&#148; means a share of the Common Stock, as adjusted in accordance with Section
11 below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) &#147;<U>Subsidiary</U>&#148; means a &#147;subsidiary corporation,&#148; whether now or hereafter existing,
as defined in Section&nbsp;424(f) of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Stock&nbsp;Subject&nbsp;to&nbsp;the&nbsp;Plan</U>. Subject to the provisions of Section&nbsp;11 of the Plan,
the maximum aggregate number of Shares which may be subject to option and sold under the Plan is
14,800,000 Shares. The Shares may be authorized but unissued, or reacquired Common Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If an Option expires or becomes unexercisable without having been exercised in full, or is
surrendered pursuant to an Option Exchange Program, the unpurchased Shares which were subject
thereto shall become available for future grant or sale under the Plan (unless the Plan has
terminated). However, Shares that have actually been issued under the Plan, upon exercise of an
Option, shall not be returned to the Plan and shall not become available for future distribution
under the Plan, except that if Shares are repurchased by the Company at their original purchase
price, such Shares shall become available for future grant under the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Administration&nbsp;of&nbsp;the&nbsp;Plan</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Administrator</U>. The Plan shall be administered by the Board or a Committee
appointed by the Board, which Committee shall be constituted to comply with Applicable Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Powers&nbsp;of&nbsp;the&nbsp;Administrator</U>. Subject to the provisions of the Plan and, in the
case of a Committee, the specific duties delegated by the Board to such Committee, and subject to
the approval of any relevant authorities, the Administrator shall have the authority in its
discretion:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;to determine the Fair Market Value;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;to select the Service Providers to whom Options may from time to time be granted
hereunder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;to determine the number of Shares to be covered by each such award granted hereunder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;to approve forms of agreement for use under the Plan;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;to determine the terms and conditions, of any Option granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the time or times when Options may
be exercised (which may be based on performance criteria), any vesting
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">acceleration or waiver of
forfeiture restrictions, and any restriction or limitation regarding any Option or the Common Stock
relating thereto, based in each case on such factors as the Administrator, in its sole discretion,
shall determine;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;to determine whether and under what circumstances an Option may be settled in cash under
subsection 9(e) instead of Common Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;to reduce the exercise price of any Option to the then current Fair Market Value if the
Fair Market Value of the Common Stock covered by such Option has declined since the date the Option
was granted;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)&nbsp;to initiate an Option Exchange Program;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)&nbsp;to prescribe, amend and rescind rules and regulations relating to the Plan, including
rules and regulations relating to sub-plans established for the purpose of qualifying for preferred
tax treatment under foreign tax laws;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)&nbsp;to allow Optionees to satisfy withholding tax obligations by electing to have the Company
withhold from the Shares to be issued upon exercise of an Option that number of Shares having a
Fair Market Value equal to the amount required to be withheld. The Fair Market Value of the Shares
to be withheld shall be determined on the date that the amount of tax to be withheld is to be
determined. All elections by Optionees to have Shares withheld for this purpose shall be made in
such form and under such conditions as the Administrator may deem necessary or advisable; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)&nbsp;to construe and interpret the terms of the Plan and awards granted pursuant to the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Effect&nbsp;of&nbsp;Administrator&#146;s Decision</U>. All decisions, determinations and
interpretations of the Administrator shall be final and binding on all Optionees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Eligibility</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Nonstatutory Stock Options may be granted to Service Providers. Incentive Stock Options
may be granted only to Employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Option shall be designated in the Option Agreement as either an Incentive Stock
Option or a Nonstatutory Stock Option. However, notwithstanding such designation, to the extent
that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options
are exercisable for the first time by the Optionee during any calendar year (under all plans of the
Company and any Parent or Subsidiary) exceeds $100,000, such Options shall be treated as
Nonstatutory Stock Options. For purposes of this Section&nbsp;5(b), Incentive Stock Options shall be
taken into account in the order in which they were granted. The Fair Market Value of the
Shares shall be determined as of the time the Option with respect to such Shares is granted.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Neither the Plan nor any Option shall confer upon any Optionee any right with respect to
continuing the Optionee&#146;s relationship as a Service Provider with the Company, nor shall it
interfere in any way with his or her right or the Company&#146;s right to terminate such relationship at
any time, with or without cause.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Term&nbsp;of&nbsp;Plan</U>. The Plan shall become effective upon its adoption by the Board. It
shall continue in effect for a term of ten (10)&nbsp;years unless sooner terminated under Section&nbsp;13 of
the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Term of Option</U>. The term of each Option shall be stated in the Option Agreement;
provided, however, that the term shall be no more than ten&nbsp;(10) years from the date of grant
thereof. In the case of an Incentive Stock Option granted to an Optionee who, at the time the
Option is granted, owns stock representing more than ten percent (10%) of the voting power of all
classes of stock of the Company or any Parent or Subsidiary, the term of the Option shall be five
(5)&nbsp;years from the date of grant or such shorter term as may be provided in the Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Option Exercise Price and Consideration</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The per share exercise price for the Shares to be issued upon exercise of an Option shall
be such price as is determined by the Administrator, but shall be subject to the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;In the case of an Incentive Stock Option
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;granted to an Employee who, at the time of grant of such Option, owns stock representing
more than ten percent (10%) of the voting power of all classes of stock of the Company or any
Parent or Subsidiary, the exercise price shall be no less than 110% of the Fair Market Value per
Share on the date of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;granted to any other Employee, the per Share exercise price shall be no less than 100% of
the Fair Market Value per Share on the date of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;In the case of a Nonstatutory Stock Option, the per Share exercise price shall be no less
than 100% of the Fair Market Value per Share on the date of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;Notwithstanding the foregoing, Options may be granted with a per Share exercise price
other than as required above pursuant to a transaction described in, and in a manner consistent
with, Section 424(a) of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The consideration to be paid for the Shares to be issued upon exercise of an Option,
including the method of payment, shall be determined by the Administrator (and, in the case of an
Incentive Stock Option, shall be determined at the time of grant). Such consideration may consist
of (1)&nbsp;cash, (2)&nbsp;check, (3)&nbsp;promissory note, (4)&nbsp;other Shares, provided such Shares have a Fair
Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to
which
such Option shall be exercised and provided further that accepting such Shares will not result
in adverse accounting consequences to the Company, as determined by the Administrator in its sole
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">discretion, (5)&nbsp;consideration received by the Company under a cashless exercise program implemented
by the Company in connection with the Plan, or (6)&nbsp;such other consideration and method of payment
for the issuance of Shares to the extent permitted by Applicable Laws, (7)&nbsp;any combination of the
foregoing methods of payment. In making its determination as to the type of consideration to
accept, the Administrator shall consider if acceptance of such consideration may be reasonably
expected to benefit the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Exercise&nbsp;of&nbsp;Option</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Procedure&nbsp;for&nbsp;Exercise; Rights as a Stockholder</U>. Any Option granted hereunder
shall be exercisable according to the terms hereof at such times and under such conditions as
determined by the Administrator and set forth in the Option Agreement. Unless the Administrator
provides otherwise, vesting of Options granted shall be tolled during any unpaid leave of absence.
An Option may not be exercised for a fraction of a Share.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An Option shall be deemed exercised when the Company receives: (i)&nbsp;written or electronic
notice of exercise (in accordance with the Option Agreement) from the person entitled to exercise
the Option, and (ii)&nbsp;full payment for the Shares with respect to which the Option is exercised.
Full payment may consist of any consideration and method of payment authorized by the Administrator
and permitted by the Option Agreement and the Plan. Shares issued upon exercise of an Option shall
be issued in the name of the Optionee or, if requested by the Optionee, in the name of the Optionee
and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the
books of the Company or of a duly authorized transfer agent of the Company), no right to vote or
receive dividends or any other rights as a stockholder shall exist with respect to the Shares,
notwithstanding the exercise of the Option. The Company shall issue (or cause to be issued) such
Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other
right for which the record date is prior to the date the Shares are issued, except as provided in
Section&nbsp;11 of the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise of an Option in any manner shall result in a decrease in the number of Shares
thereafter available, both for purposes of the Plan and for sale under the Option, by the number of
Shares as to which the Option is exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Termination&nbsp;of Relationship as a Service Provider</U>. If an Optionee ceases to be a
Service Provider, such Optionee may exercise his or her Option within such period of time as is
specified in the Option Agreement (of at least thirty (30)&nbsp;days) to the extent that the Option is
vested on the date of termination (but in no event later than the expiration of the term of the
Option as set forth in the Option Agreement). In the absence of a specified time in the Option
Agreement, the Option shall remain exercisable for three (3)&nbsp;months following the Optionee&#146;s
termination. If, on the date of termination, the Optionee is not vested as to his or her entire
Option, the Shares covered by the unvested portion of the Option shall revert to the Plan. If,
after termination, the Optionee does not exercise his or her Option within the time specified by
the Administrator, the Option shall terminate, and the Shares covered by such Option shall revert
to the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Disability of Optionee</U>. If an Optionee ceases to be a Service Provider as a
result of the Optionee&#146;s Disability, the Optionee may exercise his or her Option within such period
of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">time as is specified in the Option Agreement (of at least six (6)&nbsp;months) to the extent the
Option is vested on the date of termination (but in no event later than the expiration of the term
of such Option as set forth in the Option Agreement). In the absence of a specified time in the
Option Agreement, the Option shall remain exercisable for twelve (12)&nbsp;months following the
Optionee&#146;s termination. If, on the date of termination, the Optionee is not vested as to his or
her entire Option, the Shares covered by the unvested portion of the Option shall revert to the
Plan. If, after termination, the Optionee does not exercise his or her Option within the time
specified herein, the Option shall terminate, and the Shares covered by such Option shall revert to
the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Death&nbsp;of&nbsp;Optionee</U>. If an Optionee dies while a Service Provider, the Option may
be exercised within such period of time as is specified in the Option Agreement (of at least six
(6)&nbsp;months) to the extent that the Option is vested on the date of death (but in no event later
than the expiration of the term of such Option as set forth in the Option Agreement) by the
Optionee&#146;s estate or by a person who acquires the right to exercise the Option by bequest or
inheritance. In the absence of a specified time in the Option Agreement, the Option shall remain
exercisable for twelve (12)&nbsp;months following the Optionee&#146;s termination. If, at the time of death,
the Optionee is not vested as to the entire Option, the Shares covered by the unvested portion of
the Option shall immediately revert to the Plan. If the Option is not so exercised within the time
specified herein, the Option shall terminate, and the Shares covered by such Option shall revert to
the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Buyout Provisions</U>. The Administrator may at any time offer to buy out for a
payment in cash or Shares, an Option previously granted, based on such terms and conditions as the
Administrator shall establish and communicate to the Optionee at the time that such offer is made.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Non-Transferability&nbsp;of&nbsp;Options</U>. The Options may not be sold, pledged, assigned,
hypothecated, transferred, or disposed of in any manner other than by will or by the laws of
descent or distribution and may be exercised, during the lifetime of the Optionee, only by the
Optionee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Adjustments&nbsp;Upon&nbsp;Changes&nbsp;in&nbsp;Capitalization, Merger or Asset Sale</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Changes in Capitalization</U>. Subject to any required action by the stockholders of
the Company, the number of shares of Common Stock covered by each outstanding Option, and the
number of shares of Common Stock which have been authorized for issuance under the Plan but as to
which no Options have yet been granted or which have been returned to the Plan upon cancellation or
expiration of an Option, as well as the price per share of Common Stock covered by each such
outstanding Option, shall be proportionately adjusted for any increase or decrease in the number of
issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend,
combination or reclassification of the Common Stock, or any other increase or decrease in the
number of issued shares of Common Stock effected without receipt of consideration by the Company or
other change in the corporate structure of the Company affecting the Shares that the Administrator
determines is necessary to prevent diminution or enlargement of benefits or potential benefits
intended to be made available under the Plan. The conversion of any convertible securities of the
Company shall not be deemed to have been &#147;effected without receipt of consideration.&#148; Such
adjustment shall be made by the Board, whose determination in that respect shall be final,
binding and conclusive. Except as expressly provided herein, no issuance by the Company of shares
of stock of any class, or securities convertible into shares of stock of any class, shall affect,
and no
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">adjustment by reason thereof shall be made with respect to, the number or price of shares of
Common Stock subject to an Option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Dissolution or Liquidation</U>. In the event of the proposed dissolution or
liquidation of the Company, the Administrator shall notify each Optionee as soon as practicable
prior to the effective date of such proposed transaction. The Administrator in its discretion may
provide for an Optionee to have the right to exercise his or her Option until fifteen (15)&nbsp;days
prior to such transaction as to all of the Optioned Stock covered thereby, including Shares as to
which the Option would not otherwise be exercisable. In addition, the Administrator may provide
that any Company repurchase option applicable to any Shares purchased upon exercise of an Option
shall lapse as to all such Shares, provided the proposed dissolution or liquidation takes place at
the time and in the manner contemplated. To the extent it has not been previously exercised, an
Option will terminate immediately prior to the consummation of such proposed action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Merger or Asset Sale</U>. In the event of a merger of the Company with or into
another corporation, or the sale of substantially all of the assets of the Company, each
outstanding Option shall be assumed or an equivalent option or right substituted by the successor
corporation or a Parent or Subsidiary of the successor corporation. In the event that the
successor corporation refuses to assume or substitute for an Option (or portion thereof), the
Optionee shall fully vest in and have the right to exercise the Option (or portion thereof) that is
not assumed or substituted for as to all of the Optioned Stock, including Shares as to which it
would not otherwise be vested or exercisable. If an Option is not assumed or substituted for in
the event of a merger or sale of assets, the Administrator shall notify the Optionee in writing or
electronically that the Option shall be fully exercisable for a period of fifteen (15)&nbsp;days from
the date of such notice, and the Option shall terminate upon the expiration of such period. For
the purposes of this paragraph, the Option shall be considered assumed if, following the merger or
sale of assets, the option or right confers the right to purchase or receive, for each Share
subject to the Option immediately prior to the merger or sale of assets, the consideration (whether
stock, cash, or other securities or property) received in the merger or sale of assets by holders
of Common Stock for each Share held on the effective date of the transaction (and if holders were
offered a choice of consideration, the type of consideration chosen by the holders of a majority of
the outstanding Shares); provided, however, that if such consideration received in the merger or
sale of assets is not solely common stock of the successor corporation or its Parent, the
Administrator may, with the consent of the successor corporation, provide for the consideration to
be received upon the exercise of the Option, for each Share subject to the Option, to be solely
common stock of the successor corporation or its Parent equal in fair market value to the per share
consideration received by holders of Common Stock in the merger or sale of assets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Time&nbsp;of&nbsp;Granting&nbsp;Options</U>. The date of grant of an Option shall, for all purposes,
be the date on which the Administrator makes the determination granting such Option, or such other
date as is determined by the Administrator. Notice of the determination shall be given to each
Service Provider to whom an Option is so granted within a reasonable time after the date of such
grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Amendment&nbsp;and&nbsp;Termination&nbsp;of&nbsp;the&nbsp;Plan</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Amendment and Termination</U>. The Board may at any time amend, alter, suspend or
terminate the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Stockholder Approval</U>. The Board shall obtain stockholder approval of any Plan
amendment to the extent necessary and desirable to comply with Applicable Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Effect&nbsp;of&nbsp;Amendment&nbsp;or&nbsp;Termination</U>. No amendment, alteration, suspension or
termination of the Plan shall impair the rights of any Optionee, unless mutually agreed otherwise
between the Optionee and the Administrator, which agreement must be in writing and signed by the
Optionee and the Company. Termination of the Plan shall not affect the Administrator&#146;s ability to
exercise the powers granted to it hereunder with respect to Options granted under the Plan prior to
the date of such termination.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Conditions&nbsp;Upon&nbsp;Issuance&nbsp;of&nbsp;Shares</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Legal Compliance</U>. Shares shall not be issued pursuant to the exercise of an
Option unless the exercise of such Option and the issuance and delivery of such Shares shall
comply with Applicable Laws and shall be further subject to the approval of counsel for the Company
with respect to such compliance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Investment Representations</U>. As a condition to the exercise of an Option, the
Administrator may require the person exercising such Option to represent and warrant at the time of
any such exercise that the Shares are being purchased only for investment and without any present
intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a
representation is required.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;<U>Inability to Obtain Authority</U>. The inability of the Company to obtain authority
from any regulatory body having jurisdiction, which authority is deemed by the Company&#146;s counsel to
be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of
any liability in respect of the failure to issue or sell such Shares as to which such requisite
authority shall not have been obtained.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;<U>Reservation&nbsp;of&nbsp;Shares</U>. The Company, during the term of this Plan, shall at all
times reserve and keep available such number of Shares as shall be sufficient to satisfy the
requirements of the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;<U>Stockholder Approval</U>. The Plan shall be subject to approval by the stockholders of the
Company within twelve (12)&nbsp;months after the date the Plan is adopted. Such stockholder approval
shall be obtained in the degree and manner required under Applicable Laws.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>APPENDIX A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Additional Terms and Conditions for Options received by Employees Resident in the Netherlands</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The additional terms and conditions detailed below are to be read in conjunction with the Plan
and the Option Agreement relating to Options granted to Employees resident in the Netherlands. Any
terms and provisions not specifically defined below for Employees subject to the laws of the
Netherlands will have the same meaning as defined in the Plan and the applicable Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Definitions</U>. Notwithstanding the provisions of the Plan, the following definitions
shall apply for Options granted to Employees resident in the Netherlands.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Acknowledgement Date</U>. &#147;Acknowledgement Date&#148; means the date upon which an Option
Agreement is signed and returned to the Company (or the Employee&#146;s employer if so designated by the
Company) by the Employee.<U> </U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Employee</U>. &#147;Employee&#148; means any person permanently employed by the Company or any
Parent or Subsidiary of the Company based upon such factors as are deemed appropriate by the
Administrator in its discretion, subject to any requirments and provisions of the applicable Dutch
laws, including the provisions of the Dutch Civil Code (<I>Burgerlijk Wetboek</I>). The term &#147;Employee&#148;,
however, shall not include an individual who, either by himself or through his Relative or through
a corporate entity, holds, directly or indirectly, 5% or more of the equity of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Relative</U>. &#147;Relative&#148; means immediate relative, namely one&#146;s spouse, parent,
parent of spouse, brother, sister, brother of spouse, sister of spouse or child of the person or
spouse.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Eligibility</U>. Notwithstanding the provisions of the Plan, Options granted to
residents of the Netherlands may only be granted to Employees who, either by themselves or through
a corporate entity or through his Relative, do not hold, directly or indirectly, 5% or more of the
equity of the Company. Consultants resident in the Netherlands shall not be eligible to receive
Options.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options may be granted to Employees in accordance with the terms of the Plan and this Appendix
A to the Plan as the Administrator deems appropriate. In determining which Employees may be
granted Options, the Administrator will take into account whether will
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">provide additional incentive to Employees and whether such Options will promote the success of
the Company&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Dutch Taxes</U>. Notwithstanding the provisions of the Plan and pursuant to
Section&nbsp;4(b)(ix) of this Plan, the following shall apply for residents in the Netherlands
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All tax and social security consequences and obligations regarding any other compulsory
payments arising from the grant, possesion or exercise of any Options, from the payment for, or the
subsequent possesion or disposition of or from any other event or act of the Company (or the
Employee&#146;s employer) or the Employee hereunder, shall be borne solely by the Employee, and the
Employee shall indemnify the Company (or the Employee&#146;s employer) and hold it harmless against and
from any and all liability for any such tax or social security payment, or interest or penalty
thereon, including without limitation, liabilities relating to the necessity to withhold, or to
have withheld, any such tax or social security payment from any payment made to the Employee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company (or the Employee&#146;s employer) is at any time entitled to withhold from wages
payable to the Employee any tax and social security amounts due with respect to the grant or
exercise of any Options.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;On the Acknowledgement Date, the Employee may deliver to the Company a signed written
notice in accordance with Article&nbsp;10(a)(3) of the Dutch Wage Tax Act 1964 (<I>Wet op de Loonbelasting
1964</I>) (hereafter: the &#147;Written Notice&#148;) with respect to the Options. The Written Notice will
indicate that Dutch withholding tax will be due upon exercise of the Options. If no such Written
Notice has been received by the Company on the Acknowledgement Date, any withholding tax will
automatically be due upon vesting of the Options.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company shall immediately send the Written Notice to the competent Dutch tax authorities.
Notwithstanding the provisions under Section&nbsp;9 of the Plan, if a Written Notice has been received
by the Company on the Acknowledgement Date, the Options granted under Appendix&nbsp;A will not be
exercisable until the competent Dutch tax authorities has received the Written Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Merger or Asset Sale</U>. Notwithstanding the provisions of Section&nbsp;11(c), if the successor
corporation (or any parent or subsidiary thereof) intends to assume or substitute each outstanding
Option in a merger of the Company with or into another corporation, or the sale of substantially
all of the assets of the Company and the rules and regulations governing Options granted to
Employees in the Netherlands (the &#147;Netherlands Options&#148;) do not permit assumption or substitution
of the Netherlands Options in the same manner as other Options, then the Administrator, in its
discretion, may provide for the termination of the Netherlands Options upon the consummation of the
transaction or provide for the assumption or substitution of the Netherlands Options in a different
manner than the assumption or substitution of other Options.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>APPENDIX B</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN<BR>
(Added April&nbsp;24, 2007)</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Additional Terms and Conditions for Options received by Employees Resident in France</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The additional terms and conditions detailed below are to be read in conjunction with the Plan
and the Option Agreement relating to Options granted to Employees resident in France. Any terms
and provisions not specifically defined below for Employees subject to the laws of France will have
the same meaning as defined in the Plan and the applicable Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to promote compliance of the Plan with the principles set out by the French tax
authorities in their regulations 4 N 2431 dated August&nbsp;30, 1997, in furtherance of Article&nbsp;80 bis
III of the French Code G&#233;n&#233;ral des Imp&#244;ts, any Option granted under the Plan to residents of France
will be subject to the conditions stated below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a matter of principle, any provision included in the Plan, the Option Agreement or any
other document evidencing the terms and conditions of an Option that would contravene any
substantive principle set out in Articles L.225-177 to L.225-186 of the French Code de Commerce
shall not be applicable to Optionees who are residents of France.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Definitions</U>. Notwithstanding the provisions of the Plan, the following definitions
shall apply for Options granted to Employees resident in France.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Applicable Laws</U>. &#147;Applicable Laws&#148; means the legal requirements relating to the
administration of stock option plans under U.S. state corporate laws, U.S. federal and state
securities laws, the Code, any stock exchange or quotation system on which the Common Stock is
listed or quoted and French corporate, securities, labor and tax laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Employee</U>. &#147;Employee&#148; means (i)&nbsp;any person employed by the Company or a branch of
the Company or a Subsidiary in a salaried position within the meaning Applicable Laws, who does not
own more than ten percent (10%) of the voting power of all classes of stock of the Company, or any
Parent or Subsidiary, and who is a resident of the Republic of France or (ii)&nbsp;any person employed
by the Company or a branch of the Company or a Subsidiary who is a resident of the Republic of
France for tax purposes or who performs his or her duties in France and is subject to French income
social security contributions on his or her remuneration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Fair Market Value</U>. &#147;Fair Market Value&#148; means, as of any date, the dollar value of
Common Stock determined as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If the Common Stock is listed on any established stock exchange or a national market
system, including without limitation the Nasdaq Global Market or the Nasdaq
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Global Select Market of the Nasdaq Stock Market, its Fair Market Value will be the average quotation
price for the last twenty (20)&nbsp;days preceding the date of determination for such Common Stock (or
the average closing bid for such twenty (20)&nbsp;day period, if no sales were reported) as quoted on
such exchange or system and reported in <I>The Wall Street Journal </I>or such other source as the
Administrator deems reliable;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;If the Common Stock is quoted on the Nasdaq Stock market (but not on the Nasdaq Global
Market or Nasdaq Global Select Market thereof) or regularly quoted by a recognized securities
dealer but selling prices are not reported, its Fair Market Value will be the mean between the high
bid and low asked prices for the Common Stock for the last twenty (20)&nbsp;days preceding the date of
determination; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;In the absence of an established market for the Common Stock, the Fair Market Value
thereof will be determined in good faith by the Administrator.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Subsidiary</U>. &#147;Subsidiary&#148; means any participating subsidiary of the Company
located in the Republic of France and that falls within the definition of &#147;subsidiary&#148; within the
meaning of Section&nbsp;L. 225-180 paragraph 1 of the French commercial code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Termination</U>. &#147;Termination&#148; means if the Optionee is an Employee, the last day of
any statutory or contractual notice period whether worked or not (provided, only the employer, and
not the Optionee, may decide whether the Optionee works during the notice period) and irrespective
of whether the termination of the employment agreement is due to resignation or dismissal of the
Employee for any reason whatsoever; if the Optionee is a corporate officer as defined in Section&nbsp;2
of this Appendix&nbsp;B, Termination means the date on which he or she effectively leaves his or her
position as a corporate officer for any reason whatsoever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Eligibility</U>. Options granted pursuant to this Appendix&nbsp;B may be granted only to
Employees, the <I>Pr&#233;sident du conseil d&#146;administration, </I>the <I>membres du directoire, </I>the <I>Directeur
g&#233;n&#233;ral</I>, the directeurs g&#233;n&#233;raux d&#233;l&#233;gu&#233;s, the <I>G&#233;rant </I>of a company with capital divided by shares;
provided, however, that the <I>administrateurs </I>and the <I>membres du conseil de surveillance </I>who are also
Employees of the Subsidiary in accordance with a valid employment agreement pursuant to Applicable
Laws may be granted Options hereunder. For the purpose of this Appendix&nbsp;B, when applicable, the
rules set forth for an Employee will be applicable to the aforementioned corporate officers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Stock Subject to the Plan</U>. The total number of Options outstanding which may be
exercised for newly issued Shares may at no time exceed that number equal to one-third
(1/3<SUP style="font-size: 85%; vertical-align: text-top">rd</SUP>) of the Company&#146;s voting stock, whether preferred stock of the Company or Common
Stock. If any Optioned Stock is to consist of reacquired Shares, such Optioned Stock must be
purchased by the Company, in the limit of ten percent (10%) of its share capital, prior to the date
of the grant of the corresponding new Option and must be reserved and set aside for such purposes.
In addition, the new Option must be granted within one (1)&nbsp;year of the acquisition of the Shares
underlying such new Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Limitations Upon Granting of Options</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Declaration of Dividend; Capital Increase</U>. To the extent applicable to the
Company, Options cannot be granted during the twenty (20)&nbsp;trading days from (i)&nbsp;the date the Common
Stock is trading on an ex-dividend basis or (ii)&nbsp;a capital increase.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Non-Public Information</U>. To the extent applicable to the Company, the Company will
not grant Options during the closed periods required under Section&nbsp;L 225-177 of the French
Commercial Code. As a result, notwithstanding any other provision of the Plan, Options cannot be
granted:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;during the ten (10)&nbsp;trading days preceding and following the date on which the
consolidated accounts, or, if unavailable, the annual accounts, are made public;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;during the period between the date on which the Company&#146;s governing bodies (i.e., the
Board) become aware of information which, if made public, could have a material impact on the price
of the Shares, and the date ten (10)&nbsp;trading days after such information is made public.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Right to Employment</U>. Neither the Plan nor any Option will confer upon any
Optionee any right with respect to continuing the Optionee&#146;s employment relationship with the
Company or any Subsidiary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Exercise Price</U>. The exercise price for the Shares to be issued pursuant to
exercise of an Option will be determined by the Administrator upon the date of grant of the Option
and stated in the Option Agreement, but in no event will be less than the higher of (i)&nbsp;eighty
percent (80%) of (A)&nbsp;the Fair Market Value on the date the Option is granted, or (B)&nbsp;if applicable,
the average purchase price paid by the Company for such Shares, or (ii)&nbsp;the exercise price as
determined under Section&nbsp;8(a) of the Plan. The exercise price cannot be modified while an Option
is outstanding, except as required by Applicable Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Term of Option</U>. The term of each Option will be as stated in the Option Agreement;
provided, however, that the maximum term of an Option will not exceed ten (10)&nbsp;years from the date
of grant of the Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Exercise of Option; Restriction on Sale</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except as otherwise explicitly set forth in the Option Agreement, Options granted
hereunder may be not be exercised within one (1)&nbsp;year of the date the Option is granted (the
&#147;Initial Exercise Date&#148;) whether or not the Option has vested prior to such time; provided,
however, that the Initial Exercise Date will be automatically adjusted to conform with any changes
under Applicable Laws so that the length of time from the date of grant to the Initial Exercise
Date when added to the length of time in which Shares may not be disposed of after the Initial
Exercise Date as provided in Section&nbsp;7(b) below, will allow for favorable tax and social security
treatment under Applicable Laws. Thereafter, Options may be exercised to the extent they have
vested.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">An Option will be deemed exercised when the Company receives: (i)&nbsp;written or electronic notice of
exercise (in accordance with the Option Agreement) from the person entitled to exercise the Option,
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and (ii)&nbsp;full payment for the Shares with respect to which the Option is exercised together with
any applicable withholding taxes and social security contributions. Full payment may consist of
any consideration and method of payment authorized by the Administrator and permitted by the Option
Agreement and the Plan. Until the Shares are issued (as evidenced by the appropriate entry on the
books of the Company or of a duly authorized transfer agent of the Company), no right to vote or
receive dividends or any other rights as a stockholder will exist with respect to the Shares,
notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such
Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other
right for which the record date is prior to the date the Shares are issued, except as provided in
Section&nbsp;11 of the Plan and to the extent permitted by Applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Shares subject to an Option may not be transferred, assigned or hypothecated in any
manner otherwise than by will or by the laws of descent or distribution before the date three (3)
years from the Initial Exercise Date, except for any events provided for in Article&nbsp;91 ter of
Annex&nbsp;II to the French tax code; provided, however, that the duration of this restriction on sale
will be automatically adjusted to conform with any changes to the holding period required for
favorable tax and social security treatment under Applicable Laws to the extent permitted under
Applicable Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Termination&nbsp;of&nbsp;Employment Relationship</U>. Upon Termination of an Optionee&#146;s status
as an Employee (other than upon the Optionee&#146;s death or Disability), the Optionee may exercise his
or her Option within such period of time as specified in the Option Agreement, and only to the
extent that the Optionee was entitled to exercise it at the date of Termination (but in no event
later than the expiration of the term of such Option as set forth in the Option Agreement). If, at
the date of Termination, the Optionee is not entitled to exercise his or her entire Option, the
Shares covered by the unexercisable portion of the Option will revert to the Plan. If, after
Termination, the Optionee does not exercise his or her Option within the time specified by the
Administrator, the Option will terminate, and the Shares covered by such Option will revert to the
Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Disability of Optionee</U>. Upon Termination of an Optionee&#146;s status as an Employee
terminates as a result of the Optionee&#146;s Disability, the Optionee may exercise his or her Option at
any time within such period of time as specified in the Option Agreement, but only to the extent
that the Optionee was entitled to exercise it at the date of such Termination (but in no event
later than the expiration of the term of such Option as set forth in the Option Agreement). If, at
the date of Termination, the Optionee is not entitled to exercise his or her entire Option, the
Shares covered by the unexercisable portion of the Option will revert to the Plan. If, after
Termination, the Optionee does not exercise his or her Option within the time specified herein, the
Option will terminate, and the Shares covered by such Option will revert to the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Death&nbsp;of&nbsp;Optionee</U>. In the event of the death of an Optionee while an Employee,
the Option may be exercised at any time within six (6)&nbsp;months following the date of death by the
Optionee&#146;s estate or by a person who acquired the right to exercise the Option by bequest or
inheritance, but only to the extent that the Optionee was entitled to exercise the Option at the
date of
death. If, at the time of death, the Optionee was not entitled to exercise his or her entire
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Option, the Shares covered by the unexercisable portion of the Option will revert to the Plan. If,
after death, the Optionee&#146;s estate or a person who acquired the right to exercise the Option by
bequest or inheritance does not exercise the Option within the time specified herein, the Option
will terminate, and the Shares covered by such Option will immediately revert to the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Non-Transferability&nbsp;of&nbsp;Options</U>. An Option may not be sold, pledged, assigned,
hypothecated, transferred, or disposed of in any manner other than by will or by the laws of
descent or distribution and may be exercised, during the lifetime of the Optionee, only by the
Optionee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Changes in Capitalization</U>. If any adjustment provided for in Section&nbsp;11(a) of the
Plan to the exercise price and the number of shares of Common Stock covered by outstanding Options
would violate Applicable Laws in such a way to jeopardize the favorable tax and social security
treatment of this Plan together with this Appendix&nbsp;B and the Options granted thereunder, then no
such adjustment will be made prior to the exercise of any such outstanding Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Information Statements to Optionees</U>. The Company or its Subsidiary, as required
under Applicable Laws, will provide to each Optionee, with copies to the appropriate governmental
entities, such statements of information as required by the Applicable Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Reporting to the Stockholders&#146; Meeting</U>. The Subsidiary of the Company, if
required under Applicable Laws, will provide its stockholders with an annual report with respect to
Options granted and/or exercised by its Employees in the financial year.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>4
<FILENAME>f39432a1exv10w13.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w13</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.13</B>
</DIV>





<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EMPLOYMENT AND SEVERANCE AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Change of Control Severance Agreement (the &#147;Agreement&#148;) is made and entered into by and
between <B>&#091;</B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><B>&#093; </B>(&#147;Executive&#148;) and Fluidigm Corporation (the &#147;Company&#148;), effective as of
<B>&#091;DATE&#093; </B>(the &#147;Effective Date&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>RECITALS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>Whereas</B></FONT>, it is expected that the Company from time to time will consider the
possibility of an acquisition by another company or other Change of Control (as defined herein).
The Board of Directors of the Company (the &#147;Board&#148;) recognizes that such consideration can be a
distraction to Executive and can cause Executive to consider alternative employment opportunities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>Whereas</B></FONT>, the Board believes that it is in the best interests of the Company and its
stockholders to provide Executive with an incentive to continue his or her employment to motivate
Executive to maximize the value of the Company upon a Change of Control for the benefit of its
stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>Whereas</B></FONT>, the Board believes that it is in the best interests of the Company and its
stockholders to provide Executive with certain severance benefits upon Executive&#146;s termination of
employment without cause or upon a constructive termination following a Change of Control of the
Company and to provide Executive with certain severance benefits upon Executive&#146;s termination of
employment without cause outside of the change of control context, in order to provide Executive
with enhanced financial security and incentive to remain with the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>Whereas</B></FONT>, certain capitalized terms used in the Agreement are defined in Section&nbsp;6
below.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>AGREEMENT</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE</B>, in consideration of the mutual promises and covenants contained herein, the
parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Term of Agreement</U>. This Agreement will terminate upon the date that all of the
obligations of the parties hereto with respect to this Agreement have been satisfied.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>At-Will Employment</U>. The Company and Executive acknowledge that Executive&#146;s
employment is and will continue to be at-will, as defined under applicable law, except as may
otherwise be specifically provided under the terms of a written formal employment agreement, if
any, between the Company and Executive (an &#147;Employment Agreement&#148;). As provided in Section 3(f)
below, Executive will be entitled to no benefits, compensation or other payments or rights upon
termination of employment other than those benefits expressly set forth in this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Severance Benefits</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Termination without Cause Prior to a Change of Control or After Twelve Months
Following a Change of Control</U>. If prior to a Change of Control or after twelve (12)&nbsp;months
following a Change of Control, the Company (or any parent or subsidiary or successor of the
Company) terminates Executive&#146;s employment without Cause, and, in each case, Executive signs and
does not revoke a standard release of claims with the Company in a form acceptable to the Company,
then Executive will receive, in addition to Executive&#146;s salary payable through the date of
termination of employment and any other employee benefits earned and owed through the date of
termination, the following severance from the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Severance Payment</U>. As provided in Section 3(c) below, six (6)&nbsp;months severance
pay (less applicable withholding taxes) equal to the pro-rata portion of Executive&#146;s base salary
(as in effect immediately prior to Executive&#146;s termination).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;<U>Continued Employee Benefits</U>. Reimbursement for a period of up to six (6)&nbsp;months
(less applicable withholding taxes, if any) for the costs and expenses incurred by Executive and/or
Executive&#146;s eligible dependents for coverage under the Company&#146;s Benefit Plans, provided that such
coverage is timely elected under the Consolidated Omnibus Budget Reconciliation Act of 1985 or
similar applicable state statute (&#147;COBRA&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Constructive Termination or Termination without Cause Following a Change of
Control</U>. If within twelve (12)&nbsp;months following a Change of Control (i)&nbsp;Executive terminates
his or her employment with the Company (or any parent or subsidiary or successor of the Company)
for Good Reason, or (ii)&nbsp;the Company (or any parent or subsidiary or successor of the Company)
terminates Executive&#146;s employment without Cause, and, in each case, Executive signs and does not
revoke a standard release of claims with the Company in a form acceptable to the Company, then
Executive will receive, in addition to Executive&#146;s salary payable through the date of termination
of employment and any other employee benefits earned and owed through the date of termination, the
following severance from the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Severance Payment</U>. As provided in Section 3(c) below, six (6)&nbsp;months severance
pay (less applicable withholding taxes) equal to the pro-rata portion of Executive&#146;s base salary
(as in effect immediately prior to (A)&nbsp;the Change of Control, or (B)&nbsp;Executive&#146;s termination,
whichever is greater).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;<U>Accelerated Vesting of Options; Restricted Stock</U>. Then-outstanding and unvested
stock options in Company common stock, stock appreciation rights and similar equity awards held by
Executive (&#147;Options&#148;) will immediately vest and become exercisable as to an all shares underlying
such Options. The Options will remain exercisable following the termination for the period
prescribed in the respective option agreement, which will not extend past the term of each Option.
Additionally, any shares of restricted stock, restricted stock units and similar equity awards
(&#147;Restricted Stock&#148;) then-held by Executive will immediately vest and the applicable Company right
of repurchase or reacquisition with respect to such shares of Restricted Stock will lapse as to all
such shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;<U>Continued Employee Benefits</U>. Reimbursement for a period of up to six (6)&nbsp;months
(less applicable withholding taxes, if any) for the costs and expenses incurred by Executive and/or
Executive&#146;s eligible dependents for coverage under the Company&#146;s Benefit Plans, provided that such
coverage is timely elected under COBRA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Timing of Severance Payments</U>. The Company will pay the severance payments to
which Executive is entitled under Section&nbsp;3(a)(i) above as salary continuation on the same basis
and timing as in effect immediately prior to the termination and the Company will pay the severance
payments to which Executive is entitled under Section&nbsp;3(b)(i) in a lump sum. If Executive should
die before all amounts have been paid, such unpaid amounts will be paid in a lump sum payment (less
any withholding taxes) to Executive&#146;s spouse, designated beneficiary, or otherwise to the personal
representative of Executive&#146;s estate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Voluntary Resignation; Termination For Cause</U>. If Executive&#146;s employment with the
Company terminates (i)&nbsp;voluntarily by Executive (except upon a termination for Good Reason within
twelve (12)&nbsp;months of a Change of Control), or (ii)&nbsp;for Cause by the Company (or any parent or
subsidiary or successor of the Company), then Executive will not be entitled to receive any
severance benefits and the sole obligation of the Company shall be to pay to Executive, an amount
equal to Executive&#146;s base salary payable through the date of termination of employment and any
other employee benefits earned and owed through the date of termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Disability; Death</U>. If the Company terminates Executive&#146;s employment as a result
of Executive&#146;s Disability, or Executive&#146;s employment terminates due to his or her death, then
Executive will not be entitled to receive severance benefits and the sole obligation of the Company
shall be to pay to Executive an amount equal to Executive&#146;s base salary payable to the date of
termination of employment and any other employee benefits earned and owed through the date of
termination to Executive, Executive&#146;s spouse, designated beneficiary, or otherwise to the personal
representative of Executive&#146;s estate, as the case may be.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;<U>Exclusive Remedy</U>. In the event of a termination of Executive&#146;s employment with
the Company (or any parent or subsidiary or successor of the Company), the provisions of this
Section&nbsp;3 are intended to be and are exclusive and in lieu of any other rights or remedies to which
Executive or the Company may otherwise be entitled, whether at law, tort or contract, in equity, or
under this Agreement. Executive will be entitled to no benefits, compensation or other payments or
rights upon termination of employment other than those benefits expressly set forth in this Section
3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;<U>Section&nbsp;409A</U>. Notwithstanding anything to the contrary in this Agreement, if
Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A of the Code and any final
regulations and guidance promulgated thereunder (&#147;Section&nbsp;409A&#148;) at the time of Executive&#146;s
termination, then only that portion of the severance and benefits payable to Executive pursuant to
this Agreement (other than due to death), if any, and any other severance payments or separation
benefits which may be considered deferred compensation under Section&nbsp;409A (together, the &#147;Deferred
Compensation Separation Benefits&#148;), which (when considered together) do not exceed the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Section&nbsp;409A Limit (as defined below) may be made within the first six (6)&nbsp;months following
Executive&#146;s termination of employment in accordance with the payment schedule applicable to each
payment or benefit. Any portion of the Deferred Compensation Separation Benefits in excess of the
Section&nbsp;409A Limit otherwise due to Executive on or within the six (6)&nbsp;month period following
Executive&#146;s termination will accrue during such six (6)&nbsp;month period and will become payable in a
lump sum payment on the date six (6)&nbsp;months and one (1)&nbsp;day following the date of Executive&#146;s
termination of employment or the date of Executive&#146;s death if earlier. All subsequent Deferred
Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule
applicable to each payment or benefit. The foregoing provisions are intended to comply with the
requirements of Section&nbsp;409A so that none of the severance payments and benefits to be provided
hereunder will be subject to the additional tax imposed under Section&nbsp;409A, and any ambiguities
herein will be interpreted to so comply. The Company and Executive agree to work together in good
faith to consider amendments to this Agreement and to take such reasonable actions which are
necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition
prior to actual payment to Executive under Section&nbsp;409A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, &#147;Section&nbsp;409A Limit&#148; will mean the lesser of two (2)&nbsp;times:
(i)&nbsp;Executive&#146;s annualized compensation based upon the annual rate of pay paid to Executive during
the Company&#146;s taxable year preceding the Company&#146;s taxable year of Executive&#146;s termination of
employment as determined under Treasury Regulation&nbsp;1.409A-1(b)(9)(iii)(A)(1) and any Internal
Revenue Service guidance issued with respect thereto; or (ii)&nbsp;the maximum amount that may be taken
into account under a qualified plan pursuant to Section&nbsp;401(a)(17) of the Code for the year in
which Executive&#146;s employment is terminated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Limitation on Payments</U>. In the event that the severance and other benefits
provided for in this Agreement or otherwise payable to Executive (i)&nbsp;constitute &#147;parachute
payments&#148; within the meaning of Section&nbsp;280G of the Code and (ii)&nbsp;but for this Section&nbsp;4, would be
subject to the excise tax imposed by Section&nbsp;4999 of the Code, then Executive&#146;s severance benefits
under Section&nbsp;4(a)(i) will be either:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;delivered in full, or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;delivered as to such lesser extent which would result in no
portion of such severance benefits being subject to excise tax under Section
4999 of the Code,
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">whichever of the foregoing amounts, taking into account the applicable federal, state and local
income taxes and the excise tax imposed by Section&nbsp;4999, results in the receipt by Executive on an
after-tax basis, of the greatest amount of severance benefits, notwithstanding that all or some
portion of such severance benefits may be taxable under Section&nbsp;4999 of the Code. Unless the
Company and Executive otherwise agree in writing, any determination required under this Section&nbsp;4
will be made in writing by the Company&#146;s independent public accountants immediately prior to Change
of Control (the &#147;Accountants&#148;), whose determination will be conclusive and binding upon Executive
and the Company for all purposes. For purposes of making the calculations required by this Section
4, the Accountants may make reasonable assumptions and approximations concerning applicable taxes
and may rely on reasonable, good faith interpretations concerning the application of Sections&nbsp;280G
and 4999 of the Code. The Company and Executive will furnish to the Accountants
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">such information and documents as the Accountants may reasonably request in order to make a
determination under this Section. The Company will bear all costs the Accountants may reasonably
incur in connection with any calculations contemplated by this Section&nbsp;4.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Definition of Terms</U>. The following terms referred to in this Agreement will have
the following meanings:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Benefit Plans</U>. For purposes of this Agreement, &#147;Benefit Plans&#148; means the group
health plans, policies or arrangements that the Company sponsors (or participates in) and that
immediately prior to Executive&#146;s termination of employment provide Executive and/or Executive&#146;s
eligible dependents with medical, dental, and/or vision benefits. Benefit Plans do not include any
other type of benefit (including, but not by way of limitation, disability, life insurance or
retirement benefits). A requirement that the Company provide Executive and Executive&#146;s eligible
dependents with coverage under the Benefit Plans will not be satisfied unless the coverage is no
less favorable than that provided to senior executives of the Company at any applicable time during
the period Executive is entitled to receive severance pursuant to Section&nbsp;3. The Company may, at
its option, satisfy any requirement that the Company provide coverage under any Benefit Plan by
providing coverage under a separate plan or plans providing coverage that is no less favorable or
by paying Executive a lump sum payment which is, on an after-tax basis, sufficient to provide
Executive and Executive&#146;s eligible dependents with equivalent coverage under a third-party plan
that is reasonably available to Executive and Executive&#146;s eligible dependents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Cause</U>. &#147;Cause&#148; is defined as (i)&nbsp;an act of dishonesty made by Executive in
connection with Executive&#146;s responsibilities as an employee, (ii)&nbsp;Executive&#146;s conviction of, or
plea of<U> nolo</U> <U>contendere</U> to, a felony or any crime involving fraud, embezzlement or
any other act of moral turpitude, (iii)&nbsp;Executive&#146;s gross misconduct, (iv)&nbsp;Executive&#146;s unauthorized
use or disclosure of any proprietary information or trade secrets of the Company or any other party
to whom Executive owes an obligation of nondisclosure as a result of Executive&#146;s relationship with
the Company; (v)&nbsp;Executive&#146;s willful breach of any obligations under any written agreement or
covenant with the Company; or (vi)&nbsp;Executive&#146;s continued failure to perform his employment duties
after Executive has received a written demand of performance from the Company with specifically
sets forth the factual basis for the Company&#146;s belief that Executive has not substantially
performed his duties and has failed to cure such non-performance to the Company&#146;s satisfaction
within 10 business days after receiving such notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Change of Control</U>. &#147;Change of Control&#148; of the Company is defined as:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;any &#147;person&#148; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended) is or becomes the &#147;beneficial owner&#148; (as defined in Rule&nbsp;13d-3 under said
Act), directly or indirectly, of securities of the Company representing 50% or more of the total
voting power represented by the Company&#146;s then outstanding voting securities; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;a change in the composition of the Board occurring within a two-year period, as a result
of which fewer than a majority of the directors are Incumbent Directors. &#147;Incumbent Directors&#148;
will mean directors who either (A)&nbsp;are directors of the Company as of the date hereof, or (B)&nbsp;are
elected, or nominated for election, to the Board with the affirmative votes of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">at least a majority of the Incumbent Directors at the time of such election or nomination (but
will not include an individual whose election or nomination is in connection with an actual or
threatened proxy contest relating to the election of directors to the Company); or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;the date of the consummation of a merger or consolidation of the Company with any other
corporation that has been approved by the stockholders of the Company, other than a merger or
consolidation which would result in the voting securities of the Company outstanding immediately
prior thereto continuing to represent (either by remaining outstanding or by being converted into
voting securities of the surviving entity) more than fifty percent (50%) of the total voting power
represented by the voting securities of the Company or such surviving entity outstanding
immediately after such merger or consolidation, or the stockholders of the Company approve a plan
of complete liquidation of the Company; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;the date of the consummation of the sale or disposition by the Company of all or
substantially all the Company&#146;s assets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Disability</U>. &#147;Disability&#148; will mean that Executive has been unable to perform his
Company duties as the result of his incapacity due to physical or mental illness, and such
inability, at least twenty-six (26)&nbsp;weeks after its commencement, is determined to be total and
permanent by a physician selected by the Company or its insurers and acceptable to Executive or
Executive&#146;s legal representative (such Agreement as to acceptability not to be unreasonably
withheld). Termination resulting from Disability may only be effected after at least 30&nbsp;days&#146;
written notice by the Company of its intention to terminate Executive&#146;s employment. In the event
that Executive resumes the performance of substantially all of his duties hereunder before the
termination of his employment becomes effective, the notice of intent to terminate will
automatically be deemed to have been revoked.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Good Reason</U>. &#147;Good Reason&#148; means the occurrence of one or more of the following
events effected without Executive&#146;s prior consent, provided Executive terminates Executive&#146;s
employment with the Company within one (1) year following the initial existence of the &#147;Good Reason&#148; condition (discussed below): (i)&nbsp;the
assignment to Executive of any duties or the reduction of Executive&#146;s duties, either of which
results in a material diminution in Executive&#146;s position or responsibilities with the Company;
provided that, it being understood that the continuance of Executive&#146;s duties and responsibilities
at the subsidiary or divisional level following a Change of Control, rather than at the parent,
combined or surviving company level following such Change of Control shall not be deemed Good
Reason within the meaning of this clause (i); (ii)&nbsp;a material reduction by the Company in the base
salary of Executive; (iii)&nbsp;a material change in the geographic location at which Executive must
perform services (for purposes of this Agreement, the relocation of Executive to a facility or a
location less than 50 miles from Executive&#146;s then-present location shall not be considered a
material change in geographic location); or (iv)&nbsp;any material breach by the Company of any material
provision of this Agreement. Executive will not resign for Good Reason without first providing the
Company with written notice of the acts or omissions constituting the grounds for &#147;Good Reason&#148;
within ninety (90)&nbsp;days of the initial existence of the grounds for &#147;Good Reason&#148; and a reasonable
cure period of not less than thirty (30)&nbsp;days following the date of such notice.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Successors</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>The Company&#146;s Successors</U>. Any successor to the Company (whether direct or
indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or
substantially all of the Company&#146;s business and/or assets will assume the obligations under this
Agreement and agree expressly to perform the obligations under this Agreement in the same manner
and to the same extent as the Company would be required to perform such obligations in the absence
of a succession. For all purposes under this Agreement, the term &#147;Company&#148; will include any
successor to the Company&#146;s business and/or assets which executes and delivers the assumption
agreement described in this Section 6(a) or which becomes bound by the terms of this Agreement by
operation of law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Executive&#146;s Successors</U>. The terms of this Agreement and all rights of Executive
hereunder will inure to the benefit of, and be enforceable by, Executive&#146;s personal or legal
representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Assumption</U>. It shall be considered a material breach of the Agreement if the
Company fails to obtain the assumption of this Agreement by any successor to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Notice</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>General</U>. Notices and all other communications contemplated by this Agreement will
be in writing and will be deemed to have been duly given when personally delivered or when mailed
by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of
Executive, mailed notices will be addressed to him or her at the home address which he or she most
recently communicated to the Company in writing. In the case of the Company, mailed notices will
be addressed to its corporate headquarters, and all notices will be directed to the attention of
its President.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Notice of Termination</U>. Any termination by the Company for Cause or by Executive
for Good Reason or as a result of a voluntary resignation will be communicated by a notice of
termination to the other party hereto given in accordance with Section 7(a) of this Agreement.
Such notice will indicate the specific termination provision in this Agreement relied upon, will
set forth in reasonable detail the facts and circumstances claimed to provide a basis for
termination under the provision so indicated, and will specify the termination date (which will be
not more than thirty (30)&nbsp;days after the giving of such notice). The failure by Executive to
include in the notice any fact or circumstance which contributes to a showing of Good Reason will
not waive any right of Executive hereunder or preclude Executive from asserting such fact or
circumstance in enforcing his or her rights hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Miscellaneous Provisions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>No Duty to Mitigate</U>. Executive will not be required to mitigate the amount of any
payment contemplated by this Agreement, nor will any such payment be reduced by any earnings that
Executive may receive from any other source.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Waiver</U>. No provision of this Agreement will be modified, waived or discharged
unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by
an authorized officer of the Company (other than Executive). No waiver by either party of any
breach of, or of compliance with, any condition or provision of this Agreement by the other party
will be considered a waiver of any other condition or provision or of the same condition or
provision at another time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Headings</U>. All captions and section headings used in this Agreement are for
convenient reference only and do not form a part of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Entire Agreement</U>. This Agreement, together with any Employment Agreement,
constitutes the entire agreement of the parties hereto and supersedes in their entirety all prior
representations, understandings, undertakings or agreements (whether oral or written and whether
expressed or implied) of the parties with respect to the subject matter hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Choice of Law</U>. The validity, interpretation, construction and performance of this
Agreement will be governed by the laws of the State of California (with the exception of its
conflict of laws provisions).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;<U>Severability</U>. The invalidity or unenforceability of any provision or provisions
of this Agreement will not affect the validity or enforceability of any other provision hereof,
which will remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;<U>Withholding</U>. All payments made pursuant to this Agreement will be subject to
withholding of applicable income and employment taxes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;<U>Counterparts</U>. This Agreement may be executed in counterparts, each of which will
be deemed an original, but all of which together will constitute one and the same instrument.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the
Company by its duly authorized officer, as of the day and year set forth below.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">COMPANY</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EXECUTIVE
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>5
<FILENAME>f39432a1exv10w18.htm
<DESCRIPTION>EXHIBIT 10.18
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w18</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>






<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.18</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>HARVARD UNIVERSITY<BR>
Office for Technology and Trademark Licensing</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Holyoke Center, Suite&nbsp;727<BR>
1350 Massachusetts Avenue <BR>
Cambridge, MA 02138 USA
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">t.&#091;***&#093;<BR>
f.&#091;***&#093;<BR>
www.techtransfer.harvard.edu</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">December&nbsp;22, 2004
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">William M. Smith<BR>
Vice President, Legal Affairs<BR>
Fluidigm Corporation<BR>
7100 Shoreline Court<BR>
South San Francisco, CA 94080

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Subject:</TD>
    <TD>&nbsp;</TD>
    <TD>Letter Agreement between Fluidigm and Harvard Concerning
Harvard Case Numbers &#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dear Bill,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm Corporation (Fluidigm) has licensed a number of Harvard University (Harvard) owned
patents and patent applications in the area of &#091;***&#093;. In particular,
on
October&nbsp;15, 2000, Fluidigm (then known as Mycometrix Corporation) licensed Harvard Case
Numbers &#091;***&#093;, all exclusively or co-
exclusively. Fluidigm has since terminated the license to Case Numbers &#091;***&#093;,
and the parties have mutually agreed in this letter to hereby terminate Fluidigm&#146;s
licenses to Case Numbers &#091;***&#093;. Fluidigm is retaining its licenses to Case
Numbers &#091;***&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm is concerned that Harvard or a licensee of Harvard may file claims in the previously or
hereby terminated Case Numbers &#091;***&#093; or &#091;***&#093; that cover inventions that are not
separately patentable (as described in 37 CFR 1.601(n)) from inventions covered, as of the date
of this letter, by the pending or issued claims in Case Numbers &#091;***&#093;. Fluidigm
further is concerned that Harvard or a licensee of Harvard may file claims in the previously or
hereby terminated Case Numbers &#091;***&#093; that (a)&nbsp;cover inventions that (i)&nbsp;are
separately patentable (as described in 37 CFR 1.601(n)) from inventions covered, as of the date
of this letter, by the pending or issued claims in Case Numbers &#091;***&#093;, and
(ii)&nbsp;would meet the criteria of 35 USC &#167;&#167;102, 103 and 112 for patentability in Case
Numbers &#091;***&#093;, and (b)&nbsp;are not now pending in any of Case Numbers &#091;***&#093;.
Fluidigm believes it has rights (through its co-exclusive license
agreements to Case Numbers &#091;***&#093;,)) to the not separately patentable inventions
and the separately patentable inventions, each as described above. Harvard is willing to address
Fluidigm&#146;s concerns through this letter agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Therefore, Harvard and Fluidigm agree as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Harvard agrees not to file, or to permit any other to file, claims in the previously or
hereby terminated Case Numbers &#091;***&#093;, that cover inventions
that are not</TD></TR>
</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>separately patentable (as described in 37 CFR 1.601(n)) from inventions covered, as of
the date of this letter, by the pending or issued claims in Case Numbers &#091;***&#093;,
without the prior express written consent of Fluidigm given after the date of this
letter.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Harvard agrees to first offer to Fluidigm for licensing any claims, filed after the date of
this letter, in Case Number &#091;***&#093; that (a)&nbsp;cover inventions that (i)&nbsp;are separately
patentable (as described in 37 CFR 1.601(n)) from inventions covered, as of the date of
this letter, by the pending or issued claims in Case Numbers &#091;***&#093;, and
(ii)&nbsp;would meet the criteria of 35 USC &#167;&#167;102, 103 and 112 for patentability in Case
Numbers &#091;***&#093;, and (b)&nbsp;are not now pending in any of Case Numbers &#091;***&#093;.
Fluidigm agrees to inform Harvard within one month
after Fluidigm receives express written notice form Harvard of the existence of said
claims (together with a copy of such claims) whether it desires a license to said claims, or
else Harvard shall be free to license them to other parties. Any license agreement
between Fluidigm and Harvard for said claims shall be negotiated in good faith by the
parties, have a field no broader than that now pending in Fluidigm&#146;s license to Case &#091;***&#093;,
have commercially reasonably royalties and be substantially like Harvard&#146;s then current
license agreement with diligence requirements based on an acceptable development plan
provided by Fluidigm; provided, however, if the parties have not entered into such
license agreement within &#091;***&#093; after Fluidigm receives express written notice
from Harvard of the existence of the applicable claims (together with a copy of such
claims), then any license agreement between Fluidigm and Harvard for said claims shall
be on the same terms and conditions, and in the same form, as the parties&#146; license
agreements with respect to Case Numbers &#091;***&#093;, (as in effect as of the date
of this letter), except that the license will be a non-exclusive license.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">C)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Harvard represents that all patent applications in Case Numbers &#091;***&#093; have been
abandoned as of the date of this letter. Harvard agrees not to revive any such patent
application or to file any other patent application under Case Number &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">D)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fluidigm agrees to pay &#091;***&#093; of Harvard&#146;s reasonable out-of-pocket patent
expenses, incurred after the date of this letter agreement, in Case Number &#091;***&#093;, and
within &#091;***&#093; of receiving an invoice from Harvard, up to a maximum aggregate
amount of &#091;***&#093;. Harvard agrees to inform Fluidigm if any US patent or patent
application in Case Number &#091;***&#093; becomes involved in an interference proceeding in the
US Patent and Trademark Office before Harvard has incurred any expense to allow
Fluidigm to terminate this letter agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">E)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The parties mutually agree that the license to Case Numbers &#091;***&#093; hereby are
terminated, and in connection therewith, promptly following the first meeting of the
Board of Directors of Fluidigm after such date, Fluidigm shall issue to Harvard &#091;***&#093;
of Common Stock of Fluidigm. Fluidigm represents that, in its last institutional
round of financing, Fluidigm sold shares of its Series&nbsp;D Preferred Stock at a price of
$2.80 per share. Harvard makes to Fluidigm, as of the date of the issuance of such &#091;***&#093;,
the same representations and warranties with respect to such shares as those
representations and warranties set forth in Paragraph&nbsp;4.2(c)(ii)(1), (2)&nbsp;and (3)&nbsp;of the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>license for Case Number &#091;***&#093; regarding the Shares. Paragraphs 4.2(c)(iii) and (iv)&nbsp;of the
license for Case Number &#091;***&#093; shall apply as well to such &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fluidigm may terminate this Letter Agreement in writing with thirty (30)&nbsp;days written
notice to Harvard and owe no patent expenses incurred by Harvard in Case Number &#091;***&#093;
after said thirty day notice period.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">F)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Harvard may terminate this Letter Agreement for any material breach by Fluidigm of its
obligations under Paragraphs (D)&nbsp;or (E)&nbsp;of this letter if Harvard gives express written
notice to Fluidigm of such breach and such breach is not cured within thirty (30)&nbsp;days
after Fluidigm&#146;s receipt of such notice.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">G)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any disputes between the parties regarding this letter shall be resolved in the same
manner as disputes are resolved under Fluidigm&#146;s licenses to Case Numbers &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">H)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The parties acknowledge that each party may currently have a different interpretation of
certain aspects of the three remaining license agreements. With respect to the three
remaining license agreements, the provisions of this letter are intended by the parties
solely to provide specific protective mechanisms regarding the subject matter licensed by
Harvard to Fluidigm. This letter shall not prejudice either parties&#146; interpretation or intent
of the three remaining license agreements, and is not intended to constitute the parties&#146;
interpretation of the three remaining license agreements (including the original intent
thereof).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Sincerely,
</DIV>







<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" style="border-bottom: 1px solid #000000">/s/ Robert Benson
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert Benson, PhD<BR>
Associate Director
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
</table>
</div>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreed to:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">PRESIDENT AND FELLOWS
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Fluidigm Corporation:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">OF HARVARD COLLEGE:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Robert Benson for
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Joyce Brinton
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Signature</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Office for Technology and
Trademark Licensing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">President and CEO<BR>
Title</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: Dec. 23, 2004
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Date: 12/23/04</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>f39432a1exv23w1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv23w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;23.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Consent of Independent Registered Public Accounting Firm</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report
dated April&nbsp;12, 2008 in Amendment No.&nbsp;1 to the Registration
Statement (Form&nbsp;S-1 No.&nbsp;333-150227) and related Prospectus of Fluidigm
Corporation for the registration of shares of its common stock.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">     /s/ Ernst &#038; Young LLP
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Palo Alto, California<BR>
May&nbsp;23, 2008

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>f39432a1f3943216.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a1f3943216.gif
M1TE&.#EAG`%>`-4F`(>/ODI7GL/(W]7=[1TMA?'R]WZ8R&ESKM/6YZ6LSSM)
ME>+D[RP[C5IEII:=QDI7G<+'WJFZVGB!MK2ZU]3<['Z8Q]_F\5Y_NF)OK+_,
MXZ"OTG.0P[&[V?7W^X^CS:F[VFF'OI2JT8FAS%-VM?___PX???___P``````
M````````````````````````````````````````````````````````````
M`````````````````````````````````"'Y!`$``"8`+`````"<`5X```;_
M0)-P2"P:C\BD<LEL.I_0J'1*K5JOV*QVBQQYOV"O@4LNF\_HM'K-;J_#\-'8
M3:_;[_B\?K^,A^=\@8*#A(6&='Y@@(>,C8Z/D(.)7XN1EI>8F9I.DV*;GZ"A
MHH:=<J.GJ*FJ9*65JZ^PL;&MLK6VMZ"TN+N\O82ZOL'"PVK`Q,?(R5+&RLW.
MFP@.`-/4U=;7V-41V]S=VQK9UL_CY'H%``PEZNOL[>[O[B3R\_3R$/#MY?K[
M:PX$^``#QJM'\)Y`?@@39BEP0*!#AP0+.E1(L2*4``\S`HQ8SV!`BR!#&I&@
ML>0[CO0\`A3)$J0`DS#9H9RG$E_+FPHQQHPYT]Y$_YQ`R[W<R;-G37A!DSXC
M211F3Q)'WRF=FDQ!4Z=&?^X)-VT!L@1<O5(-=!7KS*CNR`(4@$PG/+9C^90U
M^11M/KEKV^:-NT>@`@&``PL>3+@PX`J($RM&[,'P8+7XX!)S^TXR7SP"`Y1A
MUBB@Y3P"N"9(0]G=9Q.APYV^;"7SYDZNL*3F2IN:9<^!``#4C*9TN].Z\0%@
MO<4U*]A;$C28JV[X$-Q\@L/C?<8W.^``G1/'8IP+YRD"TC%O3@3ZUMVD]Q*1
M_D[[]M8!J6_Y'B7!>';NS>MA[TY^&>OK8"?<>]S%]]HDL4%AWWWKY*?>?NCU
M]J`0_+7C'H%3=#<?<E44\/\/@^0]-R$>%;+C'QD`JB,@/!=B&(6&6M#GA`,@
M-EC>B'>4N,Z)7*18PHKMN5@%C%G(V,1R-9;@8&2Y15C=B#J&**041&)A)!,^
M_NC8EH&))81^H(F6'I-%S(;-:E,R4>455RZ1)1=@!N,CFFG":>!Q"%KQ9G$X
M]C)GG55DF:1`=6EEQ)Y:Q.G+GX!.(>B@&V5U$!*(9J&HGWTVZB:D.Q4ZZ1&5
M%D@F+`A,<(T`!1#!:!H(""!--0X(X.4="PC6H6"S/LFI62C9Q4X2H5X!IIG7
MC-;$`K090:PUQCI1@'(?PL/``0B8L.H0RU9#9Q$(2"`H`0W$NJ6VZX5UQ`02
M6.7_#K@.I+H$`@``J(`$U2K1JKL7[<HK1[ZN`^Q'?(Y*H9-+#&53$5&6P.,1
M!4@0K4,!J/N6$0FW6$0!#H@'XI(3#W&.Q@`18+$0"4@<7ZY"^$.`50?@V\2C
M^K;C*<"@TFSIA`DOK*S-`^.C\WH/SP6D.R,+,4'0#')<V1#^E*2`RR9,`+)#
M!-0[Q`$$P+5``P1`K03,,:\S\TJ4\BPLS@0K83!2"*=M!`(FCS>TA4DTQ*G2
MIIFP0-P945<`DB81X.5+".@40`$!'/`$V&&7,/;!-9.=*-H^.[&V5&U7GH0`
M2#,W-WY(V'WWC9$ET'E&HR$P=4F*"W&`X@$`4,"/$Y2P_WCC&3W.=N20WRRP
M"3E;;G;P2"R8Y.<VCA0SWNTP#H\"QA/E;NS6)BZX"258O2GN$$E:8P#@AR_^
M^.1K_R7ETPDO^1#$OWWZNN&O#F5V.PM$[1#=OD^_B-R;9"SUX&L``TPP.Y25
MK7\!T1T"KV,$,+6O8,-S&P'UIPX"T.MB"7@4\J0TA"PIP'Q"V%M`#D"86<&$
M`0X0B^EB<C_4\(UN)DB7M627O00,T`G.BYD"%ZBB!J+O'3\CPN72DKGT&0%P
M^&B`UXA`HSA5C%L!Z5H2"O!"=AB0?P\A@`,H9I*6E2D@#0BA%B4PF@.8KF@C
M(9\:!4(`-;KQC>2C@!SG2$<Y<O\`CN'#W6D<*,$C#/$NZW%;[4;8A(3]B(L#
M8F)`FH6$/[)#`DK0B!*/L`"-_`4)\MO1$$Q'0@%PL@QKLD*;L->X/?ZP/^KK
M7<^,2(1,KJ-U3$"`$_<W!"2ZXX9+J*(Z?I:1+28A(UX\("OU=H``,C)@FO,.
MAY:@1Q_^[H%JBV`RA>#(=3!@B4B892([V,<B,$5:D60C"(OPJ&,B<IAL"&45
M1MG,(O!QFM%<WRJ!6`31P<.<X?P=\&@I!!\%<9ZWS"<^GH:E*(ZSB/2D@SJI
MP,Y2.K-C[.OF%^6Y3WCJCP!1N!9`8<A-?.!2";I4F$#?$<SM2>N@"$6E0N^D
MS#P%RC/_7'*,U]Z)SLU)<YBR!`@L<3B_;;KN4D.HI$Y'FK>7\5,)T%S#0J<P
MRG]1%#[/E*@0;YI0DBTRHSUE41&B]PZ"(H&*5_UEILAYU"0D50U+7<8R'64V
MJ$)THR9*Y>XB.DU#;HMW2TLI1X4PNX`HP("(BR(SQZJJLB+AK&E(:Q2:*LRY
MBNJM%:UI(ZFJ4K@R,%_Z?&(]V7C!$`*`@B7PI5CUV5BB.0&Q:%`L%!B+5\Q-
M+JKPM"E%'VA7K&:VK!X"T3^!2E:?(E6JH&3IAEQ*A6"Y-:]TE:P?*=N\0`)D
M`K:%;&2#5+_Q>)6HO^&I;\T*7#*H]@FL/51;AW3*YC:!JT1T_^XP#8G&UF97
MKZ`[`GJ)<K@F\+:PVSUL=^VTW]6N50K&)2]LE;O53R6WJJCQ:W21>V#3(N%H
M96DOZ:1;VKW^-K95L,``-LSA#G/X`2`.L8A!C`$/F_C$*.YP>'NKRK,-&,&A
M,Y1E=TF$O@+DBD@(Z0:5I(2_$>4`.#["?3NJU4+VEPD&*,4(GA(!)3OYR0G2
M;HN/6]0&FQ<)(I3Q="LKA)"6((Q.L">#9\QC)2S`E4E,`#:Q>]F"YO<(J)5"
MDDO!Y"?;^;\+=JWO()NPCQ8!P@\Y)XR;"!!\&D',8]ZRA6N,Z`JJ$0"QHO)[
MW5QD)L0Y"G/N1)WOS&DX?$!/XZ4"3?_A@3*&E$307)Y@%+?E8X'L>&2?A8<$
MUNQB"KLWOI8^\A(R/8E-=_K7(Q@`J)\J8#X3TF.Q/C5\-;EL"WGM'*#M8;/+
M3`2XP2-KB24LD:F;:PQ3@=>)\#6P[PR"*P18U!.:;_.F@;68H/K*'D/S.@A@
M1L`XH-T9>36WWH?2U]I:O&]^=URU`&X_B'O<3\Z`N4.=H0D)M2D4%#BS)PHI
M?7M,?Q/H]V,376%<+^'24"AX'`Z.\%)L``OG;K@^<]B\0;88L>J6F\0Y2.C[
M,"!V&A]R/PT+9UTK0>1P('G)$W$!"Z"<X50:434=,IREVV[:.HOY0XJ956XK
MFD$,@&XVM;W_\X!#?0M`#X/0AQX'A1^=V.@F[3<M62^GSURD20!T%ZU5=0=;
M=5<[G3#';YV\;A-8SDH>.]F_<`%A9R'E22>M"6HN$`8PTNU?[W&C0^9+C5Z]
M[T*P99(@^="]`[S2'_=Y$L(.!L$/7@0=V`+B7Y2I!>`[S=5U[.5IS`37@Y8!
MLMMVE:WL<0I%^RH@U#G=O:Y>&%N!]%\P/<(O$`*C#\-5`&A`^*9QUSL4`%T!
M>%@;`:#Q,SS+RU?A/#(TG.(/C_C\)2Z_^LOO?$V=8NVZK<AWW>^++#<OIH)!
M1\CD+USZ.P,!G7--4A!2_"=Z_E<+``@/W7<$FC=Q"3%_!U@+"W`ZGGGG!`]'
M4@7H;1$H)_BP@!<34H96#A"X@:]P@;O7!*H#$'Z&$"-(@JJP=!]D@9/'#B$H
M@OWG@K[@="700@\V@^P`9AGX=SAH"SG%1K%3#0<`?NMP7131@D-X"BSG-+2F
M#T[XA**0@)O'$E5HA:&`A?=Q25IX@URX"PL0A<]3@V.8AHT@``VH$0S066H8
4AYFP`,HA;^S``.'B@7(H!4$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>f39432a1f3943218.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a1f3943218.gif
M1TE&.#EA^`+>`^8``+/6ZW.'JZVXSMS<W;&QM8J4L20V9]K=Z9QG8R(N5RA(
MA[>.;^?GZ/W^_21">1<H5"E3E6MUCA$A22(X=8R*C9NLRW%N<,;'R3-%>%)H
MDTE3;456C,ZOGY:GN6AZK-7H].KHVTM+4LC+VC5)A04%!N?>W2HJ+S-8F=+.
MGE=MI1@R97"A:A$70SA2BRE:GW20PXZ<PE=D>.?K]@<2*?OY\38_4S-#:J28
ME,S6X.[X_2$G9"0YA=;6U!,B,H1Z?*VFH#$Y:6!85Q1%AA@Q6C5EIVMD7]'.
MSN?>Z$@V4!5">+C`N2E2C*&?KL"]Q(.T@RA":-[HVV)8:R<I<3QCF-;.V#Y0
M>A)9HS\Q,1P5%`<B1C,X=H(Z/O+OZ3A.9,W6S$5=H2F8SN[WZJO`WQLP0P]D
MK"8A(!=$51H843IL;V-=B!@8(3-#C?#O]R="C2UO5UAZ6C4G8`@C4R158**A
MPP6!O"E+<RUYO(^]UVN[YC(I=`LQ/@8Y9A!C2AYBH3@\/QT86R'Y!```````
M+`````#X`MX#``?_@#4/"82%"0^(B8J+C(J&AHF/A8V2E9:7F)F'C)J=EY&>
ME*&#GH^BI9VGFHBHK82JF;"2CJZ0B[6QG+FDJ;J]N+*XMK>CO*^^PL#(N\G-
MSI6LQ;2N#X(2U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ
M^^:$_/\``PH<2+"@P8,($RI<R+#A.'\.(TJ<2+&BQ8L8,VK<2`\BQX\@0XH<
M2;*DR9,`#Z%<R;*ERY<P8\J4IW*FS9LX<^K<R3/E@YY`@PH=2K0HRYI&DRI=
MRK2ITWA(GTJ=2K6JU9U1KVK=RK6K5X=9OXH=2[:LV7-ASZI=R[9MU;1N_^/*
MG4MW)MRZ>//JW5OQ+M^_@`,+ON=WL.'#B!-W*ZRXL>/'>!E#GDRY\E>/EC-K
MWFP5,^?/H$,']2RZM.G31Q.@7LVZ]4?2KF/+GET0-NW;N'/35%T4D>[?P)7:
MENF[\L]]Q[<F1[D\>,+F_7CK+$Z9.C[H(ZT;9;'MC/=LVIT7#%]NN/CS/+%?
M.X-^I7GBZMNS)$^TA_T>+.Q?P[^9?LCXX;PGWX`PC:%!%`@>B."""(;0'X`?
M0?B-@`16N%(-3."@X054X"`"%52(H&$!%KXF78DHNN1'$PTTD$,.+<;X8@-,
M2&B1C;%1F.*.'*W8`!LYL$%#BR\"F0,3/&*D8_\Y.";II#P^PDC#D`T,2>4-
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M"!_\JCC+XOH/A.<.VL3_IS+(<*B++B*[CL`?@].P/0V/C(ZO(I=\Y[X1QB,N
MR-_6JBL[_:+,G,3(49RPLB[?E\U]0`<M]-!!US!'QDC+P`8;&3/-Q!A$ZZ<?
MQ`H#]"]V,-<+8-8G8UVU.BQ'Q+6_$II,,\4U0WOM.:Z:;#.O!^/<[;K,CII<
M#V/4$$(4%O3==P2`!R[XX'[[/?CAB!]N0>*`]ZT!O6N3#+#=]'A;L;_/^?JV
M!)N7MR5(YM93<=G8+AQRW`NG?>>M$`><LMV=SVKVSN.&7G#L,DO`@H$^$"`"
M`Y\&+_SPQ!>?@P@AV#<&U%,SKX'&QKOK,><_X:YULVY_K>O8<8\]<NF3:Q[Y
M_[6^L7QY10B?GWNLT.'8I"(%H]MU^S.S7[;LO,JJ^=;U4JW]ZW!CVW%J$`$"
M0`]&&XN1`A?(P`8J\``U^`8+6*`!!"IP1D2B$=F\9[G_`5!D[5`?YE!7+NY1
M;W69@E78JI<1[=A(A.-+':WN1S[YS>IV[J,A_O2'-;3Y1E4]Q-_I>'9"A_D/
M72^\1A<*<(`<*$U,5(J>%(O7`!%$L'X22`,;AB4\(L&(1$@DH>G2`3\ROA"&
M(+QA_[[7JNXY2XBO>V,8;R<!\SB+7&:;G?VPV,;6Z1%["TEAP-#XL1]&#)#W
M6$2L4G8-`Q'`B1J#H@,G24D&XN"*7ZM@`_74@`+0C_]DQRDC&><VQB+.8Y`=
M'.'VD/A'/B+"`)]C7[(*:<)!`NQLH819*^-GQ&8]S(V5(YO+Y#8N5H+,-RP(
MP=&8MD5)5O*9D[SD-N*@#4TRD)-@=)W+5"G&8=I0=+;<5@]S-4YN;A.)8?N/
M+[NIQCTR9(;$%.<W%UG*7LKRFZMCFSU92)@"O$AC-.!"IZ!)T`9>L@?:H&8V
MK.G`*_62>[:+5CPU0I_9[?);I-A(J@Z91GN>,F<F;.<IM3E'1B+R9/WS8$?7
MR4YO8B,&!QA6B^+EIH+:M$4'-:)"L<'03;:H1EW+GT?M93W(E?*B<*39*CDG
MTI%^,YT3$]\H.YJ]E2*5E:#_+.GWMA;.EA*1?'0CZ?MHF=5K)``&0"J4L6[*
MUIPRE6!12.`U?PH[H2*GI!*=)T85AM3B1+1RN<0&5,G:J%"V)*3\T```<D`E
M(=64K3:5)L]Z$%=H>I(KB/7H29I#FJM^$'MU-2GU0-I'E.*5I2L5;5)5.UJC
M'I6>HC4L:&GW5:6.(0(?B%%-J20CN4)V@9*M7V7GJL!LIO:77MWK:6,X.;VB
M5EG4`9]F=P;#3[;NM+"YE6>G&U6LL><G8S#!)B2PO)^<8;L;!,=.1ZNZY;XU
MNB88@TJ69P(3(/0GZC)B%AZP7N=ZU;K^7>U)6XO%B3*7M<T];AC]P(0W09&F
M-"B2_V.-1>$*6WBM.#"`$;6C`2Y`\<(TZ!.KM"M2O\K1G&]-\?LV*N"8?="%
M2]6>S0++RZ/&SC:937%#V`.$-%@@#4`&<@06EP$;<'>8^?H)=[33W__Y9SDV
M6!S@TC!DOZ7!R,E-,'+-F+,:DO*>-2"`@RW,Q=].$H(3W,8$N:,!WNJ63$,"
MZG6[/#<.PM./A?3R;K@\D"P$)`$6T!C2E@:I'!P@`K$D<&G7=T)"FE+1Q(PN
MBKF1!BX2&F,1"*.C9^G:>8I0JGPF\/[4@T)2T[A[23U.#T+`HMU6>`!-N(`(
M+D#K6MOZUK*>-:UU;6L15$`#-0BVL(<=["CD6@2Z1K:MC?]``5!+FLXZCC:C
M76E@<9*:C]*&;I:=*UU5"G(QB:YQ0/S<XCD_-#E%`!*<(44#&40`H8]&H^44
M*;MG__66HD9C!'IK)0_GX-WG5G!$@VC.Z.+QU-T$E[GXMTY1BE+'Q>F!!H3E
MZC<QH``:.%#&-\[QCF<\01[G>`P"P`0FS&$.)3_YR4M>@"B$W..8S/9X7/AD
MVBU<=-/N=A\?3O,`WQ/;V7@/>DN("'*7>X\/L``-PA`I"#.=`1:`]\-373UN
M+9P1*;7/FKDC`?Z8U)#7ZT8$`DKF'/@@O@\X+PNWOO6JT1O21]_>&3<,8#@^
M.^$D_JKMROCV1]=[/QH0`<>NZ<3_"-@7WO#P43/=3*3IZ;FI^(YVWU,Z=;^K
M%,4"VR@*Q6AB@[?-VVZ?M.45O0VA#QVLI]^>TBD,10:DX;OGJSPPPR[[:]1@
MXR$(`<S#A[K+.?PX:7!UL7YD^%`>XO8:R'W(:W!?0VH>U;.O-ZAC*]OT)IC%
M[AU]HWD/_;"G-/`R?7,8EA:`,43^'"9@T1;)C"ANMN_:+9[ZY.U.GMJ37O3:
MSGY*HR_,_N_=ZD\&?Q"'5S^D-=@G;794>SG6#?E11\3V@!`8@5U0`^;G&U$`
M9S1`:`T@`Z^G?;^G5:AD3.2A`15`:TUP@BC8!&(0`>9'>;)%<P9W#<''>&["
M!@#G,&,0_P,"@(*W)@`"D`92YS6]%X.C$WO:,D(PF$L(1U+Y%WV=)W=/Z&G8
M5QS@AT&Z%09!4G[G!84TIC[!\B,"16:4\C),:$PQEEZ;9F)Q-$[O1W?<!H"_
MDH1S5%'P0X9_AT]BQ88&B(?0(2`*R#72M3LU$`4^P`05X(,IF(B*&&NUQH-S
M$',6\"+&\B[N=H;V)W?NQPU1(`,.Y$3E1WO[(WTX,X/A5X.9%C?V$0%6>$'_
M5H&0=G4$>'4WQTYPV%6-%H.TJ(:KU7EDZ'D@V(;6)P%5Z%LN8H-C`'O2)X+3
M50,L\B*=PGK3<RYUUXLR]G91"()-)7M@1W^81V\'2$)%^'>G5O]YUZA=_`2.
M,)APT#5_G+4EX=B$Y@9TER.($2``.'!`Q'A3!Q`"+3@&D;A6+C(EE8AM/(=P
M?N<JE&4D1>)%,O")=_B*XB@Q^^9%'#,D-M@]J1@\4R(\+*B&!7F-+?6!!^F+
M_><P=CAZL/*.&U1UMIAOF'-OCU:%G>AN"?!=W`=WVO`H[.=XZMA]\58W<!B2
M2BA@2LAW!"=YZZA-T@B2FN6-3-E:2RF*2FF.VF>`*EE')])WNS1BWH<-!"0`
M3?0I6,A8!'5A#;"/Z!*)[(:%+L)T`XF)_->+:>@;E"6)%>:)%2B2DJ=YS3&1
M&KF1%\E4/]$#JMA`G_)N?(E5/IF,J!;_3BFI?]O7?57G1LZVDB&(A$;I5P_I
M=ODEC((W285WC,H8F5A%;^TBEE,2*0AT69=YA\\'EW%9B_A7D#(4A;CH>:B$
MFT<FF?)'F4JI1M3HFT-9E<Y'F;FC0NXX?PJF3WMH>P$0EB["!?'R82!6G4.R
MCRV8=,ZX=`CDEJ<(A8K)FT$IA7095XQUEPV9ER?YBKBY')7&1>=I**?(0H29
MCR\"<*%XB^$IBZU9BV7(F%IFC9LCH#UWB\.9;Z.34,<Q<3Y5C"S('L89H46$
M=:?Y*:DY(T<R7A**H/T9C/>7D@(:B]^(CGK9G-F6F;HX5'+I;'K9GCXDH0$H
ME_X'"I:Y>4JU_X<LD``1$)8@5I;4>9W\>#!J228,&0$V*8JGI9L^.6I=9YX6
MYHDFH)^2N9)FB`WO.2QKU8HI5I^ZM4#_UGR*^3(_6:._V)CZAW4!^GMYJ(L%
M:J"<-VJ=TYD,"IK&:)DE":+P\R@8Y&9,4!/.AXL&:HW6QZ(L68>`ZJ8[AZ8X
M29I)*9[N5YPC.9KGUE7/`GTIJF)JZIHT2J8#5IMWEUZ4=0%.=)[2"6&,1TE6
MLE;[&$J1^&%0Y&X0*I65N8YK6)?Q65-XB6"-(%+!YT59.I_8P*4.)B,W*%6)
MF93V1X>>>I*&JJ)3J:BSF&J_^&D\)7@51R1U*H('V`C%H:=O%B,U0O^@^<E_
M7+BMXCJ@NTI'Z,A7CRE$`%BESNIPM!69XPF5+(FI6J6M9U0^&BJIY0:4\KJ'
M"4`!32.=%69F#^0@0OJCQ6*#L2J<P2F4X1-8E<5)+I*>TP2HW"I=8T>DP\<&
M/O!=^468:L5X7_I6.[64X*-(ZG.H;_J2T/J"<IB9OOF0<KA/1<F7R0%^!XNM
M+`BQZ1@W_?6%;S9\=*4NZ1*,5PFG6GF.5#FIW(I@HC:C3XMWY"B;FNI])!FS
M=/=^<K.Q(VH=QP"GM-J5M0E`838L!DMA1W``#)`T&?.V&7,`&?,!!_`!'X`T
M>2L&&E`<JW=A#OM>>'J5E/>FKI,&,55FPY+_GC`9M5KY5A.Y)V]B@XC72!'`
MB0ST3YG&=05X/;=9KR5YHI!JKR(YNFDJG#;KM8;+2BTHI5T7>.=9LEQ4?LT'
MMF9('E^X?E5"4^`:M4N*-F&JC096.BS+CN,H5OLI?RO;IB@*BSZWNHRZ8>ZE
ML;P8.^W8K.2ZF-H[L<+KF8.G0`$5!G/`..0[.&D`!&_UCZF:0>ZV9`9YDQ^*
MC8*Y:A3`!`5``?A;`/JKOQJ0EZXTAUC'3Q;06Y)[LD&G`11PO_FKP`40`(_#
M=5/*>0#LKQ(0!Q:,9UV[O7XF/M&ZC5,;K15,35/H?$B+"#T0I<H"-1H@!A@4
MGTX$)&<'P81U!1>0_X%NLG1$*F?-Q:0VA+7:ZWL#ZKI->[/@R)LCJ;.@Z+L>
M*KS#*:9*"XR!6K.M,[8?>91Q9Z=MI`'-V*5BP@`^T+KSU()3@PTRG`CJZV`P
MTKZ6JJ1?0QZ=N9Z#,`:XD@#^&[TN";7<$+DSPELGFTO^L#SEQ53R-:FA^U!#
MD*[>8,']Q3K8(,<BVI7559S*J;*/.IP)$%_;$%[U)7$7`[X;J;GUA<+I@%"`
MW'5(0`!;=&E!LC1*\S29;'YXLSP<>J?E6$Z+::Z%;'E1N<8>>L3NNK57F\M5
M^IKTQ[QX"J]M3`J*BLR=:I4VHL7?FX&.!75@O)MP><:XNH$1P+F'VIN[>/_!
MIL1?398-97R@`&S.WJ#'4D*L]Q4WC@R_4LK(X0RP*0L=ZR7+OKQ_NHR9XSHK
M]?QBQY$`:>`#B.,#!FW0-X`#"50L[B(#!'#0$!W1$BW1@7/0@.,#?U,X5?8W
M$3#1!GW1!AT%NURF'LBD1;BFF\FHK_FN*1VQ)&K.P7RF+,W,+CW+)[V9T9"]
MKOMXD_/.X`#-"^U89L?/EZ@-V!Q%VNR^=JQV(QK"BOS46/?4*9L-$'JIGH8N
M*M&>V7"E>\S.[+73-P3%G4FZN6S+'B75S%QO:M>O)::M`'I_W%#"W0/.-B``
MQ).!3[0TP]I;1@(D"CE%@%U%R;,-I,PY4;!%T4/_5ZE4E;J\:8':S]NKK\:;
MF-:[H32M<_,\Q&;K;<N,S)<#$9-\M3>]5,I935M<M)'B`\'KP;>DG3>,U`/I
MF(CP'<J;#5*=7RSKU!:LE,B(DRDZ"+K#>V?`U>M,)/B)M))],)OP?CN%VY^K
M'B*LSRB;+HD@PGRG-=[A'=JH57#!Q%0[E/EE`V+04$("1<]HLA+63`B[0!"$
M4)R[#3TU2>'JE,#<.2KK.KZ8V[U\D';JQ.$)HT[[E)[-0TVLU86<J==-IF^'
M&9.=A*J[AC]]VE4R8697J-6W-JZ]OA&FS6[(#=Q1N_V)(U`=W$$G'57\W_L1
MR\OC,]F@S@5\W+M]7;3)_PTJ'EXJKG7,"5;/ZQV(QRU/S:BPK#S[@;HJS8N6
M*@',^*.FRGJ/Q8K6>:H+=&%6))@3>@UMQK`4=@/I.N/2B*0_/)2(3+;_;:AA
M[K7]')67B*9I;IL.SH3GNIX`7N(&OM^37;9H!,V%DN<;Z0,@_"I'725I_)W\
MN@NY^4.:8'Z*S#F54`.F<*]0*;AY$P(Q$`$);'+Z&P`1$`,A0(%91,`7=-R"
MQ>B?L*'B$FP:,.D!L+_Z2P%#%@7!AL_HLCR%`,BO4.*80%+R=7M10&41`&3`
MQN@]K%!^E0"FONN]G@8Q`&QT;)S#/I7X=`TL4`,4]^0]^R/J398-^DP'&URV
M1/]!4*[A0$6@".I';#RC\HNHLP>V=W>L,/K2O.RO0"S;;J>F7+M]QRRIBI0`
M!D#$:6W'6S[GVD!!K49V,<)T#:#:,C?/K8+-"_26OJ$!,%!R$B_Q,#`':2#'
MQUL^$8!R$R_Q<X!QIM0%'-_Q)=<!,=`#@DH=/9``&E"/!]!,&]/7(L`$4>`'
M`QQA>VK<[[R@(]_Q)Z<![NLZ[#$&?A`":3`']ZB!7LHT."``/E`$+I<@#-(W
M!\T$`:`:X%6_!4#R)L<$S&=64),W$5``3?#RP</T3!`!_8N47<?R$5`!(J`T
M"BD#'L($%D"!\D5C+(_LF%33MC?MT-3D46ZTZZU`5H3_\B5YY8/O8#I<Y(^*
MC2B:M<G[[K\[?<\]F>0*ND:.[HT]^<&[QB.VTH6^0?K.[Y8-UHAZ*[6N9JP6
MD%.BUTQ7X9WMY['+>`[_$Q&0](2V-$S3D!IJ;W7D3WY]]FP@`FFP#5%`MX/&
M3#+P`9\8HFVO`040]Y]2C!LY?A@S\P3PR8<211WISI<K][S/RA^0:32;H](O
M`G1;_9.KWL/"!@QP`#AP`/1?_W++-!^0`P(003\!"#5-.3(Y;&PYAH4'(3T/
M$A(/&@$"!XB).32:-)@'8A$UD0]G#Z4]8QH%(@<REYBO.0<"H)"BD),%`0$%
M$3:VD'&ED,*U-1<-FS0-R\S-_\O*SLS)T=35U3@UCK6_M]#.RIK+3(^UI<2B
MY.;;YNG"ZNS#\/'EY_+SZMSLQ/CXZ^WQ^MKU.\<-W39T`<D9I*>P'L)YO_C9
MB^1O7<2&`1D^2)"@'\"#``F&!)E0)#V*!UF$$$"#2S)P87+X>-31H\5R%2%9
MR`3.F8P(.,=$.)`H69B8,B@D0*B0XB,_!9Z]7'8@S;H>461(HW&4T($(8T(^
M.A>B`(Y"13>Y?,D&&INUF)RQ`5INC(D(B9I!2P36'3Q4!2ZTS2LUV=J6UAKD
M+9I70"A(?@@H#D?C$")&)B3TJ!%!A*L<R,!I"L,UT8$"H<RQ,!%%%2)7+X_&
M3"0"E/^CCA)21=!0HT:77;YRPGMD3#&LXW$3A^:$O+GSN-AZY*08A8WQYLL*
M-"VI4>SVDO4RCOR(<J$]@?*&[UL/'B13C?KRL0\O<#K[[N*9TJ]O7B)!<QQ-
ME)`_\75'8'[Y!-B/!DV$P85+R"S3%@T^C.=>>#=)L!-EH2WSTQG#2"`4*[$A
M%4!FW(58`Q.%3<-#%&.D@Y5UHQT62P!AA80;"PFD(4`KADQ(XTN4>:-)<LS,
M)1U*/5A0R'*;&`+6.KCUV(2$EA&Y"37A=/@*5UQ<0D!J#T0VV2:'<,)(#SW^
MB(F61C%'"!,UL#!&`C7X(`(F,C"05HE<S/95#1Q)`$0!,7#_%D`$4=2PZ'@%
M2E"<<I1&(^=SF+[2``Z-P">,!J`]E]U8!T4*WC[D#>C=1^I!Y)^I`YWZJGXD
MG8>>7PR)Y>E]M.+TZJ_SY<?K>P`I:--#!\9:8'ONZ0I)#PQ6%J9>E=%E4JD8
M^KIA3Q$V\&$\(TZ8#"84A#46K"OR-%4#5,008RTS0AD.(11DQE!';'9F"!<M
MPMGE<LL0EJ2UPC2)B)9\21=?`A8<@\PAS$!HS9M;'=DB:(X5(X!B'<[+0PA^
M^'!!(FENJ<E;AQUIG0P^F&""!DPP$+!U\IX,390YB`#C+72&`(,&,<SA1RID
M8D0J))-6JO323'.*4COO@AK-8J`U_Z!=0<LRZYW6I^;Z-'_O*'MKBN?*FFRJ
M8>LWMGKT/?1??*KV&K9?YXX4=RF%(A@I?+L:?2Q%+(`[QN!C0,O2,]2RX<,8
M@3=;2^/8@K1MM\S\-(]01]3,"1L4^(%2',@2QX0A1(+&0QKO!H-5(46&P\")
M!";00PA,?+`OG-14K1AI>^DNX90A"F6(NEOF$$$/I-04200X$!^GMS@T(4`3
MJX1Z";5=)F-=QD@/DH.#+:TEPP$!,-&6N.L2&>CF#1`011%-/*B)2P]VB$R8
MHCG(12),+-5CO2&80P0B$`!"44`#=8M;TJ3"I4OYCFD07`8V;$&W1TC-4HAK
MP#C<)BN],?\K/1T4#]R`M;4!B4V$P`HA>DH8+!7VK8(M;,_<R.:10A%K5=@Z
MX0EK!0D;$'"`0!P@$YI'&HF%)@Q,B$$,TJ#$)CKQB4^T`6ZV,3EO>`@HZFA2
MYBQEB,Z]S1S!D%0!BM*,O.`@!L``G01B@(ANK<5;2I'(9L:("=ZE;P`7((`>
MC4"S[W6),'OI"[@B@!;06+$!$3"!/#0@@.^E["C,.4T40D#)$%B``$09GO/2
M5)AE-.$Q$HA,(L!G(QF(02O]H@$(>%`"?@'L&0_*P0`(<`SY$8D!`RB!:!"6
MLVP\(`T4F-T<"E`!"YA@#`?D53^*TSI_(:<:_HJFOQH@`E\(2P+_&]CE-+JT
M0;9EC6X'(@\+0<@?N^TG(^3\![%L%<)[Z%!`,03;%],QQ76B4(2L2J=";'A#
M9_&M;UMK5AJ:9QG+R(!?F4"&[J`Q`!PX]*$0C>A##W``')!O*0VI(C-`8SE;
M8,Y^H4F$4LJC-C'^R1EG?$@,#'DS91`"1V6#A`E\8`G2W&]^8<K!!RH0@1CP
MI@8VT(`%*-!(-LB@=QDT7HS8(3SG=:DOI$I``5KQ(#O&,@<"2%2.-#.&&EA@
M3Y=0WP!N8($@]E1Y?MA8)NS8$J[X"4)'RD$3*)"&*$0A`HV$TG4.<[_])8(!
M(J"K7?7T0(#)P"H2J`(3_%"6$,3@1&6Q_V;HW"&!+HC`.&74%,"0U%9,7$]I
M`J,&#H+CN-P\L&K)88*GU.;-#B9KAN,TVZY8R%H8GG,^'(1M27<[0MO*ME7V
M5*&P%K:4<.:P*?UD+0ZW@94#6.I?`7O@(2%()Z=$P@*\<P9'Z>*4H?!$&@$;
MZ='B,01AU(".TVW`Z4BACBBP5+LRP)$H=/`(UC3OJ&J9'R$(D"AR!(X8>1H9
M4KTTI2SB!:3SPB*I0F"$!N#/,&&0P1RB(`$6K$=$:?#,29\Q`!\4MQ;!*&\H
MK[3)_![%K[7IPH>Q*0:]DHRO7='I+`A581$-I8$-F$M8$@"#-$S"#^=U5`0P
MNI'><J0+,!"#"/^6S.0+,+D)33`"".8%R+8>P,E+-@*3MZQE$71YRV!FLI;G
MH`$@].;,2$#"F6N088>"^<LBH`(%_#%%X7XSIO]$IVO]\T_>?E`BRU65V?[F
M+#NS#2(X-#1N^\..`)W-N*_-YSQM$@7GZC6"E"*2U1[C#NQ"EV,=I<B(OIM4
M\9IG",H[;V(&$`/V"L.]"%9,?'>,F]FIU:F*80,!-)`C0)\B`C*++@-UO)`#
M_^NIQ48EC>!"30V8P!$-Z8B=;JPN:<A5`XW[;Y%'?*9I1/=(#"@`KS^2@`"X
MF'3%,PTM(%'<S3CL&R<;\BUXP>NN1J``DEWA1O)F@RZL><TVL(&9TQ#_/Y<*
M3!,EH$`(>A/PA@?\WQ"W`<!#(/'>1&$.8I@>E"^P<8X+@`D+!VK#&5[Q&@!A
M;8JF83SU+-R3B*(F*:KMG^,!<Q>ZUN7[+EMO!=VU8=0\Y3$/5@(,<%M(1UJW
MCZY%I5N$Z4I-!37W\/0AMWNY&Q\[O!CM3WF)$Q5KL)J]2G\OXEX:(T<G@`)'
M0+?V%,,$9QN((X5;R4:K%HZYD,?81H+&\6PA5?NU]1`Y6&S@ZAD,4]0@KWY7
MAI+H)F(_D%A+"J79`7S@AU,8:WF[Q.PKL6J!PBV5)G>:`S1S/.1'C"$-PQQ@
M+C2`:%,-8ZL@<@^#(I0<U[7L%,B5P!EB#PG>_]>"]TT1I>\,<1W53J=4)<1)
M;?GF6Q/.\,X@3+X[_XP1@P2DSBN'5$7P]G-)#Y=KWQ_TW>9C`*(7_;BO;6&M
M/+)TYRU-FE,9%]1)-0:I:]=;!(.$U8V$=>N65-5>AT;G`&M71W8(H0$CPP9A
M`"6`)P#C9EREP"-=IWEU1S#D@'=;L0Q[1PXU(!DI8QV'(`,6H!%#H$8=,5.H
MA#@NL8`%@"(_]P""<":=-#P,X#ZRLQ"UD`8RLR41TA*2)V[/5BB[5V0]4``T
M\PVDMU0B8@-ID`8]50.]IG.VD@!**!^Y<0R]PU*5T3+]U%OCY'@U<S[(L$&]
M\C7@UW/OT5KA%RR0TO]\\.1-!F)]/0=HL+(?,E=]*E=!NN)!SX<?V8(.Y><1
M"%*&<A,W=@,)E?8GZ64-\,>#.#-_3F%_981_$+%_X*48IB9/8I08ZS6`8C<O
MLU8."0!L'/,2II$&"I.&RA<!<S=L&QA&375L>I>*E;4QZW((!\!Z#"%BHA8#
M`_!<^],_@R<0,5AMS]!&,@!R/0!MRH>();!Y#1`&-,,`0\8";%)<8]$18Q``
M*:@7I,=]-69#8H.#"*%&Y?$I`A9=AK06XI5[<\@=QB`N;`4.-X!RW+&&:[-\
M<EB';#A9>NAGT9=\;DA"[#0K*?1".E=2^O0=?:B0U1</@6@2>V.(>2@2&1'_
M`\Y56)2BD96""?,G#/6779/84<1@B:66=5US7DC2#"_B:H]`@*(1,*%($34P
M!PL5/I=0`77R?=W5BHAC=Y$`BWA!:AVC8+=@B]X6@A2F$'$0#&$$"2-RB?-C
M-42&*V`H=@JU*10`!-AHAA6F`3S0,;1'&Q:0`-HV0@G@`=T(7L93$^(8"3`7
M(ED3(L!P#EF0!9\R"%FX#"ZA.,JS6SB83I+2!.+R8)6A#-UD'W;69]\44-1'
M0JZRF(4HF'=8D.>$<Y(97`%I:*O5AO]8#T,W$?Y$B#&'+&>C`7,`9:JIFH(A
MELA@4SP09K(YFR(0`-@X%I*X493X"R;9+3F0B;JE_Y()%0TO\A`P"5*SI@X:
M<%E%\B!&]0$%5B"%UQ2L*&QE9"U/.930!0Y&*0$VL#'TTU:500AIT`_3"9(4
ML)9]]9M*R'U/06(=4W>4=Y8,R0)@Z9H1P@.)I'P946[JB2:EAS;0%X?YL'42
M$`)ZJ8X_*6\/<)XV831>,Y@Y)BWK,@Y/Z3@-:9D$FD(-.9E_Z(7^-*#B]'S\
M>)F>J9ECDV@#:8BFR4ZYT@_&<BQO2(=[`Y@(@2<0UQL9-J'=TA(+J'#]I@%=
MH`%$6J1"V@4V4$F5Y&^W^0`A^6E4%SS>=768B))]*)SI59SP<)P^42_;1D@U
M$XTY@`.LEY`@1A#5B5G>8/\\"]$#&,A`B&000,`BX=E62-$_\E$*C",(H152
M.K8/-@2&0\)`:R).#Z$!OYB!'/,#?J!(R%4@W/A<U8)])DHK;X@L(8"%!J<[
MA,"@V0)._E@+5SD:W"(.#[IHOS);Y`B'_CAI%J(L(\J/(8I;!1EI@<FA#&FB
MEZH?RC,W>?9%!J(.,7JJ@GB/?+BKFK$DTF&-"$I\>N%7/M`#D%-:R[B,K\4P
M(JF;H69Z4\I_55J9$B!5?<H,K&:<6%DY]2(*R'2NQB$`7:!<="D,:9H7:ZI@
M!?.F]M.=9[=6+Y%39V26&T%S#\`F-,4QSA`3!["4`R*HB=<`:P*J[Y`;8:FH
MH/'_`T7C-^00J?`VJ4%'HK$R3E=H/Z$U%U7YD(R6(J,*27'%=NYHC_&T6NW4
ML45G*^!JJ>,76_<T:2AD3M#GLBN:L_E(01-)'^)XK+GJL<4**_64$@BZ'/)H
M"".8?A>V6]@*I;LI:MUZB;]9E9,5KG14#5^WI5@)#4F!(N'*(B!%>Q\).C4J
M#&G0BO7Z$&XZMGIWHS%`!0TP9<MQ5;5!9,^RC'EB"85E5(%WL>G`;3334K$0
M`@;1E.DAL=02,!IDN/>P%-OXG_%6<['*<C'D:NJ*@)1#1@%CFS<$L<HD#(Y7
M1[P#"V087&E8J4"+CS/KA7U(3K-EF2+4JY!ILSL7JA69_Z(7`:K*5:*/RC9%
MV[:BR9G2]W*B.7MU-QJS42&14Q#K]PZY*;G;JG]$0:5;NWSFA5[4$+;M-;8>
MDJXT(1EI"PWM:%L/,:^&M%''`P]SBV!U6PIAM")9$ANT$0`A0(75.C1FX2VE
MFF,YDP8E>PX,VX-'P@B-.T*0FX&<,+FQ9T+:J+'80[(TVYFQFQ!CD*G:-9R*
M0;I`YX7%\28NQ1P:!'2(5IE(*T/G][HM=ZMW%EN:Z9@].\([!,/&BG*%5J-;
M8P!-.K2XNY`8J[--,7MK02,Q-A.1X\/]<5W9BKW<=8'.Q;WBY:#+-#H@W`SB
M^VKOQ8-E:UZ2\6G04``'K*KN&_^Z&WBO=*N!0:E&)F`!.)!C;0$E^^,M!.`#
M%I`&%F`!@:$5)?-'B6#&<"D>"9P_B^N2#0IHB%HQ%E-=`>44%EPQ&)S!+(PK
MX:J[IN#!F54\(HS#&5&,H@O"XZ#"[S1]P\MS,<2[-]S*4JAHF_M;]Z3#SO>.
M+JR&12R:X?0`0/S"JBR[`+4UH`,Z#)(#2;P)LQ$!Q5N:`X%1UPMJW%4+O;D7
M5]Q:)K7%Y&H58AN?9%LN8OQ*&30'G':I%PBW\*LP;$R4<0443:E&F^$#`Z!V
MAI%3;,``1\``3W((*8/"!Z",X?J/AWQ$L?"N`8'%9]#(VA3!D,Q;X3K)A8'!
M//O*I]+_E-YW"^_V;74'4Q)=R_\HH9K##*7L0CH,KSNG6[A,O!R-LQL\PXPF
MD"(JF"VLTI>\T9%,4L>5<RM'TZ2YTD?;SKEQ)5J2S,4[T\/QS%&Z#=/<?X?&
M=^!+G`KKQ=Q<OEN5`"S"@P##/84($&E<KPHC8G.KSLS!SA3-$3W@!TR@%8>)
MS%'R,&T4)`[F;0T@SLNX;>\1T*,QT`Y)#@?]B[A#)Q/\#BOFGY(*T3S+O#U;
M6K4`NCCVIWY#("[7C!*`!%?RT:::AQ<1T6K8F=.WT3HDH+GLJW0]RWGM?0OY
MV._$PV7(9VFSC]FH?HBM(^9WD"J-TJJ*0\7<4@##Q(Y]R^DA_W56=-143#F8
MQ3E!&#95(B)1,`CK`UVL=I82D`;O^TJA:'I,P!4)S0DZ(XIDTQ&L*"=R`57J
MJIUYIQ@%)@'!4"B.@@,M)9[2\!;Y=3)U3`-R%APXG1`QN(!LB=<RE]AAR0D1
MW"'5A8:7^USD_8)PJ#<=T:@FP!$,SA%PX#(O4PD4->$3;E&U40,FX`<-ON$<
MWN$='H/HXQ;6$=(\G5L2#;(V-QR:2UN%W+O&6T^@_-FX6LLPK*(I;KJ-1L0M
M.Q^A2<12BX9&ZZH_[4<]&@ZZ_:([W-MV-))3#`EI4,69E6/U@GLYQVYF:26M
MD#X-,`!1X-S07>1D*U_D0`%OD;CC\O\5YO)!'7$&W;V22>@7L3C>QH/.Y%`H
M"1`#1N`2ZVA+)U.G,4D#1T``:6`"]`F/5X+?F74`[WJ[%M3?M8>8ACL@8Z"6
M@UUZ-VXJG$$!/J`+G!X`FNX#FCY`&6!60)0!3A@!/I#JG;[JK-[JK!X!%/"+
M@YHDUG$UG,N9XX<W+:>\ORQ^OJ41<;F8[>2AN'[KPOZS/INSPZK3^_V[-T<K
MQ6Q3Z]T`1P[*P^#;3#[!VINVB9`4?[EM`>L'!/?H5C0`B&4+7VY%86XND!`#
M.``Q##2>`4XE^,`1@=/F?4IL3(6O"8;.0^!SIA<$,0,EH<(3TLBIA(`#`A0"
MA6,>FBRAB#[_=XH>O-@'N=[=+6/23I..N1PKA41="]\9)#(P\B-O&7.RZ(23
M\H,SBD31"@7U\C`?\S"?=GEQA`;7`!1`3Y0*(,A.0\O.\W5#U.V@('")&U4>
MVC$,]*SB:+?U6T2?'D:?TZY\?:T-RSA[7#]ORQL,LI$<']'.+5O"Q"?=-9VV
MY-H:`:20G55\2(=`R`\/@V9A5.YMU<M@[B>1[M[H+1J--&IUB02,`ZBS'C^'
M4<[KYOK.QE;=[TRA/&/@!VCG8"N()'QR`"(@/;L!A2L_[/<]-7@M^!EQGQ</
M#1EOIO"0EIA+>@8NH/`JRJ_01LR!U9$P.(-$%)\A*L\$C)EG,=0N_XH&SMM`
MBY#.GMGNF?0520^]G^NQ*_0S7LO'W^NR5;/`WOQ6_Y@W#!_%G%#3[F$LO/BZ
M"\5TOUUI3PY/#LXY)F$[&?4BH@$=8#V<%+[E"0_I/M[)6><4$-W9PPD$$`**
M#"!+`0@L8S$".30-.8D-BXML$6,2#Y(2/1&)-(>+F(N/DI()"0]G"381!`.(
M;#F(.$P4%`4W!10!$6D:-C63D0\ZH9&@#[R[#S5-#6&,C(D'7<.>T)X2&CP-
M-(FKUHL$NM'"SQ()`3+*FH<Y$:'1$N#0D<]QDS4"UC1A]V'9-%PYW,_2#Q*,
MB7``$::#"!,J7(CIWB%,;#!QR73$@C!O&/^!_<+H[1_'CP%!KA/YZ5M(7K\\
MEC1),EK*D-[4C20I$^8PE1UQD@1VL:5/CNR>@=+Y<V9&G.R`)O6D042.,`_-
M'?*1`)S'I9\,&*@9R0+43<L:R(BPE%V:`PF7Y1`3@D7`E#4B")`19F*Y<H<&
MI(DT9%*459G,B:4P!MJ8*"*4/3S$A0V;`C7:>>IA(HH8&1$7*5+FJ+`T"9;J
M,0+;Z6*H45%@X%B5PW$#-@(BU#`Q)D$-KE@U]I4TI&:T><CN,G/6<EJU:YLS
M^6LICAS><^F*?O843QAPA>7Z1>98=2"#>@S#BS_8""'414TT2(>YWBA(W])]
M!TNZ\61[[M!>P@?_273EI_H][=0?4/;=5Q16;R$H$U;[9?114%<AA6!33T4%
M7@-4K7/3+L,D``00!KCS@%?DA3566:"AA9!:'U@`25(U1%%`06QP\=5K;#S7
M``\Q\"1,%#D&1IX,`4!24@T%Y#C:08VQ<0`3&@P5E#!C:.!#$ZUEAD@VC'0V
MB20#`28D=)YY,D9<<RFBR)-15L4+A/^]Q-U^P"6370[-H"2G.]18@XU@3&P'
MWSN?C'/7)HXT^"5`''K2FP37@9<)#3GF,(<-^+$3P1'VC%?B7:!N0NEB![$Q
MAR[J("A2,/DYZ(FB/M$'($LV^<A<3_LMQ>J`#[(WW7^+MN>C5<!^":M+_R;-
M]]E5L>KJIH3("G@4KP\V91!8HOD08$<:!F0`$*Q>9$%$V"(B5@1G#%,E#I(N
MF4-L&H2@@2D%(3018T%*M6,,;TV2!F!++B(#8>Q52<^U*V9R`05IA%!##2&$
MD$8!(@1Y7EBB>2E-F(:,B0A9&VLPAPQ/!8G-#7Y0ENJ;LK*D:DFVUJF-6GD6
MFY$&J&"CSR'<O!JLK(8>2FETVS;[P!!(0TH/N<AIP@4B!&#ZX$`'..2I>$NF
M!=X].>"0!BBPHI3?L2+VVVNT1IO]$]@_Z<D?M4K9;&"WGX5[-MG3NBK24EI]
MHY)'=O_]\J_N3*F4M2L*IJU.JLJJK"3CEFNN(_\0"F1,#G:!9R,B!S1!0!-'
M:/(5/@.4("JI^_+FKYB+7#QPF1<-M)K5Y('%!@Y-,,'$YZA,ND]@.W_<PTUA
MBB88.C?5P`1K][S6V,!^F&!"HRZ!#;8$+,`9K#1^T).,J-C4S-ZLT^3\)U@]
M!PAX<T*_1G3;ZR!MW3&2B]:/#9'$P5=?*&UZ]?_8D<H^PB`#R-B-6V?S%;?8
MED"?%>UEND)@<?SS'@>ZYR-A:^#>*%@TC,RJ@XS:F^"2@A1/]&V"><L)M%3X
M-V%HX!@=\]U40!C"=P@E&I$+C&;<]R9A)*``K1&31#*GPWIP@1\Y6!@!@HB7
M!@R@1^[XE_%<1S"_%8K_9`R0R$(8H*2L105;P4/>34##NN.1Y1UCH,`'#%*7
M5*CB`C=X10#F.,=7V/&.=O1!!"P0!0W4P$BF,8G2@F..\&E`*+G"V984@;YN
M[&T,05,,1-YWH(P8XS5%!(]VM!<-J@'PDV#!W!'SL99#6G![J!P<X<8F'56&
MD)7$>%M_Z`-+&N:$/QQ<4`M;&9,%I>V5="N<X4!RPK)=\)C4NV4*._)"@XB&
M/(OCE0UOZ(D<6F@58SE#+--`LBP),'%ID0$!BA`""N`(5$\$AQ0W42&!46!Z
MP>H!DDAV1-1!)'&-Z5(3F@`\P5".>*'!%CO/Z,,.-(`!$PD#"#2CBAS(X*$0
M_Y7!!R#*``9@QJ$49<``1"``)D2@"VZJU2#MI`EL?,"4K\*-"X_SIYD%2B>I
M8M\.$9(H6Q*(49`ZAI8DB0E_#$X"G@3EU?)I#BZ0[`+1H67A+@@W^<R-0+O2
MFU)F:2NU/=6##]KE??3$E:MN"X+#9)0ZBOFK`VIPE<9L93,-\<Q-1+-M$*HJ
MB42UPQ.%HRI5J0$,$H&91=03+**Z:`,.$``-4,:<KKE+.J/(NJ=D8V#3&]0\
ML^08WTDJL(G`00PLX*?D'()R[N"80*'SI@00X*`U"N41L].03&X)5`YM0@1L
M\"+VR$P9AISE2CNKCT6\%(.3D*FYHE)3N/'GDK7+VO\FESH)JFT&5-"-[I+"
MX!ALL$$,7PN(*EWIU9UT][OK,>Y5Q6L@[N+RE3]593"VHLQ<">XHX)T&#!/F
M5EJ)T&__2,!<KWDNQ[%#9*MIS;T24D]$R``'<T@#$![``B2=;U*I.]HWTA"D
M<VP&LDA)0!H(0++1,L3`<XB"?GGK3Y!MS!(="Q@Z/*.I@C3@KXM9Y"4ZI3,N
ML14\U>U:`3106PG7X+3?4PN>B+.3/B$G>+]-ZZN"-F-$$>V]O704_R(%3DPL
M=V6?(<ASI<OEYQR1-4^*0F0&9-Z;GM6^<8O)4R.DY.)0"T'B+3-X?YD;9"93
M)M:38$J3J6>T,C=6B`L5AM#_[!Z6Y9>SKOU8!(,2ER9D47('<:@(8!`!()#P
MAY=`9QI49Q8NW84-[_P'RTAQI0%T,=.:T,0`!$`!_($&NIDPL9DBD&J>EH8=
M-?`!%2RDP\J22B'/);"5$R&`,?.E&/2#[0>(',MU:*`$TEV.B&I2FP!T,6`T
MH*0*RR:3W>2TRPVH@*7/0.ZX?H,@X$XW3Q'!`P+,%BO>'N%]X:=,)8>5@VV6
MLYRS^DN;=E":<(XR#0%^7E0NZY0/8._=5L:X-,/W)R(3P04D/G$16'SB%KFW
MPXN6@!A(W.(@!WD3]F(?4(RA!U6B0!,&,(`C8(8-#V4`[@H0@S_2)QP1N+@(
MC&"$_Y`+(`J%TT#%0Q[RI(J()RQ(@`8H<`K!ED,&!UA8"%XD@310@>@[[[D(
M-NV--%A<ZU_O.5*CT0/]$N`(F8$PI.OG17O<*[-?(U0QF/#QBP]=`%WH\R0T
M0`"L@QP'D.%5`B)P@:N#G.<3OT!V^8T?=]1@#@>(O.0G'WD$1PD.<+">Y@E_
M`!Q0?O(L__P`/D_Y`?``!Q=@@@5"$%+5^9G0P8Q5O_U=;V"FTKC[UOL&=1_[
MQML>K`>23+T9F/"J((NJ4M70"JU:O6]]Z/G09Z^Y:YE,H4#_^A]2^/:6`@0,
M;"`-$8A`+3*0ABJ`B[F@`((-GK_^Z!?-^=%W?HB*8H!Y%?\`!AT@@/Z94(`(
M^+$^D8!]U[<?'F(#[7=]6[$;'!(C%(`#I[9EZI8P];`*3*`.U9$`\`<B"&A6
M'82!`OA\*L5*P'"``J@.705<8I,?-E`%&J`!+-B"+E@%,J@!:<`$/W"#.)B#
MNU-8,PB#+<B",OB"+NB#1$B$0;A@2_4XL!=\TY9\MB<L!^>$9&83W%9>:35&
M3(A5K5)>Y-5F]C4?=U4]LR<M9O9PPC1,YJ8JQ-=L$A)7^W9O&C=5&C=&<$A>
M7/4P#_,L9LA)@:1\;C@VH<`"26<!(L!.F24``K!/BM@$%W`!B\B((G``%?9%
MU]``!!`"U%%[O*=\RY*"<#5]2\C_A:#(#CT@=#-C+IR1#FZXBG!F.*S(AUOE
MA',VBYM(BUY%++98B[G('//GB6[62ON&-_IF4W6VA;$406Z6AN8%.+0R+(A$
M>P(')F5A&ASX>G"54I:3<S)@#WXB`CX0,3XH+T78@E$0`11@!)X%%NG1A<#D
MBS?5('AF2WE627IC.,1'"=8"*OFD,0B'9_,H-^AUA4E8C0;'2S;3(=T%-]RU
M)\)'D,P1@L'"0.SX-@"YBV:&@1X4+ND59]2"-P7)B;*'0A6$*U;T9Q2Y2I(!
M(.R((CRA$;%8('$S%*4X,MMH#SER`.F0/7_(BI1!B*Z!$*L@`E%@*V'%+-OG
MDB*4>UKX_X0&HA^^,0U.T4\O]EG:UH1[YH7<Q3CN"'RQZ)`)R7PO^7!/N54E
M=$`3>3>WV)$025;8:(UQ>)*RR)1OR6<*9&<967M@18>^HI<%R8PNJ574^(7)
M4I%0>$Q#$0)+Y%!NIPH5F#T`09#X*``_&6D-L(ZZV"I$`89ZUH6#LI*/Z8_.
M=@&8=&21Q@8!X)'%HH17>)8GP68LD2KUJ&8A^9%BB&\HV1XFN">^%)"A6!->
MN4&*TIF]!Y(/Y".::4+SMV9VV"'"N%U:24(K<8)-U9FB)GS35)<C:8W](F?A
M,A]2`I:SZ#;L$`(CHPH3\65;AY2?L!MQ4!T)T@.(P4B4*6UE./]><'D?NT(4
MF8DV#B1?%])DKW&:"&>,<?*+<Z-+C'>@M-E=O\F@6(:=7M6@\;6<-'%!&-B@
MSMEPP]><!<="@ZDV/51!CG.,`7>&=)F="[01@=-4_^&)RI(`O8%!6,8J',@.
M;!,.!4`R-4DICE$`H1!5T=">+J$\#24IJU``5&=6^644?PF>/D$V]3&6]@F&
MH.!MIAA*AF`7*P:<*JJ1&KHVOGF"`TJ@5:@18DJ83YHLL+*;$V0W4KJ%Y#44
M`+E\3OB=9BF%K+D+&*E[L(B5:JF=K+D^!4=+P`>+KHE?;Q&F/G.6(VI!+ZJF
MP-5+B@HS(Y&;$A`%!]!DE7@$$6`"'B+_I5TZGCEJ1!/14)K%8@5ZE4H*C(EJ
M+/'H>_>UAN/3G_S))XD12B56&-T9(!RH4O_XF9%ZEZ\9G&\JDJVJGH_:,D6Q
MAJ`YD5/"K-^@A'98H&[#?$H5J0SB*@TGJ^B7G$!JAIJXH-0WAZZDE&CZ,R5T
M=%W8J/$1F*LBH7!(A7."FL$EIP&!8C$$$05T&_V8GPD0!4SP'4-T#HY1;+H:
M%-S*>)-Z2PE+$QY9K>U*I@^`.)D0/*:I*,@*'TXIH6@#F><*5?3&L9#ZL22;
MIN\HLDOY'ARKK&93K0AYH'BSJTP9BGDZG+-ILEZ(9BB;H-'HG68%FHL"C]V9
MFQ\D@@X+M&`)_X9``$2M06`-@`,4$"6UT:4G5QM^`#$4<`$144_GD0C7E0:`
M%(W;62N^YTK_.+0WFYTO:GP$^JU76K%2<;%[EJUS>ZT]VZ5+^*TR>I5..J8R
M^JIC.R=/.K3&=YPIJ[+^F)NAN*QHJYZG1*_)B*S$H+&0>Z(?R2`82I82:XSY
MZ;`?4KGUV98V0Z/C\Y3,"9O$YYMM^ZZHB[:V:3;BD`@(92\"`R_\JA'24P/S
M0G<59@U0X1BJ@)-AZQ^I"[@06E;,ZKIW^ZZU2;S4!Y90:3P6*Z"C&Z6Q=T#*
MZZ9.%4)Y!K''V[R":Z:KZ[>OA+TRRWRJBQ]KF[WD&ZRIZBN)V[[,*_^'T(L3
M.]MLURNLN_B,Y/NPWJ)^YS>S:T.2%)2X:TM#$IFT!FRT&3FIJLM5KBH,_X)J
MJ<5.,L!1KA!^%F`!/G`#?==-!L$T$-$UE89(\8NTK<JWY;NPQGNVN:+"O8J-
M4:6:+G2K<#LS-67`>/NW7"K#*OHS,CRRM>3":WK`Q-NEVMM>VCO#.APGQ!JF
M26RFK2M!-YK"0^S"?5BKLR>A;$F/5Z6WL^BF[8J%`0&".3O`F6(KOWJT#DN-
MV$MHO]K"N$*Y$A`"DEE4^_!V.@.\+65=2E+!YS``LC&L\.C&*MRW5LR?4*S%
M@`B<0<S`TO"V.X3#T4&C*YO(#F*GT#HX:US_J<;[OI(*I3O\O*X:PX$IOJ([
MKP+7I)?<R=-FR<6[*C&IMB\<#5T<KB49E]4#FV%Y+#6ZRXM*.!<:S$VIN"KK
MR:S[HU`JJ39*@&Q#P^#;HB&A7^PB0%M[#S:B0Y2"#5S34#^)'D705<^<OHQ\
MI\!<Q91+N<3<R(,;$PK8;?R3C])%O58EN0W\NJ3<H,'0L(?,08(:N.Z+RAV[
MS\LLMGM;Q8(;S9Y,T&U<FP19HRM)%`JGG^GZL4!ZO[@LJ<K$G.O<*.E;LT)[
ME<XRN-4(N"/=I+MLN&K3N6,;"KFV&C@B0VFA18L!%5Z+&8<@`@40!6/@&4OL
MS'7;SPT\P_HKU`6<_\#]`K0C:K>2H`$4$W)B(`:*R%'O8[@2ZLHE]Z!7?:S4
M5,_L,2#\7$L"_<2]^JHC37NN[+I+_;?=V]4@&H;-_&\=ZET"#*_+9[I&[:5S
MS;B@.U6JBJBZA]&,#+X)^\L/Z<9`7:&E!;`X0#).,V`*41<!U`@+$R4MV=)E
M7:L$.+=R4[-RL\8_>GQ@:@`&6-HD:(!;`3OQL;!!.[\)G:AL6J''S%7J+-N.
M6LJ^=(^RZ2J:_-KX&;^[+;\*ZY&RJEO*3&]02+ISTY&J'+%Z9H(6&9*H*=@X
M6]TP%1<=`-,Z\Q4*,6#WH`H7/`?^YP=ZF-BV>"R>[;Z@G,D1F2HZZ88Z*?_+
M[CBF/YO8,/7)T?V]^8V=TQU??!VQCNN@&*U]=/W;?ENL9TS2&&O0\^J_VZF>
MPG?/O.JNN43<7JB\K\O:66QR9Q(%%$!WW>1IN,57G2<"'N4P/3T\[(S((@VB
ML/K&XMHK26Q3M8V,1PW,CWR0-_[9F\W.-K[2VRO;(7K%#XFQ_\SB>QNO:EVR
M*Y&M+HK1?4V@F-OB],>V*+K718WEZY&\E>N0/!'6TZ&9&IG@W#K*\JK//<[*
MLV+?;UVZ;G(FNAL#$5``<X"(CXB(<U```7`+76!S='N78(W$>8NW/W[EKPQ+
M+\N\<I>]NCFC,-ZV2HW)X<O1U;LM]1W!/113&([_;^A=58W;'[&<RZ?<LH1I
MOL-$SF&=Z)Q>M*]-0G=ES-6YVUL!UEN\R/LMZ;B90:F\VDTI5J2\W].ML9FL
MS*'0TST-"GB8['@H);E150R^MQ;=Z[8-O[P,H=48X+B>PK34N(?[U0>^K$4^
MV+[=Y2BJX?U:S+6]XC/!P@C:Y-3G5)GNVCB>58)*X&%,N`[9[NC.Z6!JDL^.
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M:\0%`L433^/=QM:)W_C&$LJ`*,>CF_-23^1J#"#=R_>P=,`F7/H'C]\@KV:H
M3N%9C]@*[:@MW/GJGJ+%>KKSSM^[VI*%O^)[#Y[57O1:KV1KZ.EK`_B!K^`:
M;?0F:[Z&KKYGNOK3;I'!&<%9WO>DO_;XVQ*]H;@";?&[S4"/<\DNS[>"1\[&
MC__@_L'\J@JZUJL2EHSH!2_CHC_+(`0("0\/$@\)@H:#BH>(BHZ#AX^2BXV-
MAI&/EI.3A9B2GIN)A(^%BIV@E)JAJXZ,J*RP0*JPGJ6IK:^7LY2;H*6NB["0
MNZVZIK:9PYFYPK2CD:?!D,'1QM6"G;C-RI>\@Z5#A!(2N>&20PGFT+J>FL37
ME=C#EJ"SV,C=^=KXT_W+\\JR.?OT#!$Z1*^8;?,&K5JHA),8>?-':9RH9-+R
M2=36J^,GA/40_?IV4=2]B^U(ZJ.XSJ.QDA2/\>/V$1@^8JL,X'R82Z(MA<`^
MDO+V4R$KH_-R(0,9+^C"H\4FTN.9T!ZF>K>2+K,:K]G_1J&XIOK[:FTB6+(<
M`6[MA9!MNZHT5[I-]^"@*K0.Q=)T*DQO1'HA>9I-JS:K*7TI!_LL#)BP6;YR
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MA3F!5V60T&6YH8A7GG<G?:Y)N&4C*JJX7Z$K:J7E?`*]UV-S/Q+)G&[I4>;D
MI$KZ$AMM%SZ99HA_WADI>Z!^U8E.-0;:9$";&EF>G6FU%J%*@WKY7D&.'=(=
M,`G*2J"J`MK&HRJ7;5/F9[""Y]^!.:H%88:UJ-?BFXU&0F`PVUG(G*6E)1+-
MLNW5BIZ1T&$'()9:W@(.CO:1RNAFB="H8)3[R=L;ER5JE\R6Y>I85&:/NKKC
M?X@=XO\0?^D6&?"^R_TR*V\+:TC<M"..>V)`#B,WZF+SC),MH*O.B!:QQ9)Y
M[6QL]LK5F8>%:MBSWCEB$9!C*@*$+"2KE-%L<7*9\J)BYLLD>91MW)[+[-SJ
MZ:`L&V9TB)A$0^.Y?`*[I).<3@UTT-%E^>/*1W=]M,K#1MSJUF%CQ>3#,",\
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MJ'!^>MW4K"0D;IP*1,Y+X`)/MYNOM4MW'\-.-^J6I(7,SV_.R6'4,$45"-JO
M::*K4`R3-D2>F4L:U@-2=MA$OWGY2%6D4Q`%JY<WWA6P5,9[(H*(!K*=><YT
M5=,@S:2RMI39*G)=B6#>YD.UY$S/1Z!1H*]*B#0L186(8>O6"[\'JN`HT%W;
M8TG!I"&0LGCE9.B;UN'R)S@O-E)Q_S(T$1C_<D!$$LR$U9K(MNS&-)+\YF"&
MO*+*-*F_):J))INL'@$CHA@<%2R'64EENF`U0R7.S(?B<R#@:M.-O'CM.:&!
M#R^L-A+YT,]15M10?13Y1A**PY<8:6:33*6+T#GRE,K`IA''5#/1Z+!EV.%A
MIY`Y.-MU:E+D4DJ1%H+%8[2PD6\3E%]R@[LO$48YYZ'E752SBW;,SXQQS-.9
M^FFM.P[O._@CZ"K?Z<A70J)S2ML9/4MD0:<A<H+2B=I0_D0\R$PT<8@SGBMI
M"#T'L5!B4QIB-P_)%46>U#2+.I\X%+<U@&4$3AKMBZ>BF<8%_D^DN%2;QJ0I
M).D4@X+V0_\B+F&J*'*>L9"U[-U"N87',[(P>TX;4MUB2KK)Q70J0A5E;B:Y
MCPOR$7$2BY2]H@>EO5C*C`;+WYR,2E#D[:=+M_O&3%8:Q2"^S'-$M%5+P4FV
M\93R0@+A!ZSVECDWH94U'8QD\XC4V"\VT*>/R>E8*5LKRXY0F;K9E@\!:E#8
M%2VBA)`>UZ`$RR%ETZD3P]5IKPH1_&DE8RA-7=&6."\Q8G"FJ[(>9F3(1Z!T
M!9U5[!94&DK+WB:QI'6-6?C0B;[-#?.BM>1F_$PHMB`*D[/$D^)V^=1*D617
MCU";+!JW6%G/MNLGN!,?N<SB2Q`"%GJ@S9XKVYHPR:F7M95!("/_22O;]@[L
MD@)MX3(;MJ/,]J22>!ML<_?WE#X^DJ;4A"(CV[KA.]TRN77\1Q&1IUTQ'I6H
M6B/6$[MX,>KJ-KO1?2E"[ULC3Q)X<BS9".NH1+[4S9>+87PD'?/+-N(*";<N
MA"U'V<7B9$IVG?2R:$%)]5JL7BI4O^ICKPZH7"]V:#I[-8#W4%8^WN*"R^'C
M<!V?&\./Z3?+C_&F=G#,2:ST1D8[]:AJ8?K#UG5U;C#\\?TJVQ`L[VZ`C84J
M6M/;QO`E"[(/E602H04U%%YXNS2[G'Q1BVA,3QK*'87M6"TIZB\'"(/`:HZ8
MO4(:,[\4BH7@X*B_5#Y[OC)]4Q89G(%\_Q2M^2_.GY6KAG/\L]].D,P+=57I
MXN9K#K=Q./9](&2'W#/A`EK9QOZ<VURM[7A%UE&KW:RH:`U@]X4UF:;6\IS0
MW6RVE)'$D0U<JB?\H3'W>M+8/FN::5S8)%=7H?>Y;JXKS*X.JGNMKN77P8`Z
MM/B!.]E*9!\5V:I4;M'ZDD>:JY!5J\1<%;O','I@NUU78P>'VVSAG34971OH
MAUO5Q%,=+RN#.1T-+I?%S:TW+%:$W9S7U$,553/2Y-DZI#23A`N6EZ+G@N!)
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M?7^3,2I@D>ZV]@>UZ*\=ZF3_[I]!5O-!!8=Y&>1RP+=U._$:GF`7-V)\JU9#
MV.52KP9AW\-M_$9Y^"88\E1EJ&92#653%7@W^2%]Y:9A5X%"D))Q4_3_`+O"
M?+2E2T^#;VED:I$6:<46+G^#&"AH;L?S75CR3YME@J5G>((E1SKA,2Y(@E[S
M<BZT+SQH3#\H@T.E7S5(>C?(3AU81353=!W'@@]X<]>G0UQH7O0V4`#C;Q=&
M'<Q"7B1(6=N@1D+C/O/'.2@X=E45?9=0A_!756V8AXP&?_,FAPEW5GCX(9JV
MAU!4B!S$><+S2]9SB*]3A(%(#[+V))229(#1@L>#<_H4B5Z2'\-3?I2P@Z1'
M/J%H@(YEA7VH"(G""H8R/`9@`SBS"%]H4,A'=M/3B6((@O#D<]L1@-=U=@GX
M@5/X9C]S*B0F/T(X:J=5"1`5BOMC<%?8?)^5_V*+@#,%"&95^'LB1(W:)W((
M48G4J%Z>:&A6HR>6AVZ5Z%^'YBMR)6N3^%L_96S^]U/-J(SS9AR6-F#%1V8I
M%H&/H"*'T(KJ8P,8@`&SR#D#<8N=6(K;UV&ZB#8P)I%$\GUUMFYN&&'Y"([(
MN$KG"(Q1>#H?N7[2&(_MEX.L-VZ!:(XAA'WQ>%D?UWQ\9E=5-X^!XAG,"([%
MY9(G$FN=9X+/^##L6(+UV(UN\W"3:(Y=6#9XJ'B+%X:#T(J#$(L8T#BX48LH
M<8M^%5C&2(:)YUTD>7%GH4_0187+E8)'"3\[Z!,NYH<I5'QA&33^IY*2.(9O
MZ8A9TX0VB8$5:(."=?^4GZ.7M3*4O:2$07F7F*AO$31N:8F`Y<=&@\F%"*.'
MIYA7W2<V\'92&TDQVL=7WF`H,D,.5JD+9>*99C)K3/DI&=B+;FF!*/:05K:3
M;ZAR?!B)0E@TBWB'T+B">;B6,6@T9Y:8F+D1N1D2%E1S7>."GL@FN:F;R>B0
M4Z.)G25"[/=0OMF5'7*([-:/C"!`>DB::/@5RJF=?KB3X2E`+K>,TK><&?6$
M&B%?WPDW.-0('S8,LK!R6BF!A<B4JUE<$"F&^P1CU'&&-:,.=FE^)JF#@6=^
MXU@J0$"!@9F4.HB-P[:;U4B=F0>="RHNAHB=Y^*2IJ4^FPET&WD;Q4EG&)K_
MB[X!C^[WF''7H84C/1O:42Q:/RX*=^O8H@WZ;0`57GR(>E+9#`P(@8W##>B0
MGSTTCTXY54[&#M<IB$S:@R"$-D7T:Q>*G'NH$36J5!6:?2DJ52H:F_H%H7A9
M<G^$B0N#CM,9CF3Z*NG&A.X',B=HEF7*:&$:<7(:?.\#F6V:A<\&4Q#JF%X*
M$H'*0#:Z-&MT''JWIU&)"0<QFT<Z%P]Z"0:*I/Z8IV?7I)TXHWK6GV[WHU1Z
M,J<X0CXZEPT:@LR)1?VXGO6`GA\*AS`H:#?:@32'@:MZ-Q17I_P93*XJI\V)
M:(`IIW8F?VOZ9I`8CN0TJK]*A2,3GV-:FI<9K#&)_T:L&C`&>A"%(J0,>!>H
M\J#R::F?$)3\B&91BIJI>6DE]'1=>)(LE5J+6'A+YG#7P:(>V7GD!:/I.4=T
M9H7VVJ_/=JX(Z!X@DH3UTY?D-XT9QQW(^H_I]R@#NZOT]V(H5I(<9YT,>Y%_
MZ);YVI>L-V%A]%^.2AN%0A<LA2`ZL:S@ZH_3^)":NI<KBXM@0HA@LX6.MR:1
MV8,J*4P(YWL>6J]QF(C+>+-_R8[GNH2P1[0_&:9\YHWL5DV(*)Q6Q'Y!>[%T
MBJN0^91&*[0R6:UKFK-RLWW5N68G&'1S,Y#T$0[=9*.Z\H"FV3ZN<2P36U-#
M5:Z=*K>*BJI).IO&F*0T>?^2M\=PM;JO@"M9@HN:U?:W31AZ2M-)VTE[O'*8
M2OBU]:2DL4J.NNJOEMNE1>=93>6X]BB`&6JX_;>O8NL*9%NV`QE!(TMJ@3BI
M`9>RME)1UA>1^?:C0I<.8@DW(+E\(#:*"^N*T;J-H.BZD9N2(5F*;1FU<!NV
M:FMA6LJVM$HW`7:5[8FU']>-NF*PJ2MZ8ULCOHDM/CI(Y,`\!FAM1LF>G1I'
M8T.^?<MFQ4F^]7IZ[[=&@=HB`NN]#?AO3G&?)`N[YP":=;&M6Z$B.B`<!*DR
MY'IT0^H(JYL=`HE>Z)@9W@H+.N`*:"MQ#"S`]D@7F@N-^#6.BE#!3K'`A@#`
M"5#_P,,Y6E`*P.$P!H""*#P'L`5GN\V+=Q.YN5%I%Q.!#@:ZNX9+6CV<8BL"
MPZPX&5[SP,,@POW[958BD"V*N0GTQ$F;1\"8<S4:(#'<?LL3>$+:3,L3J?Z[
M#.:`*`J,N[S8,[!IP0Q,2TZL;!?\<W75H?<6E5],PCW$B>IPG]U6;9U;GH_:
M1=MJ$$<:M%L7Q`N8(B2[G-?QQU*\M,=KMBV[$8-,*)$*#&"<3"0\D(P,(A-\
ML5SY97E,<H)@*$0,>C=+8F.LPR@2P'PZI<U[HWVLN#@<(RO;G7L4D#?*94-D
M%Q5E`'H<QAKRQVTHP.B*IG+[D&W,@RGXBZH2I+%QHEF6_W\W$CPQ-X^!C+Y]
M2<P+3+0-FVTC>\'B6A=4"Z(>ZJBO*(2HXL*L#!*DO()3F\,":<AR[)B5ZZ+-
MZ*?<S`@]K+TA`9K9.839EFXTV$5W&F/6"*H)N+!J!*+)U[^^#,R[=(-$>+:\
M%0E#D(0P2Y',0:\$RK=K:+:03*F1EW!+*-'2N\]8&I@0=VQ&*\X`Z\\UFS8$
MZXB-U;$P2M$PYL1^&[UV,<8;@Y-F*3]H)FY`*XU<-BZ_Q('\-[IO$0XBS(_1
M&Z]!\:Y6Y\'98M/8QQ^7?`[XN[8*W;NXZQ3'!]&=BVT3G30'O)>N&;?`X[%-
M*:<`O'L!7(7(=GGZM\JEF'^4H/\.VNE/(&3'P=;2(L3(C(#"17Q<_*?/DFQ_
M7B>/R),HDFS";<31:!=J]]P44FEU[K$^(&Q[OG4+,-V`)_RO7FNO-<E/PFE]
M'IV).7G5JE*C"[H)J^L:YC#6$&VJ7!W2:0R@QA#/F5VWT0/97,P6*C`^M!W#
ME90H#ZS/SGS8IJ>H:)I^^R>FHTR]SAVRJ1##B9R+1\@./NV\:N-;`[AB_<##
MR!J5+KW/.5R,=!@A#YC)<PK/,2C2)9RM#6>*=`@)_/NF`[/7+EW=AHQT_]J=
M=-W:QS%H4Z3:<_$Y?1-WN>VD+SDMVLT(Q!O&QON_6[W.RI>IZ_Q\&Z;*WGW1
MS3T(.E#_P3=DC/:]T*J@P^DPXB0>V>K-GK08VUCCC,XHL8?PR_^MR=F=I9^[
M",7]S?*SC7Z*LB:XW_80S]U9)O'<*B@]IS<9#H5PS81J$``]PF3<2W)<E,!R
MG8_,%"D2R!>MP@2H=Z<*NK^;M5V.AH%$:`N])$:7/1LZ.A[N&A4.&Q5,"%DP
M#GL^,Q8A`3V`'H,P!N/PYX7>YV/0`SHS4WJU+!?]3&,0Z1(P!OE1Z(50"L4"
M9I;N&I:N!P^@!Z"N!^JL"*+^`(1NZ9A^Z1(P!"Z<Z3Y2P%*>!7K0YPDP!K5^
MZH5>%_K`ZH$N"7ONZ7'UZ98>J9*.Z=[BA:8NZI&N$H+N+?Z1_]?98Q'%/K[W
MD.ON_0V*OA^VSBNC4`BX+J*-3JFB[NF_(`&R3N[./@1\+NDV6.NH3NBV_L9+
M[L*G?@Q2[C&I^TR#'NGKH"*EH`?CH,ZV69PXH^Z`SN]>O2UC,`2A?NJ,,+Z<
M#`11R>=94/';G@#6SNFM;@@;K^Z!?O%Z]0"RG@6V?E>\OO#U3@B&,@ZB+F;H
M,*D;;T6`W@/+7I3"JYQ9A+U3JL?XRN%WM-/N[8,J92VQ/;MJO,:VS)`)\`2'
M0.EB%FLV4`-2K\Z3+O4UX#%/8``U<`AFP/16C_'D\`1BK_527V^=8"BQJ`$Q
MT`5E#PF3GO5+G_5,G^M5PD%S[PI`4/\#J"+V3V`&-1#U&!_W8@_XZ@,$ISX&
M0)#U!B#V-5#LN631?-_X4A_U6T_HRR/V_[+JE'\9$B#V9F#P+,@X7E\#3T#H
M#U`#;/\A61_IIG\(%?P$5C_Y$F\*"5`#&G#[76"5EN.0D?[WN-_XII_X??_Y
M"6`#%CSY3,\(IG\="_\$77#[QL_ZMB[V8!_`SM_X'A/]?-_TM;_XZ0#[6_\A
M$B_IQ?_\OU_KRF@(LI`%"9`!$1`!70#O3V`#8H\.4F\1?,_J9"^+HP`(0V,/
M!ET:&C8U-6,2#PD)C@:/DP8&-BD>,0D]C0F5D@^1#Q()AEVG!A*DDZRL!@]C
M0T^GB`9/C`G_0#9`JH2"!C65I&-CA555IPG$I$^V9D-F9C4VB0D28T^+BD^>
MBHR$3^%/>IT)LN$UH\-CIAI=B@E9JZ&3CJWWK*'VGJ#[D8_[\`FL%Q"@/TCZ
M].7[)S"A0H0.(QZ4U.J@P8>3ADC,6$FBQX\2:@2H0+)"APH%;+"0$,%DA0`U
MY$FP,3+`F!XM3Y;LH!-&C!YC1I8D>3)EKRQ#8L"X(P:`&#$=(G3IU1(&C*$%
M8MSLH5!"%Z$^5XY*D(8HSY,Z._P,>H?G4)1=>O3H4H`HR0(!M,I=!1#@F!AN
M=9*$H4%"E@PD(S!JY&A(4I(!$JPDY>%.A0@]9M0H(,:NY;@BVW:X_],V@-0Q
M>@9)B+'SI`";6;(`U5!``(#;`F`H)F7O@>.;-2)TN.WT9=P$(P-7(-PCN$G!
M+V/$=*3.3,NFMSL$B*LG`NG=JIX$L*Q!GH:A.FUV<2O:[=V;>KY6(`X`Y=J*
M`/7$$/,!1HT9/6APE5T"*-:<4.Y5\%H\$L2GU%,?U!=`"*J08H!&OG6D"A`!
M.)7!7KE0E,\3+=W6V7:]`(&0)^8H%$-=]*%40P]*+:>!'GK`TL6`&1CV%PQ/
M8:?;(BU9U@$,HY$D0`4QI):395AU,8,$B!UITQB/>(7D'0$8(--?HV$'500U
M\(5?)9#PL^)"D8@XT$*/@,+BFG"^"5%$;_\6=.=''^79FS\87131$"UVQ.>A
MH80T''T`="!E#QT"\($8/<Z011<5?-!!9I$R2E\$:O0`PVT1$O=!!?^I(A)]
M04I:P!A3=OH4<6(4$%<OH^Q'7`!9L#`*'!&4ZFF$F/50`'T??(##I%+.H(%M
MG@)0@`:<C+4B+!Z0BBP.,60Q0Z2O6II0'!%(BBH+Z([Q0H0!S*#9?(R*(64-
MBWH:54RJZ,KHJ[*-$4%3$0H`L!@V5,BB1B$%,#!V'P30@PFCTH>#`"',$!2M
M`$\:0,&]?$6J&+8E6^RQ`#@L$[VWQ>"N!M@Y==NK7;0<;Z.P:K`H5!5`R&]"
M+*K2A0`?"/#?RM#_$H>#31;#R^BD,>FQF:1.`=RH9*L,(4^.A#ZP4@VC5M!%
M;`(EW%14,$3X@@$K&931*&-D@-V2.4NJ,LJ-QL2"OQ&B:O&_)E;`5,IX1RBS
MI#AX(%>DP@)P@``:N)NMB=2J<O%MJ(+]K^`*BK%LMYWT<T^;$-E)$(OT]%.Z
MG!0%JK:=?:(99^@5(>K10+WU-7KLAQHJ^^Q`Q2`<Y1%H`"L+CU,>UPR8`@!#
M9AJ8%D'$TD8000"-BWH;E],'D!>L%G<885:&O"@M]^4"<$<$OI,,`&8R7=-I
M?:F2TKQIZA>0O91J1'I^]J8-_;,2TO*=PI+E-4Z4@SI9>)P83*.]_KFK_WP%
MR$P6$I*%&)@K`5.ZVPMN$P%WC4$#@*%<#+3RKNQ(;R22$H.!0N([[*BE/#W0
MSQV25:!#1,`VC5,%/T:QJI?%`(0=BJ`:0$@R%4;!!-TSH>\B)H88&"9A)LH*
M"#N`@PA^ZS;MND86GO8!E<T@`;Z[@P^IY:\&BK$^)QS9]Z33!=\)8&>E4]$U
MRN?%S-2@A;?1#;4LMJBH2&]ZBDGB&%_4&6NH(@MZB`9J4A,*%CBK*;#IG(J4
M(0&614A*8Q"CO*H5$,<\(`N6+%D-0A""&"C,B_KZR;LBY,50;J<&;>1,#-00
M`NU%H'[9JUX`:/C'/_ZG!\4KV4UF<D::`6@_D_\*'BP)V:T)UD-TL(N=FNSA
M.6@2I""JP\?LYL2FANPNFWL"%.UDI[MO.@02LL$)%C/CKAF4;U>PJL%\-D4"
M`*U,C'<8FCW'<*PFSJ">[6RG!;'(/7?12)606F<]_;"H5_F*A_,1@R:]B"ZY
MN*L+^/2#0=W%@DAU,*`!Q6C0:E#/`$6L`ZGJC4:R`,&"@A2"$DR48<JE*5@9
M1@\D<UA`(]6N=HYA46@PZ.3$4!X)9.:G3O&BN^CF*'8BCTQ34H@@W,9!I_[E
M0^U$P_4*ZJ^J+C5D$8A-5Y-JU1%R:IV-V&('(M0XGT:JK0;-C!X\RDX[0NZ?
M[:R!\'J1BWI@M%$:98'_7!R)5``HU6*C\B=(,S/0]7'5E+!JC@:FAY<,:,`:
MHP#*+N]P*PM-TAKZZ@()>C`<,<R(K_W0R!@>=X<QD."UHSU%#T8;J0K<!%S<
M>UP'7/M:`!T"I#4XX]#J2E>`VM-2[S/ME-YIS#%$[%6PM9@&3JL0-^GIFG$"
M@N?<9*?M?NZZ]!#=.2EANVBRZ9O:I,Y#PIM>1)73G`E1!8#*URZ`LJ!\I+F-
ME/PP3Y"2@&7FTX-Q`42RCX(40+7UPX!)L!*#\O2?M(T0#,8P&5"^S#O*T\,,
M*NHMS>#3I;'"8D#5$%`;S">?`4WEAO\T!)9D9[8'5N<'K#C!4,3&@E#8[90:
M_\131[;SP3Z-6.,`6@.`Z=1;8XAH#`!:P;L.^"86,\@0#$"R"0_88CWP\4#O
M@$0/1DIEKTVRI#[*S^^Y-J!`<5=.#;C%`K`UH),;<D!IFS*0:L!$!G)723=\
M0$?4(`->39L$DI8RX_*SSC&N[9G;V8--:$9AC*J`#;AB5&=5U9FM:$[$;'+G
MDF6F6FL+Q5!#P+W>AO2,P6N*8K\5H0Z$P**]=>I2-4E2-#].I^XB<3OQ6^<$
M1%2,.G9N=HX'X7;RQA':I5TW@9!L;TY33=8,K^O6:Y$[/?-VL`L(?%7',_;&
M243F?"]\(7%(EKXL,^AR\?HLV!\S(+4#'19H4UK+4?_"DNPE#?3)4A?5P=%*
M4-;N7*=OSYB!%6=AK,*;#^,`5"&CQLQ\^DPWR;@4@`)8?(_(F_?0",OO7G5"
M'WI(@8F<-ST+D,]5,=5'DVNZ840"F04'YZE3^8MH!V?'IEM4<CNSH&A&9YFC
M9G):IM;'SG37F[%;W;!FO4HCXK2U!M`ZK`30]6.T&H9>;Q:L("FJ"L)^&;CP
MDB@,\C(CCOX)$@;8(&>![@B@G)'KPF[4";7WG\(:>,=NY8^M8#D2&TQI#$B>
MX<[H-&BN98<\Q(!E#=:4J+:)23O!*Z@CFVZ^&1)=H/3I@/VZP+W!9N;A`-`G
MDA_WQ@9FA9T0[-"$+:B;L<'_RMS$@;SP#%H.[,JIO&F"MNFB_;K<,[YTW?2V
M.,>9#VQOV]OAQ,?NN9T0<1__D^HL&=#5+;Q%O4$.PX&!MR8S`UV)@7OHNEN]
M))6LAGW>-HH-3O:"A_KKG1!:2%O)I3+U?1+(?`9GR+]A'H[B#:]D<E!3?DB3
M<>;3+.BB!QOD:6+1(G$0<L54*B/U0`*G"F?02.RF8S!W:.LS?3P5;W2C5((%
M:'6S826D6+(1*9LR?>HP"OO0'&_G+E/7"$8E`6=@5%L&*V<`%*P5`1DP'ARD
M81X&`-SB+OE7A(-V10!``7RF5EEW5%^'+C4X:)-31U.'$_R1++$72#I$":F1
M*1-F_W:.<`TOR&>%A2Q=1&B&96RA8%%BMH&OI0:+,"7HY%Q!XP=`P3/6T!S'
MLBS21P(Y$0&890\ME@5/D(#TT1:J1'7R%"/ZI!GJ0QQW,"UR84`$V'\P%W.F
M$B')8D7NQ"X8Q27#$3PWMU2/&$4W$AN`(GS7A0\JDDW`AX>2@"&/H!'8=5Z!
MLHJKHQ&$HC;59(N(P@H8@H?MY8KZX'S'9U0PE4'W56=_I1UBM#Q\9H.J-CQ=
MIX$4UT"JE#QW@$I0(RE?&'"F`D_UI@<B6%^65`$:]7&7HG'1Z#[78WI9P3W\
M-UPQM&9?U!N&41G940!G`8CS)7!94('J<('#<W`%%BI&E?]0GK9C'PB#,22"
M>K-4.@<@"IF"DS$(]/`06W1&;54AZD"#L8%?.+ATX>@4F&%/BYB&%D.#*L=S
M(C8E6R1D,,@""4`R/S$9:36%,#@*%A-"GN(!-A403@-)U&@/!_>"Z)(%"7!&
MD6@5/-$X8Q!U[B(/U&%4<7<^T]5E&Q8+F*A<C*$/Q&`#_;0HJ&(LQ))E+`@0
M<N$<GD)465:%&7!&381N!M4%'J`TM%(]UL`"-D!KT8B)YM-`%:=*X!@`<^4R
M^=0%HV@I(E$TD-@X5(EMQ<>+*_()M7AMJ]--=,)\X=69&<)=PBB+:R*:OL@G
MNWA-!5%-X'01QK@[$.%RY[9CRVC_6/54/K,"`]-'>=\7C33);Y,XB?OF%`Y#
M`E]1`&>T/+7YCO4"5Y*3@'L7`R_H3`\P%^R(DP^P9K_I5/PG)8+%`F;@FU$%
M$/F8'78H%\0PE<DH#UGR``1I*8CD9M+'"7*1@#JE*HNB,@TV5\\866BH,EFF
MD/0F.>=$04\`+U[T<?:@`PV"7QAT!G>#@@$`)+>A`<:5/"J)CY]TF-(W`Y]$
M-XVS$BSP-(:E!@_U"(GT=7+(DT#11B5B(E+"5\J@!S8`29G!%V/Q@G)Q<!&E
M&*E!#$<5,1_%&.1V8\7D%&KQEA)@-9/S'YC6>/1E!KIR/FL%`,VB7H\`9<W1
M1B.!'04@_QE4IX%6MF.5MJ(9\`+ULEN-IC5_%7I1Q3:WMA7`*8'2MZ;MHIC&
MU$Y.,UG\2"HF(Z2?\R:]J)GB-7R;B7RYAQ$9TFR"DHJ9N0_39DY_V@J]B(M]
MH5W/IQ"C`)O2,I7(6&@DD)(O]I<#M9N3<3<VV5L#)@&*5E)C!5T!-V-`<5(:
MQ6=R4$Q_LRMZX$P.QXX-IZI8A*H`)1?SR&C0.:$K%B<MI@>/$T&FMH39,F.<
M6B$L8$$XH&-B!9\?-7E`MI:+TE;"*D8?\%%'9:!Q]4ZJY*,2(`EFH@I#0#+6
MBB77L'C6T'U)MY5T18?2,JM\=!LOH&&(Q`BQ@"/WYRT>RF=;!_^#D^".:3@9
MA``KP2I#3A$Y0AJ6-!IEY'8W8]@#!Q<Q8#9@D-)JKZ<."6`#D=4%PC$KK`04
MY!84$<*D_B`!3P"D[E*L4124%S$&9<=H9N"N-9!N@D5?[,07>&50.TL<\;..
MMY%2UK!:8U9L/D=?HU4V\D*<HWAPBV4&\+(I-::*U.8)K8@?@BJ9";&+HLE>
MQ.@0IVD`R1:,>$B:A@IM>/(1IVE-=!LBETH/@]@=`J=TE[-DR1E[Z'9(WD>-
M4Q=WAP52H_H3O<5NX5*8_P1@PK25:"`F3G&K*$65^\>K,N510XMF/P-Q==E'
MKD63KS.>C0)CM&>Z1Y:04Z<!RB(`S<+_A.'*:'/%+D57L`#20\HE6$`QD<(Z
M=#`0%QH[%Q%0,"]+)5!SDG+H.^D@%S?H5AST3_HR@-%W!VC@K\60`1EP$^6#
M4@:E`6=D@`^*:+Z2)5,H6%/W`!L`57KVJ:7UHBN2>/,1+E_I(S@:0X;K<S_7
M6`8B5E7@`?'`3FKP%ZC&"9``%&XF!AJ%:5EB>-("8VA0+T'%9Q=A`^CC5'_;
M`9(AG]&'-.H)!!<,8<DY*9&5N4D;GM?P./V&9AI+7X][P?\UBJN%<7@5*<NS
MM=2T)[SXM:0#7H-:C)/*J)H)?-\63M[F&*/S65X+;I@JMZPS.MQU#Y)@J7=+
M#R-$EC\T/"AJ_S'J8Y&JH)NO5XU3ZD=_1$)?%"D+-%T]!(W15P#_1"/8@32&
MZP>+P`[8T2U<\4G#RANJ<&_HTTN_]'`J)$#0XBA$2$VO`'L5@&XX:;K[`\B:
M044S%@-:RA_]]T$^^4*PXFM8-$(H1%8;IE=\4S(Q\&K.ZT+!,UDY\Z+^L$7>
MLT`_9$I0<1-$A&>S-SF8,5KO%$@SX`<31SUZ6BOQ-'34TT;/Q3U@U*)2A)9+
MBZ*]L!\^\0Y\]S(V=1&D<"QZL[5`L`%4)2WN<!/Y"X.,X8@C%\OC85M!$0/E
M*:(G.0A"ISPAFP]CU40WL1Z[@D%RF";IRAG@HPBLD3(UFH<T]2H&=/\-G$%V
MRP2D-6K";*JR"AL5OB,]TH%@+TF1*R/#.8/0=S1T!UH[DCFHKG`18&M\B"K$
MYU7$M+BHH2F(19Q=UI61AT)>J%FW+$+%=SL30T<JS+)AN[2![01@FA*X^9)"
M+JLU^$I^FN@U>=>-+1,N"=4PC!8LT7MGDZ)@]31:QU)3I+N.3)//?9R)Y2<O
M%]4RY3<IP6M0+'`&V;4)-.7%UQ`*M;LTR=)6Y[$TYG.2(9HI$)BT)-"&VM)J
MRCNMPY*">S,X1`T@6"*>Y(R%IM(NI,78DK)P'QNN[,2R9[E4$2,L9_FWFET?
MS=)].&"&,(!!,F@`N_0!%@"#Q,!N@D-^(QC_GOJ0PG5&E>H[.`T#*TDF,M-'
M"H-F,\/RP#W`'_71`2XT--?P00!9>X!'+V(R*[<:O,1`Q-Z#+$Y1`$@D:%TU
M8R7<QYJ(+"KT:<I`G2V+V-:`'&5=UD2%8)L(<)9V*JZ5VXDC.,,9F=$T$95Y
M>W3"Q)':%VQ;786J)^REMM74W\((Q"T-;2*-*(1BF8)"MVAB":]PJ7TQ$OQH
M<=HQ-(#1`6TU><\3%>BF#LVC>4%IU,*A>3Q1`%<!$W!&&PJR)$?"OC3"CX39
M/3P!$P)R&0!'&Q?N*ZI`$R]!VNLI'!9^XIHW-)MA%3"`XO8S>SNI$"KR%_P8
M2`_E&->0`4>2Y$/N_Q]U&0"N(0#:06R/AA)#7@`DM5I7?B1X8<;A1QM8[I01
M@$2?%N*D41JS9\"S"'U0#C<F$0$:A1,G;N$J3B-(LD=VA.(7[E.`01*=D14Y
M^T'\*`!+,B0;I>-8SA/@H2K"P1P6`QRFU`&0#NEJP3TUQ@J&,:/C8RF-4`41
MBN).J4K(\92.=&R)TCM701K+`54TTN5[SCV28]Y4VN3[8%3!X>F0SB1^\!4U
MSC&M8,%U\120<2-F5]X9@"2!!!0.Q^69<Q<8UVB,0!-'\A_E>PT9;G'\6.,8
M?A*).(F@9"4E*QS9KGD8!Z..D=*8&=*5F9D]K$V]-[:D2>_,)Q#^WB=KHO^V
MC_!9#QXZOWC@,-U[4<P/:&+3\+7@UG!P<!JGB`UEAT21%M6FDI-F.Y8HJ9&=
M0"'4=86SWB!KDPAE)(AE(A^T7SSR)H"6C$#Q/V>C.-+R*B\7>I#R`)<V&''<
M*O]0L4T,%6_Q0J4(B\!.O7+Q(L]1,=3TQA:#J"'R%>5C0&'R6.J1:_-I8T#'
MBH#R1;_Q+9^=-\&[%X_T)5_R2*_R.X8E%7^>C"$Y.5\A6V'R-6"'`26DJ;,2
MNS27;>^C._^;2@><Y0L1AG%4WN"C:(;U.:\,H-04-/:5+8C8BN`'!<7SY1M?
M<N'U2=]."P@)/BI!1,_U";#V3@4B`$OX,DCT82__]B,OSG2_%2#5]:8?];57
MJ!_M;`?..MN$F:LI98WJ$63K&P[O.MQDQ!LQ3IUY_*[@.A`/J2V2\0>600'5
MR""%*_(5]0]E&-.OAM+?_>D4;QFT]`=F7_.0&?64;C8&4A4($.)_8"#:_:DK
M^;TA&Y[/D@GA8]W/N^P-"#."$@\2+(*(B3V)C((L/1*$$HV.$F,2BXDDB80/
M#PF@!@D/F919DY0S$EF*D9B,KH>I/0F&J2RXL9J"D)^%LC.0D0]CI8*;@ZX)
M0**@AEUB'QTU,UG6C,B0P#.Y":*%GV/8CCW;C)"C8P$?8AJ"69^C\:/E,R3(
MW(V=GA*UYHFG"(%ZP`J1_X0A\5"EDM3)5K)]"BF]2L2O(:=_C+*,\31OR!!0
M`^-Q#`E2'DA/H4JJ5,FQI<L''TV&G-<,%$*4)&>^M(G3`!!F-;U]\_724\R5
M)W%^,E"S&5.F()D6G=J2)\Q:67`5K);5FB$6KE99`SN,WUAA#<461`LQUJ-W
MU@*NPH2V8KD>Y7"!!7DI$BZ4!$]Q0XE0;*)';!5FP>N*F,B;WFH58[S34*2X
M8Y75PILI;D,6IXR!Q57*:]B$:LGM'87Y$-G5./F*E07:+:Y@7\/BK9A@<N.-
M7^L-JFB8-L-/MNAR$S@P[+#F>GGIW>?3),$>$0!\"%!C%><>:_W2I=P/ZKS4
MP_]=E>95J%]V`!$6G1*9$MP8VM_E[SL?:5%T:R,!P9HEX(WD#&V("//2)8,-
M-!!F<=6FWB/]@..,7&%=\\X8?4466TRQ&3C*2O-$]4U22%'E$E+R?,*,AX1=
M)9.*('D4RHLUO0C85"RRN%100CW5E`$J\CC4)T,XYUQ[IQ'7F)-/$D4<DR4Z
MR61;)<X$"H?M9=G</C?M:%2+2\Y4IE(V>822*!SV]8`.;X[8I4N2K#37:<UY
MTM>32W9YTG-4RN-1''R.U(PG.I1$)Z"`E?6<,_V4A&=2DXXHBI)GT%<+,1QJ
MIE-['K;5SZ.BV'A2#V/$$(`'74`RQI>6.+-E+SFQ5!'_6$H-TQA(50000`;B
MJ-(3D%LNV6E#\0@XHC^ZKEG2$!M5I:A=D<JC(T>1"/5IDUSN%X\!<*XX2I2=
MV&HJB?4IJBZQYL665)$ALOC3D6&22.-0H4!EWKLO'86B2B]JJY)/4)7$#+PM
M^0N3`3<)U)+#<R+\\)L6'KE32F0BJ28X\<`!QT\M+J-ECA;'XV^+Y\I3IX,M
M>G*B@"Y!EJ6!\\Q,U#(U,53ND7E297`"*7MI5&'3X@RBE^/N:&^M&RUS<,LS
M1Y)RT2:!_*UL-%4G8M%*?8O0$/-NR8MO(`&*5-,>?;2OG9G^7&Y)-4S&2X4N
M/MWNN-4J6AXH(/>F4QP/:.U-_\`AG3SNJT@-=6G@!Y<8K;M??H007R>)[&RV
MRB9E:L%7]\CRH3A3;2N\GC->XT[MJAC3Y`/#G(`-,!=EKXC58?QS9"K90*3$
M-2.I0I@Z!"_/XY"U'.:*.X8+(XQ5`5F5"NJ"]''L*&5NWD<_I5VT*'"<-#5@
ME7O<HD^)QG[334'5I.FR*3K-;^7X6LZ1#MVWY)/5IE<_8OT/J&!`]_"#BO8,
M%CMMN6A$!427%%*4+/-))7!/F%%)/)8YOE5N%#KP">S6]#+V.>M9AHL(+2KW
MD^H!X1,U$)2-UN:Y96QP*07,!&/R1C"@,2QM'QG)$&KH":LY37\:BXKMWK5#
M'KJO;O\(M%0+403#`@)A<LUXE>O0):1IJ>U:'L)9UW`G,"YJ*5\R@9JX3$(L
M*]),8BM1FRA$88,J5(%ZTN*7H9151C`.3'>\.YH<$28G-&XM1+*;W<EN5KN6
M`05_/:H7QA0YNMG5C7,7^R#46!9&EGPJCO*XV[3J5L$ZSD1K2ZDDONXWL!ZM
MJ7&X0]HC>U2P3S8.E%[,9-]60BQ#9;*.XLD2D`K&,V6%DGW3,@#L:`FK)X7N
M1TIDGON6^,67Q>]=RTS<TG1T1*&MDIGC.J(!?10Z;!JJED(3(@/%!+D@25*,
M>5P:2("``3=BX%#E])D=2Z*O"@H%CWRD)-!XQ\^I'$5&Z-S_VCX%VK(N5F66
MT4N3#D=GS7C^B"D!B^0O=9*3V/@$`S;P((\N2!*:86Q?/L0BQGY93FE.=)O5
MV]TQATA,!*HTHLFJVHG0E9)"[DN3J4QEU-SENIOR;)LXE:;@$)FTE+JTDBR"
M94\3F*Z@LO*6)A*EI:BWQ/0Y:(KS=*I3Z-D4!/KR6S-]INA,2<[.1:9X#.6=
MCV[6QBKHCB1!(5T="VDB8>ZN2/\*:#_36:LBG>QX@R2CNA[ZE%J=;DR-'*<I
M!P=3$9TT9"PK'A#:B`%[;A1%)0LE!X>41'J63I=DO&G[K&I)KH;6F9;BK$EU
M>2)29K64+-4G9@GG1=7&$JGPFV4K_W-BVU%&M8&>%6=LQYK3+HHVN&0U[4.1
MR\7=>E*<9FWJ<VEJJR6>,28").XE23?.D0P3:=!$9^+TM1*@X)-&^]SD7M=K
MDU'\,Y_J71HR'=2,L"&U&<>;W5I;)Y/"`BV_Z54)6GO'21]N%R8*R^L!-SNP
M]!46B57Z%B)W*]RGX(^H[",E@TG2R9\L-9D63:`]TX4SP=&U5I-5Z8D9YQ0/
M*PZ5L_7EX(8(NOO%;EZ`7*>,_1O5?$'4L_%:9T:7547AEOB!*^5HV.;;8"72
ME9K1(QA.1EQ<^[JHM5(EJ'Y9*Q/641=AAI,CBF@+6;URM8;>N++(&B=/,FYL
MO7NUXAXO>_]8@%:NG"][:VG5&V;0ADS"P+1=F':X+'\-$*!;`Z<85^A>P[80
MAD2F,.C&3&9+FA@H32E@+RL=S(#=S[GZK-Z0%VNYP5&8HU4#2FQ=]MU/-YFD
M2X'=5DM+3?L"V5:3'36%76:]2HO5A%2FM%&)F6,//WJ;OGXF1R9+3>>I&8:[
M#'764)U03!JP=]0&I#P-=['4QO?`P\(1/<7-YD!2$L%PCO,7]6KN37+;EH*[
M$4,%S)$^@_>;Z@0:1=GWUS2]3TAQE=**2N4E3[>OA2S4:#?AF5=6.H_2\Z1V
M&2U;)6_H>=*!3FJ^62QO/',SEA6OX8DS;LEF$QF!PRRN;!/J21/_&KE6M=SF
MRNV;\&/ONF9.$U#M@NRY4U>7BTI#=4EK],_DUMDH,3MX.?$7QZ)`1N3\+1B;
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MYQ1`@FE1@4?G0U[[=WS\]"QI)3$XE&^6YF,C$W`E92"[13M1EEAGY5%B%0K:
M%EK7YG2,!$:P%G0-=W^()W,^1UW]AU56N&KH9U+7QU+MMX6AUF3,%'`Q9UB<
M<W/*U5S`9%:$XVQCN"ZBQ'?0)5RUEX5A98=TASON-U''E5!E>'J:-8(G(BVM
ME7)'$S3<U$K_M/]\?M9?+N1&;I1`5!%F+49SN\<PI\0PYO=?/)A.)W(4E.A7
M-F)H6D9?;A=33)0E`*9.#T:":;0^X)==%05<J!0SD`$9M39_?8B(T]15)Z=_
MQP@_'_AL#-2!#A*`0#5=MS:%(X5L?:<^!Q<_\.=3I%9:23A;WE95T09,-=9:
M:$ARAH=;NL54QV9_8:A;TCA2-K-YZ(AVR*4[RV>(E8=I'=%FV`2#;M5'4.,O
MSP11A/,B;X5$3-%\X%:*"2-@1X=UAE9F&A9*/#8L1[=(2@A-:$:"879NB.5?
MXC<R-JA"2;>,!;ANR25]^'*0HX2-H_6,FL6,&#9_GA=XH!.,A6=1],7_,B<%
M4@7)>CTID.4X59:(C)`&5RKF.AA&-9P#>E>C=\<D@+^%4MOX,NQ(7"XS4\[R
M2)I'$_^B/HDXAV.):C8)7%/9;4EE/37T7O[X<O'01AM0!>_44;@G:)O%2SBR
M04XC?S9$B@ZYB0)V+H$973*18DEEDP`W29+(D[2T1CX$EM07<6Z)76M35H+X
M(F\V1A]I=*%7>'#)9$>H7:6C6*79<S\GEM/&@8F9FO571^?T64-TALE45?*H
M7P+#FK&'7&/7C+%WA,-8CW`HA!_G?`KGFQHT8G2F2VRIF<SSEH1#'VU%@9@T
M%,73D:XV3`03-@N90ZG(@X;F90,5F+[I:8@W_U=BJ29V1'RE]`FP(V-KU9O=
MIQ/8Q0P,*4$ZMETYV%H]Y9E#R)RR1);$V9.$&#OQ5D88)W@_:92;!TFB&8D!
M"FLOMX>?LW_8IX]KB"[4='%(^5M>@EJF@X[U1V(:6A,OY'K,%)5<I)/#%9::
MY"XC>8[Y5I%_5U!AA6F95AT*4Q68Q`PKF)),F!(Y9&>9AFFR9I!$V)"E^%<[
M6IBM2$`0V$B?)U!56%VJ)I!II4ZRPTL%18X&*%ZO-H]CA$WCJ)L8NIN_AI%(
M-73=F'X#JG$"RERVJ(9FVHZV&:<4&H^P-3/[E84A2(\C")J'2&T7)):.Y%B`
MVD)AIT,$)7)H]F/G,O^+/-611!EH=F9[MR4*(&-CG(I]"^FD)WDZ.G5[>504
M3<**`B&6S,$2S]%*%8%T8TJB(%0I^S0,@]2/XN*6>`@C5V<5A*8WE*(DB+6K
MB@(BU08..TIOS-$UCRB#I#)I:>,G7;:L01>4JH>L_-!7I/HEI]0<6CHTL9DK
MA(`X7Z1'WT"M>:)(2%A8;P."2?.N*,,Q154B2=*NZ>@,XA>C115?8;*JC9*O
MWOIF=H03JR,05Z<S4L(O15=M[J9E0C(O-,AU`&M:98=^1DA%./(B(-,WS-98
MH#I`Q?F#/`(3Q/`$9G"R*/L$8Y!"H&`#*-L;\]`%-1`WA)!!0/,$,YM"!]'_
M2B9[LCE[LGI0+@]@!EW0!1SB/3MD`T_0!2A;`T_0#V/0LV;`)2Y3`S(K`?0#
M)Y9`M$5;M&:@!Z]B;4\D`68@!SA;`WH`#PD`!Y^`LB=;&`<AL]$""C7@MFUR
M"1CY-:!0/V-@MY&2.4,`ME&K`3&@`7&3-![1MT6K`4S+(87AMDU;`RIEMU*Q
M0Y,#N2H[L^XU!#TKLS,[M4'[(X@R!DJ+LH40"D^`LU+KLS-;#$X;N3H[!D/@
MMA\A$'%SN#HW!F!KM83+M&"+@>ZUNB?+M*W+`E%[LM1WLA'$#Z7+NG'S!#>4
M4H'KN9?`,`_T`*GKMIH+!UM;MCFKN9?0MV:KO%-K_[7_LA1M\@2$R[A3.[<P
MT;=$6[A&VRFO&[F;8K<)4`,VH+D(5K=FH+*N8`">>[B;.P9%BP9%J[O98@`H
MRR'?6PMIUK?J6[B&>[0<\3LU\IP.:V-]0X,,=3[6!:Z8%22R]7E"H7/*8@,I
M!Q6(R6X.Z8/>E$=#T`4P<`<54,,V7`$54`#=40,14`%W<`<O4`,LX`E5H,/<
M(0GQ\,-`'``)D`7+T#U`\`(5T`$=`,1B``,!L`%P:P`!$,0Q@#C8<L0Z7,4=
M<`<!4`P)\,4V'`$)0!8;T,0)<`;C4@,94,-B``!Z7`$1H`&;`CD,HP<9H,,=
M$`!=``\/T#TUX`%!+,1/0/\6-@`#.DS$$J`!0-S(=Z#%&6`#C^(->OL_M4##
M00P#&K"JF](%$7#&>@P`=U``:5`+D?`$=WP'>BP&K1P#!$'#.FS#.5P!'O#&
M"<#(=Y`"Y%I$#S#%O-S+%9#&+.#%0%S&5?PK3QLIA:$!-;S#8=P>-<#&05S%
MC:S#&J`'$=#(5GP'`A`#X"'*F;P!?>','5#*OI`J5)S'>QP`,0#+`\/$07S%
MW2P`=Y`!++#-=_#.":'+%:`!8.'%^PS--]P%)'ME,/'%?+RYWZ#0`\W/,-`%
MQCO.R@S$0\P"3_`"F?S,NUP`1LM1V!L#(DW/8K#,?MP>3Y#*=T#/0AS&VPS$
M9VS_SC``!#/P`,+,S]`<`Y'0!07PS!GP'`%0Q=F,$ANPTK4,`V[<T^/\S#DL
M``<]##80`36\RBT=`*6\'_Z66=7Y:?[%I1H\-9XS:!D<&9<YH:*7$BJL+!FK
MI.FV,:LCGGV4;N,"#:NLQQ^@'15`Q&/P'GH<'Y&@`8!-#651`Q6PRG?0!3,@
M1<O0V'WMV%\M`39`V<`B)95,SWT-`^(P!C!@V5R1`1_P`05P'X6PS=JAQS/=
MVFGL+8GR7T,PVMK1#M:PMJ`0`'U]U(]0`[0L!M0P`XA=V:<M!@6@`<5P-1Y1
M'9$0`WT=`/):"S80`)XM!GG\`:!M#3Z<W0"`W8`M#L5=_]G:D=HSL,9ZG,8C
MI"TV0,M^_=>G#0-Z$-D5\-??[=UH_,>)R]NK'`'%@`F,;=_D_=<:@!WD#0`Q
M<`@:X-G<L1<P0.#"D@`9D-TXT-*T_`$5T"J2[3(O<.!^#1\SP-AZ7."LT06U
MG.`LD``=WM?P+08V4,0C908/#A^&<$`2``2VW=?MH`K\O<JGS0XV$.(=,.`8
M;@-JJSY#,,ZN'<39'0&74=T7?M_:,0TUD..K+`"*W>,LC@,1(`C`O<H58`/"
ML`X?8-B6H.1<?=ONT`-:?MHX\`$X4."1W>,V+`"MC<Z$`,)-ZG3/XJC^]:N?
MDD8@*Z361L)L^J$&HYTX0G`?&_^$&?Q]JHA#(RL!-9#'61P#,1`!F1X#)A`,
MA,W*D!WB>=P!"2`LA1`#G@T`&<`8=#OC7JT!7US8?5'E>HSG?Y(`&C#(Z<VX
MBS`&!=#7!5#J/0#=`!``Y2`!7ES+7CVSL`X`,"`9+9$H)+O@T9VVV?KI=^`.
M(1[<PVWBA4VX20W8!;ZJJK;:*[['1`P83]#C!1`#-:`!$=#2XJ`''K#*[=X%
M\([=I:X![OTKF([I!9[B_&WL/>U??`T`[1X!"M_'@C`&0^[LA1L#H\T.XWX5
M74#9>KS=DA$#&9#I#W\'FJ[PI5X#JJ+L?BP(7>#>A0T>"?#K'^`.8('J?PT#
M[O[N'$W_XA;T"1L0`1F0`;_^W?:L\)#]Y0!0\7K@[6(0`]R@#GK<`1W_[_>L
M"J7W!+8=`8>P-Y]`N#]?`3%@M)']'C3_[QT?VK8-U9FN\&&\&@<S!OS^UQ'@
MN:@L!EVN$?R-W%T?]]/0`UT@\:Y=N.*0!>\A]V>O\#7`"B).SVE<#?R-SF!Q
M\%Q?M#%0`$GOZ7L<\I@>`=20!=#-#ICO!WZ@*N<\'U]C>GZE;_H&<+HH2/<9
M1P5#=3YF1*0GA]"V0;4#1TZ:,J,TI!+9KQ*0\J!^#XU@X-$M#I6.X8I="+Y>
MRWILWK;[\&AP#TQ?[)/A\+5>#DEQ".KPUTJ?(#^_RMM/[`2O__GT[-_`']F9
M?@D,-`3U_MU[;`:1O1F?CO#$']RE/@/>?@=^<`]Z7P!_#0@%8RP/#PE`-A@&
MA1(:8@!WCP`:,X4/C6(?'P%C,R0S/1H1G345``"",ZJA$0DS77>079ZJM3UC
M`:<!/94)"0:^78]W&I^UM6,=IS&TL,L]MT-C,:=BCV*48Q+0JQ&GJ:#'-;%W
ML[7.IQ\5-3-C!:>4,PD='P`P["2?/5T1-3T)AH!=DI!%E2-([,3%`C#KEAYA
M`,3$4-,N%X``M(S-R"+AEZ\$8\S`.!6!5\>/"0K&>%2`%HLQ'I;1LM7NG<29
MM5B<M&%`PAAO'SJ,R;=*@SEA]4;18O^5<(8W5+S40'M:H(?&53-*G:K&;(;%
M&+SFG:HPRUB-&)1Z/"V9[RJN;WK:MM-00Z>$!T.&%/JHUY+?O'J'^`+VRP`P
MPPD$?P26U]?>PK[Z%E*,&&_>OP:``('LV.-'0YP1^T)T:/-B@7Y3JU[-&C#?
MUY%9RY;=&*`$B!*A03/!JQU590"8^7FT;H:$;3:&H1F)#=3Q!,S1Y/-C$RRH
M&N\FS2!46T)-F;9L=H@E9I8&7;S>`A!Z59_Q,2@C2WBB[$X$X&!/2O`FI@+P
M"#/X09XKKYQR1T*?'!0<1QUIMIDT0U@4002/['*73Q'4L\XG+/3&#36GF,--
M.[S`\@$QNHW_T=MW%_70T6,)V$`>6+>,H:(JR<"C"@E:!0<*0'K$!,"$NNBA
MTP,LK`(B>ZITJ$H7!M9@3!8:D/,?+]G%<YXL.*TBP9&Q'9=%00>),90X]<5@
M@A\UC%%E1!I0U(-%N^C6FT_P96:`C=F5Y*(AFAE0$%6KO"0A+[HATZ<>NO&V
M78.*//`35WYT0I-:4>KCX8J$@@*-11WXT2BB69ER1P>/=,#.5Z!LZ>,QGH+R
M5`"BVHFC17?$4"FLE:26V&22_?4K:"@9QAA>C"F6&$!XQ1?L9'P!VY=@A@%!
M6+'7$AL?0)XA8D-\H%DVV[BJN892L[%9`MA`Q[7K[KN^V@;1>@$4_U!O`2&P
M\-)3:#Q50:7$L7-7%AF@-ZM)'0%70`PQ%/"(=;S4@-]VA@P!C'?0/0/*2R/=
MT>\W^^BBBL0DY=3ABG=Q5D@/2_HQJQXI_V1-!"N=:*,R8DA9("1^S$!1.\`%
MD(5.A%4[Q!,C,33.>H.,F4``]>Q"@HO')3F#'E`#(("E=R4Z@XRG='"OO0FY
M0Y*+S#(+MAAB%^!V`?&(!0`:.%(8$3O_/$`?)'*8$79=/ATW5=B6ZJ3B/@&K
M,F85%6I@2GE8ZXBI/4.=/.:('1G0V%V2S@"BF29W`5P';L-0KX%IJ7?'VV[G
M-\9>-@#A4](`_@D90195Q<V<84\8P._,D/]@!G!W_/ZV=:"9-D;!6U40`,V6
M5@3RU+>LJ!M5B$(CI!ANW]O*R*8V3)(>3S$SN:KZ5+W[4]R/71(H($8D=@8:
M6)H%L<_.)IE'RGJ$KF,6&Q9GAG49:#4K6+49C$`*<RUN><8SH"&,M[(5+G)9
M4%V60$D"F669RW0A`R`$(<-&.$(0=H$C>#&$#BY1`TFD`P`?P$$,O#.Y+D3N
M(LZH0">>DYT8D``B!S(."Q)@BJT8\7WZZE%7)&`Q@60A8\'I01:@,8:.L>EQ
M&EA)B[*RD*[4X'<1^)T&>O`2!?[J+1^(@!I:"(!UY&T_RW!'4D0'"4M!B6>@
M>,!W-O&ESQC+3:G_4E%U-I(%[)S-.)PC2$7J495'&>)P^UA(.C0QB?1D9Q>$
ML,1QDK,537BR*SFRA^^N\3ZJQ2`6,&!4$?,#&A4]!0:=0%L"MO&F(`K.1`'0
MPY*Z8)%LT"DN+GM>&)42D+Q<BR"?*YR^;``<&!Z@'ELA!BC,-DE/IN(DB)E=
MR8SS@&N-(4@@XX9Z3H$#'&AB%P%J9B?YR+F``&$,3W"8$;\1@TZ8;1.(TD^[
M7"0D&/"B0Q*P"`P]&92$D.P.8X#2B40AD\F!XR0#R<(X!ZH)'8)OGA$I0!>D
M"!\(0HN#K8E/LB;S/VT-1H/BDM9C]J?!;05J6]=J8'QB1YB]7/"FJ5%6__^&
MU<%"!,"%&)UG`(Z30AVL4`)LI)?O`J`!&CYE%FPL7BR$@L@WL2>4&N`(QPQD
MO,<%`&\U2!HSCC0$TW0D2U)$6\<Z`:+554@5PXL(,]2@`7/B`(94[>@O\C*&
M@W9A:A.[RZ1\Y`RI1L2.43).2J@IM"&>9@AFL`C=/%<A;12R3R8YPT>,I!ZJ
M'FDS-D+<-R84QJ]2D4Z\T*SF+L')]9`VC&53)S1SE4^?2$@5!^O!`S3CRF_L
M,%R`1(AB)5"%6&!$C@!X`7`:\LL9A"`3`\4&-'QB@"<X:)8LJT8LJP8V5+S6
M(MB0DT4JX+LP6J=!FRF$2,[V1,TX4#TP6,4MQO\[MH7U0`U^&)TP)]14Q[CS
M`86,0`6L8<2;,!9AX7*7D%[0)$/@2I@!H$`]+PHZ4(D5MW]SY&>.\^#76F=D
M$9#D0,ER"VX=BUCC,I=HRL4_!5XK?ZWIRVG2QAGW+L:,VT():3H#4IQ:D%H.
M_$Q.]?*3"E0`!ATPLG\ZP.0D'SD&0^.<45EXC7A@)4F3*X93YDG5+)!O+#'H
MPBE)LL,Q/(Y&D4Q*>I(6#X)0JR=AE0F#,F8F$H1R*QAA$3J_*$_*]4*!0]!E
M-2+0!<>=PI^*E=`GGF)$Q`K7.%DPT9"XN9A`HR,`A0X`.38JT5QLHA.&L.DM
MMK=#R-B(2INVQ>Z>AA[_Q6IN"$@EQV1C-3+@P.`^B>7F;8+6A2YD1PP]&T/L
M;/1*4#]F&@;:J#8PL0E/W-&(#7D*>TP0@0(0;Z-_,@`&;/P`01_V1[/<&XIJ
M888NKH).\N7&_4ICFR'0[D<-#+1%XOL>5@\)DC=:(SVB>`QH/.9:!;E.#`)0
MQ*"H*'?V9)9`VK7@'UU"2*FPE11[Y`<>%7$K76GK+#B'DN,\Q0/1TQ<B5Y'0
M:E^<$T,$@@Z<=5.]%"LQ!8Q@8_3DWQ3"*'\;-,S^:(XMSRPPQX?@R;9\G.+`
MM%3(0[Z$C0ZW]*8[?2-2/FI2BW$5?0V6$A8W(E6!!DV@]H<=$C65ENW\TRU2
M_[,K=LE<(2_\GCC?H>(S<)7(KH:KH>R&*J5>#%ZR4PT7!E$GZ":!'Y*FW2?E
MF@59B!\EGF.M122^P$`%D*R2O1%&[+83S&/(=FPC[#&@6AUP[_<0#_4H)L)Z
M:=@@RI0*B9\>E*(>+^B$X>S6]TXRHZ^@+3:E%Q&*Q-K%$1^HRM3X+CG@EX?D
M-2L'I9O(EVE<(Y:^F`_._HH,\L2C!S:1_(XJ_W*?O&";-@)43QRJBB^I)WC&
M^"<UZ4:4\N^E,K]8T30]_2_/56,6A)CE;H%PB2P\A<'_\"5"T@%J<!60UB,Z
M$S_@40-;\3[MTDVS%%`E8X"&8SVN-SJ#`('(@AKK4O]T0%89ZN)BU0)2`D08
M@3$M,^9?"F0MBV$:$#1`Q6(:,$)T,;93-Y=!/78)\L<K/,AQ*P=@;-0<=D)&
M^Z(CJJ!%A&,0T*5D228)H)0FJX`.[U-%<>0B8R`8/J$'AA1%TY4Q000*`H4*
MM?`F]U8+0'%-?#$$D28)3N8?3M@-<Q=W+@0Z.Z-\>N`F^W9-`7$Q8_!]$6%D
M33@6=B0)7Z4'=S@-`>`*/:)1A@@?`\<.A=40C`(-2=*'9%8C\*0B2Y,KGC)=
MJD!$\/`)2,@)UY$T_G&*DB`(_Y![OD5IOA!)7*(3G]=(KW!QVI$5>>@/GQ")
MKA9DB:%+U]`S1"4!-E!$(I+_%56&(YC5B?[&8[-$A4-"1?!1`R#Q3?\WB=(S
M:4TB."Q`,EPXA'F230F0`?W0&U,#%+#$(]!5B'=8`QK@`=@V6)Q`B1+03[&D
M&XJ$@,IH1*!DBAI@B'<H"F/$.Q=QC]4C#]!3"W;V#I^F$SK@@CDF&3"&@[]@
M+1D4&)G!@C5%4A%4&8!!&2OV*RUX+2_E/S#8<S26@S3X/T*F&!(Y=)HT-(JC
M+S3I)624,OY52&Q86F"D1Y/3%=G(-!L!<;5R"QF""O8T.@P3`,JP4#B2-+?V
M.V`$'QF@:=^0`3,$"C;1%#VR1<9QE,D5`W+`2X\`2XH5&]XF%"F"=QBFC:#@
MA]^V_S-B($PP\`@?<`_E%Q^W00XT8B/H<'T"U0$1H`$9\`X6U0,%4P^"N91B
M$$3H4``>()5,U4<O,`R2&0`>\`2PN!X>\`+V$@`9@#'`@763PV^16#VA,`P;
MQXI(>98)$`-A5`T!$&:T9%P>@H2:MQU(2%Y=4`-/H7R$8!CXHX9:!&Q09PA_
M2481@W$XXH>K(YD18`/KYD`/L%YM=)D>T":P23Q8R0[J(7E$90AGX(V"*94%
MT`_AV!G?QYN]-F8?T!6E25Z$Z3#K,`VX!@DTDP`=(B0742]2N0'>(3$?D#/G
MX$+P289SN921,%<=YI^$AHOVD`&]R0^9T!Q$!0>K)1@E2?]`K`%`QH(:OV(Q
MUW52'`22#Y)S/]<LAU$T>N(@,253V$*1*DF#+)>&,0<CGQ&![W(&[^(N*%8(
M62`'005#8N`*:J$)0!D@18107U,!]9"D)!`"6S$+8R!B`[4>8X0CLE4/ZI!0
M,#1/%E5%]=`4]@=#NI,>M(=1I'@2B3$?,("DL#)U;9EGO"`CT&0I<F=$Q9,0
MTRD8*P<J9U(+;XI/=0-46P$./V&EK8@41L2EJ0"-%*4)Y>%Z&.5),%`09@:G
M^U@/8P0BPJ<HZ'$2DV)PKED`E-1)D@=\M!B4\=`AAM9U6Z$JSM%-1:,7!+,5
MPOA(Z-`0!/%LH$1\G:1Y;`H066#_G9,$0^N@!X1G1+ZT3>V4`.,I6^D@`,IV
M"(XQ6/,TH!%@`L@08I4J"'Y@BZ<@`'@3AE^J"1%0$.,00^R0)%\&'E(Q9MD:
M1&I@KE=Z>YX&3=%D'>%7&,:4D29H0/&"@\;"+&\V@BH*<]B"&`G$L"%8L`[D
MHCOV0`^T%Q9)D:OQD1K;H48G4@+QD3(ZH^0R='T5F9<YE:WR.UV0)">C`2AK
M`_X9<K[Q.][)D]"9$%9GL]#I>B<+FH@R<&L*#;H$/+;B)M669*0SF_Z@$_XS
M'S&+%3,+-[S@LK.9'M!`M:28%2=+,QN%(QWE%PE06E;6&U0["KUAM`5@9/92
MCK;`#VG;_Q_G:0Z^V;.SN4-52;?>2;?V-;.8-B)?5"\Q<!;/8PZV4+8ZZB;`
M\UN24I@G*[>`*WMCPDLJFT?746TP8&2F$V;I\7XK=AM/JQ^^23:/TE=2V:[+
M<[+=(S"`PGG5)IF?:;:M>YEX`[1C1%0<-+<]6XXX>3$V,'#6AKE]ZRDTY+:`
M^#S^8`)`:YX1T#,L\YFNBVDC(Y7V8Y1B]$_0,+>72SJ#B2A8V[@"QY1.%K=G
M&Q\VA@@%FT(=^!A@RT#+`K%`QT"-!Z,@F$&B06,&8`,T1;$#E$&:H;'^^[\;
MRV(NIW,M5G/J`L#_>T%ZN0TG8RNE1X1I9Q<>$EI-,EU#2')#N/\BA@-)&;PI
M&:QJ^*@-#8R/(($H?54#U(@R=W&QC,"R+M+!Z98B":"<(S+"7I,3F4."`-$;
M=L$(=O(E5C-$*'PXVV'#)UP#W`K"'9S!(_P2-](.O+'$&&PG6,;!E+B-@?,E
MNK4-#W@):8>3VW#!S(B/G*.<[D)R;-(F*!-JHY%>C'`A>7FX7_(HCL'`GK)T
M=D+!=E$:E_!(V1/%/[/$UCM=1\*1>+S$X>D1BG0+**S&MD#!TX3",UP+4M$#
M)A#%X&C%J$ER*L*R^X2/$G?$DYP30XC)(Q+)0WP,3"N<[%:1+FK`PA(L(EB_
M'P&1,<6".F8:/Y>"#XL(#\)SQE)`BL'_$PA<S"";=$!F@S;W%\9\S"S&09\A
M<CS8)-)<>L>1$SQH.""Q#;!RRK#"M-L\S>)<P61D"RDSQ]OX$8,PS1UB"96!
MSO6V;/)G-23G&/-<S=_\)\GC7_",2!V%SD=2-=ELA=JP@_*%S[QRQ>.,T-],
MSUY2T.RL+SX!$/1L.%5#DX4\$`Y-RA5]'*_C';40,]ZQT2&=,B]J&]?L?M&,
MQ6=,S@:MRG<!?[,TSN-,A#GQM>%"TC@LHRG=@WC2T[S2(3K=B>*L+[H1Q/K1
M;X:P3]OGTC1],D7]K$53DOA[OS)8+C>ZAP";AB0J&HCQHANJ+0WT4841*!F9
M&"NF+/>[",W<_]8@RWPX=L!N[=8_*J(.)#@9W*,/B-+MLFP^^AE^[1-]''[M
M`B9US(UAS,5`#%"VRRZV^Q$^:F,B3,:2HE?6JDE@DAD`$=CP`BB;H=>%;87M
MDJ,V9AL2S7&'W=C#>-HW>=G[9-3MI-B?K,WO\L4>S=E:W-?+ML>^(,(Z\<)[
MG5[ZI%?LHKZ.S<`;')Z,A]+;3"QX_<./#7\L&&J/70B:W=>R`=I?XM'6G5[6
MNMW<"-Q:;"/[!,9[#2[N(D59S*8X>M%&72,4^=II5V(ZB-BB^BY4\]-_S4%`
M#%&WO=BZK=?;_!P1*)/4C),CF1E"%W20X=:+05-7;1DX!K&$@;^-Y_^,]=NQ
M`U2^N/R1"A0[<]W6RW((1=.2,!?B(FZ_07;<7<RQ;XR3\0(NU/VCZUMS/MI1
MG%U!JD&B(<LL^QT0H[$(FF2Q+MC'.][=(MO'O?U^/2<;,*DMZ_MOT/S&)A6!
MY_+8/AYJ41[;%S*#.#H;K8QT0([E\\O/"!ZRQGTNDC+1-4>B"XNC9J3DL`SD
M2JY)J'W2.#@0=2RCC$#<])LM/=;F*BCC6/YRMJ'E,]C81IXVEM>A'O77(,K7
M-%[C>:[7<%X:U2)T-*=S;:VBKURB[H1C#_[I05:_,`*Q(GH8@8*"D-&_*([`
M'LOC__/JQ2SHNUQT4;X:0(>C+U7E0$=!%+G_D1:[8H^QH?5[OC6NV9"QX^:K
MV8[NV3(NH\"\6AXUYW8M4C0V[.]+OZ_,N3\7Z4P.+K\>DD,G9.0+D;Y8[/GK
M0.2>-B2Y0#`*S;T.&3(-HD2NYC(^&--]ZN[\[FV<[Y'.<P2K@C'%[BN^[!'$
M;;Z.\/ZUH?I'['%=Y7"NZQ2+&MJ"RX.>[0.1YB`*X57][\D"ZX!A+"59&T#&
MOL4"X?$N[J*.D6;ML"[&;K3^OS<&:`(4&3,/P(-^TMRR00KKO[$,++)NHKO,
MRQVIYF+=\QU)RT'7>.ZEH@4KD=6"RT5?R]9B+2A8&P*A)PX[&355D0!A3!\)
M?P&LUEQ]4H%QL?Z:_[#:GJ,JTT$!Q.2<>V,8R1A<34%:;[!8S_:M#.UT#F@-
MR[!Z,L#)XC_0KK_N:V*=89%O1O@G;F/.KN\*.V,1E))[&+$8;V(K[U_,U_AQ
M?O@FZ;Z"P?:T:O#Y7MKNCNH9FQH>2>(NY\KQF_J=<6+F_D`9Z2WQ2W/&W+ZA
MD>&V+U.Q$R/NRW,PE>&>CO5N7K^(D/,:ZRP:JCD`Q/DY+\#+WN#3XN$&VX$T
M/_8?2D`N&LQ0'\PJ-M9`3AK-XNWP_J$T15*)H0+*KBZW?U)0;MT?&L`;B"Q8
MS^DBZH(U!0A#@@8&0P^$!@D/BX*-AH<&0(2&0Y$)@Y*,@X4/E9P&-@:+0/\V
MA@D)B)</J(F""9*NFY=#F8>9E4"/GI.=B(RWIZS!B8N@0)=`Q[V(G*RZDXZ\
MM(FG-C:GEJNOPMC*V*>"RY30KT#%P,RFVXNHP</$K_"$BMG<Q*N\\8Z#BL*K
M-L=0!625BEVM(>W<M<,WR9BA2.%V29NERQ7#<?=P)8.%D%TD4=P>:3,(;V,D
M2:=(4=SG*"4UA`2I44-)3:!)F9*2U5282F$W3@B9O?S8JM-*ED@]%G(%#AS,
MHTBC.F(4S%2R?M#"=9+*56JZ98@X/D.T#]N\B#&7,NJ9$!7`>:JV$E7EBM2Q
M>]JJAFW%$A6_2LXZZ22%MY&*</Z2@FV5]:35I>3_[!&ZJBCHV:RTGESZZ(IO
MS["PC*8[*QC(85JY@EXR:_9C9<N0U:(N5.[;.Z'&%&F#:WO554R-6A%</5EL
MS&]60_VT/9R@SLKM=CKEO&O0T\\GJ^):&GA[MW?!=#)[8GPRWZU&*5(LZA?2
M2;&4/'D"MRA]+)3=<DJ2J5L[T^&4.&,`!M?$DU`B1`6$X&`#N9/*4VF=M=TQ
M"$T#V"FK=+6/4DR]I.&'+.45X#P7=:4)B$A)F-433V"VR5(LD17?B[(AM)]R
MNXDWBU)P-9*2?OVY,Y].44'6&B\?$5F?(RJ<QLIA6Z6("'G!-413;)3\1LM;
M1:EF`)7%Q`89A+:D5DXZ_U4Z!M8NR"U4FV]O[3AD>9OA1QN)KX12#$!NMG;5
M;@C.TR,QJ%5V$R=@*7F@G<3-A))&/7X#RC5K/@A-3416PB5?$ATTB8&V49AG
M:B=):)TT%1JUX29IHM*BC#&^=&)?-27X7$@GWH;A5OG]R%\\H""(32B$X<G*
MH^JQ)4RI,#W`$6E1FBC:+#W.BF)7[I"$E5C17OLA,V(1Y:)$4L*($:R8`$0A
M9/M!$^6#/B8H'3@-O9IB<#0V0E-5W0)FHS)<$?($0/KFXJR>%LJ'2S_B9=6-
M#4_H"QD&2W'D%W6=RC89P8)%K"F6MGQW)&9NA5*P*0@;+-]PMC#3#SYV,5P3
MP?_R:<,FI-5U1@JE_N0&B2P",=:NPZ`06%DVG-E"(W:"FAL)QTK_8_`VDFXT
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M*YXHR%<-H^-<$,$GP!W)*;#1_\EB;%`%>9BJ*V=9Y0=/*!5VL$*'H8L2"`,G
MN"-I21S9>%=/`@2@EIA'1J6BS?0BV46XG,,FM.DAIKCI)MKPD3)].@HWUNG*
M.EEC)B;+C62FR*-(0A&4P7#CF0+E,J6\;6Z+](8^@SG%Z>PE/'%BXR$&.KL$
MSHF0@HQH0&4RQ+^Q1G@FRU,@[12[Z%$+-(\D9($42C6786R&:7R:@MQ(&$G&
M)(VW!(])4^>38NT'.@"BCP!+"9>=&#,;"DM@,PN8$L<U[4R4@:=&)R@N(`:-
M9:/BY1Z#!B+A\.8_.R7FN>@Q5<%%9:A@!<^P0G&/!6)(@P6IISK?(RIQ4>.G
M<^%)I/\"<JO_]+2@(Z3:;7A9H'GMZJ)M21ZFXE:</.Z,87H"57[TV;#O492+
M.V3GTW`4QM@]E2!B=%\'8:*[N05J.<<Z8["`M@P@8&!JQ4I?`Y.1V%OQYEA:
M\(9=3#JTG%0O6,*\VB4;VYJ?V$4'H]J,G#8VD(:!JVE/DXD;+;'`U.W.'\!5
M)8*6^U:!7)24BH.KLMQAG%@&::C+"%K,]&B2=]B%,BY,JZXL\Z_Q2HI30)2+
M<#:KU:1,18>DK5!]6X+3$<+LIDD\3K,0^=?U^JB\R[H>?<!9UOPPIFW!M`P]
M\IA$BO*$EQNHPET\M"$"!O.R=X4+&%-KMM&]=5)7HB<M*#;_+-2UBS7LL`'Z
M&M5!-MZQO._9ECJL,;M5+I0:ZL(-2N38'QG_YJ#T8FE"\]9!W\PX0N"PB^U^
M6)"@.&*V(1Z*<C2%.9"&5U_O+&"D,AOD08+'(TL>!F!SZ!L'$V>;%JZ0$4'8
M3>9^MQXF0:%"`L0C+//SO,)B8TO%+"NS\&W*&Z/-!?T*YX_N-RKIV9%U\_IH
MJ?C$K_`2XC2U*!QQWO1Y?D16WN)5U^"LD2\Z$N>=8GJA;:1J"+Q,0QJNP35J
M?J-E0<DH`U<3H3Z2RC.,05\BK6N[NQ+GR,4E!HH3.1],""6IT,8*3M[24M7`
M!LG@;-.0PWA:9AOQVG/QS;JL*AP>_U]6'WR,)#K)/3IJ6^QLJAT=+.9L9RP_
MCC<*)H=K3]>?6-K:'J(2$$5E@4",2)O#7W7.3M)+"'/S=\\^L@J"YT&WOL+R
M+AA_<<053.KG+#)0^GV**51DKDH_W'@D6EC(EWE"FQVSR;UU*IH,NK8.]6@[
M*@7*M0V7RY7TED3,_=0J,_<9XD0$'QC8P`9HK?.^>/*X2"[XRPMIZK82ZMFL
MI5!>96N^3^[FV.!B;3/NZLA.]"*#;4ZW]T1M86<HY#?^B!#=@+V9.X7&S7'/
M9L79S8WG4&70G$D+W>Y>MN4@YFL7.<[@N=-WWVWSC&U)7#W5H6F7V*CNM".W
M"UWXWM64$O]"V4D5M=S-G0]JQY@_@JEMR?K8B1<6?KV-16AA`03-J`\F;!.K
M,TQ>RK_B^="QX#U1+T*5G+Z/-+S>]"V#">@`NTSV2QP1N+`2<]74^*F?@M\=
M:[E'IP\?DYL)LS$1+6Z]H6D^^/P'@?"#UM\=[;/#R'4H)T6=6\XOO$"]W161
MT6WM,)D]5Q5_<"(*!Y,33=$YR'=4UF='L%-EN/-(_6%/PB%EHW)SU_4F.S<Z
MB"4*L,-^PS%.!U<0\U0?[:,)[S`(7`)\;D=0J-4@GM1#(D=Q<O(O&80VD;9G
M/V4]H>8:@J(N!4)7<X=3W,00L5,LR,!K='&"[&5R8#5RB$,A*,3_>W)&4![2
M*"UT)!;!1P<X>RTX1#;'&^=0:C0R;[KB:`L!,\]G+-)E6R770W*%$-:`"7N4
M(6@H=`JX>P;R-"%E'B/'AZR!)ZZU(*'T.1\6;GUG0)X!A(J6:FG"/FI6<$L(
M=S>A==ZA39>1?`[R$W+(+/]E,?-&4$TA-.N28H<G+",T#6+U*2.&8(UH=987
M7LBA<EH8:=,R1FN$>PN#>392,<KQ/5"!2VCE#77B,P90!;UT@_Y1=S!510XD
M8EVF((-7'L]W-&>D$1IF;0<H1)\('_LU5'UH=[IQ<E*8=_.UA=/TA;`728-D
M)X&B)&HC(4KT*<&8"T845^@W$<=55$W!_Q2#YWEN6%,7M!\PF!?'\EB9@WXV
MH1$I]5IS@58'"%3#YAHX9WXB>(L(=#K0R(Z=EA8C,SW?YE'5-HT<Z7BT$P__
M96@SP6P3Z6`:,Q0!F7WJ&!9@9RXK:%PP&2E-56RV!(KBYDL/LF#79&2B!QUV
M5I1_EE3`*'*M5#G1$6HVH'37`"$!QF3.L2EJ=&K'XV<QM1Y\B$!&<TPNYY&U
M\D*/YHW-\2<$*23"AR>D(7)3>%7OB'OVIS,[F'R!5T!IA$9\(V]O`Q(Q<7D*
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M8B5AUA=!*/<@6F2B[GD9R$46?^-W]N-+CU>&Z7`;%O.70/,=Z::;.GG_5OLD
M;4Z%1/4@@L.&BY.B',PEE<4F"RJU'\+64VYH>JC1?.FQ;OYW?'Z5=<)P7ESB
M$AM!,,""8*'(<8&T?\UTB@@YC@(*@90FE6I9:1#A&XSF50[E4FC!D,I%HG\C
M-PEZA3E6873:*,JS$'(97!]F39*I=2_X)F="J*H$<2X%JNXCD=$)J@4#+4DR
M@19V/AQ(21!Y)>6C;P:D#%]3"2SV)H3J"YQ&I'B8"96$;KLX.-T#8)J9.`YQ
M"*=%J'B3:G4X-:<9'LHVF%1%A(6F<8KEC/2P7.&B?*G&3LUT=7=W0>]C6A33
M"RY(I5"X;%\T=[CPCP>8'#$3()A`+U`(9]L5_T&VT6VU-%U9)Q_GQ3J2Q&&L
M@*<EV8<T1A?U&7&;E9>`JCKUQ9]A=6E"M7/05UB>92K2&BD<J1Y^)"27,V37
M!JP`RI(!IS4P2E80MZ.#A$!=!;)IX;(<A1]!5JS\6!R9]Y,_.1A11&/GE%(D
MZASREH^<]5$RV9&6@4X!J4OE$`MA43VCYJ2S%(@YB[.^DGEK9)@PBBS1]%*V
M"6^`2%M*E",XVUY5ZU>=08WB*DAYE#A0Q7,?.'<M]3F.=J%(Q(P(:DUU@XGU
MIT3AX2O]*IFYT7JS5:=`:KAX"H/-ABM9I55`=#MBZ(V/E@^O-;&&.R_/*9OO
M1#R'2F`5=HXHB8O?>?]%<A9:=6(Y=/1#PZ5HK!>H\49LA7*I(/N<T%9B@VH@
M(RJR!X6BH!!^MU6W4Z8EV02:V+=H,N.=6<=/.CMO$/59GT27Z$1@I<$[D<6\
M9742JRDNG`6-CO(]-FIHD*=NHO(;:/H=T$LS/.BRC&:CLR%Q&%MO(*&&21AT
ML^5G@/:N\/I1-T&=CK2$(UF=V_:T+T9+.-9$<;HOGXF$QQ5R:B.E)<ER)[0H
M&Z6=S32YL6&Y0U50-@=WBF02?-.0TZ$C)3F-[LMX0/9D![=<8ZJ0T1L1V9>"
M2+A%H81NUC6E(\R@@]HR]BHS%6(,,'HG(JE9R=JTTWMVWU-:F8HVWF$[H'G_
M=GWUM33501BS#K6!1=Z+<VOS5!J1/4RZ4+UH50*91+7@J2Q(@,F%D#WA<G\2
MNV@<$((1E>NVETCH22#FG-&)?J+))A&*AH[#6KWX.96`-4#4?L\UO^26CW!F
MK%$TM_[*R*7B9YQD32YSHJ`G154(L9/[L?T;+4T8L>Q2CAALE^?XI.;5<`;3
MI",LD@G\J'\+)['I0UH:H?::9PRL`@:YI9JBI6ML%D>TA<GB;6@9>'##570E
MIYE%3V?R$`%G></*9?6:2_,U5<C"7CHLF<BDD-%<$O1(/H6R4`:C$N!&0LXF
M<E1L)VYTS.6E+>+VGXV"@J,(Q;`I6RXHB>-+*<&"_ZZ?EK__^:HB&[!FXIV.
M$L6<5C*+]ZY?(@B"'"/&&GWSVU9O>FD_I`W>4S;+YHQS]\@,:K'1FTH796OC
MB-']6[IAY<FF5J@C7<H+=U3141SW:EZ\5EJYF;3AE#VAQU9DB*Y\0H8UI5(0
M&V(:RFWI['(2.\=N*+;X4(/1ADC@PTC@-C_"H\PI.;0"<JL*1\V7Q8XS27%+
MUE0-^XEW6%N)5J?LF"6$U'8,-EW9ZWJ(Y8N;Q6".(V:^^%],/$UR2UP']RC(
M>+`U)C?G*:="K;P>_0L&/'C4%DA-E,6;J,#EI5\_LLCE6%#<9<HU[(,;)EX$
M`QKGY9\$-JRS"\1I^AI,>/\H\R/2(TU,C:%-H2RJ;GVY;.MG$[1/LF%4N(2Q
M&[RY><@LEB0)-`-Q=Q%F"LT:.I$R/OA=N#EAT@&HF+TMH280Q=H/1@.'W88.
M=JU"_R-BC(&G:_>H%.@2Z8D3OKL4,M:Z\\BJKQ=GL)981F8@[;D3#*+)]?!.
MKAR^#20/,3H:`"-CKQK=/IG.2OVQ0>/*B@`$54`L8ZFZ9*H7X]M8(NQ*:62"
M[52![SLT4ZJ2;[3,=+DQL_UBE;G4@-NZ-OTLDY6UXN:!<*>GD2.%*(BSS,+8
MEALXO&*C[=/B'^+?YK5_03=S@ENY>P$C7BMGNN-1>(=0#0<2P3<?/MR&E^)L
M('C_.\XW6/0JNT^SK-X<X+E*71OS*O6=H#+F,9/$4HY5A/I!R:"@82T6X!]7
M=UN+<>O9K.%MQ>$'C0O4O`I615])FP-"5VVW1=@F/$9#FK6IC\\6CW;6#5_)
MFO>$U9$:+-[&C(XV3']G0#F=Y11[MYY4?G<^/OYSLA."G(>#VKAHF+:U+8Y:
MD%QKTU^,8BP%2H>E5UY8#0A:PYYP&BC>-?5[#%J"F)(+(@H\EJD-P26MXSQV
M?OY&/1HN6!&FU`-+28-4N7Q"NK),&YN"LH-P&N\[$Z$J5[VR$BK`#G`89.MI
MD_TP,`KR*CI@RT,4"=UV&'HGX7R)T'I^:$_0;1]^4[!2_WMVE^#!\PKK-]]Y
M4RLV'HB#OG9*[5:9"7AQK'K[?M8+WF(-5,J6I"Z(!.[#$&;)-;#3UE&-HXIT
MTY[;6=K,W:X37,-6F)MR5:@AOC2'AKV8PUV4C5*=Y3;$PCQO(VJ;R<=9,^M:
M,S#!;@R#^7`3>RUURGF]KNN0;=D9I>3J4S+Y.FSK.%T(I;H=V]C*+B1ZA"Z0
M(PBV/%YF+3@]<>M:D1]^?,)H_7;+]1:+T;V2P")C7S(71BJ4N;&P\&Q:(`H&
MH`7G2G_TH2;@AYO(YD=6]/=^N9E*G[IP3TF4A*<`[L5KN)`'W+,D-5;^BI>M
MQ].85,P"BO?ZSH%1SU8RU!>=4/]+0HFN[8/K8$5Q6PLCKK5M-.[+G>I;FW/D
M8!SV#UG021*$25*>:M2=N5ULO(/ST<"&-DV6&,Q,P`%8J:WK'2M2[NA;NT5M
M\R+"%^Y:0;9M*#F6DX6<=><[6P,R.ME2E0N0QQL?'"*A6EKV?>7]#&(`U!YV
MV,`B6%.XB?3M>_YL*#AC`T(Q]+/N++V@M0\("4,&-AA`"0E`-H>)-@:(BHP&
M0`:3C)"5BX\)A#:+D)2(GIN6E::3FXBGDPD/"9Z?C8R*FT"AJY6(JJ:VNX6S
MH8F7D9RWH4/%MKG(Q;B50]#1R,C*EI1#KKVHS+K=WMZYI]&ZO=1`R)7!WMR"
MW..KQ:K_GL>EZ8O8#]29AZC6FMJC1MU:%(D=)P,8;!Q\-.B:M(<0(TJ,6.G)
MDU*1E$W<R%'BLX8&.HJ<*&BAK6.-Q$FS%E+5R5S@*,$L.6F>(%0+4^WJIRM7
MI)#0>@*M]A':QZ('@6"H@D'5NJ!&'28"NM+A$"!:3@Z4:<L3!@.N1KFR"/:!
M@8O$$%E4H4)9,U`_S;5TV^S)5Z.CZEER">2)(VA*#:C`27.2H:`_W=*"^RNL
M(Y?=:AIR59-?JEZ-8,UZ_!:=(D,EYZU*6W,>M5BL'E#^K%`UK5/)7&J&]`E=
M.V%GJ0YR9@HJMF<(SX&,=LG4-T01V^W>.ZXPS6J'@GK+=_RY_\QH&,7B3D<I
MV*#M7+4J[J[YE-9[R!?.B[YKI/N-W&7^<J3[O?W=K:[6O]^Q6_>$Z.!B%6`R
MZ9283LLM@YQ2FA"6U#+,I//,5+),B!PK(*V"G5%`]63#!AEL8%EZ#[5S5&\)
M=FA2*]DPI(@CP9BBVA`781-5+#(-M@PM@"D$3HUO74@6A]V,H1HAPITER!@7
M4J("9*HEPA0_T,7HB2H)N55*29BY@H$AM^!R$XY9QH@9A4$5HDE.;ET%&B?K
M`</>3(E\*8EQRR!)6X./O-A*,>^\A)U#O:$85#A]`;7-;L1=\E1$^:1(E2X-
MA4902;<YU8U!W#'43F+&%$B*>0JBDO]1F)UT!0EM+Z:SBS($1<>*<OS9=Y8R
M72U28ZVV4F45IKR2Q&5>.`5H:$,%CJ,479BRU.0_?W&C58>[O21,6`5Z<\TV
M$A(7TD>W?9A!!DU-Z(I'&@DSYA.[L.A**T!H4,4CL/'%X0-C,`K-$S7TZ5!;
MI!`5D@U5^+AM.`I:M)P@^4Q*:;YGU3`&DXK"9`LZOVP9)"\%RCI*/.:4M!0E
M:PX'5W<H88:ANIS8:<U-Y50[[9C&!`P6(89PUXHXYED+YV.]':1<I^-@=^*@
M@ER\*(2SHHF<L-*8I&)/7'U,Z31[1=F<LY&]>`Z<*!-*9=8FQHGGB_0AVI7`
MUI"'RS0BJ1#_K%%/R$=0M'/W5]0D>8M$Z78-&IT.1+CJXEBV3V,$TL]26>=H
M4MH<\@!TDV(H]M$H?EK%!AM\=4U^$RU-%!#C1N!!!!EHP"Z3$8@!0Q=C8$C<
M839$$$$,"4@`31<9H-X%;2MM4F--0XR1004!//'`KC@]TT4$`=ANNP9,QM"[
M]!YL\(`$8SRA`?31QZ`!57GBNC:/1!YT&D._C1)RPVTOXC[,(3=R-9*C"A5?
MJS9J.5=M>$&-)*ITDMH(;2H]T@G.9'4YHR7*(]\ZBJBB4C$7$4HES8D:W)9S
M)DQ5:#'2,58OWB44F91$+B<9TS\&*"J4!/`EK$";(M25$=!L:V9`_YB7QNY#
M&0[M)W@\B]4/^P81'1F-B'YK3ZHNX</K8*=NLLO'3V9BCIFUC"`P808,@<4Q
M2K2H%(>*SL4D=31FX*4**+L:?$)BED(,00(UJ,`'`$!'.A:@!ED8@P8"X`$\
M,LE($M`=W#)0QQADX9`1F.,=8%<#1*CFD0C$ARLFY@$`P`"/^(H2G3)PASH"
M0``QZ$$7!.!)`'R@`&/H00T"8$H`B(&.'9#8(XLW(UID8STM05;YBC.M``U+
M.`Q*H1;IHI_G-(."@'F3U\#%DD8-JEMO,0PCU.0@8="E',W81C)\."@G/F1I
M=L$@-Q=WE<^=;X@2289W/(2:EG`I%!K!VO^6W%$/=1XHFQI*CR4$PH]YY,5N
MK>*8_(J#Q0FY!W[1`-@0*V(1A_@%BNA$XA",N!R)ZJT<2((B$(\ELZ*XJ3ON
MC,JRDD:E:DBG'^QIXDGTP0N&8(AO/FRIOGQ3SIKDLB-J,P"3Y-@!#3R/CAK(
M0@_&4(,:]&`&0WU"%[K@B3%((!^$M*,99O"$#M#Q#D9E$L&6^H0WJJ4+3YA8
M6,?`2E3.0`]^T:E94F&#/;XR`-2;00TZ60'QQ2`&7>A!#R)@1[S&H``5J,$,
M\M6%*C`57J'"%?FXPB5Z.22>*!V>>+RCE^$LK53QR>RB.*@HI34P11U3K#X%
MA8EC(@N9%24C1,[_<L9D?5."0]G*2MW#EUQ0QQY?BT<V^%$W0'T1FU2CQZEF
M6-/*=BT\W(F395+EB0S-XS!\T<K3>(A2C]*-$<.+8$0ERHDCVLBBH2/?VUYK
MW0SI9HO0J&6#+A8I<<9TM=SA$($49",V"NZ!5_DNP_9EB]Y*9$;?)0U1*P"`
M",R`!#5XI09F,`,-="``8T"J#0H@``%4H``:2$`/LA`#3RZXPU<5[%XK4($[
MW*$#$:@!]V(`@P!DP`,%R"M?S<IB&%!/`K'1JP9>&0,&RU6.!B8!"7P\UU,*
MEL%CR&L/8A"`"HBAPA'XD\;B*SB@4.98,&V(9)DWN"I7T*/;D&)T:AI3__MJ
MB$/7:*_8",4\UQIM:/&L;\7DO%'[UMD`5>@J!#OD1?.>ZCV02\66,#N5_<%0
M8_J#B5G65H\6JJ.C%C2,_`PFB\6$)Z!?6Y;/:B5!&PQO$'X134VRN]U@C<89
MX#7*:H<TB8M4I+\GN@A9"M7070VB$&B9TR\^,^97)ZJ[Y31I3#7JV6E%3KL,
M[0NH?W@61_A%.,$3W"`2<I,$Q!$`L?3#C",\@QA\0`""K4$!`(`\JU8@J`UV
M90?$$`&RGA@`BT1J!&!@.U866*]\%0.!`2#C#P1@J'(,@,2>RB`#2*`'.P9`
MCQE\;0QWH08AB+`&Z+AP'S.X"YT,`),%`(,G!/\2(5\YTJ%EQCQ/\XQ0[NM$
M!!^JT?U]2Q.#H)N>57[K:+5:HUJ&];3Q1K1@WOHPNK3*S6^(-U`[-+O,(\O!
MJ$*P<SRA8!&4;T7^]W)-P()8\DT.Y,R7PD%/43%]RMD8@^NIK=<&5,QYE0F?
MM6N@H0V+51/4Q0B&Q1"^YQ0?`E$&4L#W%.S=`X`/?-\'W_=Q[9WP?#>\XA?/
M>,,CWN^#']?C$]_XRB^>\I*/_.01?WC.=Y[O'J!\WT._><!O/O*?)WSF07_Z
MT:M^]2DPO><=[WK-J][O&T@;)9AD57*_\MY#[G`%_-!M<@MV#`2&</'O\-<[
MM"YZKCSRQ/3:A0Z<\JC_WF;W72/,5X%W/P$SR,*5GY&%A%?\VJ7\,+R[P&"]
M'G6O\%[P8+.J=@QLP/.L+WSK\U][UY,>]J*7>`*X?P&(>IP7>X4'@`@X>J&7
M>ICW>)]'>P4H>?]W>HYG>J2'>H>G@`S(@+(W@)C'@1^H?XC7@"%2!?,B9G$Q
M6G&&$5\G:I]3&";$#<PE*DB":95V#TI3"`7#'M/E'I.P.;B'@D2(@IRS`43(
M.4;(%$Q(A%_RA%`8A5((A458A5;(%$^(A5.XA5)XA5:(A%;X)5[(A&)8A66X
MA%>HA)N#A%^BAILSADY8AF"(@DO!A&KHAD6HA'5(AV=XA$4X`G&XAVL8B%DH
M_X:=4PN.D$?F5F]WP&X1)GRI%`#^U@-#QE?#EVYBT`4@EHD=AE5(I4?04P"O
M5`!']0:6Q&WRAFVBF(GM1R&<\`1Z8'Y']6/D)CTIMGSRAV,2P`(2`&+((SX1
M)@$P80E[B(>"2(=P.(>#B(9G&(=PF(98^(9-&(W/^(R&B(QZF(9N*(ALZ(5E
M>(QF>(7-J(>"2(59Z(3+B(=@V(U;Z(5'J(Q5.(><(WFYEQ$P%UPHT2G]H%PS
M6$(*PA?$@EMQ`@I"5`]U^&BTPA%`80,OE@%0)V<%!&V=4".1DFK1%A46N4;>
M]5U51E[EQ0O?9'4V\!MC\Y&]$2GP\Y$H8V57!EE6MO\2$/4(`)9>,3<YYU!>
MV&%RM*%38V!]`7!@,V!O74`"'28&J50`'Q`!E%A\8B!874!'?C`&G81*?(55
M)$!6KA0]5@4#I7A]/@9_KN1*\L<DA58)L<AC>D6+2FEQZ79O,_!4B)!'$;!N
M=01A0Q4PC%!FXI4:"=(HBJ(P".5E'8D=-U%!J*4O*?D,B0D6:":1$N28-*DA
MBREG)RD-"!68@^D,^6%=%0D8FRD>0&-RMC81%9D,,->9BU,@!,-W(E((?3(7
MUC)?C%5SA^`UVE(-,1$?IED>_L";`%4P>8,!+[8!-R,<D%"',&<7NE)J1`13
MF\5=U7%:NK011'$;7.,?V4+_'6JR7B7D'9XA3)A2.$]C35="0E73'AZ$0HL`
M8,V2:9Y#+6%4#+,&#3V9E$N92``@6)T8B?XV!I5(;O[YE`!`?#%P;DOF2GY`
M`A/';R2@!I)(BC-@`:<485DP6*S44Y9X?(!!%F-PE@J7EC5@?6OI?C.0`)W4
M`4JF!S40`ZDT5#7@8!_0E#V`8Y+#'-6R'C`C.@-$=95"(&&4*YVE#NJR,$/P
M,=HT=L)0"%]16RXU0HMB$\913E*V3X]14Y^3=AZD/Y[1GL:F,M"F,!,!6064
M)97A7AJ$CR]Q+F(&"CC1%\/Y;%)J/ECS$AAU$F`"GFU3=NHT*I4Q4O"4$'GQ
M&)&@_R9ZQFE/,)QE83)=43!)FA"CF9'ZHB-R8U'5(12%*1@*62_X:"'V%!D9
M8S71Y4(H]2<[,S/3,%Q=LP\+`15H"FV9,BO+LA?IH0Q2I`54$3L\)3X1(``?
M``./^&T!*@9B$`,O^DI!-G%-.63<EDA-V9;4TP5R!*'>YJOAET</"G#^9E2Z
M@PK+PV1VI`'A5@$XH'R?J%<9(`8?T`%W5:"!=5<2XP=(V:P]@`GD-&U?$:5M
M<T*=40HB]TXMH2>$<9TNP6?&B:]6LD(B12@P(SFO,&93L5N*\D]?8RJ/<S7?
M@">$@2P"H4"?11&/-:8KY!:HV1R8,%G#:&CUX`DO5@52JO\G9V(JLHH9:U-:
M4A,UX6&=_N0(GV"/UD(>5U>H]U$)5>`!&6!K/M,5@/J$`P*I'R&IJ5:IBQ)G
M&Q%H^II9QW5-DG$ITT"U6UM=)\42_WH>YW!;^KA.E,*SMR$M]!(K8V2OCC6V
M^&``<A2667EDD$@"2_9*>DNN1<E^7YFA)6IO%0`#I/1OQ6=6@825I$B4PLJB
M.%8)JK$!^V9*YR97'8`#[894\YH[8Q`!!#9'KM1N,:"WKU17/<`"FA0JR01,
M/E*R]M4F6%I10ZHG*9&P,CD<M^9.C@6;-P$@5_$7>_J9QLE>5/,ILD)M;@(6
MS8"D!G&Q%B,5L7H/]+0K=3.I$+'_3<40*Y]@$U.;3>PA'EM""P#Q(L*9`N=`
M'NE"GD?;1=]+.5`!MIOB-03T7`JQC[;I:?RA(P:P=R,)11>C"-^II*(!J<$C
M-QP%G>L0I;B11&!K1OE*0FW3)G17+(Z3"I[A*HECJH56<*"SIQUTM@21$"%5
MO!1KH[OV)LB!+]^SKGB%BC60.MPF2M!S.S&<`-M'HC(<5ZK$9!&P5!J@`4=5
M`Q$`Q&_)/1H@/I0X!C'0PS-Z$*K!D+>SKN"GQ$P\5,*02D3%9-$35Z`8`-%C
M5&\I:(DU&IPA-#?$9YRA$4W#$K@BO;JTNVFRI%Y'#@+3%;I[M-^+'EK"2S#D
M-=W4MN-Y_QSXL:7J9!.;8EZ8>KULNK`R!$/"(EWM90_K=6B=X)H8D#W(D+.M
MFB1<5YL3.Y#2(!Y;`Z2)<&NYTG63ME[,^1#Z:P!$VS"QNELE13!+2L#>E1L$
MO"G[VK;]$5UZ"K]-PAH$0DTHL746G"$QN*>U$!+RJT#\-#7?N4!_,[#JXRP:
M&W+3<4ALV7[;7*'M-XM#!<YZ-3&Y0Z)(Q0)(M<WN-Z-/M3T'Q\U?N1HR*0'>
MS&`5FI9'!4=:,0;U[,VSJ,Y&$DW;\B6,J2;QA!L%(<]EVCP#L:2O4":"1HS1
M`AZ,=4P/#01A,259U)N=I5D=TQ(C<YRQ(KP=)!W501CB<='I:_\B^*5U%,08
MGU&J3N*Q8#2>MB#"TI0=7=%5-I`]@SK2G4S'HE5;?APAG>)!/7,-!70IN'%U
M5;/*&_4$1)M>B5"H*B<+2W%33+N7N7Q<;PLZUIM.,G@=S]$M$6+0]E.DGA,C
MODP3]K0)B.$SWW(^5W,J[I2;L:H3-.LQ*`U2W^#.0H7.B;N+N\B+@11(Z(Q4
M[W)PW/,`J-L+!^=4AEW8[L>+$\.+4:(:@63%N_B6C@0V[CR+AW38A[UH:2H!
M#,8">I4`J?3-#(9C41(,T/$)>8I-)`.<ZU,G(UE.LKG'*R3&=.>O'Z4/.0JV
MHM$F#3'!U'`7#.*CQ44,$?PY(+$FFKK_#KB1O?O03#]XP"N!-`R-1<E@7:/*
M"8;SNTLJ:KT)<T#@TW=3FP4)#"TE.8AQI^B!0@Z[.,^`*V!R&'\Z4#B!OW=W
M"D_@=Y-B/J^9O9Q!P"BRM$]+*5%*3",1$\SRG1VT0#2WW+$9S!.>KRQX,>J2
MIYXJ75O;)#^3.22UUUU*L]V@V9H-EX_T5.W<XCC62']M320$28AP<(832.]B
M6ZY`XQ-#,>JTXXF;XW!Y&:EPV(E@Y'_D5)I2I6"3-")<LM!+IKA5MGQ&;>%]
M,IZB%#GC+`51+#6')6GL,Z_0@Y=F#_'%*G.-(VD$RS!8QAETP;\K3%OT@PKI
MX%R!&,SL=L>0_[!">K4%]1^:L1M2G0$W'3;*-;`@OK7+A,$:S,@&TMXHY35&
M6@D8`+0<H;_:X'>NUBB.`,L6#"'0$-9]HVS+9LOL$+!N#&B1T0^Y%+QP8@]:
M_B?$+#EJ!IZ`GBD(W<9P!]=M@\)=<YP@%11M1%(1LI*\BP@Z8#@D5+S/[BXL
M$PF.X2\,RQ>Q?>V0'`_J<DN;4)ZI*Y/=SB8L0MZ@(')K"^69(>5-<2[-U*?0
M;:3:$7:[C1`*`>C6'I'$?IR>,N8[%Y[6$L&T_0OV.F9U3B\$O:G&.UG,,LW_
MOD#>,D\1[H]9E*KP\-8CGAX+`C1]XM1X1[2,QES<N\$9CBP<;$^\_/_6.#MI
M;]%V?8((2Z'I$\'I,$?@>S,_5WVI4/T>@X&_K6;JD!H;NH3G'/&#.?'+=/I8
M:-X3=7*OLL+(*>6]>KU/-QFR,:,59*K+MR#"F($-"#0K5<0_39,`S0X.>'G2
M,#$;^%,A'LQUK1HPU"WO/O(RL-[UC7893.W;O##)FV9-I&6;J1+>)L^^><*V
M`Y0SQ7`75]UH7(>71%,:<<<X;VVR+"U,P5:VC?,TRY3AU9604/,@U;2P7^V"
ME9J;W)$E]V`*/=V:>Q(0@LKP_=[VB(B;W2FDDBPAKS!I?:P(>382P)$H%V'S
M>T,Y#O*<<S.I@R$3.*?J.2H7&D];":R/-"C_&1YS*G7-]4Q$GDC!,7>MTKCO
M]YQ\Y5D*J]/"/F>,CRAXDXY2]J^>4[<Y"RXSVR7EY6L+&K3;[#>-1KJ@!9D.
M"$""@S9`!@:"-C88!@D)BP9#"8*10XB(53:.CQB#AHB4!H6+G9)`G8Z4#PF@
MBS9#JXN&E).%J8H8J).ZE)*M54`)DK*@AX/&N*A#LJ:&0\VGP<,8A:''B+FY
MFD.G&,V1JYZ-PJ#7H`FKFZRSU+[.EH;K0,_T]?;/FX?EE?7ZC8C5/@FS)$R=
MNF>4@"@Z5<T?!@\9SBT,.*M0L4/J]`T2=HW9)DL7,Y:S)HJ:0DV?%F)X<N^>
M/FY/*HGRL.$9*'H`_VV,NY1/D(J60(/24_$2$4NA2).VU$?.(CY'2I]^Q+>O
MD:1UN8)=%*<NVLV"\N)=Y2:.WLE$.A^D\Q1L4J1HM'HZ&BEPG:EQ4(%4V;#A
M4[Q-*@P::UMLKL)X=!'+<N1JHRA;K"!'KD*M4:@G,4VA0J1%D:W'TH9@_LDJ
MF\Y)QYQA^T1MH=]2\*1%SCJ8+<=VNSI9!$CX[^1.M8_=/LWPVN%(Q6`]HHR8
M;:39J;):4U1P8S.G3>,)DO?<<"M-WLDA/F2/O#VP!6O+Q$D+=%NI5PUV]6PR
M8<PG56BR&^4YV'&NDH`4"E2\)?*.1G7-54XSNZ#ESTF*`(.4/X\-M`Q--O]%
M`XLEU&T""4Z911743T09\!,\_(BHHDM_\22?B`8]I=XX\'1RUB:V9529;^X,
M.%`QJOGE&7ITN<7A-5TAY]<Q**YC%3H&[)6)("$.H4)@`R50XH&"V&1#3`!5
MT@M9LW@RER+__"60`1@`<Z,E(0XV4G3$S8.03&VB9:<_897%X6?-*0;<888%
M:@UAN:3Y'"(%M<E?;S*Q9=UC2C[7"YM3$AJ;@@DQ65*E\)Q6Z%_Q.9E*BY3L
MYHP\I\K$CS_GE6K3/A;Z8LPACC[YD7P'L:D;(ZB=E=\&W^%2C6M^<AJ78=I8
M%B23^93SD2AZVF*(9[C8"111"<%J"43(#4;5=K7_T))ABBL.]4Z)Z*:K(K?S
M/'".C%,E%6-\,W*WFE5I"F=6?;J2Z=NH3')C(T_].G<DGX:EHJ1Q6KUSE5Z9
M@OG,E4"]!))&^L`VZZVA/F=390L[.=*G#VP,,J4ZGI:<:#%5RXA9GY!7&$X?
MHD:P)PM-K%4A?W8G;Z(,MEHL;.NPRG)ZT7@'#2$*>7PH1T#C1#19_>)%JV`\
MD<6=N>36LI/-%/IS8JE0,3WF4\N,4D4:&YP6(-H'"4C,DD]\^1"QAV&[WUD#
MJY<1(3,'BV2TH>`[$2H*/<(?M2,^*.910Z20`68FHAC?6:!^[&X_SJCP"4Z?
MJ^AB<C'6BA2O@AVZT\%X_PF\JB\`CV5X6VI#4IVDTTJ:=6&1W9FA<:9"A=!"
M!F!^,<9+6<RF3G#J=/;'<0*=<E6#S94+2X]]>0B)!DR@<=>1):<"9EX"[?AN
M["78Y?#F7C+-/)P`IS5OL$`._ZKM,8-)0P0JRSG$XXES18=^W3!7G]YBB_U9
M2DVK,ESL"K63_X0F/*CAUYZ25S.-T:UWB5.<(C20AA("`SVL(Z"!L,:0Y#TD
M`S([Q+&.)9M1D:<GSJ%:0_`%(%M%K1J1F<BQVO6Q0Z#/)B%*P0:4IQD:)8!H
MZX`>3C*7KA+]Y!+\8%[ID,(N4U0M0!92W8HJD3ME)`8=K`A.[(H308+MQ!+2
M&?_@R=(V$D"IYRHNP]T^R+6LM"E$AD1<2LW0="1A3$\?3+S)3;BAOEXL9H_K
M0B3]$":JQL4&&7:"B[E8"*GL-0D>491&?P88&W)M11I_U!>A;M=`%)ER.W*L
M6BB05ZX".E!?3EGD=CYYJHV@ITD)[$5!#)A!A&22(K"J5SU4^`YYX&(#<`-&
M=R8H(ZY<HF\6L0%$7%,?P/F-CH?[QNBFHXOV]=&9O!"$22RBETI<Z9W<&HP4
MGU`S)6K.8*22XW&R1,_EU0.>_[02(JXHL2TJ)5)[8J)!6P)0+YG$5-?D$;5"
M,8X6[A)QZM,>(UIXE3EFZ3"YX(BS!O2^L-'E@5K"R)G_=(*F87;4B:%:DMS>
M61YZ\H^6^/CC,%252@F:\X%]C(M7L`>@-,9ECL2D%&\2-KN3E?(]Y;H%],Q$
MIHPZ=:*-2`>UI!J<ISWI,+LLT*M44Q3RE657K*2&,@7ZCC%)JC\<,@]-6>3+
MD[%I`S82"RM^^=2O0@T(+'D"1/*&EEUDRZ)+&A,.X\+(:I0S+"IEIIQ`LR-#
M=.$H\+R24;YGE`X^P9XP&T0\P4C12[(G$M-K*$(%ZL&%'M0\R:.B:R<D0T)`
M+XU;6VE[AA,_@G%$2,!AQ;GJ&I92-"Z#V]EE>YZZ#7(1I2<VZI"L7H*C1E*F
M("0JST60HSZ90*8;R$D4CBC:_R?%3))VKS"L9:[F435&L3O?,-C,1''"I^FQ
M6Z$*H_["Q"'8.%6R?YI+3C,)G/Z241P:])1.IPA;"CDC'#IA%!CG!QHR:O=]
M\E,J#9TEVVTE1CCE:Y6LP,(6>LPF:JS9YJ<F*D3'(&N"_XVB25;&%>%6!8?]
M:<Z7E@=/4(2(GM7#$)S:@9`"_RD8X1C38[:5VEY8<;91D1\\0C0]*-L$?C*L
M#!US&QD0IX(Y??PP8_)*/P&!]7Z(K6"G%+774FYF3UCR(M1,G)%H`>E-51Z*
M$3%\U.Y*RLM%W<?QM-8>!!^&M#AUYI[>9U0$L26CL@-J6'<YO%/6F,4TLLTG
MW<&Q:__NT+Z+,M##3L2N5V4F6`0<X$"BULW(GDVS0+@BYO24D]08(K6"Q)0O
M.45!VY'CQO`S"3VC%(`,N`97A=#&;B(\$3(:M;2]9(;L-@G9R"[#)(R[5A6>
M0"+5KBVV2`17AAB1,G\9+(^#8.NP`SK7>);:RDF1<O*JI$5XGXB#=`K;LR]*
M->MX,2!.#%96?IO#G0!\+EC):X)'TJ3!N>)6>QV<GMJ(\/?.YA6@J+<]B$)/
M67[796KEA';$0BUYUUBH4_7XDD+M[]NE>KM`*\G(#0ZM!9:/TTN=1"9$7-YQ
M3>I9EOEN.OV*G5I*HQCL.B13HMK7'R6".:TR9'E&1Q3I5`;_&S/&XJO]B;-L
M#(P[8`?AH;N2"/O%I`H!6"+0X)*,",OPFV2'%E/[I_"Q7%*E[LCQV_7";1Z?
M[65E,X#E8&L;%STUL2D)Y/`(VF%XNV21^K-20QT_6D8BV%8WWME;YN%16[5I
M4,[(H;)JYL/HZA%(=8H10`;U#X3?!9_GM$IQ)#'P##:^'ZU`94"N$S&+=!FA
M!2NQS9>ZFMTA3C@G/7PHHXANF_&NZ1XU#LD8&4`]238LT*L*0WI4?4,'A."?
M(#7N'XC0<Y0#@*;-L^CZ[JL6BU5E5:YR^[4LGT+[)O<T$M!6])$?&)Y_AB>A
M#Z[04K]68\\F/YTR8UMV.*.B*JNQ_Q)#,7D<YRIH(GB70V51L@W!$FK8<1Q2
MMBU.%GZ.YV&7`EA9-%<C:!3&Y&B(<0O'D`ZUA'ZU!%_!!!D5!2T],BF,82SF
M@5Q3]1Y@M"^^IR#NX`B)XB._%AP")()<-RLK1"9LIE0EN!T/`%9$5B2_AR)B
M-6GW1PJ-]'V7]#45Z$L$V`H**'S;53,6]#`$XE@N<U53>"0504&<(AV]%((%
MU6[RLX%W:&O$Y&3RIX:-80/,\7:WXBT7`SHHQEAJ@R".EE'>`4LCD1\I@!(G
M5!EH\D?1@#Q\E"Q]\E)@-837-V#FEQ+)MFT,]7<6,VB5<X$F8AAYI&65=@OB
M$CF<]3Z2-_^"_R1OL*%%>>8N&@<OC.>$Y.5&/.1U8R%6J=8-X-%]!86%Y(!M
M$A,L,?=UFJ%.A9-&#8-/(#->LJ=688B()I):5R4GT9A]_:-'B7(Z5$4>F@(Y
MW&%:ZB5,FN9\;;%/&?1[3<%.DV0F:10;_V8I<A,_Z\B%/K(I85A,TE(:H"=5
ME[(>?@<O#T-TW81#BI)9B7@^8+(XI%`FQ]9:>O9G"J1F#R,I4@$UA-8)+W06
MV,)ZW>,:$09670(63A4@";20+E=-N]8WVD`-O_A/E6<PGQ41FH,,AWA4:S9L
M6_=//A$;/^E:&,,\)M=WNL@\]\9GO!).31<@[3<Z#H1A6>$4.07_<'-S?K)!
M+=F2?V4W#XSF>G#Q6&1G7V=96<LB+AIY;TUHEN3'?1NC4_.R?09S@ZL45:RB
M,C-7(\U5C>8V+UL%$DU2BB2S".,E=R1G2D&WEPPQ9I*V*GOX%1C!)EF3&^N%
M0&!U#U8)3_JRA\NADKCC0ZA$E?7&,2=1'\9U&HP@"I@U$!Q'@$9'70G)1MH"
M:A:"#81($\0Y@/PH<VHE"EE6<R>5'J`@7I:&$?LC%CN50#LF%%$Y/@HA;H#7
M0KU69&7R/1MW+B;R,KKX>,YG'I3W:IH5)S&1E5J)?Q\#<%8!#0OA3#JA0.5"
M2G+(F6AA(Q6'8HL$G0T"G@IR*G<(>:XP_V,O90P$55#G<5)*]B$EASH>:%O_
MH$:,M1BVMR:)(7.5UBFJX:$ZU6?\&(`$,5$_4T$NTU)?82">8!(3\WV,N4J$
MDCBY1SC_8'EK`Y3OI$*UR).Z(#(G)7Z[:`R&U6*J`2;]-"NL@!G"=#N*%88,
M`1DYJ%@F<PJ#19Q-HXFM<9O68B-$EA<UQFDWB9B;9%^]HD[[F9VFF5E;P@^"
M51/]%6L.97!5TY_AEUH1&B[DF9[:A5!/"94\IF2902&CMW3N-7H)L@N9,%DR
MFG_,6:".)CF:!$XP^23?4UP%ED8$U2J=X@A/D`VZ4'$T)J&YZ*E2)))3(YIP
ME"F+HI=9ZCN,DO\;6J$-FF(X#\5<AJ8:52`AG+![Y25%'T8+?IDG_74P:G,6
M:/IG8C,,]=61C.9C]!:1'04Q/,.LTX))I*9^A^@W-U*IB`@GFX5[@["*SJ@7
M&"!VPF0WGU"G:-EJHZ!L,5D2V4*3/61SA,2,,.8G.3@H1!:G`/5N\@(N\_85
M*UARVO&FXQB54OF0Y%FHL]5%4^9.%+M%[Z2"C.0J?&)FU/8=_-)7F69US81@
M=,1.>%%>EG%B6'IBAV8KJU9V0_B9S2$GL)2<M2))2'1K0'F,.W<DS^`1/&57
MR*)76`=R[5J%P@I+?[9W^Q0;N4*+.G>;"G%)*-8GHH@-E/$/'Z(7KX#_-:QD
MB@:X>L"":KYR&SB7H<BT.\=Q2:<YJ^]`B#QC#@BG#^[I8=GTIFK(EK<V5H!5
M)?5`":0V3+DQ$4='GXX:"8(5$<S(;&X:@']$65:[>8Y!%8(&88.0%3R$?&X$
M4E70+G**>TET@>AXLO@H#ML!L33%08SWK?;FGB:'IP*%@E"VL?04H1<3>*-8
M*,@S-@#"%LKJ"TU77;,P37;U&M]778^C(%@2"G&TH1]Z@T#"AMT*,N;:;B72
M%+JJ?0[H4&U!#`M$#X28=3G*4QYB/P%87*%1OCS#3F06*<LYKL@R,<$:$`>3
MH:$!7K6F:*W'KD\+,6IQ;IATCSCX0TY*N+O+_ZA"0DNBEP]`&A0D&C5>:R<*
M!2?'"Q0^>S'&P[5OAG@THD8VH6+$$)/8DI\\21%/"TY>-C29(E0@EJT*IA"A
M2["VF[VM6*J4PR;T@Q4];$&.(*>PEAGK=X+IN26)VI22]["QRW'L)S&EMG3[
MUD9FJ2!S%'.R8$J'MQ.]R4,.&$H>.)IAK%*]`#A\PA,S>6>=:`D/BB*:A;>H
MJ4$`B'7K=5L^+`RNX'3",7%C*K"*);[@*;79ARS+9C^+,6[-57MP6+>X,E^T
M(1[B!5YYQU,<:7WXZG0D,WM]Y0N$-6R;];`,DQ.-W!TR^21C<</WT*ZW0W.X
M!5LVI1I+464!1!]'=_^TE`JPC9O%,8EB#[<==$N(C9!-M<-RB8,C7J>@M%*6
M5-6&&*!^DZ=G^C!XX)9[C>B#-"+$R7$3&'G$)B>Z&?LYHJ,%F?.!1<04/L>`
M^$<@Y2!>J-&V/H./`EAS6DN:?0-!^-I!W&4`\O)B_E`GQ$S!9&$K'85$B1H3
MF65#V,B6`P=>AE4F*,E,?IE`!U0:*9>B9W5^P542AKR<D>RJ2@:M6)<2I?`I
M)_9A:N8<J_<SF['0M/%7J#N$<)+`^W!%-P2U5,(O`1%A#^J+IOEFC!H=^3QE
MF.-./^MWUX>LW9LE<W0B==I"UV2O&S&;K9831I:E$Y008@FV!3/%*YL*E`/_
MI$*\L<DC9!S4)9-;G9[2#T-\GH#XS,!H2*YB6KA).CS&8$Q\FA*X<6S"?G+U
MK4*\P';K0+X0'5IV*.EF3E/:FQ%7#+J3$"HYD68\V/](I63,>:(B3WNQ46^X
MS5@D)R=R&_>88Y1`&]W3M4;8"1+IN](T#:.06!@MK)R[D*`0K).4Q1;DD:0P
M#H["<^V<";Z@RT+2P/<;JV&;2E(;J?.CNNI+"KP`'*+#9QQU/,F).C;+#JJ\
M8&K<'6^,0H/:V8DH#QGR8HXYWN7Q=X`SF8)@VFZ[IC,1$1=!'P"SN:T!<%?:
M4K<$G7L\5;JZ@`5SGHS+$F$=X/!4I_10JC9`&IIR_Z<452(\=BO"*'D"'N%R
M6C9:2+@)FXI_AW`TM9W?@Y<1>-C@)N%AC50]LAO&_"C\`F0&;2498E-.9)+Y
MX%B<EU@\!7LMXB2<A)218(/K\#8ID`;[.0]$,>(9]M'ZJXR[W3U[O.(&H`7B
M?":%*&;<X-OWG!JY)%2FH81\M!D#.$@D`SQ/1!EUDB/L>AL`0YRA":E7][13
MKM+Q_;98@T3;XZ(1XXB+#;^5Y`"H-<V`A0^P<"5JL0JK$"`12WI^=[55>U0]
MZD&O$AO(0Q6V;7_[Q"]L8ISZUY+CF2?`K9P;]2R,I7S,AXWW4]:9(Z?H(^(C
M/GB55L!R29UQG7&EUFVH+O_B&QIT9G(1-CSD,G*?B;@Q2+K$W3SKV(S2!9@(
M@IG096D4!HTQ>JDU!Y<70^0UR<L.HM83FU?`'%,\:>3C&=#I$2B5;SS.)HA/
MY]:P?:NZ7`40:$2%](5)3E/`7)&9Q=2Q<%0?B@`-2B@G]3Z>5'L*+VS`')C3
M][CF(WTICN*FJ_YAQ#%PX&:NX1U"3!&CE:FZID3$B)!4?R<*&A`:*I`RQ(BW
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M`04@`!&P#1OR(T8$)F=CA%,BOL.9/(M`E6PL.@K8K,UB#/';P0(H9!A,#9Y,
M)5FQYL<)'.ST[&[$J0FM2H"UP4(,]%Q/%-+L3CRL'3LBBJTLD47\L.,OX`XF
MDZ(&/K2^.540`30A*LX+[$P."!A`0X0JAH>(B8I#"09`_X^/!@D)0XZ/-AB"
MDT`VES:2A08&3Y&$H9!`HHU#G*@&ID`858*8DHVHK0FMEZF,CJ^/A):=EI21
MC08JNIB=-I^FB-#)HT_"F4"Z&)^OJY:<KZS$"2K?D6,)73$1$1K.!@\)UZ6W
MJ)/%E:B=C,<&F(/]5:IT2D4/$C!-^USM>V;@FB-,52#YPN6+6,)6KQYB:RB(
M$)!9!O&E>D2I7Z]PJ#SV(O<$G"-2!`DA$Y6*9B9'@D`5%/5+I#V,3](%*"``
M1X$8-<:8,H4,IB@5IOIEPD"SYL21SJQ6(I5UTD]<I6()(D@)7\M^'C8(&Q7K
MTS>IF09N<\;,8+-.FBC=&JCJZ_\C;9*DNH*JZ!"IPH@+&TB1051+809UC9QG
MCZ?C)U`-:#F9N+-G0Y5$,0.,TX:T9)^YV="0)D*!"AZJG*T\3<5+E>`^>_;E
M[5CHAP(S;H/T;&W#D*AW]6HD^6'@2C9F07R'#)4VR?EZ%>O';1@O5@1Y>MTE
MB/!:J$-L9R8FF%7>LCPY/;%1#1_/9[J>U.@2H0*.#Q7$8(->6555DG('8F7+
M==!]DLU&;7TGDD0^M>)1)_3@U)%4`Y&TT$C"08A-`K5DV)Y[<ME2%2>;$(-1
M.*^0<])9:[FB8F`8-B0=6<E4!PXI&9%TRQ-/:.`:#!1TT$$`[`PRQ`,/,-6;
M9<-$5%'_3<T]Y!0^'7K%)7*X!!032C4]D99]L:3BXE_-X))55I%PQ$Q?_11H
MBTB6..>>-JF@!YHB1.J&6",IJ$5-1C(:9)),M/$$Y%8U"2II(L9@(LM8=RTE
MJ"DVN,:.!C'$T`5]-QI259!`9#8I8BKRLMP^VG1H"W$GI<?6?/5E1FM&P+A2
MW24@&9=5)IM,%EDPW-4XEB:_T&;/FU2E9]R?Z.%TEJ^,,/K;?*@-P\TD^\40
M0`<B?"!&`!K44`.R-&U3:60:G91G(_Y4E2,N@2DG'%]78;.GL3419PMVI<3;
M'48/K?E6AR-Z(XXG\D9B"!"/Y0D9MLSU%LLLO#UEVRBHYNM8_Q>@!C`4DP5T
ML`X[-4#YI%<%Q3E03MI%8G.:QL)YTEXA3<1GO4'R:Z9:0-:<BCPTJTG+6)$,
M&U&>"0N98$H$6XK99X&NBLAB:N$)&6#?^&(/;1*S11AJB16R*2++6"H7TZFJ
MO=L03]1A9`0Q:*"W!J.2.C8YFPESEGI:)T+GE*`H)\L@7B$>U2-`@K-7K-\Z
MC(V'.@Y4DDW7@"?)KL=@7LFRPP4F7HM_Q2U,-.FA]\1->YI>"7PE$?D(5&F^
M3"*HKJ4L0@<%1#`J-O#D&5.=G`Q(KW9/'N<1[`;,P@U8%R,'F)=U&B-]);,T
M3E',T7+$4T4.BI51L/2(\V'8)WX5(__%&1'IDHTP;X*I-C)1&=\_4@.AM[@%
M*`"3UM&!"JR,'0F`$I0FP1LWE>@>44N>FS!%%I'P2R^<B`N>II09#S3&=LGX
MFMOBE#Q+V<P94RD06+#T$UG-;@C1D<O@Y):(K!7.-H6*D6WBIK&&T:DZ%<-`
MKG0##:U%J!9PZ=S<0B&+#8#*`NO(F][ZYB!D;"8S5[NA8JBTO(4=!"0#*\@,
MMR*(1ZTB3>Y`1D$`LQ`X]65R-$/5+O11,-3AC"2B8,2!9I836T4%/;^Q"[Q,
MQY,=GJH19[%!.C*P,A\P001,H`#>NC`B#%IL0A:9%V[``Q9QQ$PGY=".18KU
M.6*8,B?%JH?_,11R21-UDCU=U,>SK+><+)D*9.GA5O5\4Y$=]4Q_**E,`FJ@
M@:&\)G@'A('*0A6##&@@@?#0RU?H0J%3N>=HKKA$7+"$R0IRLEY<8EA4/`A"
MT'!I*C5Q2ZPBTIR/X$5-(^%31_(W)6GBY&G9R$T(Y6;#PG%-A\9S"V5>>,)I
M2$R+G7F*K=PB$&TV="6+^!@XZ%:%#50A'1T00`6"Q[<I/D$@F[@BC!"Z1?U9
MQT$:NH3IZ'&6?;XD<GFLTR_HI$UCQ2L8@91'%37&'NWLKR[\&-B*^*2Z4$1%
MEQQ))UEFDL<)!>,!16)F!#R`MPA0H"@%\($%]#8@4#AU?N*$6NA(_],6:\;,
M2=@1AUA==+VR(HQG!</7!@N&/Q+E1),&FYZOQ-JGK?7$<Y!QX3(XT5">Z2]C
M9+&!N"H@AHTB<V7B\@`SFYF!*E`G@7JDES8<8D]])4\C2>4807EQNE:XPR!B
MB1-Z;)`6F)AJ0@Y))UZ8EC!T8L@3!:J1C<!A,^D-*3>$040_M?;/UNV09IED
MX.@V:[00DK0PH?%3\@`3G6T*P[A^-<5'+5H%=70``"(0`/"D.,48\C55SS6<
M_N(CBZ[FZ$W'>VFD;/72&WF#03S1J3OB0TV:QFJ>^S.?YR0J&ITR3G9Y\H>'
M;KF63%QK+`:RIWC@(3-BG@RRZG!-![1*WO^N)K`@:?PDB$NILS3BE3@=(5AX
M!*8QN`3-20[KXY2<.AFPU2M#;633OKX!8O0:;CXP1L@P;NLB?H%V)O5[2`!P
M(-XE03:*&?!`&F+0FE"MHPK0C.:SIA(M!I8%B7#B(T0N,36UGC5?UJ&*)#*#
M@;1XS%8P62$*B:J1N-SDOINEBEY:#`K+X81_G`%4%OV9P]:M60LHY!%\VEO6
M0Z47,33DGF7;8D)>*4:[=0C(10&8L@IXVH#DY5L7`C(]?6`WO>MEKUQ5O%+Y
M>LQ13F%.V]BCL9LPIT$6FIV<W%$)V)9GIE3:V#N?HPK/">:@(83:?C6RO-.I
M(HS$Q%L`/!T`*4[_-HJAZJ@&6N(ER<2%MZQ$;9'7A.8^_\6W?FXV=`:1P;G@
MB$<9!,DD=%82BZ0II?/JQV;R!1%F'9&_3KIEMV+Q(P_-NJ<B"EFV8`8/(\%@
MHQ%@$A2KBNTI,S("&;!R!KHP!@EH63)`#2.9(-8,.VO"&8.E]9DK4Q<[Y=?-
MT55!G,OWB>@0%D2"L;E)."0/9.%+UB;Y!CSL)#\:&F*XJRJNJ91!CIQ(=!S'
MAH00%7IJ2142TA(E!YP>NAR/)4(8T0D(R0`H20ITN@),FB+)%,G.R#S:K^M5
MG)5BRI=GTT1^307X1M!<+Q(Z1'^RZ@O.F#63=D--X"DES30&'IB?]14J_Z]S
M4BPJQN.=_Q!FBEU9RF"`MXY.UMJ>9R<H'H`\1<DUCVFJ-TKY$;9LR`70*M4%
MFNO=91Y_]GE)6U'H0M1XAKQ%W[SMN6QE:I]Q"!PTHXB6UAL&+%FY+T/U2\`3
M8M`!,2PSPP<,@`?W1MG/8]P&"_2+<E8\EPZ5W!G!P5!=YCDU2"@C-&)Q$,+;
MO`&TW=TWB:>M-F.5L_^V9/QQ4AFN`A\$-SHM41A(-RG%96B+]QL&E5IAIF8N
MD71WAS;J!3E"LCBU$!HSH0BCH&F9I@X%0`%F1X)FQP0!)%EY0S+MH$A`4AEO
MAWB6`0F:16OM$GN+1S'R4RW4\"+\Y38XPC#B0?]C>H0S8#2#[:8H7$1IXO`Q
MIH)'$@0_IO)W,+47(1-&"50#XI)VZG`R*Z@.H;8W+!@#LE%L)O$N*T</[C-3
M98-:UR$^W:0B&.(U^W.#G$,)M4!Z^%*')O(+:;)#O?`1T8)$]J(57O=U,M=<
M6U9IXY-OQ^`5&E``8B``Z!(#20(#)F,R'L1,W&=M4I4!RG,+S9(=?_$*.E,G
MEO)WS0`2T0(+WQ-@;&02MD-_TI*(MM,PC7`-N1=#@@@C$4)!KA<G,QAXP=92
M0")H"*5T3DA(>92+F2`FRW`<,6*!NE$5-[%%L:`%=S9=?=2!U*@C8K<!$1=`
M)!A`YBA``<0DY-4%0:'_`2,2<V^7:G.86L+X+OM%7X-1+:VP(2UT*;F(%8/$
M,YDD=7SR,0MQ#3;8B`BI?`2&1RD2*1SQ.N7A1]`7@#"S`<>4-^I`@AW`>=JV
M-_\C:IZ'`3]!$Z+A('$(0?[PC[>@!3\E*PZA$C0HC1XA>FQ$<`^A4Z*P.(&%
M6O+B#PU"$RXY.FU"'"!U"YA2*NI%&`4#E-D@"T]C&59XAH3`6@7@D4:2,AHE
M0";C3)_W/U*T`:&2`0$`BDPE5.DD/:EUDO&GE@1I*1FQ%VTB@"MT$$(4"V>R
M0UH`$]>%'8OS%O)$%2<D3_L%.=MDAKOB+(BD9SAA&4<W:,15*"6U>.W"BW1!
M_V?$]3%3]VU#V!`JI!EJMH,>V&?1(9);&``F>(Y$L5'&5&W:)ANCQBO4^%S[
ME!X%R!:.(8P7`V2((A)X5PA1B%:Y"!+NYYMXQRMT@2&2`4,1H9L:,B>6,1%B
M%FB&Q`IG$6>,()'0<PB"$S"8HU@"I)%7%5Y7J3(@>9Y3M!]\TTP<5P,#,G1/
M8W"FA4I.97[M8@LV-PF7HE;QPB>%Z"J!J`\Z\@^,ACD886+]F93B,YP;`94;
M:!9.H4_!Y83']8/$T'.."7:?,`9C,'U#T7DQ\!K`4P%+0E49D'$9]WG9]C\7
MAW%=L`DJ4G@.H7--8W)SE(K^64KW!@JV@0E\Z0U$<O\-0V,6OR0:O)`TS%`@
MQ"`F-+J3`M$YO38*==<M]K>C.'-;D)ETA5)UAK-#23H0TG%7U4AUT/%_=R&;
M4-E0H(E>LWE+\Z9I8W<D3&),JFE]YZB.VC8JHP*#,9AWP@@_TT`D8R0C$;HM
M@II''Q,A1L-'TR`X_\<KN=@E,T54X>&,&;1W,15C=V5<N/0+B>)S]`&HBH$9
M:-)=Y.4:%2```&!]U8<N($E>*]@%LCI9Z=(7'<*7\-=>.#*(('4<9]53U/2G
M&\.8UZ`+P6%Y^4`S%!17PSHB*VE>9QA0R/69A_`74P>(TTA@MJ$%+EF#KH(!
M^]:9JE`D&(:J8B`&!$``P"/_0'@SEBJZHKR#<5'THC"C`P>R33J#8BG$"SBJ
M)FYQIK0AJ,BF8,XP'V<"$SL88,+(1S.*#?Y@<V"QKS%!,9!SB%N#K=?4%B22
MI0JXI82#C=9Z;M*Q#1<[F=5"*KQF,1NC:?*1%;;2I3Y34?\SCC#`E11@3$S@
M6$M"IYGH3"S(CD?9ILD8J+[74A]SJ`KU"Z304K:B@V/DF1A1@()XK2>+M&CV
M68NBJ#7Q.8%Y6(,5?X]7%=5I"3`5)%ZW3[+'",0D121C`2)*%.>ZKI_2B6`I
M:NF@D0(R!GD2)3\W!`ZZ0E$[AR2R/6OI'<\6=FMB2D6V'&MI/IJ5"Z,S"],*
MD/4`_RMZEEK9&:2Y(B<4JUI+MS4'BD+#$1GV$!4:X`'L6C*,Y5BK*TGAJ:)@
M.98G>J+--%41`'[P$'X)<Z:[(!T@<4HC1!ZTL`W=$:$Q8IM3X1A5T%KRTU>Z
MYU,<L4T3E)S].6PGA+03>K%;P14D1Q_)N*6&!ETV04W[^0D>F!BOEF;U<2IA
M1SG1L;24^5J]I&DBJ"2J68(1\'!T*EZ9F(ZP6@69A@%&]UQ@1Q6V\2B5<$M+
MVR?)@8$3Z&J4.9\"BC1Q1R0,,0U`14=$A7*J!JU2N7-M`:YG:\`X):4Z*$J/
MT3IET48_FPXI`SP^\!IB8(X1$`)CQWUTF\,;)QDK3"OA`/\M!&HECEL=Q?H1
M5H)K!#%=&].@RIIB-"%O@M@=U+LG%%1@6+$AG',^5D(/L!,:"'F+7G=JR^6D
MZSMCPM`%9)FJ(YB_8@``,%`H&Q``JHJ)Z9AQ.`PJS#2[D\5(Y!1^C7.#PFM"
MIS5G=!$O`:$YO'&7*:PKR1<^]-<2Q_B$Q-AXM*`@@FC$*A4A:LE'PN@93Y%4
MJ*@-LO&]77-+?F4JU=5NT'F^K'(V4^</+55@#@H<`D$,A_!&`&&:QJ0D*&B"
MU:<RZ9B.'6DRYHBG>!P0&X`-,8A%#!')W+E#AVI.;.&Y\`="B`D1IN&9+^5T
MR29$D>,SP$@B<V05I@5&;@K"EVG_%;9!PJ3Z)=5E31P(,^G0KGK3'Q70RV:7
M47@30.G"@NCYE2"9<3L%)2N2LB9DJ?A&CR7F+SU4/@[ZE/&D"?3H0,_&-'R1
M07>U.#FI3I0*,=JA#:_SR9`39XKB)P(G"\E'(Z'1$N[P`#8091X@QR*`KDP`
M`S#P`H4RNS!PKDH020,$J^^:;7D\53'P!.$'#WH44,)6Q)]@HX"99^,3#E/7
M5%XJL+U@)AD@J(ML.:%!E!C*C8GV$FY#&F-QA+<LM`-G+.TUREID`&<2O@)W
M,R44*RC%RNA[*`O+."N[(P!1L)861D:2!O\3``^'@@7`!(8=/!V``TMB=B_<
M.ZV9CIVG_S<;4`>C5@U]JDN)2*47Z!2$@R^(%VM16J#VQKWR8HVTAFL;6`MW
M="I@:U(!,S.Q3#'5&5@8L`$6]:C"!"[\\7`P8-@D&G$9Q001(``B4':1U,__
M_)5=0$SKB11J]&'`PM`MQU9RT6]I.;HQ=6[^,M%LE:P\R2$V\0^6<"G"8=&T
M@EOM%;EJ-K#T,740NL`.?#;W\8$8D*@NP6TD$@,QO0X44`$B<`$]799?\`4I
MX`$>8.`R30`WRZZ>2+M!35D('@.7M4#Y$PSN],Z*FT(/FV>I`W`(#(N8\1)H
MD0&*]X1*"'8>39!+O'.CD1,8\I=.1U^SN=TUA4*YK45TXT&JXO]7N'4^4(T,
MB-<9R-L27;R@;7'(<+$!I$+C+1*B`D`!&WG8'<`$<S""`63<61Y`3&`R-7N5
MX\*:0U&S<YLWEMT%B(*^DA+29F%_GWM+0*"-?0(97#$XIK*T,"5L46P9D2=$
MF;$_?^?%@H`_W($\#Z,T"*-JG-0*1><(ZUPQ^[`!&<`8-5=)+<([1&'<3=`!
M!!`\/B``'Z`R%_`!6^DIRAV[*MK<_IPWNQT.1SA^IL&<>E:^<Q&+\["RHXL@
MCA`<\7#(YL<GH\,C4)DT^B+KHA&F#.N=VYV\"EPFU\G`L#8*(V#`)BD,ZO+2
MVI<WKJ'I3=#I$5#@!YX"7W`"&5``%S#_PZUI;;.;HK0:KRNS`48=)3!S%=4%
MET$GN3_SC,@>N(IB'`[VR5+:9B;.&6SA<O0B*RR.3L3QXN-W*?Y)WUND*R:W
MZQ&A-=7L`2F0PGXZ,Y=3E(Y)8&A]$#OIS;UBI7NM:;%L&\M@)'.``Q=``(B]
M412`V"@8210@!HR=SS/=X.,"S)A(S%PYV:$2%);5U1_[\>HU<)1W@!3:](D:
MKLD6>6&#?`A)6D;\4/E]EZUH4'(>G>4\("3T3C"25!@Q2_0RWH?1$PW1J-PS
MZ2;>'%ZQ&MSWZ2(@`IU.`.$U\SB@K@*`V%$>!6X;`>J"ZN\J:BOZHGI8;PT%
M-.<U?IRC(.OV_\0C2U;V%JP%8JS(E4Z7&Q"##F&YL[MW,1RQM2'7B`^*G&R+
M5W2WN;7;>#"VP!\FDVU6Q01-(`(XP`/A!0,>E`%?0`13,`4MD`([+5Z2%/NR
M^ZXIN@Z[3]1/(`&,X#*S$A=B<F_M]3-XH6G$B6(J)7!2WRT''!UN)HP*FC@^
M/`Q<-LY3N\%+?,E.Y\GS@^N/4/%6MQXMD0(IH&9=G9/-*4&B"`@&*H.$A80&
M@H=/&$\&BXA`D4]`!D`8E)5`51M5&!@V"8BBE9\V,4PB%TT"K$P%KQ0=.`04
M<QT%MP5B'0&ON!4!O;V^!3`%$3$:,<EU554&0]&&*J+3U()#I-"5C?^)UM.9
M0-TJ0RI/-I:8VXZ1-I>BSI=`-NOFGHR)V0;HD92AH98Z93(0ZI(->I:@V:C2
MCEZ";/,07:+&:!*B)T^R8?!&3M.&#?+\U;"A3$,(910$X,`A@`F!E050"1!!
MJP`.)A0HO(K01=FRGT"7:>A9LF>7!``A'3QX">G`>4`*-AV"U-*E;`=%065Z
M[UTTJ`/W>:5J-6K8>?S<W6-(M5):>@8P,!P5$-0^A]P00107B5RY0:2`9,,(
MJ1%&<BHB00-H:ABR"!%Z$4AEA`$.$2(Z>,CPY<N4SU\\%)@CX%@`&`&"JLX`
MN76$#*P];(`6C6HTMYZ6MO/4Z6"DWG*=S>W_=T_QJ$GG@%"[G;Q*@`U8;4SJ
M1^DV=72AH%DMOH^2IX"4^'4UR`_1-\""Z`HOQ?"\H5$#GVS&6+V@\"H(O5Y+
M;_Y;-7)Q->()--1H,5$T`X8CUT;1(%656M+5H`$3.#2!&0&NX$0!$P?4Q$0%
M'P@PS(C$%#",B<6@ED$R0C7SC#[O]1<C-8]0(XZ,[AW"CD5Z.8*1?MO,(Y=@
MW2U$WG^+6-*--.'`-0J$4)$5B1:17)5..]6%]4EZYZ###5;*$?*06"'-,Y0&
M9\8000<BK(2#&`(TT00!`F!8YX:7S41!!`)$<))J0*W(HE!H:I#``UE!A!]8
M2ODF2E8`]8.=6`3%_\404@N6MU<_!*6C%U1H=6K<D$-HT@FG#U:YS99D+765
M6((-\8A6]&%32%B5..,=)0_H$TE5&D10C(F0!=-+!:PT,0!F'UQ0@`<I1!MM
M9RG`($8%**(&Z#*P=0L;9+!Y@(P!8XS1('6?A$=/IHL*"5PGIR;@CCMLT<67
M>5PJAH%LHLA%GPJA0"2/E]D\M!T_53*%CI=HY?8=IQQ9(Z-6#J>;XRB`W;@(
MO]TALE`\"8,58\0Z>L.-..@\`:"2`%LU:4`,ZD-*11C5T(4/%US0)@&OL!)3
M:;@44$%F.KV"K3`!W"*LB2<2"U05S711#WHXOC<@C>-<`T[$HDS7C;WXH/]G
MZI:_P@S5->4L@D]_X3"Z:BE>02)/4]V!JHYB$5E74=X6%;(I6E44VD47(:C9
M@1@BL"(&XB+(25-*(KADIP@%6(!+#!+ZM)J@0`E>%6U8HNJ6HX&%HY1V[Y05
MBEI8:D6=W)B\HXWI=4F4KCM$N@7Q4UZZI14Z`F.SSX]<^PA/)Q91]4\"D6B0
M1C'8^F)L`#G%9&&;!R3^[!?2IM!9`!5<B]IIJ:'YD[>P!=HM9,\\T&O;U%7Y
MB:X+XQ?<)?<LG#\]UK73"&*.D$XC;"`;P^0O/9LJ#W]V$Y+ZH6,N69$+ZXSS
M'ZW=RH+[$=+\G`2?#J9G5%60330FD1MG(.Q46_+_3P<!0PA/G4,B_(D+_B@1
MD='U#BT"Q,@3NK",I`E`9S@I`&8*$`LA4BYHP\+%B6!P-&(88T3(\$D7FF$#
MF7EPA8YX%043<<45VH@ZU``0[CRA,H$M2B#].I5T`#2(?O#(/%=21S2,-"^"
M0,15&X&?)>!2PTFL3!)*THBMMH&4D0AN<(,+5HHZT`%DB>$`LVC"`9K`!,<]
MC@`'*(U..H`Y\VTN!BORY%"2D8`Q#.1O=/$-)H34.]AAY3NCHR%:%+,ZA"D%
MEK];)2Q9)[=T.64K_)L9)E9'-]S9CC]>8@35;+01<6!@`U5\B(.0PD/PP8F1
MR!+`T5P#.1$,P$TB@$$$_[K7&2)X8`Z+"X"P*A#%9;@&?=QZ#2@AHX$AF"M^
M_:,CV2JV($O]1F%H^2()_S,\<<BJ@/-Z`AIAMSM(-$1W>]2$+8V4J5)08FL>
M?`_`2'$0_'31@UEQQ#XV$Z3[I$L3W.$B1S)Z*RW\:"/7H!(7)5BI=/CJ(%W*
MX0Z5$1G(%&`5013`'(@A`C&\@@DP\-DK2(2:837-%_+\R>#P<YN/'H=![+@H
MVZRZU:QJ]2+H(",D2-&)N.T#A2K;SR($B"^(.DDJO,P.<<C&,"'1D$I)J2I&
MU*(=;-2FD(4:"B)[HB;(J"DEBUL)`2RT"DJJA&<S$8`8F&`!"E0@!HD,2OI`
M&?_*HI2DEK5IVSKDI\M@]HM_IA(,>"(U2]=AJ50)0H14>AF5U69B7G=;"CH2
M@TNY.<E3E,H8RM1!('^>U2'3Y.$Z)5NG.33A,AUH36&%I1(>&`$'D"P-M+P7
M+2)D(`!BP$'T&IF:Z;X&?=]R#;B>$2F"(`6V94T7W.*;,':%A$SBX%$YO*H7
M^6Q`;>\(*7%DZEJHR+4KNE%0_EI;/);N!SZ`XZ!5\ZN8;$!+E\]D"%1`5BF5
M>A@^@)G.6;%JE?]I1!VXBXK`'-"%&KAXIVH25VL"P(26'+4`*JG`AHYJ#&T2
M@Y'!0!$OC)6BI8K+G9AU!E?Q9:`/YK%D2R;HS+XVF$;_E(4@*AB28O9C))8=
MARE9$L16WE&53W!'9F;KCI1.:AQZ/'@>29+97W>*)L*=I%!J(E0,+(`*S/A9
M3I=A`H62Q00V]8E/,$B3^N*9@<#B^1FC:,OK%E.65>[6M6U;6*B^V%K&`!>X
MGM;CPEJIP=P1Q]+$A5@H%J&RL%#D1V%"SX)N5(E*D82ZJ5""KE6!&6`8=KJG
M$0,/>$"%R\#I!=-*@0?LD('G50``1DT:,-R)7M:X1L:O>8T&OC9-YD&)*0R)
MARI/I2LV_^8>_PL2_I;DWW.<2F"@\A*7J43+-(('5-_1%=[JP54H0SA47HRA
M2-4FBFBECK1CHVH%/\I"WE*"_]5;ZI@RTR/3A(`%(W6H@PU<;`/"=LN=01:J
MH(TF@NCAXEJPP`4%DI8MH0V9R,9X@3&BNJ*,K^W!'IQ(8-!#M2BKE#YY_+>_
MJ"&>U^K%!B!AM5X&TY7<Z6Y``)E;NNSH,7T3K$D0<](?43H8VM!9L'=V9Q3Q
M[,[#U>E"+VG<]2ZCDP\DSA7`\.3Y!&7M9!#6?!GH0KE^=:BZU5M2NM1EI^A&
MT[AHH::`IQBG8!NK&NY1(6BT:=3EX3K206SQ,AN01KXFPRU?PYF<"-)O8F!-
MS#36S[10K]@CTX$!?---X@V`M(A`A"^$*WS1C4`%.*FF:D?``^K\?;9=\]]#
M*<_;=O\5BSM`4L<Q,D3+<\7`"-;6M1F*HE3\4ELC-')`"-OR^E9AR`OC0J_>
M3-KG)OMH#4'\YH?SPS`I^._:PGJ?A4;Y$!317R*T[SHN.D#S;H%(&$%8G)4!
M:(`&ZQ-D'[)[ON`*,8$+`I`+$-A4O:`T2P4#3Y1$&'@,ZY,!PO$$8])!P6,C
M,H5SZ'=%H[8.680\!,=]QG$;"S()II5%!B)A<Z5:TB%#$9=Y54!")N8(6F`@
M$=<W\$$OZ.!B\I)GB*0Y/94,@044?$(3.\,$JL!8?48!-T`G;+<F!3`H!2@H
MTD5V4C0&S!,5J?):S',DT7%#N2$1'E40R!51QG1;;%@ERN'_,MYQ*L?T%:KD
M):M#;ZLR'1>U7^GQ?Z?U))IV%COH8E$0`366,W)R/8FS)^KU:S/V$I!D!*ZG
M7=U%>RE0>R\``#1Q`S?P`TR`#%]H;9$1?(\!+NQS*`Z"0S3$%?.C8;28*?20
M'-L1<39488,P!/OR7]T0A![33U6%+I@08O3A42\$(5LRA_YV@ATT?AC35H_P
M"-P7C`'D4!]S#]78;QDT0&'#?:,P)$PV?XAT$,&R<J_!"5.P/K\W#(T4@<3@
M,X*V23_C1+=0-"D29*_`2,40?-^29"^2'FCC.Q<Q#M*X9.=`?5E$?S#5+P81
M0T:RC5=5@YAP1_%#1K-V(YF'/U@E_U!BU3=:@QM'J%QVAV>KB(H_\80@%UDS
MD0HSP1)]1@`84@"+U866%0"9A3ZNT9*@-"AZ5X8.D@G&J#N)<A>S2$.PY"FS
MI)'!45JT=&5.^3`VU7F8`&ZR$S_JI@X\=Q'SAU5WX1M>0FHD07KA$R>.LQ*E
MX0.5*%WFY0-S\`&3A%UP@AHI,`5$H&QYF0(O$%Y-D!/:A`SH!1D8B(J5""VS
M\0#9<19X!&8H%9F=D(8CMA`)HY%;)!$<4X[Z(SL>DWQ<1!SB*!'?!C$]MY`>
M1(U7A#<"`8/!2(Y&J2L"AWY),CIA0R-P\1WRMH8V4`==,(!J<B(1H`$;T"TI
M`!G`YPO(PO^`KP`G];@+#PB0)0(]3>4+&XB!ZK0BK+$!75`%7:`/.C!36"5B
M)HB:&",K1V*1W2AP)[5T(R:#2%(<_N!0,Y.+N,AYZ`DA;95%`T(8_"%-6(*2
MCA:<ZJ0:@N43CQ$`K#`9S5))%?)#.M,A*9$]MP`#G&0SW`*/3>B$+@F+V.$4
MNGE#"59KI0-;&T%,$DEI5BF5*M9FU6$508):4%<J)G1YF+!]M?9@)0.`GHE#
MMU,=LE(%:B(T"[I8*U%R>V(!;RE=ZD4!3?`!1]HF1I4"&=")1/".NF!4/J`+
MT:6AD;%-Q:)>'L`O9>@/2.$;]C,W:5J1OM&0N!@>H3.?Y;B9@-'_D9;'2M6@
M%+1V%PJ%8"(3C>;9-1+&-@FA@]N7&#80?SX24B3D4;,990'F)4_P?SAZ:KJS
M#70D'6?9&A1@H=D)&](2CR?"2-J4$QW@"K?`!-?TC\@B/4H4D$%3@;?`2*@A
M3ZRA`0LA-=>79>-I'.49J,>!%CH4.V5U4820)$E9=1LA;^KV?8]B*MJ17Y>@
M0]N04V+5(Q&6%R'H%.?`0REI7@4**"Z)BI7%"BH1.9/1!*JP6!)*)VW2)TG#
M$WBGBN0C%/9Z=WUGIA)%%7(A*JU39ED26[/%4=K1"52Q$!0S=09388'A%+Y#
M$2TJ$/*B<Y)`&#"BHP^6)$1'9AKD&P[R_P2*-`<58`L=$),B,`<4X)9+NK*0
MX:1T:2$'```PL%V>.*89X`%IF0M*LR*N(0S(PHK@$AL>$`,(41\^BA_U@[1=
M(1&_\7QE8BH*A"\"(D+%)80>-4M0$7%B(PGP(4&YD6+&^JO`JIH0-JT,4IN"
M(!\9P`BOY%!7)K8>E%^6PC_H"5,4<16O-&H:=P[!@IBC41K!<%Y5&BUC.@Q%
MTZHZL2$H1ZNGB@L2*#0F!SWJ%&1,A(&H<63T5`5KVR,U0@J<!ZQ=A)OTDA$R
M]",XM0YJTU!]RFI4@X>I9D)3IWAA!F<2!*1*T2YF*DW[0!1+N":Y4%[;PJ&:
MLPQ\ECB,HS//Q?\2%D(G+6%HD+%[F(6@Q<*<B"E579`!&P"+@$<<EW)+J4,P
M+C,SMA,[^M,.LBDP;1@7\_D=:<@PKV)N\A-T2>*?5]1S["M#%+,4!&$*D6&A
MOX!.;'D,2LJR+.L#%(!)JI`G,/`"T$)[8YJ7'O`"SQ9=<GD,\;2*X`,,@>N*
MR#D?#]$J/KHN9]11=F@I\ID6""9T&S,;(?:UDY(;;C,87`L?``:_H,M59)NB
M2E<._60.T,*VL-E+((;#A[<=J/,$Q&@C[J`=C\FWJ]<+@N9C`MD]RA9DP\!$
M$G@XV")H6OR`N&`,$HB!TIDMT5,!OM:*'PB6U4I@-\R0965E0>=,08?_.IJB
M#[/FD!UK''8U-@MT7V!5F7+$44]9E"0A.,H`/MK$"UZX+2[Y$VMBKBLQ)Z;7
M.#.)(2Q1LKX`A:VQ>Q6``[S7.1*"61Z*%W=<11K)2[`U:@D32\+DAJ602GAH
M:R>%.V79%-!*5F=F#GR1;BPU"D&XE'`VEF=Y&@Y88WX&N`2<S*<AF)?A9XDC
M>U/`/;1WI=5R+0'@`T@%M#"'(L?`P<7"+XP9/_'VM5$I'N4GG_+0&_9W)8Y`
MM4#@4DUVJ9E*P\!U?>[0J+/SJ&TLJ*F91]<JOH-`I?3KC<JS5OK\C?QI:=]!
M@H+@;;HU:A@1+&*G$W/@$FE)+*TA+>)R&DP#_X$16&BH.JLH]PI)%;D=T%2S
M.CZ5RT388HD\T0P"\D&']Y7[O)K(4Y'6D3+*=`W:EX./@D)RI$$1-]0$C2\<
MB:FYPA"MY(*XXQ0==TC!8J%F/&W!VY(#"H6&UB:4%(F95).&=AG'@&-!`1E1
M+`.'-G9#@:%'H3M2D7A[\4P,`J,TFD=+C)5-"<-@P1@9-B9+/->U)#=)75LP
M3#JP17!8XV$EF0Z8$G0=Q1J^L"&3@0-0RD[)S++!*325`SEK.:6=Z)<>,`4>
M<`>[=Y.U.F.1T='/@FT]^QS=$#]CLB@2I(?\\"YVB%+Z%->?T&3^Q7U44JGR
MM5";XI"9T)!=@DN`VO_&U/AY--3:ZY9%B$"EBYJ#GB(PG^M%:G4@9$(@,/K3
M^'$.3LQ-K1$3<S`9T>:*V[71L>K1I^J`DL7%CCN!Q7#2S`G&M9HTC;1[MU"@
M-YMW5/0H<US3$],C]_P;TW=]6;3="4M!V1`/#;D8OL5+PN298K:T'6,5!J(<
MLD5^P_W4@Z5(+*TT5=TY)2%W/P$YX=4FC7,!,B"%B2,GQAQ=EM6%CDRDF)$+
MJ`C5C1:+D()UE"9N"(=;[;`J>AB^@?$JEG(JI)4K11NP#Z.?2LFP`):05]-%
M!W&F.:1<_H@+R>MVIUC9+#LB&YP2RGL9/+-=4Z!L-<M$N\!ZW1Q\26/%P:#_
MVL42`)N!$!YC`.'LC!HV-VIA9K.X(`M&EC/L7^I+C'J1AM_16W<AW*QV-J8#
MX%U$MHI1UV[X-6I#I5*1;GM45=B-,;]:@L6X#4(XG^6W%.;ENQ;@R%NJ/4OU
M>V,ZIM,KQF)LQNO=WB`M62<]J]BR@;2*Q26R>U)=J^&2`1GW(K$%Z?N)J4'G
M,%I5#KM87/R9K$=ND:AS;EDISAC^-E9)$2-P>)[I;;M[2'86`Y`+XB'.R&@2
M`1:*BBG!"A<`I39Y&1=0(2+P`4V`DP>PJG'G3DS$"L!0#'#YA'GG/@;&UPN#
M.HG>"10A$.!1"0"A9#3*7J62#K8\V"?5AJFE'E8B_YOCFY%%OJ+)WF%[A!0*
M59S?`L4O09>S0`$#[.65*#36#+2.B`.\]JXS.[C33*4XNPO!`)"6F)W`]^JK
M#7QT3K1C]0#JV[%-SAOSLZS/($&6V3'T`Q<']5\&8""\W#`,O\0-$W1U:MS(
MCL._I3&XM'GIH1:;X9K*KG.ELQ_'W3I?9$Q0H4,=%SB'W(H14-$^Q:F^T$C=
MC)PS1M*Y4&.)#-*.2_BG:J&XOE1(E.L58`SEWDA*<UZ;L0G='?9=E1Y7D[IN
MQ#9[=>P)[20:P8(S2%'+J@Y^7*U5(H02026VY!2&5&<M9C,\-2PW?N[!NR94
MO0R0(P`',$F+E;Q&BB$N$?]9;CEMD5$TF+S!PB>\RP`*90J@DB+W1C@SS737
M?;@=Q#5JCG(P57*U0VZ5XA&[99&#Z$M"9=(C[H6I!]$3K`%R$(CBJ6<!]-_R
M+B\TO>;W>.^(,P$(30(X(A4!$1X>*40>+RDI`145`A4%,)41,3$9$9F=G8F?
M`:.)`1X9-@FJ!C9`KD`8&*TVLU6QMD!/3["Q&+BM!KQ5538&*@9#3Z>Z&%H&
MST.LLKW/K+@80,;5P;'.V]_@QL?AY.753\7'L@:[[-C&T:[<[*?/ZME`K;!/
M0T,J3[:JJ1AH#I8W54"&(9-&RX:N+C$B!.AP2"*%`A0Z=>A4X%"!#I)@5$34
M:93_R0(H/PH0T*'E1S$L!3#YV(%F2Q@P0-9$V?)DRPHM:Q[B=*A*A@P+_9E;
M6F[<ME@+H0;3)>];+PQ/M+FC%NT90`RLLE6S,0Q6%;'5L#W!YM3`5;#!LM'*
M!R3!@QH:\G;96P-O1(F=-&G01+BP8<&((UPJ$"'OX!@6.GP0(0*'Y29-/DQN
M@H,``9D%5OJP4,#0J$ZD*6:*Z&%HX;PQ-*R2AS!7E0T8$@0KR\N5C5B^;YU]
MA@'WL]_!#"1PY2OW<ENR?K_"QEQX;K?$B!=3[K87OWA7Y>UZISNY*ANL3PV6
M6(")`,H5,EJP\*F^?<#V*72H3*```1P;$58?$SA<P(0(_P>(44D`,#B2@B)3
M9!")&&(PUH$`(YU67RDF:8A(`"D8($%88>D##"_-T7)<*\,TQUP^T`5T3#++
M8/4-$%K0Y=LS"1&3S3'J-/,.4]L,U!:12Z%S#CI@=065"M%P-<0CVQG#RT)D
M(1/-6F@1%`Y!KV033R[HT*++0W]%8D@$%Z%T2``1G:92!2(APF%*>*;$1`4$
M=##3A7X&"E-.*`'U$4\P?%2))2D!=<F"]65@5!5(5OK-.`1)Y998Q^@R%32=
M>O?-6EJLLPU96*FX*3=E%<E+J?:$>E4PVYWXD%Y].69?;(\=YNMA$5R(44<9
M:-#%8Q%,0@@.'S1!`&6$B/`L#O]-''C`'`(4RIAAQ@[&R2>:=`);##:,\4!8
M0Y0W3':LT`*<6*@2!QUU9C79&W?-O0.+;\!8`U>^[P+''7)I40,E-UE]*LTS
MJNAFPV`!E+91)Q=UH"!*]V6L\2<%B%%(>RLQ<8BOR0I`0!.4B9"M)8Y,0<0C
M*;Q0@1@423Q2*':VUB$IGWB0295A\J@/P"_VZ,M9^QHP#*I7$N?!!NF<^FXU
M^<S5ZE/462J.EUJ7HV0NQ#49)51;DFW`(V0?4VI=0_2(S#A@VR-WD5K1I5PR
M2^M2`SKK!=9Q1X=NZXE$HX1&24<[IY2H)8N[%W)[-3$1*"5!74AG2BX="A+B
M-TDBE"C_&70A:3]==ST!7%<2=`Q=GFZSED-8'1QD/M`<APN_R/0HW=S="2RW
MN\,54]ZQ@QG;1:Z[\OKKKX&%2X')!?AP(9RQ040Q@90=(()[)U/+Q`6=/0MM
M!1()$$$(40CVV%%'D5128\778%=<I-\&UF^U8N-//L!)IV\LQ=A7E,1BM-[@
MXT0-P8:[ML.+`)[(=_PS55>TL1;NT,8N0(A!Q"+0L6Q53``*HI[&_K*\<.U'
M##,Q'$9,LIK"3$0`%Q``R@0@DA<T:!&->`0,0.@H28S$3CL+X@]/4:[DL$TY
M#?1%T7KQBZ']9AK448M;GL8[621M@DOK1;_V-22G&(EK13)2_^F\U@JUG,DA
M%>224_:!@11DH(+;6!LLNO,$**D@:5L#(Z:"H86AY>U,UFN>!F$"N)']A2@F
MV8\(8$"X4;Q`<1'K0./V1`E#A89F+@&43B2)DY`T2B@3D80H02D1#QAK`U68
MX!B;\@P'8&`"8].*W)C41?!08Y;OXL=8KD$I6C%G=[@L51>/018?N4(57:@/
MK]9SD0!80!-1T$#Z2FB89\:I)1FA`!.8D)$,$"8O\_'!>RH3K6=I3X;2P@P3
M_H.A9!7@FW':$(<(!S]-V.`!#UA.F&SQF[.49U^P"*`2@Y$N@)QE;&*)SC1L
M499TT2ILK$++;HBA&RMR8TA;J=*H@/^6C02@ISXYV68'/M,!"EC`,1'YEC)_
ME1<./FYF):6`3!DUE*,0YGG4(L`%8LC)&SZ("$3@X,RRQ2"1G"(#.A/BSC:$
M"GTJ1S<.F]<L%,A/'UF-&$I,&@`Q\+2NK`XK[9!:BY`!E;7<$AQ?O-07C[1*
MKPB4+=P8`5IL1)`GUJ,[6A$F$`:"`;DJQ:P"(=(M4'FF)]1A`]_R9K@"0*&2
MUB=B`=A`#%J#DAT2E7",P@G@)+D3GJQD)Y]MB7L`0*>:;$YS+I&$XG("%)#<
MH4Z?Z()1;*#*58I1;K%(V%HF($NK^&XA9GT2U8!CHZB@,F`'Q$9NN:8%+E71
M1V4:3&M:LIK_1F8"I8YY3'9+R$$_9>10%/"!):AGK(C$(#0I^P`.W).RG7+&
M0$PX``X.!Y3KQA.(IM#0:6"C`0/@TZ.RB%+>"!A0J>"/=-(PE5FL-%:SX&(;
M^T+.'=<1CR<.Z140'8L5)=H/NU6X"FYLJ24BP`D?7K=;)&Q>"WT5@/>L#(3]
M:5-I:-:1%6NBQ1?X@1(N`)\`V/`%0'T91R@DDD,-):DFX5`0>T8NW:1K-C"Z
MW_UBI,!BD*6?T7D1$ZE(NE+M(FH\PHHOBM$V+4K8BVQMJZ70$21Q=$=,;ZY=
M++H:9VT(5Z]V%JXY.E4%#81``WM#AU'8IXGVE4\`<^"F3"FPP3A%_S(E,BU<
M91EYK(A=(E%!$42?*L>22W1:DC#5["5J8BA#,:BU,-60(H:!"J_:UDMM5H<#
M!"N+A!D)1>^`VU8U>ILJ"%JC!J'K.;`R1U?G%B^?>)X(FH"GD55!MGW.;K2S
MB]+")(MF,\7(3"5'"?(>*R(%:,(!4)93S.#@`":;[TO&R1C)M3`1#VI-(DI1
M$CAUX<]=,,`8EM,*W024&6A!$0/UE:,P[_7-*`I;+ZIR47D@E']A0TN5@"D-
M#%L0N.RHPC<U$($7G*(%"E@"4E<,FT\HUE?2C`C*^L,$"BE:<I]!V;+G$%X;
M;\`#%<#,M(AZPY>]P!$>V"%E$LU-4""9%/]!K'$GD(J*?"8@'E0)$_Y2!`PK
M4MDWKF"H+ZAX'.5VR0!K<X@TLE(O3JE5S9;R$IMC'>:P[:XKRM@`.IB1,.UP
MXXE984;LRO%T[/0Y"M'<RR:.L@$T;&+I'`G9-KF9.,;5.&*.[T@,CH<7!H&$
MM2-=R20$Q9),5F+4-P$)4%K+DLV*WG-*+PIBZX[V/.L2*[SM+3C6@@ZT1"-'
M]S+B5@](BW5AU.#%K<;:*%P[&WS;A)01A*'4MQ?B49O:L3&,X;@)7IDZ;B4L
M(2]Z/$(MSAQ@W`0X@`Q4IK)GH9#'C*%`):R=LWGKS&>!V4M>@#:7:$P=P@HD
MX,+Q#X1T,:WAM`+_0!)''62&(@P'6/\`%PN39P&%1'?##C:`6+R"5(KP!1MP
M`B>P!`K`=-@%&S:U/!%P(-5"`7.@,MS$;2B#&9@A`A<04X'A39+58IT!/H34
M$3"C""DP!2G0,2I3,8S1,_FE5#Q#8HB0`4#P`&U#8`[#(F<Q9CI2%KP11;)0
M%ERU`6TS%Q0V#L%5=Z\#(P?%.V[6>DS!-6MW4:YS2PW8#T_@1L5E$'+F.WAG
M5EFQ5M405>MR7AB1"3;%/GSX+9&`:-A"<X5C::`D:8SC3,?#03$P!AK`$Z4U
M.9\E.3#!:=F2$Z*':3_1$C2#:9;@.:+$,T4A*;K4-6`49G6$5Y824`P7_V:_
MU7!65"L;L`$6)WRY96L#$6%DM@H/@U(%4!GD9`C,UWS/MUT"<F/O45(?H6CM
M\1D4@GTT1#W'D@FDD8(B(`/5PAG+=@$H,QFA\0$K,0>A`2>>X'[NQT+@(G_'
M@T%61#KC@5$&R(H2A5=M4Q;'H!!C,C5=!W$`Z&::,G<9%B6ST%'I`FW%(UV*
MD`$;\`5?<`(N<`(ML`$A=GSC4D+HA8S8<H*?D3(%@AD\IC*?4VC1UT$@Y#%B
M``.GH(-!!C,P8((NX2%'IU3P1Q0QH&_)D1SI@B)+8R95<S33\$M$8P/U0!>J
M(A;!I8`"IE#I4(IB.(9D:`-K)##J(%<',V;:@/\V;Z,"2@0WV=%AOZ"`MS46
MQ;07(4@9S[@:1^%&[),"):$H/)0GB5(1D.=XC1$"YS4S!:`!?H"'A@(#W#:)
ME1,4>]):+?%9B8)YI?$H"R)*HB02<"DI,>!KLC>&@<4+IZ@I1+(ZS%%WMM0,
M-\)$"EA,2!./52-V8J0C#I$`>)%=I.$QOJ@@+60\\M<KR@,LD]`?[5$)UI>1
MVHA]!.`YJS$NP4((XK8].M61,N0]Z*0]*$%#)K<SY0B7F5`#>V$#-2`T1\00
MP&!_`FAP6",T>E4O"[&/7?=$N;,.8!)6IO@,L$(Z_%(73_`7XL)QII`!"KF0
M&'B?+=`"1X%BU18#:6#_&!'`3LN):"C!!.1F&>2DC=HX0Y]#8HHE5-AG&8:`
M@XL0,XJ`<^]1DHMQ,T+HG.WC`4UFDQ,T9LVQ&[N!#=D113$R':O6$/%(>W-4
M.V85$$.@9TNY2DKB6UI!>Q<U)&RX'<V`1Q"8=RHBI.$0EM%X(3)'<WH8`6B9
M`6X$?X4#$I-HB9\C:3@A$H#&<9,@F"%0`QR4$X12&LZ8*($Y$UEZ.8KY$YYH
M.!012HIY.8W9:^&Y2OO`=I>IA<HUA\/6"@5'-2U"@,50'%ZW40[Q(UVA3[20
MFB+FC`C";-35!<8GC!/)/#R(C$!A?>/D7B;C&7XR"=O"*Y_0`=%"&=I8C>,V
M_T,KMW,7(08_U"'SUB'UT2W&D@K^AJ@1YH[[=W?<&2]^=Z+X9U'Y2#8!-3MT
MXUQN069CX@JB0U.,X6-'E0+U200*>9\C<'/%\C#+Y)_61JK;@UZ*=C+D]'T(
MRH(JZ%XT-C(/RD&4,2TJ8U2+8`<PHY8%````(!*;8PHE\7-"E%0;$@"H0%#I
M,B;%Q#]91PQ4"!8X&1U9404O("D/-D&D$C?#MA8/UC0WNDJF<H:VUJ-Y9R,I
ML`$0J$0),%!@:5&KN%$80#PQH$W;Y!E-`"F?X$;S6F^0QT,MR1Z3)A*35P,Q
M8%F9&!]]P2"E`10BU:6<Y3F<-GJ9:!.J!4*+$Q1Q^O^F]!0#QM%6^])FM769
M[""'U1`/6J!73E$<U<%`J$)QUNEP#6,#WN1\4:!L@K!.(J!>/A`!X`AHL4F,
MAV$!+28MV[02&.$>@M`$/+:;GN$9E+0F`I().+5L\H49`U`@VO@?WH,@Z@82
MX-)(L.IC%>$SM&JK^=0*`U%F%J9_#1&`+V(-P^$65]L;4!)!63-A^&.*I,([
M:J.`IN)O3P`1IV:;0O$(]?D%+M"0P>N07P"B\L<KTP1N8@`@VD093"!>XBI?
MEE&][46XRR9SF+`A$E$!*K-3E5$AIT`$=@!4\(9S%Q.8J<>O'2JKB1`#1]@/
MNE@=U6%0MX!UJ&)0#\551AC_$,$Z1[I!3&#U&[N0,+^7L5JSL5RC*7=$H[WC
M1F/#IU3I%0%AI*Y3!T>S'I)3H-LD"(BS=`]2LS:K?J25>A^Q.(=07HK2$ILF
M2A'@!R%@"9MD"2#$$H)I.8,I"9WGEXI2"9?G.1&CF'>P*&]2``B)2DJ1=G2$
MIV/4CG7W5:4R<&5TOT_!3_W2%1%4%\@4=-(8!6,I!MC"@I[Q?05@`?H!/WE;
MJ>$2@HJ'N`6J@H2[H)I&`#]PN)IG2,A"`>*6&0=P`<4)/LYB&7_['IVA&.;S
M6$&X9!*B/,;2,'RD)73A(K121OKW/U(X"^F0$$UR=Y)<<<3:BF#T!-ZP(PZS
M`9@U_TZ4(!+`.ZU`5:T8F)\V-2ZZ@E[5DGD$\+(Z5;VZ7*ZGRH(=.5_9US.C
M.KF<`2"F$&2,X'&0L$,X0#-SL"`F\7,OL#/\RBA,]01(>).XTR[UXB(VTAQ+
M,T<P<@K38+9"$H]TA+MBL@_HC,!+X0#^&PZ<28O]USM<)H]E!Y#S4!YU*&C/
MIG'LL4W+.,A%=S,W**5R(DF(8VFJU1B5MWF2,U*;]A,QX`>-B'E6.K46@TFD
M5EJ30#DX'!2I+!$@00EW,,17"K"(15M[QC6S,T!+.2O!2EQ@@954"&>J6S5U
MB)W9H`&1T!%MXJTR(6X'0``4<`$?H)QG3*EZ(9LQT'*+<O\RX2I#.U75"]JI
MAVO'A]-"W]*+<ZL]!T`%34`%;$`MRW8@V<)./J!^'<`:]`2K_@H8KV&K->H,
M7(DT%W;.5,.K%44IVHD/N>5O48@Z4,0C8>C27X4EK2`Z&\012F`9%6(*;L3*
MQ7N?1G%BNB(`D_&W8L!R[K'+H.W+5MV1Y*0R>>BD]1%^?NR+DN`!*:G,4%H!
MS<P3JI%?TAQ$BX,Q2T<NV1P7P+`*^3(O_%),`AC)&P"PP.`_A3JV"W=P/.(-
MJ.C.1#(!\*R`X;`VP]6`RO!&I!.D4(%KP3`"T$TUDRI_'#0*,K9H!@H:#%(1
M(1QOHC"(<9FE-89L-N&I09'5?5+_T3_[*)7ST4K[62SA'@HBM9WW$Y13X)9X
M"0I2`2A]&J/@1E"S9P(1)`D3MJRG9K3'P&#W1/Z+:W:C<%/CR''Q;7_H)W,P
M4M!2+0ARR^1V`$Q`&A4P><ZWK=TK$Q<Q$[EYKJ.-&5BMWRL10KLB/8-`&3(P
M@_(%/B=SY.MT3C)17_'=2$I6$9*7%VD@LGTW),4D+[FS+^S"#94<<`+3-)HL
M8'7ABLY-#EXR),=BRJ<1&QRD!()`8S88O-1:G_?ID)<]RRPX$RN!N.MTH*!=
MO48PVJ1-3LU<$]U4'W`K")6!(8O@,H]PD!.2RF]92HXDS?SZ2(4#6Q'0!4@8
M)C@]44<#_^9&$Q"QX%$(^[!A88`,]U6M6+$0M;5@Z,ZN9-W@@+'_,`*;;)69
M8C8V,`*S5KOF$8""QQZ)PFB9,U,$0',\<3,7BM")(Z:)\ND^JQ\#CM_Y?;@C
MU0%X&2RG%Q3-6$F=1PD$7DE4VEH,3FILVA$6(PD4(K/3?!2]A%:7LL31O933
M(9H\F;J:K%7O\$2_/1L/DVQ%#AK_,7X4$'[=9Z!%31^5`)N.(9:2\%TUX0-K
M;:`+VN,JJ-]9C7TT,Q+.4P#"F=0<N5/A\P'P1;CG5E(K,3C]6CB9,!'5%0'"
M8W]5HXI7DV!#`AQF/CL&&W$]:18#J--+`2:SH`$JE;EL'!19>O^0"GGGKHR?
M@\9Q'O-B,K%.GH'H/`#:1F`$.%#HHYTRB+YL-4&$]8%>TC*WS";9+Q-OC\`@
M`(`#CO*6':+I#<+II]81(@'J<5&'M^I@U*#)WDQLM[!U1O@Z``,.X4$WZ@#=
M[V)VT@T.IX/K@95A;48/*1!\@'51XS'>DYR\<8D2V58`SQRX)S@3^@5_'Y(X
M.H$Q@!8")5,!,!<HE:/?(\4$7PKN2EO2FH=JDTAZHT?N)<VT@,(8H7$'S6AJ
M)7$*Y/(EC+]WEGFC7&3=W8R/N/9;4V>K^=`W)D0A*/2\XR;^X^8#3*!>(\BS
M>@$1X/:#[9$1YG\R<=R1[J6"/R[1G@'_\B4I2*<!"`('33@'`S@7%P<R%TR#
M!"($3!<X'10%`@4Q$0&<`9^?'AZ?$3$Q`04%G1$V!@9##P8854!#LANT&$"N
MLD!`&,"M!K[`Q,7#P*Y`557"51L8-KJ\TL`83[R\*MDJ*@F^7:>=FQZEIA&I
M`A4PZQXI&5_Q\E\G]?8M51D>`A<%3`(=F!2@P(1`$Q$'#N#@@6.`0QP+C1@1
M(2*118H3(6K$T:1#@0@@0Z(3@T,`(1$"!,#P\"6%2W<N`U0`($95APJ@/KV`
M`>.%3U0P/*8J`"/"DS'*:B7@Y:M:M"?5F%DCYHO9KPT>,MBH6F56%6R\H`+3
M`C9;ME^O9'4%_Z)E@H%M9N/*G4N75[*ZP[1H.:OK258;3S"D_:5K66`,;ETM
MM=&EL89-!>8(%4BA\B=VJ@K<%,#D$HQ.H4#FO,QSSN<876K$Z`"P0\`.DI@$
ME.V:@&W;-RG4\"/S9@7705/^=EU!S&^`%8176)Z\0]#DOXO_)GI3C+H[=SRN
M(E4%+C=M!K1<<W47KWFYVXI-0V;-JR^F7:TJ&V9CJWT-CTW%>(PNI8`Y_@B`
M@PA-<$;`!TU$0,%!,H@`4@41:-`%?IQ\9`HJ$5A``6P&7:#$!115=$$3)#9Q
M&VZU$6`2B=9U,,XFI6!"D2(-"GB`"#]$(L('C31Q0$H$:*9*2*.)@O_A.<6=
MEL!2!GQ37RW+=%6-+^G9\$P5KQ"VBU?D32,-,5T-(U5]6]G557E/E!774EV@
M8R%(^IF21@0I!:6*._#,\P41)[C@0CU?C%"%!Y$P`:"&<]A&R480.70(#E1,
M-*-%(%($48B7`K1*2!F,1.`%1@R(TSLN$>'2.P&((89`KHVV$PP%^$0=K$(&
MD,%1MK@RQ)+T`?&E`5LM`\TLT4Q#+#-6!K"!KUZ=*9@K3Q`V'EW;B/>*E5O=
MY=UYW,Y57ES;)M,->QYL8,!A;U4+S&%@V3*+8YO``.!0`]&K"BJH$)72)3=]
MYHF1H!#%$ZQIA*!:`<,1P.%MKC%!6P<__&#_6T&LZ=9%`-4-QYJJPMVTV6;^
M':>.:ZP!A'#)%:0"G:HXI8)*RMWA%=@NLCS;[<U@'8:!%H21)Y7-=A5+<Y9;
M/1%.G/J5TE_*!`F(PP<B^$`!1`(00,$-@U"`#@S[Q3`DC/IMZ-^'!28R:8DF
M,DRR;4HT<4%*UA45$HP4"((0U`:12!$A!TAB$D(BJ)())Z*%,@HH(&W88@1C
M//!-8>S1K-[0&.!2F);24F47-,BL19\N0$LCI5/"Q&6+!@'`:DY^^^%W"@R=
M"0R3GD3X^2<]+8RP00`BX*!)$108U#NC//#@4/%4\""1B"":;2E$H5[ZMG:<
M=HH)(DT,P$,F`:00_X^IHJ3@P0O%E434O3KYQ,XZJ;#VV2<Q/+%4`HXOY>NO
MPP![IK-`Z"Q5,S;(BK20Q2QH10MH9ME6S<CD%,3<[(%Q^19ZE#$M90QJ`[:H
MP@@$DY["7,,[5YH0.AJ6"H<-9$,"N5?[/!(0S3"!)^@3C;U2$:$:1&%#&E-8
M0=3F,-I$C`!*4!AL!,`X#6@&.M'Q3\<VMIGDM&8Y'9..^Z3SB0ZH2E5W^`11
M*I"=F-%E71V$H!C/!;HPL:<]0SMCF1(P!%L`H0;A*$4<+="ZU\V0"27)D--P
M0`$?($0=J2@*AES7-8PI40EM&Y';$H&VM*$H16B#6\K*021T?&`CO7.;#/\&
M`2(5-0(2(M`:PD`3@5$`#'$@*8!U/I*`,2QE&M_`Q6"*-0UI`:,9G1-,E-+H
M'C'1@HU:@ARPVO,4M&C#&PFP000PLY\)F0(_57#=)>JUDE/-HW9^@H`]<+$!
M&."``!FR0`$H,3R-%*]XD)*(1"XB(DSA('H#"I')1(&G370`(@3@P1&,H`X8
MI(`(``U?!C*P(/.E;C0!V,DZ@O(9]+T@`!IHXP-V-83['2-_47*/KWZQOVLL
M(RO(LDHTI'5`-8''+>&BA:_.M,&WC/&!$L0+,!(#K')!Q1B8<Z`RZM.83<C&
MA/X8BFR&HD58P0H5KLE$^]X'FO.Y3`,U"($/.A#_1.*0[*H<PNJ)@G@;`<3`
M#S$(SG*((X`6";&L3DR.<<8JG8$Y<6,*8TY9D_H1*_XF`[4P77AT\4H'O/2!
MVYB`5P03F%;H;#TN'0O/FL2K&F@`3OF1T(3XDSJ7@41%DA$(12A@`0)`Y``%
ML,!T-/%,#8A3B;8A4?,H52(@V>8':[.-`!!9H)!]1"0@L>*`C,`#!JCH`WW+
M6T(R(0A`:@:W"%6:(84"52;M@EEE<J,UH$*+BFHP3!P%BWPR)XW#OD(%MAS:
M8:`K)L$L:4DVV!U/(M28R4XHFJZ3"5$#,#L]V8,>7VC!&C90G-#&P`=,.,AG
M!\#;Y&DD1&\;D8)!%"HJ_U`AG>I,'@\N$"3#9>`4%1"!&/0FJNY-@0AV`"@1
MII"!5!G'.9TX7$)?@+"4(144.TG!'AX`!S:J($UL2:,L`N.L-`4#68495`8&
MZ\%;2NF!,[N?E9C1E5S]]3PQK<L$'.#`;;@$EV2D!3)T7(,$.#8"<YA##U,X
ME#G@1+Z5'<HTA:0R%[LL7YV`JM=.I%78DDQB6CW1B52B`;`V<:P"H(@2A3,R
M)PKG#B=>QUM9HZ([I(QD`OA`)JSHF@)HQ2RV^)(OM.``FC[9/-MXPL^"X=+#
MJHDP/-L%KQZ+K]:U%S_Q'5)E[JD0)EC`1PX3<^\Z8(&I7J(4=(1,<DZD6DHQ
MLO^V52-`Q&#;U4$KT4750P<>$<$#**1D0$`,XH``E)(=0>C7I/#$*B[LIJM&
MR`;GE48K-EIJ:VQ`&#P.QKJFZS\L$ZM++JW9NJ!EC&-\:4E`<-W6V-O>@N-'
MA&P>2@0RX!(]Q6,*]8``!%J0`79PMM>3,$2D>(O.2VF8)F]+)*B&Y^"-&\'!
MQ3-"1V[;B4YA3`R?4HA*NB=B$4\A!>0#``!<!`H8W,$GR]%,2F;%$QG3F$E3
M=L![#.AC78CG&L2:1;;ZYP[1$2-:_]/RS9;!T?K,`A?J_K1YHBQ3#C[ARF5)
M1F!,>BYG!N`_/10JJV*7,D\,I=(N6V%FCHHO#8PA!B/_4QM6KQJQP2],SRJI
MP1@BL!SKR!4E(:L.<J"('/^T2(KKN$-KB$.3QHNA9##(@!E4,(%Q29T]GA:[
MS-IC)9NEY^D(9,M4EJ2:]14`JG"4K'M1UPFB7*()'Z!`$1R1$`+XX$"?7V$'
MPAD##0G=/\5F+;*3K>P4J2@E)!ITW46"+Q\U!)X@8L`W"=2A@GQ3:G6_DRC@
M9($(2&TH\HISE[=LOV^EMRO84')A+8@EM9Q)&/>&;Z%F)2T5%L7P"^BV4>EU
M88^1.@0W60<73?!269BQ<"W1</-@#_70`@Y0<3A!1\>7$(EP3IAD-L?F-L]S
M8"'2.[QU")I"7SF!,)?4.S>B_RK=<RKBLPJJ)`:?\1M,0"`%P1D'(0G95R=I
MT#A[4%'W`P3>\00.4`?[QQ:B$PVX\`N^L`S=,SK]%A]:=S-1%R92%X"JYRT(
M=!Z"15COT%TULX;9L!B/I0H4$&8.<PD"01E"0BNW=7<I!"M"H1E"`1PTY%B8
M$%MW-G@_I&>(N&<%8#`RH0YI96C*P3&.F!(E(TG$P46.EAU'U'A<I"H`@$A<
M]`)U,`&EIP+'H"5CB!?;T#-J,179<%B[X!W14"8&T":4&`$UD(L3DAJ[V`4V
MP&J5P5EX%!L!UC<`!A%04QDF@UN7`'W1)R)*H'UYAGUM$XU`PARW53CH<!`3
MUCN1</\!FV00!@$U#D,%)O(?++<=(.$#"A)FZ3`'G=`%7B8,2R<>\/8,I`,M
MTZ(SS'(-^7=DTD!!'-0E^Q87QE05&P!K8`-K&@!?#<F0KJ,9MM<]%Q@/'E!-
M]'`"^24H*4!#IA`\$'%.#.%Q!$(BZE0I\*2"EB(1&O&"HX$)`!!/EU)-I^(!
M'S$GRQ$<B6`$''`#"W`#'-"3"Q"4-U"4-T`!07`%M'>%L1AJ3DAEK?`-LO<S
MS6"%Z64K!UA&MX1&6Q<?EE,?0%8ZJ9@-9(<7@N57[T!&ZV(M<I$/,O$^/S5F
M'G$)%2`02#5#F1%(%(!4,^<Q"N<'-0`#GP<;R]8PLE%XLH'_B-9';/OB!R&P
M/H;&&H*F1%!$>?Z1;4(D>7CH&[\AB9>2)"-`BBKPA$^P#6M0AF.90&S8BM9@
M%L1D%DP91ZJD$A'0&+GGBXRQBXY%"G1X-U'C1R)0$`7Q`6+`6?02$NTG-OS`
M3A71!(A4-6.E5=CGG&U#?5<U)'"B(`7@62*@!(=@&WO3!,4HGA0P(@B10LN5
M+\_'0NH0"NA6'P:`%/"9%\34#,R0,[1X%V)X8QM@+FH9-/DV.:XP+DF1%E)W
M-,WT&+#V:A!)(>S3+R_@/?&`<^W@/1K8`G60`2P6`,T7/`FQ$"39G*`2E!RP
M<1VGDL]C*36!.'"&,!`!*L,%*UGA_Q(1D`8;L$Q`<@$@4`)!N0`(\*-;L`5`
M&J0($*1&&J1(L`LZH"MFX(1Z,33?$%)8LG:MAP%9L67+L)7$I&-XL25,]FY5
MVH6IB6]C!`Q7:@!A$ABI=RXV$`.=PA-:%"`5P"_^(!1QBI<)MY?M$TC.@8=?
M%0/+\5IVYAH2(S&)>*AL(UM$Y`<:@#*1J&&15QPA4U:M,5M<I2*60!"8&40?
M@DA>P`,*DT4.0'JS\`3N@A@*-*9,(1[8L'8U,S-F<1CBD49-00YO)P++QXN.
MX8L%UU.=4#>2X%E-T'Z","!]5'SU8ED9HIVL02D(ADBWH3&Q-9U%^$C$D8V0
M41F%H`B#</\0W$IA'&$H!'`#;N,P%P!S.+!S)',!`*`PT7@O-;1TO#*?:,HY
M:/HS:;<+@$&09.F*;(@N`EF0KKENC5$?FU!'T&1PCL&0D/$)R_$"[C"A+N$3
M+*&!@3(HJM.ABZ(\S*-@$N&C0RD1Y\22\>1.5).I`1-TJ2,&'S!A`W`$&H83
M`Y4!<Y)0&38`)<"C/EJD1]JS/GND2(`$<%!C:?($=;`S?,%D7@<$5&8-0J:O
M1C85J`A!'!4?@E$Y_:>J9"I&@I45/N9C?A471MLI1!(`E8$P=$=4>%E4>^J'
M]()5#*4*,5`#%D"8L"49<[!LAXBH>@:M!I$27Q4!=O56Q>%XS''_18<F!MD1
MJ"1"`!R``I`;N9([N9#+`3]``1JP%.*Q%X11BEK+#0"++AW4F@.JEA?5)+6X
M`>=``36!&@7[B[K'&)*%#JDC`)5!87%8$#?21\!7"$S@`Q4`C\BIG1UR$8F`
M2%5E>++52)>:F="Q*>&F2N\$HR9R`.2($F)`$T+G!-S;O=[[O=R[`N(;`V:P
M*Q,%+&GQ)$"@.\:"?P*K;G<!L/II,S/%'OWZ%`89++IY"A'2.KIG<`UZ"G\8
M*Q%KD3SA`2W0`AN@@;HS/A:B(4KP3A.A2!\"*DU0I`C``1PGDJ&R@B%B',EZ
MMMCH$QT@`MK3<3Q(7^)3'"+`6RBP``MP_Z1`^J,T7,,VS+-&FJ3Y6+KM497`
M0&52@A5@RE&W-'5+)T8#!#K!<(6J6I;GX1=#EB94%K:Q6@<9>F$P`@H40"MV
M4E1DIK:P,H<"HT*L03)&=502$@%JLQP1\[@H<!N&RK>*0F$$\'E0Q7B4J58H
M(5?J@%:%"R1*0+F"/,B0>P-%$`(&`P1P0!BEV0VI.J8%B;3W*\GMYHJ[8C0:
M\(L!($ZEL*"_6`4%VZMOJ"`W@1`)\;N"X#"N`7RV!KS9N*Q-LS<6X;?6.JV-
MY$@DPQS4PXP%8,)-8`2,\(,E@:D@<@?@V[TKX+W)[`3BB\QO@`9R8`9Z,%%I
M8J!2TG7Y=T#C<?^JU1`TWP*KC%Q>DZQC;@0$X9#)7M/)!]>K$`B1;<)FS@&Q
M#8=S/8&!][`$6/$U"G(!`U"2V;=(%P"R)4HBQE/0RP,B')$R,P0<<<IB%6`$
MQP,1-,$R&78`5,`!.RO#"U`$06`!%A`$(6`!-^`#05`$'QT$"."C/QNTM-@-
M2><`#H`-\/F%9IH!K?@,4W$77-HM1'QZ1,QN3[S3<N'$YG%V*5`%,%U!KED%
M=:`!Y%:V=XB'ZBEK0C)-`].'>:DQ\*<Z4`6LG!DQD6NY>\NW;7..N!H#8V!$
MDSB)5\0<G;E6UN&<A&RY1OD#37"Y/OD#E+L`)"VT6K"O0S`!>["FJ1G_OV3'
ME7`A+5'9=KYH1$J3'[S*4^P,:YT@3I#Z-`50!`=RRL<G`YDP35HC$I4Q"9_B
M(8BT;)EY52I2(F6=-E<U6N&&+S3D"(EP(P=A'?CT`TIPS.+;V]_KV\T<OF[`
M!^4[!$[8#4]0A<G4D`$*.FD'=68W`B,00?0[+>*BEGJQ%VT(+%U0!5TS)`S)
MH`T*7PB7&<LQH]Z3`NRP$@NL@2>@`.HU#A&`1XJT82LRHC]0HAS@`S=`!27`
M`SDKLD8P(G:80E9D,EK$8JF03PQP(^FJ<P!@PCG+`3B,I'Y@`4R`B[DX!HM7
M%+FX&WZ@QA3PLTC:#4FP!WN0!$*0!"R^BEXG_]U1)T!1TGJ9(]0PQ97$TC,[
M/31$#&6H>3/O,%U?Q-3G3+8QB#X2F0J@;2_Y\D)X^+9^*3`P-+<A\`\<P@1@
M7;D2T[R':A+@V;IP%%;#0:EDU2+.\<?0*L@D&I2=(34!]KL^(#7Y[<:1NP`?
MG<BN(-ACZAUG^!8`*Q>;6QX=U#.V$,KPT\FXF9OL#('\RWASFLJ:6@C&YPB%
MT`0^("2\W*QN@[S*-JC2N2)E#22^46D(A1FD<'RK-2!E]0%0L-O'?,PD`[[+
M'+XK\`9=8`9-2GI);1_=K(]"/KJ&'8O\ZNNM6AZVI-VHJS_/H+IDB[`+VZ`-
MZB9`40`P\0X7*;/QH/^!2T!Q.[')[A=@%0$WBK1._KW?_0T"(P+1D4)A12G&
M5@0`_82GYC<@.G<I.+"C*GVD('WAG!4"ZXP.$>#O4:`!(<U908#2%8ZD<'`N
M3E@'+([BT9)15O%10S986I)J8QA,ZE:UM'@6O*`%/39V/]XM*;`!HNLM1.Y,
M^@`:.CA#EX'5]@+S=L(OE$@=1#6W&@`#`/%:B1HQM-RWT;B\JS*WX?`R<*-A
M)[89:^5$B$3GD`O#ACH'_@$@?`D#E7'I8T4B3H\"/A`"<"`%;N%D8\J*?5X7
MMF12S*)JHI;)`/],H:RPT$XX@AL@?W3I?4,0_W`C[1<0N,6LWLKIU3=XLE7_
MC7X;>0.Q':D#0YM"RJK>.V*`O,SLV]X[>,%K&CQ1:;0.W&\@!WM@!AN4'FL1
MSJ/;+OH6R<_R"VA?O^SBS93,;J"LNOQA#J6EH-!.^Z>@Y)YQ@]YSD3P1H>[=
M`@I0<9_AT0!VVV7U-JHELAM7`E1P`R(]`%0PKD9Y`_[@^.PCY0-#+P*@<ZJB
M3B^,PS\:!(1C"L%V"10`(W1D_L1/1ZC01T.:P_51!PZ`XGO@XE/X)58Z9%SH
M=2,/"`:"@X2%AH0854!`B1L;51A/AP9:&)9`3Y&3@Y:;GH-/*1N?@IEU754:
M71H1`1X!!0&P'06QL+6XL;4PN@5,M+B\$04=%17`_\"X&GXQ%03/SS\$/])*
M2L_6UP39!`(7(@(1(36L!<858@``8@+MQQT"8O("VTHH]_<</S<WT@0=W02\
M(]8AF;D.,`@TF<8!'PH*06HL(D7QT`1!6K24LG3QDZ6/@U088&2C9(($-JIT
MB1$@@BH-JDIVF;D*ILV;$2*P!'9!A@`+/G"($'&!0@$<.`H8I24K9TZC!$0T
M$<#M7\&K_JAF:\<582RGL(S9DM52:0`!..3A\*+$B=NW;W/)94*7;@%>LPK`
M?;L"C9PZ3R1A&(%A@@Y&&`RH4('8AB4;@CY"DE0I$B;%A3(E-J`92"G-&#R7
M]+P(2)48,%GJU!"C=>N;-O]3L6;-LI8/"A5@I-C])4,`&+E3M&CQY02$$TNJ
MI,B=$VB!>%(O-)G^[8(1'B6R&_E!X4<3[A3XA6]RX("`7##2JU=?J\,=`#B:
M7"C!80&"+5L0(/!A@:4L"T!%8(%1!0!%04ZU4.##;?S!TM)M]^6''Q)(E+3'
MA7LPAD%)A)&$@0<I)`+)1QM69"(AFCU1$@:..!):(4!49H!C!CB`@0.>='*B
M(1Z,LIA(GJ1T6A=/Q/"*++6TU$I[<N'R2Y*S_,)$>[SX<M4N[`7010T1M`,-
M0-"$R8TUVTQWG@8UU+#3.?+(PZ8`!<4CE``_V.,0!\\(,`=P5Q5D3)]@^DG+
M'(3_SC'-`@VAP($%-<"1QXXFVJC12)=49$DEGA$"A`V;`G&2#;2A1DY,-LQ4
M:DTUV;1**RQ50!<.`E#`A$(R#$`!!3@<(!03N-'BU%,`<46/58!F98U677WE
ME#D"C4564RS%(X8U>SEQU7KIU<7$#W05NN==YP"SUQMRF)')!!-HL89BF@FB
M`FB/@/+1I(A),@EB&VT666@EE322IPF8AAHK+;DV,&P(&QQ`!07X@)`K*?26
MPF\P]'A"<2=D/$(5'@AC`8("2-7$4!=\(P(/`Z"<LA'?W4`!@.$1,(`,./`:
M#+;J(03#"S#<(0(55*"P`'[XA<`2&BO%$$40/MS@@P8`_Z)&00<^!/%Q:Q'P
MVII?<L30`41$3TBA8A?:Z)@-G:7D00950,)I:9">>';;FSJV01J09+HO9"(E
MHAF.D^@8-V=K*[;8)REM$$,5I_CV;``Q#"/7K5:B1SDOR70P!R[%B,'P7075
M$D$-72P<9C>G9Z.Z$M(5.$XYP`F$#CMP%B-L.T,ID>@]U$"3&W"_7RD+\.G5
M<LPO5]YZP^X6A`#'X*1PQ)G@G]A;F>`BE<9I`@:D@JJJJW0ADRJIRK:2DKXP
M,=3(O`XU7L@X?%V,LCG=(BP![P`*S>KM,*5D!$9!!\,>][@E4:5:+R`(H!;(
M0&`8@QY*X8M;R-6%.DQ`0Y"A1/\G1)()PI0((R3ZS"?P-3U]S<@25>#4]DZ2
M`'*@)G(Z<0W";'*P@44.!E\S2GIV$[&.Y<8#&,O8"5J0BELX158"F(Y\2O8-
M'%S'"-992#^XT[0F4.$"!)@2@7B6,YVMAV<5N,`1A!:A+5P!"18H0`S\D"8_
M^,%A/JA!",;Q1@)08!QT[-(=V9@FKX$M;%N@D&?V8*/'9&I#0-A``-BF"$;H
M#7J>.)R('L&O*J2!DJ0A862J$!CJ%<*3.WI"X8`TB8N\"Q6*T\`3NM`*`AID
M+K8`72XZ,"6O*&5J\!`#+](3.AC$8`P:@`<TN&(H;*B.`!<8@!)\$`(V1H!/
ML_/<.=[_\<!YM*-D#EF0=^R(H&G^"7+/%(B2*-"_/@4@#<.PTSTH4`/N0?(0
MTBMD11YY/<`-HC03`17I6C,3V/23)JFZ2>0BQP3<E8<)%B#``4IFQR;@@`!*
M`<Y7QLDL=H1+?\;<"E/`8@[/C05*9.E%`"C@EA7`Y04O:*!*^^2+,-FE`R4M
M*1K,\"Y!="$Q?<-I(JNP24$@!B3SU%&[2M&V$66*A2CA)PQM.,/7T"8UD2O(
MK8H1`!XN+#<O2($0A;B!\]%/5B,C"A.'8H3KB(``-YA5%F]``!S(@`#\(1"X
M<H;#+Z(4.%1H@GWP4X0@S-$""%T%:D+@L.;%P`)]I8`=0Q`%_Q^@1H]!*`)_
MHF`!&%`@"D703QF1L(@D%/)%BC%-VT"THDJ]<Q,=V=<&,L"OQ.4M1J"EU$<<
MT$D3<L*VH4Q!!DZ4B2JL5@.@:B62'D<0I>`"27>!05D*@D,JX=!/QP"=+7^I
M@0H(9%C3R&@V+A"K(/B!L%.S;CO":M$[W(&7Q9BF`!RRS(_!HP(4:,US9-<_
MG0RC'?&-ENRZ40%PGD4)/UC`/180!"3`P3,JF$`2]C"XH0XU;A,@D214,(1_
MP0U4_8R!8%6EJJ*J!!4VR4`!6L$P"I#'9<C,E0!\T%81/'1J`H!!_1#T"V%A
M='_'^AH`E12`]"H7N7<Y[N-68%*XC/_X5QQ=Z;5V<25B/!<N*W"#&1R@`$[=
MB%V6^"P*.7E;H%(DPIIX`MTH!0FZ(34!0T#):5A3L*<F+`,O')CB(G`,'4)L
M-RCEV0N^L`&,%:<%(U#D5SL@!K&*`(H7P`%WLP@0NG1`!+J*U8)DI2`FS`%Y
M.-O9"ZS;!`[H!S_[\4$,!10#H\1W0`(B4`08E$9?`3#54Q)U<YKFM,W:@+88
MR,@%]Y6(19+HD:>-GF\IN:(J>#"VC!B!O5(4VT'0"'JAV*W<6)0!MA4)R#P>
MWG$)TMP@YR7(!]&9[8[!2_9H8`Q=\M*LKC$=;`RE`U%P8Q`H<`$O.(.6'7`H
M.`1RA]\]5[W_#F%"#(O1@1@^YQC.@)-]S0'?UER5FA6PK^E>)N"'."]325`!
M@R$U5$9,"GI:'L00AH!/3XG/A2\1U4U`/$,VC]A^'QA90S]0\.>01P2B]MR!
M_M>><E[E=/5P=01\U>-CA+2Y['&6+(KLA!7(8F!$`BC!FG1+7.P\%TNR.@6(
MW'0T>#8T$[#1$]XUF,0PHFV.L1>O<1L22@P"S!HQ36(ND3>3<`_-#TAJ!M@<
M0QHZU<VLR8`C1$P+N>IF`[I-P:8#T.<^7^P+@!:QQP`X!]PIV@L\6,BL%N(+
M,7S@`S'.17CBVJUK%6-G/2LT`8:6'P0,Z$`Y$74:E0)`!1F%+K=1_XH/GD0Y
M!?E"][<"H.X_7;1,<$H+NS:^:7KDF(D$VT29:%'>#"`BZGW$7B@4C&V?W6#=
MAC)QU2:2?XXTO"I!*;E)(D9N.$<+@@?C*JXB2&XZH"4N>6E_7"D90MW(BJF1
MJ2#;D$Q2(3OKT2?.X!`H4'`Y85T1)U_N<%W]!3("`#FE)CO!,H$22`%%8`$5
MQTR9\B/H<B)@EB^I!3U9IB,C9V%`4`/]@BI)TT\PT38M!Q-IT!1T)@8.]0%%
M<113T02OT@25%GK_0R`$!R@UYB9']A3M\0_.0@Q8@A>RX`$>P'1QX1)=,$<`
M-1,Q0'7!$&1+T61R`5-\(0=[@`'KP@BT!?\:LB5A768)DO!@A]`9@H!VC=$O
MGL%"0Y!W-C`PK;`:+P1GLT%#@5=M&3!TA9=<:\,;'L`S/=("?;8&PQ%Y=S&$
M"C$41*$$=/$,=($6!R`"`Y1^L.![='$KEF8H3``<;K)Z]Z$??O4:(9`U+G$U
MKT@U40!`%C!OYW%8+U.!:G18MV@!N1@%2A,""+!7^*$B"(8NUY,):Y-V%Q&"
MST<*O85)DJ%VS`89G4`BFG!;D!1M<=,(@K=*?8A<0.9DNY!^YM<*?%*$??(+
MT<4$?Y(>HU,#SZ$0"W$[=V0":D(,R$-+LU)O7C```S"`Y%97S[4-^,`!2A`K
M.1$/_25?M,,58A#_"U/##I`S(+<3#[:`B@@E6?C`*%)0"@9P027H$9LAA\'F
MAH)381/!@J>R82\8&[+1<I'SD`4E*^8A*R[V`3C@,G-R'@5%?S9((`RH/U-!
M?[\R4ND%#"'E9$EG"Z]`A=9"?R\!52FWC@N$<.VWE.T!?\?0=!,D!^>R2<H&
M&BK$AOO2-I$00CFB"2SR$8L0&HZ$5'F8`"L!$T]G0W!V,*$2`]66$Y'CA.D!
M,1GP!8:YB$!DF)`7B424`DER1&AQ5DR05@+`*QV``SPYD>084MTRF0M2BM+@
MD`7A::"V`/'F1F[4):-#1R%``2)P1W,D1P4@`DPP1[8YFTS@5W@$C`40_P6V
MZ0?%R'I;$`(3(1+7DQ@VT(R24)+1*&Q%M9;Z\@2$P0D=LDG0R8W0YGT<!XY5
M(`<$\RP21W6A(YBZT&U=:4OP`"<*I!Z_%`(P0#M3(0\P<&[`1#$,:%Q,H`1>
ML)\HXP47<`U;F3.[<PT"(6L,2('S=0[BI([M0(%G05\-6C]B@5@LQCM!``<'
MYAGH`HV>$'8.<!$H>5HY)8=I9F$RD6$Q0`ZKP6$W,9.I`0L`]#4%L%!,<`&O
M\IHLUD0C5E`O1U'`<Q7)@F2S4&>40Y%3Z6^U\`)D(97,Y0$IYQ0:MA+HIRWG
MR`LZQ%RW0$O)A4-P\09UL`>9H@5T,P1"<DAHV?]!VO@1S(D(K^4(A)!V$X%4
M>5<%>Z<:-B1#H4*(?@F8-9DE+P`BBKD;O_&G001HJ\4S2K)[ZND+EZ8^'W``
M`/!*LH!2LP"`3'`;EL8$B`(G_\@!1+,@:*(!OAD":618%N";#A.+`C)O=K2!
MI$9.:O0Q`C)TO2@@E$4!QAA(@F`NRS@C/?)V:]J<D]!;:FE]D&``0Z`"?H,(
MT+D9H,1;VLEQ=4"G&=`%74-`95$\YV<07A0Z7E$\E)-+P;-DU!4RN!-Q-3`&
M^P@\T15`V`"0^ZD-C"9N!)"06<0<.4%P!B<0?2)C'\-P#NI-M!1#5Q4`_1$!
M!)`H"Z`!<.,NP?IV0B7_/<)Z(W`I"!4V&BP($S#Y=S/H9K41HW,`:;K2,.21
MB<]1,_F:A/7#9-!5>$+Z7$J')/U:/)0:`$R*I>03*FBR$L^U4I@S3=+5KP4!
MEDXP4Q[W$6=YK&VH=FF*EJ3$"8^P*6HI+XO`*08@IP:02GUH,%S;&H6(9`9G
M2T$6,:*0`9OF.7\:,1G3`@K`,5:Z(+FGI;X@`CQY'G)!%DK*,U=!**5'`?I!
M#%9$FOE1!#%D:C`C($XX($=64)=*:0ZCGI26-6(`4:8V#'5F(&6T!?G"$1-0
M8;\J""7XL-`CNM4H+T"5=J9["97RK-`7K5\&C6*V6MW9!8Z#;<@UGJ$#"W6U
M_Y&]9'[0)18X%(\%<&XQ4&CAD*[K>@[F-SLYM`W(Y)_UH`3,A4,_@`_2X!4#
M9W0Z,5]%*&/==!X"<A8(5P%[`A;&\#\P0`WWX`-(D`>90E.B"V8782/V)*S4
M%T(I^#8C\3VH(5@<FS`&(SD`=![TA@,OTU:Y`H1,`"OMX&0\AB#@$EU\^C&_
M(1;8&@`OX!;36R7/PG4:S%+]FX7GHV1-UK/&DS_L")91ECA:H`/4MP'.NHV@
ML8WWJXW7<PB(X5L8(!)*.SU/4+5WR$*)A#4%$\`&4XBQX!I]2&*Q\#!K4VTI
MD!YYMC-?L`9KNP0;T#'`)U<G"RMRH:23FD`5S(Y^<O\>Q1@5]1$A^F$!3YP@
MJW8KNX=[E*98^.6$Y'16[6&9$"0KQI5%!W(K%E!&FT(D=0!:0R!*&_"T(VF_
M(RFZ]ZLW'9<(RD:U^_+#;-E]TE81&]H1L2MXJ$!^0<91Y@<ZO_,[PW.()^Q`
M\5`[2ZE<Z?I,RS`&K&20QL`+#*A+Q,"IUO"?V^`%\ZH7^<`/3.D4,-#`8*%#
M6H0^QEP_2,+!2V)=2!E[/E!Q1>`HN\JAA`"B\22QSU>2EV"U,V(#W+,(JY2S
M&@9X`E5#KW%#(T8++'8`M#1S<$4!A8842N&R3>$@D\BG@7F?%URI@)(D'A`!
M1%9D@J(Y4^(2H-*_+-&S2E;_JP%[4<0BADTG/L:6+B("!!7FAANAEM9XK/B2
M(LR*"8&F"9I4"3X5IRRTAWS'M1&PEU@C.N.H)/.3'A0@"XGW"NJ154$T1"-@
MMGAQ*S?=`0#0B9^#"WF6U+N`PNG9+!Q@!``@`'L5(4$0`2^`&E$3!8H5`54]
M62867PP2`PN,4+>!N&<%,X[E`R+0`0=[J@ZC1F%3(8_QC(KQ(8F<S8X\.)L<
M@B4H(X.P,3O\+AMCC8"&&5HPG=37PW'CC2;"UYA1!ZO%-BMQ)$)VMS*;##`+
M;NU!;DHI+?,7+C+F1LC;T/[&K[,C%L\A!@4A'=G%4*%#4@.FN"WQ+`RG+%@C
MU,(U_U^6%4.18Q2S?=/,$LVMP8'KI`4'9@![@,UOIQG:7!CV6Y*(01)WV"D)
M4,XP&8B"Z)?KS-L[(;-H@11%<0.@-S6_(!0O0PQ@`;9"6E#J><%WM97"TQ)O
M4-#6PDN$@F]JM!(Z,<LDG%[#^XHNH0$/-P<%P2U/5E(Q8`;4-P*$T2^2X`"%
MC'V)P-&<P:QO*#@3_E.5TBY]`QD!HP4`DP!Y%RK\#&?<'3FP$`^SK1,]-LH5
MDP%DBU)KT]-K2Z?['!;IL*A)DM1*C96VXR;P4#*%EJMG]$PI*D=L1,_,9)LA
M<!00P>1,<`"YR>1'00"C.D=JW0$Q8)LU8`&YH0$A$->5$O^"*N``/0(D&\K(
MC;S)G]1L;$GATT,8%WY]<M>-KDL*?,W)OA5^UZ;/WG:.7K%^3`:%#+>4ZQ<G
M_1.\\1@!8S`&I%V0S&M=M$,[#-,_UX04KPE`U8L"/U`$M2@+P!U1S3)B2GPK
MY3CJ+=$?M7'3<C4_]`-`#<$!42`1"I9@A8`N#L;-P@K=6X:LG0(*X3,;*)=R
MM,$JK+`D".*]\/`<G7@KN3(44X(4=@$EK:3>L@`/_@-2>,M%O'1++8$&!$W?
M7*@4JC!0K#3N5!<`8!XY,"$YN7`#<E'0$2`'ASP"+1!W699@UE>QM\[1(\AL
M.+7@B2%/D9%!FW*U5YMW&^`2$3#_T%BCIZZ!Q"(@!BMN7Q)U7+I5F(I)XT+4
MF+D1%NM`Z`6@I"//XW?5L^@`#MWP#=,A!CA`F@B@F\.PY:WA5ZEJ-?PQ;R)0
M`(0K:F)-FX2K($4PFVP-0&E=F8=[6"./!C%`?$B`2!.0W!=DYG>]YFJ>YH8@
M=J:K?7`^5&PH&6S7NIG\NEC/&=2Z`:OD.+G`8P;)L@,12[TKKNTG7OD3C]=>
M]^\@`%%M._3E.4-:U)$67QK@`_G`'SX`;K>0R\-<>[^''N*4S]>NI:!>`/]P
MT[-="_VPOK1^0;:^R"4TOW#^W-X,P\VW0A,A9N7.T#4T&UNH$TLQD<G>"@+'
M@[(R*]+N_P--\`%T&RL%`9Y"BGZQI.V3FA[DMO9H@`94F`QTH:WQ=3Z/);;H
M'@OM'N`]=HK94A?%TW1$-E-F&9>10'8RC)8H(K'5=T+VU$&`,QAC1T+2O3UJ
M@C7<78@P#2RZH"0.!R<4`(6)N/%!!`@0)X,G(U4!=V)B=S`!C@$%!8\OE)64
M,)@P'15B``("(A=-33@X``0+"%L(/A8Q$1$6%I$4L`44/DP"'10%3+>@%[X$
M3!2D`DQ,Q!0".$V_M!T"!+<4`1D!/ZI;6T#>$WL3$RH.'ALJ!@;B$^GM[N_P
M\>_K[BH3&!A/3^E/&U7[!IY4J9*/7Y41!M#A*YAN(09Y$-\]2?^1(2(\>N+X
M8=B0(<._+A$@19(4,E*'D9`JP!B)J4-+ERX+5!!0X58!:6)H=MA9H<*FFBMO
M]N0)0`Q/GY!V%H#!"<"'#QTBO(K@8P&*!122]?1Y*T"OFB%#[I1&<R4D&#1A
MA?1)=I>C7KMJA63:80X!%%>#)%"'KMTZ!QC8`<;@P.^ZPXC969RG6",^&QBJ
M`#&0H+(!;S:J:-`0(T87SC$V@^8<,D!.F06D1F@4(1*3`P>:B"@FFT+6#F)P
M$(!5,T!IM6<Q21(9Z=&DI9J"WBS@^<T*)\]_;ITN`$;HD*$#3)_Y:2O-F34W
MA^1<8-IW[M/8/G?R1HZ9)/<PV+B,;]__D_J.\:=3/#@=D`T;R,>08O<@I,(3
M(SQ$WV0&1&;#@T`\`$0&G:G564<49J!6:ZD%X`$L&JY64R28O$#1%RBB2(@@
M@WQ1R`8OB-&;<<998LE+FRB2TP4B$-#$`$4IP<$"W"#@6PP6M!)!,@7XX$,U
M!$R3%32@S*8,$S?(ALR5S%RP93(42/,+!3?XEDTJW"`QV6'DF-,7/8O%>1$\
M3P`&4$,#*1C90_K<1Q!`D=VY$$%RRC-1118E1F`[#M1114?_:.`!<2.9=-)*
MFIPDB5":2O>34C=]HM-T8\'TZ28"B.&E2SW5@IQ,G1@5P"N^6765+CV)6LU7
M,%C3FDZBGM3+_T]>00)L=R/IPHMMVODT$UXH^%"#/>RL&1!AXMQ'F#N**EKH
M?GX%VN!`5<R7CF5`//'99J%UT5EHHX%&P0<B4+#2NZOYYHLRI1#@`P$X"-`$
M`6$>,(=-Q3D""W&/5%H`)30BE\E)1[[RW`HK\"3JQI]8!]*L&@3`\<C??5*`
M>`&09U[)`D=9DW/0H;$'M?A,!I@#^P"AG[;Z->80/E4$R"T[!^*G[60Z/_B@
M?-Y0UD6&CN"+(2Q(:J+6U+9TVH@'&:28XA13N,#B"2Z.L$$`+]!(HXV1O*!)
MKJF*(8((3?!(]R=-:%,DO+E8H`$LKC!#01$^X%($!;-98!L%%KQ&0/^2MS2N
MFY.X**Z;++$03D`',011!`+;J(E8F^?LE]&WA3:F3IWY`,1SS3H+6M_K=^J<
M#Z&HNW/H8H?%<[J[%';Q]%ELF9D45S=M(E10MFW"TT[=:24JJ3EZ^E.5(NS2
MDR.:!`##'>`/QV$`MB[`!%M1[M(I\J'Z-'VI/?D224\P$)"^2S#,L4NE0\W$
M`5X+Z((ZQM$T;>UC,*H;8+=Z)Z?3J0,?6L`303`PF<I8Q@`VV,QGVA4OSHC&
M!P%;SKMB().W^"`"H"A&E$C1A%[@8&YBD`12&C8<1S@,)304#EU.&(,40`)C
MSQG*42I`@!](@SD?R\ZHID,`MASE9']+&0G_/V$_[]C/?@5`0P2>@P8S["$)
MUU+0!.J@(`,VQ"'[<*`6S/:0H"G(='X9P0B><*`$328SD@$"A""4`-"$Q`,7
MPA"%.-,3$$V-0A%0WE(<X8$4>(T(8!/;V+[0@CIL8%(?4ILC+#&2#HRB"9^0
M6_9RD[U45>`&V]C"%<8P!C_\*P8UJ$$(_!`"Q%$@!+C$)1,^P(0H!"&7!)!!
M$WX9!5U^0``6R&4M`Y9,7-8@`F(@0!1HB01N<`,(>]#"FDCW)@?F[EMU<D!A
M-#)'@Y2S(0D"%`;..2X]O?&;NS.,-^$$QP$FQ)(<\4P4D7.2DMPD*-RCGU"X
M(L0.,`$WR,.)C*3C_RPG"E$``)A;*4^R%4W4<#@%N(`2\,(!(XZEB3H9BQ-+
ME3SGL64[F2II04^JDE(QX0?_XT`4@"".OFA+,/A(X`(3D[K&`(9!/]/99(8P
M!,O88%V@$5YG1#-"%/*B8A6R6B\*5LI>?,!?!;#?W`HPBPJDQ#<+,PX.Q<J2
MX@#'AM"!CDN@L92=_.(DGHG!K+H0@$L=U*#)R"L3,I&ROT5@,W7-J\3RVH$`
M=`$-SWF#%^%S'VTZQC&N^QFXZAB@/\F''XLRP&`*XP`[XA%"0!C(@PQ0`PT@
M$JHQZ(@&W.4(S@BR(PLK['*6X@&O?8$(*R+;(%K`VTNJK1*;9(DT1#&*C?^)
MP!,S$8-UK+D%7&H`E[F(JP5\20%_!<%)TRT`#K@Z50L0X`"/RPKCF!`P)Q5#
M<3UR4N02R019V`9TU]R#M4@GSV^B;@+BO--]Y`BH!#$J3Y!M!]`*@@_[\H,B
M0Z.G[^;A)XY0J`JO(-'$8K(4$CF/)?&;W[%Z\E;PG%01^)NPQCJ!`QZ]4`0R
M8@W:AK.3_^&E)LX[:#(T-="#^L(G=P65O2IZ$I<JSS8RX<I*-C'CE^)%6C05
M1V?+J)]O-F:!_$A(@PH<GW$"1FGG,JIFV+7:>+TBJE$9(84B?(NQR(9>MAE`
MCY[!C`,PP;PH\8"</>2!M`&7K!([4FO&U($[I-7_"7@=RUU74I.X@JRNI1)I
MHI4BGK_*5=&++K0&+N:&+^:70>GH3Q@9I`4TMD-;0=N`N7):S_W@HS`Z,\2`
M,2-:(.PEM;222FHCT)'.U%DJKQ6D/^/<-12YP`4J(H2P%3`%3>(957A#L7ER
MDBL81&`^S'U%Y2P0BR4E0[VV\9$`II0,$;R0&,1@@@@.$+`KW>`"!^C1#<`$
M"F0LCDR[0&6:T/&$<=#7=-XT,$2T-<XPZL,A_?X9P#]M60KBSK[QQ'>^YP$N
MS<XQ,K`U="8P9<.Z#N5M.WE))T,*/>TAFZ4QF3C\2.SM4N`@AJ6IX?<JX&(4
MV`3',XX*+)A2$R`+\7R\_[`%35)C#?`<12[,`(M8!#`'M_X`@#5(!SD*K%E2
M&_C)/*W'E-W9;P/JC#(6Q*!H/%A:>$F%79B0]85FO9K4&/1)Z;:-;$I1C`[0
MJT=A*NP?)^4AM-V9AO\\D@6\9YN90.=B#"VH\@R='?@U="O24-YJ8<$9[=B%
MB(C?"G,F#9TW).%FZI#(0L[H#LG>QT\+L4].%[Y9`W2:7'B<S$#T:(,$V*#6
MJ<$7K2ODFUSKNJXD&@[7?$V$%`E[14OPH;%MB)-D#XP`(/[)R<9`U&@OCMJU
M^-<RL@(,NMW`1]W^@&Y&08QQZX8`%R!&$PX0?F40C`!T:_N;J\N+;6A@')GG
MIO_"];V8R/3;`7]*R#I'$,%,XP[T/F5'EV$(!P=/""9/"\<8F;9.^F!)&N(1
M[B(Q%",2%W8\(^43;\,6F.!S2Q$WYX&!$Y<IUX,#'T!N(N!5I2%6/W$#`!0+
MY4$3(!5FB403LS(+&R,-%2`5LY`3C!,!S-`=W$$!2"(R`A![$>!S1'07*,`!
M(9``*I`$I&9&^L8.O:-@4K9D"^@`"50?>H1U1&4`7;`![.(9[A(:\%(#=`4R
M[((UD-`:%6`;WI97S+!=L\`CY-=W'3)\:V-ALI:"YW,P0(0Q@>=0A<9:GJ$=
MB>8:,B92)P,2?Q4RVQ%Y\1,:;^`$T%$'^95Y]N1O8?3_:0*7#P5F1H-Q)]PR
MBA/@)^4B6GMD`TUC6B'2AX84%@^H:[0V<Y>"*2:"(D30>R[R>X2P!%-`=W8'
M,6VE")]`-RN4$ZR2@S50&4/P`,SE+A80!!I``14PC84S7;9T.$W2.&XV"^<5
M3/XB7O\B3$YR`XQ#`0<@`*U@&YK3`=/E"D%@31J`,_%7#J6C0`E$?[H#&/YU
M+0<!*`?7:?]8(`]!;WM"&09`$`68.PFGC_O(8.@T.S;`$;36!57`(701%(DX
M4!NW<S+Q"1T7%[#";(D6@BWA'20H`GD8,3%!/D?6&2\(>;L@:VB1@YWQ@]Z!
MDS:X;17B8>`1`.XU$USU"CC(_Q,$X&)Z,0$)P@ZAQX\\E8";-V7V"`]<6$$)
M\(49-(9*!2^>40.O,(:I56N=`0G#H@LFAU57M0E9D3WIJ&*3D#9J0Q)@51)"
MF4B:$@`7\P:)-%(B-8F&&`+-XBPT)C\'192-MAGE(4226(@PLP)UL`<7X4";
MIVEA%!GEPG1G=$!,-T_^*'J822ZLYPVN9@"F-16RMR&U2(L;XCVRE0F[=UM>
MXXLGP%LI()<0DQ+&&$K'>'+G$0%=8$$)\`#0:$U^<)S'R0S-%`*R1`';%02_
M%`)!P`0R0``QX$O0V00YT`1%`)W020`Y<`'3^$M!0`$R()ZY5`.(@TRXU`4A
M8$U(H/\?\J>/_&@H"1)Z]9&?#&%Z^FE`BO$ZH/@0FFF`B*)P$3DT"^A?19,!
M*<`U$'86SJ,<)94I&#A0RG&4R"8=[S,6*+F!N2(CFY(:)7$),)`V*>`#,3E%
M)U63,T>#.2F2N?*&.E>$%0*$D@<+/\@<KP"41.1B,X4!"E`84DA_B%%J`S25
MVF(8X&([3\!'6;<N2[5![R*68D:69-8:R]($,O!FXN9M,:2.`=,I-:2'US!"
M"N.#D;`P,;"7?>F7S@-7C9<=C'D2=\5219B8&O""331$DM<<%Q.9?:&)5LED
M^TDN>4**"X%3#W&*F_A`!8&*>4(H0I4`8_`$KD@U%7(ULPC_6ZJY,)A0<0%P
M(K+9BX2@(BTP`BE0HL:A"4"XFSSB<060!C4P!@E000\P!-&H`<542_"H`4DR
MC11P`8-C&SY0!.357K[`.-\57C^`"XY3.,50.'!'?51A1+(@"180.O&A&!A@
M#@A8G_$`H(2B$`31?PWRCP3Y1@:))^DT9?KVD$4*$9F%A0;!H(#$6O-#,2FW
M"4'!%"%U<<_C5FU!4;$R'1VZ@2C7&F8Q%YM0"1XP!750!"FZF#2Y;;[!"5XE
MD\RV,211'C$TA!O#'1B5*D6I'2/3!'AA`9VFA:,(K@S4<*NC:99)3U3X&*R8
M97N!D:/Q&5\'&N^2:Q5BE([`"XU3_YW)V@$!HW8GAP-1L1-Z^"&#A#)FD@Q@
ME3)C@`:5UY<^EG'W$D5E*8("&RPD17N!XW,QYU:_T!F5>(F!*JCSP'1[PB!Y
MDI!O2QB:9H7QL0^0$:GE,IH&4%0V<"$].Q6KB34;D@$?XH:2$!0OL'N[R(NE
M"B`<@1K$@80;FST&Y1/`V8R7,9Q9B:O6)&T]6`O5M3FV,2:R\0S8)VXEZ",#
M\P,X(`.QX2/$$+O.D`SBEVX$<P.WH`MWP`3PA00JH#/YU:T;\*W@&@^G1K?C
M<B=K](_[9:[I:A!O-*`.>8`&&A'[N&2NPQ$?H@$9V5899RD5&&3K(Y*H,A,Y
M`J)A4K`5=?^PSD8>C5!7F%(!#KL!3S`$07!DK@`#.=$=G^`K&#LK)+2Q9"&B
M'JNC.@DW")PJ,.`*1_B!]O,_/M!_")2\5EB*<*N9$;D.7#@?PEE:6W=44YJI
MMO>*)2$6D2!1+.D#H#0E."%S=*E)7Z=4P%%A<N$9":`'6`L=B&90-S02J@%6
MO=!6&#BP)&4I-C$602S$$;"VD&D/?K%O^/$S#S*W`.%3^U<8+^L.W!L0A@HT
M=X253X,A9G@UM,:IG0H+DW)#)7HBN]B++M("&_`%'N"_*<:8Z)$J)_@V)T.I
M"5`#K4><GVM-"!`#A3.Z3B(FV48;SK!N`R-NY&8_D1R[L]LC3(#_;I@\,.61
M?C?P`\6`<Q0`7^^G1_=Y"!G030F8O*S3LDTF</QIKNL4>K;S1@2Q4_$J$0?8
M+08*99UU3J_7H'\5OBD9<@-%/Q?GH2^7*BSC/AP#@B&8@U(K%A>'-@$P!03A
M`"JPO]&BL82IN9V!%F$F5Z,R%JH19`2,0H>7L6M!HSNZ1%CR/Q:0$!><8+A\
MSWY1)U)V:F?4;PQ$(/^Y-%@)N/[`=>[R=5\&:Z^EFI#@""I17>16#,TP-P1#
M7M4Q'+1B'#7<=<!A%@K3!6,@`1+`PY;88Q268XFV5QS)"Q:*$RL*$]-S8R."
MTHMFB9:(!O5&'_MY$?BQ1I9%$)#!=#1U_QF=ABTO>SKXY5\"80,",4'FXJ2/
M\H"IN<8;(F>M62F/T&LM@B(`X@&<T`E%X6T]AK[MME<J$0.5T8RUVGH6-`0&
M$(U(0HW,$`%!0!464`3:Q5V&XS@^:!L6H*5-<(ZX0`!L8`3MV(YHEB3%BCAB
M$`%1$`-H$`3P%044U+S=BB@YK8GWO-E='!_MM)_T.LN:.<OLRA``R-GANLO>
M`I$[U72!D0Z/(F<9H`%HX#T;Z+0E<6%"84JGHC'.(BH+A1LZ$F(2DP%HH"$-
M4U%9_0]--P$2V\WD3)C]%,XT.)32;80A:81'G'%#3)2JP:\[,0?QC`)%$!!-
MB8"<C<L(.G67F?_%WD)/D/$$79AU&R$:7<#19EBEK&D+J9&FVH4#R8`,`#,'
M3_)"RC@K*7@DJR6E);$U'Q(:LRH!#W"U:I4\'!F),=H_LA6A9.%08QT]0682
M<#,]G^!GT+$!F$B0N!.12:H%<TM@"]%_4.8[BF$(2;H@.N-8>N1J"0!A(2*X
M5*V:B;LPBV0<M>4U==R@,!!1.-8!<W-7!P4*"W4PST:KI,GC/+X73\!<L50#
M?J">`A`!RA0"!;"E08"=40">CU,$1>!+X"D"\=CFX(D#/A`%;5Z>.4#G9_Y+
M%&`$8M!,<A`"G[,%]8@/Y50%C21&Z;WH"H9?RWO+Z(0[_FBN`D&H&"#_XP.6
MWJF-*+S,VC..0`=2!0U*$<<M,4RQN*A",4LQ%*MNC!\'-UPAW`"``T?\J4.<
M232G$FG#-76@`NA0(,^]`$2NQ'7Y@B)*',)!$F[H%F'%,&H1DG*W,!Q2#?),
MO.[-Z*C=>?_XE+V\VE,FWUBY%T%CWSS[B/K-FMB`4;X@`L)48KTP&\V#*S/!
M&B2Q=9E:86`UV\V(E12>,6T5%'M,,M\A<Q&3,&?:%LB0/"0RXAQCXBM0!60D
M1Z>WTU8)U)BI3@.G0/.G@%C8D/1A+CO^`*;YBE--U7)V\F;BT6<1JAD`(#Z$
M":94#3C82<S&5QJ0`!)0JZ[&BA9$FOJ0JW>>_Q73A5V'PY**@X[>Z"]R2``,
MT$)<\EW">GT5_0$M5%W%0`%*L&U/TB3!BW_ETJ2'D`*X,]0!@>WXG,^PC"!/
M"4&,LB?Z4,_QD:C9KLN<OMIS[^B!<2"^Q35:)#&(IRG]4U$F(9*#O[',W''&
MZ"RI@;B-@-Q,<0<C\@(>40=UH`\.-P)%\#]8`8N]H-$A#E4)GMQ%B%H-'1(V
M-R-B9_J%(\^=!M!FW^D*1MJNG4:N/^.<YPU%51FAM74V_+-CF<:T"%L-(PW>
MEFZ_X`Q8Q`P&!5%&H5QB1WN?FK@:$$N5<;.46HG^/KXA*?#3HQ*/N.#D+CSN
MJ0%H(2J_D%`!?X.6^/_P9.000:V%[9`NC+H1_S#+EC]U"\$@V9++A@$(#A@C
M&`88&$\&!D"*BEI:BD`V!@DV&1D1`1DQG!&>GZ`1'J.C`1Z9`:D!!04O'BD9
M*3``8A45,`44%`45`AVL'6("N+<176,/"8S*C)3*-C9/-EL(6ULQNA06$13<
M!`0=NDRL%R)-3-],3"(?!]_O.#(?3007!$PX;.[H]TT?.`0HC!,HXLX/!-60
M.*ABX$D5&Q@"I*A2!<.$BQ,,8-S(L:/'CHT437AR2-"A0XI.HDQYB*3*0BPQ
MF/SH,62C)[!$UM1(DV/(DP94/,G@P=2E53!@V.H0(!.%#KTJ%%`JP%:OJAW_
M8'00@'4K5V%5>XD1!L/3JE1%IV9]X6J#M"IU#DW0@D%+$10H;A2(P"D&MZ:K
M"@10*E4P7[^L5+'B57AOI[.9%D-=?!AQ`%T<4/B`I$)GS\\@>5[4.`BF(`>)
M>'KV&1K#I"?+$E320#N&AAI=_![&Q/N2[]\9!E]6QT0`#A'W!!`0(4*7&!'"
M*D`]4,%3WP@%?IV*D,9&@F0)%C4;\\;)BE]0<67GRI4`^_=5R_:=3[\OC/?C
M;`&["I_K'2?F=>%2:2\Q,@$0&1ER4D4-M:2(`R,X8`@A(CV1H$8V:>3`12:9
MA(A-0#SB#!",Y/;))C%@$HHGI9A"2HN"!884*U;A_Z)85M+QXLM4,`2@00(2
M2,!,([*1N(@-%4UCS1;<Y-*D+NVQ(@`3%%QP@`CHT+-..]]H&<\!])C#Q`7_
M]$-``00<1R4X%-Q0U0W5;*'0(4E6(=$&51"2$6A\?I3A2(,(PF!*+50!"2,.
M;#""(B11E-H$)V4D5Y\9-I23:#YA^MFC$T#X81U$-87)8&K=LDH'7O6X7E=;
M@?6>+:_"2DLMJ<2(5%*">;!!%QA4E`BD+6`0XETH++#7)S+.J-0OAIFU6*TT
M2K4**-DMMIA^T]Z("P6966#@:GWRV0B@A"02Z;BC>?0K1B*E%$U=E`R10&Y]
M==&%!IZ@&,$E^:JX+[\1X/^"':H$'(!#$^=0P!64(E30#045X%!!4WX%]HEM
M-7RG3`)#++*(&>4Y@=XM^[7G7G^VE+4B*BM2Q94Z^F4':W^^=&">'&:4MHA<
M+FV8(%W"]OJA28PZ6)J?-K$[DH<41M(,O`\`4<43->AF'2?^?O*BBZ0H)M@X
M`500G7JJ>%WM8CW&4,,#;,L6B3/A00--11@LN45N%@2A@<(11.&##Q8440`.
M3%B@"^!,N.-#-A80(,,%?Q].0`[-+0[X#6PT9\'?15``701%6!!#$$LB`2G=
M56SP"MUZ'AANN!C&KJ%*@YZK8+E"'0))3*E-*FZ&.&4`+KN:]I0TA(N:444*
MH_#_A5U2A*$J7?10<<5LJS6+[:HP'13WG#!B`&#K8.H9QI`A%24XP@8G$4M!
M4\]3)6VMTJ42F?0IQUA`568%++WUBM'/)WA1/3$0X`=X*8)J7O>ZFYP+*`OL
MR1,FJ)J02,,&)`("QX;@D-K$P%ZZL8W55L8\#XSJ,F@RSC]P$(XF$&XK!/!!
M#'R@/<=@QS"<T(!WQB`;9G#,`5H``LC,,S+U0`55'7C'-Z37@3F4A390U$`.
MHTB;_;$'9E(1R!&1B#]4W<P,C]B=7!1DD900`B*(")0!@&8@HZ6/-(20T(46
MV#N52$@\D=`"!N4F1191K!/;$04IS,*UHM1J%U`"P([*_X:*5&2E;&4YA@38
MUK&0R(L2!D"2:X!`$KO5P`^@]`/?0D!*4A9`!DP(@BI#$`3'$<`"48B"*IN0
M`QSDK0BJ)$`#>."#(.`R"#?(P0`HH,H@A(`"Q[$`*;L0@M*-)"ZI4UT&>D4W
M80V/@:'92+MZ1J`/%2V-*DD-&?<$*8M@<S3!NR8V&T).`WBJ(:'2!!H&DQ6H
MY$@P]^$>K*S"E7MJ3SK=\PISQ@(``$#K!4E!2P;.QY(-$6@$6@@"7A8`F*4(
M@"SO6X4OWI>)J%SE%_2;F"JB\A[![&(RJ$B/5PB0&11$H2&1.*<$Q3F3<GYH
M)!NQD+ITJLV;1`,(PNKA$VJS"?\-F"@#??S7RIJ7B5\(9`YC,EA`FG``[G4C
M`AT0`5>.-94_=J&')))-#30X!$$(,61%S`4KLL'6MCII97"]SQ69<,^U[L*N
M&070"NJ@@HLTPR3FDLM"5,*()Y3+G8<]R02/)K0QCH91&LK(@$K2B&9([2%2
MVX2*C((U%KVH:X4TI"H\P9ACL2R`,1*8#9#1-H^1:`B7%`\&\!04(-@M!!HP
MI@9XD3<+B"X*GBM`$2QG@<01X$F-8T`3='$/"A"``<T1R`U\D+CHJF-Q"(L<
M!7P0)R0D(42S35T`-H"D$9@7)NJ4*=(`91&A-6.-@S($^\1I6&^R5[TCN11^
MC><IDH3_RH0QH*=6;%&KZC5&++[@S\P*$PQ7%31\3.&1*W15AYXU8K`E04D(
M$&@L*:'J#KU@ELR8M8NJT+6?J$I*S*)UXA`3!U764BD!E-!2%&B@,RH(XGX?
MJQ%Q1LJF.R:>`S/HC"Y4H8\?[`)O4J144*BH>1Z8"BN8X(,"B.!@)V,"_'C$
MQ='RY3;?289X@%"#&AB@8PY(PA`!%(`C;DL79;N,6TLF'03_KS!+8=92WEPV
M.`=@!8#>:U]#,A>()*)1%0&:3DDC$_;R+I,4.02))*TTCWBH-)VY"44>8H,4
M;:"/J>@+)CY+:M'&^4;'LE\C$Y.K#82Y;1E,!&QAVQ"@JD01_S4H@C40@$@+
MI&)Q[:$2<5QH#R7&0[GUH`</&,``(R",'@?01['O8:6#J>,&-Q";`!:`D"T\
M80]:R(.@5)>"-.)ICGRR4&<HR$">7!HE(8IT)-3(:'-NQ'?G3&?Q@CP:P"X/
M+9P@WX!Q9!6`MHID!>QGR=XC@EG58BVN6.@3.E8:"0DETJ>Y2`AN@!<"S&$.
M`.4G%Z>'Q)"')<]+R1&,D5BSDMM3>EKY1DLY$(*^'@A!_+;)T6QJH7VO,R22
MP*"1AB`U*>;P7E?KS5*AK`KFBL!@6BV`#Z!E%AC#SS8V*+-L8$VB,@,!S4\P
M`QH`Y(3`6.OL:+?6.)B`*K:SAXOA$/^(>G21]KJO0*]/&+1H]+B2V;+/0;$C
M281R]R%J+B)UKM%=^@[$3I#8="4L01)Y#9"Z*M2@TYFHC&=+;<@6G?I9A(PS
M*_CBG1XF@Q%#[UC'I`'!DH0@"KN^`0RTL8K%N8=*:-*+"\^QG'ODPQV['Q,#
M!O`-,5U`!L1G`L**@P.`H.D'NS#@`I;T[4=T"@,M6)U*M``;1."<)C:9X#HY
M-)/2``UH@]4)8#N";VSJF]\[\5`54)$!-&0">C42C(Y.WD]8U>):^O05S_$5
M\S,1>5<AY80:+]%H$U`#/H`7YP!R63%@]P`,6$%R`85$XQ`M2T%7<%=7(;9R
MM]!V"%0L9C;_`7NP"/"G")U1&A:B6)6&7Y4B-QET>4;'"?:"+R@",$QU"DSE
M+-R`#E=F#]9R-5C%%/MB5%E7"90`'N'!2=`0%$_@`&8@!W<':#P"/7"WA7#'
M=B7W=ERT'S"6'1^89UQ$=F_P*ZLA"2^Q`?-%3AFA`AW2*4TC-!51>71C:ZC'
M4SWU>#)!1JX!#1G$"+@1*E_F%UOC(J=V:I%1*UX39S&PA`E@9FZ301QS9AV#
M1H!G6"/`2DM2!+81!$_16Z`C.")0`)NS7<4E`P*P.*K8!&P`.<0U.3RP7:K(
M!#*``]K`.<AT`1:@`8$3)UM@`'N`$1)B)PO%/@U!"$+#*2"1:8)P_Q'K0BD8
M,8491C>)@#SV51)PB!'MQT#O!W^MD23!83^(D13VM!>K`"N_X'9C$1;,<E%U
M=E';LT@F5&$JD(\+=`CEXA(68B%`D`9X`7T$5$^H<E6EI59;9$]7!3%9I`MF
MB%*9L%7=$``>2()XX0,GF"#B:$9EY((<THTR:!,0(0E3,P8V4!M\`4+[PF2"
M!&4K<Q:[L`Y7HG`!<!V0$0.6QT.#V$.5R(:3`%15>(7G47`S$RM&R1_]=Q5U
MU@O[<4]0\0U)"7=DAP;KEH\;T0QNF`CK@PA9J5."$"'NU'>I@T&;QB`Z(Y+I
M$E@+B!+*("SR`H7S9XZ`Y'F+R$@G!"V)H?\8'O`0;H-)S"`)&J0(F1A.(:$`
M+:`!S;0D8V`"-5`E$5!*-1`"!?`!J61,K\<$.?!*1?!+DR,">2-+K=0``]!+
MN!0%P80#O;1*%'`E%B`'BVD-2$",&X(A#O`*O;(HZ$,GZ%4\(C$($9(N#<01
MUP@3P'E'`W)-W_@ZX2B.'2%XO9("JK`)I#)PJR*/P!`=*R>/7D&/8<$5-A(!
M4[-N?+@G(Q`L_OA80*`!"Y`7%K`_X,".A[$_$V,648$J7'&3`;8POA4!'@4K
MVH`-6^4\7E$!,I=`-4`\SOE`>L(HJ-&1(.)>8T!YM.$)1M5'FO62/^@O-](]
M['`<(M`!,J0;=/G_55R72;$1'K)5!9,6=N6!A5FH%=VC#ES(A<1!HS0ZAB_'
M"C!`HQ_W<6UWAC>3@M/H5YSDAB.@B67$>.YD(8!%1HB6)'ZW@-?4<XM%)]6$
M0>*AI2K::461=()TEW$&"F4C9?HG&$A59AFS"'%#(EKZ7JP'>"GA`'6@`;"W
M:Z-S3,<%C-I@BJC(.,9%7??@`P73!#YP`TT`?8ES`6U"#VUR,+O07!30!`+@
M"7#270:0!$EP$9U1![@Y60\Q6TU3/!.T$!&"$OO%:`X@"-S7$KW3H/NVG.'2
MG,Y9C2Q1!QL@G:HF<`4W@1Y%CP9W454A@+V:&!X0`W40%`VQJJO:3IZR_Q(4
M="0K4"SO*95UU@'SF9^<`#'94Q7ZJ3`"0`&=\)_Z(3K^*0`V5*`LA1<W$`((
M\B!!)A(>\H(MH98Y!R(408-/<"]^81M(ER^;MR\::D*-A!UB@`-7$@Z$]`E&
M18G@T0@0,0FRH8^7!0TRL0=H$&@C9Q4@9W!):93LL4\%5P#%P1[1\@W]=W+2
M81Y.$`%F(!3E&1.55P@_U@R=LB?UBJ44@2=T@B>1!H,=<4>H,2%N2#=OLS/>
MT3&28(BB9I>+V&2-E`HV8C]@AGH:5`ERPZ6-\!+BI"!)(`1'MB0(L`#BNCB>
M,`<5*!#C0%580@!>(@/ND&P$,``R(`/(<0'0IO\/]'![5(4#`G`#8-,!'"",
MC%",G9(2NI*-YQDTT31?%=1C82D3W)BJ"<B/WF2-?^ASLMHG^E:>M7H3=5`%
M\72L`S,5(98*3R&L8ZAM_!0^W&-/-I(!7:"L<6AIDF5>J<%N&&0!&7D#2R2C
MU<$)C*&?_NFQ]?F>^C&N9B@5GS`9HF,!]^%Q/]!2&@D$0KM?/5=O<+2DC_6Y
M">)><_,$"3!42,:2`BM(L'!"IZ`OG6!%8J"P%"`P7[:$BJ`QRQ"Q6JJLEV6Y
M0V"%1/2QMD```)R4*#.RW3DE^^<>'2O`5F$S@(8&+XM3%[&I:Z02(U`[K4-.
MJ9%^\N6SU%0(B.<K0+O_$^@334VC`B32@E^GM$IFCGUD:G$&8*'P>:80B9,8
M"4]X)!#!HG^II#I'"`J@`#:`!(LYMMU@M@*Q4<Y%)<;1!"2K)2(`M]]@#S=P
M?'%K#\('$,IW)LN!'$]1%A0P?;()!)KZ('EWF\+3(*=*31N0`<H(4]\DN6DT
M`N4I?N`X""01+%L;G)^QN>EV*9Y;J^C4*\'Q`J+R/%VT'MK&<OKTCDN)*Z[P
M$.CB>'XR$HQ"$<!4+#>@!/SG,*2U50''?U5A&%94`#&P#4L)0*DPH'YQ%=^`
M%QQ0!"12C:_C,\98FQ-2"`DHR,_YO748B)%@="N95+ZQ,OI25`&F@<]",0U;
M_R1O\X29N$>,D&G[>YYJ-G9WAS]&Z1YEB)_?"1]&>9W2<6+O\0XUHE<K@`9U
MP)$3?'T@7`@NX9'7!%C4%&E%>X<\VQ+U2A,+PK,055G*6@@J`%L.48X1H))W
M>1CY4C%Q9LBR6V;2@$F4`%1S$XA:NB#P',<R\5TD<J<(4`1=X)\^$`7;D#?(
M)%R64P2X^$JS^#B1`SB3HXN;$SBX*-.^Y3>?0PUCC()[,,N)X*D;$!-"@T9M
M[+A%(Y9J?!*VO#3NUR$E$;E\XL>@T;F\#!*LISH!X-#!@7]B00L(9@O<\Q5>
MG7]M`0W.F"D^-QJY0Q'`!<M2.:SHVA0-AHK[^<UQC?\=%V7*?I&RX!D9%X6M
M?@%#ZZH99O9]=JQ>'GFE?UC5%1(3\R:(S5`%G7#0]-*2+IEYG>6O^,(C/"J_
M6)<Q#_O,9(4D<I-W?662%=$"5&B%=R<RVAP55+(R\5MPX+Q/)<,L'1O`YER?
M@.8$;U`'<0$)-^O.R3F6A;?/'B'"F^:S"P54>')>=K0G&])S"UA-<W1A&0%;
M0%`QAZ$!FR4C3O9DXU,`'J!#&2,)1)))<V.Q&+1)AKFU=5$2'`T$L;D%C]F*
M(3"9DTD!ELE*QA0$3,`&`I`WQ?29H9E+#:":01!+J$DYJVE,52(&/F`W2$#&
MFNK3!@#4#S((>`A4;NR&I@'_08K0E9'K3A-@<]BTJDI=<7TBU9L"R%6]4Z+K
M`6RA"5L]8-HS%@15"S/SCBF3'A)1!?HXR=K$;CNQ6(1`$6G0GBC``1X7GTB(
MUQ/3"=93<%OFE,K;E,SK"0+D%]$[O7@1`Q$TDMO+EK7)V(\E-(Y@38(I'BJ9
M9%8SV7_T94:%=*>REX?1!9089D4RB,L@-7LD$[5I:]@W`FH6,F3'HR3["Y1M
M+X[>1V0HHUW8/72G%;EP4C=*'(*!!AD+(&ZP!X*G!7'H*>AW(5K0H$*SU!OA
M(1!RECLK+!0!5-7$@&ENF!B]JHO65S(!6_,23[;AW5@5/O5Y(@N;%IK@'64F
M'C\9_[$5P0B"^+/>U"`GP<<DLA!WN@5!0%V!XP,1X%N3^J=4\IX`$0%L1V5I
MLESHL"97(A#?(!!^RUQ4XKLQ9#<(8K@8?IM!;=QNR#Z7%4T,`C0C@>0O\<\8
M(E.KRHP4<4=1;6_Y!N,QGBD.D0*&''$1@%"$$18/]IT^7G"XT!;1FEXW9SR@
MB@$:\(!-?@]S`&.'$393'F`1"=@N+Q59;G#$BU)>?D`MM0"3((T[ML?'3>MH
MGA*#0C2*`-F2(,P7RMT5,]G^^NC)/.PKV;4:\Y-!AWIRHQ(90>A5T`)UD`2=
MGNAMQW:F[.CW0AL@1(8UBD1/>3V3SG81X`9O<(5R4/229O_<<0$O<"SMC<+P
MU2A'^GR6O<*S#`($S)C!_<:,DL8(TQY'XH>5D"`O#L$R(H15./`!8@`_OF%(
MC72LXFMF4:@,$RTWG.;>]1SM@-@ZWV4#@J`!NX80VT6H'B<.N>!"6)+N6V*9
M270/[#`/[J'[<'L.ZK`_5Q(0-\!MI4/&]HX@V:@KHB$(^RZEFW82PHT^=-P@
MU00)A]W4R*/P"X]?5/WP2G/)NBHJ'@"\8:&=[#$6(7<+/9(!D[`:S>H1LPQ^
MD'+!+4`(P-A2/W`#3@0(!041A`$"`H.$@@4='8(!A145B1&+!3"/A1T"'801
M`104'"@H108&21-/$Q-)J:RPL;+_LQ,8(QBKM@ZS!K2^O[.KO;88PQC%IZ=`
M-D!`3UT:,1D9,=`Q$1:>GQ$Q&M[?US".W-U/8P\&3\T&">U#"<W+QT`&0!@V
M5<<8#D\&QT\8-K1PT"6"DX-.&DDZ5*":MQ@0NT7K(*FB18M,&$ERI/$BQ4YO
M5CA9@>;)KF6W_@'$0.\4K%,`J]QR20NF/@Q5-E39B;,*O9O')O3:56N?OGKT
MBN+$U4NH"A4&;$@%DD##IP#4%(GY("``)$(>O'J%$2"&C00UF,6C&I494'O'
M<N[<@,S8L1$.TCU)H@6#D#H8D&S9@@#!`A\6F!!@$FI.`0H$<`B@P*1)Q@L?
M#BAN0N#&_P49!Q9?$'!#P`$13"K/H2Q"`),;/Q`,WH*$7I(]$^*I,N#`PP::
MJ@).T[EL9SZFP>DFP]#"Z$Q@T%GQWF=`Q02BT(-&__4D10:8VZ$_615>:+H-
M8B%E"-"(H@`Q8@1(@G^H8@<89%-4&0_\.M&FL*Q5DWDX;5"'`U5H$(4/I/Q`
MP2-?52))`9#$D,U5Z7WR4800!4`AANQ5T,%7%E)`"@4A])+$>*RX4IYTK#B@
M3RY!]?=B><(LQ8H^YM5SRE3I=`%1!A$\=$T!]0T"433=0%1)A1ITD<`Y/B)%
M3SML2;545"S!=50MXPFDA9`KB)10>XTTU$45UWP590PP;(0FFO\B"J(01W,R
M@9\C91[DAAE)K'$/$%KH9,-*6O223"_.&`->3>/UQ5)`^1@W:3X.W$(44<3(
M6(PZRQV7UZ)/G;)32U9YX$$$8050`0Z=!+`JJQEN<%8"S+2EC*G,G'J,`87.
M=1PRQ-C2SRHK:C'"7PX(-IAA$71AP;114"!"`5%8@%@1!82F+06($2!#$]."
M:X&X%R#F`V(%R)!N$=12<(-L@R5%2S^]_3:44/CLE(%/^E2AQ6[^Q%6%/WCA
M).-S-\:R+X#;:=<P*]U]E\[$LK"(8W5/K"=6!B^(N-%[\-$GLHB88-6/C4TE
M0QXK0$1W2D\..+"!!DA$L<")7H%8P(3_/3L)BE@4_EQGA1WV[*&=1W/CPR@+
M1('$P'MHW`J.YEU7(S$O9XT=QC4AC$%P>&6=#%12_<@FD45&0X$`'\B``Q.$
M--GD54MV44,"0]0S1-](L9,`._48W,RO*QVS"P9U1+7!"#9HT.>9[4U231="
MYBTD11==)!\3FQS"2>4>=8#0"GSLH8*R71!J*2ZZ27=Q+RN;Q-UX2_74;S_$
MU%(%/QIG>E,R+0%["XLNNRP5,PD\855Z'B)22,]A>1##$WO7,)XZQ=MCPYI:
M3FJP<8D7B\'`TIE1AQ9K")$*$,X6%H,<(83@1P@4X%!`_?PSP08!,0A"$8(0
M@@[DX`(6$&`0_X)`@!S@P`<*#`(%9"`"""XP!!:@%VWVX**8X89BO/%-RV!B
M@Y[PQ!9:B-ET1L`[G,S$2RALV/;`5A0:5NQ1-`1;.M;S@K&(83ZB>P\`XB.B
M^Y`E`TSACRQ&:!Y/K>PE+HF)/OA1AQ881P-%N`$*.+"`4(1"$#"0SV,@,:U*
M0`@3&GD,)3XAB"\*8@Z3"$4V?K#%(M0&?;&PVH`H-JJ"C:T6M\CABX8Q$S^.
M2G:+JI(UB-0-"W0``!^(I!B4])"Z,5(J-8@'.Q[0CJ@TPP8&`%S!7G<P/QZC
M+Z4\H1O,=!#.<:)M4<(<YJRR$-$1((CUJ4"<Y(.?"@A`";G<R.G08/\&\LA(
M)O;023_L1<->C*`Y3SA./EK"-7_8JAY/Z$M*-C6+FF&'/^F0RA-*"(2_=0QZ
M`7@!A61%*P]DX%984@OSXL&34P%AFAN@2T[BTHP3GD\9A$K8/L;3C-G0BQ`6
MJ!8!*&"!!S&4`A>X@0]2`RXFX(``$UT,:R8#&<8$0`P=\`%D8J-!)"#!%;B!
MF'0P(,*:T20=Q\CG<=+A3.6D8P3YH*G-?J>CK`DR8G_$V`TO]M/M=&VE'N@A
MTWQYAUH6\6@IV,`3H*+'E\!B%S,;P?&(RI^>1/-WO-F)5D>@A1I8@!0H^,%K
MO(BD#G@Q`@_JR#H]1!%P40"N2W4$!;SBRP+_K&NBI/!!")IQ+Y7>;F;:Z9TJ
MBNH+?A"26(H3!B(7M0QZ,*EN$A)`:]QJ@5A>@QL[T=O@E@'*=IC6'H=+I,%F
M9).;C&!FQS&#&PXB$L[5*0)1>,B;/!"GA1#@M[<,HHBX\8EI!`"X%C$=0MX@
MAZJMC%)WN46B#'NC4>D(A0!QB=B$PI/BW.2J%/N%\K1TK"?\K0H8>H%Z>];.
M#722</T\2U3J406I$&<>2Y&+KRHEUG70HR\*$!XVQQF"*!B4$6Z55RA$QX0?
M<.`&3!#!`4+SVQ]$Y@`X:,(/VB."(XC@AWIM0@DXH$':`&$/*%X185_"TM\<
M52@`T6H^^//54R(J_QE:D`E0$D4PQOY"8A,;ZHM]G#%9N+0*2;5$;RE"Q#U1
M2#E4I6XL'!`SI5`JBL?JB3UF7(4Z(*H9(6`0*3C@(*_\C"R0H(`O?0F?!,-5
M$E]AS^B2))8X^94".T/!#4*023Q6MV8$VBK75#'D'&*'4X6<XM<FFXRTV2`B
MVEA:`3)2)&M$(`,:L,'>$L#)J3#/M%PJ(2@790.=Z&XY^GAF,7`"$`?4`0T(
M.4A3^VJ!$%PC!B&(0.A\B<M>=R`&-8A!60J2RSO<P71F6H$<`/7<6XS@<8#$
MA2"QZJGO)C+:Z@A(7*98':M*5BA0+!\]T`;*<WKE!2F;WK\$QXZ65%89)?^L
M)\#NH6VY;/F>^E1./"1%C,`)+P2S(<P"NNA0'Q"`,Z%PQ`V:<`0JP$;#$)4!
M%5+#F1M$QC**80P'2!SPVDP`Q;CA7I6%TF*5$J5\S3Z>+5*2C$RQT(D\*C21
M:P@V!W@'AS,/1C=5<$[\@-&7C8"/+H^H@97IY1=`P.H$M)GJ&>_F"<^62\"8
M4K-XU`!_:/W!#7Z.9E#X<@YP9,@B@"8(28CCEG4J>QQ'H><@U*#/#:L9>;(J
M[4XMVL?<C#;=7RR,1/9M'9EKDR4>1(Z(1`F3G(;'6IA'ZIL<"Z;'L>DJ$J<3
MF(X'+V9X`VT/<HE)U#H&%,"UKN=$>C0UQ-;<*$C_:L2!B5@KVPPJ6-'23_E,
MLLY^'X:^JO!8VP]5+*Q+T)V'3WU_=S[>9-35,4!]G^&Q='YE51J8TN!VM0YX
MWY._6XZWL+9M0E-/DU"IAEU2'*"`>SCK60@HPMLH$`1M)90"`.C`MWQ0!"8<
M@5P-18S]T^5^]1_!"#Y0&!WG<1R$&P*"5/IR+_T&$RU@4SDV8[R33REW%XEB
M.SD7"T`6=S='5!>8,4?%#T/0'4O&9">C2QZP'U"1#+[W"P,S'5/G#SMQ+#F1
M3_H4$WDQ=VNA`6*F9WN",O=Q"7,``W"47!]Q"8Y0.<%E=K[T`PY&"@L0!,V@
M!0,S0P$R<MV$53`E:('D_Q\=""/5M(`ZUR.+,@3-@"M"LPDHHR01H3?:DRN*
MAR6?-&HMD3A:0&/*IT\YY1(KQQ,KD4TX(0>:5R9]<A\18&L!T%D1`#JE5WH-
M\3S=$`#BT`B"2%O-Y2/1-@$J-Q.2P@^Y!PM`D1>$1G?QED_(8&13%`Q`P12+
M@A.@U`6M(BNKD@%=<`YC<%IK03B.$U/TMF7&81R]$E,ZL5_.,"R)4EE/H``*
M(`1+H`#P<WZ#82T!@#G\<P,RP`0243\%P!5-H@$AP`1<46NYI0$4``(<-QLF
MU0RWP4'OLV((.!2`YHF%='DZ!EO(L#`M<`L_T1PI\4^+U8496%T;*',S5U6$
MIO\"=>`JHK,1^'%$I:A$T%%E0`&!-Z4/,K43^$`7*@%"GI0`6-<@J=$!!%`1
MXJ!+[<%Z'<$Y"!:)%.$8D\:$:/6$F40HTJ%'[-A-O1=C?Q1SQG2!UI53>D==
M<T=9\+4,F?,)%2!TB=`--C`&8^!)]?!I@S,5O[**PV,3/&%J,%8P4<=:.58'
M@,A*3F!L19(&@V`5[]%K:/E#W5`)W5``\2$`!+!Y*_`GUG$X>"$\J[`P>6%W
M-/2.65B5*D@IO3@V,.%-*Z<I>51M*H%CN%!"IG(5[B15YY!X5L)XHV5"TX03
M^%8@]S!-^D47]\02]:0XN5$<>.$^2=`,)A5PAD$!1>#_`X]A`05P`8/`"+4I
M`IWP,XPQFQC547BV`"5F8BV28J59D_X@0B9Q:(.V$OMX%W71*<JR<F/C6D'E
MC]6I@19C3')'A8RU/7PW51OP`F(@`@#`"1.R;EQ(:-OA@M$UE>DP@W(QBL'H
M$U:8#GD!!!B$5F1F811%`2`Y)XG@GYSP&/Y91$ZV+B:"5CZ@`5$8(WE4A;Y@
M$I.G6(/VCM=!9("&D[@3C\4'18GT(X=R64L3B]T@?=/WE&XX6J3EGC#E>'27
M$_=8%X5C:L;R21A@!G(`:R-A)BE0!W!2)!\5'V+0!$V@!$9ZI!?0!$*WEHWH
MEDIP.F4R!4E@';G1*5H%8R:A_U6+$UEQ=VB[@#O'@1=Z,3,5*87Y`&Y:HP]6
MI(I6]@\](BFC=BCI(`T;T#J)%T^WV$E><E_UU7W#,C[>)S[YE!))ET+7AP')
MB&+7(17.2!@(P`'`5#0/HEFX.6F"(`(X(`($,&E;IUD$`)P!MP4VH([IV$$'
MV(X7&B.]`WG-`5O01*;[`5MY"'72-#;>R9T_]8\O8G/9&2/>!#P=*E2X2C''
MD@%;<0!#5`$OD`$."0M6$ZPK<4SG\P]Z\6PT:)&"*55`689F14=CYB#J<DMT
M$GHQX`.;,`C9L&85L1KKDF<H(%@R"5X72A3-P'?701XNM#A;F'<6BC&'YHGW
MB#O4RO^%O_IB'ZH\&C`-GI`&W2!:T]=)GD85@P,/0+$HY7,,*F`LT#43M<,3
M./5/)E$'7JEY(W$0;^`&PA8M$5`1O7:DPE4DGQ`E`7`'L382:""RKY!C1H$+
MDY<+B,EM]QH>%IJASN2<JD@,49=M9]JB<3%63,%O4]E[%1N"I35.G\9)\,`,
M4\$WRC!U^`6,]J:9V;H?N1.,H%EE_'8+M^$B.*$@H6H8`Q<*&M4!33`9!3"W
MK?$@&K8`-P"<P8D$>X%2KO`*`N(B>RE"LL`UO(-3K;I=P9$39/67@:9C7$IH
M%EA4NEH>O/HHOPJL/N:=_4JL3Q``$A9_)WATFGM5BA,0(P#_8ZSVGCGQ+_UR
MK;VGGA.P`UC:##50!.Z*`@N04#YPE">S4!8`>KX$`T["LL#5M_II`3:@!0[P
M"L#@#,F9F"OC<N&'IC.7=U)$([C'1^5!*GTC%1%!#77*%DC!-UGK#$`"4-FK
M**;T*;^R%!^[BI%7!;@+"R/@E6B0;"OP!F\0`&@@![HV=$,X!\`%=F"G2[)X
M#6C0OSMZ$!$P!35SIL+C*5\Z0R:A.-O%&WD79-3).\/RL2*\:F1E0LX)M=0Q
M%!5+:IH6.*!&6KE"/"\8F@4R%]PWG\.23-LW33NR;2;A"M5V"S;0J(5A&`^6
M+0PE0=Z2?^K7!'X;JJ)J`"%7JM>Q_Q8Q$[U)X%+Y`AQX27):Y9QA#&[FDVH5
MJ`J:4BQE`R#!.C&9*[0!Z:O>-!YM+$/;T[G.NL'KH1\P835"_`O>E*9Q01?]
MP'2XD%]F.PU@11Y515#T@)\^X*V^NRX6MA@(3+P-!4<PP+")N!A,R'9CY@-1
MP`S!D)=Y-*Q0Q#4.T`+-D9YX!U[&\*6=\C*7*S,?2@]K`A%=8``/P$F?="75
MMZ+(5SC;MEB/E8FF4JLTI7SY\&R+=@]/T+_^ZP0GJWFVE9"_)1_V@09=$!*3
M0UO$)*T\$;VD&;02JC4SX7*@:&C\H)A`439?N$^N0[:''(SZ@#YT=TJ)%&_E
MA"M445EI,_]]*N`E+U0XQA&HF&DI\7;#OJ(3NS=-8UHLKH`4.2.`Z!><"\!%
M;VO1LQ$$=U2XA(;%SM`*KW"<^E(SND!3+E0,*K!3QU(+`1L<S7&?4D0/4.=L
M6Q5>C/7&V[&Y1-6Y=(QW=-RY[^A2A#*'MVJ[5[@I&GNF2&O"ASP7&Y`!,F73
MC*Q'Z2"%N`L'0"!!H+Q%&_<#E^Q7E3`'B)`&TU+)7_VN1?"\U`J]*S*LWBFO
M9/P<S%$VH?O*PY"'LSQE=<P+9T.&4K$FO'Q:\I0K?^,/"[THT;:O9%,L.<4<
ME$N8,&@+&[`$=<`*4B@I7?#`(0&E(J$$3960M70(QM8!``R693+_P-W6%Q=9
M!4E0?M];U,:DI6'%0E=8'DDW>;\'N:OJ*<>S3SV!4U(D%])E3$9K="#*BA"[
M/.T+$V%:#-?QGO,Y=?LDW/GPVJ2X%/A@16&,Q;F#`>FX!S*B(`8FQ:S)T>@]
M&./!09M=K]LCTDE'TJA:;=:%4WE8OSORL7L9QEG&'$SQU';'B3M]G0#9J_XQ
MQ[7\4T1-U`YZ"C)R<DE-"X#&GCLQ*CDF>5N"(,]&U;'JRL!35557#]$0R6AU
MXF$]<#>P<1+E`[W;(`RUR['G*?5JN5USQ[KW'PA"F#VU*7_]9V3L=*N:,3^^
M1,E@3M3+;HM'3J+D)4M+Q^&7E]X;QJO&_WW4>A/&013%:!QRD*/?7+-@'N9?
M_K_+1MXKP\-B]:L.FIXH+:873.#5>R/4&Q,TR$*TT\Z4RXL!\]I2AQ0XJ<]]
M3&\L\6GXL#SN]I[.V7<!0Z/2U,.7(BPG5"GV_,A:L-#_L-GQY@U1$`4`AWZ>
M;E"A6C_GJ!O2*]^ZT:^'^QN_=Z]0]\YBBB]4[J(;^LZ'[)QS[&,\'1T^K9T*
M7N1"V^#)F=<12I"^FJ8Q\3M=E5-@"E8]0=6?DI??1(7Y2S&GI`4E/G`GKI]K
MG>V^NP!%T`6*,[B><BB@>\HW_JND*46ZEW.!C&TX:2/-=.1C>@JCQ0XK(:>-
MUQ,LH1<XJ2DTAO^TRIYJ^SB1QQ`E0;%OS"&R.>H&GQWF#B_F)[MLUA'B#\B9
M<MR/":ZJN/?F/BZT5;:=`:$3A$Q\>TV?AO(/]53=_]6>?22P\_"4]*!]W9,X
M6OKOMT!*@,I?,=6+A_J9/J'9J#0C4I@'DH*MWF!2!;;>4HP$-6`&BOK>(+=T
MQ1D/M;PI)HV3G"(3H`A=+'+7&WJ/HP(0]PACPIU5QW/.!=Z7<9S@V^GK/0W4
MO!W([>[*0NM:4J13)W0+=7"7-XP+7R.]A@HL0B'N*?%]-K`@L+'MV?Y@X)(&
M::`!>[.9NU`S(IO!,8,^W$G@;4XLK<P;=,U8[SC+U337,F3DIV!.H%3_67I:
M0O>`[S\1?A#.&X5/F,`3QCG10F)S%/_0+S/2#RW-RAC@#1R4HP$@$I,(VCO:
M)RL0`6@@I7L`+"G4%*X&&*.IYFRNX[J@%')']\#P3?R`R/FZ_5(4?*P?\J6&
MD?E@R%'K1S-&P_45;\A'\ZVK*(ES*O@`J!N03#FO#]<'"%55&X)56@Z(&",8
MC`X3#D]/#B,*E8X."AA:0#8:&#9`H:*CH8A:IQ,324F/CJFOCZJKK`ZACP88
M'AD852T8!H\C&R-/!KB^D4^\&[_*O!BIRB-5OP9/TQC%!MB0$Y*PX.'BX8V(
MYHCCX0XI&4^QDN>0\?/T]?:1J?'YZ.G@KL$8_QP\*S;0FB)!`0$JDS;"@0%^
MJ4YM"O5DUH01#7D9"M4I2I0@08J(M&!A),DB09`@L<$(%,MA6O;5"8AO0DQO
MR?*Y>\2(IJ)LP"#JZT=OWZ5\/Q,M*@;OG+IYKW+",F9LB#66GQ(DL&'#@`UJ
MC(J%,J"EYZ)NP18M=0<,(P9"/;,YFR:)$:YA/2,Y6C/,Q@8%J\S(D>/FC>$5
M*]X@-LSXC1LW:.346:+`P2E;B$;4F;2(UUE$[B"V\L;Y5]Q+]=*A<\;(;4]'
M#W\NZTEMT""XM*MT#INL-2,M5+T6XDJ<K%F@09\]"\7(-N[FBC80`DM]>A66
MU`0J^BS+09U*@&<E6?^4K[+X)'M6.1!O$U5WT?O.(\+\4%?<UFKONU.FF[/`
M1=9(<Q]O=9W5U#^PV*-@(@$MN"`[>K7BX(045KC@:*"EHH@RPT3R4`O,>/-(
M?\8XT$(+#FG8`C'6H&/./O!(XDLCSTR#"#7&$%2%)`TY,X$U94'G&TX.9"?)
M@:^8PY0BE_QDE(50-DF--^4\&>6+X`1G@%6\$/<)$`EX=9HQ^6#D5I+X&;E3
M=,\9LYUKS1"2GX>3Z/96%3FZN<R.@NB%U@08S,@,,'HY6<Y/!I*&H(O_)>3?
M@0J^$J"`3.+2&36L::1<(9SNJ)QT`.9H$S7D`4'5IM5@19U<9"(:4%FAV#;_
MR`A`?"H(7((`(2M<ER+4YS?:)15-*S\!H<4BFU@3%#^H79E:';H()",S3/4"
MH(:ZN;DB(S_B@NDQ*SJ@`D\].DMA.>9""*RY[+8[CPK70(,-D\K9%91NDM@)
M8"2!-H-:DO0$2DQ=+6#*8T-(V:@A1@XY,XQ`=PWL+<)0Z02,DP*Z>^%H@*[%
M)+/NAJ.E0<3E:H"IN(SYB(#8Y..-6\*`=O$&OB#$KV]NW:R?-?K"Q=3"N,I%
MSK:$/!%3HUJLN`^]`XLCVG;R-!+:A`\1I-92L5U*B$!V8@!$9]/A5D6M8>_H
MH:6>.02$CG$9[!=80*6(*'G&U$J-=)L6$K2NM5G7_YI`N-5DUF>0[,<@<,]H
M]Z_&S^IR34/"^!MY@('ZXN8(OHCH0-$\?5QF@XS7@ZZSZC8;^ND6MNTU?]F]
MC)QGG_W4&Z;[6*EDD3U&TDLU13+CT$.8_SY)N%3BZR;>Q=1)DRM8_B@@OP:B
MKL\_/UW,G>WF9DG5$UUQ0@A+*!OD6X8\*I+Y3D&>.>E;BQ3MH6R_#G@6H-F\
ME1?ERTP3ZD[YV&E;_>01QK6TD*F$`(Q12&D$H&A'(6W(9BF:^PF(`H(0^'6*
M&KK:4R%,(R#=Q$0;6N@:OS"EMVQTJS2*.-J/:E1!L$CG?W$)VP:PTYQ;[2A'
MRO#%9YKB)ZZ9JC6%<(CTG/_R"`]L(%\H&HBP)I87)G5+4PVJ%+$<-41SC.Y*
MI9-0%:O8BJ"<Y2TM8,HU#&:B0?%K@A?;78X2AZ5[_,<5&3N.GV1S'!S2:T#'
M<5GSGL<UT&$O9/SHESMDMRC&:2]E8H&BUY25,C-!0W-JH5;A)C$^HQ6C8&_9
M0,.H!#8`-M),D&A$!8GQCO]]BW\:ZHF<VK:([#BB+OCY1QN=0DF!(*-"@]P-
M%55$L^;HLF\;[(FNF#&(\1WG*!V#CK+VE#]1Z8]AK;#;=LJ"#6'<JH8:9$9+
MGK$KN5"J03U\I3ERQ3=>(.,;6C1D$3?0(C@Y*6LFA.(:OZ@1\L!C?ENT(NA(
MUX[_=>4SGP#A&N:J89"SZ"\L:6R(\AJR1FH<8D'%2`LD#+*[4.:,)[O+Y>NF
M83E+@>6BIE,*4/HESI">CEQ1Q)H_0C<L\17.+O4"QL7>!,Z%F>^143/3P$SS
MPF%HR&K1R4:/%.D,#I&J:8#"%1E=)K421N>C)NQ-?BKVI(M<+7E%>1*EEO*G
M8'!*F]4LVW(NV*<:,2*,*^O8;@B8HPUDX*`XVLY!?N$BF!&0?M.0U2<TTLTG
M5&<V2H1;/)"$CA"2*ANZ,=C44#<!:+$S>8(`G-DB]KM,-D-&*.+)B7Z!4N;]
M\XI1RN(_1\NPP%8#KRU;(M?ZPQ]_R8:6^JC::X%1S$*%_TL>D?M1&;-!P-T>
M[ZC0(*(5#02U6&!(>BI2Z#.<ET]\"(BBIK);9W[4VP?B%&W82!Y`!B*-GH9(
M'LZ`83/DNIL;@16<VV#&00D;EDR^\#BR2T:C"%<[HRAG?UG5HG6)*"'6W:>5
MUN$$,.]4*P!CQ&#%8T2(V,(0Z;!MH)V)T`,_^"/;"$.;7KM3%3)0&SZ)=:^"
MT"EH8E0/:63'5Y)$KB,<VZ(;70V`9QJC-P^"H]+(#9JC95"[1)MCZ0$O(`)\
M(N>`AR-OG>]#FFQ1,5_QVG0.UA7Q;6TR\56FI50SJO$"<D84.I3.O5*0A!TB
MME)JPM2<[F`-:P3*"BP[("0,E/\OXDQV1<2R^F%J!%_0)ASO,@RP1$.NV]&9
M;LYR.7/>TA$TP0B'AH$WB@X)'XV2FNTTY+M$934>=`0O3YH5&]]D\C9><Z$-
MA:0W,SYX?N0BE<WXS(UAP0Z";M(-WC9E'81@YS8P[)N>%17.>`1)2-(!E3Q.
MJB''/>02\](I?J;+R2@6EY.,RC$&-L,N'O?XI*4-HJ4$R!1J1N*9`8D-ICB#
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M@'@?%#3N5,ETHK1`^Y0V<:\'T,>7AG_GF-O+5ZCL894&1SS?P!?PY`QJ3A-0
MB-/F,$1E%IIY2ZA\__8O9B5%<T1R.N9LQBCE4KAD7V)J"=K[:XRB$^$K4%'S
MT#I^7I@K;I9-FK,J9F#Y/AJ@/Y(_>&FTN6<>U4AS?YBCIH[>_^#F_`U"2D'^
MM<U7R@;'Q6;/`([]^L>Y#SR5'H1BT$Q+Y'M<![?S,T)RQSCP,$&D84T.1`@K
M%%24LV!(-@)X9SDK]#`5<AKZM'?]@0X;8BG;8GJ^L1/\E6])<7Y;=":-$F=;
M%!HYHSC'90ZFYQ9KDW`,@TZT@37)@S<5%$\8=W8"X0T@@CE)UAO-02UAL7=+
MP0M&E39T=A:C%'L<,C[=P!`0A$IMM!W]<4#XX"H-<D#IAF@R9#=?,748I!'O
ME1O8)&$5=S9L`E4WXQH1I#^@1QNUIBG=)(=-QT8.DD"\D`&X`A=*@P['QBX_
M$G]"(5"`%D9_F!US(T3U%H!MMV-PQ_]UC&@AQ+(BH3%7-G%AFL!Y<=4+WY)4
M#`4[?0<7%:)60&%5U0,UL'%E"Y04^:9%3.8Q](5<$H)1T(`VLS1$@S<EBB-?
M4'$L5P4HR.9(SL,RI\0^RT`M@Y<?5,(Z_[,R<_$<E9AW0K4B*E=9/G$<D^-7
M:K@R"Y4-(!-M]V=`BO)Z\J:%4%%7%S8OY2<(7.%"A!`TS%1D#B$PA%0,07(;
M;&,6`_=OY;9&<"$V"F9#?E4_[R@G:D%V$T(:/",=>GB$H.-^[R>(BS(BHL8[
M)!4,!<,\PL*(_>>(`!B)(<,0D_1,G4&)7O1B`]449A)OOA0H"'F'"512&3F/
M)AD,13,SW'?_:?&5;]_(4LP2.ZAFCBSE9>7CC8%W#@>3%]U`A`^I':U40[H3
M;&?WAW($>>EX?0M4<V_H%H-F&@C!AF@C#4J!$9ES$3.R?\?4DRY"4S?QBDX8
M?"B7&0"&33($;`5):K=B:J38&6SE&?4D%XR7%_`0%US%%#0'%K?&?%#U:;P"
M%E"B%Q>V0;.2#!!I#T+IAQ(I,GX9/.%U3I:(5PDA@J/5D=7VB"#9+D9Q6Q&(
MD$EU1.U$,VGV,"C8(?P2<:YTCK2D6V>B?T"648AF)]X"7"4B7"&X7$MYE.H4
M+".$E9"H,5Z5(@H3;47Q.,MU;'MI0KI%8W#A+;P27(=P+!W(,P%1_W.+ETO:
ME"W2DC=;Q0V9$1`]85.YI3PA^%(B]HWV=5`WX7W@U&M#$8S6M7ZXEC>XQI*,
MN6`,D3:S4QMR@2^9Y`L%IX_+(U+JITIW^2G,,&N$<R5$-J!5.!,E99D7`G]&
M9)VP<"0R)AO;4I)GUPJM!I*D^78?>9K9,YC8D!RM$RBTR3.T4SDS=H$DIXN7
MUD95%DK)-"]5Z)10$U]`0)R?,6=J>5(EV"A8)7F`&3VS^&35$F(T$5%O@C!T
M@A'(4R^^]"+@&6@&$%?/@1:,-P@$U`Q<J4EB.5^+UR/DD5P7:5UZP2-=.8B&
M,Y;(4A;Z\G);USF[D8\%21W@IW[N"&K/L/]M?HD3<S5R-30-L@F9"H>.J`*@
MII0F<N)"*RJ)@[4K8X,HMPFB`F&9(OI81WD(#]$U%:6!#-59?Y1C+_I_,`<E
MS1EW59>0GO4(X5*+TU`6,Q(NUG,I':@7_6$6MT1\LC2(-K64/*HC(_!!D_`P
M3")?>?JL?31L3\HN!R)OPB*:4>)X<68C]1=<@:=%WP`LX-8L75HXA8=[^+*&
MK5,W,),1]3-!'W,TLY*-$:4_JU<D5@-*/P&>P#A?#BJ?:W%/"8N<I+&<A'DF
M=\6K\HD<BP9J?;(K&,:,N`<=@Y:P"7A@V;%,Y&DPV[$M"^<JS!&$H^9\8+IE
M&9J0ZLHA8*JL9%G_+B8H3E#S=4[A6,A7%+)33`^(KA<IHQ[*+EX7)=J`0'#)
M/%;(#SS[#\!PI<+%++>5"`08,8=PB9O5/S>$1!F!(RMH7.DF(0PS'R1E-YQ#
M7@JE'JJP&O*VFUN$%('Z8_N'FI:!3NU!9,B&(KCI9$@2.<N!"OW2'\PAF7K(
M'*&`-Q@Q`4MZB0='=L>"%^>V6ICCH.SJ@YI`'O/UE/]A$QK9''50#(*+++80
M)%O76IOJ)UQ'?$!D(+TQ="V4E\$D:H5`*7*2.5,KISM1*\V19[H7L=4`/;YT
M&62!-XR[J+WD&MT:)5]D)J-K84S!+(:9HELJ?[D`=V:F'62G1`H%>3):_X%(
MJ[T)B4/#^2.S2'PNTPJ4*9U($@LYBVF(H)H7P4`GPE`Y9$;1&I7ZX8K<`D>Y
M>H$V-5=F52>#F`1R,Z]V"%`"9!O:"J7#2S\K1';U%P_G"QM.%@V.Q@MN)B4(
M<0J"L`D!:BQE(97X4A8J<K*UX!JKQAJ1:93_86%38E.U,:VH^R(:YPTMU"#Y
MB4L<>T-YRZN$N:4)5TPA%&P5JKS6P35NI8<(DYTA-[V`>F!%\VDU*S[W9R3`
M039^TUH?%K.YNJM"!"*CZUY?(#3IA*/$$"C#%B/9RY^S)#"K-<,V%KXZ-KYP
MC)1QM@$IX`$ID%E)E0*"3#&7P,>Z@+\CD`%]K/])7>0`7R#(*>!3)*I5M^.C
M&7-T^#`"?DQ!W>M+K),!&6"(/8FNA<-KXZ)C=#LH:@LYWUL[26`-=)<(COFS
MH?-0]Q<L9XM<L(QJFY,!H_LXS.,.=:!0+_,PIPP;)N*&8)%9KX0-MT)*;\%A
MV24;>G@0((P7+M0"Y$C%"'EBN,>M_]-+(1N$[GFWGM%1N]>L$W(SSD'!H#NK
MPU6-'GA0-70;P5:[>94!`?`"'A``NB`(^GS(TWL0*1``%[H+GLPZ?:R'VU(,
M5;#0RG0J;]IWZS<;_`'&&C-(OZH(H*R'9O-[PV-GT+$NRI"T*"<AD>5O^J>K
M`0A:4&+2)78@&[#/'L#_SQB@`G70Q_S\5I<`#!M0TT!=!2I0!4!M1'6P,MOP
M`OP,U"W`OGZ2#`\QN@9Q(K^<0R-GD@X`RC837NY9!76P`4J=`HK8+087("V6
MIU"=S*@Q.7<!5=R*(`+C#@-UBSXI67%])W-[IAY@U$_0`D7]5EP6#2/0Q]J\
M.4#]Q[?STWOMQZ$\S)NQ$S-QC#QU'2S[+1C`88*4`4;$&KW@T+3"")KM`=H\
M#>)9/0;'CK,2(//E.Q^#&BPS*.0H-5#R>M''+9>):52(4R-D)Y"`:\'&8=K(
M(063`4K=SV$]".Q`?KU0,&[%"#6=NWKF5S7-8>[S!&`-`P9]&JJDH&)(3&/8
M_TN,=0X#)7VW4LTTH5LD4B1D-U#]YC@;8T7)BI`J)ZXM?;<6`M/3Z2(I\`*^
MO-_LU`+\/`Q'C2'3G0LO<$3[+=KG!!M5P,\GDN!UT`)?,+IUT-BBYU9__`1?
MO=`;4`<&P,?L$,HM(,@MD`1/4,WEG=RVE`W[#0,O4-B)+!TM\-4T0TR*',G9
MX%:CS=!<QH&[E\&T&$JE*IT:0U&*V9+VW2[7L-_\K>$>``,I,`5*S<C\\-`O
M``,;H`(C\`(!H,A0WBS$'0`Z_<\"A,`SWM=Z6#0M]&%!.!W6G0)"?0W!9AHC
M]>0OD`*Z$Q`3I*\$J8=U4$')LUD[7`^11%<W&*'G,O\W74-U"K)LYUT@\ZW>
MWF5*I?;3`2`(3"X=FXP!?;S8U`WG8,W/D=SI]@$M_*TIDL#D=Y[C[*`+(.['
M7[W81D34'K`CBJQ)=,TX/H@W9)/F63B?PP,YMUG2[6`A>MJEWVO'=VPN^`UX
M_JT"&0`#ODS<?CS(0>'D!ZX"*2#M=1``4+[7288(25`'_/P$./W<8"W6,ZV'
M0%W<HWOCS_T$3[[7Q3WOFE'N54#38JZ,W>['_+T*Q!W6FKS4TB'(-9T"%7[G
M)W[@N.,*@#KHV+.3:\?2[M+=Y]E*Q.!C@ZW34W`--3T%T.(!G^H(@TWO[`36
MM9[NWA@)Q-T."?_'?3SAFBW_"(L=`%W^YZ1N1(:\V*1."(H<1@_MZ?<3ZE/^
M%I!L1'T,T8H-[C^=`L3`QWUV7O%;)]RP58CN(%P)0'+E("[GKHN>+QWV5=I4
MS2]4TSMRW>R@U(-0[PKOW^3.WVFNR/N\"_N-YSG4UWNMV7B>TTK-WT1?ZQO6
MXDC/WT1]X$T!SZ"Z8LR-V7GI,V`&]DEA(Z#QQO1]#A/7\+D,&LKNTO=-OA>2
MU5Q>T%C.][HPW<.X\&(^W84/ROR\(Z!![AY0!^?.WR$_V)=NZM+!Y=%KR$W^
MY%.P^JN?[@L/^'/E".D.X!Y0$5(>R0V![J/;`HJLU-/FX/Y]K@2!&S$;9VRT
MP$2N_^O_Z-VR-B.,-0&:[58O`/()W_='%`^:#2(';@U,OM>%[0HM3[K\7`=?
M0/O]7`=2#@@>&1XO'E5/&QL9+R\9&P$P'BF,*1XP*74I,!EUA!E3*1E5&*-/
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M!^Z@^<I94]TX;\E&!%/\;*KKM=2PS8,WJHHHUM->,YWP3]`D#UPSD"24XN2P
M%B11T:K36)*G8=L*9C!0E='>5E]:V5X.L<Y`22\").)G%F,+CZG.7^8X2J:G
MSKQ(QH,8;T,E0L"GT.KXN6<B=.&$1HXPI(!S$CKRB+/4.3:M-0V#.JW4#3H(
M;A,;A:W)%@\IM-&6"#XC>$?>(P;_P>6*0)Z8LDD5?R$'G">9"%3%!`8$5`@C
M4TA7UR,8J<#7;\SAUXA0NNEVCRPT\8)/:]/,HU-124;8&%=%$ECEE:^A@V4N
M&>0&E3D/M:(/?]MEX(`M&QCPQ$87Z>,/0-3415(B0!IP'C]5Y55%)P&,T!%&
MAZ7`X@N"I850+VW]644+SE#'6R%7$9?$!ILD,9$'`4BSD$$DCLF(!U_02&`R
MOE2HDE&+5J%%3]Y`=Z672U&8"#**)%(%@;!N24U`9#&2`7(O[/F7EN?EU1!P
MI[#U@FH6)EO19X`Q0LMV@D*T:0K_!+`1IG6HQY8@Q$'TA`H.,,KA(C=ZQ)\T
M&*1"*T"=_\TC9)K;.,G+(2Q-2)I0J4'3FFG%,(A,-4(M&N%*R,CV[X31I%-O
M.#:5@H$HL\U6EXB1O())0+)\2AQ@,!P$XY^;<K)5MWNBZX@F'HR0REX=O5"'
M9.%I9LC$Q^H#EJY+<3,33;4Y,XT[\2!H4X4A=D(ESTPW#<W!54KU9;FM^.H6
M0OCA\D4C$]C2"G!N!42<@J#A]6DA3VH%PPL8O-7*MH;\0PLA7\3(526_`F16
M`/#@U\HR/9T"5F]^<CT!G\O$"!ZA=>'';#7F'@,,K$K*Y@`0J+T*FU+E!#.;
M/!\ZLX[3L"DF-R9W.@*95A[@LH%B\/VI"-K!!'/1+,"IJ5\D!__I9\A%'-NB
M[:%[?VO+)3&'$E-[9-7"D.H>2#-H<?']?HEWKT3O3C<TS:I4PA8*8U2""T?'
M#M34$!U..2T9_0PW12GSE/@YA1,/YO#8.NO`9Y*%WZ\<P90BOH:?B8EG(&1Q
M!'[&HHKLI$E)>*L-O`*@BB?`!1.\&,O7:H&!3L`@5*0CR@2Z,0];P<-AW5`&
M@5*E(*/T1#%2"Z$,LX0^W<20<\08`2HV()C</"0#7VA!.?R4N"^$XA#4*9<B
MOJ":T&#F$SP<`?Q`]AEW)`)F0JM5(@33@E_5XR`3ZQ(B9F6;4&2%?8S2APJZ
M]@5A,'&$8Z3&"+[PA0_-+%IF&L<ZCF+_'&(T0S$-.^&_JC0YSE$C&)$C8RFH
ML2H9UJ427)D8`3,0C$I$QBV(R%V[-JB671&P%FN!2R-@1@NJ<6(0!-S(51+1
MBG=(0CH&A)0RVJ,=-=E"@8;`'G#D\1M,J8(7OGH?E+#QNM=P8WS'L-(PCM$J
MIPRR&N?(2?A6TX*<'(P4@(S'$[10GUY$*1NRD,6M?"&+,&YG6A\*VB%*R*A#
M).,9BME`'3NXSBWR$!BB(85W>$B:L.B"&3,<"H=,:!PEMDU?[YL`$7N"G"X%
M]*%-T1*6;C@5;@!T+9T;$,"((13XK81&[)/CVXHQC90X<1IN>>&MW/*66ZF)
MF<@0U3.WX<?:_ZF#8,504[T(`3A7L2\=QJ`I-/[S.2<5`TO\$ZC\TE%"VK@D
M-C-DS2@<9B#S+:PN2!$?A:RA)@I)L:,CR$LX&#4K`R"#>^ETBS>V6!MV*6(4
MC))?PN0I-)_)0Q2TNI5*TXD!&^#,(&<%QCMY$0Z6A-0:ZSA:3!D3L9DV!4+"
M9!6&3G)"THQ`"SCA4/ZJ8(.BX0,>W9!'AU")J5I4K&W4"6V"U"18Q<"CFC[K
M$/B@DS#%@$:G#DC"/S!Q48A>@U9"@PYMGI3,!WF5(A3,E6^7J]4M4=2PATS*
M85V%$@505R7*1<EA<UA'C6(WIVOI5V[&A\QP`$.Z/;DI;9_ZT?$"\?^Z*,F7
MDFS%(6P>53>K691CAV$4`$FC'E_(WS,P@-E@-))TI``---97#M9&-TZIK88*
MR/5==X@JI5\(``;W]U5^(0@9N-5LHVS`C=FPJB@->]W`6(N9VB!QF4>3F&>L
M26!CV&1_N[EO/M_)V`05";+68$U276M9<9R#0T26AU%,Z$YUFG"'^GL=:\U:
MDU*,T!C*$#)H:^2(A'5CF4LM'W^+&5_F6J@F@ZR0P&(C38H@0Q#A,S-S)7JE
MYUHCNRDM<U(0ZYKM9M2[4'$),N0'G78F+*DA9=^J:JR%15]WS]`)S9]5\I*>
M+(JO]H@'?*?"(!6NA%$442$VO4$D!S0:TEO_&A].]#J!1N.4TA\%]&EP\I][
M#5>O<LRR>5'BIVI&`WY:T*$SHH&_1MOKO^;#1W#=P0YZ**FM.5E-8GKA,!H>
M>M3IR"ZL1X6AS6$SV^^`V&2/W*%U^D)_HP%N";TLFW2.PM7N4V9_HZ$%6J6X
M%P=^H7]I2]WIRIE`Z\OU39)1V`<9J!S=NN5^_RU#.D?-H7WF%WO]38Y)6S>Z
M7Z[I1_>L1TJOJG8$!TT]<+'0WNIXVS1R":0G4)DR[\;6L[+!K&AR5/:FE]<1
MRJ%.O'JP;<YF?RQ$=52U84$I"@BQZ-T-0$/:FFH:>4-.<EA04\/C5M=DR1@`
M`J^[#(]ZMZUR;5Y'_Y(6">-[L.N@LM+)4Y[M#8J??!VC)FI67;X@K_Z+FJ82
MC=-MJU52X8;9\R"K4]O]H:P?PT_>'`VTA:8%XW:;?94S';L8VK"%;UK.>2^0
MIUES9CX*8ZR->,>C&1Y"AQ?)SDJQH'U:4<':V?2F?D0ZKZ]">Z[H,?8I\7?'
MRYR:8$_5DM!A^>U7[@!47$6(?.:(9S*P!&$DP>W+_*QH=\A@89S:]=0]?A+<
M(5&=)`$U0,"<%GMA`QN`X]_8J`,BZX@4H3^X&BT_ZD:V"DVA]2N'XC8R?Z-Q
M\(#Q\)U:D`COT&4J]FM^\FU6XB>.(`K0-%<Q$5P44BKBT&L%@FQ,D75`X/\A
M^%`'<X0+%P)4?/8-VA`^:]8D]?,-`S8:DA<GR1`ZTM,>WB03YQ:#@Y<DRN`S
MEK9O\;5D9"8Q%!)PI/=^UU!MH_8TFB8^<O6#SQ`4/*9>0<@TIF=#$-<40[1`
M`)%G5#$4C`$6TW4G7]-&5(%>8)%$/A4,.T-=SZ`FAA8+*:`:T\"%N+5[M?,G
M%Z%@.>4RE,!Z#J`"$P&'7O(^`Q4T`;$!)O5EWN8.LJ`S'`@S54`=S#$*^/.`
M9A>%`75DW8`[M-,Y?J9G$S!A(V0-7N,_0L1]*X4R;E$.QN5E`&56<G5;L>5:
M"]$R!O`Y?D(:QP!7#A.*@K`8XS`0TE((@N$OHH7_=A&#1-MC02GP!7>W%D!0
M#X'G#`Z0'5,`1R1$&E.F4_%V(4LU7H*D9N%0()R7&QRRAJ`S#UTF6B5$4"*F
M8MS`&*1!=GW'*#IA5MU8;4_(9_33&EAF7NY050_"0S]!@=,@"5,%A/?8-)3H
M&JBW$E8$C)C!%<H7"D)D%:C@1>52>P1C(J\S?[(`#:#D,L;71HC@"&^D"*LT
M)I'B%:;0"J&@?/HP1U?!"6\A"T:4`:H14M8B">I'#K)3%^=7!Z"P2I<(1*%`
M*Z@@"0OH/SSD"-N@"(H13BUI"IP@%C&Y$?9!>S'!=?E#;68V/FKR&\X#'$-T
M?LRPB!PXC]SW.NHW#BP3_TXALBC?V%3?H`]5P4,&4CFL0E;F]44<U$4'858[
MA'AD15`2M17QPC\CM`@:ADKT8AL4XU3J:"_4(3M/HV"C8%:)X`BW8A\CD`2/
MN$4&8EG9A$+4U(JB`4A>R4RO55CC`#10MUGT=8O*UE?QD(X!IB:-]S3O](?G
M\(W5!!H=B"#KX'YR!GF$AA-'<4SFY8Y.1TUIV!C8<BMM=Y`(64.OL9`J415;
M,7*-DAF_D0QY."1>,PN$.`QO00G'%R.:<4IKPQ!3$".^LEM38"@+)"@DPGIV
M@S4?DSR,T$;$4!6$L!^_DGT&,7)[41"AX!%FD2[5<C;B,9\6T1O7T3)_\@HB
MT_\Z@X(ITR(<<Q,)DA@+6\1<1P8:"]H"U%$5P^`UVI%)55,<DD%`_ED,G9%E
M9X).P'@?Q$$1!,1*&A84O<&2C%(UN=0*ET@6&M8+KT`)I/&;I^!+:`8:C3$M
M7R0-5\EZ+-*CA>!-1KI+B^"A8Y$F:+))"]1%P#$IA8`IP/$01IJE@(2&1_%K
MLC%O>I5,[RAHE#<^)!0-_P%TZJ9(/T-0:F5-.1%:!M>F=QI/NT:<I$=_#*6"
M^H6*/$%UT8"*+-(E:U=8U,DS"3D5V'EG47H0&I05Q$$B\%`(SQ(M+T(+M>,C
MZ%D+22!*=&$`W=$=J9`R%D$(4P`LM<`FE.!%6_$GW]+_+:;*'ZZ22?X#$=9@
M*+\A,HU`G@O:,:T#/(JR"+A@"N+1$=-!*5TB.)@R#^$!K171)?SA;IE)<Q#E
MG.O0)H[)"2:B')@`$1QZ-XWP)X\S`>A26N#`DE<8+HR`#I_B/(W@(AS1GC'A
M"8H0I'K!(QS3+K0@''R#3?#`H<U:"P@RBWF1F5<Q"@)$'[_AK,3Q&X4C"#JT
M'($1I9\`C(LP!6:Z.*(0+F0A$T%F=\*0*D66@_VE7['Q#89*0J%#;:*%;N6&
M;DI692-X$M%D'&@%(".8J=9056!6K4.%J0Q5K??@@9[S"-,1;H-F>4P;4=:I
MD%/(%-/P,G*C"O6).K1@!N61_PDPH&%7,8W.9Q?J!Q8J$"V-8`;2,8N1$".7
M!):2`*J8LK>9$*"8\*NT,`1/0!8<01=F@0EP="B/T#S6H`D;TQ"U8(6"LC>E
M>B*<H!Y+0*U[`*"MH"UR$3)#P!\(L;G>"BB7\"U-54)=)J(.0TS`>#S:HA]S
MPQT&(:L)\;$.*:-9FDYPL3954+>$4`>\FZLK6@7^\QO@<"PI,`5BHYF,^1?`
M@ZMFL`A<<6.CF[O44QMS(AQK`ST,\3N-4"-E8:H80!:;.S-V\2?;<+QF,`E3
MH!^G-"V6D*!#V@CO0R"N91/5**D#]HW4ID*"M6#]`AM-!33J9@^\T*<,7#G'
M,)RB,?]5T;$K6S1H4M*UF1=X%J)J#V(P`S8^L<$HR:6SHM&U6+*I4-&I`](1
MXA$CG.!+>V&5B5)*]-$M+5`9CV(0X*!^<N,1TD$M?*LFW:'#:S)`";$HDZ`M
M6Z$>PFH>='$>GU$['M2RXWM(T<@/TYM`4ZJY:VN_)5,14[`6&H.\V"K#@[$G
M)B$[BBD+D2"(B?!&RV4J+E0'_$`U%&H1M5(1P=&[S2H+CX-')09/K/`1NA`M
M//1*0X#'C?"V*/DI&P`*`7H=A)(BN/L\:DQ"6P,<V1/!GM`WS>JA?9R_0#FO
M[)NZ>($17WDC7]`X,F,`J0`1(^L5IU`>L\,WN;$:=N<YLU3_7Y^7#2B<@."`
MJ8+E)&24,.DH?1JX)*PA>$:+8EMU5@GBP:I'-IG:*@,\2SO'FOJ&P/.S0JNP
MO?)`<AZHPKK!PDT!9[HQ"(\AEG+S-7XB"8_R&2X#HZX7Q/Q@(B;,"?KQSB%B
M25V%H\#QHY(0I"V*AUGQ&UE:+J6T6\'G`!!ZIG/"@B22%Q14$3V*+-\JK>6+
M$4EP`I0P,S%#&30CI!.:""3A'7/2+B0!"<61/YK)M3P3/ZVA7T;L*XH9(J,*
M1'X<+67<&8HPH/#3Q#,6I5_C)H^,-E2,O%I!"Z#P*XH`"K=ZLC*#$"W@.\>#
M+:'\%\R68;3`$.(!2*20/1R:-Q34_T7W^ZX.T1GXT3<:QD60@!'"X`D:T1E=
M@3,S?*9"_(%MIEGV,Z?%>(0`5\Q,`B6(BF8++(,@6E1S!0Y!A(-Q:L`78DW]
M!7".I:BE1X0&TB2$5MA/2X2OPPT$>2NE^;7H'"NHW<)FHAO=0D<\Y-1TU5T<
MD3ADAGB.<#"(Q$/_<2;(=T_2ZH$EIU#R-$]*]!\*);U1I'K(ZR=?,`410D03
M`9#L@TA3$$3W`#68*0N@M-WAQ-T4XPC>,9A@,1$G4+]UD`2=G-X3H!_16S?>
M44>,$F#^(1.,,@N6:H[0Z%LHV'?5,)\;A)+WP43V@0N#0(CW#*35$(IQ?4L!
M!*IGZ@'3F/\)-LER9$H<6<U)*@IGF5`+`X0?8Q(4@X`OB8%*BTD2PLP+1TD2
MIK7A9N+@:#*+]\%!WP$V5VPIN3`WK5-\K1,FHC`(V+)Z`8HOI^EI"_9A$B,_
M1V'D>6HNUF`P0@:-;^6G6^FG`[6GV19-2ZMOGD8J1J9"FEV)G9U"O2!<'CC`
M9$9P`U;?[$*0";C?J4U#SM7:QK3+PY=HKN=ZS\>%E)91FN@@R)KGN5=3O35I
MVJ5=&F?HLO<3V94P\BA31B-.M;D1\+"3Q6`I/!SH-0IQ#>.;[.4G]Y&EH55"
M]BA#(ZJ;U<!]]%>6E[T:_/;!/QQGCUCI2G)'26,H6:4EAR5/6=;_+5D5.K2%
M>/#`0=S`$<KV$4*!>(G064+37P,E"MZ1$U7`?B?13G/$%44G9$IB7HC#<@H`
M$"'"/=4D>%]DCJ&^2_[B[$51/P#BOX,&#D2W$TJ^,`5BB^N>CDZE@7*I[Y%3
M6!$8(0^"34[K'TBQFT\HP./H[U*;&ISW3B6<96\F1C8=YT6BSDS!SD7"<5K<
M;\,'75J8Q.TG:]"G*\3Y3"0TC."F[+;"["YH6)71`LK(75+T;?'^FP#WMM"-
M3=U0;X3M-)156#S1YQL/'><59_AX9JV!*FH%:H?T2&VH;3=ULZ6@4Y`%%K^F
M/R>A5HKT6Q8S/UY^:)@I@=M@16,%C19E_[,=Q`V9,7M//XM@Y,"*IPC^LTL&
M<X0:4AOIP$RZ1N]+VG-(UIQK,>V)5U\5@U?=,YMZ_SH&<PU\-##$H.98EC;_
MYCG=W.6&5L(98M@E+"7R@NT(3/$5O]KK3.<\4]VO)_27)VOQ17$7YTPM0=-T
MMQ*M[Q3Q<'XX8700])@RYTTWZ?%A&&0$#.?R2%N+DEL^4FN%&E"H,FA;3O)N
MMT=4VT\I412NT5]CCH3.;L"VD3^2CP'S-/#U[52/?Q2TH2;L3FH(92OV""%A
ML1%>(E$;$L'HL,S,;)?&4?<-@]FD`@\L"`@8556"(PZ'3X*#&R,8AQ,.BAD;
MBHI5&QN7A(.+F?^9&((8F"V?AY&@(RV&IZ:1+2V'(X21JZVVM[BYNI"#=:08
M3P:BE*;#CJZ,AZ"8QQBD'AM/#JFUNM;7V-G:K2/5VZT>&=^XD+NWY>7CII#I
MY[F@Q[GLZO(.$Y"IH%4MCA/&PIV699HT(EBD=MD*%;KDJ$456<"D8>CFH$ZW
M$8R:4:1WK9"L5_'.(;2%D%TZ=/><P1(&LAPHDO9&%C.%L=&L8@Y)P8KT,-,O
M?Q@F5"$(\M$33:^J*#LT:)B#)XU$;2*4B-"PFS0OAFPUP4`B2E+!;L*DJ=*E
M5U\*QAJD:J*C4%*I/9%H5NG3J@_W!8T4Z1-#2V29,;PT4.RT3%6^$+O_2ZW;
M2V4O_27C^=$;QV\3+-JTJQ?G*WXJW_95%95TN$2.+ZM>;6WCY7"LL<F$5&=U
MR6M:@#K0$EF+ED<R28X\N6Y"/DO\C',"%A93AC23JFAYPGLK+D?2>"X#YF#?
M/@<`&\V=1LK05PQ`@,2RO!JBOU=<R5T+_@X^95.Y=Q^JOONW__[[[;974TUQ
M1]XH51DBBBK\Z-==!OS89X\#@C&23B@CI$4+9:)@`)!`H=AR42JZ'(>)%A@)
M$AAB4Q%&BE7[C-B(*XUT$^-3-'&R2G;>#?($4.\-$A6,GF2@SS(!48+7*!OP
M,YX@#LUXRV/.K/)+3;&-4\<LLMRHC"JQO"(E_XUA@HE!.%4NE>6:E[E&3QVP
ML2GGG'1JDX\##KFB"I=4873)).6I$X];PTQWR"_V'-4D(H=Q-T%YTO"RBG7C
M*!1FG:WM1$V=EF!%(8N3C7;GA&5U)M$GF-C3#(-B!54E1-,H9<Q#MDR4BE+9
MT=260U:%LD$&A`'3U*_!7N71+"%>U&`Q;"UFBG=@IC113CM)AA%9!1*RXI$8
M3.)4AU5-Y*DN*J4H5:^48IKGILHTV<RB-,%[2#*0>)#"F)CF6R)[V\`ICKX`
M!ZS:>PUM@".>R1CP:9B8-,FOG:!Q8E>8;R45$GS&?3;H0^E^,VIJ`E]*)J:=
M3BCF(DI!\E:3#,W3@O^W34J$)Z\9+27*M?!(U"4AW4B#+:T7BFF9,_LD`Y<G
MK:K8\'+85H(!BHYT@R@BBHAI2XPM\1CAQ+$$5L5150#1W";Z(.:7/A+/0A\W
MS$AE#)4!5[(IE,NVI6NTTXR@@"GV/AQRG6ZJX^_?A!?^CE6I+#O:4SLS1XIB
M'6,SHIF#,/M0@X0J@W74=G-X627K14[GG6FNS9HE-2I(&,<V.[SL7(DQ4C-E
M#4]Z"BF45*[,B-_%*LM%K=BJ54Q?DC;DZMDJ7:K9R]$X+6G!/\3N[L:'1`VM
MN<JR-(&=D'6D)J5N$AV^DK<E?NV%O_I[6\(KONGD\;00P+^&`QRXEG'6KW__
MR#>K=%_%EXL:LC[C-VLH9%%>61`KL(2/4"',$)#0"62:PI&/%9!.&"L=P`H1
M*#U1JQE]Z08E(#&7#%$B&>$ZB^[>A331*$)[S.%9C7:2H]_=`B(';&&!MJ4T
MLQ&C2LC9BZH<4@B^'(I:$Z+%GIRE)YP=#5C,,!<S)G&4%GREA2[!1IK<11CO
MB6Y.1#N,D\3(-AIBA(:'@8;I]M>>"UIC<&R,(\G:DBJ*M8(9B+A$+8I8*7B<
M\2V56=6D8K1'"JJD+1-(!!$KM1%;?5%.CHF@&]?D##P6D6BP*D8FCC.7<BGB
M*4HZ([+Z@;-,%.-WB3O49FP5/!MUCEEE0UXT;N:U_V5,HI8*064S0$&:/)U2
M:HHCCXJL1QH8:0MI-4);P^`B)+*4!X1:+$^@?@5#(PIL<E)B%RHF0XUX2"U_
M<H3D)',!QW":,S9N01CF4J$D4Q!1&D7SD,X>HPWA<8Z74:L&1&A5I70X!DR<
M5.0X*88/-,9M5&`2V,H841D<-2:8-4G1>;K3B&3T;$&C:A<_,&$[CYA2$$R1
MH8@NYXUPX8XPW3DAL#1Q%%LZ1R!3R:CS$OHEJ>'K5<%4B9`ZV;VR0(18OSB:
M3S)B2H^I8GM7<:"^'@,2&06O+?]$HP+`9*]SBE,UY;2J5AG9B%WQ(Q\9)9JX
MA'G*1YYR48G\HZKDI4Y!'O_LC!/RTU[\EQ"0D>AOK!Q9P%2V3PE&+W%"'(W$
MF&K3H_&*=&A#*:,4T39<O3"G,@H)5!IVMAYN\GA_`A4CA.2FY]&4%PRZZ<E"
M@M.W!&4$T8EBC0*S49Y15DAZ%-0HOF"DJ]!T@X)\GC=GAR5=&6($X5CC5K-Q
MOV]D=;C(W==$X+7<A#($)Z4@*RV*2ZZB*.P7J+'84Q8$R`XNKFL64B1H.D*Z
MEOPMDFDBG'V&XJYUD*>;NT6+K`"9EW?Z26HW"05AS,,LLLB"&V+:BK+&U$..
M':6BGH"1B@:16N9%I94$%-%GN-9$S&E.:LW@S;408Q/MM="CGH!%-^G!3LH*
M`EC_9J5D3>%Z#([&2U73@B!PIR#<Y.X+J^"TL8XI5DFLX%&,Q_B*&8M2TW&$
M]:L<`YDPCT.KW0%3'UW"YS5()].`-?*V5DXHE'1$S(^`<!@NA@>("\),2X$4
MH^/2B1X3N9[IY1-X\"0$HH:%-+(E-7<-#M8I)*.Q=4`IE0"^U9?W-,;M"BFH
MTF-2TE9D$WA\CF4<56$L4JRFSSU4A#)2\O2`2[\=&WF@MSBNIY%[)S%9R)T-
MBA)-G7'/(P\TO5&SY,S*V(\PQJM!5X1RQQP9.L*5%X+\RV"#"*2X]GGC7#^D
M[[5H`4CXSN(LL"*EP^IXC,;8I=HCTDR2H[(B3RBS:</<_U8B/`C97A(32K7J
M937*%3&;,&E/7:7LBW#8'HZ&&3%$%AT\:M-&J4VFDNZ[+:='K0[J:D/4!+=J
M-Q$%1,U9[;V>69:KOZ'`2&CA)\BH!G8E,SM;JZBKY),PMBD=&R)CC'^I^62<
M4[FQX;4BT9&9KA=G]#NC6:4\F62*V0CLF.]DSY7XI<58EF:6+Y"BMDK2!#7E
M,C.9ZK1WU)O67)D2X58(;495:YA7580[?I0E-HGCJ"/.XMU,&50URB)&!$,U
MO5CD..%3!K4M$`YW.1XG4&O7N+-^/)I5.2NO]70@JX'H2U7&N)_/^FJ[#6C7
M,=6X/:J0I*\WHLTC`B_03B>-VO\O3$TQVRI*A$J<#:D&Z7^'KLG\;I:[J(08
M;Q'(AU'F!%)9C;5U0PNB7M]);LM=>5'Z=RQ%RXGT2&Z+O?$%B%R4,T?YG8LS
M7K[XZA`:F/+==K=WNNZMD7LKZ([]_?US^$W/$U\CMJ=!P0>G>\2R-20CG;@^
M/#3NY&A*\*937A90+P4EOFJDKB=?VV=3[<!N]$0C3N<Z'74M0O(2KY(7G',K
MJ8$7"$A/H1$XB8-QFO,S"[$M^0`^W@(1J,4(A4<9@/54@-8,TG-;A_1*2C-A
M_R1OR^5HT'<9$X`B7N0<C,!\$,90I&%\IJ``/`@QAM!UM>!7(O)VW7=#VF<*
MW'>$AE/_+FO!<*_T&0WB9@34@+]D5N\Q)M-S%I[A=WN4$2MT'>Q294N5<NJG
M+\-3?8_Q$5H6)EY&@EAB@BUT"N(B0BU`,"^47^XF/7#89`Y56*BQ".8#4U$$
M&BNR'!OF8E03);H3<085&GFB@&*"91?A/1RC:#;",0.(3KQQ,D63`011?/9T
M$=+#@S[X@]HP54'(=D16A-?'A"*2A(>PA+!X7FR5&/U`1O%G(`S7%\[B70]G
M0%T8$VE"-&#R(S/#2UOC"OH03+=0%/"'<C1WAOF25Z.2+M2`9>KC>8>4;(=A
M@U1"#9:D.LOQ'J)"@5$R`OPF#=?#,WNR"0C614UQ*Y25$3]E_V*Z<2O:R"!H
MY%F4&%IJDHV7,W2CX('4.`[&QX.H$&_=$QV#8E=7IS<]>(H^Z``5>0L7J4J8
M]D"51A-&6(MYLQH?"9*$`WC"Y`^+`$%5H23#X!J`%4L5\W`UEDZ@I1<LH11B
MLX*NXD0&9T?)&#>_(750(2'5Z!G;I52Z4(7[T8DC&''_1C.*R!?BV"J\H8/;
MT5PILF?A%TS2LP]0U6Q#@3+#I'0H-BS1X7HQ1%*\X5OYD`ZJZ'05R'/L9!>W
MXB*+<E=H^#B``@J@N`$:XH9GI6ZM0)$9B0T*X#I-PE:'8(H>\`4DB80B^8J/
M:3@@4RZF='&P0!W3TAGTUD2(PRO/4_\I`E=4A_%@+6EQYO)*N-!X^D=QYH<Y
M!TE)YK<*U6<-\W@3@2@U,U%)"]=B"29A8C=&W>08"N(ZGC(M#A.0E[-)IG5G
MWU./R]$]RS1X22%:3=DU-L4VV6E$`KE;R`1OUW1T7X`V?4D1C6$EZO9_BTF1
M1L4J9V>1/=B8D\D-LG@((SF?"I5R(*(REL2;\9)?035VR="*VT!72O1FIL17
MB%,CA("*3R5Q]2D;4](9MK941@EQ!3J/H(%M3?D6LJ<D4.&5FJ`F)]4EG?1"
M'^$*7=F&I4D1+E%S&5%M2T-$7<)H^K4B(=22B_02V6AZX><-3A5HK!,OH]!+
ML2DGSM"7/J3_=7;57J*W*859F'$G>AB@`-S(F(Z)GR&I&O>II5:V"FO77>WE
M/%U#?S&J$*I9H,58)F:"2-.U<`4TAA&*&>\Q0M&XB2I64[$F=Z&A%VO(C\T`
M3\ND2/8':X<"*J!P*F/!(;5W-0`II,O2C:MD;[D#%M#Y>BX2%3S**EU69>=I
M3>=)3(\36CUIF(1YJA?I"!;Q*TJJ+8IA)AFW.Q;5`J<XF`Y:(GI2I=Q8I1Z9
MI19YJZ:*JL+*GF@8H5WJI64X`OZ0JR;RA8K'?WJZ=>XEFOK47GP&&4&5IK%X
M#-J*I)-&5M%H39@RAD=Z'3.EJ4T$$3*C9HA!6&7W*8N0J*C1>K^E_WC;B6J`
M!AF%E8)W5S0?U@G%XBY^B3Z2V!-;@7/>((5`6CVGI+"]!*RI.*R$:9&-4`>K
M:H.=H&45"%4$-%6JD)&UF@T*T`U6BG6>QX,#MY[T(+$L"[%94JK8<*S(FI=S
M90P:!1FC(*,T]#9$20_<JH6ZUUP5DSJ10ZXN2TDE!IO.F)>P:3L49WF+0B7%
M=`RRASM?F`)-DF^KXRX2(5YM\T.3F!R^Q3ZZHG4!IJ+7@CMCJ1C!D@Q=9("H
MP"HX6!.^L&Z3J""J\E"001ZD,;2\NIBVVK*"2Y&/81%=E[7_]Z3L]+$>RTXD
M.[$B.[@>23]2&K&#>ZK%&IDSNS_I=40RVO]Q1*96N=JS@O)+],ERYM:YS9=-
M[UDGS`"%K4LR5S:GGH6W-54@9J)U'IH*BM%V+_(BHA$K$J2Q:MM*&#8H]0B-
MHV&U/7>I`712'$6<FS2:QD.BB;FP9SNV[A,247JYEWM#\C89(]L")T";&U"^
MBZD33PJYP2J1PSJYZUFYP>J](3NN]:D`*9`"T[JY>"5PN](0&B=B"N:G!'HZ
M2L9="[60<<>ML<LF_C"7CS6G!3<I2\L1<1N"[Z43IB5]#\=>*I$=4TF@`!=E
MVT5`6.>&G=,CCOM464L,-:<87]L-#29U+:EDZ9JP0F,+@KE`(\*]N&"*]-NR
M@8N<62N1&ZLWJ5#_JV<D?7JS-T$LK!.Y-TG0`G$"N:B:"T^<Q<0J.1&:`?<R
M`4?+OW12LE)224;3N2,<:\83<@;<(/D'F&?H31#:FM'W6@!7DI17KD8FA;52
M8KG:C;!`M:/`.N;I.M8S;<6FL'*<G;"2C3O["CE+(##<NT1T%H-L$Y"<L\$#
M@I0H>K&8O6[X?#\<OUK\Q%1:)CZHL"-K4ZO,*DC<Q%I,RA0[Q1XP!=Z+Q:6<
MQ782H1O0F/@@QGCEN<^R&#;;+HQ00I;:P/T&8'^FNJM)>6S,)MMD@ZA4P/F2
M.,:GQ]&'1$O1`D;W9,8<*-CQ,K_I#/-2Q/3D)V?QISFQ;CVJ.'J$"9J1_Q.K
MIWKKK!=^B3LGI"T0\BL[4;(*^Z`CYENALC?`!+,8F<N""TQVHP`G<`*T:I%B
MXL378@@C^\VOX(./J]#LB;\IX,0<'=+?R\6LD0+0`,SU8Y*P0B#\E8QB18;B
M5`N`E:+%0%IRJE!%0UL.ILVGDU"B+"<QT@NW\U51N0R0K*HZYQ,84+?G^&!]
MAUV_--`+Z3TX4@?#8,*$L*H"H;9ZL3H08A:SQ6%ETG;LMK`_?9X2_`U7?)&G
M&)=6ZK$9[;%+X+XZH7D%&=<BG9$94,NDG-=^C;DDW1Y>[)C(B-+26!&U(4HE
M]$XK^0E$AH-RX@L[\02^4`5;PB\6>]FU4;=T7/]/%$,L=Z:.!R5C/*TE1Q1/
M;7G5Q\DRN+;4X`-OB<V/W5`;6S8*:H))-$79D687/U('E`H]F0%FS@1\&'BC
M.L10KI/9F^V58%(;4/&I]%EU4<S6J)IIUGW=UWVJ!_U;V`S7<;T$GV&X)ORQ
MI%`'(NU.)OT%Y@W2?]W>WEO:NJ``7V`O&P#9AFT_YK'9JJ`P*15D8C41=3`>
MA=T*29`$,F@/!M[<ELW4]^!>`*ZNY!$?=%(5#M%8SK02V8$0!8Y.&U&W#5XG
M*T?5BM(\<]%)FT05TJ`HE"`FFQU9=9!(QN@M2Y$@J9%6)],6BF35@ODC/@-I
M:./;_^H(S/`K5UFD+;#_V<4#//RVJO>:P?"=)5>\F)E-#?QV+15YF$?.;QZ[
M'LLGT;)=RCT(WE.0WDZ\!.Y]YI?[Y+KP*RD`BE\`P_48YW(^YW1>YW9^YWB>
MYWJNYSI-64K*YDH*BH*^YX0>YWHYZ']>CU^0OX/.JG!>Z(1.6Z#8YK]B+R:-
MM9`.Z9+N'*^:Z80NZ)3.JH(^ZG[>YHF^`8SNQ;?4EZ.^ZI/@Q:8>YZ3.YIA@
MZJ[N'),0ZKB>O[:NZKS.Z*R*ZFV>ZGU)[/6HZJ?>ZK<T!<P^ZE_`[-`>[=(^
M[<SNZ7[YYMC^[-.NZKN>`M'>YLS^[+`^!7[)[5,PZ8P.[M2^[NP.ZVU.J["<
M_\O8/>\;?>9JWAI3\.:C_NO\WN_^_N\`'_`"/_`$7_`&_^ONWN_[[N_VXNX)
M?_`!C^X*[^X>T/"PCNSY:^FFGK^T!?'\?O$/C_"F7O$9;^D:S^LA[_$"+_$L
MK_(`G_(3/^P(GP&+;M(DC_)>?//A`/,R7_(HG^K^3O,)K_$2;_`5?_+V<O0W
M_^M*W^N7+O(IS_,U[_)43_`GK_)+S_15__)?`-%ECN9@/[CW;KEA7_9F'^7%
MY\F'8G0Z:[-_;0T4.0(07=/PL"V9*F9;',7<"+@JFTYYTXE%RK93(](O\=9E
MLJ>_2OB@H)#5IKYOKB!J_'[+Q<D*.+#`^PI678&;8/^(R*VI1#RFO*2[%1$F
M/='"7K=9F*A'B3$);/MZ-JA=:>LP%KVQ/EUBLK_*]:[%2[#[O-_[OE_=)*N^
M<RV$&/&JW0#>T5O\LH\6.FCD+;#[K^#[TB_]9U_]@COV]ZU5)*LK*R.T;&1\
M+C'-1,=W3]N#][,Q)QYOB-O9!>K3V$]B`*5UQHMA-C.)@>7-1!>I1V4CP@((
M&RTC(X,.APXC&X*&#AB)7QN$(PX3B(,8+8PCCXF+GU55+1BA59^+G*&*@HL8
MA9PM@YB'"HFQL;6UMK&$B+Z_P,$*P\3%QL?(PPX*A8/#A8(CS+>3FH+#2YJ&
M"M8MS-"W+4O)Y`I+Y^7IZNO_[.WNC<'Q\O/T]?;W^/GZ^_;?M1BD1,7*-(J?
M07N6'%G+D*$*!D&D6NP#B,A5,TK`,E59->+)PT4##];K9`MC(9(B\[TZ-")2
MLT.=)JUTY"B:)%]5OJ38()#DJA:A'HW8.&@F04*B.+F2Q13F(4W0'%;<D.$3
M4*`/&U)UZ/"C*9[:OFYR%#.<KD3->"$Z2\^=VV+2+M;*%HZN,W#:8DF2-HT1
MTW`GO)EK=ZXPNK>($RM.!B^EX\>0(TN.5^L510=0FZ&<;-!2IE.E6FG:3`]@
MITR$M#F%^=4A3XT124?VV4C1B(2<XQ%D*8O035_5"M)4I+?3DR<MJJZJ0I,@
M4$&._S8Z+PC4T5!1CZIC3BW<>KC3T+XP)75J$_GRHTR9B@31^K1)_WA36TP_
MG=UQYGCE/Q&X*+7PT:06338;3#%(-B=,$9AA##98F#D.1LA@?132UUAN&&:H
M88;?\`9+=QOB\X\VUY%2E3:7310+6I,`]TE5`(%T6H@E>4@C<+4)]THO-)5T
MDB\/R9)B%55]!212K3Q1B$+<%010<!A9)],OKV`5D6]`#54(>^+%U@)[T6#U
M%8J/+%64-+3(I-\RNE1(80LG7)-?-,R<(-X2U<B)8%R%3&%@7WKR)XZ$A!9J
MZ*%N)CK,A3<VZNBCOW##R4TK0DK9/T))0E6,5FU0)C\6I?]&R4QU4/5%D5VU
M`EZ*DUE6(UDT:O:JAS==5N5O9/DE$2(;[&3*KL/IM4%T&$R0R4?`/F4-):X\
M-260X22U$69[1:))!D-Y.B8JJH!TJHRFY7437]ULL$1;BI;C(']QAO/E.'#B
M9Q><XFC##(*"FC48O1(2<^B_``>,7[KI,&KIP0A/-LQ''R8L#"*6:/-:KXRP
MFL]1+6%4!V8.*8(J>3&:%J)%,!FL88>S7C((KAY6>II?&'E$U2)?*(4(-#P1
M8MI/(/*,DID7VI:7CIJ`N9<I'G\"2RB??%$STM.AF4LST="B#,'(`+Q@OO6:
M=0Z<"])[R]>"+F%G?X."C8W`;+?_#3#6!4?I\-QTIY26R9"QU2-ILCGPE8G/
MX5W:16E%^=DB,'YT8K*<T6:2X(VWF/*1O*!4Y2@D!3F3WXB+9[@K(`4%T*_4
ME)SEYLO<3251[85K])76@*)*[.+Q<HLD*S+S33@8P:TNP+&8;6!A_!G6@H)I
ME_WU%R<0S_R@^+HM_?34'U8AY'5GKWTPH>JMX<X90:O4(`+!G(_>F`Q4AV6/
M;'`JJJ)4U1Z&9\V$>JR-J"7/CMT=%=)PC/!4=#;"D-3\(C,0$86//(4:A5P%
M6`!QEU.<,S]/?,E3DO@(S7CRFE!<D$1"R\"9I'0W0OC./O\R1W^XUA^R@>T<
MQ4,'G/Q4_R_EF2V&U<NA#@V5*.QM[X?;4P:D[@<MWCG"):TX'UL,`95#U$$U
M&H315S+PA:Y@B#:[(N*&&CBY8*B)62UK1)G\\HB@)&<O<J.66*3BP.6<QG:<
MJ,CECD0X\N!L:3G9H&^8Q@I))&45(-F826#VC!.N;7IC8]>"Z%(\L-$+0HY4
M9/#PU;P=6O*2/$R,#X'(R4YNZ!70Z1$BD$:<&.D%1/V0HW]"4CA7;&01IF`(
MC$0IF?K51A*XH1$7]5>/RXEL%_\;(RL<\,3V21$CF1J$TU!2/I9=Y$*VVU59
M[G85+`$2ENH!))@<<COQH.(933*A[@R)2!?.4!SY\1/9%&28!/]5<@E^:EX-
M;8C)>MK3>F[9I"?WR<^4?$9`R"Q3[(AB&9T=9!I+R<[*F)5!1<22(9'(7(;L
MIT_($(<E+*,E,*()*\Q\!U;$@8I#9.82EYV'*F!D24DM1PT,"-%_$@'/[18:
MG?*@PBON`X5&/&8-@DZC-^"LSST=!#;E@6UX12W,#"N95!C&$'I#C:I4'V2,
MBO;SJE@M368P,:U.)(<AK]F-8[X!C8J@"*.I8-J)@#31D'"Q;YQYR:S@NIJB
M9)`B2Q$5D*P2"X]T8W.QNZE`(3*:(L+'K+T1F?\"1),\6N,CF9#?B?)$,[U@
MZ7;B%*=BILJ@HK*+G8)Z:O1"*\_FL2O_;8:"@&HYR]JV'<.J68UM;)\Q"MO(
M)SM4A&5`4$/7>GP#=+CBK4)NJE8!=C0W%$TCC?*7T=[>[)2*G4Z9,J4I`:K"
M<X:`;$B9<U'_?6H7J(N:8MW%+.`Z311\W"`J<%8>O%C+&?YPQ\"*T=IV\B>>
MQ*.A\Z;PM2DPCZEG^QI4(Z3:U=;WP)DL!FQERV!^%A05SQ5%3DNQ'E<99$=#
M`5U*,?$*J!6.+=YSC.1LVRBRHO6@36*IJ'P2P)BF1Q#H_=7&-.'!__F2+&:Z
M7RM]`9457185(K46+&VG'"`_ASW*"2H*$=R@`=]0D94\[:#\RU_AG0`"^;WR
M.0S<H`)[F<M,_PZSA!;<X#)K#R.\X%^46B(_GM1A/2!!$S]L\T^8+(+'\RNL
M0.6\C,>P.(MD/DAR1>P?9++H0D%R7XPHL2S1Q#02?\.17GM4);D!K6=,*:%F
MW->-@036*N#(Z7KY\A8Q$U61_XTAJJ&,Y25`@%U?CK6L9^WE?\G:U#H,M)EW
M[3",&9>+BO@6>H,-85^$&":L4B##,)I!C.JH:K2H%&1H`Q$N-FHF31QK<%1<
M%*<`"'0UL0I!(@AJ*HV0TM4P=%Z7A&YBW^))*S,:-'C*:=(U383$V2RN&03E
M_SIOA?'$\JMA3>N"&_S@!=\W]73-ZX9#"H')@G!$6D&D#>HC10^)H/]_:C*I
M\E*K2?"0JV,<=SCE?C)')C^([3R%&YR)L2;;Q(!?=Q*1CL7.*![2\7]@0E:7
M\0;4>#WCS#@2NR(_1[WMS9K"_Q6O?D?Y"\@3'O.<RA^$6_WJ6"_PTO]U@I0[
M_.O92S/NF)7II8C%5!F]6%&2PFREE+)DC'@*KIIQ;!$]=Y",VR*VX5%W?:29
M<<3!^4^26%.>9+,5-P[617`T0@5X-=,WFP2TE^*^]PXE%D:3,.8C@41&S/>0
M6R]4OA2I("B;7AP#O_*KL\[ZUB,\].WT.MAG?S!?CRH<WB%[+$&RFHN]!"HD
M<5\<,>"2-S(75]SPQF/DJL7<_,-^:8?,RLW__2R5<M"X?D-B%;&SBU`B5G\"
M/9/<HCFCD!KB(IPFT<R<AI>FP8P0GP<][)^L2*<.7$%4-FV"2D]U+:_>]0`8
M@`FW;UU'>P8(*2`V;A=E'83W&4*!>0W1>RKQ=VSG'9CC+M/U=RTE'WUG#Z[2
M?&WU.%$B1/[T>+S$$MP14#E%8P[@$8D@6;6U*X6V&B5$:4:$6!B&@J>4%K@3
M0$UC6;136?8"?_-7&%>W95?F3OO7/!#@)PJ"98HD@%(XA5:'8`5X@%@(*:$2
M>(83$K=31C0C>WWW3-F%%<]5;;*"%N_F"5VH7!TH:1Z"$F]X$$_"(]FV%G.H
M$EA"?0-!$6>'?4]$_T4N\2-;R",/F(;RP4L:)RO@)"SF84$?U'G$MH(@H1];
M!X#%\W\)\FKQM(0"YTZJ576N)FNF5XJF2(6H>&M#=859V(H*HS>V-U=&M!*%
MH`K.!0P/QD9G-5S(I!IP-T@L,PNTT!9W5QD,IP^3=H+?TPW<1C1)@PG458G=
M,4<V6#K?UQ@_I1\40342%Q?N-V\75'E#<R"L%8"F>([GZ"=$4'7W=P(N@([P
M&(_R&(]6-X^J]WI=%FM<)WNNV(^")G=[>&*_>`DU@VQ]F`_15#EW(S*%A1<P
M458>U43A(DW$:"-=]$DWD7S\*!G_)&THJ!F+1GQCIQ"L<TK7:&C@51"/8_^-
M=3B+V2A\A_:-/^$T0D@-]66.]@B/4[".GU5Z.?F30'F*"&>/J=AJAL**_IB4
MYX.+``D.<"=&:;B+>76+IO-NO&,F03=VW%$6I:,6A\AG#Q-M@`:6(S,+)):'
M(Q=-*14<S-&'E7AYU/58J@1^.<<C4O(?,K5X:A)G+XE=RB0>3B,LY'B3F!B4
MI=B)"4($ZYAZAMF81#F4\UB4^ZB4E&EW7K07'(8[$H$=S>)1FF%;>^92OD5Y
MO3@_J_!&K2.5Q889!9E,CQ!BMC1(*!DB%Z61R'8CA^AS)3$:/T(5F(<Y<F>2
M-FA`E^$_:YD7)K&(P$<)R4<BXN(NB^!??#680X7_DXX9E(QYG=I9BBYP==M)
M<`#8($A9F>09EFOA41J&41%U"#W!;$YRASO2@8Z'E:;#+#]A?&17,18(;Q+W
M4?/`?&*$EB@62B3&)E3I3\JR$GA50ETA84KC57OQ3<`Q:<]EC6HH?CL3)O"U
M.X*I'Q+#)2NS%U-5E!#@`B9ZHBB:HBIZCCSYG2YZCBH:HS(ZHR2JBK%7GCAJ
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M^F6%>JC2:FZ09T%F)5AIB"QH5BMFTGO>`Q<FE'MMUQPV)G$8L#[C`B5L0@M8
MA%:Y(*"@DE<<&"G.MQ:BR1:RVAT:26.[01S<EV&!5QN)V!@EQ`PN14V%]!E0
MX0\\>";"<B=H@PX!DXHYV:Q0)J-?=H\E>J+\8:*#NK$H&H\>*Y0EJD@>.[+@
MB?^RK!9K'GL+\,BQ?:JR'XMUXSFM.2IVO\$1G<`-.7M3SO:4<<0D_4`,:\(B
M:K:@:]H(,R9^RNAX4X-R\&H0,<$3"1JU!B%$;:(+^*D6NB`@GG(2EQ9!V6$^
M($5&D6=$S8*PA[:#/:<K[N*R[\0V%&N/,1JS'!NR[)*B[,B8%FNG?&JB7D:W
MS>I9,6N*>&MZKE>S-JN479MFUI1N6LND80)&&#.#IO.:\@`7^L,,Q?9VPU4K
M"SAC&II&6`N@AIH2)"@KOM@HMJ)\Q[6;\&`1<>IVF*5`(<5[0;>#WN:XS<*A
MCIN-^A$7MR.-(X`O3F9K<RN/,AJS7O:.I8BGGU6*^D'_@C"A!5;#%W:1CC[Y
MD]"+CMV;MWYJN#"+N*VGN(M+F84C=P3*2\QHK4\YM6"4;W5G#!9V%.Z)FF7"
M$9*JH%KK.`)IM2*B"V0RI6P"P!/!L]=0$201J4X4;"8Y1F#Z)`*QAJYC+0'U
M3'RR#.25.M0D$Z&F*VDA/<5J>LPZOB0;N.CH2.,`,0:@`BZL`S`<PS+\`$,P
M!"Y\PRI@`!.PP[FD8'![F-A98(#;O,LKOC([L_5XNN>+A7VQ9N(1;;_!*<!8
M7A\Q%:!K+^?YGXS*/TU!%F`[N>L6H*_9M>N+3`:,+LKP=ME6#"$BP)@9M([7
M(QP5>:H*4KQP4UP,C<"U065B_XSS\;3S,0GS(@XFQ(."\#7C(,+/^F7,NIWL
MD6:/L,,MK`(RK`,/\`>87,DQ_`"<W,F>_,D)8,DZ<,,&4,HZO,-I0DUZ$0GL
M4GDG+,0I:@56X+Q&3,LKRWI3H,1+;(!8FJJPP!TLX8`/X1L7C#D]J%"\](:+
MIX9=DF.#U6P_,6]'LA9Z^7+TLS#T>99:VL;Z8V%:J\$KTQ@]]AK?]\0GT;!M
M%&R>PQ*0"%^W9S[P][:%_(/3@XIV6\(F+(].TT+$<`@34,HJ$,H)$,J:7-`R
M_`<SW,EG<`:?W-"?7,FAC,,N7,JXT7,_;">I5L(OF\\S^\I-J,N[['#;G'SL
M*C&C`O\=SWR!F"-,E<([FU-WH@E>VQC%<AENF+I>DE!W5UH2.WO-.P.U!7S&
MY[.Y/Y6`.[J+D+B:21U!G*#**FD-$17'/!O(`RL8PKN#E"4(B]0V5'C/C:S/
MSV.A$W##FOP`!GW6,8S):KW6;(W)9U#)G(S0<*W6E_P'G%S0!&W*N.%2:Y.=
M%VO+=NO1'IW+(<VXV[P+?S:UM74(PN=53\R`QD5TSI#%PJ"U,C%-GJEG%A0J
M7GD:MI1%.?VZ%S;26+2MO4/9)\=G!^M6/=U]HZ`,X6"NPU52[XEY4>P;%OR1
MO,.P,R43!.+2FH`VQRLAM*:Q!2:X44C$1QR/\^'/`/W":!W_W6DMUY7<UIFL
MU@O]UC!LW=BMW98<UV;]W7'-T.(=WIL\RCE\R@F!#;%P6G'B-,SCD]][G81=
MV#E*5KUC6PNYJ0(4S15:$[(0?6C\'@^YAIY+$*,[C,L0TW2W"Y%"O1>7J+@(
M'1HIU")QI?B*X5G<D;61&M;R70_Q7F(TN\VQ@M`(O.Z,XGS1)#C-"%N=6K.&
MQ(ZYO"A\>NCDSV--UM*]XP:=R=/-UMG-W4(^Y&O=R9ELWN5]UP\@`9Y<R11=
MT4U2=>[HUXY9W_9=GN&W9I@YE>&'(@LHJV\<TP$,;T&KIHH]M9K)G#M[KZ8[
MQL8@$G'<9[:05XLBX(Y"=RGR'F=1_YR7([SGP=K`=9HL'7CJB]7@1$@F1%Z-
M")W"/=Q;9AC%O;<U_I.`C8XBK@P\#-W13=!EC>2:?-W5W=8PG-VD7NJF7NH/
ML-"?C.JI3NH._>KA?=<)C=X4O1;*:N573IZTE2.AI+#3Q6EVYGTM\;6U`J_$
M@*MHJG'5EC[PQ7-8=(AX^.9P7C^G`-J[8N&HNR8DQZX+'.#$_$1DR](006<8
MN+!_Q0F.AQ>XL)>;4+S%N\I^<2@&%NF2/M_H>+>5+DEII@O__-P2K>G1[<D2
M(`&G?M!K_>F5?`8LL/`,W_`.__"G'O'9W>JD/O`6/_`3']=P#>N=/`030+C;
MB>NY3IGW:O^6!!XD*Q(NM4(BR:2@IFHU0E2_&"A=),87`-&X:$)B.ROM_+#-
MIPEA,P'ACA*YD[WM"Q[3:IGR0-8ZR!*G$RDL;E<X.G/2_X$F\BP3)G[(A%*/
M)JNW='N.5QG)IFS*`UWV9G_V9B_P%O_P#\_DG"[*9\W0G3S08U#W=4_W%]\#
M>K_W;-_W?K_P,Q#X@0_X@\_0?W`&UFWP=MW)*C`"?"KR(X^H5I-0:4)&F\,P
M&KAR*96'R%"A8/18EKH2"V.7G*M\.A_M_7RU,4]&)@UBV+X/<9Y\K]D[::;@
M66YXU.&#C_,B(H1C.!,)O1HU4E/Z)$(,+N>PE0@2A0*9ROJ.N'#_%OT^]F./
M]F6O]A+P]PU_\4R^Y!+P]C)L`$``!`:0`.(OT.1O`QJ0!NJ__NJO`1H0!>X?
M_UW0!390`_9O_T!@_]1O]W4/"#V"/2PSAH>(ABQG9W^.CSHZCX\/.@^7#PXM
M)YR=GI^@H2=3(PZFIZBIJJNLK:ZOL+&RL[2UMK>M"J8*O",M+:88#B,;&PX8
M&,3`R!@MQ:6:Q2V^I<C!M+S9UL._(\+-&]Z^O]V[NML*XR/ITZ;>#MGQNKCP
MO1M?Q1M5&/<M\[ST`IY2L&T<P6W)I@D;>(Z<LW#<'+9S4"7<AA1?%#(CAF_:
MNA$@)7[DY8P<2)`*?DEKL429KPT.E\B4_PEA)H2;.'-R@B"JI\].+FH*&6IJ
MP@0#2),BU9&@:5-,#R1(E<"BJM6K+*8.FCJF:]>F-<+:&&L#0Q4-:&UHB%`@
M0``/$2*D2$,W@MN[`>+:O:NWK]^^=`,+#APEBH80"08-4M-#S:%%#R9)GOSG
MP9D'!EI\.>'BI^=.I`2*=J4+8+U<_^8QE*=Z%T-SJUNKDMTZ'FK:K'&Q-CU[
M'K)Q`YU5<Y9Q(;%PPH13._8-@^Q4\NH!Y#V.6;-IW7P)>V=:E\%AX7JEWAW+
M=C9X#[]DV'`=.,,DM\^/3I7,>[%_IZ@Y;T/PF"EG%2&GW77E-%/1>N4<\Y!*
MZQCW$DS^#),2.?_AC-"2A1*M1,X2O]1$4TTYA8C39Z*X8.*))GJRA`)".&"4
M4C`BE0!5525BXV-92?7`&$XY%=838W4AI`8;I)%!!G%Y$``,<U0@P!P1Q%"`
M"#B(($`%<\!00`$P=-GEEF"&*>:89(J)UYD1I(%6""&$Y68-3AD`A`%-16+G
MG79"E=D&G?#4IXB?A3;?:$(D(80";:S!WT*F#>7H4*K5(:D#\`UD76^FU(&*
M?-8I^J@":X0J7QN)6L?,&J9>>EH;EG8:J@-#&>KH*JF2QMQ&T^@"7T4@5?B+
M:L*5]!TKI)ZB*3P#D=:+1LG`I$XPI966T#O$1+M;;J_(PVI_Z:U718#_*CFG
MVZ"L*(,?/-3(A^R$#R'3CC*_"'./-_D@)VQ)Y:0#GDGIA)1/=B1!N-DF)[`T
MT\$B)NRGGZ%`D")0*)IHA14G,@S,44AID904'"<UXXTVLM"#5%\E4`,0-8QU
M%I%%'IE!"A[$+'/,;KT`@Y-BB"""!5%0(,;/3V99YM!$<^FEET4/?29></45
M0PR#I;$!6FB=19?+6-=;;Z#0D$L/B_"!BNBMKD$GFS5$;2K;.\RMHMJECP:S
MD"FDIGJJW=:H&X]SR(2Z!JR/MN@V,[:Y?9"IOLQ31X#0I+2!`A-P@X\ZSCT'
M#ZFLLF+Y:L^VUPTSNZRS2Z[#H#1N+,D<YTP&__M((XVXMVQ.[H2-!U.==/\\
MV$(SU8S3S3T8U.&Z2KM'9)+HCA__$;[.AN1+1@3_<C#""N\48D\W/=S9)Q%O
MSXDN1V$<HXP2S$`""8F(//*."0!IP\HM'ZG7S/2[13/-`=C<I``Z\^PST'.8
M0](&2,"D:4E,1TL@TK:TP##=!4Q+HY_,4D#!"E+095/X@GJZYC5Z),$TM9(;
M!OP6*BV$:@>A>I2L`N<H59&J.[Q(VSR28*A*X>V&J*J5[,P!PEG@QFVGL(YW
M?H4NX;A#&D?\0A66@RQ5:`I1F8..YJ)5#W50XW.W*DV\XL4.MODP.K,QQV]@
M4@5O520%$.).;\#8P?_R)&@ZZ8)-,%0"/8A09!KW>`:!5E<\=/D.&*73G4>6
M12&/<(A/G)#>]&RBL!&1Z`2`LE[V3N2)BXU/*4XIWPQZ\!6QH&4#,3A2!25(
MRE)*L&8%V%__>B8"``JP@+",I2S#]"4"ON"6N,RE+G$909D%@(-MK,7>;HB!
ML6CAF,@T(0EAU<16(,YO:I.A*0I5*+G1!G<`R1S?DI6MZ/B-5*\Z1N'4A@UV
M1(@D'NF&.O6QG+DY$5;%.D44I\B;8ZC.>6U#EN^*X8Y<'8Z8Z*@G=-;!BVT\
MI!AG7`]RD'%-'@83%J;)%^SBB#M[;D"A,+%='O7(NXL^(W0A(4>_S*D\=D#_
MJ!O)VX3!%OFA1CX2%`S[A$XX`9'PS4E.0$AF,O;1!;08"4D1,*62WB+4HOHR
M?ZETDLY\P$I7SO*I4(WJF)9&U:I&\)</M<7>O*&RBRHT:H(11PF/"=;!'$D?
M?0O52Z#A*-7$+9^M:*M`OT9"O]EMC;&(IW,25\1G:.J>Q(`&05<!'R%@#G,0
MG2MXT@@[WTCC.,X31D$!BHP79JMK[UC<D<R"T87";E.QR2IJ3E$@Y#WK-$?,
M8T;\`]F2(",?'8E7Z%3BK'3H8D&#])=#3KHAEC9RIB_UC$P\D<<6?*M>HARE
M49?+7/S5#ZD54*H(?!"#_PD@:%+-KG8)Z!8S6?6[_W@!IFB5!2HM%%,M;*G`
MS]:KL_6NMP(9*`LSU%(``>0L9SIKI7L%`(,(5.&8&,A`S#)0"DB1#5FH,N\J
M6)BV0=EMG(`3W!K'.3;K$/$_7QC!7S6#G=U9`WGR"9L#VF`JQ<;B6?JJXO`6
MR[9XPB*>_>K:=!:2NA$$*$"N@X8[QTL/Y/TJ'8P2*6H)5(SU;">=Q'O)$I]!
MQ'X5\B.Z1>E)5'<"Z!6,I8R,9'`#-84N9W`*+K,@S)I+YC(+%971%4`3IEM=
MH&%WNW".<P'!2U4EB9?'0%R#"8NI@0#@X`,RR(&@!TWH0>,@OETHBP9ZVH1!
M-^#1CR9TH&6`@P)4`0@;\/_`+3U@#**D"IS01`6#9[4+2.WP%2%<,*EI!0\#
MMPH9%0%D*8RHG';T!XC,1%0.08<-L[V&&UICST>3X>)7Z#6PQP*(-<Q2KV7T
M8UZ\QK-`II,@<9FS<@013K/2^(MC5(&V#RF%ZGY,R))(*")\\HB%'E2P1"J`
M0UA>0L*V#(H->+G+8J:@F??-;Z.B^;IK9JK/KHNE5\H9S@<\N`/I;%6"7NOA
M$(^XQ']33`^(0`8B@,%SB3HS]HQ0K2,8LRGS4@`QR.```?C64#G]C2J0A2SS
ME2]E;2=971QJ/!!'Q;%4,6I7;,.AS'FY6?;!#-J&-#?SK+D(7RY?;.I-.E$<
M)T?_[J'$,K)'MB/T87Y@`I.Y)<-=SRB&O.KU#H;J[5P-Q:;3)<YV*D9D//OJ
MIT:$E0]OC/&BT#L).+(##0K5=EDKF;(S"M;;1=ZDI2W=D,$\<>_&YUO?_8Z\
MY(M:LYM)E[K6+;C"-Z]PAG_7X6T/O>AM\_4T"$`&<TC#?Y.)3""X/J?'G``*
M=T#[5#SA"09X@HN,8H,:="$&'?@`#OP;U+>P)^1/M5\*C(P!W3/DYLIF:&RR
M(3AU3?-3$-;YSIEYBDR+*0)HO?M:><@:LU<8&6EPX`M2`/KH="=4F"O<"#(R
M@@QD&,>O.\;?1LW"K??*66W##W6'?U,F3JQ1.\Q14-GW_VNCUX!#9&OS<'3+
MH0[$,6SN\#+$$T@K9EL3DD90=E"^0@Z$AV4X,5R'MP20A(*@T7@O(V:3]X(P
MR%R5ITILEGD!Q'DXN'F>9S^_Y(`^R';ZAP$!('QI8`-T80%0,QA/LX1/@S4N
MPX10F(1I$`4U`'PY``,:4$;KH6=5``.`)@-LP`8,(`,R`&@?\(5DF(8G=P1'
M<`!4T`0$0`'@9P-/@&W2<2G6-C;QT"+0%T.F!A#?E"AK@"VLD`$F]X4?D''^
M519,-A'D1Q#:\!LYU&<B@(AG"`-5L';NERCG<6NJ4W<;U75"U'8*XBR_HQ"F
M4`4:=%;_]PUKT'X`,5@%I5:H,O]B_%$VOO:#H8<>I&,:JK,=7:<)L>5A[J)!
M9+<1$!(>I1%2`!-2Z281BF1XUW-X5?8%+@AY,9B-VKA<,WAY;28&5W*#G%=+
M`Z1`Y)B#"^=YL*B+['@06E`%%9`#3*`6<W``.'"/59*/.H./]YA?5$(E!W``
M'V"/_YA?]S@'BQ8!'R`&,0`$UJ!G-M`!@D8#%-D`A98#D):1#4`#&MD`#(`#
M%0!^-:=L(&$=*(%8YT%#*W0M&U&`V&9]I_`$&2`"%RD#8A``6<A.=C1](F0J
MIO<!%WF%C)(;NP$ZH%,2%]4ZQ=`1S6%^$D<1%9)1(>4-+>"$W](ZQ/AP#&%W
MJ0,ZZC+_6*?1CD!(._+Q/,OP.?A"(?02#JJXE++&C.'Q@0XA;NN`E/27;O$&
M*(<W!2*WC7[YE_Z6/TSBC39H<`=W-.5HCHK90#I(9^LHEC[H#1,P`@*0`Q0P
M%G.``SS``_AHC_Q()?R(`T8P``/``!1)`UQ0`CR@FJ0Y``=9A`IY`!%@7FJ%
M`5TP!SEPFC3`!IX9D#@0D`S``$<@G,')!1RIFQ99:1H@<TLW%J8B*KPA#]9!
M%D``<ZF"<ZU13&D@`A9)D6$P:`=0`$7X+>B@-KYA=P[P/A%`D[G)!J<I:',P
ME#`9B;?7?+?"#V:$?QYG#;J'`:SWG\A4$?MP)%RY3V=%G@@E_W8[!G3GD2I:
M8$W2@5J028KM80[JY%I[YR[$0VM:0Y?L4A+9X(PP<2$.<$@:1#PDJ&4%,P6`
MV:(N2DK=R#\U"#2:)V>+>:,XBJ.=MR6..:%BB0P[4`65>9DV4(]>$)#VF*3W
MF*0'P`!->@"M:9H4R0:J6:6D:8\("01I\&>S*0R3B)NGR05-X`-_4:844`!,
MT`0#8)RH20,Y\`%SD`%U&$1?=Y77.1W6-W1%(AA/$W[39X<$883<F9MMNILY
M<``"X%]Y@QN3-3=2<@!@>)QLZJ8(^8AE`Q!/0)[[L$3,D$?$D`'A1G&W0I[$
M=%Q5L#A+Y(B?ZC+ZX%4*]0WB11[>1O]TI%J2YQ"!YNFCUP(/,'$.SY`.^)`<
MHI@0OW"BJ4-;S^`-V5!((8JLN1(2)UH2*2HBOY!(+/JBV.JB,;I4WQB.AIE=
M.1JNXJI`C6E5!?"8NKJ+([`#E&F999&9%\`#5,(#`S":G(D#5%"O`[":`^`%
M_7H`A#8`(C``5`"E^$@`RQD!7.J0J`(D&@`#@?9H;)"E_NF?E**2M+<#YF5C
M$9"98<`%QID#,H")R\8/2_(E*4!T0C1D%\46<Z!FH-F/X-@!;8%&I1`VH%(L
M!26HCZ:;4QIH(I!R3]1@TH&>P^`!8@"4.6"<7``"NID#E>ITI@,0&6`T7A(`
M[$&>(-AUYL7_#"E@-$P0MF([MF/;%L97@.#!JE40`9:G)1M0AU\W?67)%@S4
M`1I71AYP)-]&8,/PB.GZ<-GQ+O]R.R997-7@+(9K@"\A4H04>(=$>*8HC0E3
MK3#!HF_!<=F:N2^XK3,*CC7Z5.,:NJ++F#AX)@7@#W_K@WTKI.Z*`16@F4E*
MFO1ZI?F:KZM9`@,`I0S`!H/&``-P!*5YI8B:L`,9`?5Q#ET``R![F@*@`5W[
M#H&C3<W'#R\P`*C)!;P[?&71MQL@!H/V`996!YUH=^:5!DM2B4$9E)0F``7@
M7_<)0ABPGCV+FE1`!6[*!M\I`@40`XS25M"'`=69?NPYD2+`!!>P_Y$T\)T(
M61]-Y#L'407!%V@BRP8X@+5$5UQBEPHC4`"!%@9AX*;I.VB!=@"M!`-OD0:_
MH1(98!8%(,(BD`%]RTWUL"A:8`,;$``#3&D%L,*9E@)YX</&8"VI6W[4DD??
MD!W]X'489A'`0($=(2`?P5LCM4\B2'@GP"$KE675PPE?,%28J[E@S&^5EV;<
M6IA0-;IH/+KHB!>G.\0..(A)P+H4D`P5`*4E\)OT2J\@RP9<(,(2O+3N&89L
MT`"\FP-L,+L#T+Q:$`%.&@&E1A!5P`0^6P&96!J#>'T,1D,M4`$;^;%N6@!=
MH'NW)0:H:9%,T`41=G/($`4^T`1@Z,&"1O^&`]F;$9N1-,`#X@E@SM%6\6L$
M&7D$[=L$?.RT'DD`**P%;<!"!%'#:4``,H#`;YJH&\#)&PF?^S`"_,$B==`"
MVUP<&)`&UNN>#1"R`J!ZS9)D\R`X&%``/6N<%NEH&2EHD$:H7$`%-Z`FR7`3
M)U`,<X#`#7``*&QS>IAL)50%%O`#3CMH8N`!5:![58!&'L"CQ@`;;MRHUN%1
M&KH0(!J6?V00@14-X88N)(52Y78/[9;%>2DB0=$)77P_8?S2^S;&2H4#F$>C
M`91PY\A`":?3:3RZ3*!`8DNN:_Q`J%O1H0?'<FQ>K[N:O_F[]!J&ABIH86C(
M.;"[NQF&A"S5HTG_FHK,R++YR&8!`Y-<R?\KQ/%0"A/`R`C,D7.P#_I2!:3,
M!18)RJUV*-,;`:XLP@=0`6W1-&F2!G$1`'/0!`<0AAX<!B)``<L9/(9R#A'@
MRY#&`!%@A$QP`&&`U0V@OQH`!&$9J!LP)8,VR)6V`>\C`#UKS8S"B]L<=A7P
ML5*-D8>*D\[@1Z(S3<'0PAO)!0,@0#LM-#<S!R)0V(Z&<5A;HA"@&1G0S^Z,
M`QN@!0)M+?"`?C"``[DI:/H;`S90!W6Y?#[L`2D`2+F:NGB(Q!DE6?M";;9V
MBA^M&2?EH=6*4L\*;M$8;RV5$RO-Q;X$T_I-9C(MHS4-C@$D-+'4TP0>_Z[H
MR*/=5=1&S79(/:1:,`)U/`!W?`!Y7`*\F]6\6\B"YLZZF>$R8`2SV]6-#-8C
M``,3:9&4+"N(4F*@1D):`,X(+-<"P!XY!-<5F0-T;6IF$0'>2]4'P`01D(7^
M":`8H`&`7=F''0;A681U,"N]G)$,$``UK`$%@`.%S+M'P`0Q$#HYE`%U;,B#
MS`87$`%=4)VL6\U0FXD^MB+"\2T1<`"E/`!-P`"#5L[\M`ONI,ZXO9M-@,+>
M<)5JHH5&3@'U*,@6&;25O,\;``/0S-S.[2B%I6OO&`'.C)$-(`.)NM@,I0PX
M5ML@H8D^&K>=HT%V5]OF1I;+BAUU!PZ\50K]0O]XSQH24P#K]$T]*LTP+:TD
M^[WK@;DD9-RY02/@B5G@Q)ZC0QT`;;S@;=?@EOG@2^V:^CJ:%YZ;V`N&8+Z[
MAGS5?4R&FTFO%>"\7NW(K480)3Z1@I;B<D4X,*16BSP`N2W7;;UG12X"-T[7
MZ$(1."S5-KF(76N2)6D=59#O'DP#X:D!3\`+'[3(D/UHLHD,F9K<`)N;X]P$
MB\AG.*SA;PH#*`RW9^ZF--#6UO!C>O0^$DF1J+>>$\D`/O!M2^`:C7+;&,F[
M8J`!<W.5..9RZNF][FG(`I`!3^0,C,Z1.>#H+!(KI\$/H!W+5"">SCF20*;N
M[J#L>6-$'9T,YP8O=O3_Z='P(.(`C72YN,H!]M5:ZUILW[B>W[R>]J747:I$
MT]U:<#B-0`4>X.88X'9_]S==[*0K5<BNX,H.<<Q.`284X;CKN[Y;`O)LR,,9
MG,$I`PQ@G#LOAH[/`/0*!5`PXXL\XN,^#"9.:.BNXTX9HD-.`0RPUC)0`/XY
MB1=`D8*&^J'SS3TN:.4L7Z\X92`1*J>"*C80`97YL6P@`I,M'0J?D5\M.D_P
MV0<POV&@G%V0!I4M:+",`Q3P7PS<\1L)\MS`YI.CG33Y:!4<`W/0P0U``/JP
M(LIZ'GH>\SD@`D%L3I"E#`"\^R(P\$./M>*VZ!N9G,W]*:8`"%HC*7,?;#DY
M_S("$1HV&(\8"@X*E".0E)23DIB<G9Z?H)P.&"T;(Y,M+8^IIPXCK2U?II(.
MKIL;+2,;7RVNN:6IK`JOI1O&J<?!+4O,S<[-$-'2T2<N$"?87Q[;`=O>W^#A
MXN/DY>;GZ.G<`05S`@(B.#XQ!2)B[W-S,`4%,/[\_@(*'$@01KZ#"!,J7,@P
M7\&'$/_Q`SBQHL6+!5J$VLBQX\8U"I)4$9"#@J`*.'CP$#'`R``>`]BPH<&@
MA!$>-XVXY%&""Q<V7&SBU'ES0`4-6M(P.!"AE@(A"A[!0-2`!HT*530I6-.F
MC9"O8#/5&;M!0%6K#42DT;)F#88G&D14150`0RVW5?_FY&AP"$<$+6RYMJE5
MJ\XH#",D?54P04L$'`VXR,@A((93!8[E-JAZP$-B(9,01Q`@@P:7,&$8_+C1
M1*;,1(NJL,7DH$J%O30VS\DZ(I<"5J4P:)@C(TR#'!725/$@U^J`"%6@6@*9
MZ>NH`GL1B='@H$XP7;D,+^$5M0J%TE;9),>%H4J!S<=Q;-#R5/JC&`%P')(A
M`T>!-$`\(L@IHE#25B>$>:0@1ZRX@DM4#FI4B22Q]#()8:[XDHHLB.'2&RX-
MON(`,!N<,,4RP#RCHC/32(.--=B<H`TWZM1HXXTXYNA!`.QT4`$\\M!CCP`5
M.`101$CZT]"23#:4Y),"823_)482+FCEE0:&-%))B%5P0`DE#'``3#S)5!47
M`Z29)DP#,""350R0^=(!:0J`5`1+-44)5(A-A=95654R`E?UA>5`$D]@D$$!
M##00!@UA?%!`H!#&-5<.=46"@0V/14:###!4@=B!M"1A'6(A@=4&9E4P(8.9
M!P2P"681:+894UIXM9@#-L3`Q`%<0$H#4+D=QX9_&CPRZ*&@V;87?+MAX*$Q
MDJRQ0141'!`&%SG$&D,=,>AUEIU)9$*=8J!A@-UQ.6Q71V_(>*A`'=><D`L0
M,3071@Y^@>@>?/QN$,E3#FB!K0`'(-)M;,JVE9A6M"BP:B985JP)*J9HF%A4
M'>8R_TEO)\PZS,.9P-M"!@(+`TPPDKSRH2S*+*'`BL^TZ.*++L0XXXXZ]NSS
MSS7R6$`'[\0S#P5BW".`0_M`B623"'4@]=145\V0TT].J?5$55;L]4:)B402
M!5VF5`(.!]S$`P,_\14G3FN^U%.P0:ETTP5LVNE8GIKP.0(,9UDUAP8!:H$!
M8*,09I<C76@0@!@?3(;(`05LX("A56A&EZB6:%`!&V>)$(,C;:T*5EB8G`X5
MKVG8VJ[EE&2V&9Q_K7%Z5#8L)X8,@:/%0&R&I_Z5V&@=MUL5P<C2\@9ID(2:
M#'.DD4$+RQUP%E.)NS+"Q*>NBXB=I"1FS(<@"[&$O4!H8/\6I&S($($-NOR[
M60YJ0<)K%,0]2S\%HEYV[M<`9)!&-,0Q35'"0R/*F"<2)*A=P"P7D0!/+!+S
MBM_`;!<26L(R:+8$FU$C1B[(&3:FP+-N`.V$*$1A`%Y0@!\!Z6@`4!J1!J(/
M@LQA:@;)1P6*Y)`.P&"'0&0(#Z&6CZDQ#6L#88(2";*U*74M@%`<AI;&=I*4
M#`!M`SC"`'ZR%S8P0$UJ`A,#_E03+;8$!W6Z$]_V%)6_]2YZ:8BC'.68@0Q(
M+P+M0)C"%N8!V5QN5U40P_PP):I'I$$,5K%*94C'/=5QPI&84=]9Z)<!3<CN
M+`SX2R1.9XGVI*`"DT$-#;KU'V7_;:Q0Q"M>!4P!KU:VP'$)<PYT=E''.<QD
ME*M$%256=3E)J"L[[4J#*8HQ`D&4X@1U,)4&JZ`!`IRE?>_[31I@<(CC'"`-
M-@C0<@3``$2PX0#10PIAH((@#$71:ZCP6"LAQHF5^>83EZE$,8Y1!0*M#$0.
MPD4REC$S#G;0@S&JA@A-Q+,4&G0<*4AA"A;*T(2"8X4_%(`81"`""E@`:4F[
M1PT)LL.`;!2((`VI2$=*TI(B9(<W[$!"E$0UK%E$(DU\XCF_%K8MD6T$*.$)
M#E[EQ3>EIYLR>54.N)6#1-*D?7%2D][PA#TV]JEW#*"H5..A$Q$8`0?Q>-7L
MN`"""\PA_P#*R56AR*(Y0D+B,4;M0"$'QLY5;<R1EG#/+;OE`;O02C-P\H'A
M_F@=PB1A`_50V`4HT`C#M:5OUE%?(HTW3'46(UR'"`,;!H>\DVV@4[F)E0TX
M)C%T7>=9:5&.+L8'F-$FTP'C89Y9LN,^("B`>=0$';^PV:L"X&!8B:CH6K0P
MB=O!4V0S[8A32G&*=;*S9,!84"<Q:-F')1`9PWA0+$"4"IGYTX/UPEF,2'A0
MH#7TNPSU!GC#$=Z?O>`%$;T'!6(0`8F8<!P\BF]\,8)$B,RAI/C-[TAUN-%]
M]",@3>1:<*%84RKBU&P[E8F;?.*:;N:@?8?X"5!^@EL9,$`G,/]9ZAJ?4A[`
M)7);>Y3<'D?\8!J`P`A,B$`4DO4(OG9G`V6=%"0"\(%G!L`1`]M$'3"QJD?L
M*2R6L`&-T2*#%]BEF+6:'4WT&@F^SBH)Z8N`&'!0@?<%:%##N,SJ1E*\'(2J
M0J$9[6,0P84#I*`]IOB"'9EP"$0TP3*7T<IGJY*6*$@K%^.#A#*,4876`8PI
M'?J757+0A#@&0``?>-8!8`"=`0F/G`,&(,;L.4!;_#83QP6%LF"6@2^XC!+*
MB$7(2$3=#=8,&@`%X4"YV]T<@?>[XA@O0E_-T#K:VABXKH*NC9&!%`1@'Q&(
M`7L]D`*4%5(+0$@V$'!<A0W4L=:VCK;_K1?Z[(9&(`(+O?9"@R;?;GL[ON<]
M$A(#S`^91MI*!>823ND4IC9/IIJN4=AKN`6?03X8!U;4<%,YW!X8?!C$"IN,
MO4%;;Q-3000"*$`$TF`7<MK%4NR2,6(*@)X&R,`#H_"$82#!<7:N`<FWS0T;
M.G#D2](N>+WLA!`ZF0$/;,`PIWS%CF=5&P$L-@=ST*=O7-%G4)*9`*:H0[/Y
MG*U$Y(`!`:A%CF7F2^PD4G3-CFN>7[R+#=B`4T=@%QL$($SV!`!@1O`!$R"#
M"`8,5C9M^1\#,7&)<POW-QMH&7'C^5N2*9<4LJ@Z;4SV!5Y4R&3!.(&*((!J
MFP5TH`1MM:ME_[V-AL::UIWN.ZY!Y#(!3<``F$]``G2@@P088`*HW8"O/:`!
M#42@&RG`A18N;P#.ZP#SH!]!KQM/[5M/WO:3S[WN<Z_KWO=^!+ZO)_"%/_S>
M[S[WT][V?P$,4R>ZW6OI-LF!!Q`FH;H)M`^6-YEQ@Y9#M(]-`]"WGCCL"C\E
M$IPT+,@.*7J`R5CE40<00``L%QKAE)4):YT*:BR.\1RSG>,-XPEN`01HE1O(
M85<F1Q,1X&-R9FD<,T[U@6D51!M<9E2YY""O\`@TYDU48`&OI0I1UVRD\2@T
M(`9?0'>9\$N#)@(1D#'$("_O4@JBD@8$L!?<XA?-=@*?U45<0`6\`_\487`!
MHX,8V],)+09ISV<EI;`)#7(Q;W=*&W%DR!`+LK`QQ/!`GC8R@(<-IM9!A3<-
M`250VU50BD<.KT9[M$9M:M9IN/8=G607&#(!H">'K/=YF-=ZKI>'!B!6SK8-
MC7-Z'C`]:[!ZER<%.B`%4O!YHT!+>=>&\7)\;9A[;N@RE%B)KY!V;0$8FJB)
M=-B)GOB)F@@$59`!OR814>)\27@ET=<E[-9^!\``1_`:?,$%#%"+ME@3;C(3
M0&&+:9-O:K1OJ_,WB)`;-,!US=9L&E!9J6!\&Q`#:8!'`@`"1I4#'P`#EM,&
MQ10%%S!(^`<)4]$VG3$6&],56^$6'(>)F.#_,D_P&#XQ+`(0*!B09->S@$VV
M2Y=@&(BE.J`Q"FJG6&<1!J%2"[K`"[5Q&\/X`U$@!#*R5KH6``D3+`.0='*V
M.BIX"&J1"J"F#(=23*^0!A7``(\B68-C`]Y!/=AQ2P-``%3PCR+01TZ1<FUP
M"4B8BATQ=Q\8,3@9"IH`A5'X(1LB"R=`,E687)]V3*G`A=#PA3<#0@%%0O%5
MAK/V7=&F>]0S`G4`@+SE`)^XE;"WE868AWDH!1/0%:60`>^C`;Z6`IZV!CL@
MAX9XB(GX>:3@B*%6E_'""I;H,A]GB0Z#B7ZY`X#)EH`YF(0)F!-0F'38EIV8
M;#:P`:6X?/Z%BC1I_R5"T`)C\P@YU1(O\1)'<'TUH38XP1,\X1-#)10Z<0%J
M@Q5:D`(;YC?F)SA9`8`8,IM*UVP>P$W;@AH#D'.&HP4:L(WS@W\?\YH7YV/G
MPG$3^`F#@@%`D`$X$"Q\\8[O$H^VT@`,4%?U6`G^IW*>T`J8L`0U5RPY$`:K
M1"&YEBWO]P%]A&?78DIIT`2>$@;OZ&.<T![K8I$:\`3*N%Q5\`2YDP:'-D:#
MU@09@`')I$&`16<YP`//N#O;`@(XP`2$TUN[HBR3Z1'P(G<2DFGPQ*%@$UV_
MH$^ST`(GPC+]U`PMP(4QPB+9M92'UY0E!)4-Q8:3]QVR&8=>F:,Z^HEW^/^6
M8"F6#M`&99D"-F!Z`:"6@]*6!H"(<`E["427=FF7>9F7?DF)?IEVA9FE.ZJC
M!A`@&8!>$?%2YG:AH5"98Y,[7D)]/#`F+\$`I5$5205&7P22J$&+X*<F\3<?
M*?`!^T8)_694@*(5VPD*AZ(H'2"@Z1$`A^.;VVB`^%<)%)=(%T<Z#F.@XOAH
ME+!C@_)QCA%R#X85W4&=]99)#/A_6$*?M5`6XGD5C;4$[9$&<_"/`C`]IM`>
MJ0`)51``1V`:D;*`0>H5N.,>WD0_$5!'VU!'<>10`=`!(L`VB70$<]""+;`8
MN@`X\S,`RI$!,/`!VV(:3>"K0-9)/'FA<K9.&>K_H0,V(A*R`25Z#!K4A2L2
MAH+WKBF*#2ZJ:F/8:L4F>=]!"[.YI0`;L%RZI&#)>8J(C<Z6`;G3<DBJE5_9
MI(HX6G7I,E&:"U,ZI5>:L8*Y`QA"F`*;HSNP!AZ0)!4!`V-*II^0!);9`&2#
M`3FU$CCA!5Y0`LY:-VJB$IHI5#+0$J&I$U[``ZK)FGW:88"Z2H(ZJ)KF`'Z&
M%I3!<,(A2,%9!9@P9,&2`S?69!/CIZ,RKKOT<9QR`.DA`W5Q&/*X&:2:G9QU
MJI*0!$K;!(E45+LQ`@3I``0(ME;!%!BT,3("GH8D`-Y'&3&P20XGK.-I&BN!
M-OB&-@>`-C*0:.P"&P&0_P%#5VGR<QS/874;``-V&Q^3\@1]4RX=T7;GAC$:
MZIV3J:Z_`#-3L`'ORG3^%(8;E`K1D*+9%88AE*\'E7K.A:-R6`L?^[O`BWD^
MJH>@MP.Z4$=%RK">YK`$"[&QMT^3.+$7.[T:>Z6#V;&#";Q;J05?BB0E>[(H
MVPDJ:Q8WE:9'@$5I0F&F\44WJR8.5G9J<T4X*P!ZNF%^*HP6"#O:J2`C,`&>
M$SCTX[0:`+7'(9R2X`%@"YTP8*%&N+6@T`9>.V2CU!EV\0AE:YWT*#+TJ8J'
ML@2Z8'.#1@.A\ANYH)]Z08S@\R`CPH6QHRZ)Q@9A$"MV-;C84530B0B24V^>
M8O\L!]`$_\%G$=)TL],MRG$MCKF2[=,?E3/#IA*Z&YRNK^6"34BF!/0RU,5T
M)[HB]1I0-5.[MKMJK;:\ODN'M$F;VGO&7-F\8*F(._`;=50#&L"PIJ"8S8N(
M3BJQH4:)RC"]U%N]?PF8V)N]:$R'(S"RW@L0X!N^43%%+,N*6;13DR%4\N8F
M_,$?$/9@[;.XFHQO&38?3#5^?%(%KPDHY3*3'K$#-K`ND,(O"RAT@N2H65$+
MSEE4N;%*3[!+J$.)NE0H?BK*Z,$O*4`@EV2V&7RT%;,QN5"!HR3"@2*##HD;
M#$!8:+9K5>`=UU(%-M`\,#Q*A4:AS:+*/E$"5+"X:!3_1MU$@I23+,7@2\Z6
MS.\Q%]>D!7QV,"`))P0`'0.S&(_4P$@+1;Z@0$W(M>>&S-)UE/8B4Z\+N]`@
MKX<'QKG;"F5,&)_HL(-<T<);L*]7O!:4`?HIQ_U;B&]IQQ'K3A9;B9/(QWSI
MQUAZO82!F!4]`1B0`B2+R(H<A1@@-BQ;152`$P[V;J^1?:ZQ'TG,'P<0#_&`
M;S^KFI_<-QV&&U6!%:5LRAO1%>H".J;!RG:1.0HZ*811%MS7DG:E*]2*G)AJ
M2&+P8'R12[%SP6>KP?W,$1B@01[\GF]+`[OQ,;)'$F_"`$PP7Q/!(^C%0NQP
MUF];%Z<S9Z9!!11P>M=F`=?F_P,4P`0#L']BRQM<V"$E0CT!H#_7=(S'J`&,
MLEB4DQ5-S)WU^<3G-&D1T@H"'6D3"!XDW+K6Q0R4X$_GLUWV>J\-C;LI=(*@
MIY5E_-+"S:-J3+P.T,:QD`$U,(J!N`%K((=+&M)Q&7LG;8EXB=)4JM)9&L@>
M.\C<"YD/0=,UK6F,+'THH::G81I&13>F<1KN+5FGX45RPB;Q]XN@W$93H3]0
MC3H*4@O_:Q7<4C^U(0),.RD3X\+/`CVR\6.Y+).HLRD48#U[$2M:,<P87*I:
M>\S\E->K:K0QB0$.V:W#TGZ6+&]MYDW%(>(-(`9I0*&?E4B%1@H0]`C-1HIC
MA`C^`?\[*5H,<RFLF_%-*&,*QD#C$=`:='8`3,!PZ&JJ`V:N4PQ<27A*&)E<
MGM`,61RO\OI!#"V&(_30+<VQ6VG&PXW&%UVP;+S1HMAR*//<$X"(TBV6U'W=
MV'VQ:6>E*KVQ+%T+6:J8:/P$@#73)CO>H/`*.-VR:5H"7L`VM.@3C!XLZJW>
MNG@:7Y030R$FJ^08!]"GEB",174<H,IA"S2;HA"/D/&VR?$(,,:T^#<8"O`$
M&7#65*$6-D`?^BAG/Y8)O5*#N%49%<[6Q<SD5K+"K*"J@[1*$+0!MY&;H[1'
M.LPN]6;#1$8!A@$6(^!TW)PLO9&!JV`,!5`"V8<#UKAI<1?_":7PSA,<S*.E
M=(8T!];S/"(0`+)!A+31"<F))1RZA!HCD':'LBJ303-3V[1MV[<=AF`HK[?;
MY=WP7CYS@GK.L1P;T10]YF1>W*YWL+VA9LE;;"W`YM'->2(=YR4]YW1>YYMZ
MYWC.TGO.Y\`+!'].LH$NZ-UY"B/1R"[[`24`!3S1F32;2+38F;5X!#3+-C4!
M)EHTIV&2Z;D4`6*B)_;!Z0:8<UKQ/QLA!+F.'KDA`_!>3*F^[(]Z(>H2R</"
M!$.(`?I(3K[%G*#MZ-\4`%W`1L-,$]CIUJ=Z\3I8@7.1<WSF`=RJFTU``'ZO
M!$K@]X+?]X)/`(3/`PK:!)8#%G7@_W3?DQ5?8>6U_4H%T'XX7``L5B)+`!6E
M`#C9<4W@<0IL*S$.`%@X4+@-<`32C*K'U=IO-S*8$"+R`O,8HQ$8^>]5+O!A
M.`4GH.4&#\9/Z3/=0'^$>=Q[+O'"7>9K+(<A>S(*&\?%5DS0S:1PF8@@+_+8
MO9<E;_(I[_#'#[)>6?K+UU\#T0^)'+XB4@7P6;YCP@,_2P5ILJM6`?0[O=,\
M8/\O800[O9ED`@@\.#@555H1!P<1#@I"0B,8(S`Y.30--'-5#AB;&&L*H*&B
M#HP*&0(RE5QL.1=I&%I:&Q<T-)1,5:$.=6FH;%PT1W-I-IREC:*C-AL%.`UL
M-#(P,74*;?]""H<B#=PT#!X8&`K'X<GFYPH82RTG(U4"M;9AF1L;O91A7$QI
M&AII%C'X]?,GL%^:-,S8-.`2YD.`7*`P%*AD2XR&4NM:C`#EH$65&!UDR&!U
MH,`K#.PR5BG`K4&.`QE::-SHB".&#0'$`*/!Y@B,5\7$;41']-R(HZ$V,FJQ
M882#$3*=%IU*E>I0!3);8-V@=8FY)6##BA5[HNR4LF4AG/B"]@0$""[BHIWB
M(8!=#WCSZMW+-V\`#QM([1@L>+#A'1,2*U[,N+'CQY`A&S`@18?ERSH,)-ZQ
MAND&&U4R>(BY)C'ERCJDJ-;\%.K,H[!CRYZ]IO;LH[5SZ]Z]YK#_;U(.?!M^
MC)AQ\0TO8"B',6>Y\^5:JTJ?3G1CD@U-&E!`V0''``:)#AP9<`1:K9Y'Q(\O
M07Z`^P$'VL>'?T"`(42*&-7$4&52I4O#\%?%@%7<YMD&*00``PYLA&&)2R)$
M`$LL&XA0RRU5B&-3!A7(0,,J,EQ`00P9`E=3&Z1,X$`5&T0@``.4<#/'9W74
ME$T$1K3D#3CBD*,A=>DXL$0[[SR80P,5;#!@`*E0<L!#_"G)(B20W+1!)!K)
ME$83'W*1@PAID)+.1/$TH4$Y1S$%B0(;;9!!`0=`X](<,80S)%<K=</&!RD@
M)8HCV#A@0PQ,'-"-#&)X<&:!5P&)SD9*_[DVCFM2.6KI5!M%-617R8SEZ5AF
ML676%*2V599<9M5U5U^LMNI!"X(!%YQO*CH0V:VXYMK89*AAEMEF6VT`1&BC
MC5#:!)1=IIH4B;7VVFW0QJ8;;FO(QMNUO0EGV*Q::.M8<8L=EYQR<S3WG'/1
M7:IN=0Y<E]UV(W27R"#T'C!2#C(P0"\.!WC'PP&"[-MOO?55`40&!WRP2"/8
M1.)?/"+,4<!R3)C[W!P5"""&"!_DP$:3^(HA8235:F"A+3G@\F,Z&)S""BOX
M-A%`!`@-*""+,410P!P,4O)2@-78>$B.+7U3CH^62K7$"!O`8PDE28(VA\]L
M"-!4/552R@A4]?^DRXR'M<A0@%02'<E-$U%$DA171RU5#YPMR<#$9QWAR=(E
M>V;PXS'(C'-3`")XG`H.!<00U,I`#B6F+EM-BO7BZT8N2E0*<*6`5Z%\JCE9
M:'TA*A%GM87J"739]9>KJ.>5`JRR%K9MZ[K&+CMCO/J:FF83[!#LL&FD\,4(
M6B2FFK*J-1LM;,_>9AMMTF*[F[:'90L]N)LU)JYSY9Y+;KJ2=^]4$E40D'(D
M%7QPQ`>#))QP*B)]D(C[\*L?WOOT)VSU(?HN<@V;#E,2SS-4>YK/!M@2E^"+
M%3(0@4DX88V2G0Q##`Q%.`B%`Y^YY`@X$$$3"-"<BA&@"2*PUP!E(`#_*$7"
M`8"Z$=&X8;0>21!QTE$**+94"P-&#1$MP8&$1G""IJP!`TD@E5?J0,1Z$#$)
M=6C1-H#!!AQDH!-W.UO:/C$IIC4E*570`!-D<`E\=:!.'?$(2RKQDBOIH@W)
M:(T6JN"B5"!P&$$9!S8<I91C/.5QE=,(*?S4O<0E0U(R`8LH-D?(=:SE<T0`
MG>A<,!=5G2YUJ%M=ZPJCF$G.[I*QJYVOI(`[W7EF6`AJ2O`F,#S+K,9XQZ-4
M*JU5+58ZKS;3&TQN8@FNP2@&,==C3KDL=C'N]7%=-*E#`1(8F`@$H`"F2Z8R
ME\E,TZG*`Q2@@(0V,`D!A`D95)I$/,Y#$0<]_ZB`X.0&&_0E@`)$0!,HW(_)
M:IBR$HD"$D\(#<\8P`8YM<1C]=SF)61P``5>$2F`:AB."LB`D8WCA4D;!R.:
M]DTDV4,`1ZH%`=*@A<N=8"8RZ:%66LF52"AI`U.KA9<*D"&)%-`B:[B&$!@1
M1K#LD6EIF`,#:!"&AE3@%5R#P3UQ8,:#)F4VX=A`!0;P($2=LT!RG..EAJ*F
MI>BQ-;],6J,"F97+#;*087E+6-82NBDD,I%I&5WI5@5)5_5IDK.JE255A,FV
M/D:3F.$DL#[)H@PT13&E3(U<5;3*J*P2-JTTUK1>"<M8SI*6FZEE[A*#''+M
M4GO,\654$RJ$)R`B!_\P:($-GF`#&\1B$T]XPH2T$([2UB$<I(U%:4F[B5AT
MH0;%",`!<E``&_A($OCD`@AL\0LN^'85]0QN<,=C!`+<0)I1Z$(Q&%83!ZR3
M)VQ0&=^.TJ,JI($"/Z`",,)YB5J`8`!&8$($8M"%)#BB-@R3X$"/]!(>^91E
MZBI%%2IP'E;,2+8>H\$!*'`F%*ZC:XX3+-?J<:41X(@&(.!"`T2@-QM,I)XY
M$,,&K(&-)<QQ'4LS%DS3P(0<U!1?,VI#"]*@4TK(@*=[/&AI2VLL-()B"04H
MP<M.3-*AI#!QE&JJ%:7"Q\DN54T9L>J+L0H6=IP`+*0;%:F(D`*PGD"LCBS_
M:R2=LE:UPHZM;LVR8N"JK$YVIAZ@"<V5\-JK4_(UE5GY*VT(RYOH24^6A8UE
M8F^YV`DT5I>//=<<).MC2ZTH`#CX0`DM<)!"%]H"%H@`S3)$Y=(:^M&'3O0<
M$@8#O2&.:2G(M*8WS>E.IR`#=E52E<+1J%"T(`.;OF)1-F'%%.`E`.."00&0
MZ8%/*RD<D$/'J3G=E%Q[#].JR\`(1%/K6MNU!9&`Q`9^IR&FS*0.GLF*FS1=
MZRO=9-,Q(4J1L^815./%U8!A"K%JG>D6H(@Z0I@VMGM,G:P1^`O_9%N??[D$
MRP62R)Z"@)'+XKE^?V$*GLOTO]L"<"F759)H3;BM_[3,\,4D*Z[%FX!'X3TL
M1HV2E*4TLP.F=;RL^#5:;&:S8>(,O5D))['%L24S'/O8/$=VWI%SP!.882\9
MN$\]1\@Y`QCP@9Z+(041_*%0;PZ>^<TO%1^H0)U(K0N^)5RA"I>54>IH5:F_
M=]63).**<3W)Z2RN#HNC8N1@8ZLP.B79>G1-1TG-MJ-PY:)UL**S+<Q2,0$'
M%"M%D:^3X5>T1R4<+,J2Y:S.IJHX0E9ZAZI4K7BUINP8YK^T-U?PG6]]SR7@
M_P;X%WPG*E*1RN"01'C4@=/PTF^Y5\1+3+*O9``,``%W9$:-F3G#<6AY_.-K
M#ODKVP!G6KKN,"B?\\KQO/]+E^\9\NMR@"P"4(%`WSP\\.OY!WX.]HA@(`8"
MD+[VM]^O$I)WQ:"HQBC$M'486I\Z=BQ%J:L2&[!WHK2C<%3K?(P45LN$U%S;
M<=^Q)!-[]U\C`#9^H+`17C%'=T<4SD9E3`-O9^<F_>=X"B6`5*%43<=NT^%1
M7($UT89\O\0.H"`3ET-Y6:550W)(OJ-Y_G86I4(7KP9ZK")ZH[=PIM=P#[=)
M$T!:$Y(`$E`#"?``J6$:IV%*>T5[N1$MMX=[RJ-[V,)[;5`;O#<]OS<<N6-+
M4VAG$T-\Q6<QQ\>!EK(&G6`/BA:&8AB&M:8)/Q4:$>`!8[B&&4!>H+$F10$M
M4Q?_&UQX#BQ&A\"$.?$75;"!);W&)IXA%2WP!3,!B/`&'(.8@1IA#CW&-]*1
M9@/85"Q2!0F8;.:P=^>`#5=Q@'YV(`0&@(18AY*3$EC1%2((%F^!%FI!.IO7
M;Y[G5:3"%G3Q`G7A@GT!@Z,W@Z57@W%U@UI@``\@`2PP`V,@C"S@@YH1A'KE
M9;4W&T>8/$FHA+O!>[GQA+%D<E*8C8@Q?%F8A=LCBE5!1*&0&^57CB13C6V0
MCC8!"^:X8D^14NH(CNC@B&,'*?%%C\CW%(&X-92S@&S#C^ER>U=W#I##B?,(
MB(M("@<"@'^(C^C&$7U$8*`&@`S)9_+(?O9V9*>(BJMH_RH`QWFO"#HKZ`$O
M0%:VJ#JL$X,RJ(M9QHN7D8PZ.`,R.0,](`$RR0)GH`.OEW%#V(S.>(2K)(W7
MTH2'Y7N4%'Q5.'Q8Z(U;>)%5\0D:@7]701MLDE+6@$;4A1M]R$=^(G:2LW[R
M%U6$YV>8V&=\8SE0P35,\3M^96J*J``7]6)`XI`"F!%>L5"$^'@RQ!%ER8$9
M40\3^8!557A.21T@:)<;F8JJ>'E?())+1G`D:9(G66LI&8,LR7`N:4H&H(/#
M.),]D``L$)HXF0":-'L^*1O2EF9!*93.8XW7F%9(J7)7N)3%]W*%B0[JZ&+3
M`1O)H)L*D%)6"23B-UDV8G@4&/]S="D=?3EO8F(YIN8YK),58K*67,$4$DB!
MQXEN%=:/U1D5CE@*R3D5Q9D,0N";NG8@=@45H58/!P66MZEK<5D6&[D$;U&?
M]JD67N68H=-()?E(DTF9*IDBE]F2J-=E.A":,R":8P`$QHB3MR-[/5F$1OA_
M2`@MK-F:K@F%5#B%*;>-5]B-M6F;[SD5OB8$@O2!`\B;>"<$2&2/G\`WV)"=
M"E5]`YF)2A6>1:&'@Q0*:$1%#GD,G:&CG2(=>EB`[484BT./X#F8F;(!2[`4
M90$K6Y$EDF6!?\1^-.$(2^-LTC9AN]EC,BJ7CGB753&(3&%7=94!\`:"(PHD
M]O8%\UG_G_39D7.1GZ72.;,HF5+FGPBW`P%Z90.:*Y-A.YFA`V>0H*(I`0E@
M`PEP!H[JJ#I`2LM82:>)FJJYFD5XH=-(2[3"H8GE`"M7?!4`HN5BD6V:#.(7
M4,7)".77"$A$1!UAHWT3@7<)=FC2E\=))34J'6B$1NHG8+O*)D/AE2,@I(R#
MI%)%F'%(%1B(?UPJ;0.6?^?@E<?9!C96%-7"7`.X;&]YB1`)D8$5"C92"C]B
MK)@"D4U*8(#I.:IVJNQ7BA85I_=I*G.A2*'R;Y$YF7S*.G[ZIZ07J()J`(0Z
M`0<JFHZJJ(SJJ'\`J9)J9BJR/-#RB9=JH0(F6)KZ/-J2H1L*_WR$$:KE4@&C
MVHTB>JKB2)#'D$);HZM/`0HN!G8C$(\\VG2Y]E)9HZ*^)B9;Z9YVJ*+I^*(C
M$'<"9GY$1%V_*7;JQ[)/,;0IZ@`N-A25<HEV)*Q961V<4'^$^:01X7;(YA3^
MR&/<RB*W5@[(`']V*+9;PSC450Y*)2#JJJOCIR%^DK8ER[+62FJ6"(WP):R,
MF"D,Z"9<D9?NNINEV`*&E)CV2:^(2SJ*E*?ZJA=]ZJ__"K"W,JBV0[!G@)./
M^@`)4`5PH`-_\+DYV;![];`0&QN"B807BZ$]6XV#D8Z^P;J=RK%^R@PABS&U
M6YM-2;)$-)RZT#;IE`S&D&+J2`KB0/][/)J.!=F>NN".$92\_/-^4SN/OML:
M7N%BK1%WGE`ERAI^&#"T@J6W+BNLG4"SYX:BA<>)=L<WI^6.5%NU[J>WUM>L
M6[-LT3$"\"8@&'`X>,<R8JN;K":V\9>VX3"N*S:)X6!N+RHK<'MV*_:^+[1B
MU/4$L,HT9[<1:K,V##E@[*H5RQFX28$54;H6IHAOBIFX=UJO*IBO)[FOL0*Y
M*RFY;R6PE6NH"OL'.I``PP($EO&Y-HPLD]HL/NEQTD(M(B<<J<NIP(>4O6&%
M(0NR($NJINJNNS!N>'$"K!H.J)9JI[4BJ%92'B5LUK<!Y)9IPD8*")("$4!M
M97P4GA,I/[O_"<16;>QR6F)L;5IIK9^VOD<!:BJ:#G60:8R&%'L,=,GF=I\6
M"9S0`KX#"0H);A[P.TBAR/_D%"P";L(&EIL0&IE6AM6W$5^0`012R6LL>=VF
MAF'X::2`(AJ0:8&!J@@2`1/F%`AB:54B&C'0")2<`6)8,P#,Q2E08`+L#VE<
M;J#P0_RA:*",6AJ`S.H:`UXZ%'[XB1W!KO`6K!Y\#AYW2"-,9"5\N&7A9&VQ
MN"ILBRP<'"[\PC"\*S(<5UH@!35L&3AL,+W2PZ<QNAM7J3,AH1:[>\*1CO[L
MNMKBA$V(Q)WJJ1.PQ!YKN[=;?%'<INZ0`LLQ:R^0`7[#'QT@!K(&_P,O8&W\
MD1,PP-',%QB04`4>70`O4`"O0@H9\`+)(0;E!`.`P0G4-#:[0$2*#`,5@$S(
M1-$K^U/(`P,`4`#`G!M?4`$B4U)"-3:SD0)&3<AQFQQV['8O(`#"]C<50,@M
MHQRS5@"K8\'4]`):<10DG=.S]BKFYPZG4`&PAM,IL+X*D`*)4EHN8D(#!H"`
MDT$B(`)B`-8HA`$1H-<IP#?A$`%B@`,>8*UU$```0-6(3$V$`"N0D`$\(P(7
M<`%Z70$2\J)_+```X`%4$E0!(`!Y+0:D'0`#>,PBD$'@(`O-AP-4C2!VT=4,
MY(^!J';R=LV/.'E8P1:&JQ;>?`)$8"K!'?\JC+O"CLNOYYS.D4&Y[&P`[WS#
MP]+.ET'/RP)[]ZS/U!(+RBVYQS$Q'^O$"UVJ'@RS[E``&$TB8-L"K<0?`@`#
M)=4V@%<`Z$-2Q=`,>N,.*_%S!,*;4'%](I`D-J-L8E`!/TM$)(W1EC:)?2RU
MD`#7&B,A<5<M+0,`TR<ARS#@5!(;,$#:[EW(W6O441T.<-WA.6%")`T`&=`%
M-_$:-U$!F?44?AW450`:[?I'+2,"[FT#&0``[LW(+:`Q:7`P()N>!]RW+5)!
MF&U,8)P./M!>*\L(=6!9'>,!.]"]P^1$_,'>$188X=`+#2!>/M`,7Q(`GQ#E
M$0``,A``HY8!"W+_`#FM*BE@?5T0`":6"3;@`1^0"F!2!1`-TX[W%/#VR0R)
MEAQ<K-:,VU-J41?5V_,*W*?RS?8*<,5-SL?=PI"[W3%L.U+PBX]JP]"=(>OL
M@\%3W93:C+6ASIC.DEKP)KH$WN&=N]?<,AAM,*AUA^SMWHP2&Q)13@(0`9UE
MWI;&'^9-##9SP>.P`1C=66G9XAU0!:=5!QDPX`;CQ9;X4Z4U7Q7`(15P$7T8
M[3#0`3>U#`(P![(1&F)@%P+@U-0%`_91R%3B`2*#?4F2Y1@`:.?4!:+5[>V]
MM0Z0`@#P1?G+=.:`Q6)`W]%.4I;H[?FM-_50(%W3\!$P"#[0#QG"LAC0_^0Z
M9(F08`,1T'-4GK\3@0-+QQ\5D`--(-(W`5$%H`&P]=<1IA7Y>^9IOF(!X#XK
MWP4:T`4#`BG"_B6#$`$:L"#9%R&A<1<3%@F;!VKI.8BA:+*(_A7.MMN++H+W
M^=L>:1:D(^GC[(+E3!BM<Q@"*J!SENK(LL[*PNEG\+GP'-VAK@.C[K#7#;$<
MEZF[0<2I*XVQ\&:R0DLCT.<?^]T@VM#R*'8_"VAZ,R!*OW3`\PXB8!>T6&!K
M8`/L'@,PT`01T`4%@.*LNA(\?DP!H#=VA.P=@";IH`$@6P75<N<'``X9;J6C
ME@814@.RM0BML089T/B],`<:$`5*T`%8"0E!+_\`4:`!L]X%?<CNP+P1+L;N
M&'/?&D9-_SU>*FXL*0\#5")B@%-":1#(/08),2`")50`X&\X5X$!'M#>`L#Z
MC$>):L+Q."`#35``3%``H,_D_"0A6F"Q?OT!WP`(;1@:!0TX:1@*;1MS.48;
M:VL8&P(Y!5556H0R.%])&!@1.#D!=0H*&Q4-`E]::0$%%`$M#FT.57,-<P(R
M%!8X(@4,!Q$8:QG(&R.3*<@9+54;&]$MI];7V-G:V]S=W2,.(RW@(QLGU4LG
MYPI+[>[O[Q#R\_(G$$L04U_JZE-3_"?T[9OBX44`#QX"'$3(L*%#AP=3;'!`
MT1;%BSLR:M3"4<N$"1K_0WX<"9*DR9,C=WSD^%'E20,&=,B<J6."@3]G_OR1
MF0!()BDT:QJ00I3DCDB13K6(U&;-B!%50$$=X?2I5:>1GB+=RK6K5Z\=.ZYI
M0_8B19$?UW@<X0$&C#EP*\"=2W=.-6]X\^I5X,!:G1$O`&0`M:%M!1B#1VBI
M(D",P@(!HHYH8P.&``UI!(AX)5C!,@P%<,!0&"##B&L.-HCI`$K!&@6#!%2H
M(@E#`&(8K%H]==HS[&55`@1[=:!`G7!4,X@($`I'`0U-8+3AC2&-"`$1(C3.
M\.0I*!ABINT^)43#!1'%$KE>MB%"`0'8M4XZ7"4<["H9`E1PO"%W;VO+Q'"=
M_T*[1);;$K"!YEPF3[4@S08MC(.!#:+D@(,8UWE`RR<^R$",#:!4%<H!'WAP
MBPV%'-(7*G.PT00D[%7RG`::%,#)%`Y,6&$I?%&RR@8VI#$'%19FX(`0M\#0
M0`$%?$!``0<P$0$#'S`G21V3/)C,@U\\>-=>8(8)YE.>.=A".NK`HZ::]+29
MCC\`G4`$$0#Y\P]!!B&DT$-\\KG01!4Y,(%9(&6T$DMA)=K1!(NBA!),(\$$
MJ4<OQ1244#CIQ)-/6@!%DTTZ%)725M<@54X:J*;ZX*JL:MGJJ[#&BJH&F8S5
M1D9F.:#12&I-P)9;<\E5%UU?BFDLF`[4X0$`'DP83?\&EFV@!7`"P*"!#5%)
MM0,&EG5!H0AS@!<#=06(D4$7752QS'^I`<#::4[=<L=LDE"(`W/^@9,-@KG-
M!RX,!5PWD589`,`<(4T$0``,"@BQ!"@!X%`M#!7<JZY5X&5+D35"=%&!`/W]
M]QFV&8A1P1?>40)#?4_E:(,-&\#`K'_98!"#&)?8H$$'8J2P,6Q`>(!#!"!Z
M%PV$5($2P0<?%)!&!!EL0!X&'0[]!`9/Y!C5C@X\T043.6RV8BHY7+!!&P&*
M8<FU058B!@2PV4N**;?D@H,'-G21AHT'I'#<)+F4AL,!(@R=Q@<'!`!ALN)\
MT4PR4&60PA==%GOLY<?>)0[_A.V<\,5=:X;>9IN>V\./G7?:V4]!"^W9Y^L.
M?<'718-29)0#6@CJD:(CL>2HHQT]\000'$TX(4PL&1"II4'9=$9..^G0TT_-
MQR1J2UO!&\E1&P3@UO<P,,%$!W.(+SY<3(0?OOD=A-_!^_"_/RS\<Y$?[EMP
M*1Z21FOLG]):A@F6L(9E%\P9D!M/.0XEQ."!J(`H`.$)!P88`P-O204#?>&6
M&+*E'0"8*X.@$4,,A'<U,C6L71TXSGH44`63T88]^XG,<<BT(G;PQC,0E`@F
M(K`<<BS"8,`)#0XJ<(HE."`#U9I&-,"3&*A81C+C86$'0'8@`"T#6_M)S"2J
M18YP_VS`6P80Q0L2\1]K8$`Y!7!6P'SV&L]@8%G%H,IK&E0-[RSM`T0#46ZJ
M034/%2`"*6B&=V)0@1Q4(`4QX"$;5G:*)%1!%6:#31U*E@,FQ.`58I"!"#P@
MA`3MR!2P28$(9&"P-$2A23@8C"`RTX#(5$`&,JC`TW!0I7*T`$LMZ%(SJN`@
M:41M'`<,9N:0%J%S((@=H6,3Z?KQ#P@P$W6H.QWK]+00V%DS`[.SW4=T-1+<
M:4%X+P,"$%X&B@EBXIP/2I4ZL\/.A)#F,4P:S0:09Q*87$HHS].4]#CEJ9F`
MZGH@(95K(A$.#X@!!PA-J$('=X#!)50$A4-H0R6*4(@N-/^B%8VH12LJT4UB
M0"-DV1Y:"N6K`,ZA`B@E(%PL)TS,]26!DP3/:!0BFY!-4```@`QD,@#*.CQQ
M!-B*V`?O\P+1P.(@4K-&:L0`@]XX!145Z("$0)&!_8S&G=A<43M.D1J4.G""
M'Y,=5;Y@L`D&Z94P.*8"#)H"4(!H60'X3!5DQJ0`O$!#I\#2?NI31`6TH"V/
M86H+_%.RIO8K!0!3"$J;B(VG*,<QL$AB(A"T#*%Y`)33P893FE,E3)A0"'6@
M`"P!0%H`P*`_&.B"*#[@P<%58#!]20+91""U9*F&$Q@:G!B*T4E0>&"4`3C2
M?0(@`*;AX`*C$$$,^L7*N`K1:4+_DT%<*0>.7F[@EY*37,A:RMV\F*E,)SAF
M,D5'C]/YHQ[1#`@1_F'>:;K3FO#-*NT$Q<UN;B"0$"$-D_;KE@X("Z4?@X^`
M&R.&`AO8P")@8*>41Q)[7LIYT-L4]3YE/2DP.*!("6DDM+"!P``#HB`.L8A%
M0#B(GN?#($;Q>4;,8H@6^`)-@&@!1K`_7.TJ)2IYXV'B`N!@$:N[!WSI".I`
MY,*\X'LO2(%N@G.8[YG&&@GIUP1?\(*)_"8%37;+"[[0E[MTV`-D:F/W-.24
M<:3&>VZIP)9OJ%8%?.&N1GOCFD\1,R5#!0.(]4##V%&0D*GKRZ<I*/A@X($3
ML",<"OD/_X):@-@F>T`9$AJS"=^<YBU+I8R>*4<!OE>`1^<&0'A^`4]/,9T:
MDOJ(;FFBR*`%O@K$-3<Y,HQL%-<:WGA@#@6XBP-:\`(``\P#&:A/)V&3@2/[
MK).2P(_W4DKH_D2B>W-(00ORD^0JI(%BC^ZE.,KARV8X3AF?!K*X;^A7SOEU
M'44<+WF=^4SSPBD@<&+W%_#4NFK"ER'VEB^AZOL1':/TP``/N($%?.`!&_S@
M.*L"I!K,O$])(9_1FUZGJA<J"X_J*QP&CQ@$$.,1PX<N%1#QQC4C!KA@Z#IO
M<3&&#JSR@8N@"8V9L:[X_9*63,#?/$YI7'X\[@.VS#_24-<,C?]VSFV+;+!6
M\4\=COD4)?(2F-<P.JGS*HY\66777BH3QVQH0]T\9:N\N=B2JR`$A_G5.U>/
M$&^@@HD(02C=5@'=5I?`[<'2K$%1A(HTUH5I4&-B[Y?F"V_&8<+,UHSMV;H&
MDJ*!B;^<R3Z?$0<FI/*E<&`"-=`X9SFKF"#/DGH-@[5!'<Y9]%,XI0H:D,8$
MIT&87RH%:;:\;]3`W?>>"[-!ZUB"--"1[C.I.Q[U>":<4I?>?LP[!7EZ[[T;
MDF]PY&I0+E%>%<KU;Y3*!L#8SWZ`M6]]V5P?^]Y?F85]9Y.&^_/A$=[GA/U9
MX0L?Q51;R?C(5]QQB`J`"9O&-05.^G'_@%G&U1$`'@+0:<15+;M0<O$T%_#1
M/@30@#A#"[33$H:"$CB7?2=5%Q7`4K8G)J=A0K!A19]13J;&59E&%218,^7D
M&U$712NH%4F70-W09FI%)NZ05RN(`:8`=MY`=Z>1@CNH@R"8%1YX#?Y!,]M`
M)IO'@DJU%R/86"+X,Z;71A21+]F0%-C0%`FB%5$'"C4T'9]A1NK1,,B6)0[R
M.4JW=T54.4VW`=]&#LNP@<+T)1&R:+MG#;^W)J/3#^WF3`)1)^OE#\AG$*3Q
M.H,(.Z:1*_2E$I"R`07`?5<5`1Y0`"<U:`B!4J6Q:6DV4YNV:16@4R=U"35!
M*1_A8-4#<1)F_P/])!,V0106AST8%S,C5S@"T(":<1U,TAAS``N2.!INP22Y
M^$Z0H1\5$`'"J!")!1EN$5D")G,7T13]$Q+:U&\>H'/:AX$:"(?'HALMJ(11
M-U`(Y'5#R(TE*$<="([&4H/L`$IK-V1<EQ?FB!?H"(+:J`W@6'OC^([=8'@<
M.(_98'CB:(6?)X1AUE@>F%GV*(:=M'?6M2Y%5EN[!VZ]U"7EB(W<E4MTB#38
M<(?`MTSMI@Y$,&\`,2?[<`*!^$Z$Z#JOHV\[<!83."@=YHC9T3JC`8EVA0Q4
M)A'>DP)MX0$ZF0('P23$&"YS\`)5(`6,PG#W!&'Z-#TV\&!#013N]_\5:C%7
MWH<AY5.+(N!J^I%8OQA93'54R>@]D'$8QMB)U'=4L$`QWC>`SG<1'*$K-T82
M%5B-('>-%'E``GF0>^%UV3"$?:F%+:4FVP"$0`8/V^@-XMA8(-B-XY:8`.(-
M`&D-2%&"F%-V#N,PZN!VXV`FO2$.FKDY<<>9?GF78"*';Y=+Z):1&MD.HQ-\
M`0%O_K!>=0)-)5F(?H*2?:*2$;A-MZ`?_L4D*`4#Q$AH.ND!Q,@0DM,,/*D0
M&5`0"#$:S5"<NSB455`3]61^JF@`IJA^35D]K!B5&#=7&U=@U?(>)Z>5P2B6
M"N%?LV:,`O`^7]F)O:B59'D0[M$8LT@`;%G_8RL9ER3!%MS78W5)FG#81@;$
MC:.IF.)FF*JI#829;H,YF._0@BVEEWI9H?:8H)`ID`9DF9@97KFD.6Q81W3V
M.9G&AF[(;>M"H&)R%]_E(.L@#C*XFOC0FJX9F^QE.G1B?%_`.B;9)[8)$0BA
MF]%8.\&19NMY&"D`B<W)DQ%P&,"6$#QY5\SWG$D6-8CU/=1IG4CIE-O)E#3Q
M`$+QG1?G%4DRGO:W"RXF`(IEB>]D?:ZF4P3VE9V6C%<5``$X4_H!'[0X8_P)
MERYA$@`:H`,4%W;)HN)VH=_0EWBAJ#$HF!#:9NDFJ1.*#0XC@]<@7LC$H#UW
MD$.FH1Q(;@1)D*!*_X^F%XY'6$9]AR![MSF$)P[G4`W($2$-\B!DXJJ.BJC9
M\%VH\'9^1:DT:J/S('Q^>#KSYJ-!RGS)BF]#FDTKB1'==*1A23&(X0P\:9S)
MB`QH1FAZPA"!U*22@XE:A@%<NCQ)J9WI!Z8S(:83`!106:8&VA1)0G`7HE$;
M!YRSEA#[!1_(Z#T"9I8_F9[>@V8$^Q[+2&,AH1;^^9_32*C6J*L4>:%D,FP0
M.ZF<2G?`V@XFM"9V:'86NZG)U*`6BR"<&B8D>PWJR`UM5*KC6"J1*8]C8D4K
M^)>J&HY=PDM(LWMJEPYF5B80<IK*H!L86;'>M;,GX*MJIYJK*:PWJCJP&?]-
M4U";KO-.5&MO^+801'H6Y=>;F;@?AP&)HX$,.ND6P)8?W\.3R=F<WUI-[M$^
M,$"4Y3J*V(E/Z>H30!"F->&NK9@1`D46MB">`I9@)V=_.J5?F+A?P+E_)M,8
MHR&)*,5?"`@PNW"+![L_Y.<H@QJ@#TNTQD*QW-!)$CL"97>$W?4.+!@Z7X>Q
M2LN#(ZN#2^"Y&DNRR72ZF@JRD)H7ZBBI"O`7?6="*QNZ'M@5BL>/9($-=5"\
MNXN/F4:JO0&ZX\%MT2"1J_<Y1N179H@<;*@,GK%[NN$@G.L-1UL-,.JBM4>C
M-3HZ^*`.?`A-.3HG<"*U]5:UN%EOS8H1A&(3'R'_K=D'`V-;MLL9`#VYK64;
M$<U)I0GQ`L0(/Y%Q8>;JI75;!7>[KGE;<499*%OAMZ5&E02W<4UP`1Y\?XA+
M,0%F/ORW"P.F@`*&PA<(']W'K\[W.Q38L)H[H-];PX&INS_(L;8;.G88LH8I
MF.:[PSI,H*7*CP,UF7\Y)IY*C^%H0J"Y*GQG#B2K#K"W.4%;#I^S&[9DP^2&
MQ>)K#E^B5K(;K*VIOOS`;K(Y!3OJD;))DE1&3?*+F\S:K3S9EO8;J!.@O]@G
MG-G5K<5I$.)Z$`2;$(E5$,>H90KW*.?ZI7:+MZMH80R6$<YH*WY[IO!!GAS7
M!)H,<Y<\G@='<`AG<)@<_\H#%E?/V!1:\*<VYV^$2HV'RL6P/&[F.\NT?(>Q
M?,O!!$PJ&B&\7,6]1*NB24>:^5U648><J\5L.,7AM2]SIY%,>\;EQ6YR,B?\
M0,W.%(APO'Q]HF2U\*R`&JA5T!:#UHN/`3XO(*[PTU_Q$S_@\S[?$QFA6$^+
M_,`13!,P\:X2B,%(<13R)V#Z^<D`_<\`?7W\Q\+81T!,8,()E\I:L&$NT9*K
M+,,.*Q<9B,L6?2R5VKJUO-$<S<,9W5<7'=*=^9!7/`(222:YI+VX6LPG[<6W
M"GLU;,7GEIJ9VLQW^,SJ6UZF,\USLL:K\\;N9+7:C!#<?"NY8B@4$<[CO-1,
MW?_4O?C4_B>N1)D`##R*\[R4C1P4]]R*A8+!(<7/L.C/A2I`!ZU2)Z5S!*2E
M`".N^_4Q"[T##;T]-A?#K9Q2%/W*(9W7/=S1?-W7'*W7(?W+O\P7*7W%J)#%
MVYO%M;HX6&RBQ9Q4%=N!W(LFM;O70KQN99S3PVH/:-S31.`"S%005+JL0UW4
MWBPHW<2UB+O:K'VX=K5?YUP`!B&(>Z(0Q$B,C4B4"]=@5QUQ62T38KK5[K<#
M?ONL2-'/LD$^`\1]&%C7=/D6RTT74U1@EY#*(X7'<BG1FGO7@-W=#NK7X!W>
MJ^G=L(S2E=/+XY"S0;N]$,++#N)U[QVBG'FB>`V'7GS_"FD"H?MRV7@HK-"L
MTR'9TR<`VOX@VMD\U`YAVO<;K>H)C*MMN'7UVHAKDK4MR(0\&ABPVY'2VQ)6
MSSH0W$\YW,6M86MP<Q"T<10=8`.]X@`-<*!\R:)L,LU2*,^:$H["RA-]4O5-
MWJ0IWC[^XT`>CSQN>RB=O754AJ_*O:?QRXNM+U9,>**YO3O><R&Z.<N,3,P\
MQK^'TYP-X-7,QCL:M4!-VMJLX(@($UR;6.>LB_RUVD[-:9NXU"CE`4"@X5;M
MP%@-P8X<XCA6W%&X!@X`!%@6<)\\RAL\<@?GW/L+/CN%`30^*#`LC<Y]@14]
MY#4<Y)B>Z1UMZ?:]Y",JV2V=_[TO#7NYA-AK6(*?WG0FBJA+\**9J=]*R]_*
M9*/_O=EQ4LUIC,U!C>`)#@Y&?>8&$&M(9LYO7NQOKCAV?N>EF*X&H.<SL1./
M+.)D0=R*\'YYK)-Q+-2!U)/;WNW.\.VQ$NZL)X$PS,`XOMTZSNG?J^GLWN[C
MK>Z-.7C!7.4D+;3:^Y"O"IIU%[01.>45N>I@;(<2:KY<#N"@'>`N(.!BGB=D
MOGQF3BB0<D3OU?!$W>T6_^T8#^[3``0]@=J\C><1U^P>#NU#L=N2/.W$?2L;
M)DYN!2*)@MIA<2B(B(BY4TZYXY:X8PRZXQ%F(<D:P9(+>W/:S=R&"N\]/L1[
M[>Y*[__C65ZR1G\YMZJ9@V>KUEO21EZK^8[D+!VTJTZ:+;`.XYL7M%SPKGGK
MN.Z^"R_(V;ZLN"EM,W?:>)PC5A>"FU?WH'#SSQ?I>E]^'"X]">#L,D'RD-SG
M(*7/NK%Y4IGXBK_XE(S!_.G-_K,KF>NP<^'O3X\Y/+RZ2[_Y?=WT'WWYV9AI
MO;1V\KWD$LD;J8[%5USJY%#J$=+U1+YV(WIN20N/LTSVTFSVZ@#:?X@G#+_V
M<JQ\1`T._=GST#CSN^GQ>[_\Y3ZW,/&E?S_R8VKRQ%WXDIR7Q:P;7:']V:,5
M7"%'BA]233'^7OWXAK(K>#;IE0_Z&\CY[O_^(<O^QN+$#=+_TKAJ72H]V&92
MQ:X*"`H;&RTMA`J(B8J+C(V.B(:$&U\M"BU?)TN/C$N=GI^@GQ"CI*4GIZ2G
MJJNL1*=3'B\O`1X!MK>XMQZ[O+:\'ADC#@X[.\/#Q<D[$\S-SL_0T=+3TP8&
M.MC9.M9G9W]_V`D&54#:X!,&4M;-Q6W)[N]K:Y&#7X/W@X7ZA83[_O[]_OD;
MT4:>P8-M$B9LEVQ"0PP98%282+%BA3D8YU3:Q+&CQX\@0XI4$*JDR9,H4ZI<
MR;*ERY>>1LJ<27/DB)N)1EBRIP`GO4HC!MV\F8_0"$,MA#D(>N\HI9HAZ=D3
MUN*4)I)7-\%<4JHK!%6I6(EU<<+5_PE8LFCE6NOK5RU:O#(H(&;L&%UE=AT6
MH\:WKU]KVK)Q\P9.ASARYG2@4V>`W0YXRI09'#KBH.7+:W!BSEQY'^7+"@MN
M5AAYF5YC$2VJSJ@1JNO7L#EMG0W3J^W;N'.7HLW[9.S?P!=1[JG3P:4-.`7Q
MG'M\V,U+0)TF[6G(7J3@C9;P(_3ER\U3&SMYW)H;["BQZ,F>13OK+5M<;FOM
M@OL%65V[=^_GC^SPF6EH^`WCUS.`!;:-`=U\$\XXY61SSC7K,,-0:<7LMQ>%
M%(:V4&B;&:0A9.TD!-I"RCBSC`,;2*1:1:QMA-V+,,K6VXPGZ6;CC;?1J&-6
M,?8HTU`Y[?]DU%"'(#45D90L=4]23!7RE(^6G&"/4)$4@HAXX]6&FWE?H;>*
M"UU.P9Y:[\'G%EQP;3!,0@'B95<RQS@3H(`#ULE,@8$-IJ!A#"8&6(1Z@0BG
M`Q)2@R%#'R:JZ(09AG;H?_UID>**+&;D(I28PK;CII[@Z.FGG/*6Z:@=#9=<
ME3I9LIU3R!&YY%'X\`,4(JF^>$EW^03U))99OE0>*N=YJ8H+Q+X22WMEFOD+
MFKNHZ0";;>IWC+1SQODHI':B<XV!Z218V&$-8@/.GXU)^!B%`M(IS:$DAJBH
MH(>:6YJ%>T&C16J43M0BJ?S.%"IMGP8L,&[_LM3OP8[4JBIRM![_UY-QW=$J
MI#"Z>@?=E3#ZU%T**>`35'@?D7>;6&$)>T*QJJ205K)K]?*6?,Y&5NW,U69K
M\YW;YHD@80LBYN"!C#EV;;TF#MWN.XL.?:'2?$V:[T4857`IPE0[4K#(.`JD
MM4`#DW*U2E6'S<@E)V!\<<5/ZLJD4)-,'5M6&TV90<?5+?E)1[/9YF7)PA*K
MW@DJS\)RR_+Y0HN:\-*L>%XW9YNS-MWRS*?/V#P`-*!*-U2TT:6]"R]_IS%-
MC=/YSG&1U&*GKLC7HG3M^NN@LLZKZF%#5RM2N$]%:U'(7??B584X94\&&11"
M_"0;@,(1P%[M':S)?J>\\N!FD@GSLS(O_ZY]XXX;N(T4WO8<K@Z66Q.TO**C
M?RV\[PZM_J-]D4ZIZ::[33O"LG,%^_[\$RS[_:EC"I!N!10"[FXJ%_.13HZS
M@0Q(@GC=F4(E0F$UYG7%>5V"'LH`-SWJM<5ZA\.>F[2G..[9Z7&"`9_DP*6-
M\J4#<YDC6@S9ES3X"<V&HU-1Z4YG/P#R*W_](T553$;$('KM?SZLVE(PH0@I
M;4171MF)DUJ%*2CFXPLIL,=33)(="YH"/7SS4O1.$3@/5N]E(104"1=GPCJA
M$!N1VQ,+L^'"\X4NAG=\E.<^Y+[-46A`\EL1_5"71*J%RH@C(V(1$>F5?Q72
MD"09A")R)XE^]/_C*3=Q@+]XM+I$,"DH632$`Y'GHI)T,6_-`^/S^K;!,IKQ
M@VCT`.*RM\:9M7%`;_Q>^"8WOCK",(;`=-<>CX8A_Q03D#J<'P\?B3_>,#*5
MBHSF(I]Y1-HP\V`M6`+$7`2K$Q1I$B>0%<;\9:6$P2HI#)P$KL)IB:M04$98
M^R+)5BG&5G;0@_.)Y2Q'6,LYW?(OWHOCM_I$Q\N5*X_!-%JBA$G,/_H1='X)
MY&J6><W?`+%KTLRH1C?*BM?EKZ*V"J>5M',(1+0M@5?BY"-XM8^L7.4Y4YJ2
M\*JSD6Q^+9$<9<48.2BX5^K"<!ZHS^<JU$]__E,:N=330"E'/H/>L(__"&77
M8X;94(B^3W,13:8@*0I2U^2O))]2Y05SNE$<G<!37WUG5X'C)&X20CN%`(](
M8J(JDX83$YIX*5'HUAU8$4*DXF$=3LEZ"K_]S94^S85\A'JHHAKUJ-!(J@$>
ML$*"5LZI5SUF9C$$HF%>"QI+*U%6GW:Z^JW5JQ<=&`;E25BR#I9+-OKH:7]S
MSE0=115.*EM(Z*J(#8BT._J@C#JGXC&X8DEV>FMM87>*V,3^-*@B1)=C\0/9
M:$B6LG*T;%/-]TNH1K51RO`L#K^+K6DXX`M:G:AI9TN3U*I6N?"-+[!BBT3V
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M-(:[X8UP>+J%H`XU:-E%ZA';T,SF3?/3UIQK5W-JP82UC6$C'>UYOU:59]5-
MP=K=7D^>8E>\/24GX5HWH@Q)G1S#Q]PV(,&\OIK)1-Q@8<?"7"@G=K$*J"I1
MJYSM.VT[0=[N,G<[+.X2(PT>5-5XO="=:G7OT'2ZO7-:.P4!_<EXWCBG]ZS3
M@W-/S??6,[\;OU=Z7*PXFZ7[6%U1@,L<7$VQ@8,@,+-3BMR!%2OG6)>VQ:DW
M'[@$->/PL`\MURC:;.=2"BKLMF&^_3.TVQ&8[WM?RA>:4/3QI4)I-MVZ*Q#_
M<S8'W6MRAD#6<;YS#=K;K+!M9-`#/O1%^/GH2-='.[=9%0(NP3KLG,04-B#U
M4-K4S9Y"V>"S[F!JOVP77P`[42]-=JQJ^NQI_Q;;Q:4#MW?W7*8NC=SGKJ&$
MCK=HJM;[#OM^X\6/#)&CUWGA5_$ZYI\'Z#-OO,#AJ3S'DU02E(AK=T2*%#X7
M>]G9_WS!]C?&Y!/^R0]^9==YD7H2B9V?)"S[Z[V'=F[+GJG@L#W)WW%NT#6*
M]RKG>^N"9A(A?,I$?"TV<UN2;QC%<^;G@.9W?F0%)M!T5A;X<[L1?=('$B;1
M0U*B'<O6"3,%5U]0/$N`/%A$"7DE?LXD,(G7%7]S_S(16''I9T;KAWJJ5Q>L
M%W^N=V6P9W\A-S[YAW:W9VW'%&(`:(1U)VH$>#I[AX#V]54+B($!4T\S>(58
M*''3Q%IB91M?M8&+MCPE<2E'426WPDYEN&/\P'3#I8*0UX)52(6/)H-76'I1
M=GI?YW[T4E3RYX/T%WM!F!CZ]U1*J'M1Y0Z\YWO%9&+`EW>K!H7L!7I<&'KS
M9H59>(G)EU'$,E;"HF\V-G2,1WV>D$U7XB399P_75U/;]Q0?Z%<J*`HH(6,O
MF$%?DH5V>'%XV'YAMX?]U(<6]H,@MW;X5WM$N'^,$FIZ-'>*^'N.$7R/F&N2
M2$]A%4TSJ%,[-2R8&(,1M_^)<SA/7BA;TO=XUA<*I*@J^H`\5R$E_>`4#G05
M)=@/?!9.HUAS)B&+5*B-=(B%M^A3-YB'N[B#VN.+U06,:K=EPSB(ZE.(_D=N
M*;>,FC5NSOB$T(A<-L>)<BAKVUB'&?DW.9<>'"5XM$ACT!<J&_A.+9$(!%<5
M3A<EVV=3QZ$/W?&*O897^E,C]LB`7)B/^BAI=^AU_@@M$U9+`@E99Z<#6C9[
M.I!_UG![<`=BX06`G),^$)EW!D@1>@=S$[EDU813\*:).\E@$1A-(>F-7JAX
M)%F2!L-%@O!;_>!-W!<0VB$E;ME6!(<*\?1>SE<*D9:-Z$=M;8&#S\(F5+9Q
M`<G_B'YH(&B'7?<GA+6WE,883$[YE$FH<85X=TW(&E4)-7,`B;,U?KO!9%TI
M31JY?`RVA3>R;VAI,*LS'94''>?(=-XW06>H#W)I4V`16"LQ8V0I>-?(ESQY
M<7_Y=8'9!A9B'T)IF+_XAXH9B&WGF`^%1Z=V<F3FD&`V@,''&JN!$9QY6IY9
M:WF9"KR)CQN9B1HEGCFUE^;9B<'B:'7&*6#X$DHF19>0`IE0"#/YFJ^HDD42
MDYG0"5U"CQ7)/W1&"M>HDSLY;388G*DWG,5)%\>):@.IG)UVD,X9F=3Y?^US
MH29BG529$=FYF5GY;J$)6]B8GJP4EJ2I2/2FA1\YDCOR_YXN@9)QF7V7%'Y5
MHE\!P0]W)4%GT9^]=I&Z.:#FF8WJ@:#XI*!SH1`-2IB+TX.'&1B)*3D/@)1*
MN93/>:%(F*&101HE!Z%X5X#862G:&:*;`FT8%'$0:(MB002N("93D*(IRIYF
MZ9ZIN1(RJI]M`PD%U@E28J/,%FP19)LTR15`FC7_8&LL:J`'NG6#@X?"J:2#
M>6TSXZ3)B9A2L)SD0Z6-::46BJ5;.IV?RD=EQJ%@ZJ%7R1K;N5;=B9$=14_1
M0Z18QZ9L2GK6.'II6HUD):<9>);A&*/!!AZ6QY)?$&P$!)/68:P(=A:8T)__
M"6.0QI&UZ)M&RG5(RJ"1^J`=Y_]QEHJI4TJAG&IRGLI0HAJJO><^7GJ9V'FJ
M&9&J(+6JK`H6FZA(;CJO]+H>8B(6`E$%58`!-M"O3_"O_^J8`#NP!%NP`.NO
M3V`#"=NO#%L'&/"P55`'=3!$8MFJ<[HI,*J:OQI7OG6*W*$/?':*<BF/A2`F
M*KD*G?*FNCJ-$WA^L'I8C,HRCKJ@7/I^@])ZV8H.]#=9A&$Y!ADN"J(.MM>I
MABAW8E9#TEFNIF8H$Q"142.F(,J=;Z@CN2&G0P2>!!H]F/`%4Q"3N((/A*"O
M8ML%"EL#9GNV"3`&:KNV8V`";FL"91"W:C"W=$NW<7NW=_NV;XNW9;"W?-NW
M>ZNW;CO_!C9PKS(H@["F;[O*JUVE4E/+1:/8I_L`3MED>7RZ?9<[K/[9I_TI
ME_HC)2IKGP1GIKOI%>KQLAU)%JXPK8UJ.)6F`!-2+4PZJ6-70C:32]N`76?P
M`)8#!",`M$.(=A,@!43K>@(R-%H@KE0U55IJ56?6M).2F589->P*0`[W;+=A
MM?/%@$X6MOKZL&1K`VC+MFIK`CUPON@KN&^+OCWPM^ZKOF][!7XPO_1;O_9[
MO_3[MO5[M@Q7JQ588XM+IZESDJ+($KEEG]5!LMOG:YBK`)SK"0\\DX/*M6=%
M<]YIL5.(NH2GNK_)CZXKG+@GNY(:+?!',S>#NSPK1YKJ=L3;_PQ:\,):H"YW
MQ(2/DKS,FXCF5K1,BR(I)J9\UYF/.R-5*T3;JY=@<@IUD`#LF[YZB[]^$`)0
M',52',5^<`7RZ\18?+]3/,5GV\7TZ\7U&\51T`55\*8Z=3(6B9,UAIH#O'CQ
M6+EM1;$T.42GN*P5_*-FS+D7:+@!FI/J:;H;I,&5R,&L*[,?3+.[&"T\6,*V
M=+OT1S[<5CFS%[1N!P2-`<-:X,(QG&DW=*7[,9F(V+Q#"5K0V\/3BY52RVB-
M1L07B)-C]`1K6[]C4`-0'`2V?,NXG,NZ;,M;W,M;3,M2W,7";+;V2[YC@,5B
MK`%=,`7X>+IA5*BC<#6JX\;$RFO&JO_`<\RYVF<5O=:URRK!RTK!+UB>M+I<
M@GQU9='!ZG?(29K(^#&[(LS(->/(EOH'W.:SGK9EV'`&6];/_OS/_@P$`@W#
M=G=';Z*\H.PH.MP7)R)1*D:]0*S*V<O*>?DWFU<#8Z`!0:#1O+S+'NW+(,W%
MPSS2PMP%76"V)IW2*KW2&M#2&I`&:6`!,FT!(1`$,=`%&Z"%')FH].5(;>S&
ME<MKG="2)!&3+HFY$ES!7]'`?9K'2@VGT7K.)Y/.A9PL:/2ZPRFI\#PG5+8]
MC@-[]MP-XK-EO'L&/>"V<SL#:KW6;#T#<^NV"2#00/#"IY%'!XU[-YS0#74S
M/*QF$)W*[MK_%=IKL7\S"#7@!RT]Q2N]V"K-L#8@MI`=V9*MKV!;V99]#S"=
MV9J=V1F@V1$0`!00VC=``5!,TS'0F^8LGLWZC3Z]2=3\+Y:G#Q)$-GWZJYBK
MQQ7,N;3XI@`ZA^_JE>=,%H0<LU;-SEE];5M-PC?+1E^=`/7<:2<]!CU`MUB`
M!21PW=A-`M6=W=I=W6H`N#5@`YALPV/'?PB=A`Z5+7TMO?KRUZH:Q+TQQ*-`
ML5Q2V!MPV"T=!3&PW_I-//[]WX=V#UX[X`1>X!QSX`B>`O&Q+`70X`X.`Q`.
M`QXJ`!,A``(@`A?0!%30!$40`AU>!<U\NHDZB]',QL#VVC/"@K;=_[G_QFRK
MD$U]>MN84'-?X<WA/`7T^!6^?2,F6JN"/-6K2]QE<M6/JH?O/,)'+L^/Y48&
MX-Q0*@7?L"=3:@)J,`/<C07?70;5O>76?>7>_=TF$->8')3AE;0)72&C3`WK
MS=X>6KWW(]&-)IJG,`A=D-$:8`&V$`%ZON=\GN=\KN?NX1X!X.`-S@2&;NAS
M0`"*3@`6+@!-H`07$.F2[@647NE>,`"8GNF8#@6<SND,P`!0\`&B_@$,P`8,
M4`(EX`,A$`7*3`2!+.*^3>(6C+'C6'VUCN*<0K$0S+6"JKGA5-N9N[D+3,%A
M,99JG+65*)K!+195/>2*)1=939S3\BB8%O\@M]ODB`D'1DD^#R`!5<[=UUW=
M?:OEV-WEVEWN6QZW;QO7XKT&F8S71_LA:["\R&!"#A`1$OZTI[RNG1G87D'?
MT#/G&V`#=FX!!9`1'=`!%:#P'0`#"D_A%BX"$B_Q.(`#$U_Q&'\``\`#F>[I
MG0X%G\X`(##R'S_R)G_R(``%)A\&)L_I+0\%81#R7``"7,`%JAX$8TQQA?7,
M&+RKU40C!>RXN'XU9[CB*LF?<>6Y,;X*9KQ][WH;':GLRPZS-7BD\`'MI"'M
M-MO5U2[#N(3M4&J4W<`":N#E7(X%<<OEYQ[NV9WN?&L"X?WN";6\UM8X!]6T
M^*[OFHF9;DX[<)[_O=2(,AM0YRUM`00@`A;/\4;``R7``Y&^^(P/`C0P\RA?
M^99_^9@O\I6/ZB6`^2C_\:@^\C=0TS%@`\,RU;!N[-_I\R4^]*X?*D?OHW(Y
M[-]\*][\;V(2SG8\H#`H@2H:W,*M"E\@Y.\AZ+2`]1MRUT'9]5[_%V\$!]K^
M`-/=]FZOY>)N_=N=_>8>[FB?MV6@!G`_YDB3.727WMQC/L)[[V`*M:C:[]@;
MY[^O'H,_!K9L^)CN!:B^^"!@!`0`"$H@)80E((>(B8J'A8V+C(V$`Y.4`Y&7
MC5X@4#P#/#R%'"$A15U++B>H)ZNJ+JZKL+&K$+2UM$NXM;B[O+V^O\#!_\+#
MQ,7&Q\2QN"=?S2?+SDNK7RE?)Q#37U,GV[2SMMBRJ:[DY>:JXN+GZ^SMY+!?
M+R\!]/7V]_<>^1D*#FW_.]HX&.A@A\&#"'<07,BPH<.%$R)*G$A1H@$#.C)J
MA`/'@`DU)$*2P(*EC,DR)%.J)#ER)1:1+4^:,&'2!!`M6B8D--B&Y\Z#_X+V
M/%AQXL6C1XM>-&I`HH,4,&#,F5.A:H6I6+&>4,"UJ]>O8,.*'4NV++*SX-)"
M:)%.W2MN7<:$"%+DQP4E2HP80:&7PXT?(#Z5X/$(4:%/B!%7JH08DV-,B@A%
M3G0AB)]2TE+%0O>V[36UNW2='4VZM.G3QL(]6__2(IJT9M:>,;.V!)NS*=W"
MJ77'&YUG5KV#GXL5;QZ^X_CTV?/`SQ]`@01_(GQ(O?K`HM@M8M28,8&!!"!#
MICSI4N5(D>5?QJQ99F:9,4!L&-"R8PU0Z?@14D1Z48>*__\E55%3V6$`E514
M69555EN5Y>"#$$:(FC!J@</6;ZST\<H4<<U5Q`U>X,6#7H(--H@AA@36"60G
M7E+8BS`B`@4(7-1H(XT@#,`%#24PP(4A`Q3A1Q`:*``<+)UA^%E:H=TRX9-0
M1GF::*LQ<PTNK<7FC#,GL#6%EMNDH]8XP@VG))EE]J89//(@YV8]RL'97%`!
M+92?0M;ER5!VV?7'G0[_"8"'7DDFN<0>2BR)EYY*[<GT$7PW_10=G@5)9Y04
M4O@'X*8!(L4G109-@($'44UEU54+3M5@A*RVRJJ4O51HRX48NJ"A"[AU&$00
M-S!@A!>?>&+$)UYX<<&OQP;;(P@,I!CCL\\R(*VP%QRKU[5&4-$$`1<<T403
M1C1AB`5^A!"#`VZADF1;%38)`:SPQBNON[F\F]DV+5P(FVQ<9J,EN^"DD^:9
M:*;ISIK3M/FFFW'2PUP_=$(WT)UZ5GS=IP-NQYV@Z)V$*$GM77$%38D.^M*B
MA,K4@QH)V(!30G9.3*E^$6&:*7<`!JJ#I]B%JA.H.XA**H*GIJJJJT@G/1:\
M_[+:0G`Z4U11PUQ!4``%`3_\D)=>%Q!`@!)>@YW7BM!"Z^RS/_)0[;8W4$#!
M#4RT3<`--WS[@]<_-,$`!5>$$(4-&VQCZZW#N8)-+;`T;<N\C#=N&CCUUB8+
M-%]<^&4LN&4>9KKO<&[PYZ"7<P(1"1NW\)O*>9""`D(%)+',DEJL)\86282I
M1@E\9++'((M\Q<?JG=>2>HNV1Y/'9;3\LD&P^ZQ3T!%=)(4*?VHDQ5(2W4DS
M]-D';6"I"5:5*@P5K.;X^:,I[O22X'3^2FRK2%U#%$'X``+8!`P+2@G5CG@M
M*&6#D8VX$,!#$-!_%_@6$YA`@&TQH6M-$`$$M]4$-O_<H&]1"($&K&$K*V@(
M2><(V#?4A[X2FI`7ZH-'E:S$#<VM8ANX>9IG0D=#T*6"=,Q0V.D8YK#5M>X?
MD\*/[!J"']H1:`*W`]08PJ,HY)7$=R8X64J&1Q(UL"0]:C">>TR2Q1K@A#X'
M`>,7<1(]C>$.4-[!WO.`TCI+%254WR.:^,97OA/:D4+J\P;[;.$^W\2O!C78
ME05&U`1K70!8>O'"C`H8P!JAK490D($,#H`#$8@`!S@0PR4Q:4E.BJ&0(BCD
M`6[@!S]$00,;3$4?/,B9$*YOC[*ZHRSGE4=87$XVL]G&$KZDC1;*<(8U#*9P
M;EBZ':*NAZR+F,0H-D0[N9'_=C7K3@)Z,`.3$<IW??L=\*[(392!;"9;)%0"
M;@+&H!EDC!,PP,VJUZF)X(=.17RC]PYDJCD:S7RSG&4>]5BA/B)I%1NHP9""
M8(%C-2%K6<.+0A4)@C!`H02.O-$`"7@(*$!!6AC-J$4M*BU)+`8Q1KB`&,0@
M@`ITP*0P*(!*4ZI2E=*#`E-9(`%\X(<K!"$&51!<'VY5L'*($);MRJ=0H51+
M>-!&&E.H!C3"M+E?>DZ84"T<#HMC3!X&0'7)?,XR\]-,9_X$FK;KSAFJ.<7>
M^6X+0=C"[[QIJ/1HT3U5+`,<EL>]Z*VS>M=S)QN'DA^]UE6OHJ)G^(PF%7P.
M]83[_]3-;M[RCG>TP`;SHTL3*BD``5Q@DYC$P0<^<(#-'N"SE,QL9BUIR9&6
M]%17B0I+Y3$/#[CVM2F(K6QE"YO:UC8-&TB#;M-`CPBXS0<A,($&8J"!#:B2
MI^WXZ3X/RUS0^"*QKPP'E[#Q)1C&!H=.?6I4M_L*%TQ5AU7-!S)_N%4A=K5Y
M"0%K.J7)Q.&5X0I;V$(1$("`(JAUFVYU8DG&\U::6+$,:K#)%[FWG0<8&&='
M3$@;[U21OP(VCO5$559*95CFHB^Q(VP?8[M+CBG88*!%8,*V4)N@#G2`I07(
M1P16S.(6IR`#,(ZQC&5L6]O.=K:OS?%K`[#2E8JOLDR(@O\)S%7<XW)X'<H%
M*N0L+-2@HA"ZL7#:+6T#&]Q@]S/9!0YWM]S=[YHNO,L9KS*#*)WSHI=FT,1(
MH%8FQ??&-PCTC3,"[LM6Y,&U4#4!IWNB:)(>)."+-:.>#@S\`/\<<8VN`XCV
MT*Q>"`]V011F,F+WF6$^,K:G'*J!!G9%@0)00,>Q51UL9TQJ&;^XQ2MVK3U:
MJE(FF/BD%:BLK"U;K6(!BP>VWB@4.,N`#\C@`Q?%*`]\8`)3%G<*@SNR*Q$W
M"R4O3M+ZA"ZE$R?EIMZ&"%?68W:YS&UBYO#+8':8F+5*YMB=-YYIOL@93C82
MF])W`?".-WWI[,U&H62+'M.SO@'_7!,@W.1F!V[G!(1"<$7'+KWJG8BC%03I
MPD*[A-.N=.=Z>JM,:V`4/G!;CJ]ZCQ3S6!X%4"WY3B6`D9J\DZ(5;6<[N]G-
M2O+EDK1H0V4NHXHR:P`6=2@EID6!8I\R<,EN!9)?2>VF/=R.THYXL['L0FZ\
M$&&JR3*WN^WE<",'J__(:E#.S,QS.P]C%YDF>FP:[[++^[X?VZ:C[CTR.YM@
M9/KFLTG&N3&!\Z3@VD/TUQ,>6/`Q?,(./SHM,1QE6JQK'3OM0]2F5DH?,$$`
M^%/H7;Y6K4,.((`9S;RT.%I`R0S"D09D1,TM48(!,.`(`[B@36,`])V6*>JR
M6*[@897T_Z2S2QS87D7NLPS,J6\9AU,(`+BM?E6L.J?@0*S4HLVL?`=C)U`<
M(\$5$&#VZB,@!&WG'7^-YS&1'0^<4-QWH_R,.S5.H/G:*X@#G+)^OD=/X8+]
M.U8B/?MX0;GP$#C\.1*_>('ZP0=B<``#H#^W%E(\H&N,E("&X2*-L#\+.!B$
M(1B)(1D$X`=#QGK(9BO!D0JPAW^*4W^E47NVQWO85H)-Q7NRX'M<5G6GPUI?
MIFK%MSK.D6A"P75E9F:,UB??T0/B409P5GUFAP!(D'WLD3)ZUGUMIV?A=X1:
M%"C78WX*L6@YZ'Y&`7]^)V&`-P<5!H(3<G]%IW_F4'%2$P(UY?\#EZ0VPC(8
M%V`79%,8CO$(CK$8DZ!K&P6!A+`BI"<8@R!`*!!<?A,XJK2!+M"!19='7(@,
M(BAM*#@ZV':"6L8.9Z*"OU=,5J<P\H!U6D=P-FAN736%2O$=U=1NU`>$92>$
M<$<3;W<\6D2$(8.*,X%-<>>*,^%O3=$44HAP5%@[52@1CD85#4=_ATA4A/>%
M?B0ZYA`U74"&)F`!2O`M^5,M7*,UP3((P2*'BW$V#_@8VN@L81!Z$X4($45`
M7-"--,`#03!D40"(@L@*G@%=P?@+B1B/O(<XN\>.&Z@DDLA=I(,;X$5\R'1\
MR+>).\%\GI@Q8R`291`"/D"*I>A]2GC_BF_G?6^5A*\(B[$(3OXV`3G1,T0!
M=IYB,R`9DIAR:.EDA0AB-'.@6EKXCL*H=$L"AD+G"E.P`<D87$&@!#A0(BB2
M(Q!5>A#8"0-P`!<%!8LAE(TT4105&3+'!;@V(A<0+`?``P=`!0?P+5290"%E
M"190;,>6@?MG#O\$,.[(DO42CT6%@H-(=)\3B?D85?LX!?TH?"X8E\*7#SZ4
MB36(?ER%@QWY*3LH$B90!`P);QRP`$7@?7`'18DID4H(?MCDD!=I`D[X*2)9
MF959,R%I.R`I/65DDBB9DBJYA62)%L,X0C#YB#-9DT.F!&$0+M`X(FJC!%WS
M-5NCAPIXF^`8_U)=DS4RM4`B)C<B,#=8TP0'T'-7,%Q`AWA@R8YBF5BC:98N
MZ52&)SK:!8ELV9;"M(]458G&<8FKPQ7(EWRW2)!]R2=_&1+3-Y@<4)A!D)@5
M.3*G*)']]9X6&9E.:)F8DHOJ93.Z&!&].#ZA.9JHX86F68Q])),T.0I]\P-7
MDS64YP5&(#9W<Q=\`4`X\@AT2'.*D*$<NE&Y:5`$P`1NXYL4(``+5$A>$YQ-
M(`,7=(')^974B3#BD'3/"9TIA(*U@`ZDXQME0C#8"57:Z0$O`(/%IV-&>J2N
MU1P*EI?CR9=[5Q1:<)Y8H)"DN)[KN0#M.9'P"9'9%XLUY3NE=)%:]/]O^4F%
MZ,1W(/E^$J$%@O6+`2J@I%&:^-=8U'D.J<EX?D`!`W`LR6($DJ`_*/)0V(B;
M,I(B9Y.A#+`))!)2WP*-A<2G=_&H30`%/V"!YK(!QG6/,JIMSC:6@F>C:9$O
MHDHKL5<A*<BI:'("F.J(,61+FI,Y+?2JLBJKL8"IMGJKN(JK55`%+;"KOOJK
MN[H!P#JL58"K,7"LR)JLR!H%S-JLSJJLQZH!7=`%THI*58`!:Y"7SR&0E"([
MY=DG8D<"/@B$5FJE6`J9KYBNX/=]<?>8I0217JH%>2`%^EFOTB,@T,.F(K>O
M_`H#H@FGL2*"8DFG!_H.46,#9)BG`Q@NDI?_0+*9(ES``(M$J`KX4(D:&`1H
M!#A0+(/A!3C7"<4R+$;``$H07#40`QE@7#T5DYMA.*AJHTP&JHHSJOG2G&FQ
M83SJ>JB`J=K0`DM0!T`;M$([`L0JM$9[M$:+`76``=/:!<0ZK-+:M%U@`S8@
MM59+K:B4M5J[M=&ZM1K@K,\*K45@`61;MA80`V;K`Q:@`5J0K5OG#_8!1'MY
M;I^2$Q=QD.(:!-57KN:J5MID/(CYD.RJ;^YZBO/9'GDPK_1:KU3('P0"/4_1
MKY+KKP!+#(DXL,H6DP9;!3:@`8W'L`[*+95W`1"["0J8E)%AJ(.ZAR<""<W2
M(Q1%0(9:<Q!E!$%0_P9^@+*QX0J$`T*=00[,5HB)>#XR"YU/(RL'VK)6@`I?
MD`$1$``1(*V`-+W46[V`-`HA<+W8N[U2JT%;.PI;"[;B.[[->JSEFZQDBVIF
MN[[KBVHLY@/P&[_Q2P'PNV(9YS;X:P%5T+;96B=PZSIZ.1TX6+?1\P#59`)P
M-E_OQK=7JE:J&#)+&)$/3+B/281'B(IPH+B,R[@$0J\7$;F3RZ__6KEE.8(S
M.IWJ4J=@>;`7=P4%]0G'0I2<1ZB%$".>EPC86,.0@`@7JR**D)1,603O%049
ML+L:V%V/J&7!6VDBZ#C%JXCSN%BMY$>$\P4\-@<4$`7^-S79:[W6N[U@'/_&
MX*NU47"L13"V[)O&%F"_^-O&\BN_;1S']#N_<ES'<_S&]_M;$9#'^3NU;NN_
M;1"W`C&WG4C`Z20H/MB>:#6*#+P`:"<3$9RN;D>?4)1O^"97&HP=B[O!%9&9
M_/G!&1#"(DS">%1[F)O"!;LAG-O"0:`WXL@%@@H%H'>;JVL8MHP(:D.ZSG+#
M!L0C%!6A2D`8K0N.)4!L)A`%+\9!ZY#$9++$PDNCC?/$<NI4!V./+:N!)Y`!
M+U`!!$`!EE%*Y2+&XCS.8;PKYKPKYZO&9XN^ZHRLZERV++9;\KQ;ZPRMX^NU
M6CL*1:"V?JRM@AS`!T&0!'P1*B`!,Z`&<^%N9<?_M^=Z$ED4D?":BI/LF/*)
M/,@#!T"0IA/!GYR\T8MK,YR93@8`PJ*L6B-,PI<K)BA<,(^HRIV+?4%``!>+
M(B4@<X-Q>8Q4`M=2RV=CJ$;P-<,RNXGP"3GB":"@%W?(RS7"-\(5`1G0TCQZ
MH,[\S)XZ>-)\H[QGG4=2C$3082_0`5C\S>#\KGHVUA88=V:=UFKM!U[<UF[]
MUM.[O5P\"I`%2-,JSE=[M53+N9V+2J<T"E'`SS;@MLD7R/Y+R,WD?!-AM_^1
M`"R`T$605O-%F`S=GMI4$A"]9TP(8`%&N#5UR4X$8&<`!_2*GV7:T4CDP8ZK
MV@X0RB5MTJ0<#"E]POF7_[E0#5!8.V0_`'JSS#]?(\POTL.,$%)^BKI#G1<@
M0"(ZC=R#L;ISPZ=X47DA%<R/0$I-G;(92#@X&Y-3W:F&&,U7C=6+Z#DR:F00
M,`4%8&(%$`/^%Z8]\-X],`;R/=_T3=_0Y]9``$A4N]\8T-_]_;3!FJL"?JNE
M5N`%/ELU9ELSE@+*0;\6D'%K:P,8X,^';5YTRR=V.P'4\P`(75_Q]6X+4-DB
M@V<0[2C@1"A8\-"$"TX631X`Q@*DG=KXB=J8F2G>4;4UD``90:]L&G*O3;FD
M#*H84MN^&]4KG-M^<`,U8@BR*\P1&M2\O(<)E,M&("S80KJ1T00W0`!J\RT*
M9?\$R7T!."V[-/+3GX`_6',!G,`#LVRZ/^"'3IV<VHTP!-O=5-W$J1'>)CS>
M^&@F2.)ZW!``ZAT#"3L&)TM<PP6MQUK@MBIC&V#@D"Y;I79CE%[IEF[I2)KI
M.D8/K%8`\$N_&N`R%/XZ`#W`Y]=^%&&W!B!H9Q`""X``=`'B(6ZNEDWBE9QG
M,Y%%*-'9%`S:-?%?:J`&I&W:FTSCI=TR&;#>8_``B]OC/P[D*&VCM:*Y4[R<
MPMH%45!*%#`8-\`!&,L!7\,!UB*;PBR[A/`7L1DVT'@7%_`(>\H#OB(VQ^(C
M3"ZQB[11DO0!`D``D$<`(D`)OV)ZE``%E5%L$>`!N,'_N\;8LB"$JJ6JYTP"
MCQ`O*WR>@MN]S)O!4\&7WNO=!34@WUV@#YJ.I)7N6J$V\@U3#_,PERP?PJCU
M\B1767=@<I5E<C8_4@"0\SJ_\YPD`DQ@`?3[-P`Y$(9-ZC'CI!%Q,4J11'"0
M!C>``/`59PO-GB/N*/*IV2Z^XA+LT/P612D>[!E,[/E9[)2IT9W\A$`0`^L=
M*/0A!<[^XR<=C$+^&Q=?Y.9`.E70!3'0>#I]`TK`!1$:-MSR/\N"(\V2E4;`
MFTK@L0P@`PP0!A%+<SV"42$BNC@@@).@L3M'E`ED6;/F^0K$!"+P64$I`UY0
M!,46`PB?W0L/0@U/B'<^\;*?_Q85CX]V;XS%J/$\U@'KG;!^H`&<7@#Z8!P%
MT"8ZQ%K"%W(^%A4O/VLW__S0__P[G_,XK_.E)0(\GW*B-?W<O_W3GW(S%?02
M/NK4T:T7KO1*`2AP@`04P`%0_UZR/NL-;6<5_7U<?Y$5G>+D,1+!#@@)4H.$
MA892$XF*BXR&C(F%0`9`734)!EH34EHI,)Z?H*$P)TNEIJ>HJ:JKK*VNJQ"Q
MLK.TM;,GN+FZN"XNO+V]N<'`P+A573%^?A8\7$8@($9*31?5)0Q<7`PR7`,\
MV#('#`<'.`3G2A=>.#@\U0,,`U!0`P,7YP1*2@("3?[W!9AX&<!NWH4.!1(6
MZ-"A`O\_,7,B6&`B@MR!#P-\F#`1Q4.&$[WZ]"GF2U@PD+)VJ;3%LJ7+ES!C
MRE1)LZ;-F[^(D2PI3*2O*0$6,K$00ID?#05@5*B0M$+#I:(\0>T@0,S2"E8=
MBMG*M:L($5VWB@!`MNS8LF3/HEV;%L#7MVY%L)O+CJU=LCCPTL5Q44`$"CZB
MV,#0IG`;!PYVK-EQ&+%CQSL>2YY,&?&.1(@?+3*@(P$2'QPX+"ARY<H6!*@7
MJ!9-NHSKUR9*FX#M>K9K-;4WZHY]Q789++A?8P&NQ@0<`X>2*U]>Z%'R!)8N
M(=?!*:KU4:^R:]_._93,ESA!EM1I4CRQ$U..Q2@:Y$*#$CS_XE](EVZN"`)-
M^-8;4.X^.@(.\2,@!100,!<\`Q!P`X$)-22@`!18$`$3>QT4@`48%G#55C"D
M$04%%94CS@V]:1#!1R#Y-(PN.IV'TW<PQBBC2^'5:&--+19CWBXNC/23!P$-
M590R(5`4EH!A)<D5`&(\^)"24"[)9%AH<0776GME^95];X%%5I1@/A21#S[$
MT`5AAAVF&&.5)=;FFY1-D)EFB1C@F04<&"$:`EML$401J2T0V@((7$%;&;R]
MIBBBMR&Z6V^\S88;<(H.IP9N<`#!W*:<(K*((7E(T5ET@@S"25+7A4)*=ZRV
MVNJ,M81W$GF_F%?,%!MTH4$()H30_P0#!##!!#X$4,7/03X4R%<Y[`1+(($,
M!2A`!Q;$0$$3'Y"3K1(W1!!##!$86Y483*21!H5TB8`0@P[>494`!4SX%@X,
MY/"#'[V>.$6*/OK"DZTDU0CKP`3'>N/!/-*:<(XG[<BB3^@!*:P/0_H10@$'
M-&D5#/IT7,U656[EY+A(@FDR5R-?I?)2#+7<`0P*Q5Q``#33/'/--7N@\\XZ
M1^#SST!'4("$99ZI0!N,J;E88Y1%!N?3DM&92`)`I/%#:'OZ&>AJH17Z6F^N
ME;;HH;CM%MM&LI6!VZ6P#4=<IIW&O9PFR>D`QP81:#"&=)ND@&JJGZSJZN"$
MLU)P++*.Y_^B>`#_E.MZO1(@`T(^![64`%H5\"V(<WWPP;3>QF"!AEB)["T%
M8M!U@!),4!"44I<W64$`'LP!EER>$U#`#_H`R`_,!7CP5P$44'0`&P2$<$4-
M^O*K<./_OGCX]#(B;/U-#+NHXXH/CX0+D#!$I(%1(02`.50O@/+"^NR_$`#[
M-'OP?ONT\VS_SBGDK__^_/>?P?\`#*``!TA``>8O:#[;603DA[.:5>!G%C!:
MFA*SM#8Y#6H8=(#4#*`!)EP`:X1"#0)4(RBL<<!K88.4V+#P&THY2@TL1%MO
M9),VMBEJ-L-1VP/DQL-#T`U44K!!`"[@`S\D0`M:Z-O?`(>=PF7_YSN#*]@)
M$(>38>0(>B79EZXT8`(_,$$&\/*6SY8BACMLA5HQ*$!%V'$1=1'O!@Z2W5+B
M%8`*S$$`;+P`$Q@B@#N040PP2*#/?!`!V_$E6#?`A\8>:*Y&?N@".&##!8*@
MC!AD8%\,R\D5PT.]3L+H>J!42?9&N2+%^0@7?@M?WHQ2`W#]3'@,K%\*\!?`
M+]@R`_G#9?]V.4O[]?)^/&N?,-=WG9494UHE4U*7U#(O"'9A,$@K3&*29L$=
M6/.:%\S@9!YA``Y>RX1[&B'73(C",L@&;2V$(0M?&,/2S/"=M@D.;7*HAC/`
MH8?X1(1R)J$!HO@!"$CL&Q-!(3@GFH)@_]OQ)$RL2$H736%?(#E!':JP'C]0
M@`&`W&.QM"*`.7@T7@7P*!YQ\`$<,.$'/T"!$ASRE8@(SUP12(/Y>``%$<SA
M!BE%`0'X(0(*-/*G:N1+$SK`A(7\#G-B%)W/"B`&$<B`!Q:H9`8V\`L5-90D
M"LTJ3&[TG:M&3Y->75PFIY"!`!"5`N,SBK4H\!>VV@Q5"@%>4I;XB:>H["&W
MZ])>[E(6=GC.(H!EH^=*FJ6]W@5D7_K2D43V+K_\3`-`P,`(DL:T:38-F]?4
M9F48H04@:``TX!0-"4L(S@48*H6VV8@Z85@V'!8'4I%RIVL;I5JWF0`)APB5
M(WZ8S^0@)P]P"/\N'/*0AVXZ8`KI&V@3#7K0@254JRQAJ%=Q\=!?+*$*$0A"
M"'PP`(@,2Z6E(]?/TA#3-'"N'`3XP0V<`""6$L!#/R7O'+P`!1P(X*1.X%U1
M@P4TFE'`=A6Y!T(*`+H(_+$",&CJ5IIP@!(4\2B7!&M8B0'="M."JS*9KB@G
MK+"QEI6H!=!`#8P2@:\\1$!8$5!"KL*//XK,F'Q<YE?\L4RQ@.5((\NQCG>L
M8Y2-*TE30FQ3X^4S#0QFLH9YC#4OB]EL:M8QC/"L#Y@06M&.L[2G-2?8V`F<
M'#)J.+J!9Z34%IS@X#"']RP$<7W(V][F%@Y(B#,2@BL%`S@@`\D=:$'_F6OA
MK.+B)=*]:BX@Z@(BM`"[%@B"#WB`@PZL5PGGX&D!&KF!1D8@/YZ;5@'@Z)0"
M72!"9$H6@0@`2?LZQ:@4L!9*+R""\,EE7B)82@`RD)!O$5@N\9H##D3`#QQP
M@0)$^A\F.=PB\$RQS[`Z6(8UO#!B\\3#`8`!0D1L%`OPA==-^LH9&4*S#LSA
M93"3]E6BY5%AX0/%+!9`I'?<U+=H3,;S8D>\"TOO=,&[J?*6BWU,*J&\#69I
MTH2,DRW3Y($_F1%(2,,-JFQETI9V"[_1<FI-H$ZWU::%88[4F-5&YABV\#<F
M0`XAUNP(-S,'SE%`S1;F3-SJ*'>Y?$8V]70!_VA_35B4AD9T$"S@A0.<E;V:
MOF\$XA?M@%"#'=,:,%-BX`-UYV<.!-YU-2")N4`*38P=((`71.`S`7R`U_D!
M`%)-!"\"5T4$\8(!6/AQ`"[<`%\U$#86&_J+6;C`8'^6>4M"F7=:;+)&SAZE
M25J$'J!(NP!1&+$RK)VM<ER`IUEA"A-*1C(!O875<KG(8'?=I6KHNS]?P3R\
M1S_U)O3#'ZA'/8]7WP]^-`$_GG_+4`AI9`P`O+)+GDS!#:[916CA0R8<K?`=
M#D*(YW#+B*JXI5X#0T>Y4X5;7EOS-Y)#+)A`S0$MN<F3`]PHW*`$'(A"G+60
M!Y<K=\_=T;M":5+SN?]GDD6].'0$?%"$(ES@<P.F2JH+](-U0+TB(C`?7O`!
M6>$SZP,N#2$7J08#N[85D+0Q&[`!2A%M2W$!8A``$2``:\=J]B4&(/5N3G%J
M3&!'=R0"-)`\761)PT9L+!(+P'!A*Z%^M\!WMO!W\!=X835X`?-0'@`#PE)1
MRA`$3A4/.-`$W\9K=_1M1+5N.W4.YH8?J2<"5$`7C^=ZIB<`TU`-ZM:$3C@L
MQ.(R+>.%J4<-4S=U\$9O@#4/4+`-1\``[I!>33``;=@$%D!(@F$#:^``229P
M3(993[9-BH`!H!5\PT="H44H5W!\BX(%)$`";N-ETQ=;\*0HK,5.OZ$&.C#_
M<DFT?7$#7"%``2AP`T$P?N67!@EQ?DL@$ZH@@YW$?BX1:((V>">`73Y@`45`
M`)\S.^`R,]92`10A`F6B:T6(1U_G%-X"`W>P$$V2'TP0+F+W$$R".3037O=%
M`3(S+.G`:YBS$&1X#UY(+.G@!5S0!)0$82OH;+S@@B@Q@YRT?GSGBG9'$S@X
MC\^V25,@,4*B#%?@*SG``%0P`$:@;O<Q+#=P`^;6>J>7>JQF!*%G!`XY%U1`
M!3RP'Q19`@=0#Q8QD$\H+"YS4B=%`"+```QP!!=)D?L1'RCID"II!!?P#V4X
MAOCP`^E%`/]X!!=0A][R3(3!)DIF<+OWAU$3B#YP_S6E58A&62B*Z!HLQ(B.
MZ(A=AG$R)(F^<1OKI)0LI`8/``3$57Z<&#=V`P<A$`7B-URA<BIT%15)00JJ
MF`JL.#TUT7XLJ$FS.']%$`1,<`"F5P#_`Q4.T0%-@'8&QEAB4`Z8XSH=(#+W
M8)"MLQ!&A4>\=FI4T6[IU3+X$(Z[5A5+X3%>0%-JV)E0X`SEJ`$1-H]U-Q[L
M*#V>]([P*`M?Y7[T2$HZ2`Q$$#$!02U#LH\$D`-L``\,T)+^(0+#<I&`91%_
M-9PG.9'U$!_)B9+QH9)?X9#>B%+I)2S429T_\)'$DEXH)9/GL)TH59`X=9W@
M&9[>N9TXA5,L>0%&()$W2?](9@)-/,F'NE=P0/D8OA<%R>)P1GF4QF=.5OD;
MC1B@;J-.&2>58^-E'Z<&$J"5)-=F75DWP35GPZ4%W?0$>#90:=F6&IH2J\F:
M+@B+L4@,Z?$7B48!]M!103$N8%%4,6.-#D(.ZM8Z5#%UV8D.Z:`.4#`?^9"%
M`4@O;)`M\2"20HJ7_G!''56"$"$`Y/"<)<`%)1!5?M`%HTF:Q7::N2!SJKEA
MSQ.;KYF#$G8"LXD>?L,$<^!/1,($.<";4,`#3<"2/]`$.)5ZW,F=W?F$W5F>
MZN6=!:E>!<D$?6J>7BB>)X52?BJ3W[FGYDFGTJF=BYI>!@F%^.`/W?EZ^%&0
M1B#_#@=0B]Y2>]$D&;OWJ?2I35&F`6E@B^(40OLI?%N0B)7B-@':B(^80[P!
M3[)UB?])?>O4`PFPE0_:*2(G!;Q:9P9@H>ESEJ&0H1NJH6\97;,2ER**707@
M`XIF#SOE"4BB;M[&#\4"DE^1+5LBD)RW+.(P#O(`#6H(:5XP'Y`FD_[PIA/)
M`PYY#<!BBV(9!1I`JC$5!>="8Q<P`%P``E`:=P_UFK:"=S2';%EZ/5V*CA)6
M:-0UIAT0`2&@>'YP`VG*`-`P`$T`K[R#4M.@#Q10D"'KIR);/'Y*LN49GG>Z
MLHVJG?G@J"_KLI+:G=/0G?@!:>E%'Y6)L]>)'S$YL]A(_PWIQ0X$$2$QQ:D#
M!ZI*FUFBN@A```0V$`)($`0BM#6IBH@(&JNO&JOM!'U1^7%J(ZL1IS:"0'*]
MRAR_:@@5BEPO8*QRA:S)RHK+ZG?:XZP]X@O02G\^X`5>H`2[U@2]DP]>``(R
M(`-J"`*>.0`F9J0>93N42@7Q`*\E<`T\$!CF<J_WF@8>$`4A8`$$X)#4,``E
M``($4`0A4`3ZBB%3=@/)8@0,,`\#`0*_!G<Q4%WT.'@P&(.WX(X)BR->VFQ=
MRJ4.^U`0*[$42P$Y<`T9&X<)<@\_H)(7$)Z)E)W?Z++$4KTMNZ[$XK$\Z[,S
MZ;TV"[@X6[/!$K,MZZ?9^::HA_^=ZHEYY6"T%H"T\[FTH-I[BZ!!DS"U(H2J
M5TLHQ@<VC_BJ3OF(B').9S-F65N5EJ(&"4"69^MFPXIGIV@=<75L<5MA&$:W
M($I*IR0>WD-1!%($%G`!4.`%IM>="X)3D'921E#"*+"94!`-/E6O]6I>$2"6
M-V`$[G`!/'`-`T`!^DI>/U,\!,($<BBZT#"Y):##SCFS^`$-YCJY;L<KK62[
MI-F"5GH3W]&["(.#OKNPBM,BLTF\"]$!%'.\,B"2&:L$HDMJ3?"\\B&]AHH/
MV$NGT[F]=NRR/"N3W1N3=/IZB[JNW#DL@4JHVZD@Q7.GAFJH'UD-^7$1!S`4
M$E%[>CC_O_3[DTVK"-8T`0:`!!8@?%:[GT@I'$PIP%Q;P&!SP&*CE&66P/7D
MP-SWP)RB!1)LK#(S"A=L81EL=QO,P2WB/2VP5D60!A?`!DV0!E6P`56`N3"U
M*^?2DM1`4R#``T`<!1A2AV0B+#C%`R#@#5"<Q-MP`-PP`$K``2KUN?^JQ"!P
M#3)P#TT0D?*!#^VKGDKP#%R`@D=17:Y)=PE#1:%DL`EK@\+[N\!+L.[W4+2V
M1Q0PL=66QA@KDFTZ`&]Z`3_0K]Y@D'GJLAGMA.3YG8N*IW=<HXPJG1Z]O>9&
M5-7I:"&[(`0B:L\2:LE2BS`=:KQ3'R*0'P2`DX*A!95QR?6;_\F)L,EW<@.C
M%<K\Z67#(<"PZJK`L1L%_+7I])]6J08]`,NY)<M2<$\ZT$UIJP6F.,&@(#-P
MF\M^9B,UV+!7U2_`,!)3$,P$8@%10``,<,RD^E-#EQ`1<`/T@L3K_`U'0`5'
M$-B!#7;XX;K_^LT9RU/>D*Y*P#OJR9(=8P370`5$,<(M.1\+0FJ05L]M"@V3
MU$4:L`&$QH(Z`G_^#$H`G:57=,6)`\8-"Q)$@-`!H-#4MGC;\+H@T)NNFP\4
MW:8.V:<=[='2N:>,VM'C"9[/DMS*/=,R78O8C"&`<<VJ*].@5MV@YMP6$,+9
MW=R>!FG4\)<"@"'>8@,\75D$Y].AFO]!C'`9$W`GP[>_5]N?+:34`\R(3;T1
M$>>U4TV5Z[3`5@U$#YQF7-W5M`;6GR#6N$S6,<+%%AR/^\PP:AT2+M#6&A"R
MB78#T+"94/R&_L"F%Y#$VL``DROBKW<!)0"0E,H[7N"0\/J7W,P`3'"O3$"&
M8L"G-YL.TN`%UW``K&O$D*:>YT`-C?TK&)OA1>`'8]`%HHW6L.DP6,S@4"Z/
M7BSE8+Q)A`<,^U)6"X%6BG<%17`\0FH/%P`L]5R0Y0L8U`W3V$PFJENU@.+F
M(B3=(HPA<ZZZMEB'URS":9[=!-)6PR,AQ),L$O'6>$XF!9DL+`T8-[#B]\##
MZDF'$K+3E>S_J>B=WAC$"(BA!7#F`T0-RJ<JREF6U$H=P&"&WS'TM0-JE4OI
MWV8+X&>K`YG(U9K`R9-0X&>)X`VNX%NURZ=]L!]:C\06X7=+X<4CK13PF;W=
MP^ZPPHX]=2PIV4[Z`Z;K`VU:#8VMPKR]GA+YF4V0+-4NJ1XKOC0UNMTLDFT(
M`O-!SSC>DLWPS0ZF#$J^@DP>>+N`.*EM$UM\(_P,Y:X][]05%-/6Y5$P`/TH
MKT;P*Y`V``MRLA3P)_4G0F^.&CZ```]?M1)O\0@P\:&6\8"1\:'6\2T-T]%-
M)J(S\A+!Z;;XUB//!,U-)F@>TVQ.[=(@D^[@#N(=`S8064]3Z4VF_]Z8X0":
M#@3X^=Z?SI^GE=2E7-],:7VUQ?0:=XF4PK66<@:MKF8\!.M8G_5_<`9<?P:P
M3@C=I$]20*QQ%=:WG.NZSJ&HW54-,]`-)>Q9A%TL'P040`X^@`2W&(`M^0,$
M0A_=V*_:H`2*SI(SZP_ZH`[DOL[DG@U+K*,S.77</+F(G<2)/_F(/;M^4,4B
M^N`<INN$Y_:MJ9H/-?H%30PB8571,TI$`/"(=YM"V(_^R@#2P``)WSK!HEZ*
MMK\8KQH6S_L(0-0>GQH2/_'!CP`6</'(+T(?#VHKX/+-OP"L^P8+X@/-GRQ.
M0"8K\`8?7XLMC>8;*^T4<`&06[EU&`,UH/_S.Y][?FC)O+=9<J)!$7JZ(]3[
MPC<H)$3Q[C3?6UO?C0@(929E6(4FAR97B(2%C(6/6&HF<'E2EI>8.IJ;.@\/
M9Z"A+*.DI:02.IA2J0:6#ADO!;(%,+6SMP4G$+N\O;Z_P,'"P[TGQL?(R<JZ
MQ+PNSR['T2?0U=;7SWW/QM4G7U413#Y!/C@R3$4434873>T$!$KP%SPE#/;V
M7/<,-#Q-2C]^*+F@1(D1+R5`@"C!4"$(+@H92GP(@D?$A`XS9L3H<.+#&WY,
M^(DQI1LU;"A36F/6K*7+8-BDQ9RF\MJRFS=5]MFYTZ3,F%,"%.A0($8(/WZN
M!+F08Q\#'DH&-"'_,.`'!0),?MR(X@.!UP5>NR(0Z[6L6;%D?:CU86&LV"(6
MUK8=>W8M!0H^*-S`2V&%CQL_V.[-R_?&6K5W#5NXL9=O$W\W"%"A<F0`A;@Q
MN@#!X*"SY\^>=XCN++HT:-*E=YQ>[7G"A,X3I,!!@F3+%J^VOR[8S;OW;@1;
MK@C'0J*X\>*02&`1Y`A1HD60HC^2!`<.)QU_LH?:;FH[*`G;/7%*D$#5*BFM
MI$R`-:L6#%RW6+YLAK.^_?LX7W:#QJTF2FTT\?=-#'L%88$(30W```,#$$2/
M$07%4T\)$($P@((/031`0@TMI-&'(&K$T4(C9AABAERDR`4!(8BD04G\_YWD
MWXS;N##?C?--@Q-*W/#D8T\T!IG2CRO]5&100Q5U5%(A--&4/4\UT2`!/%@5
M$!,WP.757!9$L"599GE5!%IB+<"66A'X8&8:A^$UIEH(X!477GE98,%=;+VA
MEF%1Z-6EG`6P%9=:"]!IJ%J/-?$#`1<8,0`/ET60AF:<L?:9:0ZDIMIIFEJZ
MFFL.N&;`;$&4E1L"OJ7*&W#"74'<<<8EM]P@CPARB'"'."(=)&IX!TIV?UPG
M[+#$7F<>*Y:L%TM[[\$GBWPX!H/?M-3F]TM-,@8H9#;;9'O"%%7$H%<112@1
MQH(0E<".11X.\!`/%\1K1#T5.I3BB1V5&&*'%/_QFU"Z)GX(Q4--!!&2!AG(
MF.VV*?4'3;0XQK2,?SW^:/'%&`,Y)(#6^.B3PT6>$$&2%BQY10@$/+F@5#P8
M024!@/V`I99?A8DJ6&;]%B=8<*+:5<]WA1466C6[A9B=*^#UAE]_^2#N97DA
M1N>9>$9]V`_PSD,/I'"EH8$-E7J:Z6AC8PI:IV)_!JJHLT61,\ZJIHI`$<%=
M40:LQT7'7*V(M*K(KM*ID0`<EJ1BWN&7<'+XL(MCHNPMMCB;"\3"5&OYY=#N
MTO#"(`L)8.?@:C!N$`0P,/!&(BIDQ#_Q7,"A1PWIF_J)`-M;PH2Q8R21$>P4
M],]`ZA9Q<,+\,4SQ3Y3_"T/CPLM38\7ST$<??<868X/Q-1IW:Z1)4XQ,5,E(
M7>''#RHSV*@1/WBAQ`U9,69G66;:#*;-0M-?/P)SV3\T86HEW7]>3EC!&^ZR
M-$-5[4Y_6<"=#$.G&SCJ""6H#(5^`!<+?"ULGL(4VLZ6FK2I[34[B(T.9E.$
MFZW*A'$S5=U>!:M"J$$-M7*$K1*!*UH!;CJ3*%PFBL4XQ/FP<(9;Q>/:([EG
MO>0FO\"<$J=UK?H4R7@N^-S"OK`!T3'!`J0+@T).IY%ZJ6M>\ZJ'A_*%+XG(
M3B,0*DA`6L<1+O"."V'@4,O:49""7.!"/D`*POK#/"B&K!K)`X;$DC&DD!'2
M_X\TNIBVLL$Q'74N1MVC!1,B<!1%^($)Y6N0%WA`@-7I12LW>)_^1JD_M=AI
M4*8\S)G@)"BKR0E/%F#:7:(0@5!&X)6AO-.<JG87.OW`"%0HP85XP`,&$*""
M7]."!S7804XUTX.AFH!H8B,;.`2AA+Y!H:K*0K<@V*V%RED.(]10!EWUK8:Z
MNN$D4A'$5?!0<3^,IR82-\0BQN>(2\RG/IN8DR<:3XK6F,(&ND`!<02!"2`X
M'1=GQZZ(B%%%(&H9.PC2.B/\2U\)2:,\%F408LIC?0XDT>TD&D8O>.$A>?1#
M%S(PA3XB4F(/"Z0O!HF,_S1R1\7KHQ-UM#&>\+0:C?]TI,2FT#T*U(*221')
M#3+9J`%T\@*,@5DH2W@6+LVO:*BR&04B$!>NYL6K/DC39;IT&%3*Q0<%B,";
MTH"7--PRK*\<ZUBC9E:V4&!K%WH4&YJ`3!LH,VW,--NEGNE!UT@SA*."PQ60
MH)O?Q$UG90E"$$)PM[S%\+*/.*<B#G'#1Y!`<.V,IVA'F[@@ZJ">]C2B2_3)
M6B7:9&(OQ=XTB,"M:`PT'..@@.D&-B(&>(B8O(-7'2V"$6+V:R&\BY?O#,(0
MX0YD7LV]77"G:U%.!B0@`VD403XJ1BAX04$W.$H-6.K2V)I$)93CD3+^\PPB
M'&,#&_C"%TX`W_K:=P,9R*__?O.;@OZFP`/]U:]]=ZJ]\M)$I]]J00MN"8,.
M!,!D?J"`#&2PH06YPZF-8HQ6Q%$$G&7UPR"&W]S*<E52DM(NEZ%`6B.P@@AX
M8`4K2$,`6AP`Q:CXEE#+BYE<^1?M,BJ8#3!"!:-@@\U`,S2$1;*F-E58PTIA
M<"8HE393:#]OLE`YX2PG(;0,B1G2,%>==2%Y&D=:=\)SAZK81.&TD`&AI'86
MF9-6:^=<K=>NU[Q`G2TCI]&%&#"!`ND(`Q<6JI![J&Z[=50""EKV40((9$0D
M#2/OA'D!>`CD?+S3J!$<TK*$4/2ZK8O7=BET+@7EX`<&JP%)#(SG15HCO33=
MWFNG_Y#?+^C7OQ[(M0<"$(!8N&<.%:B``,1`[&*+00`5F`,,7L!K_V;@"RW%
M"5'+RPV=$K4%X2IH!R@0@AHDQ0\^8(`,),*`"S.*!QIF'Z!-S.YVV\_#^[O+
MG0H0@#>\(0(L;C&+4WRF`MB):E/KY64<Z*@[#H`+0;8`7(ALY".7C6P<7/*1
M#1L;\B"APX_M#2DIB^5PQE#+Y>0;#85CJS!'8G`^#&V:YXDX8ZT\B&SN]9ME
M,875TOGF][%)D.Z<2&T!:4!_'M-30FU1!E0("IG.=,OJX;)%7;>CO*OC!1;R
MJ.!6^NE-^$?4YX&A1T'A*1HUR$1[IP0>7$@$[8!JJE?=:O^5R+KMQFLIDCH0
M;&$;6P0BP`$.#G"`#^C][WP/O.`''W@`$+L"'7@/KP/@@0BD(+]$;:E[W0Z4
M*6!;7$.A@`:\+3X+#$`&$%Q0O)SZF'3_6<KN#M-5YRHH.:'R,FR:FIWD=,LY
M48TPL[?K"HH0`2>\P:QR:E-<'I-V>O1#X1:(09$QN!J(/YS)@Y4X-`UK`!7H
M(`%(L$#&W6WE79$3Y"'GF]]LE4[IS,`$0`""D\O\3C6WG.52B/FRWESS).+\
M_DO<.<]GI`V'^71`L@`7+7-=D7$^YU-'%M5<$X)HCG9I[A`A4X<N>>4/4Q$/
M&]4HOV,$"\(@8+11UQ40C-%+9:7_<$4P67Y0`QHP7W"W.;#E1RWH'^XU!1X@
M!GI'>!]`>#@8>'F55WMG@Q_P@T!X@S@@`F(0;#"0`M%V`D1`6SPR:^"2;07`
M!`6P>=]F`4;`!I6Q(*M3`@4Q`%@B,T&7,S8#;[I1AF81?*LD*/^FAG*QAG>2
M8N+PAOS#/WMQ)[XWA["$)WCR2TM7#VS``SX`%\K7<!D4?<ZG9!N4-M1G?2/$
M5E3F;DA`'+S2"#,4?ELV<G;S'.7G<5C0`T"@!=,D*F5F9CRT."RG`_(W<P50
M?[Z`?ZZ8<S/23U#4?S+R?U44A0IW1P3@#O'`.HR21KM((H\B3!4(#\9X;NRP
M#N*6`SEP_P#$M%U@&((A*'"F1(*3%0+8B!3:N(W<N(W=]B(PLH+1$(LNJ'_*
MT`(I4`%^MTF"]W<[.('$M(,+4@(#LUL+DE#T"`7ZN(_ZN($3)@,Y\`$O('=*
MR(3-(U!5T&<C\QY14$E7$`47P`8,8@^KPP`$416`P01A2&+N1E6CE#]>LB4?
MB6+S%@!Q$0`1L#1LX3_R-C)I@F*%LB=Z^!@'1P,-P`8T8!F">$&`98C0AXA)
MYBE:8%B,"`<:H"9R8Q;D0C\>UGVU\D+EE"O@%Y5],PB)4'[)H0:?6!H4UY6C
M"$0N5UJ&@XIM-G^IE82OF);V88Z'A$C&P(1]8`7:0$56I'!4PO]11/=<RG4!
M1B=H#\&%'TB`E@9*6B&"IZ1PDG6-V+@DW=B8CNF8XO.-1+6$XOA(L68YS7,3
M`2`&`!`O7@!,?V=V[SA,HKF!^K"!J(F:$%5HZ"(#J#EA8N`!T\9JL[8!":D!
M"PD#1I$42M$$$KDA;M0$%DD5,!.-'IEZHX078=$6/;,6-S`W:N(5%(`_:%)[
M<S)[%J"243!`UWDGOW=*>J%*P==)5&!T;,`%-,``66(!7@,V@,5DB0B4@B4V
M0^D:C'@&2%`J8`%9<Y.8UQ0F_!F)7<8(S#&56N8<5FDWG44",P`'H!A"AB4:
M6E"?7>D:\A268#F6J3AS:*F6'KI_V/+_@E#TEMD@ERY`EP45B%2Q419H$`!!
M@-,H>_[IGXM9HS9ZHSB:HS8:$MJ(H&7P0D!*0WYP%%TPF0;9=M)@8/F4F<C@
M7B>PF6@G:DEW$$I'3*)Y(:_YCVS@FJEIFBKRI2JR@0`PD+,I),:`D%V`F[30
M`>`C'"BSI16V.FY$``=0G!J9)6?!D3<SAF98%FC8%FXR*((:%V[AAK6T2]<Y
M0';%%TP30'2%&(MZ&#=`#^>I#RE"0>S)DV(36(>(&M+G011:E(KUGY%E&Z::
MF&\#;]XTE90(?E)I*XIPH#8$.#.0``]:H5TYH;JJJ[A*3:5U'D"4`!I:EF\F
M%!UZ##;WH3DG_Z+B:#S?`BZU!#58<D!V4H*)6:/>>!0Z>J,&DH9V,EDTNJV+
M60,F0$X("J3H*@E(@8TU8`,M$([-&HOXL8+?`@-X)VKXFJ\7(`)&D'<X,"\'
MT*4+,F%=FB*I*0-<X)H(F[`#*P`9L`'P2B-3(%^VF:8C$X5()1(A@$D7$K#^
MP`Y4H@04`(;H<!9D&)VI)Q;OTS-NJ'!T@3^OAQ<CLU4!<!E"D6*!\E6WU&(^
ML`)ON`"A]!=\X0,_T"AL()%<()$$8"<QH`%`8`,.%[6#U606R@G501M82QN*
MX*:215795!9V`W+B9*"+0)4@!V;1P8GH1Z&]BJM+EAJ]:@`49P!T>_\)Z\%K
MQ;J*RZ`?3.J*\=IJ9QIM2[`8EU%!Y!(%DB6N-CJCC-NX-^`%Z]`.6E&"BGNC
MY.H<KHJ@(J&-8Y``+4`-/L6"M,DPTT*O7]`!49JO8J"O^XIW:"<"`7L$IBFP
MM%N[&T@#(A`!\15%Q:,21#"Q5%0%&H";[S%)1W$(&YL#^B@#?O</BB("33"R
M&HD.QXF<]D,T]_,S@1@GVML69A)+^'87CD<!]U:S,7!+7+55,="S:9`&/JMC
MD$I73!`O#'``1^":1]`$3+MY4"NU_CN?IT%QI'@=W@%#6"`2I+H;%'!""+"J
M7/;`9XLK6Y:YL[HK90`'<ANA<-NV'*S!TZ3_*5WI`%\@<_:$M\<:9S#1M_CW
MM[%U$TM`(*$4!%%@C8E[H]P8`HV;PS0:!.H@``+0`1KI;Y-5`]BHF#O*C8<0
M$H/PH^:*N9*`"&/P!!`[!93)PJ)+8(![NJF+KULL:J[[N@%KNV(LQF%P``60
M,$=*FTL(;54@O!=KO$I<`Q1P`#7X`2(@`$T@`@2`=ADI,RYKO6%!A@CPG&XQ
M%M-9R*;D,S[#)8+Z5>O[>W<!%X:";S!&R?\6?+*G#ELS&8ZBOW;"O_[[OYT*
M&@)<+-XQ`[&B%/#SM0T<MN%GP:U"H):X-S>D!H2#'A3WMAO<P;W*E=)D6"),
MPI*S>'J[M]=RF;)H_\7*[*S*L`0:P#XE$P)%L"28R\3H&@E#JL/:K`$QT+23
M-;P:T&T\VJ.8VP-ET`/H;,Y0:<WK+*LF$`+@W+3P-9M'NLSV7"094`%='"_[
MS,]1*@(#(+M<.L8$;9HR(``I4)"]ZW;>\(1J.A0^<!1C8`(UX`.NVW<'X+I[
M+`+L<UU_7#0>IC-P<S]YB@!<Y14A^;)L<3]6A4MP)35Q,1A;E6\X-BCA:0%6
M01@W<&%9DRAV$@%$UK^A['``3,I.9LJA(`%JD#=^X)&L7`1(L,18V0@T--7D
M!S@,F@!`0+=<K1ZYK,M@W;:^3''![&;#;,)(-%/(/+KWW-8A:@P0H`%#0?])
M(1`#-4#!MR(<VDC$,QK.-5H#@,V-8^`'$WT(8]`#)I#.Z#P&C-W8Y`'8[6H#
M-M`%1^%EB="-D,VN2-$%+H:$T19Y1J)(;@VXZ?BZ^=K/HN8.%T`%`3O0!3W&
M"L$%(N`!($.;QL#&7<#9LK!M&L"C-1`!<Q#<PCT'T\NO'1T0/N`V@9QZ^:,_
MS,D6<"$71C,6:>`6$8"2;XAO:%)CN8=`W8UB:V$F\J;)9E=I4G(!@C*(0QVU
M1?U!54LLX=$#+23-C05O)>C*G775%DS+@(-^=9L>O.RV8QW@AK4!>'O6:,VL
M33C:#-["W=(%`=`!$=#-=OV8C;FYY&P"A6W8B*#_C0D`V2`.V+F=IAH`7Q2N
M7S&0!MVLXD'@;4/JXH[I'#WP0F,0`P&P;``&;1MPIMER/=A0SPWN=J6]KZ?-
MNJDM+PKRVJ\=VV8<L:/K#=^0VS&PVYHWSE%0LY*2!F1U%TV``QJ&W,J=LE_"
MIW0Q)G]:)T:3R*:$;S%P)Y)2G:'T-&\8%X'2R-6X8V?"**N]+AD=B,E7`T"P
MWD0]RNXM0O`="@\@W[!2!DW=IZ;4D":P'&$FMOO]RM)A`ND13UR]Z9F>P1.0
MZ9?0U9CPWT!@X,0,'XMGK,D<(VT9Y*Z.2`JY>8#=X9NEN5*)X2<HV;D-SKS>
MZ[X>SQ1^F!3>S7Y-S3Z:_ZY`JMCFW.$AL)#,Y@$L!=HGD3&&].H,7=IYK+KZ
MFG7<'J5)KN0$[1`'33P+/8[60%O?\@U/T&>[/867:P)1$(4J%H5,``_SZ^6`
M`1@4@'KOQC-^"A9W4C]YL9S92])ED3]G58=UXB>$V[-;5<DL]ITK8!A%P!AV
M4;3G(P+$A`/)_>>$*.B;2NBM<=2'#@J)CC<D4`;TO3]A%0$9L'D_NBO(\7&O
M3*!+##AE,&8^Q.F@SG[F\=\&8.JG/@NIKNH*KN#6_NI!A1)U`-D]BMBVKKE#
M&@547_563_7@S*Y$O)B\'@-1T,U8#^,(.N/HK`8S,`-`>O9HG_9LC\[.X8TQ
MX/\!+S#W`>#9T094'O-'2:]>0][%JYNO6=<.JDT/L@ONJ0FF"0L1X@8`";T?
MY<X]+?`$-F#C21(%E^L'49#'@>^O+B,E?Z855M%A(@:@\C/FJK<E5C4W<['2
M*KWZN$<88A47@9$.4',9!92=4F-`X\D[."#X=T0!,VSY3_`$(+],(@\;T33`
MG!`>$H#*Q7'VZGI-A]'9CS=0"6#`TL&)F"7IK0HX@E,>7_F5H56WEA#TJ8X+
M16_T((I3>]_^YWZD2PA?O-XBN+XDV3BDE9O_?^WBN0((:H(S6#.":C.&@UB'
MB8>/CSTFDR9^?B&8-7XU&A$!,#`!'AE34R<N)U,NJZS_K:LG)T2NL[2UMK>X
MK"<I`F(7(A?!P2+`PL+`3<)&`PPR`T?-#-`Y;-4R,@PYVFS77-@E`P-&7@,@
M(#(X'J>OL+JV1%,M9C4Q`04P!3%^E28A349-`@8DH.0'`08_*!!@DC`*@H=I
M'DI$8&&B101%+EY,XP.!CS06?(BD$*&(#PHC(X0DZ<G"2I4L4<8XN=(E!0H6
M(HCT<<.'R9TX+?PP8H3'0`(\;D2Q$*-&#2`8'$B=2K7JU#9MK&J=NJ/K5@<3
M)D@-*T6'V;-GS[`X\^>!A!DD2,P8DZ"N'C]!0GK8F\*.'7A+GB3`0A@+"<)Q
M$Q<F7*8,8\>,332&7%A-`@.8_Z64U<RYL^?/H#GK"*W9P(8`J.T56%T@=>H"
MIF#);M=J72YVLVW?WLV[M^_?M5T0R;"A2Y<:8WK,*',%4PA+EYY#GTX=^J3I
ME"1/GBRH\2%&D,)#<B0>4IGLEIQKLL0IAJ<7+T21*C4KEBPB1$[I!LZ_]PD/
M8H@0D#&_%$.@@<$L$XT,U#2##0/A\$!4$TH00,`/-]R`D@\N%6%2"<VD8YML
M[MABRA,VU'-//GY<T6((2@!DX84_8(A40@LQ08%#&CU4T0(7`1D2D!.)Y%%'
M)W$8TDY*BN022![EU"1**VTXTDTB!1`!!3?H!)1/-UE`Y0W!\&#,`4P4P=1Q
M4'WU%?]6;EK5U0Y?A376!&6AA=89?/YQQ@-PD6`"!E$9,`0G$?#5EU]]P%/%
M!B%<L=ABATVZ76.%;3<I83U<1MJGH'8VFJB=F>8::ZNYAAILN9%8(F^M[M??
MK+36J@LL\&2@@0;'):>(BU=HQX]DCW@7'GF#?$=8=]V5H086W)7GW;*+?*=(
M>#V<1TETNV*RZZ[N?0)#?!ZD,%\IK=JJ;BZP`"B&$LD80PR!PQ`S;U'0,*`O
M`3<PH:&3%A01A'/3!3M)8_T8$:(ZMXYX"SQUI*A:`1;L8T)S!`S@18T<8WB#
M$AK^P(2_&4FT`)%$(I#R0SX(V=%$2_J@$D4Z8501116IZ63_1%%^Z<,*.*VP
MPDDHK>!$`"=I>=,;6UI@])5<BL3$!5X<,,`!^C)`@$LQA/!45'%:!6?87'FU
ME9U@X:GGGFOY^8`:<B70P@AM++'$%"GPY9<==.R==P$W%'$%99LNAJECE"&,
M^*2=&C"J9FN'"NKCD)=ZVJFIJFI/;.F^XINLZX8N^BSXE9Z?;*64LL&WW>[S
MK+*,3#M>>7"#]VSLSC9[.WB%&\9[I=)>JFUV+H:P5`2>W+0:!05T4($``E10
M`3X%E&MN*5_$-OKVNJ1003%&R(O@,?86P\,SS%Q0A,4';_=([]"&H/`'(C;\
M*BT0V]#):C!$4,,D+OK!`'A@H0H9_\1C&F(($_*1LY!0I",Z\Q'+7N9`(^',
M)2HQB4J4%!*5=+"#,5@2\L2$O)NXAR7(<P\'56@!-"P)2U"3&1.4<`&L,8`+
M#&!#$Y3DM3:1C2IC^^&<ZB26M.5I;3I0"UO^I)P9U*`%"H``$?9"Q;_LS2\>
M>($8#D`%`O@@"$@8'*;@!ZW)9,J,E+*,XT03.<F11D]YXHRI,-<:S;$J5JBX
M#1ZYQ\?1E:X4\(!%ZE3'JRY\"Q-^<!8C*E.L9\7%=M1ZG>S>1ZU%;BH\VZ&$
M\-RW26U=(@I;8LW(.L":YT&O`AT`!?7D,Q_\L*(/?;15NP0@`H(<:'SULE>9
MPL$,'@1!D?_P2XPP*Q6_"QR!?@$8D6Y`5YLEZ"\"_//?/EQT`Q[PP`M>N&91
M+J"A!(J,"2,L0LT<**6=N,2<*G323\QIDIN@,$DBT0E*O'03Y$4@`RE`7@8R
M8,]]VI,D.9%G!&8BLS#1Y*`T/,`1\I4#(RA)`U_[(1"S(M$AGJV(9$&B693H
MMB;68`,0<$'>KFA%OVGQ&D>@0A-Z,K!(7>&E,)7,&3N9N&5=9E1F<:-.-3JJ
M.;ZFCG;D7&[RR*[.Q?*HLTJ%*0:9NGT2\C@U<`XB@Y4[VS'KD97)*A8N9H+7
M%0MAV;E.=:1*5O;EKA&$4(3MKA."&#`/57`=V<C@"H-4MF84@)3_11_VBM19
M3<$#T+O!#^)5+WH5:%Z[M!J$?CFI84YJ=X<H0P@NP`!DJD(6M/%<*V"IBRD$
MI@O0O(<T+^8'"IS/FB`88`EXD)`,]:M&+^N1;!\2A-BR;$L44!I)"A"3W7)H
M2S+S4G`CP#0/O&$%!>#G"I2&O-6(I#448(('F@9-"KRAGMA-*#9PR`8>4$!-
M$/6A1!T01+)95"MHRZA&^;3$!S1Q#/:Y8M[*A9\4I"``8I`!%TJPT`%<P&-6
MXJ!/!O;22VEGC-!:5J<X`P?*Z?2-/"V+3S475#PRTQ6QNG!?-VP+03)UG_8U
MEZZ,PQY-2%43Q!)$),U#TTV&-:R7J(YU_UZ<G;,B@C#74H,GHRHFN"J/MR21
M67"Y%H,8[*H+-K!!"]:Q5\YR^',96!X3"%L@P\[+0.>#T`"#8`(RTNX\Y_%'
M,PX0@,NB8IFNX.LK3F2#T/;O.3"E0%&L.<!E&*&U&1K9#VP[6XV4#&8ZN6<(
M[ZD3I@34@\B360B'&P&@!4!H`<@`I'G+-(#*+`,B0<.@>7LE'SA!A@2X``ZD
M@4,N#."[%@@OV,9;WK"=URKI5=MZ^W0&'71U!CUH00J((%]%F<L#%?B`#,SQ
M#"X*Y`)-($"R_?4##@R$I6+4EJ8>8XC'-?C!GT%B`C0JX<M1.*CU21>)[B.+
MV^BUR>A.MY-SH?_N=C?9%:Z4#7XRO$?\F6[-&ZC"KJ)09/?8,P)1&(,:*E%B
M)*@GD8BX%IB-)1ZK?I7AW6G?9#1)8P`:[&!6]>0FC!="IA0Y"B>VQ$O#"O'S
MU.!14R!"'ZQ0&Z7&IMS;@_DJTFT%EE?!!IR@0`>"<>S#E@^766;``7!0A*X&
MKY/9$?,'R+R!E)_.5>QZ`CU6TP$?/`>`%IBS->E,0,%RZ9O?]0D"4'*DC%#)
M2$MZX`35=':?6"``YP1*W,44%*+]UI\#]7<*8Y`!#,:`:?8L,G"#<G:7#!8'
M.%QH,YBPE"A$E-6M=M.<Z'31.QUQ;>SEDPX2@(@>V`"??K.O%>U;@0/_=`.'
MTC@"+Z\V`"H@^Q_AZ*^$*!`"`![XC#;=MFA`<Y;)>2;"9C&-![YM1YFSHV'K
M&.J3TZSF=<_\8:6CMZM`9[I[IZ(XS@E"$/@M^('6O@R2<)$E#'[P%"^+=V0L
MS&%HY]6!5_S]-#9P6"^NR19/?/[B#\$&-A"+=[.#J:6#5'N%'[!D<SC7!6(R
M-;J42X:E#%=S`$-7!/;78I0`(P>P=`&P`5_@2D]G?/!6;E*G(AU`>Y9P,19P
M`69"%"IH!/S26F`7$F;W,F+G)`+V$![",@%3)4PB3QR")6$B)CW((43#%)Z`
M/%I2#UJ"&KBE6_:`$UN"6RLQ$AP2:B+`!8G7_PP_H"91T`7B]4-805&N-GE$
M9'D\E7FU!@>.-`8;L&M]LRA^000IH$4?(&QL@'I9LU`+9354(`)4\(!6,P#\
M902!$T9<A6"580*Z5SF>L6TY]2D.!GR7L0'#1WRGXH&9Q4<NESK&ARO1!W5G
MEF'0%V^76"O7=QQDM7T?IP%>4P:&,#SBYQ1>4X+`Y#N[DWZ,1$F+H6,T%5GR
M=QTI)A[.DDD6)WXE%E5D=8P:T'0NL'(LUW*SP4>;>`K5-P5X%T),L(#DTX`)
MPDM"5W0O1H'",@D6B(&F,'-JQALX)X*TAV)74`3_4$!*$(\7T()?QQ"!TV?X
M"#,O$6C\1!(S$5!ID/\&>A<#QU-.6`(T,T$2`3!/K9$H6E*$_A9=G690/_`+
M^B4-S4``6A@"74@V7RA$8EAY1E2&[/4'F^=(:M`%*D=2=F!?^'6!6%.'67,-
M-)F'X0"!.`F!L7<$1D![PT@XC)$`0+`9H_$X;91M1<E3:%$6D3B)E+@JT:AA
MN>!*+<=4TI>)5YF5N_&,ZI(*-^<48.D<K6,"/:!B)!!Q7!4=ZU%C*_8=*O98
M[!>75E4)QA@"VK=]10!RZ#%6Q]B7?BE5T%$#7:",?4`&S8A\HQASTM<"&I`!
MH*"*%/!SQ8!8RA`^VQ@.$.*-WS@\!R:,_:`$`T".3':.NU$'G&`/.@)1P7+_
M!4%``.&S@D7!+ZXE,ACR9QJQ,@^!F[E),[]E`?PV0LBC)EJ2!L!)>(R6:/[(
M(?[6?8)F3UQ#=TQB)6+2!*,&!8HG`UN3ER&09.-%7I&W%9-'>>B%4;*&1&;X
M!YP''EVP:R2%'\`VAS(0D]Y`DS69DPIU!#B)AZKW#$D1!(-S,=&V&"8`!PE0
M.90#1[_7B$JYE,$GB4_I&C+'E;"2?+20&U]PH1B:H1JZH1BZ3Q[JH2$6HBE'
M&S"7;I^H+K!T`BT`55X3ENIA=(&"50AS"0.S'JLI&89@BW!YB[P(5O.7'FKB
M$D(ZI$6`"7=YI$;:E]0!F-415F-@`X1)!F2P?*V`_UFJ\Z$@ACS2,S!RA@-&
M0)F2*0)$X8"\Q`-%-W(UUHM[>0E*<($X4&:CB6ZE^00:,#&.9S$AX)H4`B_P
M8B&N%5TB4P#(LQ26YG:%&G<4<1%%`$/&"4\H85TKL0("55UY]V\#15W(<UPD
M<5P%)80J,31T%ZH4\`O0<)U-$#!1`%$VT)T?:5XA.9YD.&M]@IZWDY+L&7K`
MA@/7H"]<P`8Y9`VI]X=7@X?VJ5"\=`0EL#6)-#P(-G!P,)39!CF-*"J]MZ#5
MJ@/"]Z"I$:&I<)6?B#J9R%13\`4@%J+F.E]4M!>H`1_L"A^J]*[P"@KP42[H
M<HGS)I6^D:+YAG-@V:^`V?]5AB%,X$%P[`$=!L-B:DI:,I8>?WFD=QD%2"I5
M+?67!+.P"QM3]V<"G-!TI[!RB7E4F)4*6?2NSR,&8A`]`E``F.`#<T8%*H@#
MDKF"VWA#XG"F%C<=V1<$'A)WS"-8S(!,_&<;_G<;56!(H94/*-8/0[&G-!0,
MLNE-_N(2$^0C)6-!$D01MHDS2>(E.M$3[20E`0,P&'1.S56VH05-2M.0#.F$
M\H0321(U%D`F(L`,&"D#(N`#49"J-6`#J^:1WZD5X3F&(RFK;(&>/6`8:E`#
MMVH'Y9*K'Y`UO<H-W(`-^+EZ"H52Q6HUJG<^/'D#_KE)RS*@T,I[TRJMUVJM
M>9+_K=H:`#!';]DSKJ_;H?@4HNF:KNW*&O&J2AVPN[S+N]+SN\`;O,([/>/"
M%]E#HJ/#65-0'/WJ%#B;"0@W3'&A8]H1'258"11[B@Z[O=P;L0V+I!9+'3"%
MIA+G/HQT'I<`+L1A"B'[L;$$"QE0`3@`@3A0OW,(LR*0LN=D$!82+T90OP#\
MORHXL^!P:MJW%"^4(?Q+0]G$2U"@+]\P9OG@5*GC&_FV/ZO1%'CZ`UX`FT3Q
MM("*(?D8)!A!@S@1D(F"/`')3Q$0D"C,017!(3]!MO\4`"<T74>X%_9D+O9$
MG#`$%%0RJG.;>LW@4'FKJGT;-JT:AJ]6%;%V>7J2>7]@_[B%80)5$`M^85\P
MH*L'8(5>+`.^2JPW:36FA[F9JX<\H(=9&&UH!"U7D(A(>:!P9*TYU:!.^:#E
MACH@2KOJZAKMFKN`#`/#^[N]6\B^BTJ&[#R##+S%6R[S`8H5>AMJ5@I%V[SK
M\;P6XTC#I(L:"[U^L!0>$LJBG+>D?)?9^Y<R9J0'G+=!T")<]7[10BG2N\G4
M^TE%YJ'B:A\<5@H``L#V`L#S"[/(1B,,P3$%E`PB4+];1Q3G,T`#P`8`@8(Y
MZ2`/DC5"IY/A``7'>@`$P#_C\@(>H#VW<<%':P%)ZP?5%(\5,B/\PB4AW!.W
M*1$=<3(F0\+MY)QN)62$QUMMN_\ACRH3S.EQ^!PNW>=6%)!.-_&U!R5JS%`"
M(`(A>&MD>YO$<?*%8,C$1"06ZF6>)4G%X)$`#O!7]B6'VV6%O,H&^)F3PWJY
M9IRY$<(#5("L>X8$MR>@C-A[OQ?'IKN@J>N@JYO'@I0W]D`]J`(*O!O(\9K(
M3``#3,"[HY3(4&W(TE/(,]*[C(P:'O"ZTI=').J!R\A9UY=O4%6PU&&,F1RC
MT[LMB!0=I]S6TL'6:^W*\*<=;ZE^LWS7TANP6-4L;*4!_O:AJ2.TSK<]J8!?
M8D!E+PO,@*@O`X1LZTPCM$D0`J$P$.+0UCS-C!T.#EW`JZ?9JN?05S.'HBT`
M'J"!NU'_!?IVM*-U,10@#@DRP!@2VR+3`1YT).RT$R/L$>[D`V\`Q"E1A,3Y
MD!&`!D4X0B>Q)2L@)DX`-"BAJ8TV-&'2VR(!-+C%$SA!`3@P0'>H+Q00!!*]
MJA2]%19]T7'2Q%01%AH]`8ZS7FM1N&^C?BQ@`WB316)`AUYLTL1:K`M%D])P
MQC@9#MG=>DW@DVU,&(BXWD@9QW1\K<)WQY3X=+#0`OJ6$[@+5Z(D5Q@^!QH^
M!TZ-X4_=NTQ=5U"]X1R>R!L.O.P\!XM<`?-Z/>(Z2/,V;[C@8<O[E6!9'?V:
MR7J]?CH&+,3(E\<8OO17?[.H?CN.UT@^RX40EX+0`Y)P'>UA_V2[@MI5T`+E
MN(S!0=A38-@]1S[$T,PIG34/+'0XD&P64B.NA12K=]EK+G3ZJ9^;#0[\%>?,
M<(%+=P!SD`8;0)7"40NHW9BL$0%7=S$^P`/J#"_"\`/Q6(\_$#`2<3-%(A%5
M2T&VO;/SY$%#FNF9[A,_(9P_981)>*G"?:G*V;;1>78HR`/;S0`[(M%`X`#A
M+=Y+C-$7E=[KS=&SFIZ(,09I@$\!(+^[R@`@X,77_.80B(=WF-+^C9,X<#XJ
M=0,A@#A`B8AU80";L7L)NN`,+HD.3GP0/@55('51]9O,(U=QY>'H_N$=4.*\
MN^'K3N+P3N)3_>X:/KP","/0D^_Z'O\]%2`&=T"\\"$*UO/(X*H?M8`ZJ;-_
ME7SC9<WPQ'(8PN1^<[V916[727[Q>`T_[.?D')\=8T`78#D&9/GDE,#Q8_`$
M5MZQ]C,ZJ5``)BL``A'ST),,13%`=,9Z9SRF`W(UUMSS#@P%*MW9@.C0>!CG
MJ\5Z=AL!&]#GN"#A79`!JB'H%G,%%N`%CRV/33`4/2E8L-5G1-(D(L$1O\4A
M#J'"$9`"(32<*90D4>@S`/UO&=!]'YHW]S1\1HCV+V0!UR6=:LX`1`\-@4.0
M7-B1;F+1(&DVXYG>4,PVA4NKE1$"H>`!,```PN;W-Q2L]JF?T8#YRQ[T`Y#=
M%T![F^(8EB'_E'"LB-2J[76,K=Q.B>GZ=#4N&/X:!<%=`!INX>F>^[L[5T;M
M[KNKXL);XH,\!_'*&JJ2KL@C8A^Z?RTP-R,P`H0R%59>K\ODB30NX?S:O`TO
MBYJ\U[5XY!@?_AE_?G')\>;?`Q__\75Q&37P!.Z?9#;0!1A`Y1*>;^&>`"R0
M"/J__ST`"$]34RZ%+B<G4R>&C(V.CXXG&3!B8DV730*:FI@71D8\5#@X/*4#
M!P>CIP,\!S(R#`.G!P.C(IZR`U"[4+J\O\"LK*`#G\0,'TP9D(XM55T9`04%
M$2%^)B9719\7W=X7/T8#%#<_3$P4/@@(/NKL/D4(%.OT]?;T[104_Q$1Z?H^
M%O[IXU=@'S]^!F-8B*"0@H6`!GT@Y!<@0+^(`0OXH+!"WXIV2F0Q&'GDB(P?
M1:)$"5'#!@8',&/*G-FFYLR;,G?HQ!ES@D\'/J7H&$J4Z)FC?Y(F4(.E:9DH
M`CIT$(/#E0PN;!B41"6+"I53)E_!*GE$%JJS:-.FPB'":Q,?5YK*E:O&!)P$
M.@Q(V<NWK]"B@`,3_6M@@P</%3WPR\`XQH8-52(3073B"^0G-3+7\.,G<P@-
M:2),@\%DFNEI3*16J#!'JFO7JUFS[M"Z`Q,8IPM4K'BP-^/'CS5$'HX!@XWC
M-H`H7P[$@'/G/R<`U:(%ID\%B1117G2(<O^D[%,@=]'<F;-YSIDY8V-*HKW[
M]_#CRY\/?RY=IEC4J"E3ID</;/Z9,,:`"6C6D@U=)#A<%1NTT,(@$$8((2(1
M.HA!`CW,H.$,^FDXQH.,4,@=,R22.$4*E%B"B0"5B"%`)]^((",.7O!@BXR?
MX##`2+DT0<"/0#;!PXX@@+!++EYX\8T22A#PPY,$&*&D)]V``H4K(GA@"!%$
M,.-,%S%(HYLUV)@01#=-`DE`$S\(2<X/Y5`0SSKN/+2.!??D60]$"[5CP486
MQ,#/0A9$T5L$&BS6ST41K+!"0$YL1,$;;PS4&T`*M7.#/NEL])$/!/3"0`E:
M,<`&`86NU-)+/.'_9%.K,^T$JT^T3O"78$<A]<=2<CTUAP`BI"(D`Z\<@=:-
M7UGUBE;&;J76LZ.,XA45!!01EWU-U=7<4'SIX)=@X`)&F&&)I1!#9%T@AYP&
MDR5B61V8&4B>9QHL)"8,N)UVZ&Z)*790!FD$#-QC"PXWP@C%):SPPL4=[/`(
M54!<<,$#5^S@"`XH\$4*7VS'72*(&-+'R%M"*!YYYZ5L'C9E8$'?R^UA2U=^
M^NW'W\TX\Z>??YT=AT$5/X_@X-`M>.QQ(2,GK7322/=A!=.(0&8#AAQJV$,"
M#X[H+B$E=MU(ER=6H.**FW#21)4RSDBC%S)><+;;31A!+`.TB`"C)THV__DD
MG)O^X^<;%E#Z1A$4*.'-+1>(P,,N=,/0I0M<,G/",V%*$X`&UUQA)I7?@$*`
M$CQL"N</<N)#)S[J`$1GZ@"U`P\"A/(30Q$2/<20ZT7\^:=#?[J^+T.'QB"H
M[,._$4$&,;@NT1N`?F3!#4..6D));#21J@:KPGK3J]K#M(/VM=)Z:V"Y'O4`
MKTV928`75;%Y02C'CF*$5U4=$)96M)!E[+-JL26"_^`(0LNP10(U)``OW/++
M7L+%0&\-I3"'"<!ACL>8#*3@@A?TP..^$!X;R.N#Z,F,!@05`'SAJP`>B,%X
M/JB9`ZK+)0E;4,6`4T$+8O"&.,SA!6L8L!YF8/^&%5/`"%(@00X.XF-''%$D
MIF#$DVW&/%>(HLK\H#G]R.P^-=-/SK:XQ2SB!UL:4D,-8I"!+YC1C%SBDM%"
MMH@1]<$%2VL:R9QFA:>]L1!,_.%X3-"#,=2@#E.8C"$0P4&O&;(08$N!V#!Q
MB;*]Z!*),T+:$->-ML$-DJO842UNY`T".*0(N2O"X$`IN%(*S@<_.!S<:D2W
M`X@A!8AXW.,:,3DP540WF"M3")H`A5*`8D@E4$(3!H`.`MP`'>K8@CSH-`]Y
ML(Z9L'N(G^(Q$-YL1%((R0=`]+&[;>Y#>/ZR"`DI0A%JB"8`%$!A/]JAD3=T
MQ`+OO`$K27($-ES@>MG_ZYY,VJ!/[W4O?+8*5_G.\(`QJ($$6#"!'XIP`2BP
MQ4GO^Q\J_#>*M)2$)&<Y0BOYEQ;_I<TK%+@6`6=PO@0JL('A&M=A5LK2EB)F
M"B1SP08PP,*::N8S)"S`"0,0@QH,:`P2&,/YQM#'"%@D`A'DEU)-<TO=\,NE
M+MTA8U)0P1X*C(9`W,`(M)"&`I0F`&9$F@LD1-8)@8PR+3#.9K`QQ929H`Q:
MY*)<=69%^\",/C7(@':ZPT0S1LB(-<3@2G%8PQ]NP*PA8\3(ZEC'.#(BC9$[
M)(G>:!@6-3(3E;B$BR!)R<1-4I*7Q`0.>%2"`4S)"-^XP*1,R=K6/N\"7C"<
M_R<^,:0=,8`):=@`'*U`AC<>L1#B$91IHJ`>$^RR!+ZD[0":-`#2F:,#!7C(
MG/1$W3RUXZA'-6H*C8I4AH2&'ST\2.OVL0(G\,-1W'V#-`[US=T5)`+MN,A#
M?N`%(]!B5#O"`06"$`7L`2$F0H#5]_J9$UG-2GP"94&N'B`!#9G)`C]`A0A^
M%*R*GH4M]5/+*Z`5K0S30A:EZ+",O%(M$URQ@`?LE@Y4@%+!(-"!>3%,2Y6Z
MFY?&=*8VS;$(1VA4G>H&45U(P$^).H8(Y&L:8LI-;G;C5*6V%*DIB``&"\N8
M'L[PA[^I&%>!)0(!>.`+8EWC=M+X,0J%9P,V4$];5?_&,IS5U:YWC7-\9E"#
MQX"'B3ID:45>P.<^^]G/$CS,#?6JG<2*;&E6@*-D%RW6RJKH12Q2T6;/UME)
MB@"TC+Q$L.@FBRFE%AP^:*VH!1>0D-0H%[F@Q0&:$($-G(".OE4$<)^1J.$6
MUP\$8`4/C#$D'PW`F,^5TW2K2^P%W$DB$0B4\!BBD&4S6W;@#8A$?+=.A?3F
M#<-C"!H$93SA[8Z;T@:4#U!@HQ*45I,44(E_GP"3`+=JP`3VGH%;12N]"'2@
M#59#$&Z0:QG@0-/0HL+_Z@<+_N%`X)*,%BI"C&H;16O$5'@+$@:(+37TP%L+
M-`"+6PR8%ZMTQC268`!@>D?_'.N8A>;)3!=X+`W<B!-[1#;R"96\9,N%'#&!
M]M=!/)#!*==P`X;-Z@9R^YBMID$,J!"#!UP-QSLRNCMH]N`8UNS6,LCYZEB?
M00^@D0*7.IFEA]IY4OGUYS[WB^>$_BWDGL[V1GO`LIG`K*0?F;@86?H6C'3;
M!48;"UIX.DE)4L(-1CWJ4J/:+&GY``Q<302G%>($D15/HL04@ULSH12[IBT/
MP,$#3YX#3O580.H<$H5KZJZ;#^F=._Q$*-K!UT_7#+7Q."(13GTSV]`.`$`&
MQ5U[&76UE.*F#S0"*`J(8[1'*"W=TMW?&@"!W=V#=[QU(GV>U'M\@!GH&210
MEP($_TL&![B%$8Q5E0TC+EBH*%8J+FPW2"8NP]&J+2LZ[+^O4.$'03"QS#CT
M`!AKG.,I]4`REG,A)W(D!UPT=7(V=1XBE%/3H!@J-$9'1G.GT50A9U2\$784
M1%6,,06,81D;D`(-DE57]1A:L`$",`I*MP$=$U-/1P2*\#-=,`;9$$57X%8*
M]598MX-Q5A<:8$&"ED%@5T'"4X1&:(2]L5(A5P`O,`U\%FA456AG]5AM5R*4
M]7:/)G>:17>=E5IMDW<`%PL[<@"8QPJ`]P/*DX8=<0,K<`-NR`10\CX@UG#U
MDP.OM`@Q%5DR-1P]%EUKI5#0DUR_9`0_P`."]WDWX`[4M?]ZQ[8.N<,.>,(.
MMN<[X)8.ZU0$ZS0HO7,0O/%CZ;0;_3`-\+4/_R!MZ90/^K`ISQ-B):%\MY42
M_F4#_51]^D1]_^03]@8NVM<#:J`!37`6:3-1Y7<`J'4V."`6J>!PMN`V:W(V
M1N!A#H=Y`G=W_S,`$0<7_%%Q:G`&W#(4&P>`@2$4"0!!B*&$7V=C)9>`"JAC
M?E`@F1$#%%`!95,`(T2!3)5D_**!_("*^G!+8H)V-L0Q*?`"/-=2(CAT)?@S
M<Q`M!5!&A[8T$.F",74"2U`'&]`%&5(&9:(R461B//B1]%$7-:`!PD&2)'F$
M,6"2";*2++F2)HF$^L@O2D:0%Z3_'86&2+.D:-^A1%8H4UAX69&VA9SU:8>#
M=YEFC)QFC5;Q`4SI"E[@)#_P(TS2#4G"`TG28;I@6D/R":(@<%4Q$HHG:Y`P
M!<,1#:+XAWY@?(*(>>%P`<>4&DSP.L0VEXZ(B8>Q$!Z(5%5F.Q:0._L(7AMQ
M/`=!1"MP/,;#78+">JWC`VDP)YLRBOP@>LEC7\>8?`-@$M72?$`@B[5X$]3W
MF:!IBP>&B]A7%-K'`B9``6O!%L`XC.UW`<KB;]W0E9?T?F>Q8:O)%G:7-M+B
M%3>0?S<S%_L!!W``8^`(+N)(CGIVCB-W8^JXCNPH9"'@`Q4V"@*0!E%@CTV5
M3D>&+ZE!_PT^T`%F4TD#UV$-F0$>``,OD`)3D)X$"6@>@&7`T0*0@0'>]S\P
MD`&0MW:2]3%+X`!U0)]=,`/MH1_88(,VJ(,@N:#OD1\F4`,MF2`F29(K"9T0
MNG(G681A)Y.C@2]/R#$LF$3[Z5BTQ).3Y9-P!VF9U0235G=$Z5FAQ4B;AE]T
M(R.N)#8'$`N\H`L,\`OSUV&I@`N;-S^29%^Q\`%*9VB-$!Z1$0WK]8=7X`/B
MD'F_Q`.I9`1O6`YR60_J$`_&Q@[T<`.KLP[ST#O29`%!(&VG!RA_,HJ=PBD`
MD7K3E#MX`DJG@P"T4P_QX`.)R"?D\!`7@%P@8&Z7*0--D!)14/\#3\"9G?EN
MH2F:]%9O#%0^#W`&/1`""_EP0/H*.%!)5L%IJ"51>)<XJ!`6N+F:1DF>O'EP
M5&`$;W$%9:`Y]J$&<``$I7F<19&<,K:<3Q5!!RA3SVFA.C:=U<D6%J`!VED`
M`C`'<R`VRRHVE2`"%9!..)`#UMH`V-H`UIH#,O`!_L93&?`",!``&70'[_F$
MAZ%7930P50`$$3`C`@!+8):3(6(T9'4"#\(8&$F@!:J1V5`F+<.@`EM`==$9
M+!0"+)$@+71`0]:P"6"PFH&A(Z00"[&A3:53)O0"Y$IHWJ$T52@R*)J%0<FB
M7/BB,'J4D)2C(\$&!\`$1C4'`1`:!##_$D9R)+)@;KVP2?0W8KM&!;N&"[OP
M`3CP`J[&-4L*&57@I-0`I18PI;S&`R602CB0I<@$#Z;W26H:IV::>G_"3&F8
M#XDH*6([MF_ZI71Y#XKX.I7H.GU9B#PPJ&)8/:GB?(P:;[,X;SA1*[F(*PMV
M!@GPKAB6"C."/PN7?A,5?J0J8<]H/V*!C,=2C"_BHJOJ%?-S`R&04!XY%R8`
M!,6)J\BI`^.XJ^;8J^@X:\*ZCJ7WBQU&`;5&@7-P`,LZ!S\R!Z4AGB(@!FOR
M`=MZK=O*!F*!`QT@#;&Q&I4PKD[&,6<4=%S5!"H(5D9T1(,0D%VGA&4G<O$Y
M@QSB,C&C1>PQ_[`"RR'_@1Y"UHX?Q+`_%50-F[[NJ'(OZ6R'@G,7:T+JR7,3
M0J\?BT=O!VDJ.C9TYZ(FB[*7P'=C6``!4Q%I`(\B8)DBH173TTHX(`"K,0?H
M%W^">&H'\`$"T&J!E),P.`7.4#EC<@W8L`V[EERE\`-*<`!N.#KI<+9S::<+
M('H^$,/M('JT(Z;7)(EHJWKML#K71#O&UL,Q?`^I1Z?3%(B$.@`E(`/WQ%\L
M`7W3=[>C*:GWEBL2$`,"L!8#)PH>5JH3U:HC5C]L,0!B,1)BL3\7=@$_(@#^
M:VE$>HW\D;E-44!V\6*>&QCC6`73JX0X-V._2I:GJX"E1P"T$"VL:_]D]BC&
M#P<L8NP*;&"M;/#(#4`#-."[K_`!7<8B99,)K&%"\@@#\5E&(&B"4.$_!6!G
M)P!T7<=G\MO*K6QV*60#!J4&_.J]M@P?%M='Z3L&!]3+#2L!P`S,#U!0#GM`
M!B*A$YL![PN_%XNQ'KJQ1GN_C#`%`<`)UKRB9D-I)ML-`-P$P<(&I"(#%1`!
M:1``%:`;3)#`ML4C5)`_,G`$;]%#%%!AR<@-F+<X%XP##;D!>CA6BO#!B!'"
MFK,Y]67"5JH$#+#"<>+"]##$H6=L<R)Z]@#1>T(/D;@GL.<0K)<.JB</%PT[
M]<#1XG8#R5:(.)#$I&($:*HJ4&RWLYBW`(7_BY-:/C6PD!/%LQS%"F`\8FJ3
MHV=LJOWC(VMB241Y<)YP`W%!<7*!8G9\QT4QCLHANM;KQS$%R(&L8Z7'!(5<
M%?2(R$J63A<@`]P*?K:PR=U`"J'`E7I7)>1)42<]/6$1%B)`P%8&'%J@`9FJ
MSS_D@14!`\,;&R;DS$C6+XCB4[2\(;><V%:CR[LL9+O\V+T<V35@``>B(`Q2
M04@UNDRF9'ZMGD54:&GTL=1L6=?\:(^DS=O<S7M7%JYP`&<=?C)B$B7QSJO6
M!%2P%4<@`HQYP!'PB__3JE4J)>AWP?'*>&]T1VA%+K@DPF8B)(/X2Y^CPN7@
MALWDI:?CI8OI.B*M_SR1&(F@-"==.EU]&4V-R`X4S=##%HDW0'P"`1`WX+.7
M218,P`-H&@1/[-+X+1,Q3<6ZF"M%)L:W<&FM`"TVDC8PVA:Q^<X7!7[',F%,
M0``P"C>GS;RN:@0$($#9:!\S(`$(9`!./1B@^P!98`-Z5HY4?4=6?=4V57HW
MH".C\`%S$`5=17/IE(*P790`]V\R,B2;APO6R,TO(@+$(M8Y0,DTD*TY\,@R
M@%M6!H(C8`,%4!4X,`<1)*Y^O1JN?(_^F!C'HP&RS(N'K2&)#3,;4N8;$N:Y
MS-A#%MF-G0!#,`2][!S+H2Z6'1F/44'32W9\9H\=ZJ$\9T3[686C;0FEW?](
MI^V_+]K-WLPC(Y$6=#/;:.$VMVTL=`.SH>C;.E(,RG@+9]$X^MET3G<(#])C
ME\/<(0`ZP3TD/]*R%'`.58LGIM?#VL3#&1VG]S!=/9RG"`!?.GRG/=S0$PWL
MH6?1>PH0=*H[4:"6LJ`_`^`#06#?BIK?+KW?X>/A57P&&B``3:F;B3,+_5,*
ME"M),Y+@L,`L:+P637`.P*)WF2``:ZQI$7<!5.`#2""KPCD#+%!2'_[4"=!@
M),['.:>$?UP%*IYCB3+/FX3!!\SGA`Q^8A')EFRMJW8.S>@D:\*,KLX$O_C(
MN]OQUBH#<T#.`?.!D`$$`3!P`J!36-[*%%B`:'?_&425(67NO69>\S9?YOZ1
M\\',RY%]0,_Q\T\0]$(O]'50!S]#,1536'NLY_8X<Z;1V>/*GD7C1HEF2+X5
M`)4`:5K8[IW0A9^FZ,/T`?<5"U!;)*65HT<"!:55`E!@)*W``!;&%4-"C+QY
MN\-MAQ&`"$SS.-E!1--0>66"!&Y;I4/2)`?@>1W@2;F#*6QJIMQ4>ONPM>DP
M70X][`CPI6E+Q(K9*5\K[)>/MEK[;7_B!;L`U_BU7QK`$M$N[01&[7H[J2S`
M`C50``UNFQSU89A74:;:N/1T[@^E[IG<2$`2Y/\SFZA")O>>[\;YX2S6[S/P
M[Q$$5:4[5@1?\#45`G]R_P&;%'Z(DF2Y<4P,D.2[FZW9R@#GQQ6D8*J03.0>
M?\E,R93`>SQI4$$@"`1I,'#2ZLI.7X$T!@@>@AXI*1D;=4\)8ST],X\DD9*3
MDH^6EYB9,XV<G9X28P\/8PD)!J=`-3:KJQBN&%6QLK(MM1NWMQFZN[RZA8,>
M`<(!!<7&Q\4PRL;*RB^"4R<N+GU]5M/8V=K4+E\!8F)-`@+BX$WBY.<7(A?M
M[N\7Y^?I\DTB!P<#`PP@(`P,)4KL.P#%BY%]`$L45.)%Q@$<'S[@.\"CXD$<
M$`^($($CG\,"T:Q4(T)D&I$34U(0*Q##CPF7?GY8-&)Q0),?`PA08,+S1I$B
M%O]\"`U*P8(%"CZ"^HA!-*E0H4@12)U*M:I4"T6N6GT*U`?5(ERMBD7@`VE3
M"D5]*.%1`L21M_LH!`D1HD:-)P[RZMW+MZ_?OQ,""QX\V(".PX@3GV&1(`)'
M?!@C#W@[L;+ERC(R.SS`(/._MT<FXF!'@"<!=.,(J";'<2.["U28^"@2X@J6
MVUC4L'AP6$KBW\"#)S:0X$$58`&`(9]2;=J4*G:C2Y].O;KT$$8O/,0H(H*&
ME<@*W&#"H(%Y!A6I7##"_IVZ`6S8_&.@+_+&>/,J-'O!_X4P0BE\8<@M:6Q@
M0QH<C=8!#,<P&%XQPPPC2"$4?A%-"Q@`L4@C:JBAR27_'EK2X8B>E`C*&"@N
M4DHIJ`#A(BNOS*+!C+C@\L6-4U@XQ8X\[MC+CQD8$F0*$40P2(3$]/?"@\TX
M6$"3`:1`1#5]D-''-EAR\\4+X(Q#CA+FH"//??#`(\X\X]1S`10RZ'.$#&S`
M)9`^!\1SP0#Y0#&`%TIH!]E!^O!`$Q4BE';:'`4PP0,7(!P@1@I36"&2"])0
MBI)*Q+3TDA]7W,##`.S5=,$/."BQ$Q,W_&"44V91<(-12"45E`41F!7!4+=Z
M=1564R65E52ZDB76`E016Q6Q2I$U6UE/&75K!&G0>JL%4:1!@`C[@`;?#7/5
M===?X(8++F'D"F:8<#J<<48:_P)$A@,/..")#P.A3:2/O)?AHYE#1W3VF64\
MD&::EZFMEJ!&(E!!A1$",%%4;5B0H$8/O$EA,;H8`V<*!AND@)QR1T[!C0O/
M66?RR==%2T`^`V!4@`81/%@,$P?D(`,.:3:QFFGNZ-Q!!?HM4\!_@Q02`:0D
M)4U$CX7<N,LM&&C0+D8=R/P@DLE-6(@N%FX0BPT&H-B))B5^@N(H*Z9M@(M/
M`,%**[/,4B,N0`(I9-V]3&$WA;\<*4P!_5D=7I,P/`-II=H@OLT)6XJ1CI>.
MSZ-FF:[=5P\Y])S#@PST'?!69A-Q?O,Z\MY;$9X,&+'>Z?#B'$$4$03@71KD
M,?!0`/\B4W,E-BAE\'<$-;CT$@4E6%23$3(UL=,/I76UJEG-HF5!#&6M*BM2
M70';JU04C"6L]U(9.]4"XH=OOK!9*>5\]3XTX29<FS-1A`;>XB7N_>&6J_\$
MYPK'6`$(VTB\)D(9>]T+7P0$3;\XMT`&L@PR(F@"3YA``,P53``)ZH@`<6`$
MG3G,!R$H@VX2T)N,F?`W!M@`R+*VPI+LKF0HBZ%UTA`!)@2$3C#00`8<!)X;
M%`-H%7@!#'#@C\S@H`,=N$!Y:-"``Q2`"&2P@Q2G:(<I48E*9,AB%D>2-`#=
M[18C&,$0X54!P84':X,X6B]N404,/,$`0WB`'K)`QSI*0`+_HGC`$/8XA`3L
M\11K:YO;;!"C6=2B!7-+)-X6R<@,Z"UO>^.;QP01(<#QQXQ,:D:4,J"X$U1*
M<43XP@DRP"4!*`%-!*N'*IOP#C*MDF"FO!-]$&(["'+$(1UAV;W@,@!!K4Z#
MH_&.!H(1@QA00`01^8``."DR25VC)*/\7?!,,+S45>2:@KJ!>D[%$Z.LBB@1
ML-Y1KE<4I33E)]I+9[#`URNAG(\JZV2G5&Y``;#$Z@9)P<FG]*0/&1#``O2S
MB_WP1U"][*]<I_#-;WBC@S^<(0H="4<3,)(O?!SP7I:9CT8_IQE\5`2"#3/-
MY51C#_M4#@<7*`T3"@"\W>C@8J4X_^$)4P@,(P4#9,%PH7.@(\.>2B<&-0Q(
M"3I2@6(*S@..G$(!<$"#'+#A`Q40``#(P8:F0G5*4B1)%:NAQ:YZ-8N3(L+6
MUK@!#!1`!/`2`":-@36BJ9&L7JM#(D[!QS\:X`E/>)LKXI;(OM;HD8T,[(\D
M:0A)#I9"N^#;"L&S5IE!*06>C&QDMR%*4G;)@JE<I699B9]7>JE/"-$7`812
M@#E`BP(7<`B>!M".@\R'(NRA2<M&<P`!4"`"<Q##'.8@@,K@X`46<H$5K,0[
MWQ$#>,(S@0_0@TV+W*`=R[O!:(T"EAN\2B@_J=ZLFM*4I^@J6+\RBCQ[%17O
M>24K\8QG$?^@%RM9/=<(;2D!O=C0!`O,Q2YN<\`$^+)?P11T+P=%J$(/\X?$
M_$%J(A```=91T7PA<"(:G0]'95"O7G9D-"&EX$A/XQIXN$;!I7D9"5]ZF)C*
M-&,T50[15*Q3DO'4ISZ%&04&$)"(&M5J4=J1!T20@QX+H`,0$4$2<]"`'%0`
MBL[4HJ2ZZLPF.QD"+A@K+[Y05L?`2PPP:*N6M3RANM6HC:Z0:QWB%@N_UJB1
M@!6LFGM!6,.V^<U].U)C'5NX)CTC&BB)!I9.0DH!B$$)C\NL*KVTV4*+XY1&
MZ,Q$3)N&-+`T#5%@PF;HH[I/_<-TIZO/A4<#D4DS``H'@"JD=+?_.TI-X7<A
M2*X%H(!-+USS!]"5[@]^X!18X=.<TG)6.'T03EC)ZKM3"0H"RCNLJG@7O<9>
M@/6B1T^T.)LGB5*-M)G'R@&`X)HEN(`/@G!?MVE!"P$65X#'S;_^`0<(.V[8
MM7))0'HUV#+]VBAE0&/17O+@(2F=8`7EH6!RK`,_[C#":'1&@-VFH107TX$I
M3HQB%:J8A1'(0*/3T&(8PKBG,/,!?$OPD.Y\!\>._(('!-#C`\!``,D4`1,N
MT&,Q$,'),(]YS"$`@90`J:SL&HT(LKSEGDL(0(LT\]S67+<>$;V1?$LLG)/.
M"TD621`V'<:<K<8@_NP'4CS*$DI><`?'_\'RZV#/F:$UJYW-/*0`C2[&K5;&
M&5U>U',LDV\O]S&`#^"R[?N``A0^\*C<-6<:*`D&2U--31,4@0=><+7B#?*#
M/KGJ!ZF:#:Z',DZBP*J<0V&6L(>]/66-5RK9=0H^?4!/'\PZNJ<AJ9UX<`'6
MK^,<?6J'$F;-O#[9@R/:YG9=7.2B<1N4W,`WE[D1\X`$I"&J/&G"=BK3&7I7
M]"T1II?S11.OUD5P#OH>=#K:P=D-1E`U<ZA`!(!00H6/F.'"2;$@"C2CM_'>
M!A5_\<5CF/$+'`%/&/%.`)R$C!=,`0(GD`(5X&,5`!$`8'<7P`0B(`,`\'(P
M)P0RYTQ",($3:/\%"J```7AS(Q`%<Z!S'>!S()@U4G9T)%B">--F0[)T8T58
MOA!GP?`W3](,0!1V0+0@0D-U#&)GA!`-)+$-1&!9?Q9V0DAH8[=9'2$1^'`!
MNV4/Y$`%\Y(/ET8G_T!A\?9I>O=IG?$!ML,Y"J%W?.<!>D8E@#<%@A<`A.<2
M0>!J-(%XB8<\!.`%U@5YM.9-F4=Y[:4K:,$J7K$`P1(L%C!>WN4JJ$(`D"=M
MJ;=@.E,PTD9!/`%B2O"(D!B)D;@.]X`/(N`#4=!M+F(`Y)87P?>)IZ`"!$9\
M-E```H!]4[,1$+8OG"-]GA-AGO$9TP<9&%$1W)%A&L9O9](.KD%1EDC_<+P5
M`#;0&PIU?N@''.H7`0;R-E6@`1O0:!$0?_/74UU`*TUP?Y`1`#"#*$R2`6L`
M`2D``SE@<BCW`0````<@`Z>(`P"0`DL@!!<8C_$(CVU`@?*H`&W0!O+8`D*2
M!KM`9<U(,QQ1`2$(@EIC@@BI="SH"RFH@B-X6!12)!(I=<D``T`45>"0D7Z6
MD1N1D1[ID5Y2`7/0#)GD(%>W(YZ$#5>R-!Y0`5XWA#"9.47(2CC0BI<VA7;G
M:1NE450X'U#`!7JB=Q?52\6#)V(`AM)0:J;V@F:87$%`$VN(3:K!`]9%B+2&
M76#Q%-@S3LZ#:Y7'+`@@;%!!3W$X:X9X.>>P_XC,0WM,\`,39)9*(&VG9"?N
MPFD=.0Y=\C,5@$1\R5(ST@4U<`K\TXF?"(H&((JCJ'`1D!H8Y"ZAPXJ:,860
MV8H*5"^TB`-48(L)AGW9IXOJ($"701H%5T8:0(R^88S'.!P.!W6Z8%,L-C(6
M-XTGTP4JTSEGMXV.E0)KL`8;\`+J6([GB(Z9<8I'N00.H(_W*(]+<$B(5"-?
MT((>4"13=@NEJ!$X4P!,69!HY$5WDY!'AU@*:5B1Q#<2Z9I,N21/@D1``SD;
M^9$:&9,$<UF0XSA`,Y+\-SC.$`".I#B6D@(O$%7P.80SJ8LU21_R93O_(!&<
M@W<1=G^3<01"-2=#>?]`;,$#>R<&`;`!_&EJF**-R14"!Q&5H1*71D!/M+<L
MOV862E$611$S]'0,2+12AT@`'%!!JP%BJL$\JM$!.\H$/"IM!!-!XW`?"89!
M(N!U!,"7*P4A2!([%LE#13(,$1`#?PE(@2&8A9FE^G,*J*D#,<!;/'H!CHD/
M;S*99AJ9TE=`ESD:-*$1*M69DM-][%89&Z$:3#"2!T=B)9::P4%33X=3RB$R
MN_,%\B>;)@,[-&,[&%%4:7"?S!`!870<(N"2'X`18J!S"08#8E``7M.,SSAQ
M3P>#=\I;O:@O'V!:$<<+U!D`MXB=VLEE12.>"?F00W)832=E1E.>$LF4S##_
M!^J)E^XIGR\9H#AZH\3Z=7OIJ!7I#$B9DF.X?S#`E^MYK)DE=IMU)WK7#R"@
M=T)9;Q,ZE!+ZK1/*=QEZ`BZT.YYD7"_SH00P``M3$>L!*@1@!#K1E@ZC%`YS
M*C,C;6AB#UZ'I'OIEAU@KP/KHSRJH[;'6:UE!)5SI)>%1+NU4DJ2-4%""&L4
M"[I`0\=53!K0!1[KL34P!C4`LD/`B>4&2":KI5EZ"@:6+D"06W%Y>X]!IA-F
MD_,!F1MU&=Q1JFXZ07=JK:P$FI?1,@E6&B,9`20T8%W*I^H'J($Z,H1JJ#$$
M.S>0CMLA`#'0J(Z5H2.@0IG:E\6`?;XJ`,H`H&(@_[2AMB]L`"<]UK8VXV/2
MV0MI8`,1P!V;2DFONIU:PW2+M'3AJ9!L%I%'0R1^LQ(R&%7KZ9X.^Z_`.JQ@
M-ZTAV0$A20`54$'4BJQ`I*S)P!^$$%G0-`7_N9=\:8,_`TN."Y_]*@_8"@5=
M*)3B^KJO^RGCBJ$:.@U_EZY_$P7L>G^?PCHZPP/*,VL\L1,"T%GQ0`[3YK,&
M.[H_0P"0V'T<`0#<,7`70#!)"FW((`SEN1(!X!\LE`%5$`,94$PQ\#4V(!TH
MX@=^,`;4M+[I&QTAH`%4^D8H6[\JN[+#ERY28TJGQ+.>TT"QR)/[\AFN:!F8
MNA'W5B=O^K,RN0YS6AE$J_]@=PH#$6`82LNGR%@%+NBTN`.UA2JUU"%C-7EA
M8O`ZFML@O"4`HGN1"F:V->.V,`S#-,`&YD$#-!`&,-P=T"*W&(`@K9%ER)&W
M*[:W?%NK"[F0@Y4!1^.:%)F>,SB?9WNV1]J>CG.Z*@QVNS4.%SF2/_,S3SHT
MI15^%PFYEPM+0%,UF60X._*Y7'<'%XE$R\`3TAJ@X8!9JB1+0^FML/NM%36N
M(E"NI'8EZ?J"FM*^-Z`Z@*)W]'H#$N0JSB:(XR&\AL@!'/"(LK<>1I!X7F`F
M!%=PNX4H$ZLDG$L(V2FE$C=Q43`C].,M(:N^KJR^=@'+=!$"W,9M0$&'UE,$
M41#_!360`$!0O\"<LO<;S/6K,8[Q9^>`MO];I@%\LP.L0#I[P-@R`!&DO+QU
MQP[<QQAFM*9%?A>,P<-1!>;IM-#@P2!\,AH0%")P!!?6'5'P)(Z%`SWV`4?*
MLQB13&E+9.:QS_S,SS/<5#8C$3O[QXT6)+N0!E60<Z-!D!RLG<KAD!!=GMFY
MK!8)-,%ZT5_'N`0#H"FLPAWPR3!``1#"<T#$4C&3#"REQ/LW@V/\Q&6\T<I:
M.)P+67D6`"Z)N4IZ#`8+H'X&DZN$QQAE0'L\U'!')P=DCKB3E&(XR,(0`S50
M>%>`6A>@R8J74G8JETKP&O<A!A=@Q2HLDA/$5@$@TDS*_Z31:5-/EZKCJ\HS
M0A?5\<IV,<OQ&P5%$`-1P!3>E,M'85]"P6T4D(G;Y@<_X<JD0,S$''R&3<P*
M]QM`<%;L$+0S2[/,;+/.[$!#.UO2S`/JL<`,K":1;1GZP`X2O%O"J*<Z@)C@
MK'`&(,[D?-9*+*C3$+7G;!TAD`;MP\[;$0!1L'\RPP3R;#.=9C.9T6,R`,,U
MS$3^;,/*/<,-L+;J>`S)44;^:-`9NP$:T($+S4(XY=`X!=%.%Z4K\<07_9Z7
M.ZWK64:\)9(W""%3&@,18B06:=+$$-^"%X/GW=(OK<5XJ<(\=`Q"--,[T@(V
M_;AC#+;&(,>F.ZQBHKH/^F!N-__4;\<RF6;4]V*._J?4S<'4`>#4A><':O&(
M5)UXCU$Y7G?&?.D@$TM)G&M)S^!%6I.J5-K6;AW+?A`\->[*-2#7&E#+/]'C
M/^%-/E[+L^P'V&$!ZFOD)D#+)E`&G/(2)H`%)G`%'5(&/;`BB6V_A7'E6JX"
M^?L`",9!D-T1M00:`QQ]$N9@[M*P(L"P'C1!I>MO0?O`$$S-WS>J`5`%QKBT
MQV@*&JRKC1;C`647L-T-'SS;T4$]!(#;+@,[W!@>"L@&`1W0<%+<Q-VV7+#<
M,QP?;,`%G!YA7+"V3@14<:L?J7HWC58%%'"+VDW.!NFT;P9TA#O?&/F1\>G5
M8QR29US_MD`S-#\#@Q1\TBD=`QZP#!()5&4K.S$(@S$8@T)3T62<WU\-TSRT
M$DJR@P)^NBW=TDCDZ&^>)D)*A'<"H0<DU!".:7H\[N,.`/YGNTL]2M$I.T_=
MOA9`>Y!HE=&&QD/S'[(3.Q#"'RQD"'%;)!S[ER![,O$[([O,%`A/US]13+N\
MX]U"%Z_,*5=0>$M>!AC?(;EQ!5*.!1B?&R*D!KDQ(B3?",6G<"K`Y5J^\BQ_
MF"F/VCH@"A%PJ0>@.KUH=S3;&6AJYK44S0-=.>T@P7)<N@K[V9>]$6V>91N0
MYZE=8@9@`\TXX^I+31FO!A(SZ+)MZ-01!3[`!(J.`W-0+8VN_],%T'K@AWT4
M(`!MLD#^P@^<KK;Q`9F;S@7$+60\+54"4.H'C=!URQ%WV]J%"ZN`JH+!8)'P
M:8B([]+TV=,JS*F^XQ\IH$(OT#'O'G'#_@P9$`Q")-,.DKE-4I'"0)+P7`"W
M#NT$KL4,TKU+`H.0?VI>;<;9GNO((-(,_'7A'J[E#F&V$RBNUUH6RD]N=P``
M`!+4("D9[NZQ`SP6'P1HL0).\/Q.L`)OP!1(]',62[Z'$`L>R\HU/AW=+]?@
M'[^US&TU9*,K!4*OS/$6WP@9CQLD_R&/<!LB/_(B5`867_'M^\JD4`HO#P@J
M@BH&A8:'B(D&$XR*CH,ZD3H)"0$B./\'1B*;ES(R!T>A#)Z>#*:GIT<'JZP'
M.*^OG!><34T$!$RY'1T5`DT7P)>MJZ&K`P,X(K:Y,`4;"9*3T=/4U9()#Q(L
M,VIJ6%@DX>'?WVI$+GU]+E-5->[O\/'R\_)1$12KL`)I,<T%_P"9%*@5PT*$
M"&FBX%MEB@L7!@YIL)F8HZ+%'&PNROC`L>.!CAS%1$B1(H-)DQNJI+F4K,!!
M#S!CRHP9H*;-FS=GRB3),\7!`#`JB!$CH*B`"DB3*EV:=,X<I`+$B!!0(&HR
M`3`BQ/#PSX/)GP4"A!6+M!F,LP6"5E!;-NC9MS#FG%7*"VI1NT;SZMUK%._=
MO&O'OGAA<W#_`*Y"^2I63(!7AUP"_S&)JE>$L6.8C_'@D1FSD0NV?C"Y<8."
M:1\^*/Q0<D&)E\Z;C[TJD.'$"73I7-B>\C-"C3$F@H>P@/JT#PM%-`2)$2-(
M$`TAHKOS0[VZ]>KPHFN/7CU$C>O!@_O1D/J@!0M!3'13TZ/'^FXSXJ_'HD;^
M^_;MP^L//L8//7=`N&,`)00F,$2!"0RHH",,%D)(@XBH,`TE!6!RP"4L#7`$
M`Z"$XN&&'WYH2C'YP`++)L"DV(0`MT#&Q!P$^#*+")P=,,J'K`S`0S*VS!%9
M&M!<8\V00S[0PPSBD*.DDN:DH\X4&]CPWY14OF,/!53HB(D($6@`_]"7D@D@
M0DV2525##F&D&08-;++9P)MO7B2G#```,%0O%>SR#P45C,G32295H8&8./#`
M1$DIZ!3!3#@U:I-..\E$00%/'<74I9@BY=13O1`UAY@B$'4464B%]4];9VU:
M@5.KQG547)>RFM1BM-9JJV)E_5.386*9*I2HO=!ZR[`$]'(+B\/F60`O>UEV
MV0`E?%C",:`U<0-JYV6;FFDW_.#M!0-X<8$1.GJQV;D#K`)#;5^<HXYN)TSA
MTT$A4"?>=M?EJ^^^UUUQQ7[!E5'&>^NY5_`,)GP'7'CXF8!?#^$M'/%U[U`7
MCQ\)^#'&QF,D``00!@PA\H&4B$S)`P\@J/\R@A!&*$@B@SP8B8/1_'%&`G/D
M<XF./(#"@(?#A"CBSZJDRX,11E`1"XJU-,VBCP7D`J,`,^)PC(VHJ%(B#J`)
M`'4!0$8B!9%D5V-D?4NF70X13JX3995PTW/E!0<@\TJ7:8$9]8M'?'```!QY
MXA$F&>70)@UPONDFG#0P@-58`1QT$',1B%'`GX!NH`$,E_!004D9)`JI3HXV
M.KI,`73`Z:IU9>IZ4[+VM51:<ZT%5U"[M+XZ5*L&J]>LMP8O_%[`Y[HK83>E
MQ3OP>PUKU+&R+[6+7DTXJV-G`S`P[0"?&:&$MS\0D**)PQQ`A66?O++U4"]\
M8=LY+L0?K[R20_?_';_Y`AR>P"8(/##!WE#;DN+#C6X\;`P]X%C'WA$"#42A
M(`<Q#4!BT(4:F&`,5**.`CF&GXZ%;&0D0YD(1SC"E16H92@TQ-AT,#9*&"`2
M*4M`#7*6C`M8S6HVDH'6@H:*$>$(,\D0@=(X(0)@U`)9N!"(U&2T"1QBC10[
M/-&*OA8!((BM;%B\QI%F(,`E-2DW4))2W,;X#@U$P`=-J!LLN@04O4%&!!^P
MTU".TH$O,0$'%3F<'A?W)BZ4H`,U40OM`J"!&FA@+3`A2>8P$(!D&$$`H,O`
MZ1A5.M.-#BA+4=7K-BDKIZ1*=66QW5J88BG?_45VPTNE*FEE%S&4Y7BP_P3(
M7(;B2E,2ZY8Q"E:GCE*4QL3(%[6P#(=@PQF>(:V8Z3K%1SC2"K]QS8:P6!$N
M_K&H%$SA??&+WS7I=Y!"6@=@#PLG?@`8P+2-HXOT64_":M#`!TJN5[`J"A%9
M\0%2?"``71C##,90P7=L<(,71&`X"43"@AHTAB9T80H+P4(I./2A#HV&0G7P
M`!NDX1Z6P<$Q"X6)(WRB%1XBFM!(I)GS:0)%*I)FBUS$A!A5+5T^\V$K.*H,
MKT6FBE?,(A83<"02H),<96!;;K[P-C*240-I\`$3U(B)`IAQ#GK;6U3RU(R<
M:"4&3#@3FO2H.,3!R8\!H)P'(I"!&&@@GSVHP?]9QJK(DVP``Q%XQ2,CL(&3
MD`0FBSI=)1T%DYIX(``OB(LF-TE8I1QEL(5E7E]0^3M3KO*QJ0P,Y/@:`7BR
MQ;"LG*I+)F6:7Q;E%YBX'O:NAHP2T6)%-BW`:2S`G-9&(0H.9,X&-C"%:][&
M!?#336WEU5<-*-!A!F-/.(7[,`(6L)SD])_`NO&_]Y0A!!W@Q"M`4D]2:%5.
M%;%N`6H0GW]R4*#B%&?'#DI>$JHL$@72@2)T>HT34D(#<\BH,>HV#$]H+110
M%-HP=$2%\Q&QB$X;%DNE%J,F6FA#(P(%*TQ41!8Q85(1L$%.V3LD2FSQI]\(
M:MN(*D:CQBT$2;T!4S__``,-9$`N;OP45<32@:J>Q3<U\,$!\LC5!O"Q`6Q@
M`#XQ6`,94H)C@Q(`6R.9@31@8"6%$H$'-A"#NIID7I/<JY0QF=@J._8NODML
MK:X,V2Y'5G95+=U8#_*5OU[6=7<8"@QB\!UVAJ`(N8A1,)<)4X9PB!4B6*EI
M(G">&,!6.],1CW7<T84JT':WV4PT;G<;ND7Y-H$;"^\_16:`)SRAQSSNGW(W
M33`EB4,<,ZB!`%R!"1QTY+K6#9P]G6EJ&/!42A*00'AGW1[B]L"@L<ZUKLN+
M4$J@U]>2>&&%?YW0`24`OC)@`"Q8<6=6>*)\T(8V#_I[4EG40L`#AHR<64*,
M_PTENWP,!@TN*!`Y";.0PD2R,)(PC`4-#[6H'HY;4O%1V@_,@3E?L^.+[JV!
M&$RNM5UH3PSP6)'$&;P!!4>X`"A@D//\9%),Z,`%8."!M@)*4`*PVI@TH('9
MVO4E>IVRHPI@Y4OQ!4]+60SO*./EEKN<,<_32QUU-?)2+=G0&0!*[3#U%@\4
M\GXF"(%I)-A2EFQ"FKE0K0\B\&?O7`P[%9M'%SI.V_BEPPJYP<V[=.M62]O`
M`6!W``8P,(*RCZ`%+9BM;7;#:*WXH1O?^+3<YTYW/RSK'[N0"PPZ\%E"N>*_
MH2(*47Q;A;%FH(()D#4!PTNP^/1``BC3M>0GGVOR$O_H&I`@4LPVSWELV*``
M'U#V*V;Q"A[\-XC+CG;Y!D!M%%G;P=F&S-1(?^!1?'L8X5[&GC$P87130]U)
M0J>[U<'A>(]QWDP]@`#,ZI2H4NK>-3"#]'^SL03T)ZYQL@@;K!O%5[AR%W`Q
M54T.@KF+P[?4!8A!%0SM\=")[I(B;Q3)2XY95BH65X#A\LOW/SR__,65584\
M./$"`F`G+[`!=6`#.)<H@>46</$"7F$2'.=-)N`'Y9$M!D$!QX$>TN$?_%(E
MT=$%%22"4V<2M84.5I""6]<'6+=UNU5;:;<![E-;7_`%-$B#-C@%1$`$\U-;
M&:`5)D!W0CB$X2!J%R(58@#_59`#%I]"2WI!%!'0,7E5$F9E`XFW1<9U7.\Q
M`X]'>5[HA08%;),0,YK'>6:H`I00`2*0`S9B/K604DU3+:=7>IM!/OE`!9H0
M#*>U4K'W(@4F#,Q&"N!V(J#A(^3F`570>[YW#2AC,/\C?$+U)/!F?%1R)2)@
M-P<@$EZBA'9$*99#.9(C.10``QG'7[.`6JN2;X\"*3V1!D5F<1=7!17R"AUP
M>.LW6TYV5^]'2?%G$\I32LM#6,*C?_Q7C,:8%[24C$D(`X`E@(6!%#>'`99F
M:54@28`5$R4!)=68`55@`P*%,!;`#"X1!8"&/_1`@FZF'1/(<5/'<2=Q32R8
M@E:0_VA]0`9DT();MW;QHFC\F&@[B%M$,`7N%P-!2(0&^6E^T`%R)`9V$GA&
M44>1`Q11,4>)$85C8&(G(5MG17VUEH4$5!]<J&LL())?2'D%)0V8)PA#0H:1
MH)(M*2$)8`-SP$RF\'?5TC0X^89Z6$0[J32FQ9-$=&VQMS=^Z`N`R`I`,XBQ
M(&X/5A,:(%&^APVQ-I(LT![]82_]HP;GY%/M%HENTV&4."5S0VH7TB44P(G-
MD'23P4O$LRD^,AI@0FXW$8J0(CD^T1-$YE880`$L40&'UP48P'Y.YGZ0THN[
M0B9!`8PHQSPF%SS$>(R0V65SA&6M@A9AP2N-LE89,%LML/]^&+`!?26`%?=D
M,)$!A81`,^`'%`!*4&4!$U@OTT$/(4B"ZUB;Z^AO=FF"MN&//'@"+.@D6R<_
M:Z=HPTF<^G@"7_!D!'F0S$D"8U``RAB=#$D4S%A9)&<I8A``&V-BS*$!@K*.
M(N@.'.0>'NEX(LD"Z%F28$A"*#F&:%B&$H)>0@*3:N@W6*,*07231_19.1F'
M.\E@0,DT?"@9D4%@,2(5%I)#(/516U-#NN>44*E3)Z,-VS`#Z&F5^5,&Y#`.
MP_>585DE9H1&,J`^.$!(/@`UEAD946.9S@<0-P`04X97H3BCH9B7H1,E:J@T
M`M`E7:"`Z\=^=L6+O3@6RI,ID7G_I)`IG=%I*7I'<P>1!E":!KB8$E4P=EJ`
M`2F`F8]R&-SHF4\0,E6@<SL'`X01$V7%CC40`W4Q*EJ1!M#A=.D8`K1YFZU5
M66P6IUT0`WCR*LQ8<=9TG">(=?VX@X3:C[=UG"<0.NZGG`79G$38`P'@A,@X
MF;2T%I%S$&D1`S*T**9Y5B3XJ?U4,1L3'!WI>%6)GA6:GB2IGI!G7KZ6`/%9
M#4$2#7!@#2$@`.EC(]Z&GT>'DXN!D\%@!``Z(P`VH&`29]#31-W&H'AF8(3X
MH(04H3NE#<95E0\34!=D,=^AE4#EE6'TH52B`<1!``Q06CA08A&`HFD)&?_@
M#RWJ?&(V_TEC5J,VF@)I8`-1D'$XD)T:8`/^:@.!":1/MHLB9Q@O4`"$03N-
MB:0,NTJ3.9&`T:1CD4B;.5L_.G8V``1:H`438``0];$.57ADBA.)5`5U\*4A
M@S)5X!:V\Q9K,1AE2E:4TZYY<JE:89M35Z=@T:Y[AQ1IT&9PJJ?26180.)HO
M.#_Z:(.`.I@\(1,P&UBC]`)E55:-ZJA"V`.5PW*;=`>6ZA4!UP-;X15FQ8XD
MZ*_TD#$:$VGMP86IVK:H2I5O^X4%)8:_AR!P<+=WBP0<E[$$(F,,^C.F\&Q!
MA%+]:12_$*S.JE$\:41\J*($^DNW4#T)2B):DPP$$$S_=0$.9O\:`;`!TDHV
MB5>ABQ=._!%0_L%.?F`"X-"5;?.MX/H?(*94)7(`%5`0S8<6`[:NCONNDY43
MIR,Y;#42L'@21G9^.```3O6O_EIH@AFD-"%E,*LW:@$8#5N]>R%XHA*Q:.%7
M3PJEFN.9&+"QC0"RY%N^$`4$&1!8SE@3*;`!*)NR#U`%#7@[;S&_(XM7916*
MK;61_>:I9G0J4'$':9:,,!`%_E&;:EH41/$KR?@J85&:&8"#>"DZ9,*S:TI+
M=<*0=0(`Z]):56NU<V<"$:`6=[))9]&Y0Z`'8_`$@M*=$_BI9@LW:8L?Y?FV
M-HRJZVE>%48@>8L$2/!:J:%:"'%13?#_"1X54X';;"<B"RF"N"QA(OEI1$C'
MKOJF8L@BN4CI;*X`&N'S"_^%=)SKN4("NJ&+GA8Z3@843AMSN@T4`JI+`E\D
MB6#YNO$0NQ30,Z0F!G[F26]!H+O+NV!B2?(ZHSQ!5H"2`5^0!H)2`!?"P12D
MO,M[BTS[O)7TM-%+LX]IO2^GC)39I(?!5MZ;$E:ZL5H`!.9[RJALOCJ@!3FW
MOH>Q`2/@``Y""6%JR0>+L'QEIA54F_W$3Z<9DQY@OV>&%`$0`CW@!R'P6F<5
M`_/'R0JLC$E!I@V8%-))1'5R"0``>)O`D&O6;\L)PD)H`LS,%I39%LA35ETP
M!&-@!I(DMIK3_Z/N8`.@*L]Q@S&15IX62J$W/)*3%X;6$$-`8`/$41S=\@,<
M<-"12P7EJB&J@&`@``6F`!(+!L44G:"F)<72]):Q=RS9NPD@%447,"R@M31=
M,VZ3D@:?*ZME3,-KJX7PD1_]X0YM[`=E8`+>.HET'`_S1@6K@"%,]R*WDV\L
M^JZ]$L@D.SHT2GZ&#"C>*W07@@,=\,C^^C&1++`^0<F.8LNW7*2:O,EMZ0\V
MRP\<%[X;^S&F+`5Y@-;FFP=LW=:I_-;E"P<8$,PP^\DEL0$M4'9:,"!82F3"
MFYN''"@&8$@O7$$(Y`Y'DD`8>1)YM2NTHP'M(4/]=$BB(JF?I:1#L?\)*[8L
M#'F\V:S-VCPC:F96?O;!X"P.(MQ&D=.=H4I]8Z`'L&T&79"^24$8=-6C5KA`
M\2S/N#U&:HN%U;K/)NFJLRI10/"_3&#0!_T#-W#0SFT$)<`%(#``.H24V@,%
MV?-L'Z%ZW*TS-XDL?8BL+*>LUOU1RD``/S`+,P5@FWO2*?U[%-H>%PK<C>=X
M">0?#00=R#P%N.$"1-7:.=UA]H!&'X`)!>X#:1``J^(B&DT[?TS4(C>O-&H2
M_'#(KFBQ<.4*`+"CN!W0-O`$_QJ8[4>P`S@8O%LI7;T82@IF546QN#@"I!SC
M<#WCJ=Q0#V76`!NP/[H!43K$JEVTI8D!!G#_I6-W=K`L=F0WI3+(F7D]`F,G
MY`^0I_M;2,!%GA;J,2".`6FW6TWK`2.`#8BP`4(AP)A-2UQK.V%QLSV*OA6P
MP41$2Z`M%8'7S<S1`Z=-=SW`<:[='EF`05+R!"+8;];(%F_!I1,H)=9GE3+$
MCC$\1C-LY:/;A</]`.U%Z1*5`"'@`\WMW`>]`)[>+1R0-%FB8#O4;=TF4B.5
MZJ7^=ZCU-"SEQ[NP;:`!3>F2E!<B`+F@KPFJ44:P#$WI#+/Z4!-"4/E1:^1D
M'UH(,?A=0?X1`_P-1AL`X'3<82%*`/;I"A20!AY@4]D&R%&U5XJ2U,)KHVY5
M!4"0!C9D)Q'0VS5@_VE4#;!63<$W<<GOFIB97(P/"XS;>QC=B^%D3<II3>,"
M[U!F'>-7*LD\#J5W-1/B'J5^UF]`(9I>86R+X`!$7G9%?G9-;G9KX``=:VS9
M8`-C.X$UL$6HFL\N]`0.H/&[$9`9\.7J=0@;\`)T89GC)SFME?/=:58)(.8+
MJ8R<D(R!1\"D#=EW/G=JP&-YBA*%MA6!9!:9TJ>;R7%5(()B)$/PT.@?=C&D
M:C#QH:J2)T+H9>GM%06:SND<X.EJOP`<`"[7T]T?K>HA@NH@C41)Y")^7`&7
M*[E%9`0U@B-;C`N7FWJO@(<AG0LV\0S0$%%U^V,,$UP`)!_&Q1[9.AW;^?_L
MDBCM.2W39T0`KI`/3'!1W#Y@LN2NO%M),9%7I],3B\K4LW7N&5<GA%0#?SZ-
M[NZO(DZ:?548"0O(_G=R]SZI#5Q*^UZ:4OI6I>RQ`T_CUV#6[QZPL^6*5UW!
M\'KS3/=G@18PZQ$?<+PYS.A77O$$(E0@A,`(8C<">*T`ZJ\`'O_Q(/\`0("Q
M4RV582\V%:_Q:+=VW:A0A@`(-C$1A#&&AAJ)AX:$C104!9$1-ALP`&*8F9J;
MFR(B!3%=&ET])%BG)*FJJZRM)#TQ!3"S%;4O`1$9&1$>'KPO,+7"%;,O'AD;
M5<I5B8E=738UTM()/6/3-5W9VMA=(<W@B2$U?B;_/3/H+"P2$@_N[^\J.O-P
M2%$4-POZ^CX(14%%?/R@,N#`@8(&$RI<>."(PX<0(T)DP.!(0A%-"&@DP*0C
MDP(?07;L4$%`DPLX#N`P0H5'08@&10CH*$`$CIL&;U(Q<H$CDP`!"FQ(8&">
ME'E($RA5.B;!&',]U$B5.H/JC%-8T*%3T\.$B3%/P8[I,L5%GSXNIFS@AJVM
MV[=PIX6PX(/)AX0X"*2)(&!.QSF`/<*(1+BP8<-`$RM.W*NQ8P\ITDC>H&&#
MY2H8,&C9K$6'!B8B,`708,,&D"=/#*@V<+HTABH;=*5HK/C%X=LP2`K8S;NW
M[]Z:?`N;50"HK\DC,FL!_Z):BG/GS9]+GTZ]NG,@R[&_5K9!\FP/`6Q'FD5^
M<'&@C6)$T1`BA)]RYJ:B<T6?A(D(,!BGV&#@G=('0RRE@@H&3*`%!B,DF.`:
M&#C@P`2KJ09AA`8HI<-2JP$!A`.9(9A@%1]"HV%I-H"SB`46-!)!`)`0UH%N
M!.Q&0`5B=%!9!3@`H...EW#"B2<%C#)**:;49V0J,]@7`3&R#!;,8(L9Y\$P
MQ,#P@C'(),-,.,]TR8U2<;W5WC<:+**>,]*,T4,/ZJS#SCM##)A`/1;<D`\"
M06RQ11!!(''%%2'<0-!"=S%DJ$2(1L2`#!6I),(%`FCD44>%>:2;`!>@I%)+
M+O\UY%!.&3%!0!,VX:02#E0\RM%Y`0Q5X3RJ67@A4TR9,)4:6LV')!:W2E7&
MFE!]E0!99J&E%EMA)JML##X4D)-!%T@V1P5_S5$>893>IFV4OC0BF60:*%.:
MAD`L-<8#\R3@SAGL_G$&$`',0=)H-92&6FH1/@&$#:_%EL%WX`$EWF'ED5>2
M&`*4]!O"NV62L+61H!?999IQ-H%U&$N11\;2L<89@K!UMU<O0(U7,&&X$&*!
M>E&T1XY74:F!RI$TMS)##%`&`!E_\"R5`%)(Q2DAAR.LL=F#S$DXP82Q$A4A
MN21Z&4Z9C*CX2(N6;L2;$IDJH<1)F38AM@@$Q+`!CCK_WJ0V0VJ+<(F.8@1I
M0Q5=)*"&D5CE7:3>/5!]""'HK5BR+0&49\N5QV2Y)3A>/B.-']/X(=;D8GEE
M`GS8M!=%#'LM@J93:Z[9CCOU(+`/`EM<4<85?DJ%!`4B&%JHH0LE:OL1BUIT
MP*,9^>01MI/&:%*F*:'*0Z>?.NH3`:6:JA-&!,QQ'B@^_^<..SX_94(9\N6J
M"J^]<A7Z^-=H4-99:4V!K++LMS5.%!%04'Q,$>#<%WF`Y:^_M>:AK'.WWVH&
MB6J@(3A4SV<$K%>)-)``=CGP@>_"CRSH)8U[48@U^^).;``FL,(4[(,T\E'"
M:@&Q_T5@,IC)3G0XQD+JY`$[_Q\+F<AF$QY@E`<PYJ%`RE:VGG&\QRO<PU7-
MADA$$H0@8KY`1G_@X9]Y^.<=.I"'TC:3F:19,$,C*HV)_J:B^&&-"20IB49V
M\[5,F?$"3>#:!3QA1B.XT8TV*5LE>B0&3^!D=CFY27!`L8P:F.`JKLB;(`=)
M`C74P$1^XZ(NPJ.S&&0@`+4H!BX0T8SUN>\]C_O*>^`SAA]>S@_`"M;E-K>7
M+J:'/=1X``M,@`0?Z`,!J+O"*<I@*Q*4P0*QBQWM=IF0VR6J43>!GN]^)Q*/
M"&]X-CD(09"G.YEP9%3-2\FI<`"]D`!%`]=C!_9JX!2E^"$!E@LB.K)"SE.$
MCRNW"O_=5PYY/K0007WMBV?FWA>_7![@`R*H7P'$4`'^$8<QO2!$`!,QK@(>
M$`X(U1`2D/"-S:4H?I%@PAQV(X(*:,!=['H`!($@P?R0!C45O*!J,@@;V9#L
M2H3YX,F"T4_B%`>`EBG:9C;6PII.AS,'@LVWTD";)L&`?RA+SWI0Z<D@8J&(
MJ<`*4HOHAZ#H+`5*9&+/U#6KGR4E*1[#P&GJU:5F+*(1/KC:(V[0D1]L1"->
M^YI)P&9&-5[@C7#E2:;B"L>\F.T%=\AK+1KFB;ZJ+4>:N$,%=):!*OC1%'I#
M["`7>]0RA,!,*$*1BD*QC5%D(Q;YF:1E'X=)L*PI&S6XAGO_+O<RTI:V!J/]
M85=LM=I/UB`(47BH#U;TB)2=4`,,A24L4Z<ZJ43E%180@PQ4PA"$\-(@OD34
M<(,)J6%FJY@2%9[8WIJ0@@R@(#)HYO+6V+P\HBI43*BM!IHB#5'`[X3<W"00
MJ5+.H^;MG.D$UEAB4!:SI&4MT9"G/-NC@?@)8'8B&`WGP$50#5$#@0G`1C,V
M-X@5$08PO+&CVCX@@P]8V""%^@`.T@!!"3R0H^89332>4`.1/HU?)?W725.J
MTH(%(`V6J=AR;$ICZ&B'.VE0,7A\2A["4&"V/'09?&PEE:,N]<A(KL]]_@?5
M*BQ1JNC2`1.E#$6@*<4`58C!0[WX_T51$:`#QQ2`UZ9[QK>6.5->\`)=C:!F
M-J-QND;@P1O3;`1/5"`#+?"`E:[$YSZ_``]XR*N@Q<`C,<`@`\\P`6*3RMA&
M-S8(D35$9`&G6:+6(`I1*`*FV[-)^/AAM*@%I35"VQ7U?M(KD+.<-+:7ZLM=
M`=7P^56I0Q"%L%[-,(_P01'^@80R&%DKMHR`"&97J(<<5R')C4A"4M7<21$S
M>#%B:S(5<MT#9'=W3>A(C"1L*F56,[R0P$50"I`_`02IT^L]!2`5JP9:<@]\
MX(OOJ+M`WV*EY030T"_['(?:_M8%(V(30`2`\(#_M,.!$DA`F21#B*O]A:*F
MHO`'<I"#"O]36`8YL/!=<(!'O.2$PP_TL`/A@!\H:2"D)L8BBOU%LO"PN,6S
M2($-C%+C%FYF#99A."]*QN,<SO9,/HRU5)),]*+3#!9,+NR3H<ST*COQ`0GW
M0`?*NI&T>NV,?<WZFM-,9S=R_>MMINL9X=IU3P@@!1#P`)_!P/:VNQW0<,\K
MCP#P@F=HP`1Z<_1[]68"2$<61;.=K"AB,(ZY7,T'*/I'IC4-:<0C`=V=A%D9
M4MV#3YNCU9\&I1I,D%I/>WI[F[^<YE(4UDCX`-.QM9,/@C#:J,R@##$0PX5[
MJ>QC>\IV%-$=7GCGW&?_)=K<+15R#84#\$+3)GXUR`"H@$:?/`+_)!V8EOZ8
M8`%T@UYF,TMJN]TMLR+'>RIK@EP-ZHV^*>`[O_H.$[_;T_"01#\#JF0'"R!X
M!@T(8&W6ED&%]7^7_FO<_\1%7#>A8=-T3]1T$PR@82"'<`]$<O]T<C6`+RDW
M4AED&3H6,":C4BT5`%6@`S4W'1K2+SG&"SN&/SGT8_43`^SA2:!G9$;W@C!X
M)$C7"TVV=$W'=$!#94!0`&+#5FXT5W"5=7\59\<C9VP&=FN6A#QP`3]&%P3`
M`S?19FL$`&>7=H#F=EB8A7\&=W#G`4^0"(I&2(JU=]['*_816X=@`46@'OR%
M2JCE'B'`!!PPAW3(`3]PAS]@)WKH`[W&_U#OH3VL!DJ3YT>BYQ6A9BM7X$=J
MD&J35PZ-2$OO,16T)'KP$P7E$"@\D%T#8`39=@.(1P%*,'O()1&V=WN(DCNZ
M@RK4U'R]5RG:ME;<Q1(O\2G&M3O+@RG-XU<ZT7P=X7#1-2D1X!Y%Y7VL8$Y3
M,4CP90V2$P'M=%_YEGYQT25RP0@>E`$)(`'S1W\L8`/#ED?39&'4)'P:EA+\
M)`;45``=@`,(@P,54``5,'5B1`#2=!<1T&$/E``E5QP0*($3B$%S8X$IL'/C
M1@LD)"\D,2TPD`8:0E/5D0<.F0><H5-I\!T\UV,HN#)C(G13$8,<V9$UHP8:
MD'0\<X,WF(/N`/\$,+`2;L0I;U2$1<@2Q\,I+OF225B3<$4`[G$%?G`#`T!-
M=#:%`I`!$(!77%B45WB%8(`'+^!V5Y(!=9`(OF9D2D5(6(%]\<9Y4<!Z8_(-
MXW!()P<YFG,#/U"'35"'=;@`^.`#?P(YGG<YMC*(Y6!YI&4YY2`5/Z0&.AF(
M7M%;5Y"5<8EJ1*8!(J!_"L$H1W`\4,``!U$1`X`HI8A[^I<\J,)[K0@\<Z`1
MTY5U+@$3"E%\M\AMC[)&NPA>ON@[!$`!06!JUS<S[W6,4PE?7'%Y!=",:F%8
MT+@-C?,,-L`6M`8_U=A`],<N+%`#`C!-X>@)<>..[H@)5=(!,+`BLQ#_`040
M8`%0(P%@;BDS!RD!CA]0CR%WC_E(04G3CZM1&MRA8T%A,%3BG`<Y<`DP':K!
M+Y512AZ@+<5Q0IOF!Z_V;A[9G_Y91"!I0E%%DE4F57^0+@^P@S@`A0M*!0XJ
MD]<U`"5P725@A#R@9EYP/&HVD\=CDW"%`S_@:3>@-D=89S@0E"=`E($V=SHB
M=W*'!VQ'!S+*=A[`#'Y09&.X6(BE%;[R29_6,B_S:3[T.`P5`D5``6,YEF:Y
MI/NP`$7P:IQFB*;&EJ<VB67PB%=:EU:*EWX01([%!`8Q$P5@`4%P!>C0`SZ@
M?\ME$PY1`A.J?`?0*(YI>[B7>P?A*&@4*<[V_US&M!LGP6W7A3N-HA`R\8JD
MDHN9TCR\"&X4,"EF)0#59SE`9%2MV2N"Y"OG)&M!(`"T.06VJ6^YZ26EX3C/
ML#G2F5+6R`[!R0)`4)S%4R,=4!,"$!2S6C(P@##G00S6V3_%X20KT@'F>&$?
M$``Z\)T.E``9\(#2P!PE1IX&\`2N45(TE)XLI3"\(0P%D`8AXQVF-%F;1@Y#
MQI__.:[D.D0S4`/&D0O\H4W:U'1/!P\'.@\2H*`QR0,M01`1&J$3*J&;.&=?
M1X0=&E<N&5=J0P#Z^1[R<Q-S9A,"!P$I$`!L!PR"-K$3"P!W``8R.J-@D`*&
M=0XR,X8?6Y7M1F23*/]Z?N0'*TA:7WE(PFBD%+"D')`/,,L!^Z!KY8!:Y#`-
MC]=I>3FI[?8>5VH"^[F?4@$H0EH$!$"8A%E\/E`&]F$7UK9Q(@"A#4$1BEF*
MM)-<!V&OO`->>SHIE^FGW/57+V&G%V%\N)B+?F6OB_IC!7!6H\($(>"6/NN:
MYW2IF%J&OE)Y%'`!S?A.GZHLH3JX)+*;ST"-$7-HUQB<9\`""=`!!'BB05$!
M`%`!X&&YB9&2<0,>`VBYIYH85:(P':!+%!8`<#!_&'6/::"LTF``S4J>4)-B
MTRH+T](P"-,$";,;N!!0]=-#/K1>25*NPCN\2'6NZ5I80,"N;^*N!OH'?W#_
MC0KJKVQ6A/E:H0,``A7J$F_T5P,KL"_Y=6K#!._1'O)#A'!%!4T0`2,P!5/0
M!T3POD1@!W;P&'Z&L5@X!6806E5QJ4%T*Y!H#B;@1UW1'I<7I8?4!6#A#?H9
M!/APAS/[`_MPEOSPI.+W,N`*:W3IB';9I8](MX!B`:+2!"DA`VQ`30$H`S@0
M`E@0`DW``"7`!0S`!L8I34<P7%B[2[ZD3#OQ9I+RM2-1N\@D?`?1F(+*F-0$
M7F$;?*4R;:C2MLU2$VQT`9$JJ?T+FXNU?65H3MS3=Z-27RZ0/H&[;X,KJE%C
M=X/PFXS;N(_[`0"@1[(@>[.Z3_D1,+4@"_M$CK)P_PD"@`F[4T?%LYT<5P"G
M>P:I>ZRK:W)N$2%.0R'DLB__B)Z1<"F9@)R8$"0OXWK!2[R:O,E(50/@D40;
M0'#*.SI2]:Y5=J#S6@`X\'4OJ;UP-8<=^I)_M:`T:;X#"W8W8;"0*#^U;`0G
M&@$MH`O"G`%H4,SL:\SLR[Y$D+$9"P9)8`#1$#-%-K+AM'UNV0.-&'X$7'DG
M]Q6B`*Z'5&MW$L$SRZ3\$`08W(@9O#U5FJ4<++19.A>@D7^$N1#&)0,W,!<N
M01$#L*:EXJ`-<</&5CN)HGS+QQ-BT\,^+%%A^Z=V5(L.8;5X:IHQHL3XAZ>D
MV2S"EQ=S*ZG7!YLA*[)9;/^,W.,'/J`$!$`$7_R^YE<%Z"=/8ZP-8^(X97*J
MA)$!0X"-JYH`!1"YH9%,AA8)$S4\,8)_:\.=TW02'%>`!5`#V4A_";"Z$P2!
MTW!`B_PT6?3(-&0;/W4PNF@03*!HG#S69,U4*P(9R/`$4#?*I3QE5.9$[Z+*
M;L2@-\$#)4`%31K!V4O7K<RA?FV$<,4#.(EJ(WJA08@#2I`+_Z427'=&*!T]
M,6`#RV%!#N(`"J``+6`98U`50J0&(7`%UOR6X13`Y=`5JQ;`J'0-A">T0>`#
M=Z(GNF4Z,[L`$KP`"/#9>=F('*R?W&.E5QIZ5SIY\CR8#%`0@VH0A+E\/+![
M*1'_T6IJ$=<%A3=LBLF&.][U*#+B%PL=7:/BT`[J$H%Z;34,*A2=F4(H33$!
M*1Y!`19``8ZR.T5@.:_VT?[[VU9I"I8JE<:(!29@`1NATB[`TB?@TND7TUO9
M'H-GTY&`TSH=G`D0`(42CG\E8?>D<0883`PC#+$J`+':C@5P?PEA83``!.O@
MX#@SU=A@U5>-18X\-])*,K1;$H<ZCP+@!V5]XSA.'TN&UAN@UJ-\!FT-#T\'
MU_0*A8^29A)J!+:]Y+3-`7<=9W4=L'_-H6NVA#^&#R+,=6]D$Q=P0A40IS(`
M`F(.`E!0YB`0!CF``X0P,<A@`_@R`BTP`I:1`%O1?77)_RMNN7D_!(E!&J4H
MZT,:T#)7T-K]H"=;H%N'WN3E3+.G\]G;D\V0Z&DX.R:8MFMU(<(D/%S8M1#Z
M5]RI8@2->:>ZHZ;UW)/H3:?5G3QXL8JXJ]`^?)G",[8+JJ^XHSNIV%R8"3;G
M?>J[TQ.4@G@^('SBNY?[6<4]VH*H8(PCC5@R4P8,G(<W`.`"3N#M$]-><N`A
MD."&P>!/#4$/3H"G\G\8IG$#N#NYJ^$OLE=[;!-U=''C>``%0.*,&]5.0D'<
MI.(B!34D(KLPWM7KOM3#%01WD^,$C^,[KJX^_N,9A8-O/0]Q/>M&OLH\``)X
M;3JOM``H4`)R-5<;.N543E?'@_]&%Y"AJYRAVXO8)S0'NE2$9=[R4'``%T!N
M_+1/EFL9-J\+,4"(/Y1YML+?-[IY.:EJ0<H>HK>"J,5Z`5$$APY+I\/TBGZ6
M<YC71?#.7C$#?M#>8P5&8`8V(TSJ-GRGB\+I2SM7"4$1R$WJT-V3TTW=M[,0
MX9C0T>-LT`48TB6:Z%U[G6E&CY)UN[X0JO+K6E83."#%>ZF1_KN7[V9D^=UH
M)GT#5R/M[S3@+ZU^UMXEV/X-9UP8W+ZJ9Q`![[Z=[_Y_XWAAW+8VX<@P?2$O
M$9,R#-3MJEOO5*WB*TZ!+;YR)K5CY.;5*D%A%C#P!?_[G'SP:;W6H^QA)5EE
M#U^$:G/_/!K/Y#3KY!J/1E?W5A[_\2#O!6]U$R,OY3>1V&F`(P8QO=%]/#TI
M$SB`PF)P3P)`D"14`!$@68A'%XAWHY>3)(`":ZK)E>`,'T@`"$%1144("X<<
MB8J+BX@<AY`^14AE:B8F,QHB!P<R'P<?H0<,##*F#)RH`S@#HYROJ:8R!T87
M%T:<IKFR,@Q'!P.ML,/$PT?'R,>DI+^<."(734T$!$S6U]A,<P0"TDT7(C@X
ML,J^P0?-S^#B[.WA[,XXM=5,%!&#3"(B3'YE5WY^3)2II*9@P4M7!&(AP1#+
MP()8%C:,J`:+FC)!*/C8Z(.("Q=$B$PY4<5&B"XH4]98R;)&_\J7,%.&F$DS
MA(88$0KHU)DA@0069X(*/0,T@J=02#^8RG%4G`@Q`@14@*'37H0(:6)HV&H#
MB-<$8!,\D$"6[-"S9Q*DH0HC@`:68>."-4"WK@&O0&SHM5&ERH8-&3*DB.`A
M0(`",.;,$?`4QP<*91A*GDRYLN7+F#-KWLRYL^?/F<O$".`A0H8-3\:676WV
MS(/7L&._UJ'C`1`F.'CPJ&7K`@\&("YP0*'(2(D2O&\96:Z[N?/GNI=+E\Y#
M'CLCXIR+NW!5`*<!NH,-6.[%B!(".Q5;F]-A3@7%B@G\^''#6@$*^"D4&5AF
MX;^*5X1PB0D!$5@#0`(A$4)")H001/\1/B0""2,44@@))#=8`-!-&E"@%#"@
M</+!,K/`(@LINHS2##JEZ%)+$R*T0DHGO/0"C##%Y*CC*T<P$P\T30A`3S;9
M;!/5-^L8TR,S)0R`S`$\Z#-..U2RT\HJNUU0S7WW1$&!"$WL1V"!!!4TD`G_
M"%110Q=5$I%D$5D441DA6."#!7AV]%%((Y5T4DPOK0133802BI)-..W$DT]"
M`=6H!&GH\Y144^D4P%5II+&5!GL!$=<#9[065%E#O38J6F>II5-;;]4@EUQV
MU8777ACT]5=@*:3@06&K=M!!5/I08`)HQ!9K[+'()@LG"6J,YD$*I]F@&FNA
MMB;;M;39AEO_=-%\8UP)32QRPP]&C&<$#\$TYX47T+4;W73G5G?NE-E18>]V
MIG6@1!/G"C/>!4H$C)X/$?BP4WX%&$9!`4Q0\X-]&BWL`T%S]F>)'Q694(,)
M%U\R$$`)T;G1A9#\4.')"RARR`T4X'E8``)\>$XJRQPCRS#G+$E.BR[:$@Z-
M/1[!RQ$S[_A=T3KBZ!20U!#I-#?=@/..DC4?I_,!S]!;93OBZ0;FEBU'$84/
M3=S0#\AJFHD0@OU)9-%#;Y(0Y]Q8^%$$GGCK"9)())G4DDN`OC13X%W4=.A-
M.2G:DP2-HI6`!B&T%!=9+(B*ZE#97J[YY:HBYM9*K\85*UVSZM6%_ZV`X:HK
MKPQK$Y48PBHK^^RTU\[90FIH0!JT&TC+FJBB_G'M;+7=EMN[S(TW#373\`LE
MN\]EYRYT\,Y[P794VDO%=CZD@=\/OJ4")<!*`$Q`!>A3,Z0VVZBO?@?X^4!!
M/298!!%%E\C]3T0$>FP"$@(12`@V4H0@!&%!5W@0`GQP@Y,U(F6/6,`-6+:P
M`+R@`C@XQCD8,")T"*U$'H0%*X3F"UB4HD>F4%X3QI&B#YKB%S@RFGAB^(JN
M4:$Y^K#%\IR6#?5%35+C0$>)DN&+$BA#!NG0VM;$T;4H38,)7(I!%"S`A"*@
M*00!(<B9_@&RR$S&(6Z2B-SHYI`ZX2U/'O\!R0FF,(4J%"XF+1$<X6+RI\(A
M3E$%2`&C+E>YGSAJ<ZCZ`R`'>1;&E2H-BFI5Z,(R.@,\P2M[L4&M;J6Z71FF
M5Q40@!@*,"S;>?*3H$16[G:5J]Y-BW)$&94AA3*\;-F`"5":'@_6!;U7'"]Z
MLG07<Y"WM>:(PPOV$(`M9KD;'HPO8`%K0@7NDY_\7"4G47$?`?!S#0KX@2(&
M,4B<\E>W+%XBBP/Y1\CF5@8T7:$(XS*9`TDFP1OHY`479*$OED'/7B#CA49#
M!HIL-(!H7&``):I1"9VQ(RK-T);9P<'V1,";(#6-A]=0GS2D)@YR)",9K3A&
M,=@QM8I^!QA>>R+_ERQ0A`AHZ`I("$@VO^D'FEQ!C,R"F]OB-$:+V.V,:-S3
M&MOX1IBP9(Y`K2.B$K>3%!A@E:@R%2&7RE1"/@"1.U'D(N=B%R`\,B^T\DOJ
M!+.Z2R*F/9KD9"C'2M:R?A%W&B!,!%)@2M:PX*VJ+"2V='`&&W0@EL\Y!Q2@
M("*L06-=T+EE+J?GCASV9ATXN``%`B""\BRG6X^]130$4``IBDV*6H%<"&)0
M`&E6XP8/#0%_LDE:B%@B;1<Q;9OX@Y`K,"B!#'3@`]M9`'B^0`#RI*=N=8O$
M%>7HB/@\`)A@Q`D7GD*C6-/1$JE4G:49`1K=4A]$K2'1;T@IB#QB!A'/_[$*
M*DDJ2-?%[I5""C:3XBD(`,FB05CJH`/6#TZC%2,9^6=&G.J-"#MU(Z!H`M3`
M&0XE=U2449&*%J4V]<`(9B54=2+5J<;*JI#<"^H"PU5+7A(&'<CD)CMIU@Y[
M6'8T54,(U`HMW_V.6D.1P%SK>M=V&<$+MD#F>:A1/NAI1["#15>6NB6-&2^/
M>=M9;!/.@TSF'=86E+5`%&+`Y":_I:44X,:,UV>-_:R6/V4Z"#C+T(-R#NC+
M8/[RF4)0A`6H4[8<F$_";.N=3NSVS37S[6]YEH[A7N`5O/!1<HG!#MTL5U+/
MA6YTI3M=:G3#NE;R8#FTF\1G2$,`<X#B3JRAX?^?P0(\/(@&V,X8A`-=8:5C
M<E`1HB!:.+5I31.96T7HA-.\I1&_;-0O'>O8WT'Q%\")$O!1-P?7!/NZJ4]-
MI*NF2E597362$ZYD82X,`_2)@1\?CK:T/3-3BM2`,,_*@(E/3*H4MY+%>&U.
M+:9,`!G;HCR!Q7$NT_6B^4CSQP2X'@Z`R5CR"8P`2/*&-*!HE6=:0"M^N+:4
MW<<$"C)A8C'ULL>TZ`?WAGE`6([XF?B#A7-2X,RR?5AMX2D&FL'YS<DP6LV&
MH>E-C*)%RR"H+;&6F^4^0U)'UJ&0",U#0T]42NAB$3-*H><!2$D$8"/8ORUP
ME85U@!N6_@YY^<UI/US_H4SE;*FH"_C2AHQ6#7"BVYI,`*%6V^G5^:VUV&52
MJ``7==>`?.L?^:CVM?\Z[0_@;%2'3>P''UO"6J5PKBQ\&,0T6PP=\,.T!T_X
MRVC]VJ3Q@+9/>>*A"&]XIK+!',+MRTS;(E[AP5)@<^P<=O/XYH953I`](()9
MFJ=;ANUQTW22C0+X8"818,*05?_9^ECSZF<2\YC`G'N!/(2T7DZO@^Q$@0:B
MF0-,L.T+Q/`)X("`1"?:[47E;,*!BK!YY=)YRH>QQ.V]G*&"CKG,'PI1F]_\
MADY:TLY]E"Y)499@SXQ_P1;6,,9P/TOEM5,$T)OE;[;W@/T@&?$E7UIG$75R
M_R>M=E\BP5-C)W:%T@5FIQ,1@':\UG9M]W882!1Q)VS$5FRD<W=ZD6P5MFQ]
M!P-_5P&"5W@JJ(*J=FVD5`5``'EE`7G7(CQU50&4YV<SA&FZP2ZLL'F<]QR/
M!43,Y4N)%4PZ5#X^`PV"-F35P`U(`@W3Y`.RUQOZYCX_H&0`Z'0+YV7E)'%@
M."``X2"#0'P3-"XWL!'C@F;)9UO,-PH@\'S[=`K2=U$Z,B/%8&?9IW[6%P]^
MIE"2$HBA)W[20'-.8R03!0[HEWYQ]B28]G("<'!X\DR&48GXP3"+<6<BA']0
MA(!W(B`541`]8"#MA44<1@(41QGSI0;GA(`)"':QUO^`#EAV:85'$XA4;I>!
M;Y>+0\$"&SAW'9@`=A=A(9AWRN95?E<!8E`!-;""SEAXUG85&U`%!C`$#Q`6
M-`@;M3$\-F@#.(A+Z.8<Q[$;F(=+0?@N1MA+Z-)=.&`/%7!OWA"(Y$$^^`8.
MO;$O\J&$RY%#L^>$V,`R=U)`6%0@_B.&+65`=T-\K.<KOB)-\P&0*X-QB[!F
M'-=\7,`%T$>'NC5].F(CKX`*K_`U32`>?,A][6`O@AAZ*:E#A4AE10(UTJ`/
MZ$=$C`9#/("2D&8/1&<P.V&"/MD>B\$8V(4U3K0EKA@$3Q>*IR5U!@2*5@<W
M9T5&K.9U.?41+K!&+=!3A4/_:ULY.(2R*6"Y%;1(5#HQ8'_4:[J8EGST`!JP
M$VX1C*.#%UA5C)0T@LNV*LTF%2$P`\_8E[=#4Y41-PVA&3:E`56``9Y"%J\R
M5]OX`+2QC8_Y`#;@'<6T-48P4<\1CK*T@YQ)!<S!1%NC=$#2!!W0'44&>@PE
M'?2(;T-V;S_`FN6#'4SC,-?PF@17<!I!4E%@0%.T$?@Q04Q@F]+$!+[2,`\C
M'[8)D(8P01+Y`PE3&,LW(L"Q6[T`9R'7D2"Y45KR#52@?2#T(RFYDKT1B-TR
M<]-E)#\T-3IW44KC%$W`;U:!B>Z125%1GS"2=#_R1+E)4AM3)J,8</_7#Q+Q
MA8!9_U-DY`=VDB<<L:!I9)5$``%U4"@26A-A6:$6NBD1T'=E>52YR(MJJ8N^
MN`&*$@-P^6"E8P-U,$E;M7<6AI=!N9=^&:-CQ&4*)X9J4FWS1499IP;".`$&
MH`-DT0-".@:O\IA&^IAB8:2260$?D%A2,U'?\)[YL(/-P9G@P8.$Y5&7)@[F
M(1\=8`W[B2<4T`W)Y"W308Y6F(AIBB0^\R+DAIS"Z5ER*J>V.1]VZFYSBIP$
MD(8C8WR)H&:)YP',!P5<\'S1AY$@]R1SIF=\!@U"0EP;]0R!!G[AJ9+0]6CD
MEPT,"9,4-90DI`Q$TPHOUP21UC#0`$4-`Y/>,)Y:RG)3HO^?&V$!_&<09W*0
MNRD@;G.C!"@GV&0"0;"@P.J;;#02PYJ5$_J5-'&AR@J6&:IK/X$6'OJA&?@`
M(KH3)-J!<7FB&*"B>K<Z=^EW0:D!?"FC'29?9M)[Z36&`%H#-'$@NJI-"U&`
M6J<&$F``/JH#"6`#`2&D0TI5<H&O87&D#]`%WM&E\U%PU,4\-])Y5+I+Z1(>
M-S)#[KE#^WE`9$@(A$!T\[.JEW<NNX0\R]%R+2<=\L`<CZ5O\):G*NM9<;JR
M[G,>/Z`1/D`R$_2<A<%\]:21UJFH<X9<&R62,%)1A56IX3F>J3=SI:JI1V=S
M4J.>^L1SOO4,6\($]G<`%U"?46/_M-=EDN/P-?6`@*!(JP0B:KLIH`Q13A4!
M4V1D$`@:K,!*`;G"HHK7E<=J$\FZK,O:K&?WK&<1K=+Z:[[8EM9:HG8!@I+$
MK<KVK2;H'@(0!5A'KF;EA6N3KC-AL1)J0%MX"=F$HTH9)P91K_>J%@3S%B;0
M`VK0KZ1C`+#RHTBJ`07[IC^@!.\P#EB:>=!!I=QR'@4'D`A("*;H/P=Y-[ZY
ML3#2&Q];/6?:9[GQ7/*0FI%U6"WILM+[LON"LOHVGAY;-AIQ(104J#A+(A]'
M3SR[(SY+#*L07?<IB.*WOH<%<SI$#4FKJ3Z4ODD7-/H$0HZ&'O-#`)OP"8[6
MM(+(1+F`_U#N60VY.:OK12`/(I#OQ2RZ&I5C9":_ZK;#2P%4@9<%$`&:-:%X
MV\%AJ;<;RK>]^+?26CF"JQ,D2J1U9VS$*$DB*+?(F!B9Y+B02RS8=&4*41D7
MDZ[IQ:[LZB`T@;DQ4`1,1L1;2)!IX[F=BTT](`$),`$3H`-`X`%"4@_W@$5"
M>KH],`8U()=U01M2(`6/XQVKP!SHIG0]"#T/BVDP9@ORP;LD54!-22B8^R`'
M]"!Y4GP)>R2(U;'(FQS&"\CL:[TI.[WN0\ALZL?44:54V@3T,;,<@6V[\KTH
MLI'3=YU&D\E^U3Q-R[Z>;+0L:9X]1`#M<VB!B%U+@@Q*`R9SP/],469RL$"T
MZHDS'`6KI,8Q*Q6\18!%:X(%EU"@!DH1-B4_S53,^=$!>%0`%L#!'MS,&*JA
M><2AT$K"'UHY53"B8R`!*KQ(=+$2$!9)+FR,=EF)>)E),?"X-1R8H;A%/,Q%
M8VB*!2$9:N!-4E>YF$L(,8`W3/9O318#ELL2,P$Y623,O$H13?S$6I``4YRJ
M45$!\*/!^ZK%"JT77D$76@`$!J`!'6=,K\#(5IHE2A"S&B''`\G#08S'=D+,
MUA"GK<FFI_P.#$6.?SP=A,BQER=^;SJG*'MDB[S(MVNEF#8`32+4`^#(/H``
MDRC)E*RSESR^FJQHU(<U/&:/GUS5+/G_8Z-L:(>&6*C,:`/U#)%(,`9#M=@5
M1"^W-$!$0]]1R^_9,@N299;`KI@;$`-ZHU&IQ+Z<$<9LS/4A:3NQS!+JS((-
MPGD$!"+<.-2LEA)PS5$U!ORJS2JLNG/!$B>J%[4BSH*Q*R18S@)@`>@,N5@6
M0.Y<SX2R$O8<.5EDNO-<(%]Y64TF-@:TP96[9$1\67AS%<L\+#DJB@BMNA%`
M#UJ]>A00`[_;KUUL`UIPT1K-<CW(&P)#'_%#4A;K=*/-E,++0/5AF]=KU2S9
MM+_$+C.MFIZ<B/F&R(3,TV?ZTT"]WE3ZL.'!`SM4`)I->M(9?0Q@1$T=U59J
M41]47/@[U>K+_]U4/7[J$VERNJK8(1X\8H=^%8G]1@';L$)#B37>QPY4X+2*
M*K)2F(91H%ZT>I!-:;;^T#91F;8.88#$O-?-5!_)#-BT*-@>3-@I8-@=FMB*
MS=@,YM@]P`)"JLV,9``M\03''4F779>9S7><'0&?7:XWC&JJ6`8@P\-21]I?
MJ0%+)D6HC2!C"Q"",!.F;1-B0VHVH0%"G,\1T$PI?HE09`&=E*,S,`/"B-$)
M$'L)ZSZ'5L7#'0(ZOL43#00:4&YV2D&2,-T,,B!<U%YF^)H!HQRS5![KLH_A
M91VU$`Y>T%B/+B7)`3WA_;R#'*5JBM[IO8[<E7GL7>JE+M//<0';4_\!NT-Z
MU6G?^$T..[+?U?="*%1GJYJ:@!9^XN>^@[:R?!P.,73)JR"%&3R)/K`8]QE$
MR(4T\$`C-P,,QR.%;IV4N5R*=,T0FJNVV.2Y#H%.Q:?BO\GBS*03+DZA,.[!
M.`'-'D#CT(J6-NYK9('CE97-_,H",]!'8"&7<@G.IZ-5J3,8FDW.R2@`$>!%
MGQ2OY_IE4LXQ<6,F(=-2`/'#)SW$&-MD>,)DK?(W!U(#6W$@?C`&`:<!:2!_
M"IH?V`"%UF5I3'"*!BJ*#S`!&&T#=!Y1+XNR#D[<?L"O!A+BU/UEARYJ9@A:
MBWX!CDX>XO;HZ[(UCD5+3O_''>M84._)XAW_R)@W0Z1NZEJ_]=,3:*II791U
M%8S56[T5L1IT4#K2+DB3WYP0)=VR#N+IR:/I4'-ZYS=7UKF0G<"P/6UM4D57
M`(PA*3>4<VU_0\7`D?%POFFXRZBE997[UKBC$+NJQ*L6`N'.,F>8^6?HG%7Q
MU\R<[LNZ[HK2[H<=%&H7[V\W[]C,KSO>=F6Q[W/I[R(H&-A&\(B120>O+-C4
M>^Q5TI1;$^HE-Q>3$*0=!!:?D'%,"%$0EE)4H5/$SQU.(&/`Q1I`=`4C/P7P
M*T)94:(0J=`F-R]_NC-0KU[1!35?Y]6EIE&!S/]FBJSU#Y4KO+^IZ$CR8DZO
M]%(_T\UU'=(!"%Z"_X.#1EY&B$87%XF&C8^01CR3E`.6EYB9FIN<G)2?H)-&
M5)&*BZ=-J4T"'0&N(C(,1S)'1P>7M9@'N[R]MYR^M<+"O#@B%TV+1B+,(L;-
MS!?-I\BJ`@38V=@"W*I-SC@#O@?A.%35!$Q,!3X1/A0P%6(X]")4D^*[G_G!
MQ+OT])I0L!#$CXDR:K"H66C"3XB'!M60P'(0BT42&"UJM)A0C8DB-T**%/FC
MI$D"!5*J+!#CH4N7&F+*G$FSILV8,2($6.D!B`069X(*!2JTJ-&C2),J78I4
M@H:5,<;TD-"C!PL6,Z[.R"I!0H($!H#8&&L#0Y4N5:ILV)"A;8H('CRXFO^;
M,EZ%`"8PZMT[\>)>+'HI&O1#N+#AEWYJU'@9(DB4("$(FSCH,;*)Q@\7AX@2
MHTB1*`\A!]$`,V>$"!926SC]C@*%"'X\3O83Y70$UQ0$'/C`F_<_8\@(_&!R
M@X(/"T5,+%Q>IGGSJ@_"`M$00)UU;02\-5&B"I4`)@-!![%`X<8/`HP*#>*!
MZ)"@3^T/E4(4"O[\^?(EU>_$O[]_3Y3<%XDRIE"SR'9*)-B$-AVL4P`.L3!`
MRRZX'*'++>-T@@\_PPQS0"WD').*--`PDTB)!Z;"#3?8$="-`-Y(@X,^])#S
M3'#8,)&=``504,`<,,[XSX;\#,`#%53PPXLP$]K_&`X!QX4P&4(*J=%#0RY5
M1$(9R@'&UT8:J5%&"!0P8=*9+6:W4DH!M,18"#?%*>=,M>VDD@<V_'0444SU
MZ>>?24E0!51C4%6555E=I>A573T`EE@VI*766FZED$)<<=%5``QSW)577U4V
M-]F4$@7&$6%7)$98"(K5D-B;CL4@JZP6Q*"!JX7--EECN*XZ7FI11%%$K*JY
M4X`Z/1X[QS;<S!$"<Y=9T)IK3"R8S7#%&9?:L)!%9I!SX#HW60_1C:5!!-;I
MB)UVU21##3.I9,>((_K!EU^]H`B82'WV/<+O?O\%+#`F_XJB[RF(&*BP=@EB
M-QRR3.#`P,1-5@C,+_Q5_\)AA[;,(L,!I(RX3(DFCAR--<PR^R*[SA0#T,GI
MR-LR#M^Y*(8SOAW`0SA*ZHPD#_UX;,LM/!,PD)0(=23FJI9Y.1E@7IH:ID(F
M6)!F-MHEXR!4;\[I=9QU\I0GGX"6;7;9@D*5@*%5+>KVHA(X^JA9DU:*J5R:
MPA`/!7YP><7?A@5^A7)Z+3>E0XQIX!AGLZI6:PR,1T':FYFQ&G@-44CKP^:<
MEW===M#,^,$!,I2.P[,9+;V99T6H]ED0L+MDV-^#C\KEJ+B/VL,8!MC010S5
MJ8,=C`S'>($2IY1,GR()0\+OO@7[6W`H`U=O_273LR>@PMRCDK6U#O]@GOC9
MEO\I\<0@8I++?SCPVSZ1^7@H-,C(D&C,B217PV*+*W9CO!$O<P:\<J2C"]3H
M'R)8!8F6A+%QF(,*0EI2+4KW,8Q1H0DWL``2J,21*[W*#U<H`]0X&#5052DA
M9?###1;TO>]=8&LI.5KBOD9#FNA$;'HZFPYWJ)2TJ20&:S.45MY&1$;%[2M`
MP(!9V)*!2V'*%779FZL@4AC-,`:$E)'(F*2$.,UH('.R"I;D))<XQD%N5K*R
MC05"4!43C,$AM5E-:]#3,@I&J'2W(,7QAD.!9YU03+E+%:IH5[O<&7)4A<S=
M[@R`@7,=2UW9::&[#I2@%(V(0(V@1/OH41_H90]@_L'_6"=$.3#X8:]?^H+$
MPB29H(9=[4PE&4E(7%,<SOG@!CP80`E*,#2,I4]#1]H90`"")$YJ[!*]\$<T
M2+2,[J'L:LQBUR*8`9P#I4-X%T`@BKYQP%F,PQ?#C."'/%9!(QWI`C>(0@C#
M!$C$100CS='(ESBR'(H4(5Z2S!H,4[+&E]3PGS*YX9WR)`$>&O2@01G4#Q-0
M*"$FJH@0/>*C@*"%)3*Q+:>12P1<I1C$,09VH(E,(1<B&<Q4<3-AG!R<OABL
M&*PF`+:Q30!<TR,*:$`-,Y!-#7)BG)XVX6-&L@0/<"0^XQR'6R$((4+"!:Y#
M.O6I)DAD[GC7!4<RH0/8R*>[_Z+1R@-A4A#T.5(QB?E)?O%GEVA-*UJO%[!_
MI9(:I3"0-UJI!&C"TB2R'`EN<&/+S9$GET;BA?J&IHE)(.FPB$VL8DW9LW\D
M[QC<>R8T742\[C`39L0YEC1V<0P8R0@'BQ`GB+X)SI;M@DEXO(5AC=#'BM"3
M2^XTP0BA%A@3,H<B%$B@5K5C'96\1@-=@,E#`/JUL`TTAT@A&T*7*Y2N8(!0
MA9K*3R!*W:L4Y0$ZR&X"=&"`[@*!HEJH:!6LV)C%B9%QI&F5JKYE@L6X:@QO
MQ-QJ4(,<86D.-S?XG/^0(0(!%$$B'&E($/I:'M=P;ENQHR*J#`+5!COXP66H
M"GQK$/^!8V4U1I=LES0SC*\`10*4_5&KB$><5NN5-5]O[9[W1J0*5Z;IKGF5
MY5YG;."^.NX'Q]0$A4YI6,2*];"3>*"/[P'8"Q4#LJM4T?Z@>8T+KV)$`KR`
M`"H`GC*AAQ<)C*3]#DC:+@_`&/>P1"\JF,<D7<`"$5F(0F#KDG620$PEE-H?
MU7"%W&YGMZKH;0PC8"N8Q&2EQ(U33NR4$CP5M"ADLRYS%WT&YQ(Z*E+I2E>J
M2]VB_"&[F,YTIJ40J3\[)DY^)LT7;>6J4<$W`370@+1F_+E)2D)]LIB%$2Q0
MAKY,I`RIHIR"04C(7DOUP<`VI'.60VQB]Z`&%BC`A;VJ8@/_B0C*)P;%?TB,
MUB,P0*W7BUXJ$]%L9Q:/KN'#:XQC3.,:]]7&CO,,!9J`B)_E6*CU4:R\D92(
M>R#"'$$NLF"I@&1+6F/)DW7R5@>X#A\Q00`B0*`WF%',G76Y%V(6[,X.*\Z)
M[3A)32A""-7,$*9)*2%8B"=?)@+R8M/9!QK&<P=6OK7C]'FX@`[T308MM@<8
M)='*9;1!':V2",`WTI*F-!&-<FE-&UV[-G")9A3C$L[4JJ6TDN-K0E"&&5S)
MC3NUC6L(4'$[ELY"IA!.+:E>3S$U-=AH3[OMAJUF>8Z\2CWP@P9\,(=+]KO;
MU+![AQG;B1%?@MK8)EBTM;?M`C6[_SO%8UA=6W2F<9?[\>>.O%\=MRW6M>X'
M"-L7D0'BOL/B3V'0>%?H>%:,`F4MX$R^A@`6T:P>O>-831#=`42TV5YL4IP/
M!Z>0<[F+#TB(`3L>`!.2*D*E-22V(Q3AV^E);"Y98)(I=V$Z&F0=U_#YY3&7
M>4UH/E";(QK1.=?Y#GF^J0@P%+Z2#KK0%47THQ_=`']V"4CM.ZUIE4D=6&5"
M$/*24X_0IG/F4TWQ0@"SI"W(D6#?(BYJMX!.Q53-46Q@$H&A<GR(DSD44'>1
M95G^MF+3)`+29@F`%X(EP%;P-CTIAG??0U?<`3[:`&/C5H"/5VZ2-X.31WF5
MQSH^$$D9)O\"B-`,G&0.CS`-_J:!+D0BX"`D]:!AJ*<-<_`YV-&$-=4.[W!P
M$51-,])+OX%[N><RB"4DOD=!MC``5.`#2-`E'<%F$%%K;R9"<981<R8;(<`$
M";1B+70!!(!5U.<@KX$:?:9]@B90;&(#WA<4BD:(X2=^.B0!SU47D/85Z%<5
MD[9^1U%T[I=I0!!&JK$YN*$NW"`CO[$;,D``^Q<U5!,"K>,9!X9@W>(MO(9(
M#/B*#@@N)K<1<C:!A=$8K?,.^24\&4:'O=@]F40D:L4Q1R"":U5*G51X"'-X
M60-NC.>">16#?*6)1D6#UGB--7B#(($U&E@B]4`RD/5O_N,-3;;_#=WA@[T@
M(HR7+NRH#LLR!_`(CS!D'*C!&F6"<$?&#$"36BZSA5U&#Q2G)&!X!$U@`1MW
M0K,!$83S9@DQ<FYH;+?C!Q20@=*'5=/7(`4P%Z=A*WXX<X"8D5TPB&=0B"-Y
MB(AH-HJX*9L2%;OCB`V5?M-5:99&B968708P*SZ@#JL'#J1E#$F(3OOGAAR!
M:R`4.+-#2*\82'_S5`Y83Q+H);1H0A,H2.65BYZS;,MT,M#';)E7+T2F;^-4
MC+QD;>C#,8"7,=DS'YC$;:LTA`@2<-!(;M(XC=A8EW:9BJZ#@S]@+44H>MOT
M3/W3/_PC3:8%6BSX,.V8+LN"#?+8(_5X_QM[>!L69D!'!D`?0F;^Z(\`20I<
M1CI?=P0_L']48CA8TC2@XI!"R1Q75S7)`'V(%R,Q<X<KAY$4`%,;V9$VP7V!
M^`"'5I+@=Y((E9(PL)(]8'42]G,P&9-%1'0TZ7Y2P%VJ1AX#`%0'`'Q&PF\B
M@BT&."P1L68+L50*J':W`V%<TI1M%X&HZ9`G)"I4&02MLVKYE0TK>$G-2)]P
M%5;O9@G#,#%E*9:UP)]G"2`GIDJ1E60MMH1Q*6-S29=WV:`.FHTWZ)XKM"X#
MJ#):M3\`AWK]`V7(,!QW=1XMDBZN%U.T`IFX\2.@(U@X\&J9V:(N<R3+P&42
M0@M'<`-($R81:?\9:@AR;2B4"M$#$38J18`>6TF?W7&'V<!RR/(:CS,YN!D3
MG/&1`8`!#T`4.4>2P)F(-A!%,5"<6V$ENX-^O)E^R]E^-6F)&B`K/G`>Q`&#
MQW&`"%@8M1.+X9*4!R$JLMAVZ;FGJ?F=XRE('F65\4D`"C))>.8N(O.!P."?
MQ%@+`=I6:3D@WB9)K_2A+U@^TOB@FKJID6>#EE<$:\J"%;J$2E:.+K*$J&<F
M+1A+,,A7?-A2&^E2IV%P'5`!,&):.H,/%/*/+IHA]0`0XF!MLS``/J!48>)!
MN0(U/(J:4<,0N!.'<YAW=&B'V-%;!F8!DJ,!!N%%_Q0L,Y%&A):155#_I89X
M<UGJ)SI`=,UE`SNA-QM5%3BU%5<R!E_Q`&,:B6\SD]AUIMDE%J'A&*NX:[W6
M@.0YG@Z6I\O*IZ;"'*(R&53YK^^Y:K2D+L83CG-E/`KC28-%EOS9G\-@C,CH
M5G'5;<4S6;!TJ0L*>9RZLBSKJ9^Z0MZ`JC([LW;5ID;E.B#UGBZ%1J9Q?;/*
M!+:*<-3$"SO36/]@>^&DF57X,@`Q3C1P`1J7-+:HHV"BL(5CL#5@9R2;#"V"
MD37%I*!A`CG57MD'4."Z$@$PKE:J7"9YKD;!FT'Q!W\0%!*PI<,YG'PF)3T0
MKPLA8?5ZKS^A?F_+K]J5`.+R:W8J;`:[=GD:_Y5NR*P:T;"WB(NI08WY!:)9
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MU@7`=1L`,.`@5\6^!&$0>XM3?=N27Y$`#APW#1S!7U'!!]NX?I&>0\G!H9&+
MO0NB\SG#DL2!\U(@>^>YN[#"LLS"(@BI,7R"JVO#-XS#*<O#OOS+/2R\MX0M
M2_RF30S%NE;$1ER[P@O%SAS%3BPL3G<:CU/%A(9-A<E)N<=E,X)'+=-82';_
MCF0\M`-P!&?6-VUG)138-U#C=GM:0K(Q&4'`;IJKOMIPQW@<`5%PP#-``E;G
M$%YS7F@$R"(YR(1\%.<"4S60%?]+M^S:6X_,<NP0R2:`P`D,IC^'R0V\T6?Z
MG!*<`)Y\ITS5QO,$2`G9&!^\BP)GPM4PG^RRRET)/;J`/F,YRS9];<=8/=HF
MJ?-"D:FP>*O:>-$(N^8&S$8]NT3-H+:4B9/7Q,/[S%`=U5(]U;##.E4]+&(D
MJ[;!LSM1JXO)3;\19ENL>]2+1TE[9!OXO,_@#/HIBNOT6A2XD.YLM84S*B'0
M`8;7;'9,'#+(9]KJI1ZQ&/,+==:,MN/*OP=]%.U%_T;*`12*S*Y->!T=@,KI
MT"-K%!$)?-%7(C>7O%V:)@6@#=HZX-%P`-*?'(OG2=>%<W6^8I7J<!XBG'<9
M]M,NW9?WJ;%_MTN8<-.\W;$N?+K/DPB%D#"JK`IVQ:HHFZE'O=RTF]2PVZEY
M><Q4/=U3;=50_*G8S3K(42Q;S6>G\2/C:%IBF%B\!TY`,V9FO4FV%\Y0=H0^
M>%@VZEJV*!E0&<JJ[<^L?0-YK6)[C:E[M3EYJQQ]"]`WD=4#':YI6]#FFMB(
MUA#CT@-QZ]`!D(<6*9^KT&0WX`-%$!D(L17^G-DLT"CV^MD>'=K95=J'A,$\
M.M>J725K/!Y3&,*MR6*9V__2W%&H>(>?N;T):+7":>7C(5A8.596(^N+QEVI
M)RL2SLW<3,ZISHU?R2V#>)ENV4W=5O[$V9WEVGV#R;N\,54`'2"T0TL.UTEO
MHR!:3B)8GFD+3?L;8MR!V?O>%T`!9<B&\^UFIWG?XUN>$KG?SA2BZN#?TX@:
M45`#%=U&@ET39G3@`YR1&@"W#(Y0O(D!P>.$*QTO57;9`N[A7UILAQ*FI];9
M##7)Y]FC"CN!#NLKJ>$Y.F+"LUWCWG/"TI,)/][;LDSK(YAM(GLPLMUB0!W4
MNZSD1-WDQ#Z#3TYCEYKLR?[?YT;E6O[44@WM5_WL66Z#Z5;-\S53M7FB6(RT
MX<3_@_:@A5_&#S-*"U^&A-_H5<X@3`%$(@1@D%TRE%$E&6I(TJ<^GA%`PI&U
MCDNJLGYMZ'T[!JE&$[-2OX/6Z`&P`9`>Z4OQ!]XGMV=@KQ$?\0]`Z>RH#76(
M#D:CX9:Q$/V<GIEM<J72XG!-@:&1TL+#'6YYJ*[F/*94;:([NKSM=R18@J$@
MPRKFZTB.W,*NW,7^\S1X[,H^]$0_U$K]ILZNY5!-[4S_J=;NJ=A^&C.U)C\2
M>UE8(W'>F<5`[F!X[E4HQM0T<;ED#O7P`S[0O2343O0NE'J^%R8=`UN9\WO=
M[P56;GDK%0->58K.Z"J1\$/@OPS?)QOM*`U,Z7GHNX?:_V3@X0.28^@"'J\?
MCYJ1_Q>HOL;EE3D2BW_94%EU>+$YCI_"R$ND:^M`GM.ZCDI%3I&_?BU)[G@T
M!O2P'WG'/F-%7_0?>OM"K:!%#:%-W_O4[CI/'_R5YU+9OA(030!'.$Q7;[W_
MP/5?Y_6.I1W/6[0VL@OO#AF4L1&PA46EPN+W'7+R3`!^OC"K3T"!KOOM6^@5
MK<ZI5O"+?O!]OP%K$_C7-?CV;Z^8K-$5/^'I`@@$@DU*38:'ADJ%B!<730($
M3!0^%E%!(7Y^)B9E:IZ>,S.?:ILFF2&H0446%CX4%#=,@H6+AHV-B82(NKNW
M1K^_/,(\`\4#!P,ERD?,S`S/T/]')<W.T-;*V-C&V]S#WM\\P.+CO[>XNXJ"
MZC_L[#?O\.^O\_,^]O?X^?K[_/W^_P`#NJ)'L"#!>`@3*DS8KJ'#AQ`CME-(
M3Q^KBQ:*:-S(L:/'CQHQBAQ)LN3%""@#%.C0@8G+ETP$B!"!HV;-`P=LXL#)
M,R?/8CB/R!@J@\$1G2*:J",@H,E,F\=RUFSB(P22$";48-FZM8PI366PD.`J
MEH39LVC3IL5"RD0()D;,R36W:RG,N_(,1K"@05,H-6-J:(A!N##A"`%@%"@`
MX\6&!!(BGYE,N;+ERY@S4W[`N?/DSJ`Y)Q@]^@'I!!HBW"50:U<O1N<:I7-Y
MXQ6EC$7_@N@.H7O5P'?L9KD>3GSX7''"N&T[<,2:\^?0LDF?7D*Y]0'@AI$;
M-_<6(B5+ESY,:'"2P//HTZOG5[[]JX7PX]_X$4^B?8CA\Z^#2-ZVQ9(@!0B2
M2026=!LK*"&V6`4,5C#'@R\1<,%3-_&$0U0XX<!#A<C@Q`!111V!TP!)12(+
M4T[I%!4.25&`"299<>6)5YEP(A99:N6H(UN;U$!!7-W)A4YX=[T4SV(%T!-!
M#%BI(4H/-80PF&$Q(*888XY!)IEF7%86VI=@@DF:::>51EH--701P2L1YE*<
M<8XHHD1WAP@@IWY-R#8GG6_F&>0%P"1WW0#41-,,=(@ZI\V@_\9D]\UVY0B)
MSIWAC0>?0>MEJNFF][CGGGR@`G??J/?I9^JI^SG4GWGY%,C*1@5ZY*I)][1B
MCZT#+=;!'!4(X*LZ+SE%84\6ZL1A5"`6Q4"&):K3%$T[`863"!<P$<45?F#2
MB8Q8>'7%%5F9A:.X9>FH%H^F^`#DG^=\9U>1>.6E9!0U9"6*"8)1B5@'BS7V
M6&02="EPF&&6]N48G$76P\*?W)M)#7X(UHI+@Q`GJ9^.V!(;NW-I?($B[1Y"
MER.-;"=H,=25D.C*STB3<G7;P%R,H(YJ!VF0KH%7J:7QE,?IST"KYRD]H8)*
MZM'MH*KTTDR+YPY"%;4ZZ]2O=D0UKO^XVC//8DS,P92O8`M"L;`<6C@3A3N-
MB%.R(0Y`!4TSV0)MVF8W88$?5Z"2E2<REN%MN&-Q==96YN[HE0D6K,MNSOFQ
M`R\3"2TV#U\F].!)#]D:9J5BC65@`,":21!:9`27/KKH8Z2>^L(,AQ**66H<
MGFT0%K!)P)L=8PQ;QAB/S&?O&<MEA';#Q"S=<\T9I3++R#/S\J`U9[<=78>D
MTWA#\?D<]/;<:SVT047'A_3X/S1M?GARUI*^G(F8JJJ\K.)S]47][#6_K:V,
MM#77'7Q=)R1+21'=BF4$$100;3P92G.&\@RW48%9:+-)3T10`$QDJTEDT4KL
M-M$)<I7K1H3_*QQ:NK6)(@"*8[QSEWY^\+AW&`E)DZ!7Y>Z5KRJIA',O\!SI
M$@::,YBN=``+HL)81T0B;L)R&RS%*4)0!!_$8A#4<XUW1):[7J#08^881_&4
MDPWF*0HZ+L.&\Y3!*.LX"E+BF"(B5OB^516D>W#<WM#"5S3RC>I\>#15^OK4
M)^NE"AY1JU6!]F&0)!'$!_9SU:U$HI%<1<A7O7M$>%)$K`RQ:"83>DH"9<`<
M!7(2!U2PR=F,E;::",`"2)@=!F4T([^%Q8/D"EP(13B6'FPB"$T`$O"BJ,+K
ML9`)#7F<2Y(4@;[8RY8AJ-)*6-(!&&0@`0@S&)D2,,W3J*Z(V,QF_RBRJ<2(
M12D5OGD/,%GC)TP&+X587!P546B.;W`#&\K+1O*\>(V4E5$YT0L'&M<U')VE
MBF<]PU0<!_JS.=(1/G9L2!X7JI_UL8^/5F1G]9Q&'_C)CQ7Y\!0,"_`2CC(!
MAOY99/XR8I(B6*)V,)D#V/)T-D?\2A`"N,!.RG8`'IQME'03"H@.8)2:DE*"
M':H)!8/P3:+NC2QL<:4:!A="PHV+EB1H2P@(H$MU]A)5$2D2#/GBAQX\R0]1
MB(#D`E#,:()IB*P;A9-<Q]:VJH%UFQC#PZ04A2A8(`*.'"<Y<7$!+T0JD]3"
MV3K5N,L)`<.`!C0"%;:XG*`T0QGT3-3+R/]XSVU(;Y]5),3.VNC&0Z*'0`25
MXZ<."H^$)HVAYG.H(B:U6HA&E%W[_*MW_#D1^!4D>P0QY-:$^5'=AM1^*+%'
M(DT:A!A0X"5>@Z2P;OJ(L,64IE*Y*;1ZHL`/=9(!;IO;`*5U`+NA(@26T`3?
M6!D[K3"U+$X5'%2CZC<__*"J?V(<:L56I$DPJ:LTA-@1O<HP)*IU%&W]R^5*
M80HT\::X&'4%UT[T6G86,(WL[`YRO,$-QU;#.?-\1A=7]KQ[1B^VBB-9R/Q)
MT8I21'L",5!HX6A0TLZ'?/.=KVI;X]I(%A90(,:LI/Z8$)>PD$CP0A)(!\*F
M.:040L.4G'L0:;__ND;!!Q""Z2%&V=+F0B)/`[00%0X(U*#(X!C+6N`!J!#*
M2N*$!],J0!3H:H$@^&%;&1S%!YL*PEG2DBV8NT&(!3ND&"^E)1^U;[V0:+G7
MF<70KOOO6PF<B0OJQE84\*BSTMF(P':G%KX`1LD@_*?$!NIDU_&0<T*480U/
MX[&3E0ZC\NF-Z?V.$"0N\=.@)E#U4&W%F?H>+$)E6H7ZF6G6>^B,6]LG%&H:
MQSE.-G="ABHJULE46@VI*[IFY`=Y[6L5:(F007I(E%C@,"?R7SGGALE##$($
M9H[NW"HI`BJ(R!DB`F66SUP3`E@`O%7BRQ7@'&=/G!>]=2[7G1?](XE._^K7
MZ^@?H"E0S*XNC,!>_40/_+:)1J="%1@59_G4L8@@K3;"![0T%H?'@RU'R@A^
M)?F&-%3A"RL*LF`<8ZHG>QV:M5K'A/U.K".RD#?:^GXBH02N_:'K]]1Q?`AO
M:/IFX5!TU'BP(%=V;(4!*9O)EF/2S3HZE?+G818DW`"$*=BRG620;MN0>Q$K
MV'P5/)S>-&."D"FQ1"05G5@(&1.B1G-$%,JT'6,`\A8!$RIQU[U@A=]Q%KAZ
MTVMG6BY:70;O<]+#TQ*&QR`*,<#()5*1>4C'0J_DA'7'+T9I2D?8L,BYY]SG
MZ?*7OTSF'8;>&7.<V5C_<]:TKK4_@*[BD1PHP?^_SQK0=!T^.^9QZ>C3V?J>
M+L73'T?JT"<'J_4)8>DS%BDX-5:YS0VL849(RH:H6-@(P)(B]6_L%7`)2@JP
M]IBVG=S;?P0EO6Q)4EK($#_AJ0R.4B&DX.`"!8!(B,1PAZ<52+45YG5>'J1>
MZQ55MI0X$A5%DY='IT5L<,)\L+$[0:)%Q&`=8I0\\!19SY%J-<=8TQ<,U'=U
M.1=^LF9BN:=[_<![0/<?^T`_FM)B1W<T?N9'>X2!N'-ZT1>$)(>"5$=U*L=J
MKC8\E84=H+18X"!*(B=)2M,4+D6%O!-VM\-+D"`)KG`[D.0=$Z)]529_Z,83
M']`30C5=&1()`Z134E'_?RS"(@1@2*Y0%39R@$\E2[(D<`TX%GZ#2WN6.R'#
M@A.8?(Q#8\4QB$\G8408:B-B#,SA/"[7>H@R<Y15@JV6@B9CA.2P@NUS>Y?2
M'C$H@Z0H=!<E/T%3=$8#8PC7@P_E@PT&6T(XBY\V?;:(1HL%%+*W(63FA-]0
M=V^W=>W7%+L04]M'C&$(A;A@(M/F)\"C76D8?TY!+$,!AQQR`01P#/'629R4
M(<(@5'(H":\0@`6(APRHATC5AX/SATH0B$+"2]RW@['VBK!8;,^G1:$F+48A
M@AA6:D8!>QZXBS<7??#H1RW8<YX%$*2XD"K6/9YR4*12B*QA@;#H?+1XD=9G
M_XL:>5G(D8L_84;?V(M]]U/1&(R958QA2"TL!5V`%S<"P(5,("R5)EUH>$EG
M,V746(UP:#9K\X9$06^B%(Y;8X>(=X`CQ'AY"%7=4@93Y8Z^,V*?*&--9T7$
M@8B,`#P9:1V/."@\08F(@FJPEPU+:%D<N6R!.!QL!%"U`0N!]`\,^9;S(S3?
MPVMW%&/!MGP5"76,B)%\J8E'N)&`^6&IAR'(`)(K1V8D>4EBF'4M-3(J*4`S
M02QGB!,?4)EG*%21D(74`G\T42PV:4YAN%,_F1.=>7=!05W5F#8;<C:1,`^2
M4([FJ'A(>8Y*&3M^H&?.QSOKPW2[F7R\29$4Z8G-M_^)%*8<A6(->I><AG(H
M_2@B8]DH&NEJI%<]4;E9+HB0]<`/!"(@(0&7"WD>.+B*]I%TPX:7%I.;?1F8
MZKF>['F"P4`L`IE/B4F2C/D4@=69:6.9E2F9R?*9%`)X769)6F<+!S":!<I)
M;C-O:_-):*:3&?(V,_&2XS@'+L()!FB.1QEP27EG9>`'!>=\K/6;E+(4_F2>
MO$!LQC:8@R)&T/&!_M@\S&!F9?1A5A=;\%B=UEE;+PB#4C,2W/FC&-&=WAET
MX!F>"\&*J95\Y6F5O'!C650.?+E/[3FE5$JE@=(3V-&!SPF)Z59)\XE]I=FE
M;TB9/[F?Q,)RZ9:&0M5V99;_-OM7=\?PICWY?W(WFFEX`1(::10*FQBJ@'W:
M@"3D`Y8688DPHDNC6O:(;"H'G<I1F"@C'5Z)G/X8EI?H834#?:\&:^ZCEK;5
MEO]Q$3\:JJ+*$4,J?.SQD#D8D:@U;&XR*1KX)U%*A,JVD1E9I;8*F%?ZB*#&
MI6):2<:@H%*!(7%(FMI5?W4'A0B4+`?P`6^*'?H'(LOBH,3*=1+2;@W:C7'!
M`Q_2C3R1,66H0#EA4]22I[)0H6$1F[*IH;3)H8@36$YZH[9'HB0*)YGV:5L:
MB6'$G"S3'/:T:OD4A"=9%[Z$>VLIBJ,8I*.:L*$*(*MP->C1'J15*G99GJZU
ME[$J_Z6WFK&VNJ5DR6KXI*45UJOIQETB6Q,`:K(`>K+&4@S_%PDN]`-Y<J!%
MP1P?TC)="0W)$J,MR3OMUDDQ2F9HUE,9X@AEN*`C8E-X&FA=8ZX7"G!VMGCI
MJ(X\4@1Y\JZDQSZT@(CW2(3%N:(R\TZG%D;P1!V6"K)96I:=>$7Q&(^"P!_8
MF9"?BK`!HAMTVQL*>[<-&Y<!@:ITJ:H3.Y45"ZL76W4:6[@:R['0Z;'=8+:\
M*K*..[)C"17"Z@C==SLB$+3+^8]TMT!L\X_@.F9HIE-TYZP.2@58EB%&RRPO
MR35[>H<,V'A0NZ$#5P91("%6&W4<R+@5Q@W)V;N6J&J&.?][*(AS'(.6F\I9
M!>MSN^>C'5&WSON\JH"WTCLK>\NW\H%T?VNBB0J$&&FXWON]V8&XB5LSN3B6
MCVN^,KJ$DML3=%<ACYDGBW5=.M6-\YLLSS`4;)"_;(`,K-<<'C*:22%W$J23
M0X$#+_E1Y7IX4;LCL]EXM5D&06"[L*JH0#)ANEM&RZ"ORWEAJ/:U,PH.`,MG
M.1.O!"`1@&2PR\M(S0N]+!R]TCN]@U2]X'.]2/-KB%JHB9B;];H=*9=CX/O#
M0`P.XKNXX%"^Z"NR1PR?0ZR-#DHWV$$R5*"-,DL4V\HV5DRST;"M]_N3`0Q*
M!?1`!<J-.!`)'B4`-Z#`LNNG1BG_M;'S%B)FL5Q[P<8S'2^JN6+KP1\+PGY)
MO&HK>0.KHYT:/]I)$A[1PH9<MR]\MXKT#\37M^.Y4!2[O189JT%<R;NZQ)B<
MR5V;Q&*:R9E<DSS50`X$M'_WK`RTQ2"BOU3\'-!:Q0=`,F=30&UX`"(PAQ[5
M!$P0!*[KP!FZA^M:F[?YQG-168O"NX8R#9):J>,KF#<3>2$ZD;;'J<GKJ7'+
MO"M\R-C,PHEL-8O,R$;*$'5Y6DVSI#<<BPYV<B#6PU-GR8KKR>[\SIA,88Y:
M6><+SXZXE7\7H/AL88]H8:SLN2!RG%6\?\P@`RV;)^+0LS]ANDH[![4<!/NV
MP#DB.'BH_X[BH@8>"H;#'+)W;(FR-S-HV\Q6Q5J&FJ,L%%#*>[`,6\C9W-+8
M_!$NS)W=W`^C971'ZK<,5<ZPYB9:.\G'1L&#"\3Q*<?V7-1&C4]1C,_<I96.
MB\F/J\0DBZ7<\$#URW=DAL7-4\7*":U'0"A'4,OE<P%]QV5':P1D'&D$8,#7
M@GB%0]%KS,970`$:+1<,4!W3P;$@+-(G1*C])'I8I9;4/,@EQ=(N7=B&W<+<
M#%H`,5J._,CC/)7T>)[<.[AHQ,Z.<M28G=F:+,3SS*5+W*6-^M2=W+B^6BQ1
ML4!6_0M1S+D!+0-L\&6E1M!%40Q'P`,F(A/14G+$4!-4@(TNP?\F`H`#35`$
MX'*A(O2Z$MV`I.`#<\U7>$S$PFNCSEP]66N0+4BP*5W-A'S-A]W=WFVW&A'3
M0DJDWLS8-XW3>`0>>$F15&EZ3QK4EKV1FCW?]+VEE)6)E[RE^4V84$W:HMW9
M0]P3SX`,Z_)`KOW:U96_6&T-LQT./(#+LH#;%09*(G#`O>70+&(!X'*NZ,7`
M<Y;&(D0*%C#7(A/=>HTSBEB5).Q+)P:W/;K2A,W"WW5@WUWC="L@M$+3C8Q0
M.KBJ/8C#YZF7'$/9<1S?[5S?2)[D0[W?SWG!H!VR__V13BW@`[ZSE<;$LDW0
M\X2_7^8=)L(4G<D-0D6M+H';..`#>,/_X>+"P!D*XN;2+2/.5^T"U#^=J?V$
M?'_MMB@=V"+EHZ#*$=W]738^Z`'2D(1DWO`!3.@]SCJW"#_>?#J\:41>B_&M
MY)9^Z9LMQ&2)N(P5U5*-Z??<E72'$Z8+13MAOS@+(N%`9DWP2Y;K=]+"(DKA
M*UXC!IWI(A&=7F_>YK]\W&5@`54;17LMPL6QXM>]H]DIV-L-TX8\X\[N[(-.
MZ*1*$D3WS<#Q$CT.R188V:\ZY'$AA'M,N$8.ZN1>[NX<OI!XMGC=Z4]N[HU*
M#&8F(MCX8_,GZD3QVD$AW&U2M+SZ?TT!"2HU(0=PQKD.XNGJYH9#M<+L;&]B
M[+>'/6Z4PH/-_]TR_NP6?_$7][R"'NV(+"ODK0\[+CXUG-[F^>CTFJ(7.9"6
M[>XLW_+VK.E<ZDY<F<<GT^XN#]+PGI.O+`E/%$!^HECA`#>MWB:P[I'(D!2&
M8&3$>``$`-$<WNOG4M%]R!81O/"V0*UIJ>=[GNPUN.QSV\(8'_9BO_&[D?$U
M/B`YGE$0"RJ*7I<YC;7L#>F1+CRTJ$^5?O-XG_?Q+//<Q?=,#=U::O-Z[^G[
M*7@N!"_!\6/^_N5-H9HFMUAC3KDQ0;1V(U[)_>92#ZAJ4/4VEB=M*\V=JNQR
MR^R'//:F?_H77_:'G=AIK_;E(1_8'A$^'O>2/?>2OF=_%83C/OCDWO^OO#_$
MZ$Z8%";'4H[S6S3:^NWW[ES\.W&9:5/A2T&,N\`$/L`$);+O:;-E)?,V+'(+
MF;F9(N`#2+#+?(CYF5^;4V7U>7*=V2U(*LR=I8_Z\C__T%[84>#QOG>JUEM:
M/@8(/X*#A`2&AXB)BH9*C4I-D)&2D1>5EI>8F9=&G)V>GZ"A1CRDI::GJ*FJ
MJ@.MKJ^PL;*SM+6VM[8ENKN\O;Z_P+._PL#%QL>\N`.K!P>MSLNDKM+*K:>Q
MS=G9TZO=L,W5RMK:."(BEN47YLTX303J!$SR3`1-(CC-1T<#5/TX.%3.-1$@
MS]Z]&R%,E,'"$`L)$@X?2IPHL:'%B!0S5E3_$^)=O4E-+E"@X*.D21\64JI<
M6:2E2Y=!8LJ<*3.$S9LX<^K<R;.G3YPT@P9YZ7*ET9-(?8Q<RI3IC:=0H\HC
M1'61U4..LH+<.DF3UZ^81(D=VZF;V;-FPZE=RY8MLK?(9`V3"[?N6V6F1I4"
M-P!:*6YK36$;QS<:VE1MQ1$^4.Y?.7,#F^#3UF2>O#GV\C$XX@P'*8`"XS$1
M$!+'CR!7%C:$B%%CQ8L,7;MF&.+'A8]=4:HD2E2H[Y_`@PO?6=.WS"A1B!Y-
M:K*I\Z51HS\5-(_JH*N+LCKBRCWD)4A@PU\@2[[\I\/HTR=>SWZ]W?>]Z,:/
M!;_^7%MY]3[;YIA:_[3`?PTV#BSI(=:>+(L-@(\,,CQV@0"&7#"9"*+-4\\]
MV>C#63,\!%1)9:.5UH0%J;4&D6P3P18;BA319AMNDEQ@P4O&Q32<3G[<J.-/
M-0:1W$M&J<2<4L^-=(-3TMU@V53678<=(MIMUYUWXE59I7E8ZE5@6@=VF9A]
M8(8IYIADQG5+?M+HDTU__EU3#2JO++;-*SQ8LZ5_[>&PGS9],<C8/[?1`PF$
M3!1@H3W]45$G.1Y>`")IYE!!08DMLOC:19:FB(4?+VYU01%![2CJJ,35^&-+
M05HP))%%0I=D=$LRT60A3R;RR)0@6:G))YMDZ<F=P*KGI5IU55/FL<@FJ_^L
M+[B@.<`1FVWHF*)UVBD87G"Z(N><=/+@V2K_]$/%MW@F5FU?FAW`PP$,R/!G
M.>Y85L"\]%SHV#)[@F/.@_((8(X(5""DD(F9L@9;P:QQZJBG09#JL*@T(7=J
M4:FJFE2K2+[*A)),,NEDK=EIA2MXNH;G*Y;!HC?LRK44B\NR,,<L\WO-EL))
MG>UNQHZWU')S[2R%L0(T8=T"I`I`XOKS[<H':`@.#]`>X5@S[AQ)00%/T>/O
M9-"T0H41YPBD3KP7PA/$P`AK>G#!#OG!Q,*YAI"C'W373??#P_6(G'*I#HGQ
M<TDN.>L/(&,EY<@EFVQ$KYPP?K*6*:O,\N2YN'S_R\R89ZYY"363<O,`[<H@
M;;AM9HM@UX:9HN?I`W)C="I)?^U/N>V5H,\RG->YS]0?,-9$`20920"&O0.T
MN#L_;`S5#Z01-)HE(_JQ4-J7KEVPV]Q=@/>.0DV,:M_,_?VJ5,IS[#&MA1,0
MY>&(E_SX^[]&GC+E]!.S^?WXYV\7+:<L7@D/#(C6`<:%-&D([1M\\IGI\K6-
M.9&"@*=`6NP<<Z\YH0XP-8O3,KC&CLJ0I"04((``1A@/X)$D`BB,0'.T%@]_
M"80""5D1]524MDW=('O;*U7$)E:QE/@-8^.#5:P&ES[#16ED5$J<)1XGOR;2
MKGY>TI\4ITA%F,D"%<<;_T\)!#@M`QH(@=PBD)O0Q;JG'2UV2C,'!>.40)_)
M@EP%K)8V-I0-"C%A)+I)20RBH($^]C$&,4`AD0QE"$&I@R!1,($:")8I&B+,
MACB$6%`D!J0>_E!\@8O5^=!71/8A,5=*_`K\G.A$*$ZNBJA,I2II%HN\\.!X
MD#""[9IQCP`=$(P7M-88AY8@:Z'1'R+HQ#W6V$8%VK(4_0BF$<2U*#GAX$'Q
MP&,>5X+"D<S+4)<Q!*0>Y`,_+))ZU9-A(_UP0ZY<H&$\F>3>*KF<B_W-2+`R
MGR:;5$1%K*\['TIB/O4)%OB1AY0%,J5`[;?*@AJTH%?T7.,61H`;$$`?:ER:
M+O\#!*!=TF);=OIE0/[%T8B&\8UL0AHG_G6)8(ZKF13LZ$`.H<DE8?,0WFD"
M0LH`3K6MAFWD[(XZ^58QI+PS8QJSS.`$4<^K;,>3H`SE>/PY%H"N8J`"/:A4
MITI58R3TE0N%Q&E\8`09C`M@I;-H.!98"XQ&(UQ)(VDE.DK!MOZ#6]\2*=CV
M!3=*1)2C;OT'1U<Z!WK,H9#7E$<]/O2#*$ROI@_!%$[+R94>^C!\/QU?2X=:
M5/4=D3NW:I]2*\%443CU9U"%:E5'2]JI7O435<L1!=;%F)X9LUI/U%8N)QI;
MV?;2,$C3ZSDR$<Q(4?`OG2D%6N>J5DD8@A+JZ*A'W^7_H$&14#3T,B1!@G!8
MQ%J/19#DSJK>&43!#96H147J)[.WV:5RMK-D.4QHN\0Y*);VO?"MXE5?";TF
M_*`(5P@!$XX`03%>J[;HFNT7;V%6X>KV*Y%*VC^\%2[?;G2WFH"$(L"#5[<.
M\S&[7:EHS%</`G13G#55K*6RRQ7N!G6RUJDL5IH@LBF55W'H;6JPUGN@^-KX
MQCC>GW_I6]>9%H$']^!'G89,K6L`N##=$NN>V%A@!M/5*Q4V!W'_-=(G1UC"
MA3P$:9+[KY1RU!(BB`2A8@5#-2`V(Q99;'=.W%*A<E+%C1AO5U[LN!A[=L8T
MKEV.]\SG/@=#EYV`FR&*H(8K_Q#`7?CJT#**#-J*-MJV;=Q69QQ#4BN7=%_(
M3:Y72%9?+"MBRVNU<(:Y')IYD,0"(5#-F6W:2!)OI<UNKHJ*H11G.?.3SN>U
M<WGFEV?W^/G7P,ZQ`@,="4/X@*9!N(`SLD$*#I'5T;&];8`Q2NG>?L6XI4D'
M)O"93T0(5IND\4[8+*W<VS04U8I<)".MNVXT8X\[](2S=FQM3EPO4==9<FJO
M?1WL?ON[JL-N7+&;X`,3D,`$/O`,%?IR!"^B);22'I!CP!9A")&,I$ET,?2>
MNR1$A#NI7%:'HPA`@2A(3PTH;_>959[8CG1GUHQHL<:A9^][X_L\`-TWC?_-
M\YZO,O_@L(R$!0Q.`DXYHTXR&,#-`CI0OD3\799VAP@-4M=<<7K;SF5I2ST>
M[I)VF@D6\(-"4/[-52-6#5'X"(R*7;CU9197-;\YSINH\[;X7(H!S'O>[\[W
M,@%=T`08ND/48`$1Y&"`G.G'G6C\=&CH-L/:9/O4/;5IYW)<D]<DY-37BO&J
MH3HU*"^#JLT.SC)88.!;N2>]YQQ*N?]S\?N^CUOZCC^]ZYWVN+?/WR&A!$-8
M@*8/N0(%H,7:U`F+9;0[%Z2IO;#G)L]"B?CXM2,S$`A52![SDJ:1M";N<T2S
M""&X@D+*8(+RJSO-I+>4"2C@CO;3N^8PCO%G'^U>RUTN]WC_M[W^]\___O<?
M_S>V>Q(V(L`'$?J5(0JB<(QV%BM#+O[A@!6T&$?@)XSA*"-D?;!6+Q\W9R#Q
M7!5B0CX0`2NA%)IG"#]``180!&(W?N1G?BF'?MAE`CEB$W[`<A/A!^S789YR
M:_"W5+KV6757.0#89_Y7A$9HA$-86JUD,_[C:;^76!!1!$9P>,XP"A*D@+$S
M8&PQ#D#F-=42.TW(6?W0%ZT`+7ZR47552/-P`YF'34SP5R)T@5."@=BW%"BQ
M1\B1$BJ$$N"W@N4G>N4W=F1W?@[1$&I`?BMX!3E2!!:#$@6(73@H=6MW=3T8
M%O@&A$%("TE(A$?8B9X80)LX6DNH_U#=YGMF=B('1P'N$D"><84=@D9:6`U$
M<R_\("[^PU`$\#$1\A^$H6W&I88FU!31I8$;*`ET6"C!B!)1$`0:<!-T(WZ!
MJ!#1*'K4^((8P1!J8`(A,!3LI"I/.$XY>%P@%W<_.']*EHFN$(I[]HGLB(3J
M:%H[EE62:`&G.!$=X2X[HU%)HV0?-0NM^!G?\C70<P@_\!1%@A(^X%!4T`R<
MT`RBLR9ZU7P$T%>%(C[?-GE9=WW71`$BR$<T"(W3.(W46`;GIRDHIXU1T%/?
M.&(A<$,P-8Y*='/FR(#H2%#O"%_MF)/\=Y-2-8I858H$4`2M@8U!T`3;\(K,
MA`H+*"`79?\-7_,)P21A=W1JH!("2'`WVXA.<I,C0>`#]*`.1D`.?P*1F$:'
MR7@23/%M%WB,\H)'%K",-.@'(!F-@2AZZN8:)^D'W,B(([B2V!4$/]![XC@)
MM[@KK@<YL%>3]<.3O["3JJ23D'E[C(E0\=B$DBB4FD("IH<#^*@@^ZB4BF<Z
M2(8-7L,)`EDUI]8P=#-^%I&-(UF7Y:>7%D`!7SE,8TD.E%:*\F"0@"-/+16,
M5!D%-G&5<JF(=:.(XD>2($81V9A?W>B(!5,&@(D(6W&8<U=*BLEOR0`+D]D+
MCIE*D1F>W?ESE0F4F%D1$K%^9*10Z85,H:E\!*(H_0!+#>4#H++_@JK1FJ$W
MDOQYB(`8B'K)B+3Y#K;)&+UX8'!SC*^"-4^1?4P1@F^)3L3I!Q/ZC&.WG!,Q
M`X<H@R'`EWWYB"AB>HE0G4PUD]Z0G5\RGG7QG:@4GI&IHJGDD_)X".>96"OB
M!X=V=%B%,@]49`E%!2-7D/89?OEIB&3'GZ])ER9@G,<Y@QTZFTI"H!RT&-,B
M$)ZVAE:#,24Q(\+)$\<Y?F4G&QI*?LZ9$AX*G9EB>I(XB4U0HOJ&HO0#HROJ
MHG1:IW;ZB7)J1:,XH[T7!&@6&UA0!!<@`Y[#6<ID'A1%#3]9-3[0,!?*&D>*
MI)+:@M%X!4SJC%@9$P)*`3=`.!<R+GQ2_VU6JF%8VA1(L1MPJ1,U8*'*:8-8
ML*&*&`1!@J;JYP-K.IB0L*-,]*9P&@YY.C-W&JS"2J>_JBRG99D=YJ<M@A$(
MMRZO!&&Z<C-)<S,EP`/V=0.-&GZG"!N#V*W>&JE(6JF6:C=U`Q2HPBI3L7;6
MIW7*\Z!;:A1%@!PV@A-?*H@V"!$GJ8@=ZJ'>"**R(7R".:*1H*OM::+PV:OW
M5ZS+,JP,V[!XJK#'<JS[Y`XA\*<W2`&M<`&D$)._\I07<(*.>HW8^*TD6[(D
MFZ1*JJ27>A.:RI?,$22\\1+RJI68ZH=VB:$PJ*'9R*&5U##W6G04$+#4.;`&
M>WP(JPP0N[`.N_^T3*M_2>MW>RJ/]E6QV-41RU"8[N,_C?,#GU==^FFR8!NV
M@\B?*5NV@3BN=H,WY"J7?]BJ[:8BK[JS,LB(?(D:_BH;Y"2T+YFK17NP1ZMG
M3WLL33NX31NX8W*L02=3?H`B@!H$#\4#G18CF9!QR$,!9[.L%_&M*%NV(RFV
MWKJY9INRECJZI%NZICN7;:N<)=EJ1@J(5R"K?!D"/_L0^J6WN-JW?ONWVFFX
M8D*XOMNPO!LF\T5LD'`#1&<B)J(&4G@`0(FK,04>DO@#/A`"V\JMZC:V2NJ'
ML5DW9MNYGKN?DQJ^W1N^=DEV,!AB##$#<4M^>XEJU..XM@LCN*N[2,O_+/01
MO&/RN_H;K/BK>S)JF4U``<>[K%!X<+:*K.+HO,56D-B::C8*M^M+J6N+E5ZZ
MMBGKO=^;P=]+DN9[4^G7$&7PI"E!M0A3!%<A"?-+OPD['Z_PM/O[PC#\?_VK
M8\,K<"%Q;*QAL:@(L+?XBP*+/$<RO290B`:3N>L+H&D+%#V"(W;#N=7HN?HY
MLG$[B*]JI.:[NNG'G'[@LB3<2!80O_(K.2I,.3/<F#%\QH1;QOY;"_W3PQ9`
MQ#J,BGY@`3]@#]`+(R^9BT%\-BMBB$8,ON6WLBSK(S%KIBZQC#1;L\]HJ:$[
M?CU0OF`KQ1",H5F<6%?`Q6E3!CZ0BU9!M.HU_\9DK,:\@,:DS+2B#!]GDA_0
M@YG+*4X180*`.8"4X&D$B:VH`:BM^<?^^9\RF,19Z2.$_#WPRAN(G,AQ.<&K
M.;Z0[*UP6\DL<LDSXKX(H\F<O`B>_'"@?$JGK`NEW,T,N\TTS#^J7`D$$`3G
M:Z,YG")^X`.>2I#@98)"FA"70L6Y/,6`O*1,ZJ0LNTZ.-<SQZB,S.Z\],<&C
M*Y(8C,7.K!&P[$/@=P4%LW[8<<TTF<TK`\Y;Y,T8;:<6#1>IS(260`"RZ\&7
M4L`8<<DW-`C+0PA'4@1$9Z-7/,E63(V52JY*S,\S$J\QF].'+#'%+-#T2JZ,
M3)<<3(@)[1H+[4/2;/\IY!31D&!\)TK1PV+1&3W5+KK1=X$?X_RQ#BW2#US`
M+1($G3H^!5D$-?C`1CS)9OVJ9'NV^:S$W=,2/.T].BTQH?+3R2S4]#R[9P;-
M'MK%*,(I3-T$3OU44!W5X$S5B*V35FTF;)S5/V!P-S647*W.14`!@I`DC4HI
M15S%A"AB:M.MX7JVR,PC/6(<\LK$VEN7]%S4&K'%T3S"!5,;@3W8MU38@'O*
MB9W;#[O8Q=#1I%@)CVTP7IW.59N0TH&"1!H1F6N-UX6YW!K!,AW(XI?/:ZM#
M\TH3@ZS(;-NV?YC7K)T1<VP4?BT;'3';M6W;%7W8NKW>1<C;VSE6^;$X1D#_
M`9VM$93<(C+8E0:YI>`WQ&D-TQX,X"HRMN(KKM2MS\%A-T'-@D/MV=\M$2'P
MVBFQN"/FN-@19[2-WG'JWKW+WCG)X6+"%FTLWS[@2&KS2)>,%.`GV0+NX$4L
M&P%NO>1+E^-ZN@1MT!WLX@^NF;"+U!3.(H17*X^0X1JNS2!N'Q[^X4>^QO#M
MT97PQB9NUIELJ?N*&G_:XB(-TXR+Y5:\RY,JU$B:U_>]XR3`UROQXR%J`4(N
MV.==Y#6VY/61Y.T(Y_4AXO%M!$U@SE'^&M957<X-X/\-P:S=XH1XO<U-YK,1
MX4'RX^V&<&M.Y&YNV'1N%W+.CI/.2FK1QN,!TLT<_\?8->8VQ>69V[F3C>B;
M#>JF_J^R&B2R.]P4@8./WN:1OKN7?@R5OMNUSMA-3HH\\`,UV.DG/F(SI-:D
MCN7AV]GGG.K*GJ9/RI>,V*AW6Q'262\7SN:Q..NTGNO`<.N>J.U7G>FJW.M7
M(.B8.^C$[K:B/K*3FN-ZO>RFOL44\^Q%$.T/L<XA%.O7CNUVY^VVSNU'R._O
MS1Y_L:,\8+Q['NS.[,?(GNX0#*[%CNKNSMH++<Q(3>\DH.9M9^W/IN\[!_`>
MWV?#,F2>PP,44*2HWNZLR_`J;Q'DB^X('_%FMRG=J"KS#N-T_,X1#>D<WVL?
MW_/"YB4B?S/T?>C*KMRH*/_<@;[R:0V^__GPR0[ST]R^_&J?](X%-]_..2_K
M.S]0/M_U\17RT7`S)4[TR]['+"?JIR[@H>?EU`CL4#]B\,Y3]EF/:*;F.'_"
M.K_UZ^7U?$]:8#_R/""49/_V(VW?@&[XG:[RA)\IL,P;(UBC=9^+6(_W6J_W
M]=?WF']0?_]*KZ3G.A[Q?PCQ:=_5-93NB_](^\I3-/^V=C_YG9SWEL_UF3_[
MY-DE0=_YIW[Z6)"5X2=^85KZ*_?T:7WZ(1J@J@_;-B_Y(*/QYQC[BTG[T!\S
M-!;T`Z`]N7_ZJ=\2JBE^*E?J"8WRBZ^-.?WX#IW\NMC)A.W\]!O]["][4!7T
M)=#_!(L[^,O^NC';,/EIL<)/_&4/"%=!182%A1:(/A8A6"2.CY!8/@0_!):7
MF)A-/)R=G0.@H:*CI*6FIZBIJJNLK:ZI);&RL[2UMK>XN;J[O+V^O\#!PL/$
MQ<;'QZ_*ICP#G$8E!'XD6-76D-C9VMO<W2:#A$'B1>)^5V5EC=39U=3MW=CJ
M\//T]?;<6'[@AH>(%D4ARL"31"F3P4N;/'E:QK"APX<0E2&;2+&BQ8L8,VK<
M:#&BLF:=2ORXXLZ:O'LHZ979)PZ<N!`FTI7L=G)>S90X<]HS$8*?(43D_,BD
M.:G208,)%7+RR+2ITZ>E.$J=2K6JU:M8?T%5I;#$#1,E_Z_I'!NO9Z%Q9T/X
M6;OVRI68\6XZPJ)&+-F[>/%=,4O('\"W9>H.+'H4J=)/6Q,K7JPJJ^/'D"-+
MGAR+<:F%)2B`-?DN[U@_/LD-:DFZ)<R3<DF4\:/61&K/L'6N#A%B'TQJ0XD6
M+*SI\%++P(-OI4R\N/'CR'$)#[5P@`^!G%_'GG<EG*'2^T2'\^,:'L\@`:?C
M["Q^;AD3Z&.:I$?0*&]+294NGT^_8?+[^//KWTB_^?.PY)57CPGAD%;@6:45
MR)TZ-:D!6A!@"6@/7=():-=@N[U'0'R^=8A8?2`NM]^())9H8F4ACK(4#T5$
M=Z&$\*QTUHS7C6/@=@*Y\X@@0?_X42&,Y@D&)%D$:8B0ATA^F.*2BIWHY)-0
M1L8D<R`%X6*`0VJCAEEHD5,C=MB%<`5J/?6898SJ_7CF-D4:N6&224XI)U11
MUFGGG1C-N901C%RY)CYE=ID=F-AMYUHU@I"38WGHJ(1>;O5@`5>695"0X7L<
MPBG?G)QZA.>GH(;JBY[---&GBW]R`UIH_!#J$EK@L3::CQ:NU1U-Z*B1DJ0+
M#GG%#9?REJFFS75JK'VB)JMLLJ1&,Z:?J6I#X'6LBN:JH`5&.*&:CZQV:WE8
MH,,M64'\8*Z;33BSZ;'LHK(L+@S$*^^\]-9K[[WXYJOOOOSVZ^^_``>\[[L9
MB5)",R(^^8C.P@POK,;##U_)&<04UR7QQ=\4`52U''<,X<4NLM868-'-)"[(
9$FOS#H,HM\Q97-7X8:FP3=3<A!)-!`(`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>f39432a1f3943217.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a1f3943217.gif
M1TE&.#EA40+K`.8``,;&QLK*RLC(R,#`P*:FIKJZNJZNKDU-3;Z^OKR\O$A(
M2+:VMD1$1*NKJ[.SLZ2DI+*RLK"PL(R,C*FIJ:*BHJJJJJ"@H+BXN`("`I24
ME(Z.CH2$A):6EIV=G9R<G)&1D9*2DHF)B9B8F$%!09J:FG9V=G1T=(*"@H:&
MAGIZ>HB(B'!P<",C(X"`@'AX>&YN;GU]?6MK:W)R<GY^?F9F9FEI:6AH:#T]
M/6)B8F1D9#DY.5]?7UU=75M;6UE961L;&S4U-5A86%145#`P,%)24E965BPL
M+!$1$5!04"DI*?[^_OW]_?S\_/O[^_KZ^OGY^?CX^/?W]_;V]O7U]?3T]//S
M\_+R\O#P\/'Q\>_O[^[N[NWM[>KJZNOKZ^GIZ>+BXN3DY.?GY^;FYNSL[.#@
MX./CX]O;V^CHZ-C8V-_?W^'AX</#P]/3T]S<W.7EY=;6UMW=W=34U-#0T,7%
MQ<[.SM[>WM?7U]'1T=G9V<3$Q,W-S<S,S,+"PM75U<_/S____R'Y!```````
M+`````!1`NL```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=C4I3
M6H)>%1,4#P\=)3$Q,&U_2@L/%&:";GMO:DU*GKV^O\#!PL/$Q<;'R,G%2E)9
M8E]D>'=1@FE^=F&"2U964=Y14N%22X)/WN1_4%UI9GAT`7=T<7B\2EM83KS*
M^_S]_O\``PH<^,^)'3X7!+"ITV6+%2KH?BUI`D5*/3AR!%#[HR4BP8\@0XH<
M2;*D229MV+SZPV3,E"9+]/53@DX)G`![V-B!<X:*3)-`@PH=2K3HQR5<S@A"
M":9*T"=:R)AY)Z`.%*-8LVK=RK6KH"9GS-S9$\`,E:XTMTP99>8*$Z]P_^/*
MG4M7TQ(M=P0$8*/F;-T_83)F^TNXL.'#1:_^Z4+'RD]C2L9L2:9$'Q@[8M8B
MWLRYLV=@3MH$6-GO28`'!O1L3.8D39P``<B\_4R[MNW;@I0X$;2ESF/*;0R`
M,:.E2P4X3_I%80-!@);DN*-+G\Z5"9@U=G[S0WKUC9<_3O`,H#-['Q,Q=/)\
MI\Z^O7N"3+"\22!'L3\G:`0T(60%.BPR!I2Q&T!*8.'7>P@FJ&`O2Z"11P!I
M^.?/%;@XM8@3=P`@X79U!""`1PN&*.*(BH0AP!U<V-=/$V\]@<5OE1G"1!9O
M-;'?3%-XP0L3&Y+HXX\(?K':/VHDP(4B7V2A2/\7`XBAG3)8K*''@$!6:>5G
M2V31AQ@#,7%&``!H<2,B:!R9"!-;!/!%0$M4`<<:>%AXY9QTUF4%`F@,I(4<
M"ZA17B)H=/')4@%-$0`?9E!9YZ*,#J5$%>0PH>),8>@A0!B**A(H)&;XP<63
MR$Q1QQQV:-;HJ:A^)$4<?O38CQ-U#-`'B(ML^H@2:"#@QY#]4*'''E*D*NRP
M_,3!@1FN]L.$%9DV8BLD3G`1`1N@(A/%G\1FJZTG2UA@`@7!!L0$&V58\FPD
M3XCW1K/\5,KKMO#&ZX@2?0BQ`1BT\N.&`6E,&LFYDD31!@%C!-0$%P0(*N_"
M#!L"A1DBI*!'M<I,X:__)&9,=@D4["K7\,<-2R&&'@?ZHT06>5RAB1((W/''
M$GZT0$\E40SP8D!6H$$QR#Q7284<5\@)4!-J(""`T)4T.(`?`=2@P`P%E/!"
M'CL;8@4'0<!`1T!/V#&`4CV'36<9`##-1D"/`@#`%V-:TL0;:LH!`PXA\)'%
M%02\H('&C4`AP`LM4$##"FS'9#(<?(21K]B,+SA%%'+`T7:[`@R@,B9-6/0R
M`C;($$<Y`,SA!@`L*-`(%1#@<(*9?YA1@PL=Z,$Z/TX`($"RC><>71-XQ($.
M$U=4+8P4="!`QN23*!'%'&@PD48*)2P0[E)X*,#"#R@LTH09*[0PQX9/0,`*
M_P%[0"'\+[`B@(7N[$OWA!H+L.&$$UF</PP67&IR!0)<?)$!$GG`EB`*\(,C
ME,`*B[``!M8`*B6XX`@#6``:IK>/*?2I?1CTC!*@4(<\L&$M3YC#&^S7BPV^
M06&8`,5NGL`%"<3@`4I*1!\V,+4JF$,?T0J3$AZ``QE\0`S8>EL*4!"$/D0!
M#G-@0Q1(V(DK^(&)&8QB8N"P@``,H@L+0"$_P+``.6B""FTH@!BZ0`(D+,`0
M7$!``#8$AAW@``$+L,H92$`$(OC@`@2HP!0><(`'K&<):="``O+P!PW4@B5F
M6(`;I,A(88GA`FTX4!0*$`8H>N(*):O$N!R`ABH\@/\!#QC,()Q``"(<X0<E
M6,\@H"`'%]!@`310``?2H(0VJ(`%(!!$&!Y`A`=4H00[6("%)'!(053A<OZ(
M`/(:R4RAQ"@*<E*"%Q!@JF00S0X=DP04X)"'.+CA`C8(`1C^A(4%X``(!WC!
M#A@`!!&\P2-U*`$05."&,-3!"TUX0@TR,`@F?*$%+(``V`1!S$,HP0]EN!@Q
MR!``9#;SH29A`Q^0IX:)[D,)8C``&QR3"3,4X`U66,`!)##00<Q!"#<8@@?$
ML(00TB`)#$B!RIQ0`'MQ(0V".$,$TC`'#)R@$&>X@2$*>@A?)6!QP[A"22'*
MU(\\`0!]F,)/E-`AA0JC"6+_T,L6D-J(*A0`!SN0@!S.L(`4G,`.*G+"`E8P
MA`.H``^*ND(%<,``!:"`!CN`PQB<(*DK0`$%!3R"!@HA!@8,M9@RTHSYFLI8
MV\3(":Y2`ANX"HPG"``!^;.$Z\PH@AJ4P`4K*(`ATI`!'0QA!P-XTA9J\`,@
M&"`,7MJ@%=8@@1&P``,ZR,'Z!B&&$1RV$6"X0PR/H00M(+"QR$4&%9"86;1]
M80T#T((`(U$')`BA"`1XP@-,$`/Y$8)X*="!`E+0AXXQX0([6($%_-`$*D#A
M"GAHP`J.H(,4[&$"1E"!```PSC_T]K>,4$(7]OL%2U;"JV!(KH*%L00U#"``
MNSU$_Q@R28PH&$L#B[R$$CB`@1O@`0TGP`$!)K4%%!S@!S28P#(%0884O"`%
M5+"".M+`!3<@801#"`(!]$&`!U@'`8+Z;R&(&N`Q9$`"?JCF,-)0@.,N^,F;
M:`(8!K"'=PU""6DT,"6HVB<RN*%R$8Z$$I[08`88`0-(J`\AEA`&#]P`"`H`
M@$*5D(82\(`/78/"5;3PA1``X;8_`,#T(E"!I?"B##H`L"*6L`4$Y"$,`R!#
M`I1HC#%`P,E0SG3RT@"```P7$9#C6S&VEQPR*,4+LWO$%-@@@"G\D@$=4+(6
M/"`$%AS@!C#HF!8DX(,45,%E2J#"'>K0@A$D(0@;B`$[5__@Q3\8H-"$@,,/
MXB`T(B-""P#@@Z"N,`#PL`$!U"J&&[K-LR5@@0M,"X`=ME"%;&JZ$U/@@QQP
M5P@M1X()9:A#(8)&B.54\U'!*X03X&``-53!`$DH`*]"JH,W&^`A(4C"!0[T
MJ`X,80":"_8?I@`!F`)!>B\30P^&H`,<<`$"T!Y$&!3004(8$A'*$X`P]1&%
M8J)D`GB8;B_Z4`![5^D)#I#!"39``@M8@`0::($,**#*=W>"";N92".6H'-?
M,.D.%$2$&I*X&RYD(`<^V,!NGR!1-LQZ!R#(Y!4B$(0AL*`%:"".$K@1`APT
M``I/X``-0)`&.XP!#)]*`P%PD`3_!7@@U9)E*P-T0()"N,&W@]""$EY^"#WP
M`:>+P((<"I!J7R@A)SXG$4;3^P4H,.&807."%-SP/PZHP:I.OW<7$*!O1S`!
M#1D.ACZ:8&5$+`$*5D@`$3QP!2P8H)=,;L,6UB"$O?TD"@`@P@V,<(0A*(``
M6MB-$IC`A3*4@`5#(`%L_X`%9E%(`3HP@@BV\"0GT.$`1_@`82%OBP74X'-K
M%@1$#'H(/<."LIC`!`B`6-G2!`_``UY$!B20`BT@`1^P`2<@`K4`!0M0`BNP
M`)\6>Y/0!4D&";FR8IN@!*,#@G]P#X<0`"-@`GLP;X+P!BL`!!]``#*``F<P
M50N0`[9V_R]?L`$C<`.O%&R9$0%$@`-FL$%@P3$)@`-&8%=+E0@M@`,`,"9"
M-@A4L`(HT`;D``5T``>*(`5VH`A5`"$`:`E1`'N-D@4?8`)RD`82L`,$,`!F
M$`9<(!H/4`-K,`H)$`(KP"]FJ(&$X`16\!9,,(94B``9V`EWH38UJ`AIT(1_
M(`)'L`-\$`=\T`92X`1:\`8;D`0J4#"K%#.+EP)TX!=4P`<F<`,,H`()$``I
MD`(-A04JLP1M,``F0'(P(`=*A@A.8`8T@`2MZ`?!,H5_$%(T$`!R$`!]P`>=
MI`C<I@A-X`6R,@RAER!ML`,>L`0&(`0.,%T!@`-S\`<!0`0'L/\!>0`!*1`#
M#I"+?D@(3/`&<$AOH+8`HO`+3.(<C:`&33<(6Y`!"@`$1&`"!<`'?:`88?`!
M-&``4A4`.S`$0R`!7V@(]+(!1X`!&Z`&?P`&3F`X?$!X/W`"!*@(<?`",;`'
MV]<'+A`#>O!X7V$!..`!Y3)W:^``95!UY,<'C7`CA#@)5?`&P[($`D`#$4`%
M$O`"'YD."(`##J`$`S`$*_`!%5`")K``#B`!%T@&[J9I3W`&:R`'.C()?8`'
M.0D)YL8&`_`%-$D(^`AJ>L`#/S`$,C`'=Y`'8)`<44`'+O8"(Z``-G`!O0<%
M=Q`#-'`!70`&<%`'#+$&3N.#/@`#;S#_)DY`!FS`?OV4!@\0`PTPCX)@!1Z0
M!!R@`&&X`JZX>@-`#4S@!:.A"%A`;I^0!G(@F9W@!'S@4(SR!`;0`YX"`S.0
MCX+@!!U`!'8`!FA``RP0!"[0!U00`#Y0`Q/@!ZX$`N&VCF$``.I3"4]0`'TX
M"5VS`/CW"&E9;TR@#Q>``4G``B+`!@4``/4#"P,P`AC@`8K0!A\0=K!``'6@
M!FRF`4.`3BNP?0;@`QGP'5A01D40`WE`#5I``3RP`89@?#QP!".@`R<0!`&@
M!%JI<*!V"*D)"?3B`&]`89@`!GJ`*F:P`1)`!@`0`P70(TW0!C+P`A(@`Q)`
M`!Z``R/0:R\@_P*_0@`P@`(&0``2$)5P<)9-Y02C$P=C(*1G4@".F`E.$`;7
M60C=J0U9X`=](`5XL`$E<`$(4`(W8%<!('FK-`<;L`%X1@A0P`8M$#U8`(M_
M(`7I0@36@TII0`54D!QFT``E<(X>8`?'V88;L`($P%+]Y`46@%)"0`$-X(I*
M!9<=D0@!X`=:1'ZJ^0A/T`9)9`5AR0A(0R=_&0)1$`&2B`ASL`([L`,DT`67
M^`12T`8H``,;$`(Q(`$%P$7=0P&L:`(=@(69M@4"D`69:@A>``"=\`1F\*1:
MITI4X(YQ:`$OY(E10`$X,`1(0`%<$@8*0P6#)P*T]`=<P`$U4`%IP/\E3+`?
M7/``0F!]XTD$%5`%>"`H9!:L8T`15&`'#S`",_`%'K$$!1`#UH<"XS1F7N`'
M"*`XVF,'<_`3&3H)3K`'<$*"/+,`2*`'35`#*Z";@F!.-O`"9(`(7+`&*4`$
M(B`!LI0%=4`!(Y`"YHD#0<"3R;5]L!!Z4/"KBF`&!B`YEM"=5*0&O*D`#9"/
M2[``1W`$0,``'S!@UBD(%B0$$L"/&?`%7S`%8,,$()`$IB687<`!0JL`$(!,
M9E`+`1"3(_`!%ED(;#`"ML4!9(`.33``7W,^V)*PE"`J$\"%FC`&1>DC4Y`!
M,>`&=R`#)!!F5`@#/(`#&G`62^`&QXB,FK'_07;0JAMPDA]P`5<P`3'0`@0`
M`#```Q:`!TRE!&4P!Q(K$EI0!?8&!F+P!GS`!F[P`#N0`5W@$5D0`3X@K2?`
M`40`!#M`"_Y1(!1P`R\`!WA`!5&0!@.#!&TE`DZR%%\@`?!7!`8B.8E":V?U
M)Z;!5D+0`G'P)TB!I(?0L2=$2!N#F9@0!0C@B562!C20`5,P`$@P`-/E!KY[
M``%`#G0@!#2@`T?@`R&@`"X031W+`T+0`2AP`P@@,!R0BF8``31``W>+01CE
MFID0&9K0!4FY,A6@`6H@!0*@`,CK$9)U``PP!!F086=@`$"`3A/@7R[#&P[0
M1UQ0,Z8%!!D@2H2@_P<_4`-XP`V\,``WX)'8<@8X0`0LD+\WP@1KT%R5,`5J
M0`&Y]`=9P`'F.PG+(;Z4<`8`(+/140`\8`!+@`(X0,-7M@`\0`/WIP1A,`,E
M,`<PD`()H`$F0`($L`(P8``:LWUF@`(FH'0YD`$`4`6#!P,3P`<N``,$T,!A
MHP1@D'N=H!(:Y@9Y(&B9T`1(M``-(`$],`-;U6\+(`,L,`(;P`4>S`4B<`!Y
MB0(I0`!H!0M>9P1#\`-$T`)C0"M,D`)&P)<&L00G$`,]X#M_R`>;.`0C<`=]
M8``T(`$#<'E87`A;P"<7H`H](`(T@`*I-0D!(`$HD`#V5KX_H@03X`/R8_\#
M+2";N=$`--`#*2`H=H`#&8`&."`"*B-9'?`"$S``$D`#%'`@*$$!-1`#>$P#
M;$`%%Y`"/-`!<J!WA\<^5;`&`1"IFM`$#I#,;0H`:_"ZF;`_>N`%[$P$&Z`'
M'F$&Q<:4`J!S3%``$UD")'``*8``&=8@-(`!$F`J2T!I?_`$"C`$)A`'NS@#
M(W`!F.;$G3D$.``!.#4%2P`&!'`##Q#!?3``:)`%%J``--``60`%@K,!O8<(
M63`#,>`!P%0NEE`%DQHB9[`"&S`%#K`#!9`O9&`#.,`##;`$4Q`!-2`'2D`$
M!TL(L5`#5P`!!$`!*:`"#H"978/&,+`*&4`'6!#_`32P`190`*U8`0G6,TZ@
M!K9#NK[`!.KX"6`P!SJD"4_0!R&5`AM`#TOP7&\@!7-0`@UW5HM#2@IP!#*0
MGEA``38`J'5`#11*E07P!=!\DB<P65Z@`3J``480`U%8"'>@`F]6`@2`!E3@
M!5U@!R*`!AF0!"-@K(G@!E]0!QF08DLT!7H``%S@!72UL8Q`!G=5P(@4`R70
M`.)-"6RPI.[1!OQL!0,03-K1!CW@1F>T83O`!N89`R=0`)J!C3T0`"2PV"8@
M`@]P`BFP`*;"!'F@`:NP`B80`GB`-R:PAPM`0Q``N/)2!0+`!V4`T;\0!7>`
M`".4"5%P(U[0`C1``']R_P4+$`-`D`0IEG6$4`?S=0`3@"UL``.MFP>2J01\
MH``'L`)[4-H?P`,C9@4T,`0P0,6>%`1&(`0?T!%A4`8#0``!4``'D`1]A,6/
M\A9*4``VD`)%2`AM<`)",`)(8-Z)L`04P,]>K8\$P`,U``%VH..,\`5/M"!-
M@``^$`!5<`([D"]0X`!"$`,F4"Y?L`,?X`4B&<<U$`1(P`%;"@-LT+KDH*\U
M@`)K(`*23@>F4KU#U^A"K049P``@```LV0)KL*G$$JRC*0Q,<-6+H`5@7`E6
M$`#J8P>6O`=%U0)!BP)7+0<2@`$L8,A7@.1V\`0AU`(;H,B"0`$,\`,-\!A;
M8/\`Z'<#(O`$CD$%9#.A?P``U3<SDL`$82!!59`ZR'X(7S"1(W`VBB`&1R`!
M5J4$$8`!$[``H`T)?G.([.$$:<@3A.LJ3@`"-!`$(1`\>^#D`7"0Y"`%`P`"
M.5`"'/``;$`#HM5O+F`"6&8!,V`""*`YZ;`&:;@"*T`#LT2HT.,`#X`"*]``
M8S"-"E*?)CYU>-#KSCA9G9!O7H`",4``(#X(FHD#'W#SAJ,-6W`"-``!*5@"
M:R!`2]"X-BX!`<`##)!RAC"B1```.#1X)(>C7B!57G"Y9A`L,9'`>A-P`M\&
MT`@X2PYSM(@#>_`$-/&'3?$'`T`$,)J>A4";)=!+GZW_*U=)"'Y@[>P!!B8@
M`5FPGE9D"$4-U3P@6E"``#=@!DP`!),_"#\K`UA`!D=Y`699#@XP`GN``#W0
M`Q"`!R6`!`;@!HXY`4BP`0/L`G%@!6`@`S<PMQ]P`+20^#]B;D@L#%'@`)#P
M!0:0)YD@!9_R!V.`[0:0*5O@!SWM!";;`0"0,O8@`B/0WS$P<$'PW^A0U"++
M!U^@`-1W!`=0`G3@+TR@!B#``AOP!%`0`$+`RA@`"$,D9TQ3=!=K.!UA?V5=
M?W]2%B,-64J0F)F03%E2?U%X,3AXFDYP9D^:43Y%`0AU3T]L/$9">A<-2Q!&
M#5>7GP5(-D\!%)!*<`Y?OYK-_TM+S='2T]35UM?8V7]*`3P35Q0K;]%+#D$\
M)@%_5R4E86L(.S(!4)=/(2\!*1L204@X)0:`F5&BS8D29+H0P&=@@HD8:Z+\
MDB+@0XP5+F)T.%/F@8P<$QI(H.%`"C-M*%.J7,F2FI0Y`+RT5%E&'38E7ZS,
MA-3D#A\S4S+$>"`FDQ(I$&Y@$%)!9R8Q%&A\<%`B1@@]8*!8*0+E#[$3--!T
M24%C@I,_;F9XN%&$30@D!II@4K(EQ0L#=#P,X'$#"(<`"PY@N-$B08<<2H_H
M@.#I$Y<V^EY0.!M-R1@^`;+T`<CGY)(T*Y*PB($&&B8F>UR\<""BB`\)7P"D
M&-(!DO^5##LH3"D00P(;2'F,89I2YN3.X\B38ZM"8,27,1>E51%Q@`8,+'_0
M$'E0IH<,%$)6""$R04`*"7N($("TY`,Z'`H@?`DB'%.6(!"4<#$!EPRS)A2\
MM@(#*-`QQ1<I,(5'"@I,@(=<RD4HX81*7,)$5Q-6`P`3U3@A1AW)/4&&`V9L
ML<`(&5"&B14(C`"$`D+H,,0(`&`WUQ@,L"!"$TYP`2$.C4%B!A`_K)&)&QE<
M$8<-D,!Q40!XO&$!`Q>408`)&+!P0`E7K(@#$"-@\,,-,7@!@P(8,````&B\
M8>$5&MQ00!9&:1%``5>8X8(0:FC"1!HPL*```P<PD,0)Q67_XD0#+-P`00!2
MU//$`NME$L(/+Q2%R1SU&76&&AQ.PT27&99JZEPQP)`%'4(T$&0F2\0@@Q`6
MU)-`#W,84,0`D&Q1P`8[A&#!`GF\X(<F5*P@`20#T$!*)G3LT$<$.*P`00,I
MQ,!&J']@,<`&/;Q@0@T=7)'&!#'L,$`%,_`P@&FGQBMO,V,`0.J\FDAATS1E
M+!!`%<<I\48!;TS1``XA@%%*`3P`<8,$9?Q!A@1]]5"`7$\8@`,'8%3AAA0+
M.$!'`R.H"$D''&CBQ@=7R!'#7'/(8(01*53!`0\<?,#"#WXPP\8`88C1@!$T
ML$&9&A(`H0,1$%!!QB=@F($&"CLL_P!)%GSDX<87,L20P!2::+&!$$D(@4`4
M411``PM"A/#T'UOT(,0`,CFQP`)LZ*%(V!ZDH4EPTE`AQP)43&/%`L;AJ[@V
M2L0A`P%>+!##!2;SQ$8/->P`P!-5',:&&CODH4D9,W20!1X3\##'V^LTL`,;
M$Y3@`@U!A`#`&%HXL"L')03P+0P/3`##"@,L<W4<(M#@@@PX4(!&&`6X4,($
M:Z#@0@)?0+CX]L<ML04=,7&[_2G2--'%'`%LH;U*5!0@0P8-L%'&&B:HT,>K
M^J9PPP@EQ!&D%'@P`0-N8`(#F&`#;XC"'YH0!2_XP0`L8,$0UO<'`EA`92S3
M`P_$IP4A%/_@!`<0AQ.:P`8-Q&`!6H#$%:9PB2:D(869B`(;5C`"PA1`"V%@
M`L"F@``%F.`!?$@#'#J``P.<@1DX,8`";G``"+C!-$O@@A(5H``+<*`&%+C#
M+_13@!&P``,>")L%6`><3OE)?=N`%R:B``"`<>^-UDA`$0HP!A68@!'1Z$`0
MBE`"+OS!"S1`@1<&L``:J(!U36A''%:P@1,$@0@K0($=K$"#%%PA!AMP0QI(
MX`(%$,$%-4@!%Y2EP&VH003S4`,(3&`"O]D'`B?``0YV8(*NB.`'7=C"!&P0
M!`G(`8[`1`D7UB2&Q"T.`'C4Q!G6,(<N&#,;3$B`#TX`@1(0X07_-C#!+S4!
M`!/T)07'BH83V`"$(^#`#I_1`A/`$`<$X$`I.C#"`$Q&@-H<B65E\($*DOD'
M$[3@"`:`PQKZ@`DW$($!":`@-63S@R/D@*!M:$(8GD"%@_%@!3&@0.$R\002
M'*!LNI&&%$[P@Q]8`(9.`%$`8J"`)!P!"$20"2:T,,:_F5&D<W#CC6P4S)[^
MD00T:(,=9/`!G6;""QD0@A`R0*<"O"`"`UA!!B00`QKLH`4%*``,.@`!&T#`
M"M]#00UJ@((0+(`.-&@`V/ZPA/,A80YML`(!>."%DP0@=&UP@`4;B0`P0$,)
M66!#"E9@%P,000,H@$$%#D/%JI5!C3[M_VF/`!``,%2.>T[0`YTR,88`S,$+
MJ6C)#(4P@2I4@0)5Y<-&>4*'%NPO!0!8K2:@D`!'$N`*3NB8&9S0@24.8043
M6`$0V```,V#A$@^P9T%9MH0S-*`$!#`#)%;0@?V9``'$C0,>`,"&`&S`!07@
M:35VLX,;#"$?;]B"%-;PA0D``5%(5`@/1G"`#(A!?'/IB`)*4`8[4*$)69C"
M'$AP@R,0@0,D8,`&]"``-W"(IF3\0QX><(TEA($/<N`"$I\967Q-804U>`(`
MA&"U:&@!!K/D`!.8T(`@A,P'#M@&&U!@@Q58]0$%V($`-%$'!O#J#QU`@6P%
MQH,T((`"'P@""O\2T*4ES`$_[K0+=!WP`A=L!!-0V$`&4G"`!IC@!:$UV#N3
M\((&]*G#P61"`!(`APY3P7^:($`%0CL3!1@A#TM80`JV`UDNB,!%0B``AJ*!
M!@GLH`$K5D,5"K>'##``"#B8@%R4@`,G4"$`>0!;<E4&@GMMX04Y((`35I"%
M"1QA"#?(P!I@D((V'$,/08"!&3BL"@OH``,'D(`7EC"`&MA`IIAPP@!*P`(&
MM'(:3^#-"]APW#^``0M/&,`!?K"EB/TA`A-0@AL*\(4_0%@3G,J&$PCP`/RB
MF7M-:!;=,F""-T`6&$2P`0T>VX46A.`,U;3V,>"P`SN(@0XC`8`?(2'_A@^8
M``T=N$@,>O"7+IPAX7F`P0;8D(?9S5("(4C!'C30`C2P]3(G0`$;')`"%2#`
M#7^P@A&HL``;#`"_4"C#!`K%OP(<\=SX>L8VKJ!08"[!"<9Q`!C6@`<ZHP2P
M?ZC`SH!0@TPS@PEX.($"@!"#?TD#"G<8R0*NH`8I/$$+NYG!#5S*@#ZHJ`:>
M4`(4..2!E!VITYEHPAD>4`,6X*`%`0B`$(Y`;0*@80UC@`0Q#@B`05.#"EPH
M``YT<`0&>(`,Z]/"`O@R`@K4P9A+\$+J4)"&P*?A"DR(`P$8P/@C:.!>`ZC4
M$KJR!1&`*!.`LX86V("`-M!AT$LHPUIQ+B\G_T!@!PD0PP9BX!15B"`(`-$)
M&&C`@2_XH0,F@,!F_T`%%[2@#RMX00QXP(,95*`+9:CR%FBP@?FU``<]V,'P
M7("@$YCF"7DX?P?X,`41]$"VGPC"`,@P`!&LX`0%8`$9%03Z%@UR]0)&\%L&
M4("\-R%8X`>&UX"9$&-05WS:8`5O``#=(@1^44HK\@!!D(`_$`#/E`4A0`,$
M\`7P,@5RP`%)D`1!\`)$,`0]8`$;90,>"`D2@`-G\';W,A=X``,OUP5T,``D
MT`,_8`0<$`>O=PP&8`,2\"S28&$#<`5+4`#FI(&:$``P``1`8`0V8(%&D0`K
M4`(+$`9CL$4#X$4_4/\#./!H)R`'9S$`$Z`)7E`"!B!;X48-4(`'!<`&35`%
M=S!H2O!9$G@J3O`!/;`%9W``)/!NW;*##-`!GE``1$`':Z``P+(#XL$!6/`&
M1+```P`$=C`%83``0J!^/$`$`X`&0(``E,$$8@`!2"``97`%(2`!QB$'/=`'
M6K`'M@8YO]`&06``"#")"9(!,U(")V!4TQ`%;8`"0Z`T&J""AZ@<=6!SM(9S
M>Z`*9P!94/!N2P`'"P`'5O``"C`G)^$$%W`#YF4`8G`'+%`"=94)4X".#Y`%
M2\`$480%5U`!(S!`#K`%@-4`0/!H%Q,#K_('#P`"4%)0<!<X`G!#2Z`$TS'_
M!$LD`JD0!@JD!%.P`#W@`5L0#5&0`'.`!62035]@,IGG`CJ@`TAP!UY0`0H0
M`97S!JGR!CRG!&>1!6*P`C>@`RE@!CR"!RM@!#I``UM`AYJ0!1ZP!FN@(GM8
M&6X``6Q02E&@!B:S!\!VC1%2!SD@`2S&`W<@#6@`:CQ0`'^0B#00!QF0`W53
M/33P`BL@`W2X`].W#06@`'&P#370`";C!`X0`V8``8@5`R@@`(6C!`1``Q.V
M`RH``S1P`$(@`0Y``3VP`!+P`CWX!W0P!$*P,2G1!1E``S-C`@X0>%ZY$J%B
M;FC&!'4@7M(0!7[`!PKS!V-`1"90`*'R!'8P`'<P_P8-8`,@H)K#L0`X8`0C
M\`%6<`6I@!0750=+8`44@`,:X`52`'67T`4>T%!$(`(#5U`<<`!VQP!&5T'*
MQ011@"0_.!QQ,`!J8!Q10`!!P#8B\`5\L`=A)A09$)[U,@!<P`95\2Z:H`8P
M<`"U``!6P`2Z5P82L`(&D$("^@(#4`5-,`904`5;8`<Q\(4KP)N9P`0#8`,Z
M,`)(8$;?M@E/(``WM0U<,`!S$('-8`81MIH[D08WH)@?4`.NU`P0,`(R$`2^
M0`7!4@4GD`&[]P=,$`8CP`1-\`0N@`*&QP0FL`-6P`$C8!<,X`!-H`1+@`*$
MN0]F,'HF8`..MP,O4`8HD/\",L$$8V``#'`"$V``6=`"%I!V<3`"."`$VY02
M2B!#+Z`##&`$&7!S-GH-3A``=+":6">C5X<%3(``.D``@44#->`%8A`!?1`%
M>6`$$@!#F+`$?,``(_`#&*`#*A!:??D'51``@P($$I`%5>`$$O$'4.`!!\D"
M'X`%D`A8&C`$0U`YFP8)43`'#=",)%D%D+@-5.``1F!>6Z=&5;``0R`";$0X
M4V`#"L`&YRD%,P"L&``$+!"CQR`&5C`&'P!3!Y!`3["@4]`$5X`"?'<`J#";
M<(`FR@4)*=HM$2`"==@,:I>#T\`%W7:H.W$%'(`#I_`"(."H6]`"1=`#&D`G
MK!+_`60``!M0`G-`9WW``P10`#;@`CAP`#BP`1"`!1KT`&:P`R10!@;0`D$@
M!#)@%W]1`Q;P"U$``</C+T[P`BFPD%VPKF=`!@30`A[@!12P`T)@`GG)$FE0
MF@Y3`A#@J`:[#KX3GZOI!/[1#&WF#'S0?7N0!K]0`6`R``G`C,8)"4Z``#Q0
M;)Q7`#UP:AF@,$J@!UI0`31P`F%P!72B!%[P!BV6!`J@`8]@#62`!`'@3)A0
M3]QT``M@(T^08=2P!;OW<$+``D5@`%4P!6C0&%H0&BU`!AO@<OA%!AF@`$.@
M+F:``JBK``T@!I11`"7``XC3+5BK!RGP@C0P`.<9#5+P_P$:<`<>N*]>D51M
M8!IU8`<<Y@1C(#YCL*I5NQ)24`(O,`:L8@#20`;C<@`$$`5,0``^$``&@`1[
MQHGJ8@4`@`24PI=*0@$D:P)%4`1Y<`$*L#G$J@<B\`)T@`=ND+GKHP00P`-1
ML`6B*P1Y0`67H`1HT`,)``$*\`(^T`'_%`0^(`)-VQ)1Q`<UL#0*X`#Z&+VV
M>B=A<%F':$PEI@E/$`,L<)T!```2\01EP`?3=@$YR`1L\`(,,`0M$`>3-@;N
M-0(*L`!64`!"X`-WL*1N9,,(^`,F8`;+ZB=<("A!8`%5<`F,&VRCAP8(\`;\
M1P94"PEV$)Z0D`8AH)P]0`=P@/\`:<`AGR@"&+`#MWD,4T``!S`"1F``([D-
M<E`#0%`=?+`%#S`"'0`'A?,$RW`%=%RB!B";TR`%&H`!.&`#<"`7^ZH?/I`!
M<>``1`AXU%`%;&!X@@C"*H&*!0`%'V`#-;H-$"`*-"!=7M`"*``'C-054+``
MX!))&X`'$J`!FJ`$$L`#.K$$!S`'TLH!*B`&&K`!,O`=<I`*3D`001@#)(!B
M1(`#)V``(!`#`!`#*=`56!`#/]`#,3`'&:($;6`!/("1+K``"RF!2J`%`&"(
MHMP,)VP4<6":"K`"'Y`UA>L$:R`#,!`QT724(S`#78O"%%`$?.<":N`%B[E`
MOS<8&W#_9M<@H"9P+',<+/-I3TM@`5+Q"+!I`'G0SIH@%M'@!A)P`$,0!"=`
M``)P!QM%!886`:QWNC^``P0`B7+0A4>`!`^00E+P-F&08'9G`$^L">>X,5T!
M*"\@`%U04W^@)P$!"5"0!Q!`!D?MR8:W!`0US]C0!`Z0`WP@!A)@`@>M*!8@
MSB4`!@P:26$P`QH`JG"3`3A@!5A@!C4@Q/#B!3'P`6]``AJP`B;P`7<P!=[3
M`B4``#"``@2P`=SW`B>``!E;0BE0%%V``!K``S&@`230!RC0`2/I!'3``TA0
M`XMJ*HWCT4`@!"\P)ZZ)9ESP$SWGE=,9#?5L%&K0`2QP!".`_S?<Q4)_\`4$
M\`(<,`,(:@(+(+"8T`2\B`1-\P=90`5>X`1J<`*[#:QK8%1,T`7-:Q1E0$24
M>AIHP"`9\`!0(`<K8')4(`9VT!558`8"D+;-8-+1(&![]P,EP`9[\%ER(06*
MG0(BL`.D^@%P\-I9$`%"J;S8\01>\`4.P`,ZL-LN,,F9(`5AT&R8(`5Z8`(:
MISU-`)`A\`!IT'HQ8`%G(`5LP`A,X`4`$`<<IM6P,@Y>;0U?T`(UDP>'YIIJ
MD`-%L`-J^0<-T`-Z$`<)@`,B$$Z0`))\0`&AQ%*]@0!6T``'0`<00`,```84
M``-%0`0E0%47H#9\@`D^W.4&P`93X/\#'G`22I``0>`&9C``+*L&30`L/)`!
MRFTJ?N`>@IL"`_#%<*2LV^#5*&[;TA!:59`"/Y`$#$`!VZ59D##'"L`",28-
MA5@#/0`!:D`%C[5`<M`"Y;0"<Y`%6&!-(M`5!K%P*S!K?\#4<8%!0A"NX9$"
M9_`$=3``W&H4+02):"#&I\$>;"`:++";<9`'=G`,:I`"1W``>6QB&L``'.`%
M63`&2L)`%$`$+.`#((`%=B/8>L"J#K`#HD``.C$%!L!(_+0-?/`"NRT$-'!"
M4U`%>8``O+Y%B0/CH2KC,SX-7X!)4F``/0``B5.W+X`#/K``3/"[B<UN&X`#
M06`#,-`'8T#_+=Y%F*>(`LCG3R7P!J6)!Y>0>1"P`2$P4-I1EARU`3#0!&K`
M!C)@`G%0Q0L$L@4@`CD``T(@-PQ``P7?NR;6`"!``'60I"K1!'U@`3LP!#X@
M`X_[VHMC!7?@![-ML%(`O9EPVTM@"'8@=R$0`P0``J1*`P6`!G+]!1^``P.`
MX3P!!B!`76D@=RJD!BJ@`#\`!"?;5EY@!7/PH!*@`R`0!BSZ`AN`+D<+*U90
M`3UP`PS@?SZ04UB3/B4(`&=`0?1]&D,7!5*``/I<`3&`D2'@!U*X0`L026Y@
M,D?!!X'$SEX`!5A`!5(P`.]T!"6`!QS2!%80!AN0`X%=`@@0!FS0_P)E-K,O
M%W=]<`)(``0FD`%U;@91\)MF0+5*4`9[8!*98._L@>_YK@E+H`<Z$*,:L`-R
M':IY$$(C$'A@4`*M!@,2H!-CL/`K0$5%$`8[H&*<59F0@`4W@'*9<`49D`&^
MX@!M`P@#6W]_61\T9AP,.#LK(S8+=Q8[>B8IA&(*1S0\<X2?H*%@/#\E%@<E
M<UBAK*%47$ZA2PY$!T-($W5*K;R]OK^$`VB[P,7&Q\B$4G>M"Z!3:`MI7AX'
M#L1C*PI)+P%13%Q2RC0]"%!_2UX<2!Y=?TU*64]H)3\Z0S\_*7%C5D_O5.YT
M>'/NCQ0+-VA,<54@B!$&*=P1&A,`0A5@3?\0T"%&"(W$/TRZY$$0!4")'6@(
M+2E09,20!E[^6-E"[,(($694SMDQHDP5>4N4<`F`X\@/%C^$0+"SA$J7)TZ4
M2(A#I4F;/V]HZ"@02@D9#DET,/!$"`J9"'2*U3%`!105-@55ODE&MZ[=4%@\
MQ&C#ID2&*ZR4C#F!PX:$*4[DY*@@!D>#N$K"S("!A0N$'6RR$%NB9P<$/1M`
MT(AAP4P5*&9J9%A08T*#%#QXQ%A=`D0`$R*N*`%38,,.%QDLR(EA8.&4!4@.
MI`A3['B0`GTZM,@P@4,)$F3:^KJ2P>\+"V'B_HGB1P2/&T4V(-"RY"Y=)E06
MHG-/OSXK*@.:$;+_8F>-F2\6T$``&*`HH48*1HU`0P%LS`$'(4ZPH8$)#H3P
M0@=?L&&'$E4X@48+1MR`A`%I!,`#"S>,,,`49T!A!1A=E%&&%A&LT$%.H%R1
MP'DWX?&)%70$($9[Q2P1E1)1-/&'1^]HD<<>:@A@P@8`_/.)%&PD8500*O2Q
M!P#R5='`"BTXL,()#=2Q1!]W--&%`$(,<40+>7SQ@`(L)&%!D%-`,<456)0!
MQ0,GP)!`%*`\`08*"@SQ0@3:+?$%`GV(8PP33*`CA1)OB2>8?:"&ZH4$,:BA
M1PX>Q,(*&2GT@(,#4RQA``X"?!%`$`.,0203`RA0``0RI&!#$#`,P`44_PL0
M,<`%/110@`D[<`("!3)$L$`."2C!1!8%I$!#!@0$@`</!%CYAQ)7;+`!%W`\
M<`,`5E2100Y"J+`*,$QH8`0,:BSQA!L5O)"!`12LH$$`\K%21@@2I)$%&QRL
M8$$<JI8%!@%!%,%`"04,&6HO5;S!Q[T?EUP7?LU$H<8:;)RQ@`D?E*'D)UCD
ML<,--]3PP@@W9"``CLJ8F(0';%`AA152Y&%!40QP0$:F\2RPPST&F''&'P$L
M,44!+K1`A[E_3"$'#"G"X`?87;A1,3),L'''%GB,<84<?(CQA@8QS&$%*$O4
M\8$""ARPP0$W!&'`&WL3$M(#.B!A1Q0!/"$%%O]RF)`$`T$@0,4N3I0!0Q(_
M!.&&%5KD!(<>%#`@`4V?"#6!$`H0,4$6F4*H1A9$)C/%'&1DT8=XYYHL/#)H
M*$``$QSPD`9'H`C@PPL\`$`(#B6$$4,/!QRPP@XM;)%O#6$(48(7O.&@P`HX
M*`=&"B]D83L!.3P@)`$T:-%5$!3\<<8`0[1@_R<.X($:6H`#%+#@"$-0P`L.
MX(?:_0(*.?@`'AR0`QL\Z`]08$,&1N"!/&3@`!3('2'ZH(`&A*(+`X"!#P:P
MMO'HX0-&4``2-F"'X1DD`!<``_!LR,-60$$.S"-$"`I@!LCI0`1E"&(!D'"#
M(7``#$:Z@PQ8H"`W_`'_#E9\QQU<H(,\_,$)!#C`#Y*0@3,$\0]Y2,(^GE`&
M+DP!(1MXP\P^088>W.`'1WC`S#+X/_<L@0L`D(`(`,"%*-B@',#CP@P.P`(B
M!*`M7HB`$1)8@7>P@1A9<(`"-/"&)V@!1#]`@A^T`PHL?*X!3<A"$Z10AQ8@
MP0&)^P03'L``'?Q@!%G\PQ7F4A\IM*$!'4!4#X?9"R9,@`8``,,&8-!'OA$@
M!CE8P1>8X(<5B"``+R!`%[PP@`W$(`8F6,$&UD`#BQ!""5NX@P(F(`8J\`$'
M7P@%&V*P`#-`H`,^Z```+&6&&4A@;"6001(.((0/#$`/((@!'TBCA2G`H0A)
M_UE!`(JA!#\000<C4P(*9]`"`Y!A/'#@@`DTT(`/E(`#=(!"%!Z``SJT\%Q6
MN(,*8-"!/H`M"F7P``^0H``7%$!7H(K'&]8`!V$2\ZB)NH.E0(&`!0@J`T>0
M`!MF]H0$Q.`&J("#>*JP@!@P0`%2U4,`SA`4*T"`!CX0`@:&,`,R@(T04S`!
M!ZOPA3_.`08Y$$#"T-$'%=R``318`!]2H!X[```/#G3/%?Q`@@Y`0`(+Z@+S
MZD`!!>B@!PZ(B2S-``(B+*(#*#"`'1:RA#:((`<T,,H.+C"&5O2!`2$@0QRX
M8`4_$$`(!/@"\[0`@1[HH`@Q*``(<F`!--PA#Q>I3_\3R."``BRA#(#1Y2"0
MRL,J:,`%7V@##RBPUT]0`;5"L$"F]'"``JBA!P/('1/LT(('G",$*]BK$@"@
M`#;TI04QP$$!K(2'("R@`$*8@$Z#4((@/*``!S!`'ZSQ!":DP0!!X%)[Q5`$
M/F1*"B3H@0)"$%U@#.```:!#"@Y0KG>TP0.C48,R"M`"S*YA!CT80?>`$88&
MT``'>V#%%09P@B$<@`<2:"U]GA"``<!ACM2E;A/,X+X_`.`"/RKR'&@0PPU$
MR!%)V$`=$ILH%!SA"$10`1C\P(?$/:$`0,``'1PH!3#4+@P8N`%EG*`%!?1`
M#TC^@QHV@"<<R$$*@%%"`&;_4(0+#GD/"!"#%2R0A!6L(116J"P0$AS+KI1!
M2PJP`!%>X``X$$.91XA!<@FQ!2'_00)'4``?HA`%37K`U(1X`@+L"`01A($)
M_N*"!X30@CS;10H)D$-R'2`$/OS!#!]-LO#:L`(5=&$!Z!7A)_)@@VBMH0E5
M.$09MK:#/!@5"O0+@`=,``-.A&`-6=""!F@0!P[88`T06($-BL`#$&C`!@'(
M0`P>U(0M3"`%.,B`","P!L?E;@E=Z,$"KA"&.N"``'50PPEX$(0)O)476E@!
M&<F`)#!XH`8<T,,WKK"&$FS``02"`AA"8((6'.`!2_W%$JH0APV8X`$R:QUJ
M1&`^_P7,``(=IDL<VA`592M["6"``P)<D(*KR7(+`0#``Z9V%`64P`\OC74!
M8+"".7Q`""D:2![HL(6@8`$",0#!%[8P)ARD8`%58`("=M`H1B"W0&80@0YN
M@-XZ_&$+4HCZ.Z-J'S;`@;(UZ,`6S#*`.#QA#&$<0GBOP.5/I$$#1]#!`ZR`
M\`?T(`4&``.BEHS?`5PA`!+800XD<!4JF$`!0%#`#B3@!21C80TX&(+JOM"$
M*T@!#WS0@B*.(`;Z[&()5N"($_"0`H.EP>@EBP,24)D!&J2D%6O@@1"$D.,J
M--\.$G`!"B0``T,YH0H=,`$`:E`">Z:^"#5`7PO8`(,23/\7"PC8``U"X`&_
MO8`+H0`%+&!L62`""G!MG_`$$Y`#8"`!)F`"$K`!1-`#-+`#"%!Y7;$$6K`!
M$G!7::=99Y`!X10Y7]0MWS%=#J`#)N0+46`'>6``%R``;M`$2U!S*Q`"!%(@
M>.`!+Q`B)>``.]0+37!QT$==7O$".!`!OG8N=1``!:`!+%!"T@8*:L!R!L`I
M2E`'&2`$0$!/>+`&<J`J8)`!"E`#+G`'2E``*_`"<?`':7`#2:`!;T4%!+`#
M0T`$&<`&JN(&`[``&H`$+#`$">`>>[0`--`"2?0)<^,;0W`#;36%BE,`#/`#
M,`"`H-`&,!`$()`'F@4%`R`$T9+_`4T0!B1`&E'@!`T0.@#00G4@5T#@:&Y"
M!4]P!PM@`-K0:-V%#%-`!Z/&"LAR`"]0?$5('U!P`C%`!I5C`97V"5O@34"F
M2@-03@7P`GFP!6S0`BD@`1I0`C$@`F:RBBJ!0D;`!ET@!1F@`KVH!-EW!GDP
M`2ZP`R)P![&P!'D0`PWP3AN0`S]`!#Q``@7`!RV``@C``Q>0!5U``"R@`V$F
MC+S0.6T@`3Q@!$?P`7VP!%=`!R^0`A2@!DK`2AFP`A\``$V02A>P`B5@DF;$
M"U>P`/67`0D0`&M@`,L4`A=`9W+@`B7P`"K6.E-@!QF``W\E`06PC`%(!PC0
M9,-(75"P_P<G4`)L$'.MP`1:$`!FL"FML`0`0$`9(`98H`3_D`9S4`)?E@1(
M8`&&]P=/8``ED`)FX$#S``,U<`,/0#(@H08D`'N.P61>>0$4L`!'LP%'T!.0
MB"\N>`9L9TUN<$9S\&5"L&6\`'DZ@`$:$`9G]`YC4`-#L`#_8`<<4`,$,`4<
M<045H!5"8`9KTP3=DD`EH`9/H`1I,`9TT`!KX`7DA0$%`)7'H`1BD`==^0M1
M\`8Q4`(`@(%)^0OI@HAHL`,98%2EE%\[8`&QT!`+8#/.0`A-X`=KZ0;N4P0A
MP#Q*@``Z``8``%HE$`)L4#MZ0`0+,`$[``,N$`0CT&PXM`,-8/\B!,`A$-`"
M0;`#,F`*?9`#"!!K6T@$+1!TS1`$"@`#8[`&+O`#-X`"K14%<]"?%-!:N_$!
MED`Q,L$")V")K?`$D`4`6T``*"`"'+`!$``P-(`"1((`S<<!7!!$<2`!N<<`
M+9``1"@3E5*<U+4%*O!PH%F9K*"!O+`%(H`;>],%9[`W48`$(_`#.+`!*<``
M0%`#`R`&)F`XE>D$M@@#1J4$!D`#+``$,.`&3U`%31$`>7`'7R`?'[`",#!1
M=/$$`C`&"/"`.<8+4$`"2"`"O0@*`X`#-+`".M`">U"9J)E[-'`&!$`$*Z!9
M"K,"/,`'<_0%*,``+"`#%!!/3D`%:`#_`&SP>%O`!54@`3+``;A)4520=8'Q
M!UA``*H!J3SZ"W*@%**I`&)P1DP`8"M``TET!0Z8!5\P`K`$"E"``C50!Q;`
M`09@C`2`!DU@!;WJ!BG0`GJ0`3:P`CV0`PZ@`C0@!M5Z#F[2`33@`A*@C(V*
ME"#A!8Y$!6X@`2E0!G_P!3?&`&OF"UN0`2S``,-Y3E=P`4F``3H0`7M#!0G@
M`S.P!JVE*#!`GQN0`8-)"!D@`4W@`$A0`5H@!5,P!A$@!-SU&MJA!%@P`.V9
M!\TT'GX@`T2@`#=``F;P#W0UJTF&!B(P`B0!$GHP7<:@!'-P!\+D!*A&L!S2
M!$P0!AZ@`R,@_P0)<`X(=P('H`-?M@(9(*^LL%XJP`(F5`40(`0Z$+!)8`!2
MX`1G0`<%4`$Q\`93P`1>N01,8`8F0`,!(*1\HP69T@1YT')0!`I1<`<,61;0
M%H\`,`9,D)8X,`/0Z@`3``=<EP=QP54\H`%4,`/Y@`$;,P!_2@A88`!Q8D9I
M$`()A`$8D`%X4`5-(!#YUP%QH`1*X`2QD`4(H``;(%G`T()9<PQC\'QE,7<$
MT"\RRPL7H"Q,L`(F8*#G1``^4`0F0"!X\`(G@`<MX`*,(`.6^P=B``,A$``]
M$`(.<`(S@`(G8`(E8`,B@`8!)TQA8`'U]P`.P`4F@`)OI0=#4`=.$/\&@OH&
MN3,8+6`'*5!N#+`",N`J^_8+5K`#/[`#:5&U"[`"H40!L1`%`W"2,$H(*W</
M$$"4*I$$B$(#;/`'8$`'<D`38Q!<39`"*YB``V`"%V*@@O8!2``$0F`"'8``
MO-2[/;0%/#A(/+`"!B`&`2"KQ1`%#=(>3.``0#`$."!:`P"1+'``%O`1GQ`'
M*?`#"-`!08`#3JP_\`4!"4```!`#82$!"Q`"1F$#!1`&!9`#1R"P+B"26O`/
M9Z`%:Y"1R<8+60``5<)L);``W@D'DGL##?!67H"M&H``:KD##)PI$T``Z.``
M,2`#A_L")N`C?Z`"KT<##*H`#Q`*3)``-'#_`G(@`6:@`4+``CYP3R<R`C%@
M!GN0`40`NDD``G9P!5W`!(#!!9Q``3DZ0HT7A+RP!&FPD^>T!0Q@!!R0B[,J
M!270`TWP!3>P`)`85RM`!"B@!$OP!C>0`&0P`@``!7.@`$7`$RJ@`Q4``0R@
M"^<2!0V0:5'P>#O@![)@!@JP!&&0!BB`!&^P.>C0!@>P`&\0."R``4(0!'30
M!6!`!!00``=`J8M&N3Z0`L2I$FCP`T:0`\8,"E90`1AP!!H`11T)`4`@`3KT
M!QD0`!N0!`\0!GG&!$:`:SE``DDA4AC``B3@AR*-`JV@!.!F!"F09TK0!`,0
ML'?H`+A#P\,C!?PC_XJ$L`"@"[H*``%FD'RYJ3A.<`6I=01.BB<$P)Q=8:T@
MT0`Z@`!<,`;4``07L`4"\`$8,`(L8`+,00AFD&9R@@$_T`DZH`,LH`%=(,D6
M^01[\`,QP`4BI`13``!`%P8TP``<"0K@$`()F2<W``1_%@I3@`(9/21/<`5*
M,@(VK1)X,`)'\`(Y2`@:T`9RD`')5P:C@09@8`5?(`16_`8%8`0_P+(74#M-
M0`&SG=&690`:D`0WH`!H4`5*``>)H[\Z(`"D9)T78[_)(`7PXCL1@`.@.R<$
MH'F\7(1F(#%7$$#YX5H4V&U(D@$[\`9U>'T@$0<KL`("X`55<`-SK!(9T/\#
M2B``<T``_I22?S`!/7`']W8"+K!3*8`"`\`!/2``$X`#$Y6YB[0#)5`#]?T"
M>D!J*4`$0M`!$0L2O3T$$1`7`3`!#H"&@6$`^N@#?!`+3S``*1`$4C`5KEHP
M-@`!(E0"^;,"H,L".*"/.T`$/T"I,V`!OB`%`A(*4:`'`H`&J,=(/'`"`""W
M1&T7`!`"L/8'=/`#2^W*/5`":Y"JO,`%`V`&&00#/P`$DPD,$I"G?\`%&N`#
M(Y`$,!`&((`#D(4!1+#!BD,'`%`&>B"6[;P?AIC6$B",6N`^4E``.S`#_Y,%
M<S`'8.`&Y88`4,D%*.`2,9``KZ`!+L$#>DP(:G#_$@MW+F^P`&V@!0?``:&@
M!CK`"J`<!R*0.*@I`R,`!#K`!GY``R6@`D,@TQUV!F#X8$:0!")@/UYQ`FNN
M``[08(3@!EC@!AN``RQT+F9P4*S:"TIP!K2$)U5^!-4I!AZ`NSSJ!`'@*WG!
M`.J:@`N@/3$@#EC0<@Y\`'H`-E.P`C/`!1W``30@!`80!JVY!85^!FX'`T5@
M`020H'FP`C$0!C6P`4JR?#C``R&0`0TP!3/@`\G-!&#``&#P!&(08%J@!&@0
M!#6@`XGH"TU0!"Q`M:4+!`R0T0Q`D%T@;;L!F#\0JE0@`SF@!"'`#"I1!HQB
M`-/T!U00!![@;WCT`P>`_P%((`1@8@$FH-6@P*5&$`*?L'P+X&;G5`4(1J4\
M4``MW^0\I`?_7.55O@'7'0J)40!;\'B]"0PJ8.:$0!1[()8:<`Y*(`<\T`)J
M@PY40"1+(`5<5K$,<$<?`-A!D2D.?$0#@`!>(`8:P`",&PIA0`%),`(*,`"V
M9P*Q]QR,L@=[PP1;,`Q[D/)'``*A(`8,P`H:8`8:1)=,``(?$``.:@:[<`4B
M(`0+<"^L]@E0`#Q*D'%UC0,+D!)JNP1+X`8Z4`.MY@<7[D,T#O9+/8!<?VH]
M``=@L`-0WPI9(-Y"L`&#0.@1(`?I30.'Z.A_8`?$<0$',`$7L`%<ZW8?<,0`
M(/\$#=`>6&`!U0H!(K``=;`#$\`*%``(1%9.5R\P:4M_BFTT#78K+30\*Y(X
M*52*F9J94!\M8)DB"AM&#"E%+"Q!*'&;BE8/)B\C(E8+27.N8P\E*PM_9QDK
M'VEL'1P&`64$.#!3KIE2,2D+'YE;:4[037PJ#$E"(&:)T.7FY^CIZNN97T,8
M\/$81Q#DZU=["&3L!0<#VHM`$#&RQLZ`+DK^+%EP8T<8=EDH"`'W0<L44`'\
M6.E!!,4,&A2>;.KBX0"+(@TPN5(")\:1(0VJ-"DCI0P4/20.),%PPX;(3&)&
MN))@9HP+&`\S&3@Q!$4:`7&@*$JSX@8!=DO8P)@GQ(__(B\>8F`X$.4*.TU-
M%,B3!Z3.V;=P-WE)@:*-@!<&K*P<`R-&$0]5G"R@8:"`C0(#,M"PL:*$!QP=
M*-`(H`C+'1$[9$28(X?&@"::P,0@\*2+'1H9X$A)V&0.C@80<C"F44/#&RYW
M<%@P0&,!F@(Q6(SHH:$+.B5NCFY1-.:#`AXLA(AHH(+##2-#1FP0H"5A)B59
M!KPHD8(!#3;0E)R!T&+%@"\!*&QPL:&#!ADR.`R0"FT)FA02;(''"6$P\8=W
MYDRA1P9(,'!`"WY@84]<%%9HH1)]C+`6!B-4`5<38>SAQQ@(FO/$&B;`T$<4
M?YBA@0]#!#'!'7G0H048`R1`_T`,#X0QH3E.N,C`#0?,L<<87'SA1``G`*$!
M&:`IHH05`_1`9`9M&+A2&`OTL`$;47"!!11LF$&!$3HH(`$.2?#`!QQ0)!34
M4&8H(08).!@@AB(-S#`"$B8(<`<?;FPA1P(+S&#"'2JE8T4#0AQQ@P9A_<#"
M"WI8",>&&.A@AH6@HD,&#Q1D`4$0>90#0`XUU*"'$E-\T,,7$_CP12914&"#
M?M@<`(HF2K00@Q-Q4+""GIIT@`,:)*1P0@@?O'""`6J(<(`=.[;Q!QLAK("#
M)3C$84`,:"BBA@D,"-&`.GH$8<!/5AQP0!`_\,B!!A!\8``!"AAA*0\3<%&B
M(F[`$/\$`P0,O$D:,+S0`1Y*/!&&&6JL=@X3>?@`@2)ZZ'"'ENLXT0`.0"1A
M`P%FA:KRRN=HH:$\2,"A\#IE#(#>.GKL,$,;;7R@1@E'M!G!&Q1DP.(?6W!`
M@P4IJR-&"-\48<`?5Z0@!`U-*^*$`2^PP,`&RY4#A0,[[)"R&V>,H84!#+#@
M9<HPZ!`"`@AX..<F1&6"A0IX7>'``FP<\0,0$JPA0@=E:"F'#290QLX`#!R!
M01([_`*JRVO%8!S++%-1``]KA''?%S_^044#0?00@K9FP)"!%@04D65H.%#0
MA@$4X%#"`&$XP00<*V000`D;;+!##SQ\H$<?)Z`@@`P?@%'_!@(GS/"!"!D\
ML$4)+8R121-U6``#&6*0<4``$B800P\VL`&0.500L$(`B4`QP`$O$#'$!@9D
M(,(#&WC`_RCPK'X-00$AT,,5?N2%`LB`&F&(DBN8``8#S&`#`S@#R,Q1A0ZL
MP`P`L0,,XJ*$+00`:@H(@@K8@(69<>Z%<5'#RS"0@@*L@`-L^,E;G,`%13RA
M=*ZP10Q,H(`5G*``)!A2#R1`-S2P:`EM$$$,(O"K=$2!#2?0P1`8\`()H$&"
M2L#"`$QP@Q%(X`W\<446$+`"!N!A#%3``Q2RX(8)($$'1V!!`3RD"`B0(`]A
MV()(P'`#.FD"BA\H01`LX8$%X,!2_SO0@`ZI!@`8;&>2YQ##!$JP@"JX4!U+
MP,,#:`""'\1C!8V"H866\`$A=$$-,9!`.;S``0;LP`1Z$4`.1-"'>^T@!08X
M@R+`$#P$"*$],H@!$6)``69,``!YD@H<2O`")!3A+W@0P@5*A(8#7$4A"KC`
MT<QU`@K<80,AL-H&2E*#$F@A'5GX``]NI9`.W``%0&``!R*P`0)4P`4..,$&
M&I"!!?#O`3=@P0^2P,EWNH(.,EC!`\0`Q$Q`,P8-\)XYO+"!&+BA#?N@F@I`
MI88,!"$)1FA!`IZARI;"90ETH`$&6!`V$@2!`VJPD!WZ@$ES<$`!"P!(%U9P
M``P((0!TR/]I)LKP@A@,@*7E4`(7V%`%)FC@!TBXPR:4P(84&`$(1[!&.9R0
MAQ3L8$5:JD-X;/"2`VP1"1;0RQ\,4(%-]($%8YA0WEQ1!B2L``Y-4,,`##:$
M'WB@#*YX@!`\0(9/_N$);?A4J+KP`!R<@`I,D,$\-H`%EU9H"7;@`0'.4(`=
M`.!]F5C"&VKP@B*L(0I;\,`*YF`!$^AA`!_8`0YRH((.[*``(("!MJ1*!PGL
M@`,%,`,?</"Q[ZC!75D@`PE*$(<L>&<*.PJ``0!$`@FL@`!]<$,!"".!$K#A
M#1<XP`\.L(,(2`$=36"#PSS$$A/(BP6ULT`*(,`!"U#@`Q5H@0C_"-#/_E(`
M!1M(`@N2,`(4O,&3P%)#`<B#@`B.E0P16`$&2826`+S``FR80QU4H@4AF&&#
M<"'N!A2P3`[0@8^>C;$YS(`&",S!.TJX@@-1T(>*HD,*@H7Q.90P,/#10`<,
MR,$>E^"%9S"A#B&(@0.RX`J)`<`/;EC#"E`0@!)5(0`UN,$0G#J'%KP@`$*F
M$@Y<```K1$$)8&!"%%PS`@:T8`].&`,$D$`D"HB!KIL`@P[\<#-%[!4:5%!#
M`M#PWD?IH(P<:,.$IK"`$C@8&E:(PP!H8J$GU"$#,5C`YAY[`@A(4,;L4,(`
M*C>&V/5X@@D(P@IB4*<LG&`%:`#!"G(:_S$[;$`('8"`&`:S)TU8(0@4H`(:
M++`""%A7$5)0C!V"FX(#>*D`6;C"!YBKM#?0P00E4`$*3#"#%0`@`QN@IQV"
MH``DK`'%T+@`#1`@$B6T`0E$&`$+FNV!#!B@!"((>`/T10$50&`&&<@`,K)7
M@G[]0`<;*$`:%;$$*J`H!1TX@PN78*H23"ME2XB`$`@0`*HB2`M&,($'9F>A
M*[Y@`#L"P07>B^J::ZT>/U)"%YAM`6&FV`D)48*/SR&%`,3@!D#@<@#F0(9$
M/($--&C!C:7$A3VL@0MRD$`-!!"GU)(A!`H8P@%@0`<21:$`2$B!6_ZP!VH.
M``YG2,.>EI"&#?\,X08T2$#7%0(&#>AO,1381%"8\!/0''H39)A#`-Z<"2:(
M`01!&((0)I"U)7RASA./0AO6P`:+52@,H/X`%\@Q!:G\T.9G<<`!XM`$&L2@
MLZY8@@78+0+C,((`4@#W.!51!5Q8X0(3.,`&J*P(*EB%"T(HP0%TYP,)7&$*
MJKN"`CQP!3`L8`<C:#@#1,"%'6R`/TP(@P%P4(`P3,$`2`#(`GB0NB\X5A$;
MJ(',%#&`I-]`"#A@PP<RX`$.0"`%$_``O^4!'M`!&0`!*]``O.$`#_``%J`!
M$C`/!T0:$T0&%5!$85,.36`&'9`$-``#0O`#$@`'$*8)6\`"#3``,2#_!'@`
M*DI@`@#`!70``!V`!!2(>C)6#.8P!@9P`!I@(590``(3%TR@!R]P0"7P!5L`
M,DT@!R50`[>R!@/`!5H0`SO`!U"E"$S@)SMQ!!*P!-=U!FZ``/M&`SU@`!ZR
M!.0`!3&@`RQP/C2W55]``BQP!"`@>$*1"7$P!R>@+="0!E;@0EU@`/GD3=[1
M@P<P`FGD!4.3A7'Q!!R@`Q'@!IO@`(Z(@^>P!2E@`D^P!T(``?#V!W"``@=0
M!`^0"`9@`PX``!:0`3L@`1&0,FNP`P.@+!E@`C'``\)'`"30`WP@<@'`!$Z`
M`+)``R50`@XP`$@@!_8`!7>@`P'P!$S0`#&@_U&9,``T,`<#X`$$H`$I\`$A
MT`.HL7NSM`(JH!)7`'8MD`0,8`'LT0$=X`$-L`%^Y&\S$'#<*`$$)0$3<`(2
M\`$:X``?$`$RH!9'0#C[L552D`?>1P#$EQY`8`<%T`%"0(G0D`4\`&H20``I
MX`(>(%EO,50IT`(]P`(Q<`*MZ`(:D`?DB(DLXP0#(%?ID04D0`,D(&1G(04`
ML`9M<&H_QA\+03(CH`%XP`1>@%A_P`0&,`(W@`"?UAN.^`49@'1G^``C,`1&
MX#-+\`2=]04X<`,5\$Y-\`96,`5OP`'ZQ@`.X).QQP5(`#::<#=20@8[4"I2
M4@;%-E:;HP1CL&(>*/\"1W@`)]!#.K<&`H!:<9$&%O`"(K!W0$$_+ID.9"")
M4N`!2!!2KH`&0I`"0!`'2Q`%(8`#8U`!,2``$X!_I+@!#:<&/K`!/;0$75`E
M*S`!#B`&%4`#8(`@3-`&[I$(6[9!3T``06!]([`#,7``#\!2"+`#>&`",M`'
M!M`#,6`$1#4`[_<'96`$"Q`E7J``V'<I*$``P68"%[`F^B<"%C`=-7`!DK$&
M),`!D;$`-@`!>U8`&D``%D`?$J@`$0!O2T`&#7`#,""3FR`445`%&M!#T*`%
MLH0%`M`"!P`!?)"+:[<.9F`$O+$`68`#6%`&':``&L`'']"4D0E#4]"2KL#_
M!14`!`YPG>4P!7$``01Z#F3@!9H@!710!-D!`UO@!P:`"4[0!7X0*10PHTW0
M`$"@`T"0!["7!0[P`P?D8$[@`@<@!U2P!-J@!$[0!">0!#J@`P"`D^>P`B\1
M`@`AEXI0!D*```M`!UB0``$PHYMP!0,`+&[P`))S!!X@!EJB!%)`!2YJ#E;@
M'!I:#EG04R7*"0:0`WT`!AN0`@JZ"5!@4XSC(62``Q(P!@_467XZ6#10``@@
M!3#``:C%$B,P`%K`!AMP1._3!<ZB!R>PB9*@`0M@!><"`VA`'FZP!R<0`PJP
M1,>8!RL@`O2U`$9P`#[0!N_7!*[86'_0!)`SG4``_TP@T`$$5@T/4`$ET`$H
M0`$3@"\2``(&``,=$`+<"`+5(`(1`$PA(`(&\`'`H5X_8$9S,'$'D@7CQ3\I
MXP1L@`>%]`=.(`&1N@E9D`068!Q+4`<<4`+WV0(;8`%P@`Y0H`$YP"4Z("]'
M,`%-5P4-,)(6(`$PH`$`$*B)JC*PH@$UH#TD5`5S,`=I\'YJ8*.;(`5DHP-(
M(`$5``$!H*!1L``OT`*2]@==\%,Q0@&."![*LF`TT`%?@`=?4)9.X&LZT0.X
MMPY8T``KH`%EL`4/\`(DP`5AD(=_@`8;8`,+P`1/!@$%D$K0($9[80$]I@1J
M4">A@@<?D+(E6+)G`0(\4/\'6L`#&\"6?X`%&<`#<$5E<G``!=`$/L`!;)L%
M/P`&42`''$`$!A"'<!"A;]`#,."=N)@`3/`%,>`!>C!R74`'UM(#*>!Z!H`'
M2$`"A9<&'=`#""`'5L`#'``:2N`!-"`$*^!00V8"*1"QBM`!0+`"\PH"%;`!
M$Y!.>S`#)$`!'-``+6``()`""+!_!$`!`>8`(N`"!?`!'?``_@8#!C`!)K``
M$F"M)2`$\S`".9``T!`%`J`!/=``5^`'<6`%>1BP`ZL)`7``'!`.-@IG"V!6
M"^`!-M`"_YL)`5L"(>!]&]!:1V`$F+H/4U"_14`![!$#(ZNW+;<.2U`&OP:Z
M)!3_!@$P`$,7L[-D`"S`(1[P!6NP!E'"!<*9`0B``X_V`7FY$AW``C)``6_0
M!U`P)E"P?DDP!$<0>"L!#7A`!"U0+IE04@S`-DGI`:2"!="*"9I7`&EP#FZ;
M(`"0!Z-&(585!-R'#HA:LGT0!!ZP!`_0`VPP,W<A!+3[K"A0`V+@`!P0"2&P
M!B+Q!.LG!\:CFC%``SC0`@1&+A*0`\;1!)56`S0PD@+@0199?,L%=%(`@4*F
M!`VP`[%U`C8@!"&P23O0&Z%X2'+@+IG0!CW@`S9@!*,A`A+@`"#03"50`1I`
M`1VP`0L0`A9``##P`!)``B1`JQ+@7R[0`1\0S"@P`!OP_P$-<`(5$`(DT(H7
MH$P_\`,,<`(",#!/<`4C$P,&D`4*H#4)Z@K1A@,LH@0+L`+#[%!DX%THL$F*
M3$\*(0<\L`/S.2%94`$KH``ZX!AN,06RA0(>T"T20`>I#,+G$``@J0YCH`$O
MX`'`^Q91L,(R6PY<:RE(\`!["`#=\0=0P#9>R+::,-$X\`%ZT5E-D`5:D&!'
MH``64`53,,`@X&038`-%$`-W`!I;8XQE3-(.0*97B0(X0`!-H`4",``;K1`H
MJC=U:@Y-$-7L8`?"LI;IL``^Y]!_(``[\`"P0`-]4`X"<,@]L`=-D(XQH`8[
M+0(G$`0]K0((8`%%``"*8@=_X/^D&X`#)O`!'_`&S*;7F6`%RM(&4N`$#-`!
M38`@4E!P4O``)W`",A!Q@*J4/#`'Q^@!QI,$/\`#-+`QZ+`$`3!YWN$&WJD`
M/V`"!.`!*+``)Y"/ZDL`(A`"$2`!S00"Q-P!(L`_&C!@]:P"_I4"$8`"%M``
M&C`!*<"-!J<!'6```7T$1W``(=!<2O`%`N`A@]@P/[`:3I#.FO`$%#`O&Q``
MVB`%!L4C5J"&>T`"+5#/&[`"I<($`-`#/;`"A+U574":!\``)M`!6@";!$`>
M#Q`M*F`&@NO5T``%!6#5Y3`',-";%>(%<M!3+`PL9_`&6\H'E``#3$D#-=)T
M=QD)!1#_AP[,D$3@!U0`55M3`PJ6`I31!DN(@)PDO`BP!Y1@`0'0`B6PML!2
M!Q+0+V9X!!K@F6B``'APB5*R!Q2U"6&,%GXPU'%!!200`R2@5.@PAB0K8U"P
M(XT5`QM@XIE`!1)`!"_P`6I8N@2P!30@2Y7QSBE``?NQ`Q?P4#HP!E7PQ!F@
M55-,`QX0`,X2`SY@DWW@!'40!!J0!CR`.!>P`BO``SP0`C2P`7?0`_)K.B)@
M!$A@`U*N1K=&<U#0`$GP`@R&#"%POB4``1D`C["H`@H(@.++B[!M`0[@`K?M
M`10``@A@K@M@OK_]@-`L`0;@`A.@<!0P-SMP`X*SF2+`!BAF_P62<0)\T`)E
M3`8N,!P%``9YG`%Z8"!-0#9'I!=*\`8CZ0$6(`0CP%X=(*9\-;M"L#^B-K@2
M8)/;90(3T.0*#L8.;@YG@`+DG.#'X04#T,-_<.&/I6@:4=0H4&Q04.9`P`,E
M+E4L-0627LZ*$`4C0P,C-N9>D``\\!)YM#MF,`5Q:$-F$`9^X`1GQP(VD-^9
M4%P,%@.%9@5OX,7OQP0!L`8E\N2#NP<)T-4DA`8,8@``+ZE\(.8E.W[&L5V(
M^@4G@`,^,`&K40`X``!/\`(9(.8`0`1@8!DQ@`)VH$-Y@`,+```N<`(T,!XH
M0`=/L%P1\#D00`8&$`)$0`3'B`,7P/\&2``!`'$%":`!R,@'6H`PB=`$C2P$
M%9$.7U`"`NM#)Z``)3`$1/#<,#`!K6@`]RD!$G`!);"])-``&QD"I_ZP%"`"
M%?`!!)`!M=P"#S`!TLR/O5P`,-!,'C`!""T",X#Y_D7J\W`#$L!RFE`&!F`"
M+``!<:($:7`P._`&3)`(;9`!,G`"=-#8M@`#.?``&<UV),`#Z6Z#::0$:,L$
M"K,$;FT"(Q`$UR\&,T$`/$Y0)H`"73!T^4XA3I``&T`#<=#0YP`%*@$(2G]_
M:EY_2EEK`&=R*RX%2X.#3@D_/SHE`7!Y>)%*:"<X`0`F+AU>5'U*2F(!"D`_
M+PD#*RP_.`#_7X-M5G%-?79P)B\-49*'6QH*0S005(-*<`4!S\?6UE:"@G]8
M`X--:`EFU=?EY4P+-!QAYN9R;.WQ\O/Q33!V?TX,NM=O03Q`Y/RQTL$&&3\#
M8/!8HR52$S9"%CPX$*.'"08\`*B9($0.!")DE*3)0>-$#R0]\&3HL>58&0T[
MFOSAPN-.)$E.$`AY`@!!BQT%_)B(L6/!MG9.`!!Q(.G,#APP?M#@(\+$``T;
M#*B8(,'`A`-S4$AHT+6%`0@O"GC8\(##!1@$(NR`($+"A`\!9&3(0Z.`!10=
M/N39(($/#0(=7BA@88`("R,_8LBY<O/8EQY!)BQX)6/)&Q@2V$@9_Q3`!XT+
M9R)E$7%#A)DH;1340()&TA0[?R5LR+`F#)-K2O2LH"'D!@DT4I:@P6&B@`$D
M*020HT>]NO4ITZW_"4-D11LGVB4]29`FRA<N5P(LH-)&A1!XQY:`@3%$B`X%
M"I+,8(.FI:0R2!S!`Q144/&;'W3L\,,1/MPAB1)\,)`?!VF$(9,82[C1`1)&
M6:,%`3<P@,0#OTG2Q!U':6>&'EI<D0<493C0QX,/ICB/$ER46-T8!83GHW52
MG"!(%C:,8<T3!-```PXAN?'"!G"HP!8*!QR00PAR@(##`!O`H(L8#9@01`DB
MB&!'"#"P(\D7)J2P1110C!``%-LH<08,)?]TD8$$)3S91Q1+1)'!"P'@,"4/
M1K!0Q`D"R?,$"#3$$<D2`8Q@@PXZF+!`!APT\($!&8@`P0P-B``"!%U)``(!
M&S1`0@8$A$``!QI44$(#%(C`:@6$&9`"`1:00``*;6E@``H65*!!DD7L4,("
M&K05@PY'Z""$!F0\<8T9#XR``0Q@-)`#!`M(0,,$OBW11P<FJ!#'$TI0$8$$
M"@A1Q`9N0/-%#!L0T$`%?A1`0@DPW"&%C4KTX<$*1/A@`P1C.,%&!BE(0,$&
M)7#@ADP_=FR=&@-`T?$3`Y1BA[;A37%''@8X(``85<20P@4B2\)$&"H<,$11
M3RPQ0`E`,)!"'TW_=`'&30.DL((>=URAA@L*Z)!#`2@_"*`.%'C!!!E,W/$!
M#19H<0PB(@@!&0YA",($'&)[/,@7`120P0!L5#')`PIXX,0`1`AAAA(2$($#
M?&X?XP4".A:N^!]3O&",$SW,<0P6*L@`QPY[*$$'#A38\<('V6P1P`8]O"`!
M`7C`H,$5#[JQ&195#%!$`79+$@8.&9AA`04KQ`""`%TT`<<*']!A@@=Y2%##
M#CU(L,`,)^2Q@@54*`%&#"QT!X:-UBCA10@MN"'($Q`H@+T.,"RP@0<4?/``
MK!VHX$`&'1"0P0,:-/!7`QK`2L)=!+B8I^['`:Z0H`$GF,">*L`!5-%O_P4-
M\(`&.C#!%+BO!`_PP/UT8X0AA$@"<IB"-;86@144P0@`L,(?JG`'#;S@`7&`
M@A/4X``<2``!8]!"!D9`!!!T81!,6$,-%F"&$[0`!#&@P!W,@``9G(`/9[C&
M$\`P`1S@8`>',4,5OM``XB'F,&P0X>+&^(T^]"%QX1'#`FI`@CIPS#I,N$*I
MU,`$!/P`!7`HT1+`=(`;*,``XAO$$K00@1[@QP)F"(`<QK`$)6C!`#&00`84
M8(0#+"!?W;N`#RA0!Y7]@0X&6$$&VJ`C1R*`!CI@``@H\"0`>.$.`ZB=VYP@
M!@M,(`LZBL`02C"$"P`!"2/8`18PM8,9C<T)3/]8PA0J0QTGY*$-9%Q<%8[P
M`4&480<2&(T=>F"`*$3!!G]X0!#:P(8##``\Q^!`$*3@!C;@(`6&D(0#>B"'
M"_1-""^H`0A:4@`A!&`B?+C#`W(PIA?8BPT%8(`>)#$&`Y1@`PB(@Q\4.@D<
MQ.`&$!B-//H)@1)=`0<]2($.BB`"!88R@H_@0`8J<,`6>&`"+]@4!PCPJ1)D
MP`.:ZH`(VI>`%E#``#0P@`4X\(`-0.`$((C`"RJ0P0Z@H`4W@`$"3#'4":``
M`B;80`%40``)I.``1^B;"C0Z-C@\``<Z(((9!C$%"&S`!P\0Q!+H0($1("$&
M0AA`B:0@@ABP80%(@(#_(*#@$QJLH0EX\$`05J"&<IRH`T(X@`UV0``E+,$/
M&<!!""X``AY00(S1+!P3"H`/MRGA`B=(0\=Z<8$]["`)(TB!&*;0@0,D00$0
M`*TUHN"`1!V@!&=0#^O^(`4'*.`'(<C",6KV!RA0RP1PR(<%%/``?N`$`D)(
MPA`L0(9!Z&$/&O`!`!:WA6ED1PDK2($9_`"'"]"2`7L8PAZXH`0YN"$+`<#"
M`21$`R`TH&KTB`,<N!?:\$1A!S:8`'WAX-4.U*`"2V!$"IS%AC48X$H#V$(D
MIA"!$B!``BN``0V*T#P`I($`S;&`"0)@AP64``<Y>,$,'L&GZ/[A"60HP`I:
M_Q`',J1!`6M($>52<(8!3(`'(0C`&E(0@RVA\1I6,,`+#NO=%^"`"$"(`0%>
M18$,*!`%7/'``U!`TPI8(`43.($'@D6!:'G`+I(D@`@J<#\*G"`"(="5"`P0
M`@L\0`40R``(+/"!%!`!!A1HP00XL&80&.`#]3O!K#PPK!``80@Z&,$$``S$
M.AC@!D;H00'*P`0L^($#);``&JH``!WT(`>=&`080E`"-X"!!@BPQA5:\`(L
MH*$/;UB`"R20!RY<(PII,,#R<%"""9C!"F;HL`0TF`)5Z[;`X9%"'@+IL26,
M@=/:64(8XM8!'S#@!D#@80;H6`XEE`&F&6A`<81@@?\^".`.6A!$&!Y0@PRX
M@0EH^$`,9H"`91I``><VH@3N\$9NY.%2"DC!`,30ABIH(0!56$,2#H!.MVE!
M"^!V`@]84"\[*$$*.^!!!5B`!"($H`<4*``.SH"!#,!V`T.H376D\&1L:R<*
M&I@""C@GPBT,((H!L`'!3)"#$<P@`RM``@]<P`$V#$,`-)"`3."0)`:L(`0J
M8'`*E"N)`*0`!6=P`AF$$$^<O.`$;?4`#%I``BQ(P@0M``#N1/#5'V"``:.<
MAQ1D$`-R?)H&1M!!""+0+P*D+P0>>'28)Y`"/'O``2%H``J(VH+YG4X"#D#!
M3E?`AYM:-0(GD$`%3`"!H9+_Q0"[<4`)'-`6V",P`XQ7X$LE\``)A``!64$!
M"X[P`SJT8PHXP$`+(MG8/VR!`BX801"0L#I)O"$'!'#"'180!!6H5A(A,($>
M4E""$L@``7L[P0NJ?PTI)$`"^RT!"A*@3/7)P`($.,$*O.%S'UD!`3_4?];A
M!@&0`!UP`S\@`6UW#54P`3&0`5&T!&5@`44P!#C0`&8```%@#-Q``$1`!"\`
M`58``"U``P'`#2]P!$*@<\<0`"N`;CQ@!DO0!%/P!`(P`&N``Z"&`CU''5K`
M!@2&$T&``U4P`C#@!!G``GT`-U"`!"%`4@O``V*``4LP`B30!T9P@@*XA<Z'
M`C?6_P8$L`(B$`"C<05`T`%:H`$RT`%*0P`(P"4]H`$?4`!>(&IOY&T2@`-8
MP`4$$`1LP(&#@`;G(@<4H%@X`$,UJ`>4%0`QT`$0P&16Q@%R00$..`!-L`1D
M<`!&,`(;<&W7P`1LL`,34`U3$`('\%I!<#JG$@(9X``M$$&GDP$&((<&<#HZ
M10%)]0$?8%44,"L/\"E[`GL6(`(S=3HBL`$.L!OMHWXSH`$P,`$3Y`$SE7D=
M0"JA4HAD,0$/$`./I@-)0`,W``;FL"\V-P5BX``RT`()T`5I(`/U$@$:!04+
M@`-T$`<E(`$?`&,],'OCIP$%\`(&\'$3$P,1P`7A$@,A(/\`9'<,46`'!(!@
M6&0`O-`&[$)I&E`"%?`=7'@C63``*M0QZ3"*;'`",8`&2[``)[`!=6`=3M`%
M`#`':M!PQ]`%%7``*(`&-0,%9W`%'+`@0$`$$<`&?0`%F/@`/.`!1C((4<`&
MR[<#*2`'@'AC=``TYM,T?P`'8S`'!7`&4.``CT&&/Z($<;`&W&8.3$`#+:`$
M,I`"(L`"`+`$>)`&2K`#&Q`$(A"%;D"%(^`!;&`$>T`/8/"6&QD>9T`#X"0)
MJ_$",."1'&`Z:```*Z`!1Q696"<">\0&/0`!@*@$#O`">U``,.`"!T`#&A``
MO_$&%[@`1&!+*U`#"J!9I,,'FD3_94U0`"E@`A^``@`P`#W07<YW`C00!`00
ME><``3S`!Y*P!25`!#;P`SU@`1ZP%2KP`+NB`K`2`KJW`'#Q`1*`9X\6>:VB
M`1+0`<@(`AQ@`#``*B%05`;``:`W`P3@`1/V`Q8PC"[&`2#`%HJV)PO0`J%B
M%RA@`&\V`"I`<BL`!&M@#GQ!`4K``@.@+4[@8C20<J(F"5>@6&E0*"(@"&;P
M`3:``S20`A0@!SE0`2F2B1,P"%@``3G0`A=`G(/`DRN``TAP/)*2AI'I5BL@
M`<8TF.V0!@L@2]HQ!2RP`XS!``QP`#U@!>CF`W^I'4XP!C(I"7Y0`C%P`7_0
M28S#$RTP_P0,@`.N:00E``!8X``'8`)V=PU0X`$'D`$+6`<9P`!`L"5PH@1,
M,``%0`"JE053``#\@B(^$@U!:`T;<`-SH`,]J0,?`'P*@`!)T`$*T`(G,$YZ
M20)WD`1:&`]@<`%IZJ/TP`040`-X=@U4$`<2\`(4,`!^@#$$L`!L2%02X'1.
M68+$P0$(```HL`%YT`+X\@4%$`-$L`/I10.XN@%J$@7A@CMRX`5F4`1OD")>
M4`(40`8(X`$[D`$(D`XT(`-M,*AOHP(HX)M_0`!"T`,CH`.2=@*=@@(-P`$<
MT`'GJ0&K)&DBD`$4,!8?L%-LP0$6$!B+=IX^U0&4%J`?((OK`_^=7=55/!`#
M2#"C.6`!O#<#)C!F%$`"'E`!8T$"7"4!%ML#0\`#^*0FV$`"*Z"%++`!TQ,`
M9X`W/#`#7;`-;_`Y5&`8;V`-8X`#&F`%;,`!/H``&#((5,`!--`'*M8J9@`'
M#1`#'"``9`4-4U`'??6A*8"!6?`&0BL"185FI.2IW:,%G:H=95,`#0`'%?`%
M<C`$:<`"*#`'2E``T-8&81`"1*`#&X"H4_H@==`'2?D'`(`!(6`&,G$%4#`%
M`X!*(Y`!:,`$4Z0,(Y`$1W``*M`&S/4@M<0"$N`$32`'(0!J&)`$'M`&6G`&
M=[`[(A`!NN`$D2`%!="P"^")U[`$5W#_!V6@'5>@`B,@`5>@`",P`B50!2DP
M`B*@!3W``+["!B4`.'?@!22P@.9P!D+*M>T`.#B@!U`@`>W`!0*'`GY0!^H'
M`GOP`"D@/R'``!)0!\E(`Z9A`AJ0!BD0`K(D!0MP``2`DQ?``WL["$_``VB8
M``:@67Q0,[XK`VN0`R=@`B#*`@P0!"F`2?%0!B6A(PV@`S7``CH0;YD7*V[5
M`0]P`K7H+RT0`1I00.R*`A10`9FW`1I``2'`9_>#`J'':#,P`+QW++6X+#,`
M`2KE`.DI`?Z9`A"@`D'@`R/P`2$0PC5@/QQ0`"ML`4)P!"5P`QV0'8/`!1L@
M`P'X!TGP!%L`_QE$<``^``+'L`8]L`!/$``5\`($T'9+T`(E8'4P8`)"(`0B
MV@5<<)M94`,RH`9KP,8<0,<48`(E,`!-:SLBL`(\L%BY\P=@@`+I"`$?$)EE
MP$S0^R/9];AKU006$`1Q@`'#!P=)H`<A@`(!<`0T\`J\)([M\`1V@`#^(0='
MP`PG&%PG<`-#$`.Y=@P/40(_P``4$`0U0#B2\(\?3`%<$*=&L`,@\`*@A@0B
M$`?JXRU'L`-K\!MNH`9XX`8$@`,S@`?Q()8#$`<P2@^2+`F18`4X`$V3['-0
M<(^C`73R,`5FL`+F1`9S`*8!<`<P$!$Z1BAD0)=2X`0G4`)9P$QZ,/\$;S`Q
M5)(#?(`%3"`21K``<!`$];FP-A`$!:`'0M```X`$`;`$3F`&/P`$0&`!X3PV
M"24`Z.0$+\``/8`!0N``:38`H2PW!B!I"Q`#`,`!*@`JPF@`+H``B;9H$``#
M%E``LT<6!*`"!6`*")!@%`2Q"P!V>R`#HG(Z(6";,#`')>`!#<`I)T""9WH#
M3";'K_4#)X"IW*,$9J``%L`Q37`!#'`&*?`"/&`#0C`'',,$!A`$<$`'/-`"
M*]`#*^`#)Q`'<=`#(K#1""`%5[`'*2`$?8(#!F`'.H``->,]":`#,R(%:)#/
M!3`&"%.J)U`$2_("?T,%?O`"-E`'`+`#.T#_!ZZ[D3[SD=5Q`R,@!@I``^/Z
M`P``!7RP!28PP0&0JY5"!TZE!3I06O&`N8?`!&?`2S]0!#5PKC@`!Y-[#$[@
M`#NP0@1P``;0!5@P!6Q`!'CD:2P0-`I0`"*T!&9P`TD`!#K``D,P!!D0!/'=
M`F/P!4[P!#*Q!00P`BV@-=:P!%^P`)*+;4`GLM:1!5_@K>G\!"(0`C<1!=9+
M#V4@`?S"!G2`)Q2@!WQ"PC/P`D"0`!8``B5``S40&H)@E&T0`C@@MC!`!`Q0
M`RAP`CL@!WT8!S'ZB#5`&(3(`VW#!C10$7EPM\=@!2&P`M\W"!TP`CS``)H2
MC/L*9BNLPL?R`&W6_P`@4`'#`GOPFC_1D@$K+`$<$.'00@#YMP"`\8NSV`$3
MT`(8^P$>P,%R7@'5M@'N$Z`JP`$.\"E>=0+4,@(W<``ZC@5?L`55$P$Q0`?;
MP`0;8((\8%&1KN.#X`:`G051:!1-X`<:$`,TL`*:D@<+80T`P`/\1R8=]P=-
M``!"$`<#@+5;P`4HL`(G<`=/M@1WD`$E<``Z8`$J]`9"X"!_(``E($KWZZ-F
M0#/6$0,B\`<J@%M)8`%_<`5KE<TL0`?$K0!L$)U9H`,L.`]:(`!ML`1[$`-#
M$,T1<-W7P`8Q(`E:0#I(@!]Z$`!]L@-'X+G^\0=G``!W\*OWCH9_$`4%</]<
M1-`!8#`%7S`%7/`$;R`"-1#@0$0&`T`'@VP=:,#H!?8%@IS.\E`'.E`U%'X=
M>L`#"N`'7'!P*0`&:L`#2$`'QI4$]O4!-\!T79P"8\``',"!3A`&@4-$52`'
M-+"0@U`%D@0%5C`!+C<%;\``AFEL'8_,UYT"1_!W=Q"9`^`^*2`1-&`&MYD\
MK**-Q,H!*5``(A`F%V``/!``%,"N)$##`W``!AB@$E``8!,`.]``!4!FMIIZ
M=K`#%E"+$#L'+@`#`0`V@>8!**`'*N`#=X0)'$@%<*`'SRH%&C`$#-?06T`#
M#U``0P#'06`"S`4&#-`!2V`!,2"DL*L`9"P%C7G_!CK2!.%U]+R[`FR]3$Q`
M+U]`.FU0`;Q[!9`O!`PP)P@S!6O``#^`!`2@`P70!+$.*%;0`$/P`./,A5?0
M-M3Q!D"`!D"@`2.%`'T0(:/<E@V0`AL``"-P!R*``MVNW#?B!'L0`5J@=J]!
M#W+0[@]R!0<0``8`6V4`"$U,`3TK7$I_?V11B$UB6(F14@A&0$,-8TQ,?Y!1
M`D<5408"4)&FIZB)2U8G!WFIL+&I80-.LK>XN;<+!*91)XBZB4QF)R49>`@E
M)@UL&C`M#S`N%'`$"G)E?RT@2Z9*;T(!=186.!EFD6<K*!4T(2D["BP*01Y2
MN'D*"ZE3)T0L6#`PH8&`_X0+(D!`B);A@X$9$#IH,+"!`@<-$TXTX)!AP@82
M$E10?.!!PP(4#3)L*-#"@`45!C-XV.!`@P4"*%%XL!#"P08"#3[X)&'P0H@;
M.DPH</`D%9D8*MJTB1-G`P,8#XP((=+C@K<_2@CL8&/%#X<8!2`E6I<A@(P4
M*8CL@-'`2I\8&=#LD!`&P88>"FBXH)&A#PX.7Z$,*%&"BI(R'VB@L)-J28P8
M$;HX4;%C!D$M?\1L*+%)F.G3N%`H:-'&1`\?*:2$4&"BR8$@*E[XL1`F0((H
M'[B@OA(@#YE@N,P<<$#%E`D223H`".`E49,"1%Z`$<;$PPX,1T244>*EC'<,
M,__*5$$=R0P,&A&:L+\E10^`K_/S"R-`PU23%0"PMX07!O30`AMX:$`$!6^L
M$<,*#E!P0`T_C`&`1#NTL(=C3`PPPAQK^%"!!@KL@$0*;`2``P%BW<%)'AB,
M,$0!MMP2AP(WU$#'>J<T$08)!]SP`PL\+%""!`B$0`!&'+@@0`@]:4#!1!2D
MD,<'&T``P@,A1$!`"0649,`)$\!0000T%)"!!`9D8``*#R@3`04AM+G`"20X
MX,($#VCPP`=Y;,!!`3&P``0.-[P!BP`*)%!:%`W<<(<5%F!PPPVDJ*%&&1*L
MT,4`/J"P@PTO[#`!%V;P8$$!XECAQ@0[U+""$$%4((#_#P@T]4<39A!@!!MP
MG%&"!34FHL0:0F#AAAQ>@)$`#3FPT9PI"VSPA!LK:)#%'UY\$`,B3K30@'[D
M?J$&?K(TH85\3T@QA7Q.:*%$%T/4H00CQB*"'&I;")!'%OO"0HP).Z2AJPPG
M"/0`&'D`,,44`4!`@!`2R)N+$EELD(0"0&CP!@M##'%`&/,Q(<8,0:1%+BQ-
M`#`'NBO'C$H'1P1@RAP]V#R?$@&48`,%9$!0@@L%^($"#!)\8,((-P3`P0Q"
M("'#!B:L0,8)-%R1"!<&F'"B!'2<D$)S2ER0`PX%Y[(`$C?`808**VQ@AGP]
M\I$"`S_\@$0)'S2@`@0B?!#!_PP/-#3!1"!H``$,/+DI^`>";U"X!`ZHX$`&
M*K!$P)H32$!2"QYED$$(%9#>@0H5M.!!!B!43L`$/`Q!@Q`Q"(>*$A+0H$TB
M7M"0@A)+&,`##S)8`=84`#`@`14?'/"`&6AT+<0.*<"P1P,OI/$-JR3_T0,%
MI27B!`0,N!'!:"^$($!33!"0PQX9X""!"<QL\<8))GB@?2(J@!#`#@V@&UA.
M@(!$D`$&Q9*9,)8@@#64@EQ82`%H8A$`/B10&&&8SK1P\885O$``?WB!&T0P
M!!8<H`-U*$`!ZI`(*S0`!Q]02RZXH*`CQ"@%`6*/$M30`@AM4(&)Z,(%U`#$
M(IH"`O\FH($<:J0$.93@!'6(PGRD```-O,`#<;C`!EZ0@`$\H`0@$$$(9+``
M/53`!35H@`.^\*4OG`(`1&"#%L*``QB`P0H(\$$=T8"+)X@%`"APXQ+8\(`7
MI,`,/#)%%0!P%"#\8`0XH(A01)(!$<QD`2'@0)LF\($.?.`$!@!!WPKB@0Y\
M"0(2R``J";`!"WC$)1)`90<RH($*R,`"'&#3!QZ``B6EP``/8(`1:C""#6PA
M%6/XP`J("!8[F(`"6JB"!'RP`Q1,JPE^X`$!FL`!UHPA#&4PPQHVP`((O($-
M+;#`%IP0#"EDH`1>((`QXC8'*BQA"KD+6PP:H`$A\"`')TC_0`MJ\(8,R$`;
MDU"F`Z;`AK-P('HKZ(`/!`"S<2;"#C;`AQ%U$04YK$&&^8%"P$YAAA7,0`VZ
M,HT3Q%`*)8P4%6,H0`TDH``0T``$$KC!"'9``CR<H@T<P,$%L/!25"Q!#S%@
M``)`RATN<(`&%7#C1O\0!3XP<ZHQ6X)C'+``,BA`?72+P@*"$%"FJC0"9`7`
M%U;0@P[@H0`^`"4,</```N@@#'7(0P96``&`)<(-..@)$GSP`A\,00>0%$$N
MJ+!%*4@!!5<%RQYZ4(,%C"$55."`#T9@0Q@H\R03X(`((!`#`DB#`"`XG`@*
M,"P"I*`!(.!G"`*P`@)08`,34"4(_P+:`A0X(`:'<TD)[,:!!H3@`6QZP$HT
MQH(2C*``+W4##S90FB<,@`@)",T*B."#`D0B+$&H`Q;4P(,(D$&`92B!!N:@
M`R"4H!XI>``<WF""&<!!"!M`PPD\R(`5/,`%&V@##$LSA0_4,0,%L,(+8!"^
M1-!A!&BX0AJR,($CX*`$.#"K$EJPAD28@`A2Q&HNOE"`,!05B`$@`@KJ`#-A
MG`$/*97%$AZ@@Q),$`PP4,`1#N#`4RBX!P/0:"RB8(=$LD<,'5!`!6*\T26$
M6,3DDH)!E#`'&"CA"36)P0*^`*\`[-4"=9C"?!;9J0D(H`(S*$$>$&`!OL6/
M!R:PP0/BL?^#%7R`#0;8YP=@``<ED$$"/V"`$`K0X,K(`0<LX$,6I-"".,#L
M"6R@@`E08`:B^G@`$AA"$HX0F,Y1@`"[Y(!%8(*"#!BD<`3H``H,\`$+-``%
M!K$`G0P0@@]HR2(>($`+0*U**7V``\A-2=]*0(_IZ6&D34B`#P)`MRN`(`9M
M@((#;-"#%W0X$6"`4AN0J`$:X,!W`@@#'>AJ`!L$0`P#^,`.HD:$?:Y!`1+P
MPQO*\`4'M*`'"Q"`&V@P+E,XX0([:$(9[/"@`%QA$TZ@PPHFX($2D*`'!^`,
M`;9U"B;HX05,D((#@E`"(4-9%E<`P!U^.-4NY%D"=;A@+J)`ACS_;"<7`K2.
M'X+`@AO$(``>?T(<)*!FDH,E"@W"PP-/PP0R>"`&#[#=1I50!:U]?&5<&(W6
MNL"`="3B"2E`@@780#<H>(`!+?"#F.=#A18@@0-R`"R^W6``BA&J!P90PQU>
M4`*SIP`,,=B`?)0P`!Q\F.(ROFX!T!"$%5R`YQ`(0XOY?H`7%,#IIYC"!A1@
M!`Q@0`,S*0"P35V`';@$!@L0@4$\4``:=*#-"_!`!'IYZ`DTP`0&(,HSYA`#
M$DQ@X1F(0`9:P%H0%.``/W!-#U3^AR=8``F0!^P,J#J!`^1@!T+^P@Y4,(8,
M^,`-?[A""/S>`R(H``T/4(#Q(C&%%<C`_UA'N`/PKO"&``C`!$"`@`-*GX,M
M!Z,"2)!#\X?W`B/$P`"]HE0;D`)>4`!!(#P#``MY@`0```4J@`-A(`$>]W2Q
MH`<(,'X?=PWZ,Q^VX%+SD08X,`(_@`)W`#-F\`,:<`I+``<+T`<G=@MA\``'
MH`$ON#)*``87\'(4R!Y-<`<XT`$A-D@Y0`J1<`4+T`(Q<`%A(!]5L`<:L")B
M\&2G805Y(`%:=CTP8`)SX$79P@$;X`()D`$[0`5B``8TP`%M``84,#P9H'2I
M4`534`4H\`,2``=/P`1IX%H]\`-$4`*656A1$`</$`,A8`=6$#!8,``SD`0_
M<`0C`%PMT`$4D/\!%2!J$I`E$D`!#2`!%2!Z))`""Y`"%,!JR/4`(K`!;:)*
MF2@3%N`";\(!G/0F"J`#*W`#!C!VIK`$=2`#$G!,?S`(.%``3Q`&;,4#%)`8
M:Z,'4&`#(K!!2C`&!J`#5+`%`-`#<Z`%7W&#9_@%B2,#.*`"=I`%3>`&)K`!
M`4`8Y\,"/R`$(4`H,Q``,=`"8K`$7<`'$A`$)I`!%M`&:?0%[[0!,0`'MX,%
M,%`"9@`'/?``61`&(3"!.Y@*6U`'3(951L@W:%!H',4&9#!T*D4'&P`$(T`#
M;.`$3*`%$]`#27`"D1`%:8``>&!DPO`$<+`!$`)X6&4%;V!6#YD+3.#_`$(P
M`!QI<8<!`*6Q!%=P!R%06V;@#5.`!AQ@`AP0`,2'"TI`!79@A0\P`,KP$P#@
M6H("`T!``Q*``RE@`C$P!-SE`Q;@D-^E!AO@+>\H`B\@`@#0!$XP!A?0`&HP
M`RS0`A%@8J?@!&I@`"Z@`0C@BZ9@!7<P`PQP!$?``BFP`1(`:KG5`0V`6Q^0
M`9O8.1ZP`#!@`!Q@:VXB.F-"`3/!21`@6AEA`9YD$$8@.PR0!S$W#`&0`QV@
M45@P5GM@<280!#M`A+N2`32`!ZAR@&>0C0HG`@D``S#P`D60`A?P!4P``#)@
M`"%"``!P`CN0`STP`PV0`AZ0`#&P9$R`!7J0_P(X4&H&0`<'8`-ZP`9M\`5B
M4`9B*`9MX`!$X`!P40,;<%FH``<G@`)I\#\+4`K$B`<UN(-*P`0N]00)NC)+
M<`8B0`,6@'VGH000$P!@,)6I(`5T8P470`,,,`(>T`"UJ#Q2-09SL`=6T&*X
ML`1J0`+`!08/FA],X`U+X*([B0LAD`->\%).L)PCL`#%,B`00`,\H#-_H`5S
M,`/[P*&XD`4%\`(*$`!D0`!!``-D$``?$`0;X`$F(`,MH`-&0`(M<`!R,)NG
M@``'4``!L`$'8`%/4`4#8!4TLBLM8`)ML`=&,`(K@(&^T`<9(`0RX)^YN`4.
ML`..>00WL!(XL``6X/^='^"9&8``*1`!(X$"$+`!*(``MY0`DVEK']`"`.`"
M(E`37`(!'U`"1T`#![`#D64*%,``>%`:3D`#-0`:$+`#/%`";1`)6K`"''`%
M(M`#,7``*\`#*>!&$-`#>D4#:``&`Y`"-H<#@0$`',`#OPH6;@`!"P8`[2<$
M<:""+/$'=K$",#`&4W`%8G`&=B4!.;`"*H`!+&!]!<"69B`$#>`$,NA3B1`&
M2'``,4`9.QH+2@``.?1T6M!V$B`@6+`'2J@+:-`%O@``16!Y0P`"9H`<7*"3
MN2`%*7``$$"Q'X<`$U2PIG$'P@J3IW`O=;!7)""5QH(%`+`!,M`!9)`(4F#_
M!R@@`R+@!Q.I"U3`!A(@`QXP!PD0F1'`!@X0`A*0`C$03@/X!2=V!1GP`B7X
M!TY@'B\@`0"@!2_[`AJ@7F*P!CC0``BI`Y)S!JC@!%Y@HNWHAG^@58O)64<P
M!#`0`B(06IMC2C-@$)33$1*PM[_T:R6!6J:V:[FT.17P`41@!"\P`BW`EF+0
M`BW@BTU$`Q-`!8_%G1)@:4O`!SM0#2D0`EE@!0&@`3%0`R60`B7PIC`P?A@:
M!SO``6%0!6U`!'UP"B![=[P06`F@%D[0*05%=S%``T2P`1&P!]X1`2_``6[`
M`400!`H``=Z@!60@!EH@!4O@`37`!CBV`389@06X_P(G(%4H&YAH0`<8.54#
M0@`Q(`)L>QI+D`4"$`!J4(-V(+?F2@`N8`>"\`6&RAYFD`'_MP4ZJD!4T`<%
M\`4)G+ZH0`?Y^<"G(*7OE8"1`*,-4'B[&T2>V@-RT+ZY0(\7L`(X$`!X(`)(
MH`%:,`9(L`%W$`04P):F4`,@P+)80`<Y!@!*0+/LZP$'0`990`,;@`5\L(XP
M@)BF``5$*P0?X',1NG&+R@"YMP(#@!.7TP`M$`(+T`,.$`$:\0$3T`(2,``O
MT`&@=0)(=`)Y4`,B4XL(P)'`*@0/H%%\)P1^\`=9H``XP&/(00`,4`=7<``&
M($!+``8@8`/K80`^P%1XH/\`?'`&*2`V/%#'_WH`'M`'/"")/3`"KL$!:S`"
M&=`%1?`!4\`$9U``/"`$*-!*Y(4`3!`#/%<"71`,5'`&=?`&`\``.C``#:`#
MH7`*#(D/49``.V"A$.QO%&Q$8=``(T`LJ($Q?C``-HD*$RL+58``>@"HIB$&
M,-`5W#Q5;K``(YG,N=`%'"`$;K#,+?L$:+!%;I6-4Y``)O"9)J8$4&`&:=8!
M2SD?4:`'6=@!`O``)HP`\+@&":P$>[`<(JRU97`#&3`>8)`"&D`%?+`"PH@`
M0R`$&J`#1U`"$R`&`=,$5D``+[`!"5#-^`P`U.J81O`!,]`!$Q!;2B)/!;`!
MJ37_FI+HBB$@.;&D)!-``T!P`#T0!%2+"E0``4&P!U_!!<+IP`:P`SL0`_F[
M%H9D!6HP!THE0T[@`#60!Q8@`3`0`T)P`@NP3D=Z!P10!`,P`(,Q/*I#`U?,
M`WZ0HU0``$B8`0\0`'9``W,@0%79`C-@!69``38``3P@`3M``$$+`#3@`5Z0
M9`00!IM0!7:0AF+0D)%P`2?`LN;\!7[@5Q^W!%C``2M0`=UC&DIP!;B8"FC`
MOZ9`!5G`SBW+!I%!`%50H_FA!&X``'P@4N:,"U)0`B_0VJA!#!I@`A+@K[2)
M`C_CBTO0!E:(`M4Q'TW@D3'0`1.&!3C`!K>@!"M0,VIJ_PIFP`(Z\`*B0@)7
M,``[X%T&<+>FI`$\D`08L"+AK,<34`):)H6JL`<A8+=)`0(5H+QTTK06T!`0
M\$L&P6H4``*D8P(/T`$\P`)"H``Y(`:P\`$^L+&)L`4O8`+KL:M"4`(8G@AU
M$%%=H`$R0-8TX(=6(`4GB0`2\`)F,``>,#LQ4)9!<`>YLZU5P`>J^Z5QL`<\
MH`>!"=)_(`5KD`,(L$&AV]Y0FP(8$!U%$K1LP`.%'#_[<W5E@`9P$(%2$`=]
MH`9F4`,='-R1``5V,`!VT-!%I`1]``,\,`!!FPN$K:;7?`I0\`9UG@M3X!T9
M<+(B)@5L(`!'C>:QL`078`-_'?\S2B`%=#`#*2`"+*0*5%#">[(MLTO<^D/;
M+:ODDUP!RGT'XYT(:4`$.-`"+O`!O]TCUO<#;U`%<X`'<%`",*`%::!C*?!D
M3X`'/7JWM87,D=`$7=!FF3.!2R`%!;`T1_`#0'`")V`!J[.)F[,!_%1)$G`X
MJ=8""R`!26!S2C;>;(!T=@P!/C```F<".)"0=%,%_`$``P!<[@)(,6"L*P`"
MBU$!3$1%56H%3F``*U#-7W"VO6(!._`!`,`CQ*@";``#*Z#?/M`#7.P'QF``
M.```:N#P+4`#/XH*5D"39;'8_&T*8#"Y32`%8L`&),H&;.#ET\*@R>P$7S``
M9$&!`S+_/Q8@M\SQW5LP`!P>"7F>"%G@!VM0R[<0!:*M"@$`-PLP!;I-+F=@
M](@>"TTP`#T``484NB>PR>B;Y-\I`Q,08E&0!RW0M0-,=`/0`CR@%2#`W$N,
M!!A`!''3NBT@`.T$Q)SU!DV@!&9P\$K0!A/>L*E0%3ZP:97EV5O0`56S!L:=
MY!<``SK0B*NA$:_5.9O:`2)P`O_U`'3R^#=`&T0P`"XJ?2!@JP;P/G\P\$$P
MY\@A`D*`!WHQ`:;`!*77`5H3`[5Q"G2`!&:0!A[``>C-;(GP!3(<`&4=`CV`
M!/QYOS2@`6`06$TP!0.``NMN`F3L!S2P97`!`S*@DU2P`BG0__,\,`$O2`>Y
MGPAWP`+HW@7AI!9AP`9W`'DH>Y1KT&<V+P`NL`)Y;$!'``@G4G^$A8:$5&=*
MAFA=A$IO`W10AY6$%CV.A%D9-!QNEJ&BHX5294^DJ:JKJUHM/56+K+-_3@D[
M)0!8A4I8#0<?<DZ$4`$[+7Q9M+Q.#3@*+$4%8(M+"$`"61H]-`PR#R4[!@4\
M2#U[72\\)@=H4`9'266RH4QF-C0823`#595+8TH0F8!GR2$E[WJ,.')$R(`8
M*!)L:)"!``<8`4ID6/`"0X\@.ZY8FF)`!RA"6TJ8N/(DP@$:+ZP4^A(DPY,M
M%%:@:5*H&0X_(F3`$'*`@ADG4`CT2/\3(D@`#C8$TJ#0H<@6#D3\*;E2`0>,
M%#/4^!E2AYZ2*",L0/FR00*"("!T##!XB`F"`PBJ/,#QA9`42I7@C*A3R`L-
M%FQ"*6%"5\R``'V^C-E"Y0F]9;.6M+D`!K-G)5MJT%B`)0<&#$-.IF+2I\X3
M/&.:J'%`ABZI*2M.MV!2A\,!!TP\TUIB9X$7X<B%I[&AX7+R44O6;(CA05FI
M"2Y6&$#U)\J`%#$XC!$N9<$&!D:$<,"S@(4-+H2\/##!X(")%!]4X#B"0LL?
M)6`0\`43*1SA0QNK+('&##NP@($)!E!AR1@9K+""'#P=$H4#,P#!P@]%;/`!
M!3`8`$(&#FS_0`$'#!Q1PP@M9'C(%"[$,`@A=10A@A-3:,"#$!ML40@:.T#@
M1@@KU%#$"RT,(`46$M@0P`H2M&&`!CL<D$,*.<1@1@HGG(%2`S"L\,$#95#P
M0E^&M'&``%M1P(,?PQ`R10,T#"####Q@<,,).,AA21,.[-"/#"9$00@3"\QE
MB!(%"`%`(78@069BJBAA11AUF&&'''OH<=0CSXW21!C.E3H*$PF4<,!IIQ&!
MQBI8W#$`!`-(<F,J5Y@`ZP\QT."!D*JFX@08P16KK"5+Q('$'K8M&\H25'2@
M@`9O`/;'$FELH(`!9/#4"P4C>*#&KL-AX=L!21RQP`4*E,"&A$VX_Y&"`CS$
M,(,!73S`0`9U3+$$&3=@4(*,E9S5A1AD?.%&%T]$`0`2K^H`L**'R&8#$7ET
M$>U_5V0`Q`U'#/'"&BYP8!X%)#`P1`M'%)`J@"]04*<2!BC`AA)<P'2``:44
M,`099`0A@A1=M"!$"S0(<:T:0AA`5YP,E%'%$B9D$.T2:B@`@!AF4+!#`ELL
MHD07-&1`Q@H'["!#$$$8UX4).0B`!`)GP!##!S18=T@5*M`0A1H'3##U!`8@
MD.P?4#300Q^$+$&``F9`D<+.J:ZB!%U.!)#K+HQ3`<7'SZ$1P!6+2VM(%+#"
MRL(=I(?B1`$#I$Y*%2.TC@$0(JENR$T%I/_A^_!_8$$"#AOLL/?7L?L>100M
MK&`!=YM08$()`V0H!00PO&``NK10`8$+2.B0@P<%;)#R&(N,80`*V"OZ?`HJ
M&<%"`:-<(8$,$GC@/PGP(\$7E+"&%.Q@"$>@@0%D4HDO9.`%\AJ)`4R0A"3\
MH`<:R,`$3'#!&!Q`>)5@PAQZ`(%2B"`%"!K`1V(0AT(\008QL$(!=A``0UC!
M`#A8@#]T,`&$*:$!2!C#4TKP@@_8018(<`@.X=<#(9A``G2H``\ND(<>.*!X
M$SA!$`ZP@0U,P`$TP$,?:J`"$V@@%'W``0FR0($>U!!'=$"!#@NAA?N`C@HE
M<$%?V``#+J0!!7/_*-5BZ'(&.?C!D'%H0QFFD#E:@*$/XR'>?S:@N].P8`&D
M:,("]&"(/O"AD86@PZMT%S-0/B<+`)@#&_PA26EAH04E*`,8A&#)(=R`"%XL
M@!_"0`7;*<L*`^`;;3*T!"Z8QP1X"\X6`A""'!@`#-2C118"<((A*$`(&G!`
MA3SP!BHHX0P):`$RW;"$+.QA"#H`0)TJ\00`T(`$:P``'Q:P`-HAP`,Q,$`4
MGG`'#@"!"#'8@0?"$,U:6,D%&PA`)`NQA"WP`09#\)`/@I`$(?"@!+.J!!4J
MD(,]<(<+].M"%"X@!"*D0`V/`,,+2"`&)I1`//1X1PP"T``0I(`&)@C`_QF6
M@`4+K(`-&DC!`E+``QSL0`)[,$`,^/`!+SG!#>DK@@Q.(($U5(`&='H$%P`P
MA`"0X0TI<,``:I"\"##0$)V+P03D4X(]/"(`!$#`%Z90B#J8X`-T_<,74@`"
M(65A!A%@@A4BD((-\*%LQ>)1%KK`A2^\X0YZ*,L?GE"%RBQC"<%I0AG&H"UE
MF0$(E;3D`A#F0C2$P`5F,`088+`!/Y#V$6P`;6B!$(9E*4$*9Q```,B0!5.V
MTC,7V(',"K&`(806`S\P`@Q:*04'E(`&#UCG'\KP@!7D@).$T$(%2F"#"11T
M%EDP@`M8<`,3D"!]-9!`)+5`@13@X`(9L$!>0_\Q@1ULP0PQ:,$$0N4`"9!0
M"AMH`6"@```-L.`(.+!B9Q>%!P[<IX65X`)VC&N@"80"#$'0@(P`P(`"\,:]
M`[G1$B[@QC><H`02R$`)2O`&KE&)#S@@`!X:D((B*.\%/LA`'XA``%9RX0%<
M(L`"RK`"#["RKB,X0Q.HL`$9M,$V75!!"Q)``V^Y*'IB"`4*8I"&.O3@`QG2
M0@=((`'5*($#.,A#(>ZRAD6P800$>)0=2.""$F"WE5HP`QZH\8<IL,$,7/"E
M8K:`!@$(`(2);8,&Z%/)(TA`0H9```Y*0(=0S*$%-*Q$`XX06AW$``1^*]48
MUA"`-QSYM\L:``T*$*W_)M`A=\=M`:K'L``)C*8-&6+"%R``I@)P81%G0,`'
M7`"!-`AZ-5U`0`L8H``<B(``(B@!`>Q@A26<P0$R^$$$$!N*%"3@#Q*@P!:V
MX(:'86%*!9B"">1`CRH`(`,'^`$-<%"!+TBW%G!H[P;F0*Q",($+=Z`='"Q!
MP!<0@(%/>``-`+`$.-0`!T$H`&"N0``:Z&$/-1-`4$*``AB<(#P/(4!CYH""
M&A0@`%G@00,Z*X4"Z(`+9@C`"U#@AUALRPPT($!&2I"D'*!`#V!X0PE4H-0(
M#``'UPN+)<Z`@@TXA@8-\+$#3D`!9!&""QV@-"&BD($8"&H)$+#!`K[;A#00
M_R`%$AB`%YJG+,P2H@EBJ(,=_$"'.."A#EO`PK'_8X4RL$%46X"";V?QA"\D
M8`(X:-=ICK`!12WA#1PH`02T`$HL7``_=D#%%$[P@U\E(><)@(,WGT.MO$HA
M#/-%M;0R("9+0"$WE?P!2E7_!S=(8&]RL(T2``!+#[2^]AM8`;:^RPH\J*`'
M0-#!!PHP@1BD``&#L`,.:."""2ST$"M0QL)Y_@$4C`#J'MC`$AH``5]6`0$V
M(&\05G"'F:E:!@WXO;%F&$B_J%@-2K@`$79``]6,P00KP`0.<`!X4`A60``Q
MT`!D0`55D`23<@@9@`-6(`<($`,2L`":\`<$(`1L@/\))1`#/<!%\4<`1!``
M"Z``-80&#[0#%Z5`%.`#7?`&^?4"'1`*QF`!3O``.5!I_Q$&#]`"(B`C7+`"
M)9!76.`"+9!E4,`W&34*`V`A%-`&@Z<Z9S$&;7!(K"0&:1`&&',(3Y`&`[`'
M9L!VR+$$7T`!!X!`%%`&MN8!>^>%>Q$":L`!R`4$/D``_K$L4'`'<X!HM/>'
M+D0"2:`[1"``8T"&TK($6E``IP4!8D!,9#!!:?=K2N`%"%!G`S!`F/%O!>`"
M!Z``._``$<`!-6``*>(%9D``+[`!=)"'A7`F3+`!G)8$&Y`"+&`$"F`$(*`$
M(L!JH7`%`8`#-[!B1>``\W#_"%!@!OC$`:MD2EL0`B9PC$Q@!R^0`5.`!2)`
M,12@"4L``#Q@`%?0!C@0`-'B!2J0`690``7``2NP`6Q0-F40`A(@!R9P`H2%
M`R^P`QP@`!D``P)0`B%P!DY0!@6@10C%`7$``K$D"TS@!A'``&;P!0C0`W?0
M`2\``S0@`*\5!<V'`%[0`DY'#`EP`AS`!Z#S!PA0`PZ@*$UP!PJD*'"0-:$V
M"DZ0!I*X!EJ`B)(D"U;`!64`.E[0!W!P!EM@!5,`!5;06[4@!E@@>,K2"P40
M!#U@`-S&"F<``3LP`@]@!E$PA:JP!%.@!?#Q!TW0!5+@E8`X/'A@!*Y#`3CE
M`&/Y_X=RL`+400:'8``^(`-460AXD`,[4'7"P01L8`)"``0,,`%KX'T*<$=*
M80()X#<`$`0#(`;[H0\]<&4I``;X50:DT`$[\`<6H`,[@`,9``>^Y`0$@`,M
M@`"05@EJ0`,AL$X#0`2C!08AH``]H#7$L``[X`=F8`$1.!IFL`AAD$>J=@(&
ME`$1N"\T<`)T4&02L@0+L`)[0@,2``8FP`$(LP0?L`)D"05```&IYP5!!0`A
MD`))P`)[$P.$40E:@!5:0`8X``(9`@7!E0+D^`@1T`/?1@B1P@>$$`=!\`!H
MR5`+8`,I\`#REY:6\&]FL`<(```!<`=FT`:_U@1[L`9O0/]\PG%#+R`>R$$%
M'H`#%-":PK$$59`&:)`'"9!:#/JBE7`%)<!I&Z`$3T`&#4`E:Z"4JF=M`_`"
M)^``8L`YN_8"$@``68!98?`=*3``8:"3#2H&";`"0H`$0G`"-."*?R`%>-`!
M*Y`!?F`%2D`&*U8`"-``&B`!(=```A``%L`#["8*;J`"1,`#,,`!9\`&SM<"
M/+``G:$A:/``,2`"`7!63!`!&6D02J`%,``#:=`$?,`#\]8&R?*1)P`'!&`#
M%]"!.[`#0I`"QW,!$T!I2M`+<F`!.]``>)`&6]`#:Y`Z5O``!R`%;U``,9`!
MS<@X!7`R8!0#)8`#1.`!>^`&<V#_`Q;P`25@!A$`),*7>H]`C1TP!1T@)=4@
M!AD@`Q506X0`5B'@']]4`AL`"E/P`2^`(,)1=MBV`0B0DS`J"DOP!%.0E$H9
M!6Q`!W6P!$X@H68`!EIP;ZF@!&F@<!/`)LEAA@:0`P]@KH3'!75`!P$0!V"0
M!5$`I>V*:DU``$G&4#VUB@O0A:H'!0,`2P00ETI`!0YPD0:05U`P!RX``QZ0
M99AAHR'+`,G'`7V0.DM@!22P`BBP!E+0!!#0CAE``@U@$<BJ`6=E"6AS`ESP
M`RB`!0,@!!'P!!Z@`,$B`3!K"`WEI1N0`$T@!1-0!'$@"W4``RH`,1,`$BO0
MF@ZG`=6"_P-P4`WD>50.L*1"(`:7X00[<$9U0*8:,`<80[4[T`<5D@(KL`,Y
M$`)\X`9HUH%"8`9/$``M@`-"@#PED#XRT`4.8`/347[_(&EK,`424`)V4`AJ
M$!04X(IP0)J`\08KP`'^<04S,`-V^1RW9:LA0``S6;'0<05A$!P;T@$:H`$@
M8`#O^(:%0`4M<`)#^I1<<`(HH`I.H`6@DP4"\`9C@+R\^Z+.2@QX(#)F!8@&
M>P,MH*V$\`1V8`$W0)^$X`1?,#DOT`4%BE9I8`$*H`#F\$:&,`5FL`(C``%-
MP`1=('=V$`=H``8>:PEWH`!K\`1,Y@0?<`!M<`4M^P5HH`,;(/\$.1"7AB`%
M<:`".G``*W!D91`UE(4"/,``%=":"S`"M:,F)LHX)M!C:T``(5*[C*,16W``
M1:``)@`!(2`$$!`&=78&02`!6"`%:E"U)H`"-&`!9>"KK:E9'%`$9&`%'0`#
M3E!&2H/#AM`$#Q`$<A`&:3,(3N``DM,#"-"%"*`#:)`L9H`$#L`39U`X"_8<
MFA0".A`"2;N]JL`$4*`%9?`&"/``(M`!>+,MHL`$6O!:JK($O9,P=%$'!2``
M6NK'F#P+4D"N,U``??Q;2G"R,4``UR=F5>8`=1(%">!\$9"!R]`$#>`J2;`#
MN%H)6R`!B0L`'&H)3B`V;S0%.]#$4$#_!SD@`E$``3P@`%>0`SWP`A_*P860
M!BEP9!80!$<4`(09-P9H`2]@!FSP`1+``RWP`.W9!CP``A,95#&@``R0`AZ@
M%!Z``#S@`*6:`/0C`A5B`'K0`Q%P"%*`0?C6`PL0+6CP`AXP`2W0`C\P!#/P
M`F=K"5Y0`BE`!0$0-4K@;A&X!',@`#T1`B^0M1S``RZZ`$&P!D^)!S/@(E*P
M!`:P`S!0`9&<R;2`%$I0!VN``'D@)F?P!;S4!/,[TU=P!IV"!GT0*GMP'#*=
MU,(!!7"0`D``'(#(!&40FHUG"%!@!RC```90)Z<B`AA\:C/M!E[-;"^`*890
M!7C@OPV\&A=Y_U98\`,&`+0,D'LQ$`-!/00>9@`WD`$*T`*7O`4B0`E*@`0I
M<(@#$`3KO'9;UP,F(`4&<``!L`9.,Q3(DP1MT`$'H`@HZ@<KT`,/L`!N$``'
M(%F1XP8M0`*$P`<*\$F&L`!$8`9K@$XE``-/K2@!,`1Z(`&..@`\Q,""A@<'
M``%+H`%!,)8)8`0F4`.,40A=D)LWP@0'(`$BL01)@M2"A`<*L'BM69,$``0;
M$--*/0N`/`Q1$`9L$``(8*8+``!^4`;)P@1.X,B\T`1.D"Q1$`<7YP].<-YO
M4)15\!<_'=X"7@A5D`%DE0?:*RU/P!'CG'IAX`&K>`&`\00.X*L.`/_>FEP!
M,8`$0R`]`_<HY!D#^U8/^TP!AT`%$F`%=98%<L`#J>L!/H`'3&8"9%`%#T<#
M-&!]A#`&''#5.V`X5'`"!\`#'T`/`!`U44"$O4,<$E`##9``4B`!.[!@7(`$
M$LX&(A`#8U<(6?`59O`5)Q`"&X!B?@`&T0,')_`"9Q`%!,`T0F"D)C!&'+`%
M%B#B-G!G7VP!-,`&82#B\$$%<6,$/)<L2Z!"5^2?WV@08R0")YD<8R`!L(9<
M@E()0"L#$#;@I;($2,FN4=`&<9`M_Z&99C#JHU[`$+L(3W`&5B#?F-[JG@$0
M"P`#.P``/OV'4@``_D4`3DD(73!4-(``M6[_!=(QE5WI&<(>`D-`!$)@+K8C
M!A$0#G@@79`B!`5P;U-@`VIT;G%#!010`]UD`C*`!6YP`,:<!T<0`PB;!6/@
M`0L,'&$P`T[C`"+6`$[Q!QIP`N!M!3[`!U80![[A`91'"&Z@5F3``QM`N310
M`P,P!6XP`RH@!_H8!@+0`3R``EDL?'``FT=6!0*``RIPQ1_``5'0`N"Q`EY<
M".H"MV#``R1`5U#`!QA0`$!`/\'!TCG08MMRY`G`!$K0!CTP/:2G!2C0>:V#
M`J`$!7?LZDJ_]$RO&&&P`3G``9/^AUKP`$CP`7P@75^@`37``6\@"U.0FB&@
M!PD\"U1@`<^@`RM0_P#R>PAJP%TA``<#"?4+2@A6<$GOR0-EL#8MH`1H,)5*
M,`=#D`"+,`7CDP(NT`,I\`,*,`AY0`-!8`.EBQ*Z[04`0``24`0A,``2P@1'
M/@$+$"(`F`-%<`(&\``]<`$/4`2)H00/\0)"$`,K``%4QH.+`@$WP$`%4`-F
M30AL4"04\`$F4#(;4`,4T+VUAP.QB9>5E@43</D8@``W``,HL`1B,%7$,@4H
MD`-U@JH*>Z(-T">5A`0!WO3F?_ZNO@1FP`$I``-LP.K#TP45<`(K,`#%OBUO
M0`%UA@>5"@@$*2L(4DI_B(F*BXMA!"5#!S$>7DN*36U&/"HI"@Z6C%,H4/\F
M+F-L/`]5`#<1EF09*R=D37]<$!([,2%P2P8X.#9?B$IG-AM8%#@$&3L,,246
M'D5K'31Q?U)Z(CDY*!)L$2]TBE(`/`Y130P93H>(2Q-%6@$I(AXE*7A/3`,,
M%R%,S/'`H@6-!TX8_0&``\*3$"O\_&$"XL@<`Q@0W.A01LPN+(BN[%!QY<^3
M?&@4JESY!\H1##!C8F`QAJ7-FSASZMS)LZ?/GT"#"AU*E)$2/SUR#'#SKFA.
M,BF(3$A3BYB>`S4N=$ETAH80`F2"@IEQX(`.%'ZH*)IQY5"#`J`63<$1Q,"?
M+SKR,/DSI<(($&^>(`H@:<`62V,T]/"P0<$.#DW_"2_`$F,%*"H%A)1XX(#)
MBA2,Q-QH\\3-B0YJFE:18.++AQ@ID!QP4&9)E0\OW+C8D:8#D0P3B.Q8(<1-
MD`Q-)B"AL$.-PB8.D,1)4^+$%"5?<!#!$,#!D0`/IB`8D0<1DS4'"B!Z@^-#
MW*$47LH\,L"I_?OX\^O?S[\_2R5W:+!""V9`T91_?RA1!@4IP%`(*$KLD8$+
M(=0AV%T6F)`"'57\M(0:!)@PQ`@U4(#%7C!X@4@%<"E4QA$D"':%!RZT$``4
M2U#A``HF3)`%$TM(^(($:!@(@`Y(!%'`.U&\ML<?(7``4B+%$-$&&`"4$,,"
M5EBBA!HQ0##'"B'(@,,*_R[,<04>,7R`0`T5D+'`!T$H`%L,(+"!PP-J_8'%
M`BB<`$`<5O30@!8OS+`""FDH!,8&)8BA)P$&IA$#"]OML0`06#R100QP'"*%
M`2\(\$<3<^RPP%Y.1;&!3!@04!6"M-9JZZVXYFI3``J8(,`6!])JAPT[1"#&
M@?ZDL$9;B-2Q@Q`('`N4'"LH`(0.%IBQ`A>(3-`B(U>P<$,&;$2!B!PTT'"!
M%X=XL0&V;23$1!YV-B!$#0R(D<@7,ZB@!1Q^/$`$`674\@0`(PQ`P`$;"/&"
M$$@88,8`0P"0F1Y_9%$"#RX@H<`("0!P@$2)4$&!`ELXX00.!AS(A!](S,''
M`O\:``&$!3L0\%XB9AP`PA($**"B%&%,H,`/VP4@`!5@R``:(EG`$,,A4(B@
MP(7V!8"##C$1H>O78(<M]M@\/2&'"#%D8(8[MBYAQB,GL&&@>0&(@$,&:0B&
MG04OE("'(3XM4<<$,>B@P!$/7+$$BSO[F4,"4A000@T$=,$$$W)08,()@2F1
MQ0(;F`#!%4Q000,#/)P@A7F37@'1!!+P`!L,#1CTA@LGJ&A%`!_@8((''I21
M`0QN**(%`3CH,0441A0`.")2J+""%A6D$`,.*,QAR!,/Y'!!V@8P<$,(0<S1
M>!,$\"!'%2^T0,823CQ`P,DL!($!%U,$L,,$M2@1``__!*""$L:P`PE,R2E/
M:(`-`J"$%F!``6$AFP0G2,$*(D@*9IB`"S[`!RO<B@EE6(`)0E"`,R0B"F^8
MP`I`$(`.-8$,$7#!!OC`A6#EI`EB@,`*#J"`AFC@6\3H@PF,8(`O,`$+=Q#!
M"BRPAR@X00T1*`$(%M"%)8Q!`"=`0@8VP(,<$$`+Q(A`#/CPA11(0`Q+V`(`
M/F`#&'#``'"(00>R0"4K+.`&5!@#&%8P`14EPET2B,,]5E"##2R%"60X`0K8
MD((3#.!302!""`P@@0TX(`8/((,%8N""$O3!AE?H0`G,<(<4<(".=+#`!BP0
MM!^D(`55@$`/]B`8*!1@!1"(_P(3!+#$/CEE-2YHE"TRH`=66?"8R$RF,G/R
MA#F`@`$AZ-"ME!`'"C#`!5M0Q!/V(`%)LJH)9B#!#DI0O)\HH0TG`\(-A)"`
MIK`A"`,(`\YBP`9$6&$`&SB`!0YQ%`_XP`5::`,/=L""'?0@)>:A00K*@`8B
M%`!KB#`#$LY@!>JL@`[&U`,1Z&"``^#@`#FH00I2LP8A%"`"2.!#&A!@`SO%
M0`@'6,`>;C"'"XF'3@[0PQL.\`4Q],!J'0`C([(C@ECV8`Z':,((&&:!!C`@
M"5^(`@]6L#I$I"!2$YD`#>Z`'S#H8`*^7*98QTI6L48!#QY8(@"F<*L7&L`$
M/P06(O^B@`8"K$`$`3#7$\H010TDP(\]>4(8Q"@$!M"``'WPP`%6$``I."$,
M#D@!"AP0!MO(P1H6T(/*P-"`&RA`!C2071L2@8<2B,`+?;C`"C:`@#,<(@H#
M\$$!*+#:%-0@!QM8@!P(0(,!X`,`81"`EG"P@TXBX`$E,!4BN,`&J=GA"U,P
MZ7NH$($#M&$!&?@!#&B@`AJD@Q%/R`/+M/`I,"P!"B<P`!"0$`(+&"`#<?!#
M"1I`1R501P)MZ4((4L`N^S`A`C@80$+*2N`"&UB"3X``"H*P`&FV;0X?Z($$
MZ%BR`K0@9Q>"0@!0@`,/U.0G3O"#"$8P!`8@[@+=O,#JF-#_!P[@@!>(J$)D
M:0`!)I`@!V<20CL2L8<1(&`))Z"!!6300Q-D```IP$$9%&HN$)F@"!*0``G"
M,(,9F"L1:=``#+[0!"VP0)A4VAP3&A""%KA``GA(Q`ER$(<@>*`"+#B`!&A0
M3X5((`=UX$(/0K`7,9#A"!^XP0%4D*TH7,"DB;@`$1:`"#L4P0(.+HH2,C#*
M`UOZTIBNE1*@H(8,V*`#>;V5$]Q0@1IH8``.GH(=8N$!/T#!)&+@[9$/R),F
M>,$!//C8"PBP!@[4P`-TX(<7"F`"%$1`151@0P8**H0=V````XZ"!FA0!CCD
M8(Y,R$(>#-(@")0!"`NX\A^6D(4,_Q`A"E9X`PT*4))$T.$%$`#`-W*`!$&-
MX2@K(,`>=N"!/5P5!SY(;PD^0``AZ,$,G"@!21222!"X(0$T-A`8<B"`(X2`
M`0<@`!NR\`%J6X(*'I"!',Z[`!L@8%9$40(9AL363+O\Y3!W"GEI`(/RX&H*
M#:!YC14!!Q"\``5ZN,P$3&`"`(B[)Z-*P0U^<-@X:*`$+0#`(1*\@A(08$HL
M&`$/<$"R;)3`!&08`PX:<*`F&"`&7FA"'71@``HC`@`U6,``7KD"&K2@`:_>
MPS(,0(,%S*$%.!""#\R(`PH@8`<)N!`;3B"#$Y"@``C@`1C4K8(7>(#6B0##
MBS_'@_(P8?\+%U!``#`@@6=PP0LM2,$[N(""&DS)`SRP`W[8D+.6Q_SVN,_]
M391`!32@K0-W0#F"G@##NVF/&%18=0Q($(=70^$+'=C%&L*Z$R>``0+.`$()
M*L`'$IA`!`!X0A.Z4(`7;*`%)HBLODXE`!P4P`T#F(`//F`81$!!JWP000EF
M\`*#<B`!<2`!)0``9?8&9T!L*[`",6`"+;`'(:`!ZY=&?@!7<*`%6=`#?G`@
M6N!B;[``)6`$*4`#&Q`#="!\I\);?5`&+;`!66!?-P`!#G```'`$&K``8U``
M-9!X"1(`-L`_?V`&,I`!D484Y28#:=`XNI>$2IA[V*$!(Q0`N3+_!B&7`@4P
M8(B`!A(@"[*'"%OP`2(U`!#%$U/P`"^@`RS`1P$(=38'!3=@`G7@``]0"TQ0
M`$4P`%-@6R:``PQ`!"@P``@7`W+@`B8P!>>Q73Y``S/`*%7F=D[0``U1!DXP
M'ENA"%`@9$]@``V0`RW`)="S`35P!SO`>$<@!!M``V:@$$J@`37`!=HB`N8"
M!1F``0VP`$0@`#_0`%+@`$$``/#@`#L`A7^@-2*`'TJP`2L0!DN8C,J8A%-`
M!R;@`VO@0;?R!'@@`4)0`6,`(52`+CW`!WT"!6F03Q#@6C_1!%FF`PR@`S#`
M!O6@`!HP!`10`QA`''LP!2>``UF0!D"`_P!/L`16P`<[0`0N0&-X<``.D0A,
M8`5!)@5+($I:<"!VT`,!@`8?T`$H(`0>U@1*T`?I@0<L8``(T&R=D`%T0`0=
MX`!#\`6($CL?\&JAD0,<8`XW@`!,L%=9(HMTR`9[4`4;TX)_0`6EZ!Q-``%"
M0`<V%!1+4`9#@!#+V)1.&7-VP'@2\$FX`@<?L%IK$!=*P`8;(`,;T`;\Y`64
ME@+U`11<4`$[``1#8`\#10!;T@(^T`,?DP)78`<\T'6(\`0G(`)=A@`*8(>*
MD`<Q,``%4`(KT`,X(`$V%UL.@#,+4`$PD`/#,0,P@`,)\``[\`9S%0`A0`,H
MP`%^T`$O8$L2UO\0QJ0(^O,`3P`".#`,6K`",E``*8`!$;``'E`%;(!)K%(&
M+Z`!J\-Z,=!N]E$!/#`'I_F4R)F<!+8$7M``._`":/`\M.(Y`V`"@TD%<5$&
MN)8"T7D(6!``*\`#>^"3/:$$5:`')Z``&?`&4Z``"1`%)Q`'!J``AC-?.V``
M5E`53N`!0L!-1"!X!K4&65`%%H`#9D`!-N`';%!Z*T`L*[`#<!`+W)(-??`!
M/``!`:`%9D`$PZ`(HA`#6&"70=`!/.`!01``C?,$FX(&57!5':(&"\`",9``
M)8`!!E`D;T`$GX`(=+`##H`(!*0")B@431(#8*F<2)JD904@+?`"&0#_!KBB
M!'"@`3$0-XM0#R8``FB$"&H0`B\0G\>I$_9%`CB0`@G0`BV@`VOPDPY0`@KP
MIDG``"4P`'+P8@&0`Q[`!+"U`3M@)S/P`;RY`0ZV!1-0`A-@!TO`15:("%_@
M4%50`!`0`ZS%*IJ'`MCW`4*``:5@`M07$K"A!`.``Q.`"%U@F$D0`X5Y!&V0
M!2+``\[Q!T[``32@F?^U`QAS'V1``Q^PJ$K:J[YJ05&P!W9#`J3Q07'`6R$0
M!\\#!7I``C'``5%U*FKP`%[)!E5PE+M7!P\P`RGP`"?P`A3P!5!P!@C0,(4%
M!$&@`000`"]0`+.R.T+P`7"`<RE00U12!CLP_P`AI`$X0"#7L01Q\`(5X`=X
MVCM5-P,%D`=!V`&VJ@:?80(39A1U4`(><`9\T!"'<`'(LP)&$'<B$`%C<%43
MZ@4",EI1@#QEZ13@)`2J^:LN^[(5Y`1Y$`(Q(`)NIVD5^@(J`&;C%@`M4+-"
M]0=HP&$HH)E`@0<B``,;,`$GD`(=@(Q;0`$N(`1!8`(6$#M^,"M+0`$P8)4M
ML$,Y(`+.\003L`,(4*`7T`$I<`"RLP%2(P`2@`-U@`A:T``IX`(98`%X0"9-
M8#<A@`-/`EX&D*]E<%72^`<21@,E``0UP`9,D``\D+)HT`,4D!![Y)OW`04;
M@`.`!;.>^[E@`P4#P/\!,4`!<!"&_K$$`4!;'\"B3`(`&5`#&:`&K\@&:AL"
M=W"M@5-7*:`"%!`")=`!;1`%98``:\L#<JD`+A``8^`%*%`"?B`!,#`'"6`"
M24(#&C!M`B"KH\4$8+``*1`$(C`!9*!#IZ@(;;`##Q`&?0`$9O1S,@",BT`%
M#(L&9!`#*G!T-G!G)8`$(F!'-`",2[``-$"3?\`&5ANF0K$%+7`"<`"Z$!S!
MNL($K1H"">"2MU(`9W(H36$%!M`#+3``5]8$O)0"!K!^/\$'QV`!'?!B`U`2
M:6`]1=`#!\`"B-@!?=`#'Z`(87`"-F``>J`$,3`#0Z4#<H`%PLHR$_H'88#_
MOQ_\`BQP!#R0`B:`A$V#`DI0`#U@<XH0`Q)@`R>0!EH0`CZP?DW0#*?(!(,;
MN$ZA!&;@`P0@P7(\Q[5R4WQ4)-BJ'T^PNB_P`7UPN%30:R8@O*O3!&R`7"1Y
MN+76!Q/0`B%``EG8``62!@GP`D%`7!Q@!B<``MF4"$\P`#2`!WQ0.R4:!QVR
M!'30=P60-BB0%%Z\!@CP`JJ4`G"P!C8P`S)`=HQ`PCFP`&=``O&;"%L0Q']@
M`QH0`7WP!C8@`FRE!'8``Q(`1EWJ`G-K'U,0`3NPIG2\S=R\'U&@`D*`5PK<
M'TI@`$+0`H6@"&.`J1H0:@E"`0PS`#?+$TM0`')&_S-!P`%T,`5-H`<Q$`,\
MQ`-'@`/1^`=54`$*(`=T8@`K@`,*<`,J<`$-,`)T``$^0`[^(P,R4`,]0$].
MV@06T`,,BY>),`4.<`-WP`7;Y6!9,``VMP*KD@`]D+)L4`0>L%PTA[I"804A
MD`/"V<U`'=1#89YY0`#S7"M/P`8>T"9X8'M9`&$K$">OF%@KX`%L($`^8<@J
M)`$>T)D&4`=2D`:7Q`-!8(8Z8%L2\`8OT`$>M`1B@``K(!40,`8D<`(FE`BH
MO&AF0`<_0`(-8D9EH!!=\$I=,`?>94Q7H`(+@`"'<`9A4-<(%044$`-XH`1+
M$`$Y``!(&!1D8`*)(]2@'?_:-M$$53$%87`(5D0%_5A]&DD%6#!@3J"[BJ`$
M;,,23P`B3BK"Q"`%=?!T(G`'"?$$7L`W$E``0Z@337`+-O`!%O`!IG4C6E"=
M+T`$.N`#!C`&0A`!$+4$`P`$G'8!;BN@F5<"$F`-(7`$/V`"*Z`!6+T(<2`#
MB>,``8QR`1`FZQ<&,%`"_<5Q)E`3($T#`I#'0#$QO"K:!B[:&9`!?[`'0)`$
M*:#&1@`$\HL32L`!"-`!0S`$*X`(`U`"06L>P)<34K`'660!&*P$6\"#?TD,
M4Z`'*L``%J#(/`$%<L"?'#``**``!1`%X.@!CB$#0<`",.Y+>4`$<>`;(+`#
M-T#_`X6'!?:\RBG@Y`>@`4(@`$C(!D00C:U73HE`&1M`!B#Q!C?@`"Z)KQS0
M(5N`.T=]X&S>YD1!`1A0`DK`?P3``FP`!!D@!#BP!5Q@&'WP26)0!@&`!7KP
M!>]0!BM@!B_E`*]*!6)`!66P!N?[!Q90`INM$$_D`30``FM@>U``!]M%`F]@
M";9&`;++!P6>$TP0:U[\`"HP"0'P>05``S:0`T#``D.``@60"W&``B[0!DPP
M!0#@`I<,QGFP`_0%O*SQ!C:T!1Y`!&F0JR%@>XC@!'C@``$@0`20F5,W``RV
M%SW*`4/JYN1>[CLQ`4%0`G^P!5,0!SK`*VMK/2R``4GP_P-'8`'U?@1)@-YR
MD"`3``-.H`,_P`"@,.L<8.\_(%1<``3'?1-(G`(,X``'T@7B)01L``I2$``:
MP';CCA/;J`$*H)@2<`-9.05F(`+/8`.C>`%7D&^+V@0]YK@>>>S<``)5M0A7
M0(JB>P-^L#-;0`!.,`=QH)<FL,0J$`2G_0<=50<'0K;8<$X`T.\\T05.D$%#
MR`32M`074.!A0.WF_O7*N`17E0BY-@4F$,46$`2S]`/G,`-'T`(<,`1V``01
MT!+MX00WX-`[L!<&P(=```8*8!<)H@-<59Y.``N]N0<8/`5]L`&6]P8)\5AH
M(P$G5XYN,'0J,`$:X`+`%@5G,/\!*;`#.6`#&3`"*1``PHD`-$`!D'("&#`$
M,T`##1"F2I``[C<%'+`"/'LJ=-`!-_T$:$`#$G`A9``#&4!'6:`")B#C6U`X
M0-`!:(`!0,```LX(#C`#,S@"0O!A!OT#$@`],2#C?T`MU0_VYO]RG=0M+&#<
M-R``^31_>-$%*^#V`[``(S`%-V`74P`$<0P(;D]6.F-_!D0;(TXX!'^/.@B/
MDY25EH]*:1,R)F^5=Q\K)V=*CV(9)2MT2Y>MEFX6+24$&2DE9G]G#RD[.#L_
M.C5S4@LO%*)8$",MPI=-%SM^6!(V8I5+;Q\1;7]L1`91CUPX*E-_8S`F799[
M.GL:2`/_1EY656@$$U^W6`$6`P(@W$R:(<&`""DC]$SZ@$'"HR4"KN`AH*'*
M(R9"U+C:R+&CQX\@0XH<2;*DR9,H4ZI<R?*1BQ)_*ARA\X<,@R@(1@3YH`8(
MEQ<PC@QP,&+*#0-_HO3PT,0%%B\WLOR)D&A1HTDW`JAD4N<%C0:D)C61@V,%
M`BT/P:2@,:$,DY)+TH2P42%!J@5>F'#90`-&#B`LA&Q`(.2"@!XF4)CX<FG+
MAAU;^B#Q4&I2EB\-)BQ@\N2#CW!_E%RX\49)$ST*#%2N=&6%@B$$)&#`@`/!
MD1M'CN@X>F3$D1\_<&"ZP>9/E0^%'N'Y,6+#HRY'*/1F$>/M_Q\+)EIJW\Z]
MN_?OX,.+)^G"!)-?07#442`$"(T@$M(D.?-B!H8!$&Y4.?J'B8@34"1Q@`XG
M/&+``2<L$@0%'J@A!1#KL"1'!BML4`<KCS2QAPHO:&!(:'AH\$(+?IR$A@@P
M;."`!B6$@,8?:E"P@1!'),'##49LL`$!*X1`Q25E\!#"$P4HL`:&CSS1@0<2
M!#`%%ANT4,8D(O0@T!\$]'`'DI5\(400"G```0P$L-!`$E[$4((20%@PPA(W
M/%""`DDJ@,4?;FQP`QY)I?""CH]L$1T+:#C@@T5_#)##:N,UZNBCD$8JZ:2M
MI`&'$@7H*`(67[S`015ZE/'$'4R88?\'`E9<X8<2`USQ"!LO7-'%"R)@N(4=
M8/"A1!M=`%#%`$(TL9T3>RA00P!78*B$$P[<\`(;YBC!1``]"-$JHR$QT8</
M+P1P01`Q"&#%$D[480`+=#CAA!X,+'")$@@HL,<4&01;"11LM+!!!G&LET%E
M7JP`PUM62&""JZY`H,,5"0`AQEM$H#`"%C'`\$>;"C1Q`P0E'/`(%0=`,<43
M?RB@P1][S(;!#7?\(2@%(X3AP`Z(!K`#EY3FK//.//?L<TI2E%#`1TMLT,!W
M>FP0PP9@K$8%`GX^L,5%:$A0@@9VG-2'!!4Z$(()(K31Q`,X/,P!#;A8,L4#
M*_3!10DG2$7_B1(.&$`!'W%`@`0`POZ!!P\BE")&#BK\N-$"291!@+,H=*$#
M`0M7?'$'&1]E`IW]C7!&!BTTH<`#4ECA00LC\&#-&$=8<(/,/%@AQ1\7V/#S
M[+37;OOMCEYA>$=*:&'==Q#I8`,;B":IN@1FO![:&@>4$(`5)\5!!`X!0,`#
M$B5$,44(*!0_2;DTK`"J#NY2HD43#N``PQ142(!#95$XD$08?RP!`!#%=51%
M"1C\8```L^E!'I!@A10X1P$5V`$3D%``%`CG$4BX0!2.@`$%9(&!CP@!"!Z1
M!188H`A<*$`)!O@'%5``=RA,H0I7R,*0A($/4\!9>)K@AU!HX`R__Y,"`F#P
M`@^,H3)Z<!\(\/`[D2RA#R`PP0;(\!8J6(`&)$A#%:1P!3N(8`4N6,,3,D`#
M,JRF"7#80`1"0"HOT$`$AL/""TS@A/YDP`97\H@3`*`1)9Q!#E-H0A64((4?
M68$)/\)"$T0VB1"48`E>"$`XMM#&/T`!"I/H0A.HL"PI,&$,6#C`G5K(R4YZ
M\I,[PX((2F``./2M44YXPP1H(($[0(^#?B"!#1K0!G-`(0X$\-0>]D@2;1F@
M1WO`@A3H0(`-E$`&,D@!`020A3I(``5IF-L>,K4!/4QA#SR80#AVU0(+K$,,
M(8`!&!Y%!Q#L;B0"X``HU\G.=KJS)5Q8P/\*>*`:2$D!(#O(P"8_EBD<5``T
M3```"(3DA9,$X`,Q2`$:BO@(,L1@!Q`@&26H@((%%$`J&\`!8_J#@!P,X!%Q
M\,$#L#4>)I`4)"9]ITI7RM*65L(+")!`"AR0!H:&!PIRD),(7#D)+>B!`R:8
M`!JDH(0HR($`)LB`KTH"A3<8X`0PR,`$#&"`#IQ@1TRT!!8\4(<H@$$"*DA#
M*;#0@1CT08\SFP-H5J*$`/#)I7"-JUSG6A([H`(%:)!A>*Q@`!.4P`+>XT(&
M8F""/%@G"A!(00HH8-.04.$.<X#```*PSW=IX0EG`%QEPE"A-D;!+\IKB09B
MT#*ZFO:TJ*7K$KK_D(`6P,`!;CCE>*K0!Q+$0`1QV-T6`A`"&1C`#)YE`P%H
MT($]A/8[5%@`#P#01B7L(081B((2^B`#`J"%)4K`0PHD<-W4>O>[X&TG`%:P
M`A&0(5);0`$-4)"'4RKA"S"(P0?DT,@I@"`'(4``)+T3A1#X($).0``#/KH$
M-@3!`MN!@Q`RT-CP.OC!$)X=$]Q0`!><`"\-[HX2KA`'#I3@`=":Q!@$$((4
M&,`.K+@F!V)@`3J8HR5*8(,-*'#=+LP@!6500A9$\`(TR#8E5"BK'3(<X2(;
M^<B.<L(:<)`"J45*#"U@)1M^IP0SR(!68GV$%S1``PVD:R5+V$,/D-+0_Q5H
MP!QC.($+7LR2*:"@!FE#LISG3&?P,*$,$!C"!E[YJ"NP80<'D,,IEY`%`!R`
M!QM50A7N4(,(JJ0!(XC#),XP@@*PH@D]:(!$69(%(73@N'4.M:A';1(G0(`3
M$ZCL>.*R@1=(H`^-K!\;3%`##22Z#A^@P0;D4)(NF``&AHO"`PZ`"R<4B0_;
MN8`/AD;J9CO[V1V1P@`^D`,"4!)2<&A`#5[PA5-&@0TDV$$(Q,"*]QJ@!"40
M=$C2\`)]/D(**<C!.)=0KSB<U"1+,,`.`J!7:/O[WZ2NP@1>0$I0CP</)>AR
M'5;CA#FDP`0/N-)TK:8!,_1[$D3:01XFX8=OM/^1##;(P'Y9`H<5M."<`$^Y
MRD7=A0:4X`4&>,*]O4,L"FT@+Y.(0@%"T.X?AH8-7-R`&5):"3Z&``=W*,42
MZ+"#"(@#!Q(@\DB4X`4<?,![*\^ZUN5\A5QN@`\_%H\2XE`"$X!@G&)!P`IF
M4($(H4RQ&I@``N(@AP%0X`0T.-+'E'8&1U*`V-IA@@=Z<-ZM&_[P1Y89#$J`
M@&L[2@IZT,`*/O"%6%-A`"AX`0'&P`HF%*H#&>!`!D0@=\,I(0PVV``7_F`%
M9A2>)5&0P+,03_O:0[@.*1`"`;X@=>X\P0%("`&R**&D`V3`#P8O^@!VL`!A
ME0$'&=BT2G9%.-M;__K_W\7#`UJ0`@%@X>+=D4(>-)#4-(P\"PN(;P/*0(5-
M*^$)/CW!#`*PK`'08`$S)XD3$K`#`X`?^P`8@.]D!SA``P;`!;VW'4^P."@@
M!WSV!U?P`<TC`@,P!P"0`!R@`#PP!Z7P!!2@`*^W$E#@`2/P@`)X@BCX3G%Q
M;BFP2_G''5,``.IE`6<0:T]`!@$P``50`),5!DKW?"$P-2WQ!2L@`2.7@DB8
MA*#$!&"0`%WC<XZ"!79@`2O@`7>0?'/#!S)@`7*S$M/R`H"EA&(XAI[$!&]`
M`D*0`@C39P.0`@HP`6Q6"6:0"G3P@B+Q!/JF%62XAWRH0DQ8`#F@`6O0A8U2
M_P5Q``(RH`$/X```4#TD<&,+H&HD$0:GI`4;L`)A\']]N(F<2"E+<`<<0`0?
M((GBX01IL`<)@`"J&`!AD1)V,`)(\`AOD&E'V(FV>(LZ<X._A`((0(B1\@1K
M=1)3H`"S`7,U4`!AAXO*N(R/H@5()33)"!Y%]0=?D`(#$(<DT0$J@P&$PHS>
M^(V0T@1B@`)(T`%=H(DK@05=UA]AT`(,T``X-Q(#L(VS@6#@>(_X"!Y>0`$U
MX`)Y@(Y:$P0$X#U:<$5"DX"3P`9#0(_]0P$`F8\0&9$>`05D@`,*``%68(<C
MT00$P`!N0%+O5P8MH`,&D"P=007$R)!'H`(/*9$N^?^2EO`%904#=_!C3P``
M)O@15X`"+J`1''$&)$!P^.<*3'`"#*E[M0B32KF4'($%=)`#0C`'OO,(";`R
M;N<12P`&09`!L=814'`'*G``"\`%.*,$!/`#VZ@#`9"43-F6;FD);2!Y,S!T
M:(D!0U!/'F$`/L`W)%&0)9`""'!*=E"70W`"!?66B)F8EL`$;=``*8`$V_@#
M'X!R:D,!,:`'+5ET9V``,X`#?+`%8L`#_=,!GJ"8IGF:CW`&.L"0@-<*6K`#
M'!",*'$&%I`".L`"ZH::NIF82Z`!%,20.G`!V.($?Z9-@?<%FW`"!3`&T;B;
MS@F159"2#%F/L;8$%(`$I>F1'7*0`N45@L_YG?E(0PL@`C0P!'6I,D>``[PV
M!AMP`G`@'DM@!A%0`BU0`)0)GO@)CJN%`">@`#CR`RRP`#@0`I$2`"_P4?F9
MH!+I!%L@!R4P`@.`D-NQ!-*GH!8*CE3``>JAD1?:H1>J!40@`;[HH21:HDRP
>!CG@`,U9HBR:H`NP;"T:HQXJ!2UP`CDIHXD9"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>f39432a1f3943222.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a1f3943222.gif
M1TE&.#EA_@$B`<08`,#`P("`@$!`0"@H*%%14?#P\-#0T*"@H````.#@X&!@
M8'!P<'EY>9"0D+"PL%!04#`P,!`0$"`@(!04%#P\/`H*"AX>'J*BHO___P``
M`````````````````````````"'Y!`$``!@`+`````#^`2(!``7_(":.9&F>
M:*JN;.N^<"S/=&W?>*[O?.__O,3((,0D#"5`0404'8'0J'1*K5JOV*PVZI"(
M&@V%P:``CQ2.1P$L)INW\+A\3J_;[W4`1/3`%!0*2WU&"Q@.!WU_@1B#>(Z/
MD)&2DY0^`B*7&`*9F0`!&)Z<G",%`*:5J*FJJZRM/9F)@().A8>QBXTC`*Z\
MO;Z_P(Z9;&-E#1@'&&AJQ&['2<'1TM/4U3)(3$5/&)^@2QA-1MC0UN7FY^C4
MXS"[Z>[O\/'`[?+U]O?X<O3Y_/W^_S7V`1Q(L.`_@083*EQH#B'#AQ`CKG(H
ML:+%BW,H8MS(L>,/C1Y#BASI`B3)DRA)_YI,R;*EQ94N8\HT"'.FS9OX:N+<
MR1.=SIY`@P;[*;2H455$CRI=ZB@ITZ=0MSB-2K5JE*E6LVK%@76KUZ\EP8H=
MJZ,KV;-@S:)=FU4MV[=0W<*=>U0NW;M`[>+=>U,OW[\N_0(>?%(PX<,>#2->
M?%$QX\<0'4.>G%`RY<L`+6/>G$\SY\_R/(,>G4XTZ=/63*->'4TUZ]>]7,.>
M/9&V;8*R;^OF44K$@0;?C`38M289,N`F<N^&G&#0@4W&D6V"T.>!`#48)&Q:
M]P*`@$\.&A@HQ.=/@@4&&C@(/S[Y\O<QGH_29$)!@M^&#'BZL7_0(`.?`-"`
M?_Z18HIR\"V6"?\2!62BRR<//`>>`@(\,\-^\^T7"B;SD8!@@H<YZ(``W&%7
M(08+.`"``RA&%\-^"P@QR!_(I$%(C(RX!^*.*F12A@EDB&"?(>HM$1X-^Q7P
M@`*[%-+``@J`HH`:2C*I(X]8EG!)`A`$X"6*7SQCP'<"%#!B``(4H8.%[&3I
MYA!^'+@+-@D$5\HWO?407)MO]NG+AWX&:@.@@A;ZHJ$)RO<`BP:X"$XRW(%)
M!Z&(CC6<'P\HH:8(!0CAX`B?QD%II6!=:@23GZ!IG2<'1'#`<P\4$BH<HY+J
ME:F:>))`E`D(@"$R(NPQJU2V[F;JKI[LE^LGEP2@0`!>#*M%K<5F=:G_DJ9`
M:*:OS&*P1P+1YE'M;8HR"ND##9"8S`('G/DJ>1F-NZ.O;TQ"K;Q@)1``BY7<
MBV^A_OX;:,`",P4``IO68,">5!!<L%*`B"F.$:`(D8`0!40JP@)L-OSP:PUR
MB0F3`I`<P`+H18G?"0(@X'(W4SC\L5`',"F!ITN4"<Z*E^SQ0,(D9,SP53.O
M]IVSLF+BAP`'>(=!`XBDT,5U0`,A<]$\-<=IN/09D&D#$'0J@:,D^'IT%5=C
MC9-^(QQ0@''&Z>J`$'ND@*8$$(B6MMI4+0`S"@X$H+'5?"<(D@%Y"_@WT87/
MAAX,"T2PB:]H-[[1@4-?`PGE,"R\L!5[6PY$_Z8H7L=P`Y^,R30)$GBYN@WP
MXL'Y"U/_7+GH\H!M2BU_(\[L$G4K'>S;7R0`P&]+>,)B`N'-'8`0R11WQ^PN
MF/VEQ[C#,]ZEWT$P#K;@Q9J+@\/M008`$H0G1J8!-`!`!&DP*:PF#OQ8!_4M
MW)WW[=FGHV0!PVF0XLZ@GU2Y3V?"XX;R%I`MI07N`<-)U2XNP2T_#$X+^&M!
MX"[H@]#U#P>JPQOJ$CB=L64"5P[Z%H5`T0VF!:`4$50@?4A4".;9(8,K4-WK
M8O9!>'`O`(N2%`L-`<%/M0Y-QOG.$.D'00KMAWOT>18.MS#%%'S'%%7[2`_?
M42<1*($)I-`&=S!W!O^,%0$)3UB8Q9:`!&Q\[H9$.<!P`)#%#F[Q(BB;1A51
ML`#M[%`*'KRC2_9X`BM=(9""9`DAZ^-'LA$ND0`!(#P660+]8)%_D.Q'`]+W
M#DHR`663<Z06,^D/ID4)15#C6+M*IA](=6P5GK2@)>F(25+>(TA>R)4NH]2@
M`NPA1;V()3@2-T+LV1(??12`J^C#S#`LX!+VD58JA!FYR>GMF/FHF]>8>8GV
M-,@0"HA=*X0)CBP@$IL\<`"\)/!-^BB)3$B(0!U10<X#N`P!BX/".=&Y!275
M0P#\`AT_'T*B>GCIDB[X&P`X=J.-X8@<`V7-,Z'3@EU]J@^""X2`W$<CB$;_
MM!_Y1$4IY$32DIHT<X?@H`D<I"$T<2B!(]WG1X&``%<`H`(#R*E.=\K3GE8`
M(4"\CDY8&B"7:J)#NIBI/VK:"@`,X`)0C:I4ITK5`2#$>B%%P46Y0892@$$)
MI_204OO!5%8XE:IH3:M53>"`"$3@9B\@3Q\6>HSSD`=E0)/I6'E0UHD\-:V`
MC>I:39`G&8AR!7K=JP[ZBI2_!A:P@VT;1L7).,7:@[&I..MC(2N0".R"2P$%
MI&7O@5E4:':S:(TL.,B753O>\8LDN-@(MB$"+]EVGM,H;;\<B]JIJC8[PVD5
M;G>06,8T"$WC<)8"D@'$/'I1#Z;(G#5T2XG3]E:J_[\]3\E,4UR)'(\$:>A&
M_+ZA.LE)LPKM"1RH^,#,T#(3'`]X`!(`(09#L/*H`J`L*JAK+]Y>%ZJ_)19B
M"M`Z4J@A/+U4UGIU8<8WWBE."-7!)N2Y8`D`(+X0<%0F?%D`#LM3:[S<<$%;
MP5])6/>_%PCPM!:S*)@IBVE@()N(@=@T"3R3CM]9E+X"`+\=:"U(OIF.T]XK
M/&4-9Q3.]-%A*5'B2)SXORI.J4`/LR\%"_"9:**KEKY@G+P5XG\%[,;U=.#-
M1D0O$$AE9J\P`2Y,>?,2?NM%DR'QY.L&.*BD,^9@)`>!L<UV7ZI,H/#V%2QE
M96I1(ZR9#YXI7_H@HJ#/V?]?V20;H>Q89V'602("-J'?2LSY$77N;8"Q6LO!
M:*A.OF)2KQ:J82?0BX'I0P/J```(`\"/EI$XKR\^W13_0ADA;7WK<,O"&.-5
MS`CN<P*A2Q"=!*@'%.QJ!_+<9UN9=1H8O,9#J%&KXL+J>3<*ADJV[[#MS08X
MB(=,4*<<40CYY-</:'HH.L9MAW(_-L`*,.^2>=!=TC1K'P`%1R[G;5-?VQDA
MLQQV#OH]DG4GW`E7^S<IPOK&<]`[#P87-<(G]\I'C@9#U491$?<=AV9!`#KA
M=L?%)Y5Q;B,$7?F])FE^-813=O01$G="6`67CI5GI.7F1LBSNM3:'C!<)"#W
MDK/_]Y9S3.QBR`1O*M#OC9"W/4?A7#D-AC"'*Y7&H=WK`&!^I4L-G^MCZH$-
ML!P/6NK-T)P)-A]X+Q8QW8*C&+L(63L$W*M/K7>+!(`(@/>`H8"PU5WJ=Q>L
M1@)`<F*3QN&$/;HR).#U<=H]\2E&R$1[_.W1UB<"E;>)O=..<%.$?N&>7P&/
M3Q^3T7/6!!.=7.=/,V9KM(KU+7&]6H$JOZ;-GC2UMSWH4^'NR1G_^,C?#IW1
M_GHML2C.OQ]-\(6/>S@$@`(,R+[VM\_][EN`8+I/+;`E1^'H@V;ZPF_\'`)`
M`,QG?OGN5[&^L)YUV*#?]@A0?QS8'W_P,W_W)?`LT`)7_^;W&?>7&LLD"?R'
M>2K&<OU'`HB3'9Y0=/PV&P=H#;:F?UJP@(G7@#_W@$,``0E04_;#0_9'@=60
M@9'`@7?G@6<'@F>`3WI`=D9G@2B8@@GH""R(8BXH*O\G?I-B@_9@:V%U!SOX
M:_#'@)0B>2AQ@>=`A#K8?DJ8A!VXA$)X#UQ2A'1PA`='A2WX<GPG6B>8#[ZD
MA7+`A1KGA3PH=/K6=L!W@^=0AG:`ABZGADA820="?X-RA60(`6:X!708=';8
MA95T<@M`@Q4XAOW@2X9WAE)8A8.8AB6P*/G5<:/T&DX(#XR(B%,0B%07B748
M@`M`'1JXAXKH#W_0B(#XB%\(BO^"6`(%\$R6>(FLD8GR4'B<"`6>2'JN^(FP
M2"%PB'JG"!"XN(HPJ&T_6%5"UWLUP$!20B5+@A!,2`7>1B3?$#AJ$GM_1`FV
M6`_%F`6[V'R]=HQ"\GREV#:4TP=V)2-7`A$20@('D")]4#-Z4`*XD@K=:%"Y
MZ`/A"("@EHR^Q88MLPDT`$5'!5,'4A'I\3<G-":ED#"FHCJRDFG2$2NE`P$1
M8'W!6`XFU9$=J8?YPXIKV(N\B(=R4I"[0"#LY5&1\3=B($`2$$ZA8BJ&QWAI
MH@SW$2PC,'B`N)'3U5-`&903X),A28[U!I!X!P27@A[JP1Z4-8TQ\S=_$%]M
MAB+K8"K_G6!4$?0LN;1<^T>49>=^!`"6JB>2=SB.4_@1&`,UOH$<+/D0RH($
MXO%-\O4_)("52)`I`/5-W^(%)W.&9"D-"""6@6DW9DF(:`F))7`?-;./]2<1
MC;(Q?K``C?8'^',`V!"+050AC>8NQ:>1_#"8F#>6_'B8DIB8K3B)7=`^;G@3
MN@:8H4F8I6F4&&>4$9(^A<DG07&.5Y"/Y2":B4>:/="/0/B/1CDF]0.22,*'
MI"6;PVF:H8B:(YD$CNEXB@0*?G0)E@E!D^";T^6</$"<RDB2XC@"D1,AU6F*
MUQEN:,`'83B'N8EMX+D#XAF0Y.F/L+@`+G-MB;B>3`(`>8F/__'Y"\!Y=\(9
MGM#YBM)YEN:)`.AI=MTQ2*!P-,GPFO`9FZ,YH/:8H+ZXH(BI"^GYF"EQ">&&
M0/4":E`9`P6*8@=*GQQ:DAYZFD/`<:T9$B3Z-VEP/#J3`,,7%2OZ7RVJ`_69
ME,:9EB0`<\Y8@!V1#,8&@5`3')L4HC/QH]<5I#DPI(IWG\4)>(+GG0&Q%-_(
M%%3:6U:*`U@*8/YGE%9WDTJ*$]>!!2US3W(ZIW1Z3Q9*H/,II"]:GN2&E%FZ
MF*]"=R:H%')H!0+``)C'`'>Z:WEZI7N*G\AHFZLYBS7(%`40`93Z"HB:>(K:
M<XUJIH^ZI9%JI"-PF^K5ICNA@E1PJ/^)NJAR]JDW<*;O5Z2*"8$`-22HNA/O
M4WTSP*J<ZJJ\,*:H5::Q&JKC2:NI25C*N9Q1<7M3X*MWUZGS!JLV(*L]2"M^
MBJ8F,"`/8&$U6A2C**4P`*TH)JT61ZTU8*UI2JI*@P`IUW=5$:8_0*[_9:[F
M(*R;1:S5:JSVB:S3>9<QR2[?:A1^&`7T>EWV^IOH6I#\2J0Q&IT>\F"Y"A2^
MQ)\W<+"]E;#?F:&SR:Y'29OC46`3:P/M%#2YQ&CB:@ZJ:@F;&JW`Z@KX^ECZ
MFJX-^Z</JZ"3*0%NE:G]&05CDI$!Z`4+90@:.@VV]IX7V[+E^K(DMK`SH*Y:
M>JQ>A`#1Q%W_AEH"ZL$)@L>KZ>"LFMJJGLJQSTF;#LBN]1,!5+NL,F`:GQ(D
MVDDO14L-PO6UOQJVP1FWM56SVNJO#`I>)2B&JPJ/$U9!1$80\HH#&(M:&EL-
M,1M8,\NP9/N!'KMB59`)F+E@.8:T_F`=/)"XF[6X82FV"!JY+SBYYF0%=!(<
MXP!;"E&H.>"YCP6ZN>6T,@"U?/NAM#(6!*:AL!M8LBN8M!L#MGNS'2HJ9+&R
M-M"[@/6[T="X@/6X3ZNWLTJ\,&J\0%!\%FL1!N"NB*NT]<JTK."\:06]M2N]
MURH5V3J]UJM/>/L/7EL#RIM6S!L,XHM6Y"N\YKNNM;J^5M,-[Z0&_VCRIJH3
M"/*!`%S[#M"2LIK@O0@+OJM0OU1UOS`PO*.ZO[E[%=U@);3&>,C0-$*0I`S%
M$(<[K@R<L0ZL"A`\51+\`A3<IZ0[9>Q+0I>B/$6T"XH&$6]*`_&+5O,KGZ+K
MHB^,K4$\LFLK9L>`.G\I!F6"+?48$:X;`SM,53V,IS^LIT,\+>E[OH,*!)'Y
M!2=R,D'D-4P"2LKW$)?*FU$\55/,J%7LJ%=L3EELA1N8HEN`O-53PHI[PJF0
MPE*UP@F5OU';K_H@%6IK$&V%>VDL56O\JFT,JF^,!>$GM?S[%G/[`HD<58L<
MK,$[P8!\NS)ZP5&)7ZLS(O>5&%",QY^KQ__[M<DLW,G4RZ<"%LJ?TBML%#QP
MZ9&XG(>@@LJQJ\J>QLI__,B'%,=!V##,@CGM@A$($)3,O%-#N<M@.ZV-7*S"
M##K$'"_&K`FW=8\2P<=1=:"7#%69#+/`7)2F*[D6_`/J5272B#9_)P*GFAW=
M#)[A?`'CW+33O*_5C#;7K$_/@B+L^);]6[A,<V&\V9RB6\_W'+[ES`(M_+'G
M3%Q_YR`Q-06(8&R.8B8\-\\)S<N^Z\M,UM!EN<\-T\\Q7"`"S0/;>\`)X<U0
M!<X>O;P@/0DN?0%^;,[I7)L171;@(1Y/&04\>M`+4=,P'<WGFL\T2](Q8])`
MT*3(TXYZ`@'9J\S_]!S3\CO3DD#4[?O0.IW3ISLZ6#T06@W-=2O-=]NQ7HW.
MR3K).Q"N+3'6F&#5/!S6D`#7H[O30HS71-P"[YL2=JW0=/T(=@W$>HW%2MVS
M9.99,?'7<BW%@>T(@VW%A0W'ATU<>I*#;UW51GVO(JT"7%VV:9UN._#$F=W1
MFZVP2`VYDPW)3!W+.5!X-L'8I[VQ9SVVJSW,E6V=9LI.L:W997W4M7W7H>V#
MN2V,.'#(-R';O\W9J1V]Q?T1K4VY-W"T.*'<+FNW!KK5KES!:PW*-4!@/'L2
MUKVTV,VBVOW<'13=7VT#!;L3X_V]Y0VDYWW;UHS>ZDD#L,T3[]W`\5VE__,]
MW'D-X'L]`@T0`0J\$?MMPOU-IO_=W1`MX%O\(CVJW[Y]W6:=W6CMX%VMX>L=
M`W9<W15.WA=NWAG^K]QMXM[]`K[4OAP=W("]X,/:X"C^X!P.R;WZAR!NVLN-
MVL%-V!!.V?1-BRXPPNX=XO`]XO)=XGU+XS,NW2Y0R4*1X'D,X_DJXTN^X4W>
MX2QP,"P]$E*>RE0NLU:.NTQ^Y5JN`D&M%%_>RV'NN&/^R65.YDZN`A6[%&O^
MT6W^O&\.L2X<Y*[%`O$EID;.WTCNWTHNYZ!=XZ*]`G]PX.(]Z`I>Z`Q^Z'".
MY69NXV1QYS*=Y^.[YSC;YS]>66*AZ5?-Z?;KZ?_%"^J*+E#)U^JM+M0<0>IS
M;>H1C.K5J^I9;N,(T'V\WNL4P.(,(>N.3>LJ;.NP;.F(KNN='>N0/N62'N.4
MSN=Q7NFG&]F]K>,6#MP8;MNACMM^7H/6/J7-#N;/7N71_NG3+NTK%NXR(>QJ
M_-AXP.[Z_.V`I-[*WMQ^/>YL7NYB?NZIGN[HON[+CN#ZCN?\[N;^?NL`_^\"
MC^\HX>Z*#.]W(.])3>]78>_I1O&E[>*-_>[$WL?&#JFX?ND9/_!4C>TBKNTD
MSNVK'N`M[S$:SQ(0C\D2;P<Q7[[VS6\8+U`W__`%O^D'K^<)?^R)GNLE[_"/
MCO)'KO))SO)&3]P63VS_/9_T'#_;C&OR)O#9:OWTE3/U)#'SXESS=>#UP1SU
M5K/S78_U%@'V]BSV=$#V./WRAFWV,%`UNP#W(<'V"_W`:G^7VSWRR>X#;S,L
M=]_W+;[M"VSUH=OCDMWM]4WW+5`*GS)2[H,`!'#YF)_YFK_Y`_"?N?SYH!_Z
MHC_ZI%_ZIF\*EK_YJJ_ZG7\@$$`!JQ_[F$\!B7/ZMG_[IY_ZLA_[K8_[):4`
M`[#[LC\![N/[QE]2#3`!PA_[Q,^ZSWH"<A']NGW?_#']7VK<U8_]V2^BU'_]
MW._]WP\%A&_]S!K^%V+9V@_^W5_^VV_^:TO^YY_^[-_^4C`LCLXI.G#_?I#_
M_Z,-`I@XDJ59%J>ZBBG[DBX,RS-;VRN>FSL?_W1!E6]8-`Z3AB2SZ7Q"H](I
MM6J]8K/:+;?K_8+#XC&Y;#ZCT^HUN^U^P^/9PE%NKR;N^KTIS^?YZ3D$*"R5
M``#\*38!!&`<8#@F%2R40"YB45J2)2PH)))(8F(T$.Z(WET&'#0L%`P&@([.
MOE`&)`@D/*P.$6(4!+@*R-)&^1H$W.:.00*S(K?20B(N\#8T//PE%`84(#H>
M$!>/CR@`1V)4HO(X(ALDK),[.38X&)R3&>1V-Z0H%`,PI\Z``PS_]@3,X^@;
M!D3R'AH,L`]=/!N.O"T8!!&*HP0.%,`C`RH9J105^?^4,AF)(+H]"I(U:@B@
MU*>-#QTM"'D21L=J,\79_.%HD*N<8QPL6(`,0R=?LP0DTYE.8M"J5J]BS:IU
M*]>N7K^R\18(K#8`=7(`,$2V%H"Q9]+:3&"6EH%/O%A<6IOF0*Q"+_*>**#`
MP8%*>,'6;03XQ.(K@@D;7M%8#M^`:E5,5B,*W"-2`>RMRL6WX(+,>K=L-K#D
M`+)NK`X(*%#*`*M`!_S<A@2I%&@`PT:G,WUS!.?=GY'!3@"\=)7;(G)WYAU\
M6*,&P>-LAJ2ZM>Q8^UPW<%MF,T69"P`4O`4)Y^DQFQT&4-V@D4GGR6J(8K@0
MP/GTRM%%=A5YCNS77R3_L5?_17XQ%9A.>;<%Z,9F^\G'GP@D*=?-&MV\HLZ!
ML9R72%\D[=1>%I48T`A\]<PG23+)\%6"`XGP=<XM(,(7$(E:<8@41?#PE^-+
M!%HQXR/=$`BDAXY`=:,<*#:R'XLQ13(DE6H()M$_+X&D`#;AI-.4AR:"45<`
M$(0WY(LD8?!`)Z7%$\P#L7&YS9>)S%?-F%AE*<"6A-CY`)@YZ=F2@@O,"8Q$
M@88T'TWXP&$FFDC9M:8(#PS"#1QGD;D&IS9\JE>H7HRJ2*F=HIJJJJNRVJJK
MK\*:23#W!&`=,-;!$FL7N2)3T"!+#&)=+;-Z1D>M(OQ'%C!*W?K+L7R52,6R
M2Z34_ZP!U8AG!Z^?8?!KM]S*T<]4W@Q"[E!`Z:I@MQ8ZZ6&$)XB;D5GWH3?5
M6O%V@UZ^&GT1[XR*DNO0(N>J$Y*'PJT1Y84N_F)4NEI0$I**+35P$`P*1^)B
M?-%FA3&;$IGRA<<:*^"7J3DM%$LD_($KQTOH=/?+?`]<]K`5`-",#F'IT>$@
M#"^+2Y)L$"RZULL7E2*S"`)S`;1)2!.G",Y+#'5`>@"L9P<K:1%V2]>Z('*J
MS3P\$#:(Z=!WGL62S??.*@Y\?>%:6Q/$ET=V#^9*%W3#8_77J\RG2-GS6GB>
M(Y^\VX9<<+TC0N.(S#7VS6$WE((WR*+;!R)+)&!(X\BNM2CX$I]_'CD7HC/E
@N1^?_P%Y"G-=_HOIDM->N^VWXYZ[[KOSWKOO$(4``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>f39432a1f3943219.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a1f3943219.gif
M1TE&.#EAA@(C`^9_`/;V]G!P<&9F9FEI:1`0$.KJZO+R\EE96=S<W.SL[/3T
M]%!04````&UM;>;FYC`P,`L+"U5554E)2?CX^-+2TB`@(#\_/]G9V=C8V,K*
MRDU-3;*RLK:VMN3DY,;&QM34U(J*BCDY.>CHZ$5%1:BHJ+2TM*:FIL+"PM;6
MULS,S.+BXA86%KJZNB8F)BDI*:RLK+BXN):6EJJJJJ2DI/KZ^IF9F34U-924
ME,C(R'IZ>I*2DIR<G+R\O**BHL3$Q"TM+8*"@AD9&79V=IJ:FG)R<HV-C7Q\
M?(6%A6QL;(>'AUQ<7!T='7AX>'1T=(B(B&-C8TQ,3%)24D)"0C(R,BPL+#P\
M/!L;&R,C(X"`@,#`P$!`0*"@H/#P\&!@8.#@X-#0T+"PL._O[Y"0D%]?7Y^?
MG[^_OW]_?]_?W\_/SX^/CZ^OK_[^_OS\_-[>WOW]_:ZNKN'AX9Z>GL[.SGY^
M?HZ.CN[N[H&!@5Y>7I&1D6%A8<'!P;Z^OK&QL='1T?_______R'Y!`$``'\`
M+`````"&`B,#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PH9?"UI@CER+6UZ(
M7EN;65F)7&+0P]C9VMO<W=M?#%T!!,B,#XM:TX=96IM86(E=%6+>]?;W^/GZ
MEUKT?UOG&#%`I\X0.W?P$*7;Q["APX<0>W$9.,A?``9:E`7`0N`!EXOMM'3I
M\@>DLH6#+E;XPDX+`VA<7*XLR='C'RU8P@G:0F#FNY@,9N[L^.5+!0+0O@2H
M<"VBTZ=0HTIM=+#0E@I@1-Y\D&7>%@;PP'ZYFI4DRG_DQ'!E(`9+A9+I_[HL
MV-J57C@P#+YX2?OVG=HL8D@*ZMK%2X4`7[UD80"FV=3'D"-+ME>5T`)H>V\B
M>_>'(@-EE_]D/MOE&I@L`0=F:995\Q_.GV]FV;)`VH,O[[#<%DTHG5%!7<2@
MGDR\N/'CMBH/0CEP(6Q!%)G+7EZPZD`N\C!.?RX[)X/O67Y6"%I.4+JJ[Y0C
M7\^^O7M-%`7=ENX\+'3SZIH71*FX7><_<H&Q14C3<)<.9X,@"$87!/0FC7_I
M^??>A!16:.$@"_B318,!D`30=O;]5Y*'YYS5H6@$6.<:%@2^%F(Z8+SUQP)>
MO+,%/!,Y.%$S6*EWX8]`!BG58N(00,]>#S`&XO\?'8F(I))G(4D`%BK61$"+
M!D[S0`45M//.7EH<YF!)/9WCHY!HIJDF9<8T5:,ZS/PAC9SP)"0:E3LY)DB-
MF%V3D!ABU/A/,W,F%&<U8B@S)Y]6.;9%HJ(UM>:DE%9JZ:689JHI9,]HHDPC
MBA:TZ:BDEJK-F9,$M`@8\&PAJ:FPQBIK+:A*$I\B",ZJZZZ\?D*C(#3RQ$``
M<AZ3$*M`$4N(L,KRA!1(-PD2P!<E,8"444RYBM9,-QY%;:_@ABLN</08-=$6
M8!#`DA:9S;C%2*@U=6ZZ>K&5KAA@B0@C5F(0X(46!V+AQ4M+O4;.`G.-J_#"
ML-+V1V!<E,/503/YVZ/_&`G_$;%\LPF618[ZKC9-CISY)=A*6!!;*\,LMXPF
M%PTN@$Q6X!T4@!A?G//==Q+^03,#X=DI8G0%)CE0R;GAQ]G*+C?M](1<$<#%
M7L*=UTY68A![ZR!4LQ/TGD/C!]`6X+CH(H(!%_OTVFQ3R&([P\'\('0+/0!-
M%LK*>8[<,0JRDF=>R)VRG$?7B47?`W.Q=,]M-^ZX9.#0`_,#!*18U0(-^HP1
MT(-,7KF67+;39)@/3(P1`0/U>R,\6Q)`[.*/QR[[5`(+@EL6IW4J9U/AB?K'
M[:=I#*BB.&(Q%FL"!UJ--"-;,]@TNL\N_?345V_]]=AGK_WVW'?O_?>T?"L:
M__/DE^\[^.BGCXUB@+W31>UWVLBU^?0/$C0636VQ$1;"K:;^_P`<1!?.\HG]
M;:1_>DH%2]IGP/($<'L!`!C`7/6J2$QK$Q=$!(O$]QXP%083^MO(^7X1@!+"
M[X'3$TENOE8)`O)CA+^;TH5*TY4`?&H17`#,`1U2HYO!$(4N(R""O,!!12@&
M/WH9!$L(D4,FBNIC^/F=[RH#14%,;3V&V4D%A,8U5IG0?T_Q@A=%>$,@LDR(
MK?H.2:X#I8)\A0$>`9BUFM&%[YB)<L/2&^J(Q84DJ4LV%X$C(7C61VM1"V"9
M0TYIK*B;:^#-A\;)8<IN9D:&J1!I3&J,NLXCPULAQ?]=6IA+/_82N`I((R^+
M(1Q+4C<7AZ4C+S/2DUJ^((:,!$"4-F1/'ZVX(&/\\#@W1%<9*SDK+3Q`@BX:
M#DWV![#*Y,R*2R*4*56DH@6\+R>R(8#,"G&08VA,/^[!GPCW!+`$3DB2`7`@
M,6&%1O0<#F']RIK]>E:?:EEK;O]1D3&1>9[Q5$!/[/"#%LK@!S\P0*`$+:A"
M%\K0ACKTH1"-J$0G2M&)EB$`9/!#&!X0AH:6P0)CZ&A%1TK2DIKTI"8-`Q;0
M@-*6NO2E,/7#.BW1SH!L!&;IT&9YE+F:^ACED/A4C7^:4XZ3^.\+.+&?!?Q@
M`35H]*`62&A,ITK5DYXA#0'_&(,:1.H',YCAH61X@!FX6M6RFI6J82!#"<E`
MUK.Z]:T.G6D+1<49<NR%6ENZ207*2(Z8#*A`5-KK8H*JMO_4,H=O2<=,,J14
M/Z3!`F&X)5.E"M?*PA0-)4P#2QL:A@JT=:%FJ$!&+4O:TCX4#6880QK.8-K6
MQE2NE$#C/]0('`ZI:B=V7)(?>S34PE[':,A(QQMM,IBE;M1:+(VJ:Y<;436L
M];,,]6I$PQ!:RC+WNF:]ZA@"L%GL>O>AL)W$%\KH!<<0D6O4.F\ACO@[9917
M8Q\K+Q>^-3+ZVL\QXQU?(;C0W3*(%`W0_6YIS[#5D7)4HF<8@W*ORX'N"ABF
M:4W#_X,G+-/P1H3"WL6L=4=*AJ]:%*2L;>T'1E"Z",`!PU0U0XA1W%H+VV)C
MU'D$=PC!8M>F80QL=>D#5BQ1-51@K*45@1'0L(4RE"$$6`!`C5VJW30$>,E5
M=7$M<C4=1RS-$%#.<D/),`:2DN''K2UR0<GP@Q-H&:4`/K-;I4P)YMW)C7@2
MA#7>^P](S3<\7,#.!Z/X)OOAKR*KD]/OO"`&9&C4#&5(LYI;BH;M\CBF%7BT
M1*G[@-&6E0(1<*I"M[#0R)IXT2=5JZ1!;5(V3P(C`0`3.<CDDFF,XRCP6$KI
MY,2E+BTF7_AYTLQ.%^M:VR=,K?9#ZPBP85)/EPP+R+%9U?_0Y9(F>,$Q_<``
MGM!63C/T#!+(@0*,/=(SI%;3W"ZIJ6U%+<X\\P'-V$AG>`0/J<WH-%(;F-FH
M<Z(/(<9G[8C-%O^3U/>5H0)^.`,#BAWNA9ZAA`2GJ@5&/=$S6&#A+ZT#"+!0
M;&M[%-H%[_$8@)SQB8X[$M$YIDMLIQ8J08A*5PJ3R>]#Y71()U*^/#F_`2O=
MR7;<HQMG>%G+T.R3EN$!(47I&X1@`(AR0.=I4,.);Q[1!`=`YS?_."2B<\U8
M8^0!*T_F%M-3):&Y/#^:$[D[9^ZBFF.\X\BV=&G/7E(R-\$!)/V`$HX@42-+
MM`=I6#K3'QJ&&R<\XU)_!$5"X[/_SFA$8#)ZWV\&W74'A68T,V-7XG\-6"X7
MM`)_!_49,N_6C\+4#%8PPK8G2H0H0+V@=I=H`@X`@KU+M,.N5VC@'4$1LK"(
M2=:0X6&^`H_#@&%BO<7"K\2&%:U8\_?M\'TG021PM0X\XV'@O&79GM(`K"`&
M$X!H&18@?3^\H/O,[G[LF3[[1L1')=3Z2@5&$L,*+``>1LDC-64819/$T'5O
MP=;[R/X./Y"!`1;P`.*'8=3U=`*&!DL54PE&`$5``PO%!C'@`FHW45O@8!-E
M!G,@`^/W4`DV@>%6?IK`7L'1"F408A5@@6IV<*?76F,P@'5G`15P`065`#80
M`$_V4!9'_U(9<`>CMX$,Q7/@]H$@B`D#4T(,8$ZH0`8$8`8+`'`^N%P.5U8^
M1@1#L``KZ%`Y2%*KUP-/V%!7"&5#F`E941NNT%4@!FI8!64X5E5L8`*4TP`%
M<%)*UE)DX`(DT(5>Z(%G%H;>P&U<YH*N=09.&%,L,`>L15U+<`1S.%)H@((D
M15TAD`)XN%!_2&I\V`VD!H1JMH8OE04CP`/7-@808`1%5U$\`(A>N``-,(D+
M=6-?*&"7R`V+EF`>IF8;Y5)L(`91X(@!9P$C0`$590*HZ%#;-XS&5H`W.&&Q
MN`UJ9@8V:&QFH(<4Q0)/$(0/]7,'@`$4:(P.E08:D`&L6%!GD/]L6K:,VJ!E
M/,>+6K91R=A0+)`#6>!E%7``7A!18E95D74`7Q".?L!LZ@B+YH@-?H`&RH9A
MJM5Q-5=19L`!)T5=*T`$"8"#W!A1<,>/R%AC`2F0/@9TULB/<-59[3@!.]""
M+A59!$`$6#B1$H4`<<"/F_=6.Q,4_]A0M@-4L?5+&L1%&=D(!?4``SD&AS&3
M<'4&[0AJ9C``$L4"52"-)C6.-A"/"W6/;V4&$0".'GE6`V=D8^"3(Q5%^34)
M+M0(5+:3/.D'"]!=S/9CKSA5SEB4H'8%",!W`L!Q5/51W[AI*CE183`&>5"1
MK&@&'?E2!Z50@^EM4M5A4E4&9K`:#Y#_*/G59X-6:(9P(\UP#)(I/+4S7[@Q
M-<;C(H_B9X[A9F0I"&-6BP655@OP`$YF66C`?3Y(!DK04`G@BF_E8R/0!WX@
ME94U`3%P`R(0CLSFEA0UF'Y0!@00<`1@`03@5.-@`<^G!@#8$>"1#KJF5ZU&
M"..@!?X";+"T)92#6%N2FM_I%D=!+.FBG<V`:J-)FAK%E9R5!@^0;,+9E/-)
M:A6``@IE`#D0`GDY46E``&.0!/U940[P!"#@@),8650%@`_'`%\E76C@DSOF
M!P'P518@87BS$.E0;R4"#_LW"+!T./TF,`%A.GG&.5SA%J+Q&0LA3["TGG^@
M4%;8=&;`D5<Y_U5D<``%10$N(&&F15T$(`!LT%K490-^>:,HY:#C,%H!V*`%
MA0;P^56#&45?=Q_U-!CT!%B#P1&$U1T)\4H`<TPB`J,*108^*E&850%C()03
MI0:FB8<5P`-S4`/U.54U8`$NL`$*]0%'ZE8']Z9=>`9L&E&#"9\%!5)>]547
M$8!26E!4ZC56JJ58.B:<03EATJ5I(QM@(3];0Y8*=0;N25',]@`&6'UG.HD&
MH`06,*3,Q0$V(`4Q8`%54`("4`%6``2+^%;;9P+9-XD)>5+$*5IF.5I.Q0`=
M5:%^0`"L14L:F@6/UR!7^CLRL@60FAXEBJGA<3*D!%]CNIX+=6"/B/]LJOF*
MC3:H':<`,<"?%B"#KE4`4&"#"78"5<``$*`'D04!2="K9L4&-[`"$7`$4Z"G
MD[A]=5I0Q/EE_E<!;KI4!)`&2OA5"E8&.($3,3$;Q6<6DNHWZ61*/D4..8&M
M.0$&!3-`SAHB9*I0#HM2?1>?!0E6S\B*8>`"'E8&58"@S,4&=.`Z:54!&H`!
M#E<!`EM5+$`%464&$!``0B`%!0MJ87"6P+I0PJH2+/5_:MIE8>"<&8$OD&I_
MT2JM>51/=31!*M(=\C`30)$1W3J:!K<`+^5M:AJ8%,J4&Q@&9&4!#$E:&T!9
M%*"JW45=5*`#`/!O1M"G+94`9O`#EC:.%O#_!@<YB0%PJI8%H[[`4.#Z4FFZ
MI@IUM>9:<`8``B]`C%-@62AP`+58``.@L`X564'0DD\``<"(BVGP8Y_U;Q'0
M`T9@`C;K@\ZUM*4FN;S`4!A55:,:`&H`6:SX!B$`MTSU!F]U`4]`;07%!B``
M9DVW`"VP`C_`C2S@`F,`=6D0!'.`!D<0M#[8:&O94K[[NPO5:&<EGJO5A9%%
MEPYU!BYP5F$``C.@4&R0!BL0=!)%`D$P!BO`%BC%`E(@@!0562N`!0(P`A\`
MOTY;6>F["PT5JE3E5&GU`!;0LC?G`!I0JA(U!EQ856\0!:7H!Q_@`M3'4`B@
MPB90!3]6`56@`B0U_P$:0`!R.[\6L`0](`4'<,(;J%42/,&YT%#$6UE7Y7[*
M"VH[,`+B=P8_0%480+HB50!F0`4YG+D6(`$RBP!W``>Q>P0125$+L`3GJU"M
M.Y!`0+Y(ZE)D4$1$/`LX-U71%U&8!70#VEH&G,4-Q8DOY8PAQ@9%L(3U2097
M0`1U@`82@`4.$%I%H*\090%FT`)'`,03I92IJ5`I``)GW,8+]7/#%,>RX%"#
M6)+=*ZI;R5V+Y@$V(+_=5LHI502N65`PX`(SVI!F<`5$IP95L`48`)0FP%!P
M0+[&)<`M.5$?(`68QU2=5J&\"V5-^\P-A0:>)<JWX%"8ZU((6,BI^;Y+UO_(
M('Q2`4!W)S4$+6!I!HS`;2O`.]!5/R`#"!@$.\`&#G``05`!4O"Z"3B0%C`%
M/@!1"3`.9[K/"H4&(Q``8QQ[K2G-6LQ2UFP+#N5<?[RT&;S!#%U6?/`$N8I2
M"1`$/5A184#%!44#.8##$P4`1Z`%A.M1#Q`%";"7`A"X%3`"*X`$??>?-0``
M!)VP8V#)?K`!1UNW8"4%5AE[>WG1&^RH#TT+#V7!S'55\;G$II5@S,N60#!2
M`$";!<4!5_"R$64"0?!P5F`'D`Q6#UD'1H8`45`!1VL$#!E92[`$G#7)[;RC
M4@!Q#+73G=:6XT>W,+5QLK?4<NQ0$7R``8#'U^7_`$3@U3$5!DN0T!#%!CM0
M!-T%`R&`UQ&5`9?]`A)0`3U@!D%PH)-F!BMP`Q%0`5`@`]05!#E0BH+(@6,P
M!22`!*CK4'H=B@CMR6#5<Q4FV+$`5H`Z4:BEJZF\N2_5R$;0R1<H!!*U`7,0
MEP5U`5"PS!*5`=,M`P*`PS\G!7S0A&S<4`!P!TOH!Q[@`:PE!"W``7:``0YP
MVPKU;\P=R115!E(@!'40>XGF<Y7;V[[]"GSGU&@:`*2E!DWHS7#%`;E;5F$0
M!"OM!R<P!0)>4`A`!"L`N0XE`D]``"```CI;I@0@`3&`SV8&WG2P!*?,`Q8P
M`68&!W)04"`@!+#<4!8`_]T/Y=X.Q65QP*HWI[DE1<UMU=^__5"W3%&81:1D
M$(`<K(!'7%EI`*@0&`'=Q0'<VXYE8`-CP`(/)VF(N`%I8`5'`,EP$`4MT'H*
M5=4O<+=^0`(20)PUW@819>,/]0).$(=,Q^,@;0$H".2P`%%F6E%%_M3P28XQ
M5<_^:UD<!0!)<(=D,`>26%`8(`%X/E&:;0$P(`]_-XY5L`%+H:<`D`,M$`)^
M4`!TX`$*@``E4%`?<`1RP`.T#00`OE`6X.;R75(`0`1(`-D%=[5NF=0TJ>=E
MR(&OSE!_GF&'+<0H!0!```5Y/%%D4`564*,$,,)^<`$"<`52[0<.<`<5,`0@
ML/\$%GZ-^,P!`1@$8_7/2%``6"`'&3`%'N`'<[`#=G`E.7`%Q_GFLE[C*%4&
M4W`#.I[KA0Y1@!U7OMX*$;7?#H6`&,9SI+H!>G?2C\7'524#2\``*V`&(Q`"
M%6`!/M`$%3]10K8$.<#A_TY1:0`!5K``$>`'6=!EB'$&`#`#'N``;``$VA0'
M$&`#GO?F-&[;+J59=3[R#&5YX#7PK!!1*0M11UUC!,X`4,"N32=6%SU28:`!
M#S`%!S!P'G"'$,``IYR4`%H&5Q#I)14&$O``-N`'>4#>=ZBC"H4`*3`%#Z`&
M\C`.`0#G3'7O/`]3!4#G!8?PUVCP"T7T10]1XXCT"Q#_]6Z%FE20`TZ_4`!@
M!`>@W,=N!Q``!"EP!61``GHP[0>PP@M5SQ9``D)`!=<.WG,``737[IJO4'"'
M!WT@!#">`S<@NQHU!FQNVSLOXS$%`&,@!OUN;,.^OIX548*_"A(%^`65S6<&
MU0]0!-"-TBYPZJYE!@1``ALG`WTP`05`X5DL`@U`!=R^!,$]40`<``YPARR0
M_0ZX`UJ`!&@_^Q'P?T-^J!(UXV].53O@`O-<<!<%"'Z"@F$6:(.(B'^+C(V.
MCY"1DI.4E9:7F)F:FYR=GI^@D8FC`62C?F2'IZNLK:ZOJV<!%50Y#P$'(5NP
MO+QF#`0M9WX7-BMF8:XT21!F_SU78\.]@F`A#V=W?M(B1HDL##9[5P]EIQ:N
M%FVMY].K;#%3"V95+.WV][QDIH,6^ZVA``,*'$BPH,&#!UVA&8.OH4->A18$
M4R*'A8.'O108<4%@P9,5`E8LD,:*QH8*"VX\L%"N78H0%39X\),`2`=!.C`8
M,7`D@X8*#Q8PH))@%3M6Z=8]9+.C2AH_9K2-T8``HU5[+?V,B?H*H=>O8,.*
M'9O0U8.K:!T".!--4)H'#)Z@T*8@[:@4!TRAL6!#`KE7#K0\@"&$@+]I-0B,
M\$."AZ`/TM+,*`#E"(,65P@0>+'@"@5SZ*HB=5@@RIAD?H`,*C,B"1N[L%F1
M80B+K/_MV[ASZR;X*H":06&RQAXN2(8A1&6VA"&SP,6(%KM@>P$"YK6?.D`(
M/'4UX8@5$!N6,(@`IQT)*F,N\(!,!TD3$C>TQ9"0HT4$$R$LG"%3(<"+!T]\
MALA11HEF%#YLB!&%*H*`D`@9]!!'7!D/H-;5;AAFJ.&&N+U2!FU^+&"AA':Q
MH,%VR$6GS5L,3$$"6@KD,(!U?M2P0@`CGD(#"?T]L\`;1)!!@``%P))!?@,$
M((`?+GCPA1\`]-%'$5]8%L(.$%2051AF7''##@0@490@!)JCSFCVQ`#%;XDX
MF`B7&GQ`8EIH]-<+AWCFJ>>>G,!2@2`!,#CG512,@.,IR8W_(DL%5P!A(#Y&
M_"7("5/H]\H&5UC`@10/<````'`H$(49!(!``RMP=,%`#EZD84"1:-#P!@XQ
M?"!`%0M4$$-(*")RQ@)4'&$$`3>\5N8H2:'92Q@!<#6*FXJ.T>N@^!2"ACZ\
M\*GMMMSJ"<L8:)0Q+;4.(6&$H(EXX-@J:`0`#A:CE'&%$A.TLM\@",`DW"H.
M2%$!!P(0`(4?/100@!]E7.!'"A9<L<$I`31S!@!1^!$&'SM\-H,?#DR@!`$-
M"+'"::U0^`,+#;]P;"(6/(IL+Q/$0`9)SY9\!A[DXM,/H.BNTNW/0`<M%BQJ
M')PS1C)HP"8K9>P;;P40N!!`"A8+_]'";"YP,(H">R2BPQ7.LA(S%6:<%`4%
M1_A1@@-7^,'!$2]FT$,%1`[B00C""#)!``8`P`$26=2H!`LAK,"#!<?!PA\(
M/$`=FE*OL#$$$.6U$O8J)\PQT]&\;(7(8:P(+?KHI'_"RUF<XX.&/+`T#4L:
M59@QPA(B#;(7%`K[$:,$=0RBQ@,DNW+2&"=HL>H*$'@Q2)%^8'#P"T58@,02
M('APP`\-:""!@T+$L+P@"$AA@QI+M+`T1&94<$,58B+E,B(D$/`*&E$X?<KE
MK!#10(ZI/PCB-*4+H``'^`A8_*IG_6N%`P:0!YJ5S`00L4$0M/"6*T!0$&IH
MP0)>((&E4?\J<:V@@!0L8()<J6$!-MB!!D""`9OXH0,5RUT&$)`#Y%U!`>7X
MP*DH,),=("`-#BA,$6J(OUZ<P0)4",$5<C`FEKW/#]6P@(I.T2YD^,*("R"#
M`1*8"`KQKS8$#*,8A>8A,Y"AB%Q,1`$&(`7[,6V*K/A`?LA@@3LXX`R".@D!
MF+!%.$2@`N=;Q0?\M0,B$,!99:A`"#00`AO,0`6G*M(+!$$#$#!``Q!DPP<>
MY@><I2`'?C``$YI!AY$Y\!Z)M``#5E`L)R9"#OKR0P!&L#E?&6$'IVQ%VJ91
M!A#088M<K-,749'+08SQF,CDDRO"L`"+H2Z-J_!`!4#7.CBN0BC_]?"#&J@P
M24$H0`+18,L*B'",82)"#(<DP<CXEX8A_0!J-7#`"D10ERPLX0$7"$.1"K"`
M$_@A#7)P6P9`0``)$,`&+$$+&1C@&R0RCTQG$L0<-.,K"W3A5(*8`1-HU`MH
M3:,.9TN@M5C!S'\D\Z0HW8TK`B6(D4!S%,RRHCT\T$UTZ,`"2JB<&7"T@P,(
MIPP6"$%$5\&"*HQA`R-$("%F,0,SM*`(#G@#$I3``"9@0&V"*(IC[C8!"02A
M`D4(@&'0@@$)6$H09+C%F)+%HP-`X9FKD<(&6)`7?%"S%P(@PD-SMK-6J&%<
MQDRI8`<;EI(YBPR`3>`:E5#,M"QN"$,J_](1*C""BXR"#"L0`C`3(4(+O"``
M5P@DNX+*@C%4H`':J<,%Y(0`!,2!#@/S0PP,4)@TV*&<5[G``;0$TRX5*QU'
MH@(4EG!78A"@`AM+'1I&H-F<>>X5P1L%8:=+7=ZPXG]G@"L7V4`'+;BQ%ZXS
MX!A:H(-A32$'8:!!#&X`@-ZNX`B;3<``"$`'((#-G*=00P4T`($`=``93&C0
M":!:%S_$X49B<(%+K6*`)JP@L8+X%17V:X40$.!0HZ#M",X0AC&,X*KV0.,T
MU!"".%!K-A#YGR*JR^(6]VD59MA7A=+XCBG("2-ET!IX'["$/'2F!J\I@`6.
MT-Y$_&H%<4A`#O\(8(0CF-(>F*("B`%`@T,,0`$OP,,)^O"3"LC`!EF2`(@=
M8H`AK%,9(("`!::0J6)RP`7"66YQ+6<5+HF(1%[L11I$ZP<7^_G/E(@%_M(P
MYT'Q$\,XMF8K6+"`Q.2`!0^00)&X%`++=A$N"TC!6[_+"A$@`0)E,,.3&O#0
M-@AA`ODT;1DXDH,W=,`(#.#D*1R0`UF?`@,K4:JOJF`!&"B!MZ>0!1K_6N0K
M7D78Q!%F.Z(;6$`[^]FK8':$FYFZ2FJ@L:A4=+"E18@G+"$&(*#>J<XP!_:>
M(@TK((`.[%'))9A!:P60ZAF$`*7V<B`!56B!&0Z,HP#`P"((6,`#2I#_B`DD
MP0J[E8*`$)$`(H06,'>@@@S"G5@5$$$`^/4#"HRP<%>(&!^L&0)L1MH.-.#O
MV2@'-*(2.^.<J5=2:4F4*S+0!0P#P`@/;HX)9F$J/Q0@"2:&:0"0/(WAX:&F
M7KBQ'Q!0#R2,C`-!.&L&1""((B`LTG/QPTD.$`8'X""1>;BQ`6X`ME<L8PFU
MAL8PMQ`!78^B!O1^Q<<;0@8!^!,M?;5'`!R8\KZW&#2K*$7..!`"'<-&YJR(
MPP8P"H`;!`'#%)(`REJ@XX7D\HA3X,.E0N""0V0@!SYX`PW"0/`S^6`*(1C"
M`1@`@@SL8&-#>(T(]$#O'@A)``\(P2$FT`93_QR!5`&P45M:L:,*C.%K(+S*
MA_B,B+F_5"O.)ZF*_4[]Z5[VNPNA%@J@(.V8:QMAPM'#$LZ*"'1#@0,5D+3%
M`A#24>C7!I7+L`0J@`0":&T''*"!`<"P0#\,`(8,L`-490&_D#91H`)"T$PI
M0`)%X@%G<"(UH!H[\`)95Q42P``)Y0IRD"DD,'_,QP*+X1!D``5OP`K1YQ!T
M]1`HYA`QMF+5]X(GI2AF,2<T4`0+X'96@7B(D`$#X"QA8#7,MWX54`)F(&[:
M``5`4&S-UP+>DP@R\`-$D`"M5Q08`$I:YP?E\017,``_,`5C\#L1L`,,4`5)
MD`$G("!T<!,9T`$JX/\'-%`Q3R!??I`!!T`$T_0*$V`$5#`$9/`#:$1;`H!M
MO4`"1Z!TS3<G99!"(-=R#M$K,/B(R*1W06@5:!`!A886.L@Q8Q`\`#`'^A8Y
M[C(",#`&#B,(9;``]M-A4Q!TF"(,?;,P&5`D".`#++`D>C`%4D`""P!"F)4#
M4'<`%_`"5P4`,N`'=M`#X%,.S;0D.<``,E42,>!NSS!\H]`#`L!I]J``0A``
MO7.(@Y(&`N`#)5<!&7</D'B.8805*H86+-`LY:A\*A(&1P`%#$("0=!]B<`&
M-^`"8Z!.!44"%B`!+;%3V90(>X&+#Y!-1W`!`F`"*(",'%`""/`"G'(#2P#_
M2$('`51@!Q``!%"@`#5!#"\2(D]2%6:V8*UP$@M0`B/D1C.`!;ES>%,0`S1R
M@E?!`48@CK#@`)T7&^CXDP'4?._X)W:!`-PGB':1*!,``C_@0?F!C7[``E1@
M`6]@0E`Q3G20?E?580IW"OQQ!5408`,@""]@`$[``F?0`0=``#$`!%;PC(IB
M`160!%3``$K@`&WH!\I3=7Z@`T$`<ZP@0@\0`W]47#X0#G.2!C9`DU!Q-#2`
M!`=@::L``%-PB?8@#4"9F:(#'$8#73C8#C%@`U!Y>%O@`%,@4P8P?Y;)!K^V
M`PUP#(C082M0`V:P`NOF!V@@!5;76P0`2A'@("#`_P83\`(R``%L!`'46#(0
MX(QED)<SD`%^(`&Z@UH0-@@>HQTUX(Q?I(TH22+,$@)<DCK;5%.G$`$VV0O4
MIIGJ^3.#8`9(B4&=^1"$8YG#40;L0Q(SX`)P>0IL@`</8`;G@8][(0&C.'""
M0`%F0)Z#P!93T`47P0%L``)3,`4>$`4P!P!DT'&(0`%58`,DT`9\$`9;=`'E
M<`$Z(#7E>!(!<`*X4@%`T$2K@8J<\RL64"^(L`.CB1$[E4M"L(Y600;EL)Y"
MJBV#X*.LH%WW<`%/H`/O"!L3@`-G(`%8T%XO$`+=253\R`-0D'Q>>05$\`98
M]T(9H`0(1"$6\`$O<`!!$/\"06`%AV&/IC4`>_4!"[`"+%``%9H#0M`$?O`&
M)_!!2)D"([0I$&!U!T`JK>0'/G``U2DA=?`!:K"8KQ$'7F@!46"(PY$!2/!_
MB-`#C&@7##&DHIHGP#$--]@0"$`$4?">L;$!4V!99$`"U@"5&?!6S'&'L,`E
M04`$=*`8#'`%,=`%`Z"A:$4`$+``0-`,%G(DQ\$E%4`'8R(%#&`"2*`!9<`"
M!N`%",`#*3!_4#E(%?`"A@0"(B`"'U`$12``0;"'"X!H.1,S"U!@9C``E:(*
M0A(!>0D;#K!Z5$`'4IH,'K`"37H/:G`&HWJP&F)7YPD<3=`".3IR\H`:(M`%
M8^7_"FV@`<1"1`,K"!=`.Q<6!OHE`34@!5_$):N4=0L#!1CI*V-`+&Q@`3>@
M&(%C!`<P!@X0!(?T"@D@5@U0!`1@`;N5!1E`!*CF<TH``2W0-3/Z`RCB`(7Y
M)F8``7.@A!@!`,F*#/PA#U*@!E?PF1B!L&"K&]6"I*^``E'0J!*2!M3((_MY
M"NAG!BASI;`@0AA(,V9`!3U78$86D/[4`_HY3!3R!`,0`O'S+TB0`C$`/"EJ
M5"<@K3Q4`QX0!@F0`:+B`QI0!4JPED]$'%R":#7PG\-$HU1C%2=@`2C))0]0
M!!5@`3=!(F'[NK;Q3_<@MZQP`5T0!QN;%GR0@7.8'TC)_P)FM0<:`)B\D`!(
MP``K^R:DN`$<`"Z(L@+0@)1DL`0A0`4M\`940`51P*6GT%D\@`0Q`9U+L@$)
MD`1^L`=&,`-?X`%9,@(/^Q!U<`,H22FTFPA$P``X\!#["FR)@``0,)LQ`$02
M`KL$'!:R<`]D`"^P<`0;UC^NBB)M<`?\RPI&&1-,L`+TF0@)X+,YVPI[,0(;
ML`!Q-PA'0KRMP"4$\`#IEKRL(%\5L`-+5C&"@`'K]@5A$`0-@`=1T`,<.0`]
M``%>NQ3PL#1R$`$F/`J#%!3OFP@`8`=6`&%(,`84H@$9T)94BQ8!4,!:?!!I
MP*I&1@4>\H7]\P&&(K%/H!VO0/];[Z6Q[:"/!,``^.B5Z5<#,NH'10`!&6QD
M-J"=KK"S5]!DZ08#-F`#!0`'4!`&88``0"`!AW`#(S,`:N;%#;$'L3,(^UJQ
MK6`P]$4$02#)@V"U-V).B8L:F!4%6/`#Q0@;8``&6]S*`F&DL/``0Y4('/")
MJ6,`3R`%#`)9[KH*?3`DZD1^O?`!=<F]RU2;1I`&%0"0%2`%`=4.>``!\N,*
M+T``8R`#5``!:J`&10),])8#S7Q5^1(,$SP<"`!.%B(&RCH_5=4#*R`!GCPI
MXX=M92"PL1FU0F`&36(7?]`%KOS/G_`%>3P*:;`#I]!P3Y"[:+$!0,`@*'``
MQ@QC5@#_:GY@!",)"PG`!`]0`020O_8``%2U?A!0`&E@!4E@HZ_`HB.Q,I:L
M!)X5``]P`!CU`D4"`S/@1[]!`\46!A%`>1+"%&G`("=@5JS*+$M@!4U3!4H[
M#7*)J:-`IC"U>FX8`V)PQ0WQ!P'`!0"]U9K0R]/P*XE@`#H0`4N,%O,&G8+@
M`!(\B;&P`"$`G6D`!:/+"OH(-CNP!%-,K*P``'1`-@^@`_5B`1H``A<P"[9V
M"BI@Q"W!TL9+`#M`=D80'("2!!V@`$<0`T/P!`J@&B!0FE*```EP1#^PU&E1
MA7OI!XE=S@9D`0IG9Z<-"RQ1`1$P9FE<'V9P%`4`!&7M,U^P_P5<_=N6T`4/
MP8@U8`,#;1<[A1IGM[!=I$ART&$:\,SY*)4+("<9,,U"(J>O0`)+T!86,`:L
M=`Z_0P<78`$_<-AI/0=!T"O'XL9&$`/9#$H7X$^26P`.P`</(`044#%/\0$9
M4((\\`2R%#&KBA8Q]<GJC;9^M5^0(0$-$'^(8!)V4&SLT$Y$T(VML`5G5B9J
MZ]$.L0C^#-PB#@E@\'V\('B-V[:#LK-M1$D@8`7)N0I4YPKM1"1HH`5U,PA[
M0`57,`=2(`@W<!0H_**K(`<6`',6$`%TH$J#0`9SP`'Z)05*U\3]E2,$PA0*
M%@<_P``U2P!)E@!XT`'%_0,_G@&8&_\#^H0$:E,7HRL"*E";K/(07A`%"P;*
M7IV/>P5C%Y8`JY8#>NLV+?#=03"20CYT-X#AB9`%",4@Q\(L51#$/H/57C#B
ME,X(6?T0]`,$,4XN&/`$#^4`O`:5%V!0AD=2`6`%6J,&53`3;#`'#"`$.\`%
MEEPFOW(%TBT(`(!:H$.`I?(#B3`$Z$4JIH``")5+N)TK/(`%AJ%?&E`"1WX`
M+]`'L8/(J'7D#'!&:(WK?!,?LC0"]M<0/#``*$WL$;VA(V`XK]!A5U`/::`%
M54$#LV`*8[`%00`%7D#K2(2IN(RK_,`N6B!R^+`(O5WIE9[%#O$.#`#I=@&R
M,^X'>4@%EDG_6U<0`&,0D$X=EV\=!D7P`A40!`5``G/`!Q1``D"PBXA"-\Q#
M`F_)/^?080P0+6K081?Y7>?`76"U`Q7PC$[5`'@3!%)P!D9`!E9@!!O@`H.#
M.!W'!AT``"4X!SO2`/&PN:R`1ZW+,?7!UC0!O@&PBU$`X:/5VD,0`U"8`#!P
M`S0P!R"`6=.<"/H5A8*P`_K&\GXEQ>:X"%E,\"(^\`V1!5I`!K[!.3L[?)6T
MSJZP`\=`!U.P`CE0`B@QR_E5`4HPE6?0!FF@`/60`7(2!RS]3TL@!%9:3$?!
MTF00`<Z^N>T%L_UQ'G(;!JNW!",0!$=@`PN`!%,9:F!E`1`@`$B`_P&T5O64
M;_E^<`-TX_6QH`0R!0!8$`3.-P%?8P3";P5`$`/V(9FKP!]Y,`ZB`0`Z<`$9
M4!1`0+:"T"4YX(6@+W=*,-?98O=:C?>_+0:3?@\L:D5E\./D4@<@T.*"H))(
M&0<H`0@D-A9E80$K,4TK.09^CH^0;1H5A0E^,VQOD'X6FYMA#S.>D)V.%@ZC
M?F%J2S*>"4`$%BT6>PN4J3(_9A80(!5#`P1DCV%C$`M&%1I-"46JEIB:JF:+
MC:E>`R-GCR1+8]RICFPW*V-O#Q9HQDLU0E9V`.)^'R,M,T=]?@A^%%]H<$S-
M"U-A6JI2\_R<Z;(`34)(?R*"`1.QHL6+&/\S:MS(L:/'CR!#BAQ)LJ3)DRA3
M_@D0\:$G-&G".2)0QZ7->6QB7"'F:(.4!V4>^ICR(,Z!"CP=G;$0Y,:8%4>N
M03HC8$4:1QU\^&'QB&>!%@DM>)B'D$P0.ZA&63@ADYRY,V0(A"!P=12:'#'"
M.")3`0(#,WHWH;'@HL8(`G38^,FZM:O2IST\*<CA(J@C$B$(/=Q#Q4*1*!74
M0!J\A,Z8)3'D;<)P8!@'2";\),C@B,.,*V'YB4/XL`R0(P5<6F2ILKCQX\B3
M*U_.W/A-/R\66(:D9,/SZX\*#`@0>,(1*TGG%4$:9P7@46I:""EC`8KNVB[&
M1%8`*8"?`B\2?"'_\H-`V+&[3;7`%">HU08:"Y3@P!-`%1/`$B1X`D`-P'T2
MTSQJ_`!%%Q8H$9PC]N&G7QROF?'``3*Q5I<?`!C10GBI)&#B#CI<848J9+A@
M!`</1.`%)!LL849L5[&AVCX@^!'##!7X1]9[:EU'00XI/&31%LUEJ>667';I
MY7$VZ:'%BINH\01V+B$0!1$(S*&!3!M4P-U#.ZP0P`93+"!3*F:T<,0-ZAF`
M`12>%9"$'P,X$D$8EH2100X56!`"6&0!>-`F05;@XR86\).`"PQ$,,I2(<CQ
MB`Q5H("F(V&840$=$2R!Q`*,JI+!#K%%X$`31I"QR`<'"!"8'R18<1Y._S?8
M^`(58PP[2JM4X!%#$',`T(<4%IC*@0-V^`%'DB2\<($?'EAA01>X/4D6FC54
M4:4X7\8K[[STUIO<0W!$,*<XE*XZBA=1K$#&#PQ(<,T&@^R9R@E36,#!`0VZ
M9,P*8N0!P0JB52F/`!TX0`0.KMPQEPTY!.'D;I9&20H$0$R+1%J<(,`!`6:<
M888$&(Q21@5WO`#%C?X^<L88#`PA!`1WA%Q&"A+X<<$'%/#@AP-+,(#$-22X
MH.=#+%"Q`!D+:.;2T$L,H00$E-2\3P+R`#""'T\H(,`!$$CQA!45A-7&NFB>
ML8``\-HK^."$%^XEEBV)T\$`$CB4D'1!0V)`#O_FH0&&!",\5804N"3DP20D
M*#$,=B=`0/,98,@`N!]L\.&'"3MX8(0`2QA!=PL%\*96RI[H;H$0"RRQ@QD0
MQ!.S!8O\>(8474#Y2!H$'/!AY(ZPM\(!"[3`P3-%!#>N`1GP<(8:.2S05`@1
MS[.'!`_T`!J,+KUA>AI2^U&#'P'LX`@.'_@1PME.(`(#+)``W?7.>9P*6AD4
M]@C#.?"!$(Q@2(CS!W&\P`6B<0D9<D`]/Z1@!0MP!0<RD(!<T<PE1*#+"R"P
MK^?X`(0B)&%LIG:C,-"`!1`8`QI<8`$R/,`%#_@/WQZAA@I$@4<_\(`%EG"!
M3CT@`\<0A1_*T`+]/>+_!AU0Q1@(8)T.[H4`3Z!"!:8PO0&("0!=8(,"KJ*!
MT26$#4@8Q@P@<*SG;&`%6M`"&M5XE03P1`H9>`$#`A`#"%B@B$3)S1"#MH$"
M060X$HRD)"<YKR\@KH*>0$`7@&:3,%`A<G`(6PTFEP(<R&,./VC60W@PA3&4
M8`068.!#$$"H45+)E'Z@C2.^T`<1P%)U/\B@'^(BQ`!]P@Q4,`$9X#$S`JQ`
M`PP0`A\LL`#=I"$**"C#`;CRB,%HP%1>;%4%MF<R&CC@"'[@0`=,`()=+:&%
MXN!`"P+PAA!L[3H?^`DZU<E.!^@2G"F(@`7L,(+.^0%ZBC0F]7*@!!$TT")8
M_Z"D1"=*T>-LX0L5\40&EC##YU0S:&9@0`R*P`8#E*`?V'+</$Z`K8<9]"8&
M$,(5$G6#DIYT:NA\`0DN<!2SF:=WQ;S4J!9`A2V8@0`/`$($7I2&1<R@!0+@
M1AD(0`!=EJD"`I@>]?SF`A($`*N+^@`,#KJ$6'*M,V580/INDH"OJN$$!PB#
M6/UP@H!`!P<.N$(%M@`$*Y!)(.I2*/4*^="*@"$+%4VL8A?+$<1F=!-E`(%M
MKD.&OUXG`""XQ09R0($!A.8A#HA`!4B`!;]BQP!',,\`]K8#-N1@`K1I'8MR
M0``CU.`*X%`9RA;IB3(\0`HM@-2QC!&$&50#"@O`0O\:1M"$(T'"#$L`@58C
MMS,HL,`"%8`!`I)PE.F(HPVW(`'EX/>0.A"A=HY(P`!H@(`2(*`&<`A.!Z!@
M!2:<%YZ/,""G$$B*#EY``@&PCR,NX@4Q,/;`"$9P;Y/D!S4(\R%G""*:$*"!
M+2X@!BLP71U3P:T@"`$(.7263<I#``ET00ZB>.\-!J`$KC0@#E=80!I<0(`E
M6#6!E>+M*.)RS]%4H04M>$H$@F(`&J1B:`0`@6*HEP$;6+@)%6@!72#,!*CD
M@(4B?HA;M'"#(Q3A`2SH00(,(`<)@&`.`J##$I30@R8]`)Q`)<O>!#OA`TB!
M&YS$"$83S.<^4W+!7?F!5ES_\H`LOW$'>0A*JQA`@-PF1`_F*,,@5'J3,$3@
M`1N@0!C*T``.K("T^^A``B@@@1(3H`(,F`'T;J#;@_`.QZN2PP.^^@0UA&`*
M,BG#N'IK`2DXU%\QC:HJ`@`!*Z@R(3,;0PH:)LN$)&`$5WC;?7(6!`\H(0HD
MF`$`,A"$T2JA`D'@P%'O%^?=S%FHJ]I`91XAAL+Z^=WPEB"@BV$&73TD#>05
M!PN`8-=^*$%L\X!#%"Q``B-`8%(O>$Y,"1``.(3@``>8`"HXH`($Q$`*'CCJ
M$-(@I##XS08<"``5X@!K5^O8)@40P+[Z%`4R!$HA3R""H0<FA.G:9`8@&%8&
M)*"._X=<@%!J$$(%I#"%L;*5".!1PA,*@`<H5$$%%S"G'HB%!"O$H`5"\L-@
MJK"',80@0OT-++JO@X(H<-(16W!WO-?.]B]EP;&)@T1D/7&&`SP!9D.U"857
ME(`XYAL2#@A`$&+0UR84H`,70&H67%(>)*1`!*RF`!O@8``[,,``9>B!Z##;
M@AY/L0)*X(`%IF`I_9+BU6&_#A*@H+`S2&#PU8A!(\H0@:AXHE5)-K)-6""%
M^OE!!$_X;$+.\(1[4"X-D"_#%6QPXU2XA0'CV@,&4M`#&G2`!E6J``B`\!<G
M5.#8CBBB`&0@J7=Q(J%C[R04GI#EM`^8P&V/O_R1<UB+>/_"`SI(11FJ<`3G
M;J+0#Q$!$1`.$W`#-&-HD```=D!'-;`$!(`'!1``24`#M:8I/Y(*8-`P/B`"
M-``"&"`$2/`%'I`%"F`J4W`%$-`#%K!6D)`&5G`',5`!![`WII=?J)=?UX$@
MW@4;[!$"T;$"4I0`(.!^F^`W5_`:"2$"(;`O!0`"'9<0DV,>6[`"(X`!'?B!
M2*`,2H!WF[`#7H,&KD,;;\`'$3B!9U($!``!+X`M._@(T#4`OY!5YR=G)X<A
M.I0*'841]3=_?-B'(Q%1]@=9;=B"/S!UG@!B%0!GJ:!2+T``GI<*>K`$"_`"
MZ=``:L`")F`"*G`HCF!P2C`!FP#_!S8P=%/D`3?``V60*#N``XY0`!(P3@_@
M1N)@"!!P`T?U;T'5:@E!`4?0;-43%'QQ`"3P`"&@`HYP`5'`7[[E`OTSBS(Q
M`XWFBX_@:6,`8Q"`!F5@BJBHBC!@!E:0*)MP`0\@4G[`!ZJR!6]PB9G8`4G@
M`"NH!GKU=ZRR1;;(<#5H"N>FB_.@`V0@C7EV$6_GAP(YD!M!07'W"&4PB)!@
M"''U"!A`36I@!51@!/Z7`1UU'PRBD)"@`DKP`!R`!1!P!0X@!/VS`RF@!E(@
M`?<C!$8P!C_@>QBF!'Z@="EP`C()!S'P`F^P!)NT!%<0!W*"@"]A`1'@`423
MB^4V#P5P_P1XX'^]91FML@(]P!=ST`A#(W.CP'$@H'O=X'M3<P``]UU@&700
MT``T:9/>DI,[V049,"``P@:_0`8((`27``(C,)(EF0(DT`(,4`4R8"Q""5D=
M@@,+P`#HIX^C@`%&T$7S\(\6P06`2)"229"1>9#5PTW#IQ<7<`>=4P%MX(T]
M(`\4)F"R00<58%D2@@5!D`;%L@(O("FN@``#8`#6@0:6T`<%`@(6$`4[,`4N
M\`5MH'M;P`?<L`,H0`<J(`,,,`8G`$O2F`I%I`0"0'J[-0HQU2_B0`9WN$K>
M]7$L<`@D-T50,(B&4`$;8&0>,`+/T(HYL`3RZ`@Q)3!U8@5%0/\%$G`!PUF<
MQZD"`$`!CM"1!Z`#4!4&'4`$!F!79?`!L3D`.S!(6*`US[EC6'4`(6!^!Q0C
M7_409H!??*)V$5&9DQFB\P>B\_80!J`(9!(`K^$W%7`$]T0.#!>8+.(-`3`$
M$&H&5R`$#;`$=[`'2G%324(!0.`'/@`!5>`X8)!%?J``._`!0U`]L$0"KZB1
M+N&-P&4!S6<*KX9:+0`83ND(--`#8_!@";$%;>A;$O":-@`@:3`&F#D5LQ!@
M@=&!!PB%&&8&.F`.:'!41(`'*T`$3?JD?E`')1`<+*`_-V!(9Z!527$&)""D
M56`!-?`#+/@<XD1?4."?%[H)YF4C)?#_I:H``F-`I9O@F)`DHJ@J?P:)27+'
M8`FQ!W8B8F&@%P9`!RLH!?[9-6:5$-Y@`6"P@M-A#`R0`\J`!!<P!PEG`CX:
M`WAP%.6@`#IP`HX$`"(P=7*``:_X!`-@%1W$#GYQ!UPH%IM0'O<T!3E0$Y#`
M`7:0`3*Z"5N`@-!S!R10`2%`&X8P!8/V".=T"SCC!QL08Q%*KC(P"-/A-RM0
M!-70!(OG!T8``G"@`$9``859`G0)`D/@`+CJ4/*0C5I0`3*0![(8-$;(``P@
MAZ0`)6ZA2FKP`#L`BI`0!R!`:2Y!;GZ0$2":JCCK9R0*6:[:F`S0`$NV"13@
M`D`#/0\@?`,Q_PD?.65#20501``GL#=@0``&``4$H`0F0`,[4`?<8`/T$06Q
M@0`!4%MB8`[M:A,3(%IDT"H00(2<8"EA\!,GXPAIT`*Z1`,"@(37X;:W1VQ\
M<%1TJ1`6P(G^2@49=%054*FW]Q,;,+;DY5L6D`+((WDTD`!<P`:,AHMT"0<9
MD#,;T`!^,`9@(`P2H`,Q&DY0$!J&0``W90KOD0`/4`5SVRHMD!8)$`&J@AU$
M:+,YV[OOMK.0@`%ZVYAX$``MD'#%0`3"LI`/X@KB```[0+0T&I@#,P!Q='<[
MH`>M=`9<H087,`%#FJ2+00(;4`5C<`.P)+.,](1*80%KJJ5^8`!,4/\!>=!*
M?3L`1:`!I"H.CC0/I,("8S`%79169K)AQG`%C&F=WI<&Y;%AGL`7>5`#0:`!
M1E`$',`L88``;7`"1O8,(*``;*`_>/!])V`N$7H3T7MV6P=.%K`W"4`$5W``
M\T1W2@`$1!`%)SP*AEBS&'&SOOO#B06\Q7"V:-`C>K""61!3&J"^[6L!7S`*
MWC`&>Y`9)RQ..;`#2*4937`#)\`#4)(&7_`&L%1/5T"FC/0#CU@]H.>.'E`>
MF!.6Z=HP`8"NV#&K+K$S=R!ZS.<`2C`&3-"_HV$!$M",XVHG'&`#:?PLU1`!
MVWH%OGH-%,`$"!"MD/`%#_``?_-2D1/%AB;_?KF#`,DB*3WG"3DQ>FD`JA#F
MH7_0!4#<RHLEQ+]X$[XR`";`:'C0&T.GJ1Z4&3W`F?M;A!)0-4%$!V<'GX[P
M`6-+!PU``$)PMBY!`3]!JBY(`$'0`B&`%*GP`1)P'FHP!3$0M#>1D#?AC3F`
M!PP``6"W;_T&"?!X`#GC"$-A`3+`/K\\%5.`-AK0`1HP=3D0&9"@`!@@`,#P
M!`S@!%ZTRW#L"="U`DOP`%.`M)OPFG61!@]@QE6JRC[LRAH=005V$;W%MPD1
M!E.PG$FP`DJPSGQ"``/``ZD;#"=T'0``8H"1<'#@`2I@`&B0!Z;R!'70`,/J
M!.;`%&`7-,@<LAS6_QI"(`5T!*^/R`LY_`@O4,^.(`(KP`!/D`-6(`"HX'H'
MH*0+60U$P`*C2`)WP+0*=V7<$0-^P`.WF0+<@`5SX(I7NP`YA%T)O"I?(-#O
MJ1"W,``A\%//(J?,FP/.[(88O=&(+4D!&8BM^AQF,`=+80,IL$5>F0K"*@&L
M`'XW<0)>LR<C0`)JH`)AD!_T((D20`LK:@(5P'X+0P5/(!6>L`%8MDIV<D>)
MO!60$]BH*0YF6FFCNG5E\!0`TLV#.#0,H`0\$*O8P0(M``5QD+NG$@(`D'`7
M@`7?8+P6`#@T(`,5,``(R`(KT`"H/`-_(:-L\`+FT8B:_0AL`#;--C1L,__.
MAYW8]/U`7.`%'LVS-K$!N>T'.7#<TY2,#S$8#.#/SQ%:#1*>CM`'%W@5LOD`
M,9!"Q)`D'<"*3<4(&QD!@]0G5@0)T+RK*]4P'@`Q"JD'4;#;F^`#K>42O?T0
M`-"F,O$$$/`$)$"4J!`&,@`$%PA9XSB\-N$W!,>*Z829-``&:/=+VZK6CB"\
M?D`$5``$SM4&0.>-0_T(&6!/$=HUTA$V"AD#F/T087`$R*NA\UW?9AY!)2H.
M)"``2?%S0%$-<Z#:$8#2Z(%5-I<*"F@%;^,`,^``*;`#FD!N8<`#AR$!!F@&
M(C`LH.P'.1<%Q<4BJID&:(`%.!`#W\83%)`'FCS_"J%5$*7U=R^0!H4-!SG@
MO//0XL][`T@P'?E$"-Z8!#7P@J@0PCT+"7%!!'0,A55&#(N>)"H``GIPH&"0
M<A#P`,N<`QB0<%IE!&<0!4N@"=<9N&%0RS\`=F6FN)L@">TC!"\B#C>`XJ/`
M`;?]7&5^YN9>.&D.Q83<!D\@,,5P&FD@!(N`RJSB*@%PYX\0TRM``!>`"@F`
M!C.@/Q&``$V0`VPP`(/45`SP21UP(UOP`N]2('G[`#^P`E;`%2!``@K@`'S`
M`1!@`P)@UN*P*T&0!"#&H2SB+ZV"\H^`ZJD0`[_F!RB@MD(S!A70`U<&Y5K7
MWU^]`D"0ZYXP.1"P*`\?__%^H-58D`(L$`00H`PD"P)\@`%S`#>.H`$%X.]Q
ML((0\`,I4/!$N@-M`+E/8-2C@@0K<`.4X\".0.\A'0"(WICE?NYR[R5<D-^-
MG0II\&!'L-1#N01B&@07>61;5.60<`)EQ0-$H/1^$`$LX`%!I,%2[\A10`4,
M$`0[4`%0T`%OHP0MLM8'X`=Y``(J0`(<4`@>!`7'Z`<]L)SMFJAC$"0@7JHV
M4-BC,@:?F`HN_]649@1U*IA7\`:W`"`Y8N`"L@)W_0C)O0`7L/F=SP.?'_HJ
ML/H$8`*@@A3TZK("X`4(D/A2P_@>L`)G`/F6T0"J8GDL#PE)P$)O`$*RE+;W
MZ/\2:-``@3L*IEH1&3WW^+\<L#Q%M0X(?GYQ%F6"?A@6"V>'C8=J+4(<%E%P
MCI=^919*!8UA1BXY-!PQ)VE^2!,QC``)3Q4].A5I80$M'&9!"VQ1?@)^/B1^
M`WX3;'X>*6%^'WT^`0L6:)B."%$6'`T5AI@H$6;4X>%P=CO'CEO<C0!`4(R"
M&55C[]1D5G8<#TH.?F%F$1TPE:D0($$C%4A<&%+!P4^O7\%0%7CR@,4=`F3"
MC'EPA,"#&WZVC"IU*M4J/P#ZS0B8@$0("_3"79!0J,L#=8[*:"`CKJ<C-#G>
M8`(GZ(_1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MUJ%$O_TDME0#CR(>64(`0'
MMOD4$:&""SHQ5N0PX)/,D@$%`-BQ8J8`.`1<:.0Y1)>-C14K=$`(L$P0&@M0
MJ$AP(?8-"\)^BGQ`\H*""3\<;DBHH,:G@X0D@%@Q>ZD`"#.-?<H6Y&7`Y4;I
M',FP4%K0!RDW32^HL,2$$RM`4IX9P]I1F@HYZAC(L2)-#T%04OCIX\>R(`!F
MEDQY$@3V(4TC]"QH0<0/8,&8_3R1<\!`!!6O<%([D[8$=9Z8I#`'+;,52$(4
M%#A"E!]<->C@@Q!&*.&$%#KH%5)@B27(!0<P)H@!0E3G4P$-+`$""`0LL$0,
M9JPP1TKB^$/`$DHT]D$&?H``_Z,?0@1Q0Q!0@'$%3)BH4<$(A$!QVPU2-#",
M(&\88$<)`RQAGCAZ\47"$F/$Y@D(>-!5X)C^:/#%(;D)PL$""R80`$:F'1!$
M#*I9`$L`2Z0Q0282Z'A)+8@AL<P%A]3@!P]]I,2&`"F2L,(BF)!1000]/!"!
M''X*TJ,?'8B!C!P+$-`<-08P45T<*WAX"3EOG#/F;&<L@-<A"U9HZZVXYJKK
MKA9^E9-8#BA!I!\&Q*5J.#2@&(`)5T"J20@O+!"$,#W%ZL(,)&QA`(Q;M%',
M'@]8(`0!I/74HA`C,.`!2K3RM,4$(#`P3T\`;,F<"])0$X,-T[SJ[QF*>!&2
M(11(T?^E('4`0<"5X;`#`1-Q<,G(0%)L8.<&@J1!!;6.`/S`!C,8TDLG?HC@
M!`<N5&&"!,&%XP\$34C!P`7=%G-(!F,4$("\7F)B`*IC_#BL(PKD$$),_LY6
MA@VSUJI4%KQ&+?745%<]%1>^-A+6"U3TY@<%*^1;[9`93*%6(V2DF(\$/0M4
MP109?"9(#$.4,-H.#2P\FP,$,'!#05T<L@`7(5%1B$]G+,%;J%X[$H86#"?]
M:AG7I@."%/WZD<&C2&-RP1(+>'!%RX>D0<`3)%2PP#*UC*%`D178@#$`.9`<
M@Q00D$"`J+.A`8%:='L`@@^"J&#!D)G+%'89(Q"@WR$\N`#_H.3^DG%%"DXG
M=:'5W'?O_?>V@G7%@GZHP0#'?MSFB`BOR`!"GM3X,VT:<HDI3AI!2$"#'S0T
MD`,#"RB""PYVE@'L@!HSH((9B*"#"R#A"WDP@Q(0D`,@+&%Z#9O#G&8@'@A4
M85W.F1?UJ)>&!_Q@>@E`PMG$X8"T<&`O&/1$`"H`!C-0(3E^J(,3TO"Z2YCA
M"CI@@P<ZD"P(V"`-5CC6!P2`OD;$H`5$Z1\%TK`%,A1!"DKX0>/B)X06S"`&
M%;""#2[EN`!$;H1D,D(%#K&4`(#OC7",HQR?,A0)X$@09EB`%>B0DAD\P!')
M6D(.4G>L_2P@!!L(0!!FX)-:5*`&_S^JP!:BD3D056<!4SA!(TK@@B"<`0&B
MP=@'2I`"#X1@86US!`#L888:+"$*+."!`UI`@`/P@PTQT,#ST%@@"F1`(U'@
M0@)R,`N?9"D)/>!+*AL!,"V<8`Q+$(H:/A`%N3D.FG0`PA6T$`4(#,U-&+%`
M".XH"$>-0`(>>($?=J"#!1`K`QTYXR4,``(HDF$%05#G!YX``0%THFA*Z!PO
M9\."*DQO*=N;HT(7RM!<00U#F%A.%QB1!BUL0$5T\.0A:!"'*XS!!"T8FD_*
M\`!HB5.=U;(``U90@0I@<`>I:LQ`-$`\/U@``ET`P0>*$`(UR&$$1`@!%2#5
MDRTM``QVBO]#$<9P'T$(``(#L$$,!SJ;`@R`&&?I2"$Q`0`Z+"$`<5"=0*FA
MABM(H0=7\`@$@,`$"?`!$X]A0!"HL,()W`"5@C#2';1CTR"`H`UU\,$!"@"%
M,;3A32(4!]!(8`,+(*&G/R5"%,*SD5U2U2=H$(.7EK*%AGKVLZ#E2D+_((XR
M:*$+(I"4!LS`@`?<D0-#JL%HMBB;"[2``0*H007&Z1,C$8"<815IQFKI``L4
M@0'11(`7PO`"'CR`=.&00Q4>H(,N8,0!%]B``E``@.LL804N6*NK+CO2$*CC
M#88;:R->H+@-2&&%!<I`W\H5*TG^HAX5((`E_,"&&W#.AZ<K@`7_I&"!%H2@
M"IU`P0Z&9-E&>*"Q()```-VS7'5F`0`96(`-"%`$\LXF(-0(K8A'3&*J@.&A
M1JG+"'YI!@@H`8EVL.$08O`#\AG("DU8&15D8(86Q$`V9O@!"`K0!/B6D0I*
M6(&/*V`$!YB`#L6DUW/20`*^<$</<AAF$P"P$RA<0`E&8`!?/2R3!:!PAK3]
M$RA(`.51S0:F>#U/!?+`CS%[P@P?*8``H'O-$`B`,D]\``#:D(0+^@1$#R##
M#J#8`SEP@7`F*``0%J"$!?``8`P@<T]@((&QEOC3H`YU%L``T9[X0PE+74`5
M8+"``*"5@&/*0`@\*8-U`2P$+!B##:P9_PX5+$%OB+,`%:9`(R4P@`%;Q<26
M`L"#$*R@#`FP`PMJ8`(.F$`$2#""P/9@A06,H<$>IL``5,4&'8S/F$!0H`R^
MNDQQG&`*\AHK$H&0`0DT41`IL`+O1FJ!$5#A"G8X``$@(,]+H,H,')@"%1A!
M!@6\0`\[&,(&#J"#&G@`91O1-#5X<``W-R+4(`\Y:!-:H'AFX@$$P!>XJ?$%
M`51@!GP@@P]<$(("P.&]=X"!.,EI\!7`6C9&VC`!A(L)65M@`QI@0!E*4%$*
M@``!Y9/!`@[@YRA4H`D!6(%Z+YM"*;R##22@PL^I8:\36(#H/LE`%%J[\EHL
M00=,J-$A^DN`9/^+0U(H3]'6!<&"*2Q`!EJP``G`\%8A<`8'.9C!`6*^`P@P
M``1Y6*/&F6F$(K2[*$GIK,@WSWFKN?$HLTE!$-!0!C6480)DF.J(!,"`'`P"
M`==F@P@$P9/P/`$$%;B#MQSA!`AH,FE)][@CY&`G&3#J#MN!1P?$LH$0!,`0
M0(``%N9`\,L/M+]34,<>#+=R/^SA[#UX;YI[$BP&P`E6=M(!<Q@Q!@*@(&EA
M2%?W<6"#!Y#@#BX-"0(PT,,2',$"9A`':,$`=#`&*V!CFF8`:6`.LJ$4G]=Y
M$!B!N/*`I.43$U`N@N```G`=K[(#!"``.Z`"<W`(1<`/)B`61\`$WD3_`*]!
M`%A%*Q:P`DGP*A,P''QV"8QB!AZH*B5P"!10!@<P!=/0`7@05VCG86\P!0M2
M@_GG$WK``'DP`,#V*C?@>`77$T8B!22%!!8`388R)EXP&I(G#DH@*D90?8UP
M`IU`6%`@@H[Q``S0:9-W"$Z@$`6B%*,E@7JXAZ)5:N(P!@@(`@-@?8<@!S2!
M!BJ@3ACC"T4@`@I0!`"``+NE`4)0`19P`'N@:R#D!V90!H\!!;O7$_TU/F%P
M!PW&`2$P!GOP$@-``B+P`PY@/T00`%G`'2ED""^0;DTV>05P!"C%7S?P`%<(
M.Q"@`GYP`',Q&QXP!390`3Z6-!^@4K3W6R35_U0^$4C@8`'B@%X!P`$VH`5)
M@`(=0`4TL`4\0"@S<`1?H(A.503ODP0[0F9AH`0(V!-)\06:QX?ZN(]6L05?
M`'H]L0/N%%%FUA-ZQ@`']`3J=`;:80`&``>=8`-I]0`YL&^2T@4DH`_OUXFT
M%PGV@PDL(';O8(H!\A(LX'(CF`%ZP`$&P`%(X`<!,`8_)A1^8(PXD@$C```M
M8`5'L"<>-@0O<@@A251DTF,[8`!E(`%;0'X'H'0<P``:$02\UA,<<A,6(`#\
M`(!*D`)D$`1!B0EL@``;X%&-H8V8L(P6X`%*\`!+\`(7!P!'T`&7(2[[M)`X
M8@!<`)%A<$H@,%Y49?\&`;!WF)!Y_\B/AGF83H&/`!D.)'5Y99`#,>"3'5-+
M&=`)```#*.$`.^`%:2`$!H`$!R@&B^$E_F`B0T``=R``ZN`/]7,)&:`!AW,(
M)-D(>E8!(*`P!*`#"E`T?C`#K[,#LT@!'^`'7H`!>!`#(R`(GN('*'`&Y+*(
MO,0&63`&7M,&&G"#8[(<*Q`'?I`&(<!(E^``T9<&OND'?^0'C\%;XE`'1"`B
M-E4$+OA'`-,%&-`B=A"/4')L-E`#PVE3X9D6)!``$+`"&/!^)#`!)B`'BQ(`
M0E``$W"9F;F9G>D'/V8M#3%012,!W1=B2$&!B/FA(/J`XH`#HR<;X@F=YV'_
M`:<C`'(P`U#'(R3``R&Q`EH``H:3/,PT!A60!/^C']K)G8)P!E%P?HTPFWY`
M(H)4D02@!$+@8DWPHD53!0<@`E"P`G[G`SKPHLAP"$SP`B50!8B$1BSP#8TA
MI$0:#@7P>Z7U`#;@`;6@GL40?5O9"&9)>[G'<X2A`S%U"!;@`C&`!)DF"")P
M`S=P`2K",1@P6V&@!CH*`<-!*!FH!%;`!-''`$]@!P1`!'?P`G(@!R?0!8M@
M`/Q$!5F@*3%Z"&<P>WY``OFC/I(3/:IWATB1AR!:J_LHHM1``UTS)F;0`/QP
M"&BP!+C``#.0`0;P!NTQ`$HP!1``1ABXIEJ@F@)A_REPP`%H>`FSZ0%<4@8$
MA@;+40$LP%J?@093P!,(,`6*0"XN(``SX`,[\`02L*K-D38!@)\%L@,@<0C6
M.HR'8`+')@IU00!'8`"QL@QG\!(XZI]W1@`'U`@8D%Z.4`BJ<Y[`&E`#@94R
M<(`]<P:20@!6(`8OX'-H\!)G$"M0]``0@#$L$!P8$"YCT'Y=D*RN%U!5\%8]
M(`RF@P7[XR^UP*\-V*&V&K2&B0584X&8,&[^@@90<`0[H@E1H`&']$M)\`5=
M1`8"`$5CDC8-EC9$B:UE(`)W\``R,`!:I#6;$`%60`4$\`4)T`4M8`)/]($A
M4@,9D"!X@)YOX*`H(`0?$/\&8423!:(&R5-O1]@(<O`20T"/2T`".^LR+<*=
M#A``7<,/>$`'?G`$*&``=9JC;>H'"4`$5Y!F9FDZ?V)&86`Z!Z!>VJ@&'K$"
M5<``=RMG+O`"+K`$0?`!">`"5E`$&X9K`CH$%$`7(!%I?K`!)\`/=M",%SH;
M!H`%@3E02#%J0CN]?/@%A4D-.["YKZ(&6O!6AY`V2B`#.%4$+1``1Q`$8P=D
MX,:1F(`!=7`'6K`$0X![!0<$#``!0Q`N4&0#Z!L&FJ`!`H!):HH$8.`#(A`&
M++`,"G!(/X"BX<`"$C`];3`<W:>!%3"V0R<!++`>RQL.UF(%!Z`!$V`(%Z!)
M"@#_`@U`!8SY`%)P;M10I]H+K$L;`EKJ"!^@N0"J&F9@!C%X`'AP)K[``'M4
M`1(P/J_+&"2E!$"P`A`@`XYP`B),PB<`,!:`F3XQ`R!`B++:%45+O5ZLAP'B
M`EKLN!*@JOU@!@0P!3G@`C?P$ALZ%#\6#NS;"!0P'."%!,R26(U0-#V%QG3P
M`UB`L&A3`0>PEE*@2;\D"$#0")=!4E*0(-3``B-P):7BGN*@9QP&G^9Q3[E%
MQ!@@#NS5)0:@!W-C36C0!S'L"`_P?N$`PS)*#;/4L(V0`5I0`2NP!$R@`UP2
M&XL:`"BGHCN0=3'P,>@:$Z:S`*ES!:PQRJ5\""00AY"*_PE;H`713%5`^\78
M'(&7X`$ND+!)<P9FQ$RA\CNQVCM$;,4^A!.8#`Z/`0'.0W9'4*I!N@`,\*QW
M!@%4QP`1@`5[X@!9\)*&4AH&T`&F,P#]B:I0^P[3X7/6ERP$@`0Q@"\QX0\,
M(`28>@?5+`@;T%('``9A(`)RDP*T.`,3X``Y8`4]80$U?`EU.A`+(,\LC0`9
MD8$7<0J:,*#>/`$Z@`=DH*,$8`/'9F2"4`L$,`(Y``$N4`,?32TBG04D[0`P
M@,9$`&(W8P-VAT9'P04>FLU<'6HL7<Y)4P8+\(N90""\E`8FTKBTH@YED(I>
M4E9$8!"-X`5'P(`_<7FQ4G]-V?\>')`$.+(!DN8';=!A)A`"-*2O"Z`.%P`%
M8B,.]&$!)RG4\YR6,P2=`&`$5$`&`T`.7T`!/[`N33!D&,`!H#N&+[S2$:L@
M0.27-H4`X&P$7%-(9."1CI`!3("B9Y`&H;(`.L#*EP`P$F`#"P`!;^#9H"W:
M'K!3?J`$8^`"%VH`,Z#'Y'448$!J77W=)<8%8F"T>!0`FD8&5=#!5*7+P^'`
M'/E3C:W:.B`(&2J8:WH%59A)1R`P%"`"G3`!4"`?7,"%6M`#5<`:8=!%XT>;
M+N<^\-,3`W$'+-!O*9!`$J`$J+`#P1L#*6`0&-``=&<&6Q`$*8W:=.H(N#<&
M5."JK8W_#$M0`0,@F8?`FD#J`"_;;FB0!A;0;7APT'*F`25P4SU@X4Z2"4<Z
M#`BP,W$#`AGM84=1F-B=Y"+F1HV@!JG,=60F`02@P1;P`,O;B3T``6#=#V/0
M`G9@7E1E.E)P!)/R8W/0L"B@'1K@"P7@`I.2(--1`?4(2+AG!'1P!5>-"?1#
M!!%POV<@!PWA)`E`%Q\@![.7!2@+IG:2TJ&("=JKHI1B`1*P!WS:!@I3&F10
M,01IU5#@S=10!KX<!"\&R7BT!$E@`A6@`?R@`C#``4]P""7B`BG2Z!JGY+9.
M8@%`.(Y1`6.,1GQ+54HP`$M,!#W@R9Q8!F80.RA*RF!A`9ET_UFUP`!`,`#(
MY@%#(`A*D"#&R`(G,0`NYG-[QP;O,P8U@"^>[FX>408L<*$%0!=S@``#$`,7
MD`/P!@(JY0+%U>'B\.A$$"(Y<`,5$`6,H-)5KL%G'*9@45)X*AN];,L'$`-G
MHA'(=M1)4`-ET`%+*6LV``)04`'NS4NW'O*@A8]#_0#G[F%E`-\#!3`K<`("
M2@8MD@1F0`*1("E1`",!$`)R'0:I:Z=/H.)HQ/)@,`;-2H(AH:9-X`(,$)OB
M(`+XH@9I,>`-0^UDL`5([P('`).^`:A-8`3EL1SNK.^M_!,6L`0XP[`M$@,6
ML`<$$`-I\P3[$RL'`"-GD-_3*`34P_^Q[;<"1'`!CQ$$-@#4E^$%:4$&XS+G
MFF84*";RC!]'`N,'!3F'EZ#;I#Y"`T$$"RX!)[`"];QV#]`#-D0ML7(#-7``
MR<.:<4Q5`]$`1$``4?#JGUPR>&\`#7`%6\X_,@8"+H#XXE!E9@!"(H#W?J``
MY_`$/?`""Q,'`$0/:&#:CN[A?%HDD>#D4<`!\]64@C=#%ZH3)D`$2##167?[
M/1'CP[$`Z3("&1D!Y>$$+2#=DF\46]WX\M\]G#@&DA\.+V`&E4]"*P`(0CTK
M"S<V%F=E%E(;"S\;?GYD03&1EI%G"P]9EYV>GYYF!%$D+4H(D60(`RMF8:"6
M-"`$9B8N8V?_L+!R%A8I>`ZI""`&9I8"/Q8@$0]EGA:Z?A9MNM"@9A5S,00!
M(%4+B0]0+!95,!.SSI]G%C89T?"19686#!!'4B$C%NKQ_O%_LFSY0["@P8,(
M$RI<R+"APX<0(TJ<2+&BQ8L8,QY4\^"?1X]%!A3X^"E,@!4N7%10<XE,!20D
M'DBA4&:+&2TG/I5Y$"$G25!AHBRI82;('``"*H"#Q^'*`A(2^)&DH('`C$A>
M7OD!(<2!@!,'6%5HTF`%&5#68%E`I597F#%!EDBIT$_2BB9\(!#(84Q7F0I*
M4/PLJ48"`P8K\'P8S-C/GP!<-$J>3+FRY<N8,U?V0D!KX\]^U$S1_P':#YH%
M?3N%$46D"`$IE=XN\/&)#($(7DJ3"9'&@HL0(2`T@P=#PH,:4"J<_5A@`(&U
M`YKD.9+#``4Z$L#XX1!AQ9,6$!:LJ($VVMIJ\,HL2%.R"H,E0%:TR!TM#8$[
MP3X[.%)%S1DR8U1@A1)B+%8:/'^(H=F"##;HX(,05L;%`P&@<2!H9@20RX7K
M+'#%"0$P\$8D:%A`!QN>F$0`#XTA<,`.6JG!``'+Z4)##C26P,``GOT#PQ(N
MA.$"#I:(@$$.?;S@@@D\,!#5(14\\<8#"R3PC'G4M#48`$0LH,@#'D@!`0?P
MO+5"723Y\(0,GIR1Q@($/$#&AAQV$N&=>/_FJ>>>E'4AQEMU-F:2$",%>LE.
M51!A@184I**!E6U:$`(G'QEP1(U^Q+%"`#V"LD$%`9A@P0(Q+"$$I/%\T0X+
MU+`P`0D^D'&!$$_XD8$,(53!AQ)T^;':%3&X1$0=EZ2%%EOED32!&E#T\]<#
M;U@@`0;PE!C%.Q\YD`.9T:#1&X5J='H@G^26:^ZY=XK1Q1]^<&HH8Z>E@>J[
M9C`0P`L5Y-%H-']%`(<_!L0P@H61>#`%(DR%8`$+$D!`@C$P*$%`&BCJ4D!2
M'851@@R"\9&`"@9P<,89$5P1PDGL79+)`V"8L<(-%1O[R7E:>G2&#2EW\L0*
M@EQ!Q`7PJ%$!?O[_."#$`73Z4T8`#SQ@!IJ?H2OUU%17'5$6#T3F1QF8ODO2
M;@2_>P(9`1!P@VL#S`M*&BOD4"@L0M:(P@&]1H.!!!6\0819%TSH1PITX+&`
M"RR`4D`.%9CA@!%<^'&!`"EL)T`D0N2P0AXACB&N/`],,8,%+$MC'K(S>P1`
M&NY^<H.9.[A,A`'PF&&%$_!X0`74'H6A1@!*I1'V8`%8+?SPQ)OK105>$!1)
M1UXSMEKJ@9;A##M7[#`&`5N4.08$=$3CF<2IZ;)W&D!`\(,(GKBXG14/&&@)
M"000H($?6)"GV@M;]`#!"@TL8<'OH+!-!%A0@2E48'3HB8<!GD"":/2E_T13
MB,$85E"":,#A!PPH$X?^$Z`%S(DD)BF>"$=(PLQ,*`L%B<086-(\QISA!D=X
MVX6D9XF_#(`'%M#`OG1A+=(9(`DON`0/IJ`Y>&S@"F/PP`@8@`00^$$/?7!"
M!_S0`0D8X%]^2,,2BH"B`BB!'VBP4A]R@H<+X"$2(``#%"R@!B&LY!^KR9M]
MU-:):>@B!/'@P!.HY<!+J,%G+[#``8#VB1A4(`TV`(4#`D`;KWE+$RO<W"?,
M<(826O*2F)2(GPR2"IFUD"2GJT'%#E0&;EDB#16@`PDJ()*@M4`(N9&!#?KA
M@07\#QX?B(K>"&"J*RQA``J(A`QKA(;OY($*<__BEA,I`(1(L"$!!A!""P1`
MA!:$[Q_L>$`>KJ"#":`E2Y[XPC>B<88`7!,6YS1#"VI`!I\1RQ*:"@`';+"`
M3P`!"DEKX3Q`%P`6PF(,CD'(%[20R8(:5(1;6!<G?44`W'W2(VH(0>%(F3W5
M7.\&1D@E'4.Q@BH<P1(.H)L_87$!(EPA#N/;6@4D\`8(V(`(6QF"`WY``?0!
MP`\L$(4K$C"'()I@#WZ(@0EJ@`8$K&`%#T!"$'#1F+^,0`KCF1DX+4&57KW3
M$Q]H`/1BMXX`%<%EE3"8!3B@A.%TH@PK?"@H=O<`"Y@!@))P1D+$4($O'/2N
M>#W7%[)V$$L$`*!J=9[_&1XPT<_4!!0EHD(-+CI*3W@`"G\-`@D```0KN"(:
M==B;&9RP@B*>D@!!&$(%0@"&#S3P!'?P`Q&,X)0<1$(.?J!&+2<@`1A\8`!!
M6,`+%.90DAQ!+YWSB27L:(GF,"!G`8C`#OV0@"-<Y2-.!(4B/`>G"L3@#A/S
MQ`NB<,[`J@9`5/*="B.1$"U@`0L%\4(6(O,'];+W#U]`85[G2]^,<*&N"#EE
M`'KK77B<80L!H(%A*[I6P`22"C*TA!!NN;5ZC""?G_!!9S=P,+CZJFPE,`,$
MYK`#V%&@`%,8C@(H<`141B(`P@P#Z")@`^5<B`(K0)A+GG!5XOKA#00X``'.
M_SJ%E)U@`<$D271A89L&6.`%$-BJ'P"P`,_VU[]DT(0%-!10@TQH0@0!PV$(
MX`4MSRAY73C,`_ZP2<[4UR#JS8*:O\`%NU[$"\F;#)P9\@4W,XC-"\$S1.8L
MWXFP+"&6<!-@G_R3#@#!`XWI`!]U@0T\[.`'A+($&*(PTE2T#7:@P$`$+*"W
M*U0Z4A,;0P@X((LEV.&C?BB"#^B0@/PTR@`Y@``3C`"!RY9&!6ZLRZ\J(0U4
M4*`<`EA"UU(!A0C8FB1]*%.]$'8)`(A!"?PE-"C&\*T`@,$@`/[#`Y*G!06)
M80O=3M`6...%^V8!#`3=P@+.7!`L'.8P6L@"02]R7O_*U%LA[E8H@^*]$'Y#
MI-X,H$@`@@=H2ZP0PM+V1QJ8^I.1Q>,,8W#!PR9V`BET-Q*K6<%S+Y%9&MW@
M"L>.AM`$``8")-D!$P`J3$EP!`Y\@00@6,`,5A"$#81@*:4Q`!-6D+-.K"P+
M%LA`L*L0A)!;(@$#>((99C*8:.M"!A88=L+KTX\LH+<@7;AV``:BB2U$INOL
M35X6*K!>!G!AD^S^P[T)(F^,K%TC;S^(%J[M('^7M\\.B7M$Q+``+3Q`"^;%
M@IH]8_2IPS$`&B"=TIQ>PW*XA@$-).<")!N)"=R@%2!8`L,]8A@+\"`'A/1#
M`6)@@"!F``4L@(`%BK`$!NS_X$+QE*0E>&#R((3`!<SNQ`2P(`5UG$$*K?S(
MQ;N5@S3(WO`IJJ<E$$*`=Z_;"UJ8$1B@+_W';!F%<\=OVM_>=K7/_0_C!C\*
MU6P0+)A7[0'HP@(B<_;SJQW=`WF_%N+_A05T(3+G;?_5V5Z!+GBA_O<7$&"P
M`''F?0%8?]^G=@.U!?47/&JF?I'!;P#X7G\@@?;'7N87@%Q@?P&`7NBU!0-(
M<`.%!>''$%QP;N?5"VWU`-1&0\CG$6@P`K7B$640>?Z@`"T&!630-(4%"SL1
M`B!`"#UP,(S7"1>`-UR#!0E0!*(W197`(AD0`A5``F%&!"XC!)@&"@B0A:`P
M`X=@_V&=P`&XAP12Z%"9,&P[T8/Q,'R@H`)F$$0O^`^4=`D'@35JE@4!ESQ>
M$`!:H(=\^`7XQ6_J0@!I1Q#<1U!8`"H$D`5=,!`$L&Z-V&X$@`4/(`98P`T4
M\@=]=XD#P0!:$"+)XXF@R`7<T'=JAP5=\`"42'?@%R=90`!=`'AJ!RKLM063
MN`#!`XN@^`>BR``+P(F7V'<$%6^D&`"F6!#$"(NR2%>4N"Y:8'^3R(L56`&<
M2(JQR`!XYQ"7<!H`$@`J.&5F0`9E`(9QJ`9C4(1;0V#5@@NK,2;V`02-M38Y
M!@0T0A(T@`6M4'GYX3BF%PDW0`L<$`0!D`$C<08$T`+N<_\)]\@`5)"0E_`6
M;Q0-!4`$%2`#E]ASEW`QA7=*@[:&-*A\<>@/Y60G!A$`"D(0"P`&F\1W*[D`
M8W>"V`A?!#!OV_=NV-AV9*=V?N)_#U`!?X`\!;$)[66)ZX)N9(9_Z,4`R2.4
M2JEMYZ90VW9>X?9_!A%OX/8'I.@%J%A^Z_8'TT=P_,8`=C5_ITB)6,EE\::2
M!+%MR"@0!)658C!^6D"*!'%^`4>6'6B4I)B-#=$)QC`/AU(&:6`&8P`ZO6`&
M9J`&98!PTF8&`Z!XTJ6.L``'YJ05`/`$#$D"`=`"'!"/*1(B-T`2'-`"4F`$
M.$!J!1!$,F0$7K@P(?``[&$_88#_0^(0>GY0`DB4`D]0`42@-CM@3?`@"XG3
M%$H6"0G0`$K`F)T`!TF08-?@#[4D=2'I$0>A?0G2!5_0?`109]II5P\P(Q5`
M=]18B#IYAR=(4`$7$%JP5P.HE(18$.EIB.C5=ES`=]&8GF%9EU9GDU:'!6+`
M`-1(@?%V;P.Z?_`U(_[77N87D_B)0N=%H/*VG^_69P6JG^#7!140;_,&<!7H
MH`]JH1$!"E3F%M*#F+94`:."F-)S?%YS!D]P`)!Y5I+I"0XP!T9`)R2P!)RR
M$U"`0X3C7Y*"+;@4%6@``B2@``[`!P4P!WXP@QH0A4?68D+@!Q&``$W@6CZP
M`]00(DU@_P`>$!7W$CFJ%03#DBDML'FPT!1C4`-$"@L;0(Z?``!V`%-]U"U&
ML#K3&34&@7=MAI7K11`GR%Z!.F<_:6?L=HC2J)Y_P`WF9XP&$9^GJ*A^AP6_
MF*CYV:&H:)[UQHBP6)7]J9]QMX<54`&D^(M,::$/>G4::G5=8)YM":&).'`:
M*I_2R&^I"J(0`10=:3-EH`:(^8UC8`9I0$-HP(71HP1%8*R',J.=P`("%@EO
M@'M)PS9"X!)08)O250%0(*2?<(2@\B\8,#F.8PE/T`$4$#^T`@$,D`<1X`<(
MT`8?P$)SZ`!PH&%!(`5-"@`-@%.:8P%()171``.]@!P1V0EL0/\I@V&._,6&
MD6!*>=H8$K(%/DF>B)J36]EW`!9N!9&3*KFIZ$D079"4%MJ@5YD@6GE>8D>3
M'7J56?EV8$!WV#AO.=F@9?F6!,`%5CEO8E"`.7N6T(="X$:*7R>RMHH%>KF(
M$@$+G_89:,`UA`DZAX%[!V`&<;"/!Q(&1``).L&L?M`'7@)26E"P#QD`$)`$
M+O,$WN1`L`@*1D``1A`&#G`!N7`!^)-(D<`#`K`C0@"@#+`!#W`%'&`E;/`!
MB.8'2>`'"_!19X`!N2$!3>H'*)`30>!BT0``>$,&1I"/GX`!/X!BGV$&$2`8
MDP0+,X!S#^L/;_4)E8&'\4<0K3M?B!K_JTCK;EGPGX::B(FX!1[[D_;'`"+;
MH9:Z7K"(H:<H!JJHBIYJC;+X=ME)J7UH+]&'0C3[H,HXC,+;!<3;ELI+4*E8
M-L/XB?<)O/FGC#$9HIU`!G`:/8)I!K9T!;C7!49`!QQ`D(T1`]?J"8>UG!&0
M.@"P`U3`L.P@`1X0<0ZKJ[-T"1Q@`6/0`!^`!"]``2:P'21``3T0":DW!CO0
MIF2P!#E`0$$``P=@``<P`5PPI2E0P7X`!9&3;&]0.)JRD9VP`4M0"S:`II;`
M!G@`!>G[#P!P`\T9"I\@!U"`D:=+3A>W(-U'7UOPNE]`<.9'=P/59BIKB.>W
MQ/`5/`/5B.@U_V\!,)8$T<7PM0`+8%=6;'X&^AAV-8'@][I>J04!"&[G=6U<
M3,:ZFWX!",;U-\8EF<87B)5B/(!8B;W?5H%HO,;P95YV]Q"?B7QAT*N_:@$$
M@*+&Y@1\X`/."0HDTZ7+VFQ8(`$XJGDLZ@<\0`77<P?1,BW5$J1W0P"U,@#0
M:@!VX`$?(&`7T`8'8`%I$`5BNQI+<`,2L`1YT`%O<`0B8""A1QX\T`<`X`-3
M8+IIV@(+P#``:[`D@`5BRB%<0@?/&@G7=#'%6<2ZL`"21!!U-A#UV;I6U[K?
M1JA;(`;L%U]8$!G&:ZCD6<]Y=\8.`H(^F[2>,&AHL,/>E0ADD"&]@/\8WR`$
M1V`")Q"C+B@/%04`=%`%_<`+#*8+6&,!?!`!H+("3-`#5P"C05,!#'"XW'P6
M6\`&`,`M&`#)>2`4&\D.KL<[,>`#4^0',^`,42!ZD0`#06!6NG`W#[`%)B6=
M+"`$#EDG9#`"+U`QJ=$<&@#0X&P):+"TY%6!?Z=M/1D\6J8%T5@V%=#5%=`T
M`3&J&<J+GFC/:'W/>(*'83O%VN@):4`GXAS5)+*^A?F=!&`#$A``=K`#9?`!
M;,`%5W%8,O`#.4,!&"J=E^`%&@T$EM,79D('5ZBLJB$[1B`"T=0HW10`"L`"
M20`!2$`'%6##^%L!4O"=0(`!4V0`D0,`3(#_``X@,8IM"25%`'C0!`RPD0B@
M`4[F-:M!!85C##1`!P]`U73]$W6I(/1)JEO7QKR8/.-YLYH(!J_(!5X0<$F<
MUMJ-$.2WUB1($26QC0P+SHT\#^QK`2*M%U1P!TP@`4K@&4Y`"RS*!D70"C4`
M`;UM&OZZ`1/42+H`<0QY`4S8`3<``B,``2/@`0PPS=WB)%L4`/NZ!2SB!P:P
M!4D6RC5@+R>P`E80HT$U`NA8&IGP!#D@`C8PWL=-G>*;H5R-0EZ@;K-ZBJ\(
M>-38?=CMUMN=XY84#VE@W"G>)KUJ`1!P,"Z5#PR0`V60`4'V"7OP`V.@!U%0
MT9Z@!J_$!Q9PO_SR_P`C(`,M0`)V4%8S,`!6@"DD8`,!0$?&-04PP`$%@``I
MT`<JD`8#4%:Y!PL?L`\L,`!4D`8]&9K;.`:SW3PR``%=H)P_W@D^7M6V&GA8
MT&4,\'<Q?EYC]Z!J-F\WKN.8CDG^,->'_@]E$`++@09CP#L,<`4/<`!MH@D]
M@`0M$.B^HDXWH`-W0=GG:P55,`!ZT0+R;0D4/0]7`#.6,`MI@`+.4`1CH`1^
MX`(ID`%TXW3AFC=$D-L90`0B4$O#@0%*`,,M--Q?V^G5XKFZ8*'JPG8X>VWH
M=CP@BP6`2,[J9>F*FNGP/D*8K&L@Z>UK*`6%HP9!8`(N4QV7``>L$`-ST/\*
MH1QH$R39*^`$M&X)J^$DOD@G7E&P$$<%P%X/$6`V%U#!P61UE@4/F<5S-;`I
M'4`#$]`!"C`YD$P%-F#H+:0"$V[O;E'OL&"AU[W$I&I_8'#5H+(%OON3UK8)
M-C[6]!SO1#\UL`#N\H#B,.\K8V`#.%`B2Y`$$S0#````L68&,;!4+/\)/6`%
M##`%)"`><>!?<+(!`M8<NWY63;,'%F`J#-#>?L`%.O`$^!W*,=!91=`"55`K
M.SLY',`"#O`""X`C$7!3WL4"E[ST_;SU`>5OMH@],LD-/IF=2H%>@&@O[QYP
M]X7C1=_YY'+TH1#B]HX&$5`)5"X$)3`JHZ('927_^LQE4FI@`CUI!)_2F^DQ
M-#9'VBU1`0=0!5&@!PN`C1=@!5(."A^P:3Q`D64P#'YP`@7@`EL3%63@`QZ0
M!PS@^HQ!`TGPWHI?'XF^?!&A7B![DIY?_B2DM%"C^]T_Y5'P`JO1`EL0`3=@
M.:[N"6R@`R`7"2(`!CT`"&8K.VD50@9^B8J+?E\5%F6,DHEA9@0V*RL+#"UJ
MDXQU1%=J.BL,!7!2"0`3?@H(1F)($Q$,#PN1G[J[NFQT&KF\PL/$Q<1E`<5_
MR\S-SG]>#`$!#%[/U]C9VMO<W=[?X.'BX^3EYN=_NF')C&%C8<;Q\O/#E0%A
M9V,,$&;P\34MQF2(D6@+_P(,"LXLF+(AP*!/!000(!-/X9(5!/KQJG/CBAD0
M*\8D$)&(HAP$0/((@`-B0X4Q/:A8\$>/&`P[>FKJW&DLS`)CS;)HV09&RX(L
MS1B@6\JTJ=.G4*-*?;:+'2,T5GEJW3KI3)D>#M"<D9=E"@$EB0!X\0,@S(D"
MB5XPL$'"PA0.DA80P#%OPJ:QO&J$[#'%0H\9<'G,\`-$1(X09`#X$<#@CI0*
MP;A*PB#$A^;/6WW2'!9TJ#BE4U.K7LVZM6MGN]*@Z0JZ]E8:=!K$HV6%S)`7
M(#P4@``@.%X_=2Y3.Z"FPA0$BRRD(2!!<C$^%18\X'7A@84=$2IXPB(`X9-$
M$?\$:/%3!`\"";6DV%X$0(,%P//S%PLPVQ@7,6)P(5066'"QC!=8!`B-%V"(
M\0>!!E:#Q1?+_+=%A5]L8<UK'';HX8=3[7)&&OJ5N!4/$N#'2T<'5%'?"QYP
M`,`1';#@AP4%F'!)#U6,$0`5?)C1`D&)6.#'.A5L,(P#2CP0B9&?U)%#!63$
M<,48//AA@`%PP*5!$T(8"80?&>C!@0(<0&&!!'+,5P8P)L:YBQF>Q/-`!0\\
MD$4%?"X`#0%W#H5%G@0$P.=0#.!)@#5Y5A#`@WA>".*DE%9J*3:\C"&BG)Q^
M8L\%NY3QP!AGB)$("GZ0,($)<K!!T!Q!C*$&`1;T=X;_71N,,44/-RIRZP@>
MZ`(`$%:06.0D;-RP`IVCG@&``SMXD880?L1`QA@()%""`@KDX,<,"OAA8QD5
M1+"69E\$8$:G["JB!D7QD&O@`EL0P$4T?X#1Q1]<*#5HOO;V^P<#%W81@%#\
M5B`@`9<V[/##K_&BT2=C]-=NNV=L@84#DZ#!P'E^!)L($R_((0=<%$CQ0`@2
M4"E)<P=P8%<%C#0G`0:,3'#$$O=$)\D>M\R@,@&\^B$$"5GZ0485-?AQ@0]B
MJ-`#=(HHT$0"Z@8QAW4[(0#%.Q>'+8\96#"#\,`5@D'-'UB4?;92J`F%105:
M:$%`%F=#K/?>?)O#"QKP3B*:_]CMTE"#&%PG4H8$%MA0A09^'('$(A<,0$`1
M`60T&B-F6/%$$@1,(@@1=23BTGV20)G("2$\T$,$!%00P@X6+'&`'S6\0,(#
M2$BQ0QX,$'`#&XIT(!DB;/0Q&11+V)&X/#6,8#'AU$M<]C)O_YF=OVZ;!C?V
M6F`1?MM>Y-WW^>BG#QLO64GB3O7LDB'](F<0<``1%5!A0`$P%#!!"AI@@!D>
M<"45>6H,*Z"9X,9P!1(,`#.?@!(;0$"`-/"`'_"P1`V:\P0/F&$,:$&"`)5`
M!!>,(`_),`,%#-``CB6B#4;P0!!L0+5XH&$,@8.??M`PO7BD85]LVX+WV/8H
M@;7M0?]#K,8?MM`%,0`Q"P(RC?JF2$6]"4-3N]B<#DNTC@-T0!'NF(()A&0!
M,/B`!558``>>X"1CH$&!GW@CM71AI!>T(`!@N(6*W!&"*3%``'Z@0!HW$($'
M!.$`+ZB`#1*@`!`T(`%8\`,7N."'%]"`!&IH00Z>MXL+@&!B6\Q/&&92DS,0
MK%Y%6892Q*"G3;"M>ZH<V`+`4`$-G5)AYJNB+G?Y(6&<08NA%-L9).`\1:"A
M<3*HPA3R4`$I(&$B\U!=!&O(B!U0P`+>T4,A,[,((1"``"\8`Z!>D#F*N",(
M.3!"!6Z0`N4EP@LG\,-Q_)`$,P0!"YQD1`)`L)A@ZL<=P#3_1KT(L(7L<>$!
MTEC4$;/'`"Q(8QD#O5`N>4G1BJ:&*W7R9XG4`(7,-.<*29#"#31'CP4`(9]%
M:H,D:K`$<4(@#0U8@;$DX0,;]*,Y57A`#DAJ3`O\X``'@$`4V(`SY/B!#G[P
M0@TPX($<K&`))/B$`9I@`T1H=#X`Y8E%M\I57G(%*U<UD1D"(+(C68(!J"OE
M&"J0!!I,P@(J5<0)IM#&2C#`"M14!`*P4()%5((`"S"@NRH0!3I8@0I5<*L$
MX(`S$:#@!7CPPP&*<(40@*&:+<AA6#\S2L'.HZN@#>WYAG$&STH"*P'=;&@$
MD`.:G*&'-2&7$EP8':K5`00NHY\%_[1``4;$H0%Y)48E'H"%'1#@"'!`0@9>
MX(<!["$%1LI`"C(P@!7,P:U>`$$:4JO:G51L*Z(-KW@O58_VZ>*8W.WN3M#`
M'-`\@0`@L$(Q%6$!Z,1@60$EUP#@X@,IS)0>^:#"$<P``25D@41`8$,1X+(6
M`-3@``PH0Q%V8%7U:F:4L*W)>#?,80X1`XO#0*^%+6R!$52@!P0^0BMNA`")
M?$`8TX&"$M);C#)88`$O6``5()<(%PK`!P]8@02:9-H1U^28&=9PAY?,Y*@0
M(PU%ED0^:&SD>9PA"DK2R@)&$(,'2*$'"T@2BRT0@.99AP*/7(0#%+`.X1%O
M*V0@P`J<X/\"*.PA!_)!@016(`4@/(+*528&&J"IF28;^M#G(,89,EJ/[P9:
M,PJ)`DI[8@D=Q%D),,C.`YP``6#4#E1*NP)?*JD$M_KAF"X`M5;L&H/I#(`-
M%`@".*L`P4=K9=":U0JB=\UK;V"U5K;6##*8RQ.%5&$#9EC"#);`@!$<@$]V
M($$+A`"/2HPA`NNJV17VRQ6%6$`)+;O"#K10@?\&NR9D"$"4E=SK=KN;&?H)
M`*//O1,*F('8.Q&5%#A0@1CLH`7]6`=4[;DUW'%S$6:H`!W>K!51D?N;8*.W
M3LB0[=J\^^+M+I&Z);X5$E0AR?&(,P%:JJ)CAB"<4-W"P>DW!A?_#(\KP`,V
MQVLRAHI;'.,X/[0QS#MS3IU!"P-8=1I6[H?F6$`'%H"O,&Q,!1OMQ`<'B'C/
MY>&.-/"<*SG/.I-WOA-`3_T39<!%B31H*`%,6A%DJ$`3&!X/5ZGXZ_-P1[KU
MH_6Z;]@8:IAW3QP-]WFD(0(I^*<X=V#/J/*B$N5F^S#*,(#@]KT>:/@)W>U.
M^=#VY.K"E??CXQZ`)X!\*TZP0`C>L(`?&%Y$"W"!TX5Q@II[??/LJKSLN1H/
MS!<#RK"71^1SK1D.G"'M`I#!RC*P]`=$01@9(%7NA2MU$\W^^10-^>>7/Q\U
MC"$&IOY,&2)AUP%04`"TG81@0O>)!`2>__J"KE@8>&\;Z+N_BA4QMTZFC_Y%
M<"`'YQ=V,!02`A:4^?2+@`!C8`%O0`6?H`<+4%;UIPMJ<`^=)2?O%X'I(P\@
MQA-F8',+N`LOD`,DP15@P$VBT@5Z('K$EPBA,!%6@H%'\@2@E(&90G^%)H$R
MN#=CLVYN%%@NR`MA!P)G)U`9%F?!5P%=D`'*8@:LI'R,0`8XF(,=LPC\T2DS
M&(4/HWOL1P_K('],N`AD\`#8QQ-;H`Z9`P(4M``S4!C<!`!8X`)$QX07J`A/
M"(52&(>5,@^V1P_6]WKHYP`:T($U\84B8@%7$`2PDVL7\`-8F(619S$XU"YR
MV(@@0H>UX0YZE_^%B@``0U"%PU`ZQ=>"?@`'#2``>)A[8T439(")^>&(J.AA
M\K!]MG&'E`AVLY1];@2#DJ``1B`!M(A^D9<9I1@VJ?B+K!%,5?>*GT`&-M!7
M\;*&NB`#1Y"+Z#>*6GB(<0*,U!@B_J0&-IB#ZQ`"KZ=RQH``1-!;Q+@(8==#
MUD<XU9B.3S&.5:80IK@(WD@,T,B.1Q(`6.B,[:>.^H@.-2&-GR$K]$B.4I!E
MO!"/NP``UZ*,3"@65[6/#ED.-5&'FJ&$V>B":7",!:F0+W`$\\2.J?5+\/.0
M(AD._5B1JS:)XQ@&0#`'134)!ND^9_!%`9D/[#=*H9B/(YF3VU!*_AC_D'&R
M!04G"2^I"`70!<U'C/804%D5DCK9E)AR9!BSB#X9,B-`D(HPE'Y@`A*@D-H8
M94>)CDX9ELWP:#;&E2Y8"1'`AW[PDADP`N^8@2BI6F(YE^E@:PDYE:4%C[F0
M`A+0,_1XEX%&EV*Y$R8Y'X#IDPX``F&@<B+0!6G%CH>Y"W$)EH+9E#LAD7$2
MF>R820U`!#]@EO6GF;KPAL%4F4ZY$WFG0THXF=K8AG\Y!J#I!U+I3Z9IF3JQ
M#J&$CU,)>]86FTKSEKY8FSG)$YAY,=NUFTQX!AMG#+T85L(YG#M!!KH9)\I)
MFLB9>S=9$CU9/<\YDL6VG6*S?M?)FVD`FW98_X$-V9T/J17H&5:X-YXSAPS3
MF0A@U5WJN9X66)CA69YDD)WP23UAX)^+4)_V>9_[>&M^:&%9,`V^^9^$8WW+
M.7^2IUX&6J',\"BZQ`5;,`T;8J'9D"Y=``9-`44>6J+I@Z&\Y`5.)`8=6J+I
M$@!;8"`F.J.&!@8B:E$,XJ(!L``*XA231*-`RC=($5H!,"'=F2$R^A1<H`4M
M&J1.FHY>L*%-JI,:&@`4HAI=<*5/NJ4/F05BH*4/*08'PQI&RJ5F2BE)NF$J
M.@T:0HTJ>CUG&J>&!D1-]@5B"J-3&H%V.@U?*J=^VF0LRFM[.J;N1R!L"J8<
M<J-_NJBMH:(YAP5;@/^H&.<%10H&:?HA6R`IC+JIJH&B&)<A`2"C/WIH7X`%
MTR"IE;(%#L*IK!J6I3H-"4*BH%4^D&HVE]HP^M*JNDJ7M%JD12H&0YH^>-,V
ML`JL>0HQZ;*KREJ;Y<,,&E.I'R(@60`&<*HQ6``&LEI%R;JLW+H4FEJ-8D"L
M;6.JX]HVP8HW>".J>!.NY4JNY+,,7X"NH?4%?M*M]FH.-FJ:Z"JKTGJL2[:D
MMWJO`NL-GCJP>\,%71"P!KNPV%"P#-LP"*NP#SNQ$(6J%`LB7N"O%_NP"+*Q
M'ONQ$$.G(-LA&CNR"QNH)OL:5IJR'YLA+-L:7?"M+TNQ#CNS3Y&I-NNQH9K_
MLU(AL3PKL/GZLT([M`1+M.B0!25KM-R:M.B`($S[##[KM.)`(.%0%'`J#C[;
M##Z+L^(@M0VSK4H;MMZ0!0P0K-_@"-I`MF;K#0X5#M]4L]VP!?6Z#7*K#74S
M#FK[M7`KMGSK#'D;#FV;#7\+#LT*#@U5#G?+#8F+#8L+#H-+*?3:MQ,KLU"A
MME^@!?52`12"!03P4']`#9KK"`P@16S3N8]"MET0.Q2RI*-[+UI`(3"Z1/0R
M%$*T!:V[1*,[#1>:*!<247]PN;#[*-/P`$`T4*&J!;?K!0BEN<;;#*!+(5KP
M`,B+H=3P4-/0!01##?N"NH!B(+Y[N9Q;JJ8;%0`K_[D/B[)2H;9D6R@,T`71
ML`#86U#2(+VB*T7O&[_KJ[U_8#><.Q0$-3!#T04+T+8.=0L$$PT&+$6@*[\+
ML`EX4[;[.Q3(>[A+]+:<>\%_D+IS4TMOZZP))<$,H!W5``;2L`F7*PT5,+K(
M&Z_!H[U<`%AZ(2`,,,/W2S!*FK#FR[&KFKYE2[874C=D&ZH4T@45D"\,P`6!
MBSW2P`44XL,1'`T.(@;5L``'D\)_\`#AZB]*U%!2;`UTDQ1ED[K+0`!=D+=W
MB[SWP@QW*X2?^P#[6P%(:R"-2\0/(J+D]B!E&Z5&+!1N[%#ET\,VG+JVZP7]
M@JW2\,="?,-9F\/+NK=+H?^^$%PW+SS#^V(WT5NV2<POG=N^>(P40`S!:BL&
MX:,79%NJ6JQ*;8,:C7NXB?O)GBS!I!O!`T,W5NQ0B?+*S="X=YNW@S+#0B$H
M2@')2.%0#E4W#96WD\S)3;&D3\O(NKK#42',LDRI*2Q$%3"N"((:S$#-!&/&
M6I"WEAO"8M#`#$/`J-%0@;O*9=/*WQS)L.P,=SNZXPI1FU#$NCP4A"S+:NM0
M7>!0O\PVP0S(P]Q0Z(P%#SRDW$RYY9"ESMS002'0$9P%"Q`AIFHO6>"^F2S1
M%.W-_2*\J/%-=@I8`#W2`W.M#/"EHPO&GWO$_6+0#&"I7]RXLBR]?R"FG^L@
M;=O_N)F3P0RSRV4;O;C[SVT+R8\2O20,14<!SA-=TDRQL@[]U-)<-]&`)X!<
M`;%3T[:PS8F"4`<MR]0PO<N@%[][TB,=N(>+4+%#NH?K!;%CU80</%;]SLV@
M%_UL"YR,O9;\!W1M-G9=U$.AMMB+4#\-S)V\O@A5(-^4PG^,%%/-U4OA!1;[
MU)+KM%*+LQ*M!3=:%`NPN@T<%`N`V="`!=;`M>(#IUD@*:+](&YS/08=VI=+
MNJW]NPU\I44!!CC+M<P`OFRC!3B,Q+QM(+K-#$6!PSCKM`B[V09MV65#V1-"
MQ?#ZV2+JM9>MJ)+-M]/Z;GL"16PLAXM<W=SJR$V6PKXL_X=;0-W>O;#@S61O
MNK8RJ*KG3;&1RK>Y^MX3V[%BV\STO:LBF]_\S:CH*[1?@-_]W:IV2K3E.^`3
MF]X@&[$(3K/=O;$,WN`3>]TYR\P2?K$*?K$,?>$4"\TLZ]0<'N(F"N(B7N(&
M&K,FGN+WB=LJ?K(";J_FW>(#ZZ@R7N.5N=\VGN,ZN;,;6ZHZ_K"C2K%@:[-(
M(:WRRB_A>JQ,_+L/S@WLK:1@^@5-_N.\%+D_&]`S/,,)HRBHBC#?S!3:G+ZD
M^^7A@.-4SC?Y?.5(Y`Q=`$18,+>E4443=1JH"-EGWIW!',M'7"%P_KD\2KOE
MLZ`3+3Y7*CXW>JV8RR]=$#[+P/_:H,TV18':O]T,]`K:44KHR["CHMP,&C*M
M`NR]$HVA;8HWMGNU<6CFW;KD1)OG0>'&V#`HAB+!!%(HTMO`13PHG(L4N5L-
M74!<#R"B_N(H=P/`U!"E!/#FGDK&Q9X%,'SK#Q#KN3SK`4"\^ULHU[R_PVRJ
M*>V(&<ZI%K[J>)SE!AW+S?``FROK;PXIL?0`UI"K2J0G6N`@=JX4<,PV^_+N
M!%*OBDJIR_#->\(O2F'NNQWM6+`OJ:0%IVO/V8XVJ!C?`[OAX)X%>H(WY4/N
MS!`WZ`Y+:)/E*:W*7IHH!;+QX,/PW_P%P>.^S8`@R(LW233R:DP@L$3F2O'E
M1Q3FW&W_ZM\=V3;+ZLSPPL[;H1B/[0N51.A*(1[_(*E[[PR/,$=/S45<(8`U
M*"P?2T'_\D./[;%$\V5C\W*(ZKI*XA$?RWIR('N^#&._Z=]\]6A3[X[J\:G-
M]']0[P5/\M-ZH]I\-G"</6<_YC"_YHPN\?LKHOW,\*CXW\J*XF++\\Y*4'GD
MJ7,S-QF_YFCS^+5$]ZR$ZY,O[+K>[UGP!<?^V5H=`"N?/93/]U=/;H82QL]^
M[9[KB`7.K2RNM$,QY(W>N3C<#&^^H9^;(1>RK:91VOV>Z>=^/;__Z*:QLL.=
MID+4-F#@^XU.+YYJI3B;K/$^P'P.HQ>RZ:G8[6<:^W>./F0N_Y(\KJON7>-2
MKNK8\`4Z[Q09"P[AWZ4QSJCS7>/^;O&-KLSEP`6/\OJO#@A8?X-_782'AUM>
MB(R-CH^0D9*3E)66D0&7FIN<G9Z?H)9;H:2EIJ>HJ:JA6EE96H]:8*"O?UB"
MC[>'#*N]OK^2F<##Q,7&Q\C)RLN)BUM9?ZY_8%JXK;586EU<A%D575Y<70M?
M?UY;75E;7PL!X@O<[+*%%=FMT]6#7`M=`;A_6Q@(8K>-F<&#Y0XJ7,BPH<.'
M#[N,(K"@T#,"6!X(NJ9E"\9VA#P^^*)%&P$N60@$>%6/@)8`#PP1Z,?`RP.7
M%2I<S+B1'T9"`1AHX3*S),2C2),J3?_E!=;2IU`?B@'WH,*?"EX"C.)BE2.6
MBM,.M?)R\D]';X.TB+%EZ%76M*Y@Z=+ZARO1M/_^\-H"B^BBJ(`#"X8HCMO@
MPXA[?7D`9D%-`F892.;%\0N#F7_AUK*%9?,]7;6\9&,0EW/DR9MU$>*E^E[B
MUUP,OYX=JC#MV[@WJ<P6H*):5]`XF@N04VQISIZA@1Y*,6-I7;^!.U4]B+4U
M:+D#>UF;O3NEV-[#BQ^TH&,`M85P9>((9I9>XV2YG77Z6="KS16>"^JBGBBW
M!7GMU1<!F8V7E"$&)JC@@KAA09H8#)23TGF&5/:14W"991)*]"EGGQ9>,'`>
M:2EMX=R$VFC_&,!/J[E3%(:T?0$<8.XP&%Z!-N8(&$E<D$0(-04%\,47F0`I
MVQ]"UC5..40.DN06HS3)URVS]./%`J,8J6078HQ"B!BP$'3D8-LM4($VMW2A
MQ0/58(?4%^[I>%N2<M9IYYV?9+'``V+@2`@78'1100!^XFEH*1(=JN@QYT"B
MB"1C?F=)7I!0BHAH;D*UCVN3\)7.HJ!ZTF6HI/K29"R9-G*E)BM9PLLDKSI2
MP0.I*N5-G);H.4^IO#KJ9:_`#L.I(YM9,JPDL4:2+"/++K7%`V-^,=6:U$H4
MJ1>"_JJ0I<$>M`5WW8;;29/5,(!@0"5E<2HL'HGXQTU:88$1+ETD_\2%%@Q4
M\(5(0U8@E'P.(MB%0+S<FV\Y`1!7",$`$>`N4$(A^2]`\B;$4!<%Z8/%-^L@
MDH48,=7*Q<981)J,,.)ZBV#*+.<*B[E@1$@6&$$=QPL!8F3Q`+8Z;0P&677%
M"O+'Z7QCTTI\ZM5%S/O2BB^2K8QCU@+J.'USSCN')-`6%0!I2]<-[8/RR`]L
M8?(AKW#+Q;/@&-1QR\J<"O?<D=3"@'SJ()C?9KPP(`87BV`CC+[4$))1.8O<
MXZ4_>N&=:(C1+%+X/(_W_3>.O&!I#F18H*P0%V43\D4%X$JB\R$H6>QIK<5P
MX3G=P\@-^^P>OPQ7:S;_`:&Y')J&9.?_</^5[RSWL..P(*^VXEK!@D9\S_*Z
M2Y9Q=69A9QU#H[O)E\62/"M;2A21;IBNN!JS,NVF@H7^^M'87CWN?`^R'>G8
MX`(&FZD&"MD]@V;!>/+WH=XXP,"7ZAGP/>80`^EV<<#K*>19%@/9V1HQ#MD$
MI(#8PLA?>*8M8O2)?;TH&0C79S?-6(4+)+)*%G@!K=_5;S56"8D@4&C`NYD%
M>;<S1,S,,HML&!`+.F0A-QBW&B09XEF^(X07"O4+"1("8Y78Q_G`0(!R8&AD
M,[$7R2;(E-*-\(M@S)/[[E&5G&2!*`]P#)+.1"#+^.,?>SH$6;0PJ#^8B20Y
M^0D`R?*`!["&`#?_@<4]^.C'-6J!0`SD(P-Z2"D]#:I\O<"884#'+4>`KH,Q
M\T<+_\0UUZPM)DQ,Q>O"2,I23J)1N'@4%W+VJ"^4+)58^`N4I.&DUXG&2Z()
M!Q;6,8I4+B*7N!!#GP3Q*'/$$I8XP@6F!D%+1M"L`@OXH"KNA;+%=!`2HW//
MQVZ!!6%.95;2'`1?=!(2+5`-&#4R)2?NI<YV:D)?MRG3(T]ADU^-CGN1N-\7
ML/4`K0!'#'LBE+3.I*TL"$J$T2C/-4^A#G=J@AP.C2@BN.&*<S#@`?+K)4`6
MP<5&X((;Q:1$2!O!C49)XIE8"F4E[AF2D53">QM;Z""`!`V6F$V)@FJ;_SFZ
M4+:.>F*4$G4$G8(:T57-LA6&:1(OA`2&2L9B&AMA':H>L2K92:),_91J][1@
ML6SX](G@X(=/R;=3C,@&BY^JRQ9%251)X+.MZBQ6L1@X".I,*JK&TNI<-T&S
M-(XT$DX<!!2_TXY+6H*#P\%,(LX4)Z[IM!1@T"I<)]NKH,#3(Y<%617Q-0JU
MF$N<#LL$O([*V3\H%4E<T\D"`B>,)OG(+&89G4Y>`L@C:<,001F*65;4PM$1
M8!3P<JV_@!H)K+8*$H.M2](H4<]L;F)D]8C-QM+*3#K>%!_GI*PJ5*K=.WD$
M#"`+T184)J]`D4X,D+DH&'2"PBU0\0O9NL4*M?]2DQ)V)%U<^IT^.$>:Q>BE
M*<JC%3E7@X5]=2U%=/3:H`+"P5I\0V>0K$1?4SK1?`R")#)M1/;6^U9+?+)M
MG<05?,W*3#5EN+N;@!**296H:4QE$/H"8C0P^IX(`00>[J%5_=!2B)S9KA6Z
MV$)%:$4(?95'F)FXWCSL:D/-`:TCFQN=8'W</B_$<)^@V,Z:6F7-;L!3I"/Q
M'B.D=1XT_2P2?#FG3>6X(IWR\[HKYL2WXAPJ3N%N.=1[52VH(1G]I*8S/\Z"
M+E!(PR=R+0`8&X62/417Z"WOS[6X#XQ*`2B>?AD@6:.$!"6)"+9]2PR1%?2:
M3AP-$Y<ZNG]28':ABU#_.5,6'72N,W9$<QT\U[BZ9/&QGZ<#Z/<`&1?]A!$Z
M2$/'12PZB0ATM/4@#0M)RP\5$`2*;BF!L2N]3F<B!!D9B!-+8VJ$BV\&G*`(
ME8@^_LJQW'W$^8)JU5@;"M&;6Z\Y[F;KOHV"/Z<CBI]K<I724$;0N""9'/OX
MKA@>F\E..B)&4\07%"ZB:Y$>"K_S6XJ,3#*YD*J&8<O]ERZ,P0\@]P,9C%87
MD)'[$:R6;A;11L>_S=2<DG5$JR7:;G?CB8\_J8I*3!._?-TD'(`D``'4)2+Y
MYF16[?/UQWYKVD4BPB5701`OT,L71A=Q<WXDWIF<OB*DN[$6O"T+*9(+.B]"
M_Z*Y^4%$!>NB!3.$_.UEL(!KV!9S=`/D3)G*X,D-"N65DCJ,[+`YJ6ZICU%%
M`QHF15XN+]R9R`+D&5DXQ\=*JE%%K!(:A.XT-)Y1UY*K(W"9^L<R`2(M[;G\
M\28U4;J_HQ'1,6:E^HKVG_@AOP>0X>VX]P,:7L_,\D3X$-0X)U]"]R=YU4M^
M/(5SW8+:E*\*/EC-(H60Q8-A+W?8$=L+K#Z(?Q4TY#[WFI-CMNJ6_(2*CY-X
MUQBJZ6R;YQNJ24-]JM;$DN)1"`E*#OI])U1,BNM3@J7BM$F38'&<)CI@4V1E
M\'TA%P868#\ET6TI=W8P<3E=H$&)8%TA07(HUG[NA_\GM?!7'G4(,G9UEP`=
MP.$%_M<)S00*D"%GF88D\%`)DO02B*!/%Z8N/'-[N7<&Q#<.82!RWU`.'Z92
M9!-+HJ%8W5"!"$4-QR)'#A5.'7@G<X6";D5K#'1&W<`]5'AA5C@L**%$'?:%
MW?!56*@/V%&&8B@Z?Q%]`SAM4A1%&E%/G;9)76`!9C`&92,:%6`&/PAR:)!V
MXO!Q<"=WV+$Z:&8TJP1->9=3?V%0W'<(Q!6%DC@8M=`*7^`P:O)#.!000A$@
M^()1H",9F3`:3L>)^?!K.A-:IN4P;'((EWA1W#`P?90[NL``C@$M.N-'(X)1
MK]A")7$932$9FD!VCQ@)U@3_@&#%#6(3<F<P@>?P`&-0!F;@4J"C@SLX!E^F
M*Z3V"HK#)MJ"5K,V@4?R-I-8CH=1B7I2,JU8'^]11601(']310UG&5\S,K#@
MCC^!BA&R0G;D#D9!"-'48Y>X-B3B%-?#.[\1(9?X-_D1D/EE3C=D&3$W4<ME
M6@<X"?>T/:@#$LIEC0LXC;'45"ZW&&J@@"&'!C`2;MA4?C8UC@2E,7&H#Y&X
M/B=GCG:"CC940.P8(31&1-1C0.&P0\OA7_J%B@;Y!V51.(0P+VK2.3!&BXJ'
M#Z>3;"F1)H+$:&SH"-4W4Y?6/3NC?>9`?*.3@"8Y<@42`"5IDGX0!F,P2A%(
M53!1_S(C-G,M*4XDMVXCU&(V>9-7J6=7:1K$5E<!`A<&XS`\ISR"^3Z]=FM)
MMQHE\1+P<Y2U6%WQ4SU"41+K@965X`VJ(X"2X%489Y&S5@'>IY9AX%(_8GLF
M>9I>,CH6\&UV^5@D97)+1!RR.9?C4Q*K%4:&MY=\63U)^9>U2)0^294`96R'
M29Q1)5]'&9R[,$EB(`PZ)IG(PPV-49FM8$-UH8D(Y)6948"3($FM5VX6,SIG
M8)K$!R98`EU\B'N[YQ[/<IYA0`:@]'+9]0AL\P7015V)I5/P58SKHW^^N2#H
M"!)&H7'UT(Y@P!6#^3X5X2"'B90+FJ!&23V%]8_D,8KU0O\@*^0*)P$A@.F/
M5$:5("%C.^E3YS%)'#D)9==EAQ!8,@(HT$B6[GF`'A<&S1B'7#,&Y^D'9?!E
M6&`!?1AR9&`!V<5WVY@N=[<KA9=^_<@GSC>@4EH,Z/B*1A$S,[&)DF%A/SD6
MK$AO'P(06[J<B\D+O0@CKXA(`P-(T*"+!_F)O4.5:9HXC.8OD"`.*[-Q&%DV
MR"A8!7$O"S"-X*`G%I"6(*<&\`0Z:?!V89`&_>0%U&`!<M=Q@OA]93`&T\9/
MI^<(B$4-`]929>,.1;AZO4*J4RH>/6):RB@C3K%/2Q0-\K-$!8(=^FD.T*"?
MKYJJYB"KJKI$NHIX**B4?U*&JGK_#U\(K.^!';]Z8<I8AK6:JUJEI]FSF;&'
MFOI@839AC46:#CDHC;UE`1[Y=O0Y/8/P`(NJEGYPGVH5DU3%$RAQ4$?R"BIA
M&'8'-S5WJAXX:<N`,SIC=HW0A"2H"HO16-;JG5XU<*U9`30:<F6@4*O43?%`
MFNB:!GFQ&.CJ!V;@%"A1AO5J22`##CQ3D^90`2K1B$J:,O>*KU*HK\K0+N0Z
M58Z0E:'`F5_BF9@P%*$)@/=3FM]W!IB*"%K`LPIXFN4#$^'Z=F.`(*-C!F:@
M@=Q8=]IP1L9G,>XPM1=6?MT2>,S`3=PD:/4G*:&P>,0@#B"".H^GLLL@9G[J
M?'A:=IW&_U4S]0!#JH!GT()`L0`+ZYY]=S]I]#,PT9X+.)[/PK-J8*2TBK6/
M0%:=!`V.MS9.FA506JK3M@R3,1D0J@D8BG(`NPD=6@P0@IKW$APLB[;H%(-L
M-Y,4N0Y]9S@"&)WH^H="*`:WX`6$>K2P.P@@\X,^JQ/;T4_GN7M>DKNY=ZG$
M![F;JBKCM[C:0D7!PQ.FRB`<N`RN,(N")K.Q,+IH0QJD@!)1&@J7RTS:F[FD
M"PQXJD0`^@@#VZ>%L#*^FA%I,+<AIP;4^`!F4`:%2S7\1`9]2)\)X7&X%P9-
M6S+C!+>%4*D]NZ)D([*,D'+HE1>@@Y>.E8(Y$KT&\8\.DEM#=/\PJ(,ONF44
MHZ/!\N(N?N12EH4PB,8`X_59$@-/)"$O&EG"&SPQ!J-;?$$<,WPD-_S!&#+"
M),$F#P/#XWL*TMJ5=5.M!4))%Y9&>V(V&1$`/0IR]!D/#V"H/HJ'3%P!8U`>
MRO@295E'D!@`%YL&ZM-2QX=R/G,O+603\`!=)>&-3VLH]_*\P&#!%^48SR`B
MK6@X&)&/L-!'\K):MC@PSW)1KH3')X$OQ'&9^XC'S88:I!$0*P(C%1@4&[''
M<C&F>YP7AR0O7.4O.TS(^+(G]<7(06P*`UM.$EQNKC.YIB66$NL'.2K`,^JS
M!>$-0LN,,!$E?U&-%QM#3W2N)NFHR@C_)FGUQB@7.CQUB89@$Z5CO`;UJ7("
M40U!Q\8&1%81,[+Q#4BR<.RR"/@C(JG:N=#4=,-G"Z/\S--P-_-%NZ0A*-&`
M*]J\#B&R%A`B&HMD9;A%8_-&SS7QO=$0OBK4SM>LG:7\"1Q6LU$Z#MBR;@`8
MG__KJ(3B/^'GT*NIKN-UL4EKAE)+O_`+<AFM7.][J7V'6)9$*RO"=.H+DYWA
MKCH2?PM!Q]61#2[A1VZ2+W1$&6&R``[#'-+SS]`@$#%M%!#:H8>T)B2BO43-
MLD`-OC5%&I=KTW;*U#[MSYUK%$0]T]I;T)Z@MNL;16)5D0'X%T':T41ZD2-+
MUF_WAT<,C;>\_X`6(`SW<X=Y"#(\ZM:M-<5OY[,]Y6TS)SH`(DL$C)]!2)L,
M`@:IG`PPK1?94`^SZYC<I"%$03JMF!7^<L<_C0L"(=2\0-2,'4N=F]3F<"1`
M+2%([=2OTHG4\=FFG;VBZ]-TQ$URK-6'L';*Y50+S*>\9SC3%@`&K(!J\#IV
MB-8^"J282;M:8`%YRYH!V(<`7`_GH`5CH`;RZR6V_'W-_5&$#;3[HCLVF[CI
MDI_:E=@"L2+OFAFM&)T:LD*S@'<Q*!"=2W`QPXWF[-/D;5#LW-3^`QD5>`AI
M=!7PX"Y!,=_O`@OHK0\`SAK)4M6-G-_E+=N:\(9)_'<&&%E$C'%!B_^N49Q`
MN[1*OIM[]$FI/SBN^R0H.OB'V'&C'FXT`"=+<HNN%ATR26A$>.E6R6?,;27>
MG9$O!.#+YNQ'%0(BE^')(3(K_75161`S-\'-\]VA*T2R`8W?*Z2+(GA17"<4
M[G*Y#N+CD&CEHY@LEN$T"][D.^[@ES#$AQVW38/#8&U:YI2W(3>-$4L&WBK+
MT?CFN@4Z;C>(LB`:#R!W0M@.:ED&N0UCPNV'6,%,D9=02$4K#-H)Q@M?T'P;
M(-@0_.>UML"XYH1/V5`0*D8-*ZWH[G$>DJ,-(#4*7KMXP8<XW8;JI(X(V?`/
MK\Y,L-[J(FAAEBYMYS`*K"[-9(Z1:1>`9X[_::YCNA%NEQ:@XG48KA^]LPOH
MJ(.Z`'9H`0B2K72+C?BD!4>;>V;@11VN@#\JA/UD!M*.>&:R#N=;YCPA:+!)
M&W/6Z^[N"3985ZP<"=46FC3+W7U8N&/!4_I[!@VXW-^WK?N4Z!;9UKA7!I.F
ML.B:M,,,L<\R!FV=X:-CJ`TK"WQ*Q)\0P=F-&+#&$/L@S1\_)E-23AWTF$PJ
M?=@K/R=O#!U60._^4@(8FG=:6,7X+)2:>VA@Q:MD3NZ!XB;YHXBP`%1LW<3'
MO211J-9->Z9E`6E0!B,WJ,=MJ"DZ#:_\=FH@CZ@YD2[3"N!]&`**V))!8WYD
MB]DK&;,0,Y+!/97K_W059[T0,N/HQ++^_/+(E3%NRUP77[1WSL5T&P`6<"0`
M=;'R6X.VA]8\&+Q[&#(YR*BN++3W&WF",HW"\"P=7:2N-+GD2`J.^`PG2SOS
MO$)#(M"S70&`:D=`KBU`;64\/E%NDCIR)(2L0_"'H--V*S^&$0ZVFFY#XHKX
MM(48NH)H\SW!KK)B(SJKZU;Y<=!_DERJZ>*9HC-N+JXM9(_KN3%F\,2&WK^5
M6O$+:OWV>X`4??!XN*`$#P9"FGO"')JNPQ0\)0:0+N$*$=O#T+E^PV#7+A>0
M40_$&M.X"P@,7@0!?V`,7UH/#PP/?U\$#`R%#`N16)&%6`Q_7(P,8'^BHO\,
M70Q9HHH$"ZH+6Y*@7Z!_`02C?Z:3HKE=I):3FPQ:GI*.FW^;I@1>7)&EM]#1
MTM/4U=;7V-G:V]S=W9Y;HUD57]I;#U_G7+?@HU\/?O'R\_%CO8]86%Y970]D
M]/6ZK/.4QL^9,0_$<-E28<R9>&0LE..B)0#`@Q6V>-F2SXLH+`_"`)QWYH''
M46+&B)QGSY,8:86\8>."I0*6+R"QK)/)DYL7+3V#6LO"0".#?`PNW=)2`1>G
MI$EWDL(BBB@_H)C^:&$@QM27?ED6/*V0)=*6K<@XB0'UH.FH0UXJQ-SZ``O=
MFEW&`;6I=8&[HZ8V<ET;+BF8!P3&9=Q"`,RF+,?_DJT5LQ9,@`HGA6K>S+FS
M9YE?R(XZE_F:F`=<NBR0^NA!J%LUS:RD%\9"S'-JU%C0DL5+@`=I5H99<.^=
MFGEAS-3=I^C!L#]>_(V,EQSUK2P6IL]#8QWV`S,/P]1-%$Z:F-*?_S#L\N5T
M`/3I9:9F'9\G`0(5CFY:P$CJVD]_)!6`+J,<5=4IKVC5BR)_6,6%%UZ(%2!5
M#$;&"7_0L=9%4QNF8HM6'S(3&E!=`%442@QP\>`?"[A5@5^Z'*,%4(_0=(J%
MZ^A72CGU]>CCCT!&<PZ/M#R731==1!B3..2(\IL%#VRQT`,.(1>EDPO,AL88
M&='T0`#*E3<.&M.148%`_^Q44(9V\DAT2US_:$>&28\TIY!Z#44Y#I'1>/'2
MCV!HL4`6Y^05I#;S'>H-&`0P@A07AZ`R"EU/%>+<+08V>(H7IYPXHZ99A`;+
MA%IAQ8F,-$)3`0%,"5)J*C0R)@E0KQ"5V3&3TOBI@:AVLI4DD)W*R82#2.*7
MHL@FJRPVI^V4VCTS::'3E;>HTTD78\1SAG(ZG37&FF6(EEJV%W';8&^BG#/;
M=&/\*<H7%JP+4&TQ>9%/;R#)!I!RZQQ&9G7ZA)8.G=5`^^-56V0QXVO+LJ,%
M?`U/`V&`8"1HU77(.,+7IP521<NP#P3VJE45N':,@9]:.#+#LL#"U:NO<KI`
M(O]`<5&*6Q]QLA%%COSQ`(Q4]=H%`5M$JC*I"VW%9\1,-UT?DLXFI$UT6X0F
MZ2BJ#00<;7,F>=7,G6RM71@!&/P'`?("Q-W2IX$WDGAB5D!&&5Q*>5J5`:4;
M$CUD-/I%`$96$P!]/GK13]4;EA<QV$Y7P^HF$`*6XEE_$'8F+A4PNF2`T@YX
MSV4]?VI5)10]1:&I::5%$<YK[?0SS*)S-0B-;6U.E&."K/6%+"_QRLF,JW,Q
M8+"I3U@3I*<TKOSR05&TY#L,7R/P87QR0=R[%L0Y4D0>C[*`]MJ-T?TN8Y`Y
M7;@\/IG00@T])`\:HJFWM[9FV)3T&&98X+%J:9OQ,)+_V4A'LFAB$WO9;UD!
M6!KS1C&@9[!($IK0620(4(Z6+0-3L.C.(>8"%*O\*C\V.UWJCE&LEXEB$0Q,
M$<<^U0Q)E,Q)L[C%)_Q"C$;D*&B<,(6T7`B*HQV%*,58H!"':`VJ,4F!U#A+
M>[HCBG8\H@+F8].PL*:OZ83!'J(P7$688X'C\(U.!*&.<MZCL"[Z84[IB]>\
MNL:%+Z`+%^2B1TNDIHW-(6L]`TL2LA)(Q&A09A1<^"-T)(43(D%F:5E(Y-6@
M$\/==2(+*A*#E"")+D?N8Y!9Q(+B&D0D+D#2D8_@D;UZ(ZE7T">0=^H$97:"
MKDO2)!1;4$AO+GG)!GG$7JGL_Z,NAVBUT3#Q&B!Y%FM"PS`L6(1-<'L7%F#9
MOGG1,33'B4A>#"<W>?AO'?`"'T1"]@7?5&0GV&+3&5/5H.S0)B'0XX8=DQ6H
M09W%4$#JPB9WZ:.OI&B(64`A/??)SQXID8&KT0;4*@(-ZCEL`6L:"1JT4![5
MJ.$R.FEG0OVPT/*<PWWQH!M#"0BEF(0FB@`I@VV@(89CLHD,QV*@&>-1T3UU
M`PS16Q;"PJ*%F'Y&DOT4BO48YXX%M$@7)1T-0Z.!1&D4U4GKG(8D7D.YG#KU
MJ=QH5A.OEPU/Z(-:OAQ(/T*6R'YH$WX3J8@\PF`FKW7!`FFH'X]`DC:#("04
MF3D,1O^M^"&4+&"N``%<O]JR`#!0<V[DL-8WDJHLPT7I*QF)ST:@RI-?]6P4
M^9'$1%@EBD-(5H;CHT9=JL&Q:[RQ>(P-K6BQ!BTG8N,=58L?:;46IS*PPJ^_
M"<X9T1$V;<9#-X/:"!C`&4<KXNPC9A!G195YGC).E"7W4)=;,_(3DP0@H#(Y
M26J<PTUE$5`?-='):)G&*3$0A4B\JY6H:,0*3FTR4YZ4RCYVDBE`0A)6GG0O
MG[PP$4D=X[WO6AJ/0K7=_C;-JN[(G#8$]D]`+L"C:J('1C1B%RV@*33'#2EM
MQ;$`<<X6&M9;J=J:)#\UE)6^7ATK';&UKN2P*D)F`TT%XJ?_,-XL"X^%@IA_
M?70Q$ZIR'S<J&8UL@M]42$(?$_1(,"CXJ^Y!(BD>84HD''%D753B$IE("R.L
MT\!"$&4K99%$BF?,Y1ZA]BT<Q@9II#H*(QKB`2!%CEI5E69GSK<"LIT.OZ"C
M!2CE=D-D6!<:R3<;D?+&-U\*4R<./*\YSE,F>VJQI*AY:)ZX\:@%%12A'+S(
M;GS!IEV6!E&,DEE:V&*W'(,*`:3R"MYL:!R]6$59-"F,J[6(40OBBE?`(B$&
MD,4L:)&,['2$8_Q4YC(R]N]Z,[T9@655&W9Y%C1Z*;^VSJ,,Y/Q#@L=&+<AH
MTDL!P*L?L/A$\VE42K$1R9RM9]+M_]3-D^CRA&W%(P9B:H8QZDU<%G^C79Z,
M8P%8X(^4L#'3UWKC;\3&QGWRDUE9="_4A"#05,ZFB:;8>M^D&@4A'I$*1S@(
M0K6FD#&$M0[GM"Y`"7M9,B#=WU=(HM':F*),>),/Y@UIM0(5B+2@\?)4:)L>
M8*U*J/ZJT/B=HPQE^(U"SE$^ZN@O75I(\T'6=Y:9UY9-!W&7(7K+4M>`(<P]
M>>Y[H&&ON@PD)\&N!FD`F5W"2<.PB$OL@%,:\&HPRE%I>BS,='&IC@7(91]+
M"BK:&W%8@4I4DB!5RH0%JV#\^&(E9'N7FX&*LI@]&RKW!LL[';%D3Y6PTG#)
MEV]!YJI\Y__F?E!#DSP!)E8P^#NS4<.$GSN;ZI!1$;\ISVF<G1RL^\R+;`J`
MNYA!I2BB3[`]L1Y37)%YL*?K3&&/AEZCP3X]7N.Z!JRW-7;;]FM,+(9.&O52
M=BQ"NY="D>^J!=`P196JC>P4)<.=X%&WB77,Z#&)Q+&DDH:(@"N,@>7`Y3H@
M!(:70`:;?O(:PP(9I?$%``@=MX0%DC)Y#:))3`-`3815TG-8M@<U@S8C4L(0
M>",/<X)-V2,/2Z<1[E$&XQ9.VQ,RS'`U`:`2XD0&F24V5G1@>F,!9W(6%E`&
M'6B!S4,MC.%\0H)\53$CE99Y$)A$DI8-,(:"U2<4CR,(B=!-MC;_(SS",1NB
M.>07/.55`2]Q*4<A%8K0#`O209VR&FB!,NS'%09'%.W6&!=S/)$2<(.P2(/0
M%EBQ"(2P8D#1'+/`"8RB!1<D"GTE;;V@>[/3&%IA;5>FA<OB$@$VA-2P)S77
M1$X'87Y0>SIA7/404!\U+_4340[X=&SB6JKB;!SH)@U(*"M615;24%ER6Q;@
M"JN@))KA;B@1*"ZF:4+X+H=##8S(;Z:'A))V%H.RA#S10+U@%28'+'[W")+P
MAZ)`<):%,K`0"@3W%K!0#K&C,#P40J]B(8QP09\P:A<#1(U0?:\@%_W2"S:3
M,88P:NLH*/(3((=8.4MB3%SP0NC0<N]P_XCY@`7J2'D_LGGR0W+58A+!]";4
M<G5I]F%?L0@><U$G)7>X4!#B-`9V=!C9-AUI8!VI\3T(\0!G0'08!3^A,"X`
MH0:E8%H]`6MFUY`HAS#SMC[+YAH^D3B/!PTTE3"_*(G)1XRB($BI04J*M!.@
MU(#Z=1,-J#@<04A(*0X*F%^/%$F3Y$D>84FHL%Y-&4CZ$)69E$MP*`:K,A"6
M<2I4<7_R6%.D((_"H`BIHC#:>);.@1:3=PC$ERPN]9._9`UZ583OPF'*-1*X
MQ1KY1(HL]5O(<(-CPVWC`"7=0B41UA*@6(F=N!&"H@9I,'K2<4ZIY8C=0!K&
MUR="9W9HUT2?>?^7WU!VV,!HC,8B!.F3&":1K@F'F:$%YX$?$M)R9OD[DO(4
MQO.)4Y$3>=@%_<B/Y<<(T?8C8[<+:#(34$-'0I4^K9A[T0,&%@!ZA<DC''$3
M8?&!FJDWX;&19+0`9C0<'O4`N#</#'EM87.>A5DQ$Q84.H@G/L@.(+%US(>:
M\MEY\A%C,Y%=]I*2L4F:TA.@2]@5H]"/A;".N$DCOQ,.<2&/%Q1?N=(5,U>7
MH3!YEA1Y/K)\OH)YS'=80\5Y3%0!%B9Z)Y%(9U9T`#$G)Z$:9:`;?^95*\$=
MY1$`:H2>7*5%:-D@4!2*!(,])TD.^BD?,A@-+<8>TE`H2#0ESB<H-]G_F90V
M$^<0)?SIDU>':00:H.8%'61Q&F%!E@W"H%J1.0XFCR42%N.#"9"1&'CB&'EH
M;8>1!6`)2#W)$\J611)H#=!C;+?`E[B`F&5B'?`2`!#%1<<U;EH07"!X;C5!
MJ!QF@B/A9UQ7`=9)'9@!#?FR$CFXG,$7,EYG5/*&B[<H)"%#59Y!4U@*#5T`
M.'GQ3IPI;#[UI%GJFLFHCHQ0"_92EF):$:R2([XB#*P!%T210DW"@`,29G&1
MJIVJ.'S*;X'UHV'C,7Z"E#Q'#\^%33T*$<CW5ZYU#]%A6P9A+BAZ0A3))L-8
M9FC&)C3ZDX(2#H%$)?;P$QXZ8.+B'A`CG)_:_R>ABF%JIUC[:AYB\EJH2FQ@
MJ:RS&J!4R0VC&B0`UAGIA'2MJ3?"$SBM41Z'008P>I696HG<=@YMYF>](0;+
MU)=MAASM<AWFQ";^(PZ]X8>`BG.C=V!AL"U>=X_OD:>6-I`T5UV<QPSV>G;X
M^40&2PWM`3@S,B.ZIT#713A;,$^J^:^C]1/0=;!4&Q0+>RCQ&1171R1#*C@+
M8#AFPZ=_N5SN>AI04AYLI1UH4*025[)6$E,V"JYY`QV!M@C9AF<XZA'JAAP;
MF1'-*A,ETA;]>AT+4V;N4BB.R*1>L+6G&3()@Y-;T`_V"4A5JAY21Y\V@1/Y
M&EH%6[6>&Q1\I"S)V?\3P.>GU6`]`N&<>M.B+*A@W$(?6$!UD:IXB4J*)2%[
MBW!GP%%BSS1M?@"R!F0&0?<<T+1ADQ:Q1'4>!$5`#T<XJXD+..EO25HRLFH>
M."L-@<*I0M6J6\8.2OJS3R6UU?NYY"M$X_"JV)`UD@B0F7=8>6IYUB.[:F8V
M"Z"H<C)ACL%,&_@^C\J""^8E;C-<9]9F_\L1Y;&)7[1$XYND@G(BU9(?!"!]
M9&<3VIM%4(L+%9R^G/HW1^L<\B055^>(86&(8D9I2II3G5N^*IQ3T7&Y5<6V
M`BD]F6.:RHDUY:H=:6`VJ5%-([&1`Z$%WT)OD"(H$[5GY.:Z]G,6%:`%V#G_
M/R.Q+8KGQ/+@PZ:+;`]POM.@C1$,'^SSM<5W0(^@>-F@>V4F*-3G#J=1;]'!
MF<_K60*;B[LDOBL\Q_UTIXB"57\[?>@`?&$C=81*F&.@B3,RC`2DBMOFK9E9
MB1MI5M^!$*QE17,R3UL0G6IKF#9Z7/&Z68`K3^\Y#?94"A#C'.>*8>N!2Y:6
M*G&!OF1VCS>YM*F9.&TL1%Y*Q[3<3UWKR:H5B=>@#M=Z"YN'$QG83+1!51"Y
M8)U`=$!W=$\481!A`>RQ#X3DN]H1>25%F*HW$:S:5?Y`+S&\#59URV=7"SL"
M#596(B@7**N"O!_!,*-LA*/1/?;"?)5[NMGU-YO;_SCRNL"UO,]-P[C6$(F6
M=R1)XJ=W>1ID<)E)(E$BAK8W2C\'M`6$^AK^XJ.E@04W_#;XUD3Q9VN&S($<
MN35;$B414A1Y/&!14L760!.1,*HP9<%18G:ZIX39$#B/Y4G]:'Z3DAD]DRC3
MX*I2RDV?V32SS,]$O4O=3%),A-*9=V`J*3^LFWJ[H<T'39-P!,F:7&850)@&
M<:E8O;^KV)>$BAAEH(%S!9F4"(*_\:SJ[,MDX70RP1#"\!J;`WV8B@KMA+[>
M0R06IPC+E$B80`!Z])2I<"W52U-XO;VH.)_)DL]%W=BZ1&[3H(.].!,4"+?/
M<<1J@Q`B>!YA8[_:\4O1P?_,VQ$_#191=19A).F=U+'(BUMG:M"ME96N?",1
M`=V95WR]+[45&4%YI7R@5P.3U2"R6*,(+])N#5(791$E#S,*%E>G>#JT%%93
MBJ8L0^W8UDU$'"J)SQ.BIT46_MQ$$+BWVG$&"R!U62"_]*`<1!5B)TE;1TQ6
M*-B0<2)Z:]70I9@7."'88SO%J*'4P,0;ME=FX*<-_/!P6<PQ@EUFA_-XK)Q%
MC:)[79%^@L)[T,(/BR+&190X+GDHC'W='CY$-6=F3X2\0\+'IO4`HBU'4N<)
M7HU<651G/W.5L34;'1B9S9Q;O_$SO!6*%A!360T0<^3"V_`SG0QF/^-3@'W8
M"G[_'Q+L*QZ3X)C;Y+&]$S]Q)LZ19+V`8L["U=Y<=]QP7?;LE>E1W1]>YLR#
M6LTZNJ;1WU/;&M$#@Q@=$[:8T*=]3AZ#P'1S)=BF!L2!K>PI#QJU-`MPT3W\
M@AM8&S?!W3)QD-$P-(2"'[S!$%=+S_<A%0()Y3^HV$[]%C\U-$.C:H"$&,[=
MB,>)**?!'D';&1UNYJR^//<89ME]#4@BB]?!88\&P&F33+2@1B`KWU5G44FG
M8*%I""/;;>+$Y]"@!2EN39>=#T,'Q&5`HS3L#57,,X%$-%D`.!F!SBA74!Y1
MRLU:%H=]US@)QN^B2)7&$$3##2]7ZNS.5;W-&63>ZO0N_]2EJB+^C6'2TM2"
M=59FH-GONH'P(RF0RE)U`VA0PB.S9T5KMA1N*V(,<Y5G);?<%AIS`Y[[@!@#
M,^KM2WG1L1I#`]'V90G+M"%2[LN*$R@$<+A?HN0-8LXT=R9GG+PAXYO90&;N
MW@V*1NY!L>KU_O,-`X%3*N020X&5ULN8;1!"["V6B9F$3C]4S4"M*R>9Q1!R
M2U$")C\(,4W]$&>5J,D*B:/\P<'Z;%2*[@Z`31'+<!X5P]G1D>0;,KG*AY/F
M?*V8GN%=XLMVL<0!D`^L\#,9V.V1S:DY[PV,!MS>,.]`O_B'TK"MH5IZ2@X&
M96#W(-Y\^R7TI9Y>P)UC4U<GI/_51NP8^?<;'8T^'W&CKE53`/RB/"C%\>`_
M8!L4):T>1//QAJ,0@013_:<BGN,8@(U$@Z.O)W+WSY?J+/M9ENO-!+44G]%U
M-['@V^#SC#_]`8E5>S+91JC`[$`MQ2LG7(X,3R]'%TDEH.?#81,`:J#9JO0E
M[E/C5:U@YY:=/,(_0)ZZ@B]FT'J@C0$)-04(8G]_8@M>?UYB6V")7%L56F"/
M6EF#EE]<EII_7%@5#Y6;HJ.<CUV'I)9;7:FC7@];HEJMM+1<8@\!7YY8F;6X
MH;7"P\3%QL?(R<K+S,W.SYM?%5^J#[Y<75V^H[C8VIK28(->%6A^Y^CI?F$/
MU)<59F'_ZNCL@G]?#Q8/IUM:8V7JQGR3!O#<F0`/>OW9DN_!@DQ<'IB91\],
M!52#P"R85P^?N&58M&S3U&7:%@);OH"1E$5<%C%8!F4)($YEOPI;;L8:YF@?
MQF/]N@03]25`,6GN-LV"-HJA4*<_-WG1$F`DTZM8LVK=RK6K5X88`SS<U&U4
M-BY4-X%I9XG<&8KT8`WJMV"+HPICWJ9#HV4G0W-^R%@0FF6!!37K%AC]LQ9P
MNC!I<D7]\X`,W'0+AI*SC([OEBS3EGD;%=&:&)0!JC)6Y`5,%B];L%3BDCJ3
MI`4$L&BLH'!8T*'&"D<BNMBWEJ1*O?[)HH72;U'`E$N?3KVZ__7KPD)>RT8*
M-/*(6%[MK.;K2Q8NS/]11%/A8Y<Q8<Z82<@%C)8%!=F[PR4O79D%?7G117,?
M,=0?7&0\(-4#!\(ED$Q88/&%@)6%H1]#5AD3D3W1[(--;BDQ)M0@`8A1R6>+
MA`@&38-@T04#0G5!@"X9=@?@1\@(B-,E"Q13%BE+*:?C9S>.0U6-V"6IY)),
M-FD6*X-$--XH^.Q4I33`G<6)/Q:=DD47%G!V3AFA193&8Y%YV44^QPWRWF5G
MC&&-)F!8T.!Z%8C"D!EZJ<-.3`L]H(8:%D32R2=>B(7D,%52.6-IMRQR2WU;
MB)&)%W4-(H8DD[:D&EH$+``&%@2T.?_,D,H<VHM(Q'#72I#2>8%%0E^4A!!P
M3N:JZZZ\,K7A.SBFPL4"72#5SW>*C5,9.F44^MJ:9)0Q7R9?A(G@8%9I,=%E
MYP0P5)U]4J0&6X0T9^E">#GFQQER_?'>@7%6,""F4"KC75,,I.20&-]@8^DM
M*X'Q+[\0=2&&%[=\L<C`!#R`"R2X"LO+HK9`)0QXM<`ZW2VYW,<;Q;V&+/+(
MO3::46C#:,'`2W.VU:XTZIZ#AIQVP70NS-SZD49Q@SR0L\YS.K)%:_<5I$Z"
MOKP;QGSA+:?%87Z02<VP`7`DD)3,@#4*J5E\46HC"[=XRCTY@:%P?6+8(X:W
M9"^B<*`,I*W_Q8X\69S,<ZF83,L#?5TG1@73<!S`9"07;OCAU-T[5\O9]15J
M-!6$\A><`6BL1<P</1#L'[.F<2<Z#]X#3QH69/:EM:"/9>;1\E(CH!9C1R1F
M7&*$PXRBHF!C4KXKUK329R[!)!.+*DFR$B*I982%72V!!N("%9SKVSX1D]*)
M)L)M/@A2*5-H5ZQ'OE)-L8B7;_[YT&CMYEC#G$55NX&ZL];GZIR1IR8!6&#T
M/&BTNY9#=IE5`,(5!@L`:G)C&D.`UI0&-1!K>ZB;1[-,98D%S$YFL``#RI(Q
MFMP]P!JDPH*).%$;QN2D-:^)S6Q*:+R68"(V[@A`TT3UHBZ`049-_QL&<R@A
MC`4@9QPE&5J4//'#5QU"52!K1G0&<3]+[+!ZZ(NB%*>(.TXDBR<.:Q1:C/(C
M0FR$6_KAA!BH8AXP7=`/820$@]9%LYZ,P1SL\LL:ZR>G@ZEP>^7(&1EZ1!(^
M^<<DC$,&UH@B+]TIS'@J&M$?2G2B+*2(&C?\B`C%`;R<4&,F%<C$VDHU*@*,
M[51!;(4N4K'#YO1%8[28&_G0]<FK?.%(ENB"4;(0H7.A:HJXS&7Y.L@)^-7B
ME2G9X"(+N0E/Q(,B"9K:`])P!D)1@D*>.T<RW30&/UDD/,+AH;O@<YFE\=$2
ME\L9.\;CCD?D)3#6T)(R/#**+#SJ@Y'4E/^D+"4)6V8*8$.SE"-5@ZE8X/,+
M^B36I4H2O4E`412RH@]1BH@]0(&S&+-X8D;N<]!C>"(86PS46G`Q.$3,JC>Z
M#*E(G31(T544>X#\SGW:@19]&(HAYT1'9*@EJ'3$*X`/&`.`($*5RY"A`CSC
M7#7U^$U-00TN_=L)0J#7-.8X!%-!/88&&;J%?.$#%)9*1+\,Q@6`K61@4,+&
MT&X!&X&50G4T.8\UPD8(P(E0"[ZT!4<)1TJ'#@*5KVI+*)<SH"DE`Q^J458L
MNC"6I3AE:A^EZT@7RUBML#,CY!(&6&8U$O&(;EELW!%=U%"&JRTGC_.03T+N
M@0K9_:R)+0H`_=#_@31.A*0N.B+#G<*X1=:V[BQQ!4H@+1$``IAG1KMPS=ER
M8@\7'4)A;K.+P-3&-N2:+18"`]0-9W%(%"WG`3/:`O2D)]E],+2==OT#7E.A
ML80JQ'M)),5%P1$:5XD7>\V1G+P4V]CZVA<94[5$%VM1.5[BT1W2D,ACKHD>
M+`1`CJL]1Q@RHXDM#)5;H4-/)3@:+M#U:YELA(6LX-$?P2CSC&JP:N280=@,
M8:,=516A/7IWC]\=CY;2I0EZ7"R.1"UF5,QSC?$8DY;E+,\++1$0C%:1&_IN
M`C2@J`4MDT,,O'(L=A,[2BY&<JS/9J%K[XW&FG8BT?MZ^<O$P%`LOW$Q_]QR
M:"ZF8LA;QL!->B1H<Q5(L,PNH@FTO!$N!;RQ1!!B*9@:;<&+J=;LEO:Q1UB@
M4-2JP/[FO)+("O*!'K1&`!BPDBL+;(6JD<30S`8;"9%((2TTFR,\O<BFT;@J
M*PH%(Q?2R;Z0JI6MJ-0MNQ/>\0)I.$V!G7QAG8KU:J*+HW(1X+XG%3Y3:\M@
M3K:R2<*^C&*Q=GW[=<NV8"?6SA$=#MR$1!(LM18UQTM/0\QCVF4@!3,-R(8A
MP[BL!-IY_)3,VWL`YM0PC?T>HZ3LU49):M6T%$D"DHI<-8K^+2));HH0-CD8
M7W>BB!X=K)Z7$I6F_E90B,6Z7N:MT9(U8>M1//]@UD<N$H\93`K`6H4[B0#0
M!^^S*5Q(?!-(1)[#TKOLFJ./:B[S:RL\PCV2U$N\BRY#@V@;&S#<):;I:.TV
MY2&8S,1VSJ%XE[OG*RM2JSEG)?KU@ZWM#9J7?,2B<&<O/I@VV]A0C(MH!,3O
M<<]-Y1,]6^!GV_^=58*):&`!J_M6'\";,>;V'E$57%0V_E#?A#7*"`UB)KX4
M;4W,ZH=HZ<6:%-X6[<*B5CC)D"F.B'B;>QZ7)<42,;RCOBB-EKU(/]K'$2&1
MSF;>/OA!1W][>2;_*!"GA9K:`K8N0<UM@@!R1J,VHU02,>ET*E$UQEJH*F)M
MN!V@B.`7\>URBY:8]1;_6QVK':^O78BD%6QF]>(A$O$9M5=*4]@]\':W4918
M>]>)M9[>2.["ZR%^#!&*O\?IP7'Y]K1"51L&4I8`>[MF9)]W@"4#=@M!0;6`
M(=K!?SLQ+)\0'O:A/^I@!JR",^;V,5\B$8,1;V=D$'+R0UH0@D?S0^^!.9U1
M)G!E`9EG3(IA6<M@;V[B6V+G(M2B&UUC%\0E-L=5-F^S7)K27$`(7<+#&,23
M(BVQ'$?(8L6S"#6F,C%29%]05*047S[&9+101:)`@*2P>:XE+X[V7Z7W?U`!
MAB&':UZ(@&PX,LNG7[LE2H;@7O\%@M(T7[6R+&$0.@C$.J>`'JB@@7"B,8J6
M_S,19C-`]C2+AD[CAUF$)B$H(7K+0(>6,"PH!B/',RKV$'<N06-,&&-&9WU0
MZ%$WMCSU86DC1!N+$1N;ED*R04*99DFN(2NE$AL$X%O$H",RI(6ID`VO``L:
MUU>D0("`-5\-U@ZS5PR_L8::<$N,IW-M&(U*(F9N\G.V(%`.LPGJ`QHQ,T&O
M43E:L(G7)BZH]0<+(&[=U"Z`6(5'Y2>05BUI4`;OY@5/=P[3(CHQ$P:]Y4@,
M>&_9Z$$BT5LVH5SF(3!3(T.V<4*<!D.?EI`Z]D*CY"[]ADB8<$.*L$@C-'`J
MPB*<DY$O\0GA:'&G\E';T''N4BR!PPN$0R'<A3T$P/\`JZAKG*,%`F*-Q?!$
MSY@[489>TMB3V*%.[I)\UG-Y<?6`@5)AG2$G/Z%=P<<>:K%M2-4NQE0ZSU(!
MLA47[*8NWKAA<K**\C8/XP)0<2AET.@UVK``#L,V$GD(_J8B/D0B(U0["W,(
M&A$*DT0(K5$IBW=VA+`(A%`?"V!/#,<I^A0;$>=/(<%WE?)!T&@]<Y5EI.$P
M;Z@*QJB3"?$3^!`>QK8<T*,-_[@,0\*3=?:8,>>3IND5TC>`5KAS[:$X8Z9?
MU<8M:6!76?``2)ETY%((0B$X%99&;Y)`P&A,93`N!6*;ZR$G->$+\S,/,T6)
M4B5,`T@`EH)=YG<N\10IC$#_3X;)=O[D=HVP3P/5G73'!5HU4/^200+357;G
M+P@CE^GI"`"",)63&_81/5[G%.,E)=1X9%C8%,;X>)7X4?A0.[[W#.85@)KW
M?CU1?Z?9H,V`#YM`9\(P5?O92V?&`#^31E>6B!;H;D&S>V<P,W(!4X#A85NR
M+39E;+&10[,B9_;S$UUP1@(Q%>%U##2X$)'H29AB=-67$H*@5=.GGM8G"-A7
M,$.3"&5%I(5P*=_79SDA-B;B7&<CA(1`/E)JA-*%&U.80\+096W1%R6V<\C6
M3MBUFB2"$JX)#8*'AO"E37CCH'"Z#`Q8*_+'A??0>'-AE3ZU>J\0`/-1+)@W
M.YYE_UKH<!#T41@K=RF811&$-A+5DJ&9U(R*J&`6H`M_5PQ`21*^!0:>]*2<
M,S8`]1G#=7Z?^H/)M1IJ\XI2*@Y4ZH1*&#R`,A.^8SPUMHN,88K-,XJ8TJFO
M9H!Z13=8XEY4LY(((8"<HSE[]0X*,Y;;`Q.*\6/&L'GV,7R7,*;9$Z?8:@SB
M\VN-N0EG08F*4YOZ,#3&="<8F&B.,4&,($"$$F@UQ1&1(8!<T&Z780'(L1G<
M,DU3\4&G$*C]]UU85*-6]'$G@2)0Z!(B-!<L(HHO=H1%=XJ:5@DV-A>*<(HM
MD8K)8T*MV&F8EI`IL9`2(@@R1)<L(6JG$0E_0W+"D"BY$/\Y\.,1AT4:CYF9
M;4&2@9(H[*,G^U!^5U8(O.&K3A1?':AS+/L]()>M2`M>Q:0],)<L!J.-JW>4
MZW!-"H,7>L&'7TE'F<>0GZ6"Z9!UES".'&%`XQ`A1E>N\W"/!'$.A)(9G.I(
M8V@,P.0*?/,A*R)="OD%"E,[)`1J)Y02L!&17:`09>-($.D.@\N6%%D?`>>1
MCU1P+>*1.WM)7;`3RR,.=J28#(&GMC`KO#&`&^2E4`L]1<0Q\>F<\6:LE<BF
MPI"'0[.9=19EI9FTM#L\1R:4IA<+VK4)R9@_=S*/&D%VZ)=@WA2AP<<.F[,6
M`T01<203%<!9-`,;.=4GH=,8ZE#_!A^T"\RJ0]"Y/9XD@;+F"*LTLH3@2`)#
MEV^Y2)^!EPMC&^E[N7BY=E_R$8J`N91R,W*!3]^YG558*6DSGHG`3UP%,'.C
M&W-#;)(U7Q4*1'3#?^"(*UUWJ8K34B[H5\RXLEMVH'IBC()7N[0+&J(0MW@4
M"C19B>[UFQ31+%98"$VI(!R7>NK0/Q^!$..Z@.JQ@I)S;8\(&_=A!F0;*)_3
MG#89K6-Y$M-)DY<[*9*@$(4A#MAI?@K1OV(D"?LK=]3W?'IGGNJ9=\X75I7;
MGDD*>&B5$F3%5MIU1/R2&U^2&U['')26"AG7(N0R:QMB.TT1M?C`&:(E@#E)
M#$C$NFBF_T@QZ\'8F@7Y`CE%Q!!)$20EA6$YH[*$H%KY2BZQT6=%(T%E\IM[
MC!Z&H0:002YB03_S:!ZH$`!ME@YL]BN3F+._1@!FXTEK,PZB(J0^ZE%0(B!V
MD0A#ZEK?@,M>H#"PX:DX>`\Z.*J6"ZHY(2K*E39#6`E7NAK2-2+5Y4A,>&,R
M(A2]2@RN^XJY@PMK4J,!6)N+T+TDPBKXZ"=I\A.BZ1OS);HR(7+N3,@^B4D_
ME)G;L%^&H'\X4A@_@X'C<&6'<DP>"A&[)X_M;$9<1WOH[!.)`DO8P'N]MPD,
M<"<%)"&<JR$])@HRHC#`-30Y<<RFVC5&]]&I9:IFPZH720BJ6O^X*+UB24BK
M/G9`P\&P-18ARI-CYENKBT%+&ULILP$]*%L!D$P+B?*2N%9,?*-(,+?1"TQ\
M]=(/7HM.?C6[$TI1KIMX='.T\AR-M"2)`0I47P)O,J$YT-G)EX&U9E"LL&&U
MJ'QAL].VSR(1.Z5_)A@8/ZQ?5:-'&K,G_=$_9)!&?_5W:&$:*+$VE>!(!^MC
MJ<JJ+9$3AVW3"Z$;$.O8R'-C.6&QEP:+&9&WG58KM.&W#YE0,61J)5N1`>=I
M;4D-5=47_="/_^<)#-#`-,N91[TX71>9XU%N8.1D=J-#-\*RQAK'<;S57!T3
MKZ"Z.#::?;8R<NQ=]4@[PVM;Q5*!G'7_1=*`CK:G.>@!8/3*J`R@%A80U7Z`
M.VNA#^&!"V-`;V@P+D#;'>3\"@^!0R&2*'CKT7I;*5,SN)GPT;`Q(7&'N(2[
M"(;K"&J9N*SV2(RK:H[;%Y!$<B+4-<=13X?0Q"WBE]II3_0[3^AQP*32WGE*
M`+P!H,V8?V(!5257H(-PCCE#=,NCC3*9BXHG0%'1P9T@&<3-AH0W*PA,)0ZS
MI*!!6$/EC0$M#YY!39_CC;O`S=S(+>R"'%B`HGC6+D!V'LS1CO2`M?+PR8.#
M&_K#RKI%.&8YV+K\&0<COC&D<.YIG?FLOA.6I.[K#O![X6;GQ/6KQ'K)G;S\
M=N#)&#OR3W7'_T\ELL5D3I[K:3#M"08,,"MGUEV4`.(,>BBP@V\H5<^7C$SV
MVDMF("WWYT0BQQ,3,\@-5IF`?./*1GAAJ+JB4TYLT0\WG%D\V!"ZE]=P<0:!
M:;SBY&AH$7OK$6U[@A"#\]SU8.1'PP`?!SNWX^5S@1+PK5V(I>%+O'@2]\3:
M&<5SI^=Q=YB"#GU`BG]7O,O8MTAB!<8Y(1+PR:2`NWUJD\_D]QKTQ,Q5JD':
MX,K%0%D-`TD4Y4'!5#W4V%+>U8$7-%.B@XYA,(\CWL`7`Q7QW&7Q3.I>9NJ4
MR6L&M@VU&:MF;1`6L3D6]#-@:PEZ>AGL(4G\"F0(O1<HPQ_65BR'XO^G^;M[
M%'$UG_EH0GD:K]P.@K`+@3;+8_X2M@Q$0Z,PC8V8JE$4/>_1PCP0Q<R#16_2
M4QJ.S7RGI]JJ1%BRGY@1Q$-C8A<1)NFM4.+"3B2,>-1HWU5%:QLUA<((".$Y
M>P@E&J2";7NO-AMFSIVLU?HR8\KP7A9YJ<",I7DH._'<9Z`Q&0]A_0(3."70
M?Y3?0^5,<1U-"8(*4G>]SB)A1[2HM*,W.7*I3!V)K*$2P2Q)'85<(BTT#/?Y
M0(C2#/>*B!TPM[J)"^MOL$KU+I$:NAH`D5HIRG5EE#VQJ]'3&!N+DQ9,0SR4
M'()7+/D(8EDCPU(OUFM38Y!Y8Z0%!R2VU[O_6QT\>O$UW'H%C#+7DG8_4J\P
MN+1PK5%B-\*=6"_3-;ISE>X8:%:IZ><]O0E-J$D9G-_&4[+.O+7.Z?S3%VD*
M"'^"@X2%@U\57X9_7`\/7&($8@%;@EA867]@8%N<F5F4@F)88)I9G%N?EX);
MI%Q@IUNI?UX!6(*HKU^G8HI<MKBR7F!?7JV^MEQ=6\M9D5];`8I_75A>?YVI
M6U^O79E_MHK9G(I@`>8$NP2WBXM?6I6##%W7AEQ:CUU=7(N-\=@/PO@92'!@
M&#.)"'T)6+#A0#05^"W:4H%>NW9>NE38`NE!@'J#N&"I@(6?R`?6+JI<R;*E
MRY<P8\J<2;/FH0I9_[*P6YEQ(Z$M6KP)ZOB1D9@*#ZYU66!F@18P(BN8$6CP
M03PP%=`0#$.FHC$M8\R,6<!O(1F'`\\$>/!MT(*S:`N:$5,H@`6X?B!">V1S
MRX-IA1;NZ\(@RS;#VVA58R5L&S0LOJKQD[7%6+%HTR1CZV286[1OU:Z-$^/E
MU8)I`<1DZM6)M":D6;1@0?F'-"<Q_+(L^(:E4^U76W#36E"J-B=(7AQ!8_"/
M)2+`@K3$EEYHJ1<M`=HA*@YN#-6X?M+L_+.P#'@_91+6UK*@^9_I;5O6>H#;
MK]!"]NM1M&BSO___``8HX$Q^*:+32U&5-`A\@]@WC5\5+$#0&6/X1-$89?^H
M@1,K##FDA@6G[?(-(EJ==X86A;QUGA]C[*.)%D%YD=$#::215`!DV12`%A(%
M1D``C>3CFFJIX,8%,_6D=@UK8`@'QFF"4+*:,4U.!J5(G4`"G)-=E`))EKAQ
MHN`7[1G%B1=BC+*%4\4L8^8VN*$))"VI<0&))W&*X:(R8CCR2SHO^072("B2
MU\4#7B[PD57M@/$7(01\%Y<:CQX)V8QX%40&7\IXIQ9]/1K**(*S6:/;4X8`
M=1\8[,4WX*NPQBJKK'U*="!,1S[`GV(^"3)=<;%98)Y!")4$QB5)+B"I0^FE
MJ,:*88S*11:E'4K&LGZ$H:@E#'VX&Q<5:)%1%S;_<;$`N1,QM]`":?+SI"^]
M015F*[D19U0G:$Y++WEEWED9789E-QQ4_GY!%YKH9L01)*<TR0@6"2]#YE)B
M.`Q)CK4X5AEEEE@$32K0O)+F%P0,]JA+.X9*:$A:($7`-NJERM=/4IT1UZ9E
M/6"&&DY5MM94!.%H$HT%'>31H/,)%ZA7/;GW'HS?9-$%/+-6;?756%^D3X^W
MRJ1J6UZ4*E'3@GQA[59=A;KFBNA54$@64F'[T*A^X0A/5$!7%4\78S14Q@(5
M^6-3<DY;0D`6)--3<9'D82&PU%!!8Q@GM#A>-B5>0/-Q)2*Y^`7FT!@C2\=E
M58PX1[+0]0?$UWQ,#%1-_\8SB36N?U%*DZJ;DPDTGI3B##OFE&)[%Y($J?)%
MRJ!KR#MEPX.(85I`1\C693]@`:@7VES06&5E->$85J'I45/H?G'7S;J&FN#Q
M*L&W?B%D*V85^UG7;__],.GS]G@R,3A4J?5X7]($$H8*#"H+#Q@6^DRR`$=8
MPR]CT!Y!]"**#E$(>Q7`4%<R<0\S."1:O:@`=V;RO'9H9#FCF)/!*F,[T17'
M<:V3!>*@PK'5%04QL+A=;RR!B??(8A,Z5%TT?+>)3OAN%*P@A2E0D8E:""PX
M'($%8IH8`(&A8AC4"@X'JQB);90,0?1I5$+@9KN_U*H?VV*%%K1B-%-I05C9
M.O\7AR2XE6+I:QHD6I%X)N(5F$CM;G[A'YT*]3"2T`]_B$SD_2!FB*[5)'ZL
MZ",C\O,PE(Q*)];`%%J$1IX'P*4K]``*A@:RJ7KP;5EM'`:R&.%)AZ#!*EB1
M7DR`(LLH100+/X*%)D*QNAX6T1/OX>4H;A>+Q'Q.B!73!2H440O@R4(7O$"&
M@JZX#6-`AA&:^6%GCB0-080&&Y[81C>^$0YP9L-LZ0##.EZRD,)A@P#2$52M
M]->/4=6F0P0!Y1?,!J-X8,$"<B.(C0JQ1F@AZB*LV@U,9E29V4@/7*F2I"(G
M2E&K+601CAR<V!8$M08%Y1O[$9\:/B2=^>0M#"WRE??_"N*MG#3P`3FZ1P#.
MLRGH8"%3`TG/7@[9$BSPZ"($`,,)Q?#,P\B"F8O9S,;V>0QL*H@REC%&-\'Q
M5,Z0YDA=R$Q*B-2D:[PK2K,@36O<!:75^<8VP<E-ERQQUBV5Q5Y?PH<Q7O82
M,IJ0+"3+!SUDHYT->=,[<2F#!0@I"@FM"")U68`"74FUU5D/):'ZHSO;<1),
MV)-P[5#5H"K*V<[V1Z&-%&2Y^E047TWM'Z<J#JL(\*R'@(\CI#5#&`%"QX*4
M80SB*D0K5S0&U94M;OG,1XYHDKR55&!'@?/FD`SC##LA*4I799)PUH2,5"!G
MK-BX4KRT=!MWK?5+8,B7F-[*_[G%Y2M@_/!"OQ9G,"[(*;U=,!*1G$$+/36"
M1\2K969G5@ASD2MY,FWG?@&C*+:!EA4+J&U#2BD*9.GF?`VA(#7ZEBT;E580
MD'3)45A5B5BN)#9S\JR(1_P2MV%4M/YQT"`8NF*-<.0]78"P'SYUBYS40PP`
MU2/_'J#@AJ0TN\L@BEH6H%Z!$7>V*B$9*0"'!2==B:CR`HZ"=,-!**/)A^P@
MDY?,"[!H8)@X=EH<?<,6,8Z@J6%TZ1R&EY&YC8VN<V4AQ>E$YT^/R5!R\S!7
M4E["27N,BCZ$>TX[SN@K"[#-1B;)2:[&4**&F.&GC3!#A@9++6M1I::L].""
M=16?]_^YA'!3VQ69L+/9>Y::Q*A.-6$)`0I9^:^0"H(U?*U"E3"DIA`$8)M.
M,4PM!([R@VGDVQG0\%I(Y-F>)!3AIXF'">*=HQ)?L!R,(Z<-RI'Y<BS<!L?@
MW+ALTYETY#&=[8XT.AO&L!/CCEV#=_=#VVDB3;@XAP\YL8GWK`(;MBC>`W[:
MDN*ZPZ^@>%Z!3.@B0MBEM6AI46ZD(MN/!&NQ/TY.IHB]D:B,Y:<2!X]@E3<4
M2O8[(H7PL*I4A@B>IOKD%%TU(4`N*[/9,U?\.5(?$R20^!9B)#C5U)ZI80$S
M@,BE%D!XMAC5P:(A9",EM`D^8MUO7'K#Z?L,[P^C=$,9GN+_2$2U1-4YHT-_
M]A"']3:'[)280QG:FQVM("83Z?3$9TJQ25MT9F6(88Q>=#%Q8'2GHPY5"2^$
M*]K\)81,!\&JC_;D6D5+HU^^LZFL'IY265YI0\X@VUL4`\.2!P\!,AL4_=8E
M/GX)E8=9K7*4FYZB#*"?M&>5M!ZI&!>MFJ0C%@#[5H5-9\MZM$FP0Y#;PN/P
M8=!0$W=;$(ALXF0UP4+J27MJRE+D*4?9$"S.&<SBI.EVMCLJ>6Z-C62^3OO-
M9`SJ=M&DR%1UJ5(U_V0X(T[,>#,EXQ"G4,EYS4X\()V28*>R)\*7^1S*WX:`
M69:08W]S-R,!--$2#SB"+8)54J/P_R`%!1[:,D*3`"T6H#JB<T`=I1(]Y$W#
MI1`&5!TC='HDF$@,8&2&4"964UD@\6J2I4;5P&-Y42&P]0`1-!`_U@@Y=T'_
M0FKDD7D#H2$&$W@SH0^$9!^NLA)`8144<5SB9QF/H7[&\2\R\ES4H"`5`PM7
M987QM22\XV1)$E94XF33$"^U,0QII0G?!67<E89DLH1H0E<N,7J&0#V#L#5(
M%A@QPS>35VQ^<3T<Q(?@<08+P#\5$%`3@GS8)&.3-RI842,5`1T91E#78"XH
M^#8<9R@EN(F)U$^498=6$U(MUBOR\V(/AG"4!UE`80$D\5N+U1`'80$$U6C!
M!6#E0ANKEO]:?@0X%=,R%O$+T?6%DY%5C"`EUU4EV04O8.)6:KAE^#(O8[)>
M9X(;Z#4<Y44.!Z,G:[8P\T4:,*4,@.(2H=</V"%XLO$.[D1+0T$T:'$0I"@(
M3'%HF8A[X"%A:P%3E>9)DB)AB]=[E$8(M\=THI`=@J,2#V`()L:)"IDU/()L
MA=`GD_4JK]9Z_V-(O((786`COH5YM-B.(3@(.$*+8W$=ER@3`O8'I<=0)@>0
MS"94Z\`.5'8OX=5E6097[`4PDU`V8(8F>%(YY4,)7"`YJ/`P`O,YWK9M$!-G
ML!`R-<0ZY-$*)7,/.]<22\$^R4%[AV`5@K8(A.8%C-B.#)`B:;#_(BEC%+UA
M##:H8)@F4VE!@WAC,V1@`:BA+`Y!(>_(@AP2E'ZE$JO&!6&YD(!I-2AB+A_8
M7X>B-!;%=R$!0`W21P'Y'0GI*W0I@42W(]X0+&J@+8L2D2VQE2B)/",AD"LA
M$B4C-25C;8RT?=FV.0_C.6?90E-G0Z6SE#14;C#TE.@&.UG72Y^@34'$"O(V
M.49T=EOP,E>YDD.11LLC0F+S'()"<(2`!6/)6P+C!8BC#/J8<.5C`6E0!G:4
M4`J$:*R$4Y1G2$`1%"8AB'%!(26Y'UOC*)Y'"`?Y$W\9F/8)*X3D***YF!9Y
M-2K9F+M2>%5V-#]&'N+@$3T&$<,WE@58_QD+H"Y[21//N3)**%$L(7-/@4O2
M<750I'77`':9(':6H!J:0&^S(**U07;%I`IHIZ++1"=HYW;DUPO%*'?#@$[$
M\$4N49`R,PV0@!2?PV_]11L*@:!Q`4*B(!6XQ1$'*$%(^H.T"$K6&6,^YSD5
M\(IHXY!=,)WGD0:9N([9,8XL(52"YPCW>:8#0EA$T7S88*&SXFDO<F`N%P\4
M00"M8X/@4Q\V2(N4H@AY]#T/@!/J:!,CH3*EAU$;*([X(`L5X!/?9TPV5QO)
M9%2)D1$Q.GZG<$W*<'Y1Y7Z_4%73YQE390NB06]7]554E5_%R9D@F(05%"JS
M,2[:84\^)1N+UO^1K[0W@#5C>2IS&*(&C>47'1F$(%(,B%,]PSIYJ[:EB.@'
MG,0JCA``"%0)H+@24TD-8G"H:+JM,4&$`$&,C1)[6".*IM58=`(J3],R)6(T
M#O=&:H`&X@D4P]JGA%832P$C(Z2M[N!BNU@!1*4%/\(/7.9>S"`175@;S&4D
M7#@DPJ@)1`9667",TZ5=8(*&7.*,428FR?$(D3""*@&?T#D]^Y"'(.BC6N!!
M&:DKUOE&PT)!EOA!E6>=JW1/S5H&\SD(6"!T[3@JUAFQ!X@M*(4N=A@`AS-X
M+K%ZU$`N^LJM3+L2]]9(B=I(IY4U"04V_/H_*-$Z9Q-<CH<%[#(9^%3_B_14
M$XV`@5>[(QZK$@&)G&NV#FL"3]45L6*%C%^%)1F;AD*%L>*U+UKV)E<6,%^V
M9=A87V469D=!%OGU$O5JCNL@$65[DCV*8<1'2A;@#3,R6+XPN0[1%0=D6.>!
M6"!X@VBAH)%D!FM1$MFS%417CAQ2#`[)@83D;TO;M+2["*\[BI/UGU?S@A7)
M=*(X'VGP'8*UD<F!+2UR'2C&3@ZY/DW#MD:ALB\1-J5)&$FE&Z7`DXP3;8_3
M)4$9?Y53E$`IE&^6E*K99M_&;0:SE*ACFUT2E?C@O-6Z8O/3)UT"#W:U"#XE
M$7_*+&Q2"%=J8/%1'C15*1J1M>#9$$(X@+5F_V'#P!YJL"E]9T^UDG14J3QE
M2Z&UF\$7>KLKME']$)K.VQ^0!',MV%$TEU-8.0@ZXZ06(`T<7%?PY*HD/#7]
MJ:CWT6]'D:'PY!LBH4)$E3E2YQNR&6ZT26X*N'4YI`D[Q)L^Q'5*+$3!.0Z<
MP!S'N:.LNYS00;0[%;(`D:PL-1[@TF-;D49H<BD:D7/AT7^[):52L\8SHYXZ
MYPW1EA*>N34#UV](MA#YJL%\/)K8P5-XV0\>MX(@W""Z`AAS&DGQ%3V&\K40
MA`9GH)4Q$Q/ZD12Z.!&L2Q$/6U<]`Q-^01]'`4LARDN7$*(F.LICAWTOJA/(
M!#O95ZG`H%305'XURO\8Q(,X.BH?'#RH'%(+A1D2>:@%S3IC!T4+$>LHOP:+
MEU0!9$!2U/*S!/%C^YM3E#8?R=4(7(H6-CM"2L0(?+6X26:N]XO!?5S.AG`4
MK$JNF'S#54/"'$4=&':Z[H*O?J$&Y=EA!""HBH@@^(`=0MJ\*M$(.P+/RS8_
M==4R:1*H];$+X)=4E'$DY*>IV=08ES&J6+@)SE`:7+A5DW.J1'9"6\`<^N>J
MC@6KXC*V@6&N'(+&#Y$0RM!S*GN*Q>=7_=B6%0=!/H=V#^#%Q+;/FIMP&^DH
M,L(H*+T2GBFFA#"[YIS!<-H.K]9(3I&VL?(U+?9RLU$49E,!/5<&&9+/_GK_
M$B&<E="FF()7R,LS*@OQCA<:FFP:@"VI!2>X)`GK7+_8A9#0L&M2B<8XMQ.K
MC/)BL=Z%L<A!`(^`2R2-R?JU%-`+8!Q\O[]@>(<2O)N6N7@1E[MQ>&70%7.)
M+>59$CGQ(&&+%F3`/P2`I3Z&+K5Z+H'*#7PECE/99P15PTL]V^Z<9&2]"),X
M*Y=\KHAYGB]F.Y=`"J;TI2[AF;RM,NJL"<C7)X"7$DNS*RPAO5U"&)7"AO.2
M.T(!7E<F)CHIN/_B0]5IDSUY;89"O\HPR2L!SNN(=NQ!']NQ7_6P$`RZI"=A
M!MJ#,YVDL^A!WZ.@()UR'AF9PH)PB(>E'M:9.3&&_\9(V@@*LK&NRZH@R6_^
M=1$HDMRSO=14K;9K@9C]9=96,\(>+CX>`3+`O)&>O,]8Z]R$%WNST2-CFQQN
M^F%1.YJ'&PWPM+W49J(^B6W=6TRM&6='.;Z>(VZU"0L!ZR<O4=2'H-*(T`GH
M'>&VDGD7I*?7,R=PX\6\NJR:UJ4"WJ8L[0>8!@X]]W.8\AVY2A[F.L%/_HD6
M_,*?R2')>^$:O-N4Y>']Q7Q8L[8`.BC3@DM%J=(PT>(5"MTP5A$LLQ,7#!0'
MUIE7Z]I:,`I(43%4EQNFPZ'E5D4?ZIM*['6]:42HW&"W(U3JDCY6C&+&349(
M+7ACZQ<]UD:#D%,R".`5T/\0`;"K<;&`>>$4"Y"9T*QS!*2>/7TM!YC9WI,>
MC:8/?B"L;%,57`H1K47A=2&D<K[4N1U1A/X3AXPU:[KB!S;A/QB?*J'D%_'4
M\&-/[ST4$>+F`>C!+1$;&Q%]1%4.\B:IJJQ]K,P*WO?*2,4.1(6IM+RI1(O+
M)7D1D(L?A8'MRO#+Z^A;_S3,%O`-`Y$&%%:/#]!::&`&U](5HELT8T!A$&$>
M=IGQ:8F#@!4M.[@6P4L&9F#?8![KT>)!LC7,$T1\E-)HT(X?WCKM?:SG'RNN
MB$K0H9CMDOD4CD*GUPI&)MZ9<H3%AHS(!T61.TJ_;0T_;[T.EI&IOO"U4X@F
M5<C_'YJ1A<V%50;+L*TQ(\L!X;^E7SY5M>!`9,H9&,7<2;KVD6$@$+*5-WZS
M4CY'!FL1`&?P(7#$[*04Z\02-W%Y/9KV2E_NCI(2*7-S%AV_[#DE>9LB*3>/
M'TJM\TV[[>TSM1C1Z%8SD:5L"=+.3H`.$RKH48`AZ+BP$<%]ND?CR1\5O4XG
MZD1VU]CU7+]@77QM)7Z-'-W5C$;1)X\0\(&"XMZD/+H1.(V-WD:*/M>0'!9P
M/==B872T*=H3^<'%:#V=!IL"%SXG-UQQ7),'A!^TTP6Q`&,)$6CP\I+?\M_1
M\<MR^=5QV)K/QZ]W$;J[[I`%"'^"@X2%AH>(@EY=%5N&_UD+B9)_7@0!DY)>
M%5J-@F(/7()<75V$8A4/6EM969]=7V(,75F8A%E=JK6BIPM;6`0/M%QB6V!>
M8G]@OH)?"V"48LJP?ZV7?\W/Q\JME%BO%5VC%5^Z?UB@AUP/R(/J6U\5M(=;
MZ->X8E[T8V5^_?YF6D+!0]/O3(`'9L*0>3`&C4$+8?R$0>BO8AD+%LJ<(9/F
M3+\Q8RJ*]/>`GS\T$$=6G$A&8@",(!\\.(.RI4J5`19$E+@@@,I$6A!YB52N
MJ-&C2),J7<JT5A8M6N0EXH*E`I90Z<X%\-)4EY>#5P=A>98TYX.P1>$MR.+E
MG)92HM81ZO*@4Z&GEB!I(>N5KO\8K+7H:1%S2@O1+P&V</FR2IDCJ@$$8MGB
MY8NQ+<7^0!88+8ME,`RNR@2,B12B+P\<#4(-!LP#<H=R8J571B$X+Y`LJ/$W
M!BX]@BO3/`APILP8"VGZH7E@\^:9![O]E7EPL^+"G33]+!SC<>3RELN3^U%#
M`"*:"L"K^PL#TM_SYATF^`-*OZO]^_CSZU>ZR.[4+;<E`F`77.UG"%5G<97%
M`P4>-=8PPS4XR19:?%&A*%+!PQ<74(V32'^8$=`(:9,@B(6$DSS5R"=6J1;`
M5LDHTQHM8`1`%A9BT"@C&#0FY@D66##P#CCEJ,/.(\!(!<8XGY`HR@)P_4'/
M3OU<%%7_?V-4P,Z4U9%1073^$)!>=0LTUP]#W:ED1DIAP%1!0F18L$]%YQ%4
M!GJ\A;10FNI)Q-Q)%9BT1@$V9#`?(D$A:N"BC#;J*%)?G>5D(13.DLA343TJ
MR(!>N':B410&2,\KDWSBA1;64/K::JG4D\DO6U7U:3F<EK,(`6,M@.L[U`3`
M#F%@</&.8^0L@H4GF`G[119@8($8`<OB6HZ%JAE"3V5T808**9.Z,T@78U!)
MYQC!4#-(`.'VJ<8"(OU9W41F]*,&1L1=E-%([?EIDT)HEK&`!62<(9Q'U_4S
M47)KBJO>>6`N!-P:#M00@0>''OB`4(EJJO'&'.]G(HJ/++!7_R)?9*LQIEG4
M6DL7!"S0*52TH(P(*5X\0$"U8KD*CV&3(@)A`%TL$&`Y8,!LZR^S="'+,5SD
M$XX@7?SU1S0\_B4L@5#C,_6"KVTAY+0>QA;0()6XC.II%9#%14]]GE%!(5J8
MU.4#P*%1AD-9DJ&P']_U,[!V#*&!1MX&4\1WH"/%N8!&:Z81T1@Z*0<P>R'U
MZ8\:>/K]`)4)T''"`C)43.FQA^#2\>FHIYZ4RA\R@G,AD4K]:,FIR3Q53U(:
MQHK))?NGV5GPL"5K**-$*>4FQA<UZK*I2.64R;I058$SOT0U3#Y@2+W%`N0,
M4\PP7"@C-1A=T`-*`-#2RF`ZIK734__-KP^R)&Q3^]3G0H58.*=*!8>QP`)F
M^)<:PF"&-U&I3A^IG'0PHH8SF.$!%JB`3=1`M^KXRW[*85>5T',PR_FC8`G<
MR00`<`0B9&$,!1!=.RHP*4RI[H4PC.$CC"8)Z:'E0.>8E:-B=XO4I,.'@^@A
M9?S2M(,DIBJ8N9`H1B67<]4E?D;!5-I<5Y1%I*9G\]@$,2K0"6VLPA'5$,0M
M@L48&;V#`.&@"_TP$8"Q60QG[@@>(NA!&M28"5]/6U`$7Y&;.X(D(BQQ3]YL
MLX\U$:1-\5+)&;($)GEMKD\360F>]M0W#_H!<CM!9$5F$(`4"`$,%ZB(Q?A"
M"'B<2H:H3&7_ZF@'14((ZP%8F^/0'&5#Q*P#,%\@`"G)=A!\#(\:T3@&`2:5
M&5'0)6WV`=&I<(5%'%JEF7?AQ!;$P(FG?6$RE;E,,;$0F6N(X1=_&4WTVF<(
MU$`O>!1:XUR>1@T@"<^`(O&?->C1'2NQA2YZ.P/;^`:=D1#0@&HP@][TU38"
MB,0,XJD.`A_2$PM`,`QW&I-ZY.D>=_FA``;`@A(Z8(*1%,);Y?10QE1)TI(V
M*G;07%XBBK86C0WHF@FBQREB^=%/;&5`M%@$*:XXE0<(39U-:4L%H#4JD$F"
M=9@H&:[(A\8;84%'Q5A%,A*SA9OE,GDU;.(C/!2I@\#"5:[$W::@_V.<*^JC
M.Q-1#1924I%%-B(,:6#@!B4J$B\=-*'5&0,&#4:N.UZN@IC;C4$(H*>96#*0
MRLF<'V@P`!/L8```,(!'R0;$0K@&-B,UJ68W>Q\;0M-VA[A%+C3%TI0-%384
M:ND\WL*L-O9"%+_,'SC`BI^?Y=*GSL-$:6V%OJ2AD5?&VE2RWJ$%:(%!6KI`
M32OI2(AS%,]GE047E0PBJ=0&`)E_`%=U'&C8DSQRHA40R70&JA)-\M.A&:&N
MXZSS2.%D\D\YV=M-SB,WA_E#!#+`PA$D0(*;K"8>\W!59CE+X`*O;I9"H6*"
M>?HHT:Z"A@Y&1(2S2%/S+0":)/,%D("4(_\G`>@U0BS*A&LA/>JUK!5<&`;6
M1B&&!3"HJJT,;=@,$332T$P+I`NI/-:FP.`,IVE2>0!>;Q*`1J*$3][IIQ_B
M6J9_F@')[YEK00;Y0.*P)W)_5`YT*&?)\52P'P^DD@%",(87D,`$-%C#3Z2T
M*AJSDQ)$,;"<YUR4W;Y*4CZ+[0ZS%6)*9&M2*#U$:0N3JK0PH@M/904K?*&%
M6T8S*L=U=%\8')A-8,;2PTC&--41$)8!54"T?=+%VH$JY<ZQS>KPZT'C+(CO
M5B=A5:H-YAJBDHA*!"0TZ2LANT/??H#0/0^$T[^28UX_1!2Q'G1OGOPQ@3XX
M80Q/.(`!UD#MGS3_Z4!B_5:,Z<SM;HL1%]O6C$V-NBD$,ZJ6O22>K(R*(!@]
M8J?A/L2I1E9#`'6SE$J+3`[)G95GED-%#Q;28GR!QK6M3Q>R^>$W)04_>'QZ
M:JXJD^7T2BEXJJ0W6@[``[EC+[D!#I!"7DD!GWP1"&;N)?*5B'`\GH:$7F<Y
MC>Q3EOV4R'Z8P`8>$``8,-`G<A("?OD;M;>'3G2R_7E"YB9$I7*[J%>^8M_E
MIJFJ+"5;IF,B"P`.(A9$9IBG*CWK/T]W5:6.":1.0JE/95DO"!!.-V+BN8?0
MT"[JDK(VNYDT.4'R2J`T5H<Z`D#<68E<#I<>Q6DD;V6(+S]5K9T*I*LB_^BR
M7!IJKIUTQ1=S=+U)FS!8$V9S(0!*>`$5X."&=UD@QZ4$NR)F7/36>]NS*:)A
M:$6V2T8M766@O8O(JK6@ATO"0H`9E3$442-_4Z*RKCP'78J6*:+ICK?@J-%@
M8%4DY!/BLDJOD'/3<38,;<HP'B^<6E/BP&>RE!_+44V<Z&H<@`E,H(G-?$4F
M+Q("Z+VNCRR#&?:?)3E]W))1%G_^L`9%(`0R``0U0`%JYAS,$6#JA!J^YWH2
M6&!.QV_,`#WRIF`-1GNVPTH+]A<LA!1VQRUY5@\<XGN<<EOQ9@O@5B345`$,
M\!81&'2U-U:DT20^]W.5942PI"!=`##>11;:M?\2"T$@HL4]GN!J([%(>^4'
M%7!_@A=SLP:%*+=D9#4O!-`2F&1)O>9KW>4'#B`'(8`$&C`'=;`P>&((UY9Z
M,SB!;LA92S<)@=9O-W12KN.!E``6W7(.(6@4)3,(VY-40@<)L;<)<U@+5J08
MC#(_,\,`]Y9=X:!5L@4;:X-!BI-3=&$&U]4](7<3<5)H4]-C\V4!(I$3\L<W
M0`@X#I40\[(X*Y$O^7(X`[0`HJ@>Z^</5=@/7E`%,2`!`F`"`&"+7U8()*AT
M!_>&R-AM>E&#R9<@/E-4FE)+1"1N$1):3V04Q#`(+F,+BE8(DS$(H59.V7);
M.O1V>H8?S(5MD;$\.$;_+7.D1*DV$L:1"US`"L1C4=7Q-H2@<?=C`8<45R2'
M$>%'>)H#2%["<7WE!\]!;(;C96B`;)+W75SF#W50!%(@!E/``S2@'F%6,1R"
M>H*`!6Z7C"1)9R!2=DD'B+#4AO8!(4]G%06B4K9P(CF$8<@R"`$!(:@")-?E
M:%F08UZ'B.@3"6:'=&3'%#4F;\@7`$+B<(BPAO`PD((D=&+4A!<7)5_@!0B2
M$"JA;`N)!JUX>!+T0=TU<Y=C`8OS$+J!BLWQ<HAC2;'807Z@9B@@`0U0!4P0
M!_*15Z*H"-8'=R49F-P&>Y)@9Z$E>XZR/+@'%7SQDW/G;K\7)6)P7;(0+"&9
M_QHV@QE'0BI%XER?@)AE]WQ,L398Q0RJYW#7,C-1H@FG:##Z2&JN6%YGP0P,
ML7MP-1Q\DF5=6"5]57XYP2;[5&O'(1(+D!Y_1$&MN1(64'.5Y`<34`!=$`(#
M$`73]BZ=*$I.Z4J2*)C<*6<_8X'4T(()YCN-@C)V=I*.^76<F0BH)A.$(9(R
M,1D)PC*`097_9@G?9GTILGM*`5+68G=L=DTCV0ZS"8@:9)VJH6$^B(_\E*!?
MMDA"QB_[<!'V@YR*=!`MH1&%PW@541(5(7$4]6M]TIRVIF9K``)'D`<'\`)R
ML#"I*!+T\(#ZV9TT6F`RV3J4!CLUJ2D@,F$E!I)B!/^:I62"-E--GK%]`$(_
M0)(4#-`.I'!T?4&>M2!'A_`)/7B9.G4:E549YH`0\G4>\@`N9="*.740ZW4>
ML/$)"D-`"%$<^V<2(NI/Q6D1U"%SE:-_"(41?V*6(ZI8U[$&'-`!?N`%(2``
M41``I:=0BE41#T0B6,>2-1JIJI1[=-@SW\FC.<1*Z@:DJZ&!JM(@]"`T(FFE
M5SI62:$T<<$.G\=,G6E\N@6@ZQ0*+`4E1H(VE*@%<I(@-L4GF,.)>%56CW$.
M/@4;TM4E7T(G2J@2YX%DU\5X%'5)BZ-_7%0;%F"5<Y,>\34H#]`'8"@%3W`#
M'R",]P<2_PF>DGJN)'621LG_;R\5C39U3<^4GA^2;N6$9\2W84$I"@EG%*09
M%')'FY=VE/]1JJ#6+3CF2EIB:@[HE_LB'#<5.+<I$"_:5KU$8]8J$O2W'EY:
M'1;J!P^$$0$3;.(22'().`[!H!PID;3HG&<`!%=``7Z``#_P`FR@'KDH>/%2
M"/N*KCQK8&UAKP(BFM;8?(_"*0`R&"0&=<E7`0$0@;:T@F_T!ZJ@1,DP8VIG
M=4%+=7>GE#A#+8^*""*)%5&9.!8P"Z(5%@,Q4:]%"/;7)\H&5P)UFX&'?SN1
M+Q`:,,(1>+W6G.ZUFQ.G0(&T!@,P!]?5H@;0`QNI>;%()ZGHI*79LY"K69<J
M"<M(_S(8Z"CF*;3K:@CDDPI`TAI`XF)=P(Q)A5U0`1AK"''U*)ZZ4+FD!HJK
MH4MLF)JE$R6N<8H46@A/"$D/L$NHL3_XDB[G00:)%Z%Q`KQ95K(&,W(;\2]S
M:FLA9%\>5+(,TP\HP`!&T`058"B\JVH(U`]Q`;61.[XR5)2PXZFP0Z^SPV>L
M&WM$ZTJLX$YLL12,*`@C58R0B!7JX&**&*6.`'2KE5JT<"T[JYU'XAHIYQZ9
MM;'S-5K,!R.YT4C/VK$2467%\2]K8C^=YXECV:&95*U6F,`BL<'C@2=G4``I
MP`!V<%T4LS!*AG]\<@W81;XT7&"4ZDQUV(SER"BQHZE3>O^Y^I&.]AL7.:8.
M.>:.A)FT7(2UVQ>>J9"E<3=:(3EDWN$APX`CQX`F59RFAE6$F"A!85!)<>J%
MW%$<O+:H-\$`(E$!$1%EB]NGA?=($R`%&)#"0!``2^`#(K&`4C82-]L/]5O#
M@DQ@>#BP`AMUYMJ2F7J.\RII^)&4A."OE>6.8F2UO9"2$L:ID.A*W#*CU,!Z
MFO&#C$=!G&@&95"$^:`%P+L0Q"J*_C(RPP!^'Q$Y%A1>C,JA&RHO^U=E'+2<
M7;8G>1(&:P``8M`"%_`%*DP$%:#'GIBLMU:+"V&3@SS-,'2([ZBU,_2^C6*T
MF/Q12ML4E7@(>S%C7SM6!0*8QZ7_6BD"I$9LP*QQ:N>,J[!T3Q'*7@*!CW%B
MMAA,+L2C!9375EG"%WYSH!Q;I^XA)_+7>1,1`*?L4'03@!X$:SQA/V"`!DS@
M`@CP`0Q`N%?@`7P,>;0L>%0,$M),S2:M.A_COE@;GE+L**5EF)N[%/X)-ZXB
MQ/OJGY4X8ID<=&"G7(&LLVXTML9&>UMY!NQA36A<);2'&SN&LB)Q!@0P"(XD
ME62Y$R^QG,4A5W2")]5;D-]K.1.ID']2``C0!1Z0`RV``1>`O<J<!1_-$[7(
M3S%'42==UP1FOC^'OGF=HXSB8#I-N4*:7*H'-X!1C(!)R<=7+<C,UUK'AJST
MJ$+,R;;[_V6"-"+;@[1L!H4%`:!80,7XDBK`X2]KB2^1(Y<'>09N91/V1<'M
M(;U@?9V]%@958`)CX`-&D-9MP`"::`,\)WBJ!KT::Q-V/=R;!=/RMJ.5RJ/C
M"*5G!\2O&H&)PB&IXI_9*<,9<D6,W$XJV2`UPR"0_%%:Q27E54!K!`\B?#@2
MLB#DY4^G5VX.-2=WFTGY0L)5(I!LZG@1H6PTY['./%\6);U,:0)YX`&WC0)P
M@+US$$I;'7->J#"[2=P0;E)_?2#C)B#=G!\V)%0Y+!3J6RKA&,G7,,DS'*,J
M23^!3`\(EIYANX\NPW=QU[OG$M*>B'J:@,MH^GV#(51/]M1`)/_>HKT;_Z1Q
M[O+5(YPE8^(O.]$W;ZP>P.U>;L`#""`!#-`#3^`!0$`%?=`!$%`$#O#1%`S2
M"O/E$3[FZ<K<I[:>G*NYVPP.C)%T\.#-SI@(^`L4Y9P,=I>Z>*XS7V-GCNES
MQ3/3ML!Z_5T1O:H9OI"5!\&5^%<@TL6F)P)X9QRFCS>5`U4&&FJRZM)C9%`Y
M=0(OO^QJ[>$&?$``'J`!#$`&2)`!0/`#7^``8\`%="NGM:C?*D3FMOY"22QA
M@2U&M*<QI27`VRU+1RG=NM!HH.HJ/H>_<^YG(^+7!\&_X4NE_TDBKK'C_(,.
MJ&$&:C`&JO`S:0(0]_C/7L)'C19!W1/_G/Y40$AF`9JM94`>4.UW$((SL7VB
M>!+ARVM@!`-``#ZP``RP`PV0`4?P`!E``XD;S/Z$LGP*OK?>\.5[X?;@R<PN
MODWAU[07V8=)M*@Q8$!1V.P4SJ+0?:LGL)YU*S>3A\/1N]@7&Q=&FPYU%8`G
M49`C$(H%H7^A#P$$%S7#>%:B3DY=BN'G)1R*0.<1`&1P71@1QDFMN`H496Z@
M`%8@``20!1'``$,0\'90!0@PE^N![H`RUR"\9@X_]B\4AYG0X=[LJG:8&JC!
M`$<R";"T":E@(>40W2*/TS,*[!2FE1)258P1CJ0)B%KPCSWX%/=RU&.E=XZ^
M&)YAFLE)!JSV_P=L;*<&0P;:7L$6]T'^B.D)!#CM[MN`0A!K<`0%$`0"``$L
M4/4U$``><`0IP..JAGFP7QUD7_LOY+I3\<T?!8V/0A4,4`$:#DT#QO&*`L`R
M3$JCP-@LW4J&24?+'KZ#H*9U5;;W!!7C)\+X$\G)V2:O0P_6'D_[A!*F3#B[
M5I`A7#@(PU:6T]4FNP89@`$2X``K,`"H?P`,4`,-X`&"NM52"0AD#V%^A85H
M%6B&BX9_CH^0D9*3E)66EYB9FIN<G9Z?H*&BHYA>715;F%L575Z56UI=6:29
M75VK75];#ZV56I*_FEI?%5^/7@1@DUQ8%5A<DZ8/6]"265W370M>6O\!E,3*
MCEUCC(ME"UK5CF(+Y>6(D6(6:NZ%9]/K%18/`5ZK8XH,A7E`YE`B@68JF"&D
MQL*^`(7&D#MD@4P8B?7<J3E8R,R@-6M"<)`@8L4`"!P.,*CQ(@$C,A8",I)(
M:!%,F?5HZ=S)LZ?/GT"#]F3F3!VE+%JTS#J:=.E/+K8>@=&R(`LL69."0=**
M*:DQ2%.K4L+E2A)1+&4C?6'0"M\D,,4>:3&3T9#81UL6G*DKJ*R8+EB^F*I@
MD1&BK^,,"<J%U$(9/V4JT/,C:"^C,&0JC+%L*`#$0I'1#$Q3]^4@0QC]\/CR
M@P.4`B91WF%`8@VC-*<O+_B\R&/-ND*#"Q__3KRX\:!<=O6R=$U+*DJ#G_/D
MXA92\RU9T(63"TP3%P+/)EVK'FFJTK&LTOZAOH68TTB[U'UY4-H/;FA>LF1)
M_@"@.S/IK#=7&0TI1=1"A<!D#!?=E%.&!5J`<<88%OCGAV]\T;?(`@%5A@9!
M]:&V0$VC^4'#%Q;`\``'491TTAM/"`"`;:A-Q,@]!<UD8VG']>CCCT`&*91R
M[T6##3708?%`>+2P5XDT[9TB'5>.4&F)%DJB%4T`#XAAU"-?',G4>>[M\I4D
MMGS)98[NC-&%(W"9X5$KC4T6T9M_>`&B(1.B\L<J#@5('9OE3*BA8NV4AHAA
MF@5@01BAA>A'&+L9_X)&17ZLX40#(DT!1@0)K(`$!"]DX`:-DUI`USL5/+;(
M0*N&*.2LM-9JZZU(G6?)65\^PH48_*CWR1?.87*6%\T\8Z65E53@""YG0L+,
MDL(ZX@677DX2IA8/?`%LK^OM]DAVL7AQ[0-I_):J-W_F1ID%50V6AAI+.D(,
M3GPFA,5ZU7C1:GT/X-009^Y4YL=&^RQ`+SD&AS@0FX@H`D`&`B`1`@LV@'%`
MJ`VT<`%(ENYI&KX?$EK?K2BGK/+*/46G2GJO\!(M)\3,?`FTNU0@++.3B,&N
M([D6B1<K-J^G9#^2Q!?5,M7MLE=#54T;P%[W/!?`B`Z.X=RO@3T;<%V42O_W
M1W:EA6'!9V>D808:#SKVWVEF/'H(`Z1=K6Y=B+A*V0-GN,&!$TD,,$`5,-BP
M@1()+!$''(SB6PAN=T<L:2,L5V[YY9A'@NR2X()%E=#C-M5)S9^$954L3O$<
MR=6]NBR>Z),H=Z8MW.RK;05..:IN&6/@`\L##\P"U8Z%+F#[(Q7<76CPJQ.D
M_*33@$980XZAT3NAJ:7FQX=J7$1\7?3*I+L?:^51Q``"7&QX'@Y88,#(;8YQ
M=\.3^Y'Y_?CG3^NOP5Y"KMB:DY(FIE*T38P'.]KY@^H<`94%]$\2R"J*D?PD
M'@)@J1MZ`B!>NL7`Q+CC#%S:CB,60)K2I`%/CWC_`(+J<1A'<.D!"P##@0B&
MB%GLC3-](@,(^2$(NI1(>J(167T$02*,K`$#6V#`$XJ`A/2Q(`1\>((#WM<;
M=PE$5>6(V_-.IK\N>O&+P9'=)5RWI2YUSFMGY(0TQ!"F"BQ@5VX1HUF44ZT\
M9<DHU.F"&`C0GKCT[`'5H$X),Q(&`D2"A*5AW7K$@`4O_8-@">(@%RKEASZE
MXI$'X^`?QG<CCYCA#&I(@R(>IIA!<&]R-"E$B=P`@P/T@`%C`$$#+,:!$+R!
M!V[0T0>%&)'O30Z,P`RF,$41M$OPBA+3TE+2`#F=+'TA6;V:CPC'EI1IXN5S
MRP!6+Z19)DVBJ0OJ\%E]_P*`POU,:X6O<I.]+)"&,GBD'U-Q6R2A,:C+Z(L+
MY`*G.'R)D$2!AC=VBY3#SA:R'+TA``>8`0.4L*G!@4$"*$`5]`:Y",F]"EWU
M*\<P-\K1CGY#3+NBXRM@]@ARIE$4..-%6KY``'U"4(#BZ4*Q8A>+8IA)2>!B
MT,_LI9`M^D&=[>*2@8`U-8&XY5XVD5F85&@!?1)#;Y<1!`"[$*N,D,&?E20,
MI1AFQ;K@R!"12D`-:M``)9A@H4EH@``L\(("&`93Y1`$R7B94?MY]*YX'>:Y
MLF6)JX`.:*);FE""YE<SB=0LT#22&9?)/ZB@4'/5R0(YJ0&LS5RF2^O(C?5\
MU_\?`L61;^YXD%+R\Q6D>I5*`9!?7;1XH0<D;`$,*,@8L!:BO)7R#&M(0`K&
M4`.$GE4)("!G!#[`"($R`D/FX$A=%Y'7YCK7B\FLHW42^-$*/*`X2T4@`Z3C
MUV4<-A+1+>D"'$N=XZG%C^TJ`QKN"8LQN`H-,_7@(G;XC"Q@09E8D%M&SN`L
M2&#!9.48R'/R,PM,E@,CWJM)``C0O07PLV`QZ0S67E`%'XQA!PA])7`#P(0Z
M2)1^B]#>;9>KT>>:^,28(\L880K>+AWII#O9:QNE\[^Q8#-VK+@&.+%$+`T^
M:Q@EU>^D%I,?!^YC00VJ1QC2H+/IU@<>D""&9=U1PV?_*81+6`@#U/16HA\>
M+!&DE!3D5(D1&B"``53`@0!V0(0(O#(/(,`!`!C!R8M2M!!V(W&)4<SG/J.L
MF);8')/6XY9C#B>9SY1@GEX<TYE:`Q49)-T?`RG?E\!K9G0]L`CU9*>"/<`5
M4`%>/QH#U2]_);\DPLUF>$<0013D4FPBHFTEI3U2KL$$6$!S!@:P`R$L@`1*
MW(!$O4=EN`I$Q'JFG)^7S>P@7<>81#47>:R\G.%`2YME,70`I]&K!:Q"%Y^F
MA&`%69HR4"EYI0$J/K-@KE,4YKC,U%..%I.%I<Z;F7^HM&(J5(:TI6$O%OWI
MB,(G*;/%ZI1K8($8<L``%^`@_P`]"(`&7L"`'@P[TP%79::3W>R.>_PX4#KI
M*OA8"=,5A["\<(J*$>L,]2CI"V#`-WBQY-\[MVFG?XCYE"]S-IX&(&ZR.-!O
M@&I:L&KG7+R@)T8S4H8'=-H,DZ$41(@HJ9*!]2`.```1TL"$AN^Z!U>0P`G(
MP(:*.MW3D$1$IY/-W(^[_>W(2>PW4`&[1OL8*-D%=,[K#A^8X?0/%0#7?``8
M\U*G$T^`*@HL%@!5`<-)N><HUC_B9CM8.,X>8T"O(S8>8HJJ02^D3&5ME4MU
M/5BA`P&X`<-=D($\F&`$!SA5<B]?YT)LY/)LMRO<=\][G:S<.IHDXTL7.QP9
MLSB[E/^8"BN`AG.>GBDOLK!W@#'[!V#5)#-TZ@*F(K.472C/4*GX`KN]YM,$
MF1?PAM=E&.(&K]ZU2NJ3DZN("'%F!C@@`'A8?0J4,`,0$(_JEX%L>U-^'-=[
M!GB`H&!R:*0Y=X1,R2)=/I%,]L4YUH(M7U)>XW)^[?(5PW,&U@-I7+)"\/4<
M^G8P\,)N`1`+7Y%G2F8&;P0)Z(8W?I0?[99I7;9T]Y`(7R4IR+55?C`!<9`!
M#,``(D`$16`$#-`"<A`!"#`!%1!BM&5G!Z9:N9<3"'B%6)@)Y`(&\8%,T392
MU28<N)`%7V@TU&(OQ2(&!A)X_A4@A$919Z`O7E!9`1`7.L7_=%H3"5CP8(@"
M'^BR10KB0JH"(2CXAP6U/6?W.*;T+[1F(V&V`R$@A$0H!&*`A"W0!S%@&^XU
M*0Y&98DH$)14A5:8A:18BII#``P@!JH@,Y6@=\*!<KDP-%T`%U^@4W7X*R@D
M6/,!8$.6=/K!0)QG",SS"%@0`.4G"/0D4T&G))]T&\PT/'R2>=1P-&60&8I@
M7#0A?PZS=-LC&7Z@`&$0`E.`!D/H`$00`V;0<`90=@=CC)EF7!K'BZ*H;*98
MCUF8)G+7BGRG%B`U'#.6*UO@"ED`/-*6"EB`#9LSD*K(4[AG"&9@7@-9'T`U
M-K/`C)"$9^/U![L(&5IS29IA&6ZB_W0`%H>*=U][T3!F`Q%C5EO&1G`8``0\
M((YKP0`=T`!#,`<K<`(250&,:!J1TY/SZ`[V.)17.&[?!1TL!D$62!SG$AA8
M@`ZWD"=^A`7UUB4#&6Z.0``7>5G35(?RF)+VP@]8QA\6,BE`E07*54F]XR79
M\0#.$)9K]RJ940V%$(-?)7I/1GJG80`NT``8\P`4,(1PL&9%@`*,H`8,Y@XL
M6$H-&92Z1Y20Z78,HH%_@CICU(#+D"40.!1EZ`A8(!U4N1YUF`4F-PY;>0@S
MQ246`&G,J"Z.EW,<L63!4B?T\AQ.XP[K5R^0X"^-"3U?40B(E#<&%W^@U4LU
MH0)6@`1/9/\#'S"$;2``9^!6294&=^:#SDB`01F9VNEQ3M**U%4)_(,TZ!&&
M8<2*>7*&H6DM,H4=1Q(6AM="#+(JZ]=RE05PN$-^<95RR)*>M><.%O`>Q%!^
MCL<%*5@AO1,3.Q@BK,6)O.$'';`$`<`"5<"<0X@`>"!1/R4_`W%1`(:7CCF*
MVQFB*-:=*T9!?66>KZ,KPP%HN(`5NWDD7X`M8(`-L19N\A95Z9$75($84>@@
M%B`V\U$?D2$L<+%S9J<,@Y<@!+"(O7ELCLA+#K`$`P`#53`%]:<"LJ=*H:A9
MWO@J!/6A/"*B8OI<[L$)VC8F?Z61_2@<KN.*#/2`62)9_(`.T/#_5!G1$.>7
M6O5Q0I'`#Z>Y-V6AFJC`!>Z97,:`EL;02^_2I!HW2+.V"%$J`!RP#P@``3.0
MI94D1&E0$`0W7\$(IH4PIJ**5Y+6"?Q!GB]EHDI)?&S:@,*W0:U`%O46EKU9
M2(>4?DE%3_?E2/WA.`!"3W.A2O=D;V6`&Z[0A7\PG,CU9"+3J1+E`!6`!!LP
M`BZ0`!0`,@91:FBP``!H*6D)JB`ZJN(*3*4*"MT5:)B)6&=X:%\H:+WB5X"&
M!39W(VY!6J9@;#.1D;M8K"I5)ZB!)S?Z$NFQG]FB2!H)(@+(=,JUD@[*!>P8
MI4B@!A(P`ABJC8Q``%2X;XP*JN/:L<"4_Y&TL(70IE)@N)D](4;\@ZI;F%T,
M(D^LTGT*T3L!2:._<1%X@I8X`1.R,!B9MY!V6@]X&F5:<2^P0IQ#E[%^0`(R
M4@A1&@`O<`0B<)T!M@!=ZI!=!:[AZK%:RVRO&CLIIX\J^HJP<ZXO"H)+<@V$
M<9B:I`TUL4-B$$%KTW2V>;60@0ZSX!3S4:N&Y"MQ8296)RDLF)*+L`8ID`%`
MD$M^(`)+(`0P0`.Z-'UDP#LAQH=8VW9;>[G-=J;B\9V2,&/%T::<^Z;TR0\3
MB"#W$2[?DYO]L`6VL!3]>2/]18Q5M4NI<"VQD())P05%5S;:DZ!^``!;X`)E
MP`,34`@%\`,=@/^IP\DJKJ(A15NYLH*YI)!K0ZBJ7X04HT"H"I2F>&$)]P4)
M#)`)J8"]0'*J)MNUQS"63.FJ4G*!T48D:M@-(IDAZD$VY1:[#*0%+LLHLQ!S
M2(H%+=4N?WI9$`.4:R`$+L`':A`!Q?N-""!1OFL(G?I3:`!KT"LITCN]LD"&
M!`!CEZ.[H_"]M>@_"_2]CQ"^F!"^Y"LD9.N`BF86G1D<X0EJ^0BKXL=WGP@9
M#0J<[Q&P]8",+F1=N3`8)D,OQH"LU*&*6)`.5?>)%EL(U,$"))`!+$`CV&H0
ME]>M!T.U&WO!&1S"QQ,\7Z`+B_0<7%,66Y">2U&+NAN08Z-,X_*+R++_%,C"
M5W-L+[J`MUSP*V9\J/IQQI%@7S1&E8[E!;6HQX`,+,9PQ^N0QN;%`,AB#",\
M-F#"`/JA%$S"R,<ALB%%LF.!HF+XM7]"4M;1%*Y3`9P1!FEILT!S7P'))>E2
M#BD(K*LB6F``MX1PNMI0#3V6;W@2(K=G"`QK"#BP`$8P`C!@`%9L$Q%V8#UJ
M'UIYP;_TQ:%@PG\0/-SR"\!3`=Z@!16@!88$P.!L#"BL%&@Y#6!@002@'@R`
M0>HL0TL*0WGRS@KT`-RB#%S``-11`03@#=C;SBGXS7L+)^T,'CE7T`$PA$L\
MD/BLSV[Y`!T\A%J`#."L#'7(DX]L7>OL&1H9_[M:,(1HR9-O1-')\"/H"Q^6
MB:8G5TUP<F-E&Y!9,A6;^',7-;=JX$[48I'_:BV\9$G)D10!``VZ6`Q)_`A#
MY"X)ZP<OL`0"T`8R,`$8:A]7:YV]X1`#+,V62\V><)#Z`<`*I(K8RP6!!\G5
MQPWCJPSEK!][>QX^`[[&(,+!TU_>`-=?_0?%N'=PD2?Z_,_D[`IO6U*I,!5U
M+5G?B\G>,!5ZLGF7;-?[,A]_H,^`]\BIT`4!,)#5]U@JW,%>$+YT7;XUO+D1
M\B1)&1QMNJ85V"5SR`MY`=%'*H@UBQNKJQD>X;/?BA`5($*,M$&&3![I1EO+
MRP@3H`(AH`$%P`$\$/_5"1MFDVL?\XK5>Z;5G4"]#'#;VVO7WPS.`\G-KK!@
M+IK6Y-O.V0R^56+/'XT,BY7-'UW=CAT`C&0[YOP+*.R6XGD,.OK8_K4O2K'>
M"VE?!+#8Z&W)P6#-]DU-?[#.WB;>WUW/28'"09(<I(R4UKN;Z2K#B;57%ZB9
M5\$+!%&-=EB"D=0*XE<6,=>;\`4)>0$-LXRHD4!(H1C!A;`&QDT$!V`"&S!G
M%S6[!K%V/W0&6.7<60O=F2#@U;W$]X46IH"*^]$,#+`OWAT,2^[*XJU`@/&]
MV<$`'1P+15[=!:XGS^3>BXW"1V[)4L$`Y#W@GHG?L[#.'`31WNS?4TZ5`?[_
MR(#U!]ZVS@CNY%*>Y;6R>-QK-"\,7C$L%.9KAG`LB]+@'.VM=,T-5E2B!;C*
M)_C0Y0?YS6^R"]6B9"*3<8M@`#O@`!DPO`I@&)D6S!6%KW3KX_0(Y)H@Y&Q]
ML\DA#E@@0Y4YX,%#OG:.3U%^X#FGO=21'<^A#+H"&,[R%XY0#/_\++`N%\H@
MV';N+84]"\(^-M=US8NMZ[?<7X`!OL=:Z50;"2J,Y];^9^AP=[YRE'X8B\1Q
MKM!B#0]@R634!8N.&CA'#,U(9?>Y"V!`FN"LBK,\"?:N-S=1#QB0`R@P`6\0
M`XY;4;4]@(US7/*(ZH^IZD%^?N>QV5NP"DD\D%M`_TXZ5N"-U-_D*U/9(>>C
M#`9+_!U@D,[^<-M+K.6XH-<;[RS'?LUBH/&/L`"S:,_YIA18\I3<4&#+QU(F
M;\F(N@HF_PO<G,Z/'$-^LMDO>,+YCN=&W_(I$W(WD](IVN<\P<ENF@U;`TU@
ML+\'!K`.%"P&5DK&D"9A20V")0GE,,'+.KAGD`,A8```4`9T\&%?(\O/#&*'
M0+G.+?&<P.K=1P`D1PP,X`T,TL[0D$0B3[Z+[X:.P.`)W;>&;S73;0RZDL_A
ML`4$$!<SC_@[Q5+]["R1CT_@<1Z<+P[@30W?O$F9W]&L\,BY]C/4=_,`/ODN
M%/LKH[G6$+HO_;DPY3HF#/\E_J#:V@=@`T';KK(8-RQ/]S%)Y434T[;B276T
M[@`2&^`">F`#7+`&`&#C'3'5`ACWBW`H$,\(@K_^G&#G'?5[$$[N[DH<Q[0Y
M7`)>T+1XK&N(VP,(6EM_?UL/:'Z)B6466EE?70\/`5Q<#X.$AEQ?#V"$GZ"$
MBGYC8V&)80]FHXIK:SQV(UY*$ZRD8[9^J62VI;F*`6J_P\3%QJ'(R<K+S,W.
MS]#1TM/+7E^?7E[4?UR/VM*;?U]9Y%G?7EAB7,A<8EC?VZ%?E=?Q]J%>D=#9
M]_WQ8%H69&G&!4L%+.N2M9L$SQ]!0UVT<2'P("*R+14B9EF@Q=VD`!7J&3J5
MZ\S_F`<-%V#Z$V!!MY#.4%D(H`C-`UZC7/D!0&($BQ$&`+!*E2:736&C4JTB
MIH:FL:=0B3F<2K6JU6E8""3$@H7:1`9=NB[#LN5:O2Q:_FAAP)9!URP4*SQ(
M2(A+!;D$ZC7;,G"9([3/NMCC$H#9%RU?^"XC_(?KU<?(LG01]#!CPU`0^T+&
MK*5+V$*=-7_:$CK?)3!9$@8P52R-6$)=!G'Q7&CN,S]G;M:L@(@5@#8B#M2(
M\H'$&E9H+.!D588W<MW&'D2=3CW1YNO8LT/#XI:0XVE9'C1^G6P@0C&$`#L*
M50%31U"T&R]XMMXON;3.&-@#[*Q^^;3?:7>5:5O0I0QI_P(M@Y86G@@H1@4,
MIL=1@Z!LQ&!!!R5$@#%DH/1'%ER)\8`6E_S1A4O0H%%!&8IT>`8K:["PPQ<@
M%*&'$@6X@9QSMG1(TFZ]&;-`D-45.8R`2":)'19::#4>-Y.)A05`F'RQ0!?K
M=-&>8U9B6=`ZD/PA!FKII>7?A^*E1QX#"7$QGSA7KI,%&">^%%$ZZ`$DUE]I
MS;;`-5YLT45?6W3GIUZ$`/1GHIW-UAXY?P0*I19O678H?%L&4*=W$2HYF$$(
M-2,99<KDTYYV#WQA*B:K&ABIEH-@%-&#9/S(2H=9+H":016`X:9@T!@2I!D6
MV'H<&U%P($841G"@PG&CN)A+2_^V^M$AD<604921W.;BZ;?@]L,5I4]RE-4@
M#&@1``->3#196@\0$`!7$[5D9E<!?1A`7^J)AD5AY:4)BKM:`"AO15M0]`58
M?,E[D%KWJ;5``%K!M2\AZYK9F9.$?"'O`A5\R$!+"\0[[UMIF4O`%@FG&A#%
M=)F<50"3-/9`5J*%*XVLER%#H*O8@`HT50%B&*K1KB*M*!@&F5'M&%ZJ^PD8
M(5FRDC,B_N@+C'[0$($01V@AP!RUC$)LM;IL/4H:#Z!-3"K=QCV*SG37W0Q7
M<!74%99/LOO'`UF0Q@T!7@#&%9V$H`37@V9]<9:9;>D78"C\@2+X1.@(!A#$
M?_C]61;_(?-I%\9\A0R*?EXX2>J'Z'7.DEC[`HBRB>LXYLCH+*UDN.;P:H.X
MW=,HFC,[0BO#!40]^_-%!4GSG(EEH2P40.&3L5S!&"^&,3$W)68RU_(4.D,;
M*@]LFQ,"?MP@00Y':#"#'#HEHG92Y?>"2W46O"AWW,#WW[_M7.E*.Q9`@*[H
M!V+?X=-XN-.6@:PE?)]0CQC*\:3_(".!()K=>@Y8'_WP*0N1PT+E"*$?_DPN
M"S3SH&8,-[L!%A!B(&S+:UCXH;1$#C_^B\:HKG8@Z!TH-%4!W#(0U!?A7:0B
MJHJ$&+90LE,MKR]N<@D84@4-+I#K#WY(SG)&<888R$`.8[`#_PC&<`0V*((H
M1GD`4LYH@:54)PU;W%^1<DC'<#G&8OBZV0(,2`A'8)"%6!@4.6KGM\B8231@
M>!.4/C$14$P/@W<\I.LXY[H/`HX<A<,A"6OHG1D2H`MB4&$$9<=)$F%ACS"\
MI#E&^23`,*`<B*JC,W[6#",JPT(0C(<8`,8,"V%",MVK4,$*9)``Z`4FZ"B1
M)O813!5A2Q$)P$,7"J`!!)RA!T))A$WBN`@>*2(WW(S*&18@QV[)\IQ(2N`+
M#_@9#@:N3X1CH>#$U"Z*`(MRDF0DQPP!"B%&BDV7(UPD.<?.2L%0"ZE;!VI&
MZ+J$JF4ECO&"?CYC%\,51G`%A9A#R?]4IE:FI0(#\4+KT/D,HR6O0M6K!JSN
MX07;/(.67J"9.O`!D@6X(Q(%(P")5`(;OCUC>7HQA/Y&H:,+D.``#QA`"EP!
M+3\TYYG6>L!0M>E-([6MG$8BJ58W\QT0=J4"5^J..PF6%A:Z2TLL68!$>]:O
M4$0"#`D+7\*V,,7"D-6C$I-H>AR&KX@5C&*9#,7(U+(QNB3,("645VA6=M@1
M_0&L7>A.0+SP5\)%<&4#!=6IMAHL'ZKT$D/C1O&H<::2%J\@-^N92"=S,W9L
M+UA4Y%2UW``#"DS`"#6(`!%@$+]$2,L6`2C6K2P`5>H$`ZMSY*QRI\*R3\1&
M')W9`KXP9I;_.(GCHH.PTI^LJ(UT(.,+A3%F]"+[PE!D!2P)Z=(ZF@O>&AYF
M:E<T9GMG$Z'V@D(,?3I1+`/`(+7^`2!\ZT)X!5*8P\0&9?.8#`0%S%Z`,8D\
MRZUEP887O=&R`WG2V*4]G%>(C,02%&=J*0^9@067SD8PMLC``.*PA1S$X`XT
MZ*T?@HNV,,PO$6QS6W70<#_D3B?"0`ZRD(=,9%!`(IA#].Q%@#A+E]K#E@L:
M'C\_\<1HQ(=[K<O)#F(P`":`8`0<2$!3T]9C^IE/$3>.6P5\3)TBNUE4X'$<
M.Q#%#PK_-+0$^;#/3LJ,<&C'SV^N2DP?,%-FV+(\$VI&:?>3TE=M_Y8E6C!L
M;)UAB9%R8B6CV$`-,A``([B``V:D7SBU.)0V(G<,Q66SMP+-ZM-)8RV3,20H
M''-`TMI95)J,7F$F!PV&)D,Q_?!UJ_N!VG>(JM')6)4R-"SH2!0H4@8A$2]K
M@V=YK`YTB!I%`,P@@"84X<S:5*-1JHH;Z&"U*:J&RK#7+0TV"=N\$)[&HOU!
M0_#D.AGS9G?=./S90A,O0Z!H:;4_!7!E5(#/`P-)4#T$BE8H00,.P,(7W##F
MI^;BMT!2]9K3?0Q]+Y<<+2D(8AK#*"S-2:V7*I0(`92);,CF2O,B>6.N^*$&
M)6;F?/-C0L1@#>M:J5.$D-245F>B3&UJYO\0O!1@Z"NE1H$N(I<*%&F^0"5&
MB85E$9&-@LU[128U"$__I;F^HTP04)WT>!7Y1KZIPN]9@W89D'AT6H&FB`]\
MV@UUT%&TKFJ+L]WJ$.E>P%0YOFJ/<W9F(UH`R%P'0I(5TXJ%S9@K^^C7*ZVS
M,04D=,=,!\H'E5@PCN!I0C_VT3URC)/I6A<\9':P7=^,`*)Y6<521BG&%G!B
M+3M,8>&B^!&I'BXEQA>EU/-ZO62EQ.ZH`,4&PC#@M];PXG"V,]K.F8E-^SJ'
M9N2#]KA0$$6B"^$[L3(4`8``L&#,B:!6+M*<8XYKB_!2@?Y63_DAT^E'/S%_
MG6`<2ID2VI#R:-'_2&K!1T(D4I]@62$Q0:64!6(@&$ST.RC!`->0&JSD-_[$
M28$4=G_C._>$.P'`%VG!-P'T)I[@"/S7,"2D#8[P@=P0.H,0@$["47\34@]B
M'H+A-RR(._(W:/YV2Q,V1#HU8INQ0\G&-`$$!A\F8LLP"CA``T.19KI0/ZQ0
M"CI63G`#?[\@?_,W.ZXC2IW$27V#>@#H"/A!:Y/D5EO@!:8C*!"B42%S8)&S
M$0R`9)-'21@X.S<402&T=&)`0!+'`)^D@A$S'OSA3FO1%IR#%L)6:Y-4AX?(
M%EK(2,&'<-&'9)]@@LXV<%1!2QEV@<G0"GIW1N8V"J26%#.!A7[`=Z@X_S>1
MB$X#U85V^(IFZ(CW84)\Q(BCH1*"44S\Q3DA<7"!5`[KM0`,H#O_9X<TY$JP
M%$&J%%BFA$HQ=1<'U4F%2'D=04'KH8CW=H:->(S7""FM.!I*EFPR11=]*(D%
MEQT8(EX/<3,#1WX[LD:D2&[@M(IPM(JL$([G](KW9R("=!!=<8*,9T/K`%(P
MN`ZHI!\@]5\=2`"ZPCF"LQZ:(A[SQ'/`$B"TR$H#M9`&&'0Q&#$%!08-HD(G
M6(T0\QDLD8@(Y20L2`@+22<+F8$9E9+Z.$IK5Q>3J(9`0WW7P40(0X%UP8`@
M$RHQD0BAZ`=J0&Z^)54[PB*KB`;DA(^*4)-UQ/^/C*=88;$GA360CZ5X!JDQ
M%,-'FG4U\9(EDZ!3G`,&\C(XGA$RBH<S%4AYER5=LS.6(*8N\51ZD25QMV<F
M:E4P73![FP1#6*F2A`58GS"6Q01[C5B85$EETK<7=S%2R)!]V<&`3%(P!4,6
ME!@*%Z>*9B-<>Y=JZ28=4FD=C^D_#=9':E%RQX,)E]*:[7486R!?=N492]2:
M,P=AM5D7BI=(+%$/(P<GBT)?X=->^,&.L/&!V>5@8C<IGC";T=45`"8GB'$I
M]I6<UU"=P7E=T,EU3=<@.,2=J8D--$.4R@`0/WA+R,99O;``;I-F/G*:,R:/
MJUB>^)F?^IE#J#4]"L'_/)4HA$&7B>YY1@M09J((;K=0A817!@B*BOL9H1(Z
MH4DB*['TD.9):*&%-%HEBEN01A^:%!-#GZ-@FE))H2B:HBHZ%63W7XHT,).8
M9!9!4E7V73`Q,);X+5V@9RO:HS[ZHW2S*@`JHWQFF?XS17IF"+%4HW0#!M<'
MI%`:I5**'6KHCKBV=D280\MT04Z6*)-&-Y8PI6(ZIF3J#XDD/908=P+Z*F]G
M-YXQ-%<V&EU:-_Y5IG9ZIW@:/4-:&SO:#(.&GA5V$)UY'6[RI-P3;V^:0V)`
MF7G:J(X*I1@J3#<I6@Q!I-^BA-]EB85:1U[PHH_ZJ:`ZH<!9*BNU%TBT#.IY
M_VN/P:1&=J.,E*/],Z>A.JNTJH]V,7#)!*C_L79'MJ95H:2_]J7BL)#[Z*NU
M>JS(RFHV544BXI_,H&RE4HZ;(2)#4V*N@J0T>D_)NJW<ZF:;,PT0P:-!8Z4*
M$:-6$:?PH:W>HXEV$V_=^J[P2E*6,*B[JJK<T*Q\QI/Q8$7NRJ_(D*CQ&K`"
M6Z8!P*C4`*W,$*X*LI[V@*GXH*E7,K`2.[%0^FX':V$^R*N120W8E@Q`%3VP
M&@_C,$B"I@WS(`UR1K$JN[)>P7!3L1`SJE)R1U,:&@V$@5"_-IQ4UBM5\8AY
M031]%0W<H:XL6[1&&PH%"QF9X:?!MZ$EIIRE4F("2O^MH4`UXAH/]8&N]\!K
M])%+1_NU+&NQ+)IH?8:OJ!H)>U0.Y."D#\!3RJ"U6]JS_))?7;>HLW9%>N*;
M`M85:3@GF_(K,OAT/<<W)T>O8'NXGSJOVH&P0W2J<&>$`21">.:O;H4B5Y&U
M7:$RZ/)<WI%Y$\17$A.8?85XH-<9W9$)%`$7[](8RL>NB/NZC9JT2,*AO50P
M7KL-EQ8]$0L9/ILEM6-`#5&`#5@I`D@N?L0[$[$.8N<(`94YL/N\R"JVFX%V
M,4NJ,\NQKEH7(3L5WW@B]^J'W,B-'62+"(0RY'N)&41Y7`N][)NGBALNI#$H
M3)N.-DLSEP$^V.$?'J1'?.3_:NA+0N3K1^9;AN0AP.KKKNV;P&0JNW2#2^WH
MK)2&$09KM=E1'ZDS2>W$'@-!)Y_#/$Z"2@9\D`,(8N\T..B`P`J<PA4K,';#
MN`=2,B)D/'1"KI8CJX_1&5Q1$5VYE^$[EA;S,)4UNAIDN@6<&I]4,!6DPDH<
MI79QM>!"NXOAI"2BF04S(C&<#$>7'?RUF6`RG;IYMV*1MU`"2H-@3*OY*_E'
M77#"-\VUQ&[\HVE,1]1KN%6TNQ[W!7MBK&^\QS[*"5L5O_9JL]LK9/PP,!11
MEM1PLGR\R.4IK.CDP/>`OY[R!08;#91,8O&&#CT8#9/*R)[,;NM+4JVR#27F
MQ%R%_\+.$,I?*+>?W,I:Z,="9E+1@!&H[!"*`BB8\`X_Z'7>09M6`C"W3%GK
M(<9H3!Y,PC=,U\N"\,L?(ADHLA[JY<K2W&HI.V1H9U/BBD*5>AT>TQ(A4XC+
MLR7*QYBIQP"F5Q8?\XN/DGGX8GFO<5C;H[F=HR[F?"Y9P1&'5"\<,<W\O+*!
M@E/J,BXD`GX"PH";5(V.$9,W>`V4@3>M(SE=D8,>W$>O07__13M]P]"#$$#B
M@3F.`(%TW,\B';TDZRG:['^;9(9BR#EWE$)/\HBO1,!4!H@6X4+]NQZ1:XT@
M$H<CW=,^33F?%$I@"-'=.$DX+4)!3=3?.(B3$XVAP[]&;?\>`:33P5C2/WW5
M(AU1)20>>I70-AC5"Q201(V2E/#!KR&2FY11[K1`\&1%)4Q/6!W7_'Q8%8`Z
M(T.,-@,BX\Q\<LD5="TYEU2804QE?;G#8M777''$^?Q):"77CNW*_)5(VC!U
M:=&I&]TIVED(9=Q?V<!3W'EBN0E??&-@TJ6;XL4R_Y*HXJ5=IOS8+!LYV?NR
MMSL6*Z<\5^L?7##;XG`-N`B[JNS:[?M*Y*`/5O';R8`WVRAOJNH?O[U!*2HI
M'&L>A1#2SS#5P.W&C'A`Z*`9T@5%(G2R[<`J@8(>)W8.VF`-W'`-X4V-9446
M\G!SZQTI$J$J-;L%A580BE@7GG'_WE<<=!K*+A)7%Z%=GM*K#&8(M5,AW->-
MW9<5*3I%`)Y`,6LQ$`]0`03`F)*@?*P;+R+$%F*A86@%G!F^:RL'0EI0`90Y
MQ7]CX21>0PR$0G*1)I)``,0:0^]`$0Q`(2\^A_&2.!5NJ.%8X,?=OX_1VPNN
MP.E2,-W!)>+A(?,".O\4,;?*)*"1Q.&QXH0Q07W"/,B=@04!8GD2,A*E-POX
M!Q^,&ES]2HD9T0[(PALT$%_9@JX[=DJ.">NR,H5@$#_K,1G!1[:Y%K)A,M.6
M,(,U@&`!&VYAY$<>W/^"YVHQ(FO1,2)BW7X$(4V2OO66UF2HUSF506@!!N;,
M0T=]P`L(_Q<%`Y![HAFVTQ>,Z-P(9.F,F9H@E'S_U2MB0`"8ETCS@>(J5TGD
MP`#N@.L*UH9U48QJR=O@)X&&@!:*ONC0>T`BTD=9&='I<C.01"E<<<)W"&),
M,B^2@^WO@-RUD2XD7$$A?$B@$T#I&XM!*[Y\C4#@3MVM=N4--1!<(#F%@19J
M"!M\]!=IHI"3C4.YG3C,I[R2,0AZY>PJ7&NGXK:>P":O(R@NR8#`DAJ99<P!
M01IIT8#IH3=H(6<)+Y<<_UAX3)V'M#P=\\\3O^9_('JX_K_N-/)`^9@F66*0
M&$GDJT+5>$`C!!!L\>Z;/I@*C^3BV&%,DQ8$L$0%)%&U^4I,C_\19&XX=?HA
M!01\_V0]'L\@@/,@Y<[T("$F((7$E&(7`3!%YE",H:3J:H41`,;M]TYY3[^G
M5%F-AE`61*V-7ZCS^-&/8.C@6@[T^1V^0__LH'`JZP(3A9(1#ECM`Y$P>#Y0
M5E_LZ$(H%[[1M7WXB%(?"0,3EI#T&_]*RU/H"<.P5I\Q!I+V:^WX>@Q]")WO
M=V]#VM!:>K])E!%KZ='1Y*R^FM/L@[_(JT3RUUV-)DX`K\\2<='O@Z@?H!XO
M`D\1%P[XJ2,)O-_[>PS/I@/<T!W&[\!SD`+=+`,I?.MRWI$H8Z))>#PGTCW=
MT(8.U'^XDSKP)-89"-?)\<`=E8P9?>__#_#_"=,/"'^"?UA8@X>(B8J+C(V.
MCY"1D15??PL!DIF:FYR=GI^@H:*CI*6FIYU:68Z%HE]<J'\,8+"-65I_MZ2M
MAZN1O+'!AUM>C[6E`0P,%<6;QXI>6\+3U-76U]C9VG]>6+ZJW%ABL%QB6%Y<
M75W%W;ZO8F!_6V*#\^1?Q*_ATH?=_.7\O'@9)X_@H"\,5@$4)-"@F`=?;F7!
M4JL=HG?QYC$4QR7=NH9<LGBIQ*V214%BM@#;)BH`249@#)VJX&M33%NX6.K<
MR;.GSY^/O!#00B">*J$/*N#2HI1`%F7G"#R8]4?+`RT,`CP@8"A`A0</<GW=
M<E1J!4P,S6)*_TH`$Y:O7KR"/825P1^V;N$*4J:J@M\%W(86I7LUZ]:H255!
M??O`"P/'Q2J`$4HTGE>_,H&B6DG*;B?.B'1I'DVZM.G3OPQ]":L*3)<_7.P^
M_B.F6]?76UAC"H`+#"X"L!:`R4)`D"HL@+GD))1<"Y@*W!AP02X(N*5X@^P^
MCSX=\"!=Q+DX)J0Z["`MNWL[?QV;//.]?]1AP=5JM2Q8%3*C;N3R"V\&TFQ!
M0%9?^+6%2@1\D5-_`70!(!8,O/9',EK`$@`64G%!X3`$$"!-@1[^X1]66Q18
MP8$8?@&B-*+MY^*+,,8XC55:8%650F`D<]=9Q;0"CBPWNB?14$QYD_^3*C_2
M51,OQQE"7(WY'6(7DQ/I!UY.=M%HXWFKM*(+%SE.:0@O=CGF5%57824::#+>
M^)0YQ1$@1A8/W'*<9$"ZR8`88E30!1@)YI:%.FAF44%*#&3F&#S`G;7%8V]B
MZ$6-$^'I**3+M:GIIIQV2E<7A1A25@4+E-G%@%4&"20X7O85:A:B(5D3EX-0
MZ65^A<PJIG&I?H>+:%F"NA*K3FHA%*F[DBG(`N9I(:R1@K`IHRITPK>G>.YA
M@99GU$)WWXV@PEJ<<^YY)L@6$L+J;1=SFI<L)@4*PFZ+GM9K[[VC+<"/41-A
MTAX_SUHBC5!!MAJOB%[$FH6^\@["<'QB2$C_27W>?M$,?!$+,K&5OV(IL"#8
M\2JD%MK"EJQ,93)PYL.3K:O?IM1Z+(8R74PW)LJ\`LMK7<H4;(BY[@FR)K1`
MMM)JM$3CJ_323%NSA63SW?C0PG8]T*Y*"T0CF;,^YX++66#4J?#3.2Y'-F^.
M;>%5T&#7*65T:D.WDJ$1>4QVU+2V.G6IS-D&WR51W_UU`("^K&G,\''3ISDW
M)XYXGK(J6>XAO"2<4ZX>&UTLTO0V[?GGH'N2#"4W<C%5``2,5$%6N7`U(0,5
M=JU+@:PK_#KI@XQ>B8"D\T([6MF=2T#O^G&AE,ZWOR1[A:>G3ERH>X7'Q9FZ
MB^@7J/4^7K6%T).)_XY3R*O2(&Q+=?GS(=O]0=-LDNFLN<F1#9=IZ/37;__]
M^(^F_81-#>0ADU\1F\=NA!37$>L/4CE$4I0RH>&%16=B^)],4/<5K^7O@AC,
MH"*XH#R!2$(?GA`))T"H#0\*@H--(T8THG6N<\!F3K`Z(1;P(1!^R(08^SA7
M,6(XD4.4PR#VX(8-7PBKF@1QA1I,HA+M1R]I#6,52=H$B3@116RTXC6=6Z(6
MM\C%+DXCBX^H(B>DDXI9;<,N8/2B&M?(QB2F@UR$@.,,M5"B2WAM/I6`533P
M&"UGA<1/T2B&;VX(!COZL`L+V%VBT$>R$W:AD;!YI%'$8,B#+(!<;Y3)?/]J
M%LE&9@$[.)1',;:PBB)FX5%&XF,;5\G*5G[.*BEZ"^I6`;MD+`!#I!S*J6Q&
MG`4L`#I]PL(#NB`@B%"K+5$J4HC.XRS@;$AH7'F`(2Z)2S2E2)DA0V`7DN&%
M+DCS`6`0$'(P04T/'8R,\9$&`0!#S$)0J)?,<J4\YTE/&4T/%L.A"2%>PX!*
MT)$\X:F*2KP!G?;,R8+@4`7V#"70"2G*.O\$6@"D8;SXP*(0]_R#_*1QH4'$
M96?T&`EU-&I1]SC//+191U+4YS<T%A1H]8RI3&?*$GIY1A?<,M_0,)<X=#$P
MH1*!SP&%=KGSG4<9/2O'`KA"KZ%N1$TSRP\'5;;_CA<NU1#L*ID@5E/(QQ2G
M%6@<($W'2M:RGL*F1(6<3HO*TZ*=A3=!BMRJS.<KI.7).#"$HC1OV52ZGG"=
MPBSEJ5X3%[]8\Y;RN&0VVS*?```&K!:\JUDG2]G*0D(H%GI:E_@ILEQ!-"9$
MR](JR!+703D).D[%;$.!AKT)Y0E4JIVH4T5#$Q?>`@S8D8V\#!&;!SSCDFK3
M`CT@BSS+&O>XQZT1ZKIQEC/E%*#KW&5;[>)-U"TE:\?TBJC\:IQFP@)HQ.'-
M:TCE(%&A)W6IS0I4OSE#KEQ2?0LHKR!62KF$S*P28`U`<9'+W_[2](W8F0]V
M%K2[$ETHD?(PL'%@X\M"_WK-/Y48I"!<DN!#(K@JB/`-)Q74SDY:IL##(!D6
MXC$?F6@8%AQ62;0D=)`**>A<TA"#%ORS8/_:^,8X7B(X<\SC'ONXA!<S!0H_
M090?&_G(2-Z%X4:11DG,,,E0CK*46;%D431YREC.<I2_$-]:;-++C=06(I_A
MFPM_61Y<#D`Z%G#16[`(%VM6GI;G3.<<3\^QN`CF,`D133AI!7B."8!6:).?
M/2L3/7M>QBQUH85+6*?.D(XT<ETSWX&4$A=N&P@67N.;[U0`G[2Y=%6&BT5<
M4&73MZCHA/@AZ5:[>JP00NIHN\!`H!WMA*M;@"]\6KZ1Y4DBBD%JE5]-[&*O
M$?_5L)K.6TU-N<T-HAQ38:Z@>WVTF\I*;"(TMK:W[472TF92H_W:*EQSZW#L
M+-S+DT67]&LLZPR'V_".MP:GIP[H5'<HA,C/B<J-0$$#Y][4WAP#'K#HI9PW
MR/).N,(_QV4$<Z'!WBEQA6EL28=#?$(@IO$LR$5C`"_\XR"?+$Q#3O*2DW7D
M)D^YRETY[)6[_.4PC[G,9T[SFMO\YCC/N<YWSO.>^_SG0`^ZT(=.]*(;_>A(
M3[K2E\[TICO]Z5"/NM2G3O6J6_WJ6,^ZUK?.]:Y[_>M@#[O8QT[VLIO][&A/
MN]K7SO:VN_WM<(\[*DQI2CES*F$Q'`7>LQVC@5P2/6;_S$01$1ZCD"1;[O-$
MJN*5T99G:"K6*.]$,O@BHT<MG@%L'B-4"A^RIR@C\(AGX^47[]M.09X4JT.J
MXT]C^='/+Q+"AE&!,N/YA(3>E:-?_.MC='I1.$;QV3S-]'*O#%9+(O8NLCSM
M97W[5B)5*36:BN*-7_D:[9X3K5<&\%#3^A-]4OH#WP3R]S-^!=7([LWWXO@C
M^7PNEDKQWMJ/@U1V#.,A5?R;=]'ZTR_/_5L"J>@G>*#W'7GG"`GS#"$1@(P0
M$0JH"`.R#$A%>(F0,(O`=R<$*PVH"74Q/Y`'>GJD",@7$:OW;`7H"%D@9R*X
M@(>7"/ZW"(8W@OR'/_[W>XLT_Q]<<P@RUFCG8GUBH0RX<PB3AU3;5Q4UL@4/
MAWP"XH/*0Q8UDF&IMPS!MP@(`15(17W=14=@X(/1P(/2)Q/*H7C+I%'6]PQV
M8BR+4!?QMU7.XD*4\X"P(V?"-BE"F`@:HGAJ%F)-""C*`!'D,X>(D(1(%3L3
MQC/0)R+6ISSIH'B<%(,8U(*I!Q@SHPS/('T1!X"+ESJ','^+MWW"QC/*$$Z7
M>#&]=RZC9X6)$(F/\8@@J'U/.!U(A8K^`G[`MU5(E4V35QR+H(E9\PB:B%0)
M(B7:YX;Y-PBRN(?U]7FD9SJ;.`RCAU*>>'^U5Q/*F(R,>$$MN('1\7G`""#1
M\GR7!_\\M7=Y%^.+E_>$=E@K]Y<6H_=HC("&\<%XJPB!/D@(WEA\]#AZ\9=Z
M^E$7+)8(V1<A43@(6>AZV[B.QWAYF0%YPNB#HU<+PU>*QC%ZN<!\$Y9[+5>-
M3=."O:>/WQ&!W8A4NJ:)RS%_[<,S(0-_N"6,=0)YRS&*FN@-[[<GCH!4G`:`
M+'AYCS5ZE9!ZK=&*\D)YV6&/+KB0*A,`A)=Z'A(V-KD7SX=;3^@+#UD42DE_
M'ZE]@[)X\`!^NU:%61"$:/$?/MB$T<@02`5.@(B+&&D_&IF.\]>2\UB5WJ$^
MZ2B75)&-B\24RM`,D/=I\S67H_B`<<F3ME"+)C.,0;F'X33_7(H'DW99"ZVW
ME3TC-![)"/_HB_1P$*](EL.H>"0QD#(I#Q0YA=QXCQ%RF)_IF3(Q?\`CF(>Y
M?-I(&TOYF&FIEH:)CI'IF4=5FE49,II(@I>)EYD1B!VI?;9I+KTGFB'C%>C!
M'ZK7E[!SDWEYD/W(#:<TG+97F-<9:VFX")69F2C1G/-U%:Q6EL^&?.^'4E5!
M,U59$SQS#.-W2A>#C:UIG;YPGN79:`,XFTNSEI$9&Z])F%5Y#*.("-TP?GXX
MD4))FL4),I,I"=*'4D$(G>A)F@%I211Y%_E7%T.X"-V4>\TP>=L)G9R8?]*W
M?;%V.>"9GLNPC4O&!8"8*>])D=(W_YWZ>3_\:2[21P^B*:!SJ:#]($R+%YS#
M.)95N:`^*@G^R3H,^HF(()P'Z8%>L7@U,7G>\8`5ND$/L8PJ>GWSV:6!&"KS
M`8]'NJ4LZD.4I'ME*IG_69LU2IMWB0@D:9N0:(Q&6J0G%(1!VJ4(>IU'VGL#
M"@F>F7M#N']_R@W/>*&>5QP[N@E>$)/-`I2,L'[(1WSI.*#R"9R#$$$$J:=$
MVH)M&CK7"*F)^G]*:J>FBJ>89Z!#>J&CZ*<]"@F]V(Q-6IN%*HM#<:&RH`Q?
M$(D3F@@1L60\$Y'/V0B2FG^4&IF6"JFY>I>!.G"LB:EJ>IV>^JF?XW]).J+]
M9*4'N:UV>?\BW[69J_J:?5JIK_H(YNBA:5JGI,@7\4"DPGJFI:H(D&=WO7>I
MBU"L=TF3=%=$IDJF78J4+F2O,;JF;TJM]>-_K9=-[_>G`]I[K3>.X/JF[MJJ
MZ>BN7(8%1@@-QYJ@R_HR?QJGT3HKD4AKXJH(M6<X$3JFZ#)B>MJQSDFCW"JL
M,+IY-,AJ`ANNUVFO@O9D!LLT^_<%#XB6WRF/'-BCKAJ9=BFD$LNJ?IF.-/B;
MD">!J!B%-)FN_>JOH%FR4_B$CI"D[`@;#V@>K?<2[@BMT`JR\G(A))&LPXJI
M[OJL+ANR/ZDRVPBS/>LI7QHJ,5FP(I*G,>NC';@LJKJTXDJQ2)O_>GQ)ER$J
MN)*8"'4AM(3ZJH]+#D^)",+(I;DY<-@QE4I*@]Y!@RR&KS?DG;6'%FP[LXMT
MLD/;MLL*CA39>I?9>J9XMYVRL5^K,9R)"`V;CI[)%9X8NCB[)$V+M)`G33Q3
M90^X>_/:LF/Z.GOX%M,'IXKWFS"QL?$)DM`KKJ+[5S2).I-YNF6:I%G1BVD8
MM,@!*Q3YD%GAO51)N_ARK+^8")HHM/W:>^I;CR@UL'QJN.9B?Y=WN[3(IGVK
M#+\9N4@;K?!'G,RXE(ZPM]]X"**)IBT[?I"W>"P&OEUZJ#XIK++FKJCHM^Y[
M+Y0Z8]P)DHFPNTC[CW4RF?HKO,3;HT![_XD!&+@."*D&/'*Q>B%OZ5&^&`E?
M.'HT6IFE-\&&&:L#QZ,'?+-W&<.^6+/U(*7N^HX6',)*`Z9@6B*-()K4*S30
M\QU=##*KXSKDP;.OXE&A<C%50GM?S!"G0E42V$).-%`)F2NAL<:U,B!X8AL4
M8;G*$)>0L`5+Y8-=,(!4LPQ[W&S>@,AF1!8^>,A<O!(#97QEK(8T`PL#E4U]
MHC)9H\<(EQM[.+M4C#^>^<;]E:2@',I3A[8\]K"H?`I^\,JP',NR/,NT7,NV
M?,NXG,NZO,N\S,O"MZ=VBURPX`6(V\JNW,O(G,S*O,S,W,Q^<!K/>*7'5<'Q
M:LRBX,S8G,W:O/_-MWP:O=BK_I5]F&C-I,#-YGS.Z(S,I[&7&6A<M1>&Y'S-
MZ3S/]%S/IV$;&=MCY2`.I!S/G%#/`%W/:[`&M#S0%V`&",T!NNS/81?0#DW/
M!`W+`^T&'""$$=W-#/UU#[W1VSS0M.P&;E`"%IW+&:W1''W2SCS0%^T':^`&
M:U#1VK?2M5S27L?,!.W1KRS3L^S1-RW+*BW1/LW1:\`&&7`$2'#42#T``S`&
M3S```G``1\T$&$W36V?3/]W3MJS26KW26NW26XW3#^T&-4"42+4$8>#2[P<!
M4TW56;?+8)W3+/W3N?S5L?S5/*W5&[T&"!`$E%H!=0#2:;W6;'UU;JW_TWM@
M!&;``C0PUW8MT6OP`7.`!6D``'2=UR)-J4MP`0[@`%#`>((]V%67RQ,@`@A0
MVJ:-``#P!,HP!@"`RVO0`5L0`R9`V3M=`\H``050`#L0`V00!CI]R[^]TUGM
M!R:`5'/0!@B`W*8]`T@U`&>``"KPV:`]=;7<TFY``0<``9<'`6`@`,J0![0=
MUQ/]TS.@W4$@`G2]!D-PVPG``[>-!A=]TS@]WGC]RBZ=TU?]VU[-W`P``6)0
MURT-TUDAUS,]W81=RQ-``^>*5!#P!MX=(;3MU2I]WVM``N;M`#?M!A*]WOU=
M`.ZM,E]0W^+M!Q(NUQ'=TB@.U!.0`08@T2"]_P;%W=\Z4-<N+>`!0."T;.`'
M+MP`@%1(T`9GX`5`#@<`\.!=T-KW+=XMS=(&@`(4@`%L0-`EO@:VW=\)```4
M\.03$.4Y[=5*GM\G+N&P[-(D$`,X$`<;\,I>X-0"(`5(%0("$.=Q_@1/?0!*
MH`11$.=$(-TZ_G35[0<]K@Q,L-6O_.#@W089D`$=$.5KD``ID`%]0`,&@`89
M0`$TH-(&``-D4`,<0`>W70`*\.AH0-E#_0$RL`-D``-MH`)P@`%>$.H9(`<`
M0`,(L`$RX`$3P-)UL`<D``9GP`4[<`0@T`0ZL-AZL+%E[0!AP`4:X-FVW.>A
M7=TT@%0Y(-\>;>0`H/\$$``!!Z#2`@(!*Y``+[`"$-`"!3#0)-`"8,C>)T``
M$!`$%,`&*A#(2+4"]DX`!W`"V[X")A`%#P@!&B`'-=`"VLT`*S``"'`$=P`"
M."`':Q".Q_II`QW8SP[MU$W+)"`!$H!4+G`'=W[G+.`'V/Y^4*#258[;%LX`
MY^T&18!4+1`!%L#@"5`&[PT`TN<"0$`$_ZX%=K`'BU<!(T".$*`%*Z`,*[`!
M(%``2$`"";`&)X#LRI#9'=`!G:TR?&[Q2U?+9G"L0"#R-`,`)&_RGVX"%XX`
M!9_T;@``2,#>--_?7P#3$'`!;L`&.P"`-/#TMPT$!3`!55"6/@``_$T`:5#_
M!`B`!R_PREB>Y2VO#$*0Y8Z?Y3NP[1#P!%F.`5>/]4E7RS'@%PP>!)X?!"NP
M!5[/`.`=]@-]\@60\D'@`'@0]4T_T#'`]N\=XQ#0`2[]`DCE\'C/`',P`0-=
M]580[V[0]@10``A@!AYPXBSM!B1PVWC@TR\]TKB,^5%WRQ.`5(,^XJ-_Y.^G
M`1.-^JJ/`*J->9<^T!P.`3-_VU_@`("Y`2;@`LIP!77@]+>=`2J]\0P@`1%]
M[!T."&M^@X-KAFLR#`P0-X1^AQR*#`&"@HZ7?YF:FYR=GI^@H:*CI*6FIZBI
MJJNLK:ZOL+&RL[2UMJ:7EQ.20KE^`HI=``N*$FYN_P`!BA`%)!`,06T#BE4`
MAS7+"67+:&LFSY**%G)N:R?+.(02BB.$6<L%EH0&'"4<0`0$04T<_?[WDBCY
MPG2KH,&#"!,J7,BPH<.'$$\-'+1+4:]<P!@((\8@!(`V2B0Q<P;-P0M)+Q2P
MN6`AV[9%<FC(F<+@BA0)2%X`>&0.G;IBA'($,!/!B[Q!>B1=,0#@`LUP4!F`
M.#HPHM6K6+-JW<JUJU>)$RLRN'@IHS`DDK0$84``'LD@#@"T7!1"PPJ1VI9]
MF=&60(P>6\AL,5'&P)JDB](-6L>@G1\U:L8L*).&ZCM%5VCX\?(TJJ(5"*CZ
M^DJZM.G3J%.K?CC1#P!>OO^>*!H#X`0X:D3@?2NY!LV5<!!"P-NC%ZWG149H
M((;@P1+C$8;*E+%`X$P9JB]KLMELX_@B/-M;#UI-OKSY\^C39QUHB,V,&D.^
M/'*T)D.-&AEHK,%P!$D.'@H@L$,-)DR@0@]#D#"!'VZ$088`8PB1`0(Q[*!@
M`7'4T$,=`!RAB!56+&'%;3@4,,006]11R1Y#U)"%(6J48<8899!AB",B'*$C
M$E7T^(2.0`(9`P9LE".>'^HEJ>223#;I9&N6'')4E(7P9$@Y;-QH9"5KE+-&
MEL?P]$@YY;#0%A)U<!%&&&C<Q0`/QU1"B!N$&!*&&6B<848;-\YY)0G+Z"#:
M?'W6BN?DH8@FJNBB#+5&IY1TUBFEEI-V.>4A5DJ9)8/S/*#(``ZPP04'PM54
MQZ.36FEE&7L42I\AB7P'I:M5,6KKK;CFJJLFLZ::BYSR!%O(C5P..VR4AM`@
MFTCA5("#:*BJ.I^DU*[QQC(Q'*GMKMQVZ^VWJ6DK[KCD6BD"$B.*U((07PQ:
M[J\.D$#""RJ\.QJX^.:K[[X'V>OOOW6&\85T)R!@#<!0(GPOOPPW[/##H"@L
G\<045TP0Q!AGK+&W%G?L\<?;;BSRR"0_"?+)*']<\LHLMYQ:(``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>f39432a1f3943220.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a1f3943220.gif
M1TE&.#EA^`+>`^8``+72Y24T8X]4,W:(K2A$A"(N6/>QD:UP35!4:,W/U?W^
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M2%A<7IJ^VB@I;P@G3D9`@"E,=#LO<PLJ.BE+B2I,BRQ.CBE/CB'Y!```````
M+`````#X`MX#``?_@`41@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIY*"#ZNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL^Z@]#3U-76U]C9VMO<W=[?X.&WTN+EYN?HZ>KK[.WN[\CD\//T]?;W^/GZ
M^]3R_/\``PH<2+"@P6'^#BI<R+"APX<0GR6,2+&BQ8L8,^:;J+&CQX\@0XH,
MQG&DR9,H4ZI<6'*ERY<P8\KTUG*FS9LX<^H<%V&GSY]`@\:L*;2HT:-("1)-
MRK2ITZ?FED*=2K6JU7@]KVK=RK5KM*Q>PXH=>U4JV;-HT\HTJ[:MV[<=_]G"
MG4NWKD&Y=O/JW3L/+]^_@`/3!"NXL.'#W/PB7LS898K'D"-'MJ>XL>7+'PO8
M>,.YLV?./"@3QDRZ],D?%#0D6,VZ=0(6$5+0JVRZMFV#3!(HV,V[]^X*!63W
M'7V[N'&'3+[LA@&#=W/>P(7#HWV\NO5W3(8H``)CS&XW;KK_CCV;^/7SZ.]E
MWRY>@1LHS,=+?T<]O?W[VI(O?ZZ@^?/HY>$GX(#I_*!=?\^%U]]OP05(X(,0
M=K,>=PGZUQ^`PT6HX8;53-A>>/$I@.%TYG%HXHG#&,B>=^Z%QV(%Y&6(XHPT
M`J,?@LXM*&*#,M;HXX^VW!BB>[V-2%^)0";IX_]C0K((7GPPP#B?._4I:25=
MDF6IY99</O:#;CCZ]ML<74(6%9)7ILG7'`\\5L`/&]0@IYQ;S&GGG7CF.2<(
M+%3@YY^`^LE"G7=N86@-AF[!1#E5JNDH5W-$&ND/=%1`00)>S#"#%5YTZNFG
MH(8J:J80_)""(G-$L$4";H2J::<SN-$`F^$T^NBM546:@AP@4.`%$6[L!H0;
M0(AI[+'(EIH"F8\]H(5D-7B!;&^SBF,KKN!$*I.DM!8W!Q,5:+!=L=L!2^ZT
MZ!JKK*2OR!8MLB%66RN:V*[#[;WWFJ1MOK<]M@$%0!`1:[H$IZOL*E.V^<"[
MOOD7;[??7%OO-?A6#''_1A;C6]P/:11+!!&\@0=>P23OMFXL[DJ;KKS@2#SQ
M6Q=?QS$10!3;'7_$CERRP:;2PC"Z+$=,[\M$5Z5&#2!O-\,8S`U)[,X\)^S*
MSV(&NUO0@Q5=SVA:K#+T1W?<T;5A,;>2P@_*]=;TVDU#C>[!"9/YP!8J`UWV
M-BYK/4W>$86-V-VKS$%WPVPSQ[3;TZX;,ZU4YT@MX-GP/=77/DF-TAU_WQUI
M`0R<ZUSA8S!=^.BDCZZXW($S^V[HK(?>---8=R.YWLJD&K@KND+^4`3<LM)L
M8]K&,@?:T\+@QL=`B%[Z\J,K\(6IO$/,9LH(KJU\<[$G1KE;VZ<4P0:$SDF'
M_YURZ/X0$S7T4`,=[+,_IQR6[Q4\+'-L("Y_O1U/<\V>(^Y;`C^X`+/:);BZ
M]:9FC[-6]XZRP*.DH``5(((&--"I"<(J`5LPGT-8(#!->?!CJLF@!M?10(+,
M[P&88\4<$"`N8X&G6#.PX`1G2,,:VO"&%*3`!C97@`*H00T][.'1$A!#'%*0
M"-G#6PF#,KN8I$`-%1B7CF#@,1"@[AA+Y$8%K.8;&()@62-$1Q8%<L(4MFD.
M(+C?D%JD``U48`-P1(`<YTC'.MKQCANH%`724`(*E."/?OQC&EB``#@:<@.%
M-&0A?\"H,?K$D11AUR\DZ3L(]B=GPH)A#<*("T@^AO];LOE=,U@0+"ZZQSM>
MJ,&RO!8;X6@L?HEA11/S(;@6$FXW"=ADF7:Y)16ABP',VF4C:<<+<L@F>I(2
M92\N]L`H-D=GO"'")K'XBP*\X0<_8((VF8!-;/)H&2Q@T;F>DTKA2&,.<M!F
M-K?)36^R(H4G3$L$&D>A^&B@!LG0C\W65J1O'HF8P:"5I'SX`SD8]*`(3>A!
M"X#0@LJMF0B"YFYF,$UOK!`"7_C"$(8``8Y"``(4P(`SPBDL,973%05H`$8U
MNM&-9K0$"+A8/+4RML71DY\:R"`R]%FX(L6(1)0!""1[,=2](6P.:F#"%EC`
M@#^6@`90C:I4H^K4JCJ5!3W_6Y8SC6=*!5"4D]'@10-F@"PDCE2<)E7E`[+R
MQ"@B*Z=R.R=8E5'47<S2%[UKQ=$,R![^P!66MH@G\>K9-NC\])];$^HUZNH,
MWCT@J2!(PQ`TD#3_]>8+;UB65B/:U:_2=1<IV,(,:@8L!=%,`PT`K#!(NIVT
M'A-A:F#!/C_7QHJJ<*[)8&PN[KI,?CV@@,;R:P9=F;'B^E:?82HE@U1[)H#N
M0EM'`UC^7`>UY]3L>9J=PU8EZE7;:H--:"3K#*!0O>.A%K>Z8&W_%'!2KZ&S
M`O5LD3VGV:W@F?$J%5/AX,0D7+D95Y(6<P5R0Z3<'3%WF,[%A:[DT``P/1,*
M\,$?_[I&-P8@?&$#IX(H<[CK66Y("@1D;9X7DE@,];HV=>\]5G-R*3W[=B6O
M^I66A'OSUV,@UVHCLYJ1J*3;6T5*#BQ0V1C@0]N"D<YY&.:=)3?<6>]F0U<@
M9EJ$FP:$$:\2G&CU37LE)0?XA@E']ZRO).^KE3&O8J\Z,E:-C:&BTEZ2BU'R
M)X\3K.`YU$!<R>,G&TE6N&)]@0E@7#)72]I=]+)R&+H2+>N@T((6P``*FDJM
MH6]A8BVKE1!M)2Q.Z?M;,S^E6XZ%A=]^^ZXUTEBGJ]""JE6-PK"-NM6NCG78
MQO8E!1!!=%"`9I34P&J@TOD670:9&[S3-)$ASKK.RZIV.?]+Z`YO@UEC[8_R
MH%#A&:1VE%GN37M_F^DOSY=,`G5Q54KBZE5L08W'@NLJ9,WN=KN;%<0+7829
M-K(XH[!'OY[%M[0S!@4]FJMN&*UE@0"!S+8I`MNU&KF<_=TVC16!)FW`60FM
M;;7>3@X#6"]O:MP32J(E*^=.,V\@7-M)RR+>8UB:Z$*G@#'LN!V\?4J/8[E"
MW;!N/\&:`0TJP(*>^_SG0`]ZGQH@!U8(6F<+=S)1BRH&!CC]Z6EX.@-BBFV*
M\V;;JRC`%J3.]9V_@59RU4I/A)/=5P!WQB1/Y17-MJ5V:8EX1"BLVBH0S#(A
M.-_Z1H!N#+>?8GD!#>#]+XHEY8__HRM\HDK71@2"R'C&S_P5E:YXPAH?Q!\"
M<7$F'\CC8Y&5CM]K$-S:+W]7C`8U@/&_J)?4!I3SL=:[GF8,"([@[VZ-S;LB
MY@*Q_7/U'M&:W=P+=#"T,M>:\&8G7AMV!\;7(G]UB[NB66::3$_,.%.[ZO[0
M$HFY-`I0J#RA(0U6F#&.O,``/9G__'=J0,\#!:@^#0K]/0"!#6A?C>MC7WZ\
MIS*%O#,#-`PU*X)&)*U5:&MU"YG7"F!'9FL%,55""+=W,<RW&UB'8JZ`.9&2
M%:-6??J&#=KG@*^@6]*@!6^0`0!@09\R0ZLQ`Z;F'.0U`ZM!0:,2@S+H!6WP
M=0JU4')0_P-$-(-CT`"=)S148E>P(#&X)PQ2480("&,(DW]0TAP>TP-UEBH7
MXS<:]DR$)DULDA522$EAPX6UL(7S@SF%($N$AR]9A$S/=V6MP%IJTQS;%G@P
MUH4>5X!>LU8>V&G,HH&M4&X?2`ZC@6D7*$L18$9H8H:BMFZ=%SU).#^$`7JR
MP!'QE`*\9V3(TE6692S8]1AC8S8+PU?'`AL*I#U[0X3V]XC=<X>/B`T7&(E,
M^!S\`050.(1]Z(CO-&H!>'BV9EN@-#VII@5C1GU[*%=YI6I@Y(?(I"N:-7RM
M@(J"B(S+LGAR4`#.*!QL2%M8=XP0PVJ$)TMF1PC$^$F?YUAF8O^'@ZB`?8@P
MTI&.]V>'OC..DQ$XTB`-?!@X6C)`*I0ZB@@68[B'M_5\"'`@EQB0Z()==0@+
MHA<RWV$UH#@O2D0O\C!&?H&$7Z%\/$$+?_B'7\B,;=**R]%:1!"+MJ"1Z]8F
MMWB%%350X1@!:H!4<O-J#)B(93@(*[F2=,@[*IDQ"7&'QGA&Z80`-0`"ZM=S
M<+`%",`$Y?,8U;@?['5IGI>2-[DO/3%V!<DFK/8FB/230-D`6@D"(%"4Y1-,
MWR@9\$@>'2<(+!F(['A_QX1-5UD#B_0#IO<8?BB(;0)&/4E'&^!09@)>T3,(
MOW-,8#>(_0@6D@B0;2AW`HDX0V`J<TC_*P=Y2PK@@Z$8.2*)%=!0BI6)17=5
M",S$D0M2++#82351A0)(+EBXC`B@E:JYFEHY?V8'"]S'FJP)`D5'?6\@FZSY
M!K,PAI^$/A4``0E`03/0>C/@!0DP!`P``AOP`'#`(FVXE*_E-;>)FUJY!8S$
MC<<D#;*A!C]0`RQ0`D,0G)GB0:^2`!3``"S0`QN@3>N)39OQ!G.$*`V``&!A
M`ZJ9E:Q9`YV7A]W9``Q``>$Y00GP!1#```VP`4?Y@'7Y+=[YGZV14>=YH`7@
M+&18@-:$`&\0`#\ECZGCCX99/8B9F&Z#7;X%7H^Y((4EF0S)@?M8"Q#9@8UE
M*T.3F71Y>SQ!_P@G)(E[)R:@"9(N2B^DB8NGB3`%P`(:0)[DZ07J-I*_!0L_
M4`(=A*3#67!UZ(MT(Z4>A%H%N8Q:^``%@``L``&4I7%:-@1P0`&6&!_;UA,%
M,`"_\BJ>,IQEH'3)A$Y@>BFCY3DA&G#&V5)#D%$9]8(P"`1IP$BJ]H^OXD&P
M,@,E4'1Y"*9B.IS'4F4)4`(UT"!1*8UV&J:_4ED'5&4%B@"FEY81@``#T`"(
M(@);`#\5V*%F\X\-8RP0-V',4ZO-<SKL$GHR1F'DHJ(M4XJ<AXIH\J*7>7TT
M&E;!NCT3\34XJC&_E7_'$IKC4`M!:I+=\D0<)'+1M`6/$39=BIVH,?\M"8!A
M[)@"#0`RH=,_UA:=-KHL&\`""9`TRB-M\9%KTS5C:NI\L0%%XLII;%<_%3`$
M(&,XOM<Z1+:"!9,&HYH"&P`FQP(!1_DM#?`%GOIFPT9=VY$`1"<;W+(!%1"O
MSM%OK,-WP@(!-6!ZY(``!EI(-E`#!EITMP-/[3*)`<DV(FHRC%2BYN:)^7,U
M!ZB9>,.EN?60R]"B6/&0?".LCX>-^,*$Q@(%P5=,Q%&M`SBD'<<"P\ED(/(Q
MW%J`WVHVX9IG:W1A8/=;YPH$PQEWY`4#`G-MLO!$->`KO.$ZMJIGS_F&7NIE
M:[1BFQ0\XFAG%%!9K?,ZC'8]-MM%G_,<:5#_`%W#L+J1/$M#+`&C`!2PDG96
M`M*B:4?&/ZAE>FS"!"`P!&2E`!!FN#9;+$`P!/C$"C9@H.#3`%N`2`R@4UEX
MB!OIL`2#L"`J?I:UF,48"XWC&U9#8I2I0,-*0LOHHK+8$,&#+X[;<@366C,0
MM9-4AR59M2>)K7$W)/%!!%U+&#%S-A2P'WHVKA`36@-[NNN:O+[S`^$"+.1K
MMPA"<M4S+1/894I9OV&6*H3Q`_!J-?QD//"+(]V!:[I+NJ:TN`C3L-!+9$SC
M'94++GM'M\P18<%BL\<#!"RV0C2@,M9S,R#:10276:?2`(5JJAO`)W*P=8Q9
M$F,'J[0JOP,H;8=S_[,$F9,["R^\0;PL2G^WMT08:83$0;06^8$5R8VY-;3Z
M:#'/RV1$DG/!QTMM%VIL6GS8*U#:N[O=^T5T>#O@.KY:O&([9#:BI<43E41G
MPP"C!1ZF&Z(LR+O--Q\05;]ML[_&I`8@D``UXS#^@71*^BL()#`U'#)04+&\
ML;BAQ,!L`Q_>,00]$$'?,;*%!2(VNS]O5`,0@&/,,5X)TA\1AKA>``(D*0)P
M8&=3IW[UPP"ZV:2W-0AW,'9O\`44TK,M\AX0IKO\TV^U+#*\+#)UJP"EXK6"
M2:$YS,O\X8H\O%C`R@P-I'W%6AY@\0:'@BC3'&0X4DHC,P,L<$C<W,W=_/\&
M-D#%CV7%IIF]:C``Z4M;1,#%X(L[XAN__&&^9!QB(>Q5LQ*^0`8RP/)O_J'+
M[B$P%E19`4=>R()U<\R]?(N6&SD$W''+_?PT--B5/@D"#```I&7(#>R<ASRA
M;:+(A24>,P`!*G@SP];)(=-3+/<%:4"Q(1,KIGDN`R.\ME8"IM*F<'`!F%P"
M)GL!3*#*K'R/V/D&`HNP[R'#!T0SR'.SP,Q(Y@%RGF@UAP,#R5Q[RQR24OL5
MMJ>/6GW$0INL2=S5Q_!`#::D-80IH!DZX&&O[N%2@-K6;LU2;0T!/KB-AF>M
M]-BFZ:R4Z\RN/]UI[US/N#3&OE/&SS0DZXN=:@#_!QHP+.[1-CKC!D-0`5T9
M1S4`!VW@!<96T,Y'DFZ%T&TD0MT"1>CJT"UG-2;[`\GT`-W)`(M-,Z.7`!4`
M![(-!WURL@OLL'P,'\=S,V.0-!J<!EP)`A];OPO"<@)3,T_"&QJ<G-[9P9;8
M<A66`)D5`2)`=S4`4RPP*RH[?S+5+D)-IE-TP*X]PR+Z/!?0CFQWHL;"`C]K
M#!)9Q,6$U72UU>NXFQ>)),?J"Q>I#+&%T<N!:VEM(>"=+D00>[='SKMAM5Z*
MSL%E:SK5SK?UU\<BSV9$V(W-'];6O+%A9^)"!%/V3`/S!?.)VAP;/3^P!30P
MNIH])9;T5J#-"@@@RT5-_V3'LQNJ"VYH.3P5H.*Q^@4]\$."L'@3FBK/FY`!
M/F0>SC0?TT9O!)>3(@(\.VPZX^&:LAL:,'5?R9UNQ5\5I@$(\!C7+4<LH`:I
MR03JQ]%)"`MB``$!$S"O%RLBRUW*[3'(PS]V?N<7_7IN_GH0P`0:\T.2PD*V
MQC^M1^B1V=[%\-XQ:M^8"4G'FM_$X$C,V!-J$&W&<FMKD]EJ75VV%GMJ6-=7
MS(YX/7H.KM!]K2WABBP4CC`6KB#"DN%W:`,0,"X09L'!0@0EL`$TJ:##0P//
M'<<H-0`J5G+S,P"4M;W/L>0)(*K/>('BR#$:YS$,<)T*\UN\\[RH2RZ&$RLE
M[?]5-(``7VD[#V`#8.Q"KF@U5UX#Y=.DRU(#/$Z^8W!/;<)@LZOK1S,`JBSN
M6M@MMNB3YL<^/6"D_1,?->,%%=`#ZH-^"H\GPNUT?N+P3U<!#%`!;JGPKKFB
MOSJC3>W"-JK?PYJ(7$V.Q\N^YV`(*+8LV9JX5(3!%_QH&AW#Q09,GX[@N<@F
MK[S@XZW.(@3A'9KJ$S[&?J,%(+8@3X*ZZRKN.&]K!DR_-.#G@IA"F)8".FB_
M%G?S;;I>WQ8\!5`";1X?2EXS%:`&-1H]RT('N/T<O:W!JYMJ%D@F#8M`3Q/"
M*<=>+!#N_!N5(F!UA]D?0P`"J.VU:W4V>CQ.:R/OJP#_9"OKG0,04TCOJK#F
M^(L8*8)..).[P8@^/-JA/VZ.W,'BZ<)#\D!XF:+YH\E;$_N]=/9=H\HKB*;?
MB%4MM7XX/?U]F+W-\J_SZZ/'-D1`=S]]O=$T35;/X+?DO:;>8JI=[L:RZFW2
MZEQ49=?6+3&^'25]^PHP!%]^]SD9&ZB!^^UE]5O^G&'&RK$LMLT1.DA-!V)O
MQ)W&,466<LXO]N4(3XX+]Z54P%2T&U]`F[^[APT`"`H*0(*%@E!0,`I$;0AJ
M*0\1D@^1*0400(J",)R*&C64$7,%"`TL+%L_<Y&1$92MKW>NE'.UK[</M7,(
M&@IN;H8P1$0*&ENZN,G*RZ\__PF^AM$P%060S-?8V=K:D]O,LZ'@K;/BV=W;
MDNG>X=_JX:[GL,OE\O6OD^ZAR>+\M_GC]-:Q`XB+W#EP:AH0(Z2@TQ@@8\9P
M$O3+#:>'T3(6ZJ1I484Y*<`5J-`0&#!#1$"LFE1@`+&.*(^QHF7K3J15/RAH
M+)1@PZI7*;;,"%8(R(P&]U*H(5D(6"="QB)8:_>@`(,Q.Q5XJ0%)W<A-&C^M
MI%3C&2>+#6$`T_##VBQ9K&JI81%,42<B%1X]N&.35HH-9GVY0701JQ<&;W[Z
MN[4%BB"&:6&,<0-$@P@>BN6Y*E!"6B>M7&^-*E"@G+M_N'39>J6KAA<%$2$;
M$AN)K_]M2K;YQMK7]Q63(8,D-YVH@-K4?0*3*R\8</F\?/&<[T/-C1YU@N^D
M7X.^>!WU=."B>P,?'7SW5P4:R#8$!*+$IL`P9LU(7!`1!H]$DE0+#:5*6"V]
MI!$1,H&S6B@XZ016-#UE%M10&QER5#AS_`"<9XH000,3Z$3"P$D:;=452TS!
M5(A86LQ20R\MJ&71+X(DT!8[NK4RQUST(>(+-<G4\E<"$U7$T1A>&-?5/;C4
MX-@@FW"D``0-5#../YMU1I\B(J(C26;BY8*,:+6X!MMZ)X+22F^X[=6A;Q<*
M)UA#@ABGW9S2=9G<=>8-],US7>9ICYW*X'G:==59!\]!X4W_=T]XWT&7Z'A^
M+AH//JXD5(8&"62J::9$0.3BFP]Y(>JHI)9JJ@8:#%#.5_R!:-]_LP0(9T8$
MCN7*@5L^D--&)C:HSX-$%3*AC0B\AF$Q!<Z3"SX5N!I-EEZ5&%8-8SV`P#,M
MN@BC`CVI(<J9BSZ@!@,:340$"P7,E`Y(@`7Y"T=>L-#6B/6HN"1DGR50PR,A
M^2F))59Z!MI4A$;:I6II>CF'F.WM9$QV>KY37IZ_;8+5FYKP&"B2$-,Y)Z#>
M@1RR01*;UIQ`B)[\L:33&3IIN'H2.G([C6Z7RP\((+!!SCQO`(=99U4$#%XU
M%&WTT4CW@'0-;\"#WGXF19/22INY_S2KU,ENJ=@D*>S:)(,(."A4L((,>RL(
M.VDR!!,IS-$<I9$TFQ6T)"X8#6VSO($M?]`0,@,+M4PLR@9?,"D-LOJ,PRZ0
MBFR;UA=,N#THQTH^1HA%$Z7Q"-7J`AAP70-3J3)R+4>0FRAAOK;>9P\#Y"]Y
MZZXB>3<5-W0QC!FG&R@YHH_NL3F^;P<[S%1*2MZ4L`S/\GF1[@X[/Y-"__SN
M'>N#:,?7(]^\H1`_K_SQ-/.^C&I_`2<<C)-IA4;P"JN&NGXE]5<($=3J4P`+
M`M*:->JL<.VUDSP)6S>`%2%A(8457RF7($H@A[8=BE$#J<#%0A0:TVU&6AG!
M&R7D0`%/G?\$&`W[@D\<F)T4R&$`0VF/"BFB@"\@H'>+<Y?%8$`!.<RN>#.I
M'`Q4B#E%Y,46V:M2N;`4&M%)K'?$H\0><&,;U"W,6'692.LDIIK9P4X7X/E)
M[=R$NSBE*T^3<]WOZL2^TCE*/-+SGF:Z83*3'=%UKW,9<WH'/N:@IF8Q\][T
MCL<][>GQCP^T8_=(9HL47`LV6-'1269`A\Q<XT`XK`K4Y%>V^B'0:B:R3[)H
M`C==*2B3W!(@U\96P+(=<(-I2,OABE,`]TU/'A*<6P6?9K?9U,]TD6B`%R3#
MD/<0@@@E")O;.#<'.32@%\&9"!"&5H$?&,]'[6I<U!110RM"\!7_.FQ80Q+!
M2N1IKRJ?XU7HU$'..P[*B7/(31.=N"(,27$+HLGB%;.(Q751@@F%4^6;"L$C
M0#Z0G%H:8R119K#FP4R-`_F'S+#CS^7!D7EL5)X=^\BQQ!'DG-BKXQSAZ$]&
M&:QX?#S>+IX1$1A`P54SZ,%$KVA-)R)PDLZ:P2VKEC^L56M9;*2$UP26@+#!
M8@ZDK.51W*93G=0'+&X`'#(0VHU8[@1:M+R:+7]R!Y!<"P8S&,9@,M0>(E#`
M$=:`Q!R84`$-`*%3D1D$,?15SW/\2(8F`0($;!C1B&63(7S[R$RF="B`#1$T
M;WSE7@$BN5JHDR]:6Q@R><6Z`J4Q9=FC_P4^O[9/+W(T.^`36<3&""C3T!&A
M%JV7>2@5T=+:Z9R@E>CKC/=*A;HV>BQ3K?18>TT_QM%X):OMGYX'%VN1]#./
M44!*?_+8D)[#%JQJG-3^<\F:QN0X-R'JLBJD$VV"C9ACLPM*D3(+&T!`GQ$Z
MUY>^Y[0(.)6"]))D+4]4()N8D`5>."L1>NA+(@R!`0VH0<Y`4`$(&`MS$8G(
MT-#5+_*LPI",JRPAYBK=RY+%,3#9%H^V9I!_<>:O6PGL:E/35E>@B29A6FQD
M&DLU/7(4D),E@D2$9HA^WK:.&G6H0#<[,\$*DK4.!J-!<6SBZJGVLPP]66H]
M.N2"T/9M0<;M2O\WS-<*'Y82AP1N0_S6R-!BYW3_6$5RY?=+2U)"5J"LU5Z_
M=:A:,$%!._'5)(`Z%.U*Z)0/L(%13:0((%3`AL3-K#A8,$%QTNW+&+Q;>RG1
MM31TB@A0"/!3'D.$&8AJ!K(QJ4.P<A\.J<L\"#ZJ(1C<T`=4KB@OLNQ!>7?A
M*P'VQ-R9SD\*BYU1B&)%^!H2LDK<4>>!!S"+"!IL.N)BU&9TQPO]V.@6VEK8
M8@?5T;-Q\B!KW)5:U+3)UNT?-UI0DIFQH#)6]I$=53(JY0;*SY#J#H5;Y2JZ
MDJHVZ4MTMAQ3YGX9DP/:'YEC=^;Y])2XE,AN_`QXBUUE4A,,P/,-ES?_B_.*
M4Z9'`O1Z!6&,52!6*@_80`G0&IDQS&`,%)=&#P$(S#=,M\*BR'0FV\/I[=EK
M(\OLSX0=F2@YA/-K6?JLS")0FF^9^^:[Z`69AC'KM@ETLIE0+@L5P`#=8=:<
MP]/LC$7&;9EC#XFYU:B>VQAM;>N89#:>&!U]7-H;]TG'#HUCC'/K36CC\#:'
M%#>59<?VFR=#W;A@=S1F(!/TP%M_@9/%:LJLAK)4UA#WQH6^^6;*?J=2TQ.A
M0%NL&'97&/QK,JU'`D'9\+W(0FL2'XH;9I`(2>_0#?.%#3>;9%+'`"$!S>Q*
MX$#N6TT/0JYTQ>.GX80YRY8'22['<!&W;2?9_Y$C<#@/4P+D.XSB#^/T6U!#
M2W.515N#IV)2]L7%BFY$DT]]QMA@>F2C?D1F\S[:W[>V\VP]2$41K]JF_35R
MQL[DNMKVC5LO>Z+`SHZTPV3<1*##LVF\??4&:>YU]V[.-3_'X#:]%3BTT'<0
M\"YIYE.,T6;[5GBO(`?[01]8T5-'LGV3P&>F%GGG,'EA(1.ZL24ID`(VP`!>
M8!(<41_`)324001>``')IWJ#91Y1-BMU!GL#MU&SMX*V!SWAX%>F%G/AIPRK
M-PH(4#1T<#0]@`8]T`,(T`,-P`!IP`!6>(586`'Y10=<V(5>R(5*^(5>N#0U
M\#,C!@T29G1K)#B`A/]]RU`:!+5D!&=MS"9U'75]U.-\H]4G.-0H)I9JX7-M
MY2=:XG-LM'5B@L@Q:2<-OT0'A[)1#V4/_B=TPN)N57%WRX6`L]!@0`4<1@%*
MW.(3@@>!A"=<<#8'($`FMJ,5Z'(>2B8W`O-GZB55[.5PNH$,%0("0]!#H^<0
MG7!213$#$,`"D1,2NI-L#X!@<*().<A@PO-@C$4<+N9(XR"$L;A[=]@CR/`&
M&:`!634#X)A5C=8I&L``/Z`&Z)B.:E``<J!\9!5?C1:.X>@%\NAHXFA\\2B/
M7I``"R$9VP(C4-"*+D-UT^:&R0"'RN**."9_U2-_8C>'[!<0;81$$@5U=LC_
M5/VW6WTT=8_8,F3'=:RGD>A418L8#&OG37EHB)/(98M@B6J`B?YQ4](5`3;`
M`F8%$9T7?2*$7:2X78E3+%<R;D/P0D:$'1,P!/]&1".R&70A;@PG@@\G"K?"
M!#20@H2@"4)R$93A!E[P!110`36@"AV39^KP(\O8)"0G!S<F#ST(0!6PB6$D
M%06``[KG%O2'DIP$$F]0!D3@>@US'WH!8JHQ%\0P'X:9%5TE$>_1%%K1`(&D
M9$JVAV4T)Z01,1/YD1K6D!@U44491I<&?Y!Y4>7D;+]VF4W7>(+3F>XW6[)U
M1IF9;;GB6^#%2\*U/@QE?DDF=[-"/^(`9@/2``B(_R#B@@`,L!!N@!71%R.B
MV`WZYCBF2!.Z\EW[U`F0AA<-%"[UU#9O``&N-Q%TPY2UI`EX8Q.Q20I5>1:%
MX`440`-M0`$4T`8E8(6H@`!B"5UG5)8WR#><`'N<Z0Z?]AG2Z#0WE%-S69>1
MF#+/82U#H&(C=VC4MWI.)`IR@#^':5V'21'M45*",`8ZPBVPDGY0UWW!]CN5
M68,@YWWA@EH[AI<7^5&!R'WL<(?<=I^*LIII)$9&%GYCAZ.)<Y=2QR?@$&4K
MB!$R56$P"G_,`A8346<?L"^79T(5`"$<H4*`F0L(4B$U<"%8`2/.R1/+Z5X@
M`(%<Y@7`B0P)T0O'N8)9U?^8RJ<%-3*2"$`!M><9E0$*G',_0:<)VL16>^4V
M:L`$+,`XQ$$$PV@#!1``-F`#/,`#`>`*)6B7!K%J>>)>@)&G)[&?<P6DV`1A
MZ/EZQ:$&8W8K4EDEJP,-&89LB]$7$'HK&^")>=H1OU1T;8.`#_<`%.@L%WJA
MF<2AG$<,:T.:(2J:2D<G)6J(5W>D*@IL55=1:Z@R'$ED4==C&75L012CKZ5;
M2]:B%FF'@]0/'GD+0KJD1%H#_W2D[S>+=F$7@U"DZC`'NN04P'56+@02RR('
M-5`"K[%#%Z$(HW==M4$)#2"F(&(493I,NF(E3A$1@@$,1?(#XJ`+<K`!985(
M25G_IT`$GN!5)IQ#"6]0`?Q8"!>C`26P`:T$7:QA3^^P&HQW"[C6"9>Z0YE*
M?M`8&2!$"#_T/%L#3@+#L&82B5?&2>W:JJ\'0$QR']7P+9;7#118F+G:M$-D
M<8W6B@L)FH0XHAY3K%<W6\N&H*B6?3!F;"O:FEHKHYP)DM=CHS=*M=%ZK:K9
M20G5=<SZ="-UAK294H$DK;9U0:0'7'1G8%N0@F?H"XV6!O3Y`S90`PR`3";5
M,&D*BH''G/FS72`A.631"Z''8CPW`Q30`&\@!S0G!SA3`5]`#"55L5Y0@`#2
ME)1'+91+"FD`(8QV5N;H2MWP)<S15I`T"RW;J9AJ0S+K_VE+XK)UQDK+ERBE
MQE@\>X@=`Q>K-Q-"2S9%*ZNK4:NV6@%,Z[386W%68%\.J)G5IKP&B1['2&3%
M%9)YVVD.MH:E*:W<BFP5F;60=:YL^)#75I`YEK5Y=*VR-;=I!1O`,%Q-1K;5
M.'D^*%QUMR5^%[C\001?4`(E``$?*QF2<6CTZ'HQXE.0BX,=\3='"&B=LI45
MX0L7)P@Q2`,54`%I0`$?.[31]QFGJXE5H;K3\B4(,'&2<3%G!01>``=5-)(0
M.CNX2'.ED;N4L+OZJ0C.V(;`N[<MUDIOBT4Z&XU8`D^T]K4"2KFZ>R%ILPBR
M>@N(9:5+.V(K.,9D7,;N%"HLX/^[H"E;ZK=TT/%%CP52OM:MM8:(S^9^:UMU
MHYG'8HNL>.R9W49:!J6LX`>^GMFB)L>_P+7`/?!/=;RUXE(B!4QWCG1F5^DD
MG`",[(&3+7)6$""Z@1M`V)4_3L+!HT"O.C5QB[!,O\"I%JQ6:#5?Z</$+TQ4
M>NN4W,*Z6F:]GJ),*@0!($"&-;`%9+@%QJQ?",`$YZ@+0XP+RNBR7U-R/[K$
M8IP[D-1M!2K%6E&`Q:NUJ]=;SSM$PM#%X:!NQ62]U5S&ZDS&&**P%!`Y9%F'
MC^*0;OS&5J:_W)JL!0F_/*;'+R:V,@J_[UO(UB-V0Y:-2+I'AXQ^^#NW4J8)
M1&";YYO_SW53S20L@JP1L`IL4N`H&>`H$9*V",&T`:G$H='WN+>R!<0`KY\Q
M5#-Y*S5LG"#-$2?ULB858()``5\P&38]Q1>+KJ`C%C[B7>Y1QD:A`5Z`U*B2
MU*."*DXM*JB2*4-``2Q`GZUDN\FXB$LZ$=+LHCHTQE[48+6[+%&\MSZ]JE:\
MB9(#%^63L2-FM`139N<\T^M<UV!M@0_Q!=3B<^358]]+8\KQ/4;'1T"&DI+Y
MK(<-K8089`-=9&MKR,;EK>K;;7+(T%FGK5\KH@2IV%&VF'4KT8D=4L=&P#-=
M-HX5<I9,631=&/51CFWA-2"](&J6TBN]<8I@RAM;"QO0!B_Q_XLYV=.EW5-P
MP-,VK<.L:T&S"!\3P59#_5V-EI.^F+U/M;EXAK3)B&L]E!98T=6;60.]S1$G
M00U8K%!E+<;;#,7Y"P^JNM;_(K2+K-VR*R6B4PL4J)C2/1_$L2U`\`4J46!]
M#:+(:&7.P52#_=^NB:.;V=C05H=TO.`>E="D1=E;"[=UE>"6;:0*'>$2_M^H
MN;Y;=T@*RVC$P$AWZ\CR3$L9.K!G)8*UBP`08)R7P])'I9Y1DHQ>HXH-`@^U
MH-*P3'M&`3C=TS82*V)'-:3I8U\J`0>XNI\B<D,M`1DA'".Z;$+%.0Q!XS@F
ML2UTYA".41$YS'#R`E`_TE5XA7%/$O][+\;COJ"G:*4QGED:V9P1A-#D;$M8
MS)<.*;"=;HU(9Y47QX%%K;04`WC?H+,(E.$%P02J/$K9>QA_<SPRXD$:^RS`
M$ZZB,N?7#8782IS'&Z[IY&O@.KI:H9W62AS0^"R;UD4(?D.NE0[0YI%`<F[`
M)>8E:K`!#+#"L3:H"=`&#5",N5!OAG-=$>`MHD!*%JK#W&5L!5`#:;#"6>&=
MP^@3<]`LJE@9*G%#<D`N61$5JO$&:8!,+$81SK+(*_C;_"$,(RXO.)75SR`;
M*@0$-<2CH[4%JAX-#$%]''6Q//!RGOHPUA3JQZ/G.Z'J@#FK-Z<4%$KH%TH$
M";"YOH[(F^[_OBI9*&A4<W\XQW^=K)!YV&0WZI@NR)<^Z5P[6IK]\18>O^X+
MX(]NZB=Z#S4,`10``4,@\Q!0\U\``:PNP,>:'@EP\S4?\U\0]%]E\7GR`S70
M7PD`N(PV`QKPR<G\)7-@`P-0\S(_!%9O\R70-!&P1+FP!3+O\S9_\Q20?*Y5
M&FUCK_VE`9UBH8N@`4/``HDQN0T`]E9_]1#0!JR^%YO1`!#P!74_\S;?"%<]
M"S_`]RFHY2WLLB[XC]G-T1<H3-T@<50_^51_9^6*HR[N\W]O\U%23EHCE54A
M`G]O]S5?`GEOV!UU>0_P!FW@U)N"*0D`^^:H!G)0^[9_^Q(;^["__RF\W_M.
MO?N]W_-?N05,4`T.9$$HS]@=[_D5":3L1_2=%MF>?W3H:^K"6L=M>/'H*_'R
M^\CZC+\(+?$L;V,%\`9O\`,;D/X;P`3K;_XUE_+%!AXX\P;JK\SJ_P:M),C#
M3@EJ``AO-0T5%0P,%2P--4P%<X\1D1$/$39O&YB9&TR8!9%[E'-RFC^<&V^H
M`922DJL1CX\%3%L5)1`00T.W-"Q;3&HI*;$_IY>:F&\_#P]W=Y%SQ,>HR`64
MRP^/:AL@-%XP"C#A"N/DX]_EZ.!0X>QC,V-`0"S5K6I,3,:F/S]O-IZL`",M
MBU#`V#%.R5P-%#BGU1P;QS+M>Z-J(4!7`?\!.ILDI\:6&B!#@@0!<@NA0RA1
M%C+42Z3+ES!CAD3P"Q:D2'<P7K28,:-%GCNO"=4I<.@U@CUW*IT$M)5"5DV+
M$IV4%./4I#VO!M0Y]:A/JUFM7HU*%6I1LUB=?DT;MJI0+==L/DA!-NW0K7.'
M!J/;D"%4HZ_4J'DTEZZG@9X@82-<F*X:J:\>[0TVIW`HHD^?(>;'Q(8-)G(B
M[!UX#>XRFW/H#FSVC'#E8`^TF%[H*L6%.2`2A!L3#HB&!,`U_`9.G+B&&3.^
MP6C1`@HX=D`4E&#R4ZCJQM6WMKHN5_5?27V1+NX^NGIFMCE;I[X.>_V<&AK2
MH=.P)77CR7$GHY;_+`S6=:^5B8665Q=5]9U;!(9E%"7_V&6>6@5"**&!;+$5
MU8-G.;C4@4PII!563?$D((=U:5?AB1-V*)"*D<U10(,;:BBA12^*IE-X';H2
MX&FP<"@>CGVM`@93$<@AAUPS$K51*Z]8!QLV0H5G$6H=;K0D*SMBYLQ<T(`P
M!!&[C:%``G"$])%,)K%0`01>C#$&%&ZT,PX$U(7W3X`PXA7C0E2BJ!F6`4[X
M85+IJ;>@3?`]Q\YN1"A`7RR39!E4CYKQ&*15.&;(I#5$,NFGITZ5*!5@>;:E
MJ5NA>HJ9AY^&V-5YJ*9(88XFK@A9A:+6FFN2?HIX878R=FKA*@EF!16._P0F
M<5A<&C73#$8WJ77-E2\ZPNI%F5YKJZA$P?(/6,\T^]=&R[Q!`Q'Q`$$$NAJP
M`(Q>>MDWAQIO5.!%/&ZL`P,\"D#P1I`1"EO66K*&EY.VD8:[U%&[#KQM)`6$
MMB!!C\"WZ,5B:E!#M`@6>R)0K@[X\:I<#9HCJ;8:*^NMP+*(ZZYBF0PBL3&B
M2%O-INJ9LJ]C@>K3@2,&:U>2L/H8JWD7ICIL@J\&A2524MZLM,.A=J4TSP2?
MBE2GRVQ`03Q@0@%%=!7\T!]M'H[W"!T)D+-H=!0PX2)CX`:-<\*CINRTRERG
M_7)`WT)6V7M>@&...(9K3-K(/FNMJL<_"RM4K?^.V[S@-34*_.G4O\I\Z^>:
M0]XK@2$/K37368,HJ(B@-KRZW7KGS#17>'&+UM2:YSXS["#GBC"M'3M(;,G@
M_O4A+!N4X(8"RRNPC@)#4)<BQQ2K`4+AS4.G0!I'.L+8[9M:CO7NFP?UH>C@
M!7I:#87+E_@6I,E</.@QN^XR\+&CW_'ER]1(5O'VJYK.<N<Z_35N6YX;5HI,
M!KFQ:*5HL:L<D>KV0%S-2'P#-!K?0"<H\+5N5:VBW>ZL]L'?$;!I+TK-#TJ`
M+C&9@WD-R%3M`#('KS'/#<MCQS@J<"09SBQRDH-@^>87OP.:3U<BFD,/VB>?
M;SR*4T`<6`"]PD`C:C#_:1X\&?]>%$`$RL^`"**<!!DG1MU9*(PS+*.F?#6K
M@)G(50G\X>GBB,8"_L^"9:0C\986PBN6+&>5`4%\@"`F'(Z#"#5(P=;*2!<$
ML%!=V1.'QFQR-ZH%JUA-*]_].`C&R!QKB>Y[7V4V1T6099",<L3=Z/B'.7IH
M$G\17*,8>Z?`5]XO1'T46A8U.,&81?&5L+,9B6CYL9QM,E:H#!T(@=BRR>GR
MEYDAYLJ.Y2(&Q(,W,!`;.=QU':4DH2AJ<&1TB)"],32O!&8C3"5'9SPWKLYR
M5)N=_8A%N"9*LCX^-!TG\UC+!_Z1EU]A9?]*%4N]=3)U"+5=.W>YT"'>;GRV
M_UQCVNSV/Q&>4'7&W%`7`5J_=0I0=J;LE<\PE$HW`E!J&;WE,E8(A(O!:7D)
MJ($<GF2-MQCF#7"``+K0%:?=C".FJ6'*E9(YP,5Y$([('![Y]L:*;VVIGNA8
ME*/P^4OP=9)D&"V+0ALJ/(%FSJ,%.M\\L9K5:9:U=&9]:(DJJ,^0JM*,"J(9
M4]\:4+3U#*Q^7!G,.'A**V[0D@=%(S)Y^0"6*N!-BW)#/+Y0`03\8%EY>8!@
M?E`#%E!@!@H`P@ST=8Y#PJ&'?>MK8.$JJRG^KH'HB13[#.<V'3Y*AG;LJAHC
M:$"DODR@#_BJ1-M(RD&=C[>2(V5?C_FWV;).F&E<:/]=BCC&Y`[V=$?[B28S
M>2HZQI*-(RTF0DL+3*M&H`*-(@)GP]$\(B2@!`QH``C.5`,0L(`!%$@`9@_[
M#G:X`5T*F`$#S,8*<@T7C)C\)U.M&\]E?JR>B%-4QJC:0;]&]*\/JZHSCTNY
M!>F6=/YTI^[&FM8]$9BKTR6L6N&Y5!"7%)>SY2U:.:='";=L@RCV\(,-?%;>
M)=0J6XA/3R_6V7&X809>\()PO-"H<F1SO/CU0MDX]JSADM:=$*5K1F,,4&.M
MML?@<).C8A@U$QY5P%5.G>><6=`1MC)_'^;C@_'HY"<[U[J8B6*:;YN_-3/4
MDK:D,%[/V#H-E]G/;L[EGV?_S+<'R($!C7(#-GGLG%`>CL?G(,(0&L#?Q$B"
M-7Z>GYU'O&E]1@X;B7*T!AKPBJS->;N=)NQRB7=F.0/:I!U&VUN[N%$5>[=5
MMP9I`K%KT&"6U*1Q?K4#C59`'U&4A"F6)G!AC,3?6I%`<V!"!>)SV/%>3%%8
M=FFCQU2!#0RF1PO!-*ZG7-4/+I"!Z%[=EB)0`P@4Y]T)T``$:M!&/=>[P;G>
M,(3YVM":#G2Z8EUVKCU6:[!^V**;UM:+!SUH7C=7I*HLN)<=K'!3^_;@50QQ
M=4_=$U$T(`'1(0<0<,CCYS0/''$RY"$30(,:>"\QETIQ;P\H\3L[N,\969(<
M$("`_PWP_.>9X/D/NOMK=O:ZW+T='H;_?=24AEGF:V9KH#VMZ4Y+5\IX9J;`
MKTM@W_+9H#:G];['C70[GY3C63Q,`1!0@3+,MQR+[BP,0HX.('@!`HU5!H-2
M7=RQWQGA4$=ZH>85H/UD(^NU=/K6^5YBB0X4[2:.*.2!6?"Q#]OJDY_CJP[.
M>$&_6N-E__K3'=KY8Q6D`?%]NZ/+082[,Z`&_I"B>#+OZ=%'/?.%BH!@U$,I
MG`QUQE@L?>>1IMO14S?A$!,^S5M<>X:KCJ"2:!"'9?2MRJ?EJ]-O\]0[K/C%
M-U[T`J=]I`KP`P2```ZU&`*\B0.!-%1`O321V#)^WZGB\_]]%=*/8V`S-UK?
M-21S#=$C@=-]PH-<RB=Y\<,@`Y@W-[<L%>9K0P1X1(=!9!=V71=L`16!4$=K
M-#97!EAO&X6!MN*`&OAYHY5O#N-6UQ<`EB`&+B@&J.""_I!_<;2`%@AG@(<8
M5"%VGD=B**B"955G6%>!*4AY*F)_]R=^!"B$!SB!0^.`T/=<I><['&=]$->$
M;.9\?A<ZR7>%"<<SS?2%B9=G2HB%WF>&J6:%T75A&(=JC*>$9>B#4Q&%RW9'
MH&=[MW>&6YB&S(=\37AU-Y=4N_5*-HB'R$6'9J>'1@=H:FB('YB%9"@02%B"
M_"=U9D&"?2=\8'9_#08C>Q>$`D/_>](W?!!3?3:'AD9GBL*7?Q62)YB8>/:V
M.32(;T3X<(&'?RB(%:^89T17?998BXB';'989<AVA9,8486(@`!1B<J'B)O&
M?]Q7/I`5C7[BC,_XBHWHAM=8A'RGB@#W@>+G/Q.7A[;HAUZ8$=[8>>+8C&B8
MCN$X@M"W:UBX7*A8CW%8CP=H?U9XC_BXB/VX9M8H7)!(>G]HAE/T>01IA/\(
M.#9(9GCF.]^7B#4C@E%8-'L5?<QF/'NW>5WH@9&W(0&IC0PI.T?4?+KD<.5(
M;!)(5!Z9D`6F:J5X=`HRAL:T1YY&4-Q2=9A7=*8V5]05DA_)(?'X99!(4/YS
MAX"SBEIH_TL-"7XB66XY29,E6(^ZA8EW)85-M91%IX-[)HL[TY.!]X@4`HU/
M&7ZY^&39Z))H=Y5:"8R@R!8#>!B[)#_+2#5LN)"*B)=+67D-PY=BZ982J97B
MQX]O^(T*28IM&8EJ)'%Q"(B.^)=Z29C2^!T<)Y<JDV8K:79$D8R0)U:QJ%V!
MR(LTAY"PAHUIF'PZF8J(QXE':74@J)=>J8-I"67YN#-0%'6\4IG!2&B7&%S*
M"",%$`!`&9J:F)EY.)PN&9%=29K#MY*7IWUY"9@9Y'5OB91[Z)2P&9V@J7S[
M*(&_4F/I5I"G!$#;J12NB)R1*9G9*7FA%YE2V126Z9K2R9OE>?]`0*F>YWB`
M3X&3_KB>61>>S'F*V4F7D*F+`;":A(B757B6`=J>84F<VIF42>@I5LF'BS2%
MG_B81;61&2>0[NF:^FB0]'F+O?B@PA22NJF`#^F$N86>#3JBYLB3!3J8_EFC
M[&FC>0F!."J?.]JC\^FC0-J*HWA=66E&M/>9)CF0,^>@S3=F0DA'R5B+-)*.
MP^2#0QHY>9*:T[FD8P@K1^JAV%EA81HP!)J)8(J.45J79,JD9XJ.$D2CB=F?
M:#J.=8FD^9FF\80SFQF?I<>G>0JAV66=FK.+QJ:,3-AFQ3A+5S22?>F=@:EO
M:FI55MB:/(J124IU?_=,;DJ/DGI&"VC_G&TY9_IWFDQ"J'/*B5/YEAD&E\E9
MJ5MEHO49I#$:H8]8=;C(G<\9>OAYG?=64)@IH+'ZHIJ$ITX8A)PZJ[)HJJUH
MFW<XG*`JJW%ZJ;Q)K!<ZCYXSE/BXJN+)JXS'GS7:,"Y*J8<IK0#IHF-*KC5*
MEL5WJY':$U%XC%NCHJ-Z(E"XI(CHIS^*FOH*3_`J'AT)E\")D,B90/5J07$I
MK"A2+;I(),Y8*OCGB58CK@E+A]1JJ6@1D+_*JI^RKO_JIK#*KM%JL8!:I.T)
MKT?)L:E*$`5[?>?Y8'(YB?U:>X2*?3THL2J;:@'[L(G)$]X:L\.Z(MBG1P0K
MD2\;L(9)%3#K_[,)BV?,B(Q(:YD*:UIU6JU*BXPT>Z<O6Q95N[$-HK`IJ34K
M"ZM9J:)H.K*R.7L,J:S/52VE$K/82J\8!;40ZHE)\557FJY^9;0(NHS(B9[F
MNK=-18=DRY1PNYR+I!5V.ZS6:+0U6+&6"J5Q"ZV$"[@BRZ7/R*T=:YY%:C^"
M&Y,=.8?_X+5Q6PUQ9K,Q>Q1Z2[)5R4<VRW3ZZK,@ZZY9>K/41[*V"YR(Z`H-
M&WU0ZXR(@:](*[M_TZ^)>ZL5J;MM$:+F.KN)R[NUE+IERTXV*XE%Z[Q\IK?(
M&[WDT[SU][36:SKHF:$\>;5="[QC:;YH6[[/"[0%HKZJ:2#N2[L=:_\RT+NY
MGDN-6RNV=>NX&AN]L0NP0BJCE;N_@4NWU[>LMDNOB^N*`DN(?WN[!UN-"]RN
M@^:V$;RP"5RW?&MG=MNV&ZNXZZ2T^<NR[JJIMSO`YUJMWYNVNG.>W(NE9+G!
MI3C"\EO"NIN_HMMI53F)L4O#39O`.:S"5#N<00RP=PNR;)NLSF=_$XQT.=RY
M-6S$]^K"3BRZ"VRJN"NA),QFJPO`$LS`+!N201R0ZVC$&8RF47JR'NO%5T'%
M@:N+5AF.IEFX7BS!9\S"U?C&9QRUF=N_<(R^6MS'>-R,-)RLI`NL][O%B"S(
M,NS`"JS$B2R[@'S`9FQ)1EF_VGN*%[R_#TS_QG&\M*L9M5H:R'`,M(M;P!`"
MQ7I\QWK3KX-[B!79R(H[P?)(NP_,JD6\QB>:.:<,PA/K,*JLLA8\;L>XF0(9
MNJ#\L[49Q<)+N:A<FSY;R+R,HA"'S&64O\:K(<OK"=%,L9><M7GZP^!\B4DL
MQ"3[13.\I94(I2)\GSIKOSK<Q5T(LM[YL%FL80MQQ=>+B>-,H5Y+O!G"P_:<
MNY\+H/);L5&9SO-<@`HLST0YE[P;OQ`]P6),S+G<C1W\,Z(\O%:\R:29SQE=
MA%X+G^_JO>HHT8;*R"-+P#"*H'?ILNMXR[?SQ'TJTP$<R3>*TQ\M,R\\HEU,
MF#;=RO>\R"3,E1@]_\GENL+QC-*3"<Q#/;<NJI/'!\KXN:N:*+D[JJ,M/85$
MO=6/BHK_2\G5J:3M.*`I:[!(K<MJ?2+"6<J/NU`#.Y+.?*%M_-2:LKRF#,D?
M8M?'#,8QF:%H=[)^FJAEIL;0F<S3^]8?_,K3R,ALJ=.32L%WS<%94]'.*Z^.
M6BNC6,A;R-<CF%4MJ]C\IEU9S+EPM</!>X1&F;R87*#_^K<]0\VU2Z%Y?;1K
MS<$D*-@H3'I![<?+S,PS^MICZ]HT'-;-+,@9Z]`]6*I,#5SY[,^LO-O_^=KW
M6H>,+9HFXMDLN<(A&B$U,L+\.]:HFI\J?=S8?(\E_6>W3+$YO4M=BZRERO^.
M8TG*=8S5VZK(G9R,O>W+)>S,/<W2J/+>6/C?&@S<Y'S98IU2^RU+-RN^">ZI
MS5V=8`'>S3R'"-ZMT:W([2O@N+G!!!K7Q!N?]VG@[2W:OIW,I(JT;5W>&@NZ
M.NVTXAOA#I71@^+*':G<\?R]LWNAP:F.__C21XW`DUO6<]W418[!=@R0NMRW
M"\G97,N=+X[1)Z[,]GFY.'O;W;KC4D[?7JGB>?S*-QW*V^S!:XRRDHSB&9[+
MZ2V-U<WB?[Q]1E[@27W"4:[4TNVA;>ODORS9=Q[&=,SF[`WF2<[23J[G<OW,
M0O[@"JUI(]P73,SA/(XBPKG?IKO@_5V&D([A?YW_C[X+TVH[Y(;^R'UZX4KN
MO^8\YYQ>9I"7V!]<VS%\TF9HV8Y<F!E>KD!9QN=[OY3^P!8NU^%K<S+>JW(>
MUW0<ZL-^Z]NWVFM*Q*%+[+3=R,@N0GE>YTD)KIE.N;MKYW+>WR9]ZK"VUM<^
MZE0MZ@=]Y]<:S!B1V#N\XGZ]2)0ZQ>Q]X_R+VMQ^ZGD>TE.NX6N.Z_`LS-9;
MXT@>T:O<KA@;R:VIMZS.M]J-[YE[P^X+\-MN\/L.O/<>X03^YJ1>[^3>OUO[
MQ)-\C,4WQDS;[S#,\-#^Q0//O:\NQ"+OTIP<N.Q>WQ$=[R3^XA?=T0[\S<%>
M[MK.W=Y\YFC<\W=\\_1N_]Z(KO`#?^BRK/#-_O,+3?07/_15:[*07LZ#3/4`
M/C`>K^@"G\EAOO30WN:#C/1ION-)&_4#;,\`'N(=>]$'G>UI"WTKKM$F795S
M?Z9SC[M3O+!D:_?AO?9'7\D96KP*^/?LN^EVN^+9"\D\?O>XIK[R2A".3]_%
M*_G='IP'JO1(3N/";-/BV,$A3_,-WN-GSK.J&\$.S<=]'JEG/^C+*)Q&+?EI
MG<B0W_@VZ/9:>_G/++3NWNR!'^;56\/!2:56']Y6G[G_W;`[K/="+\E[_[N&
M+-FE3;`QW.[@K:YQN?/6.\9DWN!?+.(>[N^KK^:KO/)_C+[:S<FA7_[&/\P#
MU?^W[Q[V\/_\N37Y)([[NL[L"9_^+P\($0\1$04%A(B&B8>"B(Z/C(:,A(J.
MDHN/F9J7FH6<G04!D9.?DZ"6F8J#E9Z?E*:OL:FCB["=E):VI+NNH*:LLIZ-
ME<"^K[JDN:>$@\*XL\'%RH*KMYBRK-*0R9"B@IR]S\S!A=#8DL"VF[#9H]K2
MO^;IX<OBP[OWULRKO-OYB?H@H?(735N]7JJ$\5-GS!HQ=^@"QB/HS-D\1`L!
MROM%[UJJ6NLX,B3WT*.KCK>X53PYLN#`E?-:EKO6#F0NF2_3W;29<MI,<2P-
MNHSFLY5#CB8A[NR94V5$GNL\_GS(3BA,DTO)126:5.3_4:8PD7ZU5_-848E%
M^T']R+-DJW8RQ4Y5:]:A3[=U*]+D5?92I57>!,9:*)?66G^$\<6*.?:MXIF,
M-?%K]#8IKF9/MSHV;/$0X*JY$DO-&[$90<)2#UWZW!C=8[PH]6;NF[4A:;JU
M&#VH]J\R2:.4`J><)*K4P,B[,4X^5M;B/:L)76M\%MFV=*Y_"P7&[/EJ\]3"
MIT=GJ;$4].[75V):?A;@=U\!J.E3*3M3DOL%DMB&_#C"??NAM`1,$N_-$H`W
MIDG4GSJ9F=,63MJA-U%6Q>A7'H(!W99A@/+EAXB%VS#RGU:O8*A972<9R!"!
M(%KF2(N*Q!927O[-<A%%X%A5_V*''=I"H(@>DF,AAYW<9V1;X^B%WW:IZ#?B
M4)L$)TIR\!0VDCOS`86E1,+)=9>7B81W8X8AR@@<F988.6*+_+7$YHOX9;-.
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MM&^D+OUL2,BR`BG2'*-+8Z\9QTP5IH^@/%^CDWC:M("ZY>:BL-BV_%MKA5;<
M"L,_/2E@2%OZ^]]_7AL-I3YYDS@;?2`CT^7+2L=ELU&CZCV7R:@*-3&.3EMM
M=)6^J@Q/E%SCJQ18P68K,C(/4YOQ63]&A.BP6X_EL%TB`9SZZ#`3ZZ^^YB1H
MKH*''<UTEMGZA:5YPQ0=XGY.U:8>T:+CC&+,E.D%W+I7\<[_^9<R=ZW5HFGC
M7(RXPP^F/%P,TJ43CH.^7NS2-\:&4%5>9J-?<DS'6*:&LG"G,+/C9\)PP@QV
M'S)EI=D=R8#WM0V1CV;;"U_$$N<YYV7O1(`;$[!JPSRI%`=3?P/=I8K5N'2Q
MSW-!R5SO`(:C<C'001WA#8V@]QS2.((]TJ$2,EX3)=3\K(71ZU'*0.,?N63$
M:2$4DM)&5I?]O>YRQOO)_BKE(K@)8PX=,<5D?GB^V>FO%%%K7E@P4A<96JP`
M<W`B$DVV.*Z53575H<>ZC,@*-H;(C;P)H]#&)T&\U$*,9;N>^#IG%1G638H#
MK-(9HZ8.%M;/6=DX4`$WR$@N/B\M_S*C'`S-Z$@%S@2&EI)?\"@!AD6"Q':@
M<9W`_D2]AKUH6/MP#"&,J!W%U>YK3YF20FSW@%]%`(]1\@LH.BF>>SAI'+HD
M!_PZ5YEUQ>9FK!#-<1"6RK_PBWVT:TIVT$@LSZBP7E',D?465HX/&I`LNO`?
M*,?UE00)LC_`O!]T@@-+8U#I2[#<TR6?N)I6XF)_`*06)FF""AMNPYR(P%!"
M@+G)`O`2>800:/_>:0CX(:Q?L_H(#P_!2G96]%DHZ^-*XG.S3"@3,@LD!N$8
M`0;P"<*)/NO3@0:A2(4,4'NZ606(`B`'B[G4>42DD&:,-(EJ@`:*6<0<(<!0
M4@!"#!50E/_:D&!ANU5^DI.WS.$,`=6G`FT1&N]L1)?(B8L\5J^J?P0K"1M"
M0$@^-&N\L-!RNM,0(U$)0[_\T,RLV4.,E4.F!/7$'-8JK$ZQ***F^1A3+]E4
M6$TM=,GQ%)74](@ZY>=]XJ#B+?&9*7=%U!XLK9Y#HQJ+J2UG$'$J`&O>ES?\
M^,2N`&W&R^ZS&]#V0Q&0HESSLN,?1=5(K2!UE7)<L5<KE@=3D@+MJQ)DPV;<
M(2,`19%\"NLJ7E5(;G^"A=SL<T-$QHZ'"*6:&=6)W1.2D2#%Z9_:J@HT;G@F
M!0_8@Q;6ZUIJH/>N^P#M`U*PWCNL5PN[>2\BM+`'];9V'/QX`'__[ZN%.H%H
M-P2^;RU]9%_\\@;!][W3?-'[W^.NM[_J=;`C^JL%"H,R+Q9V<(?QJX@4O/<I
MK1V$:5+<O!2S&%003N\>-C'?`JOWQ+OQT&[VT.#;K,;!"$Y.D%N+W_C6]TY:
M,.J!Z+2'UEKX`7@;)C,ZW`P$<_B^E!!P@F^\XAUWN,E%SI,UU5``-42UQ@T.
M<W+2#.1XW8G-4$[@"Q^@!C5XT7KOZZ^67;LRRF28O_"K,7'3JP4CSC>]=\AP
MEPEM8RHWX@%O3C1[I\C>T/QW,)!NL(`#25N":-.!U2$+T+`Y'CD'2Y3S4Y`W
M:(L2@PP453^(]0\"<(7XS#@)!ZIUDW-L_X-:"S@)5\C/%:X0:S(?*`#]!?9]
M?E#F`ES!!@4H\)3W<(4W6!O:?]8"L&M=9T.H0<_CB(^V;5!L_$+V"DFHLQJ(
M_8,ZZUH+SJXUP6(=`#44&-?L5O>WU]M#94!9V48R=@'Z&XIAV]D9M3Q0NZ<<
M;QYHV=FQ#E"9DXQK43#[V]\VL<]RC6XRQU3`:OB!M=^`[@B$F1Q[`/8;Q/`&
M9/-W#P$*P*P#Q..*WV?85\AX"D)1JOZJP08K?\/`.1SR'UR!&H-@=[237&M9
MSUK<M(ZXL(M3[_ONX0=`MW;.36[.2:1`#340P0`P(-J$T_KF5_!OO--=<6^_
M?#?K#OK1.ZR*CO]>H0$B:(`-^&V-.R1!Y&]`@`V2H-Z4+HZ^2<CZ&WJ=X:('
M6[ZU;/>L!?%UH+/<!O7>0PKV0&N#%QUL]*7V?=1-[X-'H-Z33Y#,95[V':O\
MVL%N,@?1%DV<[NO4$*H)ASI*:F+F%!3(6A4\A;H>EXI6#0W(0`EP@(,2+/\-
M_!7#`)P_`.BO-P`#R``.]OX&'"A_^<QG@/-QT(#^UH#YS7=^"3*0@0E4N@#2
MST`=YJ]]$8C!WEKH/OC'/X`&W)_"N'8':H`!Z=<`]G9<#S`!ZM=\Z-=\&5!^
M>W!^ZC>!&8`!`H9]$TA]#?`&]M94C-!]#>A\[-<`\]5]&3``>Q=G^I'_?]/'
M`&_06GM`@"4P``%P`7N0?.`G?B6``!>`?.G'?PU0`TMG<MC'?LRW?@,@6M3P
M!B)0`O-7!QG``!B0@OE`9S]0`]E7!V50!S.(`=]6`^.W?.M7`_1U?N@'A"]8
M"+MQ!U=P?D_(A0,@!NJ%`$CX`_BU<PVP?ABP!Q=@`PR@?$>X?'66?8!XA`[(
M`#9P`5IP!02HA?1'?@6@7PBG!0B0`0"0`6^@>3^0?2$X`#]P`7.P!=KW@]2W
M=_P5`%@H?X]8`TVF8Y*!?&4``)Y(7Y3U##:``0SPA">(`-\&"N]3`&_0`-Y'
M?S,HAYNH?09XAQA8`@T0;6K`A*H(A3.8B6_P_X<+>(3*)P+V9H:!R(`(H%XV
MD'XH2%^)9@/9-XV-]P99J(L#@``ZE%VN]%7[A#FO,1)KU26>-#O;XTK^TE(E
MDVK_TS``4TL,\`$:````\`$`4`<U<`$7@``)^0$?,`!JX)`%4`(*^08/&8L(
M&9$="0`,T%\8X)$?"0`8<%]7,``>N841F0%[=P$UL)(1^0%U@`#T10B)]@89
M()$TF8@%=@<CJ9`(*9$=.9%\V``\^9$2V0!:<`$!@)$(R9$260?-B%ZR4@-U
M0)1%:90/"0!$4`?61RM:(`99"0`;H(C\!0<:\`$9\(E[(`(S&94-N0<#0)2Q
MF)0NJ'DI<`4X,)1#"?\!GYAD-6")"CE_"0D`3%ED$6&.AVF8$ID!WP8"9<"3
M1-D`#@D"APD`+"F1$`!]@W`'ZMB8=1"1%`F3C_D#Z*4%:J"27/D#ECB390"9
M:K"3F:F4=?");U`"'3E_=UD'>X<G+Z0%/\``&E`&#>F0-J";)%D"G[B:0JF4
M9:"1%[")=[F0+6F'CG4(0#9EJWF0)(A>*/4?`2`"DTF5#5">-NF!27"!#9"5
MA3E_$CD`_567-"F=#Q"4`,"#*8"5[SF:2[D'")"5=ZF5"5D"%1F3S_F<&."0
M;^"1)ZF(R!>1T=EA`^B>6ZB%\:EY-J0^F?-59N-"9V,\&<04V020T<,)!T+_
M"N$5(ENU%](!#('QC%B(D%3)@0Z)`%)IG$VI!@4)`)_X`PT``E@XFB#9`$9Z
MG#%YB4$*`DS:`($9@X=9`G30;L&XD(D(DPCY@`@PI/%I;S@)I9JID`V9`O9U
M!7G7`'`PFF7``$PJ`CQX`4AYB7!0`TP*`AOHD`'0EP!0`C40=ADPF67@A2GP
M2?Q9!OT7A'8JG3C*EH'Y"OE'FV=Y7PV`D`Q0D=-9`Q5`HQM8D3>(D#C`I'!0
M`G?)`*C9@V\`A@C)IYG(H*_Y@&]PA;JYH.\5'ZHQJ0K)`%,:C%OXHPC0G@H)
M![SHD$E:`B"PI2J9D"*@7BDG`E/9CB*GDCAPH`D)_YD7`'*L*9\V>*H,4*`@
MD(E[8*<UD(=9"@=VFHS,^@%26F=7.']NR50W.)FEZ9!JL*7;NJ<(L*HI$*</
MV*='RJGXR0`U\*Q;6)%\-V>$T)0_``$?@`.?&$9PQ)<?8)P.29\-0%\>US7Y
M!Y75MP<AUY[8^@,:RX=Y^JM\Z)H*67WJ.@!4V8-'FGRIV@`8$(0I@*5R:J?E
M*IT_P)$`@`,U>`$0&XO1R:!EZ8DI:Z@:*B6ZTUV:@A3-PG/G@`VAXQZ*Q!IB
MQAG-L@TI&E!S)0D7I!V.DAZFHQ+^F`T\(%HS2[/4ZI`;:9V7V)PX$+'2J;8F
M"P!QJ[8(R@!GJ[9R6Y:5JO^W%[`!+/"),#F9:4N7TQJ)*K::"TFDI7F'9ZL&
M;UL'9^FW01FM?JNV!5"O;]J#QPJ6BKA@UL2?:7NY$,FH%Y`"265R.KF0GTA?
M6C"I>VJI#DD'J2J[^2J1<*"V<X`!9;"6<%"19PL'"FF9:JNX]:FWR*>?8<0(
M^<>WLCN=3JJV&T"D@BNLL1B2#KD'RHF]^:>I?"B]7MB5Z$JPJLF:<#`'I^N0
M09F[EPNG"#D`>=N#[LF^Q<N+@ZH(<*-MD2NXZ'6VQSH`>JL%('"R[7L!J_L!
M%?"\-F"`\HH``^!].#``-:`&861BG0H`-5!H454`/!``ZWD%M`D"$RN1QVEF
MGV#_7[!+MWXK<NAKF@N9B;9JH#>:D+>YPF\0OWNPK1]PG&J;`D&)O>V;LWZ)
MI$3ZPL)*P]7KD#]@D]6J/;0R(V>2M>V1+Q"50\>63GW6%"ARQ0#Y::>GM;]"
M2N1!1#D2QAS286@KNUI0`['(A0AIF7OPMBJLMR`KD4E\F9[ZO'E;`PJ)B>T[
M!V?+QFPINTA)DVJ`NH)@`SM)E1CIN29F8O(:N9.KMJ\KD9;;P\7;HYL[G7WY
M`7!0>`#Q`&1INNU;NFUYNN4P!X]*DU=PNO0%NS*LMK0;NSU<R/1K@ZS)G.E[
M`11+QX3YR0YYMI",NJP0E))[N9`LM`F9Q$$)P&I[K#C`_X<WJ)"Z[+<MC*`R
M3*'FB[YG:ZO$>[FPZ\Q[2\UW',Q)I1O-RY4.Z[_OJ[??JI#)VKX(>LS6/+/(
M5\01:9,.:\!969IAXL&J::MM^0992:K!?+]@M(:OVY$,[+>/J[&Y*:9VFY"!
M^KSM&\<)R<,3_0%]&\0T^L8V6)"&Z;D7@)F:&;[(/$YRI4&K0\9ILSX0X1IB
M$ADP+9#Y8E:&83\)]3)A>Q31\AE4VPL=EJ1I6X;OBP"2S*,9Z9"`/)T8^0'2
M"<E@"I(#P`!679IO>:N6.@?J!HJ!3+AN.9Q+^0#5BE[-/,V(Z9`/4,$]N,B3
M^\B5O)`,4-56W8P6*<>;#*<2*?_#H4'0MVJD+,`"T?N067G*U2!@?ET'K6QB
M6L"LM#RS^TG-P(M>A0R_>KNH09N]=8F8>0N1"!G5@`S9)\8,SKFPD_W(HLW/
MRTS)(PF2;NG7:<VY!,S43;W1V8RZYGO0"_T!WXS:%XRMQ;O9"SF#-;`!6\T<
MZ06[;PHW-4:?SFS!<5H'<("F<,`"/$B7DAW,\Z6W`ET#U@8"?'JZA_!U=7G*
MYUPJ)J>XFKF%(*"NKVK"/97.-,H`#8``/_"]9TO0BYN0'6W`"DNC_6??9QO:
M/=C)QXFZ)N;95&W5]&VI&Y"J*HN)#7J"HTG2^IVE_3>EVNTRD2`V8<((6X43
M/P0/R%+_XCH11`@1&"'^-_X##`D'XCR]XBMS+%OB._Y8#EK0VG4PV6N<D"`0
M@?RMCDL-BNCKF@D9U3O&NS,ID1H``14)N2=;L@TP`%0^W8(KR(8ZY:TJN!2*
MU^++UV"DRC\@R>;,7W$ZE!))!*=\`07@Y;N<I#O>Q*M!EFAND`KYIH)\RJ/]
MJ`NYV.L%R^3[`'R\LQ4)R&IPKMA*7P9,FU%MN)P]T:S[N:C+W`MVL*4-Q(.Z
M2I/.SQ*9B(RMX_V7?650!I>LU`#`OO,%18*@B-A,L(/*FL1KP7#)VY`=1@*&
MUHD>1O+]G&NZ`4?;"NFUV8*+3_S%F@S@D!=VYI1)!!4PLYM=_YJ/3&3&V]\<
MJW$F5\F>"[J4(9S'FI#8&J"R^`-^E-Z^6N=E\+N[K-Y3^:8S^P"VZI<+R<"V
M7N`93=M&O>2<*;@_\+Y"+GX`T*V++)VP2)0\^8`5*65M`J*64UWED3IE'!RM
M,WSX$TFJT;4"I$K+`^,4'U`6WX^\,+8Q315@&N<=MI\):9FS&;'B![>GFU^K
M.\>('*&:&>J'BKZFCJT;,)D\60:3FZ1USM'\:V+Z?<IU7`8\R`_"V9?TS##)
M79B'.@`5T-YXJJ<97&B;!^?`.TO@OJ=S70%S?>5@W?*>P.>*?;I_7KMH*>@*
M:;EPA^A\J.@ZN=06>ZP5B^SS')B[<?]1S)L$SOWVK+3/?OT!GKY>K;WDAEJ]
MILZ^#JL(Z]7JBKASL*[6Q7[R,^NPMQZGV-H,ZU6-1'J0>XWWVE%34%[#)I94
MB7:LQUZM9N[T=`VPI_OL?*AA@G#V[XL!K_J]*9;C$GV_"+('X9BJBTP'8)>0
M"2S><E`IX@9VN5B2LLC-ZZ7(0EGWZ"6O-<``.GN8Y8?(7V?@3$T-<,X`<!#^
MTVVI0DR1#;J6MUG')-V#U8_/44YAT^&/*=JBFZ&B^\A.QT#_#]+QB00($8(!
M!84%@H:(A1&)@X2"D(N,DI.-AI>+F`&/BI"3GXR<H*.,E7LU```9:A=:*0\U
M90!P%Q=O=:G_N6^M#P\I-AD?`+LI<Q$/:@T`'PQ[M<^U>PW"):P_#0TXRV4;
MM36X97!P&<L#SJTI6G"I=0UO#>0`YA=SA0\_.!]UW?3'TL(,6$%[%D`;``07
M4J3[Q\Q9BD^^Q-3YD.%'K11[YJ3PMJQB0BV0M+R)=Z65%BW*`.!@=?)4JE4F
MU8CX\&'>QE-E]%F,-D!8@XWIWN0\6`NDH`>+'D"Z(Y/FRH2>)CVPA0N`C8]:
M,+P$`4<6`!'G+JCI":!9PGK'(IQ$19'5Q@(#EOV\\$#+GK@?&CA[8"S"GF3"
MYBD]%DW-FQHB<`FKH1!2`#G(\M5Q:^S0R;AEB]J=-NM<L9N</;Z"_U3WPH\!
MLF@"_*&EUX,[=S`L/EM)J3)F:O`!9+"LQEY$CS9>V//C\("J^T:WXEQGYRM?
MT8IC8."U8C&U:K1]J%%+:2]4\@0.-+ULI9H2-,VI"59F%[2_AZFS^Z%0*250
MF`YUJJ0_48%-^B'BB23Y11)@*9T40DB`]U&227\.0G@)@`8.V,@D`2CBGX68
M[(??@1H*&-4@AJCADBHLI</6/!>0I4LKQ_P2S#`)'?)`$K<Q,-XS""Q3!T+/
MO-&1>PA,!%-*`.@5TXRYI"+,9'0)HL45P=3AGG?2I&+60&\9!.1PM]`$0BT5
MIE#D!]7L>`%;,/%25PHC">/>23.IQ))=X/^E>=)8Z86E&YKBW>63%JV8%L\\
M1JE1P!ND%9`$GCX"N8<O$?!@(U6I6*105N4XDU(=W"5T"DW-P3B'%FI<H886
M;(HWEER;8B2"7,YHT1=3*2'*5R'CG9D7F0H6$)E.M?15UQ[YR*/9/TFJR18`
MH>[AUST"J8%``PPHEM=42K6F%;1GS5%/AGS.4LL/)>1"D4721F`,&$KQ(-XS
M($0:I8HYI9E0"@7\,.]P*95!WRM:)*%=J(-%H%5-80WT0[[.P"$,0FI,U%Y"
M)@[T:J90(8B?*,#U5Z&&EXBXWW\@6A()ARA#.#+*41'(((,+4FCR@"!70N*(
M_RW(W\OW>1AT*/__J6$B>#"=Q&JGY\8C9\>_3$3C0X>HL;"^>_PEW`\S,K"3
M+1WMU*I8O'U0AJ2Q"(,##G64D.YLKYQ*I3Y7JL5L">QFG36ANH%*J+7:>73!
M@,?DZ5POKJRY#-[#&6VT%NCZ)%QV3-MU8II[;"8,'*P0A]IBA&Y4KI+1W`9J
MYX8-T$!=`IX4)P!X._,7!@.P-M4MJ;C7"GCSJ%&VE4$.57NM:M30`"MA_GC.
M&^A],"9=F]'*BR!_Y5IK+V\,X!LTYWV@`<(]8\<`L?S.X=I=J0Q05-:R*8L.
M-,#0Y/7>Q0_`2J"G+5,!*XRDD`P`/TH(7S[!IW6=*UU,\U\!^O*0!M1N_R!A
M$HT_>H0FY_#+@?2!1MI*E8X4&*PW13G*M^P7C3T0S#032=,/:H``9_Q`:MU(
M`08;]@VSL0(I(R(9:4(QLIAM@A,7BE#*9I9#!0$Q0I'(&1)Y!B"7K<Q`#0K0
M)F(6+,<0T3X>XEG0%D&(:_$&`&5H``)V0D$69>E%#XF`C)9!#+3LX5MU@`,(
M&B`.=]PD;6BJP0^NX2.Q+4X@7*.)1]!7$W\9[31J^PWDJN0><9UD&OI0'3;@
M,(`-N!`]*L%&!123`2#QI3(V8M-.C**6->6D#`R8I`,1L)%Z`5",",`+C<`$
M`LRTHP:[8%8&&L`5<OCD'-:"1RI*($9`OBT<-?\P7C`:`!5)1(\:#4@F:@0F
MDAI@1AYZY`AN:H&[L@CDC+"+IC7M)):>Z`,$AWE;J<1BO+=E``0(4$,:-<<P
MDX@D%7#`97'PPC@MW*$`EE(+2E*!$%O91YG"R``+6<(9]:'C.</!P%"(*4TP
MLD)U_AJ.Q#X`!V<(PG\]X:!])/&LX45NF&_8"%J.\H">[!(!;RC.^.0QAXZY
MQ(#TZ,4T=OF&-]@``9A44CJFY$OP?<='JH,#-MS!MWS]"X5FXT=/B.E3&]0@
MJ!YED(62T""6<6B*2IFBT(0VLZ$9T8H]?%`/=49%4=@,B5U%*Q1-YA\0O0R*
M0W044L8G#">!ZP(4G$O_+7RWC*E]-'X?:*,@_K<,U=`D2<)Y8S`>6X>J,$YQ
M;7D&'LTCM2_5@H(74TH*`GFV[OB"(8YM[%S0Y:349L`]S^G$`Q"0$Y&2AE6I
M<:P&:C)8O&B@M>T@%%U<U%API6`=K7WL+L432+,Y26!!>IMJ`*`!4#7S$<Y(
M1FY;FZ;;J.M7F"5A+9`D7IE,5K?B9=YC@1LJTPS%KV6X2K?4(#%Y7.\!;X#`
M=+55@BO=06<BF0A8H#*'./65)A#824,=,M*I6&TBCG4**V::`;>%#2M[L,%$
M;`)*R\`E)_HH`2XJO(T:R!,I`;J-,+RR&M,B8V&B$=8#,+#;%8.X)@)Y4T%`
M_W@=I;`EPM[#0"TV\,?QD)8?*@9C<<6;,)G9U4%9M(2$;F8A+>;U$/DI65I)
M$2(J9MFN7F[0$<6<1*UZF4-G+@"J&E`"!@S@S0Q@@'O>L#8@;2I[)7A@,31R
M!1&L35/B\K&;!Q!G-\>9E0D!$YLA`($Z9&``Z!0(GL4K%A`4VJ>$/MY%-G*-
M0X_F@C@8P%7H8KX(U"#4`\#!H%6-Z&08>M#1_)I"ZI$(_*8:#@40H(!L7>@X
M$QH'7W)U!AC]Z#=X)@6G[G6HKW(*7_LZUL*M10&P->@!E$`$;CE7+3-0V1+`
MX0TL.0;,_O8.$3L:!^[X[-K>3&@&`"E[.*A!30?KP/]E/V,/>*YL!E+Y-=-D
M(P-E:!L<?A"6L;1YT&[.]5`+D.SMM089-8!#"1H=<`:`X'#_K83_QN<1D-0C
M&]5.)4L:'CI:2PE,`^#VN=-MBY1#H`QE(*9S]L294%$M*74I``9PP.TR['*/
MU!Y`2F]^C!5*O-&,UIY`'N*:-\19T\;PQ0]J:6Y'5\#$%T$<CN+<1F%%():]
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M,;Z@$([C+PVC%'=@'W)0`!O!%E!W*K)7%$!Q$98C'+1F".&7?D:C>^2W?^(Q
M5/@6#&V"8I0068<T+['W)BBF1A<!@M/G';U@-,G7#R[8./LW?95A-UFC4J70
M$K"'$35(>C6(%KZ`*L@P$-&'@-`06T&D17CG57]'-%UF=QWB=U.H94\F1(*7
MA:*P_T6+5S*(QW<JDU9F10F#@7[D=WWK9PSS1G[B8AD#\7D?I2;%$FB)HR;4
MAWY[:(?%)RXWN&GUL(&CL0C1MB,:H88#H30F>'R'&%N3<"IV:(&*N&E[5HGO
MYX</]TD[0GVEH8<CE0F<AXF9.!YL^`R!]HEW.%2@6("5Z(FDF$8QPGK'P!>D
MV!K&D'$%T(!J$3EEP!V7V(FG>!$_4Q=Y.(F@J`5PX1,7D8$[Y('(.!J>H(KC
MX1H)PX>#83Z'R"5]81FHMWEJ08JEV(S&\HC#R"77@2!.9H87$GF"5X:'QX4>
M\V5+-`I7.'@D@WA@-E<M,T1Z1W<$(H55N&NQ5WF?9XP%*?\'J?APG]<7=M$:
M>]:`1VB,0T5]#>D:0%%R=(B0MQ=U\F>1[A*'1_B'@(@XN'@)KKB'N*@1>!@K
MZ2!0_`$BVOAPG["#KEA\ST$U*JDTMG*0;[*'O3!KE1>`K0$)GT=]=O$9GR=C
MX5<?A4@@&=(+B;B''3F5/>E(MN>3M5B5YD.5];%KU]=!#=F0GJ@T=5>`M6@?
MXB(<L*@4YG,'20!$)A(Y5C)K'.F)KD&2/],7X6A[0NDNU-=_O<`(RJ`!XM5A
M*W,L36F+'?22:7$4LWAZ>^8:BU`?N)>!=?$FDKF4^G$LQ;!`@'@4KH"+%CF3
MKO!)*S6*`8@XW]B0X;,SG<!548C_CU"9(61EC^U(=R?C,[A)"KG)91[S5C+C
MF_ZQ(&%H=R<#AF&X15%1#X!8CEC4C8\9AVAX#"8WC2S%"-29%(\I"(#8"%))
M&JX!F>(6`-0)"9]Y?(.)">.9G=J9FNU9"EA4CVD)$?99B]9Y((,YF/G9@)9A
M4(P0GH?`EX,Q&(;PG<>@!BQY(;[`G[U`C]W9E;NR0`LDC=.X@._9G,XYH-Z1
MBHC9GFX9FHM0:M03>#MD(\7(GSDDFY/0>P@@`@P@;Q;J&GU!H)\@"38I@]DH
MG]XA)?QI`R*`4=/#,_B9%J')4@E3(?;`E\]9(=&9@9TYGI<YA@%"A_:@HJCI
M+MDYH&RU_Y[3V)[;N8[NJ(_W:(]?*(]]5R"/)V4TLYR*]V1DB*:1!U!1)#11
M:8]*6E;,B9UUYS(&&J4Q6:2$(UMTE4/XV3.`.C2]2:1\.H8[1)Y7^JA\=W>4
MN8^6:JA2F*1%)*B8^J@E$Y]/Q'AV%8J0^9N,BJ=1\:=4)*DVHJE(Y*JU-I#)
MF99LF9F[-B)-!H9IT:K<^:A>BA0>F(ZK>JOTN5:J&C.$8Z*.IZ)1M(6[>JB=
M*JN`IZD?(S)DY2!-=)QT!64`&439:H9K^H]7B*AU2E>V67B$LW@V,X_^N%:Z
M.66S.JCNNJ>-MWC#"IR^J7?*:I]R^J[`<:?TJ:B3JHZ/H*SM2O]EN=D?8'4S
M8+:>S2JO8K6M5=:I^KA61#2QP/F$4;9W6]:%7>@@2?"8WTBMF^H(3G2?BSI7
M&U@CVKJG3HJ<>7>J!HJQ6!BS&GMX8?8R!1NMN'EENPEY[2BPDYH)9\J.-#NF
M_XBJX&IE.'-$')NTW'F/=06TUIJR":NP)QN0876Q:4JT61M$E'"F8J8?$3N<
M[&JQ08ME8L6F]]JL-/.O7ZNMR>FM9.NTNMFM6$B%>KN.8@JV\BBJA,=#:-NR
M9KNL0?F5`QL!0&2W'X*W.E2`:WF=A7>P/7L@BUNU2R2W4HNUMZF.]2BUM@FX
M"<*UQQFVG+NH\+JM?NNX`:DS@9>K;[O_MQ>+HFCJJ/]1A7TK1+9KG.&ZIGEW
MM6R;CP\"5T'[K8ZK,WY+I>0ZIL,[D,/KIEB6O&R*N<5K"1%[HS$KO-!K",+I
MN_PHO5CK1**JNVD+H2(BAKK[KEKXM\/IL&5*--%[LU/+,L";NE+FO,V;1+R[
MOGCGMF3:,HD'-,@9DRECG-S[N_F;L_T;9?`:M++:C][[(>T*MKS)NF/6OV9E
MFQ0ROS#CK;S[577K,O-KIM&;K@$04(IKMYI@I_];12E\L@0<ML:K(6]UN=B[
MN<KKPNO*C[CKJ!@"1#QPKCX[MGGU0__ZK,AKMEFVJP<LK@H[N0K[P5#TA4*,
M5Z%KN3F\K@O[_[R,MZL_!(8U?,76"H_P>V7VVR'H6V;)N[8CG+\RK)P`%;K=
MZ[E9.\,3`I5ZJD/8*L6E@*B.<%<Q'+Z]>L<F>S+A:A\S7`D+6[8B7+AJ&C.6
MLL0?(\9P2[_TR+<7'`I*-*Z/_""4K,G^V[Q@:\%!O+V*=[;CJ[^F'"*9V\!?
M'&9\.[L)_,H8+,D_N[>TW+N!NA^9;$1FK*?`+,9U*[8%TLFG"Y6E;,EOJL2]
M;,2U3,#\V,O)C,':NW?2##*7C,.R&\6AS,6#"L"W"QR1C&;9["$^8[T[/+5?
MIJ0VK,G8[,:;"QR/E\N0W,ZUG!_".;9)J[U9=KU-C,M#_&7$W*;[O/_.R)O/
MV!K%CYG-$T+,7KC)!OT?*#RF$;O#&\S%?IR/CL$))^QU?0RA/>/0<I7"5A:_
MFO#.?XO2V;RN]UC#!;S2`SV%Z<S0(:W&!*VW_"PA)RS$_UO(RMS//!VKC#?1
M@8S/"'W3KWG/$T+4^KBXY\K*Q9S45+JV$`W3`LEX$%W4]#P@T]S!,OT(Y!J\
M65B]?PS*Y8S(I^N%(8R^9+W+C(#"6#UE+GS$H(PSQVS`;ZJ_(:.N=QV_`YS1
M%0S0<*O..PO88"VN<(W7)MVT`TS2XS+,)KV[G"M%<LS-Q5S8+AT58/6:$=V.
MF1T)05S)G:W/[[K!H;VUG*S/`.P)'5W65&C_ON8WV6EA,Q>-UVZ]S99KP^8+
MGB^\ST2#UF;-UNK*TSY4MXJ0K:>LUN?;SOTHL,T=O8J]UW4-S=0,TD9MV:N<
MQ!Q,RX\<PV8]N6!]U*N,QLT\9BU<5[T\VF0ZI^K\,QGMWM0<R'/*T@:<KM.+
MQK79IN![RFQ=R7M-O/D-O^[-TCBLA1L,UD"]S)'`5>N[Q&)(W\H+Q6J*SH(\
MWAW,MG/]OA/NX.CKTNLMJN?<WJO=W<:LSM<MO,I<U`*=R56&U3\DQ\*LQ>.L
MLQS-W>;MXA5,(#S``[/]XL;-'S4\X^9<XTV$VUHXS83:T8CLS)P]X7;,VN?Z
MQ;+\SRG\S@_-FS>^_\?+*:Z$D-D-33.!C=0OKL$('L"(@.2W[,[AC>`3LM'^
M3-D*&\3,?<!1;.6X;./+;-F0D`1\SN5X3C)?6,HMZU8OOM'YZ-1B2]<AS>*@
MN\ETK>8;K>#?K;,H.N:*SKU/W=%R&\94K7CT;>=)#2"T+<QQ_.AHQ=9%+M4"
MC>;`C.G';.(2;;.\:0BA[=K0+-'8K,RIKM+^L>-<V]N*O.9^M]1%^[V^#+4E
M'`I(+F5L[L>-Y]U^3*J^.^IYW=``2[ZN[L1^_=9,;;/'#NS:K2"U3ISX7.OC
MV\_CKKHGG=;WJ[A!'+*,`._3+E:M[;NX3KI3&\8Y+=&6<JSN_>WUVM3IGO^^
M/\S-**[LQ2[A!R[2"/_K`OWJ#N[K/=SL"Y^GWOS?TRW?=^[CG1OPDIS0W#V[
M`RW6393/A=?M4JO*&;U$SARH*5T($C^YR%[B>[WL?^?Q&Z[&.]W#..W==EHS
M2JS0H\N_>QWRNYGE+Q_2VQ[@1?WSRXOAXGW#GKX)\-[G@@ONSZU52P[P1+3R
MD>W*1L2X>)S30%,S*BP);W7P:ZS"-=[JK6SV7UO0S]VM2M_Q(R^FKUW;A+[E
M&OVOR/VYV'S@5>O.D3TR.PSL;OSW#6[J@EM73:O8%[OS=KTS]U'RVISQ>XN[
MHEZF]FSOPVW0D_R.C0[Y-`Z%^-&TNVWP8^UX2K__V$/.UZ/[^+;,]-I>O(+.
MYU;/YW#.V(,7UO&,^3*_QQ?]\FG6NH3_\;L_^=AK()!?N(=_WUZL^'V;,S7,
ML(7.WE-HA1T"W(JLMK-9N6'(Y'/LR`1_W&5[P31/W94P[N.?[1*^G`L?MZ/<
M]U_NTTZV^+?M_DTNZ1(,"`4%$801@@4!`8.&BH2'CH./D(6'BY"(C8P!DY>2
MAHN5@H6?B:"9GYVBG)^2E0$\IINHK+2KE:.NL;:-JK.LO8>OLDF)21%)R*F6
MK;>7I8X\LK.AR]6>P=&%B92@H=S=O<ZRF*#?UZK>XM+/S,V^Z>*+S]/PY^&"
MPI2\RXK-[>'?"+&+!,R=_[M?MZ@%3&7.&C6"[8PAFVAIHK&&JI`)2H*HFS98
M'7]=5/;PG+ED#R,\.&91%+Y^$).!D2.GP$1(Q7#UXU@)C$UBX"!I!,>3Y"":
M,-$YY&6(9L:)LI*F`XAO$$=&K:2&HB@J600PI9(90S0VPIQ#+2'B(W23+<]6
MC$Z^C:!H*"6O=`ERXS@2*+5QQ,8R@^EVKE&60]%=Y"K'+%B+<M\&0'9JED:L
M;A&!,?K0JR2N'M&R?3E9\,:;(2<1<]0OTX-@"8-E\O2K(4:7"FLA=#BJ-^Z7
M>@MQ/-7Q'O%YF"[Y1GYPZNS9-EFR+%T8+\)C&PNKI+MII2,YT+.SMB1PV\IM
M0O\);>YX\5#-4<CN)#O[GN6@LY/O%)H#?C*DS;[9LUE@VI#GEED1(+7('-<U
M1=-[!<"BG3[1<5>`4PQ:-!(C8+SV"D0JS<$@6#X=:(AZ:*'CU(0UC>33:=B1
M)0A_-?T4$":+;2B?(#4Q&%U!;5VHR$I`L6:,?BNEEIM^&HT4$CG*J;32B@^@
MYM`B_26Q!UT\`$@6?#R)Z%02=^C'329V'0-=;TE0B5@!8(@X1TZ")(E(>M\-
M\@"1C=CYV5!R`!AD?J/L*2*.27@G2(G8$>;G>)#J1!QM!CT7%"[_&-@;*9%\
M2&E!]@#S(6N95(99@^90V.EOO:$GDI/NQ+>GF7N^5L#_`RG4.J>FPK4EY:DG
M:B%L!'MHX5U>N&JAWT%W[.%LL1X6L$<*>R#Y2:*YRFE3LRNMY*RP?O+3%9G0
MBL*@2F7>8>PM*>1ZHDK.XOJ`&MU`MZ$HQBKKWKG;EKFG%EL2$FVMA*BK10J?
M[$EMF5(:6\B>N*P8WQVX1J"&O.<2LL<#RAIR[(5H4?S`EKJ,_(#!^3K\*[$B
M'QM!F<X*Q`.\L^2G[,$`JZ%2<39NG&ZSPCILITI:G+4(Q^OJ>7++'(?[S<95
M'H+?RTA76RO(Q$X++H)*5RMPL0$#&^.>S\9\B;]$*RJE&OZN)&+#`G.\,2JS
MEEGDR/*1JF6WX#YP+IG&$MSR_V6UCAQPDN$M!PXPNFD2)6VZ';3IXQ&":$MS
MG_HS#GE*$J;,;?18PQ"FG-OPA@U7I)ZZ#39L5P#KJ-^ZIQJPRRY=`+`'H`5V
MGYBN>@"IJW&PK8A<<7IPAKQQNNJLR[-Z`'//D83J9@FB[AX!O(%`#36\<47,
MGOAEU>I7N$X)ZU<$L&<DM;.%?NH__+")RO3@$H'J5PAVZ"#-)O'&!!,0PQM^
ML#X][8%V$\#`!&P@K8Y=(7[>@]T5]$07]$%L*ZNS0?Q0=P4;S&$E',0?`XNE
M!9<<*0FULQ4A>(`ZX.%O=05`F`0Y.`AZO4]XHL@>`QTAI>F]00PU0(`-+H:X
M1>@'=__H<V'Z?J!!G>7.;XOHH`UX<#4.LBX1/(@&50H@Q?)A110L%.$/&I.@
MY26B@\?;DPMA]P,8NDX:(GN=]KKW`S7,K4YWN((%Q#`!!+RA.Q$(8P8M((?U
MP0YUB)SB=H#'NB3LKGJ^H\4>IB<&!;YA9MY!XB%M`+Q;&>,\-A##]KQ'P=B(
MBU2@"E4_."&*1W5B<@%23N(>D9O=<`,:ZPA*IC!R2\?5(B6Y24PX;#"`#)0@
M`\@T9AU*\(8+[`$!.$`F#L1PL#NHH9@XL('#+E(#8Y9@`#:8FR&NT(!DFG,`
M-;B52M10S@R(0'T(4HD-HEF"$N`@FMF\P`/:B8,!?&]/Q*S_PP!^@+`Y:"$`
M&&!`!LH```#4(0/H5*=P3%B`"3#@F`QXP[JV\X9H9@`'"`A<`43P43$4ZPK8
M-"<.&H``VRFI&S\H)C(Q(+Q)Y+$&Q61H&>K`@!K\@!`I4`,"BEF'G2ZS`070
M0DSK><QS_D`+:N@F1&.(D"N0U)S*Q`%!V5G/9-:3`1@()RF(955DEJ`&%KL5
M.Q]JUJ8BLPXUT,(;DHG/.M!4"\249@.@%@$,?'0"'US$&TA:U#+LM*<$G,7(
M,.#6>V)U`&JX9C1IBK#[D?2L%?.K,;&:`;02#"4UB*8(:GJ(*C7@H8XU9@T^
M*%5SE@`"S'0F!CSJ5M5>;!4!&.I"_P%@6(C6@&.$B"H.ZE!8GM8@LN6L)PZ:
M6H,]7``!6.VJ.W$UTF6N5`VY>D!',X#4L\QKL#B`0$,?VH`W.`N:T2T!7)\5
M@!HP@+@ZA:@8+F@OP]0#<ZN2Q^8L]Y8-P?))`SF34K)2BH+@1"MJ,<5@#))*
MG@&G7HHI,"54<H4,?*"A'\@P`"[<S`O4H`P9_L``8@@P!G`883D<0(@!T(!A
M&2.F&B[JAC]0A@9$X&!S4/$'&(#=\]S*!AG`\(4!D`$;.%/'%\:`<^5JX0P0
M=`XI",``0'SAG<ZXR/3S##$&@&$64U=C-=AP0QE`T`NH`0<7KL$%+I`$"U^X
M#C-V*%(?.?\-]+Q!S!\HP0\NP)]&D)/*O&4H$2"@T1*>5LQ6YK"9W2SD#.O9
MF0UP-$']](`KE$##>/Y`'?:\!RY7F;<:QL$;DJ2E/4R@#AIF0%(CH>,98SK#
M&'@NG+O\@;U>X`=N_D`&.LS.)!MT7G[5\$ZI#(&0'DL6#7!UHS^@@1+8\=(:
MV&NNM&#I"[<8TBMVM08P@#0B):JO&\8!=EE1)1$,6<QPO4`*(CWD$--X`\X4
M09S=#8"X?BP2&)@U<8N:87$+ZP<B`'2B-[V'9(NYH?5.@8<;C?`=*UP-)MYP
M'1"PY@>$><<QW!-T-ZR!1$?;N0B8=[NOS4X0.Q2^%QY`Q1Q,&6G_P$,JO021
M-\BQ.%B2+A;(^V6E)*P<`&M%YZMD!<]#!YM@]'PJ+9=&P@IP:0#@@'L-:``&
MCKOF-\RZH4IV)@,:VDRC[6&N76:`<X\Q+Q4#X*QO.&V_]QQ4>8O8N=&*[!O<
MV]`,^%$-SH0#PL^^YPM4.,]XIQ8&Q'Q6"#9@IT9&<87J=`4<-)S'[E))R!%>
MAN::.>)J-G/3&;"]<HJY`79<E\MK:/:&EJ&9*DQ"OC/<V1]LH`;BI;@6$(!J
M7=.Q!B4`0#/5$.2S@Z`&46<IW@ONZ,`WY<8_R+W3N5<#$#3@MT?><&>UYVD6
M1P!ALW-[ANO03*@*M0&_W[I#X=#\!NQ9_PUSGS4Z?^#<Y'=Y`,XE?N45_O7:
MPS5^/^AFO;=6X+2#'PZSUE/`1W%[X'@```(7`#!0A68LMF9[@`%O]GR_AP$-
MD'BDEBCL%&X]Q@IY-%0(5UZ!9W`E\'S@]WS#EVRZ1H)1AP%[MCN@<`=@!P`#
M%5D_T`"P-7P?=F%H-W=!1G'H-V6\U0`;@'<+UU#D!P*_5P/P=GGG-E#.%'(B
MAG=XA68T)H0_\`8F-@`*!X5U\'S`!WQ&=@%6=V%P4$=7*`("53$!412<P@^>
M\PX$L28Z!SF3TPZ<,CEO,6#`,F"7(C93X1*3\DJ1LP@:TA8$4A634$(6!@"Q
MMF:.N&:S=W6ZUO],G:9H*%9P#:5\IZ=/-]9K```'SG4!(+!ASK9F:N!V\,=G
MG1(!D+9A#*!PD*AW>P=9MX9JI2B&;D:+COAU&%``ZI81VZ`%879R#A57V16)
M>[=K6G=A%*=Y:>:(&:AI(?5(GE!IJ$9<#05ZD?<&F]=W:Y9_Y^=ICP:-/K5H
M#=6,C^B`*%B**?`(0<6`F9>.T?=VIJA\JJ9/(S-7FC9KUP8UL#B&XYB.O/=N
MD'AKR@=GZ78!D59YIFAV`6F*W7,P"#,.%_-PN?<!F0>+!=A0\;B,#9B`$"B#
M1)B.BB<PT8@#<%<]@Z`%8CA>WK@'PZB+Z8B)M2:/:Z9X*SEYROB(3*3_<,EW
M85K%D^6X9K2G:=[H82"6`2,ID%RV=[9F=3(8?^S&?;!H9MU#E!LFD^D(@7G6
M88YXA;\H.K91,X'H"U\4):-C<W`X"J.R*3RC#:6R7Y/0"Z?@*B^W#[AQ2W0I
M#5[Q,VWS,L9`,OM`"`>UB*#G+)$%BY&H:T&V8\YE=AU&"#\`CQ'7``DX,FH`
M!]:FCFD6B@^`BF.G%PF(@@SPB%J@F6RE:6HVD.*F;BBX:3;)DOHT+D,2`1$'
M`DTI=D$E+`C`4`^5E<YB=LVH!DV'CHN68?"G,NRQ)R&)3G"FC+,S>)KFE8[X
MC[47C[#8+N;(8H@96:&H!>N(=\235&=V82#0_YW8Y8">-@"[:(\/<`'P(H(@
M@&I.=IFX4G6V>)2P.)``L(0^J7P#\)Q[!H$).8;U9I/5Z2$\))L0MV$=Z4P&
M"'IJ4$?<:)Z0&))Z]BR)F8#O`B_2*7:<^#?O>6<.-9(/.&;#IYWJF)78%5F)
MV2YV(CR3)U#L5Y60F(,,29)5N0$@5@=+^6$.95XN:D<-J8/7V$P_`)Q,&)7R
M"(M0F*%#ZHA3:7Y01I+O,'H$ADHZQT.^-(>F4H?5L"D2$B#W@`EQ>2FIP1P)
MU@GL,`^[T2FG,#%^*2SIDE9"]S!_YU`#P``,L%S0)VNU5@.S9EY-28E[(JA$
M]@-TT%#PEUV9J8-3%_^@3)J`IZBD38$OT?B*ZI8K7%8&O]=0XK8')M::UX2B
MINB=W_DV-J(24+EI;Y"4>T8T8L!0`U"A`(``E7BK]?B,T"B.PG-OWV9VS65V
ML>8N[-::E]DNL`BDNG>3(E*5O#=>?'I/3[>B@#>;(#-)!LA3?'I,<36/J?A,
MLZ9F"#-)P@IQTGB9*J%P8UB??/:LM[:(Z)@"[C=Q9K=7-:"::W9QL,EG=O0L
M-VDA2O.>Q.F@CB@L9R:M?5I/)H>`(%EE)<"G%P5Z@>,(B7*B]%@+''-GFC:2
M^S1>`]```["G68>)#F5/.*!0VN@RM_*J"/=1Z_>=[#:.*5"EF[J%U_BC"!?_
ML2G[365V3:H9:0#`8VJ`:JF(:[R:@!+II`QU=A';IT%9A+RU3#$+B:="2XAX
M8("X)L!1'E<B.6QBA[TQIF/Y16W9EGP(<Z02=*B0"&=J%#!';<$WMW0;?+_U
M&F-*)DB[;$!0`418E.<YBCL64USG3`=C;@VX!T>JM$";:2GGC96:L1$B"_-"
MF@K7+I5ZJZ)J;5BH:[[8H)_H7.S$`",;LNRGJEYQHC*X9JBFJT&U![/*G720
M89S7E,WXDP=ZLX=GE-CJ(P601_2Y9^S6J)7+J$LF)V:Q9@;GHYLJ)R)R`06P
MB!K@;B*VHF=G?!=R8P&@?-1+!.$JBW4`!PW``.(%_P`BL&0K<077*+PI!RT"
M(U?!JV[.2Z_R>K-`UK$<.W&#EY"#=[U660&E:W[MP@AC*@CMJ'R9)R\)RU#T
M]H$WVG`A1@1ZEBL7LQ%[@H*I^!KO\2]B(''>^+$0_`%`4(HFZVHBK)3P>1\G
M$HV81F1EB&T[%GC.^ZSMDH/,FX!%2+TG!E4FMFE%6X5CF(J].9TWZ3"WHG!`
MVKT?T'=`FVU$1E/8>@T%9@UN*P\%#*=5,15:!!";,AQ].`I;;!-9K`\P@6#D
M,0[98"&X5!DE41)SF<;!.(;GIL,A5@)4!1..%+TZ.+=P@`!$.(9PX(PRN(C=
M=\`TUF&:R6(L"56)+%`BJ_]\L:5/&)R2E5"\#J=NQ0L`=-"2FA9-1/:YXI>*
MKZIAO&LG3B*<:P:$`\"2D36KU;L'N5<&QW2.NYJ[!M5I22F>V8L8'^I<'.NN
MF4N+10-%UP>>+HF/8E(3[;B((SBW2TB3['A\2@7)P0<'`X``<V!F30G!GTB$
MT6F\8BB@^F0T#R`&\5NS<D)M%E8&%/>LN%:B>R!O9S=<"8FH*`QQ1'!A-#:-
M)!%E"+QF9O&.F5C-DOJ1P@BRP8=.>&<TK?2QCOF+*Z(2_,IVN2*T`E6Z#-``
MV6RR&2"^43<`((!W]'!`.)5K")>*I"F>VJ(GK`5B9<!VPM*_,DBW1%BJ`+!G
MPPC_47#&GA?`HT2<7711$QP#I(X<=7``!R/)52"F`92W5Z\1*1&B1;?1QI`R
MN5[+&E*MECS1'ER\0DE1Q8OCAKAT<Z'PU6F,"FGZ''WR"S#W=7O*IR-;`14@
ML0`\LJ`',8$T/\1IH=6YJ?`K8@JW`9+8K`G8FPTE`MMSD1D0`)QIOJ%(N#&L
M3Z")S!WA+):[J:6:HT+[LKX(S7BG!LZW=;JV9]'RO@:*3@B@7J.-CT/,TZ.\
M=YFWU[E[,'L=V5"$#WO0>'6'``C@=NQLBL?:=V[#($/=M)'9(P4@/);&D4UJ
M+-+)CE-R*Y/)U]6)N4W)75/&J_DRF77W>P6M9B54)T7I_V3H?"Z5MLY=!V7O
M?-/'B7#UO+Y\!GR2^MMTQ@COD0(\\,\((P=G$:&/*-N6F8#Y^@'(NJEK=A9C
MRIS@/)YU,HRP62M<28O*JITTF8KIF#2$X8#HAU/E"YL#7I_N\C8GD@)#7`>^
MF"LI@*C]^H@/9W:<5GJ,RI)[FWE&(R;7-\0%[JSO:8I72'?2]U0D(0R+4RII
M#"5P*Q5N"J:+U]6&D$5U4<6\1"I:"I?Z)1MM+,4UIZ5&;C%#VN61)2('U&-%
MI+V+^*!%7)1PD,WKMG<`$(:9R>9[EZ./^I'*6W><-MG9\@D`8W`,P)(#W*F9
MM[>9&'A<:)P75Y_1@@P7W&5[I_^OA:VDN8IPPUF<U?D&$)!F?6,AX@H`7\!;
M;([4`BYQWUI0KZ,[8%=K"O<NG&20Q2B/<A.>SNHQ/X!Y3=IVP(FN>69D!R.U
M<!Z5[:@GX\UV/G)C?\=]\DN_#=5WS-KJ\9ID/-ET"4S&@T"O%TFN_"$(!MB1
MFVO0($"[V<SB-5L<1".=&;S2-\:%@0=LX/R(N!*Y/,WB?H,?[U%',SF,S9JD
MF&Z?>4TLX=RQF'S0_FZ30/O256=RX(SK/-:[<C!$P@AB.7[@<T#O__V:+<@S
M8/T;4LP+0W>V9:P(26%S&4&'E.#D7>L,?`@E-(?R;2K5#S8I76NF+Q]@WXZ@
MKKX6QY#_1X89?U\.9<*(:FG^C27`U`T5AC:@?!!U3^]U\&9GX;/.HJT8A4;<
M"`>4F],"HRJ6HRF^=[?XDUWIB*/\X#Z2"`_`W41&K>IEJBG`L4R_B+0LR,T%
M51TE?5)(*I$ESW60!F;_!1\``7TWW6=G7GX350,@!MHL<4+Z&NZ%I$$&5Q,^
M+P=#?*-]0#Q"G@QXGF9V0%5:JO3H?HEJW6_&L\N%D&]0LV;Q`$/\:+\^&>K,
M6Q37+G@5RTR\S0G9:>-E><[XVQRZ&Q%?[?*;W`60[?_==`&^!]T^M,/GHOO3
M%.KS`!]J1VK@%,DMT1Z\J2"LB\YK9JCXJQC#+\^`4QLP\YP,_YO;SDP;,TDX
M]?:RYE"D/=1VKJ%J`&5!%7$=5G!"SZ0IL`4;5@:4=4`(``@,#7,7-64?)3\7
M>W.-A&H-`XH7E!<8`!\9BEH%`06?`:$%$1&=GI^CI9^EHJRMIJ2OH9ZDJ*2W
MM;01K;B]L)VKN:*I2;J[`<*SM3RZJ+"E/,S(M\$%S*.F`=>NN=@1<RDI6@^D
M#RD7X5KJ6L>CQ1$_)1\`=1DE]QDX-HL(=1]PYQ;5`*`!0)D-E$`<2E3IPH9#
M$!3M&3"O#H,!#.I@*O.&TD0`].S=JU-"S9X&)332*R%I48-Y-2JIH0BR)"4M
M;_P9'%`#P0!,==ZH(R>'1X$]&`Y1F/^$+N>'.C$=8F*@IA*"0_,Z7OB1H2(.
M'!E``LB`$-T#9WO>A"VSY>8%-17F-=A#*2?(,BP'E*"G-5[%$G`:X`#944W7
ME25PE,@PH.I)L?8B9T#P%L??>XNI+OKY@0'="V_*U*S*%69#-?(`#*#[0(V:
M?H@VJ2GPFD'*FB40T%7[H0Q3WB"C;NTZ#T>--PVZED%PCIRJ6#SFQ,-40UVY
M`(,!@/#X-O7V12`N9QB?H88::G("W$G2`"1)S/;>[*FQ^"[+CO,_?&A,:<XG
M<VJ(`!1F)4"0P1LIG`5*`0]@4!`.#=100W)R!?2#3G7@,(!>?*7%0%A/W4?7
M0.X16$<#6KS_15-9;S&@GVJ?S30//0-$<LA<%UPUCTA@0;59;PR`(.$`.D5%
M#2C*0+--+=5LDPTSP@AC2BKMX&(+DU3VDD24I5@YY99,;IF$,\XDJ<TTJI!Y
MC#:I7)GF*4C"^4HPO3QGCG,/D`,,*FH\4-J,8CVU3XZ'\!?.#PQ@`@!":KCX
MSV>4&/:!!MNE`(=^+X*420V??33CBT^9=%B@=4AT*0#"#:=?!E5%B@&(%2F*
MPR9I1I"$HW!`VMT\`U"RP52MJJ@H96^-BND\#"!(20ISL)+$'0-E$BPE+\7F
M40W^`*K?K#>],5BF0%U1+*:8S,C08]HJ&I,:EH&JJ6^;3?59"NW)_Z4&':LR
MY9)^)11P@3I[Z!B16;/5.P^F.)8&P"8N*=I`0"F\,0!6](@%`7,7G$6+,WZ6
MH,$'U;'S@!8_6$;I35J@)I='U1Z+\![L.+->O6)I&I06&+C\%+$UZ*=9(ZND
M+.#!\WR,JG7/17!)S9JJQE0*V"JJJ;3HE@O3B%+7O%^*,@*@U;].=4;((AM\
M^^D\&(Q(L:+Z-=`PTQOA>!8UPY2YY)1IDID-*J%LN:?>>&,I>)VXC&G,D<,,
M_@PO93HS^)IGMEE-*F?6X@HVJ[C9.)6CZ$D+FWD6(-A7#)2N6$LX#5`>(7/D
M*?%%BLS$TB0IHH,!`\;M,9^&N.-P40.3G/\S!WU?%?]58Y!HJ!CN_&DA&`/$
MGJ-&#;@W4-4Z:OS00$8&,=:`#:RMTNP5(GRUP3D08Z"7".!(#.'U39TNU%O;
MFWX1"/(MZQPK$<R7F-L9J]T/]-(2]"$G`V4H`TF`!ZD4_*`&.*B#`C,@@OQ!
MHG2F4Y[U^&$\#'ZE,*/S7>D&H*$?:&$^'[)>0)*'@PHBP!Z<:@AH2#@`'F2,
M'!(#S`\2I`J?'&]#N:.?[ZHBCJWH!7KA6"'U5$(2$2"@5?QC!8-28`.]X*`C
M,=M%^9)UD[,\CUC32XP'B\<<3K0B3V+`'0;5.``;:`$!)5BCAK3BK?==P#],
M"L#M-G01V\PQ'';_TH(-U!=!T5C$/,L"AP.3D\`,?>]?$.3C\>A8/`]6+T4-
M8LPFS+$[XX!C;`_,B&@R$*%6O0&#&#$>&'V"P.X-('\9ZY(4;S&+P`&#2="9
M1N-J-29BU&UCDZ,3X?*8)2P%HY=MVA@O:&F46*@IE\-89B=H*<U0=,-QJJCE
M,PV'#38Q*&6ZDV'&`G+"/81C#J[)DTD"LHAPWC!/Z#-G)2"E*W0XPB2ZTU7M
M/`*IV@%,GGD:F3K^-911>,0UKG&G66Z9)]T%JQ'IV.<B$OHO@?*3G0F5:"68
ME<QO[@&?Z/OG.0:JA8`XE*++2N)!4<K/AGR&I.VLYR+\><*65N*?\P+'_TWH
MV<!TA+.D/&SH9Q3$H(3V<Y\/^&@7SZ%09IGC)@@U24,4]+C^N9,=Y4@JS&X8
MCH#2!69[T.I-D1JX<4AUG@/]5Z=TM\^/?J81W1C95F6XU?V5`Z<(W><X'C"V
MMR!4G_G<Z4;!NM::5M2=SB%H)2!JTK_2]:Q7E>A'';O3<60N2V>2DS'HE"0N
M_8U.4RH3FMPT3"EY"9O`$-,T;7799.HR<8BS`3(^<3=@\DURN+V2:+O9S"KM
MHDT1**DX4YH@=J9@%4^%F$29=8NGIG2XBVV$'.0`,79"5X;P3&EST5$)JIK#
MN@WAH10?<(=],@NN(]MH$9=EV0)(U!'@52\/%_\4@3R1-*"<<.]&OUO?X9[7
M$0^`+CETZM\DQE>^UZ5$0"'6B)$=V)[@((=Y^4H*XVH,&0]&QS@"<J?ZLM,1
MW\APQJK1C/I.6!7.30=^]=??!&.U5HI,<'B-VXC]ADX7`8:N.'SQ38WNM[YY
MZBMV(>9?`D-7'<;]QAS,"]%F12"^YPRQCM$1CB,/)6^<VQLK>AM,S9$83F`R
M;2>X+,S2'J.WV63<+6>9-#(UPQ.;W>WEZ+OFSV).;UAVLYPHITOD?O><COBD
MDOGJII$9^KOD2!`J`LK?)QL8T$`K0.OX&NCD,C9!`6W=4`B="G.4U#ETNE-$
M[7J,"-S!Q./`I4`9G:?_^B;-T/]M75>[.FF^'<ZJJ<;2@D']75E#>@YR"!KZ
MSDOI24\:T:WV]9^+BVF^?K>BC`9RJSOG87$@F;FX;'9S\0MJ/POTVL[Y=#G^
M,XY(2SK0BH1HS&R="VD'69;?R&JKW<UJ1B,YU]?\A"*3N&QB`YC"()XT__`4
M46L']+2=^^XZ7DP-1QMXU\;>=Z43!(Y-XVFOI&C=EH)L;A,_.M#?*/:CF;OO
M/P/Y35G>Y8)T2V(UW9:TW9@SS$L+##2OO!M@NF4OO<0XV+Y)F6]^K3#Q9NN4
MGR(6NHC<Y1#>.B<K&:Z8HQOGLDIUP4T[%<8VIG]&`?5S._G?=M+3<UK7)7W'
M_YS3M2[F:H\4C'DW5W$,0CN`MW[NHN/25B>WIN4"&@Q9;]T1!9ANL"4-\&:!
M&+FJ./R@*8S<9EWIX+<@.V@1#V3`!S[+76(\DQR?'@:%O4L"]X\GR,YV8SZ]
MS<WP<WUM<>>X@[I.C1>?V`MW=+B"'L1I:CHJH.[JG9]6X(0CT]5#;@MRC#[K
M^H[TUZ>-"TYGW$Z@?W[BS:UZ)?_>\4H6'\C)_=MG2/'+;8(2F_.8>IT7CFY!
MGWII#9>$9M[62@'(>=!]D?XLPQE-;$)ZTH=N6]1J64F4(WYK=B1L-WE19WP"
M2`MZ0B6>TSFWU&EY]@F=UTV90PNV5V?/!#C8$`VU,/]=\:9WMU`,8?8WU)`$
M.^<Y0O>!%B@X=*<YGF""N"`+G(,FKD8FTU5\N-1R-9AZVP9],U<KKI8>R\`#
M-9APCF>`K`<G9F<-/`@=DF8E9.9ENP<T^;<+O;5,,;=R,WATN>!^-_@-`XAT
MN<5U>49VC!-LI"""](=;;79;0#-XUS1^JO8<XH-ESW=+_I&`P#5VE\=0W89X
MP.!X;_:$0&:`(/A]5%*%3$@Y:J=WMQ5F:5@`858Y5AAG-"<*1K$W5#(FD6@,
MW$1,6!)G<))O?Z-,,WAGU01GKG5_L]5:I8>(.?=_H75TK*=;M-!+RU0,V)0W
M2MB$0/A^Q)0EI3AX-^@F)CC_A@5X3'+&>KYGB[44BLJX.0^X=K;H?9(HB9P8
M@L=HBC''9H83?R.XBV[F<AA8@3[W65+B.*LEA9<#@[:"3"VG-WHG35V6<D@H
M@1(X>,88B]Z7)MGH"O>'#29H@G&&#1-HCYQ3C`?949$HB?KGCFDVB-](CL%`
MBX%7>P")663B-ZN@9E]6D"[H<BF8A8]H9LBD33](?YEX#;"%"L=89C)GCOXW
MBGFV)',"C*=0D,ODB-'03::H.2+HC@39-V+2-Z5@`^YWDVP&C.\XD&!RC&G(
M#$49?ZR%B[@%DM4(@*50%(PXD&/H6E?2C%5(E$XYD&FH3<:T6<J4E$HH)D+9
M"659_PQDF89.J0U@8I>V0I3@V)1F69>I)R=.$DTY"7[&A%IK.0UCJ828(PIQ
MZ92#8R9`1U]YEHP,:85RL`Q"UYB.R5K8Z)!Y>9?B=R9%Z7]\DY8(28E[PI=J
MV)A\:91(MR6H28MR<DUJ291G.0WMAYOS^()PJ7\L1Y-UUI-B6"OEB(6PUPP)
M>&N%@R2T)5M(.)&$(Y=J9I%U4YG,:7>A]7/A-YBF5XEQ(I.KZ)9]0Y9R*7^:
MQ9N2>7-Y"8Z:>9M^*9YHB(@^F9[.:&M`-R8<>0I^,PM<^)+I:`J:Z9:ZB'Z&
M"98H1Y=Q:9O2R9X(*I[@.`L!&I?O.)[`5*&]"'06J8Z1D_^5&<F<V:2!JS"4
MF^F88Z99X#F9,3F?'3IFDC.@$CJ4MKF>4_F@C&F'6OB?B=AGI?B"GQFA>2F5
M0OF6CEB++&>8C/F41BFBV%B6#`JC!.J,R;",H[A+9F9+LL"%L)<-MA(-'JFB
MPT2?OUDWW'!W:M:-SV2%UW"*8BB==_:+_-F%TI!,2+J?`MB9?TEB7-J7^,F7
MV2"BZRDE5/F-U<1GHQ";%$A^(:H-F1BB.T=TPMF>"[J*H*4+O22=,:>&$[J7
MZZF?9_F42!JH@6J6`"J4$!I,W3@G9IJ:V<2EIDJ<@<F&>,9:HNFI,+BCDMAS
MJ(BG::HX&_.J^/D)+\F%V=!S5*G_<S?9IM^9#(?S@/WG<C`HHG7)JI]ZEJTG
M16[9>IY9HI/J2^X0F_O944&'EK_UF(-8H"D9A\R:H5GZC.UW-[6HG+`7I6D9
MF+YHC9D#BC%'B6S&"YWU@,K:>DJG"N)IGJ[V@N$8HYJE6IQ(D)\ZI_"GBDVY
MI53IIM,ZG.]XG?X8.%`Y?M;4+&49BJ8(G4OW#J8U2[BUI[^ZB,(@H.[9D,N9
M6OLILKK5EQZ)LN^'3,50IPXIE]34)A!9F,ZT=`+[K/@7J#-+I78S@URR)KGP
ME)S)<MVXKRG7LR$HBSD9A=TZ@FKYL@HJ6IX%@DGBHO*WI'D)"C87F5_;9S\W
MK_NWM-:X_ZR!<XGF2*!"^[2IQ0JRU9U8:F;*VK-:MHYB.J9U%KA6N(&MV%HM
MZI$1N&4;N$L2*KC.R*,LFJ+99#ECZENQ^@(\,)7;2`S`FJA!RH]<B)>3BXW?
MES1#&JY)=X6*6:C`Y(1F&KA,&`%@P)5:B(Y+F7ZT&)JMBY\?BZNJ2;/(()V-
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MH*7$V1F4`[G!25**5BH-HA``!ZF/B4FK,#JQ:Z*++-K`^6BV7SG"*?S$AUJZ
M]+@@\+J&2!=\H<"J_UG#>Y*AQ<1CB&I_SWB^V`N_+HR_4A<`2&G$'?4+46RA
M'VRV20DE=G:=LH#!K<REN92O19>>7/K_P9U\A6PICU(\A.DYR-M0.9H8S%V<
M6>77R??[DR::N[+[)(A9I^T66NP+G,.*MLQZG<')GU<9F]P8RGLVR47JRM7L
MR%?+G2;L@M0,R\[D9K-\EBRYA='@?L(YSIHXNJP<BDORS]RXH;MLP6]BT&PI
MAK-X6;Q,T/Z<E)6<S[Y9FXJZS;-5H>3,.?O\P!1<)W+YJ,!@6\AD%.E+<U9*
MC]HTF&ILO6?LRLX)EBB)M!6(OJ'9SZ;LOH)I6S#MS><;S90<S-"`#4@I9CQ@
M`PPL2\RY9\"8.;,<?C-=ROP[B(P+TR;\EZU+U+^0?\]@#4@YS1VMGM9`SK*@
MU!BM@8FC9\D\_V;N:LY:"%OSR+N\M:MIIM:CRUNS)9QH.LTJ_)UJXLZ86:AH
M;70F2HZ?D],;6-@%B)(HV6Y'N<V4$]9;N-4H7-9+IXA)38//##A6O8A:JB3"
MVM)[!KP%<-2%"QUQNGX`NIZCC"4#ZLWCZ@R"'+?!]\Q#;'>5J,S=<)XMS=?#
MRF?WRV7?-\B""=S_AYI\W:&D[=:'.\2NC--'#-C?*=-!S*]Y6[?07'2*NH45
MZ20__-#J[,OIV(7VC*/19,M.+*P,7=E`S#>;#;*OM;I&1]UP1MX`>9BY])52
M/`N>K'^]>LM.',PKE]&QC'^AF=TIRI^GL-FYI=^[K9U3<IZO'*5Z_?_+Z`?7
MH>S@%H[A^IK+NARPP>WAXF?A->W6X/K=_EQ^`?U+/?G:ID6\T1FB!/Z)SB!;
M.PQO#QO.P#G$$9Y9-\U;AOM^(ZY_OOG=>SW1+^SCZ(RG&BW:NBR9N_#*VEJ1
MV<W0JFBAB9B<0:S8\XS,4(RA6_XYV2W-%UJ;T+S?4TZ$4RZ[/JZRLAW9L5#F
M@DG)OMFA@VV]T%2=XNK-?>[542S(&=ISB_K8*BO8;=[9+:G<J\SFT6W$*BS/
M51["O(W*/WVEHRV`=AW41^GH+(GI]4?.^SVY&M[`J[S1_7O4)2K::)F=JCWD
MX2=^_^R<A+N&UUBC(@VL.$S,G#DFF6C.MQW_W&_^?[P(F/#KS?\=SMY-VHE]
MM:B@TX`*DLR^PP'MG(/M)@P.F$ALM@@<@`'9V!@JQ0%-WDSXYQY:Y8Z-P//]
MYM3^XSVMWM1D[KI,KX!=SW,VVM3>U4*<P?'>DE)J[/<>L`S>9;^-Q%]>S]5=
M?Z\0F+\>PMT=P6-LW-INUOQJW#MM:RQ)[[1EDW`M=43WC`4_SSA*H`E=[X!Y
MQ-7YH7X>Z&T]S-6ZXZX=@CS6K8+\CZXX3>5.6F`>MRC\H5I9HJUPRDB2X(*<
MC/\\S(<]X9J^VC[/Z6>F\26]VD$].;K`UQE]PJR(G#B>6UCMW'""O]L.#90M
M=:2`Y90(Z@D8T4FX_[IPG9CV[MQJZIU>G^3];?;Q*,;*WN)(`J=J>>%;YO#^
MRZ]%?ZK-C/2JG,Q]_65J?MHAO.KA;,RY;3<LS.P^"=U4/K66SH1AO)LQK?9)
M>,N;7]J,X^!</[M9S<+VJ=Q3W?1C&=:H7]R\>S@%O*GG=UJ5B.M$W)LG[&5+
M;G]OO9A(_.A=OUMC5N$^OR89?/1:/HOQO71CG=%=W]+PK>#?7$M*I[)WO>$*
M[H@#;\M"3G[%'=94*^S>KY4J'TWX';GH;\S"+8_)'JYV@\OD[M3%/]W*BOX;
MC<N?-0P<#@@1!0$%!8(!A(.(`3P\`1$1C(^"BH6(@SPV/(:'A)"*B8J.D/^2
MGX.6B8R-G(J?EY:8HY$VDZBVC)JLB*ZOH(Z&I92OH0&YD(>ZEY>9DY*ZA:>*
MFK6>G<J6C9^_O-#0Q9O'E[R$RJN"YM[DV(W4A<*IY.C;WK"@U4FGI`%)QQ'\
M_?CV)6$G[M@@?[LB+1)FB1LR5J9`<:)DJ%6D7[8DTAN'BU-!<<%NA4*F;5,!
M9A4]Y;M8S5XWDM9.TNKDL=E,4XL:TCSW*V2UA,5JI8.UDZ6J=OJ`F7N7LV*^
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M]TTRGW(ZQO(BC-;TD]Y#:`$X#'3YY4CD5QA.]U!IXQ$#UGB&B<,;@0!)5T`2
MO,'WFS^%\+9EER..E0D/_PX!-Y1^,.463GVMF69,!)D@"8^="J)2)T]X$D51
M1$_IR=A@0/+XC%L$>G,:G3<=^&"@?;VS&">+AHC*6(@FBLE-075E:*%-<5-I
M;/5=ZM58B7#4J(,U$54/7ZDIQJDL19IJ47;I5-HH=K)E&N692E$C[$MF96A-
M+@\4H,F;<8478D''@@.7/JB9-9D]$:DBK:4T9>54GO%(RPXPH#F;:FW)J,+)
MI*0<RMF`T%I5X)5?"OE;;9=\N5E.C`C9R6*S8<E1<I[F%=RWT`8HI2WZ&3IP
MC"BZ=V!PU0Z'[\*N6GIPDNFY&!.Q%J_%,5\BVI?QE%1!RV,S;AY\Y,,4N:21
MQ?^ZG5SDBS1)>-@I(Z'[G&DIOUHLQ?)"V%M8Q7TU)8111B@9:!7/1>'%%6&T
M,4/FJIR;8V>YJ_1'_J'+[6&Y+1?3LQM3Q3!3Z6XEWFW%K<FTOP_M.Q'=OET9
MJ3\(E1.5CL"A%*J:H>I\T),MTI>H<Z]!.2&F,:;F=EN)Q:QX<G$[^;9/B]^L
M-3G95>4G4S#'EU@AZ\6+2=NL0ZYN5[R0&FDO%9)Z-RBEW[C3M$.V*'F<DZN4
M>D+C:$=7Y`KMPKOJG'_.I&K"&B3QX'.O?B*;?.'D?-+*^W0[TH-GZ"PM0+X)
M9^=H5SXUX^CM'*1X4^W(,27-);@>WWA;\TN]W&C+R-W_OGN,OV2&O>'$BR4Q
MTE[":#4/:;7*5U8AWIE(Q!Q<1<ITLTB%[(0DNB3-[#TE@0Z'YH:J_V3#*ZUJ
MSH"&\['YO*YW.T)/S@S20%IAJ7'3^0_M^,1#&*JO?::;UO)DD:8<:L]B[.@A
M\?#4&Q+*1#6L(.+N1M:^14V#%Y_8G0R#F,0,LHE93&L=!;^!Q7XTKT>Z4\RP
M_-(@*=T,,9W*(+D@@L#LJ&D\CN!'503!/\4MHH]@^@Y\LFB@8B!'A5J36Y`*
M-CL@WBB'2JN)V0@XG<B4!U"PBHN"%.8LFG$/>*E:4D9NM9+O^!&-2%/;"'W&
M-@ZI)1VK#)\'5V:J-SIQBS2Z_]/T'H&OIM$L0JW897FV]XRPN*E"X-KDS/)A
M2YX12'=&6Y.CW&BP\.D2D@3K9>X>"926!,>1C=0(>9A%,C]*CCI08^3>!D@V
MVP`2$E?*(R+X$:MP($<K'*S&F3;)3\>H<(ZH$@H^V3,CJ!7I?I3\GR#8U9ZZ
M?>V<TZR:M'+Q*GA)[8+5`%B!*BE&L#RS%@7M4&]\IDW8=?%I8@FB#(_&0$19
M:Y+0_`CYQ!DPY#&E,ZF8U0.S`AYT"28S)*KD19=H38_,BF7J\)48+T-&%(H2
M2I\,Y8(86"Z>>M.:-MG6L*S:MH\"HRRL\A.V8#8D(=K./=!DH?$DNILF<HEP
MJ_`0)?_P<:&)ZNA*DO1H+_^!&WS\XZ]ZVT5`EK,9';HE0>FK'M**HJZUQ>>Q
M+"J*</(S5IEQU'B1"][7?G*>%.6,?9-SEM7HDR.2,DYS.--B+G$J+)Y.KZN:
MA5<46?32ZT#0M&E]EVU+V,M,?:4[UT%J:S<;2:CBL'#H>21F9V;,:_7%&;:\
MB$EPE[Q453&FW$,LG!!V+OB$\HW,Y2>T^!>0PT*OGOKCY0V;5A#9]4FY9=TA
M/,.4M7/YS[.5[,_6V*:H'6J,<QWRX%&*>Y:6_BF,_GF.?)@*-9\.9I!3%-XU
MOQD\"+]6B^YP;E:L!B20=+.JP(0F9B;C7G,1RT54:MB,'IC_4*QV173[A>R`
M!7.(-$D&@A\R["6MQU36]5?##1N;14GVRU$^C9=Y9=*&V-BK0GX8-^/*IAL-
M5$IW&N0WY;4*<P%X,87D3V;#4&W3,`1/C7'Y'U']%C:B)]D2XU@YPTOAJ::H
MS>DL*V?"Q//#KG)G$VL#I])#KGJQDYX.%>6F,&HH&PFKT/"X-,.\9%?RRKC+
M+*;Q%4N!LI2)9\?I[*6XO0M4G3%-&'.%D!L=3<2GY1QJF#Y7@R`MU5C80\)A
MN!=VT0WH'-6(:@]1IHS;Y+68*>T\`5FBST(&-5E-$4M"T'.#@<8G;_X*D,#^
M%9^T:6*.YA0-+KWBG6;4"CU#-.P,_]^:E1>!HI]VZ.C-0F^A)C%SU61=4NBR
MZK/25&AU?V*9*'-OW;^ER'/UFR#UG$R$7)S$:3IY&Z4A>M:K,W$]:F53935C
M6T'S).P2#HFX,CQIT'Y-==`47TD69FVQ!2G)L[U=2./7E#L)QHU/O,;J1A$<
MWV#8S@#*Y$O/AGQ^$74=?3U0.DUT4.2A.1A)")#Y6HH?^#C,"2/8/4Y\*4!Y
M*T5@!0)7%+]T2_E#I">BSDUOG4J`6(-?)ZSV0F;2BMO!-4_<5:SJ$@]T'65+
MH>CL3EO\O)J"GW:CW+M<MQH*O*32+1O+UOQ5'?$+G_TM9UFWL<>4P;3@1RM5
M+':Z2?A$/O_H)"ZUX($;7(CG1JM4RQ$QPHH[M+?SH)Z7>*,#CR_^G.>TD5?T
M50KGG^1JWGNP*BUK6#9&T4O>7VCV%IK?HPJ!TXCG\!SL/*4WY_S0E2D]R<E@
M`9BEKG(DB4)$Z7[9HAG3Z-<R6^-7ZO`3LZ,8EYK/_Y#G%CZN0COS3N>81FLV
M=7%BB!2Q?R%>*+%YV"14W^)YVJ,KI<))(X4?"%-_,#8:[0-,^K,JO\=X'\%^
MR'`7*C=H%`9+.18W@(%SX'<DVS%<OR43XJ)?;I1]*!A5#+5B%_,H1L)=,X)Q
M,TA=(B=5L-$?$%@EQS1\Z2(/,Z5X-R9_6`)UUU8JU)8C_9$?^3+_3_<"35''
M5V@$$22C03B7+WCC;<&U#S>5=^$Q423X<U>$:`KC-F08+!4!,`\E5,Y1"M-2
M%8;44^IG6^0VA[1B`8=D-$8H/&U(@BL(=!^3=^3&*+STA(NQ'L.7A@T&?F#5
MAV?SA0N#B+,@+GTH-O&F5VQ$?\*3B7?82]W4<9PR*#)!B#F8>L&T*)D&,#KT
M(_R")$=%"HOX2TX34RMW9S?81?M"B0$S;TKDBK#U8Q[V52OW=G/BAY18%VSE
M1;,P#5`7?5P"'5UB=6#7?N=#+N5U??MFC7<S?7,E=MDX'6@6)@$%&).`5W(H
MA\#"$3="(V<(691W$QOHB'(B>I,#=&WG_XCVD`FFN$Q[1T1&\B*XL"N30X0H
MZ%'?H5'1Y!6)."AAN%H%B63M$XFHQ(]WL2LZJ&^\R(""Q)`)AD-=U"U_N"AA
M(T!J)X0*`Y)]1QAQM!FW5PY`UX\I@7Z,B"(14HL-64<F*4BPZ(_I0A64%QMV
MXQFB`'>ATA:*07+*J##M.&KV@X_V"!B-@GQ^YAO+I9`--G:1`UA7=U=<DGP3
MV!-5Z0]3R(^Y8S]V:).)^","II;=-5.G,6!'EH&VE33]UF^=%7S1\4%JQ'B/
M<8N,!A*C)4<(%)B"*2):)2!Q11O6H7CF@7<&1%$YYR/-95\%Q9AEB#JW1V0!
MV%O2M68!F)C%$?]ET&6,J"E'X),H'M>2J*E&97=0=ZD-,Y%MCSEW4$4;M!EI
M2$>0G'@B@"E1=7=L>ZE2<!E%>5EWC_26<5>3L*:,8`=U5F<EVB8D*S.!6S)/
M26:.\$0<H_!6\Y5@)!EEGW"6:6B6:75_>@)K@%F9#@E>4,:>FP.!&L@::MF>
M@N0@$8*-ME8.>-@(#.0=7M.?[1F5'9@U-`6+-+)PJP.?QVF;&H07,`>3L\%V
M\GD4T--/D1%EXV(;&)H8;B.$/C*B'CJ`(C&,1L&9;+4IVY(@J,9R?O.?#`5=
MD;2A/<&AC($@%R>@_6.@8F-O'&:4F#,,R"$>*&9^ZG5[_=,4IHE8Z]G_?^49
M2'#R3E%U,UE&=NZ$93BQ/V;9-TO#9`3QA&4FD5;2)<%#BT?W.C2J%;&Q3P3#
M**IAFOWI?OEG%^9S/2K8H7`I%<H"BI^HA=ZE7>;W"8L82:B#?M-PHX*Z*G[Z
MD$FJDYL#&RIWD_I4BII`<,$U(_KG61,D74UZ)WNWJ9=TF-IRGX%9@ILZ:Z')
M$J:)?B-H$ZBH%T,)H/'FJG>!C-\5H$KA"(VYI]OBAFND+"18J&21J<@X(@L2
M@Y=ZH<I)J+1`8.Q2JLI`F3W8@=_UB56SB#XH+DCZ%V&)3`)CG<*I-7H$AEOW
M"&%9+Z+@/#U'7,Z667<R;N0Y:2G*IIMY-IO(_X?4X)*/IRV[ZEM$:@%,"8<!
MPE`4U8C'9@&.]X<Z^HP`FU/T2+#VH%%]^K"Q(+!R%JD`RIY^*`H"JV"Y*2?"
M"9VR0F!K^AF,%TW8P)`'>1W`(FPB6@P8:T%E,X!QY*%U)VDM:Y\X9Y#7L"D0
M65\+F8O;E1OZ:F/:-8"5PH#^&*R-%0OFD',="[2:IY(O2SE">!$L>7KP`*#-
MV(C?<6TLV"-T`V?4(X5H:Y1Y`Y[I19TQAE**<"7%(S%ME48%6']@&V"!R;+=
M(Y^]6!\A9$AH8F+^VI3D(CQV80,*NQ'Y)7A""DEDN7+&]C:4X9:X\:Q/>23!
MF88NMV:".ZJVMIC+N?\@L#%3)S:R.SA0\3F15.:?\+<5&TJ5AQL:@AI_@1*F
MJ)=?05I[3[*WZ/=O']JO_V473<M(*>L+<<B8MXI_GA:D6+<[WB&,[=1XT%FU
MGL&W0U&YL!)B$N91TL=*W!ANELE"P200K-&=9BF6DOI''S9L8812Z3INV,F,
M^0<XDQ5_#W:;4*0B/)96C4"LP>.<%;%1^%>G^EM&4NL-KFHJEWC`:,5M\(._
M+.H=#N*2R1BI3N*I,?EG:#H>G/*E1^F"W/,>3O%9(*PMSWIW1.I`/#1^4!&3
M]+9PIZ:Y)3&0(WR)K(EZ2M:A`5R_@;.%5;2L,I:MB6(,CX><&PM:1%P_'HC_
M%K0JPGCFM<!%DKH@Q-PKG-^HCR>,L]S";'2S#/472]G9%]?WK?N&LSB2/(K4
M-RHHO^;X5JQAA1ZH$-OGI:EW+*8X*B)U#\_R-1HU$$XJ?3RX#W5VE)9!L1[&
MB2?!72*8D8Y:KHW13.Y4&Q3+BJ:82VXAR,Y&R:6(5.CDQD:#&G5(BW.,5R86
M6+*#"VMHPI35QT-X9S?;33K7QP,"E)>8:&\K(`OT&<[*1)CI6]R@N+`:8&PZ
M=HVF7+$0B1V&?W@5RAOHCU!W&G(+DW7[A8?5$0MUR6#HPG5Y-P$A"](\7A-!
M3\\FJ1`Q6&PL;L`!6+U'P=<A9N/L;4T[QO&+GG\4_Y;))K]_%%!R#!NB"+@=
M*\BPI951*(5Q&[?=Z(ZN"PI>Z%*"E5L_&;:G[,ICPDFIN\U]B\X"C2@":C=U
M+%33:&4(&ZGX7-&=Y:5N&YMCS+AIJ\^>$[OB=J7:F=(T#:,H<\\M+=#]K'TV
MC&$I5\W^2J+UT=`(O77#^*.-L7TU+4GG86W,Y+828=0*C8>;;-")("98RH6(
MY%/O2C?DG'@JHQ_GJE9=&DV\\:SZE\@5W=55F,W>RT=TI5*<Y8&?-"8N@<_B
MMI39*:%8EG,AO<]F[=>O0QE*N*XN#8;GJ]=DDM0AC0[QX8739Z9[_9T%(=!,
MD]5H&[4S>@\CVHV8O<U1:_\.>!5U"K$_$(W3>HIZT?<:?_UM\428V[IXMZ&?
M81%82_P-B_>MP@'97!<V[@=4+$':49U@6R?/F-IK-(L1FDS(2KL_S3R->'LC
MK5TRAYJ.RJ,HX"#5:T?=:B2_2BC9?C7)`?+-Z$J'WZD>SF;4WAQUFR?9W&>5
M-6@0K@#=%"BN_J%'E^K.LWS5\R6O5"D4*#U]EZ$WD`-UZ^@<O#TFB+C7UZ';
MP2#9YM16U"IK^)Q'1NW22)R=!36-")%'"6TT?*4)>G12BV-#0",,7D+"SPC*
M+5*N`NAX1IQ$S0QVDJ#/4BE3C$$FB]>=HF4EXOG;),YU/"37SP4P^,`.(Z[@
M"U7_'X/TXTB>&2..V'TSW4N8CVQ9((*@6C5NUOY@Y.)AICR.Y%)=4IE1W9"=
MOC-NSG_MX8=`"_)LS.G(X"[^KF:Z%6?=?QJ>CD$EW5^F"L8-./B3)9[!B/@S
M;77>U6!B0"(6`'QXHV';"=/(G9`^$(M!/M.HR5):M]8X4G^$O&(Y6C[9N-Q0
MX>!(Y$>:2\5S(L159IU9XY40W@+!YW<=X'>9TKX2S1Z3SJ$8MW^-Z_-'R+U(
M4]7,V[I%R_Y9QV:*UY5M(Y;7K]L'RN<KI;2,6&<^Z;,>QX<-#])GX%4-V&QA
MU_.$QA1RS$U![&"W>_O0Z9%-L,2EOB<H5K3L6^YPZ,Y&_Z-!2=QU'I8(^WA_
M]>H8E#=3S>MA0EXVLN[1&:.A9);&<>C7.!`"6ZWMF"?7..#[)',3FGFUP.W!
MTK9;<M_A@<CQFB_KNLGV`)[WS`S)KC=H%2&:C-[/V)8_&FLB7_)NO-ANK>O"
M15PF!U0\'^Y@N-U#Z$;D?>0\T.O-_+PB-^^=+LVKL'U"*Y0I_>;D_<D@;M8I
M'\X^J.WB>>'/+K4LQS"VG875/-G'IDL+L:[)P*,(+=BFS<P`8N`8\M<=WPA1
MOM)Z@^D-:6UJ2O?Y!=2OV_&P'2Q.7]/H"_#)<]8?#!YO=>DUWAMM[0O/*NDT
MIWUDAQ)-^[GD.$#JGI^:K/%%X?]7]HS3B3GSQ\S#4>@E]TV7YUZ7NH-B<XZX
ME$]==-GI)7_9J:O/R^WJ=3Z#WYS"8XK1:2C(YM[A'A,FZ7W1,TWY^^D_<*Z%
M6HDO&(Z$'1],K"W1W(O:ZCSEJA[3\3'>EIG>RF_ZA*RVEJ7Z4OJ^GO>A<0S6
MFUR-2,C3JSG3)ZWE"DDUZU_,J\_DEJO\WP8(`3P\`84!!8B%24D%AH>.B8X1
M$8X!21&,$06+G(V'C(**C82(B)R+AJ2%!9BLK)JA-C:'FI>,I9.5FZV%-H2#
MOH.#D)JFDZ"?AIM)JZ&%A+:KF(*OB\67GI;9BK#`G].'D8FDS,T\F]L!DZ.$
MM-VNBLS_T)2TRJ.2E,+N]\CCZ@7DE)6#5&[8)T^LRB$:YB\;*V>64`D:A,M0
MOT:^+H6Z"''9LV&W#,$*%VJ3,F4C+19DB$S;*G8/"8W$YNS51%^?!FI\.6@G
M.FD`VY'\1>IG1(0E%2*C^8RD(%FT3"8;.FO@.'@6(QE<YFGGHZ+VPCI"!8R<
MIJ)(06[,YY+@QZ(CC9H,Z#294)>_N`&,RK,JPFPM5X'B@7,70GI#G4I5%]B5
MJ5N+#EN=J#A3RY[E;.&2!VS6NDZ(P*&,;`BGK+)W+:U[C+!EI]+ZHO&P19%3
M*V.W1`,M%(&'!74SSY[+-4_AI)32DE`,X!D<4^`BXV(*+)@W_W,>ZS:.LKE;
M6\*.;)G)P@IO^+3A@&]YH@A.TWC1N?:1.A^1>LQP&26J#G6L>\YM8/WSGCQM
MV31?>J40(P\CLFC&373*T6+<)9@(E5!1[+%U7W81(5;--I%!4X`-O\7'6%?T
M\>+.0,E)P]P_HS!5'E;A<!@=-;W90"&**(9WUD'(M",5*X3MYV)Q%LW$526#
M;5)D?Z+<.$]7I6QC"C7*-7?886QQ&)E7\;2RHT>S*4D6<(2Y@IR(W(AYUFDX
M80,9)[KLZ`AAPN3YR#>VT1EEA]8`%(R60`TSG2V@H</B0>Q=-UA$S?`6%%:1
MI0.*9R]:HM))<Y6I822[577=8A)MZ?_+=P^V<XY&F)XJV4LY&9I/H'=IM"IS
MG@&TI$#W$,=8)?7,PHZFU3G5DHD_64B)J"!E!I@[;>YEE&#+0BKLEN$TXH]H
M5RJ;1*X,E>00K#)IJ-N)KI;$ZU1G<H@51<N<2B"WNFSH(7)1@>N78']%-0A]
MSR5GZ(M2E=I:216>2-EC109E;#^%JJ84<L?T5"VHI8J4))?`+F/--:VEYV<O
M55$'#3<[GG?:4L>$MJC'Z>!)5&77'!,2DQ2&*$MA`U4H$R,?6]-GG8.%VZQ"
M_#@<<%.O#)N*D/V:(^QYH,J'TU?S&?<B(PW'U9%6!C4%M"?AB3><<K<F!4LP
M>`68BCGH`;O_UBA73_0SRF!-J4B]XS0[MT7BCDJ?E=GA";=B"\F4%('W\/O1
MG>4*=!)[DXVVK$&<33LD1N:-JY(\5Z]WT%`8HI>.-.?I,VQ+=(?S)+XJL2,D
M96?.E1AI<F,%E:8L/0LO0^?R%Z*0G&5+[CGW&%702SESU4]*.5?<65LXQ_.*
M:,*X`M)QZ>RBGR.S/-X5-J$5LR34AMWY"%1T=KY,RZSI4HRF)`HHK+/FW$E;
M^,D-]*2@!6)1V.(6MH1D`R0C\H6OND([_F"$?S3"U3^*Q)&GO0T5N\L6.Z`R
M"3Q1!VM[LLEI1E.::PE.718DQE/:$8T28L=LFX,(L%0FE.?L["$-_Z)'));7
ME&F,,!PM(5&9<`6/JFTD,\)124H,=[G[(`4B\Y"@8'!'F%9Y!FGJ2][:(+A$
M"]@`AR94S$;X\Z8:8F]`%,Q,)4IWH=U5*11X`B/UU#4[[*Q-60=\CP3CPD!@
MT:1N'EM-^D;7IH_9#1J+RHKU.)2:?ZSE90[2Q75Z<8XC0D:0QV'&)4TD.0XZ
M;#6GN!+D#B2W/<TP0N[Y8K6X-D+N9#&1VEO?K?+#'`N0XX,6S,99'N)%'`[1
M`K:4$(#R5HE=+DM8$W$%,.4ENE+NR5;VFV"^O-BA`P(K-4["3\G8D\#P?<^9
M*!E%A;8I(1*%SRAA<^8BHL@L]`B1-[`#I_]S`#@)3_J&A3<#I^1<EY$$3I":
MBKJF.@^6J_<`!*"U@(0,JS><ZW000]0DI/H2B1>3V)*5_PQF>4IYEP2UZH5I
MZN#NEG:2A?DKFO/*$L^.,QU3H$@GG\FG('`WPWB,K2EVB=M4QD)3R1ED.>7:
M!?RN9[-,^E%VQ2S&H4"EJMZI+Q?RBJ.-%BJ4*@*G>+=@R`-5<SKU/86#]C$;
M"-U%F;<]8SPR388)935,9U)3(D*"*KB""KE2[DQ"<+06.5[75KM6!3$H<=0Q
MN;I&;-[$.V_3WK4H.%5P0L6EWJ(@`",(3JNZS(P8X:?$]"D4]CWJ2`')2#QQ
M>M93X6L=D@5>\6K_\CA<F0<\F<7@V?3Y-+2N4RCC),E?FYE.\+DJFX72USXB
MY<PJ5J-2+O5/\YZ3#W\83QVB6-HIPODX9AR7:/X+X4P_IHFB8F(=W'/&E!CB
MP4K9#)<DA`0ZRBLX4]PSE;ZL[J(H-"H8&O**3UKA1XSX'5K*BQ/_^]_NH"8_
M\:ARDF-+[3:OUI-AX2*!K)J-,48EJ%493J$+D^L$_<(J4>7GPHUBFERQP5BH
M-M15(&83\0P<DULVL8F<<[#XQH'?J45X?5]T&KSD]R9M-"P3$C1;&7'Z/70`
MD)7((TM!#\Q@5:@WMR)%'CH\V2#.S3BI69IEMGI\3%_.#)8])@LB+R%@_\]8
ME6DS].&O/)D(OU!PDAE63W)'5RZETC=8V!Q);V"$+V,()R80M!-/*V9*_?7I
M%&.+3.'X@:_':L;(:^1QQSYK-+"@6!56E:U5@O>5?:'X?IE>;;D(E%@*_SB.
M7W7*7:`D/O%Y,'E?O54ZI]5:"MNZ,!+LVU@XC6/Z(6]K!I9P6<URNH6D*UVU
MR;6HH=5;!SML=:[U\4^_TTC.#`:9XZ&;E%OK2K,V\+&W=M5J^=3(UMU6ECC>
M=@$;6U>,8I1S&`J?62Y354RK`MR&,_:ZN^JTV$X65YZN53>NF;T*<^UD^29(
M)R:$DMM89F\6$(,8O(FJ\7VP%#DKK&E5E!6/W?]OTHA&M$L+9RQZ95!1R.EJ
M/;;20I,8=&>X5HNJ1"O%UP1KR6P[=^/*FT`6#GR=;CX-PH>^0E.<7#\&CD@5
MV6?2F>O(/1H=F9-R!7!LB^IIJ_H60#W2E]D8V-%O+J'$S`E$B0!=Z3O#-#+K
M.HV(HLK''PZ&VGD'FRM%-))3][IKD4TL"Z[S[M"SKVOOTMNG0">#T'3Y$(5N
MK;KL\9BW'-]3,)AV65;M=;ZY%I0H#UVAW]NKKXNVS5V.*9EA^]=^3SH\>^6H
MK\>IOG>:VL(0)9)>9?(4T]B$#<2``0R(P>LA(A;7U?LE]0R;KDSBSM45%/*0
M-VTM6</2N.').BS^2:O_HBG:&E_OV84Z"9AEZM7T4YW*7RU4$."_4.0*SW1/
M0C$5I]%-ZB#'/G\FK*S/>.O`?;7]*X*UE,H1<4]G)?A7&K94?HNB%FG7-(AD
M-['G?U27.[7T6I'30"1326E$6GMC3JZT&/WG=1GH3"N3(OG02'%484:T$4MG
M&"'66U(E52J7:C+2*0^H(X(7:<P@@!DG$WMQ3?)B:T=52\U!($%B2H3Q&S"4
M<N"C?THS?E6$"E[44W*C-WPQ'[=G2/0C!A,P`6)P%-9'$UM1)2[59G4#*PH'
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MV"Y99D#T]"UV&(#>(&(8B8+<DX$"%X!E:"A$6&'`(?]2C/%3FW579Q4/FU)_
M:O9-5X4G&;0]:Q%DV1&/**18GD@[1)AT&?=7?N1#92%60Z)AUR-88\07<&()
M>0%5A_=7N+AGNW9,*Y-A/J5Y@]4XJ`-P/_5Q-OE8+9-L-70*YE1OL<(H]U,Q
MI2=\/D23&38IJ60>BZ!';)*5/4E*Y%@?2=1G"94:VZ,T;B)R>928E$(-==)2
M52*)RG@U00,L@38G:YA'Y0A=6J5:B]&+@($+\Y=3OQ)^?M0/_C-FI163'U8/
M>S-<CB1?&P2!LC9'?$%'3!,DGN5!GX)=@LE6-_%QF>AXPO2&'<6;_70:H`([
MK)9(+;1"$?80VG`9W/&7M:'_G"?64`WX-HN&+R/S@GZ9&`BC2ZM%;S_8((P#
M6/Z11/YA58,%#LZU&SRH*GO8FO%I'):"=/T&*F3'(*B'C,1WB>M26IQG(M]$
M;;CY'/`99+]HAS,!29#Q2<"8%(\A<NM$,JZ`*#I$EH@T5![3,0_8(<$S(F@Q
MF9M96IBV44GT&!;)G")#1>CS(CX32S:Z*;622$Y657T72T<I0T"#@_C'@]L%
M(`+:+&U%B^IE/3)$G<Y`8@RF="<C46N2CV2D<FB3?(IDC"]#<A.Y4+[R0<$C
MA9&VFS^II?+CH8GQB>,H<!T33[;SHS;I9&>2F#*$</(C$@(D42U">'3'4YE!
M:F[8_T,F@Z=CX1`)*$T%FEC:AD3"$XT%=J?G*$EZ,:4`=JA5`C##IA<N$W*7
M(UAB&*B]13YR-J:Y97B05BN9HAZ:Z8["T&2(B!>L:E3@AS/>XX!T9I#2]$:S
M)SXA06"J0T2?4CBS0V3%IE\Q!C#)PI9B0P^X%2&8>&"Q4U;ZT0[Q$88F]7]C
MYF!BI1<75#Q;)0[W*)ADE%UBUFEUD1#=^B-7JHOM)WMCQAE#E)S%HW>5MJ;'
M03NG0X]3$6_S6A_K<39%@C)^-'L_5@ZKL5]+)#$.0XJ:93O/ASED^2Y8XH`F
M:4D!FU/D.CE5E4/R\'R4P:XVA7_RVF;_NBLH27Q`PPL!AO\3YH-Q0-,)AL.#
M]F@=99@^H"&HS7-FZX(YR^(QK(JA=/-#XEB?4N8]OQH^];.R'DB?KE,F+?D3
M800UW[0_LW1@!U([JTF0"G*"@J,4'L%WXPA;7NNR%@I-U?HS.GLI)X9?6;=`
M3N,O>2%";=M"(H>6/'4/\W`YVI>ABI8YSDI=JL-Y6R4<B+:0#6LD216*<6)Q
M^_.G:BL^&H:4'[M4^34,&WLWOL$[^S)F`]D-Q).Q=&)/5Z0='7::/M=OQ!%T
MW/D?GY2E;VA6IVNR";(B30A;I&4+]0=[(I(L`BH0R.4Q[X6"9C<V\:.TR`,&
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MK(][*FC?QV2&;,+=P\=(`BMH!82IH!6+&GW$O'A3FLDL\18MHE8>]FNW*<=3
M=!N0K#C4-)!CPG%2-"5S=@CY]L5O%[U*_(&X03`H^L5V\UAI=U>?6PMA3$Q/
M(ZB<6'KD,)D9>T"-LKWN4A#-&RZATZ52E,)H5WC([`^-@A/S-D4%&)`0";L`
MED&Q"KKVUG?KA\,SJXQXEHSSR1:3`TC*"F>M-K>(830,;3P-F/]."`26^N"9
M^W9$N%H3*T%31)K2&W6ZU#NX\R4[5A@X+H@U?C,6^I4<XV-EC-H1:QMME4K-
M+`TW_6LA5L:2"//0RD@\B15LP'L@+DC-#J34C%D[=P1"?/$]J,8;K-HX;H3-
M#U;*/154,\LS;$L^Y`RZIV*6K=2]&,>R^6C6*4DP6?IHZ=Q@]9P//[2.!Z=O
MI);$;$QZ<06*(-$P>CD1MM+23$T:FIMW>)P4K75MUW+*`-)/XK*,!:1M!#:G
MOG:.!Z>3EV*9TM-W"Y-9,'%NQ,QXKD&$3?>GB6,Q.<+3N2UC>+H86L74;X=T
M>T1'JQ(4+#2T/[W0L0S4T)74&NF^#)3_6JX3FVT9:P[=S%O%.(SM%L3(FIAF
MRVMG%^9])#^4++2!/#\F"D\BKUL6O(_R(W&KI],2K`?A4O9;&*$1JOMY,\23
M'3]DAKA2*7+6AC\4WC3'5I-YJ&K3@[V(V3"=+<9K9**$,-#JFWMQKB:F?F",
MJ^.2'][=ICJE04_C1.W5GEB5/!<^9IU5XAE*;0,X1EE<:,KVDY%C6BV95D,B
MK"/.P(0:+@FZ*)YD?9RHN=6Y<S&)/#G4.(RFE[@MW/3,/O=2KN_-*P%+%X6[
M2E?A,[':AGK<W0YQ+^+QY=JR6C9,Y9S-U7A+X9&</*$W.3.)R=X!-N9=YK[;
M)`#C'`1^(!:>_UQ&ZT@+GC72ZV.,,:%9DFM*M==HSFHLP7&[6PENY-_]S8R^
ML(!8Z7!0;-Z@A#:6Q65)'*JS*JAMU'DYAB._V!#2L1+E\M[(UE#U2(1_QDEH
MG5]^;+0%`^5M^@S1T$\-(].WXN&S#M)IR;FSR8CR-R_@X',.97\+::$UND!>
M_B`*1,G';A4,LW[L&#:9_F\6\Q>UN\*ZL8SOX6B`@T].0H$2DQ=XAH!H@[9T
M9B"$%;*8(%P@LN&H+>W<QLU__-6JT#<MICVKED!$(MHVF0RV@UK.6TS6?C$Z
M$18^VB4+:^$&?B:T".CIEK_]6^?)<NF=8[P'S,`C\<9^O7(=BSXQ^__6GM>X
MHD#.`D77S+UCG4GQ?5*'$(%:P81UZ\7#[#TUVR$Z%3S@JA,SZ$JF?K.]29V(
MBNT<R],^`Q[;U``&K>>;35R=*K7%#1$XOX5"V2DH@9DW`&^2"2C(0G_:6,.V
MCI$_XR5W+_`6D?`"6&5)4V@\3^\W[:0I5S!;>/K3`U:3#>$P4G^_:C1[\OH[
M+*02/'`%BZP?&BR7*XD6AM]K63^W-#9`S_RP)MIM0%_YD49M;5;T$-./-:,H
M+&XH,.M:O40?JK*),$N&&>:],AI=15B/!MP75R.1R(4KZ==S>7*;+]OZ-$@3
MP@VKC!B\V6%\+PW))%(BE"QALT9$G_1`1U/_0KUD?R#=L70W3K-0&Z*Q,CW'
M-4\;KD6ZT>U#"##JM:1@$.P#/-_L()W!WJDOY[_=B!HT#$($A5[=L+\>6O(&
M"`%)204!/#PV%C81$3R*21&&`9.4B#R3AP4128F7DP6@AH@6/(.(-J&7+Y^&
M-H*3D)&*G@&:A9<V-CP%20&Y`9&7MYBTEY"<KI*#P0%7-E>$`8JINP75CKN2
MMJ>4@[V7W(._S-^ONL20UKJ'M=&'W)'CUMF5Y]:U$06YM+:5BN:NHE6B=$[;
M)D28!`T2E<A5/%>\8/7"I.O6I4W[*.$CU&^AI'SL&($"U4M7IWRB-+8S1C*B
M+U?">''D6"A9.X$)_T="DM0-)3M+"=G)#&5AP@0QM4318A5PI%.='@5IXEAI
MZ2]"0F723%7KECV!GMAA379HH<.7H"Q%M/!/ID9<V=@E9%8SH*]=21S-$K2)
MYUV+27<%XR'+`K"_A2OZE%MQWL!A\2R8125+3+*I584IU9A/U\/#Y_)9L*RP
M4,IW55,.`U,@B^&Z$1O"ZEO,V-VY>15B*QF0DV5A"^4*CRDQDSY2@Z[PE;8W
M'4_4\\("F\?+4=)<MFR0)OGMI_*\X.;ZJDZJ,T1K;($/;!5X:5J\TJIA!_E;
M\+#-@$5I,J3)$66$])%2&C&H=:=16G9-\Y)4I_0VT3M"I=1-.;T\DE=%>?^E
MIY!(W&VCGC'Y/)7:,,!I)A$AP174U4@AFC8A3@<.$E&!L2Q(8&I=B2,&4I'`
M(M%;*SXEY%`M,<32*4NMZ`TH/CTGU"8&I@,4;\#T&)Z$C/W#R&9=_557E1:%
M5=LAZ1WCERFYF$4<,6RBYDMZ6T)G&D*@_$+2>N$)QY9"J\BYH'DKJI20DXDH
M)&@T=KX))I=N^F.82'[%=M:>5$DH:"L:AL+3EHD*!99*8D[223]^7H4>7HN]
MM=0H&VTFXU7(!-FHF^#DXE!T+%T(38:E5"J77^\T--)/L*ASC9:##=>F;"AM
M!M)YELC8'3B_$F29F1!*B2%:(_EE:5C_Q!*BC`?_7902AT[]*-V$)BZI44;&
M;`42/VZQ"=5I01)S%D*9&>K),$QN0M='0S)"TU:GQ7LA14T)Z8Z8GCX,8H8V
MF"+@)XT@I\^D,,DU[:*/&)M46B%?]5*MO?[*RT-JWM)?>1&,>C*$[WD":9HE
M58-/`&+TVHDX`A9853_SV=AMR/[5>8[0T.VTYY<8)YWQ-4O_JU2\"U;XVLY[
MRO+?Q=4^^5D!<F2TW#C2[-K)H)D1_:BBA>R']C3HV43<.W<^W<J_@'J-8+4W
M\G5ARKI$TUEY&]?Y3WCWS<8)*7^'4DC72;`E*4&K3BPS0M$`39@T%=<%85=N
M#@OYX'%CA7C7MZ6$XDPR_V4R+YA."62*&(;QY!'`.!T"+W#I\C,3VS2QF6-^
M&'+2Y:Q5^B*5)LW:=E'!FPR)I3?@U>/05M3L+:$WW\,(U-Y_$])IN#6Y1]N-
M.5,4E]T9?8RQBY<6;BR:5#=V]2?=YW1*=8T97T-T5I!_Y4<X&.*&.E#QN,(M
MS&/K&YWW+L3`\2&I/:4S1:A<M:`O44QG$/*$C"Q!JT3]`@RBZ(4SSC&62DPE
M>]^RBPE1L4`"_J17@*%5A&;(,.*L@W]<<9UJ-M85.UWP8V7Q2#':EK4F-H0C
MC2H-8Z17#!G:Q%:Z68=8[A,VB*"N@R?S5Y!X`1G7C4LGIAF$!3`P`1:2T4<L
M2?_-^)0!1<;):$0Z`9*TC)="Y6F*6DW13U_:HY(A/65)[AC(3G8(DT^@"$>2
M$`MM"O+(Z14*([/0S%4@]+/(7&9V5`*)(DQ&I],X\'%/JLETY&$KD[D2%_,Y
MSGFX8C[#B&,?%5$-4/Z'24FZ[)8^:V4IP/B,5E0,:/:@!B9WA:2"F(TQ#/2-
M36B#EY-DS"1A*=S,M$3!F*2/9()YR3Z\$H!57,$3X_B@(]GU"*]A$77J$!4-
MZZ88BY`'/IUHS#ZFI4!U7&P_8OD3<Q3X%_:PBF0%B5TI'K(?MM@*@,<D(:P:
M)(QY-90RXG1E,G[!'HN10F'\*<QT'+I#=&XT(/%@2;?_IH>()9$1C67AP00P
MP$;*Q.D5<4R2[%)(31%"*H/-BE'_^!*=67[CH?=YJ8$TPKT.361X.07&PA`5
M*H%IPT4>N>.;%,8YD3E&6+SI!WN4<XL=;<@ZMR2+J+14`,OY1(OFP-U%!D.-
M;,!$2Z";RNARZ8B>#<LA8)"@)"Z)EAZ]"Q63&,TQ(3,M$L%I8Z5P$;5N,1J\
MI&]+SH!8F8CX"GQAPJS@V^DSR02YXQ`F+^>D2"BT<\R<A6@=+DH$W7XVD:MY
MQ3):Z88X<:H7GR'.6SR1;97`DQU[@"MTV.@IQ+1C`:?<C4X_F<;4-!7)8+JU
M20>QGS'G<X5K,>,GL<%=\P(:_[91?,TN;*,(I8(ZEMI@T6M1`9SK-(C3YQG2
M)9R8*0:0\CI#!">(6%NGMU0:'+G$+5D5':3*=H)%%M7->`?S+(H<1I60T&48
M]`T.J!8*,(#EH\*^"]2',"&@P2B$*N^1*O^T`Y\3Q2)62VUJ2)]:$C%J$$$R
MO!2I2/<+8:6T20MD1/5N"*KI`.4*NRK'C`01+<FB!FL@X@9K4905,*VI0P=N
M1"D>\(#8MD49`&OBK.8J9(R<0S81T<0#HO'@=.G18$(^3;B@9"8FV\G).;%G
M2HU9@#47(A8KM=_HTLR5;EV'@:JAA.A2A9]X[$PC75OS))K$'@7[#F^.N1P/
MQ%N=A?_"T&0)$PN%CNJ[TEY5&TTFD'LPX8Z*`"A[W;'%D"I5"^V`=L+&D5XA
M']:.VX@POEA38L3D%RA,M6-&9_XD=R1X2"P/2CI+;J&)`4PM)9;FC:Z:W>SN
M.161D+5%SIO#`R+@C!]<XR78DU$:O=$7LEHC+3<IB7+:T1?P"5JZ]O[<:^0B
M2BT2JUS0<\05-K8(?4A5.(%2Q'=<RA4P!)84K(D%0EASB#X)KD'[(&%_\)&/
M[Y0YR[V&7K=27"`,>VTZD9O()I2C!BZ#[A<12H(:.+[GCWMFW;50@TAL1:Q!
MJ$'GXLIK(0Y"MTP8)*6[Z2Y2]B!-3J'WEF](DYY[)#DUI-C_T0RV2W;"&9>Y
M)H&LC'G#&SS4T$=]^$_6"4`6`@`&3EGF=^J25*^RWME!(8KG^Z-?3=KI]*2H
MQ%<;[$U6[ELN8RJLT/[-C\-V.(L.5?=Y_#SV@PQ85\XE4G0XQ""!*4P_<]BR
M?=D#Y4K7&DV>.-Y5&IX='P$]@0$P8``-$,.6!M'E&@P`!S@8@`U28%KLO:$!
MKA>![*$T;AM@P/4,$,$N+"LJ#(A`!`V@:1LCT&7]'6KE9U$.YU1RDN,8RH'-
M$(0-<```!AQ&PQ]YD*W>@('HO^&GTWE,I6HKJN>Q0S9OPF@S:M"`_C=`!!@0
M`5KP>_\7?>U7<&I@?"+P>@V``'A!_S&+Y"^HT7<+<043(`(XP``8<`5NAV@V
M,%,#$((88`/C1F\1(`8-V!5T=@7'QP`:"!K290/^YW]BT&?QD%J+%"\D1%3J
MU5P14`,04`*[%P`#``$-T'*4L'"]4`!B4`(X('N.P0@RV'\#`(!B,'`;@0BQ
M84>#T7;X`3[LAP"+\`!$J`$EP`-D>&)542.WXB8.AT*B(EZ8Q%N\E4I]9"E<
M(1LE84M"%$*8$4<)H6[(=AB4,WB$]U4.,A2HIBK'YDCRLUYSHC*#-$1_9&!@
M,6CV<A<1DW=-U1*=9U+U91I-88A@42:C1@B+\6NZTX>61!@V(`)U4`894`<`
MD`%B``GC]O\&#``````!95`";Y`"Y#`(&%`"LI@!LE@#!;`'^5`#&0``91"+
M#$""<28(8D!^`!"+O%@""/!S:@82T,-NR\!ENR-DR[!RT%!O>W`''#%NL7`'
M`0!\&%``.L>,YE@CX#!P/S``O%@'&+`'>Q!24$)]D2".!O-B7#9(J6=1DT:$
MT-B/1[@'#<"+95`&O`@`;Z`%:N",T%B1T(@`6L!H1Z*#V50:KVB1LP@`W#AN
M'B8&SYB-'U!^PQ<)[%<"Y1<`PO@*-6"3L@@``]!G%@$)+@F-VE@'`_!^U+=F
M@!8PZ28NR[`0C(`!,?D#%Z`&&?`!(O!SC#!NYA@`#R`&'U`&((G_/9N``;08
MC6=YE&[19UP&%=_X8O,F"`^0`N[X@V5@?BF@D350`0T`E`2YE5VF'`/Y`.QX
M$%529AH&-1$"B&RB07C34T($+T`2&&Q":<7B8,I@(R$AB,V6/J?`<*9P'8TR
M:['Q4:X3)BH5)HXS>91W(URD&>C$+AW5B2^U8?LTF]IPFC>Q6D$C:M6CFC<!
M9J)6%F]4"!/Y`7#P`V]PE0/P`WDY?A_`C3\PG=[("#P`#39PE0PPG0/P`1EP
M!1J)`%=9`C4PG6^@!B%Y=A&PG-%9`[97!M[9C7N@#G`)$=@1D-?RE%?P!COR
M!@$`D,B0!'>@G.=)EZRE!@"Y!]BA!0R:_X!B]P8<V&6Q^0`_<)4?\`$#@*!,
MXCPAL@<)B%%3L9\[@@H`V0S/<#.4\0NYV`!UX)WE>0%[T)UE``?NZ9YJ<`'B
M&98-('8#4`8UH`4%0%8=I$H_-26F40-EH`')B0`0@*$M%R>[\(H,4`,(``<:
MH`$#L`<IL`<UT**\F*&\9XTM"HQJ,)T)"1*U@``MF@'NR8\8^@`:^0.VYA#C
MY@P<6)!,EPMB5S$>NI'0^`9560(?T`![H`5TZ0O\R8%WD`)O$)8@>8])@`$`
M@*%O@``,$),UH'/7(797D)`!R9]BX)^S9Q91]Y]JT)T9<)X(6J8_H*5:,)^V
MYI4E:`/^V65BI_\5Q=>?5Z!S!&=GK+")3:.)4,:*GI=C,T%!71*(\P<E6P5.
M;CEKI`8KH``&&L8;'B-CR/8(6*);RT,CPN9-D0@BU;5DE7=#G-EL?T=1AH`<
M-69B\M(M',5B;"8Q*K5%=$(A?R:%W0D`&W`!%]``'U`'5"F1T+@!>^"O_MIE
M4@@-2/H!"."O;V"1-5"5`)NJ`(FP='D/P,"><'"P>T`'3<H`"(H!N8>3#U`#
MN3>=#8`#_8<#=3"E20"0NEB1LB@"-O"J*#L`QU<'&;"!.PD!3UBH>W!\&)`"
M,(H``X",97"4T;-0"-"/M?@&]E@`#:"!_'>$^SBEMH<!93H`9YD!4^K_H0U0
M`D?(>RLK`EX)(`#Y`Y>:H?ZZ!R+@G52)L#!ZJ3YZL%4Y=O.Y4'_2(^)"5YW1
M"Z@ZMW#@G06@!5WV)C+W`PA:E5>)`Q[[!JY'BP/P`!>P']U9`G.+L%S9"`,G
M!I1[L&H@J"*+HRGYBPW0JFI`L@-0`\<GM>*IC1FPHPA:`]!(E:,[J`?[E0P0
MBT:9D0/HJ!>@!>PX"%S*BQ-[`1&+G%H:`+8'`=!XE(5*M<\8C3`+D%=@>[XK
M`BQHD2HYI6JP`7```C>J!3\@`LCXLIF:`C^PLOW'`!`PNZW*="1KD4O[!M57
M'L@`'[F")GXW.@7V:W5#'ACE1;&C/U?RK-S!_V*]-$;0*E'5<$C^Q2O$>5^.
M05`7!$2=ER^#5CVJ!CVW04N&IJY"4BQ+\BNMQ!L<E0FU)2V(A&JR%5D[\RN?
MTD*C-QN@<`4#H`%ET*_*RXN`>JH!VW]\F9$Y^0EJ`+`?`*@74*&#ZKBU2(6I
MZZ\F]@#9R;S^J@:%6P94V0`:@)$7$`$X\`$X\'-VFP'(&)TV`*/..``@X+4^
M6;N3RK-?BP//2,8WN@>76@(':P-->I?&*`([]@!)W)[/2*AU:K?PF0'3>96T
M2,8I8`,,.+;9*+4`*[!-3(N"O'->F0)J,,99^K8`6P8@8)ZXJYTWBK$9"V_+
ML`</8(^NG)"R5A9$*/^W_EH#/.R<9/@D<YG%)8"EEIN7%-J=<'"C7,:>Y`E\
MJ6NH+.D*>Z"F`-``;RNH)7"C.TF%%IF5$AF3WON/7=H`(``'M(@#!7`!N,S%
M@8JA!ZNF==``.PD`D/O#/3R\ZFB[`/"P.#JITJR\%4FCNZBY37Q[T;>+=SNT
M\&F4/"L&#2N+1UG(U7RY_&B4-ED'->"A^UH')="B8@FC&%"1;CP`9%N"Q')J
M<X>OSS%>)3<0@.,8=S2LAZ<5V'-#",=P$KS"#JPI4(,/M?.;D400U_$/)\*)
M],IQ!B)"J[4\D">*>">($_%2C1-&QK1;[_$"30D^D_9!J;1@U!$E;F8B]#C_
MD='\<V#]L)\<EB5@DP&;D0^`5EK0L,VYD;0HS6I`BSQ[QSAP!3!J#5G09U<<
MRC!ZG("ZO!/[`TDJS3$:G6_0OC'YL%J0!/.[C[5(E?9\A,CLGR(`Q'7[`0SP
MU]ZIJE0:`7-0"*SQ`%=@DQ5=N&4LC%=PJ4;ISGOP`V,*!PV8`G/`N`#9L(,M
ML?(L!B%9?:C`>Z",MP1+D5_:Q$TJ`EK@KRE`EP\@;D24O315H]+-?^>9:04@
MJ0!`OD*,SKN\'[5@N<<+`0A`VW.PW$+LMKG8HAC]R#CP`X@;##'[!BU:`3]G
MNX-JM#^WMKM8QN8<DPS0?T$\OT*,R72@`9B<NX;=_[;K;)&!_:?#^U0;:9%'
M^<XE@-=:$+=N"]L?,+&OC:#/W**$^@.D:P,)6`/_";#`"*=[4+@/;<\5_0-C
M7,:'70<(\`,-*]>":K&O[9PB\3_&,B>7%Z[=*FJ)AE<XHPVY$<#E5-78$WX5
MLCVFXM1W8B,F/*_&L#8:+!54!L`BXQ_')N3<`1[7"N8T@3/_XE+;=1DX36]1
MX15`D7&Y4'0NEF[767=%1G_%HEN&.,)B\0!O(*C96`)7"<:YNYT?VZ(9"J3X
MP'3'68LO.;%J8)&&KJ9.JNAR$`&1?)4=>P%;"M@PVITB:[L`K<?(Z:\_`(T3
M^ZJ_YX)K2I4($+"X>ZEP`/^Q##Z\E[K9<[WA"!O++#)NDDK@V0B2GMR=;FOJ
M+<K$"&OC(3C&#CN\P3V1#RW2E]!E;9O*VWR7_O>PA/W$P^NA978;'?W%%WF1
M&A"3&1H)<6/%8ZP!%)#1`7NC`N,3!;"E#0L"_CH'H4W(Q&[,>R#?R%G?O(@!
M#)JOZ^FE[NZD62RYK@>?+0[K=*L&"`!\7NOP3XO.N6OO&IX!`P`'Y*?K/Q"6
M06P:]-BP#QF=<ROBWKGLDSKK36Q[(`V?]FZ[98#LR=W?)3`';\OB-XKBJ6R[
MF`RPH6R53WS8*@G.5$F7SU)%D54Z3B8W<*5@@5%`MJ+D]/5K3`YKR`HU1.(2
MWM/_#1(,BHI6.RT-%&^$1;HY/GLTFOUC0#G#.\6S7?3BU!4V*$'32JVD2$S>
M1YLY14W#6&J!$FYV%S[WVF_LSJR-NX(Z`&\[N!?0EL"@D6\`!S3*CX3>HB*P
M^"8?D-!CQ9J.MUH<EG/K\S6PB_M,ZBQ_ZAL=X4M;M2IYHZ^.R:2^S\L[M[=>
ME1:)SPFK<_G`"#H<D[EGDSYIN4+<`$9K[$M,MW_^BY)_^_XJJ6QJC,DKH4D1
M"6-<NI]NRS!ZL#\0L@?[JEK9+*#P>ULPW=-]GBU"?0GXQN.;X^B)N.-V$10*
MB]'L^:"@D?N^I5I@`R#NRU@)"'M:!4D1A6]U'V4E#`,U_VH7%WL-964,#24`
M.)`U'W4_D1=J()67#`"?%QL`9:![)1\-%S]E'R4###@#`Z`_K`BB`3P\$7LU
M```5((DED+,9MKB-`\`_`Z@-E!\U%\>MH:$@MLY[<!\9D`T?#,['J>H,>Z+0
M#?+6M<@E;Q<I$0$%!0+8L/$O@,$`27@0)"1L&(\`$0HHM&#C80%_PR`F+#B0
M1T"%"`4B3"+LRL,D*%.B?)$R(\J,PBH>?!B14,"&`P_^2P(0($J!PV3V[/F/
M4,*'&2\:BFF!Q\N'!A5:Y#D3*DJ`#6%2_2@3*M&J4(4=Y&D3:\.8`[M:H#B0
MXLR1*E.*??HOHEB%%:=^+*C5Y__0KR0#/-"RI_`/6`,@J1DP3A3C9K,0(+"A
M1IZD/8L!H!.%6#&#=6H&7;SX!AH<><8@?$@<24VF#*A`B?H,)](/11N>Q8K4
M:7.G5&H^R[J`H%;N"Y\9<(YE6<T/-0]J%BC-JH[U6I`7?S@=ZD>B?9$F-?Z1
M00.P9YH!0-;R0"+`RC9PK':F1ET&V:'V?"Z#`/6/&C;X`U`$-3V0PH$()OA`
M>W]%<*!AB,FCQ7\U$//`#Y1D4(-E>T17C':L"4+>:O:8%AJ!_ZB!R'R5@7,8
M<\:HQ\DYD!BF6@.<Q*8**Z[`(HL:)DHBBCVL[#-(10LB@`P=QGP``!R*P0)E
M>"V"P./_<MP4!P`WX14F#COAV3?C9A=8>=\%\,@#Y&ZB./=&`XDP<&!`HTEU
MT5$WA>3026()Y!9/+@6FD50H5O333WO&I>A1(_%PQ4@"V7`14&3=Y%!%>Y7%
MTTL5Y?37IWLZ9=1'>!'$Z9X[Y=D755D95"E.0GW5*J0.&?175$A!)5-':;FU
M%UQQ44K20@$5(A%;F%)%4Q(R$5CLIX38Y=$5-=3P`QVP0("?DK'\8*4&7#;`
MB@V%O5'#!G0,H`%_X1T#0`/>EK&E%J(-6)HGV<"R#BA:1"(N`-NEP$]PJ]FF
MR#[>;?>#-1]H2YPBH`1'1&W$`0Q*"I^5P)N3<&R`P``X,FB0_SIUO%'8*!^`
M*PEC8`K\1BWGI;`'8]JJ<<PVD6@AKI/#+1C!,*0-4`L$\!*FCL,7+!@)`M``
M`#(FX'JH5'0&1I*"%@+SLR"#HP5PQ1L(;%`#+&>N_`$.!:3PQBF>.-+``&_0
M:P,&#4!3!P9O*&9.'>?"L2XP*;0G:01B)#*<U>QIB>,/&<]8AV+.U0+'PHP]
M3MRZ$?OHKR)T//=Q+RD#LT<!%:FA!K?<E/,!FYV48>WI`^1FWW,UU`+";/B:
M"W<W#;^NACF0)<P+`JH-((\Z):A)CV,X[K%!\8';51=0#`%-$DP(162#!0A)
M=3V?`^WE3[(-=5T2L(L>U9)3*IT5P/]:!>%:Z_4(#740K^Q#2VJMV=,_DZGO
MR\E.6%6KG@2F@"3!"E+$L)!7224IFYK5510(%9I$JB.E>HM/T@<3B]C%)CR@
M"$ATLA,(4J52H++(%4Z!#`U`X#S]R@PKD,$:-/$H<%9J(01JT"]Z60,`ZV(%
MCI)&J@C$!QE(+`,O^!&!!UQ@10`X3@H*<(KAO$$#``!&?32@B`S400-G0@#$
M<-<`@6D)%`](3FNN,4,`8`!%_XC/.BPSBUH,8`XSFP\_U`:S/6JA=LB```20
MP:59)"(5T0%(^*[`1B`^20TI.-K%!(09!&3"28%\0^`DXI&:--%G:B!01$8I
M'=*=H@P:T(#_/OHUBT'RL!NHE%<2>6B,#,@2&138QQ[>()\VUH.)MHK`&P;Y
M2_8$[D+7J$0=:H&#.3S,80LJ@+I0X45/0$))#G,-F^Z!Q4$"H!>_2($:B%(`
M0-[.,8K@QN^`6`9O5@,6+K0EF]Z0B1E"`&%-RP`"M@@FFT$@B*J\F+A8XQH-
M_(B-$)`7#GX0/8DL)%+LZU.K;.(GF<A/3R?Q'K,:*%&DH&]1PF#)"X;!DF`A
MZZ&SLL@P-D71F#S$4*]*%4A6:A1<S24A7>G(!+-B$9^`I7XAR4M'_@*HO(S$
M@/RKGT_O$A:W!&4A23%*^H;54T,<$"U1:5:D"A$8O[!J4R,$2`UV_T&-RA2&
M7IAY4R/Z(XD4_&`+.+K:&W;1`&L)C%Y.5!%=]\F>Z(10,.7$0+5J@(`?6(8]
M!=#"FB"3@CF4LP'@J0^\6C-6>%'(F1AZA"@0`%F!V6RR*>`L>#;[M@%@`)(_
M(P:&&F"#G(FB!@U`P-4X"XHY0.<'=*LM'D\'!T><KFBMB9,\VE/`QU8+!)U]
M8ETAT9[WI<VM8P69M08CH#[U1)0W@99"(M*`1L36&9%X`P`<E@(>9$.PU1*L
M*VQPWL%.]P%[^,_;OGL!Q!:$='2+6T,+,!@,@6QAU1(8AD[[@#D$SK^0I1`D
M%"P)T8;BL[O`FV>SP=!0:@^_D[5-`S"P3_]);*"[(.OP+-Y6V#>!)[X($,$`
M1(``)SZQMW!S:UV;\Z9=:+:^)O8L9V4[B[%>0K-72ZU+8P*ICIR%@C80`_?&
M]]"IZ(H@4;%516\ZU>N5%"0@30NF+GH0@-`T56CQ:$1V6CVIU`4CJ$+)^-R2
MEIWP=(`'A(E4Q;(]I)3E*YXBBZ"&'$%%OB4A%!D604!BERK'Q2?2"I5!X$<7
M^Q7E)X8Z5E/^@=8]9(T]302(@>@5"L4ZL;$&QC0='V#A"&"MOJS$:T22TD1P
MY*>)SC+G'N80D:KQ@U[]0E!]L^9J7A=88(UU<>#F8.N<H177P*R+I;6V:4AV
MVC(ID,-S3JT%QS;_$=G/QIHW$(!K(RXY(*&Q6H)"T=@"R$$B$.%T8<#!(.TU
M9=6=))VG:E*^BPR&W)L6UR\/!%]76\VQS@9']`;#:7H%F2B2,E#@L(81>Y-Z
MW0)7D"@'LVQR9RUP%S]0SCI$QUOCFFL9:>*E;8WQ_%S<P+P&!WM.?;5<)TC7
MD5#X,5EYS'LC;C`M-WFG^R&,23'P(MNS`:#6`F5$70I\4.X@0?Q!D8O\U<MB
M$,.CTE?2A$R=63RH>EQT):JC_X-/)QD53BKH9JX2(LT;?/.FKA=T128=542!
MNZOV-Y!A%>568KF)7.2W4KF<A%'[&R&FZ&1HE<1]?A<\NEG(4K^KEDHF_X6X
M]H'PBNY/+@C8@3/='(@]2IP?DTX$VIKG!P$T3@KFXF@-I5)L<(HSF=OA/I.\
M;</=5ZRU7/3$WCRMFTAL36,-TZ1.M2C'=_JK)1(ZH$;KYLT]#(6W1P[IGOS*
M-\EZ`(!I=)ST2C%L;SJ9)S*88B%XAVSOUU!5\*EU+DI6+M)705BZ)P-8*+.+
M\?+-.ZL`SA2WAP@.WQ[J_8,.1V]A\4FLQ&R7QW/_,!@+0G/!IGO$)GH+8CK(
M9X"7%QTBX2PBUU<'"&J>-VSC%&Y^I(&UQP^V96#XAB`>\DDH&'H?%P'0\7M4
M<U<+^'U\IVC#P&AL!WD0=2IU@6Y[8E$5%'0?%?\L)S%2?[<H4'5^+H%NF>)3
M3Q5E*$06:68K!Q1I%`5EGN)02&$JAU=<'#$10A<0D`<M0'5W>9)5V2,250%4
M9*<^-I$^4I42EF)FHY%^0M@^C\93YC=`2F%Y/U,1]P=[J\9?S46(HV069FAY
M@B,I8@@1+/B!2P%E=-,?6E!*#4)KH!<=XS1Q'Q1-"6B)`V*)!`>`U+-_`B$'
MSN(1B,4#<@!]!I%IK,@#8+`UG9=(-@!;FG0!J>5E%-%$/"&!FR@=9A@I2C$@
M5/,SOA)"4-44>!$6>V)OGF2!`?$&N1B--;%\GQ(!]G==V&6(<M!3-@&(Q.41
MQT*.G#@4G^10CC@UM/C_C?Q%)Y[(C>EX78D40L3@#_^P>Q\$:PE8B==EC,,7
MD`."6*%H(-;XBHDT&MPX(%/3B?ZHD.[F$>_#/<>2%_S#/Y-29YRR=%+8=`&@
M9-TC0L-P=1S$/D>A=<$"0,TX%OZC%SEH*'G'D-^SA&Z69B0QDUM8"!,9*,H"
M=V4V95AA5"B$%7Y!5%'6)S`)$@:D)TQY%877/HI64QD!AH_V$Q3TA$?&$'<G
M2F_V%0A7%*7G93TU47TXAUX1D]EU+`'P@(518/"6B!$!?6EI%@JD?D`C+>OX
M*Z$H*R'19=E7ESHY5&?(B@$`!L;BE00"'1+B4.>F45[C09D23*12;Z2(%U_G
M_RDKR15&98;96``O.`@]%P&M>&X4U!.C22=W8BM>N8/$Z&5))T+%.)?.,BOF
MTS7Q!IE#-9MT.9LV!99W%YH?<7CFHYK%J)HH!)R2J92F5YNH&8C$.9EBF%/+
MZ!9!961SIX=<IH4&D7Y4^1(DJ1*!XBAP@9(XY9H3,`'$\A1[(1="I9)WAR@6
MZ9<\]1.)-A>_LCT4Z80V&90W*"ED@4%SYV@,\2F.9YT.,1I0.3]/J1(OX#Y0
M@68_X51<Z)3N@Q;-PG9>P9]@,)$0(6\`NI)*IWY".!0AQZ$HD19)$2DZL35E
MF61>H2RD&3Y%951NEU5;&&]U1A.(Z'8!@E,H&IT4)/\,37$G5^!4!<`2!Z$]
M2T=JU-43S<@5+K5Z#`2.G"2&[_:'/ZJB?!=HP\(6.BH6*,)`NBF,9O:-E\*(
M$C&E9W93;8>,7HJ&4+I5$9H7)-HH@<9D4761!P$_!"('1B:5=NJ?%[1E=D)D
M?M*AEKFF?2<05Q"46L:?O9D3!**,>2<M&3DX`=1F0Z83$P$I1&<5ID<2;C$^
M4YIT0`@5?`IH5Z`H)/44Y,F@&;4]YVDJB,(7\=.,7T:E8HAX/;F$O5I5S,)F
M0H&A6F%T=X@5(@FJ2_4KQYD5?X)E8[8^Y[.@#'H6@`=X6J@KCS:9#<$3D(<1
M;09"I:>E606;)MJ;,(&?'J'_+)!R!8\B/S:0!1RQ=,TI/6W!0%=1;Q#%4X(I
MJ8&W*^HZ/6>9J!<TI"JZ%.9'$D7Z<P@K9<7%G^:6?I.9HDDF!NOJK4AW?B@J
MJA8+*+F"/1;`0';94RO)J>189U<9%8+V)X*"I)IJ$F!XHH/WC'VB$"+;BIRT
M$H[RKEEA4>%*0F860B!I=(9I=<Z80:0SI+^J*T07/S?UF#:5%KS(B&_FLR!)
M*V[F*4`QHI0:>!T4LA3)=O63J%)QA\I8JZA2$B8!%ZTZ4M^I*`WZ9!8P`6)P
M5$16I6\&M$HUL4IE=,)P0C@596^8M*=JHXO*E)2:0!#U0,]YA;1J0(J4K&%G
M0#BY_RAQF#[E0S^-IJ5OAU%C>X0_`2L#1#W+>;:]F@4'*K/5>8,_1S^$X*XH
M<05UY[&H\J4].!"/DF06@*0I:A%M1W?Q:0@YX:TBFV1-)I$2U11H.Y7+$E5U
M]@*Z*P<*^[F\&&_,-PQF2HXENA8O=;69JY0AE)^&NK-8RX.ZRQ?:BRD\\`:#
MPQ6U4GKB:0A%2A#&&Q)7H`(N*Y'<^Q/N^D`4"Y8Y@9_GYJ="-[V"YIO^ZV17
MM[@X&%(&'*QLF,`C6P!@H(P309'"$ABBJH.&.[`JQ2M#:X2-XA1^0H[9RC_?
M$U0BQ+U!69TV2D#8.9E=&I(%[,!)X*Y#6*U1P18=>X9-*?\2UK.&?J%H"<J3
M/FI"_C.\829G$104?X)D-6B&.%5`QCED;3=!7CM5!+JK$&2?$*2<->L42HFM
MHQ*58DLJ#'&'",L]VXF%64MT%OG%,#6B54C"0(APR-*54'A!9H@73^%1V1-T
M`D2'C#)T]/IU2\8H:"G(`/MW8$JX>4FZ'71WNFMDE@EIB)JJ[LLI4+B1(C1V
M7SBU/>A00O>'N=(2<*R$0>5F^RL7R=@5;,L6DS:%,UMG]Z>,9W>C[/FF*EIF
M&VG"/GJ9-H6L7AJ5W;K!/77`N]JM9]<K@T;(6%;"QM+&:VB?`J%D@UQT*CK#
MT7+`=A<8):6=/>L43-9X0\EX3#O_K#>9=RNEQQ;QMTM;%`C[L%P<=GYK4QP+
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M+#R%DMM<_\)*RIGZ`Q29^1=8IH0Z.D)CF;:-IW9@%9_V@W;I2G183&=-]Q5(
MNV<=Q'5$-L^(_,S7N;.@JRAI2<V8N723/;R#RQ2M:UVE75R%K(XR[#XPJ79F
M:68IA;ZA*\2B?=/_0W;X3"FDJ]QA)D`"'79YVKEHC60E&[1]YST.^LYR/<)>
M%V87*&^(>GY\0:-U;*!`V"@/-<CO3,0V:IU"*"P:Y1(E2L3`>[2"6]QGT;M!
MP=8]F\WN7=W4/9,-5,]*;-]!!3X$;99V>Z:GNH6VRI2]J78=S#XE2ROWW8;?
M8Q(H&:?;;=ED6+86=2OM?'0TL6K,F.'O["K1[;YZP7>_:9F7[/_@C.83EZ*R
MZ'S@0(A!IHJN%VF36BQED=+36%6K[MLU`]*E/VB]93;06*:.)[HL694L#\11
MS*V9V]ET2KV4.H76\6W'GOTGUEH].J733%VV>PU`?&K<"B2844EW[/.GX?O6
M).3;+G6$S#NC0?5S=@[3)-LI$>7A*'NP&Y4]X*J#03YF6VLJ;2:J*VTG@F)D
M*3QX@5[?=*Z\33BC(\YJ1^$0OSSFVDNE0DK.LV*70MG+)0S4>?BG&#H6E=X]
M!CII7;T^6!X4\&F=LPZ40&&WG'Y`)CY53YZX^E.4+J7$D)MW*KJ$8D[*!]YE
MI\XGH2M4O]F5J1F^38:&->VD&813"8K_HG.1?A`%U#);Y4:,N?\3=$,:='1!
M57L;[0)$UEMQY8+NY8:BU\9R/4J+V2BUK\:2N%><Y?3=9$(9G84JI`5\MN#:
MEQ49[+1ZU80>$&P>*&^]/U28MR<MLDP'0#)JI^LZSI.2MQK/V!KIAD"E@[RB
M$5P6H08KJ8_>/DI<MDJ%V7_7YYC>=8>\V!/.Q/X[/?M[KM0>G85]E]GNR(W>
M\H36S<,[Q591TJ:R9J*BD5I.48RFX_SI/5A_=DJKE`0B:.0(RH[:XA-)TV1.
M/5;E4L_==PL]9=(LAP2J)_C#57JVGA8\EF9A074FU%<Y%9#VL%X_Y#[?LU/&
M>)VBUD4'Y"@J_]>)"E4/OA>"?-OPSA1N/:AW>[!+L91*-].5@I,V7NPL;70X
M33[7+BB$'&?O6[AI/-<*JMY_S[Q[3#[,7/1WDK:%']Y,>7A+G]8\R?.2CZV"
MQH-TO9F#[[,2Z=*-C>[&FJ%Z2';+_).:J<V\[_#,#?M%]=Y:,<X46O1)/K+H
MFQ<`C3U+#*<C?606ZK29/?TSH<PI_%,U1=K+;?LCO:O-C'CI#0@%`0$\/#8V
M/(.%282)!8R#@TF%A0%)EYB9@I2%B(V#!:&BHI$V%I0!CY>DE8:'B9BBC*B&
MITF"EXV+C+>&J+>AC9ZX$9^<J0&FM3:@!9S,@H2OEJ&NILR&@X?,TO_0@@41
MC-L6-IGFYM^^%F*(RZZ.R=ZAFKZWUYW4NHZ;S+/,$<6H^1($;5*[?HK:I?)G
M*0"Y`,4L6+!4K]$M?<BD5;J8#*+#B>)`5D24Z]4^78@>$6PHD8>XE,D2?9J%
MZA'&53$OK>,1KN6FAHLVU:3Y"E,C0>O*)3&%#.;&>+XB..LD$Q+)`M<>*2,H
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MOEBH4"^_I7::36@EX]U7&%XXH%\,5A4908W5,J`QR%0"UCL/`D;CA;3YA5J.
MG*#(#&V0&%(9=*[8AX\_01*$#3P^JMB55S4)TT]G^-@$FX>!N40=-)/E=]>`
MPR'49#=`F029@:,]*513WFUCGYTE(>8/55ZJR611W5`6$VOHF3?7/G&&.4IP
MPJQ(#21.1O=H*O&1_T@AAL>H\A)L'#D'#TUZ\G.D&!.!(Q2@37GB22OC*/3A
M7H_\QZ"`^9U3:$F'L",->T5!)@LD_+SXY:H'P0?8H0L!PXA\.W9B@Y?L"3K0
M3&@M!DV3IR')5XD+I>972$IE(R2!J"C2$E@G^J6@(O`T&",FC'%[T55,RB9D
M8$"%6,TZITB"K[K=D.A1@YPX$N^(0E73E;TY.;9<?A\IU%^0U#FLVTOYUK.M
M0GVB2)%ID3E663W@5C5G?5")D^IL(\;&+8HMRH1DPQ0#N"]Y$8K[B96G^>:1
M+J!$/(ROCO%\[$!<)7*K>3K7-<U,MCD8+GWR!?.*)Y1R)-E7(+&;J7Q?(?_C
M9;FW%1F+>G;^UZ1PN$G(%'7G3J2;BE,&[:QVOQ@*C#LJ\MJN//+E2&0SW6R'
MIH]M`5/;;9&@9*&Y:.IG3TJGY9G?V$VC)E$2AU&VT4MI-M0G=DNYQ(.N&D*6
M9W8R^7L04)&85KF0`!&79SA$>L6-;,.A2?+:D\C($$Q8\\YN4Q#3)FOK82)2
M#-;:SDBR8YWK%>S%L/&NUL48`S2CDR$J,DA+WLMH,E-C`ZNEDR[#9=<_UB;?
M.NN%S&EEGP,/>%A!<_.F#[)T&X[K#N>09SV/3*`BG7E>L)IN\0])2V&+UP[Q
MD^"H9!*_`0LI)#,9L2A#@9>@%>&V8;+E&*<1.WG_F+[&!B02HF89=G(.;3)3
MF-:MAC4!N-725G$Z;FSG:2+#Q6VF4AE*):\](&%($4>QN'G`RUD+84IL@"0L
M,;4++_\0DHDR4YI23:LN?WN/^RJ4F`$E*#+!$Q_&5G<JSS4&4,3K2HZ,M24'
M`2<S(1$3Y39SQ/<<\7,%I)$5K]2Z.5T''%#94A+D$A?,I.1Y<M0(S-($03P6
M@#W'2V,DJN$-BT!)1A2,RXV",C<#Y61[+F1).;#2+[LTCI-*.:5^2'F(7C`)
M+T.RI0$C`\F!N`PBHU'=W"`1&_V)+%"#V*$YKG"%.69-BPX1`\2><2T,F2,Z
M49+,UO@T%6?U*Q=>HTSO_[`&-K+AHE']T@H[D!00=I$D3G4B!#OBU20HTE-C
M.6(-<)*@S)A88QLUJ^/B0,&JK`4-H%CS)6PD8YT+EC-*T:'FEI2$P1OUJF+)
M>5Z)OK*C?H1/.I/[T$D`BAH2<E)!.CD%(N^3-[J%R*2E$1/O;*<N_71H&:68
M!L!(AJ>V:.E%NTHHUGK#IN[=RQ>='(U""D$.#4F))1.IGC4^QR-G=8B*JC0B
ML?#ICF=@ZE4'E%_AC.C2DM:%6B+YC>58Q)%[?`A$^/HE`#VE%[<BDUU[\HTQ
M_Z1(0S705\3$H$1(-4<6D05#E/H1TIA((%H!!(,,^N;(4D,8_)3S%P]]B+A,
M0?]84X&J29$EH3^WTR\=]>L>&/I,(7!HGH^DHB53?4Q\F%A8(X(-H&4:&>>B
MT5#>[.E+*'FC+1+GJ8*Q+$:5'<>++M,SW53H0:@UY5?8$4+3U(-59C731CG4
MJH^5JI0<#5MU!31&IIH%LA9ZH56/53BN,HBP@A7@9$P"R&CE[+VKO`Q?!EFP
MH1VL+M7`#7SI251:D/>(L\I'=P5KQM8)Z,'"@BTWQ@E?UZ*,FB^TFF;_X4Z0
M^61GV'T+G:8$3E<8CV'0V2IN8HG01[7VKVWAX(%,4:./6I0^9+TG<&QCPLNY
M;%4MFD9OCZ$XC#3#I@\1E2'@BXL*G>ZTY,F@YA#Z0L?_E$6E_@(*,_>)B;)@
M``/KM)/X(-K$:,`N&"\HP`L"Q:H:"104\Q*JG:)1,`-7&2DWZFPP,3A/?VTT
MH<]@&5*B2ARDD$I:U%304/ZR#K(D^71]SE-X1?PE<O1$##<Z\:%3$8Z[W+*D
M3<DTIG]I:--PTJMLVAD%/R+3+?%+D1VQQKI>P0]'/^N8_*K*+)U<9\@$L&A]
MX\:I#U)28OM#G99Y(ZGX9]6G32,UL"G+LQJISE,`U9\;,L9&HDU=5M(GUX3!
MIH$/W):(]`,M6%DV??3&S'R1=5FEI"(8'V>;3F@VL8(`0V/%XJ29">-)UKG)
M9>O7G\(U513_/2:1GRP@]L3S_V`9]&&+)?&K`%RA9;FPP`2^#.:,Y$Y0CT#/
M9WRKS6YRZK^_"$A@5\P)3&9'0);Z6!TY2JR#Y+HD[ID%PV2#.U;YT#W)$,-Y
M41*NK<1K4JLJ$7W+,FH-P8G6K&;=7=W*&+,$I$*#ENEPM>C"I2\[36+Y<$MX
M(<,'/S@IG.O@;+Z;E#YI9^D^%#I<N**\^]%-%5JJ.=<(N[\1W4^4'$*FK`6\
MRL()II5HD;2<2\HO,V%=4G%1RIR*:Q+.EDI*3\E*NB7O&"<3J_'$?$&A0G[R
M9FKB&\:0N%<PLP]RH>\JI%CSW7:C#Q-=N2Z0\I0L4,)EI,J%%$C,[Y0`7$"E
MT_AI__\4<R(NWAI^.E_-=/:[-,3`<0M<).`8,KUK(I'FSY!K*$LA;`][JQ<2
M86/!"4RLA9F;'VF?I:ET$VU[X=79`AJTT)<!#9[^28TK>_>5IZ-U6C<KF+)"
MKC5%D7`=EI!_T8(/O*==<D-/S?!D9&$6+H4G$65$8V=W-R-SMB9K7`(+Q<!W
MK):`ZT<J[T>`^3(,4K$3X!(>]P-IF!%Q9")DR+"!RM`XK+8M>C5X_[17C)2#
M_B)W$>%%#T%"4"(/TF$EE[.#T;2`$I9B<Q8;F-:"U`5O2>$S68=UBO,::K)/
M+Z!OH2![Z45&/L4_@Z!/6`83.%%[M1(\^C(FF,1;;L@*M,+_"O8F>:J1-A&S
M,TAA./%WA,6&2:NE?9D@>J)W?ZZR*A,P`=(4'^&`0S?TAN<@'\OR)I40#M-P
M?.7'"YOB:<9"5X<"16'B&S]WBD5'7QF!:F!"0W3C&\/%(Z3C:0MR(75RBS-#
M7\SS0M!3+]"0?YSXB<.@16NR?S-5)\N64QN".<_&?CFX)E?@<OH''(D4(M@B
M,A)X?!9U-3,76Y)25!0H6(*ABO2SB-Z!C2O"?C]H1,4E4G%U=.+(,F_G+W7V
M*G>5&^,AC]CB:\WX%]#A(?DX)U)A$TYU+)@0AF)X%(FD0-"S$)@G11V!=\'"
M/*=".MO"5(7W612WA_NP%DG6;RX"_XL-(D^Y4EH()4+7H'2U0HF("`Z49(/G
MF`^&P!HX5"@ZM`ICR&D8LQ<:,8*8!D'S@'D=1(TNY':#YA$.9Y(MM`QIEQ3F
MPV$N&$TX4XHR1%T1L4ZM430NR$JB58PVQV)]MDW5!1Y7]FR>0AO^IQ4E`D[$
M\WME:7;%MF2N=FA/1Q_2%D++UHL+LF11%4T($P^/@';B*(5QR5SAQR"<!IB'
M"0Y,1QY3UCP5=GM88HJ<\Y82)V_&(YD0$5:"!4PX8XO%PE1)='MUA"3^-Y@M
MM"YM-PE"1SJ`L1@DR"OC:%95%V$OHCB_`Q^9((8_@157LT_5L1$3B20FDB0P
MEWM<>!%.Z?\6J82;7S-!IJ8/`=4.C<8L[/!J-.="WC25>I.(JA!]("-LFY1(
MAG@>!UEBHE,TV:")*0$CH`8L:P)&TA4M6F4P_VABM@"/H`%&ZZ`K(R-S-/<;
M/*AD']6:$#$N7/(A/J&?9UE2K8E]#E9SQ]<^1)%M3(<0.;$Q"HIE4=F@:6B@
MT4`QRK=DNL*$20@D0O==QY1_UF`:[A<\JBA@2<2<?&6@03=M/VA:G>5K;&9O
MN7%ED_51-\>9&=BBY]9MHP4]*<H;E,6BW?6*NV:-&B=-2?(W$HHZ1[<<_3AA
MDN,CFL)/HD<@@?$TZ1.1"=0)O<%$=$6/V?8>G)AZ&/>`>,A1CK?_)O#2@!]I
M8BE:6AB)6N?7'GUE*^CA6S_&3;M'5U\J>M.A#Z?F2+[CEAZU(7LR+QF1>X!:
M6`<"A:M49Q?E+N-0HHBAGA6&85>T=KFB9TVE,GQ!)C+D00[V&UF82>)"@<-)
M:WNB6+%J$?="8VV2?'LY7GP9:D6T8@.S=#9$+QE4?\3I47G:==HG+NC%=/GC
M,7&QAJ$I5'J401\&&Y6&:4YW-__)<K=G2*J&964'2-N&,X?V5,VUK;0)1CMR
M+G*W1@TCF&4'1(M'K%TJ+KQUGG-"4A"#5]6A$?8Q&QZWIFT"1#D%L%RY&24V
M&#E6+M8H6JL0$M;%BXVIBLUVGTG!6JZ!_QZ#FF4(]7MP5A@0HS=NJ'`XAJUQ
M5HR:P:78)T)<<6K(E@MYA5$<(IN#)TGAET1YM),&TK.."45<D1A)I(E]`3T.
MEI<QDGG7HCW-$8219+3W($(.<YHHXI^WU'ZD\ID>]+0@,3KK(IQ*15(ZTU2P
M>7D>J!_<LZJ`.H]J04_"`8^;D3,Z2V1NX1-L"21XM0E,6RSN)DC!L"G64F5S
MT9J#\25/,7;GM*R&2W@XTR4\B78J86'4P:^I5GFC9!POIAU`1TP7`UY->CS[
M]A0B-3^S]$X_)SM5FB6?I6N7P4??QWZPE12D=23%AEI:PGR>V%I]]$]:,W^"
M@(@Y9!0:^8I",O\R)P5.P>4G8L*.],5#[3DM0%97K+HV4L)TF?9[.D..LQ-;
M5E,(#WJ8REN'2I2!\T*B%O5H->A#8\0-H)&`E"!WIHA2NW90+-8EH)*%Z?9=
M?Y$71I(JMMHH_AF.>)1ZP"&B8K:_6!J9L-"JN#)(.D43H'=T:N-N7M$UOZDX
MB)"%<F4QAI6IGXAH%3RJ@_06:7=RDMHH$T`F]A(B%=4EXR(D0W6G;*=2ZL)0
ME7@:<JD7TW0\82,EJA."ZD>G.)$7`6<2259B-=%8KG*GR:@^(%BWO/*9EPHW
MI\`4AE`-6T:-Q7L>;"-WOFFU:G>(BCH=V$5CQ6:_)..)?0-?T`$L,)+_38K;
MBP,S$;G9Q-@D9K&[)97DOM$WC(97)UL50E^XPL;V6<XFA65D2P2K9'83FO5K
MJP?L<[-!%5U66CX17?9I11*W@C=5>:>(PA%TH,]8BT4Q8\XR7@2;+IFQ-E)C
M0\E7O](3K]E5C=Q%BL55JD_5O9@<P<;HOA\#5*KK>&YA>+-)H^EED#*4#T8A
M'9XW*:`K<I"3()"2%OL)2A2QB^4"=D.#*T&"'!LER]1AAZ[BQ&-GJ1!53X<F
MRE7;;%-)(/HD"8@X'1FW<1.AB]>"7+6BJ&OFA63QMO(7/G&8@*PY3V3D/[%U
MJX`15R%J@Y*:O?[X;"A&)F]%)-CQ$\7H'H8)_T%)&&I8HV@>Y8MW0HU,&4[3
MA,E%FLX%+6N8AR4?1='?U,9C=:9S)&1*98JGAAP8R+!$)R(RT1*/$[-YBBU[
M"+]"R%SALR3CR#$__1(_)RRNN=#&E801*C.YF)6!DD`8.E6;,C[#53'*N(*X
M]Z6BDG08RKQ@^LQ9C,,Z.+#CS`O!24@4V5Y9D[H&O2L7BVJX*5H/-9)6;1TE
MDX^Z<0^Z,D/+=HZ,H$^$<I#^HA4;-P)@YCYP5\/GD8CT"#V8%$#ZH2%D98(Y
MN!.-TSO`]457@4]1I"8S\8E,:ETS976#4!K5)&2;0CJG2;M]93MV?=:4P:NL
M:0&()#M1^RQ"*9.2VO^S$`&D824+A29NA06M07>#UEJI*]I3[A@,0M<08AQC
MB9F9"SQ?9A*;HQFV4?1=LS>*]<6AWNHPF0"12*4F&02!V6H9_'.^AG6B$S)J
M]\-*SJP1^#TZQB*8_!L5EY@BAE4;GIBUIUAR_4I,<0)1S&LPW`*]XN/<$XA<
M.!F_D))(YW@9M31R9(0YW@*2P%D+^DV75N5PYP=#G])!M_+%\4!]DOV("825
M!AUR:Y9FKVL*$R`W9KM'\&%FJ>T;R4@X2$RP0#,V$1MG4^W7CG,3B4>O?GTJ
M6W<FD03#/?/1"5O'G%J#5-*D@]$<4&05B'!Q(J0O&"/1N/0.QDDK?#3B!&/_
M4KR=$7`7JAE=);@EO4*6O?V572G\OS9R)U,8O_AQC?Z-RTQ-1^25;:G1:?`+
MO@]XTWW^+]=30S+IY.LX$]!-T!6BJ'A7*(1@YK102*$`!M=D(RM49$ZSEGC8
M,_*7TN1$Y@[;YGL9;$&;LJXWDNX$2`;WBW1)G>L4WU9R5KW#?#N4$SR`SV\M
ME5A&J+E`+N[$M.IJKF]6*Y9TH<+Y4YA:RAE1:R@<+/`KIY(4`(0U/D4G,P6(
MKLNX7Q1Z@#;V<K'^0V)D:.7@6B)6RPIKQ)7CET48*30:SN9;H/6>&ZK&JF+V
M5IX3)'>Y7_>>BS9H>!PB4YBF5_;3-`</(:XSRFR+_XTC32OIBS05LV<)\B>>
MG,K32&<R`\>:O,_\A:$U'5=`"EE`:_"_<,;FN4;A:._48)/^L&$OHA(H[U*$
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MW^#$TA8E-GO$+`((-F(V`3R"@S86%C8\A8P%!0&2DI&&/)6/A3R&B3:>C4F.
M`:&&DY.AHXZ@G)L!D8F*A*X!GTE)5[*=DIZ2EK.;O(ZPC+_$JH6+O;*^FIRS
MPZV0M4F?PLJ-S)O:J8:*T:^7U,2>R\3,M.27M+'$!:'$[XVZZ(WHW-7OT/>-
M!3R+2=U<^5/7#AVO5_I0\0(X+MDQ5:32*8O%#Z%`<]5HU;-$BM5%11;X'8LG
MK)[_L58OFC%*TH_=2H:@-.XR=O(1S)6:AJ4217(=-IKU5,8,\*)H45OV0EWY
M&2SHI*(\EBY\!$D2*G^>%)TRY4U0R)?<M/&[^HD0TGP91S&T,,B6)6WPJK("
M5558P5YBM_H3@VA0`4]_%WF#Y`YN2%LL"UW!)=8MHQ>(]S'VB+BR3&T4D8D!
MZ9`C4DF0>4)$BGES-)CN$O'X;,H5JL*,%HKBL3FQYU)N'3Z\AOORYGT(8WI*
M$L'>UMB9C&EU',XS.N(,9XT:6,IB`*V5_O6S::]X,+7T-J6V(`D[S(CAKI-'
MK[?;ZO#+MQ/:OOH=>4C^I(-+-*F4>O`'#51`<<GDTTAH_P8YQ`MMZRDEG`T#
M4A-2:L:HQ=A*+_C'%@\18/+,)1&<UU-B-DC%`V2U"'*)AR1UJ%I5%>)E222:
M7-<63*G`(\XHUDWR22NHV)*26B],@XLK?]VX#26.X')8(4C2^,PBJK7F(Y5L
M%2C7CVJ10F4]MG$"EC*,8(=,;/5LB0]XP+1#%C;@(=6)5YXLA4Z6:=(H)BBD
MQ;9(80<BEF%42]D9D9V0"1E*,@N&E*!@Y#5#I%%RVL"<HO:!-!]/&2YU5!)#
M0N:.509&(Z!ZJP$9'90S(2D@0S^R-!"!ZWG6U(>NFI63F[2]-YA&^%4(CEK^
MD3F?A):JEXM9Q?JX*6X('030/_^H1O(G?:RN$T!Q`LI'3BK45BF3M>_EN!XR
MZFCT26A_TN*7/?UDD064P8:C`@E7O!#!"U(5=&,B5X!Z+V0O<'%%52PMA"VH
MBRVF`K@!4X,`$W+T<V"1LA#UPKTJA*:C(2J$3'!MU.!!B!Q`BA*`'!7/:%$E
M>>4SRCRR52@K5<Y$E%%5HW;)F%)7$-6?<I&B]RU`08U:V")8[>2T3_X4J!`^
M?1[MFE#@V?73=)NUHR8C?*:T6%0G"LJ)H9790@Q?B8@A"CGIH*+*-'W&4F.B
MB&$5E5F@$HJH96(]PHE+WM!#E)"?.KCDI[NXU&HO08.*=]JD[FK*G$SI&N"$
MJ/ZRT;?_-':RC4<J<V)??<W`=>PZ:(I9S'03(IOC1JS(224OHLM::X&"$.+=
MLM5$FXZ8-\-^F%?%,!7[F3]&K0XS!^GRBJ-PCP(5._($[TO4KGB%6$8>X4?1
MX"$-N5A*WMPBM4P->TI4U.0P0=G&OD;*2E4LYX]RE,J6!;;U*C`)'M0Q&&R5
MI&?8:U-06N&3:6V*%@%["YA&%22EX.1G+!D5G7X#,[`Q4%6(L1:6G)(U9!%B
M(#*25J48>+7J4:(CS+@)+'BD$&=4;F^1B\Q<2)6V"PW#`D';'I>D(\$HP2\=
MD_-8H>H#JIS\[3-O81:>VG9"0B2.4D4ATZ0J)3IKD"*'B4I<_VO$)`NU>8)M
M"1O$3+"A.C3]XG:R^!T5;<$62^U(%7,YB$%L:!\JSDR-QX@B<C)&QHP)`XW4
M^`U)"ED]M7D#-QWQ(S(LX)AED#%GR-K$84)$/F8I$H6"!!M5Z+202M91("0S
M3HD6L\J0%8-IGPA6%KR"#3P,D#X\""#8+$""`.:R*"KP1@"%QJTS;HH_`NOE
MH`K!A&8ZLYD(V((T>X"`#5C3F7)`WJ(.L[&'T:-Y!=&%M`9GFFV^IQK^*\MJ
MIN?!24!";M_CIF=HE!M%^`56XZ!=E^1DFG.80F>_*0EEI-1(JVB-1YA8D]H&
M`8Q-K!!,3<0AGU"!"[1)KC*T(<2<'O\9EF]ES8/":5.!4B(DH:FFI`0+0$4A
MBA1':>1T_X&DH+!X.)6&+5%[(L:&*@%&HX`F)4"*FD/0XL)T\"("`F)0+_X!
M$+ZX-!Y9P8@'<=*NY6`E85F"AUT\RHJ,K(0V;G-@*IP:N?U4+Z>^NTZR=LJ]
MID[`I=<HZE1-8D<+3&"M]]F+U&[BD1_%L@"*H",@EQ,`I_(-GQZM:"\L%#$+
M[*"QL3N$CE2*B^$5DA_\0>J["N<NTR`I?\Z\Y@80\(9V_@5"!4``&U:K`Q94
MH`(RH,$:9KL&&>A`!R>0`0O8T`-G$N)>^%+!%3I6I+R2K$J)!*3.R.%2RV)C
M/;T[W3O8%I3_#)["D>\Y$FM,T:8<>96-!B43TUAHBH0V$A:^"(7.6'B5)3%)
M=:E02"RD,8ZCR6UOJ@(JH28J.;R5`G<C;(U$N*M.%O:.&)\:$D,2!9J2-NQB
ML^"<=KH*RXC-]"@I2:E1?`HWDV1F78SKTGZ!01';@2U3SSU,//;D"$?M):P&
M6HCS)ID>OTX5(VCD#69K42UNJ8XIS^4+ZNYD1YVX"T*+_-:>#"'D]BZI=JCJ
MDT%$">`LV:9ZIPW&AC+(R%UQ0@QW5>^4)5'9@*G'PHNY1<-"AB]97($O>4!<
MR(2;BHK:Q\(U&EWSF(Q:EC%AM%L`00-<RX)";X&T/R",')CPAAJP_T`)M+V!
MI(-`Z4HKX=)*"$)M==#;9@*Q*%?@)8,9D<U5*K"SZ_$63CJQ*#62Z"=BB6*6
M]AD9(9U4'*@;4G]T'#R93#9!N7#*?=VH$4V6TQTD`AU+8)BQ#J8%$YJ,5(L]
M^IDR\U`38SO<A7%:IJTR[;W#D\XWD]$21F0[;0@JJ;;[9@@[]6<C3RJ//.1!
MR6UO&''J5NF7^.DG!&^X<BN%&W<Z;!6EK@.NB<R%BS<:#/_EZ).$;5PN`*F:
M;IB%X-P*J%J=UCN)ST3@URC0)*=T0MA-/%)U=-U!6YI7K1B4EDV]CVHPYT"%
MV2A5WUY%DVEFFBZVB6]*1=^GA>2\?HAA@/]R^,$;EKYT"$VB80-RT7S^4EK]
M_7EB/_CS!I[)=6?VP+4RF.T-:%M;W>J`MSWH`1MT(-L@H.#ME$:!`2H=A+F;
M00D.<(`2[GZ"LV_]#:OAEZB/0HO2AB(/U(/CJB62&HKKIG$XWYW`25BYDW9J
MR.J%C<E=N)U=,-$NX7+:FX)!U#KV[)OJN/(Y@G.74D$Y,ZQIMZ?,AM]U]Y=2
M2M4R(G3EK+0TKG#;JWT821H*O(GQ;'2=CFSDIF4[WO[>@M(AP=>[%ROZ]&I^
ML[%(0+[<AEK\CQ-7N(*,>JRNVECAZ/]].5ALK.%YE&8*^M)6#Z)J\H\CH,BS
MT?@=WGOOST.IB13_*?K09<LE$3XW&/F75<92.Q;4/G[C*3Q@2WY637_V=87&
M`B#0`UMG`TQ76APH!M)T:"'8``T@32#06H6&@BEX@2BX6FS``C(0=FM`=Y2&
M:92V!IB6:2BP`'+G=G)G`$`8A$!8!&:0=T;H`">`!+PU,>W&9KVD&59$`L?3
M-9]34'-3#:X#/S0V+=]6(__$,"H6:EFC:Q'Q<6L"+"]50^[Q#N)F1DTS;'"T
M"K=#0NIT-5YV0P.&1T;6)]L@?24R%AL6B%`Q"..53\U2@*E@=%_!-%?!2I&3
M86D3?6G3;NYQ#=>F-64CB!J68817(C-!&D^2<A<#B<%G<;R'/>;R'DUF_R.;
ML7#I%%5CU364$!BJ*`8<HG^%<X`:15AU]!(BLE.X>!CP8RW]]G#?ICMKY6I>
M83?*<B9,5F_7\59WH1QMH7^LQCI;I4C1&!)\LG&`U19)(AC)4B5DM!P!J"/!
ME"_%Y68@@0<4LVA"H':X=0)'F'=]MP(^H`-(<`+\&(,YF&ET9P8T.)!!\(\&
M>6EFD)`*Z0$>8`9%$(1%$)%`^'9O-Y%R]Y!#&)%F,`4>X``Y\)$<\)%(H(1"
MT$Q580$FP(P`DQ)&Y5)@50O3PS7D@503T(J)AW[H!3OEXEW9%32:R'PS,X?8
MAQ%#TQ!X$5ZHYTZ/\@P:%1N):#$>95"6$`RCPO]BB9%P>Z)!M<-@9793FF@4
M&<4H[W%JK$%PWE:-^P`D*45[9Z%NH98^UU%=P_8_7_EOUI-%3:$KO0$+W"@+
MW-:300D@.>DA2R55AY`JVBAP./96)&>&J@.,<*E`4<0VE#`CL)(]6=$6,^9E
M"R((;[5":P0\P+=EJ-<HE*E!&2,Z)`82Y6&+[==P3I4\$X$<W3!8KKE&P-!B
M'&0Q,:&2GO`&[L@$:@>#,Q@$9M"1]9@#_*AW.9B0=!>1T!F1!!F0"6F#-7AW
M"0F="3D%4X"1&8F1%"EW%2F$!J"=Q^F1(,D!'#"2;!"//:`-5R"%+N<5D#$X
M#95<,&9#DLE<\ZEQ.87_F2L1'#+S?%ET$>61&5(9;`NH2DAIEO?`?<ZC1S*B
M&X#24)53$F,$*<K@>9801L+@;HA3EQG2->:XH/>UGWBU)D#%2F534\J7,9]A
M"V_V);^VH`4JHO=F#QFBEX?1><7FB;E1'\[Q(+IP*:H44'GT/U[$.H<@C$P%
MF^5`93A!#]/%"+$I(E4B/5/683(S26?D:@/!'"-7*F7QHB;!4#90DTRYH0%H
MAMQG.$>F5_73/=23F%*:E\;8-IR#8#\:G'XFCR>0:1#)D(1:J(0:G8A*GHJJ
MJ(BJD8WJD(\JD4(HD11ID4+X@Q"9D'F7GAQP``?@`P+@`SZ@@113"/BR%)S0
M_S&+@GXO-HZZXA!U1*82T1,^P3KC$7B>H8G$HE%=8TCQT!-9*#@/=%`$EIO.
MH%>'=85\`FVJ8J)DD16<DT=E@Q1=J6TX>CWV="X[P25RLRM-X3B59VZ!DD7^
M8")MJ11,LU.6<8=$HC&!V$3L)AK16A,\4FR1TVXR4J"VDS,/89GYIQ:]0RZC
M@8MHJCW-I8U]M%@\,5WBV&'BDXS#V@G$*`H:U(H%&Z![J8WL9$8#2R<NH4>`
MT:;(5@B`Y!^E])**4%G?>G'*97*CP"@5TJ2]Z@D/PY+SP01BX$P(``(5L`8W
M4'?E"9V$RIV(2K30N:CD.9Y(&[2-VK00>;23^I"5:O\`%RFUF#J$16B$.:">
MG;H"`A"J*\!;3``)1@&71+E4A#AY`$N-[Y$8Z>,+LL$Z:%4.DR*(S]J+5@(L
M_J%`;+@CH4-L11DC<!.KD>%"]0I?;)*'L_,6+H:*3:08V69\UUH*L!040#5@
MB>$(2"J:89-])Y)A![<)2X%1-(%(.\%^/_65I.$D0&2D>^DH5\9*9FM]`B88
MJ'-226$/?_4?Y79B:$&921"KI\64F/2&X1$4Y`!F+&M',Q(>(+LIL'2ZFT"9
M1X95J%5Q5$$/PH,ZEF!7E!2.,X,39-1"FI.'7U:-VH2[G?ERY;LFW8M_B=D(
MB]9,/8!;,N"#DSJ$1ANUDJK_J%,;GDJ[M-_9J$'0OU1[M4%[P.%I`%-0=PL,
MA!QYA%N[M0?PM0)`!0=P=KWE#AM#`NLTE0_4#6HJ(>>R.19:+R:77E)B5<!8
M2G5I++((3SR13FEB",.RH`3F>^=HOK-:E'WXK$/!&S[L1SKT8#S$B2(J2'ST
M/LCA-/!CH8X)KRIE;LQ2*%J1'Y5B+E%)K%^HJYD"ETSE"Q,[1B42FU/\N=H&
M;*[1-!!1J\81QDVY3G)[C7;S*GNY+-Y%?\X;+LG`$2UQ3F?[<[<K2M12QU8E
MOG0;FJCE;0+X;2;<I<4ROGT$B\VX<3AR#,@T90OD0<L!"P^S&)"P:!OP=6L`
MP(L:_Y'=29Z2&L`*#,"NC,!(&YU!6&F7BL!'&\!%,`5!.)Y$F)PAR0%4\+54
M0`4K<%MLL`&-P#',P4"E=W&.?"XBMW#-H;A(TD`SYASN&H@25Z1R8QV*=[L$
MD<??028IXRR#H<2Z<C-N=**^5Q++L'EQTS<KU6`ABJ-L3)OM84-FR(S$JR-`
MLU)1H6^+\&#X"A,D%J4Q\A2JVVZB,V#-V\Y/ER6%XBDY.B?']!(U([AV$RT?
M)'`(D7@NJ56A6TF]9I9Q`W,C88;B+!*#XZJ-4B">052]YS7C&[HTID7))G+J
MQ'Q..6;PPQZ])V'RA\,#EK)NL0%;P`)M<`.M/+54&[2IC/^TK/S*5/W*N[RT
M=/>#%2FIMVS+E'J16;NIG!K,&`S,&7QV;^`P]>D)\B,=.G&9!^VR>:QB9MG-
M0Q-_#8+$=ML_#6(*+(ES^.P8;%K3@<LWQL)91^2+W5?-6R42F*B40I4]RM`P
M=7NM8&D6S,I[B-5=ZL&(MK"]X;H70=,0Y#%C.$)4NU0/NJHQ'T6B_:8[0EH^
MA,<FC[1EJ/`"Y795H')KVB56H)(;S.(G_8&*`P)6OW<)QBL0,.U"B'4L^:=-
MWF@5_Q=NK,<G:1I6M.0.9N*R,<;2/6S<7$A`]Z%>3:-J4CE>Q,(77&.+8UQP
MNE&'H-U2)J`OA?4&%,,$;!!V-\#_@Q2Y`/[]WY4*M5*-J55=X`8NP$VMRE^M
MRE$]A,B9`YNJGCD0S!?LJ0=`S$AP=@@@!P#1,--HNT*2!WF@`JTV'[<V"9Z-
M%8LA-!?:4O^B2,5W?5G$DEC">P2VS3;3<,J3-(W=,UWU.`IX',3&1<9`K3T<
MU"%=)SIBV8)8+"2=-/ATC(F]D\*@&YDB$<#P&RA4)3[%NG\8`&"0NN^J:U'#
M%PPUAQQ!62RN,4W$&.M`O5P1&SD4INKSN2LZK3*Q5;NJN`WM)["V)548M\SU
M+'VNGP7A#.R$V4F9'5U!<&'J+.#BE,^J52T]E4[Z0+(QAU=&)?<`2Z($:X(9
M83R0!0-$_ZZB=#7QR05<0`(VT$RCK`-*4-7_[=]3"YX(;,H&GNL%+L!.';6Q
MW)W].P6;Z@`>(`4<8.Q40`8^8.$7CN&<1C$`TTM5LTI"LABJCJH!83C0]D49
M02FWC:YU,C8K7L_:S""5F+<-@40$!5X.)V:2K">G3M*2%+C5Q3I`U"6*42?9
M;!!C0U6#@#9,WN2`Q)/+I\8R1,U[<A:%9:5N4VSCDX='@16Q&BJJ2U+HP#:?
M<#N#P2^'I6`65!^2]5>LH%T0(7AH3*X'$J8[&BNA"29LO&7<`P[H8TF8M*7[
M`(4B=$+ALLG3P#QZZ>_U`\CED9JWTW].H7NRX'+WG)I#U-AR;?]E$N(KSDSP
MVT=L*[H+.?MG+."S`#SK_4WK4QW`NN[*_#WVL.R_K)R1OR[+#"S64B`%6TOA
M&&SAQ+P"Q7S,S50GY"J4Z#H*,RH-?A$8='HBZ##/VASJMP!QZW%OG#B]?4EY
MN]":2DH6'(KPLRIF%7<<'TOH_@0KB+*KHAMXICX-LI>M.Q'P@<C&W"5_S#>S
M&%WTW=K$1N,X%5?;?(-33K(9CYC-_X;RF7D)'MN%9#,YK)T-!GA.7V$#*=6Z
M48]2Y+H8R;#RNN$2W0C3H_FMPO_IDZQ'IN.EW9`^%KW2V]3$[+0T?7PTX=]'
MA0Q'Q`LN_>1S9IGP!V<UB*Y7'M?8:#'_(9=D%AL#"!97`4ER3$P];#(W"R@H
M!I"."Y..DHV/D)&.FI6=GI.7E:">I)69IP:8FJB01:Z1J$5310:NKE,>#CD<
M'+M4`@)4!QP'!RM4*\DZ.FP]3'(\`2\J%C;6-M%)`=8\VC9B%CP\-A;AWM?=
M/%?DV`'2+_`O[DG>YMOEZ>6#TDGQ\NK?;`08%\W=O('7+(@1:-!@NWO8'A)"
MR,V@MFW6+#1TQZ.<N8[1Q%4,4$";.((OZ'&LU@Y>OX'KKF33=J5<1H'RWOG;
MR3->QY$&?TJ$2&YAPW'H-B845VW;0G;HEA(D1.^%M9J"K%'E:3!G0FSCQ(!C
M1Q(A(7E54\+L_W:/1P&,%-<).OL37DT;*KF2&_0"J5:3'O^Z^SMN9;N*[$R"
M%3?89KN24Q%&^Q8.+L2@[`H6K99M8-,"!,?ADTR1I&ANWL:B[MMTX$ER&MN"
M;DWQ8<>QV=ZV_@DQY,-RA-3)%5<`=K4K*N!1TZ@-$1L6:TH]LG1I%*;KTK.#
MHD1]>_;OJE*%/_5J4R9;YV7E<J`KAZ]@O(H92Y;L`!(=0H0\`YW%<6>M;S'6
M$6=(-=9-$NM<I9,_!Y'#0U\V#(*43.+(-)$[$,+FVT8JL>-1019MPY9C#&%V
MS49"#8511ME`A=2!BJ'C#T"H:2-/@A8V:).$5PS23T]`SOB48,$E5?^@<0)=
M=`Z!_UD#CDC1*%349`)E1I!*/3JX34P+QJ/32F,Y)5:8;SFHEDKOH$1:@!%)
M^5=?,O7C()HIY:36@TD(1]MAX"01('!Y8N,G;_6XA1F4@PG$`SAE%8A1-[,E
MF<2<\Z3(EE:+,I=G-0449TX]5%74F6.A*BH66Y%=J0T^G49F8F62W68H;Y&J
MA(]BL^J&'*S<8'5%/)_Q\`8;)T0G2BB=C.(=>,RBL%THSR[;;">9F,<*+>*1
M]\IYN+#7'@>_4-$+,2L8XX,/]14C1#.'5"9ED1J!9D,6<I19V6PAH3I<G3VM
M:D]3]=A00`2/'G32NR)N]&<UMU[4X&0LE1C_HU;NL'EB21:WXRAEL$Z$E$T7
M!A"3CRD%JB`_<,KU*3E=!MG3BW,Z_%5KL)TXC\G&12/O-V*\>(]"+%$YH&<1
MCIPD05HQB*'#`S)5CEB<)1H-O_!(<P]'0_E;%%Z`S?HIABZ+G)2GZ3!:6FD%
M%5AFDK6U,VDXL\4VTE0@"B;8:8R!MI!NE16XJ:(3V>WVHY]FNFK/)@<7#F.;
MAD-PC;7I_-/AOC'DLT.2<E/2/3)Y60T]%N21'(1N(0*"$JE$0DFTSW:'[+2?
M+,NZM-.>,IZUIF0R2RVOJ,?>+L2$&Q]]*Z!;WPK`K,`,`F_42Y;(&LG#C3CT
M3'5.X#WV>"%/A=*$_Y-7&H^&]5*!;A0X2Y^97QAE%).$,]N*1V0HYA69+%K#
MXP?F,8YX&I1@2VKAQO2"PAB7!8DQUQ@<18`V/@&ZK4.!^0O[&*65"88#4QX9
M"#BRXB.39(DA=LK)^#[V%(`5#"T7\5*O5'0XAAU-$-+#AEI:EI-^".<O+?0+
M-CY7L.>1!5<Z'-60VK2RO@$*9-<+(@31\3&&:(DW/[L46`0(J9\E4$-8"PG-
M@,.F?%'**8LCXM'"%SYSR`MB/1K="WR5/16HH#"&Z`$+:!"$9#5B=M*BG79>
MYSH\L@YVMF.%*G+'.UK8XA;=<@^XJ"",^##R7/1AI`#((``?+(,-"&#"2?_&
M00+DL$91HVE:]0XC(X>)L&J4(M([C".6LEQ1@B4Z"CX<]!;S)5`L#)%94E3B
M%Q!-S)>>B=C@2*B1Z5W#1VG*DH7N],$72G%J!N0)<5;4L<&HAI;%N8E2GG03
MOWB$,PG\YA3!&,P(S<2#Z$CA1=XBA@FX!6@D*A38=H(AZ%43<^_J):A$:)&7
MS`-"40N<DQ;2PD09:$`181M":^1-@B:!@9%ZE(9H!<9TGN,;$[``/2AC&D$$
MJHF.RA,N0?*JC&ZT3V3#F4U$TXT(9.HT'7*222?%J$U5KF89(4G<<IJ3!)E@
M!R10C@DL((<XZJ".T^GC[.SX'63ET8]0M0ZSJG7_'6UEJQ78J@4N/#"%*;!'
M"CDX`"-YL8MB4`&2\IDD)<MU'S:@`0%E*<?H2$""MD6,-A^"(9IX.1%`P<5.
M51D0+ANCI8<\Y`6UO$T8V=*0394P29N#BJ`4$[&)=&I%L6S,6/Y&-(3]+$L/
MNI--[!'`H/'#IH6B9S09%\2@.$9\#13(VF`FJP"X:2%'<E+07O0DH.')2S!Y
M7L@6A0$,#&FE#BS(C_IE$H,$B",ZW*%1WF:U+F61)M^4'&=<2%B_38ZCEQ%I
M1K%12YQBZHI-2<RBQ$`(CFH#:N3=V16#"3'"ND-*JV+;!)Z"*O1.T9@%^0@N
MW\N<`+2SIB,D2XI\*##;_Q+4MG`S<$:1@R&D74,%%#E$#W1@+#L^*P0@#D'K
M2,''V$DUJBBNG7C"DU5:F$(6Y,%%5[VJ2$8VDAAB/2NZBN$#,E!RQY=LQL$L
MX$8WPH-E--5H`11B*'CRQ90W^^O5_%DGB=H#*H/9$(IJYJC&1HJCM<3L3`Q3
MF*-H4RD929]C!GL1K`#*2[Z:&CH#ZB4UK6-J-'P9B/"6CO`]"44$NN^((L)-
MZ?(LH:>YIDB^&0XOU?F#93&(!3`@`A$8]T&,0\B=\^R/EU3-8PGTC?YJ\J!Y
MQJ,>@E"';_M:V2B6TT]PL=)*13-8PAHVE&Q^$4OO!Q:%&,4P%$/H?=,W/>02
MJ/\H>[.UY6XEJPY!++U<ML%^V1;JE;2&@=?K3;05,@$;Y$2'XSL$$]B@`QD@
M]5B3"+&Z0ZQ'2S3UJ2B.ZE173)[TO'@*Z9'%C'41//GXV\;($*M:=UP,^KQU
M`\_HB`F"2@_M7>8R@M64PZ)\*P@?J"M5&T2DP*T;@UYV@941E)<=S#/&1JYB
MUJ9-;,<L9H+H9H._+A)L?L6T75KM?]"41]7446HM<7HG9<Y8`D_::A,Y4.9C
M:>6`@&;,-+^K@F+8!\9=\H__N=8"$ZATMQ?$D4&0.H1*>T=U&VC"@-CS+//T
M'X%&*RG,9JZ5(H55:C3ZT%]+2=A$J1NC/"5WFN*%Y"W_G*A(?IADDDS4?929
MS*E(CA4G)C!4IXH[B,@)>)(C5#/I%-.(DGW?/_/,FN@3E`Z+6M0-]&`+(*C`
M&A@!K>VL^_7M=E:)91_OVJ^..]\))"MXERTSX!L%AYQQ+LHZ#!S[.\<"]W$P
M"DX\'8#`&47]AB<[E&PFORWTYP2L5:[\M;07IC@3V&_46L60>V6,9I&FBH,W
M2)M>AJAF]ZQVI4(]RD6W,Y<@_Y5/)@3-KO<HYXY&.O(43?``$FCR,V9C3*/A
M3^`V)^NU&5#G)%72)EMS7I)B)VDG48ZW#1.``0T&-L)!):86)%LV>(WR$XK%
M#US'.>,@$X1'327B3<5&,V:3_T_P127S!1A7M&A.5(,]`WK6\#>/!R\\Z!>@
MIWBQ<8.=E7G1-46CP4"4QS'M)4R3)13<A45;`T:*]R1":`W/8`B(P`(RL'JM
MXWJOMVXC1F*XAVZV5WNT-WO6`@OU5DBI4`2^AU6(M!Z[<`2\$!_'9U9J]6/E
M0CS*T`P(ITFPH0*'@Q?K%1*XY$0=I"1M(3W=QW73)`88,`+&)5MEHD5[]A4;
M$F:4"#5HPT2R%#3:,#$/U#9CIB$EIWX)03*)8DY4X4'_9VI+HQ@WUV@$B((A
M$T$VLQ3I9RD.=&CL@PU0,QI@@4M,-CEI`5Q?4ANCL3:=LEP0`FDI!"1B%T#_
M!6IE,_\D4P<3%/)!MZ@U>V(/`^9@'^)JX;1WBS)>;=<WM09/37%Y"P4HZ\42
MH%9^/J@_.-50!=9.^F@8BP@ZR=AKBR-,D2=AJ)@XMM5MJ;%!H#1+WX1@6,<2
MAX``8G@#K*>&9ZAN2T4**R8=;5B2DB`=N_<(+=8[O6,&V')(1;`>#M"'-/F'
MR:=\D$2(Q6-)S`!]^1@T5A).L*(/ZN<O/3=9#3$CLB5M^[5?.D,:[=.$!H5F
M9P9A0U@IZ#,1HY04A+!3"N098R(_TGAQ1%,1+A%<`*0T57,CYF`5,K1:'T(/
M6G,%?V9T0Q%$9L<^3V,4K-1TC(:4N,@A2\*%&/%Q/B$(ZQ#_(GDV$%830T+3
M/<7Q)#ZS<V46(0:%)4SG/E#4--0T8.LE4%3D%-.FF9/%98E&4)\9*."$00(9
M:<&63PR3CHOG=HN!=1EU(:AA>?<CFXB#$.@3&UCW))"A9D;A%_/8)RN"<V*"
M`%O0``S0!D,`8LBR8J#PD2(6DDF%'219DK;G;M2R>ZFS+>BA;Z[@DGCH._Q6
MDV;U;U1`23A)/,QG/,ICB-=`BN243:&V:$WA%6V)9`[C:<K1:PL!6XX"*WCI
M1,IE:R98=Y*))I9R(=&%(6P2-37WCNSEE4CD02SQ9.YP%XFY7.$H=F9"&@:T
M=$$8:ZOFH&DVC$()3J.E&N54:&"$_VW9^&G`)0^=<HPV4T_EU#E@,X)$DPV;
M.1?0PS4LLR7"834=L0\4(T(7!2B-(P_`(3()")0#J380%IO+YD0A]V?1%5".
MLE`'-C[MA4&QT4M<63!6-*;9%AK@U81VPT/X\([_PAQ'XE?_\WC]\'_-P00;
M@`#/(0,T,`0)X`77R4<?]I%X9!ZX4PIW5(;<B9TB&8>Q`)-:-0OH44BRX"W`
MTX=FQ4B?"@RB6DDZF9/*P`QLP"Z'(#\!=2*-XS0;N*<DH$89>`XU,1:\*&F@
MA&GY:2$DI784JD.^%B(+935;63_THTK&*9PD)UP9,A*C-&N(!8TVJG.3.(EJ
MZ1/AY*IT*?\(1+I*63%YFI41QX6K0\0QJPF!)!-VT5@6F-AM9O<C&"8V=V%=
M.E=GBS5E2]JA(F<F<%(A$F*9GH%G#B%,5%$7:^11ZMB*=I=0#>%K)))*_\*%
MFX-?C^(J'(-;9^9SX'41X,4R6+H9C_6:/5A@1'=?5=(Q/`.,NP$P'`4&JU13
MUJ`"5Y`'5]`I<H``J;<("\!NL?>&/7N&BTJI(^FHUA$M0.N&V7%5<PB3^C9C
MMP"36_4[G8IC`"=)P.`#DU1)\KF374L?]M&3XI8D4>$V+V`!)C!X]"<RL]H3
MC841MXH/0"<HECDA,I28MB5U]E09<IF/6`9L)5*`*A-:J@@_G57_G`+D:[F$
M,XS1$.R0(R0()"#AF-LS3PAT&W]W%\?1$E8C6<Z59'V)N1E+@2.5N-KT:3S:
M%0:!B2+0`.('0!B6/4G#(*=4@*]I%-?8<)]2$[]23]S@6]@EKN6$0U!T9X[I
M<G$3/W,#&_?W<A90$K1D9;`8+V*6/P/V4+<)$1-CH)3B'Z`)-?V`;3X4,1='
M&%_A2LB6)!#E<ZTEI07F(6YA"%M0`3>0`&@8>Y$J5>`)'MZ!M)&:>ZD3"^?Y
MM*[@`5QE"UVE;S))D\8'<*+J`[^0M?1Q+J:JDP>P##V92>2G#Z<&&#_8B/9B
M9&MIH]M;EV+WH0CY?T<&2@WA9B"TIXK+_UDIHKHDY&UHX79;MC6P]H"OF*P'
MX1HK]7/::+NAQ27_I!.-JS]Y*Z41$B'\-%]_`H$1*R5,QPW)F*]W89FHB[HJ
M*`8-T`"5MHEF>8TL<Z^UZ[LX:'V\\4D;U98H(QP'5CEC1UBM@2#ED!*\&[S'
M&VPN<G4UTUT%&AMP$:;5-EM_;)5$0Z:VM8&S2&PN=&W(Y4Q28QDPB!DV87=K
M9SD44VS(D03+P1D%$(8WX`6&>JBX5V+YZPG@6;1J"(<FN;1,FV^R@$@)W"T>
M<`L'W%4+K)XY%L'`@+5<6SP/K).$B`0G<`)BNZI.O!,!8T6(\J/FT\8,,Q?T
MI+#3O&G2\RL=L?^+)\/-"',_##-YWB2NYVMFFQ%IMR&9&B.,!)04M$N`GZ8F
M6A*`$.(.W&03/P+.4G<C1K)=`ZJE#XA+C+)TUS01_\,7(9H3K-NZ\-K$,M2"
M_LJN=T)*OF6$T',%,(S1-N)I'9%1QZ$]_$0XN30TG-46CAO$BTPQ.KC)-%BG
M^/?'C1-0OEFG]6A]!1.MG*$U$H$DB5+3A:-RAXP1"[A`?Z=->.<JX"P-*D`"
M-E%43``=T8FTLD=[KN.S*:;*JXR2K`P[4@T>JZRI,R9C8<T>F&K`7#6UZ>FI
MO7RU6(LNYS*JQ`RVQ8`$='T?.M`#"/<#9^%H'GMMN"6*(?VPW\070/?_$=F%
M9Y.[S7^C5[NX=L`)7QAW&C`D0GG:&0N$8)?-''OAN>T\0.\<319!.FRI?Z=D
M8>3*7C9RC?5JK5`QITT,-;AZ03#W-%4RVR%RT!L10AV!`6`L`NX46T7##>SZ
MMIL,#AH+#BDQ)]M'<]`<3#*!7Q-W&CM]QS8E#74A,P#32TT2--`KLPNI<B(U
M1FD*;@;Y@R7G+\.%CX%1-Y5%=/G0,WP3:=O'*W\,O:'6W8B3>,.F?@.!!XVV
MU"1@#8;`!H-Z8JWG1R"9J*;\.I6Z+9R0+=@".R8FX5\=?+I\UKI,UKYCUGJH
M2&K-UC:FM5P[JJ1*/*;*?/9AS&V%!AN@UZEK_S46"U&UQ,4/BZL@=*]BTQCZ
MZ$\4,XYR@=`=2BI!BFQL84,>$DLTTCXR!U%D%Q%`R$/0=6;#G91<P2"DEEJE
M#3(+R[F4>!=K*=0RRKRQ+=G5`%^G+1&J&<2G%$P3`,9;9\E2<F<@:C[^MYL]
M`\X`46H<C('@.@A[F5D_4W;`\4FLW6BVPC9"KN-W\THL0AI;&3^J@L/6!HJ'
M84(FO5#41BHK_4K/=A!3&DSMU]YIWDTUG224^"``+A-RL`'08;]=K535>;]!
M*^L,/L`.?BWEL0GC,9*V(U7SMLK!A^%;9<!D[57><NSNX>%^".(4G+5:VP$E
M3H@G+M=U3=<]N0%/V?\53-U)V7,YH47E]X"K^V"C6V)/#^%/GP,2HU5@;'D<
M&\%T6A[3WQKDKNI:66CO#"8.D!UF1]ZN@3V"VCBBFW84OR99XE,]QU$9-\QT
MA?:`MY6R*WMW$?N)2CP0:@$<TN:!BIG.9K,]_/0/YK0.89EFY&`"O4F4@?U)
MUJ2Q=5.5XZM__]%HEB'9:4/R]BY2Q:F,_Z+)[6U%MN'7?\=D#T<8+L3>/Y3(
M)&?/(4<SFAS4DI4V?JU1%C?TX?-!&AG508M'TCD[L@Y[:QB'M#R>6<4[NQ/+
M7\T)N4-(`;SVNS?+ZC$+%T[L#B#WWM+ARFZUH`IP;UU)<$V(YO*UZ>)O=9W_
MS$45Y+^B`D.E.+`2TC'D)H>%@0F)BO=*4D=.&R"OY34NF5,J3HTI-D"!\.=L
M=%'COKK5=ER6@6)'Y]K8F,O-ECFW*-VX=-1LW1F1(S-MYK?$?K,FT!*94.[^
M$@"AC]J*$UVF$\@FTR'4PG4K%T;A)D\C-_<DHM2<):E&,23B,:W!NV,GN%8W
MO'&%??$#A'@.ZHZ'TLYOZH1BFEJ.4(:]L8H6_N7$:\^6W6FF&1%4L,OFVB##
M_EH$"#:";PUM"2TAB8H+C`N*(8Z)C9./DY8+*)F9!IR=1453H:*C4Y^F'AZE
MG:NLK:R?KJTHL::EH*B?4Z@>#CD.J`[!OL`YQ3D<_\@'RLL'5,[./CX"TP(^
M*]?8*P<KT=G9S,M(XCIL/1M,3#PV/`$J)`0D*B\J%A;K`?CY^%?U]0&"[%[D
M>Y&$AP5U8NRQ&QC@B@U\]019N!)`(#X;$:_P2)(/HZ"$`0IBM.>QHD`>#NU1
MY(C/($:0^=2-7!C2H!@Q#TO^BTA3G\^?0($*Y,=#(,:`_W#ZBZGR($NC]NQQ
M/!C@YDN9/'A8M6H!I\%Z";O>VRGH(4NR]FKZ$_D07Y(70_OA=,BNZ#R34+/:
MT!CQXP1[-ZG6ZYDO21)^;?FI/2B1)+LD!70"Q&LQYF29DY/8"'R/HTN(5#>'
M'MUVY.0`71,"])R6K$T+%_^I?LT7L?5FU6UC&SZ:5/:]DFPC<GRI>J'+`II#
M)V3'>V1+A3805!@RHP4B1H^R:\=>"=(E1IIFO:JE:Y?Y4:<\2)'BH<@J]Z]B
M&3`%2[Y\^J!NI2K/*]@O_\7\9TPQR1Q0H#+.3$.%--0(X(TWW7#C#3@4ZD`.
M&N;(<=%>[N01SQ4@5O16/BD-]L]#<!7V`D8.>5613R`6E!!B"T$5D4G/.7:4
MC&*`.-8+,CF46P!9R04;<L%)Q5$!+G4%&UEEC174E%0"I4Y1#>T56V`+&78E
M/U=4IDY496$F5T[K;/;11[")Y:24'@D2DD4N[25319\]121B`$5)DT4GV<E/
M5(S_W136<JBU!A28%3'ZUI6WE1723D\>E2*.^*185Y3W?'9;`,AY-)R26L$V
M:EVQ];5A5C?5)"I9K#WYE7&@F;@3JV(\EN=G1'8UZ66_OF2#9SG!U.NPD5$U
ME5,%*5H`:H-L08,74"`B"7>)6&===HU4,DDFF(3G"G[ZF6>N+J&@LAY[MI"+
M7RONPC>?O/;A)XJY`/X"3"^^"$/@,<@$S,$R"0JP(#714+',@]5<8\TW%"ZL
MC84ZH($`.DR`VI`%>1#T`HAPI2BD6,/9-5"S4?6(:4?LB'5:7/5HA&6O_6R4
M:*\W4:0/B#'[)!/)^#!)Z)!U2E3:<O<`6EF53/^$D@JQ_U%T!6>=[3,146+N
ME=J=MSG)M6H1X?927\8U%:9`'(UL@@4$Y9GIQA/)V6M*-5K&%VQ3K^/D5CW:
M=/9/0*XU:&%3!8;3K_X(C6)E(3=^$DF3J<GC0WEZE)5:9MWJI9\A;6;S33P(
M;:I+E]-L\XXH#[8;3AR!?NR&ZV2U;$<'(7?BC2@_Z_I7D)54^F#/'H7<5S8P
MT<.TUFJGB+;;>KL(>.%%+YXGY('"W[KKJF>N>MBG$B^YU']/WWOU<4(N*NGV
M%XP4P^S++X`"QT_P,\]$J+#$VEPSS8/7+!SQ-M>@6#F8((<"/,LA.JN'"@*"
MDK),1#-#RM2*P`:;2YG$(&,B"?]#1A(B?8S$5CB3R-H(,JI!;80E/P,)"C^8
M.9I=1B$V.5S39B@4@<`%@U#A65]JUY&]T.5%O5J;6$[T&IZ4A2LX45.B.&4<
M%FEI9ZDIC5-"1BE)T<F!-;HA=$C3#R=ML85.`\AL`%6X?DC1+!@$XD`<%Z@H
M_4IL+.Q<6ISC&M#HQ8UEY)1D2',1%=[J*ZH+7E^BU)HTWJDWIRN-:=X(.0>.
M+BVSZHW&_&$0`CC$>#3P3K:RQ3SF>2L2DMC$)CHQ/?/9BS_<PYXJ5RD%9&2/
M%.*+I;M,"9]XH=(_`&H?+@=$H(`9XT`(HI\S(H8-97##0?PSIC;^U[\#4`Q#
M!#2@:%+_8Q$?D:12;8$:4^(F%9_`A45O\LD'=38I0*[C+*@)#%_.:"<)IO!)
MP0(AD1K3)>)U31]+HR'3J+C`@T!%3N84IP\G$K)2"8MKJ2'3.UVV'#.IKEET
MTX=-&J.SQFU,(FK,$HTPU<`Q%45-M?'*#YGVE96X4RZYRF!;/F/!E;VH:+F1
M2&`,8X&_Q(9RCC0:[<Q($YG*\%.1.5R==GA.S7"&AW4*#$1@<J4[F@:CH^IB
MYCZHPD\EAW)#TVFL+,`%$O#`>&M``;9"0"UM0>&LS;M$*`T0!/O,BQ3I4Q<K
MY[JN(]B5`^Q!'WJL)XI:D"L4?C7%O-SS/?/X1PK_81\N<PDP_X!QH%\`6P8P
MFS%,<!1S&Q%Z$/XHM$QE4@P$/<B8:'+VED%!!Z=_"A3H>*/&P*4,GLN*V\PN
MNB,/?B17*#,-1<3T6HG2\RQ8413.BJ.0F.ASAI>*R^FZ&2>JD(BG@=L+WYQJ
MN%S)Z3:<:15HXC0LUQ9W3R,C+4?DH<U(YD.;@Q)$>7.DEU3)U*,CHI)`[$$0
M<=;F(*^)VAHE&%T\#1)Q#L0J4:=B`]T=#CA:*8ZK<AK"(CVIFZ`SJE.J\A<E
M+?&#S#'B1GQG%1G)2@P5[BGD8.(U7BVEPPGF001X,(&_<($B&Y#!$-3JA>9I
MZWG0$VNX@M#6\)UR%-NC*UWM2N3UG/\+R'!-,F!ST=?QV7(7P9"K>@+D+U[Z
M\K&0C=]DZ==9B`%0F5[^LF4?YED+L6`+"'B#WBIH6JRB]D4W'-LA5V8:/S8J
M(P&QT6E:PJFT&#6)%?VGDR0J5=_JU"WS3(T<442DX^Y3:;'!TD1H9SD@VK-,
M(S%4(U]C%;0<*BJ+:0P:L4C$=-X(GYIR[LI*I!%"7^$M2_G@8'2248;@`VHI
M"I09MW0XQ`!1(+B&F341M0\.ZL5$MWD,M!R<TS%-0(90^LT04]S#(AVX9IMI
M\;#2MNM$.66BFTM3IT4C;FWSF6PA3/>HTDUNA#P;-G+HP0V\0PGE74(3I!3/
M7Y.\/;FR4LO_KFPED8O<[WOM`JY'ABOX^)J>5/""/=@S1I4'Y,L!]0+@%'H&
M9YLIYOXUD^.<[0:85T`Q<IP#'3SP:D3DD4:`-$X%6GOP2GT2-MP^MV;UA9L_
M;)BD!!9+-87Q-'YS=.ISTWI4%)7C;@'74D<#+E$;`=F+/)*6RAS1*W,\%*83
MRE.J%^<T3Y7;F!9)*<B9C(KMP$L8^U%.C-QYZ:3#[YZ]:=&?A%W2.9L:/&NM
M%Q`):9&Q];.IEYHK?7A-D@;%\(ET\F?F*+B/#V[HFWABIMPDN"W3AGS+0#+1
M2&VH9IUKE82K)AK'"R:)80E`O&\0+DO0^SOX'A=]^&T>(:\'X%H>_[@SCI"]
M?A<\KGI5^%[1U=>#>Z`8$>?EQ'G)?-S_[_D24V;'H8]9:S`C&Q9B0SEZ@`"S
M;^@B%3V6Y-)H7%.+QH/]V*U%GMH3E)CP;9-O#=)KNO<,JEK0.L-2G%KM=K+`
M>;].QS1$P0\V1"0--!@Y9WZGQ0^'@A(UEVR0\E^\,79N-$_)=BP_4W6,PT9I
MYUL]`RU68RKE1(%SAVK\9!F-]"*FU2(5]#:9,BO&QAM;918?,TB.I!PX:&V(
MPD(`\2SV9$1&E!!EA#/%Q5UK88#<97^;%WF1YQ44R!,YPCF5=H'GETZ(0@]@
M!1[?80G2<Q^S9W"U9WNM%#\#5X9V]0Q'@/]7>>5[;'@>2K8+N;`?!J<O[/-8
MZ\%\_;)\%(<,>"@P$3,PS_=Q$--9$2,.F"6(V/=,"'`.!20T14$")%!?3M45
M41>)<%$0%4$<M`9(&I%S@`1/<?%!_Q<I8S=_0N@632)<</-$"^$1(,)`.U<2
M-E1W`3@E<#$HT':+A#(0@(0T`&$DW$4<-Q)W:5)IQ$,F+4$U<A-MN"9!.$*+
M0Q%S:Z$"("(/Z,2#I1,4%M1&&I$9.W)Y(5*`>'(4.V0B\S41@N=K58%;6O%L
MB$(\%&@5G_,7WDA?J/$7SY(:<%2.HC@5]#@6AS1$__!ND`.$)*%"">88SX%Y
MA_-G8=$8UR01SV;_$B:``#T@`UOX+=%#/N5S2OTFAF/(`68XDD?P#&3@#&K8
M>VW(AF^("ZAD6(=E#.R#?!:7+_QB95C6?)-%?0"T3!.R#=1GB-'P,/Q3<F@`
M37(@!SB4<BG29P\6)IB"BVCB0I/V-K(6?L=(&#)5*1$Y:!P1>'\2)&*W(>I8
M&57'(FN43[4X)5-#;)Z!&";2)(8#&QB4D%;1)Y]V&3#U0@69$]=$;(DV&,WX
M:_-@,CCB?JE!$0:Q$DN3BCV!=OBT1AXU3ZWH9PF)0';Q./?0&A^($&M#3LXQ
M004)%JQS>=M%><)X0I4#=+U8FAT6;9S98B(XA34CET+5:=$F)_SP;LJF_SH8
MUIITB9LYM0[N(`9;,!U;*#VE)$M\M0L@&9(B29)$)DS.0`8GF8:KQ(9&MI(%
MUV^+Q3YWZ%@`XR^+A8?'\$M[N)-_.#`<YW&$R$P'(`Y(P`V954R):"'0Q`2)
M(0\?4R8N$3@S,Q0L>!&I,A$]85K^=$%=%"9GP2<Z<7GRB&B%AG[?A3B^MHUC
MY!':U'1K.264J&HWI1`BFA!'58SZZ!4`@41[%XP*P194!TD)U7Z$P@/:)"*T
MDUH=H4Z28A@[LQ<E")E!@1D6>%-18T)RXUIU01/9^(DU84(K,J*%IU*FL2F_
M,1,@!D]R4Q+DEFCB5DB^TQ<@%J5K03J>%W8S0?^D]A2FF\*5Q6(;]_5=>T0`
M*B`&/<`"K*>1&^EC2D8*80B2R""=NB=,UFF=5)"&*0F2_L:=,`EE>'A[`$>>
MC(6>YME+ZDDA.^F374:(^;-,ADB?]7F(`30.VF<.^IE-?J<1,/=1>T>-/*,R
M`-5%+7%G.%=0<01%7XI5FA9TM1J%<L(1WX2.+>A-'G&.K>:"'?IT(?B!`"86
M:;0WOLAI8`.1$=IH>SEA#M1IG2<WQ,)3^/2)2`%_3=&0#(&@AEDE0!([;HHB
MPPHKS>*7=K0QY&25Z8>*5:F.@R:A0G5:O?EIU\2F2R6"D/=]M,9U1E-($[8U
MF"A)?R1X7H0;;->N?23_!CZS@XRA*!:P`T9``&*0A8T@+N/QA7MJ+G.%>]%I
MAM1)/P(PJ(-:J`'WG*K$AE%V6+@TD[]$LGP8(,20DSDIJ35[(!C'#(!(3)EJ
M6>&`!,HPGPQ"E"O0,/9)<MD'`B"``$HY$9`H#R1@`5!#2:IG`23`@!:P&P7K
M3R-"KH=)*$\B,G%C>0R%`1)+KZ!G&8>V4SM'=_YE%JQ5:\?Z$R6"@.@7K9@Q
MET4B7:3I49$B)V:Y9I,Y)H$!>E0'1N/DC*5'%#7J:Z\103J7-$SS*#)%.5#W
M.HFR=-'U&CJS48;6,SED-8K97+J";->D;#)E4X.7%#9PCKQ2.#83D;_B;DRX
M_Y"K`WHH4Q?WM5-*I1D3V2RM6(PGU+G>NE-^L`-O(`=,@)$YMIS[MJ?`)V1D
M*)TGFR`JJ[*%BITNFYU0MBXSJTH]:[.&RH?$,*GH>9-^:"`5-S#O&XB/9;1'
M^WSV*P['U"`-,W+WN7WFD#G^D`54811W,QCQ%T%,*D%@4G3G"(4Y2J)`ESJL
MLTUH*:^.H99KI(Z+B;=Y"R-I,J^9TC5WV:51U">D66(W.'-H@;Q)@1-JRF=D
M)[<H`BE(XURSH7/%%54&6B4U&D("&6NMP2BY1C,U):;QJFNV$C@ZHQ/#"$-+
MD8$/(4AG0H1CAZ:=8BOW%3I0$L0D)D59,288&)BJ]O^B,-I08N>F#@:\<>M`
M!&`/QB.]'4N]Y,&G;4A7N4>2)YNRT]"]WON]6!:^MO>=-&NS`5.&?/@?D:J3
M.FFS\!LP@7@`OA`.01M]^6NT]%D-U+"I2ON_Y8``-J"4ZU``.]=/EN,FBRLE
M.MQ^N[HGZ=<3F?:0*%QT9)Q_!5JL`IBE58<I&KR6(/.)BL2`)(HF!E%A?_$9
MBQNMN[&+C59%(7RM[Q:K73PI(=@GTFB@&F&O5\.MND4800J\8&&V*T5?3YI%
M%B$C]&A&Z.1=@G?!IT9K5;08(.1(__IS!78K%.I<78047<256:?/H!C/%F@B
M@N0[PD(DPJEJ"$%LW`H[``'_O75Z`^`"'A_+9&#XD?\&<-I+G7WLQWYL,"SK
M2^`IR,P'GN<K,("Z>VD(68M59?'3AS=KR)5,M,40R?_3J=60M)[ZDY<5G^30
M`Z0*O0_A#B3`!2;B-5&$3VTFHQQD0:V<FT:SN"`:;7CRP#U,0QEJ+&K7RTY7
MK,>H-<4R-F*TE49T6\+"HRT<JT^J-P=UQ)*R36-$(EJ#=15[$/RP-IA3;+)6
M:?I$5;!A`[`+'$3Q(H/9$#E#85]K@'$FB@M)I$B:#TP"$R\:.LM":X#=MLD&
ML1YD++`Z2>CV9Z%7>#>CI$P58#LE/"^\$:;9N3'1*J)3=!@D/'(@'?/6>J/D
M8WSU_Y+.B<<HG=(<G;(>[=$@K3`O;;[LFYXP?<B`6I)H^%@W^=PQJ7S'+=/S
MVPR/-=/79TP4(I\'P"`Y'0W[4Y\@-P[D\,D7\P]7X`YA7,\/2W15"3-+_'E5
MQQ+-=5.&@B@K5(&5*0BMQM6$22F9:"Q`FK<.D<\HJC<2;#1)@,H2<6Q);7@'
MH2BLT1A@<Y?"-2N"ERH/V4`<!#3VP)]9TC7R9*Y6:.&#M'.,<FMI9Q3KD!)7
MVLPT4Y:L!<][-AOMNF<OVK<%BU/*8CKY6#,\VKB2.*6F#<]1K'@AJFID4^2V
MPBO>!J>,T1;0RP)#L`AYJJ<7+89YK,=[#-S!/:@-0C_*\/_2O>18U(V^T[F]
MPI23[W.3R$>S>7C<E&K(\U.IVGWGS,#=/M`!W^W=F45FEX7)`F0.BX@.27GH
M@'W,=\+.,AH5#'IS"-B4$3Z;V*54*+AG>3$9`XYJ/K,4#NS?7=V"\Z5I>-G/
M%2L(]+A:.?%L#WJ:$13+FVLTJHSA+43"**I2#@AJ*_ZDFC9;YBHD87J02H$[
M+'(I*E"C>>+6J'-ID^*D[R>OBR'#I^%0-`%)*(:0!UL[RQNB9@&QE]<ZA;='
MTDY?!2V+I`-N-Y-.PP)UD:U0-V6X!<`$5,XM5SY8%KW;O*W<7+Z]'?W1?,R_
MPWT_9S[P9'@`9ZCF*,NR_@$,[F/_GGK(OC']L\U@($2;W3VYW4+9`7P.WM,P
ME.!-E!&B3$@@0*,:6H:.#HH6X_O<./87K\`<JW?T775QWPI)@7^R$\_.H28H
MF;$X="YUK%.S=(8MP0W$@B?<KYK62#-*:'$;L:*VD'N66^U\6T`(UNJ`UZA6
MZ7NG-!J,RA$N!GC@16?T?\>N14VL6TO19@J*)2GN,SD>;0O1SVK[8=?&NJ>6
ME40(VR_DA&<J:["CQ?V,.)4BCU-J?[*B>%*Z.#;`!K6]/(APY1Z)[ZJ4O<N-
M\-30O?Q[/]L[Y@3_I]17J`BOY@;#>PL/9>O#2C;IYN89\5H6B!]WYST-#H8H
M`!K?(!Z/_S`[S3^=Q=U06P,UD&;T-`\DL`,B?&[*6BL&JBF3;5_8RH^OGK8>
M;(OY-#A,7#<?;-CDW,#O=N!C,VARTK`Z]?(O.*&Y-38AP<,9_N0M\Q`-2R8C
M\_58HDU=E$12`FS/N'ZD>405]LX$!0@O`8.$@Q86`2\V%E<!/!8V/(N0DSPO
M+U>0B8^-A8Z#CX>@AX<\CA9B8H<V`4FGB$F+-I,6IJ(!-JH\KJNUAJFKA+*.
MB[:0IL6OIH^3K+C`L[NOB9F1DU>AR*D\!0&]K"\\)JK1H%MK"0L+(2WM[0LH
M!BCQ!O5%]U/Y'OM2_?[]'`(&/$*PH,&"5!(J7$A%@,.'$!U2.?\0\,"!%1@Q
M6A3(T>(!AB!#BAP94N(1#CD<J-SG0:5+!RQ?RG29(V7-FP%Q<JSHL>?%C!97
M_`RJT2(2)!Z/7A30H6D'`3Y\0(Q*U4?&JUB-(M'!@H4.-FQZ(-B```$3'F]4
M^2(4*IB@09D.75&12!`M9VQ)!<.%"I*FMY+\(KKDJ3`ANI?>#L(D2A$CPY`C
M&ZY6BYFD":IT'9ND=I;G7&J/@;KKJ=3C4*?$F%@[BI2I0JM218J=6<QL:[J2
M#<JEEY0-NHD<J5!!&/@BV9<QI[+M:E&C%\!?!Z@&]Q;?2,`T[=8^3#*/UVU]
M9;,Q`5:L6ZB]V1;F[/LKW:5X;&M^:UC_@4J&$'TZU6R[)%U),`9.)E>\D(1\
M%A"G0A;BF<(@'A`Z8P$)*I"P`R(\R/$#`C*HLPX[[4`!10OPT%.//?E,P=(_
M_NS$P4$P$D020Q%%5=112/E$D4!$134551$)0,:01!(9Y$,*(=F0DB>EM%)+
M3[($I4PUS723`S?AE(.+.G)`E(Y8%76`4F#ZX)1#9T+E4%56416F4#WE>)0.
M7X4EA!`;J-**(-^Y1IR!T^5!PJ!_;D>*)^&9HJ=ZY`SB2GC82":I)W:)D@2!
MDV;JR17DR,:7?+:E<LI_MO52"V]]24?,+-810XE<U>F%:"^J>H-*J=8<%QJK
MW^F2C5S:M16)_R."#$?88H]HIA8PG3`"7'"$A%/?8X4D>\BBIQ1HZUR&`;K8
M=+64DD@N-L3B*6^_6-.*K:]UE^AN>H+&"C/^2;),*;R(Y@VKSI![H&P'-H;I
M%=JB(@V^UXF+R6J"H,*$'')L4,$0ZH0`8@M0P"!B"R&8>"(^*O+#HA0[Q8C0
MC"COB&..'F$EU4-`PFSC"@E%5.3-1D:4I`!)*M2D2U)*.=/0*]&4998"U=21
M3SSI^%-61CF-U`IF-H7FF4_)7-6;3B>%(YU@]2`6$V0SX9DIQ+TRX9^7!";N
M?K(40UA?UXI1VBJ1:IHIGW+'I;>F5\PB!F;1,`-:JK+<BOALG:DJ2?]_GSB6
M*E^"!=[):+X5<@7AF#U.ZJUGT])K>8$/V[9>TET"')^E@%:J*HUD4YQBK?47
M3B&NKW>=H9*Z!ZYKPD##ZE[#D-L**NT%(_HHV0W/W6:+]K5N,J]*1[=GI'3B
MW#0O2-^<#8UX)L85201H@0FK1<+$!CVP,;'%\+LC/\?PV',/R"N.+)#)!J$\
MDD<\:EE59*8U-E$!(VXZ(%.:@K,&#@E)'PG)23@@A2AY($5!FU+0@#8E)QUM
M2RC12=,V,L*6<:UK2IG:`A=H-186<&8GU-'7Z$3#L(EE`V^P00$"Q)A#4(AM
M"0,'YN*#.]DT8QF?R=O?]I:>22Q14MCH"VC_'&$;'I2'/&*@%ZK(49EF>`9W
MV,/+O]1"L%N82E6T6$M;LG,J1M`MB[_2#.G6`J@TOD9UT3G?+K!(FE`\)P##
M,8S;A,B6QR$G<Y2KU2#HXKO?E0)0I/"4-\K3BF&4SC?9R$_U"!%)2C)J-]%8
M1=R<2!\N2H<SE$R"!3#3"NJ$!UBU*!]O,C&^Q,0E%7A@0@]8<(,AI.,&\_@0
M_(89@OH9X'XI"ID'1D:R_?'O9"3IFD<2@D"IO&Q--F(3FZ[R,JM0;85"<N#-
M)&*1(X`$)16$23+O5X1]W"^#4QI:2SYXM)TPK81$@=I%9,BRI3@E32ZLT=;>
M1-`O&>4$6PF;67Z@_Z'$.4-!AAM67ERC&+?IR3*?,1WMGABMR/TN$:MX%D<U
M1PM@Y,8OM<G5X0ZITK<-$1+EXXMLI%>7N+C4;?$Q37D6]SER6`,2VZ";)6A'
MF;44*BZQT\M/>9`)Z0PGD(!<G0HBD393!$PPE``&-5Q:"!7TR1DV]05]E)J:
M-DH($;F8@#;T(Y\K@B>-.?6I)E`#*E:@ZT`3N.)@KG,<_53B<?D9A&P*@*#R
M;6X">1!48ACQGRVPH`)K6,,-@J"$RBHA"`:H&#$]9,PBZ$.9S`0(1YYI$&F2
MT"('I)HUM>DFFK56FU,1@!!@5LV,^&!)'1B2!'!&SH$D9(+I=,`ZV9D/=O^^
M<Q]$*QH]5:(T>P*0)]0D*)SV^;2H]60%+/RG=ELHT&V&R;0465F=Q%(6LS&A
MJWY\#'!4H)=.%"MNBWHE'4<JF;?X[3H\$*EA]#N9*IJT/(_KJQ';J+B]O(<U
ME$N&93BE54$TC%:$N*I2:7,M6V"G/*RT#!N/09@[$B@^?T(J)M93#%Z`KQ9O
M"62Q"G$L/@6'K(PBL78$&3A330Y>?ND3,#ZW+E$B[R[_R6NY##4+(O/X>TQ%
M7F"JF%8`;X=7,IT7\@Q$5R7+BU5Y7<9W;+"^]K%`!FNP;&6#$`04?&A^%O/0
M/.RGC_PQTT4O.@B<*Q)`D-","K>-+FMCALT]NTG_*D_Q9LN")$XR\`S.49J"
M9XV+3$43%YXOZ>`'L01"YW:$(06M+E!\`B?L;O?3W.WS0/4)WC&)]RMB>QC$
MY,`@\.6A0,5J2WX5$Q=99,-:^J)O9(X5JR<K\HE-%=^R;H/%6WUUBW:K*.JJ
M96-8U+553!T>&G7%+UHJ[C-UD^(L`K<:1^27OXZ4:"CLJ@NV&,*N")Y=K$U!
M.V&9;I6V.=ROO7V-WB0/DX;H'!5UQXN+ILI:\J:<OD"U1TEJ(XOJ.=6`%^7%
M78PQ?)),S7JDQV#!B0$/>M`#'K;0`Q!\.;)D)G,PSXPQ=\!/'?/P&#ZDQ,Q*
MS_GESD6M2-[$IH=D#2I6_]'!44[`<YY;U@$'6&%4QA3T?T+$@5`AX94NZ&A&
M&[?IC<[@DUY2)4J+$.81C"Y&4EL4H'3]NIUFB@0D`&JC'^G/WA33IJ5)IC&-
MMVP0.D2AU#9K![-7,*T8=]UVL5%='X;7L4(&8_U>NI\NQZ<E#4U@+)[K`R^#
M;WW=(U8;$YRB+@->F6GCY_2*5K40;C,2!61D$G5?FC;2UKE0E7[YY)ZY814\
MOC%V1U^#U/:6(S_#,%]H-C.Y56)H</J!=S1X(VU#*37RST#XOQ4G^-<_"JZS
M4=XAQ9"'Z0Q.#%O(/ANZ`N8;W&`=G`W_,-N1YA*=J!YD-H/ZS3`%,R`SGE:G
MI__\Y[P13NL9AGZ>V<[%K`09]/P$E55T3&$52.``)R`$G^802`<G(;02Q>5T
M]W-,$'@/&U0TD39/],01+I=UF/8T&N%U'SA=8E)T8U=VH18DW51;4#."7>(E
M7Q,6/4`VD9`8K@()"D(7=]<=FS!@U#)[?O=4D_%(P]!WZ_540*@YE%1D*U4+
M$U<;E-`GO6%NOW)Y$D=@4+@7[0)A-7A]HL0J3E@-CS`!QW$;EK!(X$8(824N
MLK,?:L-51RAZE')K;T,O;74H^V$*2-4,E-`)KS0]HE!7@H49KM%7_+((K$1%
M5P0^H^`,P-<P@NAC3-9):P%\B[`N@&4MO[`KB3<X&"#_`@W0`([5?=\7?IR5
M<J2X`),5<F16#RGG,>=W3&V&7$3#<BX70M#5,@M1<ZRU`DC`<TAP%3O'<S+@
M?_Z'4,9X`D&')E&!!$IP@*"F@`WD`QM1)>P'=4[WBA.X<A6H7!Y43[;((PHA
M<PEQ$6FW::0V%$&1728($3?W0C`4@M/E-#RQ<PG%!F;1#6TC.M"A(*_2'JZR
M8YDD&48XD`1)D%V%AF8T8Y!1D$:X.4\H;->B4B9519H05HZS;*``#:AP.;9B
MAZ_A&Y$08'VAD8QS;:]2-^20.E$E&;>$<)RB'QT55J%GAHC!>IKS2$U%'\,"
M*H*A*G$Q'.*R/6J#+31U.#56_S<VH`C;T(;!T%9.MCO[]E/70DF`J'<@N4I/
M:1ET%QZJX%5ZL0.I,`&YI$LZL`8CAW*LN&:JN(KR8``B1XHG5R*MB#\5Z`'J
MUW[KMTR4EC3-!7;>M(L9H7,^5UD(M14X\G^(F9A%YQ0^`(#.F(#0.$X301$I
MX7[W\#&,AHT3J$Q21Q-&@S0Y<6GCR($UPS57$10FA(YF,G9D9X(`)6HX]Y?E
MJ'9KUQ,!\35H$(-G(0EX0`F)\%0D@$BU4Y3'H))=Q9#(.9""E%-<=9S)^9+Q
M!@DV)61Q@Y+>(SF/M!AI5#NZ<CF5XI&+J&V1E%*&`PR=4PP\*2I\\BQ0!0JE
M`0T,YO^>JA,>2;E10,@Z?_&2235D3O0I?J0;")(?X,&'IO)B>B(M.N9LL;<*
M'VDW8P14^M9$T(-P"6='6Q9+`'=]S?=DHN.56?!M1_@=&:)+8)9RQ^26E#5F
M:RER9WDQQ!27)NI9,7&!%V1<Z@=_6.(E/>)=1H%`0A&,8N:+P5B8O;@5-&2D
MO<ASB]D4/L",2E`UD!E.8_=`U'0`E7F9KXB9V?A^4+(/G"F+W`B:*"&:TY2+
M`F":YMAIIVD1J\F:K>F:6B,SU=0F64%J);0"8+,!3)!+MW<)344=WB9PP],:
M\Q95R7FHB!&H']4]J_%KB+HY*65K@DA)K;,LL01)J.-BAH/_=[B`&?=5>6X$
MDZTQ4PH7J;B1;<>0509V&.UI&%($;U0(2(G2=XO4&KX1%WB8D/T2+)K@'*CA
M&+'#;-D3`-V02;D'J^N2<(*%5K50`-T`;^(9E-H!.KCC26:$%]"J>'I$%PP2
M2+[C587@K`4`!@$`,62S2V`69I:UEM[7KFLPC#*@!&9&<IM5BB;B6<FD04RW
M3BEB!DI`:4>A6KLHF$'ZBSJ7I(FY,E-C(UM!%73B`T(P,X#&F$A09CJ`@)`I
M%62P6U2*9U3``3"!I5EJ/Y@I@8_&$HKVI2TA-!DH0CH"$F<J72"83VOJ::S9
M%&^ZCMTU:G4J:*56CT)0-G+0#8`T_R%J^)$]J0P",F^(BJC?DE^]UI&-1)/(
MR6`%%GVW@G@EJ8BN@'MO0V61Y%>W2GD'EB`NEK4G%8;7$B[A\CI^P0IT\Q?%
M\H9W@QN">$?0D61?RX:U^CNYJCL2FI2JA&#,0$O=]E&;HE2,!*C]:4><1*$P
MA@O'8:WE)@N5`CF?XK5X@4KI0PM&&*Y$.PCBZJQ@4+IRP&4]X%@5,(QKH(J1
M%5G#>`(T-+L`6&;"5$PH9Z(FVV88E$$8E*]8,C4""[$1FW,(.V:$B9@(2Z1;
M,;S$*XTZ0#5"035W4KW;)8UE]IC;Y1#8M;$<:V@OLP(@*[(C6[Y:RIF]"T_(
M91/L&T+-I?^CD[D0$40S,ENG(`@G;5J")>B:[1A;L5F_-.LT&`$V/?`&&4*H
M<Y6%=DBHO\.1K-JTR>E4P/&2OJ9ZAUICEKIXO$&)J<I%8F0KE?`6CK%CQ4,:
MGY"&;)$[5VF=IR)@PH.UU&*0\FD!&(`!Y4(>8E@.>6NT"!89!//#G,$*N,H?
MO,-BM]0Y`M*W3,E(AR(MNUHNXW9KS#!E[S&&906%N,<?6%RVWW&4YV,"WS$<
M84P(XPH&M$JZY$H,"-``+$`#[1H$KUN,LPL6:%#'/8`&=`*O2C"*<JFEC?99
M^*J^5+(E1'&P25HG=-*+\+K(1.J+)F1;:><C.,>+OQ@458&QVB7_C9>EO=JU
M)F+WO0KX%`?@`)99!.9[RN>K3"KK@!W$7!\$CA,AOQ<Q$;95OS)+CCA[L_Q[
M@CO;6FOJ@?:W:6%A%J\0G.T!A;S2;K<PQ)X`P<GI;8#7D4\F4H^*DL*35;51
M8S",8+W!D938*'FG5.SV8,!S#/_%*H$SD3G&&<V#D*10A"%Z&2(P`IEW1@+7
MP^:&D,9P?<-S5KOJG>[95M$9+&^5J=,@S=VC'=)"41WY&-+2&;_`>W.UJMN9
M":M!"EE`(5D@P^L%!N-Z+,Z:K*#P'QCPB0QPTC1``Q4`-C8$@ST@!&+3/F"A
M`P#8NBSJBO80!%O*F:Y<$_V4%(,9<LTX_YC\]W_-.Z?:I%J0O$W16TV3'!6=
MO`(`*`,K\(Q'!\HLM`(YX`'DB\KF2US)Q-,P`::?>74?(8[QZS*V[($$536Z
MG+-1:G,_XLL`_,BGN0)@$;1,X$-I,P@,(DJQNDC+W)PXZ,P,*<&T)RZ?"J*%
M/9"<8G'+X1E'R4;L]DI4&(5,"3O1TH<3M;;.<WC]6&QIBT7`)U+BC$<J=BF#
MDU=Y);:4D$:LH)R%(8>9%X9V`Y4+;!C`I[;N^5)X<5].%`[=!JZ*T*CD;"D-
MS0J\@,0V,`Z[(`YL=0KH8P%9D-%7,"@_]%1VL-W;?2QV\%0O$+K5,MEA6=*?
MV``@4`,U$-/LW?_>:,`&>2R*I7@BF(7*(--F/7TE*K$R0;VB*1JD0MJ\^3?@
M6R.-!S"[WS3)WW0F4AT$3H`$U_2::#*EAL849"#*(>O5(TL/IFRRC/:ER94E
M.?J^`<$0'V$5!X1G:JV"D#R]+I/+N@RG-M>.WB6]-9NF`4R.83$+)*`ZKG(V
M$FPL=V<HBF38SER&_8F%1KB/C@V2)A6JEY%Y-PGEWV(J4`:M/9@PP6(HJ9#.
MC#=3AL=&DST!J\&';?@;^^CCF<L;IP14NT*USP(8J8H*Y[D<KWU6K(%&T-/:
MO;UX;U-Z`R<70Y5)D#)$MW<7%BIW3V4O4'N&B2&N`5"Z1.N5C&!3A\?_VC6,
M`7FEWF51%AM`%I\N-G7L<:M+`Y(U!"^J9O2PBKIK/T5PHV6=)2?@`)=%9F(6
M<O1MZY9%I,Y+X'LVO$HM%-&K`S[`!@GNRREX`BAP`Q!^35?#CEC]3UK-U1VN
MX2?BBA`8BRI"-/(GIF4ZOQD1L[7,XBQ>CC[2`6ZZRRT4:C'SZ]\%)B*(I_9X
M7E'U.$\HHJQJ2P)C@V,,YT9>D#XI=WQQ.1=<G8<G&TC%1@$-2V6X*M:V5=U\
MAXG#S4\>&-9R2&X4J1V</:K2S8GQG96D.T5T>`VOG%#%":'`A19W.+$-/".]
M2'>%PXBDAVR5Y#WH'MOC1YK4@]J&.89WDA62_]UU0:QE/`AV\"W1$M*8L]J9
MWO1-GU>:GE>I\`94_P.?O@%H``(>)P.F?@,)X`4;8W(GU^JL*$P+8`#Z$%R5
ME=\JH7[^_?;J]Z^%J5K6VQ35^UH#Q;-AXLMWKP/D^)?X"Q52K0XGX.P!A2;C
MY$*CK&C6GI9KYL?W#77QM+X9Z+X",8Z8%NZU);&SR?DM;K,W"]=EQQ1'4OIK
M\N[455T'=0)LL`'NP5ZPPRW[=?*-@1_.^>\%64B!MZBR:BR&.AW@TPP3B<[)
M<@W"ZC>*H2L8(@IAI438(_(QYL%K=,U?[E_1)Y2"D(9I`QU!*2H'HCFI,`Y9
ME&)'"*YT&+:V/;G*Q_]5KS%5\1'$^)%&G3#$!M9ZP)\]E](+2=4;60@(62H!
M*CP6/`$!/"J,@R\!8)&1B90!+Y>)5S:;-F]B8A,3&`TBI0T8J!BAJI]O;S97
MFIPV/3HR-#>Y0R$A+;Z_P+P+"RC%*`8&02B]+;R\*!X.T0Y*0=9%9DK49F9%
MR,C6X=QF4]$Y.0<'*SX^`AWO\/#L\ROU\S[U^?KY]P(^0AW\Y6.C`\F)$TC4
MK5"X`IT`?TB"W-#QT%V\=Q4%D-FX\2$\`2LX>/#VK:3);\=.%EG)<HI+EBNG
M2?-@+H<#!^=RYN3`\P`5*CY_"J6"#Q]1@?L6\L.WCFD[INO>29@Z]:)5C`'_
M,VK=BG2?PG0,U1U`XN"$#C9,Y,BQ8<%"'A*,,%4BU,C2%3$6$K6]@HA2H[^`
M`PNN>XF'X41L+:AXT5:Q)4)^&070Q&-6VT\6/L6RP+>Q!1N5#'FFE(0'YL97
M*%WQW#>1Z+:@#6W"_&G39QNTQ5C&FYGW(46>KPQ"5#FXWKP!,O]6Y#KQZ>5U
M_<I>?5DW6U!X/^&=W'91ZT0JJ%O"'1MV8MO+Q2?_/'>N\M3KE1ONC3IP(DPO
M"NB7^P),`4C[S15>++.!(DH#")Z2"BH3:-<*)_`%D$02D\G"PBZ^A##,`KPT
MTZ$PQ%BCQ(@D(;-,"%_<L,8-&HXXA3?%G%12.#"9_X%3#CW]U`X\0@@A@(_^
MW$-//F`EM520Z[@3Y%/L(#&B#`B!)>5"2#3EI`P4;15/11QU9%%%!^0PDHQD
MEND-3&@6X1)-;-[DYHTWZ81C4.D,5:</5-2C3E?Z,`05.TOILR-55WV4459<
M)0J5D5(V6B0;/3#!!%LDP+78)2](!MX@E:A'76N#A2JJIH548H,)OR7&PR.#
M:)I);`&0AYN#G"!F'"6O=:<(==>)\9UGRRF2&+#H:6?>9_3A55RO%C3H&G"H
M&588L9L@HNJSCPP++&?MN;;7L+79$(J#RK)E0U^<>JMK9:!1:.ZLR/:EGKFX
MAM8<<8V)@2JQPOUEAQV82O\B,!B8J%!`97WQ$(LFO872H!BC)*C@N-J]LDDL
MB4S8'KN9L7"B,QH*@T(X(QYTD#8.=(.,F@:,[,3+-S1C#0K#&*/2%".B'.><
M0@EY3Z!&ZE#0E/WX[,-8#*V@0U/^G!"$$@<AD5`Z7B'1I`Q8MJ/5E@]U289'
MB/K`@0,EEFEV26FNZ<&::M_4YIMRYG@`!T%103<[0M&]`DA)^>G4HGW:(Y4$
MA2+Z9:**&MFGHWL&R0:DDUYQR:699MKM?2^(=AQTHW;^%R&@4G)M8H7PU5ZU
MML*FG'*A`8LN=;"M!EIRIT587&/GBIZO=<B2^VYOM-YNK&'R>I:[NO1EHBNN
MVJ;_>MDAZ1[677>RP4ON;<O72TA;C-!K*O#;"=N6K;-??GH6L6:AOOK?$6S)
MP)$\DL@DJO6:G8.KI'*@"`W44`,"K;`8+.9"(=<T@@0$\`S$9$`S#8TL9U$S
MR,E&-+.4K,PEX8#9%V8`!6+0S(,&4!--=L8!J2&!)R5D'*.D-A86@H6%3<&'
M.IXB!"8UZ2#G2`B5HM2.%3@@"":+FM"\,L,5'$0'6CN4X332);!E)"1C.IL4
M5P83EY2#36MR$YNF<8X;G:,G<Z.;4.KT$Y#P9&]%`912[,$/Q1'-'80J%.(4
M]<0VVE&%(*':67J`B,G%!5.N^H[R?O,IR&S*<Z,Z3'L*_PD[]C!'6.6+E>JJ
MLQQ\/>]9K\&,A`SA&VXQ)Y/(P1>M9I$;9'V&-A/@S"'@!9L^9LYUS#,6M!!1
MB$'0ISN/4-BP$D:\Z9E`<@P[C7;.!9MN.4(%W4F,]C@Y/$DBQWO$JR4C%I$N
MR5S"#G,1&";@5X!(E&X^UC&0P\8I"@SXKP8/TQ^$%M8MXO%`?6U!(`'FR;XL
M3*`"4$/(U$QX`@IN"&0U^X85O6&-7"0`"E!PX#7*$2<4@K&%2,BA"2=*40E&
M,(9_ZI$/R%*EI=!#"0:P40X0HB<8XL-I4).:$(4F-3VM8P4&0>(<N<21K!CJ
M(53(P11*8HP83?$;:++B%;<8C?\1S@0G;MI)3U!HIZ`(`"@^`=1#C/2G-;*Q
M2$R!8U7DN)4D9F0>#UF4&E^JIRFM`*I@.0L3#DFYR>$*7;@:GS/3Q59$=LXU
MB"CDZL+GG4UH#S7/(=X@]](Z65(G/*Q1A"6+*;U1KA)\QZ+D)VZG+1M4<W5Y
ML=Q=>*>LP#02.:YI9&KZJ$M5<LMZV7EL)"NAJ=<<CWG508^N5!5-[W"*4Y?P
M#_PDD5N"R4\_!="8^/#'BG*2<YP/@@6\SJ5(A1'H7%D`5J5X4"FXO-40/1#"
MXW1P`ADHHX$=RA"(CJ$F*])DI\6X`8<T9(`1>1%'#HTO3[IX$WT&\;[V/<$*
M>O0.']'_PR`4=`!%#S"/`XPH&V71(1*6I@^#+/@?/A`:0@I2I31&F*3^F"D3
MR8"H)0K@`&1#24\M^-/R"E5M:R.JVZ;1IB^"D2=-+>-/[(&/L":%;TW9APRI
MYA2/$*YP6BD:.RIB-!J/M:Q%JA/5%API.2BV$8"4C"+G(IX7'+:6=;5KJ$#7
M%PN@:CJR9,XFIKFJ%PP+%HE539H1\QQE[<HXI9+=;&^3F]W<[SRH;4PO4<.6
MP7J25[V"3V`,L0/'L+:1@C3-(?;"2=AH1G:/'/0BH*78N/9.=9.=)63H.C#]
M1.#3$>BF;B4!W&Z&=F&V^00Y]2<*BHG!%;.PW937%]W&F&!?_UFP%&#`<Y]*
M%.`':)#!#1+@A18@5+P@TQ`Q+FA>+'Z0&-J(KU+E*R=I<.--$7QPCX2@`VMT
M%*--"L(PDJ$$?A[$2B1#B#X7[-*C(6';4^'VR\RR-"%QMTH9GFE-M821HSE`
MQ",F\=E,/%"ABK"H6UPQ"5]<MZ$<Q1]$`:M3[)ACLN:Q2/NP")"_*G&P+BF)
M1;$QC1?"N!>:I<G1I%Q=IDQEN;*%FJ32LN<,R4S0X*8W$8(%E#_Y&<.LAC??
MR=7LS+6[H*?96I,D>G5XDYC5/*Q<BTYELWS5'`6NRWBB001]CL<J3ADB-9IB
ME6B;.SY%:SV<>^GYI%<^3<KA55VJJO]L-DM=`%#;_>Z@3H)^0L.)ZKA"._E#
M;L4Z$6N,3081%)J/`O=E@5SK>M>8"YA<`J"?#<B`@P@]-H@V9+,@F)BH'I""
M`Z90#"5\T29O2BJ.<B)ZHR+U)CKT60VYJP2:/:UD%<:'$C@4HI1:U&H;M899
MV%$0[JX;4#Z8R@]^(($-Z.`&7W`"O>U]D`,0V>-:V?>AFNB#')0HX#:3(L%?
M=/`4CS#AJ9\VW<#B<*%4I(Q(2E+()ZYC*NDP*3NZB)+":C0+][\??*,U3#$E
MC;)@;"`$:^47F)(IPT%+[6%E+L<]=,&`,C<JH.,:>/$NV($7V=(ON-*`Q*$M
M$?)*N`-IM,/_:-^C9XIU.\VR:+H!6>;"3)AA&;/B9CQW2\@!.YJD",_A2=$A
M36$'.L"2&A!(2,O#*^-#'EWW9*T22*T175E0&89$"?[A:7AWA7>W=YD`"OHC
M3L>%7*[P!K<!(>:3>%E@`]'E,+[!7#'W.90@:@6P@'*A'SS``EZ@`%"0(<3`
M>;D0?@3')E(0B($H#7!B?EN$8D;E8F`Q-@[``8JC`[OG0,40#D!$8,&G;+VG
M;B;T4@BQ;3UB"VL`)>>&#T(P%1MPBG10`=`7?6;Q4C+43]8G<EY%4QSV-8GR
M-2!&$N#G4P-712\R5*"78JFW,_"U5'3B<!5Q5E,%%0+Q%%=55B5U_W\OA556
M<7W]QT9,HT;:R(PXA60D]XU'HP,;D!9.5F:`Q%H/R!VAQ#UQ48%WI0B,D!G+
M92"U$2O"01?1\1V(]BPZ*`:I$4RFU#IK%BL.8AZZL8&ZD75U)CNF\8+!0CN=
M-#O4`0IY(1K-<X_1L82L%8^^$8^9]2GR4R&KH7BKLBGPN&52Q@,'`US^@85W
M5X6A1G>)5X.B8`H(8D[GY#]/EX&PL##LU$Z&`4_;@CNX@0KH)!AO6(7_`0GQ
M,WG_,0%ML'D>M"&<YU/E!8B"*(A>M`UF0(DM,4(.%10RY"3'P`U!8",=%7S-
MT%/IEA#X$`1K*2(CXF`M-7M"\SAL@`8ZL/\B3B"*2.0#!R@$&_`#&P`":4`!
M7Y`B,I![@-)/.2"`]L`5-66+B",V(;:+`B<C:?*'H#<3")=^Q4@W+S84(G<4
MT[@W&/6,WT@EZ$!$"@$V'_%_1V9D?S.;>],5&*<4[#`66R`&:6$8E[(8U417
ME<8=H(%,T-.$[FB!P&$"!8D;4F<=_>(JQ`DM*E@\O6%S":DMQ+$Y$HB!#Y-*
MOP,\1+ETY<(;#EF29Z8M;-9)OY$KBL$JO$87AY2"SV-)K7$82&AH=.$=,!<7
M5"@P5HB%P/5ID2!J_D$AP>2%JR`"`S``_%,#./D_8=B3$=(MIJ..7G9KM[8^
MA0"<E?`&(E`&`%#_!@P0'0'J6Y)@"0O8".HS`3B0`#5C#%3)>52$B%F9E7#2
ME<K0"S>@,_#E*`GA).HE,C2#`N4&82?`>^NU`")R?#Y0>^4F-`?03_V43^O`
M;6=QE]JU!D,0?4)#?$=$!S]`!W#@!!"0(HJI`S74F$'@`+<)@-G71#,5$MV`
MF68#$U147@<G5`B'?JJW$V&4#F(D8T/1#D2AFT:FFE1#<CDP-6)A5DEB*/\G
M*'^BC2+'#U,5.&N$#QR0`RRP!9("G']$5V[8<NOH&,LI*L5I9;S1(/8S3,SY
MH7)70)MU*_%!/=B)2YGD6`6"'9Q0&75&/;"T'?#9<\"B+_D)2XU`3>#Q_Y_I
MLCN@44B=\EG"T1E81WD(JA^1X))WIW=)$`$38JN<@#\.@T[Y@P&FX#_&XI,*
M(T@2(I\J0`*W!BQG&$UO-X6QT@`,``$:0`'(\1^\A2F1(1C$(P8E$`+AUS(C
M!E17N44Y*@6?6A:U5PP+X`L+D$_])")))25!$`)Y*`S6X*3EUA0RL%[CI;%2
M(Z83)C2@F`LJHE\P)8YH0`=,L`%P@)@I(GT'2!`G4+-H``<RX`0W,`0)D`!K
M8#5MB@].H@1H%%:(TP$<QA480610Q+!XJIF;V1(O47Z="3<Z$98PUG[N5Q1`
M05:,0G)2\E`O-#70.&19@7S;J#CX9YL"$1;MEO\.4J-6<J`"7,`%<D%+%NB1
MJ4.<JSH8H@-XXBE,EH5(A"!WQ8&>J?0LN?J>UCD]EV8LV$.>">EH3U>1QW$=
MHFMFZ'F?IC$!A999>Z:"TM&<@H!EB>N>L],:GU5=)%""E!<!8."MH+:[61A<
MNY)J!K(@.8E.[*JXJ%"A.N=6WK-IC%`I\SI/'XJBYK.`^F$#"``"7P`!>``&
MB?`OC<`70>EXNN:4/-``:X`V,-)3:--L68E"@7@.D<@A>4BR0;"82O`,*5$$
MCK@0*.`&"66D3Z-/X4:R!^%=4+(&*?4/QD=O(``"J@A]N8`E,(4$>3F8J5@"
M.HNT;*JE:!"T1'L#,+/_!B?`#AK5)-7`IK-(M56[-39E8]X'<`%')EN[$@-5
M!.<%C&V2B.HW-PW7?D]UFH`#C7J[?I^*#G,S-3SA0KDI@%55<72K8_0P0Q?G
M%4B6#F>!!Y8`N*8Z<XRD*T!XN$@)D;0R=6/FN)?+&3^'"-CQ&;@E&H6DG_EB
M2H80G<A2(#@HO!19:?!Y'4B7+Q,0&YK[G@H#+)9`NYYQ6RN8+,J",']!`N3K
MK$GIN[R;A;"EN.6T()J,KA5S&WDP@RR'C\B42NYD&+=K`8]'O?^1'W#(K0,3
M*]B;!@FP!8KPNO-D`H4&%Z[4HM-T"#PP`3*@BR;"OC>J-N]+;<O`(AAK#2WB
M_R0B\PT.D`XY<+$>XB%(ZGLOE0-FL&Y((`,KD@!]^6Y:>A8/C`80C)A#$+-(
M5*4Z4+-T<,Z(Z05>L`9(](DN.[18XK+]YR1!8#4:IG$L[!%$EHLR/,,JL;5=
MRS8Z;%0UH7XH],-"059&L3=Y0E:.`D81M7XNM,2/:E8S-,113"1)DR1\,E58
M=321FE8Z(*I)L&M:1I`?V1T?FF5BO!@GF)W+95=X!2[A<P7UVDH),TGZ"(..
M=F=$5V<:Z!MXI7@*9'-+]SP,(Q^6QKK6N1GP81AXECR5\"^/@*`':J"CQKO!
M]1_L0ER:S&JNY@G&<C'P>B]!:0'S!,D4Z9^ND6LV#?\9\O,">N?5\'--V)0%
M>"`&",``&C``I+.<AV$###1%#QNQ\L4!I(<":S#9(O*Q3R-N>O@T.`$6XJ90
M)#.786I$)7-$.N`$Q";",H`&W%8!%:`#='"*AJFS$\RF=VG.%3"T,*O.3:%=
M+HN7:/`S]E8-P#='6M/"6Y,HN8B9"VL2-<RU)Z9B8.MB\45&[8<G$:>,@=(H
M+_:I)71"1CQ?2*PWJYDT>,LHN>E1NWF;JPD5!6@6"/`#]U&J:'Q8\0$J-8V4
MA7P_JZ0;6G88D=L@5Y`$=T%,B65)ZD$<BGM*YW(]DP2#US''CT%-QC-;L)H9
ML*H7OH'(ET2"=V%*IM-TQ//_6MU*R5<HH+M+XJ$&26*(O/K3A0$T"Q8JOHE0
M:@6$U:<L79:2'":`/IQB:O<A:KGUXZ,V"6``OL_;!$V@`EG@G!,P`!K``"II
M0`3`H280UW]!L&]E`]T60FIR)B=A7H[-$T>`0CD@EUA3,A)1#2$``PK@!B%P
M`QR;`V?E-$^C4MXE$3<P?2M0#4H`)>U<VHF9IDZ`!DS0`S3@!'"`BG"0!DZ`
MF`GP!3(0F`1!$%B#-:Q]EP1QE_^@79G.!D."4;0WW,1].%J2;QZ!B_^6$EG+
MW,W-IP\;C%RD5*$)T1$'%(!"!7R3J(0*%G-RQ/"5$]+<14A\#B7W%9(:.!AW
MTDD2_YE5O#B-<A:#&8=01H'O^,6*42JB7-,7"-/UF!R-B\9=UB!"K:%N?(/1
M$M7BOAVR(NX-8I'``^"Z`CN"M@BK\7.V\>`6GH%PIZO6B1>`AAG4<8^MX<H"
M`VISX)*2D.+LHL<,.DZJT"`"-$"7,ZYU)UPK6&NH<LJ&0!PHB@C^P90'JI3>
M"PGS,_+>NPBT9KLY3I`-4`8E8#%ML0,3T`5=$`,$8$U9!LG,Q08@Q>4WX[['
M?`1"/^:?FC-8(WS\K.8(I0#S?.=)NE%7*@-]WD\LD@#Y_#@G$(I8\L%G>K2)
M20$-L`$UP``,`-MP4`%ID*9?D``44`$@@`;9M5V8_L';!O\H^HP/+LM@[=:F
MH;["`@VU+6PX[S!D7G4T'E#0RZV^S9W0"_TV@2K=.4*V.D)_(KU^88(.OIX3
M."$UFC_L2%QR:GO>B^.-1++L6@.-(AVI]0#M?=2.=H6=H2L<77??DB%EQ&(:
MWSYS_KU7DZMFN(-)0XAI96Q*!6E*X&.#R-D8MQ4>C,<6SG*Z:[A8/3?5]2J^
MAQ&2`U/),1D!<W#PGT;6%HX*"J(_Z/ITL!:LVIHQ>[W7>0>\Q%-K;;$^)$!-
M>3`*(A"JN8,)X[I;NP4(=G9@@V!9$Q-9%A99C3P\*@&2DBH\%F(V-64)%0P#
M6Q97)CL[!"0JJ*DDJZ>HDP5,)P;_!D6U4[5%4[H>NQY2O\`<1\/#'#D.)S(R
M:PLH2"LG2C)*-]75RDHG)P<^/CHG2-\W:^()"3<T+#T(+&TT%6AH.C(WYE\)
M$`UO;PT-"'1PTI0H06'@)P0]&FSIL:&'D(<0(W;KM@*)Q0,6D1S8N((C1&](
M9.@0TJ%D20$"3J+T@;(#RI0O4W9@N3*F@`-%#*#8R7.6SY\^<0G-:>N6KBD>
MDBI=ZL&!4P<YHN;@L)$#52I4-F+=2H7B"A\KJ*P8N[&LL1P'.#B5^M2BU*A5
M<VB,JA$CU8X8ZW(<RW<O7KYD5PB8V#%PWP-D$5=$PF9#@!>07Z2:3)DR#TE7
M%DFR9.%R_^7/H$.[FG3EL@TQJ&V(IKR9AXU%/*Z@%A/J,N9%N#<'X+R(=N90
M8B9<$L[Y](39%E[;.#V;M@U)DG&;L``Y`*I%KX=;V!V\-VX>+W@GWUWI4:4L
M`0JH+Q"AO7LP\-W+G\\^POH"R_?5P("A@8C_(C3`7PW'H;;/<C;8ED02ZRW(
MH(/W%4!)*CR0T$@6K+`FB0D#E*&!!@P@($D!\*D'1F3PE0B&A"M*,L@D$X@@
M1FR7J2=)=F+L,`%__30`1P(S)$"$!A#(*`8&7701`Q^K4!;9))6HP`0;:P11
MU%!%)07,+\(00\PQ2BBQQ@T+W'#"-T&(=*8.%<C@A!,W!)$--_\6Z?#-FC+<
M\\470Z2!@`T-E$$!"'2``(>;]R3P18@;[K@%"P.PL,46-2#PQB-XX+'0!DPP
M\1`;*[#!A@Y?320$&]&`D]&J&OD@T3<CF22K2R_11&M+M)Y$4S<Q^9!#3CKQ
MA`)0Q,Z"Y95%(<744D^]-9555I55%E>"^2`68&11%=>SQ[`%E3%KP5751E*9
MI5A&TOJ5F+J*<<3K7X4EAFU6VK#!!"62K?:9=;]%@ATDD4RH[\"3%&R)<ZM9
M5]YMG05@@PEB3!?*;I>)M]TCNUT",6[+]49;:LI=0MMQKB5GP7'837C%;Z&D
M(AD)'L>,HW>[O9:%;3:F&-]\\^W,<WO_ZB4Q"0_!^3?`T0R44$&/&-0@QH$K
M3[+@?0\"?9_""4]6\&,OI%C`%0TP4`80$(C(GM?PO6`=#XK<?/($`8`1@!VC
M[<C#UQ_SAP&`(XR@MPA)0Z"!%3,``001"3"`08X[6("*VM"))D<L5N)R5"]:
M;MFEET=0<00'T4BSQAHR/*.#$D&<*<0&:,!1CSD+!(&$-W9JHP,(.CB1@!=[
M?I$&!A;4@$,)#1A:01H4])Y&`\F14`4!662*AQ[4VR&'''IDD7VF/8@Z:ITZ
M9+0"1'>RRJH.KD8$*TFSFE0K2[?*Y)*N*_'ZT@$.Y"3L3L42>VPNEPN@4I3U
M%*@X*RK02J!6_[8B`&H!Y@!H(9=4SA*5<!VC6<\R!E7>8A%M840NZ5+,`]FE
MKE+!ZS`B#`M&3J".YPQ,0]99VW1,LX@7VA`T-#R-:D1#"8QEAX:X^4X,`\"R
MY-B&.R.;P!5>XQJ4I6812VP.;9*3G2#NT#-!=-PD7B"RWB#B$>+)PG/28R*?
M_>R,*W+/@VJVCS<@R`9OJ$$#!I"!.I;`$PVH@1L/-"()!>V,$6A1#Z,$FJV5
MR$$,,M'4DJ""'3&`"$,P6]HHP8I5M.T1.[*`C0K6'S'40`0#`.4`>B0@O?5G
M``R`@#F\,`,8P,!P&FB`PZ;#BD94LA70D<3DJ!0$,QCE*$K9$I>LPO^YSE%!
M+6'2!CA(=3J1H$$(\:A`HKS@A1OH8%3*T$$\V*2[(>$##F+@SAP9D+029.".
MHXR8":K0!1,$8'*=PD,/\!!//%Q(#SV@@9TLXH!P($$;C#G5/%3USVRP:GSJ
MLX@/VC>KP>#J)>T;S$0FNA+\Z606/>E?4(9B+&`>!1<#3$H!*WA`:*6+*P((
M"U:P98RZL,59%L0@M";8K;=H"PGBDA:VUC7"%);*!R14#%C2@I%K]H`)<F`;
MP/2U-53\YC']2@76;J@O2,@F.#L,#21(`QN'=;6(GF$8%,&(&]1<HC-5+)!P
MLL,<[?SP8%-<:A$=Y]2SQJQB.$M1>^8P!_?_]!60\F'/@R2T'-1,8#\"TN,^
M$%`#.`P`!QF`0!DR,(#%/0=C`4C"<W@&GZ96!K-;1)&*P`#8^;R@:%Y(``CP
MP(@+-4*J6RL`#_A3V.#L")7]&*6/2,E;5#(@#:I,@!6@``,H>($(1"@!`G8T
M`1,PZ6:N>)+"()$%)G0O3+RX7#"%24QB<"4K2`B3,F0`T#NQX9EH`$$:A)M:
M+PR!!:*J``4J``)#(0](&BA#!1#`MN1,P#^D=)H;%=$$=DX`#PCI'@L6O&"%
MV#-Z+*#!F585OHQ<\U0LL!,S-:SA<$1$"/M<*$-E!5&5R$]7$TWQ8`[@@9_P
M3Z.TJ(6QB`+``&HW_[M,&:E-HS6M[V9E*QQ)RU2$?$$#7O`M(TW@3,/EE)O2
M)80[C3*\NK$1BOAT+RLNBX9[<#WS$*RI1-0,%VNH-:H.[#+#R6IHN-JPLQ8L
MBU=0F'7@G)RK+N(X.F1.<,QJLN3,!L\8LUB4,B8Q+2X1KPDBHU__ZIX'.)JO
M?/U9`1:$&0198!]B8.Q^3%F#2C%VG(_-``Y""3PPCDAH7Y30VE`!QH!MK6!3
MFW02`%F?GB4!<M;Y;P,2`(0*,"'1Z2&CT+PZFTX#3D#'66S81@F'9@_`L0$B
M)2C)60(]>8&X+:#F#"!0`]@\3M63R9#6)J>#-6!.F,'HKC&_VY%HD*YTS__P
MP3_/FUX6Z,X*YB#2%CC%#G)6H`(TD&P"VG`0/%1!>O3L%!,2KO#L9:$)_ZT`
M.$*G3&5LP9YX:)-%M)&#-=E)5$?M`7PY)8$?L.Y.&I;(J$ZP`I.0H7TO+_&M
MVI?BFJ_8#!C%Z+"*A8N-UO@6EM/%SY6E%!U/T*0GQ<JTTB45G%:0R1:\8%,0
MJ.0C5]#)%X%RE/U2%A.ZZX1_L3)>_JD#3LEAJCP$,Q%G&`#<.#429M:7VF(S
M`3474@5"/.L1'P'G(181$[^1C7"ZHQSCS*9CKODS;?:>14@`K#.E(6.MY?.`
M.3BZ\I=_0'L<;9]$#EM")7O#D?A3(`.)7M.=[O3_8?=SM'[(<0`UB'QZ".$:
M,.YMK0ER]:MGK[/2_JRS`N--(P,T!""P0`ZJ)N)K$/&W:"O$]0C(=.K'"0?>
M\G9`>QM`"2#PA>%"`0HM",'NVN"8SI#`%!>JI`HB\P)!Z%(./8C&4]`]3'6O
M>ROM%A-Y-5R1$Z"7FPF@`3.06BSP!M<C!S:P!;Y%3BR01VYD,XV@!]=C75O0
M(PNV!8G0"%M``Z23$1.6#.F0"!DG<01E._]T)D>%`%N``&K0@FKP`V@@`T-P
M`_N7/D+0#=]P`"X'<RKA/K@B*Q,A42HV&!R`<SOW8C"V41^5"\=R8\Q20!B4
M03QV`$IG+MK2+4Y79$]G_V1/808&1$'@\H4FQ4$AY%-2UG4HM%,ZY15BD1?7
MM`%G]T*OAEF_43'3$7<WA#&8(!J9$1M0Y%4-8QNEP1ML]PBEX3&GL1UGA1Q&
M9%;-@58FXT1C5#/8D6BN=A][97F8]VB,]E=_E7R[,33Y(7JIUS2>A@"HF(JF
M]XBV)1R2<"06(#06(#&CT%RA$"-BD'RX5B(DXGN!U'LDDB*0@0HPPP@`PS4%
M(`8!\@4*D`:=IC=,,R"IAP#],4>P=XIOP%C52$J<IE9&$S@SX`8S$`+D""1>
MT`#,505&4`E;E#;#J`I<8`+TU#U(X`#T)P4)Y%T^=BTG,#I5D@VJH@P9UB;W
M%O\D);`%RR<<>(`(R*$]U*,'IE",CP)P'(@-:Y`.,\(##=`&Y"47J])Q)U`!
M%X<'(%`!%U82J'(G"W943+!O+6AR&P`"%+`[YW`";/`1WJ`$2)`29-"3L_)R
MN>(^#!6$-6<_%8%S.9>$0"$4,?8_3M@4#@"51J=D2&<62(>%WF)`.M:%WV)U
M6J@M%-1T98B&V)(N\$*6B7$1@%&%104"CB&'NF=J@'@=9(:'JQ%HRQ$:F6$"
MTY%HV=$:@P@>;5=H"Y-X'X,)L'$R(X.8F*!G:T5%7<1$?<B.DM=HFK>)F8=&
M]F$C)=,<#PA';71ZFF8IH=E&;_0*5J,V$A(C&/!&8/3_FBH`BZ^@'KXH'SHC
MC%/E")'0-2NR'M41`!B0`0SP!4"0."P0($T3?:)W6-O8(P,``JB8>ON!6#S2
M--!H2OX1('#``FF@`5!P#@D0`EZ@`%X``DPT&@*C`N(&=Y%P@$*P`F]1?YMS
M?SX&%OWHCV=2*O-``S)``]4P!'T"!UM@5EE@`EE@/6R#!\$Q*0RJ)#L@!EN0
M2OZX!F$2)C1``PBID6V@#4Z13!N'!))273T``DR@!A(@`1V`*J,CD`CY!BMH
M<FA`!P`!)U^06DXP$A]Q.CMY$B,6E#TZ$[QB<T;Y*TI9I#XG%$_9%%"IA51W
M%@ID%L]"+E#A=%$8E5!GI5/A_Y4%!)91J!=EN'5FN1=H619U\14H`63AH$UC
MM%1Y:!L/HT4P<P5V654TI#64<%6O,2.`:!NL5AG%^(?$-AQFE7@><WB).7B-
M^494A#.9R(F.E@*9=WEJA$CM06G*)WURE)REN:FBQXC+42.25C/GQP?3(08*
M\0-,L`$;($?0V3&KD%F)9$:EQ8O3Y0A;M2)>XYMK8P%Y0`*F6@%#8`Y#4@%P
M``*EB`%G<`9Z4P/U!0+]L*R=A@!A4U\LX*RZU2,BX#?)RA^@U``L``=?\)W7
M9@7#=8YGUP@$`#VM8*>>I0**@&#=\PW/4DS#L(]*%Q+OM@9K,A9LTI_IH!`#
M"D:-T/\$3?`(&X!-RY"O,M`#C8`'+#`$02`G`'F"VK!?\,<"Y*41X7,F&"L#
M%<`"T^-),MHZ((`&P!HD3K`TK,6J:*"J)EL-7_`Z%>`0$,$&8=)R/^JC/0H6
MNU*4M9(#.@$L1JI10P%TEK,L(H5!#D"5&@2E1X>56QEU3!J61=9D4FI!9ED8
M.M538RFF[2*F@C$8ZR(7]I)4D,$%K.9E-J09;?>'D)`O<PIW<MJVD[%5OP$R
M?':,Y0$:?'D)'>-GC^BW<,6(6?0O-4*;D?H`*;"XC,MY9S1ILD5%G^H:HXB*
MF$J:F_I&"0*J$5!Y5D,Q000Q8A"1)O!?`\$`;1"L&@`$0W#_5(\@&?71>[;I
M-053'KFWF[2)JU!"C/\B>S:``0Q``1`PO(23!L0*`J:(K!C`G,Y:?7.D#W\F
M1SA`;>3$``$B`HN#&GEP!7G0O?^52A5P`T$RKJN$H<T5D;J7GL38)*,Q@3U0
M84B00/9*!6<J%G:2L+&S3!IV7B'W*'ED6(C0!__%@4%0)>,0)]EP<='#`!`;
M!"@@)R)!L7"``'+`#C?9`>33GV\B`R"KH`T@H_4UHFDP!*QD!>^%![_+`/05
MHP&1/'R"#VZ9JM`4@[+#/CK;@SDK4?4SA"P!5$3J8CLW8S`F8S$V8T&7%+Z$
MM%"Q%E9!=5(X4]XB%U%A!DL*A08D_U('Q*1#MH7EHE-=5T+RLBY;RW5F"19B
M'`Y'=79<@+;EP:8#TR]A1E=Q&QID-EV9T1P)<C(-8QF5(1FB4%8F,T6/6$5\
M-D7CL1Y^57ESP+B0&JD\8R.0ZS"@N2--\S2:NZF,A;F?>;B;IWF;N1N-,(M\
MV;>.4#!7$)P`\`'(Y4V\]@4UP`1\^@*V";DVDK9*=42T^<F[NPJ6`&PZ\P(V
M,@'!.[P40`$:D%Q+8ZP$PGR=]F\5<$<5T`8L\(S5*`*CADH`0LG/80/-E0>D
MP%PB``'(TUX#6`T)0`-ZJIX$X*?LZHYK4UW6U3VB`A@I-A9=T4!=L0+?L`9.
ML`8A8"8C,?\JHB)0$7:1'BLI"+`(&S@.$ANQ$:L-(>JP-U"AV;!_X[5?/*`I
M-#O#+#"3Y^"Q#.H/A<(IZG4/Y)HX8B`'8O"<=-`Z%4"CY@`!`X``"F==:'`"
M-<Q0$/6#$44_M?)31$D1/^P305S$0PPL0ENT9K#45+PL2_PM3MHM38Q`2&9D
M.;#4:V'%4('%80F%6^S5"#26A@'&8IRU09:U*+01:`S+I_".9A;'ZQ=5A#2G
M<IH*KS$:*G#'#-DQ/[09%$+''R,<E2A%A856B<:Y?,7(BMW(GAQ8E&L;E(L@
MGD0@_5')H?DTH3F*IUD`BOMH[@%Z%K,(-R,)O;D>UD$".X`#'_#_`1_R(;UC
M!:X,RY0@>08#FWU4'R2RNQ4BVK8!!@ZBRQ42&T?R6`-Q1ZE4!@R01]%G6YL6
M-O,%`6V`NLDM(&?`?-B[(ZB!`?NP."=SW=V[`XNS!>?DT;L#!3>@.Q!P<;/H
M!WZPK@4#&8)$'NJ\"`PW@37+!EY!SQ,Q*BPP.KI#@QZ'L6,"H#/HCQS,!-G3
M``7NT`4,D#J@#AIHDC?Y$&R2#&]2`37@&@WPTB)1LG!``5X0?NC0``LY`,2*
M!IX"!TZ@)\)5`AG)K/95W&E``S@@`G47``IW<F;"/CO=XSWZ$#R*8D5I/_@C
MM$/[$T2<Y%BB"TOMU"0UU23U4E$>=4W^_]16G@-<7=5/W<1):V0>M+4CI(9=
M^[5A[G5?'`YL0-,`X]8WA!EWJ`(;`UMSG`IUS!M[%LB&K+=S71EMQY!X5D6=
M<1F667F+K=B:2!_J0;E+]`8[TFF<6IJ3K<FF&6>UYME^E'QLXUH80R*Y'%B3
MYC"H<04D,`$9P-J]<^KFT`"_-HN-$QNE/"([$]\":QZD35HF(B&1L#*E$<IN
M$R.H=#2C9(J4\C0`?$H,$&%#0`-#0`$1Q@!'90-KK)[\H9A'DMTBPQP!L",`
M$EF)0L)0,`1.$*PVS@A-\IN@82%;1=J0\PCOR@2I6-.=\F'>PP;(G@#A1SHZ
MT`,]L`;7%CL\(?\GRJ0#&,@"X;D`!A\[^@HK;#!/68``(!`1(RJ#J44!RX,(
M)EZL)6NR%&`%+=`")KP%BB`"<""C.@`'\K4G]C``I5`)$-HCP\Y:6:">)(`@
MUO6P-[!0/&X3-RPK0#X_*D$88^$5*P&?4Q`41[Z4_X.D2TUT23MU49Z56OET
M;^$!7EA!3J^54Q?549@648G%-J5U\7+69?VEAH$75^:U!V`G7`8):\P%DN'&
M"?,">QD*<CWG3K6'E=!6>(NHCJ.VH3%W(H,:=Q,`B:RXA=ZXDHK(]D$QEQSI
MB/6_EXW9F&V:R]%'$:")F<D=B&`"FXLSG2YIG1D<V3<`$X#:&3`DO6/_#OGF
M!13@-,'13@$3C$#3&F+4^98?`0PR-*]Y"BMSN(G^7P`"[-+(G*;$'UMP;,`*
M<-),`R'"!!;`QE>`"-0^H!":@`T@^K_+(UN``YN`;\&*L@"Z!>DA\S&_9J^F
M"N='`!)S3P=X@)VB[_"_#H\"XM<6`AQL+_L^`^$7.Q<%"$HG2"<R6UE;;3<R
M2#IL;#HRA2<Z('@\-2PZD3(L<!5#7EX)%`,38B(5%2`;/V@5%`E6LV4865D3
M#35H<$X4$,`0)2(375TF*CP\-C993$QZ>K<6%B;4S`@@0S=H0M[?`N'BX1WE
MYAW?Y4+FY.$^[_`K\#XK'$4&!O?X^_S]_D7W_P`*'%C$C)DI"#U,*3+%@0</
M#ASDR!%Q(L6(%3%2-&/1@4&)%T%6O#B1@\F)($UR"`FQ9,D#,&.NF'F`9LV8
M-W'JE#G3)L^?-5<08K.!"8\77+B\2,9#A=.G4*%>4?'BQ94=.ZX$H&9A:M2O
M8,.JL"#&!H\`-L10$U.6VH13U)0U%?N4QQ4+-@+P*!#AP8,4@`,+#NPW0H'#
M`1`K8V;C#5L$-2(C>/,&<@T$F"-3%O.F,67&9Q-'&.VW=(HY<PKHS=(L2S4Q
M)K+P'4V;-N(`:)FQQ="@M^\!P+N0V(%#@X8$LHP?3^`%`@)FQ?@DQJV7J3(5
MU,&`F:T]`/9D)&Y=#__P8G:2)*J530#.'HX(X`W>BQ#1`,,IMM=J,&B0B`4+
M&CWXAP`3-BSU0A+4\?=&`Y.QL`4##$R``0Z]G<)?<41`D<`--XSBQ`T)1#@!
M5CO$UA1Y+^!6%74\W$+"BS`^9<>,,ZK0Q"UXY*CC,TS((0<36S1`@P:B>'$#
M#31LP08--R@1Q`(H1!F$((7(T(,="+#`A@1<,B'$?QS*4`$+"%BP11I.R*`F
M'"!4@-R;%5S20!IPH&$G"&E0\(4L,Y31A8NY?)(&`_1ML<4$%F11A3$39&$'
M#WKHJ.,$>+R%%S-OU("D$%Y^LTX'[9!SCCK>E",`.Z>:*DX\\O@@P`HYZ./_
MSZRSRIH/00!-81!"9BA4!$0.8>20&2`]-))&'Z'4*T@4=21212I9]%(.QFH4
M;0X[]134MC!INQ.WVJ[0;;?B]B0N3B><P`83Y"7%!5-T@84;#]8XQ0,U7L6K
M[UU<R4466V6)\19^\^Z;C`4\D#;8PG/8=MC#RWB&66:155SQ9)1EO%EGH.$V
M6VD@-YQ>%LK,*]=LM=6F&FXV6"!A;QC$+'-\]%7<`'`C$+##`&4`8!QR7U#P
M"RF333"""!CL0`W)V1UF6`%@F'S=4^1M-]MA*<I%PKUIX?!!&<!!R``.`\P7
M,\#,4)/'%6D-P!\+/?0``A,U-+#!90&P;99J#3"0_R4("%"PG]\(X-#&`#6L
MQT(;&@"AX1"A&!E*&UM0\R)VU.FKXHK>J>":"02$3D"BMY#LHX^KN9Q)Y#,<
MV0;<%<BPR28G*"%[(6,BX(R2:&Q2@0XLQ/+%#4Y4<.@6%82I`R]IO"D+Y6+T
M#3@(GY0`3`(:0##`"#$8T00)+A^*!^G1)*H"`8LB^D8/D/CW"`@L--##&TS@
MT7(-`S#0`X^>"A&._Z(ZAS<ZA8Y/!;`#9!C'.WJR0`Z8`1^VHI4$!7*KA>"*
M(0J90K4VV!*/$$M8'?R@!ULB+91(9"70.DE).'``#CA`@QJ1EDIT$BZ:^,0G
M-#Q7#8-2PW/EA!`GV%]3E/\"+WV!A5_8J88%C*BO:ER!;7I!BZ72`C"U%,R(
MX$O87P8#LM&L;#I>5(UCZM8;BUD,,QK+&&/,DAB4@:PPAJ&.7N02&C"DS#9/
MRUO:!"8A#+R';$BSSUMFQIO\92`#(@!=`\KP,Z!!;@C'B9\(1M`%I7E,.T];
M&1U+YC'N0(U%K=D:U7"SA3(0H0QBXT\-`+:9@0FL1'B)WA:RM`$0,*!-:6A`
M[BQ3@S?\H&\(J``#MC`$R@T3`0Q`Y18RT;<$`&$,7H"<*&XPA`0,X`VX.9\%
M2*`";D9%CBGJG%-((+HL$.`64)$C>%Q##=%-0`0E\,(,9@`#X@V!3'"@4S>\
MP8;_=,E@#:HX!!-T&3LG%`\6"?B"0M.PA;2XZ09U:I,3]L0<*T2(+&7L6PE*
M@`,&#(`%O=Q!%Y;P!P(D(PO2D)2.MDD`$^2B`;23Q.S$M+\WC,^E^=L"CSK5
M/W&8BE2<VL`ZA.`#58%*`&1`U:KF`2L*2C!***@50/9Q05QI$(;)\@A&#$(1
M8(4P(@9)5@FMU:P<L'`E+VFA0X#E$AGFD('E\F%.WHI#'IJKKC@AA`YZ8`.J
MV&LN3(P*O9:H`B0&%BS5.`N_EJ$6M;BLL0B;6KR68I\"`"8U*`LC;>;P@#E<
M-@`"BUE\W-;+#:11C6P[B]/ZLD7"/"".RKB%652[VCOF__$*E:F!S';+FYJ1
M$6:"K&)HWS,`'.!@!-C!@"FM((M9($<#1$@`'!"@EJE<02[BD<LEH89)Q##E
M15.CCM/`L")EB`"ZQZ$`"'I@QAH$21?X42(/Q(`X!$"``128`2DHD(8*P*$!
M(*@!"'0!&594X'4)&`((D-0#&@R!`:OP#P,:!\UM,$>AT1R`?4Q@#6]ZK"KA
MA$J,2A::`&A'+BVC!H=#=SD5U&@'\$S`#+P`!2M4DP9U*\$JNK&!'LB@FE\P
M*#%JD`H9."$-(&C3GA2:``@TX`IBP.\JJ)>G/6D``!3`0%.4X;(18$!\>,B"
M'.1"@"4L(08FL`$>>K`%$+R/!?\@V():K#$!50P""7C6`2'4Q(8!Y<@$T1LF
M'J*AAV<(U5.B2M4`GS'44@G`5>1(8%*5NBHJY&`*$LPT56E558`HY"$%D8A'
M/-!54FLU6&`-JQE"7<*0F)4D9UWA25!M$;36&B8F.0`5=$@/;GT+*'2]*UYC
MHM<>Z&&.V3QL5*Y0+ZM00]E0<6**TK(6A('V/E8$K+Y>8((16*`O!3#47E@+
MLH4]P`9^]$U\=.'+'_R`,6WD2[D!4QHOSG&3G;1M'O62ED'>;&QE@UE]9'89
MW6+@,I2Y%#.>J,=,O6<"><,`!(@P"RO,\^)`\`)(MQ!<M3`-/=HYC':B-D=F
MG`@[(7__F'?G,CJ$-:!Q1-!`?R',@@$(DP$E*(.3!:;B@3&`!@R80<R/(PP*
M5`#`%4OR93:P@0.S(,%LD,$-EI2`"M!`F$B:`1!@,`,+$\$+7SA.`Q"6#*>(
MDRZ<DV.+V,D5UFA[*4]I@MQ-@($!#$$!4("!%WR!X[[MF.EHH$%"WX2#"60J
MG\6C\I(5"@$1[$`,-5`%"RJ0AA(([0ME*$$#Q,"'*OC!F]@==#180\XF&&$'
M7P[2Y&6G`U483T?(@X.>@8CG=*G+SS>M^Q8&C=*=>@K21Q7`-QA=P'70`])(
M/6`YR)!`<5"!`YC6]`0CR(^J+D2#`,%(J%$-PJU^)*S/&DE;_T_8PI6H!(4Q
M;+59?UT3>@A;KCB!?[;>[RV=%((-EY`LM*DVV"36"]K5@#E;T5AE@1;_$A=G
MIR_#80/@U@`XL`7RMC"GX5FGP0/O-'`'=QDV\#"UT5KTUEEA=&\EEEDI4P#+
M8`$9$UH3H%OT41^],1\8&#/8)EPVH!5R=!Z(<1@M(S".)7%$<'%C``-C``1`
MH``*0`/Q@0%B8(,CMQUJ%UN<I'(B%TYSE%V=(UX3,'&D\`E#``&_H%#51`0`
M``+OEA?HYC=I\'4_F%!!E@;]Q28!1@<(0`>2@0!;`&=MH'$_I@,TH'%.T`9(
M\G1;UW44$`JD,`1EP`)X40W64#KI)/]'"5@ZDIA=^C=.Y,1BW&0!(\``=^<&
M"F`%,D`#%.`@#,`":$`'=,`+PB,+7E!X9\@`;`('<!`+V)-@#+`#3F$#60(A
MQF5SI(4`)E`%,1`#QZ`,>(``;,8&AF(H878CT?,[FT`(>58(#I(CNB1[,44)
ML\,&^S,^9($_#=",XL$CAT94XR!\B]8_1'4`R"<.S)=4[\A\2"6/]B!]TS=5
M5-5IN`(1'I!]U8(1'O!!JI9JHI9^XV=6YW=^KJ9^",E",9%K[.A^PL9^YL)^
MY#*1.Y$NZV(4[[)_Z=1_8_%L1N0=]](53O%$/)AB_4(-R&9$2P$Z!=!9$Y`!
M$"B!"Q,!\S7_,"@8`'U!&#Z9`ET4`4X8;TZ#&BD#2F-T,\9%*+XA6F6D6_6Q
M2IS!&$_T1/!V'H:!(";3,GUD'[.%&V_``$1(!&-0EF[P3#"@`&G@7M4U6^*Q
M-5%H1P]C-2((EV=1%060!*.1!"GB.??"`EA&`;+H!6Y033,V"EY`!"702VI!
M`"(@#,Y4)-M`)[)XBG28=$@W,1OP=&KB!9W)`FM03$;G3%PW!(4X"D/P!5Y0
M!L10(B;@82L"%C`2'DP#B23I.8QH#03@36;G'190=VU`!)ZX=TX0(GW#`JC(
M"Q6P>%:@`1DP`A+"`A"F"E6&'$.PEB^B,P)C*/;!&6]P7=<E.H*D_WHLH":J
M`'2[EP65$CN#$(UYM@G5B`=WN$_\-#NSLS\I!GGS,0$VT@2[J0R%]@WMB(Y"
M4!3?P`;>X`-(<`#GV*#A$(_O*``'\$"W8@!1Q0]18H\0U&D6Q!`8U(^_@A`:
MX4$>!'ZC5I#,PI`)>7["TI`E-$,/Z9"NHD/R4)'S-VS!5I%X!A/%QI$>^8C,
MMD0OH$3ZTA3,EA7><1>[4194%%GA91?;UDTJT(`B(`<V21@1,(!X$9-7:I0J
M8T<I`T?V!DID\3(PV!O`40%N$V!F-!E\Q*1LY#$J\T7)L$;YB0$CX&43D#"J
MD18,0`1`0`2"*IQ%:(2"Z3:NE"A[H9<A-_^4:\<,;H<;F&08W3$OLUDZ/-``
M;S($<"!/D%-1\@0$$%`#+8.G&/`%"A!="=`"S+4(,M!?=/`#:O`#=W,S;J-*
MF+$%"=`)N_ITH)D`C!.&,!!=TC0*>X(#8I!-O&DOW=1BO4D==B!.+Y(4F!@6
ML;6(8@"<,V"$1K(&3N`@_G$GL0,BR"$*`[`#)",&TDD#>?(+%-`&1X<`?A`%
M5:`THY<%)C`I;*$CK($\T#A[,052.;(%-$`)@U`[VD@)239H<2.K:C"K&Q`)
M:Z`F(/4&>;`61&8*)"!W<N<YO<=3X^`IY8B@0K`")\"@`^J@\QB/`E"/^W"A
M^`!54*6AUB<0%N3_*U?%CUO5$`%)HF"%H@Q9:RMJ$@7IHFY5?@X9$S,J$^XW
M5Q9YD4_+0SN*:XW0`SS0D3_:FR5YDB))%W?!829YI#RG%E1T%MIE%]HFFT^A
MESB)*!&`&G![&H&1I:)!;AX(E($Q!TT(IH9!6WQQ&">8K7Y$'Z+5@H1K,[J`
M<`EGIYS!`^CQ,#@(2CLP(MM$`N!9E4JZ&V;C%AA0`5H'J(*Z=0H0A%\P)C40
M&MPUE"8C6R4SJ7-Y=CP0'N/Q`MUQ%KJ:8#>@#:-0KA?G!110`P4@!S=3`PF@
M`,@!!1K"(5_`7!70"N[VL+7T"?ZU3'8X!#+`!A.K`[O:A]4DK-!$3432_X4`
M4`(8H&*@(SKFLSFW`17FA(G+&A6TR79@2Q8B@`,0L*T*8"1'PA\_!X<5,%'.
M0P'\218NTP"3-R;\,2`$D@4=NPQK9B@&+&'[02GJ^1\R99\!.[":\`B/H&>;
M8)Z6$"D(X+#N1@>@D&")]YUK\4X5L*<<VP0V<@O\`T#_\PTCZPTFBP2NDK(.
M&J',YP,NZP\SJZ'YV*$$L6H>^J'\R(^>!BPF^A`D$;3F-[2VEA(O&J-)JVOA
MX$.M4G]1BZ-O-2X\B@3KDFQ004?*MK5#:@WY\A5;P<9<@2]LL8,J1G;*1C++
MP!=SP`-X``:<!;<4>!K(QEI/`[>&(0>-(0=S(/^I8&`'$!,]O009;/%;:.I1
M+0A<B<,6;W$*-?A$A345XN4TY\&74607;,.Y$X"Y-I`'LXD753DAQY47`0`"
MC:-?P*`!,S`&1O@%238@:[<8)G<B(?<T=-DYFU1B39@Y7/`BQ*2_/Z9?%/5U
M1%*ZSY`\%?!U7S!/&P(',C`+B8>*L3JK5$8\((`&/08Y.K`&:Z`#0X`D1I)@
M">`&,*!W-Q`+Q_$%````&H85V_04?7G&:4L7TR`Z+6<!E:+),C,"^3-A"@`#
M\'Q/?9,!_45Y>O(%P+`?L/$6KFG0*N4,")`C55"O6\#-DF![M1,$LF-L>,``
M)9TN&(P$:K(%D;(%L>K_;K3:)B0])F'F4C9`JZB()U8VOG!`JFP1C'V#`:W!
ML;/I.<@8LD+0`P7J#>R#H#Z0+LC'PRK[H"U+?18*LQB:CQ#4#_AX*P$Q$/GP
M:0^A02`J0JLF0B+Q:E9\0M$RM"%!M$*+:Q`)$U3@#C2Z0&#L:SD:?\.&9P@J
M!^YB%5!8B?OR?US1QLQZ,/A"P$[Q+XEZDM`F10SX``'0QYPEE)Z%&@4@!O;#
MDX5!19#A&SB0`3@@`O"&%HZ1"Q!"'\!!7&YS<+S1E)'AG2BX@TL8`*/\VZ.L
M%P0,I9]<E;RMR:>P-F>!()C#-IF2.+?]%BP``0G%7WHR`VXPG$=W*([%1G-)
M_Y?8-1Z=E,QF;!US41YBD%_4)`-M,`,V]EQ>8'$:L`H]4`&(N2?ZY00@(`2]
MT%]HL@ITP'39D$\)1=\-=D]K<`/IO`9/1Z[QS*VF68OX/*I/U"+_-YN@EP5.
M`7=/@>$O(AYGG*WS838R*"$04KP:$L\)4!_$!2%MT`8EL!]RYEC]K`QB8(<1
M[!_^<2@<-B%!)@G26`A*8%"[AP>3A\&=L'IB(M/R&:L;D(JJF%#%XR!9D*V1
M4<YT``).D)K8`P`/R!5&/0RDH]27<PO("&GOX`T]]@A0[0-$10A7C=59'0Y!
M/%49BJ%W;H]E/54#<;,8M!"@UBO&TH]N;4(HT6H..?_%"@EKL):T,T0%NK;7
M`K!K=O5H\A?&@$TN43O&E,`I'&YV:*QL2.1L81L6%J`T2C05:]&=UE98RH8;
MZU$#$9`"?.S'H\%9IU$`;Y$%I/U:!>"`)9`!/>.%PE`"UR1%*]@;<``AL@@'
MMPJ#D2$S$T!='-/)#`>Y>_G;WJ$7=S$PF`N>U<8,>9,+J8P85\#*T7.KF5EW
M;C,`)<!XV$.8T21/%3#"<D"4Z0%8)C/>(9<YYBV`4(,U3R$&-$`$84(#[EU-
MY6IQ&O=S+"`*V^`A<"`$:&!0GQ`+@AE@`88`O#!15^<@@A>*"<"'-\`"GXJ8
M:1E-A:@!7%X&F[?)$_":,1+_+QB>3C-R=C!6-JS.21.0VL6K=_).*),4,\NX
MC)>P@R,":'>H"J$XL320)@WP!BV"`1DP/!/;GA_L"^&(".9LTT+`!OZ!)$ON
M&FV&!FU2`;W3(?HE.%LP7]++"J_P(4RF`92C!RI6!50_`&)P"V3N%#C2`U?-
MP>6I+D3E#0=P`O+@#H\V#_"0U3\<*](WQ-+'Y_C8YPSAYQCT?1^D*\+RUF6%
MD`B)M'AM0@Z@0FF5:[E&!:KO?':U`H_VM/175Y?^+;5'"3V@%5G[%?VWQB89
M%N!C#?@"98.$*/Y^V1(G`I8U7S'Y6O7F,A9@8@TS&@&03#HWX24P*![52T2F
M;K:J_VXQH[AEQ#&HJQJCG$>AL6Q6R97WT=C*<%T>\[!7,"&FX!A\M!X]<_W[
M0488P)3O#@A?"5X)@S=.@Q5,3#P68A:0-CR3`95@EP69E0$JG3R=FP%@!6!)
MEP&3/"2K)!851$,),A5>,T.W0QHS1%X@-$,LL11?7C<5(!MP5C=I3L0::7`L
M#`T;&V@5@A`0##1>-!6R,K*Q@[D*"C,)$`D:A5X:U%N/%I.=]_B=)/F;]ZMX
M>"RP(C%!!`9)J2IUFH"CQ!!TZKRXR2#"H(V+3!!L8<&BP9:/&+I,F-"@31L:
M-&2L62-#AA,9+&I8L(&!`04G-UB>.*%#AXQF#2QDF5#CA_\:-3^N5:!QXU":
M!F)(@D`#YQ@=.,.L6%G7`*`(!BQ`@*AZ0U"A!`S>-+)@H@J&##C$9,G2I,E`
M%4VRX.GA0X"`#CY\J@RBA(T0'T*$K#BQHJ]?`3XB2Y[\N/+C%3F*&-C,N;,!
M%*`W@T;AV4`1S:<WIS9]NK7K*5.*3/%@QH,#,V8<W+9M6W>.'`Y^!__-H7CQ
M`\</(.<@7'?QWSF.,^>@7#D5*@+(^+W>>(5WR-7#A_=.OOR*\>?%JP^/9"<;
M!#SD?,IW;S[]^Y6N[+#0B2U_%5?@8X\*_D'B"`883&#!%978=]^#H$R0P0`%
MI,"#&`%$,,<#'$9@PP0FJ'!)!"3_/A```P!\00$$7T!`01HP,C``''"(T,"-
M.#:`(`*25*)&$F(D:,,F!9"820&H7&&#(R88>,4J`%ZAI!AB7!25CE<DD40!
M4O)@`P(U("`F"`S(:.,C06901@D.)9#&6`/4T,``TQ3B#@2QW)#`&`K0`$)'
M]/08P)%(*I3*)T022DJA`F;A("H-$)+`#2QX`<4MDR:PRPPL5#"$#K$0(PL<
M:&P03@5P#`(/`S7\&=,&(%"P"SPG>;$&"[*P$((,-W@QA*\)P``#$0G$`H\&
M\'"#@!QX*)@%"03L`Z$*+^3#"@$$S&4?#Q,,,,%:!EH0+4-M#.&&`E!XX84"
M$%34@$8-_["`$DH5+,7`%@&),8"+*RGAKQ(GM!36!!^R`(=8:`@A6`5.-,Q"
M/40A0`<:.H#@4P)6M&"%$P,@V``<'R.#1AK#%&)%&2+@D04&<8)0`8Q?Q!PS
MJU?PD`4D)DS`0`83S%77/JO0U<1>.O35@<)K-$68#H<AI@-/CODUV=2166:9
M#YEQIEEIG(W&]=>=I>::;+#)1EMNM3E`&V^Z#><V<<;%39URSPD7'7/0S9V<
M==AI=QT5Y?7E@WKIH6>>=]4AOM[B2#2N0ZF,9*$"%Y1S49^#TZK`R15-]M>Y
MM?-=`8GH5(YD`2J89TY?`!8,,$``*41PNH8=\K!#B"-&P.$#//\P4(B*%%!0
M@O`93.@QCAA4&<`;R1>I801!BJ'E]%M62P*XI8]$)95YY"'Z!&)<<>05+(M@
MPY8!8#!"30"44>_!9);90`UOO-%`&650L*<M%4P3IPAT`H`[AH"G!,3L5TZH
MP<Y$(`8>5&))0J%$*"Y!04THA!^54!08JM4)&VP!6;'000+<4*Q,S6`&;J!`
M!2@U"%XXH5ZE"D>I*$`$8K$*3`PX1JIJ.`,(G*18N%J##G:UAA;H*18P&`.Q
M8H&L=Q""!4S```-MD#E6/&@3=O!'*T30KJB8`%L$4($#6[>-&2@`!E"`@@+B
MT:ER-24$(<A)2]9``3AL02,X&`).%K#_`*7QI&(@^!8>&H"&'QCR!PJC`4YN
M,H!'2&4L/8%#&F*AL2_@``,6P$`)&``'.M1`DB7#&,HD1P(I`I!-,AJ`CL)'
M@KQ`8@<Z`T!0A`8E$@@-#UM@6@=VR09>W2`(06!:8H302Z95AFKDD8S5CLF!
MK8%M-*0!FS2W-C:RF6UM9YN-;FP#'=\`)V]RBTYU\`:=<GYS;^'!SF.XDTR_
M%$XYBEO/X0KWSL6)!PD'0((.V-`#)DAN<I7S1.H@%*``<.X__I$6@.@3KJB<
M#G524MT5>0!`&Z1@#@[<D.X"L`,_4(M$)$(%3?3WA1+`*'@0*('K#J(D1X#O
M#4.*7B9*\2&"_]D@?*$0HX&V%Q7PH6D'.^A>00YB2!N\H08V:@#!+#`"&T%`
M`RE5T<'@`!:.Q`D#9=``$6"0`">0"BLEN)'K])<`%?ZBK"N\`1I*D@$&B$!!
M$ISI*$:QB4/9YP45)`48ZNHH%02-!UM(`+&\`"H2YDE3NY"%+-3EPI^4*E45
M0,,0B*".L.(P&G`H@5EH4*9;!.,&(F1),<H:+!BX`5CJ(D0MH$"#'HA@"Y+H
MJU\'HE!JO8`3]&F%0%9!``LP@`@,$`HIY[(*"X@@`Q18UQG5F(#^_2(G25L`
M"@`F`R4X(0T5^`@+TN`2EK!`!D&0P4[$LH5&-``9=&!#3UBP!DT9D/\:$Z@)
M_(1`%0H,01!;P<&W]-5),C5#9@8LP5O#J!\$(8@>DW@2`>H"B9$P0`,#$,K/
M6ID7!N=2"!+8I1!\"4RF]4`(3.B!#)@6M<?XX'#*7*8[L_;,T$ASFJ@96]F*
M0)O9>.#&--[F<(`3'+SY6#KBI)LYOVDWXZA'G28&W'<Z((!ZVE,\Y7GR>AIW
MSWTR00Z=J)SEQ"C1^_A'<P<-$(2`2@(J.7!`8NXR/BI1DS>DP$(\T&@$"-`%
M$@3@!;J3G<>>6M;@M:@"\QM2`>80`2TM+[[)<RB##-I0\(U.=!>YJ?(2'%^8
MQC>^KAL`FW!4`SFITL#V0RY6:EA'ERT%`F7_"-,PO"J$0Z)A&`(>0$,&00$:
M))<0@B!"!<2$`"F.H(&+*A1NO>2H#.IUKK?EQ(#NL8ED!T`,$`!"(=A[VCS=
M8%->&(>>:N&%+[RD5&A`A'L)&-96C64J51E>F>25`/:"=@@L.0N>B*``('1;
M$+50U0S6P`8:L*!9$PA(MOQ!K7YHD;9S$=``B%""-T""`":(>+2,BR?EPB"U
MX*#!&BKPM!.L`9CB;8D3VH"O3B7,U0W+2?^Z8MRPN(P&<-`!(J"P%0H$16=@
M$1E6[FLG')C`#BL[;V;9!)<RO74"(^@"'VK&BKDX/0O8XH,1C-"DD0P`9?RQ
MRS[JPO4L7#C#1SN!_]*"<((>]#,C_4O882HSS\943<4"H`*+G?F9:+[XQ=24
M336M>>.^\X:;W8P.<<ZYG""3LSG>[/'<TKG,Z_1%.R>6,N&<#&4H4UXY[=%!
M/S^A94^HF3X\^)Q_4L<#!HG.$?48Z.<]\8*:("`"*0B`#?*L@AB$2!0DLH'K
MN`@$8GTA%D.HQ@^8,`="(ZFE03KP&\!G`R5!,"H(<G2B"B*&3*BA`/;K6)`,
M,@`99<`=)F4`"#XY(P!B"`0LDAEV:?0R5`,`&26``#(,":L*#*,,JM3T"6]`
M@1OD8JLGI`B:D'R.YB@.9`D4A`F:(""(4@EXE5<7]&P00"RRL`;I`GR]PO]#
M3N`KL8!"7M`PD84-(_0-+T,-0M=)R?`RFW0,--!NOZ`#31$,A3`$LH(.]]9"
MJP4%-\`&)]$#'A%!]E%;5J0ZMF0!#0!5\R!QT:(Y*M``%8<.7#4(;5`F3O`X
M:$`Q'B=>27,#$+`%;[!=&T!_:``"SC`$AU`!1R<"J/(^+J,G&&,%7Q`48E`F
M('`556%?&*,!^+<#!.`E)`%`G^93$E8%77`&9V`"66`#S?(1C+@%$[`#1D``
MMP-+(H`#LS1;>%%A>3$!+"`$NW0T,/A+9&=VC&`#(L`"'S9,4A,9*$8U4P,>
M#D!W71,:T&1W=Z<UIQ$;U>0!L>%WO7%C.Y8WOW'_`-]$-],A9-W4&\'A'.AT
M`-=A8E9#!I!W'NEQ>95G3_$D>9BG3ST@"5E6'ZN7#U\&($TB+6F&#Q8`5^'X
M(#SP`MU2`WEF`Q42`%6P`YH#!A%0`',(`3@P@4!@;^V0`#2``#^@$55R$1:0
M!U1B8)V&:#R%D(_P!E0BCT=2`S@@`IT6)G*"/%*T;C91+R^"*F/8`/:7`0WP
M`^AG0!5`!T9A*C3(#AH`!V_@*5,Q%B0#(_=%#3MS0B\D`_IS0K50`B"``-MC
M(`Y$*'2%.G:E.0@X"A9T00*%*#;P6X3`$C.@6I-2"T2@@X3P*_16##<@`W2@
M%/PW50=3+V(QEA5@4FFP_VZXLA0)T&_MYG_"H%SJ,`@S``0SD$:7H@-KT`9L
MT!%RH!>(6%O3,A#9$C1S$5A#(!-0ARU0H@(84$#GPE5Z,B'R<@Q72%\Z`)=V
M\F\B4`)T0`>^\")I8!;,T#$D,3S10!7.<!9CH`$L,!+QL@4N@U(L,@0J-0%=
M,`([,!<`T23"I0=.UP154`5+T`48\!&N,F(ZT"DL,`]L80*4:(F(B(E-D"U-
M8`0$P0)L\(D*,W8G@`8(\`8W<R-OL`BIB$S>X8KN.3BQJ#6B48O05!JR*#9[
M1TVS`1N^V#;>5$[343?&:'C=U#:!9V35\3<F5F+2*#7T9(W:*'F-@T_JD7F;
M5_]ZY[B.]W!08%:.4;*AG7`%5;)0&LH/^H(!!?``'E(D)A`#63`H$1``.H,_
M&M![1#`&)U1#S04"-S(//%4Z!J8C"9(]-J`&^2A["/(&#%(`$E("-;`O*\@J
MUB`G#%`"!\,`$-`,944C[%<"654""``">C1_]`<'>"((&K!K+/`%:U@O:S@S
M#;`S&N`&A\!$6J%&P:<61QD*_7`H-E!L1X()>W4Y]N&`H6`'!L4`'U"5)W!"
M9W$#NG"C^&8L;D!"7R`#+2ES3L`"8S@5)#.6$Y,&)4`#HPH!_B:0WO!=V;8&
M>B20RD4$[N`%]%:I4*`.*@$,*,$$N(0'#?@@T!(MAGG_.37P*RP7<5^TA!-0
M+B-T1IE2!M30EC0R%:0Y20.4`/H5FC;IIIKU.U^0`9AT/Q10DR_CAGE9!D'A
M)0@P)Q50I6#A$0JB`CO0FR[*`WJ@!P#Q$0!1`X]PG%1'DBS0$SO1$RT!$TE(
MG4AWD2;0!-BIG0MF`MX)GJ$8!&9P`N^A,B305&(@!XO`!,/4-.]I'JYX`/'9
M&?19GV$CB[@X8WMG!OS9G\`X9.$D3G)#3OZY8XHG'L^XH(_1H`YZ`%$6H4#+
M'A.Z'@%[H:JWCAQ*()_C5_6Q#XY0HOAA7`V0HA'@*!\B.?@8`$ZX20GPCT0`
M!#AJ1@H`"X"&(ZJT/0@)0<TG_R4U53\_8`-(]2[U8U1?\3'44`%92BI3JFG<
M(">"M3'(<`UIL`U9-00]0`=Z=(54L7ZGB::LT@#-97^:"0)I0`@,($7?IP!#
MT!)MH"E6P%RPY2600"4SD1#&5D$&)T8#L@ES=0H-\@DD<`4#H`N3(@.6\JB"
M15F9XG^"14)=54@_@`TR`#]C,0SH)4EE`@Y`5"S>X&^^\@L;V%[H`)"R2@2T
M>I4JT6XRT`8]\!%RP#K"!33!"B$WTRPTQ`)B<*R1J0)B4`*%<"[I@#$`$%8D
M@RK2&BL!N2(0<"-WFP858W]G\050U0`F@`$X\"8N<U+MH(?>,A?-%R0C$7`J
M0YRJ@/\MA`@^N+0%;-`_S]D_C@@B#@L./:%/.H`$2C!BWHD`?$"=\6HC?#A;
MK9287-`$#JL#X,D&22.QA8$`*B.9WI(*&;$!(;:>KMB>R71BC0&+I5&R+G9W
M>Z<:8\.+-N:+W*1X=W,WR1&SB!>,/9:@?X-DEB&-VN&@YA&T9IQ/$TJA[!&P
M",`(1QN.K"-ZGY-F-@,@X0.U_&`#<6H#')*.[UHD!8`![6,P"5!OO9<N*%1M
MP=,&VR"4/\`@26!0SI<E,JHC<U(-"$!5#5`_8<(R89)2Q0L!+W,P<9I5YAHK
M=;0!1_$#=-"X[H4,.,%^,,)^3=$.#"`F+J)(=5A?E34G3T7_!*#5F7L"!7SB
M!='I:)#``T@I;#:#$*8[*!N$"1>T;*G`E()\6@EP`N8B*7H"E%U55K<@$>%<
MA0DSFF-8%2\#(V+A!%G*64[8;K'``B<AID/`%-IF+A`1J37D!FG4`O$&$_S&
M$0"1/`G'#P<'F5#B=&]``QH0%.("<=$2+7-8+&*K`.JB`4(IN0=SA7`0,^WP
M!>TS/QQ!(Q0C`V91"/.+`3>#`-/`)O'G0VV``QVS`X2(`2'R"9/@"'BP),<Z
M=3G3`&R@7C[!$RY!L"K#B?42,"UQ`NW!$R#P'GP05#1M(Q,01JQ0%\\RPQ:@
M7C?,%#JL`SPL.071!:EP4Y*0$40L_QGM.34@&QDB2W=,;'=-;)_5!,6N<6-3
MW)\\]AQU@Z#+0;,\%HS%Z,4Y&XUB;&)&K#@0>L;;.+2,0[&;UPD<I*$1A0J0
MX#D"L:%B-IW_@<=,V0`E(`;%9P(C,`&:,V@6P`YK6,CH,`9N8+T*4&VW4`8`
MD`$@8$@PI23U$Q55TBT=HVGSPZ,@4YZ=-B<3@``EH`$MLGYK*3P4H`$?()OV
M!P?6,(9N:E\:X`Z1Q13I##^9]06\>\O(72PK><Y?$)OM<EQE0$(-DPMC,`8P
MD`[H*VC)9E?V?92+(LW#AM/,=F=)B5N";&^$M0;8;`7V-0--)`/UC(=WN0S&
M@`9C:0U5P?_1,(((W+`-\@P,_K<%Z]H#Y=(&85DLYG(N"+X+-62]:126F^N7
M@3F0\84'B.JKZTL?P.D-4#$!?<`'?`"LK1`,OW)&4:C<2T$!8=$#8Y@&!H2F
M&B!+3\I))>T$N;#`-B<4%H`'-3`-93(C'D$E!#!U57`&(X"(!#`2Y7,C(G`&
M?9"=!%`3,J!/WM$33U,OT=DLA(0&0:U>SOF<'*'"4ET%5&W5JX#5)*#5ZO47
M1R-BHA@$J`@0\-HQGB`NEF,!ZID8;%W$W;'6Q*@9<>UB)DO7>=<:*<N+?E>S
M/"9XIN[7U,$<-?N?PD$=@..,.<NS.ROKD*'6BLW8]X1/NI[&:CS_93+`!CT\
M.7A<V9P3(F+4)!E*(*_4V5`["34A!B3"FQ9@!W90`'+@.X`&%M$6VV.01NAP
M6C[$(J*LD2R)V_13/V\P`-Y:$^-7`1FP20<#)J<(%@I4!ED*O,D@,UIES+B2
M!N=\D]ME%FG*TJ),@Z12O"4$#.5IP*(\%NM:!M%]22.P+R0T"_ISH_`-!!40
M)E2R`U32)%3$E(K"*%'9WW)%"B_`07.!K!/H!;LB`[5J#D-PE=AK#+1@+#-P
MJ>NGMQM`FA,C20*<I6E@:TO1!BP0/&1"Y/;%(F3U*Y5*!%IA!5IUH\*BX32`
MP][96ELPD!DA!L`Z4:K0=#=C`2P`87C0_R0\/KK[\N/HD)4".<KBB@@>C>`E
MD"`=62].@-WM8SQ`%0,QX`>EXZ,'V7R_:@)=P)P<40&S\%W^AB]ZH885L!-_
M!.?KA2^XQ)*KO`$<\5T"@P`DP`=YL`,QT%1=8-431F%YL1&>>#0;9H;`5'8J
MDP5\8!&6#320D)YF)P0?-AEN=\2LF,2#XP&BP4?2M>E@0W>@CHNX@4W`:*!$
M!K,SBQSEY)]P0QRPKJ#9,<:S3NN.@<34N-AGO.M4ECCWQ!-LL`$#LF6'`E`"
M)5&A5P]QO"#X<'JGQQ]*N8X.)`;Z50"V`P@$*G9V<@T:$'`,#`T00$0*;C`P
M"E!6"1`990`4#?\L#'`_HC]O-35O/PB+"!@5<'!I);(5%0,-#"5#3C4X$`UT
M&QMT(!40"0D:5EX5;$,4KZX@('`47U\:RTQ;$"4L<&AHTU\)0T,,;P4!`6(B
M`W`5N#@XC#$C.&5N"2>P$!]`8V-@W&"Q10P>"S9X!"A0($D2,"\"\+!AH:(-
M%1@7,F0(I@`8=2HFDL"(D0</%>IL,)CA)802&3-F)/`RY(:7F#/6W)"A@YQ-
M+PF<N'H'1]H[5Q72:-!`BT(%&HLHI('PI0(%;N.R?F'9PHT;(L>0$?DWQLT0
M%FO6L%DC8ZT.%D.V,&&#!Z5"%4U(DB"1I>+>)EFRA.2!(0,#/(CQ5*G_8L*$
MF`DB(`S1X$:!@B%K@-*H4**"41E.CGWQ0L27"1)\,`R0=94;`Q$8)NS`0MO%
M2!YXMFR9L*7&E@8%+9AH@H<%#9XZD.A8?D+&&AI;$#>`PV:YC@HR3N@XH9V@
M'CP8$*C9HT84"!I?=/&L08`/GQTQ5(\01*!)D[TD[`<NSD9(APY"L""9$]RQ
M@0`>31`@@@@V!&"#"2=9L$-%%HAA`Q-,]*"A$#ZLX,.''GXHXHA4Y%"$`0:@
ML``*-Z#@(HHPQBCCC`84<2*,-A9AAAD>].ACCPX$F<.01.;@0`X<)'G`D!P<
ML.211`8)99)4'D#%E50((``99&CI)9=@<NFE_Y8=KF"FF4ZFJ>::!R#!YIMI
M(B&GFBNHJ:1R;&S`Q$E<<#&822KT65(6)Y%DZ*$\F&"!215:<$5(&%44845_
M'FKII2&M@T,##YH@2`!@(%".5;X@4,)8DTSBAA=?0.#J)FG4P$(9<)0W2BEO
M;%##(J8PX$0:18%`QS"R&./%#34,0&LXL$@UU3%6S$!##[X2!0X:Q5B#20,(
M;`%'9\'>LE4"L3):D1BF(*`N`F^P2\(9.-1!!!0W."&+!D#(Y`4%(""@ASHF
MV9"%#2.A]*="ZG34D3H2`7KI"R@QK`()%@R`30LWZ.#%JD`-09H7--UPU@T)
MD#S$.,[2DD92OZ:11O\U3KU<#`7HN8J)JU-]\3(-$,P+A5<R(:,!$6Z,P=)9
M--RPEEIKL-`,"SVP,($=/%C0UWV&$EJH"EDD6-$$&4`P`1X3>$H``8'9L,TQ
ME2E`#DL4X&++.TY<DT`9B`P@6Q=G=(%!`X`#IYO5%>VP@Q]_^#%!#9ZPP`(M
M#$#5P`16;\$`+=Q9EYP,-U#``F(8@!`,$S]L\#AV,M`2G0E;;%">,&A0$VW)
M,H#@AQ^&[Z":""9,;!]^^F7!GW\`ZC#@"4BPT0.")(P@@@4!2/K@A!2:A.$&
M/7`XXO;<^[#D%"BB$$00-)9O_HPY%C$%CS_^*"61',!/9?PY'!`_E$.^CV3_
ME59BJ2687PJ3F,8D@#*9J4-LFA.<%IA`!<K)36EJ4INT8R`^E010??+38#!U
MJ48IY$$64,&C5"`I<X50(AQ,(4HLL*`)R(8$+XA``!B0@,<E@`(($(/%_J$`
M&$"!)A2@0`8T\0$(U``$$*#`#VQ%"@28HA@0`,$VOO`-!(A"#1N``]YF,`9D
M-0(.&XA=4J1"`6C-H`((>%PX0``.8HQ#`PD`HPWD\(-=70X>N(``(W(HAL:0
M8"&`Y$&[:I##,X@@`_-:P\HJ4(9\S>0+#>C!8UPH!DD%X`5@Z`A#)&8HAS%,
M(YE\`<0&12B,7*$!"9@!QGK",59I@"4=2X`,:*`+_V<$D2I?:!E2:)&4IKC&
M56THPRUET0;(P>%QCO"A5XA@!2L0`2='&X(.9#`$-M#2FC+H03&;T8#<3"`P
M'-S+V="&$#$P0`-;J)H%Q-D8,:QM"#/H(4O<@(@2X&```V!`&X90!@BT81$L
MB$T7NA"#'>`A"TS`0P]TPU#=8``#!%4-+VDA@UG2@&8-,,@MP(&=:5:T.:#Y
MG`5,H2=1;``$+^O<RAK@J2U8D1C0*&,SC\6"&/#A=GV8P#TG\)?[]!0PQ=&!
M?X0@!!VTX09KR-SR[N,\,:BS:I443L$2PH0W8$@(&^)>`;EW``?<"$8H`*N+
MQEJ^L)ZO1CE:7_M\A+\B[?^/?D.R7UN-)*2WILE_6P)@7LD@@3#]STMG.F"=
MUJ1`!AK620],;)L(F[D\;<U0&KR@"@\%0H4(9U$AJ=`53G(%"DTVA0&X0CLP
M$`,3@*H`("A#!6I`@1D,@"(-*,,8@#")'][0G@/`P0<2T"\&#`$-:L`B(:<!
MAYYI``XU2"(=2A>,(U8``$LI&0A80`$T_&`8Q%B95IB21F!)0W1T..<'/E`"
M!$A$'6\`7&]THZXWV&"SXD3)%=Y`W]_@<0#MR,`,Z'71$@``"#29204DN:A/
M7E*4$@F,@D\BRE!&)"(@N92!&8:!5+8@`3H8@AM@.8YG`M%S3^%,+%P6Q$5.
M="C_BDBBRBYWN<<YCA:GL\I,(D&T?,V`"$O9V`TJ<)8,3[.:L]1F6X:`1A8@
M0`YR"(P%SO:[@G7R"C:P6`,L@`<3[*`Q5GY,"=Y6B9\!00-ED,>"%M'B!M3`
M(`0PP6(8@Y@M.,XX%7@<#5@PN2K;(PT5S8Z<FN.$N&W!`G\;%AHTQ`;LH"X-
M(A!#%B;0`#:*$18):*;.1#`!`FQA`"Q8V30J0#(K1'<`?6@/'TR@4QQ@H*<$
M^"EQ&B!4``G!FIAIC@Z62@(,)+IJ?1%#5$F0P9%<P4(!8(*Z-`2.[HFH@!SP
M@/G&RFP:F?6LZ9O"6CU05[?N+P?4CBM<Z5IM)=WU2O\3_R"7)-!7<7=)`('U
MT&`)>]AV)[:P;Y*3#MBPI[NHX`6"$N%G#Z4.#Y)04>?JHTFNT%E*[1LC>S&4
MK3&P`QYD$@']=#.K:E``PE!@#`HH"TLPP0!;Q%8##=A``RB@@^"2(A7?&L<,
M&*"*-(B"#BPH@:NH4@UKL&!78/RN-"J`#&M`P,B,>QP<`#>`#````!G(:(44
MU2`>;&0B[R5X'G8P4,C@(ER+L&<#1E`"#;CM!MPP!@UH,).0VX`B`?=+1@)`
M"#M$."-P-PG#1(E@@!6J+X`N`Q&`@I8-@^P8.*F7*\8.CQ%/]"A#X>4[&$#G
M:;``!)Z8+@.F.V=:%B,!-/`"$/\JDZ^EO-(K-%A+6YH&E[>HA09,FQ8-&I#0
M@SY6+_BAF`7R4)A$+YD$:2:U"P<@&2]$`@9C*2(.,H`!,;1+7>I%S`0&ROQ;
MC/WY%=7)G+^)!Q'@`'4?50YHG-"&+2S:S*,((PM`4Z\TL!S0C49I5=0?+2M\
M06^6G@>*TZ"MI?@BU>TQ7-%%@.I4V\<^%N!F_4%4L+8&2*`=RR,(D#$!:#=)
MCA(H&<0%!)`'(J1KQJ<N&T!4QN8#Z.95*<)L9@6"9P5M:25M[C-7\L,!#C`%
M1T(E2,)M;N5M3@)NX29`Y&9N8B(B(8(F#;18/NAN:J)8"U0G\M8#&%(H^49P
M!V<IEQ7_(5A&28["*(T10DOH9"JP`R/0!:8%!EG@7R*P!11`!"[7$6)0`D#P
M"+8U!"70<;#1=14@<@P`7'-P13]07,Z0`.?P.,&`4L9P%5]``4-P0S5@`RS0
M!K"0!F@01EWW3"4@`IPR$>:$`PN"7XYX9@@1&`I1`&='$6+P-PU@:R.``6>@
M.W4``"OS"I"'1PUP2`EP&3)0%`P``;24+Q6@&RXT`964$`V6#@FF8+=!$IBD
M29M$$CR@8,9X$CPP`1``2[/42M!R"7](1L)4`A10`BX#8[SD#8I@?D/7:)Z@
M"'%63`+B.&=1`5Y@'`G`<X_`$G`T-#-0#J<7>L>A`P.!%FS`_P)*DS1K40'%
ML07_$@!X81_C=#;XL5DV\%!E8SC+UP6A:&O[%$^2P$6E,7P88`-OX&:/PW@9
M.0!=8#B6@V<5=1PRH`0W$`1.,'W5!PIQQ@9L<(!(H!,WT`8-D`5B`#B"MFFA
M<0D4()-_(P+$0"[34#>1Y@4:T`88D(R@,`PDIBWCQ0!B8!^-@8N'Q'^XER#W
M\7^`L07,0%2OYELWH%0'E04[`!N-,DDC%(%<P`=<\`+OD@<6@2%7I3W<LP(<
M<"(@^")D-8+FDSYIU2-%`"3YTX),DB0Y(&V#&3_WXP%%@IAJ0H,!!"8WB(-;
M=6P%5"<\B%AN`D$0=%@/%"?P9EAX@O\`2*A!#K.$).$@?41"NF8!N$@A!2<<
MO6.:AD(`,=`%6:`.#0``#&!K>-,`'E$`%L``9S@O0&1^\C`=IJ@KDZ<&<[A$
M/U`!?Y@&"=`&"$`,X``+N01IQE(!;Q``;\![NFD*+*`)95`"9[8%"6$#R=(`
M]$5?!*<1#"$AG;@@@2,"BR!F$Y`'-<D)T'"*[U`"^)0!7K<OJ:,),^%[YGEV
MFV424-<PQ4AE!?:;F001#/.@6;`7@*(.+[!))J&)*P$R%04%00-X&F`-/B=S
MU=@9V$@+FT$4Z5<+9E8,4`07;2`@-``"Z<@"3$$#&E!&SX0->W>'<:8T]CA+
M;+`3^,B29T'_36LQ+8R74)64'_9Q*210-1.0A0,5&[+!=!/``&7@>ST$!;/U
M!4-D"X5(#FVP&4_A3\57D^!2`7U&`4CE!'FV>BDI.J3S`VA048'8*@-0(>U@
M%+Q41C/@?C_W4")0-_R"+=40%C,@-A,1J-0``6703QD`H!B0!WO1&#M0DV&&
M?P.)E22@E0.(53QV`TKP$LMC`4U@`HZH:XY122-D*"00FR80`YI:I28A!TR`
M/=FC@2/251]XER(8/GFIEWQI@M)65T)"/U3B`-GV5H39;56")30H;N06F6%2
M;EWR(06D)99YF6V2F9OI;N7:F4%8KFN"@!MP8"61$!@16:;9*913_R&5I`*<
M"'"*(IMZ\0<Q$`,D4`!B,$2Q(0(EZCH=08B:MWDR$3<,<)RY"0'JX@K.&5S)
M=4-E1)U95!16X03A()W7``$]H!%1E@$#P#B`@P&GX"`84!&C]0.A90,6:'Q7
MH(FP$5L08`O?A7A#]T00D!1IT&>+)'.[J2Q`X#9"40)EH![[@@!,0"'&MYKO
MV3`;D0X*P:`\P!=:$S&9Y!%OEP6.P0-RP`+/)"T:\T,@<Q-AD3*7\PJ`4Q2O
M<!3$,'E'5(TN=4[Z5$.205TW``+.0*/45`XSL7%>$'IG\30ZH!;.T:1HX31G
M47J<TP.SQ`2\44J&(I"YQZE75A%*6!*_YO^EE!&FE&`.PY>F24,.:U`!W'$#
M-\`(GG!'?>8J.]$<X3@`.A2'P8`]<$!+(/,%9<``$Z`:`Z!S[U!&-V$%/X<8
M(D`!K[AIC0H47F"4A&("PKL(^/6)^3F0G,IH`%`'`(NY3/9_$U`!.N`#1!4U
M-9&J;?$&2Z8@(E`#PD$YLVHHE,*:6,`'!5.,PK,N"+`AKP8B.3"L*D*L>'FL
MY6,C.&(C4[#`;/4^S0H_V!:M\V,DB\D_UEJ#VYJMW*K!9-`!6S4FEHE`:**9
MZOHF9S*NA`5OGQE!\H8&#0(QB>)4$R.O")=")#!"K&D"G?48(?1K]:HH\ZM"
MCX5[_^H'(U%T#7#_92+PNS\0`1W!`ZBD``Q[0V3FNF7`6ZI0`<XI"JR51*["
M`C90`+(2BQ5PG1``1Q"P!7*P$1&@0Q79()^DB1E5&"<+.*;@B>U`::O(#JH5
MM\'R#K&@1XP#`=?(1AM0A\#4#CVC`!GSDS<DG35DB0$7O`_U4&='(12BJQ$#
M*EUK=Q:*'\7(&TS``C/P"&O`2B+J=T1Y0]$P=,1%#(-'"S5:##>W#6F<7@D@
M"YBW3T\Q!#20IL:Q&1<EN#1A'&O0`S=@N&T1>D7*-&VQ$\WP%M6$%@LUDWAG
M-@29%Z=)$IB,9:0&ND>;*F8ARS]+4:R;9T[@!-P`.(R'BAN01F.7`+GT_[LZ
ME`%PFP9M0&)J6P89`!NK`2S`0`R`F$HT(0*!T:7(12KC@`S\C%^D13&39!`'
MD1"XUQX$4`4*B0%UD`'?2P!&$&KUT01&T`03X#@?0E1P,01*4"`'<A\M)!P[
M0(&=A)KG,@'XFS45TIK&!Y<:T@,MJ00"3,#%>CY?%6T,#"0.C((P**W6-C\S
MZ)C8JL%2G:T#Q(&`)5@G[)F'E=4I/"<D_(-LLAP]L`&0B`<"!S%6>'")HL,6
M03GJA,F;I=;Z%B@NL`1G4%IBL%-*G'0<D0XU\`52O&%!@4<=-P#0A5R7\P/D
M81XO4T9I@``,H9Y>6A33`6-J/*$5]XF`%%H$]_]'-D!TAH&*C.,.<)!/'H<`
MH@4LO=3*5K$40W!$06%=X0>=Y!"@E(&D6U:H0[E:+M23^"2)UK<I,EM)"*,P
MG,2@>W&,H")*!2`'>,``;E;*1)`Q&J8`L'0,Y9`&0@</BC!GDD%#-$-D/+=:
M6]`&,BDK0V#>-\3+%5!,FV%-<_8<M$0#3G`#Z&M-:H%4UG2/TYR/H_?,0U8=
M]FT<RJ=HEX)W8+N]8G!EJ49"AS0TE@$#(2`3C!<YM+`<VV=1,N`J@".3AVQ2
MA:AA,S`.1?NSQ;N&4S$T5@``99!HC>`9S/(R@4@:&F#0Q;B*N35$\N>(`M4%
M3Q`#!,`HRC<V9HUE%[W_-QAP3P#KT490!>-D!".]`R9]TB!`,@:H'2V=!;8&
MOW[420&C:V9=:892<#O@UHHB!WJ04/U+5"<0!$)-K"CR508<(T9M@@VL/VY%
MK=N&/Q8\)N8VU5,]0`0$(NK&U2B\U7"B6%XMA`TT;^PR-K!)JPFW;XDB'*L)
MJ_I*A4O(`TJ(;W5]!F=PI0-0R:J!`UM0`$[\$6+@")L'!3H##_.P&D.3!B"0
MV(N=7A!P=&F,ZKRN&NRYB7('!FX'G+9P=C^@G@L2&V*``,5U3]8(#';L1)`7
M<RSWV0P0"]\`#.%%C7B3`*;@#(XV#22F`6?1``+J-C+P../03)ZVAO>$3PL"
M_QNXR`XX4`,&9HP+=A+JL!&9]'85@>;%5`'Q!`081@/Y0`Y)XQ0TPP*8QW,7
MI0&TA'D(CWDT-&>?H)&QZ$^RR&..,\MM`-\]0#-/,_+2M+CZV#31?*3W>'K.
MC,Q.HS3-H"&?(P<(@7:8O"@W?P45G6J`9G3Q-`DS002=('1PH#GD2TMEE`"`
M\[,(,`Q)P0`#+<]DNB"7>HH"?0Q>8`4?4`:C;N[<@E)]]D9+T<]ETUD,J:6M
M>799X-%18->Q40J>$&=O!AQ79F6ZTP5*3IM+$`5&8#90WN2/$R(^W0:T@X`(
MLFBC[ED7)'>LJ6N4`RF953@[L*E5FAAFC2%LH`0@N/\B!"PC<$[G=;Y64J+4
M^6-M42(_3^WG40WHVDI`DWE`A,YN[19OZ+KHA^XDEREO!F+6BV)E\YO60OP8
MCN_X%0'$):'6CP(Q7/#I9^`\O[T@\U`#$3`'%+KJ4AP)Y*)/EQJ+S^0YEX,`
M[VP*MP"@6]#$',$#L`&?F\1V=E``73H`W=(`HF!]HQZ\XV\*&:#:)1!RU0D(
M(!49964-3"P0:2`;/VIS""6%&I0-"#0W(&AP%104:11>7@PL&1]`-S(5#%]>
M,V-6:14##1-B%C8V/#P!O6\,)5MBMUG%*KT!!05@S&`!*CPVQB34!+9R-&TT
M,PI`7BPR4&M#0RP40SIM;2S_&A05[31>G@EM0^U#VNM;6PVD^PP0*FACL8Y%
M.8-L"/:@0:/'$!D.6;!!Q^(&&QD6&;)9(W$-&QT66:Q9.'(-Q!L2A_38T@:/
M'%L68N:R,&P"AILB:NV(4<4/'P(8,@`@H@`&C`0)B$```:=$!1!0T0BJ,&1&
M`DH#1+2IT`-$&G+SD"(UA`%'F31PF';ZDL"*%:4BQ$QH0`M.FB^>/,FJ,6$$
MAAU-FF0A08!$%@MX+!0C8"2*GQT81,!AP:*"#!DG+JOZN\-6ERXX!G0QTN6)
M$0(F"#`V8L1$@PHZ?*SHP89&@AM!E.CH@4?PA`$8+.2YHJ(XCRR[;`RS,&'"
MKBS0_VC2G)!'!6$561*;,&&!!Y,>.H*@&$^^_'@#Z-&;5X\B/?HB\.%/F>^A
MOGT'^!WDV,]_?_[^`.;`@8`''$#%@0(D2,:"#)(AP8,01OC@@@E6*(`//ERX
M0H8)RK;""@>`6."())9H8H%(I#BBB@<@@6*)(J*(Q&Y,,!&3!2:(04)QUO'H
MXX\]%A>37,W=8D-,5US!"P]`-@G-+L5Q\<<22XPP@@@X9``!`*'AP$`-!43`
MC`IBE`#$&&ZX8843;4``00DE)`#$#!109@D"?(F1QQO#V+!,,E?<9$,2!00@
M!@8(O/&&#0&\04$;-?13PP8UP%$#`AN\40,#`)2```(#5/^01@DLU$`''791
MX*8&:3#10`(5-$*'5'``)%8"#(!`PQ><R/)))S.X04,#.&C@S0UN?D$$#`HD
M``<=PES1"P\QF6`+GYPV(`:C`=CA+1@O(+/+N$P>T\L+Z`80&1X$Q0,#%#/0
M4($7,L13P0W?T%!.&R@-08-!;5"0``1#R$.!O*1\2M<^#32PQ4(-;3512FRP
M<4,/(I&TD0P;Z6`Q94-<U-"_/:SA<4@A9TR##$)P%)%#6^#1``9RW=2`"`,,
M@$-H#&2`PP06_$0-"1/@,%11"HA"A+,5!)06'%+=V]877VB0P0`,5+")*J)6
MW98&5@VP!0-E0-VK$VRYE0`+.W3_9T%D(L3M<)$6$%;%$D],@,=AS?&S#PNT
M[%2%-5A7P,()B&=V604-=!%#<\WA'$,?(RSA@FJJ&>'":5O0L*''/5"%FQ(G
M\&9"%F(`E\=P3#ZWBUS"[6#"DT<.8[NT2`J7!Q_4\"`'$QN9)WQ[Z97GG@'$
MNQ=?$?--85]]^$$?8'X>Z.=?@!QP4.`*5'`H0(,+2B@^A!0*T$$''7*X884>
M?ACCB26RN&**+LK88OWPQT\C<]S%M*.3`#0.#^1RJ%O<HCA)"B"0QE4<$N!M
M"3D3@5`*40<&>*D!86)&`"R`@S.Y00%0^`($R@`!!E!``T08PQ<,MX5<7"$)
M,+R"<L20_X5NJ0`##>`3`AHU@`SDD$\8*`$$+M6&7(D*!#_X@<)*``!#(*`I
MBVB$&O:``$^T`@@40,`6$H"6M'2B`G!0%B4T\"4X4(`3$/@$',(X@W@12P,@
MY"*PT&2%I\0-`Y"S!7=D:`,1`*"%`7A.,?Q7KF0T0QF%LLZ."C"!-FR!#>M(
MP+MF<`.JJ,(+-UB#%U:&DFRPX%^U80@^:%"GR@B"`5M@00/PP`26;.%W`H%8
M#[0QL8DD)"066<-(+E,RD%&F(9992$HHIH.1?%((]>K!#?[E+Q:4P$L[8T#.
M:'$I30'#.9AK3=$@D``W&&4&HEA*`]RA"330`00,0(K:K-8`%O_`00><J$`%
MG'`5L6B@!#/K!UI$A3:V(`65$^@"T(K1O\,H)@N!84UC)K`/?KR&%`0IH;8(
M4`4<4N8RB4N<#FH1`X$VYV8QB,$9%)K-S1%@;+$!'0MN0SJ(X&%O>*#%+90D
M2&HU9P<DR`,!H'&D'-F.45>@R;96QX6B'@-X,@@"\H9'GN(UU3W$BX\!EL>\
M(MC'>=6#WG]R0+WJZ6>K^^$`$K07(N^!ST'C&Q^%SH<^#&5(-MYKG_ORA[_[
MQ8]^*$(<7N\ZHKFFB`4@J,FVMO,_`%+#1TKB(P$M(#OB*-!'0[..8ZT3`RMA
M*4M4PTO.&,<$940@`$7S`A`^"`,OC`7_`H28`1`>PCANR:$`T9CA%0K5A1&(
MH0%(5`,(2@""&EP*3R+`@`UJ4((TI`$"EOH4#AE`CB%\B0$TH$,2?[`!5'%3
M`TBA``A>]12[R&(37W`+)2J`@`:D<8U@Y$35-%`&@'R`")24%P54"P0%#&$6
M(@`:"7@QK>B(8&`@:*$QT(4N1!8J.3<J*AXF<`8;X*$-'JO3#=P`A8/1((WW
MTL9#/OG)?U7&C(9;APYH4#&/?!)C,F""'1K)`B9D000INQA&2@81DRD39+=,
M2$/60.(-D_C$\J1Q;3S&D8I\<@T58$B2&4**`;```<OI#G\MT,/\-J<*56@"
M`40``0UXDUD)_QB"LQJPCAJ4TQQBL8(H@H$!!D!M$Z!`2MH`(`+5,&<`;7BF
MSW:6E1$XKK8CR,-QK"67+6AQ9B9P01C"P"Y2Z.#1B;O,RE@P@1@TK`92T8%E
M9$"9$\!S"\WQ:&0<E^7-L09SJID`"W2`AH\D1,PR>#0:$+"W+>?7!L1AX"V:
MDR03M.Y&MZ`)[J*\K<G&!`$B4>I2A\>>\S3[>.]Y#_/FPSPS/,\,^/%/?LR`
M;0=P.]O](6M9.736\(4OK1-BZ_DNY%8,64BN<S61_$ZT5_HAX03VWFM?X]TB
M3_?@!S9(35!-L*/#_DA)0"*!8VT*M'(]]N%8>()E=08!JE$@9TY!0/^8"I`'
M#`P`C@H(N1M,6X8,U&$HWN!T7-[P@]<R81B+RD5?AH$#.%0W+1N@U*>VNW(A
MNH,..?]!`S+`7"(0`5)4\6*OY%DPL:CR5T-8(532:86VE($%_`!(%WM5M4YA
M+0&J-2U2B!)R&N`I.,^(B4TPT`4QF``#9:#`!ICP6F6$ZQG'N5%,QA6`%ZA`
M#GC(R24@4DJPWY<!;7!")[3A#@Z;XY>:KD#GN,*Q6>H8Q3W0PX-;G(4MI.SS
M)%D(5U`R,814))06(S&):Y,0CLF`(PRIU\H\_,M/MH$-J\`#/]Z`1X*CIB>_
MR4!P8H)0+0^]##,P2K.JQKB$S4H08DZ`*+S_H`$<S`QGZ"6E/Q/07@R$M*,B
M8$'<K(2!,YA`IR:H@@E$BD>&YD0$61,(`S"`!1>X8`+0K4!&,ZJ9";BF`4"7
M<W2@`ZL&#JH0,S?U&<&U`U6@.21%`(&1'931:AZC`]RT!IFA`[26!5LV`!.@
M"T]")KOF:SB2)$,R4U>P+1L$--+!*$Q"`MSQ!EN05,LF/$[E;$\%;=)&545@
M;3YH;?D1A-_F;=T6;OMF5F=%/N@F`0NB;A;";G'E(1C";_&3/_=3/_F6A745
M(O*&.#JP`=32-D&%4P`T64U"`D)EA@^G0'P@<5>")14G0@Q`-J@4)E=P!F?P
M7R$7<M[`?1D@%$01_R^`TP"3,EV^M2AO0!<8$`#$!4:R8"F1LEUPT`#XA``$
M8W/3]0,@4'&N0`044`.)T%VB`D85T`IM804V-XK?Q11I@!0H5`(U@`<\E`$E
M@#5M0`@D1`LX('W>0`Y?P`TA-P3;-0`CD$<PX8(3($0(4",&M1T$@!S(T`O*
MX`S/\'=Z@&>AMPX](##W]4DAM@YMP#&@I`_H,&*IU!"4L1`>LWH0H0=Z,(=X
MH`<3@`ZVI`,J\7H]P$LF,1$<XQ$6DQ`>00,!21E%-GO:\"_R@GLL$#ILX!`5
MDS(,@#'!H#,BD'X]00TC@`,B(#L3@&55$`,2E!3,TBPW`"N@^"SG9!<E>?\5
M&N`%$%`+U@)_)=`F90```U-"P?49CM,_1-(<B?%26,8:9Q`J[E09L?9ZRR0,
M?>!QFO`1!BA/JD"`$P`4.:0&5OD#J`(*3G"`>&`".[`#`D6,.W`:IG9J$-@$
M@:<U:.`QD,12NK&!33`"'L@+")0C0F4!0867.'(CP\8#*6A`W8%K?KD=%O`&
M"*`#2E"#-JB8.:B#/!@?SL-MW.9504B$VV8]_"%NW(.$#;*$$M`!Y-.$Z/-N
MZY,^&\(A'K(][U-7[V,_5TAO6]@B72@#(,`$RM$V?-E`D:5`0W-`:ZA(0&*&
M?)"'(F`E`$$U)<0I^&0CE=9Q95!?(3<#^%`"TE3_`G#D!FL``CW$"%#A6X9F
M`XDH-C:`3J#P%+U5`Q4`)QD@,#;G"6BP`9N@BF!W%;P"8G;Q%.?4BFYA!5]@
M"93X%&BP"7;ABH:0'#8P%W+3,`Y3`X=B%L:B`<TE6B$W9K4@+=-R)#>R!;L(
M`AO()`'`#(4B+EF`H190&)VA!PV0,B.19+-4)X;S28)P>RS*HB0C,2%A3`NY
M,@O1D"3FC@JA>>502PGP:A@S$@Q1,B3&$1]C$.#`8PS!$(Y7$.B(CCDJ>05Q
M7ZN`,T,0-\$5&#Q"`B-P-1/0&:EA'6V&?"/I!6(V+"R0*U'C!&*V7F7@@>D7
M`Y%A07,H398P#";@$WRP_QV%1AF"N@JU,#@$,`)9XTZ/]FB7`:?#8A.$B``]
M(`1"D!"4L96J,)5G@`%O<)7Y.9\W0`$PN1-A.0`[P`>:4Y:J$1AI&:"@8QLW
MH`2Q1FN%,93.\0Q78)?2$53!AB-[)$-(0J8QP2/`NATF8`/?(0-3Q9A,93PZ
MN(,["!\_:&V4N6W=!E8"(FX(4B%)N(1H)9KK1II16)INY3X?DC^M^9KV=E>Q
M26\9^)U9L$<T41U?6EA.XI<J,*R_:7`-E&OE0@*559QY6'%N0IT`X`ZV0PT8
M``'0>13RDA5T89T*<`.;``!P@)50L0J0N"D-`0*J4@%`YPA8239@4T<;H"_O
M)/\(%*!X^MD6"=!;;G9.`;I&<?(6K%)-6Y`3\000````$."!-4,WNA!;BJ(<
M`]!E"D`$HM"2T#D$L\87U6(MH68+$\!E&R`'_(4,T&`8,M$ZQ=$+8O!D+%%B
M&#,R(S-,MF0012I+X;@1'5$QZ`@1I"!,>B`'/YH%VD!CRM20%F&/^9A+*)%)
M&,$0/,9CT,5A/3"W^G![(%`0J)1D;:I*$N4PK](`TN$C!-`%6#(`LU.BJD$T
M9.,%:8H4CI2SH<(`3A"';G(UC>,X(94CD).S,2,7@+:I=,$`FJ$93K!,I<)8
MH>*J.I`X2"`#2K`&110YD]((WR%/7[&R-(`!F9M#U:7_%@)S"AKP!?/GE3&P
M!#&@,QC`!^"K4`JE96\'H`V9N$,0J[K!&Q;0!+\A7+L@'4/B-OVSEWB9KS=R
M4Y.E<,.0!ZG!`WIPF$&@;..Q`,VZ'M"V/,I#59))K97YP-AFA*KI/=_3F9Y)
M/NHVFA7R(>/*/F]EKB&2KNF*5UJXKN@:(RE"@&C`!`%``CNP+6)`AE_*FT)B
M`]"PAORZ7P+$(WP@E\7)922$%V130@@`@AV7`63GL("3$PU#`:LE%6>11-,[
M`-1)LTL!`@E``=*5B0B0!I1@<8)``SD7>:)R%V[A!5_`H6`T*P&Z736K%#7P
M`\HP7*&2,WE*3<L!C0<&GGBB_Z!TT65`H+0#DQ3UY05ID17M=XR[$``V`'=P
M0&O^<U"+'(W/@'>_XP_K8#&TL:)M('HWQ@9KD[87HS([]K:U`1Y4*DQTMP40
MP`9RD`7)I*-*>A!KHR^OYR].RFF35I"75QF=\R];T0`TD*>IQ``.8VC_P@0O
MM05E\$H\L)M@Z7$X\!=7%@-^@']EX`4A!P.4!`&.)!<ZHR4%2PNU<%.L00W*
M@4/PQSCP5YSD!W^XNSB6L;M#\+.VX&0]\'P$&&NZ)`/J`&JT@`#/]TEBAL9.
M0`,;.1=0$4]K8;,),,U\X`=^(%)8,@(2;7^IJE#JQY2MU@,],`#D,,`N5:([
M$%RX9O^_0V+#-$&8QPHE\ML<W?&E_<,=T)`%WZ$$RK94!KR8SGH\"ARM\='`
M6N4`0QT]W):9(T(%W,.MX'/!$I+!3\C!4.ANZ:,A&P+",)+56%C"\R:;JGFN
M][.H/7`<L',%>5`W,_QPPZJ&AE58U$(<]MK#.N,7XBR'A<``&E<`7)`'9U`"
MHLLL=&)!Y(Q#2,&A)D0':D!=250#5%P&2LMJE;0!B7U*)I19>($&Z'DJ`+I&
MK8@4'V`(D3(`:>%;="$4[#4`4$8D,!=SN(9KO1!PD(-#A+A==$'%7M)E1F=/
M,[`LAKQ=PH5WM=.3(M`.PL`++P`&(7H<Q4`8)>K"7<!*0:;_HS0``B63$!10
MMDBJ3"=!,6G;R=*=HW"+W:I`=V(``3K`!#SP,1@A$MIP`YEDO-JPW@)AW:@W
M$%+:IL:,>-*$=?^R#[K'`#04#5F!')VGD;-36"0@4%26`?G5-H>5!UP&1^\"
M!4BQI5MP$\U1`_R`,RPH!CK9!;8[`*!P`TY@7.<PS>G7!3ICE)@1O)<!"@#@
M@3E3B$FD*U1!#@-#,UC#V:E0BFUA%<YE"VVJ>).Q%M)'"<*7!U@0!7]P!F$Z
M`$&9JF4Y.+^!6X8F!C`V!$H@JZ;3!'U0G+XJ;`,D96,J'>5B4VW3&=V!<##(
M'7K20+Z#,3=P@TSUK'8^5?`A;0T,_X340]1#"%::R9D,XM020@90G3ZH*=5/
MF"`<C-4DTIH@4E<E+&]=G5<IXFG"D`LSA2/_8Z^&Y3].XNG[]3_40IC&T4!#
M.0!X:!9N4D)E0`\:U\)\S0`:H'QND,5MH)$Y0XEK@VQI@-B)+;*4R(DY>K$_
M@`:B4ER@D%D,\`-,0`NS@FEN;)->4`;6)Q>1LL0ZXR59(0S^QQT!D`16J08;
M)`:^50,W@>%#=S7G&=IS:!<`P`UMU$1>D$*&3`<-8XPV(5"[%A"VB0MZ=R.%
M44C/@`$+*0B8QVGJR,HE5AO>'3$=(1%]ZQ$LJO`DMA#[,*7+R!+#T@`R@`_\
ML@:/XDE0:O^C.,:D).]<CDL*#D,0JX0'OW`(N_`;6\`+%H`S&%`,TMP`"`X9
M.;(S$W`%'$@`/[$#1YL44``%1T$.^>5VFAXIP$"Y.6$EM249J^`)C7H#(D2G
M99$U\G)1\\P0&@`!6T"="$!=E-(`:8`OU,=]P)$U7I$`3L`)%,`6,U!U#*`W
M6B$+S*OUX34&'X`#9U`86$`:88H#,6`"42#EJOH;`W`IB<%E#_%H;$"KAQH7
MU6(!*I""W6$MQNI8S^#Y_,-3UF&L;1,E*I`+&]`Y05`$-;C3S';GS\K`DOG`
M'C`%UXJ9!&(@W:,@W;J$H!F:36@^&MQN<$7!%L+![6.%VP,_]2;_/R9,Z?=V
M`J5"=P=J`@-'K_>*X/[CZ0UT<,;&'5ZI^5!"`GDX`G@X`(50L"=$]EBK`GS]
M<4ASZ]H0&CK#";`B,WA]E<(.""44:0D5""QP&QL@('".:5^1$`T!`5L##34U
M"#4#$``:90T3$S86/&(#(C5BI&\V-CR5`2HJ/&\3FV(8#2(B`PP-8K`-926.
M()H@#<`5)64:1%Y?#`P:,V,*%'`#`QBD8A:P*E<VNQ006UL3%GE9I[(O8/.5
ML@43-&PU-#TZ:ST5^,E@@:`-"S8WV%1H`Y`?C7QK#M[0P68-&Q;\6+#H08.%
MD(%;VNB0,80!BP%M;K3)T(;&0I<4-#*L_T"!(S\*+H=H'/+09`4(&M691(#'
M1H,V6^3(X?%+#`\>$[HYG2`"!PX\6:@.&$%"!0D".WQ-P#`@@X@)7;K$\,/'
MA`@("8B,@0(C`84A(EJ1PE`UPZ`*--N,,F&";(-&%9PH7HR.P80M#.`LZ\%D
M`XN`7A(,(9*@`0,*AQLX@D,(FP8(97`P`QSIT9<$":S(9A`.<@72%"A$BFVE
MS`@^!+C\,7(&0X8Z79I4,>*BN9'G39K$Z$84#PD,;8;(T'&"#5$"3;H,8&?"
MPA4>%G98L$#*@@D>MN#;(&5B1[@K5U38,)''O85:`(HAQAN'*&'`@2B@L,`"
M"3;HX($0-@CAA/\0%F'AA468H:$'9GC@H0,>3.'`B`[D,&(.'*1X`!54""``
M&3#&V$$'$M1HXXT2D$&CC3IVH*,`,[HH@`]$^K#""D7Z(*2+21IYY`H'1"GE
ME$=*B00245YY999:6KGEE%-JB80.("#`1%;L7)''#GD`2$Y7M9``9RWK73&G
MFW>Z>46=>Y:7!0]9U++#"".<<<8`=90!`00EE*#!$"`LI4(>AVJ@P*5N).!$
M-=T$PX(&%&R`0`5HJ*'&#Z9N`(<@=['`!`(-T+$!'8TTD@8$7VB0@1@%%,`#
M69CPU2D+6SQE`@F[;%$#JFH$4(X-/P30JP6$,H,#)IKP`DPP"'#"``3_MU60
M1F0->%8"`\]HX$9FZ,P@UQA.H+',!.>9T@H&(V#`"UQ;X,%#`4D4`$8!M`"Z
MWGJM\,"$#&QPQ$9%/;#`$`LR%%1!10>U<='$_SS4@T$.LY&/#OG0L(8_;:3D
M1,H95--1`R%MU!$;D$J\$T8&T5!21RQ0$,P6$;>!@`UXB!&,+#Q`AH$%`5A0
ME0BP8,``#ACP@`>^`_C[3GE>J>#6M=7BP,`WQW9U'0YE$*$`#`IDI@$#6_#E
M"PO/4"`#8#<,44$#PI80KA-##+&&#(33-,D6-,!!QP^,J^I$`C-D1H0&%7Q;
M02.C/8Z-%0EH@,,$#900R=^O=1[Y`'QD88)G_^B6D0`$%)1P+08F$,`'%G[\
MT04&)0`P`@'/->?"<T9$5T53ZX6'0P(W*''R=^&)L+1Y/.QY,'UZI@?.P?+5
MEQX\9N<AH!AX]"!#$.@;D."""SY(H?L4'H@AAAJ:,<44'G:H(8DEEH@B!U%B
MD8MT%*,8X>B`!X31C#H`)`86B4E&2M*2AJ0D)SWI`%4"$P;#A"4Q<>E+&O12
M"+FS$3R8\#[BRX]7G@(G.;EI/6Z*H5?R1(*#^:>&Y7F*"K!`J#/$0`2)PA5.
M-.,J^%!J``"XE`+6=8/8,:`;HM'`%[IU.519L0;BR@U2Y/`#1G""$2#XR6L`
MT(!>%2`"/&#&-P;T"O][6*`+A5$-+-[PAE9LH5P8"`>^I)8!.!PF&340#1P`
M$XP:T`TP@)$,"-#EMV]Y88E>6%0T%``O>:GB&]\@Q?;$\),MF,("-;0A*$GP
M%*O!#`\:X0A%+,*&B3G$(1O1V,=Z@)"(W<`F(AO(X&1P`QJT80TFHP$.7.(2
M5AR%#4RP0$M`T(;+M8$!"S&)3I[8`(FIXS$&88(>\``9!,@A`'CHQ@304Y7Q
M0*6<%LB*OL;)`P*\(PM9J$37WB2WLZ1B`.$@C!]R-P(<0."1EYJ&!DJ@K'+5
MP%8W<`(-9$"#&WR!`I@8@-\J<#>*+E0&BGE-)OR&!EHY@B9>F`'GK."%<5'_
MX#8@D%=BOF"%%LQ@!AH8`'LL)RXGZ*9S&CC-`)ZPA#SD@1>_$`'?)B`@/)B@
M"FN)PA_&P@``B(``P!O><\`3'0+\8@=0-4(,EG<#])40/%V0GGE4$`![6:`5
M]P$0#TPPOH/E!Q7JZ4\IO>)3^YPB"VQ00OH:Q"`&24A]#OIK_.17!,):2$,6
MFH+^S,"_')CH?U(2X(L*B,#*XLA'/5H@!97D0"<1:8)*&M*31@NE$())3%CZ
M(`BC5-H#K#9,)SB!#BB#'@&MYUAQ8J$,50##W>9V3E=@ZY[44XO]F"!0*N##
M$P@5A1%D``!#^`($")$`&B``/ER83AF4Z(89#,&)_U!L@`82L(DTP,%4C;/5
M763:JS?\(A/+&``.6K:%,THK`E?0E[0`-HLK!"`/(RAG("^GB3NR3A4-$$?E
M$(-21L"!`K"I@&7T!H+%H6H#SFC4MQ+@!BB4A`%E\$(VO'`;50PC%O#AK0G&
M4H$$P`T#.ZB%+,@Z#S`$X%]R8`$#(E8!53KL8VP`04U8L`8A4(P)'0F93EB@
M$YV9+&4M<0E&--+C5`Z$!W)H@$[.Q`)P/9-U00E)`Q`P`3PT@`9OD$,6\/#$
M-P`*`V(3@QT@@P,1O.,75./MO9`;PUFHX$\`(D%]=G"&`(O@"A.8G0A&L`,^
M/*<+:-,`$"XU@]>4(+X51O^#2A6#T8SBLRH@4`3CT*`SR+DK`<0J@7G#^!<(
MN^NE;_/,=#--D]=880Q$*`,&!"VU`3BC#`"H0P8@T#(,G,$79Y`3#L]:YC6W
M(BTQB/98RB("X`#/"%"E*E1',)YK5V$`S$.?#'I@5.5(3X5-LZUM>0L?]]2G
M"^$0T)[$4)X<`BH+IN"/3_VK,'\$(4)^#:S`!3M8"ET(L1G:D`<:^U@`!K!%
MDZ6L92>N0`DL,$@/9-*1/CM!C2/)@E!JK6E=VR62H[9+K7VMEZXT6R:88P+'
M\EZ@\T2G__AVA;6PDUN_!Z!\_X<$3UAT%,[PW.A"0&<:8`A\2!"6#+A!B=Y-
MP[C_NO&+G"8C#2!0PQY^L($:#+($B]K"?0N``"AJ`@$#ND(!Y$"P`N07`U=(
M0A)ND:T)^+2<Y5*<J#1QT')U`P,V>,-H&GS0+';.NI]*A"+HX/5O`<!O;>`P
M%!*@*,AE0P&)J,'2YHV6`.<+`W!I0"P"$#""!0"';"TS$Q!'RXR,VR0]L$@/
M:E(1(9"L(2*#R4,>TA+"8>1B`Q'9PV2P!1V+K`(60&5+MI"%+8"&!3#3"-J9
MP.8&Z.$=#9`C5.;;`*M5Y7-V$)8(L))Z$P"HK+609YSD1("CQF`"!&#Z+U0A
M@B[4$(@9V,H.YK2#;ZGK4F,`.4`!#+%"!P:(!A6@$3>0_U`NE@H9L"RS`@(2
MDP!>P#FO46>JADCAHALA)1NQ]AF2,4AI<%->,#D9,`(FT`060!93<RW!\@UX
MX`)+X'G',A;Z(CWJ,%1=<`9I,1;9)P)]0#SQ!U5-D&UDT07>)@)#T#PG,&[E
M9@2+1CU7T`KND29/T2>$L3UG16_Y9',&0QB$T2;QP03F\V\(,G!HF"`%-UCT
M4S\=LG#\<R(J\G`#5$`P,G&6)2,7AW&?120?%UJ@U22DE4$CYT$GAUHKAR4B
M!T)(<`(;\0;NH1[#-2<DH$(O9'.^I4.V0!B@=##EH4*J(P9V<FPC@`5G@`,`
M4`:1D!U>@!0\T`0DP$-.IT10\/\%4L<I#)`!'T`Y((!U%Q9(P-`H+&`!8!`!
M28!&ZO`#9M0K`:`42O$KPD!'-Q9(?)-)9<$+EQ:!",`X!`("J+@K;R`NDK$!
MC/,#=,``(W@-0]`#(*`=FO9U?D,!H`(';7`-4.`%93!L,\`V,%`!@51G>T0?
MY;$+L%,#^0:&A`%5)/`G8C!F/^9Z0I"`/E8";*`#$[$0`4%,&#$0/*,Q"L%C
M`+$W!B$R+H,1-&!".M8&6<-ZU*<'GH$':C8!U>`O3M,R$Z`"B99_=R86[["%
MR.5G,K9T6=!^A+$#.^`'"(E4,3`H5O$-ZD$5:#,`^[<#T58%X@$!_T=)D(-J
MS,`"%6;_@+2R$[!!!!0@!B+01[9R+I`@&["1`((A44YP&X/D!*4C&S"%@5@7
M1HN"*V-4`JHP`C$`'(4Q`LOQ!WP@)RNV!$M0:+^@#B+H$@%A$M48`UTP*`U@
M%GT0'47X%515A.+Q.\2CA#>P'0QC0M$18/^!'NTA;SKD;OYQ5O[%'EU8"W^2
M!>/#'USP`EQ0B:]2$85UAFDH<&MH<//CAOL3AR4RARP"<7:8(WB8AYG%0)I5
M01*T)(`804DRB(080E]RB![T0::56B2G`W!0`UI3'K<U5O-TB3,T<S+6%=:S
M'I)(#@)B`S?V221`BEB`!:BHB@_U3Y-@`U[!0SB@-IBB*6D@_SOS!0!`0`27
MDX";D"UX5`-,(##'&`"/\0-S$`$%8`J?Q'90(0R!]`8_\`:9L`%T!#H94`('
M%1F#I'<(@!C/I0$-\`8C&&J-$Z,CF"M>`"E"E@;O*"[0)(^%0`,46!?5\$^7
M]P5^Y`UB8!^:M#L!=AO7)`:D-&.T4`F^XI5()C,7,6X!(3(140*[QU`)2`,Z
MH&,]`$UH8!*M)#,:`3<V8Q);4`&8T``10P/LP#H-D!7!8`-J=A0-@!5;@`-M
M(`*\54XW61CZ$B@V]">R0`MX(B?N5F_NH9!RDF*UT`>526C?P&U;T9!F80(!
M%IA@\199"0,B-@/!4`V'88"+X$NPD?\K$,`7QX`&<(`N(P@;'CA0^Q(3C8!1
M#F67F0$W\Q>,L@--F#`!?!`#GN<'3)<6TDH*ZI`6(Y`6(@!-@&&F&$4#T"14
M:5$89RD"51`=V$:$FDD`TR$"T`&%<+$&3<@&Y=8$J*EG$V`?A/%6:]6%\7E;
M5*A6]B(@N,4%7G%69"@#!@*<P8D@PSDA\W-P;@B'C:6<DM6<=_B<E:59'2=:
M30*(0M*QI.6'(G=:W=DEWZE:)J=R6#(2!!$+[&$"\:EL,11*\9%;\($?[18.
M4*$>U;-6,(<?]6(!A38"41`&(N`Z@8,.H0`'^4$"Q#$`DG8I]Q@[&;"B:7,I
M,<$"['`?LU#_/0'P`B\@=U11CB6:K35`1W1$%@)R#%U7GN7X!B"`E5\``CQV
M.:+61:P2%Q7`!!4`*>R(&X#Q.`D0"<%``^8U+E0&"1'691HP!E;P&NY"!).6
M`'2[#/A"*(0B/43U%%IJ>O6`,,,0`)[1$+_W$KM'3!TQ,_G`$:T'$&W`:A+3
MJMXZ`,7'`,N@#I@P>H6Z-'Q!.[_"?4U3%I_S*U.#J"3@!T89?S<W<YQ)`'U0
M!=`+O;4#3\L;:)3Y%8)VEADP`23@7'QC3A;0?J%SM90V`VX`%.B2";!JD10X
MN%\``)B@@50V!+QJ!3`5#&=Y#(-$`0[%4CGU3$BQ:'[0!82B%EB5_U7!$W32
MXW4)2%$C<0,1$3?8*@*#%%LRT(2[I`-V>JU_4&CY-P%5E6W@057'4VU9-0)P
MT3P,\P8F\&AY@3#LL!\V5ZD[D!]`*P:5*9_J&5SJP3750R?'L@./<0)FJ#[L
ML[`-:P`78E@0&[$D\C\.MR+,25D]@K$W,B,ULH<=P'$0U+%`TG$BNW%%HIVE
MY9WBR4%FC(AHS`8H^J0$8`[A0'.\E9HI1DK%E1^OB9[HZ8G#0`ZUX`<C\`18
MX`(C@+3?)8]E4`$V8"=&L`3@-FEK,P.#6P9U4`<`\`&3M@W$(@O':'HV\`T!
M8&.[D`O+H@9E-P!G6T>],#2\\W7^R`F:`/\'6#D#-'!F%``"9/L#-?`9N4++
M3,!DBD0::2`NKY$KG6$9)S5(XD+,A[=A8R#)XQ4-0``$7L`S53IZ]?`4`8M6
M3PH.5!%]+0%E4088/),1-&`9/<8S0/&FOJ01)T6G$MDOGE$#@&(4^'1CA?K"
MZ?04<&86IA!4X[2%8B!#ZA=HV5:41ED[\2?'?38+M#`G5MD6.R"NWK`#`U`&
M#"`]]_)^(M`&_\2/D4,$0Y"KQU`#LH*`]$N!5J`!9#1@#1P0]+L;D30*^L)(
M8!<)TL4HV0H!\O547T$8>O%N:J&8,TC!5+90%;`&$$P#TD/`0J5I(T$X4JT#
M&IS1:N'!.("$12C_PD48'7WP"WYPPAFPA$VH`PB@T.+!#K)9#ER3'CWL0N3@
MUD9I'C!T!7;UB7MB"_ZQ`_#&!'D5(>L3<&@XG!;BL!G2Q(S%<"G"`<LI61%W
MAQ=KQ9>UATO"A]2YL9LU6MDYB(EXB"2KQN#)G6/2`QO``X+VK[X%0RXDLW&=
MQ^^1;_1V"F<%#[5``&<@R"[P!$@K7?+X-@@`2D80!6]AH#```Y/#TL`V22--
M+*^PR'",MK&P"[M0`A:F"6^P"714+D.S!:IV4F`$C#]Q#4#1$HLS*[F:I&UY
MRSW#"%(GEX3`.:&P!2;**!\E=73YO_[GN,,,"9*K-C-``099#[#P<NL4_S>9
M1%0VR`SRQ1*+@A.7X942>3&LVTIA1`-UZJT&$3-!<13]@I(-(`?7)V8\8`<6
M(%_%PA09D-7']6=-`#K2`Q^JXTYV\&<SSKP'0P#N1I72J[R^Y=!=&ZE`K@+Q
MUP<DP*D[N&CZPC=AA1KC017<JP)P%F*7HJI;63F7=H"D$3BV%@K2(P(H)8*E
MTSGP"W.$0196X8*71`K4UI0"0HT:44T9C0$QH%2'<AM4)M6$0P'Y1\"8`)9H
M\'LRL$L44&<3$`.%UI0CS-5$2`#<%@-.:P1=P`!+J`1W\]O@$1;3PP[H<0K!
MQ84J9,.<:%?XX6[T]HE^K&+L<0;O088Z$`0HH/\^1BS8@QT_&&+8;GA8B7TB
M4"S%RRDD=EC%DCW9&NLBT^D#,T(D#!2(?BBR$,39JI7&9CQR&G0ELD5;LFES
M<`T@O35#P/6:0FP>>`QSVKQBIQ`G,;`$1:O;4L3;G5,"2V,[/T0!,[`V;-,V
M`)"*P*8VA5`N=W2G&@TM]S(,(E`""+`!VFWP8P8K\[P%JBAA9!LZ\D@$G!$0
MMRPOJS)16)E30X`&:^H(3K!JI+$;`(`#ZU`#`Z]J[7U3$!`,SR!2A_L%D@O)
M0Y`)`C(6FE3S-7^#OU"U\R4VYS)E$DA+&Q'A&M&1&%E\+P,T0_$&JR<T((Y*
M#/`&X'29^`05N0@U::3_"F0>';F%B6Z2!4UP7%`U:!,MQ!.]'O`$]DW0XS]>
M2KE,MJ!$JE5``&$E7U1SFSOP#*,@/3\-9U@YY9D1.83TE:PVJVUI%KS0`("1
M!C85YJDA/9=K*)IT\Z9``I?);=?B"[[&`-[*`!Y=`BQP!E'@K'^DS'@.&,2F
M+YA0\(US&4X0`@[U.B+@0X5VC8F>;55UF@.`A,^A70D0!(3SV\43%B,P/OCQ
MB6"HL_C1VGM=P[PED&.E0M=#.[;`!`<K(0HBZTC,A@]KG,<IAQ3KV+^.Q<%^
MQ91-[)T56LCN0%V\[!'4Q:/UV=#NG>%IQM6^`<DD#C>W[2X$"%<D/!:%A28F
M_Q8V*BH\B!:$B(D\*B1_2TMA2QD:7U]#$`D:$`UB)G]G(R4S"C`P"C-#&1DX
M)65$"AHL(`P5<`PE)1DE#1L_"`T-;V\-<'"^#2`@#=`5#`D-6PD5&]T((,YI
M7QJBV\`@:,[2<.*B7FW=+&F^ZQ44`!JC-3PV`388P!@(%#B@`88&MC00H?`,
M`A$@0!YZ85!*C(4L60(4""!&!`,<LVCA*)A,1`T$`U@@DT9C5TL:#+94L,:`
M18,V++9LP;.%P1LF/-X,&,`C``\,;1K8R#*!088&A$1D8""&HP@1$XIF242"
M@`D2*@($8,2(A`5).TSLV!&CBEM$!`@TP<B(AUVC=O_Y7;%KH^^/OX#_JE'S
M8_#@OV)(F!@P@D"7$2.N[A"#`<..";,F3!!Q>83F`1D2`%$`*\$,+Q585&A0
M`UP:"@EBBX(@(@^?/#M`9X``8=A(@UV"QXABA(2@"94-8A"Q/(.(!@,$JIXY
M4X8,)S>^,,#0100<.N#345]SHP*$,@:?%OZ[`03L%E]N]!9Q)D8J$3A$F&@2
MEX`1N?S)U<4`&/AG1`P#E)&`#"?(T(,%1C2QPU5B6*3"%1:=]<A>>RF62"*"
M6)"A&)I9P.$55QA28EDVX($'"TH8@,*,*"Q`XXTXTFC`CCSN6,2/0/YHQI!$
M$NF``SEPP,$!!RQ)!14"1"G_`!E44BE!!QU(H.6566[9Y99@:HGEF%)V((`/
M:*:Y@@]8GADEFF>FZ<.:;Z*YPITK,*DG$GSVZ>>?@.HIJ*!],HG$`7SJH`,;
M/=A@5Q8D<,$%68P4<B$)F%9RR*:-3,+#%2J(^$BH:6'*!R9AA($#``E\,H0H
M0PQ@2A_V,:`!::YX00%!^(E&1`4@T%!"#73,Q```PVY00P,4(2!"&DY\U\U?
MO"2D`0@(0%`!'6B`8%X)SWS1JA<:]`(L.W"T!D<)GN3#P$DU1#<`.-:4@`\`
MLHIH$65;G(0``F_T19E396A`P4P4>/'0:1,A8)0-^HK!+"T#/#=!A3:\(<8;
M.M4@_]"R%="`$PN]L)`3"P-LT<._,0'%@\=BR"&'&-%598%4#$R0!08XY(?1
M8QA`\FA18HE5"0&8\K`5(FO%X+33DI@`(*5U-9)77GWY%5AAAG6]]7H3%'(5
M'\'UX<=:^.&`P02V/+?V"%T0<'-H;I#FAA>GS</``,Y4\%H"K`*N]@Y=G''?
M55<9)(8-)`IG'W+0"43#Y!"T\1&!T45#;W76W0#X`-T-4,.T[54@PQ!>B`L`
M<^H=TUH%7U@!@Q4W4)#!`!/4E\I(.S3QGW\`RD5`#"(TYI\?(D`PQ`DZR+!3
M?U<9$H`%%YM0H8DH7IB6B!:0=<5E.X@X@0DH@GH6]6%3*O\B'CVPL(:,,N*X
M@(TXQM]CCT$"6>3^'AR90Y),4M*3H!2E*I$A2U@"TY?$E$`O?6E,9&H3FLPD
M)RE)24YPFI,/XF0G/`T*48`*H9\^2$(^[4E/BD*"#M[`ERPP0E)DL12FC-.(
M\YW%0H182_<^98+QQ3!L)#`"JL*0($^XBAQ4L0T6SC```(P&!E!(``TJ4+'(
M#4$!%&@?!$#P@PW0H085*`$#I`&[-,3K"W`PAF!^@`;8R:8"6RA!&L#C-SBX
M1ERFT<"YUK$.=HA+'P'CP00&,!*2"42,!!+#9<9WA0#((2\1JPQ^(/"!!%#@
M;PO#&REJH!G-4&86RNB+6.QB`>C_;`$@'XD)LTRFDYH`C`G,0H#,F)`2)OB#
M9R*`!,\(E"+\8"54GG0A(\8R3&+R!6)K:=H$NL"6M$AMAE2CU-6.R8^O=<UK
M7[/F#THT@@&0;01\P)0)I(*#L-D*!PU`S@@0T1U;X,(-=SM-2P8"$MZ4`0*(
M-`AD#!>#/IRE,@?120,0!QD1I$0UDZ.!#-9``0@TE")#V0*W0*"#F33("1A-
M@-JB,SHOT@$.3GB5%V)3+H`4`XP($Y<59I"`W@R`GV?``"WB]KNX-.&F_"&>
M"/A@H!&$Q@D-`@$>A!<9BQ2%1(C`X5XTM*'L$<*3FS*1BC`@AK)4(@_6PP,;
M9!`$'N5H_W[UF]']#``DL@II?T4ZDEJ3I"0G#=""58(@!+W$0`@>4*YX;1.9
MTF3!.E50@QC$4YX&)<(1&@J$AR*AH49HPL4B`00;X,L,)Z4I"X"E+(Y(A`V%
M]HA"["54DS"$!?R#B2B$000*@L`1$T`5"_!AB2*HPT-<D0`G!*,@(M@""[PP
M!`34H`T56,]?$/`,=A'A"S5@P1?0`)CVA.,+EQQ""60"AQ]X"P3<\J,5K&`P
MF\S$CM)H1@D2\`$`L*`OA2#106K`7H`%K)&"P%0>,E:A&AS$H"7`P4<R\`'4
M^.T+>!,7$8:PA4#>A689P(#`*+,VGCFG)RG;`@*V(`(\,($);__8FPT*P(.>
M-``/!9A`SZ!B`4+BSBHBZ`(DSI>1HA&34DTPBP76HIG@L*4+,4@+TC)%%DI0
M[5-9RR;7N'88P6!3R%^;P`@L@`%OQ@!NA.O"<@@T2'R1""LF\(Q,3:,`>$)A
M!C/0EGX-NK>A%&1?$XC!'_S@M`F`S&]I$%GE"(3C$=1$&CHX@9ZM(X,;:&`(
MR6@6>#:`!H3R=@@:4)M4[!@R)[Q&(3.(3P*>$AWJS,0)%%`I.6X'TS.`Q'C]
M$9Y<%',5/QCA/UT(S0T:Q`(\[(<`D0G:],*&B$\5)47;2P0CRC=CM:0/0Z8H
MA&9,T(CXYN'8X6,"&V*THZ^"-4=C+8+_C_2'5B.I%4EM=5(%I42EO([)@=\&
MMUP%$,$V71!.%OSKG0(KV,%^L+"-1>R?"!5">JL0LDS(0O>D60CC@"5%F@41
M4TU`2O+%T!2Z[HH0GY`)U`)`M4-`M`:&Y5HL+$$JLU6`%^0#`088-!D1[U<O
M-G`8PA"77:VJP1:6^Y>/,B`<%(CY$!C@V^](([OL\%4"B)$,Z%0L.@QH*`30
MB9QAVZ"1/]A(UJ[`N&4:+C*L47DSHH-(8&C`"YC&XR6_L!`$..J&)&(`;3K9
MR0HAIT+/R0N%\2`S,0AD`M-+'@[$T.&>B8`0R\$`L:?W%1*X^.^4R()7V!(#
MLJ]%$G&16A.B_UF7JY5/R-<LLF&0O+5N6+Z+@.D(]0:PEH+FIPM%[T@9<@89
M$Z2"!#*%@`9&TV4PSWPD%R/1!"C\89Y@`#*X?\XSH`6MB,\\G55X%G44I><&
M70=U+.!9,;JX@?;1X`9W\\('$BP57U!``S>`5@*\,`8K;)_Z()G'I?^HD$33
MYVE,K$,#%-Z?FXZ:``:-@8&Z@(,$W"#/*I&:8Q@#L6&#Z%.D<GB84CYFD1;;
M8R)/-3[(@3V4<!8D@!M@(0=,H`-!(&W.]FPW,E8\4@1F("34EE;7QE9*PB1K
MLD%PY6WA5E=A(F[C1FYF0FX<A&X8="8E&(/M=B<E5%B.E5B*%2@[B/\$S(,M
M^29,F>)9@W`A(&(*/C9CX=.`P<8(-F`]%E()I\)P8>!3`.`)H'!U;5`#9X$*
M/O4!0/`*+3`$PI(?`M$`L,$:?K,!>T`8[+$N:3!>$I8&D.5;S0!S#9443&`#
MSO`OZE(!G``$K%405&4#6S`4SY$,_>)U$),U1?,#&K,L)5$0$X`VX,)>FN@M
M!&%U1%`[PA)S-V`%N0!'6]!)%L`,^8%>=J$"=C!*40$5!6`##8!.&<$S:D,(
M`]`&N(-W:P,6/'!983%,,00QZ25[G71XB8`1E#`61H,TE`*+U01YUT1DE/<U
MEI>-VJA&DIA+--,%?N!YG'%LB=``]U0\.Q#_CC$P3AD`&[C096Y`!*PU$A5"
M&0,U`*E1`6,&>F<`'9IC.M=Q`YA6.>DT`&G@#'"`!FC0/"S@!/;'=0S@4P,0
M'F2$.G<#.&4P%.!2`:TR?@FP7=R5,SPC1VD`+9DF"D1`!&50/&>0CCN0?CL5
M:L$38[`&.KYC!/0W!#=@'17P('*!($$C>^%S(J*B%MU#@!IB"B@B6CUT=L66
M(H6`&WGP`HW`!#W`54%P@?-#/V*E@1X8)%.`5B$(0(-")U'2`=V&@N&6@@N$
M@F5REG[E5QB$;G+9;CD(;X7R;CIH*#F06$!X`FP0670Q@%,(<"9B/>%3%^=S
M(3.F2)!0*;IV-$OP_P1/$`:>!@!EX`FAX`6D\(5+,`(XL'JO$$4PD1^94P)>
MP`(;L"YT`(?#90]_HQ31X$7L!0[L$'.L]08<!D::$SF[`0$#@`"A]P;V%3!+
M)Q8%D)SH4QGLI1-;<(\CMCA-P1#@(`WKX!1[$YH*4![VT"JQL5(J@0?\<'3_
M,!**0'=V4$RWI%]P1S/`:0$!T!0$8A=%IPA%413%5!:80@""MQ;<T6!K4SU"
M\W<$^C".<C742&35>(V!L8T.JHV`\08BL#C%0S;!,0(MN1S,@5KH,5J0T0?=
M@0.A\(ZDH7%M,`N+"!H=%S+*XQS^R3?)\`S7@5'6X9"X8Y#810<_P`1H,/\Y
M0W`:,P`$)>!3)>`+,R$/J$,$(P4``("&[/(%!PD')[E2,X`>:H$?<G223(H/
MM+$<(]`TW=2DO0,\."5J/(,!-XD@$+"32N`@H]4$P3<"9A<VH,)T-X0(PKA4
M4>-C*7(QU.,9^)DB%G$95T!9/,`$"+!L09"5-[*56YF!T?:50!*6^S.62U*6
M&V2"9%`F:MDE"Q0F#=2IYK9!+RB7<2*7'>1!/8B7/$A8];8GC<4G)\`";'!A
MK6@6Z6,6`D<^Y\,A3+EB4\@X'T(`7!`%E!D&",*DG["9@&8*6!`%3.1$I`$%
MND(!)6!FS$($#-`>%,!%$<HLP8!/68$,_F*=`U#_`N>Q.@$`!@5P#$.A')5Q
M,?V0=U=1`S;P`_ZP#,N`,?_`'-$!`II(B<^P-\R!$`SQ#/3P#';'+`DP!I9$
M`Z'@"4X`8"IQ,60'$$_!8/!)3$;A4^C$#WD'GSQP/48A32^VGP1PB82S3,L$
M>GHW/A?1BD;S=QN!%W8A!W^Q#-E$&$4F7`S:7`\:M$'[%\QA`V,3'(F7&[10
M&1FPDH3SI3O@&0.0:21*&C.P*]=J$`T@#DY0HYA6`L_A$3,A1Z;3M==!`PY9
M3@,``=]!!]9)`S_*,%4J%45J1[OW*C/0?1JPDH/D4"59DJKUD3/P`2LI?\A#
M==9*L,Q!.$-1'T\F`@"0_P%=X#LVY7[\00(#,@(W^0?)LR!(`$>NQA\40B+[
MMI2/D)@7$B+.=)1UBCZR9Q%+A68F0I6@]08(H`-KT%6-ZJA<V97X,ZE`X@'"
MZP$@Z#]D>:DK\"3KUE<N**J?RB6A*JJ<FFXRF*ES:9>*]8,\.&\DZ&[RII=^
MR3P]L`&.0BH6H:OI16R:,H4)^)@\<!F.`I67:`)<X`*4&0?$4P99Z"HCQ0+.
M"JVH]40PL'$4,!+OR@!$4`+?L$6N25Q^TU!PL&$_0(D`"P+GNAM@^P81``9@
MH`97P!PFXF*-%`"[=#O+\"\(<!#),!2WAQ6#-"_6&</F409/X3$'BUW&0`?!
M</\[^`$`7W9)[3`N":P3,.LH'>$<<:=@'&L5:U,4$'-913.,F%4(!K@VP<$=
M11<^>&H!Z4D6Z5DT>3%*`8!DTQ)Y#"JT:)S&#OH7!G$%R_%-?<>.Y<0V&D`@
M7XJY73!.YU&U"K`0,\$:"."V,UJCL)$4,K$:#8`&7L0"-+`&K\)U$-`=V@(.
MP>`WIC$#2FH%*REV!Z.0[!!QIC$&&B"Y)E"+\Y`&H<"DHA"YBG@&<;$#`+4V
M.X`T>4`KA(0!3G,0=2"YE%NY_4$"""("I^8"1C`";?`%0.4\H0M_+FQP-?0(
MG@*,9Z%#N\9#%N&4AS`B$^`HBZ`"N,$'%L`^+*"[-<+_NX^J(UV9/QU8!%,P
MO,0[)->&)"*X),E[)U1@@LQ[EL[;EG)55_I<JB[85W0YT&HB6-GKJK'*O0>`
M@X1UE["J`R`0,"J0!9.A(8<PE(V@2(G)0V%#2DB%@,B4!UQ@!/?[!R.@OZZ"
M.JPU/G\0!1?G$*TPP#>`2`?\`1"P+!"`!H=!G+^`KELD!QW\`\P"P\T0#0C`
M`P4`!G;PBF+0!5=0`$DP/9-Q,7G09"@*L`BP`;[5&BM\RU?0%,U`#Q7\#`D@
MCPV```PP!)!%.B"`KLA",F7@!E?[:!^Y741``PB0;UDC(@T`G`$C!B.@=]!H
M57<A%DM-E?QP>)?Q-MQQH9H1_S[=\YAB3!:P>*#3^+.8C7EJO-F</2T_<!!?
M+0)^\!B%$]@:NC;'PGE\P`?V404[('9EX`6L!P50<%QI\'+$$AZFP\@"^2HY
M,0\(P'QTP`*>XP4C906KL[9&6I(5X)`?2:U0L)+)0YUWJU*#BP-QLQF'=!Z]
M(4<$\KC%XP=Q$0.-W06N'0/!@1\8BMZX.+F_4Z8[EAO";`3$/`(4H),R0`.E
M\&J1X:>\9CT;,@@%=WB4`"J$4(\ETDBN2SV0@!'ZAAM88`)98)4GT&SF?,YB
MI2/J[`%%X,["&\_&>ZEZDKQ/DL]]M<\/Y+PF3KUPR5<QF*K>>]![Z:KV!JM]
M,H*(,O\37F<7/=19`J?%&4)P,91KA_!_D4!:#&>L&;"_$9</TW4*41`%JO".
MLY-]`[$W%$"(R5`"(#`8MDL-Z/H4&P8&$1`!M&BO1X<B/]`/'!8JE;$X5Y`$
MS%"PK%&+SO$QRH(M6LU>"%$&P876+X?#?X$&<L1UVHH`+,"VW0("J"Q'9?`!
MQ+"+1``%-P`3L`&2L0`"\>I)1XP55+5+74`U,QL`N(H(RP09P1$<C^T5<A/&
M8NQB');9LM[9M%[KV0@8-2`"-K`93@,9A*0?]7@S36K%+6D"5JUZN``#]B>/
M1IJCX`$")G,ZKU(N6V`YZ,`.,E`!-V#<WEDNYVJM1MIGL;/_75X0W4,Q%=*`
MRH%K!40PRI_W!R;0'5<!4/.[`Q;W!`:58I0Q%"5SI!/#'+U.2.YM(`'2'WU@
M4%5P:D;@:3H)A#J``$/5!`,2-'L1"9)@(F7!5&D!*JE[/L,FJ.D%516O-*6B
M:WJ@;&M`(Q>.X;X;)$3BX2!NO&PE*'CR)BN0SRA85Y^*XBU(0?CL\_@<]-@;
MXX>EO;!Z]/1F;WS"5K(JOBX#V499%N`#%@58NDQ(/@>N5(BP<$^@Y%F8`/<D
M"A2P!6+P!RY@K`.0[%#T!<&@7\"0`,H.!QX!!P"CPG#`PD_-P6#`$7`W!Q$P
MBT=7(6+AQLQA7X7Q!G^XYU+Z+B13_P/H0@>^E>ZF,00]L`4.A09,$!CN`1MX
MTP;(P+;T@LK"\@4V#1T9@#<RH`-3JP%Y.P8P$`(ZX*=W00(&M0_/68MJPYC"
M&!9,5CR@YVMA,UJ[WP2O^.H<)A:R?L;9F-7+C\*V_OQ#:PP;,``BDF)_\!@&
M%93QBEH)-FPJH&23))K*?@,L93*!#A[990][FP\TT!/H]`P4T+6CN%T?F0`Y
M`3O4V=S9@>F<"0@##0.$`QD`9749$!`,&%TB`T]11D9=(S$Q$U5-?#%+3Z%/
MD0T-+!4T,B=.3C(R3A0#CS$C`S@CE;D$NP1&3021794N9SAE0R?)&WB<D`T6
M5R0$)CLF%O\6/%=7*E?4U!8DVMS?$QAB/`'=$V(6Y>?<*A8F\R99/#97`28B
M12C^"P`#!O3GSX!!@T423IEBQHP'APXB2HR8HV)%#@<R9ERQPH</CCX$B!S9
MH:1)DQ)2JERYLD/*DS!CEAQ)DJ;-D1\/<-RI<2,2)!I_"@T*-.//GD5['D@J
MM.E/'3V8!+C&@QJ/>"1(5%/!M=T.$N#B[;"@XIZ8==!49#7R9,23,$L.??E2
M!D("+T,:B.GC(LJ9`1H4P(`!)4&)PPQP0"`"PTH%$2QJU,`P`<&;R_@*%``#
MAD>Y*YHCV!#1X(T8,5=L3!!Q6M"/#340_'CSXT<-!HVV-*A0(4W_!1"Q$0PX
MG&!&`A!;VJ2ATX,.'3B^&0SQDB`!!!8#(,`!P9MWFA(0-&@7@4.#FQLT#A$9
M`V6,@@1L;,AO-V$'!A$BWGC&3WE"`Q%=D,"5'5F(D`%K-J@00`!<,<@#.@P&
M`&$`<O!0VX489JCAAJ]MX"$"((;H7(@DDNCAB2BFJ.**++;HX6NO#<`.@'^,
MT$4F]ADR0!<89)`!!B3,LX.-Q901V&#&>:$!`RR4\)MDSE4P1`(:#&'D=0PP
M``<<W3EQ5W7%E2'"%@R4D<:6O<V5@!5$6)=!`^6,(`(#A8B``09;B#%/+0.,
ML`0?&`Q`6BG_"3K"H3'\Q4`#((!PRBJL_\A``P0X`'B)(;CL4DDOTOA"0"W"
M&$&,,4/(H(0,RYC01`SX01.D/&.5I<T5\GBS33BT5G.6&/)I<]8$P)Z&&JW?
M7*.@#?>T<T(0!`DD$$$H'(100M0V!-%$$UG$`48:[=111S>))!-,+)4DP;CC
MVC13N.R.Y"U/2BDU%%'Q&C5OO4X!I2\2;/0P'PD\U`KP@_,$3,\U`H)ES37R
MG$865P2`,DD4.``P%P!V?9``"V+P$85?`P`@&&$)4$`!!#X"0`00,]``60W(
M:E;`/9?E`T8`Y5A&FQH(5/J&#:<%BH$-#3``7`5P(+!!B`U0H`$`+#30!@5P
M;%";&C\T4(+31/]XP0("#%#0*'<04-#;EPGD1:9OOO56`05?B`='`S@D\)X,
MNR4PQMX*M"##G5L$:\)J!R)[9SD&9C!"%ERIT*.,"T8N8382+LCAY9AW>"*(
M2XOHW.<@@DXB'9QOKK2+J*?.XFLB3&"!"",0T$6`#TZ@HPEB&-/`G;-/0,($
MBB7`V&#4+5GTD['50(,&8%(Y!`MS=L>;E]5]064;@S+@9`4E6%^=!N(9<V#K
M@P,[01>N9X''#F<<VI:=&)C"0-O@E0`[!F?<AT$-(&S)I2LTX(UU8'>I.HC`
M")K*!0)]T00,W*(245C"`(ZABA/T``^JV@%^\F"#:LPC+;CZ8#6V<:O_;]A'
M#!*:#SO*80*S6,.#L;H'K:XA!C;(`%HH<-8"<!BM@U`K(0ZY%K8H<A&E>"LD
M[1(7NLQUKI@T<8DT65<':I)$D7SD7?6B%U*8DA2BW,N+^7H*&RP#CJQ\`QX6
MV$$UH$&LL%1%C1;`!]!<)R`N1"$440A#R"X&@2]01T8DP()?1%`&!8S,.`#`
M&`3*X`4@$*$-V`&!#0*@&1Z8YC(HQ!EE:E`"$&!-,I:QP1MJ@!_+[*8!:3@3
M<&I@"NYI8`:\@4`%K.:AYZ0I`=:C`0@FU3\T;:E[X!//%M[``EE"AP*^H0``
M/@"`QU1L!C=@`70T``2^08$&YD#6@E1@.UD$_TX^IUE-GRS`H`)E``$RF]P]
M,L?.#9EN=)^+ISQ'5*(/G>Z=JLMG/FM3"AO(279=X(.01H`#'*`O`V*JCS6D
M,8)%#&$&@X%!VC0`20;\!@UT0`,<*&`%ZUG!"EX0V_'0E`:[?$\#91B`^3"`
MFY.5H2X^JA0ARU!0#&3!`F>YSYBVL(41G.$,3UC"$B(!@HQ60`:\H<')*`4G
M_$BF45PZ*@T"N+PR-.!&@4II%7;A`@7VPA==Z!,$APJ!4B5C"PC8:A7DQ(YJ
MQ.H*V<B5K1HGUQT$BP<O"!@[RL>KU)R%&F.YBGSTBCLFL&$-`/F'LWCHPQ].
MX2$>\,`0)7*1;?4$)/_@JJ(`EKC$E[@$BB91U[J2>$4L9K&+]M*BO+X(QC#J
MH%]ES(H\$@:6^EPE'O5AXQ7L:H)\\.`LL>("%O`8!A$``)>*9!X#?&>$04+`
MD#!0@!MF`+XR()2:1&A$!1I0`YYV%P,Z>T,[[$1,"-0`-N=%[R@)M8$&!!`.
M='C1!BJ@G"\0`9;%K``:T$`VLZ7!>GX4&W2XI,K^@:<X&J`!6K56`NVQ#0(`
M0*D@LC.#D(('NVY0`!0H$+AP`HN@`T#`:M81+)R:0$#Q(,0/(A"`VESF,NV\
MG(L0,,]XUJ#&\JSGBDJGSQZOSFK_N<)]_'`).=UO=\`:@`&%I,;9&0("7AC_
M3&&&D-U3_":C7+H!+M=D!0V48'?1Z\V!@PF``\5@=O<A!'Y(0YD=Y"$&BXB$
M+!`W@"Q5@`$T8(`(?@H*$6QGOSJ`PPG^1X,I.2(2L3D1"%QQ@R'<P+YB0C,A
M<1"#!.JB$DVPW0'[$@4##6$-KD!.I3^ETEJ5,1H*\X9NP0)#&F)#'O)P71M_
M6Y^Q9&4;-FB8-?2``!;<0+&+A59CB["0QT8VLI,E8A$OF]EPA;:S*'%BN3@[
M1761%B?OXD@6\<7%H-@+M4=92KXXL"\=Z""V`IIMPF`=#6]8@RNLAD:MJB$@
M/H1B"6$8P7'I4E8O>*$-6R!!<\_0@`Q`UY!$>!K*_S(0F#8QJ0*G:'"#02`;
M&R"`-&(@)@M`T(#M`*?.'(>#]GH]A*I="#;<LXL&O'`F9$*5-[_TZ`PH@(#;
M(,WCT&&$\"`@2?DX$`(-UIZ/2B`+@D)@!BWCCGV)X(8,;VQ,:"&!&"8X@%S?
M!P>RV"97?HN#!JBA`!8_48=B//86A8YT:)?,C7%,.A&5*$0^CKL^8;2%`5QA
M-9F0DRU$8((\U(J019^=&DG0H_!$MS`WF$%>LE14[OQWRW=):7U8M35&?.&X
M9:``G0AXHWGDM!SK^)4Q8$<*J*;RJ+#(P(XNU0#^-NH4.C@!`"DZ"`;(YD)T
MD`$%T&8%`*S^$C[JPE<WI?^+)FA0!#&(X%`SX.A0;T'X3:@%6L`15X,!-F'1
M2*.0'I9&M`P.&_>@Q@3$WT(V6O\:-LA"%A!0@2#H<"`%F99"%H)L!QR;L@ZP
MB+:8W>R;4-LE+/%$TB:`4*1$[>(1V)9M.K$".K%M6_1M31$OX19&JX4$9)$5
M\'9&LB4D)Q8DL<(-:;1&N?(5!-`^;S$"1O)2?>1O$-``)O`'6+`$&%`"0``$
M@J$`>$$!1"<=*Z,!2$,#\/4V)5`&G;0!;W!Q(49,-^<<5L-^AV$7$$`'(%!R
M&\!?T.$DC^='UQ%`O00"_/4VWI-@/#4`O]%+=Z9,X,,`;T`K9S$(@D(HDG$:
M!%7_`EXP!D[@2BO#,E`P!#7P,P^2#:]3%ULP%8$B"[F"#0$@!AE0`6H@!PC0
M`%9S<K718W#W=O!$!U#"=O1DB7`G=Y[H(C!2`P.`4\CG!X=R!G9B'[!C.S2%
M`=5``!:0!<!0!X8G&-3A!@F@/8O2/VD`-\Q#)1J``ZZ(9@R0`8>!&'`0&V*`
M`9A0!9G0=SI5"-HS)V)2"SB0C%A6`;&G>PF04I?BA<RQ`=P!!S*0`#?@-"V8
M&&^`-:^Q2\7A!>>8`+XW.\"G.)8V?+O@!Y%P!J"P?.9H;APW`GS0!&%E#J>F
M#0U#;R24:A\D#E41++)V%0$#+&OT02I@`_1@#0]"`@%@_P,](`/OEU@$(2WS
M1W^2=7_YIW_:PBT;D1$A\1'.QED!Z%D#&&V@-5HW@8!6E&T,Z"T.J&T3&&Y&
MX8#Z<EH_44:-HQ8?Q`,`TWW<!T<"H@X[<%N#8P($0`M/$`<]@E)]%!YXP0([
MP`=8@`7%0$V&A(MID"6E\#9$0`1I``*I9#50=1C)Z"@M"#940P=7HP;B.&8)
ML!W:(8YI<(=;\GA4D@:LM'&-8H5@:`4S`'!X<!J[85':@P.+T`@-@`#"$D?R
M`4XD1AFHR`"!43(TD`;"HP!(MS'=93YV57!?EB<3<"AW0@@80$X6D`%I\`,%
M\`:1.(F<2&._&9R>(T]K%T\T-O]/EOB)ROEC/R`<>@(@?#`[8$$`#E0I]N$C
M_:$)$\`J&;![AJ1A,P`$N9@E%M6+)O4%C$!T/O4$9X!F@+,%=Y)3AS*?_%%[
M;;`U0S`$-``>=D(G->!Z:()Z7E(&A[(H*((&W*-EN.0%+3@GLJ%1Y.@ECME1
M\C@`[7,)#&!`?C!\"H1`?1`);N$6!F*.KA`U(N`'JR(+2`F(''AK<$4/@;4-
M90$KP*);95$^KJ-7[%`K&ED67``PAH58.Q1L\2=_Q\80DI4M*:E_EL5_5X1$
MHG42-#F3-$DNG*5$,5%%'L&3"M@M1(E:#KA%0KE%L964"D,6`2,PJ?:!0<(.
MVN`-GN#_%G%0EACS!5/RE6)``"Y`EB%C@VX@47FV*(2R&,O!`A1`!VJ`-1M`
M!UIS9R4``+;'`%^`!B?'/SEG,K*D-2"P`5S2>+UA4F40&47#*&/#)8^:<"R@
M'[E6`RQ`)_]!*&@U'V61#?A@&O$C9X50-PI0*J69`"RC-RW3`'E"%4*F>CG5
M'[%94"*`#5F``Q2@FQBR-)B8B9OX=IUCK?9TB<Y1G*)SB=BZG.`J7\U9:H<2
MG6<`,+^S=]<I)H_0!?2V`Y9I-R/C!D!`4>1IF2B#&,)Z)_SX,9IP%KJQ9G."
M=;#C4Z77/TG%"EKF>W4W`!FU7U^("C?@)1I@)TX"H)_J;UN6_U+DP2B]X0I.
MX%%64!V^=Z&U0%.5UJ&Z\"DRU2<C:HYK0`/8,0%-4`5V(@X@""N]%0XWJD8*
M*:/S-A8XJWT^&T?$L@ZX<V)E00)<\*,\@`>^-A#/4J338FS&ABU,R@&5Q9(+
M>$0Q*:5/1*73]G\%2%H>45I<VBT,N&UCJK9KZQ00.)1(@6Y)J0(?E!5,"5@=
M.%M<T0T'DS"FF)5_D4B7=Z<)4`%BL!:K408U"`4P$%)Y1@C<Q0!$<*A-XTDI
M<#4_P!U;@S$U("6R`1M<8JIE`QX,P*I)`XX:Q3UQXV6924H#@'..:CT<IIG!
M(@:A)$>#-9'H4P[<Q3^E0`B6*;P`(/^>C79YF><$(%4!3/`@N893#@0YUW`%
M?O=Y]I`%V;$!!5"I:M>]U=J).X8BG)ACW2J<X!NNX,HZM7DH`'5F=Q()\(,#
M=5";5NEW!``\=I%A@X%P^4H:<@)F8S*1[M,6\=-QVM,&VK-(7S8!(.,D6])+
MLO<*<8,#=<<`\:5HJ$`!(1`"2C(`:U.87X!,4$8$%`H`78<#)7!Z1[5[P`@^
M!O13ET)3-*NRFT*0!"M3=C$$K0!Q*M4$'SH"#S-#IB8.'JA]MP)7/*J13-EN
M:K0P>I(@]*$GMY(53=L$6<!K+""U\-=#C55L2(JU69L#V\*UV0:E4<I$342E
M:"P3*G&34D3_1>%RMJ5U11NA;<P6IEXJ;FVK6D$1%G4+;VE$%MG'6_`&1WU;
M/BC&!8$[IX1D,8A0'+GH.R3@"0T``38X!H^+'G129_^A`5_`<3+[`YE[-4Y8
M4N8E-;(AA1U'NDM5&EL0&8OJ>A40'D````V`++^59F18"',3&S:`!]#``W*@
M&:E!'ZS$'Y01*$9S8Y)1>X+*`,5+'4A5-DHU`Y6+'(&S4H:PK%9G)^>0#3R@
M?I6,`'/@F]WKO6UWOJKSFZ+SO>9K(NC[B:^Q.T(F`GPP).1Q"^:S#DK6.N<#
M+)I@#&5`!",3741`A`RP!7F0!P`[JEL`OP6+'Z1JJA0P!-:3J8E2_V<PA[!'
M-;'H.`@9@`:+BF5.,!TM`%+!2!YG8II?X!OA@73@XWN!`G2IE$J[MW()5V9[
M]E/W@9U-0,.8U@4%90N"`F4)(`,Z`'&.L`OX@1I@04-*NW4BM+/10"Q_BV+:
M=T:YYC`XA19JD15,^Z,`(P<]<`,;G$-;/&S$5FQ"I&PKV:1NVQ$Z:8";!;9I
M/)-@6Y-72A)25&T'R*4^B<=B*K=9Q(`3V,<H]L<]^S"LUEMB06]]:U=A00*+
M3%860Q</Y662[`DS2-"&!$UI*;RD<5S(`7$_4,X7<AO(]*BQ<;H>\E04O4AJ
M^%NEP#\<QP+&D$@,D$D2(@;_80["(A\4PO\@-'0:(#(9\=.JJH<!UN!`)>!Q
MI5H!&4`G%=.61YT&B30='Y4`PKJCQR("C0`L@;+<Z)!^66`'6P`!6Q`!W(O.
M:-=VRUDBZ>S.[\QC\1QWM7$?W'2B^$R;[7`X$R2,@F>5P/!2!!U1"D`$0Z`]
M2*;,=D8#;;#<:G0?I,J+Y^@$YW@#)3`"A<@H(MT#+.`*:?-0W)U?O<0E7N(%
M(QLW$%!GOF$]*^T]'_4!\YL'!H(#YME'$=:6-(5U/O53!B(F/RTJ*ENSEGGD
MV<$\:W`"`:1GJE(+8]$P>A+$AWA&VA`./'J!":-J;C21XX=3['`5&%A'>,L$
M%9``(4"D\E>25YO_+2HYQF2L;>!BQE%DURBAQG9N+F1;UZ%5UU4$V($MV%[$
MM@^8+WZLV+(EM"3T0589)">6#?%`#[L`5'$@@Q`V%V7PCA``)`)G'PSP`=]9
M&/>)=8)"2!J0F;VQ`>PX&[MQC.9E`UM05%+H<=Q#`771`)14`+[MJH2"9.S0
M.'D@)^9PY1QTA)-$`H=2-`-PSAT'<[L3*`Y\A6>2<@=B"-24`$X`'@"0GTXS
M!#WP*[=;<`P01^WPVP4\`><]`2VXO9/8O<"1G.`*3V=7WSIVWYY8&Z*X6\A'
M"^[JKH%2*8N+`WE*`'Y'#3/%=(Z+<+DXW=EC,JWP"A3@,O\A9[TQF!3P__"M
M,"46RP`8Y1QH4$Q?0%U?T&409TQ(,SUK,@-=]@$_HC4`AC0LG/)$D`'"QRJ6
MN0C5Q0@'TDT[C8H9\`$#H$!=I4`UJV09H`C&D#8W$`1K<&<#P`D$90ZZ`D($
M\T)?P;/$LD8HEN@>Q-AF\2NHH7U@?9%A[;1;0`-I/K4]]$-K?6Q)2EEO#M=U
MO!$O2>=\GM=WWL8M@<8O08#_)RZ:M9.`;L=X#)1@^FT5Z!1T"V\`HQ:F!NE:
M,7XH-E>T4A]9T059*8-RL4C%H7@-D!4$P#Z``5V/JX-ZMF8#70'LYP2(FMIS
MLC5$1QL(\&=SPXL7PP"3A`Z[21H_TYGIH"=F5/\+=@(G*Q4H>F$[!*<E:E>J
MIIH!74<W%O7`\04'A]%U!@+J-R!FVXY+RXMDU>"[.-`&KI-3^&$(PGC>8D`!
M+"`'W#NMP=&)]_2)\GZ<Z6R^]JZ<IV,;H[@/`04((SLJ65D8.#@B%A@0&1A=
MCQ-=,2,9$#,*,#`*;D`:#`PX#34U<&E.3C*J3A1M`R(B`PQI:7`@+#*X0S<)
M7@-;);4@IA5P%`E$'PE67FT,$&D5(,,5%%_+R0`#.QB6M*@40QI>,T0:&2)=
M!-RRH!4-#1@3\P,X`V?X(AD?`P1&_P`#5M&7H4X&'&42)+@1Y(:,4%6:')(W
M88>%*U=4J"!A88>)'1;_2614T=&$21(;49(`:=*"2HX6Q,B<(`9CQQTD<F;A
MP:4GB2Q,6"P82A2%40,&BBB=PM2#4Z<.HD;-0;4JAZL'LAY8P37K"A\"?(@5
M$)9LA[-HSTJ0H':MV[9KX;J-F[:NW0YFR>K=RU>L7ZZ``6OMJG7KBL('D"#1
MJG@QXJR*(3=N[#)GSI27+5LPX5+C9A,J=U2\J.*C2Q,QGCQ9LF0`@`1#%'K1
M4&:`F)QY8H@H`P1(IF8,!@B'589(FAH52FQ0\V/#!A`5TI2`4&(+CP`_$`PH
MU@#6*Q$8+"1)$N!%``L3KA0H$."*C8Y=)I@0$PM\`P0;:F#`T'TX>`L-2`/'
M_X`-3-,`'`P@\T4\U*&QP0\0;@#'=!`(EX$&1'Q!`04E:#".%<RP\`8>//"@
M`@]BC("#(_.(1A,&PG5APWF@V``AA`B0HB,"//+HW(]`!BGDD,[U:.212!I)
MI)!*+NGDDT#B]Z!V8E@@P@A_C!`#`29U48\($W3CR`XQF$0`"1,@Y(5OF4"A
M@!<TA-(`'734,(PJ,H`S!`-;B%#"?70XAT8:X2B$X9\E4&`+H4X0V@L17E@Q
M`PT-X$#=-'!4<XT51!`!@`@@B8`#*!`H]$49J*(S`BQ/8(&%:/N%.0$>>-!C
MSPCXJ*B-"4T$9(0++@!$4*IE>`';#:G(0,,$$F70@/\8\UR$T7L@>639%1Q]
M9%%GV)+P44N6;6122SQLAE)).7'Q$P\V9,3#!!4,0=0"1J&05!%3>#"%4OCB
MZX%44U5%%5:#';;55CX`!M9>=\DUU\,0LR7Q6PU7S-?%9/F5<&"!#68888\U
M)IECCY6<V&)(5&;9RI=IY"UG+K^\694=?<:9!03XH1IKNR5P30(:?````PA8
MML,($(SA&PS`"1?<`(?>0K0:&]!I"H6*!*`U#PC`T<`;-H1=8@#KK<<#2%<D
M44`$-F``WJKRB-J="`@T1PJ/I#0`RA99#),I"'3@UW4)%7P!*8-$YZAW-&GX
M_(JERDC#0FR12EH!`EMLT47_%SN<'8L-Y1(@*\T6\'!%%B*T4?>-^>E8PY%0
MQCZDE+0G"7OL2<H.I90_2MD<F%?`XL<(Q,-2/'AB8F!"%1_%T`72KQ&A@`)0
M)%`.!14P``<:-01>RH#AB-/&%@TX6S5TT0$-FS@0,-`&!=%4('\:O'@!J8>4
M/B--=$Y\L6FGM>G"JT90CPP$HP)7DD<?_G`&`@Y@"02H`O'@-@'R=2<1(WA"
M%)[@F@'PRE?`"I81NE&',@"@5#.`C0Q.H(HU=*$)$\B`;6)2I7+%Y%LD*-%&
M/F.MC7A&)O.Q@`JP)2YMJ0Q<+R.!N@K1+I]L@09#J==1EN(!?N'+#&;X%\`$
MEH.K_W"@,(0YS%<4=K&&18PM'3CC7-"RQHJY\2P8TXM8.":8@WW,8(B9C,GV
M:#*5L6QE&MFA1V+VK8Q<P005,8FU^/"$#"ZA9T.(#0`\U(8:I"M+&2#"TJS0
M/G=4(`,S`,(7O,:"&N0''K$8CABTIC4PB*$&5XA`!-9SGE6RAP?/F\`;WE``
M-;P!%J^K`?D8(((:",=.MBA2CAA0AD^(@0408$&@?J`&YL"!.L@@`@-J(!T0
MH`$$:8``_"C@(6*N*'(@8("'9@"%=@Z!!5O`0T?D80,"UN`-DAB`##&P-??P
MH`$0J,&-[.:ZV^GNH,JTG4)[M"3>(=1)#*6=<YH3CRNLJO\*SQ,5#KK`!VCM
M0`S,',`$)_$1A&!H>C/@A7$:L!T0W(T.U+B!L30``7A`0$!I&`(J>F&L9=34
M3]"07P7ZMPPOS.8<LI"AWJQA*`^A0S@C6`(68N"V$52P"R;@DO.>MRJ1ABD6
M#&`!"Q@0IWJ(%%<$+`,.JA"0$`+K'UW`00E/V`O8)&L--\!`$W:0`0:(004V
MD(D%8O*9EY2K)9P1"48.*0:/2$LD+\,A27("$I68A`N$L$`3,?N&"D01!?2R
M%[[V944/9%&+7!R8%[_X&#'.$2P+XXM=U$A;B*61+F]T8QPS]I>O;$PP=0P9
MR?A(7,CX\8_A<IEI7%:S$QUR6XG_)0$!&KF:W6@@-@F`@(<@L(6-<($/9\"!
M%98V@R&4``<E8$"'>J.!"EAP"W?;)49X$($Y@$%M)L#`#QX@RP#L,B8SNH*L
M)M"`Y?S@=;O<I=X&0(H!'$@8@?(;!0!`A(!6(`%P:,X&$$"-4JV/3].9AOP&
M5`V%E"`6$"!"`F;1AN(`01,*H``"F#"V1;@M$3/1YP`F4"Z99"$`6R@#")@3
M(=>]KDD/U=U"';IDAR9Y=TW"SXW<Q@.W3:(+#1R!'V+0G1$<HC8[.%-F>B8]
M&%3/>A08:PEL\3J8IN%GV&7!A&QABD;QHA<@&D-``7K33!'*?]B@S9]@E%0(
M&#J]P9&'_P-%<`8^F&!5F:,(!D:P.5P]TL&DR!0+*D"#-L0)`AALX`!`W86V
MNC58,6#`7%'EH87@%:\BX%(&'$&`(4*K2F(`34YXP!&6'-=FUN((ML85W<QX
MRR(D,8$+?C+8*_1$!4$)K123PA32YNM?J.7B:KW86C'Z%K:QU<M=:DON-N;V
MC1F[F,:X,D<Z@LPPQ95,O!5S7$!B)F;K$.(0-S/8('I+W])=@B,K<5U3>6@(
M($@)'V(`M>G!((6&AL`U.@4$XPCS/C]8SWC(4QX[V"$`1[-E`?;PA@%@P`;X
M#%,\;*`W.KD40KM$`#3+P`"6CGB:S*&%-8A0ABV`8`@5@*F?B_^1!@_YKPT!
M2@,XE>[G8W@A#6[3+@3@P`*]A9*="D"X,#$@!M,1$!TSR@*!WR8<#&3!#A,H
M`QR(W)PZN=V@3\:=0J-DN[@?-'=2?E`-1"#@=#B/#WDP`1_TD8@)Z&,;!.@#
MF38W@(1@`J6]^$+V%.5-JSE!(5:XQB?&6HQ,R0^[F$_`4V=-=&OXSPICX/FL
MXX'6"<I#GO!I9"JUM*I85'T`;4C$?G(E@@)-`P0ZT`&>*M"(5^Q'GQDHM1&B
M`*PPA"&$1MA!XTU8!G$8RR%KP.L`!KLBY5T$/32I$LL4&9*4,-:QUY+923"3
MF<KF!`L$V,E[?,+R&TA[BM5^BOX#IMK_;2.!M043&.DV%@*`%P4X;A-3;K1U
M;KD51^OF6^[6,1TS;Y'A%5V!1XE1;\EU;X%4$D-T!9LQ&C6#$AM!`(^T&N&E
M`0KA,T&3`"R@,KKQ!0[W<!H````P`TJC2<9A0340`+)4`(MU!:QD>"IG`VI0
M`#F"`"B'`&[S+&]P(.E4`3KB-PPP!%Y04\\``@-5)]'A/[11=4`G=)F2*=;@
M(9_`8;1@"]"A<]8#`;&P#QK`(=6@23.P"5[@7A.`'B?7-@94`V(`"?OA-@=A
M=G:`!S?U`W(0(4G8/4AF=[*#)+,#=XXH=U'6'-DA`C)Q)91@`MUR!O4@")60
M`92V.57@$8SP_P6/IP#E!1L-P`(TL#UH\$V%@WE64(,F)P+:XV=$92B<!!YA
M,@`ED"C^,XQ?($/,9`_;0`)]X#QAT@5B4"L35#Q>I3@D1@,0X`S(TWMVXC?R
M,WP0H%;@T07Z4`8C\`_,YP+.!WU^,'VHTDPJB'UXQ0`6T`2-%QZ^%BV8<1,G
MD4,Y,3.2A1(\@%BZQGZ9L5S_5B+.ID0\T`-K$`+31FW7IG]0$3#;YD7#98$"
M&!8$R#`(F!8*>$8,B&X':(`:J3'M%H'>AH'%58%\E#+(96\MHUPX83H!N2W!
M1H(D$`57PAI0XS->J((5('XK@30SJ`#)\`&]T1M&Z00@0#[P-1,T`?\V[V%X
MX2$+&_`&K_,#;X``NU0#K?@ZFU8,OE,#)4`#-)``;N""-$`!@/--Q&`,*Y@`
ME.(,#1`-WH0@AF:&#%!!TP$'=!`@T8%"90`+#$!A-\5,FC0&;O`F+-`#>"`'
M579R8I`!9?`L>0B"'S$"#3`!64`2.)`&B'@CBQ@X##6)2M:(0>(C$%4[JNF(
MK;EA$_5+>7@E?6!5B-1`L>!EA#<!!"!FO=D-7^`%BZF*D9<]K_A-M]`X*^@A
MVL!2#-!YI_`S0*,!.(`/E58/B#`JQA<W!Z%/(]`'7`4+L,`"KT`\3R!J`P`X
M=/!-P5<!,G`,#'!\(N!2R.F>,G`#-R`.`)#_"&"B#Y]BCNCH?,_W?(-70B8T
M22HX!'B%GS0@!J@#``VP$HD$1$*4+=]2H;RFCXF5$IMA$?OXDIYQ$EQ``%72
M+I9A`T$Q!/9R%/?2%!(YD?WG?V#D;F3!%;+E1FCDD1\)DB%Y%P>X6^N&,"@9
M;XQQD8F11QH(DR2(&5RB6?R&+BGA,EBPDU'0D\,8-!JP+"Y!`'^``12P-)M0
M<1]`!.7@&T!``9D##Z%@5O>T2X;7`(&5GEX)!Z0``I@V#&W``@A0#7#P(-6D
M!@CP#.%@+)O69R)6#,375!6P`=D3('06'110*E?HA#6@7J``"A2`*NWC-J/V
M"<@!`6L"!&-@E#10_W5Y&)F'``'\A")N$QZ+50A9P``4P`2)6&1O5YJFR22I
MB7>XZF2[RIJOF60(0)H2]2"_A`$D``OY13Q0%8B2T'T[L#G2B@$E\`4:,)PI
M!#040%9J2(;7H'FT<5:X.`NL\#,V*$/12#SR$(CR,%AB4#ZO@*Z:F4K;$:DE
M(%+YT'N_-PTZ<`)$EUWQ8`^FM`%,(',T<&?C``#H`":5\"E_L'P!*J`$6@FH
M\AJMMA#X>0-H^J#;]Q'S@!$R`8*^IC(;P1*<T2TY\2WKQS(QHQGK1U@XJ5D,
M&00&8"](8441^112$:-7\7_#Q3$;\UHW.I)U86ZWM:.VU:-VL5N\=9)UQ/\Q
M']-:>21<CY&D+]DR_=BA@W63QN8".U.EKS&,"?`!7C`$6["E?-`%);`TTV,.
M--4&R-`;"="4T@!0!B1#IO0#Y"-0,N<W=!(X>B-GC;.HU?`@&V:G\G,,E/-I
M`E)YZ>1A,Z`!++`!+)`!+!"+U!!.S81A-@`&)3(!^C0JEXIIGF@I&7(,VI64
MTG,#((`'?5(Z^V$IEGD(,K1*&`&KHX8`M4I0=Q.LKKFK&U::M].K3@:)D.B:
M=!)1$_4#%;4J!.`\*K(-W(`!HH$0)D=I,1!F)M!XR(!2US`#%6*732>V'K)C
MR^B)LV8)AM97QH,K5?"^??`1^U%[_`$/V(@()L?_([\'!ZNPK?L1"W5*#6)%
M`TY``T-0F=WP-1#"!'3``G>F(=:J*I!@O7ZP?%$0!1(;!E'0!]T``";D(9""
ML?BYL1B@5GF(2)?9H1[1$A^8+2OL$HM5DRU1.E>+DSFQ#C_4&4-D`Y2[!D%0
M+S?K+_OG`%)@%17)DG<$@=\F1V`!1T1[@!/#1DC+HSFJM$[,6[R%DNR&@<'E
M%9"!&"I9M34,HIB!2-`%<%V[!*NADPGADY-4MEM@`]+%!SO``!_`"9R0`!Q2
M<[CG!8RY!6VP=AM0(*.V3?G!`FP)R$SII]7T`Q-2`D!#-(CL(,A!.&2H$#-P
MAWH#BRX'J=8:A_>!`,XI_S^S4`+45P(@(`8Q,`_A!S9O8`%YT"Y7P`=?ER&0
M:CT5AV8]0*L68%7E@HOAP1E5-0_\,0$GT@`]-P>LT[NXFJM$$F70K)K!6G>H
M*:S#RCN^P[Q\YS8QX#PNL@,:16ER)0)YT)M<PCR--P2/YP;V`QP'A""1^C,U
MB`Z3=CSP$`_P@&L30#R5YF7\0:]5B#W;JC=_$L!WB:BF?(OI.0WXP0:XP`N:
M!QZBX!Q"]V:2,@/^H[":"+IJ%0-^P!H7_%91L`08E0$VB*69G`"HD)]#T`!B
MUPCR@1.$52XMTCG=0A(F*T0@2%F.51F\-L8K8QJ'!1J8=05,T`,R($6B)<1/
M(?\%16P57;1:2*S%?H'%)'EN4VQ;:X1;2ML7??%;[A:`7'PRB_%N1QHR5EO#
M+8L>(6$ZR.4":JQ!E;""IS(.+6T#*2%]&@`#BPD%0%<!P]$`7SH#C0D*U)0=
M'`8*K0BJ\"1.!@8A@6,,AC8$X^.*=/`#:-"MFO*M=%H,@8*<T`')&:*%Z\%R
M*X)HH(!I")!K626$O10`@47,&"!J%S($IC`$UEIQU^J"6\"9*5(E1(@M8C"_
M7X<#9L<#6[`@<T!D^4&LONO,P!K="26)O3-W=M<CQ`HD$+)W?0<26(42>4!X
M9K<;)B>MFP.ZKS$#;K#>T^,%VQH-##!KFDH=J7TE9P#_TG[`#5X&-YSJ'ZG4
MK>!#`3O%EGH33'Y#=;@@`VD``"4`(P4M)0UPL`JAL2L&(_?A>=$)(K5(&SA`
M//DP:X\0`P#1F^98TC7X`1_@(<:RTK#!`K12`HZ0!RIQ0R&8AY`ELD;4C^+2
MTSX-U"M3$AF1!1^A1">"U$5ALTSM`4YMQ-S6LU.-DJ]5U5>=6UFM1G!AQ23)
MM$,JUBI9@6%L,B[IXRP;,^]1.A@!62QC!*RQ&D]P(:;23&4+I]X%S@#`UYP`
M=.39>_!0!C,@A9Q&!XU,37LJJT!3`1/@::+)C8FR(36U!7JZ`6A`)P<R5-::
M77RL/?NJ-Q`P2=MD`W@`+2IW_V0R`39">`5<,A\3P)7ZT1_8:2'D<`Q?H%W7
MI<XNB`#@$0#YQ:E@`HBL'+UF)W9I)@?,S8C4[<R_VF3%OE"N.:RD&2BPJ7>*
M`,XQ`)ZZE@<JTN&&IU8AO@-]8`0DP`C%P0G#203FQ<?9B8RC`"V;T\T[<`;_
MW`Z@,!WW&HX.M*^'RFFLN`4,X%+=LYX#C%TT)8AS\DV;Q@L@`L$+VWO1<0I,
MI>$?4`=G=0:&MR+I$!"]V2M&\+PX4(-8J@$I=`-XI1`,0"O,A*SJ(A)_Z!&^
M=@7EPA)MW2W$-E@O(>8`65@X;0*8Q34R,"]35`10L>11O6T'X.072=7LMI%F
M`4<X6O_E#X/E/LJT)0FU7&[64ULR()/65QM(&U$B)0(Z*+LR7!`%<?`$81!>
MK^$S"5&V+#`C&^$'NV'G3.,$@.T=#5`",[!-D]S(C9Q.P2AY>."*$3(,PR`=
MXD0!."`&+*>>,#7I3O<%?Z)RL@#8H3#Y#H8`\\`\I;,V[.&NX5?/_!$<!;+J
M8"52=?\!,R#WF2).<SBW3##</&8!>``CF#A8-F"R@L4#68`'<2+LBGADU6SL
MNDIWRLXDUAV\#X7=PAN;LT]I!/`(7%5[X$%X.&'.1L`'X(X)[-T)&I!>KW!E
MOR@"O>TVXDGW!S(+_*.QA3?QS]EYF.*>UOA.^@X'#@4"UFC_<#^5GFA`?$-P
M"LL`""U67PDE&"(X#!5I%$Z$5I`:&C@-9R-=$X@`&5T$1I^@1@0$50,``!H?
M&EXS"4,W";$T>%D#91@D7%PJ-F(373L\5R86)!8[R#LF)"17*B0FRB;$S,\\
MS-C9VB0J/,_3%ED6)GQ</'@R(0OK"R@&!D4>'@Y2.3D<^/GX!P=(_OP`#ZP8
M.!#@0!\'$0I8R'"A#P$=(DJ4**&BQ8L8,VJL.+&CQX\-0SILB'"%0((H4P9<
MR?(DP0/%MLF<R8R'39M7KLR,LB1.F"4,`,3Z4B:!EP0,W@10H8+/B`QC%"B`
M,6,(C0%8&31(HX%"C09MT*A1\Z/L_P\0#"B4@,"`R98*"#8@J`$"SB(*";Y0
M:,`C0`TX:.C4;0"'`8186K=8$//FC0@1#3!@F,#XC0T>67#:N&*C\=P&H`<P
M$#%93`,<%4#46`V"<(4!CS-HF$$AS2(`$"AH`$)[BPT+DVV*>5S,UP`<(BP$
MX)Q%'(,V3,B6G8N@NO4-V+-KW\Z]NW?M<;=;'S^>._GSV:]_[WX^/!WL/]XT
MF$`"0Z=#B`9@FC#!!(8,&5S211<Q5+$#!A`,X84;"K@1%1`:,,``#ACDL<,(
MCXE6P83(C>#A"*"!4%<%%<C@A!,40)"!")DH0B(<(E;`@B-##!'A%B4,4`,=
M/`H&BQ4)0/\`01DB8-A`!80XD<87D$"BR@`QG(%#"7:EP8A1K,Q0Q@`-C'#&
M@`V8<DL3H1A!YB@FB'#*;%ZPX@HLLM#20!D-Y,(%"6*(8<($.V`S#3+1F*`3
M-\/L,(ZAV-A$DTR\7,&%A<2HD`<?1F2!3@CJK.,./%/,4\\]^N3#CS^D\F.2
M2J:N4)(/JSKT4$@>;23KK!A%),%$''VDJT@"O.I02L"BZI))+:4*4$R+)DN"
M-SQ8X"RC7$3QA$]/X%"&!@"4450K%"`0P%(DG%%"5##``$4";>"@KE9P:##$
M:@S`\8-T/R``!R-IE%`"$TPT\!X"=,`A,"-??%$"`@44$,!;%0C_G)4B(-A@
M0W\FY#F!#0DOQYD-W]H!7&@-K+8:8:+E&!D&`U"0FL`"$Y9&!EB5\`41$`X!
M@0:$X&P%#:!=-L$(D@T0X'Y")Z?"8F)D8<,`;2!`[P8[DK?>U%2S9UY[Y8&'
M=75:5ZTUC]71$1Y\/T1&PH`$_()?%VLC2&2!%A#0!)XE%,4@%%`H0`126)V1
M"0YUE-#PO67`/""&6-E5(@TRT'!BW0RT"%A@<BV2@!4USM#&%HK0@89=<+!P
M@Q6"Y$7D(6D-DF\LEUM!!``C\.&'"((S0D&-1LV@P8JP?2B"*1HTX,DG<I,I
M"@%JHD*$)#,<=<,-0P2Y!1X8;)G'G7SD_VF".,H8PY\TR!XZS3+/*%O--A8X
MJ@(!%5N@`A=_F(`'"YBRLVD1\=!C3ZC[\,-!J0))U4L$F)"$L.I5$5G(1VC%
MP(SHZH$0[`"O>M6KD@0K6,-"2;$"@@1DF>^#,^$"%I[PA"B,P%HXJY&--``!
M$/3E&3'`@0;&4*YS0:`$B>!2`P#@!3:(@0$RV(!9H+8(?6GE,JN!&LON18$O
M`(`!<IA#`,`0@.&(0`R+2=\5`E``X$P`91C`6`#B(QD,@`8!-@!C`ZA$!Y'1
M17$28D$#).0:@;6&`6MA`2+*0#,GD$@W&D@`!7:&@"U@H"_A2!,.)F"3M`'M
MB["90'-$``$Z//]M->CQFB;9P[5,ADUL4OO.UL:V28"!C6O9*8MD2/`+`NR@
M$WSH0PP&4`<*30`'`&B`"?H0#6#<<EM3@8$"("0AK1`&#FMA``M84(';W8`!
M62%1"6I#@Q(H@@9#P$L;#I$!?_7H<TZPP@R^<!@('*("?XG7O:)GA3',@`A$
MZL(`A)0&&9B($*W[0`8P8`0^Q$`$&1"2M@"4`77!)D,#P)`,-2`"$Q@O%*,@
MP`BT588V:8`(SJO1%X;`@BQ,(`,,$`/[*B92I@`J&K\P@0IR<K1`@8,;()S)
M-;!!`#[`5`Q;8$$"ZM<.%+@C'E((:JA:4BIB:?`D!E$505BE*@$T58+_$-'5
M13K0P*I:Q%81E,@$27+`"WI56!L,B`=C2M9<N("$3\"0;#9:(TEPE&//V,$`
M9DA#*'B!`L4<S0ZAH`,QX""(/\".8.["%F\5((UU5-R&&J"4C%7Q8A%(PE)6
MFH<KF`8#$MJ"&*RS&C.&"38#\(T(*H`&$86H-<A$3`]8H#(0T,$L"*C`8:!I
M+2(HX`8H2D`@9]!.#8"`"5],FBM',``,6(`_7PQ:03&0F2VT\)(U\.0FIWN=
M4682.Z1,SRBGBUU3JB>5-<"%"3HQ7@(PHP_YF8`%3*$?M@U(&?/\P@S*!8.H
MT&9"%6A`C-)``QE5X'DWV`OGXB4B'A4F+;'`_U8#$.':>S4,25;P`LZ"A($1
M".Y%:8`3)&8P@PQ,@``8F!*)4(1/"4\"`U^R!%96_!B@/88T&/(2RK(EO.&!
M8A2B<-NUVH115\0">@S`0Q4R4`**Y<E]S3@&GZ+1O96*SP3F+:M,;C)3$O#!
MILU"@$YYVE-X>""H4A@J44U%YH`4)*FG6FJOFAK5J,;*JG"N558[,L$#6K"K
M7P5K6/LQ5BE_4!=+2"MI9+A1'P<R*9/E@YJ`0$,8W!6:$\(*`!0@@QJ@IBP;
M:",(FBFD!DP1#&``#I>BRQAG<7$IR_&%#2*0,![X0@P88,P<H7G&P(I,1)L>
MC<0&`*,TP$&_=/GC;O_>I=,*"#'3=5G27;$B&P4D`+=XR=T8O%"!-_#@BT7B
MY@!V0)D\B$$9/V-19B8``7F9I5Y8DPMWURV7=+<;E>^V[G4U.9Y3JAL^"##N
M>,<Q@ACX(0;8)LV,!P#E46"#DA#P`A1J2(09E"!,6L&UXEA`@V=O=#*)0`"F
M-P`"F7T!MX2`S`#J@I<TL(`!NFVG..G4@-P,[$2/B,0`\F#E$V8@14,J@Y#2
M520//2$&?4B;P(&&LM%TX1)/^)(MN@GE3[B`>)Y(6P:R)8F+'J5-(8#>+*H`
M.`Q,`XN#NL(QN-TG:)0=&>.(<OG\G`U%88,/Q.C,EC/59:#60\Q[!@@2DFK_
M9J,NU<X/@:J;.Q+G6=E*SK>:LT=(4D'`6]"KP^I[F?7>9[8G"]"(.X.88A&]
MH]!`#(F>*!#*I0`OW$!=!I4A#)R`L@K0X0UT(0P><_2&`H`:#`6`];P25H!F
M74&R`0@7!MY@EBH^QHQ!0\X<6<":&DQG-170N69'"R.R=;P$2P)"`D0$@94U
MLS:&\0($F*T!2NO`+@EXYPS.M<P:]-Y]5YA`0G/BK`I/H++AR(P8!/<#.<`V
MNNB17>PV->WQ;MT%;_+F;J5D'6TD-O<F1&_@=1(U#462'T0W&4\Q`!,0`P/2
M@2)0!@HB3#``)!KP<`/P<+@F(C!2`;$@88/&`'&Q_VEW,11.``O%A144H#)V
M<1BST7`S``&DH2_ZE08P]P@:\#9G$"6(H"\XQ"5;L`7\$0-+L`11<#R9\&(+
MU@9MD%!>DE::)R0B4`7#\W3'(PH[@$O7TCP-AR5>L%%M,`%-8`M>AT5N-W9[
MHEXYP63*$#?5L':61P)9D`UWL@-B8`-,``([17<^Y65"I0]YMW<K<2J1Z'=_
M=T`)Q!`+5'AQIG@/%!*.AV>J\G@%@4%GQA(=](<@]#Y+D'FF``"$T'F"Y"U,
M41\0``13H0!5H2^)`#@?,`8W`!HLH!J@(1F486T)8P=V<#20%0$1$`#C,`U,
M<6TL,A<;0!:KT1BPMT8,4/\#G#,P<%`#R$88$$`$1`"#A@$"@546`9,&0O(%
M@21'$)`&*L@`:4"/-_,%$U('Y?<%3A`]-,-HCL9\#8!%XP!)MG1T.``SRL$#
M-I`9%H!';W!)#`A*#SB``XA*G:0>"3AO55-O8+,=\3$?]0%E'H(((X!2_?%1
M`2(9P*`,_U$&,R`5CO8%XC<A,`,":)"3I85@.4,A(L`"&X`&*6(;T987NL4`
M*),!ME$!*-)$&B!.5E`&2/E%Q92#.3=0./`A(_`$2Q`#9D1T$X`'>/`+4DB%
M+K`$7?`5HD&4>8%7,*9T.A>&8TB&P^,'N*0\%[4W+?@*%+`%3:`F#>4LSL`,
MTF#_*,>0/JR$`=+0AWYH><T1B-S`!:Y4B%LP!%RVB':7#T?`#U30F6%5BL0R
MB::"$*8R$H*'B82GB9N(55FU59X8BJLBBGGV$D<%$ZCX0<]@0L1U!A_HBGE!
MDX)4`^`2+AE@6\)T+FIA3;CT`>,4(@A@&=^B,`&0!`GS`@'``P=2>QD#:^HE
M!GF0!YEP,4<2%ZM1%HU1`X9!`]S(3`VC';EV,T!``PA@&&@0E(51&[+UFTC!
M`FW@:[91%_=""/@X(0D`!%808'C1<#0T!O(I'V4D&;A$<-SV.U<$:\:5&93D
M-$.$26'321;9D?!V-1D9HN)A7=PUD1292C\@&18`#`0P_R`<.*&P(1D`@@$&
M)PZLA`.'88M4H5M?`!D@A9.>LVFZE1<W8#"'`!BR]6!,PCI`HH$`Y7TD-ANM
M\'!$=QP$U82P$1E=L`1A$`8NX`+&<`C#N`44^B%3""*@<216$F`H@D,]UP4`
M!81BZ'1T^0E_8`M%H0JSP3I'42-^.5$#H!R"Z4K*H`QYJ">'PB?8,(NH6#[-
MP0RZ\`QB@`=;<`.7^5-?!BI'T*F=Z9DM49L!))H"P2JE24$C,7@4,554I9JR
MLJJM26=U!IL',9NC2(K$4GFWN0W/,$)/D%"4Y)L%LPI#L`7>P`P34`(?8(L-
M4A6YH2\`L*P)H$-X\"W,J#`KM?]%D@5K8E">9($!-8"-^58D>,("*P@C.Z(:
M<-`&L<`"6]`&%(".YX:>;3`$[MB7+%!NI;4(2WDS3ZD!<-%,MB$P%;`6UQ(A
M$S)I7T`B:9``1#`&-*0`0\!8#'D9`9`''S@`#<EM0',:,,-(=C`G->!_F`:`
M6?.AZQ%*7=-NW:5=&ZFRI71*#C@V*XH+:(,VS2!7'^M7=<`B'4@@(28DQEEZ
M>1$91.9:I74O0Q%(01(9++,A!,,ZL6`([/,[_-I$NH4M$(`#6-%B'H(?]F$H
MT2"%41`%8?H'!V*U&^*.XU<DE@!LT248<&!/,E`!-+`E'M(%FF<XGA"F9`@*
MLZ-S_JK_6T=A%*Y0K$W0!66``Q;0+(>2#%K4#'?X)WW2F'\8C<:@#4>#4Q20
MJ5[F`)QZ`$?PJ510+*%YN@;1#Z-:JJ>R$+`9>)EX5:WJJ@S$B;+**@R!NXVG
M9K)Y9AC$0;JZJ]G`%'Q`0BTV=05CK[/Q5N4S`0Q0?F[`(&Y0N``2K<N37YIE
M`9O1"X68$_17&M`D1-0('_)!&L=EK@WC@!SW1P[+`,Y%`:^%;`)C&$99!LM$
M`4IJ1P&:8%_`?"Q0!O@[(FOACOJD+GPT`T>:?@\K3&[`49KE"_RA;6HS&0:I
M@0%@!\X%`B1K:P`(2M^%LMZAD0:(@*0T-B][LBD;%][UP4+$_Z(P>G3F-0R(
MP"(_M"7VT0550`YR);1ND#>L`QMM4`)(6Q=.X*2Z$R`38!?[A;4)1B0[P`=Y
M("6Y$5`J0F0YU#M<N018<"%E]$4+AG14:`G@ZAI,B:#U6('?V,%U,2,W4*^3
MD+?_I"XC8*=ABF-&\`=/(22GX(Y7UR8UT@`>M;43P!EVV#TP!0W(M0S1$+Q_
M")EWP@W:6P-MX+GQX`&<.KJD6[HL852C8HHYL,E&96=/)4&PBRNT6WBV>XE;
M)<JBC*N_.RJ,++S+LCZ^<T)[7##IAQ3N\PSR5P;#Q""X*&$`<C.J0`.M@0$Y
M!1JD81EOX`N280/HB9,B$A>"(38@(/\:3Z@D("!$\W(6C'`S1+`70:R"BK.#
M_,M\`^MK(X*UDO!PT+>4^9(B%,6U.NH%"J`7"0JQ;@`$$VM(Q!C!I)$G`LTG
MW-8??2$&%,`"&PPUT85)#2B`(%RBH?1=).JRX9&`7H.B*1H>/Q!>>R(@_68)
M)9E0\E<'VU9P3(9P,Q"]]WR4(B`ATGPO<,(DNJ,?58`!,!(FTX1/DK`B9W`&
M24=<H/48)_-B6\F541`E)0D:SP%2(O#3O,DEJI&T)5*WS:05(H"NV5$#,@(+
MT;,['I*$Q)65?4#'H!`%?]`%&:!S9;`F?>P%-2(">&`"`,)(A2PHS6`,3,8?
MRV!VNRS+#*G_N8TK!C30`IB2*3\U!:"+#YB<R:%*9GLW$/_0#Y!(J@_1*A!!
M06]VRG!&>*WIFDR%N[WKRD=UBK*<+$ZQE0IU"D.1?E[0!J!'`GV0";XL%5/1
M"NF2D*GP`?'Z.YNF,E@1KHVQ8!.P,,$((VT$,$H,!T,2,D/@!,?&<0,CH'!-
M<>56%Q*W)$]I!1`0KHO@6F_$"&W]`71B;3:``$)CQ5.2")$!4!5U6S20S^ZD
M.RQ@&3?A/4`S#K"F+LEQG39A!_O'`.>&;M6Q(Z<$T1%]@%E#T2%:@!M);Z8D
M,N]Q;_4R`LI0)$='7"L";NJ%(!22MS`ZI[LA%83@!>Y[<C!2)4U4_S"0``$C
MT`2N-$?#+"2Q4%`]E\5_P`<O^DC)9=1;N00_+1E'\D>YP1;M+=6!@0"EQ085
MT`9*0DZ_LXU#!`)XX3Q-!(0>\D\%-0)_X+=A:@154+9&$$-E4`?:HCPM^*<L
M,-?6$D;?9@)YL`R#0@(G]2>"H@+3P`V6:WD-J0V-BP>%?=A=9@"*#2H<D,F:
M/'F4W7>E,MFC4MFE^HFHF9J<;56I#!)<Y7BVJD&E:)NG31-90`!I14(GU-:<
M-P3-T]WKXP=?E`',J@!0,`1M`$VBL=8?,`1L<()"U!HU(!J,%8%<8@,L(#C;
M7!9C$5O-)`E`283O\3G6%*`Z,[&%@6L\LO]I,G,Y)=@`6R"#7U%$0W(*%.+,
M6["F(F,=;[`#(NYL"J);,S!M#KLYE/%%AX,5%!QBR)$^XY`%'B,A3+#0H&3@
M'HS@"7Y=&+G@)\R1!-@C/:+"Y#L9$F7AOO-AR?5%*C(9RF!P0:L!P-R";7!R
M@O-R*UZD.)"$\\ZU$B(:[LH?76JVQR-T1/W2J%<D@@:NK$&P=9LO)9`A(>-:
MV`$"%!<][D@DB`".@84&2Y)^@^`$;5U<_090`=+E7UJV41#F3Y>GA9.0U])C
M7M`"KA!D!&`+%8H,>?`,2%;GQ;#(W[`#YK7G?M;GV7`9#VG8];.(A+[8^(#H
M9L9!D+CWD]WW167_$*\2VI-NRI5>59>^*R/QB1<DFP1D$K$LRW$3`T?]JW4@
M%`D`@FT"`5L`#7`78K9UVU:A0R(72&S0`!D``F.!';WNSFO4-,7&S6,!>P6;
MO!70`XOP'INF@ODI7Q`P%\$H6"-R)=P=1C90+R>X+OI"9%J!7/Q1B'T1`-S;
M62=T,^J>3?)%%5Y`!&UP,GQ]#`!U2,=P""@6)@UE![4`'?1"'7-AX`:?X%I3
M@/%V\/*6T1W:H10>@38+#)=``'$."%T#&0,8&!D9&`0$)GTQ,2,X&65$;@HS
M7EX9#1@,)0P,&1"C9640)0,CJB-=&!,3#2*&$Q9B$X]+2T9^KS6Q`P,,_Z00
M#`TC(@,UR@AT:"!P%4YI%&4#R"QT=!L_&RQM0PD)7PEE(L@U&\_37U]6,^(`
M&H4CD)(#,6%A<4M1449&+OZ)J(-C`(XZ`(AD"@%%'(,)!$0`&"!&S`X3)%20
M(,'#Q`X+)DQ8V`CRXL8=.S)JW,BRI<N7)+ALY&$C2Q:7*BQ4",$SQ`(4*`P8
MF.(@!X>C5)(J/<"TZ8$5!Y`@83H528X<4YM*W?H4:M2G`@3X6.'#1U@?'=*J
M[2"AK=NW<./*G3MWK=V[>#N$W5NVK]\5@`'W#0R5<.`#(V$J7LR8)8^1D$8\
M.2,B`P``X89D@B`BY,8)#+PH4`"C(0T&(AHTV/^"H8X7'35*R/@Q1PV3'V\:
M,*A0`G,--$/@_."63C4#"A1*0&@#@@6+#>EJ('A6@0*[!!!`;`%6@\XS:-,2
M$&'PA@?-W-94<W)5WH:%+!8LV)C_!@$&<RP,&BPC.@&%(>"\`\YX",1'DWLF
MB%".!3N\8@@&!PU@@ATJB-`&`FH,QXUT""B3#0(@(@#=!B*.:.*)**:(8H@B
M@C@BBS#&*&.(*[JHHHDQDM@B=+AAT`4)772Q@RHD7'%%#(.(4%$)Y009)#UG
M#$)))6X0,4,B$U2&R)8X%&3(&6<L$<,??&R41P/6C*">.5W$T,42QZ0&`@@-
M@%`!#3100\Q]#"@#0C;_SK!`@SA#E($:#GUF0P<<3FCF10(W?#$1FG.F@=TZ
M"5AA10*7#7#&$S%$2=`984011S__N!`0`2,0@LPDF7C!$*0T;)%%%X96A-$5
M+'GDZTL>$:"19XT5*Q-'\]W44DXL].034`84,84'1G%PA%+8.I455UI9A556
M5W$+E55@C47666C=1=>Z[+;;5E[PXK77O'[5^]=A71F&6+'\\FL3"7^H\D04
MK6H@3CA>S%#-!'E\QD(""KA1FG]>(G,&#EZPT(D3&]0V7(8#I`%!*0WTT(9P
MW'P'QS3)M<%`#XN*2,=T<,`A3#A?I*$,,@-48#,H)5```04-O&*T&!;P$$``
M_U>X9T$>[DWP()KJJ=:S05U"H`$,[Q@<#@4RW#`&!5LX^.!]9>#@R@0H>70,
M!A:H$``&$/20X7`;<.CAS#.7>./?@.-(HXTSV@A=X8:?F/C?(/8]>(D_&`(D
M*UV,T(=%E5OSRD$B/%*%'S'PL<,`H\Q@I1M`N%%-G.:(L(H(72SB0CZJ+M(@
MF@P$$S0$&<`>)#(U_UD#"#I4(`,-X)`M0@E_:I-W!<>%PVD)N,^YLA-.W)#`
M#%9\H8$\&`1301HEI"%RIC.\8XHLDU%61P:DFAI%&*FN>@@.(T@9:PL-W=#&
M%A;H0@9*0(N;7&%8%T%)2WC0*Y%LY%?]@LFQ#J0LEO\PRUD_"8JTJ'64:V&+
M"E[IUE:DTJVK?"M<49G*N%3HE7/M!5YP88N[9LBN>-E0+_,2BUETR!>R&.:'
MATE,!(?H$INH(&`CX,?%-`"`<23`"PUA0!<2LP,10,P24+!"<E`C`OP-0`,R
MJ$$TZ'`WO,$A:$QB``(8`(=MY(TZZSC%%N3P`]6`B$[08-+W^O0&&TQ`#%O(
M77I4HPPQB,0F\@D`#YIF"T.@21:S6%X%YD1).&`-!Q#X0OH2,`3D$,H+8Q@"
M"[:PA8K$QP(0HHA[=N`CAEV!!RK(@@HFP!PZXNU#>V/&X@+'R\.UB$4Z\N6,
M!#=,%>W2F(W[T"]Y5`,,D&#_2$_*GS4,P8H))(EMCP!3E#)``2)$+&*J\Y0V
M=W`&L[FB<F>(03_\<(:J`6-ER($`#F`7O@$$CPXU@,,)HC&.&4#@/AD`P8CH
MT`#D?4\<9=@$,NQT&6EHSPN:4I@L!D&#"HS/.OT<@Q72)H)/@6D@=1A!%'+!
MCW^8E``"G*>4-!`K3-R`:'BHPD$F8`,2*,M7"EP)L'8@+!*$1(A$=$E-8&*#
M9O5D`3\I@E(Y:*T/)L4I3,%*"JM"0F^94*HII`I36OB4'88E+5]52PQI2%:Z
MV.5=-\1A#OG"E[&8"XCZ`FI0ATB`F/!!8$N($F:DIP$B)*`$&!##1OPP`@@`
M`09N_\CB%[8(C&,`H`0(:``%0%#&'X@1.2*C`1.VT("!U@R>DF*`#0I0`#&D
MYK,6+0$BU&@!87U$#(&5SWR,=(6E!<`&C<2`,H9')V1\`@0UL$7(X$"=SX8B
M`YCDCU]O``Z#;2H<(&""TTH2/B79HC+S'.W25&`'/)2@`C:PY0\ZE$P9]?*\
MB(.1,(&97K^9EY>$8T9WG.>\O,'-!/2`1!?QEX<\["`&5324,9QTABJ*8@:C
MB1@1-,``:CJR9RRP7@G:4(@)5$XU<QH>:F4@`PJT01:@:`!Q010-2YF."&50
M$_.:8:<T.&%[;MB4!C;1@/%YCP+\?&+Z-"&"";0*`N9S`O\%I$<$(DS$'![M
M0F6J@0M_&&$11FA"$V1:`G/@H`P:P$0FH,!<%N"A"3-U3TT]@I*4Z!0G/N7I
M`TURYKDNI@$A:,%14:#4(C#5@Q^$ZE2O$E6I6J4H5J7*MDC8U:VV50!@74M9
M%]VNM+@EK6I=*[KZ(A:X!L9<^W+S7%60AV,\04P2:2*`Q*.!_PF6!'V`$!$0
M.['E(,H:$H'`\":KH91Y(CG4LP$>&H`.-'SVC!#H5`!(6UH1%"/#RJ!I`1@$
M)%EH%[<5>848W',?/H$`1,/[A45]IAH<I*%FX[.HS48A"2PKA*_L8(<7*D!*
M'P5):IJK2#U'$&TQ9,$.64!4%L3_2UYF.`Z8Y^UE>^,+\($7DT0"3V8V#O<B
M#)@`I4:H`N6$Q$K754$B:KL('Q[1AU8-&0BC48@&J@R,`<1"&!6MV310X2,U
M62_"XV-!=1HECRW\5CH;H(.EVO$H)KJ.`<"M#@6P]X6$I4\#^---&0"`8TRE
MSTIJ@P0BE#.*+XR"=QW-GV3.H.1)#,`/?W#RDPD0Y2DGJ8M8UC(4AW"#"GQY
M`'6@Z7L8T;9B(1`CS\2("MJL:9?`6<X^^4FTIB6%#CJ5"GHV2E:C<L)PF1!<
M.1!A5PP=EG,E6M&,SGQ<'`UIM4@ZAY1^*UE$;QBY]MWN&Z',UA4D:@!]CS.G
MYD,7<.!-_RQBQV7`,,=EME`#"J",&]XQG]#@\`8YR`$!Q(5&S6Z-BC<48&E@
M"(#4;&">I=%$::](T`!H6I\.K<GDL7`%=S(\)Q'SYA2<\,0DT8`&$8'`$_)4
MC@:`\(YQ>$$#5L@$$6I5H)H6J8HC@`>X)36K8!`B8`$!D`7'@0?\QB'*I%X!
MAU[II2,0^%X4.$PT$C@*QS<,YT88P%-=T`<H%0,;@5+`X$QTLPD6]B0Q(`)#
MDP!NX`9C,`/?`UA98G+#<R<54"<BQ@`%T0H8]B?I4`+80RA$H#:@T!W.P"C@
MT`(]!S[`P`)!8U%.T$_<,Q&M@`,```$6A2E6,(/E0!FI<!\E9_\.E!,#<#)/
MJD`9$?(')O4/9!=E`M$[D9!VL=(_;M<$`]$`"!(2;(9Z$!02=<5WIT<"?\<3
M2*5!'B`%A7<$>(8M(<1X5$456/%X.0!H6^$`#C!H6]44.T1I.*0NFC>*:-5Y
MGO=YAV8N]P)$IE>(BK%W,0$G`M,JHA8.+%4-2',2`U!["M`0RP$*7/0%'\!K
MM,8--$,^5E<#SV<'`5`#P9`:JJ%;"#!:T6<'/%`1PQ8!S^<>MH!;&*`;(K`,
M)*(,WX@FP<"'8G!L/D-)/2B,":`QF-1&Q.%K:2`I):`<"#8#0^`]!I-EF$`#
M",`$M6!A/I9[#V(TX3-/",@#+``!""#_7GF#;?^6@1$(7XCS(A1Y@1-8(W[#
M./[6-_7%(Y$#$6UB!$'"$M:4"B9`-^5@"(_0!7S`DO.76%[@/1#`"<B@6]XA
M<Q$&#17`.TH&=#R2#O^A&4/0!@F@-CVC#-4A?`G0`F-P?^!3&>7C,_68`%E6
M9``@`G^`).]SCR,C*9?1.^&3`2,0!BZ`!4,R<7S@"&SH.JSP*@/P!V07$&,7
M9570!*V2"G#W1'=(*Q.@EW5`$;7@*[#(+PC44Q#DBBUQB(&G00[`B$UU>)%(
M:'RV9U>%B7^&582V5:/G%_,BBA(@0Z2X:*:X%JAX%CKD5811%I>V`JW(F(K!
M!5BP"F=P"`;C_T3?8RAK@Q(BH`$14QI>T$GW*$@),4DT@#(=`@WPQP!BL(P1
M,#<8T$=*LS2U%0!VP(RP)0;#]GQ2<Y#65`R4`ATS8XR^X`DL`")L1%SU]7[6
M83H/03I_H@X4X&+B00$W4PF+-03?$U'OP`+KT05L4Y8/$1]Y$!(6\0H\D)T-
M``%SI"$YAVT'5Y&`TUX8J3CNE2,W`G`>J2A\TY'#40.Q8V$HQ0H8H`IF:`BB
MT`"M10"0$`.'$`\QZ%?\60U=!'3SY6N3-&3@D&++`P?-P`(N5H6/<I1#H#;+
MLQOF<R?@8`50,`8:4`UH4P+@81U8201`\`'PTX*M@P,E@"BYDQJN4/\9`Q`'
MIT(``9,F(W"B<`F7<3D(]Y`J;RB'!'`_^6,9++5E7D`!M=($*24&>&!(>&=!
M@/@1&F$2LLD2#;``@)>(T1*9C7AXB)=X4L$!6U&)5Z&)@):I6+5X7?%6H)D7
MH^EHI6F:IVD7J2D6\T(8E488L9FH+L$%+O`$:W@&&<!$!X.5>V)A:]H`5T23
MQ%F<EK%_=L("RE`UT?@&PQ8`8+!L$Q``<Z"-UI<TW*4"8M``8O`&;_`#:F`#
MAH``VAI9S?=^RD!<W=$A[P<!Y$",:8`&M;8!#5`"US%R$\`"7P"DT"!D,E"/
M&D`,ZEID-U"%?94^4*``7M``TTA]*O`8#3#_0#0%6]-46WO'75MPDQ"I2](Q
MD1U)H1*XL<$D.!AI@1CJL2.K<+IT(N,%-SL0._BU7R-P$6PS.IQQHEU`&4%R
M90F0.N]``8^"L%T$7,W@##96DU&:&E2*!A6P/0'KESV7"'3#=%TX9.@S!BC6
M8PJ2`<*'$)CQ/9O`AF?`!U@`"Y`D)!:0)5TB`F9:!28H2/F!"+`F&6]*"#$`
M$*L"95&&4LAU#%>6IU"TIVW0``3@!Y(0;662$QM!B(3:$L'R0`Z4J(O:J()G
M9Y+YB-FB+2@T0IBJB9=8B47!F9WY0ZZY`H@6+Z5:JFQQJJF*+I;VJK#:$ERP
M!+3J.EJ(&>#P1$/0_V!L$R>&%9SZB!SWV!L?0`2^%V$=$ESR4;86D`2DI4A2
M8P$1\+S2!S>GE`6P4`.Y40/#`2*U5@,,T`;/82??T1TDDD?B,0/I*33:T`P^
M:2G/=9,#X'L^Z9,"2PQ#5F3[V5=%5K!><&VV8#19@ER!9;9J4ULV<6\3``$#
M(%X_@$OXI*$<JX&%LUX9&K(2C$P0'"+X]"$H^P8J*P(7@:(]E@=2(Z`#(*5M
MX@="8@(#@!F5<&X&8ZR#0%S.P'Z6@C/D8`W?!0)I,`32(+7YUU=..S)*&A[X
M-P-9RAEH@BB_BP@%<8)5A#^HTK)CVW5J^&FM@`QU4C,RT$G`*`*T6CG8U?\%
M<BIE<=@$+BH)JK"WCP)%,X`<G4$`@Q!<@ZIIBYMFK!M4CRMGCBJY'42Y3Z45
MFRL5WW*I17$"F_EX(Y15@-$4Y^)68#6ZHEFZI8FZJ5MYEV8N=YRH#!03\_,$
M\\1Z\_H.J+`>NE-[$S,$HR!_P?L%+,`&"1L`T'N-8E"=`0!;$]!':M"MJJ&M
M;R`USN:,P%4G)I(;6)8=!54!V/LQ/Z##\LI2%8``-)`=.HH<XY,IKT=*YF,^
MX+8.3'0<FK%@R$$)"C`&8X!8-*`:I20296L-T\8@;^/+$Y`%`>!=)?`#!0"A
M\X5/')*1#\R1!I>!&UMP_M:1A'/!)NLBD+,!#I?_(%T@<3O0!WR0!Q""/UDR
M$18!=H^0)::0LT!09`!2#/'(?NP'!Q30GU9@,*@@/MLF`TYDBT30.\M3!N6#
M*=_3T=4`#//$2IQP!FLZ`7A0METT`)_F#PE2$-#8O3+-"9.A&T"7#<1S)S1P
M//A)JVO:168IIP30!/\@94W`!Y(@NTNWQHF%'!)"`@K"HA74=X&H9H=[>GF,
MB(K8B([H5'IF%5/A>-^BB2>PUY>HN9?J9YWZJ:!G%J(JR:1XJJB9NCXT&+#9
MNHIA'ALAJV'P!(106$TTK]B!&FO:)6F`8*/A!CT'`$OW`7VE`2S0`]8[6L]W
M(-1G'F(P`A/@C#60(?6!_QNXX0L]Q@.1)6+L"1U64P;T!Z!<"*%+6(_7<<["
M0%SB5C-6JJN\IQR3!$>9Q$1@Z05^E2<)D3I04"4O4QXT$1_5]4>OT`KW<;86
M(`<*2`'%A\\SLUL0V,_^_,\%34P:29'S[9$8_(`Y-Y0.9P&PXR8IP2L7HS82
M+=,^`B9MPDK+,015<G\`4@+;`0%`.M(5T%R:LF`-%J_?-CY5*#W;@W2NT`FB
MD$F<(MJFD#LP/0(F`!_DU$IX8+:I,-1+<!_0R-S$:0U/T`ELA`8L5CPR@#W9
MPP!4K61H7#]R6':+D"3Y4PK.%8-D704D,`)E@-:,"4&(ZHI_UZAQ;2U^C'@<
M`/]5X6+7F]O7>ZVI5R7(@]RIK6DOD%S8AEU#FX?8CYR:]A(8F2R;_L<%44"K
MN1=LUX&54<I%D7"/GCT:'4T$'Y#HW_,!,T`#HR0U9:-;O#R`AF`#NH$.R@`=
MF1Y9[%P#:5`!:+`-&A*ORF'=._K,R[D;O-$.X0#A\;I\Q&4G5EJ#JP$'`[3-
MS?P!CX5)7@`$>RHT?64)3JX=98.07B)M"&H(LH"`64`Z"'#/>'.NN<2A\!VR
M\KTX%6B!][VA,*+??L/!'\$*;A(Z#:)DFI."'^@'?#!V&%`&`.(&F*`!_.F@
M#8`#<+"$3"H]5K!@.'!RGWY1WB.5_>H[9'B/;?"E\[3_&F;+IB\[)*UC-8C0
M4>D4)?TN(L4M#4[`.VN:.T";#?D*(."``U3M8U_MAK6CU4@>$;VS30#04FX0
ML`_!*M7P'K+Y*P=*+&X=9W.V07)]>'5]B=[B+69^B6:`B8ALUR/$0H91+VT>
MR6].0W*.JJH)>JSHV(J1&+1)U:I@&>SP/7V5`*A1"(-0`L#Y3?2WFZ-=9!#@
M')SE@Y_0`&^P`=JZ&GU$2,@V'>L(!\NQ!2!PK[6&3SH\,N+A!"!0GZH1Z]!@
M'2?-8&\0&SN8Q>>GKA\PY?*1&UZJ6@/$.\BU'_B[6)H$!*E3">]8-DCCV@8A
MO;5@"--V?3R0!0VJC!"*2_/U_][5[DOU;:'6;CB/,\$6V>T?NM\\X@HD8&%N
MDL:I0-Z;LPF/@(8`1C<`8B4T*+4`:D]P9*774;6].@!!8QWQP$1E0!"MHPIG
M<Y#1%M3(,$\TCF$-26YI,@B3Y-300`-.L*^2(KL#(")XD^^>+_*J``A=&`,9
M`S$$+D8$BP1-C",9(F<B&1I>"5XS;D,T#!,$764,%EDDIJ>HJ:JI*B0F.R:F
MK[&KM;4-(2TANPLH15-24AQ'1U3&QU0'R@=(2#D.#LX..=34)R<.9DK3U=/-
MSTC*SN$KY3X^Y@+JZAWM[AT2\?+S]/7V]_CW[_O\_0(=ZGRL6X>NG,$5%FPI
M7%CK2O]"$EQ</!$Q8L2@,E^^:-@X(T&%`0,&E6!0!HB"DQTAC&0``8`&(!!8
M,&#QHP:#"A5*P*FQ84,#%@ALB&#0`,2/'QN.PKE9XD,"$#4H5-A`!PT(.%C3
M?$F08`8%$&D87&U`IP:<"A02;-0PH,86!C@:-#C+H`2$,AH`E,!@0HR8"2)`
MBI#;`,,$,1<U$"$RA`($Q4`Z>AE2PX8-"Q;\8L`!@8'A084F!)##@X<=.UL@
M-"@@Y^@/.G00U*@!&X'MVSUSZ][-N[?NV\"#"]\M',%OW!N0^R8>O&QM!+![
M_I@P@<2.+C&Z=!&!PQ"!/#OR3,!19H#V,S'\$!##8`B$&3/_B&B@,$0#`^X5
ML%9(0Y]K@@\`F)<=!MR582`$".(@PH(5C=!%%7WD(0:#&&#PTP`,9(##"-P1
M!8)M(*!1P0U.I%&"A@/@4$)^6%U5`0WTW:#6`-P-\,91&X#@A$8:J$3!AAQ6
M2`@.9Q!@A"**-+(("5UTQUT=&LS@129N)-`)!DU4D4$)8I3"T)<DM#*++#N$
M">8MN>P20B]%>"`,,<4@D\PRS$B3@S-F6%--#DIH0PTTWC`#33AU'K#",BN@
M(Y``Y[`#T#[Y1"KII/;T8^D^CJX#$$'G&(3.0V>&FLH5-I@2T40-#@!``ENM
ME<!](8DP$@0FP:"`%Q0P<!\<&-(*_\$6:&V@!E5TY%3!;`U0P,(;+,$AK!K0
M_@"675NQT$,:%<`&0G[;:L45$118!4=M=.A7`H^_XF$#`D/=5%<&=ZDD`@:"
M4.>7#:3^1=T.DU2RV!<44/"%%T1(Z84&+%2H,'4#0)!!`YK1.$%FAV5A!QXQ
MR=':4=#)1EMLP2TG\LC)%6>R;<<5U]/)QI&\<G//V4:'='\18,*#V<6`P2&`
MS=MD&2+X<20C8@S@GF*+8:)!!0UP=E,:3@C,ZD:15$31@AC2V,"\._![1H,C
MG&&A8`LR0$$;;9004@-;P@$"'2"P`(<,3I1(01EQR5I!B#.#P``-0["JT88@
MO4$5'/P-W/]11AF$/2^!&HYP))*+.$(`"3'@H"&\`,Q@Q91N>)%&&A@<J?D$
M7HIJBY@F6,`ZJ*J3@(LN:[+IYC#$R&G,`1S4V<P)=SZS)Z!F:#,-H'<V,Z@X
MAAZ*:**,-CH0/Y16;WT]\$APZ:6.NC,0I^=\&GOL/)0*$1>H5C1`&:RJM58)
M6Q,X:ZVWYMH='(4-0,076\#Q5;1(J0%(!E`"#90``0VC@VLV4`,0@`4"`1O"
MWM+@++@Y\"S>"IP3K+(WJESE+`+;2`5L4#X;V.1^@I$+`MY@`9N]P@)7<`AB
M%H0U0I2!"`I(P!"VXH7(=(4(%<"`&%K'@P#P0`0.P\!E9E@A',3_Q087:\,`
M-+9`D$&G!L-QF19S(YR8J8R++$,.;EKFLBYB$3<S2PIB3'"S*G1A!":X@BD@
MD0&^B*`\,<AC'KLP`18,X0:*F=*4["-`!-%G*ZRB0%AH1)&*=`$6!+J:)&E(
M$9#@;RYP8$$:;A"P+Y0@,%O"22994`$=R,`_'VB#_,B21CBT80B!XV0"'C88
M!("%`IS\@A6LH`&N-.YK%6I:XR;7!,M9C@15P$$=G)@!`!#!"EUQPPQDD`81
M'*EA&,@"%\:GD#&Y8@>7BQT!9L<+V[TI3KI;1C-^%[S@'2\'V#">,Z@Q3VD0
MJAET8H:A.@6][E'O>@"]GCOBL;WM?2\@_^$3'S=#%<-3<&$)(WC"$R;QF*FM
M!0(T(E!W2H!#D\Q@"&F#E5RXP@802.4'>U###Z"%@/T(C`((V,(!D5(NK"#.
M,8YA`1[FTA-M8;"BHD`6T[""(175`0!U$`%U#/,7,;S!,F]XP[UL\!<,5$0N
M(-B"7`88F+J4X0-`F(\.(?"%--"@*Q5`@+Z6VK!(5&@".SC,('"@1#!D05=,
MV%@`KT@;X&SQKR\#CA59!L8PGDR+,(--;)(CG3=@`)S8N5EU3`&8D$P(;R/(
MHQ_X$`L,("B04UJ,:AH`$ETQ8("6G0`&OD8A"U7@M*]M`X+N\YD!L,BFB+M!
M1C10A@K9A5M8//_+62]JU;@@``TWE9$7H)D`(JAF$+:-6MUT:07/60$"(XA"
MV+ZF3!$L`DE#8X011+!,0FC@`[W4A!N<<)\J-(&\&.#!0A72-5IXDR';W"8)
M+,""%M!N`0LP0)O.205T[HX#'-B3@N')C0:;@1O)>P8WPF'/0AWD((ORYT`#
MRF%*;;B@EOK'I@:24(3,5U0/X8)V)?H$2&@@(US92&="HMH&,.`E)B%"`BC0
MB0$V``)>*"FV5JK2E6X`+0'[%0(84`.DY,A%_&E,'>T@!K(@Y8,Y>0P`'G:9
MV6#HM%R=UP38:`("7*$`!0A``&R@6K%92"X*&P`%9]/`GY!25W7XP#/_TW(#
M!-'@!O&A`)P-LP/$G/8P)L@"&S%C@HD5,0!#P8->&<C7D`'VKXD-8V$-^T62
M-><VBVW941X+BC)K1Q!6I:&%((`#<!Z)#[#V[%T*IM[)T&@$A=;7&\7,H1HN
M"),X<2DL9SR4$F"+!M@*]E8T`@`AUN5#*V,!O+AREX>-8``LT"17;J#<@YVW
M#85Q(@-&YP09[1(^UWU"%)8PT6N7I\Q'2L30FF"$]VH(!P``T*K4>X/3=J$)
M9ZC#"$B0!=B=V!06\.8+2X-P4Q0\Q5R(.,(K0+M=H$#`M\N=,01PC`-48Y["
MZP:@MH&-!GL#Y'?R^/*4<6$,3^^?V>NPS/,Q_]!V:*^@F3IH^$Q\<#"E&`L5
MD>@(\)V15B6@#;IJ`'@P<&,BF*1*%"A!=YS(-@WHH`?[$99K:H+D$I2A`7A@
M`4]Z@EP,"NP+HP`##T`@@BU@F3,```!=)Y89&UCH,'[)@][S<(4`J(`'N?Z+
M;"Q$P],VX#`3J(O;YB(7N;U6F?FVPE;J<PDO0($Q6(1AF`*0>!&(@:H3Z+5H
M[&!$%02@`0><M,QF8^E+(U:P7C09<XS#Z<".[--83*.HIP/9,NVZ.R.P%YLS
M4,=38^<Z\'H/E0Y6'I#X90);H^20*%*AP!3E@CBA`01@N650EH`"3F!:`W`"
MY/]H0*FZ2B-RO=61P/\!;1(5<((&K%`B&25@EQNAZV:V1.ZT6&(,.D8D1@!1
M7[,^./`)\38YC5!OD``298!4^^8&"B!!Y@%PD4!PJ=-SIQ!7L6`!L``J#X$9
M$"=Q/&`!%*<FO8!Q!)9.">9.R/,G@#(-\>1.$08-)\`,PH,HZ/`\+J<I_3!S
M0+AA\F!S\P!B_D!BYV!P&K@0I\)B9Z`J@J,1.Z8K`Z!:@0$`0/!TDQ%U*1(7
M##`#0,$"%$`'`/0&-O9])=`&6\`#,=53+>)2K-(``0`&`>!8ED08</9478`'
M68`!6S`!-H!F5R`A$K(#5Z`")D`@!!(2=/9FI'5:\R(K#*`?R:8K)3`2&?#_
M51UQ`]KW8IB@8S4@51,@"(*0(H8QBC4B&BJ0!5E@>A.@AJI7::WG>K<'>[*W
M')RF''Z%BX(%:K27&S\@!N"41P20'1R":Z^P5)DH`M@1`WT0"R:P/LKG!6[@
M!O)!(]VQ59HS`'+!$IB5:@-P%CC!'V:%("U11VPSB6^3(XX!`5P1=U48&`VT
M'Z.S%;LT)0D@"2+@+5*Q(URQ2P`2$IM1!E'720D0=[Q%(V>P;MNU/AG0!49B
M!"XPD9/#@`K"'1K"/M280Z_U;SM0"!BXA*GP0OLU)G*$<)AA*A&W33R`!PQ0
M<2E8!,$`)^G$._0D8=4`/-?P@MD0#3B)DQ068>1P_RB$LD_FD&$B!BE`N)0Q
MIP]&R`\'Q2A**)*V@#Y.J"J>&&-E,!*1N""THH7N@70@86/3M`%P``%DJ%(,
MM!3\(6@V``8V4!@?!`(8XG4`P`!B4`!@@&9"$8J681E]EV:&80$T`E55A8>%
M<6T84`,XL!-EX4!8=18C82&ZPB)O@P!G"4$I`@%@]5$T4`+MHPE>0!2GN`.8
ML07=(08EN`-O%7KS4D1B`&YZ]0.K-U@H0XME5'N\D8N'I1R[V8O041NZ$8P3
MT`3900#7X0>;Q0?<,7><@0%\8`1\\`<[D$?2&!].9XUL$4D-@"RZ8E-I<!>?
MU%5F@RV2J7T)T!('2`GC`O\;(A(XF<`J=PE]X5@!.U1_NC1(0!,#2*1(Y$96
M]V<%1-!;T)4BQ.<P3G1K2S`)74"`_?*01D*1\G8D``=\S5D'F""!5J`K(]`$
M?.!$>7`95)D0K=`U#V&BJC""+(D'-`"3%P<,4J!Q<F*3PZ-@#@`\,9@-#X8$
M/0F#ZT1/V)!RA<)RZ?!R2JD]2\F433F$V?.4WO,]/C"55+D*#Q51$W5'6>D^
MA5`8-9(!.*0`H=,8/48C7W@#=/!C9$A3W7(N&5`#<U@`569X61..(/`&`5``
MIA<`?Q&(:%8:5_!YG!=Z<?$&MD&HB-F%2C0(%X05<I%)658"LY$!%#`N"X0X
MLP7_+R^A8T/@$E%B,'5J&3P00Q:``<2'`18PBE:E47151!90`BPPFZ!FF[>)
MFR+#F[,:,K9*1KZ9,C+C,:PWG&_P"3$P`@3@!UU@`@PW=)YG`^MC'HZ$'<Q9
M!D`F)1VA%@K2'5!1%N/'(J-SB8>'(0Z41B#P?5M1;<7U(2("?N66";QD0(B!
M`^J*+5(CH#.@`77T!Y!05E`C-><%("+`GQL25X17&.B!!5B@713AH,T)D1(Y
MD?*6",;I1!S"3)@P`PI`!)TP`E7`!REB`B(ZI:<P"Z^3"BI*`E35HBAX<1EG
M8!W7@@OF@GVR#<338/#T<3@H@]2@3BQ')T6:E.]P<TN:_Z0`)81%&'-..F($
M(:4@BPHJ%E$+>D<`L&SN@U'5AXU?"@,?Q6.F14`=81404`,J56=9AE%V:@=)
MD`03`C&?9P&@JF9^IP+4$8AJ$`$\4%6+Z5@T-!<*1"Q4@44"1%=V^$%81!7T
MJ!%?5P,0D`9)<3CCN!6]@H4)(`/:]QCP`1]BIUH-8B&:HU2190'BL2`8T'=9
M@`,,P`1;1ZC!*:NT6HNYVKJ:YAN?%IR#*VK!:C,C`&O800"<-0EBUJSIP0=+
MH@(8(*V8@(\:\3`8T@!H@`;:4@&D!#!V,2_I1W9G$3B)="(5<EK;PDETHUS5
MRB7C`0'!YBWW-P-`\`&>`%$&"O\OTDI\D0,8&Q(%4?`'?7!M%F$8,7`&K#4"
M"NM$#%N1$>H"'BJQ0Z<Y7$&-8Y`K(E`%!#!T@*BT\Q5.'FB:9$(+#:>2^W6R
M+CI@N*,[1T"C+RMA.IJCT%"S[90#RB#"0NIQ19E/!N&S/RBT,LRD17NTWP/!
M4]H*$!$%3[`$83`)1Y41@2-C1(&J@_`!)Z$`F_B9XD8!EX`&-5`"()`<C%>7
M#(``::8"!1`!;,:G:&9$)*1F*L"?$U`^/U``CL54L\$=#6"&SH*94TPL<),U
M8K`%&<`T2;%2TF)L%)`7W;DB/7%+^9$&,[(^SO0%I)2)\`$%UJ@LAM$Z)#0A
MGD$**G#_JJ;)MC9@>CS``&VP`;&H6+:YNK7JNJ0<J[/:&[';JXR5%(ZU"%T`
MO&_4:[(,?86P`WW`!WZ@1W?DC@5S"6G!)4Q7`<O+O,CUO%_0$E68O-4[!-^W
M7/[Q=1-`"/Y9`3+@O?6J`3C@%_B&+5%CCU:0A0"@=/8["5D#9X@&"?%K!/0[
M=(RT(!;J(!7!71L2D0K8L-<$)$Z$`[U$C3"@P-4!":$K7TL;LF-6R5V#"J`B
M<190MVVPP2LK)T?0.R[[)WOR8"6GPC7Z#3?(H^]$*#G(@XEB#MX3PS,LPT1(
M4$?;#@.!PTL;$4NP!`Q)'E_`/FIQ"?`S`9RU`R*`8PH`!0EP_P-I@XDN806'
MYX<+XQ=^80$!8`<J\'>G:@,1T*=^\7!]MP/!5V4(<!2A^`-1]09_6QER40,L
MP$IKN1]V\;5;4`;.XAIP@S@9@2">=Q,Y4B)N@Q;_40B8.@.<V!)$,`:VX@8T
M@``B.$2(@2'401V4,`!BX+9-;0=(A`!ZA;JI.XNBS!PE4\J^V#+!^;JH7!R*
M]8MY#%>@<`C#RATC<,M=DP>D6@(.HAW$V`69^!)3(GG'7!@W$2)HT`/(U1^L
M(@I;,!18D1;@-P3+M4L)\'67);YT4V[%NQ@?D,W1#"_L*ZWFN!>5]01A8`11
ML!T6P4>-QLY.ZP)\,`E$@4GG$A;=T?\%7S.L*4*L\2:A"FC:3^A$[&.Q$_@1
MGP#;(G"2`[V!L%#!)"#0Y[--;(L`%.!?O.`+;D*3R(!@#FZC,&AR@'("]=23
M%(X$%XWA]%1/('T0(@;#/XND)=UA)XW2-OSAZL#2(!MQ/+QN9T`>`$#346)`
MAK$()C`"M'(24+"%)Y*)+@&&?W@O7^RV141Z@"=$=XIF;S`O%(/8B=H6-="=
M-Q)5"$!:&0`'")0?3784*M4`_-$29;`%:0T"*B4BYDG(+_8%BCT4VS*I9O<%
MSXUZ&9`),@`"J&>Q?ST$=MX`%7&*IB@&F#$(GO>G$Z,"=O!C6Q"+D[V+E?V;
MEXW97?39G,W_J[$JG+LGC*``D3ES!CLPW@OR1J5:9HQ``.'[!8OAURG!C>.&
MVU5AGX,TTY^$(8-,;O^X2U90'MP!`.*[KXA$,#W2SEN3H%KCAW]AVG$@;_S)
M2%N@JLS8P]H%$HMY05"#$Y$3SQ-+K-]ESPH("2+P!%VHD2;A$2%!`,DT`"I^
M<"7ZWR3@!ZUSP?I5X`?^7PH>HS)J#!&-8-T@<C"H!"17PL#S#<5#X?&4)\^P
MH^O$LSNX3TFI81\VXD*;TN]PP_W-M*F@8A*UH(9<!D-<K^`&3KI+JE>[XT-0
M!L0')8HQ`&+N5`$0U6O6MJ0WJG*E=;+1U<&Z(*J)`8LZ&X_YB`2Y_P4-8Q30
MHI8V9HZ_8A-&00?\`0?(!9IK@9>;,1)N\U,'B=<W-`-.P"OO`0.V<BLL(.:8
MH6998&.A6\EVNQE5:.AI_:I;5^F4W>@O\^BD#/>I&WM9]!MRWS$H0T;$68P0
M>1U]<#E^D-API3F9I4?9T20(8K%C,`93^*U?H5A@X1_X]S"DQ:W\X1]:22,$
M%#"=A$AJ(0ID`Y'&IQT3@`?P.P!/$`?S^P?;X6-P8!=;^@3#2G70816FY`0R
M\'@-HK_<L<`16I$*"-L#,`E.]!@:((%>\%H80.[=H7D3[]_V56:KP+8U,`0(
MOB8JR.#'<.\N6\)\<CPY>M'`(SPVR*-!$/\$!-^C!\^#RI!A*@WB35KB#A]0
M(9[2F7+N!Z=?J,##/0P(2R)U`!`)APD:90T6)`1\73A$"I0P;C.*&1EE"3,,
M6ULU"#4U;Z1OJ&]B$R,3-B(#&QNB/[,(I@TB6V(-%14@&S\_:C]P:240&E];
M(A0;Q!L@<"`-:8D092*\<`C&<-]IAHF+%A8B)<`U<`P,$``:``,X)1I`5E]E
M&D0P_%!>+#4FK,(P`<,`"#@(=IE@8N"``1-XV,$#@8$<.<)^(-A(I^/&C[)"
MBAQ)LB3)C1L^JES)\J/'E@@ZO@2Y\J2LF#`YROKQ9@*!'5U^CO!#HN@9$2)B
M^!E09L"9+EUB5#'_0:!!F61$9LQ(0"'#@`8,TH"@@P9$!0J($FG(@)1!"7`4
MT&HX!&_`CCX[#$+`MC<#CH<-<B6-T27/CA%(133`T&!`!@8CSIS9<09Q`U(@
MI#FAD"8-`Q%'_XKJ**W"C1L4KH*.''I`4".P8\=N$N-O97G)$DPB4H%!`P)-
M'#,D4+2X\>/(DRLO2IR$B1TFBN[8T>BX#1M;AK1H$2+$`@-%I$@Y0IZ*^?,'
M.'#(D<.!>_=FVIMQ<*)]CA/N[SN8?P))_1QF!.B`?@,B@01[2!R@X((K^""`
M#RL((*&$'51HX8472J#AAAQVZ.&'((8(HH4;8FCBB18*4-UR++:8'!=%_ZWX
MQQ-/+!'%"!D`\$5:BC!"`A]\_#&`%Y10X@81F6SR#@1;!*8..R4,4,--N8R0
MQQMP-$!'9G2,\DT-()S#`AXL0`#',VJD&4T:<7VQS!9IT%'+-R#4P()<APS`
M"P/?3`-'!6SNJ$$)8@2@@ABP-%:")GSY)D\"0$!!03L:C`&#`C#,0$,N&'0J
M$`9[86!"%EG\5,XJ%DB$1PDEZ(&1,*.D-!-*)M5JZT@HY5022UWFY*M*-K74
M*P*R[M03`29T84*R,<0@61=(C="%8R)$1\"URUIE"!%CC*$!!1"4$-@O:/P9
M3EI6K(64/)T%JL%<\&0@;67K)H;4+A;D<90(7?^,,$*GL"@66#L(B8"!9"+X
M1H<L9<'AA!.`4I!0HB@Q@08--`R!2#:5/1$:#J_))AL!5>"``XVXS;5;;R)4
MT80(&6`@1G0NUMQB<\[MP(=T.^!<U'79;><="@9,(1YY1YQWGGKK.:#$@/M!
M_=[3)^`WH'ST6?W>@/45>,"!.22XX`$K-`AAA!.B:**(;+?M]MMJQVWABC;7
MC1P7,)*PHA%+V!C%&3FFY84BVCP7E0@:%)EI`A7)0X@B6Y@%#!RLEO!+,,R,
M(`:6%4P3T@\U\'F0!@R0Z4R:M60&@C40:-P`G,!(4V<U.R:20`,VB,%`!6C0
MH0Z@ALPU@`V&7H&!6W__/32`8JS@D`$$0'A1`5,:S``#%%!HBB\/`03`0PW(
M8%`.*P.,8$'W*DB41040X)%1+5/*5-.M]->:*TR[_JI_2_FO-),L"PN&#7R2
M+*K$`#$XX)=D8D``'`T``U")X`0:L!=(N4$!&DB#7VH`%C^=I79?L`(1LC&!
M'4S@''MQ!P#*<)6_B,!?'EO(<SI%D('`(H&)"<QE,%.!(>PE2K!X#`C*DAD6
MR.!A#_M"S$2`@QH(0Q8@T%@"AA`7MDCF"0<TV0@(8`3@B"PVCI'60TIPB$FX
M@0:?B4$31@`R"T#';G`T#LZF0P(56&!9-/L9=A+`G:$9P`-2X`#2E$:%(S`-
M_T#S<9J`X!,@)?0G/UJKVB+?8Y^P*8@]8U-0V59`-@=12&X9:EN%WD9*4H(R
M;G2+(QSS5HZBN&`)80C#WW`PER%HS`M<T89S_"4"2%$""ESY3"Z<EP\0("`-
M%2`&*:KQEE$T0%QO<`LPAH&Z=92``E\HP033\(QBT``.ZD!+(JS`@AZD`9P-
MR$PO`I6`+^!`##RP0>B,N4YP'8("#5C%0B9`BENL`@&KT)<\*$`$Z3GF"UZX
M7@AFT(8:B&$5!>D4`S*PF$Y1ZWQ9L(`*[!"`,DW@5?#;@/R`5;^2XHI8^TLI
M1X8U4EV=U'^]ZE)*/B>&:T6%``=$RAE^!)4^-*`../^05@R@0Y4)X&!;,_#'
M$`JAJ,Y%K'8)2%<)%((!6#!@'@P80%8)<H8:Q2$*45A"#/[`QJ]4U61^`<T!
M`8,9:1Q1!NR#0%MVUSDT](`%%<C8+2'`P28^D7([\H(7O@`NIW0U!DP,*A]@
MTX0O&N%E&8"*5?,Q"2!0@`4M:P(&$N+&-ZKRLS]ZXQU[5AR@\;$["R`:()&6
MM/.01SWLV5J`#)#(^;3GD0XPD'NJYH`BQ"=J5_M/@@RD(.*2;9-H@]"$!'!*
M49;RN6XCD01.62$!Y!&T<:1;6&,9!1'H"`)0I0`<WA``$OAK!-`#@@*`28,*
MZ!`I./C`F<+R@Q1`HQOG[$W_`BJP`1J4(!A/)$T:OD`#"K1A%`R8DEG@L*4T
M.$%07\AGPKBQ@7(9`YLK%`'W>&"!QF25'>Q8GLQ,T*RI!*``*!X@*6C8@.=I
MP`OG!)<^!.N&!+!@,1-8R$.9.`$+B,$")Y39";5A!SM0<`L%R(A(.4)2DSHY
M)2J%R;!\Q5*93)E8_6.R_$1*4S'0)@9&<-90@938+F#`+SYQ!+),8-2]Z(,(
M1+CG8K1Z562P\"H(6=YYG[`0QN@0`PZM:F(0(S"G_FDO%"B!;PQBN3Y](V)Q
MN0H&=J#5!O2NPA_\PFD89U$%L\F6"?""%>[Q!<CXZS9>\8-C9\/&$2QA!+CI
MQ`6'_Y`+,,=@>8V8SG6Q6S<_0.=4I-6;#5AP6N^`9[7E(>1ZU+.U_2S2MOAY
MFH$,U![W*"%`V+8M>Q`T[6X?=Y,.\H&X)21N4(X(NNB.[BBG2]T.6)?7\(Z!
MC6(Y@C*X:8J'&()O?NRL,Y0`"$#@1P+6P([$'`4`%6`""YR`!M0-XP=@048"
M&*!P!F0$#9V31AI.`X$V;.$-+*A3QLV%S00`(,&K^,I&I.$6;)9AJIUE,V-D
M!M$=Y$$%Y;U6$PA@@RO\('<&^8KR-%&&#X2++@EX,!`2T`,F>$\%5["!.3@+
M40S\RS$XB$@`M@"!!B0Y(U>FU9-/FN7[1?GL,!V6253BD?^1!C`8JB"9K;N0
M*N<PL5IB.*K!SAN56Z^P'G">8M>K*@]-&#Z!$)1,W^(0!B.8D(E9G8?S@&CU
M":ONT4XXS8X88!#.^.+R9WG7!VA]:RF)U"S8'/44=\2OKS3@P3?(?*C3E8"F
M-*L5504J`UVPZB9$0@1/@+5C0GW!V[G&"$L90'6>LVMXWPP+O_:QSK@03Q9X
MH8_?*0(@!=G:UE)AV3GPK=.NG<CW\-:18-OV"<@?!-IB.VSVZ;;8QH;<LHW[
M0<R-6[KWSW]VM[L#S>=\=N,'3Q`%]&8(.Z(QRE`"(C`!=40".\``D\`/7G`#
M_I55Y5-O-+`!U0`"#J=,;L$F&PC_`@P0#-%@3'20:65P8#;0&)<A4N`0/!"`
M`3W'`R?T$.Q@,B$V8GAT/B@6`+GS4'F0!R1@&%(1`XQ!"ARD/`_!1#E"!!#`
M`L<0%TZ@&[>#``5A9A;%%A/0A0QA`D#V0F*0!0$@!AG``C\`4O@S=B:5$S$U
M*SC!=E$&94PF=B^U4E:&$\924WW`0(3A!\C"!_O2A9L@`KI&%020!=Z5#S-@
M!5!@!8/S&<MS!IU2408C!B9D=>>%%(%!9P3#0I]A=0-@.7CU:(`R!()B%^A%
M+@SS08S#0DX!"YFQ<3?0.J$F6#,```U`:3@0%DBT(Z.6+O'@!U40&="B"2'C
M6+3Q%XCQ_Q`9$%7%!P?\8@1_``LSPS,!>"T">!QY\!P_QF:J=AW6QQVI=6SC
MD6S)MA[R\32-A&V45&T'4B#KL7[M%P2U52#;MFWS)S;UUR#D]DGNMF[2U7\$
M:4K_5R$!N(TUPP<U$DM/D!M?($5<P0@J`'5Y,``?$'"9,@1M4`+)\T(00`$(
M`"=P\'`9`0+7=$T;B``5L#"CD!D#,(7XP`(V\#TO.`OFTB@(T%D%H4,K-@&H
M8`,521Q9<`7=4P`!\`8S)VC_T@5YD54[I(2=F#";8'2`,F"',`->H"D!45,6
M<!T-D$"N,#XRTW-?R3U9@`,58`-R0`P:X9+\PX:WHC]6%G9HI_\_(8%E=(B'
M=1A`/,&'#`0)_I*!+[00CK&+T[$#5=`L(E`&:`$#EK(50P`12#&$!;$%5148
ML+`\+]2,Z@0'`R"%?*$)RX-5;C$->%4!MJ,!.``4&0`,&]$#<"!.BK`7#-`O
M`^`PD&A@0_`NH38#93`".P`SEN-@-R`H5C`#']`4?O`WDO4\([!JL;$4"=2,
M.$!\"B`]+V0$?`!K7XB-"KD<Q`$C#8&)=]$'/E8!U[<`Y6@TY]A]26-('@`U
MV5:?VN8>8,,!7^-L06"/4I./`+J/FH1<GI0V^E<B!9F@"%HB`DE="1F>+$(`
M-!)+2Y`C.I)O7P`!$#%:PUD/_<`X;2#_B:#QC#U0`YUADC@9#MC``#8`<>#4
M$1P$*->4H37P@QS$&#@X>5]1$-+28]QS8E%W!3XFE,X!AA9P"F_@3`]A,F;%
M"@Q0)]0`I7_B%\Z#%1IP='/A)M+S`SS0I:="07*U"K"60(5B*#BG`C'Y!FT9
M8'O)$G)I/[]2ES1!97#H/W$Y4S?!=O(30%@F##459EV$FPD!)";`!WD`,QDH
M5%*!`5?Q!0H0*;BD;\Q@5F#Q&(K!`D?%A908&(X6%L?`*N#2`!,PBITS)1L`
M!Q`P8/>0`/+R!$\:#16P&<<I0N\R*&86%C>0=.X2C*RZ4V?V&#/Z!>_P`<M9
M/E'P2L^9#=+9_P1-("1!M2\X``!><$%GM#Q5T)T)`8$THVL0JAPPXF-=:`)<
MP`=B4`,RL!VI133N.4B%9!Y'D`/S*1_8=FWV*"#5Y@#ZN2"(E&WO&(]ADW[&
ME4G)53;+E7\GHB'KIJ`%V0$,RK`(>TKOUJUVTU44R@``L$+Y9IL-V"^,408:
M"0->``%H%#`C0`_&!"C!$!._PR8LU``\4`#J(">ST`#6M**%PCT#E$.7`6AB
MT',F4`4]\Z-(Z6,/51`E)$,&(0)*J(0L%AA.FB598DP@$!=YYF)0^`W85#M>
M0`,UT"GG51#.4SA#5I:H(A'-@``@M61QZ*9O6G92YJ8UD79Z.F4MA?]E8A<3
M5;9E>OD#8O!8?O`'.!5!RX(8K2`"&JH41*AF$Y!"63$#-<8XN<!6$=<YZ_`\
M+B0/8>%Y;@$H>-9UP_FD"_,#=&`-AV`%X,(63S``0S1@7_`PI?LN,Z!-D0`!
ML2<#6!E566$%&3`=3O@\*91";`%!-K($71`:32&=CV4$3!09\)4/U$H!RP-F
MD8`!.;,#X"FQQI&X0,80),`%8K`%:T".1*-]1X..KU5)SM:._KEM5Y,#EY0#
MY,>O^4%M!0*P\_<U"1(A$$(V!9LB!LNP":NP`NRP_@=*$8N]$=J]%"M+C8FQ
M@J=HXF,!584C'^L%DZ(\+U0"7@`,%5`"77+_>9WA!`@A!BG6*4JJ58N"`PTP
M*G=T1SW;I5)W!3+<I8&;46+@<SS1M:20*#37&#7@.S_\DM1`.0PP07PR%@"V
M`>$``.*2`260#^+%`%_P+EFA`$,``OB"<QQV=Q8@I'D!,&0J$:"R!6G[AG4(
M$FU[AVC<IG#+QBXQMWEXI_?3=G4I4R+!$WQ``'X`B(31'$95!Q!Q9EF7F(1A
M9GWAN&[@!A2`1@$A`M-`&H#R:,>`$`@T`)_G.[Y`#XPC5X@E)5MR88:@>G4Q
M+9G,&6R2E<JI`0/PLTR1J@XFK.\`9P`@`F0%?!^3508S5!-P0*ZV!`B#`X"<
MQ[U'`,N[+Z/CN%;,_P(#X(=!513,=[W8BS/E\!Q\P`46L`4W(+Y%LWWL^EKJ
M**_VF1_;IAZ79`9*T)_R&W_^*G_Y*[!FTTGDIC8/:TH"C&[_=\`(S")<T"^P
M%`44A+$K=!6<UP@1A0,:F9TA&F)(40(S4)(L4`(H!29_<KHB8`,1@)1BD+0Z
MI$,"80&D0APG%@$7?04_1K0UU84Y*PJHX$S+Y"F\("7JQ$/L`"XEP`P0T)*G
MEY.*,(J4D@"=47);J<@(4).GDG)BJ4\$<4)_`4]VL+@-D+9PS+9IG)?SDZ=K
M:-5NB(<OT:94W:9T+!-X"G=]T`1[3`+]0C,FL+QY8%1L88Q04043L`D0D/]4
M6K'(;=")GHP&>OTGYH(,1;Q99Q(2X).A(1FJQ0C3UL`9J=>(5A`/TQ*2R`0H
MM3,#1+!TOU$%AIMH67MGA;#,RQL;7^PIR-*%,.3+:^455#$RLF%>S]J,R3"M
M"K!?MQEF"50<SPR!GH4</O-9XUD<6>`<?L`'UWP#W6%L'L#-Y@M;\N%;]2G.
M`T+.^QD@Z#Q)^EAM_SIMQQ6P]K=)R^5N`(DA"[JP"DK`TN6@^5PS@O`$8>`"
M9W:Q%\L)+]>`U.$<`\`MEV+!:(2!CI%!/T""*<NIH[A!5\`#-OQ0/2MU7WD=
MAF*FZ6.4*,8#J_!0C-&%.R8E?3H*I4`*7_'2F8'_`,*@!AO`/H+2=0U``;RS
M.HG`&1"PG*#YQ!D$)NR#B['-`IA)0UUX=P+Q:\[<A:EB!V*@H3SP/KGB.W8Y
M=GKIMG@I$K2"MWJJU7:\MDN>4F'-$T31AS@U`D.U$/WR+[^*`7E\+8FHB&60
M`0G5`E``:NZE5772.P@@#7!``\I0$07Q%A4VFR%I.X2]S`:1N1!#NEZ0/82#
MV87@"^RD`1\`9Q10`X>Q+L[C%TUH,";@0$O@`KQ'S`_D+]!245U%(TCH&,O<
M6+'!1:'>!58TF,\(VQHP/5W0!U6P/,9QV]RJV^%9#BI``G^P`WB`S<7]'8`4
M2(/T6NDQ(&;`W.F<'_J9_Z_RT9]!('ZQQ6WYF"#K(3;$Q4F=Q$EF4Z#C5EW@
M/9`,6L^EE+`-JC8&^Z#G71PW`DMAL%DKA`^<,"@8\*,J0,P>J@`S,`3Y?55'
M]2TI(3`;75%`60X>_;(1H`87'0`)?AT\H`*_'0`35`I)FJ3+E`OY)`:J*PO]
MU.:Y&>!Z<A!3\D0Q@:KM5'M?40)BL3JI*MGP<%40L`F7Q0!H4=G=D@#<,(8_
M:@,&$<%NA!3BTSW>8P<6,"E9(.1R6-5.9H=4/:?[`Z?^\\,P&L=R+"Q3!F7&
M`HA6'NF)!1H0M`,4SQ811!A7=Q4)Q0^$===[,@U#U.9YI3$9.E6C.@T5,,5W
M+O]8Z<*:4)$C)AXQLZ<54(@!5?%#>W%O9?`.%,4*H'$MA-$I9\`0%H`'FU4^
MDVX$T)<P`G,0%?%"FRX9GJY&1D#I7T0`I!Y4O(0#"'5!1+!5K`X+UFO;=(3;
MY`Y:/M-*).`"?<`+Q1T"ZEJ^Y>'-U6:?DV3L"L(!\%$$]:IM`!J@8'._9?-M
MX'9_W2TW'A+`!.SM'#*0X6[>Y<XB#*G>87`&T6IO=Y8`XF*61<&H15)C"7U5
MFZ`,(/"]-=2SY="E`9`$+U"1/%\`:5(``X0!JD`0U0$(%@T,(!N&&V^&"#4B
M##4(A!L("#\_:I`E)64`.&(-$`V&:!5I%140&@FJ#(/_)7"E("`53E\:&@P,
M&1D?MW`50T`S5C,)+&]B$\G)(C@#&,D8.#@B%@$V%CQV/`PX>)65DI,(=.+B
MA^?HZ>J'D^0(X>63Z>7SYN-T^'0UC_?Q]/#Q\KE[-\[0CS=]"/2)08!`EQ$#
M!DP@86+'#A,BZ@SH<J:+Q0G1`)3Q`J/%&"L)AC#`,*!$!1!HT"``44*5S0PB
M&E7PY<1)&B<)K`A-H"'#"`P9$J1Y1>'&EP0SHA(!M4-$1!RZ,I1@$+'!L@%/
M7!@96V7$B#-GEDD[NR0*EC,Y]\$!P0#"C:T#1#QY@I89CAA&7`C&,K:)D88Q
M=(DP:W6(%S<*B*3)6<4(Q(DD_TBH(&'11.:*GC.+)D%@M.G3J$N/MD"""Q<2
M8EB$:!%B`0H#4Z1(.<*;"F\.P',X<&#&C!+CQ8<KSY'C@','18)$+Z[$`7/A
MPZ]G/X"$.1+GX,&O6.%\O(_SZ`4(Z,"^?7L)["7(GT]??OSZ^//KWP__OOT.
M_[DGX("AH6;@@0@F2((1>X411@P#B`2!A!!DX$PR79@P`00*P`"#`AI`D(DT
MNI21``AB;&'#%05$4,`U`<08@`HTJF##!#6\4<D;-32P3P,-8("-&"(TD`]!
M^]!!5S$UN$2))6JH\0,<)4!@)0X3;(&#C[)00`$IM:CRA0@3L$!!&DO)D@8%
MM6BPE?\N'T```@)P`$/$#%`00<$66V#PC!@6L(3#"!98L`,&(F"PPP1FF6"'
M'"QD,,$W/\"3I#_KU),I0/[\4\\[Y\03CD!'=OJ/.$>26BH=!OU@`F(-==%%
M#`Q5-<T$(N"TPQ\--811&1D,`0,4,+B1``2.-+`5"/C4``<%MA"E01D#0&3*
M3F#:)%11BV%5`IIL/N5%5-3FE.BAY@8Y@0E96,#,"&&X4$45)G1AKI\#0%#&
M2A/$L`1$D<P$`AP]H3G-&6?%,`)678P5[U@0\Z$05A'E-(!CD.EI%6!=X-#%
M9JI1=%%FG2EH\F@A9\9::[!5$,++"QA01&X<\':$;\!QP-S_<,4EE]QR'"`A
M=`YF&!!$$-1EMW-V.@_W'1+6?<?=TU*3=\!X6)^W@GKJ#0@@?V"'+79^_O7W
MM==H=R!`@2>W[3:#3T3QH`B;3"@A!2N)L8-9.S``A`*`$W%L!M)@!<$'<-QH
MP^(VO`&2&(OGL8-J8@S@2*AS(@*D&)XPB\\&E<A2`05EW%(##13048G`SJ(B
MX18(B,"L*7#P])05(7I%=PFQ^#)Z`A]\D`$#)>``0`);H4*$&QY",<06@/*@
M`@\W#F`AYQAVP=+U,3:0P1:4_B#.I9AN&BJHFIIJCOGHJ'\//N[3TXZJ2:8*
MJJL2^Y&0K*)-8#VA9UA+1SHR@@F(_Z%";9B!`H*!K`'4``-;00,=T/"*IP0%
M=V40P:$B4KLU?<$*7E`%,382@QWDJPQ6^D(94-@&KC!#!+*:UPBT9Q8,O7`)
M82"+O8I4I!I4(`%XR\NLK`<'?*`A%K*X@1,H8"&$C6!O6!F!$:(0!;%`[#"&
M>:%5(@*!QRQP"`/PF!'\-P*0C:8B.R#915+FMM289F6O$0,#7E8;F=&L-SC3
MV<YZYC,S*,<Z>B3.T8[V,^M<YSI-R\'0HB8TJ86G/%@SCWG6D[:RC>V2F,2/
M@,QFMDJNK8V@-!D7EA"W,/AA!'4`@+X``(`O4,`9@`*)"2I`A`X!+D2$PPH.
MVB"9-^!!#/\L&4#M?+2(!Z;Q"I5C5C^<58C8X0`#<H3#DZ*DA@U0R4I#:(,L
MG!"3@;U$%JA(@"H;@(`&S&4G`_.@!G!'@0;PJ24,(,42O]"F$E@N`P#00#M/
M,:[FW<"=$]">GW!EH2XDPP0(-0&B1&""&&$`%`&@%*IJ4*KUK0-]GV)'_$RE
M#GG``WZHJFA`!D*0]PED'Y<Z$NA,P`<2\(%7LGH5`?:V&)#H8E8Q\(-"R50E
M&GAA@408`@3:4*1X=K,"):#G!37`B1$THA2C@X!CO#`N-V$@!AR!2.&:D1,,
M.?4)_^J+57*"@0;@H`XXP>$?8F"5(FZ@!K&8A0Q&]TP($8(</5#_$AQD<(,A
MB',C3QB!PJ)(Q8==L2%&>!=$\M+%&4`F`<QH6#1$H)G3H/$S.Y!8*-VXFM:X
M1@PTH&/,BN`!W?3F-TWC61%Z=ISE:*<X@R2D(0V9,T7J49'=P2T2./!(YWPG
MDI$\#R4KZ9[_9/*X_!F0<8G;GD]N]KFB:8AF_`#6,/RA"_A<I2K*4((&`,H$
M,3#!`!0X!C>,09]<"2,.2O`!"ARC2`VXU@",](9C)*-Q1I+$.>`0SU.4P;O?
MHH24PD$3H0IU8-P<Q4XHF(8PJ7*^9OJFFBA`E!!6`'(\>,,`*)`)+W%X*PU@
M1BK+4($:L``"1"`"%*)2C"T<U`06L`%+_ZAQ!0MH:%W38U<`"B"&##0@HM\H
MAT`\Q;XBRV^C'E5$DN<WD"&'],GC$#+]4.H.?;SC!V)H*0'^8`2%.74Q9CE*
M-/["ASY(S"&Y@D`:$K!`8[40`PBP7%P]J%2A9-!/@Z"`E2`@+56\TEQG\0A-
M,6#0*NS@(>8R%P>!U*,,U&$K>G$J#BH@07P,3`9.D$$:*H2!*D1$=4RHU"GZ
M*E0(`/8L"S-*#*IH12,TH0D$&,L(<`(7QH[+#6[00`,V4I:\'`@T:F0;=-F8
M&=>0``%MH$T=26O:FQVAMJI=;<_^J!PS%,%HL4V.=G+`6YUUVSN-'!IO#Z`S
MJ@$WN#X8+G._EO])2R+W/L6=S[J;ZUSHVCLS?-@+%3LFDN,])7<V"("&,*(!
M("RO!3>@`0M"G!/C06`1%`!!I4#0(P9(LU*[YEPD*D%-!)"B2AF4(PUJ`#HT
ML``FSTJ`!6/1!HK"Q)MLLL6^:K`%9;G"%PS8-"N+@H'%(6.A1PFQNHB$%0!X
M`0(4ML6=E`H")F2!!]2S`##S@KV%/?,*,>)!`.Q@@>'90`[?"`>5RU=D]I4/
MR9WB5$A%*JKY2?FDJKJ')'Y@`S&0IC*];L89+'(1\1K%B04D`%(`D`$-M#D!
M-*!!D,)8NUG0\]],9<`9:#78K&1EOG[*R0B6H-,\>`+S0+**-*JUV-K_61H$
M-B<%5QD_S$M7H`U#&,*T&F!"$82=8!=TI3TWOY<GA%$$D[_B6&(]%NP"?ZSX
MU`"NO<""E?1A"59!$&@*5;+3$#M!A>J5:%YC@2T,@3:VP4VS;0:<:B/-VGPT
M)&QO<WY"^O&0S'$.<WB;6_KG5K?S[RTDT\TUM;&G:YO4'\G%;LAU2<45'_/V
M?_5V;\-V!G$3!1#"2B9B$Z"`#3:F`A-0!D#P-RW@!"RP<!C0%YNP#TX`!U%2
M*1LP""RP!<_R<!M2`980=BE8`AS63C8P""BW$WI%83:Q@JSP.3ZT)M("`5M0
M`"^R!<2S%<2C"SC`"@;4+SN0!U?0/W[R#+A2_W1`,`2C\P6.,16UP`(TIPS0
MD!<&M"@1,0$VE@S5D`7K]75A-PEC!U)E9S[R@'9(IG9,!E(C)61YJ`_UHRKY
M,'=8UA"5X1!',0%\<"B$YC\^9A%^8"]=X"[<509$``0PX`5]Y0Q6D7,T:$$K
M!"Q@9A9GD'G3X%2*`A*`9A9EU15`DH3%`T,+8W%(Y#NH@R:FABNL0''O``*:
MQF>Q!T:X$@ITD@9.\4$MH'+`PGM[X1<P=$6"$1BN%@-Z!Q',D$]`X`8S0`,5
MT``$X`(080*;@1IY@$;4-S('HGT(DGW2)1KMP@;?9QLH,#/C]QLYX`'((1WH
M]S/"81Q!@`+N=VWOI_\=XZ9'X*%'00-_C<0=^E<>7-.0:@.`:%.`$KD?RI6`
M[2%L#!A*!$!*5!2!JF037V!/T&1C%I"!&Z@`'?B!7C&*V/4!Y%0"3K`!<R`E
ME5`#EN,ZT`,!%0`ZD@`3=/`L7V`E(G`C+(`/<W%$3$&!(("$LNA-0LA4)8``
MBW,,"Y5YF`<Y-990>?`&4H<,NQ818)D!E*B3%"9[0)0`1%`"-8"&%O!T/(`1
M(B`&*F!C#Z$]OV<"V6`]8E``;PB'%*4/Y*!1<]@^=FB'>,ADII(J('525-8L
M*/67K/(D8D``KP9K:*$:8Z9!N:)!.3539((4=0$9,#`#-]`&W@47AO.)%9+_
M%Z$(5E'`!PK5#`QG,:S)&,+4`*CW@<2#"UJ1$[IP+7,!!RQP"A8T`+%9"*)0
M`3<`%9CH!!`P*$7RDWXU!!3@&"T00H2W>6B!FCC1!7[@C-#8!'XPC7F!`Z53
M2V[0!BP@`I6Q,!.P&2MC6191CAB9&;UR?:MA`=IG;%F`!RR0`"T`C\RV&S9S
M!,(Q!<5Q;44@;=1&';%U-`MJ!MQV2..6?^0&?X9T'8T4-`NY`OS7D!"Y;F%#
M@!-I'_1AD>X!D?69D2:C&@00`ZX9!0U0-Q84DGF!`?62$Q!@<"B9<#3`FHLQ
M`!H@`F\P.B!P@N"09WJF(L+DAP.C)(ZG0@S`.3YR_P@_N29\I@%?P`!,\`:[
MA@M@F@D54@*?.5"`$G`W\B<Q9B@/459%@@'[@`%P<!7-D`&HH*5[=B8_1`1<
M>@V%@E",J$%B"!*_9P%V8`?>,P%\"0[^`)CH@U%E5YB2ZCYL1U*`2"J/Z9B9
M6A"@,XB5Z1!GT%(D`"'.$"AU,"AA9BA.9:=E()HS(%2L\&5;9#%DL@/;&68(
M`R3J12)V.@T8\"^64SN]4P$TT&''<A;KA4Z2$%\-IG()@"4LP2Q)Y!0),"XJ
M5Q1'(4RCXV'5:@6"DYU+L)W,@!,C$`7@61A]$$8(DQ<#<)Z0`0$L,`"`\00>
M0R.D82#`QAGFN%GJ6!K&9O\#>,``7E`;MS&@!<H!#N`!"%HT1J./Q&%MT3%(
M?/1^]\=M`_EMBH0=&>H=&MI;60.B_9>`(UJB%(FB:+.B+)H@(?,'KOD'&)!*
M4D6!\Y4HN,(,E>@A7B!4%A(1$`$``^"EKH"DE<(4>M8`/,""AJ`/*/<3]`0*
M#]2D$_=Q^00`#+`%`<`#G-,C\"5TSU`H^BE=/$!W;]`G>,:USS`(/@)7O7-/
MQ'.G2W%->I9BH-`GR7`11'(]A9('>4!]T:,"=C`!&8`!B[HZ?2@J@ZED[G-1
MD[I1))6'?^B'CQFY%!5E!O$&KV(87886?H)H!81*6-('>S,"%0%!&<!+S`,%
M.?O_3-JS`S^'9V"F>9JW6$#RE;FP0JMI%5J1!B[1>+^C`5[P!1B`!2U!<DE+
MG%JJ9X."*.94`KY[`]2Z3D+!`""!`U#U$\OINRGFL[MRJP.@$>5ZKE;$#!@@
MJWRF0`HP!+O6,/0Z`I55&M>7K]7W7.BH,EO0!@,;?E-06C7S&U*PL&80!`UK
M'-7VOP:`;>[G1[156\!!;N16;O*G-/`W?XX4'I,$LB$;;^Y&LN]FL@.R@"E[
M,NMH!$O0%E%P!MGU>`E`+0O%*(/P`1MXB=ED3Q&!*`!0`CP2M#3Y`SX4+J!@
M`S-Q#J,`+E_`"9`S=7#0(Y8C#9D@`@@`.0&`#2\BA7K+_SF`\L0:(BNC&+ES
M:CD,0+,LX0KFM!.U0SS<527Y="::D`I:6@L,()50!W57`)IB4&,[-`%:%P":
MP77=!62$6TQL=[B(>YB0BKB+JSYZZ+A_*+F*+'>@8P.7>Q@*8SV#(BOK@A2!
MNW<FT"AYD"L)U"''2`%8$KI6.;.XVPQG,;["A$05$$^HHR]E`)U(1SLQ40I`
M,0-$X`4B(+P,P"H41`JELTZJ8!2X,@`54`MG<KU"00SL:4)J-@ML4F$IED&Q
M%JZCV*Y&8:Z"\8R!(18+LQCFDA1>-`3KV04NL`2^9D:_9A'!-FSKF!DVX'WW
M>QNE1:"\T;\12L#GYT<]`\`%7/_`^8S`%NIM#>P<XW8`V+$T&1IN'8H>Z?&0
MZJ9<QB5O(TJBF`1O'"P@'OS!"J)](HQ#4;`#^%0&*&QJ;HJ*0OHWEYAP+I0H
M,_IP30*#-#D3SLQAY`17-0`.LD"#I..S-F"$R&0506*F;]#3=9<%52`&.S8C
MR$3%(.$G1P$7%D=1&Z!7C<<50)()IE`*M<,49:P)1*!/OLQG7E(,3,#4RV`A
M=;LP&X%U^NFW-K`E-B!1?MD.AGNXZQ,_YV.82';(4P:9FMJ84OTYC?S(!'!*
M8^49`X===<`8$R!XHBL"5N)8PY*S$.#-B58"&;`3NU8E]D2;OE`*:U(*-+!*
M..`'H"G_U1N`!K]H$\\*?0X$E&K&9]5JRQ#P1")`@Q#@$T[@5U8P!D3P`0`@
M`C/5KIVH5)^($X!!17QQ!M;<!524S59D11U#>DY5$U[P-\4`0^6<%WD0C@ER
M6?J*LBTJ71;8``E0&Z,US^0G!0NZH/P\L?P<6P&<?HADD-Q1H1GK6JZ%D.#A
M2.?VH2%*7!H\T1=-7.*MT:>AG\4VPAV)`],R!%P(JU[1M;@"`"]L!11``UT,
MU)]0!H_@$E'2DY_-)@,02R%&<LZRRKI@3Q,0`&"0U($R`3:0!#(2`&R=##4D
M!L>0M2C5%1/@>;<]%[$`)%M=`78J`C5`/"_!*I6`!ILF(K5+_P1?X",58"*\
M@#NLX!7K4B@U"R@4,5#H(B10%Q%QW9>+X'9I=SY&5LAH=\AT/5)]_9>*[-?A
M8!`V,#F&4=@S%%XD$$PSA!4XBB@[$"BKB@,)8(F76*P-H%!`L@6HEW,[T7Q/
MSJXY!PM*4@I)5Q0Q@`%M($U3#0)IX%=H:1,X4,U,<0-H(BXSX`786A5B>28>
M%!2^301E@`%^L$76DPEX\::T,L*D%*Z2W##8#-W2W0Q[4=U$`1D:4`&+X0)1
M8!5\X-V<)3*O0NT)CI_6)QH6\`8L<+^VP6S[^VP>L*`R`\#M5QS^;.[_^\\!
M.7_>5M`&36VSM1P5RZ%3<S57`UP^,/])%CG@FF31!9XV&8W@".*OHX1#+O`'
M$2+2QV(EK*"FP(1BM42:&CZKD*T!<V)Q(0Y7KU`EE<TBR*2\L]OH.1(C-6*$
M3PPYC-.538UG_(`(/3*L<.`C&(`+OH-..`=R);YA150).RA.;W(X-5P7)J(!
M4:%/+(`'4)<%[5*S@XY&.&X]&J0"`<`,;\#'E@*9ZM,^D3JI;IZ8;KZ8??C7
M%#7GF\JIE3"9>=X'@B4:8Z8HW4LF"O5$;-J$;#;9JQR7RILDWO393^X5P<HJ
MA@`"%+#;05DAVF-Q5TJ=-.!7PD`41E'S>BI/XN(&7YT!72!XK^XE%J0*TZ*)
M@_*(01?4Z\+_!S#JZV"%FJ4^157D(-E<?-)P[+=-%!.?!B$F&!`1`Z_1HI<U
M4_NZT:9!WMM>`?$L,^K-&_4X!==V-`T[2/[\O_XHL=,VH=QVH?'WP`BLWX8T
M-(H4'E5C-1ZZ[Y'TT)7D[__N'P$O\`=.\"A3;%&`\'Q`-ZV4$@X_PXH8#1HP
M\4.@C6`)"`,,91IP;P-P&QLU#7!P##@X(F(!E0$V$PU;-C\V-CPV5Y5-!"J5
M!39B8F^LK!BO$V*,((J+CG`@#2P,#`T8`R45<'2*/W0,)1!E90R,)2!T(&D)
M"10E7Q\9R"4:`+T5)0D:,U9$$#5B&%VPOP,8._`F\CL8(A@FIA@X_V\!/_X;
M"`+6H$,PH,&#"&HI7,BP%L*'$`M"?"@Q(!V#=`9:),BQAL>!!#]Z#"F28[$?
M8@@T,4*`SYDN?`@0B#%"1)<)`P!(&K&CRX@)?F+@R*`!"`PH7FX,88"A`:*/
M=-"PF`IA2`((#<0(0K.!#IPTR:A]H0`APT\6%2HX^>)$[9<$,V9X28!C708(
MPF2LI3;#C0(-`V+X$1'I+@0(;7`P&##@)^$1+HRPC.'+YRL,9\XLB;*D\QG"
M.)Y$&1VF=.G11J(,"/VD)@Y"1!00H=%`1.0S`[IP(4&`A._?P&7R-@&O=W$2
M)GK_%NY;IO+E,BW80$`C1`@4*`P4\2!%RO^1(QQR."AB('L0`]J#G$>OGKWZ
M(F;BFW&0HSZ'`P?"T\<OGG[]^/[5)Z!X.2"!'Q(YW+<"?OBMX(,/*T2X@@`=
M5&CAA1A6*(&&$G3HX8<@;OAA!R.2:.&&&::HXHH5"F`"<##&*..,-,K('!=_
M+!%&9"-``,`77Y21P!<EE."."1/$,D!1"KB1@!.\+#9`!H0P\(8(N.0B0@,@
M7&9!)2J84DDJG'CBB04\J)`%/BJHPLH&K;#"B"]B-,!`EG"DI>=7$)2`@1@,
M4,#5#VKX0T<%%"S#S!8B/.,5!=6DD08V$$"2P0<)P%%#!1`00<088Q`QA)9B
M6("F!2*X8X%O2$[_D(=O:9(0P`09U%"`'/\8!-)%`3F44$(-!;O01,06:RQ%
MO"+`44=0D232LR/5$)`_*9'"DD\UB3!"/2-T(4(9[C1&7+==K%9&;##,,$0;
M+,@R0`70<`1"!314-00$(DP@`@,@@,"-!A0,X8475HA3Q@AUE@%!&FE-FH`5
M,X2:@`A&T!KI6E]H,`X10)1A4ZK;BI"J/1C$8L$.(T@211B2$5"NMMM.*<D9
MG#W1V0BKC1"%"SR;=IIDJSW1FKGCP.`&!;6QC%L7S=7X'`'QJ$`"/%2;L&K3
MS3$''0'2]4!!"`M@5\04W7'P77A3E(>=>^NY9X!ZZLGGP-P)<G!??G7K_U>W
M>``62&!_=-?G'X,'1.B#`!).2"&+*8KH>(B01_YXAXPSOGB*`F3^8HV<=\ZY
M<[YQ882./&;PXQ!E`'!5+['$8D,#&B@@NQ=0\B+(,@"44*=`"(A1IG1@2FU*
M`9>LPHKOJO!`PJFOO.'/#XMX!`(<1M:PRRT@:&0G`SZ6D56@=/PS?9Y?S*!Q
M"4X%DZ<P7U&0<:7):&S-$$-H0`3$HK*050$\F"H&8?G:@;YP,(`)B"(`PC,!
M5@*`*W_H"B0'`0BP&#)!8?GJ6!C,H$4.LBQFC<2#T(**1C:`$A-8RP@^64UN
MB+,#$V```C@0@[ZZ0``3^,$((J!2;!2@KC8P9?\+#*@`&C8"`DA1XU[V2-7T
M($6!2<W%"A`#P"1$H($RI,4)>X$BQS0P@HKAX#!@A$`=RI*!#/@"9"Q!4@/(
MU84JX*$!!+39$HQ0A2XTHC8-L!,`,D#`;HT@,SC#@<YZMJ/21$8R.;09S@8`
M`0UX`08*&$)MHF"$&&BK-\^)42:'TT+?"+!J-M):U@C@B08,`6QBXXYWSN8`
MM:VM"$$H`GG>%@0SP$T)M92;?^R6(+P=X&\)XMM\"H0$!\AGF`*BCX$.L$P'
M1:A!A\N<-!=WN<:A2'+8+%'EMEFY:6[.<^`,)V]NY`(=A2$*9RC!CY1QE4IA
MX$LNE"$$@$!/*]P@2KS_J"(`(%"/&M@@``6(0"6N<$`$^D8%/'`3*WX0$%8D
M217I$$%"HI*+6SRB+'E,PS!(^#P$(*H,%,C`)!J0!C2@88D,FY3&-%`"CR`C
MB-.K0!H@\#Y+G>L9#:A``NYG!2=5H`86@$4LVC$!XM1#!#NP@`QW0`(56"`#
M`[!!`QEJD5T]I"&]LB`%-3B19!VK(LI:5K0^&)*,A#!:%R&A&$Q(QTJ.X*TP
MF0!<7^@Q)+TU*#3!`3=DYP8O+$5:^X)&5]!0@?HYLAN22!5:9"JI+Q3L840`
M3$V6P3`GN(\O0&#I&9X@LJ8P9@"=/<,$!`@R2K)$7R+K%@98<!B;="$&^NK%
M_T5J``*T-+$$4'WK'P,I`DKR[+<\DXP11F"6..`LAPGP`A04D(`U+L$%?G@K
M)CNG-7B8*AXL_.;68.2<5##`"Z@T`-E6^9T<3`$%87ME+,F3R_/D4I>[Y*7=
MPI,#9`K3OL:4VX#JLTP&28B9#5*<`![T(`I54YHG.M$UL<DARG'SP2R:IHO$
M26'J/H<+7#"G"V+`@!\%Z5X4Z`4E@JJ*$G`,"%!(0!O*6*2KI&X=#>`!#P(`
MAE2\(117X`%!"8J3!CC/'V^HP8W?,(%7,((%_7)$]KR2%A]!8`L-:`,<"%4H
MLU;@+641P1M^$8TT\"(MEZ4&#3SR17C%U&$?\$8)R/_R@334M@U>(`(48``#
M+]!@"S690"7Z)[()J`!JZSC#+R2!)A4H!DT=30A9KZK51BN"J\CB%4>,)1%)
MFW4@S7+6KIX5UH3\X`ULK0(!HAL#Y^00!W\J`;A$8-08N'H)@H@=G;W0AI^^
MCC8$00,<G$"-AUE!`S@X`Q8&P+`\6?8M0]JI%$O6@+M<`]EBJ91N14V`*L3`
M9IS9610>,YK.Q*`I<*B-H(?`%@:(X"4-*(&;0P("'9P`BQ0(\66*K,+GNF!'
MP'7!SLX@2.,VA@')A4)?[?'</W2!AIX3)7*29#6J?9*[X]P-="PP@3;,`&SB
M5>5WP.,!5ZX-/=J!3WS*4\O_N,TM<,',&]\29$R1*S._]A4<?Y'0WYH;2$+1
M=%"!,U1-$W&HP2&ZD(>$CB((7RAS%KJ<A*FIW0H[/3C3]<W*=C28,GP!`/1;
M!E3?:0$3](\!L3'*#!*@=2I1"0`EPT"0,;"%MOOS"JDHE8Y_40/H*6).TJK!
M`'P,1'AQ5`UJ.%0:EO'D+62@`L":Q;PRU@T&](Y+7Q&&3)$M/U\PL@2.8$`:
M+IMF7N`64V2AAA?&`,D9.(%1&.A?D@;XCIL<G-Z28-.^Q,"#YTF0K%ZM8+"R
M:D&NYK[38?T]0@J2K`Y>>E?'/[Y'$+#\\(%Z):(VP0AB\)N7)?6+M1G!BYP3
M@]7(_[K.%&"7WOD5E3P9T=?9P,P`*"",-%C6U]0`]@1B(,`I*>,P&2B!N4$[
M@B<8@11]$!2ZM0XXPT<CX`=1$`/>@@AH0%N,0`%.`!8BE0G!``)HD!'M)@,W
M`"1?P$^OT`6X04!GD&^&I&^5)`E+4!,X4P;*U5?NT`62L01GP`<6%B.MPD))
M<A-%A37"(7'C9`%O-`10@''C93;@(05I@QU*6![H(7*VA!UP`R`GER!(P$O!
MY`%TTW+PI5_V@2#TP0$TMTS]13@,$DT%AG0MTG,8XF`D`CD9XH81AH:8<W02
MU@%RZ`--]W1ZN$E&8!I_,`)U("2]MD]'PC5P-P`SH`"0!/\#5<1'0U%&`#``
M0>81.846FN(\;X``L<`#3:$LO8(`\X((R3``;P0!4P9X_^`5AT$6WU,!&S`O
MPN`5:Z$!"0``;:`),F51;B$.8\<""&`#>=!L^;=F8E0'?)0J0_$!&B`,W&,_
M'$,$3E`;2F4/JI`J7&<JID(`$]`%.]`$3:`"^D`)ML<L%2%!NK=[YPAIP%<L
M%>%5E59\QJ=\'_0LFB8M'&4#*R$9)I`9`I0D<_5%[Z`M$_`22^`MW!,QX$<#
MON@4#1`-:G$#O0877B!232%3\>8^]D.+&@`!C=%_0O-6(@,S!Z=;Y/($@L:0
MFJ!W15(")/,+=W*!)Z4+DF)94B3_5^3'46BP>5\P!-8@2$M@DI\1"5TD7/DF
M&=TW`)O5?]^B`6/@!C/``'@6@T]`?4X#.LLA0/(0"^E0,J.E7<K!!7G@'*:R
M`2R0`.%5A';C`;)4'@L0-FR)`N\U2_`!2TIP<G03AH(#<PZ`2^]U3/,QA0-R
MEV%(<V18.!*R='7(.&P8="K"AI:S<RV"(6BX=&G(='IXF<L!(WPP=2Y`7#]R
M1&4`5:5R,KX#.T#@%T1`)*"5*JOA#6]@)R34+R#`"R!`*`A@#T$U`!>X`8!7
M*+.Y>94B!EM@BAPU/?UR94/B,:^3".,S/9M'#0"P*%NP?G>2)V#Q%AJ0#?ZD
M5`/T69_E_PLX44:T"&8`\`&110T4P`(38`.O$`#]4Q-=X#]-<0]B(CSZ@`']
MD(H7L2P&88Z.!A!;Y7O[&8]=96GP&(]GE:"<QE'^8`.\(5PI)`D@F!G>4@<,
M,%KK,']5('T,D`$(F0`T0!L(H`\B$%-.`)'QUS$!1`_<`R0`H#%]8FX8T'^=
MX0)YD`<HHRVO4!.,`3.?L24@@``]<)Q!5`'>J1@L8%&+516--``NU`RV!P=6
M,1<A!EJ;E1F@,0)_0)3`900N\`>,D92<50=P(7!0.0)5D!I3^3E1]QLLU(^M
M4S)8R5UYL!LRD073H5,8MQU28#8<@(3HH81*V);F$1]R*7)*D/^7_N&%<R,?
M2J`$MM27QV27@+FH_`5@9!@AB)F8BKE@(&)T/,>I/;>I22>'$X:9EZD<JLJ9
M_*8Z"9!UH@E0,F0#-9``],1<%0">9Q`RN?.:YP!X=[<O#<`(!&0!#0`!M8F*
MT$,'+$`6^H<'>'`GRI)3PR`-CD5V#%`G%6`2\W)LW5`K,G8E1;(-8;1UZL"-
M.P!1Z>`+7)DRII.:;\$]H)=<[9()";4MQY6#`(0/5V`!O=$F9I2?AC);TI(L
M_NEHYVB.Q#)I&!&/PL=\F69\$*N@%/L1"/`\A=()*I"/,[%(!X@%?N`'VI@!
M=9`OHC8<EC04'%-G]P*5@]8PEP4DY^/_1R#)FJ`%6D75$UWPDYXQHZM9&Y%`
M0.>*&WLG/6G!"W#``D*I#Y(@6!L`!R%Z+Z:#`T7F>-!#6`$39V-7%HU!H04H
M`C>4IK]U&I%!&)JA6QE0I@K0!G(5`VI*E30B'*KJ&R<##T6FE:L7#UE#`A@V
M3G@*`C<`7@N@'=UQ-DA('DN(7H1*2V8@2X;ZEX`3(,;4J'X9-W[YEY0:("F7
M`PQ"F,QT<P1VAM-$A];DJ8X#JI%)NI*I=`A6F8=S='F(JN(TM[Q!.AN&`ZY*
M#<N`:F@B5S;P!A`@.[@*`ELP?V=`#V7TFH>G!A?P/*^I>53"`)Q8!K1@*!8X
M+S2E?Q/``WFT_PC"D&0.TX$LX`RX0%L-XR.-1PF@4`^V(PB@12<R5&JF8@-*
MA0!.L9HB,Q3VTT1X86(`,Q=`A9OV8`,[(#),=3+;@B0B0T-.Q9("2U40R[`1
MA+!8Q8Y@%7P22Q%DM6@<5(\*FE8G\3PB_`/*0P`LX0<OT04V-#(S6D8J>'"N
MIH",X06RTT/MDIL90!8OND_YQW]"HX`Q8`(1E4<DHX(D*3)YE$>.H!A2(C*K
M(7GKDQ;)X",9<+P$=+'+>F49,P2J1I$B`!!NH13PUX$O^!(%&!A<>F_G)!DI
M@P$I^%9IZP5`H`#\U"TQ6&I5R1S,@8.P8"I)0C5[V[<$D`4\\`85X/\%+4"$
M9<-QLB2HBNN6ZW6YF"N%_2')C7NYE#N%4V@@]"4@-M=,B2.ZT52J:MB&J&O*
MW329=3BZI&RJFB.[>\B#*\,S6"`"`)"[T6E&^$`/TE$"<ZP`=E8!YI8M7?!%
MS(<#:;`!*9"Q!>!110)5F/`,BN`5T"`-[H-1Z]J?\])86.9/-;`O4N)Y9)%E
M.?C'L4!D[!H+."IHKV`/'\$HC!$)C$$40&`-+O8%[E<--5`/$25CJ)6S<'IJ
M&%`*/,`8M3>.$7S!_RDL%GR@&]%!D296FQ:QRE>.(3S"&%TH5_"@1H#"3$4"
M?)!#N6'+&5!D,-P'?3`3D5`48^!7/K0%$17_M)'`"_:P`S'0&3M22;`%&JLA
MT^=FQHR1Q(X@S&#A(ZB60^QC4C%%`5541?FR=Q/5/HXU=AGC,?7@")L'@6\!
M104#+J\UDC)S!FF<TY)1S"+PQL3U!31L#FL$@Z-#0SZH25;)&\#1CW)JMZ-%
MNQAVIQ:P!4*8R"@P-HLL!;.$'6UYV.81R7(CA5+8J([+7G'CA/,QR9I\E\Q$
M7S0'A@=2((:Y(`Z"F*1\RJ)MA](439LZ8*Z,8$L7N["<<%A#`OI&RR-@=3L9
M)&6`/O]$`C=A`P.P0^I2`O(<"?50!@&<!G2@K,:`*"$U`-)1HH-U@5X!G+?M
M"TY1=PSEG!!0BZ[)_S\4QYI._+Y_TG7)00([=@5#G,1(_`J",*R8-M3F1AB=
M4@T48)WA,';FI@H%A%J,@:Y6\RHY.@&^$0"IP@FV)Q!6-<&\M]`2=,$1P>`%
MBGP>#.$*@=$4/L*]V9MR$``DT`<L@1S<^!N[:D"TXC$M9`)\$+)U1$!E``2A
M,A?XLHVNAM?U4#*9T1JZU120)\R:=QAUL!.$H7^2PC["C)$?0+4Y5+W^@`8T
M8!7R/8%`"@=O,0191`U6X#TF(`)-)%/'YFOF0^)1\`0'ET-U,)3`1=:C@X(V
M_AI%408XX`MB74XP$=<0)]?-\4GT,`$GPXVK(@]:XS^'G,AA(TN%RP$=-_^H
M"P`VZ?4VL@0?C:J%NC1RZ-&X["')E2US_=&%S$1,GHNIB?/9J'U@<CC:VW3:
MIFU@ITU-I\[:K?TYKQW;+H`%L_V9J!.:#?`)084!KR/'LE$-P$U`C2$"6&$#
M6_`,ROJ*P%DIZ[D%(*$(L*B3D7AC>C<``W%F9,$,M.>>:!)WI2)#KM.O)N!J
M()BNJU<;\0Q:?X(!BR&;NJA_K0D$"<`^U]!(`\,`GR"--2$&-;$#[DD"Z1"?
M&_T;`0!'%E``!:XL!]Z?C]9["?YHP"?!Z_CP#8Y[)%$0$U[A%B_"O4DH_J`&
MQ,,#,^&VR/%'W`*2]Y`3/OY:KC88C4)/J4D#;9[_'*/6$]GBG8TA1_0VK$EF
MD=;0XTZL;DT$![K&,$R=G1G0%"WU#X0%D1I0,(=10#4!!Q0P%UBTU5P-`7B.
MY3/I/HX%,6/P`1Z3!UC0&=YB.A23;\$5@P3TDW\T`*E#!$9R;ET$YWP@Y\$1
M2L#1*JLW#_/02<UA*M1Q<8O+IW9S7H9]Z*@4^(Z[E\84Z8XK'[)DN;;TN'_9
MV('C'YK+(.(AAF,88#@WRFFHNBRB342G(IGSNJ3:(J8=VFD((:B^`JJ^ZC,R
MU[Z1&L%U!J;#@6"4WT4V`L(>.[+!DS3@G?7`D;1*`2"@K-%]S4PA"]`@/N"0
M#-$98Y50)]^9Q"7S3PBD_P(F<`7$XYZIH)5;.5=;\BR-P!A2XA3:<+3%9I$B
M]1J><B^'\9EO40&O.0`R-`E:X0[P4"Z2``AB`2HD)#P!$SAB!3^-/W0("#4U
M=)"1EP@;FIN;F!N8H*&8E9:1I:)TDY2DF9R.K["QL&JO<G(%`0$\/#:]%C%=
M77T$629G(SAU(C%\$R)=`P`B$\%^!"0$1B,#$$0S"4,4$`,872,B(@,X&0QP
M#0,,&3@B9SL8`P-P<!45:?[^)2#@&&&"&QPZ&WYL@#,$`H4O$`2*P""BQD(G
M0YPX^6*EHP8-#";<JW#CB\:2"6:,Z0AA`@$,$2F(*P,`@(8/1,H,6!(ES)*?
MR/]T_C'BHJC1HD:BX`-Z#H=3=`,FC#"2],D.+EP*%;JVE8!7KUVU%MHQ@6R7
M'19(F"A+UD0A"S;PL!C2(D0(%`:*>/`@A4..(B@6"!Z\`(5A`XB+F''@P$P1
MQ&;,(`[B6'%DRY$;+];,.$>.SIX_@^;``0D2OPYR'%C-NO6!%;!]^!!`N[:`
M#KASY[ZM6[>$W[US2^A-NX-MW`)DW[;-O+AQY\97O)Y=V\<*MV*S:]_.O7OV
MK]][NC`2HP2`+^@CRINX8\0(&S42*%!`Y`L-!@/2D1,!@0'\$B"HH<8&=(``
M1QI.R#2`!6)L,4`#FM0`!P,E9`"!3F_DDHL-&#10PQ7_N%PA8@"X8!/##F*D
MJ***%(DPP@06W#,`"#706$,#^E1`(0X=EH`#`Q4<U`@()5#`P#80:`!$`FDT
M`$*25GCAQ1`/3L##"!A8H-\(.YA@PC8BY&&!"5V2H$(B&`3PRB63D')**Y_`
MZ4DGHICBIINHC'(GG)K($HN`@`8JBX:Y[,(+'B)AH*B+75311!-&!!/#.5WP
M$8.B0455115^_/%'%$MLD\$,I'H1$0,8`-/`JBS@4$*0#510(0[YZ9<&!6GH
MDT8_7Y210`9<#E""19J@4<$7'VD`41L3B8#C0S<X<4,"'5GQ44@3,$"!1AI]
MD8`&WEA!1`83.%,A30F4H2X$_R4P\$P73\2QQ!/S#I"!"'P0=9115*4#U#&U
MMKC#&51%\40,6(G%%39?-;P=`3M$'+%;9%E`U@[7F,`@`U[855A>?/4EA0&#
MV16"8(8=IAACD1F`5Q!!3%8$S)%MYEC-+&\FFF>H,99:#J7Y9=II2+!FVFJP
MO1:;<LFM,)MQU#$7W-14!\<;<K7!QIMUU<W&='--K["<;3Y@Y]W9:'L'GL(Q
M1%'4#@R<EQZ[[K:XR!L0`*$`$%_L"M5^993P7X"/H`%"/^(,6T`!-DRP:@/H
MH+-JEKBH8/F&8EC`@XA7C)GB!,=@4`,";Y0NR23OX-,`1>WF&.0^_3@!00:*
M9@!@*_]T&`O!%_?:J^00++!``WI>S&!J#;O<DZ((9&5I`<2*.H-/ECR8@$,#
M/*P929NL@*+))=_7B0J>EKPYIRM^R@+H#X+&<@LNNO`P)HKEGC-"%XM.(_$.
M59A0!3`QR`958I",:8@``!"(G*2&<@9X*.D;:<#/!";5`#2DPD#\F%"%[B4&
M#.`'!&A(R`8J(!,(T*`-]^I".B)QN),DP`M62$"Z]E."?\A`6C*TP@R(`(`!
MB,$$#"C#MF0RA(\0X0,?2*#T@H$.!LS#1>4*QA/B)2^#B6`>^=+74:CB@C.(
M`"A3=-$9`#;&*%0E!MI96,/6N,:MF"!C%R-3N:AA@BS88`O_$.C8QXHP!;YP
M0`J`*9G'"J.RR"C!##%SF0%BII@B8,9F.//99GSVL\],,C28+-H!CC8TUSB-
M-M816W*B)C:L7:UJJ,0:<4`)-JUES95,6]IQFF.VM-GREFL3BQ_<Y@(^1$-N
M$6G7JJ81@#G8H`1$F`^3*H`/?*2C#!D0`P(8``*%U$B#[&K`&Q87`<9!#@$V
M@$LO;%`H`C3!<KBPP8H8E*BR]*%#"&C$&TX'`@.IXT$B`)(^0*@)$""(`NE:
M70D`5*-C]0V@94`'#I3DA1/N[@M>\$8"&H"`+8A@"V+`TA7N\:(NS%&%M)J`
M(;*`#Q[(P1&?V(`J5F&^.8EO%`AH_VDH-I&^FJHO?1KRA1@^>@X7*4I19]E?
MEX)!U"[$H`I4,8)7C'#%`9"E#!`H1PR4NI4)J$,#7M!``L21@0:H$`X@J`2!
M]'&@"XVC@PR`D$+0``<GR#`<][G?-@STD&U-JWA:5:((A,@/!'F+6CN41L2X
M$9$A#$%=4)W=1-0Q@C[TSZH#P!(&1$+4)_2D)T^XH@C\H,4M4B54])KB$B([
M1?MU80DN,-@9%K85K;#QM0YC6,76DJ@SQ``N6Z#+R1(3,@=,(3"&6<`@4Y:7
MS"`2+Y.)6<V6F[-)4I*2GGGN<T7SLZ&59I.M*9K39`,;IT$M:JD,;RI!&37G
MD)>\H5P!<O^HXTK;Q"9KM;RE?-4&ENSX`;6]W"LPZ381&%D@`#9@`!'TUE!F
MWC,=%JK!&]QQHP:PH%8/>D,2-+0X^;V!G+I0)SD)<4X2B.'"'S:=.FL@.C'L
M0`05H)&!]IDC"OD0`Z\*(?MH@89;>:L,'I(5'-A:5Q*FJXD)`((&<M4`9.X0
M"#-(0PVV@`=$B(!!ZL@2`2Q@@3SXSZ.%L%PZ+'#21L1II968:9SDQ*>7GJ]/
M-DVS+&P@!T+I@@14WJE(>HJ.<@1C`EXBD\3*=88N]-FHUOA*$PC`V:3^P1Y8
MR@".8\#H&'QJ"0W$`0"DY`6(E``#[4DQ*<9:@38D-BK0:$#N*@#_CH?(L-+C
M"`8#&)"&&B+H6RJQ%NVT!-78_34!'P#"N,:8GW-02!Z]#H87,["3)1S5JD_L
MT*I=-`*>\,2+\YCJOI!2L!%8=EY/R`^H,CN",Z#6")#FPW=<"]O7,@QB75H+
M6LH%C`F\(;=U60!B^B@%*4S!9804+LH.DQ@S'#((_(8999:;&<V8@;J27$QH
M&B-=GV'2,YS4)&NZVUVD=:TVX@WO*7?#2MZ8-Y3<I?@KQ<8TY8`<OO--.7W;
M2((_X/<E=0!``B`2D>O!Z`H3$$0#E(1D"AB85OA(1@-P/KK1E4Z<&-9%%@ZQ
M.!M<V.FERYP-KF`FQ\73RP22Q#X>!(U<_^W3(@C81SS85;L!).01]80#0+6J
MDW>4`'9@/9"W`#"/$I2!"`D($@VZ000-&`\./^`!'BR*`3%<D4?/DQY!#D&(
M+*@``XK(GI=-P;TW<8)/*:73F=7,>5@8:A>%"J><6\3LGDYVCA(C:J.->J(W
MQI8`7H*].4;@!RQ0Y1H$<`9-(GN_+A&`#WVX(@"0#(XOE*`!SJ!F)2Q(APH,
M86ZH4J&3#.I7:F6UAQ%C``1V57W`6N$#Y/J2HLOP_&\!0%UTY_4`SM"'M8`I
M>E4X\3RL'05+;:-6#MY="?#1;7I-:BF=Y5E1X![;EFTB$`=QD%GO,AZA(FX*
M0V[EEDMO1`(7(_\2Y9(BT8,`+)``=8%<4U!OCY$R);-OB)$74W`9P#49B$1P
MD31)QH4SHN%<J>%P$.<7'&`T.2!Q%"<=2B,;/@@VT+%Q&6=*T,%QHI1>3M-=
MM$%QRM%=UL%=Z'4=*C>%W,%&),`'^-5%&:!5-)=-__4"^',%\4$$9#@$!M9,
M3J0,C?-?BX,+5'8(@T`(9E(]%O`#;X`'I1-U<X1G(P`AFI`[*Q8K,M$`<I$K
M"#%C/U`#%#([V((/E*"(_4%"R:(3-V([$)!B^V!J&D`.VD<$7D`!-"`..U0\
M1$`!DX,!6Q`C^4$K9V%5]Y(%`9`%A9`%=@`35H)2EL`]WL,)O-B+Z-/_><!H
M*+E@.6-"#8OB3,[B+)-%%M00147E9XT6:(_R*%2Q*4HU*<]``%VP#B*`!7EP
M>WEP#8G00Q/0!TKE)7T@?W<'0Q\Q#E+1#LQ7($X00]:B`>,0.;'"?1PA0S)$
M=XI2`LMT*VZE5>*RB=00.132!NWB+JL3`]F&`T\0!I^5#CZE0O8"D5,$*NE`
M471`5@G2:D?B'D9U?UU`%/H2!OQB!']`@/.R!.F`@`H(#)\U`@[H6A`8@:SE
M1G-4>`QB#QU"`S/0`A]C`'WD`2X37()$2"7H2(^!;\A%&33#@L_U@BU(204'
M&@\G<9V4-$JS@^]U7N!E2E53A$2X2ECS2>E%_TIBXX19,QTGQQQE@Y-R.9=T
M"1X$P!/C04#*\@6&!551H3D:$P!B``$X@7<T\&#-A`_$UCB+T(9OD',V8"A9
M,)D\8%579X>14#HDMCKW(&J&4T_UU%<R)`)XH'UHL#X$0B1E\`4^5P-BL"H=
MR0]]I8DX]@8-8#M@=3C5]P&7Q@W%XP0T(F#>H&M?P`(8=0AB0`Z&ER6R:`]X
MID(O0@!G0CN2UPCE$V9BU@F]Z">T`(RQ((P:<@6BERCN$3GNX1[+&#&K-WO/
MV"@!5`A\X!5^8%1>$0/H,`)>(0)U@`,B%0/V(@*XIU3Q20@'Q",B&0,\\0<@
MY0V59B0-8`-P<Q"5</\XWL(11Y1`7=``^F1K'>$MUC(0%&$A,H$>W_(M'Z`,
MY\E^.]4AT4-ER&9M/-$,^O$@6U`"]D@KW6:?M!)6!:(KN#)07G4_H<)80\%%
MTV8$3S`"VQ8J.+`$81"39V!&2V!4-]D5=<DPA;`6T9-S,;(%<]&!>,%''A""
M@2%<)T,8Q+5(B)$R*4,SCR1)<&IP+GB5-],96!D:0>,:GK2#Y55>S_$<0LAQ
M&T>61+B$I20`LF2H7QDVVZ6$S1&7=1FIDNHP=XF7#71^SV=8_8%\;Y@$%K!0
M1#`&7G`#^)&8R(`#>5`N3B<)HG-A;Y`B5#:9L7)V$0)6DO`."I8.^D`'C4#_
M"YDX0Q/``A0`!YO`8@"I5120BCC"5EY7`1M!HGFW9`&!B<YJ:E8P!`JE`5#@
M!(9#`43@!F[@#5^P!>%D`<X@`N'D+)FS`XQV!O=`;"*E`M8S=-HS9N#CBV?G
MG6IV!8>P.<.8I7,F6::'`7UV(A$C*8PV>U/T!'WF!WP0!9^"H$:P*2)I*4VU
M`R00`QF@#(4`>?R9!;GG(I/Y%>WG/P<$+/=3!=G0!!F+#WVW56W0!J`&)#5@
M.&U5H3I$!!!`B!C@#_O@0EYP:@FU`UC`!R.@:.A!<Q2P?^<9D7$0!O$Y*=86
M#.\Z`,'`$SL0*R`4/&@@`U_`#_LW63C@<_N$06D0_Q$1P3SPDJ3JL%E)9:3\
MDEE18##UXJ0*V&=+D!3T::5<09<DD`?G]CP,\E.%1Q9;0`-V05P"=Y1)21A*
MN;AL6DB+P5P,QS(YTW"0I#,.YQ=`$QK9=8-<R82C=!R`FAQ!F'$8)ZA`J*@@
MEU[NQ99OR1S7,:FT&ZG8,"]SVT#J@AZ&);/(%TX3T`L,8$1X)Q!`%UFN@H&3
ML&J.F(>O*@:\X"2?0`F?<"!PP`(9D`$U8`,B0`'5%"@;<#CBX(X:"@+ANP]A
M14+(HE51X4&ODR,;(4,:D%!BP"'K,%`EM"ZH@@P```-,0@%E`"YNH&L@L07E
M4"Y4)@+9.PV-%C'.@`'$H/\"%I`?-O`*VOF+^FI33M<+H*<AF\.,`7N>]\,6
MZ,BNPM9GYVE4T-@IGE)[Z8B-S),'VW@O?+`#`U`&.("Q)P8L)`"R%"%24X8!
M+R+$*BPI!3I!`40`?=`'?-!`T8!56]4?Y9(/-NNLMP8N"<![%+)J(\J/'X$#
M8]1M/04/^($.]1#&H74&(D&1D]4`KD(K4F61![$!G]D/P;,.Y?`C%800'=EJ
M:$ML1@44]S15;[LOX-9L!D,OB'RWWD85P="W:^.W?'L-%H,_BK(%7GH#0[E(
M`)=O)F,R:'H8B;2FA/0RCT1PTI49EC2#,KAPG<&YL)Q=VL6#(O<UYG5>N_$T
MND'_J*I;J!^'-(TJ'5J3EM7!A&D)&ZY7N\H<@=C@<F$0!5YT(17:$*AB`07`
M`X5W!;^T0PFP?U#A(NN0(OE`Q^XP`!5`479X(WA@`TXB5KTZ0@,%30_:O6C@
M9352(VD@0U)<`P-0`S]P.&EWMA\A0ZCBQKEBMB7@+5\,O;)X#S\"#P_M(<ZP
M4#`0`OH``2^$=]["`)FC.;%X?SPBBQE;#UJA`H['`U=4P8BH$/F:P9RW"Y-)
M9>8*5&O<7ZB79U["KM3`>JK':!'CL,`P1NV:#B.0!V>0##ELU,DP`#4L(QB;
M!R<F`OU3!=!)$4*,8`/!*;[7!0N,#H`V0.D``:1B'_@A_P9YH+6Z:6KR"W[/
M<"GVLBXTL2XE4'K^1Q:0(U=42Y'X^#A;4$\B,%#,1"L(-B.@"3MI<!\;BVGX
MD!"TL`'Y#`[]P8JG%2I-1<A)9<BAXFR*;%E)ZB(2BZ1=`,GU)<GF9C$[@#\(
MT`!MD``H,,HN<S+!-4B.6\J1>Y3\EA>.M%RYW7!6.8/2Y<H/1QK7I:>ML5U^
M2KI,L\NZ+)94D[J]_!PBMX06AZC3,7+![(36D<S+O-TL!VYA$`98,`(0(#?>
MLJF"8`$C\%][E4=$<`,LP)E8`@VT$V`EP#YVN!!OASH^9`,L4`&,+2`*X4]T
M@ST>Q*,&$E9$(D.!@P&V2:P(L?\0_I`D,D0!&"#!M[E_JU8D%P)-[V)4$6/6
M><"BD_4&[8$#9>`&7@`"<Y$27K`K7\L$YFJ,0QP5)A`,C&4"/""'6A9-KP#@
M+NT(X*D+A2(_+GK5Z"G$R_A#.Q"?EB(I[<EH59".P,?$5'T.=G:1!*O`.E'#
M"IS#-0PF3-P'*N2,8-)KZ;#44"$/,3!HL%?CBC9_;_0H).`'ZE`&,<2:%-!5
M5O5V!R(.%6H3/339T.843N%,DV4.]-(3?G`I>@T53I0?^+.1(!!3A],/*58!
M$J'`KP('.A":MP)5YX=IZ#!Y<."AWR`3`^%GD'9X9Y!%`3@>`WAMBMQLE#T"
M#OE9E7+_;F"AS#:I%OC3`S20`'?!IF8J;X%QIK--VY%[VT'`E*<<2="5<)C[
M,Y44&D2CITFC24E87KC<`<JQ2K?,RZJTR\TANDTSW2>'A%Y)':&DW=S][H7@
MW>.!`1EP'D.@X',-(^UA`P5`[TE2BN^]I?;05=P+`72P!S[.SZL&3>0J+(R-
M=O64!I;VH%:%$.A+SA*?``!0`IALSJM@MNN;=QAF`1KZ(P^&'PS&KHL>`WY`
M`B*2JBTR.=D&`5``!='2!MZJ`47RB0:\C)IS!<@`12=&#AI3,2J`S1!0`VH2
M";WZXS\0/[L@>CMUGN6"*84'J\\C1^W)>BHKGRSO!YSB18RB_T(;NPS0`$V8
MUD#WXB7V.0#,0`#8.'OE^13WMY]C?"^DU]:-1M621@X80P";LNA.L85:U1!=
MA5;X>R'GA[;NDJ)C-##Y<<!\9FTBW(>0\S<XT`8_,A';T`ZY"3LEX`1G2XX*
M/,?6>;;ITBXIY"QO8"P44'[B$D._0@_>-N@T>=F&K`VRGJ2TSFVW#FY=T/)M
M1+O<<=H3P`9#X`6#4:8>@Q<H(-N.N^Q(R:;%A<IR*H.]'5V5>W`[@TDW>`"D
M4=S6`<S1;<L7-^Y!Z-Q6<TJ(VE[M/\Q\JJBBRY75W?ZKX>[OOMUI@87/#`@N
M,3@`95]?9649`V(!%A-B!6(9$!I`0_\5%0,B&)P3.`PV-0QP:A<_/VH_("44
M$"5;/`T,=!L;:'`@N$Z'$`,(8@TU&[5T(!5I%(<`#&]OLPP5<)D,)1`0924@
M8E4[.Q/@8F\U#1C@-E=Y,5WLYC4U&`T#\_,C`Q`S4$Y.;339<!1F5'ACH:#!
M"2-PX)A@P\(.=A-$;-J11<6$,@U0_=B02J/'CSP"\!AYQ4;#@F+`85B)8<0(
MEA-V%#2QPP3-">QBK.L2H\J2*D:,$"!@Y(]./SOL#1BQ`P..,CA&Q!"1H<Z`
M'3$P#,#1A687$2(FK)38283+>76BCJ!:1\17$3@&9#7GEL##GG_\\+%)P,0`
M``,P\(S!AT__'SYP2VA(\&4(!1P-',+%D:$R91R<6G99LB1*%"Q-%4IDH+#>
MB#-G)#8`P1H.G&IMTF3`##>:M-85*"1(H$$#`X0X:J`2@J;"%R]>-$"@4&9`
ME[7'*`RY<2.!%2N[$V00P7G)F8091O`)&M2%>?-&7+B,LN1)^Q&<GYA=%W1)
MEQTDANK/K[^___\D!,@%%T,AQ<<$,B00P@(,HK!`"`LN@(*#$$;(8(,39J@A
M"@88,*$!181HQHAF.&"B`V844>*)+#J0PXLGKNAB#C.^^"(2!QS``1(<Y'C`
M"BOD".200/K@@P`"'(FDD4HBZ:23'439@0!25FDEE%$*4*231:YP_V21/GC)
M99!=&DFDF&>N8,)_;+;IYIMP#F5!?DN$$88@?QWRQ34E,.)(4SR(44(9EB10
M0@D9,+!58%M98,,T/Z2`BBJL+,=`+#7`@<`MNA"3FS(0,-#`!`W`00<J=,"1
MC)X8!5"`!9TPH*BLBHI03@T3Z(1?`+Q>$0Q,8KGTW`#"O$,./4L-D($&^CB1
MP"N9?#%#&EMLL5(7YH`#ED,C3'!&%Q-L)8()*JA@P7:3?J3N%;V:=%!9+KFT
MDC?>3%!0O3BQ,UA/!#31!`%]``544$/U,<(B9TQ51QDB/*0L#F?TT=12]-IS
M;43SS";1`&6TU<4\S3WW4F`1J60"3B>/0/\N?X4-9=,.5#601X`T]Z7LLE_P
ME@!4+9F%[4JDAF7!<YS%N];&6Y4!``25B8":/:2X)C4RK@!0`CC5@%#+1B#0
M,$0"-[C"0$L#U)"JLSDG@!QVOHD%2B84W/`%=M?UE@$&6'@60T)M_4'>>>>E
M]\0(GKDGG^$NQ7!&%$9$\40,`?;'7YR2"TA@'W[$0(!%:SQX(8,08OB@A9]O
M.*&$'`;1(8A%K)ZBC"BJR&(.'-#H8NVSVVZBC2_VF"./.`JIXP%AINEDDTL^
MN2205&;9_)3/7_G\DDQN:6221Q:?/9%<_HA\\5VN2?GXY+]9$`F>F>>'"``L
MC<TKQ(+35$'W?`'_A!?+E5`:)UN)\6@:&U"#*C8"!VN\H@$-:0`=%DB,:20#
M5`B,"`-`L`$$@``.`T!4(OP4@+Z0H"G9`I<)+'"%*]B$)B8PB3,0T`EDE0,2
M&"`%:VK`FF/(*AXXT(`"6K`&&E1`:3I+0`4@88-R\2HB&!##2TA`$PN@D`3E
M(D$,)\`#.?Q@)"+A01:T:(&4J*0L9NE$MU#(@SE]4%_YNL\.@-*O?PEE+WS(
MSUJD8H3Q#(5].(A!'LZP%9GQ82J!R<,WP`*O38BF`90!``ZT@L@ZC.`K03L9
M!FP@EJ%UH0K@0H@)($D"/M"K7A"1AQ@$N8,SK&0MBP)`;_"W"#'P@2EV_U%)
M`\`R2[`8C98-R`0R6D$!"BP"+)5)0QJD\1ID,.8#$$A87#2R`1"D80A>P,XU
MPO.Q4GW!#0EP0G5V4S<&X.$3%!"F,G*F@1G,0`,?R,`97!"&*.R-$!F(P=\`
MAYXEP"<,3W#/`-QCS].<80E!Z<(9(K>?R8V/!`,:$`%T,D(+;.%S%ZJ0Z$@G
M.@QM:'4&"$*(.D2BCIIH1">Z40Y`:CO>H:A$O/L=CSC`4A\!27@_LAZ3KG>\
M(T%/2S]J'I:@9Z4IW;2F8KH>DXXW))RZE$A*`E^2AA0F\97OJ5`]WQ^BX(*B
M-$!I$$#$*T0EABM$A(3W2``1O$`!_2EJ$Q')P/\$?M```.Y!%9YJQ348(88M
MF(TCJ4I#*W*6@1H4H``VD`<Q-S$/3MB`5RK8"Z\62TIZX<2491$&`B8KCWF4
M@`&>H(HT=.F:"@QJ'CG<H0Q8\,,R]#(9#2#(3+R1D,PXD9";*Y=L"1"S-YBD
M(1.PUE@*2\ALU:0F0_EC3F)`K_S@1P61,X()=-*O+B@$`WL90%O\T(<^$(`/
M"]W*0`7IDF\@!"P2.1H.TG(T;(QL40BA2TQ&(`8Q8,`F24192QZ2DLR$Q5PU
MN8G(OD(;9!5V*PQ096/:<%DQ).4EG:`,84F#F6\E91.EJ@"M&-!+5P0&`[-Q
MS:D0D`RO'2(\?!0!URK_<(VOU4T#``B+"`X5-R<HPSKFQ,X`G,B`,CCAF8?H
MC0:(0`3`K),]>_M+!KHP3WH:P9YURN<2EE(TI_W3!5%XCG4C%T>#QBD_>4AH
MYD9H`S$,('01E>CG*"JA"V4(=1C-:!!2)**.DJA%N],=29&`!!BAE$<Y"!Y+
M?7>`X+U42$C%'O*F--0GA0EY2.IIE0RMO$9K*7O@8UZ08NHE,QE/2V=R*E0W
M3;GS8>%.+N`#A@%PB#)L-3)>%8$-"M``"(AU!J&J%5I%4`<,J*$&;E4#,8Z1
MC`.^@50-0,!&R.'9:_ABU7^5!"&=<5L>_#4+`--C"4MH8'"(Q59)#(:H:`B"
M_W>`H`&Y/-0`ME"-S>J"#L6Q<"?*0`0H+(`"-*!$SG*6!G`+YCXT2<A"+*#O
M$5@`N313019VD,%%E$,>M`'6"5^FD^%6P0\FH*Y^^-(7=IB@DW"YBA2K@H$`
M.44$>?@C:O##1PPH#EM@P0PJ,\"PM3PE,&;9BK:"=;(N$`!<6>@6K"9@@H9I
M4BPG:R\GFB(&%4CR6]\"U\3H83133D:5JMQ9">AB*QI6(`-IZ"RB2@"'<HC`
M-L(4I@_;,`17_P;#(K#%1M#@A,4P1G].&T&P0:";+T@GFE;PP@P`T(`^4*45
M^_B:=:`P!BO,0`0W9P`V$K&,1)B:`:>I$WL^-ILS%/\9<(T;P1/PZ1Z7-!DU
M78#RX&+0!YIAU\IQBN.`L#)"/-A@"VT`\^AD/V:(.LBB:,X0B$:D(C=[E$:R
MTQV,9E0[&AG?1L1G:?!\%%.7@B][CA8T]93GO)Y&O]%")>J8*OTEIE9/IL<;
MDZ8Y3?XVG<\(H#X0(7K!IP'8RP)Y"``8)I"!+^R8`IH@+/_JT(`"X+HCZ*8J
MO10J;U```?`&\0!NF[`QMA()`:`"KA(`-L!L`3!M7>1$P?(2XN`,X[`2E?5"
M7X<;Q"0-BN<+P0`!:0`"S$0':7`(F"5='P`#-Y`)RY(`,X`<:6!;%2%;/$!P
MC+`60-,4CW1Q4$0"CZ!;[77_,C&!+X.!$U50!4[E+__R1`0P1Q=W,(M$`GE`
M%2#'1/:P`SR`7%\A2%01%7SP%I3!"7`!%>)U-YT@1DG1!;`B$UT@!B:@,@0'
M#OZV$E?P$B:``04!B(_09>#0%200$Y@#<4,1<'Y!,EZQ$J@!%U3Q`;M!`8I2
M`[!B*YN2*IF@=4S#/U&C-<WD0[KA:G?S"0W`*17@8L=Q3E]@%=\Q#\D@3FIS
M'5:@`7?S2I108:ZF`7HW`U8``8*Q"5I1&5M%C.;@$IMG'_SE')>''E"F>>S1
M>?#A'6;Q+8TS>CO@!YN6'VL2(-Y@`EE@`4R``"R@(!8B9A$%.F1F4:;3(6OV
M.B?%_WL@Y2+R6%*\HSNW4WPT@E)Y5F=YQGP"Z27>EU0T%7U2,CTZ=7U48F@%
MN50VM525%F@2*28U=9!+-7[EMY'Z<3[LA!X3$&#L5U:!81`6$`""XFJPYE_$
M(ET#(`H,$$`;8'6'<@T-$``1\%<V4!88``SM)086$!+(-1(%D).4!)3BX%[F
ML)0B0$&HL&NK@7"0H151DPM:4P-4@PT,$`QE4`&UD&[[8'\0`$S,<@,LP``9
ML!O(X04E@`"/$!-P*1'@4)(J(1K'I0)-8!,S\3+ZPA/W,0%0*#YX20"8I#D$
M$"Z!1`(<,P`FX%4R!XXN00"1,T:%V#`PHP@88!<2P7)J*/^)Z35?"%$3E[0.
M6<`.5<AS3)$'[A<,>9`2`0`.OD)"D.!502D8F\,?4@AP>V$"F$0RWJ`K,O&'
M<;$LRY$&U3`J7Y>*MG`+G54U&%$%`T`+'&$+<*`G7Y`&<8$!!*=`QI%-O*`V
MYZ1(SX$#RY$)JV(=8P`$'U`"1(9AIG8-2A-UIA9S`[`$!/`'PV(6C_2;RHA/
M/#$9(T`>Z8%Y0;$>[6%/(N`>WR$5`'5D3)$YW%@^DQ,@$M-0>-`#(+`&7D![
MLE<A"T)[9F8Z'-(A'-)F;W92+$)2(;4[M?-F_ZB/_TAGR@=3E)8F,T53/Y5H
MB\:0T;.0,U54C)8E-\H]%8D\6^+_D&K"D4K:'^?#!782%`1':N]#D@SA"%V0
M!6)`GC88*O0@:XM@`PA0-A;D&M&I**EE@"J0;(]PDDE0@24A6R3``W;``[?%
M@37@#/!@#F)0`P-@*K:`!JQ1*F=9&0V@;7"`!ASQE``!GQFP!0V0`15P0960
M`,)T'!#0``D!`%#@!3[$`-)B3D"0``U@+4M($UM1%B#$6ISP;^7R+SAQ;W[Y
MA-C%!WDP0DPT7]<EB?C1!94Q`AZ'&9)YB`W#`P$R%2IQ8)*X%CM``$ZA<3V'
M2LGXJM^@G2)D#DFA+2ESAAB0!^]U!6%!28Z20B>#6UTT`5D`#CP@%L'Z'T;0
M!\3%FU_Q_UN:!FT81I[*87<6)A:BLD"UT$S3``&JI`$#4`5?9S;II@R+L2>S
MP11?YUDW0(MK8P6`\1`ED`#AY&+5H0%6D)X:P!7/\749T`804`<9H#\0QD?A
M`6I&P$=+\4@BHXQQX!W\%17/6%6"0S@'>CC>D3B=X:"$(3'<B'IP$B">9%T%
M@0<LT`;HV(ZSYZ$0%:(7%02JTR$F6H\@]7L?!2.]TX_^.'PN@B.UXSM^-CP$
MZ7U'"B58@K8\JJ,)R6C+@VC*<VA(`J02V22%AJ1)NJ1+VJ1/*A2M!I^FM@A5
M"BLF$5:AF@9E>E9;@0..,@'P,*J3Q8%74`!@@)<06)2`!90%4?]&DHE<(B$6
M;Z`1XU`#"'`L(N"HT7!!KH&H:$!:;5`((B`&(D`!*OB4-J0,[9,!X%8"D8H,
MF^4LC&%(93`&0E0!.)``,(`<,_`%"&`#6=`K`:)O(M!%A(0?`1*&4-0$Y=(7
MG4L"51`#?D`"?H<9$[!QX5&KM#9C5R!%81&&I:DR!.!$+_$5CP1,BX1*S1$1
MD'-S*F,N+S$T]J*=2I02W>(2Z840UY8'W-J:$R!(7?4-Y7I&;SDT53`T\&4!
MI=D5?%`%!!!R0R&%V?LQ/-<73Q@#@(E)"I$!E,@8KL`"718-9D,'F](U$#`$
MB3"65:`5KA$05H"PO2&Q#),'(U`'`!#_=JZ@-GIWBSC@22+92^1D';=X-_8@
M`E@`;+BDG9LD&D\0!W82!4KQ$FY#&X0#>O80%7T@H`1J!(,3'_G$'0CJ-)SA
MH%T0(,MEO9(3)^$8OUC*`&H3`BW@M!#EH6`6(;>'.AJ"446@456[(HL<(S*2
MCR-5(P!Y(P?0.SG"9T<5)CGE`T)BD-.7/)^\/&*2)1:):4`%I,4CRH4&I-PC
MM]''/`*@D7I+?OG1!$8P,,S*<C4\39#!<W$*!CP@`@!+!!K0)W&!+)0Q`2AI
M`U7T5V[**VBZ.0;(`ZC`@?[S!NU5$`T!%IMB"Q84E13V&Z,0J5LC0!O``JL"
M&.X%&;N6!J_0_X+6H1RC&@UZE0L"F#:$E0%$D`#10&%N-P,)``<]L`765A-4
M.0%7H!7/!451%'`?!`XFD*X*H3)^,;&'2!D=QT3;,A+\9B\U@41DX1+DZ7XI
MAP.#5!9*-,=&IYW$6DEBH91(U`E!0RH,`0FP$I0QP:T!',`&31,8<*Z9"0[G
M&L`F8`<>1#,U0Q3]X5QN07H2IQ]^<#.]L1M?TP;FD$%:4POF.`37L1N^T$*N
MH4TRX"QYMQN+$;M7Q;O)(#>\,0-$``0:T#`LJ\O8,!MQP0D)49]01EQD`31I
MM4_N$06I<1NY@*&9(!IGH&1EW#!%5AXW^P2.PQD)ZCAKD3``Y<5,D?\?$F.]
M!E40`/)!R[JY8L`"0R#(@,R.$O6A"W)FAHQF'H("(5*U1?!1ON<B,3+;+>*U
M+_([-G+)+360DT:09M+)U&,F=NO)HCS*4U+*24)49.*V<RLDJIS<*X`]<5NW
M2"++LPQ562:930`4574&3Y%50U`94Y="8!`!<V`'!T,H'T`!]``6]'`W*'D%
M8#`'<U``Z9`'A\4KQ*H"7G6GHHL`H5NZ>=H)JU%#W=8`I.5J;3`!;W!9PB9`
MP[:HU_`;X:(UKU$"PP3/O-$&6^!ET')!M"AC9?P!'R`J!?0!,^`&"C`#-``"
M(5X0)828!*QOY0NGSV&N?C&6^($!(ZLRL(+_&418,L2:KF%A;2XAB1];&6,A
MB3`]+G?(+4/CJU[8<9L4%EJ!X*3B@2E1#N;@*PR1$@/7<>P@18`XA$QQAS;1
M%3@QU`!<$4W`'T%1785QQOH1+B,`A59F!#"S"!#P`8O12S2P!1;0`-J```O4
M`#0`Q<B1`&U0#M&)#&DPUB&`';NQSX'QJ*]``W%#3A]`S"502]R1&N`U'P:M
M$)O73O@I$9Z05IB1$Q\3#8@*`CJ@`Q5``YZ.,(J]*$16'N@QH"Y@3XO#3V:!
M3Y4=`T\0%-\!7$SD#4DM)YZ]B.I@F./X!B!P`QO:`G\,(=V.VJFMVJTMHAQ2
MHKW7>[[G4;.CHB&%_WPNXB.6#-QDHLG<]WS3E\H\"CU%U;9QVR1TZV@O5=W:
M@Z31=VCX[@/:O=WE,S,!\MWI<9B$L,OFW0`FX"KJ/7^)1`1#H'^GKKN!PLQX
MX`Q$9%O:'(860"R)^@/??*<U8"MB02RYL#4_P*>>JAU))"N)RHF2FK`E4`.R
M:S;#U%G`*Y8BT/+9L!J[E%6]@1E;T3X,P`(E\`6AK@!NX`5IT`-O,!(!\@BD
M$4;IQ=#EL@.4X:M^P3`71ULF/9FQJ\#/*A9Z2!7A039M(80245]_.$EBP0-)
M1`),P6\GXW,1D>2=L*=>%[LO#0E*Z45S:,%WB!4V)V4NL4D\UQ6;Y!5O>?^N
M/&$33WC&0K&(_?+!8K_G#T==Y'%=>:T8=J?KA7[H$[1`Q^!J:FDW5PVIR*!-
MUF'6ZPD?S[%XC+%X?"+?\/$'0R&$CZ02XO)/2^"N"`YNDU6&F\`.0PP!D0JH
MT^`U90<5_]1Y#X,!P![L537LTLA/!CHXI['L1O`<.R`QDND-0<L?0ML'F>\H
M=<4`T/3'W6[:@@SNJ&/('P((!BB#@P9FAT6)AXN'#HL.D)`YDI$..3E(EY('
MG`<Y')P<H`<KI:0^I:BIJCX"`J6N*P(='0*MM*ZSM+6HKKBYN3ZMP<.VPKDK
MQ;')P,?`SZ6RS28$U=;7V-G:V]S;>20$)$U51B[_!#L#`!!#0QD9)0,8%B]@
M$6`3.!``1!HE#`,#1`@<@6.`#3$3$#0`.*`!`AMOWH@1DX6'B08U-FC46*-"
MA08,,HBP88$!@QH_U*C\40-."0@42H@0`Y(.'1!PX(``D>9+@I]#&DP84`%.
M4:-I*/A,H"$#!C%O7/I+4R+#N@001(P06*)?A1(ERF@@,L,+!1!;)DR(X2>/
MF`$B=Q#`@"&+"A(J\EH8@`/#%8M:+?`@84%$EQUK,<03B$$@CCH#)FQUAT%R
M8WF5\SRU($^,WPDB.&,P(:)R/`Q])WA^ZO;IF\J>)UA0/=O$CM$3Y'7I0F`W
MGR==_(R(T65$E:TF=A-0_YNEBXGD%F[;M4VMR38CV/LLQR&B2I4^1JHU&=^[
M8-<$7X:TR4J3`0@T.-,,^9G`BX8/6177*4%5:7VF'Y0A0@Q++!&#"`.$1,$_
MI]&U58%/1.%'%P@V0)<(.&2`PPAG$-A80W34`(*(%9C$P(8QC+!?3N^!0(,3
MZ$%01@8C+/'$$F?`U1=VY;C@`H_813'""%$4N,2#43PQY!E+8*>D7#O$8$(>
M?.S@1SC@$&`!"5QRF4<,?=B&!QY;L#"$%RVT$(*:(;2YP)MMQAD"G&XN@,*;
MA!0BB)Y%F)'(GWTR8@8DC512R:"7))J))$AT<HDHGW1B"BG)H'(**\$\8XPN
MN?_L8@LSGFK:#"S+%.,#*;,L(TTPJS;S3"W`4-/-K+36FDT>>833A!_E&,%'
M.A"L`T$).&QH00`1V"-&!F4``,0,;?RCE58C:#C1`!F!M!"V;_R`0%I93-``
M'1N0FY(:':6A#P-O6(!#"72DM`&+<"AU`P0#O%'#`!H5M5.]]&%EX0`45(`3
M4OYI`$`#-O#`PQLBN&,B#B8UL,,27/4#4@G[>#%$>B#@(5A>*ES1``X-1"?"
M!#R03/(.(^R@0A99I#@1!CL(!-=B`]0!P0@4\B6""71)-@'1T4V01Q<37)'9
M"`C-U!A-*UL(VH5^!7#%T7F9,,$..W1!0F[)=6$!TR;_C'#T"+:-P,>$?RS1
MA1$CW%@CA;9A0`)B8T_0VW-JWR6>=01@Q\?AXE6C@@D%F<#E-3P&/<!8&D"0
M!@T-\+`%`P;#D883/GWQQ5@?]!6E"'64(2,`&FA0ANH!#7GC'V`K5AK0B#5&
M[9`C-.![#34H5!4\TQ8+1PUTP&=43"50("#1*&_T`PCSH4>52$_<>`:&-(+G
MHX]`^CADD1"*$*&2P\4019(#DL!'##MP&:5<7G;991Y@$X#'!%LTT`:::0J@
MFMZT`#G5B4YVNE,"![%`%!C``'^"8)\40:A'.`)1DS!4HC:8J`-DPH./ND0G
M*#5"87!B%<ZH!3,^=0M>W$)5_SX(E:B0$0U,N4(5P(B&II3AJEW@`E2RLI40
MAWBK7(D#.S_*@PA>%RP(O`-E8N`!&*9H`P8TBRPE\!T&SC`"NKA#-1F`@TH0
MH"^`!&]?#5"!&!@`APV<2PT_H$.]G)@O'B0(>6@PRHC@``$-)*`,?1$#'!"P
M`1`DKP*?\XD?&2`&&]2``?SQ2!J2XA,`.,5K:J$+!LB(`8S4X&O;XPL`_%$&
M"D``"%_PW!!J0!(+$"!,:2M(;N3A,A588TB2`9IC:+05')2!`9+1V==6EIO9
M3(`$A]',<T:#@1'DH8N%P1I=-/.4W.0ND\<:F]AL>9BS`:YM93O;VG;`![<)
MQPC$*?\GD6ITH-J1P&M]ZXW?=E.%:CRG&N$11Y?&8YUW\J4+?>!#'\`3GG#P
M`4$,8-T7*$"#-@Q`#%O(``40%CJF$`$``]K!'U!3!ZNH3D,-V>*-XA"%/]`.
M-:<9$E\*PJ&M-,"0&Q!1#5B0!H\0:Y='^5=28O3+VYSD!T!%0`42,`-^Q"0#
M`ZC;$[:7H0'U"'Q/I1N1R/<$\]EH2#$@$/O.P*4^[,!QYX"?_<8*#K7@`:(T
MJ(\``VA``Q*P@'@B8)X6^,`@).*!$Z0@(BQH*$M(0A.6V&"CD""*41Q`%".<
M%"BB@4)A%(-4L,`%#E4EBU_,\(:,G>PR<IB*4;505+A0867_.Q!$(IIVB'S0
M%1+-,0(F-E%#*[.`;`/`@XB5@0A><$]E=G`&M<#E*25PP@\N`$=O&<5S^,H"
M'DI0`3<"-8\X,67!Q!``WVT`#1XQ)`@JT,<_H@R-R).C1T#'E#)@(``!L`$&
M0N(/BKT+'I51R]>.I;4K>,9W#6BI"!):AI<@D@A?J``%O,""+50&?B:8#4".
M9A>\E%4@7?@0('5'F:L%A`1T29MLY,$93&+8;+NM3#-G@YFO8>`PLD'(#HPY
MFQ5W(09YJ8+9[L*TYASM,$1+#@9ZPQN</7.98W/;D,KYXHSN.#E[\YM:;%D=
M%8Q''/S$!G:\,Q?#I)8`UC%"/PF`_R%?^O$+ZP#F!*S(GY>$SB>`Y%WVAO2A
M@*S,-F>XD9$BO"W\)L@D`^C0"`#R'N6Q@`8%XZY34,-<.*!!(_4:@@86JJ$(
M8^NZ<*!!]68P`_3484/98RID8O#4'ZW6"%Q<`E6MJB01=$C41SI#.`A@&[F<
MXZMDS1*K5=.#H::I36MM:YS>*E<%,C!/#GR@!`$5*$$-ZE#'!FQ@(0&I2&6"
M`Y%:P6%)<=C%2JJQCC65,XXA6F>P4!D\O*$J:O@I5IEJA=Y.AF6!L6Y?T**T
MIXUW-W)5#1(8(0K?PP"S(`!F)T+1`EEX3G69I0$OI($%`3E#,W.#LC<0#`US
M2,&YYF5*?/^1A'/DNHG!HBNZ-C!,7(34KE',#.8&1(UB#8"#B63TNLBT.G=;
M`!Y=@/>&*US!:TQ3#4)JT!A(%DLKHH0``V#R$L[Y!`1,`'B69H.@NEB@"EF%
M7[6<`IJ(/;2+4[/`"*(S@K'YA2Z<.5II(CP;$,M&+0AYCFQ:[347R]9L2`Z;
M"G;3M<-8)\+).2;:1G.;Y6!@:1N^66XBD^$A"<<YSDG.<\P6-@L(CE;\))P*
M<M8%@?(!2`7=LP@@\('*4<"A8M!ZAIK81`;XCG<%B@(66E,0@;B>6DNED"=%
ME),2^;QX#)ADYQ"9,`B8A@'FNBZ,O%!I"KBCBP/0B1-N4+T$6*'_TM[ET%+W
M?.DS=)I'WTMUD6ZDE:N:FD#W'M(W","'5F_)-GWH$C8`;H,M5.!,:V7KK@MX
MP+<2(H%XRI.P'4CL8A<[$L=6*)K`03G`"9-0@-#V*-0V0HF5#)WU"NCF6)>U
M*3,$*C,T;N&&6:WR#-[6#,,`*YKB0P(`;_)6@MC`!UEB2U'0*S'`+*(3+!G`
M`!A@`P4`!EX3`!C0+!HP`Q20!K#5=/@@`B9S%FIP`1-7+S%A$#Q@7<FC$X5$
M20L5&:#1`,[5$6#!;U^0`1-0``7@<!IR(B=",?]P-%GU55<0`%P8`+&1&_*%
M2YJ'`<!3`R#!%TD5$%8!%AYA>A7@1R#P_P9J$25^X#4($C//D6``1QHK,V)T
MX31=H`)/00+&D39>,X.YH5ZRP68S&!U7@!A)TXE>LXDL$P,3,'<FD`6CT00C
M0`#'H0*Y\3C%X1W%81MZ-T^+AS]_-W/X91)M\$L!X1DB,"&\<1C-00V)]V+6
M@!W6P$_B<!>$8T\$$`,!8267=WGA@1U=`!!B$2SI40*5\7JQHWG5$`-Q)F<X
MTDD,`1!A:%4Q@!HZL1,'TQ\SLC(8PCF&=ET5(`,W(#I9J#8#P`(V@5T4\!->
M0!8)H`Z[(0(E(`-.L)`W4!_/9P4*$QDQ`!Q[Y@[6]SV>AI%"$B%&LA5A<"1:
MH55"XDQ9\D[S]?]..Y!^LO8<%F`#"&`F7J!K;85`!#0G]X=_^4<(^S=L?A(H
M?7)!A-)7B6()F:`H2+`)GE"`#"@IDB(,TB8+-H0IW79#.^19J3)9P_"`%*@J
MF8)9RO!#+P1:(CB")EB6V8""]58X/O*,OO2"_A89+?,<!3`!&0``'T`$EE,L
M`1$0*+4U:2!&<P!4+%$!3F!*.#`!`:`0;E0N\$&8A;E0)J<8+$!(-Y$@S*(Z
MH8%>:NA2%J))3Z$U),`%)(`K-@`1?H@@YU@:L@$2.@$\_T*'S=0`S')P.`$6
M_U$":2$&":876T%+)$,"66`!LM@%8F`'N>$T6S<DE)<S#G(0$W`0H8?_$&@G
MG`D&-M'A8H[3!3:`9!,@-DR#8?'#-FFS-SO&3<;QC,[!B6@G8A:R$`CB#\S"
M.A8U`Y5C(0-2'/*$3(XS&HM33^(!95%F#>`Q4"9@!-1P'&[SGX7#(P0Q`!PC
M%GX$`2:GG#B7-X;13&JF)/CE.PA"F,'"'2HU%0?W4A5``Q#P$\]3+6TDF"`0
MD%Z0`)\G$Q0B`GET`R_J$UZ0HTP!`<XA`A0@`PIY`PUI!0])GY&1),5A6R)P
M?9TVDD8"DD6R%1QR!NLS)&"U:F"S`]_0!_!S9<)I`4SPDO\3DS))?W,R?W`2
M5_FWI@ED`$$@"!*$"'DU*'YR;$(Y@`2H**%`_T(G-&V3$@TG=`S;]H`V1"KL
MID*/12F:4BFMH%D0N$*CPBE?N6ZA)4-D:9:8B@W@X`+X1@!^,`!EX)8:TA<M
MHP(!,`?N4@=$]07$TGJJ62P'P3D_$)@_\(2%Z40FAP"&Q**(5)@!F09O4``\
M0!,L``?GR"`FEQ=XH0(\T)(3(9T3T2Z\=08*!X?`@P"*P2`%T9E$D1-&<120
M)!(`\1)@81+!$B,4\!``)ULJPQU*DRM?10VR%0ZVM&<(T:.)*`]_*!O1$9VA
M]S6W08QOQP-\\S6L*)QZ`S/&A$S'-!I(XQF"$2['%'`OU@6=Z3L,02PA81)@
M00&MPQ0Y2@1`4)\-`/]UJ4@<R!0#&#:*MB0.D&,$`<4CB0-E7-($%#)0!,6I
M*_B,`<$`K5-*QM<`R0$TP200VP*;3#*C&`$"*3=>%&!*(J$8;8!(%1`\?]90
M["`@5;!>(%"K>20?.3H#5O`%`C)XA/D30BJ01*H.>C,"$'`##.D31%I4%S4`
M.X`%!4(A=3D`?Q!5G>8"0_*D>U8@6V%J$0)J(A`_:2F<^1-67R5;-/.2`Z8F
MM^969HJF:6I_OZ9`=N*F=H57B`!!/4FGAG"G&118!_@)T&9M)R1MBR5ME,)8
M6BENM*N!,02!(=@!FO64Q$"5&$@,.-1NJ8*[[A8J/C26[Y:IREMO).`"86#_
M#GT`JC'B1&!Q7E,4`:CJ2V7PHFD`$--2&1EB`WG@$2E1JW*4%*8D@V(@AQE1
MJPU0(J9$M@R#AFK8`(PQ$6AG`P$@.(0A6VM(%^O;F=1Z&P,P(@B``'*8$PGB
M#Q9"C_YB$SQ1`G5@M`,@(Z;7`&9&'P7VA_&*(2YGB(4XG?@[$S:@&KF!O[)U
M-+4!'5YC`XAA8YP1>F(3-GL3/U]#`.(IGHW('&K189RQ`\')AKFA,_X`2541
M@WAH$HC4//1!?,_7.AK```/2!W,C8R205=I4B(=#C04U.#7;C*QF`JB(`V?@
M![R">4T`C:*D.NOP2]W)&(U1%<EG$K`%-`WJ$46!_TB7PV\`4`9",0!M8&CQ
ML@%#Q0X+U087*@(9P0+V,A]>0*2M,P!5,&:/N9!?8`5$);;XP1MGH*K:N!1,
MX3HHLCYR@R%E,``K^#VK]3U*0HY/,`!V(Q!GT`5-LCU<M;@H>26LM@.AIUPO
MV9``5+GS)R>\5LPVR4!VTFM!L,QO*KI_(BA`>;I_E4$$V"C5MI0->"FRRRF&
M2I4NQ&VH\(%4"8&-VEE3R2J0*H&=PBK#:X''^\[PG+S+J[S-&P;/>U!E,+U/
M9+WU,`<!D`Y$I0%I\'JE@1H9(`974*SR0GOHBR\\4`!7((<8L2TF\@\(4`#,
MR@.TA1!Y8'/X\ZR(L1O%8?^M9,1S-5`F(848^_52.>$[1A$2EO04#@H'YE*K
M+1HLTQ(Q^+(0!/<L7E`!""`R#L,#ZE40.-.=N8&)(O8&:MA(*W,%LY$TK#B*
M-<9A=9$<K(@9P7@.79`%81,NSJ$VWA0N06Q,JU%UYD@QZ.@.P5)QP=*Q20$3
M6"@ZSC>WZ-$4AM$;L,C5!)`%57!/R1AYA.,K`^4K5R8>!+%C^.1IUL@0^L`Z
M_1498H`@6W#`GO.7+/`5[I!4>R9)AH8&GR-I3(%1H$$#A]:$^>B06#$`3./2
M%#`$"^G(D*P!`^`U0_<%OGK)`TD61%`"[X,@^<#&_B8MJ)>WW","J0Q5&.D"
M&./_RK`,DJ9&R^BD%;)V#6]S)28)%9LS!'$B?S)9?\7<:VP:;'A55Q%D;,DV
M"78ZE);0;$KI"8CE**_;NC7$NZ*U0K!""^',S<7`"RCDE32T@;;@@3RTW[W@
M0IZ2X/$,SR0XSR58S_;,!QB@#TWT+C(H1?40`7:P1/5A<-YH(8^!T$:1$C>!
M%/PFH060+([DGI\$AQ-!7W=1$040`"V&/[WE(-2:21@@F'$D(B#``B=2&@N!
MQ^THAR4B%F6P!251`B!`F7`@`P)&MGN)D(#4LP!`:41`!`P0U/ZKFP0A$FK!
M-(BA<PA1&191.]2E`EO'&8NC-VJA7@DF#RTL&66WPG#'_QO=V1LP9IW5).0-
MD2`+;"+ERGM*`6;]9NAR+=>B$Y!$.K>8'(_!"";I&3-WH7[XA'G(Z,50)A[7
M.`)^T`=5L#[XMCX'`A`0<%$]Z!%;@`?[U>3_Z!%`WCR`E!ML1"Y,4*L],03#
M4A55`WP4!]O`#)%-<1@-,$E.8.P.V>@:,#0F,``_4>C.-P-N0!804`/0F#Z]
MY&8B(&I16B,&0B%-E=R,C42(RY%%DE1)LA5QUB0'XDS7X$I<\CXQP`<6$,`,
MP-VW)LRZ5I/AG<S%K'\/I"?#)KH.\),"")2HFR@<0%@=E)2&98`YX("<T`JP
MZY251<X9""I3^0LV)"HZ!(*QD/^5C1J6V_99G++@*"_/#AYOU6UO/;(<&=!O
MPV+4^IOA!:!O$.H$;N:]&%('$Y`$'1$\3<LY%2,&,[Z_SME(I?D7#8->=\&L
MI0F=SXJ_L.$6(N`0Y;(3*=<`+%`5P+1>18$&-4T'%;`>\FL#(!$\/)$`-Z"0
M3-$75Y\A3[%>8V$%1.`&%)`6:I%@P=E)$_`&)#'ULI5@]]0$-%,1B[-U/,`;
MG%'O9W=V"79V,=-X7Q,NLB5BB5@:1BLM_N"@";(@S9.'8#%)/5%QA4GZ-97'
M-M6#/8')C?[H`K)CQ*'7/%:()D!00)(X6-8$FXY/XF$"L_SI?R#J,ILC7@83
M3YM%DVW_>F@@]H54`7^FZPF``PA1`C2=/'_FHEC!Z[2>$X!&`>3EQ,.N1*4D
M20U9UW8/`&P#&B%!>L'2!OX`/`"Q!#_R!Z5.+5TPCAQB([,,""(X&0,Q1H<N
M+H=&B49+(B-+DH\B44\CD&>&,2(B>21\?`2C!"0$.Q-B;P@L%`E>(2$MLRVQ
MMK<+N;J["R@HO+^^P@9!!L'$144&!F8.9D7-S@[3U#G6UAQ(2!P<UQP'W=\'
MX^0'*P(KXS[HYNL"[CXKZS[N`N_R]AT=Z.?Z^O;T[*&K!S#?.WCXW@E<2%#@
MOWSZ)$CP-]%?1(D4.^P@Q;&CQX\@0XH<9804"1*+FNS`40;"_Q`($#+@$&&A
M0`$P$2),P%$'@`8*`T0,&-II0(8&!7A@:""B@5,,8DR8R*,B@!T5*E[8M"'&
M@@VO7+U>(:'BR@0$/]+^V$"'#H(:#5@TP("!`9R[+$#4@#N``00`&2:8P,&`
MCEJV:"HD2/!%`PLQ(ACLA9,F384*%'R6:!`4!P2G`TIHF*'!BQL*&WCPP*J:
MZX2]-=YL0#`!3Q:LN'&?'-5EPFK!6;J8L-#%PH0)62;L2#Y\A.#B)L386(J!
MA?42%"A`8%"B1(42EL$SH%"9O/;*:2!08%"A\N4*=^&`B/^^,GCL7Q:_\J)A
M,8`!&)"P0Q<$=-&%"J?X88))39#0Q/^#'!T2TH--&-%'%7WTP<@BA\0P`$O]
M,08!#AA8,()=:+1%1V+X98?#!!X.T$`%7\R0``0:6.$%?PDP,$$7`\!4F1,W
M#.'%#"U8H4$&72@%``!#YJ?D!T1HX",&`XP00Q="!=5)%SN8L!,.(\011A1_
M<#+34T8Q,-<23SRQQ`B#X'#&(HDHPD@4BG0RR9P#G'$))!AT4445(PRP`PEY
M<,&%"X_R,1P>"+`APPT+V$++++=TR@LPON0BC*C+_$),J2@04TPR9K0*S31*
M4#/--=Z,8XT#UMB:0SGER!./.>:LD!!`OM(3D$#F+%300_LH*^PYR@IT[$'1
M2ENM``]!U`'_1MM6=)%$%6&TT4CDEFLN*2Z8A-(B.PQ01GXO94!(33:!48`%
M/)6AP1<,#$644!F($$`2?%C0E6H\7*%P50'@]D(``5SQQL2J<`65P08W4,,&
M:6U0`P@@PX%9!G39!3+':OQ00U\4?$&R"7W1L<$&(%1&60+]6<$`!I'-6,)=
M[7W1&`1""5*&FPW`,82-IE&`@!C'88!)EQ]F4`$=7V5QVTFF<"15%A9410*8
MS!%GP8#&(2<8`1A,8-Q7)6<`01D_IT?>79:Y1P%X$'0'`7J7B5R!7O/-!\>,
M\#'`0!I[=P>>=F7HMY@&E"=01I:GC$#`CRKP8(J#34184D<44MB1_X5]^(%A
M2:-3Z(<@=1#AA7Z?B4$G'&BDN`$::>@G-,E`RDCC%T[@:,7D,Y"X$]WM$9F?
M%U980023)&"001GO"OT%`-@?35=051S"QQDCC'")<.UF,(*@41CA!R8:@Z"Q
M:&7,=`:<Y->)@8:,--)_(GZ:!)T$]81._.A0B9J`HQ;(!4E9@`FLH,$00I"I
M36VJ4['XU*=^(:I0]0)5IUJ&`:"A#&BTZH31D!6N:)4#<>1@5N-`0@MY18YG
M/2M8!#&6/815#WJTHR'^8,@\GG4M:F5K'PUIB$/^L0Z+4(1;W0+71*0XKG-9
M\8H14A<BC&`"$?CD)3'!P0!J`H8RWLLH9?_X0`)*\"$Q%HTP-DB"":Y@DP($
MX"L*@U@`5A.Q5*CE!PA`P,2>1I<)+*4&=-B+_.;#`K]PKVW>V8`:)KF6&F!&
M/22R``8JD#L0M.<R+4N`DACP%N[`!PTB2X/0N-<)@#5@%7!(P!BLT`(8)"`-
M#,"!&/W5%)YE`$IM.\Z"1%&*W.@F"S$8@0EX<!SB#*=$8A+0HGJS.8,%J0P^
MT<#?WL.>]C#./"4PI<CBHY<:'&XREU&<XBRCN`HH3F2+FUOD\B.Y_D`@*%)1
M9A6$(SH+C8X`I3,=`3@D(5(4M$&C6\0?,(&#T1S)"T2SP4[@H*(>P($"I=F1
M!LH`":$TKSR22\#_].;"D[PY3Y1CJ)*=,#&"!G`GG(H#T'&"UX4HA&]\03F#
MU"(CD_O)*9DB``''/@8""'R@;X&:4_YT.8+P'2(,85!$GER`B3-$01)TBD0!
M17`&0QDA41AP%*1<(`H+X&$++%C#!#ME00QF4(-P]6`OAB%"504A",I@Q@E5
M&*MJS&J&X'BA`Y"@*W)\(QWJX.$]H"40Q>Y#6-@ZR+0BVT0D!H2'\8`L$AF[
MK&99EK+XV(<3@ZBM)WI+BJ@%5Q6QR%ISC<X")]E0242@KY?L38QB*$`$YF`O
M$HC@>A_X0`;Z192@?.@-][(!#VQ@@S?40#I7R$-7;-`YR-3@!RD#I%XV_[`*
MIAA21B#;6%I`P)TAM`0J;.386N[B25%^@0(-R`("&D`'\K(`;S<0&LY(68,2
M`&!PGJQ,?C0`@'X!S$U^&<T,QF"C-/!R!(5,A28SH`$1"#,+)S%FUP@@E0YC
MY3@JZ$T6,#"<+I`@FLV,&@Z>]"0192<[CJN,7=C+7I#-Z'`N[>;BN@F?PXU3
M9#XKP=Q@`@%Z+D:-A!!!F`QE@1C$`$.D>!#7(.21@D:Y="3!$T&-D,P!`$!V
M7AB"FR3*'IFA@04TP-E^-FIA#.#`.\VCIY2(0*(NG*@.[\V/?@D<L$ZL#Q6&
M=,I<-@(D,DGB$&+@F<9*1KF`W>\,@F``"-J"AO_Y?`$(`(A))-;G9IF(P!"(
MF&J>JGI5.,T$3IWH:OBZ,)/8CL(K;T#S$'(1BUK4FA9NI>`NA"'77>N"UZDJ
M1K#OBE=6[94:QV8A8&^UJP,@`5?`(JRPDI6.<R@V']5>B#S\$8_*-BL@#W$'
M9.^!K<<RMED0L183FUC:T3H1M=]*+15;2V\KFB"V434"'T0`@00,(5YB[$(`
M=AN!`JC@MQ0^*G%;B8D,(.!>8F"%C`#TAN9"S6U7$$,#$#"SCIMS/@R8EYOA
MH-[LTJ$","G!BRP@([;<^&-.$.5B&"`&<P(-:*H\'LXJ\-P&"!D\=ML>`.K@
M)08\*0-"3L""9YD&IQ#_*I@[F"XS[]D5V))"*NK""EEP8X+>J.`XP2&T!<2T
MN0E(-#)STY[0*.`$\/18/NQ-&M#2*<[X^.LN<K\Q'&#*1NZ$G(VJ9,SDU,C&
M$2QY`J$K!5DV;`(N&O3*35!!XK?,H<<#%$*<<!<1A':#]6QA"^S)'0MD$/,0
M*5T#`^B"]>#LA)A;X4D:^`!'_1"%&-2%R.$D3%/*9[XP+&$C)N"9GQE*"#E%
M(0PQ<,K&9E,#!L0^)@-8PAF,`A\0Y$YD%.`/]@9PB:X.H`Y$[P(B\BWJ`HZ@
MU$\("JJY6J@^G$&,HBC)5]!Z`UW?H@50N&"N?PWL7LNU_R!4!,1V5ZYR;,[0
M_RI_12N$U0VX0EC.MBN(-0Y$Q`[6!BU-Y`/)HBQ,M&VB]5FDQ0^-U0\@B&X&
M$2U'Y%GNEH+Q)F_RMEKU]H(@<6\H$08=,@+7\V]](T88P`,XD1,!0"?^101'
M,Q2\1SX9L`4!H'%L40%R(2-OD!;S!16O$4B&@5T_X$G^!0`X`#5'@5UJ0#,@
MPP+YT08E4").`4B7`3(THA\:4`);X'/>,7>!ER-EL`5BL1,I)R\J%Q128Q0$
MICA_002RDP`L4`-T,2XDD$<1DX0E<!3"I'BWL1JXD06CL""5N"!?IS8[8!S#
M(1@_PA5&`1/9H3V6\7:"XT[IE$YP,!3*IWQ\$12*\_]F;?0A#"`4H($E8I1@
MEI,``$!X##`"PF$@"V("&&("&6)EHQ!0B<=A_+,('O$@'!(^&K)0(B`:BT$!
M-$!*>-`70$,#3F!D&E`E@9(HHEAD.!-[&T4F=O8$9Z!33`$)$"85=@8)E^`<
MPC<72U$"94!TZR,HD2%4,U-?&'4C99`!2^`ADC9INY,&_[8OX90EY0,D^YAZ
MXQ=5HO8(D3`)0Q$G8`6,^Z1+FV@!%H``("!!M*8I^)=_N.8IH-)_'C0J<P5L
MQA!LRQ`$)Z0,**1"*V0-V^"`'`!#,21M$CB!%`B""K$L1QE$X*8M3$DL"%%N
MZ!!9"_&!Z48/)ZB"[L:"4A3_;RX(@UYY=:5@!#08!:K'$D/P!2.B@SR8$Q'P
M`IWV99<C`FW3CD;8``&P$PCPA3+#&1NG,K4(-2(@7I,T22<'8R\B!BVWA+@#
M!PR0']@C`HDF`C-3`Y46-+3S2@BP=W#6'D*F+U9R'*"Y%)^')7()FD+!`-C4
MB$A7!C,``3S'%1NA`HPG%083&1<CB2J`81OF$5N'%<'1!<GA-LK!B<&7:'W!
M'HRC/4[@'C(64P/@8TZ!8W`0&_,%($M!&$:A2SCPCG"A,?C8%$+A&3Z!EMC3
M'S(!C&-G*%6`=1PA9<OX3R31G@&59?Y$>=2(`X/H!-GX7-7X'M^X&`,F7!@0
M`U$P_P'7U!+=PT9.82#&USZ($A3ELU-%PWM+(525U``XDI:00'WQ`30R\`56
MT!AU<`8&2DH!R0)&\@H)L!X0"8SN$GYXHB=3%060\"="83Z)$I$?N7(CR0)M
MX&\G*0LIV5:XT)+#`&PQ>:2I`FQWM0RND@RO<H"RPD+:8%C3X(#;`"R)E8%&
M.6X:V`'Q`)4:6)7E9EFAM41H.I5()*9IBBW>,EIOJI5R.A%=^95V>A(N<%4D
MZB[_1C<&5A-L60`K40?A6#M1L0.(&@-B)%$X4`$_L`=ID3))@W*7HTF2885@
MZ$G:$4YFMP77Y4D\1P=[IST%A@'--VDDF4HX0CDT!S'34?\G@R`3,C$78K`E
M2_`')!``!9!QG4`7=,$EU0@!(B,C.'(W",`S!M(%,1`FI=`:UK,S8L";O6E,
M6L=A3D8`*M!U8^<V8#(=3"$CE-$RZK$WBQ,?<#&=RL>*_2)H?+&=2]$4$X"/
M#7`<\\H4BL8S'R((V40!;4`Y[X)TD&`"")*,5$:,&-('`\4@\VE0J%-YEI=E
MU$AA&O!O:&EA-CA<W)$?F89-EQ,G[#B/@N`E4LB@<,*.9\`931$7^C@B6:)Z
M(B`?B,06GC0T%$`($S`")4`#I[0[0T`D5G`#FE9H[T$!__8*I,$8,^%G(E`'
M]=-4_6.1HA9`6)4E^5.+AM(%BB/_2%M``QR4*;>VDOMGI'2%*J/B"V0;##1I
MDV:P*GN%@,S60K0B#@?P0LWF;$+9#M=&+6%Z+1Y($"BHID>9;B5XE>@6;M[6
M;EEI$7,JIQIAIX[;$23@`F%P"3M`6XQ!-T0!J&PY&,`EK'.A'$[V.F,D!MSQ
M`Q>0,I.$`-^A'@,@!AJW?*+:8RB'EFYH`WL!2(DT']^A/;73?#^#<^GA$QPE
M!CQ@,,)GJEB"CUV1!WS@!Y(0=6^0:`V@2_Z")1^R&>Z$FBOZ!6GP7&#2K+A)
M`F-'6V4H!AE6%1K&81W688J'O@-R8B:F'$K1%^'D.&['A#.B%S+"E_G*'8TD
M1F(T%TZA_PJ)UC:?*Y<\8TAM%C4W"B)MB)HM$1,!HR4&>RB'HB&0UR`.TD_U
MR2'*6"&49P3DXV6S<R.;P0.5>SW8PV)T(T;E\P1Q$`51X`??U:)TP5*7<`FF
M"AOS`0%5,I&8L#B7P0+P`4J40QH#<+,EH`-",#.)4;0ANC?.\5ME,(I?<);1
M,SL:4`<,1\7J$SZ)`+53A0E_DE7$5YHEN@4E.00<]+7ZYU9BRVLB9+;&T$$@
M),<UN;90VK;-H(!T>PWCT`UUBUC3]D/#(FZ<58)C*I4H2%IKZD1+](%4*<E!
MA)7?LH*+"V]U^K@P&+F6,`)]T`"18UYL%!1B$`!E-`=SD`4?@O\C4$*]K00D
M-,=R);`!>X"Z:J"ZV>%@JJ`QNS,?*4(9,(&6`[`7],4Q-),&0E9D!7G*B99+
MA!&+ND0(;:.L?I`'>:`PT84!9P`U<TD^ZP,_L,&8"V<4U],=M8@=JE0!%0<C
MDF(".]`'?-`'"Y(<.``'RI4;'\$UTZIU)]%U.Y"M)H:HB*F'ZE0!1+&N"MT9
MX=G0^TL8GLH9-6`#\[5H4!%,&+`#4C,@,=!UD)8H/?$3E"I/EZ,<ZED%`$6P
M6$:?R+C2)-&,#DN?D#8`X>AO-:MDY-,ENQ3`A1(G<6`FM:=3'S(4=5*+_?@(
M,K(7*P('3C!+O$@F0&@9\I$8-)!F_7'_.5+3J+I[`Y,#/;S(41/P6ZQW`_DE
M2M&C31W5<`5Y?GDBQJ.65%B5M*%!-"+P>6A&`VN`*;_@QF]<I/SGDJ4RDZDB
MV/TG;'),;%!J0@G(DS+$D]Q06!%(;1*86=("+<-"I@XAN,SBR(*KII3<R):L
MN.`BVIF<R9O,R?5&`H]R"7R``?UF.:5L8:B,$W.@`N;\`3_1!M0;%%Q2`A-P
M!0U``71`22E3,T5&`2]R!::Z%BNBNXQ39)MAB(EI3M]!`?KR&1;01Y$I:$^1
M"GE@C.%S$@J3!S?+2[UZ!EB`!9$!LR&SBDE+&/^A,0C@%S4"`340UI]&F^=;
M%3`C&<J1TJ.P_]\:QC4$0,\FH0+O:P(,U1=(%W+]TB^Z%!D3-Q>EV39PP3,(
M)AG.E=3=>:QFEPK!ER@B8&<CX`?*.C6$*GM^$<'0]PGM*3H6_$\?3&4#U<%6
MMM*+4$#N,K$$R21=<`:("FB&!&$_XK%R0N*^ZE)96#\M2HOL$1\?>CQ+TC;<
M8:$_0`<RL!AAU@9M`"`GDE]2<B,JRA^H9TA/G@9$4M;1HR3J(WQTLH\B4`5M
M+6J)D'YRL@11\'ZGJ8^=8-<_F@"]X+46!+9^G:0R.<=CZY*^8-C#4`PCA$)N
MZPW;P-A8F@-(4,CMP`YXRU@)D<A!=&X=^+=E2H)0R6ZC#KAEJBU0%/\1IA6G
M6QE%I3UOJ.VXJNT"E]`'$Y`!BU&0!N8;9903!Y<!=8#;+&I<G^9S&*`"UH,&
ME`1(X=HR1[$*XK5>Y5%D_V$#=Y2\2:-.L4H36N<;Q:L:ME,BKOL)`](;="'M
M<!%3A#&O.S!]LDL?#EZ-J`E3VBM2%%`#FF1BG;,:)Q$Z8B(W\YK=U"J;7;.^
M4E'PLKDE)R;6`".K$%X4U)%H;A./M`H@+O46H:J[^%L#;R&<73&A\U@^4<!2
MOT0$"?`=+*YR&5W!%KP@)1%0_PXZRUCC\(EEK+-EB3`G.!LBY+H1,\P'&OV.
M5$./<6)G&N,6<'%).9@E"(<=%=``GD1Z_9'_:<XQ`%<CLVE0UC;R$B3R?BOZ
MG]DQ!(NA)/^!"J&1G+Z#,X)(,CP#82S!Q3$0QF*,".F7D=)WG`S0!D-@'6BE
M5KO`UWW]5G\-@'DU#'EUMG1%QW1L;,T0Z8[-D\Y&#I9.0[Y2;>MPR/#@V1V@
M68VL$/IPN(/[R*%>N*-56MSBIMSRZO*&R;%^VK/.6K4^)\N*`[N^'7S(@S@!
M!LK.$Y1#`4P(GB/>``%S!?T%`I,TF<^.W!<-`APGLZO[%V6``;J5%&$=%'MA
MX1/=,`VRB:H1,04<-;X*)O$JWSQ\.`.0!CIX(N]Q%\'<B#-!&*GI%"60'T0`
M`2`@48;78:$`"$8$_R19)@,E-18V64U-!(^0@RJ3E)0DCI$[)CPD(F49`PPX
M`PTB#1,-&#4-"!@B8A,88B,C.R(BKF)B+'`5)6DEOPS#%7`@-1C)8B0C(EU=
M,5VW(U%/`R,X91\)#"5E$.`EH!@3,555!(V1ZX)&@I"-\?($[O7V[_8QS1E`
M7@DW%#)@V'&&EBM1#$*U@3!*Q(@NS1J`@-.+09HT%,"!VH$A0PDX:#8@`$$A
MP1`-%"H,P""-02\*7[[<N)'`R@P-&@3&$-$F#<TO,&M:L?(!P(`=.P8``%K3
MR]`91#Z4N78+UX`Z=09T,>(B3!@78%UP=;'$X9(G3\X,H,&6!@06+&BL6?]`
MEVZ(NRWRZFUQMV^(NG51"!X\V("!(D4,"#Z<^+!BPI!1&%9\V(QE,PXR8\[!
M&<D!)#DX'!A-6C3I%2L.K/`A(/4*`:U?=^@`N_9LV+-IK\Z-^[8`W[EI_Z;-
M>WCPX\B)!Y=P>[8$YAV>2Y\^W3GUZ]BE[UC'O;OW[^##0\I#@HN+*"/.)$V0
MX%O":Q;`@)D#AL2$`1G*)*``IY2(`<Z(`(H*8C``@AH_(%`#"!5@!-0`%@2`
M0`,-+%A1,!24T(`-=G1H1P`6Q!*A!22^8<,5?<000S(33"#&&V^(@<$6R-PB
MBQ@U\`+"1!11Q$(%%`#`0(LEN-3##TC^``<$9>#_T,`P3`ZP2@DU`:$!`S5.
M8$(6650R218#0("+)NF08*:7EI#P2!^1-&(F"9,8H@$`&3"`BXRR8)#*2A.(
M$,L()B1CP@@36)#,``EXH0%0%%#@Q$60&I,*H8,.!`U!Z46Q!`XBX%#'G`Q`
M```X$)2`PPAF$F!"%28\8D\?L+8YCSJNWN/.(_-`XLYYS91`A`9>>$%!&PV8
M`)$J(P%3005.9%B'DZX,T&`:%/E2`9-E3!4+#BP@L`$=(#C!G@9$)%"D"/ID
M4$<&$`#E1$Q#X53'""Z,4$))7SCQ+GLM$*6!"#MT$>87Y!+AQ0S^#,&I@*#@
M(N"S6W45%EAC16$66F6U_]$&`S2TP08+"80@F%TMS+!77GZ%$.Q?@1$VF6&2
M,?8RS(Y!-MEB,U^F\V8Y((&$:9R=1IIJHZ$V&FL^O`8;:L/5UIMQND'=6W+%
M(0<UU=`AE_5QU5%GG72Y92<V==N)9_;9:$="GGE&=''&3NRY-P"`8H`1000!
MJ&"!@/I1P$(I<SLDX``V%'C@#W2LT@U,)6`00`0%V(!!**10*%$--A1@API9
M\!!``5>T:$/A+[8X0C)ZLI*D@I93?B@#Q2QK#(,.7JF+1V@@N<%$:8@Z%0XX
M9`!`D3A`H,$,8VC`P@\V=&$"YS:H^8@)JXI@U#)HJI"JJJUR;T'VVJO)1Q<9
M?/^@@9@--,1``X=DPP`L(79!`$&QZ((#`!\0<=-^%SUZ48-P6`6%R.$0/SPC
M8&<X@Z8XA1\`"(D!WP!'0/RT@RK$8`GF0`>NFF`F>="J5N_0E0=U92NN&*$@
M`\")%X90`19@P`)=J-`;?K"[937(63@8B`@8P`(0A&0#-6B428HT@`D(S"7,
MBLD-AI"`&5A!`]S8P0CJ("2,-`I>3SP?!@B`@3(LJEE!$<H'()",48S@$!GP
M"`\;L(46X6",#I%B\$[%%:\8(0I1J,=Y+O8$]*RA#320`0WB$K*ZA*`%4(`!
M%/:2LKX`QF4SBZ1A$$.SQ$1&DI/<F64RTS.?D29HJ$G_3=%.(TH?1(TV26O:
M;%B3'!^8,CA7$TYRGD,UK&$-.K3\&BV]%AVPZ7)L8BM;VH9)3.]P@1Z:*@L$
M$O"%,K0A<#LH0`1X@`<]!&`$^0'`5/XS-P!UJ@0(>,,`X""2B51@&-UH``_`
M4(`73$)&8M">"2QPA2L$X)Z-F$0`K@`+$X7S#1.J$(G81X<-?,M"%/(%!4[1
M*6,4]`<(@@-,F(0#^V&I!G"@R:.^D```P&$`P1N>+!KP!2`H@`@40,8UD-*]
M1YQI`J!PD06VU,$W-:%+:`(/'U0U`/-E(!7L*H$$$W"\!+"@!B:0HJ9&$*(P
M>6$,8X`"%)A)@30,0UKGI%;B_P:8#&BHJ`^T4%$,`-3`X:5!FTR$0)T&PH=Z
M<%!Z]6BK/=81#^Z4,(3QV-4)=T@$*X0#`D7L@D/I4%`T+"M4#LQ`+3H%`H.B
M@05I2)0_JKH2:7CD74,`2**<:`4OO*\C97`4!682$Z+B)`,3X(.]LE5:?WVC
M!-P4P1G^X(=S1(-%6W@2N6!++[6L:P3NL&,4JF"$*OP!"Q8;`<;"@($U#&$-
M)U!"$`"#%T2>C"\I>V1A7H:8[LZL,8T)0A`$$X3';/=EXK5,$3"3&0=TD@,Y
M&`U\.;":I*G&:/<MVF\$P,I3!D<VR.EO+7NSM>@HQSIA2\[5MI;+7@*S.@Y^
M<#"+2?_A"@^B'G@<P3*'$-J$B"!"5YCGAS"0#6V^IYMS"Q[F4@>@_JBB!C5X
MPSWSIH("%`!$)'+1Z$;'B2Y=`0%)8@(3@(B`"<V-''/;$8]VQ((!I"$F'^X(
M.9-$0Q`\N9D"$<-_P`6DE#R9/2I)8QD8<*@$*&`,;A@"C'%!@,Y5XDT34.LI
M6M4$\&5A>]SIH)>8`8"<G`*"3&(F41%&+-.A901B&("B-&`%J":@`@R:'470
MF88*+*A"78U&%_Y`BS^HZ!8-/%^H(JBQ`2R#'GZH;??Z<"MXQ.,2F(C$/>CJ
M"%N!)0K2P,%-8I(1"%5!!`$D+!UZ$!>A:L1/(BA!#^'@(/;_U(0]8MH)!*K:
M*`HPD=%#X88;%R7:F!!L!E8"V!E3G($V9&`4;&P1B7'@(E>8`J38`H=^OL"I
M)[C`MV5`EQ&\\A4,1^$,#EEN%^:R!NE2]Y!Y6>3)_`*8!=B,N]V->&(FWAB8
MQ6R[.#-`>LT0A$TZ`#,<"#E\Y2N:4+H&OTECFF^:)N!5QK(#+5?P;WQI8-PT
M^&NV=`YQ&BSAGOO\.<*TL-#-1@(]NH!\"6`2!#P\@3S,<SX%F$`VBE("%(-T
M%$ZR`1Y<Y*(KV$`1)/I<WN`TXQC9P.RD(Y$)^-F`#:@!08@#086>))`^#6`B
M(='=DY9IE!#A8,H;>-*R2D+4,K`1_Z0,&N2/OGPE_.!@3J,(4[F$M8$`M$CM
M+9T>^2IZ!15LSA*8,`&;7*I/-$D/$EWX5`;\A!]V09$]P0+L0`J2%J7LIR8(
MJ\`&?H"&QG[+G#>$-!QPD0Q]C,`/">3#IP$DO/,!J0Q#&`*IG!$#/"[!#]V+
MAPIR)>M;U=75W;^K$<J"`R\0H5P9,G45G'R,&O3^6AS]0JG\A`&7\`XFWJZ)
M!O)=!0U#P(K65EKDH@%',58.U"C+]'H=50*G\Q_DT"(M@@<2B`=;$"T`$BK.
M-A1$H`!6(GW@<`U+0!9\@P-;P6\3$P6<=@UH$05A,`$R$`(WL`8HP#+5=5UZ
MX4C:=5Z,T?]=9L"#X"5>Y74S0@@S#E=>Z848[&49[Q4:0[,:H71?*1=*_34U
M_&4U4`,=+S=+NT1S$(9@4X-@O10V6?-S9`A,03=T:.@=Y3$61A`#]P,!TN=A
M`W$%!3`']+$#GN)`5==-P,,I3C)38O`X$:`&(*(+-N`Y^T0"`5`X,[0Z_X0,
MY"`C-;![0*1D%<$N#;`W$)!W;Z<&@<<`U<8`>&`(#4!85E95:;`O^]<`8M``
MI5)IO=!L&J`APS`J,?8&%6`POP('"-`,7:`).R4)DW`%M^`B\T1K<)(]=R8]
MU`,);X*'YX-L:60\2==$,T`!ZV,"`*</#F01SY8&>6=8N8,@@0?_*1_A"Y-B
M+"/0!V[C:?J08GTF)!2`$TG')`VP`W]`#T;@)B!D*[06:R140J[2!/>P!-B@
M`58R+B4P`>N7!L?0>\Q&$_$"`#FT0[S@$U?D;$0%`.@R`E[D*&#4+N0"!!S9
M?V?$+J1R;I5S*'[B(K"06RPP#*5&(2PPCV?F%#"0DV-@!4,`$W0R`$_P%0:9
M'ZL7!6#A%6%A!%CP'P^Q!"PX`4I`%RA@2`@G53:(@RVS71*G,SZ821SW,C$S
M&>(UE1K7<4B8A)L1<DS8A*XD2JL!&SZ@7U4#',?1-#/7'+4DAKC$A0Q&2S:W
MEV*(<Q%6AH0Y'6>8AHCY"#NE)B:T`PR@_TVO!2!,)4T1(!\6@!]E\).@!E+7
M`"`6``N>8P.+V")B\'6*P`.HB0H(\'9(@@!;X"VK<"<2H60U4%`;``="E2VF
MYHJYHSL[@IO>]CXV(`*3V`LVY!/C4@9;P`2N"`'5<A$P@1-O@0/>@`BH0`%`
MD)U>4`&M4`M[1@(60`#W@0N%8@+)"#Z7T!WGF29]H!2KAPK32%4)<'Y+IT,B
M@`5*P4/+]`45`"X^!`=.H'M(@B`@\`L9$BH+0SU=D")GD"+1@'5>)"14`D6D
M@@%%QP?#Q2JB1URME@X>!)#=]X]W13'2``&_PDQC-@%9D&P!A`81R5$UD3Q#
ML@6A`"0WT"PP.O\N'-D%)+84^E):?584.001ZI$,J;`%;:0+,M(I#C,,)<!1
M&GB-Q[`%%>`%4A4L5E`R5L!,4$J1U/`5Z)$-4Q$#1\EO[N`'`-(%3MD56Q"5
M!Y=P5GF#6"F5D#1)/,B52-@8ER%>93DS?+H816"6ZY6$[L49:UDTJ,$:;KE?
M<:D:QD&%=VF%!E9+?9E+OM2%8/.7O'2IA=FIV7&8B9F&.\4%N^("?.`)$=0P
MDUF9\J$"F*E-WK299\0`)J(+-4"<R'"+,2(&%L`#6;`%C:4[Y2013\)N-O`D
M;0=1;[<[5@1;%&@@_KDL$U$23T1&D@,"=`!`@Q=_[<$*-/H-E=8-HN+_0&("
M;\,3/##A!?W``C%"#DBQ`WZP`V*5:Q-P!9[S9J?7)F_B)1RT#FKB"?4I=1D0
M)`!0$N#V:#4R$*'0`)'%GW3@HC?T!1\!`D#FB<!)!*.R>GY"`-#`CGW@!P\*
M/!%J$02C`=*G`3D4`WZ0H:XV0NQ0#Q[ZH0%)#S'K""0J($`P`XRB(7C`HN:T
M+T,`I2C;(@)2`OKB(`)()V>`#O>1+?K1'BIY"BI2!3O`!Y]IJS#Y(S94`GUF
M,."F`&>VI?Z3HS-1MKR6$:<E`D'I%>B!F238%69J!"F8'DX9!G&``6Y*,GH1
MIR@SIP\'<44P!9K4@SUXENK5IQIG&'RJ<8;+_UXY\'&AT1E-F*A+,QI-0[E2
M4S4%9JECV+G+P9?8H4MZ"6&>6KIF&*JHZU)%%Q8$X`FCHE9V4@N".`<1H`)\
MXT"1!VJG<@BE"6.[TQ^F$$X_\`:BPP-;L'O>,J"WV0W:M`4\\"0U`%%5-JW,
M!%N%PP!T\`,@0`.09F4Y*GL-4`+%8$[-1E3@=(CBE"W!(`X>,0J3$SS.J2#7
M0@0Y2P%REZ8J4EM5P"9((0978`$[P)`M=2;HJ88$3`(80%'D$#Q<FW0GD;.6
MY@H)9`I+\@7@N#NW^0564"[KTP`4L2"]<UK>-`$<VP7CXP<,VH>?`@`7T6?^
ML$Q#4BOI0$*L-E>MEO\K=]4=]T`Q^[`-9]L`>/`D_=$@^\(>!/,!BM4GTP:2
M.:H!11%8SS"K"4$A22H&>%`%SP`1NKL01`4!W;LD'\!9P8(P5'4#I74#,J`#
MQKDLD$(!V<(`M+`$_-:V^<%N$D,Q;3@WT%"W=YNW57F5./BWW]5=4^`!.O-Q
MES&HA)L8'6>$0*BXZG7(CXL9/A,TI.2HE0M@K<$:7UB7DQJ8G\R7DWIS8O-+
M8%C*IIO*VI&ZJ<N87,%%PE,&\L=TLPL&+X`-F4F1Q$<+M`!2"'"L%0!1W[([
M=[<!;Y!;>&"\D[A[G:B]O8.-6V`#][',#")\^/(%[[,+(!!WYA1&LY@GQ5/_
M:>?$`-FD31\V4X$R#=&2"A,0,*TW%7L'`%9259@V$`;,`R1B`>OY9K)"".`3
M/H]`/I]P"O@A5*-R$O3+G0X!$11R+P[Y>VH``N<W`P!@:340*HVU)!G!*;Y(
M`%A,`"H+TK9P"U0T/*%"C\9347S0!Q9D#J)7PZ%J0L7%H?7PCJ9EP0RP!<\J
MOOT#HS$Q)UH!LGP3:$;<!IS"$ED,@4BZU$AJ.>R3'QQ5,.>W0I56$E#$*'"8
M$D3\/]+ZF\]I55.,U"P8!UZ!#:*"6G*;5.>0:R-P07S<`%-9@SFY<%A9IW8:
M<87L`7KM<8.;R$`(A&9`&4&P7H;;7CSC2?AE<G#I_QJ7^TH)IG,V][D%YF"!
M"9A[&;J#.9BA.S::K<JGR\JAZLJ"0#[:-,L`,@&"6)EV0&*Y3&:ZT,Y8@`4D
MA@%7$+YT<`%[P)H(,#?D7%%@(J`(XI_,-FWK\W5MM[QP\+!`XFT_=:O]25@N
M*HL$F#F6%RI+%SQII)(L\1`QD`>=ES=21"@L`7`A50>962HS\&A"Q0(5.`'Q
MVHS).&-CQR7=\<^@-ST#C(=T8A73."I>!&Z61GTC\-3%$!+9>IM4A24%\`,L
MX)QT(%'G=-0/X=%;H2(>K5HD?=XG?=5$8'C0P++@IX_N4,,A5+,$V8\PNX_S
M4--G-)])YQ8X@*00Y&7[PO]1^%,'&/`':]T,W43%","K\FI!L;`%.Z0Q3&02
MZ[,@#$`NS+3!"0.21YX2Q\!EL6-#/6(,%E(MPT"<8A#`.Z`FFE+6PB,5Z&("
ML,"CG=+6U<>"7B$""U"#@'P761F6.VBX>JW7#F#(AKTS'X<8?]UQ'"<9B:S(
M[O5QA7K)]P5@*3=SS/&%/+=SG3O9E"VZ$?9+GGWII@NJH&UA9@*S;@B92W?:
M*G`WJIUHK6VD`X$4]]$`M9T!<*`&%X`@<Z`&=,<0$V"\I4B)``2@,0%8)A*L
MO?=^2$MO*C6QU7((N0P!&\(#JC(YW@0@J.._(.T.6$`"]10B_]$IT`X\P],^
M);#_*$^F`17P!B2RSU\""=1#/?MJ>OE*5]EC")^P$IW"+J];)6E`Y$@QX!`T
MON#RH_('6T#V`Z[8GU;69.[[#'R`Q<45`VWH!]@0:A9L/+]B/&3$!WR@XZQ"
M#W)UPQ]:5S;LH>P@%B%4JFWK1>!P$FV@TUO`).SB13CQ#:"@(M!P#DFE"TR-
MI*;`/D)56O0+55;`GW`@`^^RI3+!:_Z3!C0P+&G00S"V(\<)*;`#(*G@;I9C
M([Q*(C:@`N/'@OL``.9"#C!&HZ-0?4Z)1^?!`&\.I]?EMSHH<8*+YYGA`>TU
M]XB\287;@V5I&4:(&81KZ(9:J)XQ2HC*2F20-*R42Y'Z_^B,?MF/3;I>TS68
M'OFIK.F;7F&D^LJ&4-JAC@MT>#>6.0"Y7'7!0Q7()@(\(`:_\`-S,*`"+U1U
M4@,%(`;8*MSOAZ-C5@.R/XDTE*TX&A2$(SE.&J[8'1`K$3"_.$\GPD^1*`L`
M#!%I,>"J@"/L`SS,IR[BFT;=8`Q,!`>FJ8;V/0EX%@GF#O[I^0BVX!Z'8M#?
M4!,P0`.Y90)V)SS%4"T:#`3F4B0U4&02Y9`3`0@L`R4X&#LQ?GU+?'TQ!#$Q
M70,B.&4`7VDE&C,:$%X:`UVB73%5)@0$3:JKJ*T$1K"QL:^NKBXNL`0F)K)&
M72(9&D-?"0E##%MB#6T9.#@9;?\,#343.R9\554Q$Q@-(@-M$&40)0,-W0QE
M&I]61$16"5].%6E?\DYI%?3Z<'#Z:?G@@$!#!T2_?_I8P&DPC9H8#"(:3)@(
M<0(/&V*V-!C1)4R8)R)^01#68`L(%@QPA,02I:6+*'Y&M`G1H@44&#!JZ@S!
M,\2"GRB"!C5`U$"1HT6FF/'`U$$.!TZ?0IWJP(P9J&:*6"UB($@0JV:^8M4*
M-<=3LSDX'#BP@NT!M2L$R"5#1D!<`1TD2.C0`:_>OWSU\LTK^&_AO80!&]Z[
MN+'CQY`C2YY,.?*.6I@S:][,N7-F$D9N&>$CHDR9+V7*B<!@H4"$"&#`!!`!
M`0``<B7_,DR:M&/$@"LV&#CY,4?-CQ\(&I2``(%!C0(6&M`I.-!@&@H4OC3'
M,*'!@!H_-ABL0`&"/0H8>`0P@0$#`P:31$0\)\8"'UA\"%P)`%Q9Q$GG8#!"
M#&<,4(%`T]$!!P,E2.-,!N0PL)"!%'@Q`P7GD)(?`22HX.&''I*0!0FM-$'"
MB2>"J"()37Q&8FG;88##<J:9IP$,%&RQA043##!`;0<.5`$Q,T!P70D@U``"
M"`D6)(@SK$'RB!]\G-&(*/)58EL)%&A`A`9?<#+`(=F@TJ*99[XR2XFKJ.)*
M+['@8D0ML9P!3#%XPM.&"!/U.8&.$XC!37OR#7#=#0D0`80"_PI804$%UD%0
MS##$W(,/`S2T00,(.J)AD$`'(=0/DTJ"4!(&6P0JQJH6M&H!)1C@80$>W4VS
M104T.('#`$\\,<((530@*88@5-#&GEU$$88+851AA`D])F#333!`45-///T$
ME%!%(974%%,PY4%94J$EU5160:755EI]!=95[Y9%KEILM;666G+-U9</<A'&
MEU^&!8988HWY2S!C`5>F\,(,-RS999Y%+/'$FG&AI@L$C%#'):E-,H(%8+@6
M6P`80`A`&3B\MYL(O0T@!@\L.+%!<>'54`&7Y;F<$1T;(+"!@@!EET`9#5C`
M@S(#F*K/>PPZ9X$*39BP0P`V6&!#'O\[J%I?'GXLL40,.YQ1`P)DUR`"@PVN
MMD,>,AZHC]LEQ"U?;@"4,"&$"7CAQ1`UV-#ABBBJ0H(%)EB0A8H@GJC9B4T@
MK@(&9=2ATC?/U&9>`C!\41*/@S"7!AQHH`&'$_8`]`62#8"@Q@47&%=L2@-@
M8$(DCS@R8!6B^(B#;9UT2807Q6C`P`X[9&,*+[V@V::;J.32F6ASG@*+:%WX
M1HP5V,^0``1M?(=`=P,PT(8S\(6?`0`::%!,.\`70\%UX^3S-CWYI('/_&B0
M_6D_#.3#T/];J,$;;$#`JKFJ@%93SQ7<LP4;O`$!/6`!#29(`QG(H`+R$<$(
MEF`$#$CJ!A/_'-^`_*`LCV1C`B(8`K5J8BUL96M;W"**M\(E+JJ8ZX9.P<I5
MJ@(OL+@K73S<8;DX@(2UU,M>;,%+O^JB+\'TA6"#<6)D\B*PA`'F8`[+HA:W
M:!B(4>R+8-R,$4@DBS.<#S6Z&<`(3!``D87,/;4I0_E69B<<U"``#9#9',)3
MD*`Q9P`3F<8&!BFZZY0G`1E`0`%"%AWXI(XA[4'`%:#6!-R1(`"85,$?SL`=
M;ISA#",X`Q;.P)`:#!(!-8`#0')3B![9C3SS,`AV=$,)!C`G`_#I'P7REH!D
M>+$5C'-<XA27"A:AR'&L<`4&ZH`R#0Y@1I8C!@R\4(&B]0A"[X-4_R&=@!V`
M0*H"-6"=<13TI-7,K@L$$`4?.**+&!3*-+U+0/KR1@0(<&0)9:H%\S"3O#=E
M)C1RV@7R8A&#$=#&2S/`WA<HD-#WE4`=C)H!)OQ1`F(4XP8WL,<-*'"#(6"'
M2]I<TI(:H)`C,:`""DF2DO[WOQK41U`3.$7C5&`''MA4/9BT`R;;:`/EL.`D
M%;"@$RQX@J*R8`LC>,(2PF"$"3#@"R"L9DRK4,(P1`$2+!A""W"2DYU@2UL+
M$`H*BF(4I-!P*C?D@%K-P@&T4`5=[PH+6'2(5JG0RX@KR*N]!$"&OO#U7U7<
M"\"D2-@I3@:+7$RL8BOSRS`Z]K%-D$4,2O]P">WXB$\!>`T8Y@"&'FG);I>=
M!$0*@<<T;&"<UL'.Z3!0-8B``)44S0`K62L;3-J`&Q,8H`6N`!P;\"`+)JA>
MH-XPP#S4X'\^XDX>V+:0D2[)'S<[60/$(((2'`@-&S@.'6X9.Q_5I@3G^-$F
M8#`#%DS$!"GZD!U6Y`H3H>AO@&/<\E9QHAB<#Y??8(#);#0&+["@;SN@1-P^
M)Q"#+`D@!Z$`'-2@!D\9Q#OFP("@N.,-#"274#ZR!)@DE3[L$2$#,37"\OS9
MF3:I"4YP:EXOHO`K''A)?0E`E!LXD3Y%`6%OC[J./8RD#V[B0\?O\P<<QD:=
M\52@?_"9SS3ZM*K_)A,0.*TZW$XQ*0<;,.'*5R8;V7I0@1LX@09K"',0E$!F
M)7A%!A+Q0VB,$).(2%AZ45A"2ZKPIP&HD*O6\NH+M15#&9JU*75MJUH'O58<
M4B6N<\VA$)]BAAS<"Z\^T&M<Z**O)T)QL(2%XF(WS>E.=_&QH`;CAEH4"S\P
MH++-F<0$,OL:SIK@F<P$K8\<28D&\``#%<CN!CRU("XU1PP%*``/4.@CAA1[
M-2IX`8@P:8'ZD,`%?,@#M/HD(`R8,KLUZT?XI"$H'X5JI/T;"0`:<(419*`"
M=#C.KN%`@9,5`M9E,,<@-*``G)2W:O%-48=(!%]DRI=-Z551$_RPN^9X_T._
MS+3'BUF``$%1XAG6!=T@LTN'"CC!'_*HCD%\!"`1'/<]<6/0^T[ZS`%H.![R
M](*'(<`=4QBA#_<Q0IGF--]]GK@7D15Q9&^.XCB#1!T:L((]JA5C"@Q!;PEX
M7QIH,*P@U2"5;S/DYUC`@FF@DB$'B;#6++`#"[P713B=LGHN@@<$:(3J5->!
MVM6.A!.4F<Q>,0"WO+(&9)B@"A[).U,!&H:OT?E/-,!<5W72@J^"=2C=FJ&X
MQA5H0A,:+6TURUNWDFC)U]4J]TK+`:C@@TCG=2Y,)(-@J_C$@B%V,:?WM.I7
M_YC&AOKUGB$U+/HP`%0G.3TBF\,<+#"`#&2@#O^@3<FNLC0`&[@'!!N`.LAQ
MF9[8!-OX#4```0=XA4L&0`4I"@`/KO`&,5PA#V+H_M,ES/74Z1J52H*#^5H9
MOGY@]P=J0("OA]8`MEG7.O;`QQ<TD`&#4@("N!0^7S`&,P`%8^`<$Q`#`G4*
M_:8B;"(X7]>`C),*:9(*!&!RNH$.OJ<=(S$#1(`D$B8CT$0!V*5KQX$&GV-D
M3`("3F!=[T$>#2(IVH$/)4!@WP`,Z),^Z:-R'@@*$Y`-SE-S-_>`-8=B*98+
ML;`$OO(C'P`F5C`#7B`/_R`__N!-D#(=3V<J%-4@`U!UI50V%,$=WL<#*F!3
M*I`%64"&U[=]!(1E3`#_03W0`VS``D$U06&V!C)05$7U=EYQ`RCP$S11$]AC
M!?R'`:&A=SXG"F"S"W_"`FTP`PH`!7FF9X<G5F3E+4500U'!5FIE1)Y(1&V%
M!&YU+HBVB3=T`F:Q%D_!`7<1:6S!+W315X(A%ZB7>I)ABZR7BZOG>K#7BZZP
M(624"Z6Q8\/'6B(3`7.0!93P>VD$.QGT'LUF#OEU6?)AC'8@9040`-WG6^&G
M'A^2(LUV'#]0`-SW0,=U#MP@`C]E*JEC*N8#`"#V*@P``L=A'#]0`SH6#RXS
M`3A`8/7P*-D!CP*"@])`4E\`!`4(!"60#$9#AL*$?>W5@(@C7V?B7OU&`*71
M_PS>\`S8Q&%$0`%C$XVRQ1P%EFX3MR33X0\$,22?<QT`43_8\6,MJ`_/1`GH
M\P%-F#X)Y05E(`(64('1,U"R4'-I8H1K0B>R@`5*.`(0$0SQ8`\Q1F#\\#;]
M(!!9^#_?$&%/%WX#5$!?YR&8I!XU]5M5(RAGAU)LD)9IJ78G0%1M269["'=Q
M!XB!R%5C,`:*`@`#$`/,DG<M`0DQ(`9X4'9;X(@)``612'@N!$.(=XG?0D/C
M8BZ$9D14\(EOD1:1YU9!Q$,Y((HWE`-%540'D(IQT0$^@%=X$8NS>#"!M3"X
MJ(NPN6F\Z(NT:28G1@"0$P\=LQJM`1LC(R,9,`YSI/\[NE,X8=APJT)<-K!(
M6=`$V*B-8H`1T2F=NT4"MP8>#*8&;T`'*[4@L6-A!R(0"'`<-K,<\-A`U85\
M/P`T01,\)5`#[O$H0J9*V:$!1+.,$#`-U;4)5@`%,Y`&TA>!J!!P#_DA%@F!
M,R5P_R8L&FEAN6$>'`8$7S`V`J0<<0,!%$`#UZ5K`S%(*@D'"]4/5O@/V2$/
MYP$0SF!0&C9/"8`]]BD"=P<)?I`(?7`*[35B1ND\K6"$?=`'*_:7U?,C>+)0
M\O."*K,0Y_!T2MH>8G@%V_<TRR9V-\4$5I9E/4!2:$=!++!V;*>'<>D50>"'
M&!44"Q"(+:`WGZ`^M]$,H9#_#?CT<GS@*EG`!#U0++LT`UREF(875I8H0V65
MB8MGBI.Y%E10F4:D%J)XF3@$1&4ABF5!1&9Q`DC0%O3"+WUA+Z6IFG[%FK'9
MJ9[*,+-9F["7'\&(,1ZDF[3T,6X$&]=T,@R0E<]$2S@P`1CA6YF5C38`'#C5
MG"H0`%E@-,=19;K%I#%E`=8FCLFW)"B5!LW1?2GS?@QVC[:$&PU@?-+P7*4C
M-/+TGCLP``LU#_[`3?O7DQ#1>RDS"1"04&,``PD@$5U@#0PHD1\RH!,HK\,T
M@>V%FQ""`^'UH%\P!'FC`!HP9--0+#68'4-`A:'3#RF)<0GP39GPDB5J40OE
M@LG5_P"FD8,ZF#XL5SRTH#S[E&*8T28YVD])Z#5+P!'4)0[,T2`5P''FL&1:
MDZN\13@$X'69!);75X9E^2<:L05Q&+1IB79;R@)YR'9M%Y=F8&9!`(@[`55A
M"K!#X%%,$V'<80VN@(998&405)@TH%4W07C7LJ=\VIA^=A2!&A6.1YF%6JB;
M9T1(@*ALI9E742Z.:A9%)(HGX!9KL0*6:A=Y9:ET045X\9J?>KB(JQ>A*JJ@
MQ@>D>C$$8$:W40:T!*-@\!J^V:W!B3(PZPRKH4;-UI#9V'U<V2H.F07M`7_B
M2#9O<%SR$4CM2`<^\S.8\J\,@`!X\![991R\5@_;@R&W)?\"RGID[U&B\C2K
M%Y@``4$/I"-/>@D1IY8!'E<#%$`$8X"0U%0?AW,XPN1>Q?20[V5B%AF^33`!
MP2F]#LH<*&<%!$@!5/<>+ZEC\B`_\_,V]@"Q$3M@7!(WY1$A\*$2&F.>ZT"(
M10*CJ&"CLW"4).8F)8MB)G9B7M,27[,-6#D?Q%H?-,M;O2IVVF<#'8Q`$X:E
M1S9!%;!V:JD#2)#"*1R72B`#<HE1>((G2`<!%,0`:*<C6S"8@ZD'/*P'<J`'
M.@Q!;*!V%M117B").U%X+N03?&:VB7<49T4NF-F)F]>V5*!7;GL`<:O%:7&W
M:'4"C\J)HIG"]=*W^2(`GI>:HN?_1(:;N&[<J8O+N(]%JJ`1&@2P`P4'@/$Q
M`:Z!N6#0K3@0:QSW<")0(#Z9G&(P?A+V0-]C-"I@K."!K`6A$247C4F3;MFY
M`=-:#CO2`.C6,\4B$/6@I@RP*B(0*O[``+ODGA.`FYY##W&S?^E3")00;\<E
M7HH"#RQ0'P+E"L=4H%#C(@GJ(1`H7Q/P4!EP#O^W?W@R!@+;(%P2O_*K=%$G
MKA``.@NB#]9U9/H@6P\*@"HC6KB4#ANKES%U"*10"KS0/#?*<T:93"`[8LWC
M$GN'.ZJ"G,O%*C<U9=FH?1=ACCBLI$]WEO6+4ES:I5YJ9F7J$T.`4=@QM4.@
M*4Q3=3I2_Q(3@`<]+`<:W<-8)L1T"&8WL-!BJ\0T\54O)%9C159G"\6`!GF#
M:L4P?<652<9OD<+F0BYUY6A:[(E^BYIGS"^I&3"M^<9$C;AQ+,>/U2&O@`M]
M<&HLN\>LIEDDX"._)T?4N"L%4GP/038,\0T8X#.M*V%'@P$3)X[W>&3MA@,$
ME#*[&Q[*"J'.P0.IY*%!,CK%0`P9D"J])Y7T("GR!`IBH`(]Q4RRY7L0(EN%
M;%#/P#24A9#;FBK%:J\&JD\LH@H3&3@MXEZ-HPHF$+VQ4\LM"CQ/Z`5*!Q#]
M4X/2+,W800X"P<VI_+(JDQ+A'!&K48VR94LP)KW5`*]S8IMO8O^4($N!\NS;
M"T@\AT`@,;`LN9`U31:=DQ0`&BT'!1#=%R&=W$!2N')202)22T*')Z`#;>F6
MX6U!8891&`6P[1/1)\4"&<0=.HP'6=##/+S1<N"&<J@#1FM!31N(2US2_+W$
ME=AG3_QGC*>V@UK%/E"HG7?%*\#@GK@6GGFW=ZMY#]ZWG=<6?ILO^U*X4#34
M1?WAL7G42!U&2KUF?&!R._:J(1'5L$$"WQ"<`"`-[6%0H>0C&#&/QE$VIVQ*
MQ\5:RL`SIY6=%>=KI<P#)#5QGGP0`(M(18,`<)!=O$8/JUP,W]$C99!-_\!A
MG<!:7F<"OC$?\@%)>5!0/Z*7J:0)%\+_;B6``&;X6QP2@96-?9B-V:P0O@I:
MV1=X&]]I2U]@!7H##YBP2B^)VC4X/R<UZ`U2M>]QKI<5($S:28-"&];5)<K+
M&B0B4,9C/'Y@/',2"_(LA!6("L3C)TS69`F("S'1'EN```.DG--G=C@<ZPPA
M"%17OT2+=D%E03+@!.?=T!M%09D2#>7#WB61PSH<W_$=W<J.97$XAT9+`^>]
MT#RA9TM,TOW=Q`(^X$FAB2Y-Q5;,+VTK%YZ75Q4NBGGK%$C0J*+)MQ8^[D#]
M+QR^Q@/3QB!>[XHEXB-.,7R@.$;`5!AY&MJAXEW``Y>K62KPXJ;!`)UT!CN`
M!>XT`,25`6GP_P-[D,G>H7[ET&S2`'_&L6NBTTT5(`8!<%SAH4J@`P)I,`S;
M$SNIA'P_4RS,JG!E<$<!(`8#4`RX@3/D8%YB<`A_P`<J4+,/01&'0#FZT0#/
MH`X75Q[)L`O$8Z.2S2*4+=F4A*\6*`*WH?#ND0%]#H5#VDW:_38@QS3PP3^Y
M43[&-LC=@`%GL-M9HRK$,P(A-PCHPP*G$*.`60I5H&:P0)1$B2(';-QO7^K$
M]0;U:!S:F`=S<@;.,",_Q=7>(`*X,D'6I1#M6)5P0(<79$$%+0.YX@3BN@[J
M0\,H=2IG(`JF0`!:FP5VT/JN;P?+3J=#:[1AZK0CW1/63NW]O6=EF__2B7>V
MX,+M:UO%5IPOA?K3Y(Y76DS&GBD5Z\Z*=M&W?AMIG6>I@\'AB1%%]K[]NHCO
M^2XQ=-SO<R(LDPO`K-''(R,)E2!'_\/V#"\)?3,`(%GQ'+\!-_-'T=@`V(8&
M^@`((!447Q`E-0%B#3\_((YP%4X07U]E`Q,8#"6/%14E$`"A)1,!*CP3##@,
M`P,B(@T--6\6)D:V)%=7-F(3K#@X(EU=(@,99749FAI#:0D)#6([!-,JU=;5
M)-E-!$U-)-?@*MXDW=OCW>`C`&49KS@0"58S7@E>0#-?:6D,JP-P#:P&\.,W
M`&"K!A@2)GR%X16O"3LB3IBHL.$`'!=QE"C_XX5!E8\?39B8-JV<R9/94I*@
M%6VBRXEBWMBPP4B-34:,-B"H@:'!A&DC,H#Z0(]"!18#]77J!*>ITTYIH-*@
M,(0"C:M8:;39VN87/Q8-MHC!0S9+%FMVTJ:5PY8M$R8]>K!AP4+&FALW%H38
MR[>OW[^`^RX83+@PBL.'#2A67*1QXRD>(DMVD",'A\L<#AR@PKFS@,^?5X#^
M[&.%Z0.G-:M&4IFRZ@.9!:Q`;=J'`-N@.^C>O5N";PFZ?PL?3KRX\>/(DRM?
MSKRY<^+22$J?3KVZ]>O8J_.9MCV;D3`NFF#(D*!2NQ$C3!2($`','#"]<)0I
M4R(5,%==_(C`$``#_P40>^SQPTUP4&!(`S;PL$4-&]"!!@MPT`%"&A000L$`
M8BA"QP8<3E@A(84T<(48Q1@R$`[&L"."&";L()(%,&9AP0X39&@!#P14$4,7
M,=`XP1N\-(`#`!I8,H((\F4@$#\04.!$>370,HU(61"04A/A9"D..26-HZ4W
MVY"`P7PX^#0`!!I804\"&K0)P3X#M>+**\00,T!#(M08D8MBN-++)9@DA-Z@
MKQSI2I*LT%?%26!VH])9V4Q#BT0OP10333CAI,8/'-)1`R=+\=/`-!C@0$$"
M"A!!A`8T=,)`!?K$&E532\$:*U5>$)$`!#2\2A=8"DU@@5E9Z*&''6P=J_\6
MLG+H\18><M%EUPU#)!`888'MU<*V?^G%5V'@+H""N(@AMMABCD$F660.4(99
M9IMQ-MJ\G^E&6FWXOJ89$OPB0=MLHI5FFFCU=B``;[P1U\%S##?L\,,01QQ=
M=A17;+%VVQ'`!Q^1NN`"`1.44)Z*Z*G'GGM@F'`1!$VFHB0Q(_"Q7P`APZ'&
M')O^0,<@+`]@00$[;8"&(R"@`0>%E$"P8B\1-@B))$-0,DHI?6K"0`-UPH(!
MBR94T0<?-@0@M@H3O*+U!#&D[0<&!=6`P-L-4-`F`Q9E4$(Q]5&8P`P:L+`%
M!C&T:,(W6JJ@TN'DH`-.XH9?6<X$&0``3$,0S##_@Q7.1)V`4?]H75%""&&-
MR0A[[N"'"7T6Q,#+!V6-D$+$_'(G!BPO:A*7TZ%.Z4L9ON$[IIDR\H9.GX)`
M*U2RZL,/'"-E,L0,8ZB9@!.UIN$$54VZ&BL#:92@BD89)(-0C3!:@(TI<C#;
MEEM,"!$7&VSH4!<-=PWA;;9[%8;__H(99FZYB3F7`1Q3!'5-IEV6P4R\/$,O
M,I#!7J-9@6WR-9O5]&M@`R/-;0AV,(35RS@+BY@(1TC"$C)G8A=+H0JMLS'N
M<(P$!/`8`<3```!4`@(#*%D`3M8>E;VC#!#@!T:.E)Y7\("&%5##'C8EH4%(
M#0,V0``(Z$#%#0A"'R""_\`$;/"&!C``#L:#RB<,@8$K&,X$%HBB3,20$#'D
M(1<P]%H,:I2A70B)94K"`!;R8`)B-``2$!+$%P!0@IX4@QU7&\`GK'"/`2``
M(C(B@#7,TCC$$4Y+EB1'.+`$.0T$D7+.P$L;!L("$-2@!BZ)2!XB$HT=-.0,
M1SK#&7;4A0EL`4D""6(J"N(*K9TR(F=(""9X`8H8;&-*(FG1'+L0S#9>"G@W
MP0GQ'/%'2"!O(-R+%5/`"(<!=*$*$\"!!F"`.7HXH9202,,7O#`/^L1I`'1Y
M'1W%<",>V%,M<A!;`-K"!++T8`MS8<$)E!"$@HZK6WK1GU\4^BW^76LP`!2@
M1/\9DZYUM8LR";S,`N5%+P$X$(+VDJ!L1`,PS<PF!_ZBC0]*@QO0^,!>"#/8
MP8!CPIK:]*8U1>$*=\I3Z:3$""XP`@%$L(Y"%&0$$U`!&)8ZAPADX2(9J$,0
M63&GK;6"B_RXB12/=KTOE,`G&)ABIZY8H4'BP`8%*(`-,N&].<$"J5<(0#;0
MJ,\`7`$3\^1%#*+PAPG$`@$<LN(DYO-53+!"$!0H004@82"E$2-R98(#`Q*+
MJAE4H`<8R,]'IG')PCG*45<J'#8BQ4D(?."3+$B&G!HP`@RX)$-NS(-L5YDA
M0V+D(ON!""8`$KX29."V^SE#1%Z4C6N<0@PUR(`&ML;_"[85I">PB(7;WA`\
M3DT3!-4,U4#J,Y"E-,41;N,0(VH0#)#AX`-`T(`S-)`/?GQ"`^N`P.2$,1$3
MX&%8W[AG``JP/CF\10@`AI\.D"`#)1`T"(CQUF``<[^',C0$"W8HA!?L/Q1,
M5*($-*`''"`%*51&@1NEPF@<2&(2RQ2"&YP@!BOXKY6NM&"YB6EO?!,<G-KX
MQCA.CDY[RN,5>L<6!!C!?"AQM09T@01@:`][>(`D'-2A#G)R14'^-!.!,`(!
MU:00(1B``#M6P)1A+$%B?\L?L17@%*++T!N+>X55UI*>]+0`&^W4MAT803]@
M))HC*`0/#7`YG&G(\X;04($$_P!1R@,@;"<^X04W*.`&;)C`$YX0`RN)MARA
M_1)H+=F-(V;@M%_%&E(C@H6-\:%%+D(U,$<`D-49(QEYU*U?F^P*U^Y`ML4E
M`0\:ATQ%B``.7]#``$[Y*:=(]HO@)7;QGN(J;,+I54YI@"G#NX%,1?,'713!
M#DB@,@VL:AU`Q,B<<@L1*W76#M<(``^:]9;WQ8\U#B#HN<KU8`GG+UP4SM_^
M\%UA"Y^K"!=.%V3:U>$/*[`S'/U,B1?NP(,]L(,O'BE+*RA!D8YF-QWL3<*$
M4^,<>_SC-MYQCT=>L6QXS`@D&$$=AGRU\J)LJ?VYR),90.=6.%<F`ZA`M8OM
M"9;A$/^M`>AB0+!&U4OPH!36L"LOW!@3/JYR(EU`*G5Q@H!$&^)N&.A#%U[E
M":4P%DU$H``"3*`1$`36:'+S9$$N,I\O%D@#7FAT`M!@`5A6VMR<+:YHK3$.
MDGP6'"91`=E/*]\MI+)TNW-),)$4OI6SK#YYS!`::3$1&-DSUY+*$$6$68,&
MO/<+7_Y4L;5,`:4TN[O8[*Y33$D'P-;$)K"/IN]V<DJ`8(`;!&`;05YA>!CI
M(D'5"(`=D`[X_-H@6C(H<$$7`T``1KC!$N8WN/2-/W#1.Z+_;LP`MU_1#7/8
MX`='^(@97N+=/!#C+K6-BV<SP986S&`(HW''00CR^MO_82+_)[G^I9,Q*W'!
M%D)U!BGB52RP'WSP<F!0`/$Q<P%Q$6MW"38@$%3D%)H@%(7$`PFH5F4##7(&
M6Q:`;BI`22H0`+N``&^``,(4*+30$P@@35CV"5]@:`-`(SG7"6*U`846;%X`
M`5NP`\5`*T[P!5%#`:&02%#%#WJC`3.@``D`!Q.`'EW0!R/16>%P.)6D#9IF
M$@2`<A8P`!]0!JL`#:,S**T5*)\3.[=5$*^S'Q9P!<5U>;I6/BW27)^#`:=D
M@F]0`\W`7HJ%/"!2(250`LJ#3=X%1C5019H2>["'$R=X2J!3AUNSA=N`.G64
M(*505V.C;M?`!9S(!00`(PBP!2RP_P8%%00"9(K.-WW49V_W)GVK2'WA$E'F
M@F$$5(N-(1F5D5'AQT`*1WX+%W_P)U.C(3#J9QLP%5/`$1PS!D(A='_.^(S(
MD7_[MW\9\T(`2``Q(!^3T`:M,`)]D&1+U1XD@B+(X`L.&!!EY%Q+P@]2!D7"
M-X(%0((V(F<V(()5<A:HDRD;`!#[(3HF`!!P,#3?E4Y?0`0?P``1H5@;@A,U
MP`"%X`Q?D"<BT"0)H"J;<ST`D`!T$SOLL`\EX&V6XP45@#;2X%F9=&FXPPTH
M\0U7(`(:\`'#MA!SLEH\$2R5,@&3EP79$$EF<4PBX2.06`-B\#9OXSM&N0$U
M4`$QR"9?D/]8@?B4@:@\B_5=U/9ZBGAM)_@VQ%81EF(#'=B&/!!XIE!764(L
M,#(2,>0"X$$`>""*,A`$!>08S'<8X?(MSP=]#B5]SV>7^-9\%C:+%&6+4S`%
M9C`%!<0N&(491Z`:O-B+Y->,'Y4PO!%C'2`PI/%2QYB,(31_-%8<R[@<S0B-
MHFE3TCB-)+<=&_,-30!D?6!U1L5:._`"/`0&78@BX6..&<$*9;16T45L"%!'
M8V,-ZW%$<D8^Y<,#WT`"$]""BU@#`K$D6R,DLP)&&P)L>T,$6B0&@H@&#@("
MW"-F,3@W90-$E$`)UG,JA(2&0(1%F5,M<"`&,-0U4W@X37`6GG7_#I8$>%Z2
M!PU0!AIP'T6'$0CAB+])3SJ97R,H-O9T!6<)=5T`B7:X$W;H.QRBE<3V"$BC
M7F\B*[629PQ2;5>)E5FI;*=D*1[H>V:T:R2P`UF`=&FA`B^0H/:$G)&"3`20
M3&BY,5A@`0@P%V\9EP"G&*F(+0ME;PREET<*47Y9+O.&+K980!K&+KFHF`B7
M<(ZY<!)`!L,1?YHI8[*!F>]78S/&F32E,*&9')]9IJ.YIOAGFFY*$JC9!ZH)
M9`20:)0`AB(P`C$@FTH&!BUIFU#VG%`U)[D`(Y;(`VF4"V.3!5@2@D=W=%RT
M$X%"/A/@-E1'3;`"`64@`A8P'FF`!M66_Q,Y&(,0L#6#P)X:4'J$$`\:4`$F
M,"8;6B'60PF[0G0B8($5,@GAF0880"-I4P665C@P-!V?Y0U9HA(DD0UYH`CB
MQA`*L70(``<9@"#V=`VZ`".:1Z(U"0O*II4(("%3A%W8E5W-)F:$\";&QA0@
M`%BANHB,2)0D:J(Q49QBD`MNF"6EL`,6``8Q&J/%)2-2`J<;(Z<DT$+(A$8]
MH`,#!9?:)Z3C0BX/>Y>LV#](RF\3!K%^*4`-.T!/&J63`7X<4*56ZHO(,:8R
M%E(=-%,;EZ9;RC!G:K+-^+*_<:9L6K,2L`.FEK,ZN[,\V[,^^[,]JS'5:&YT
M*@)#AJ<C<`8J</\R,#<"OW";-9=#1_(-;;A?ZI9&NT!/9G06G<J<-]%Y/`$0
MT-`3G5,T&P("3?D%'X`#;)0!.L<IQJ-E2UFJ%M``E.`DE.`$L^H,33@B:**J
M^M!5GL1:;`=$8L8FY9$`)8``,*)W5SBL>9<2^CFL]!FYB=.H'1AG]GITBH`!
M)4`$#)"U=/@Y=VB4.Y%L=PA8-<!L1[,]W,,/4QF[)0`''<(`/;.NWJIL$R&4
M\Y2Y,S$3/'`%1V<!2(6)+Q"<U9`%$9$2?)`V(Y%,J"FT.MJ)02429!&*`S4%
MICB7^':Q=JDM#$:Q>IE@%4LN\Q9`Z&*80<JQ@VF8&G91"/0N(99PY)?_I5I:
MLO(G?S&5<<K8<2RKIIY)?QP'LPOSO_]KLZ.)LT"[P`S<P`OL4R0`9$8PD7=Z
M'F?``^S1'F#0'T];!\#0@%([@RI0/K"U-78$#<)[5PW0@M*TNK"@"0B2"6#D
M>IP"![NBJ0R0(=S#3=UCKDM9!@A2`]DS"*775>$Y`'D`.1^P.;<2@T0``'GJ
M9`#@MH.P*[FZN+30-9ME;E2HG]U0'>/0Q>)0#NE&?-5@`W\"`4```6'[.HX(
M$W@(K\4F7<7S1]FT/=X%7@NI$V\S(1%"!W#P"7?3.=PJKUB;1I#*(D>G3VD5
MCQ,1CR-8K=R&EC>:HSO@O#<:M'S@`IQX<O8%_RUL4&!R:0!T2:03=F\3>['\
M5LKT5K'H*Z0:"Z6&J1CMZP&#N2X;EHO@-[_CQW!9"IK)J+\G*Z:A2:8`/+,%
M3+/!C,P:-\S^Z[^@J<PW9LP>I\`.?,W8W,#)2@)!90NT8T,D<P8DD,%+!09=
M\+1`9(Y(DJ<SV&:5VGD&(0ODM1_UB@GL*EY65`&V"P`#L%9E$JH2`@DTD#08
M8@$3J;<4$A5I<`.4T"8X4*GP@$74@S29,RJ=JEQ>!8,)L`XEP,X:\2JG4AX-
M_0PND4QBW)/'1!V*PW>-FB4M70T\X)78"A.E$CFI2DW2IJVG]`C_$+N+Q0K:
M,YU%PYU5%*HNJ!,-8/\W<6(VPM0[,V&OPHN)8@,C^U4`QQN/`?`"(M$XM#`I
MY38EJ-DC(M%_TJNS'G/6:`0M.O"CZ_NPJHS*<%U]XXNQ2UK*Y$(83,H83IIA
MD3$%`Z0NMVQ1\2N_5=K+OMP<FYF_P\QQ+<L<RNB9Q.S,S=R_SZPP`RS-)<29
MF)UCUIS-GOW9/&MRMM`$.S`D\X%#2?LS3`L?3[L.JT5$2'(&5Y`)"*`&M"<0
ML0`0.`!%/;&0`[(I$R)F9?#0O1`+A-8DL1*#7[#;LYT!45$A>AN$B0L`&^F?
MR`T5IP)?#/`3*Y$)J@!/KR"4;\`VL2,R,[`J$%D(6R#3?/<H9J&2*[UWH@7_
M0UY-$29*$PC``&50'D:AS]!F;,>C"0JM3:SP#\1&!]55H9[R*;!`57:8U$IB
M<[!51[E0K8Q<SDOU`B^PP8N<!<F4:O(I'2W2!=(PUM/@!VDC#3"4,4*ELP"(
M!2Y0:G(FBJ3(O=W;BM^+4-)7USP>L>0+F(_QI(<I!;9\F(*-0"![&>)GV`Y$
M0OVKOXX-S,?<I5VZV,+,I<O,L@<,V2Y+S??7`9T-VF+^V5;2S4W0A?.1S@UP
M!NH!CDMET,7@VJ^3$#$P`G<RVQ```C?1(?X@K9O*1@Q0`[_-*:L[1G?#"[]&
M>E'A1(70#JY4`M%=>EA$JQF``3!"5!R].O.Q#M,J_P8$X")RAK6_.Q-L)"=@
M1P3TT"0@@B&\H$Q\(%2$8Y_R+:P,6IR8<(<QX3O5Q2D[LY3\77K.ECRPRTV+
MM2$@>FV$SN`&H<Z]Q%RN]2(6D`V[-H(;GH$8#@;78)^3;`(/.A&I-B4D80([
M$@,<PP=^P#%]D.(YRN)&D+,B_LER81?,IXJJK)?B&XL]GN_-!U&Q/)CI4E&5
M8<OO2QF)F4"+N5'S<M@XY>66W=AFNJ7.+`22N9DRQLS"S,P,#_'/D?$Y]K)A
M/N8@[[,NU$*>"(`&709W2G.D$P!N#@8VP'AM9W/"M`/H<04(X-P;L$0#\@.!
MO!%_O@4#8';5%JU0X7,Y;/\##8`F32GI2),T^Y%H3"PKJTK=]7I$(N!;:6C@
M758*V8"U0%(#6P`0;=5:_4D$0(#J;<(FWM8&8@$150#KLYZ@UN"&<O@0K]4[
MNSY[#'X\>A,/^>"ZV^0(&W+/GH+@^BA%L-!-('P0KG6B-A!7WT"6"8KAD(P-
MD[(G:-0B+B$,)#XXU,$'.\`C(V%J!:LVE6P".=ON[DX2%G"]=8%@Y$OOK5B^
M_5;7%R9`&4O*_K;74/H8[0L9"63+B(E1(,O+H$&R-F;,\]?,^7OQSQQ3`!;]
M*RO9U(^,B-TPR\^F'Q_RW&]J`MM"A@.`)-"?-B0Y>3H!&/AR6<!XQJ`1S1HS
M9R#_`EQT)F@035:T.@?2^M5$18(`"!45:11?7Q`--C6&:8U.%(\W7PDE&#LB
M$%9?%(V%"1H:&0TF)CL[8J@VJCP!K5<V;V(3&#4-@R44`!\?&FD-(Q,-&D`S
M7E9>7@F&E`@\/`1\!$TJU-74K0'5)!;<J+(3$ZAOXS_EYC\;&W0U(`UP@O"#
MC0QI$`"@%()P<"`U-0AOSI7;@,`?"'X']U48P(#!`!$B,&#HXLT""1(J>%1K
M]:)C@1<!.K[0MLV4A1TF3H*;T*7+#FXJP7698,H$`1-\^-@L%6,'@8O0^/0Q
MU8>/!5(X<RI=RL>(43QX>K!8$P0%B@58LX;8FG7!UA!8_Z^&%=LUJ]6S:*T:
M6,NVK5NV:5$8"/*VB%V[4_(6F>*AKP<I.3@(]NO!08[#@A,?H<*XL8#'9")+
MEBRALN7+F#-KUMRA`V?/E3MWMBP:=&G1I$]W?NS#A^K7L&.KWLR9MNW0H"6,
MOLV[=^\=3(,+'TZ\N'&F!((JO6BD.0D,]KX`*"$"&`\P$<!H#X!A`(X,94HT
M?`AQQQD1>6P,@`!"C1IT("J4*`&A1"(+#5C0H0.BD2!"AV3`P!8#))#&._(\
M8L@7`^QP11X-0*`!!`TQ(%X%#=1@PQ7.K!*`*F)@T$`##)4X(AQI3)(`!%]H
M```$<$R4!P8:$)'`C4-\D6.+7_]L8<-1/VU$#0]9P&2"-^!X,TY``KV!0$$@
M)!1/!172TT@:#.@C7T,05``"&G2DLX$_2Q8T(D-94@G'B"/6X`TJ%O!P448:
M40-22"*-E(T*%_5)@BD[L+022H*RY!()*4TPPD0C=($4*3=%$T,,?BAE$P%^
M3-H'"3H]:EQ*44V%%E9?:?456%U9-59<8K'ZUEIW%?%J6VD98$9=>AF0UZZ%
M]0588CDXT)=A@27&P0&-,?:8`),UZ]NSF^6&V6ZZE5:M;*H)H>VVW';K[;;8
MRO:LM=7V=EIJTT*KKFT=`'?<N_#&^RY&1KC@`@$QX%"&(10\U`4)$00<<`$[
M##!`!M/_+?30""+$<)X85S2007OOU8`B(1!0B(`-(ZJ3QHLE-))Q&3BX.4!X
M\'0"0!D48J"*#02<!XPW-O!0#@^P/.F/+0T-X<4,,VCPA1,5[).B,A3,9R$#
M<(A0Q7-E`&'%,1HD8$R-"6S!@P5X9%&D!3_&(L:39"\I$#H$K2,EE59>.4^%
M^C30SS_I[*<.E5%FV(["!O=ML`@-8)`D"<D%:8T*'.5Y.$FDU/3H#C.!8XK@
MI;04`TW@[-1%HX*B%"E./%6:%#29NI2<4C=YR@476&#AE!%<2T476::>"A:J
M"["JNZNSQNK[K&K!JI=:001AQA1K\468`PY(81@'BQW!@12`_R%V[`'()@M9
MLY%)0,:ZX--&;;C8;MO#D][DH?XX9".PW[>G=8L:^+&9>RYNZ(9O;FWMRNO_
M__[#B+WNE2\`&`("#\$`";`3,#`4@`\B\,Z+%`81$9SA#`.`6(3:\X.#5,`)
M:7!"QG"0(1%XZ6*WH``%(%"&`;SA"F(0008V@:7YE&``#1!#S8C4IRL$X!7C
MJ,6(6)"E*#&@#!.2D-`.P8G_J#!I:;@%`G]A!!),``)`&`/0B$"$&5BA1AI@
MP09B,8$M2$0B_OC'V7Z@LW8@"!YMPQ(]X%8TA-!M`^5PCSG&Z*0*4,AO#,`!
M>3)4@W"\;(=[LI-(''B-D?#I(I=*SO].:-*%&"#E)SRI)$I,T))`N:0G-Z&)
M)SM)@!U<;B<VB8%+DI(33/6D4J=KI:=RP@47-"<:>-B"J,1BNU[B+G>ZHY5<
MXM*[6.U*+[*:%5OVXH%D%L%X4[@+7YA'/>HQ+S"+H<(!./`\P6`O6<IB%O>^
MYSW]F1,WN2'?:[:%!C3TX'RQL$`>^.`"H[S)20BHV[>$,#]S8@M_T_IG:J1U
M3FKI)C/I=!<`%\K0X/RD7O?RP\D.F$`",!`[!2``1/35I094,"+=F0!W,@"'
M#:!H$""L1PL!(K$,A*QH`&)A"33$@RM8,8(Y7$4!`N`,KN%A`CLC$0,H@,0/
M?"&*481#"<K_P+(G(E6%)2A:E!+"D`S4`0<8$(,)+B(&!E3M1LA8!M`HL*8(
MXI"03TI'078&AP&P36E9<EM#]&%'.N03CVMD7U!IT9T,X)`6;GJ3&%C!"FP$
MH``[=>3AY.2G4@`*.*DS@2HA9\E'2792-$$*.,[0*,>10I4N:<D$;!*HT=[$
ME)N,!C1,$0/5(N=1T&B=4XQB@2W0X`9EZ64+3F66LRCSMW7QW3'[@DR[*).9
MS;2+&8(@*V82JYJ'L5YCMIF8;SIF>^,\9_C4&:YOO?-\`,$#-PHG%,M"!2IC
M(]L&#*H_[HYF-K.YUD`)&E#[C8^^\^M?0_?;T*U"U"DBV-<A&!`1_Q,4`#L(
M)@'##M91\D2$1!B(&(7\B-1&T`<1/"@`QQ!&(0LEC0$9LH%A"\"#L3&)C378
MPA8\*@(CKK`,]U!&?2ILH0O!PV@0^#`(".+&0`I2<&)X9,$$;+4$W.`&"?#B
M4>$X)3A6Z<ERO#$__'%7O)Z#?6OUQQG],0N)H&(6.D0D-L!6@`@@=CN)?"3A
M4@>HQEEN)JBL'&L[A9-1.NJTI=V<)2!5RI9HT@03L.1-*BGG2/&!<*;LB6MS
M<DO8$L`(?^A#2BS0`QH,055>.54+-KU;K@`S>+#"2W'OLDS?2?.8>2&,!XI[
MW+\DURYT*<*PGA?=Z"J&"@+09G6SMRQQ<O]/N[XQC6?(MT]O]8`.X.V!V"H"
M6Q/TH0JR1`K7O`$5,3'AVDR`EGOC*]#=O&:^]V-7/\=]/_WR]]S^VRH![&4$
M`D3H@`3&@`GLH)UZJX"S,BQ#T?P601)R#,;U,5H:+ERR5FRM`0W)T),"(@?$
M&AQL;Q"B.^JQB2PA!`XKS#$4_^.?*1\$!/M)B'^H1$@6)S`<%K`IH@/\U:H9
MP@M$T,2"GDCSD;,M372-4@W"9&4]EN,-!%FK&<](BW"(X0VK^%&<1GQ@!R+X
M&JVH1A,B6S@V]V2RK.U)322)6E-:5K*5--UI1:NH$7B.<"P![58!O4G(D9*5
M?$!MI9!C+SKCY);_!.!&#2J`V]R1ZBM>L%UOVR+J5!,7U8A/O*H7S^K>N=K4
MTVQ>L8Q%>5SG&GO6]<&RQMD]8'\&?^HL=K>0C3Y4X,$F3.F#I+]>+^44);*D
M."]4TKH!?@Y[V[BO7[C`W4_QU>]:L%$HNH?_J:TVH5[MQL`,64A"#%1!!?7>
MSN9&H*\T`-)"96#`.%C`U(:4P*5*2\1.#_NA)_U`CV):*RT*,@`;\F@3\?`P
MEK!4QUN(IP%C3..30(`FA_RU!N,`5*G`#5&G%-#Q53F2`%9`!%)S(T(#56XC
M9?LP-W>U1C\71&DD$8$#9$<'-C5S6..'6$T7?20(!B.Q9K#W=9'4.#T!_W:L
MY3F0`CDO""F.U4D^P68SX7:!YA.!8@J!)CD\(6@QT"C)H5")!DO*D1-UURF,
MUF[=P`)]]W<AL&F]]&FAMA?#]1?4LWA<V(5>N&K19%RO,@75%(;)4QB21WEJ
MR`&6EVO@M'G.TGF>%U"A5VSNM!_?139PP@VD$`T#Q&Y.476&)ASDE1.6)0ZT
M)R9B(GKRDWON=1FP08?`YXBB(7S$=XD.91/'UQP$,`$E\`4P9A^6`'US4&\!
M,(34AS+]1U03(D8(D!\L,");0#<_4%@?`C8\$'&SF!\UEB4X5!!*E33S<2`2
MN`]K,E5YPQ!4@D,86`,BXE&!\P]A)F))\$/8D/\$)&8>9U`I&*`O99``.3(#
M,``T,X`T\Y!S_6!7Z6"!/U`F:>2,16=TX^`A3">"29`$]98=+[`=UI`%T!!+
M.S!WAAAGEX(472=:F\1UES,I!5E*DS(I-^AF+L$2P`$Y,M%F+GA:5_=G23$4
M.U`4K92$2Z@^C'83%B`&4-@5OE0JN5-J6>@7U123,ND\S,,\7UB3.`F&I.86
M>R$%T[,K!B!K->F3:WAKN!89CW%=OC89<Y@NDQ@;^Y2'[8,`8B![CM84S1$&
M6OF'[3:0?=@ZK<,I6-D<S?&'ED(*@J6(ZO`^\$-LW()[D/A[3TF)IV&)F'B7
MT9`2QV=+!"`&W@@`HN#_$M>1'?5&``R#`X!));@P!.#(F$-0`370<^[Q'DZ2
M8BM&2"B""Y]P"%]0`FM"(KC01/K@0?N0(6J%`.;P!OSG$"/B9>*P;$@'@O<X
MFTD@,`,3`"&"`6<0`WTP`?IB0%_@!6.@1<:0`&1UC+1X#C[7CA'WCFED=&+@
M@3YTC=@H@B(H,$VG.-0`%"H(DI82'*"#$T$1@RU(2IY#65NGD):S24C12109
M@Q-A2J9U$Y,U:);09RA!`GY02<91+SDQ3]%@!*#"`HRYDBSI6X7G*S.YH#)9
M:SD@DS49+#B9D]%DACRIA5*P:GB!AK]B+-(#/4>0/4<I&;VVE$S9E*`'E=SR
M_UVSJ(>F=WJ7)(A+85E-01RS-!QD698#!);"D1*"E5Y5E@Y"4'N,2)>\1XF,
M6&QVB9>7F#I-P&XW<3(PAE4F46;19Y@15`<N!0$.J`R,Z06/N6-X5)D@0$3C
MT0``L7<JU`E1=&/(.%7[L0X6XXL,(*8+!R5M`A#SN"$!0)O84&:V.9NN\`HA
M8E86%"@3935$,)QC8`7*D`;I:&4#<9K.*8U'AW0B1IWV>(^VV4#W"`;6X">%
MHX(W^BD]RH(],1-%J'4M^#B30FB/XW9:!X-NMTJ>HY&5LTH\$9"3(I!PIQ3^
MR0<`:HBU10,)8*!F$93"11@,&I-%J8;112S1.J'"4O^AT00KPO,7@I&A=H&&
MW:081Q"NX#2BDX%=E(&B1UH:QM8#:K4%5"E>1_$H59"C9#FC-/HN2-$'A4BO
MMY03K?.'`"N@C\(->'"I9-,#2:HM=+FPZIJP^X0&2\JDQ&<3)#!`[19@3(4#
M$Y`'9^`RA*D="K91"/-5R6`(2C8$Q_D.%Z9"FP`"[@,"#%`?66)Q\5%'^#>I
M>/0>/U`+#@:`8E!(7S8!+S2;B,6I`E.;MHE8-84SJO`&P<`F$-$F@C,!,M0B
MQ&`%7G0C7^`E5#:5[Y@D;\`-+\,*U;FIG0H&2=`1VM$1VD!>JT>J7\=?L`0Y
M?B"#<F9*=I=H$`E[HT0HFP3_#J#E$S':9RX1*((FJ]%P'+,UHUP#A;XT%LRE
M/+UB>$3YK#[ID^+ZH<]::QS@H!,:369@!LTUNGQ1N<EE!M0T>2`ZKHY!&9PG
MAYY'!N6SHN!5E04K;9<"K!!E+ZS3.O8*MY!RJE?)%'$+=_^:HZB3=_&*EMXP
ME?ET5TG*L+"1L`@+7J77O#H3L1*+;A1KL8;)0B0##A`A!E:Z'><100CS"<J`
M9%-C"%530QE3'X(0,@I11W/##OMQC"."FF@S$&O5`.[Z)!NB"E=PCZTPFX%J
M9@[W(ZB@?H$UC\V91NTP(NT@.!)3(U_4OBVB`9[))O]`)DM"CP50MM<9,/BX
M2(JE_V86,*HT.$M]:'<TVJ\+]1.N9`HV>#GL&82Z:I`^"&>00PH[R%JF0PI^
MX&8Q4(3@,&C\F83QDA*V)7AA,1?&(RPZ>1>^XJ'9U!CAJKE9O,5;O+D.*J&K
M1ERF)FO4,Q@;>DT>RKKA=*[>([O.0C_Y(QO=DH=6&:.JUX0`R[L\>I9(`:-?
MQ\0PC!3@"<CWJA1<N;BJ][:'J"13Z;!OB7L/JRUT(`3'%J=/<CY:!;>HH+W;
MRU_=NY4$T`4(DP$1(0*"-`$%,`>EJ!T%@P/?\8U:FP!08`5(1@0:D`_&6#0U
M@`;OX!]T<('G5PX(`*?^,*;7FPJ'A9W8B+01<(^(I<`\]?\R>O6,!A.+"N>.
M;E2_5((#9M>-NW`/N)PQ"0``)'1TJO`A8M"GT6R=T=Q`^Z@X0/$3*.B5AYRX
MT(!*,UQUQ4'#,EBKE=5VKRIVJ.I)/I%9%%D3?#!9?0AVJ$2?E21*E!(OIY-W
M*#D$J`(6<B$\QV.A05FZE6N4VI-KQL*Z6TQ=E!?&$HJZ#M#1HFO%VOJ3:6P]
MT/.&O1;';WRBZW)?<]D!*ZJ'4`%;.LH'?\`48`F6\Y2CR0&2P&L3WDF\31W5
M)E`%5,T'?6S50L$4](H%X)D')G!>#9Q/<0K)"1NGFOPF0:V"30B69FD*GXR7
M.%%+6AD&49I]&#`"?U,#/,#*]?;_RK`LRQH`-%Y@LD20#UZBB/"A$"4U$.<P
M)A/\#P!A#H5EG0(S!P_0J236M*B08FZR)'J55CK##O?+#B>RR[@``1I+)!(#
M`"O#,@X!.%M@`;*I8;+=J=AY8&RK9D"A$P$)=WU0Q(-[$XNL%,/]UDIAMV\G
MD7MKD#E(D7@F.:V*$O49=ZW*9SLP`F;G2H+V+A5=K(&7K,P5:E<(TI2GN6SX
MAF1P>=[$QHR!>9@'+)Z+AGT1NK%RQ9V[:L=3&#2=325JKK`+;-ZFHN;3`Z9G
M),Z&E0/T+DG=;I+DG:3:Q%+=U%A]'(`(:4]M=V!]=.K%<W4SUF/M77AH5U,9
MMN)ER)9U_^$!FQ-N;=R7&-<N,-=5U&48$$$)AP!R$'VO;#":R47(`%8W``>^
M#`+G]QX;$!]P0&47"`OX%)L@F+2`>ME.CEBOD#.6.<$4_`]+0A"B[4&C^:;U
MVPDLA$!X8`=V4&(S+@);@'0-Y\YE-@=;$P#1MU,D,<\Y\;:%*+S<>Z.$K!/'
M`9(.>5FTJDH0F9>Y*M$\N)YPECIC9\."V\*(2]V0-1P-;0(,+@8-@-$AX%O!
M-2S.^JS'8M/+HDW6Q<;NC=*=6VL3Z@'TG<:5V])FH-_6PVLW_;ISF%_3.^``
M04\6N[M<V12/-ELIJ-9:O83G=A-&L)4)[L=Q)LA"D<?PLJ/`_O\H09T3?E#M
MC_*CT0D32\WK[+;'`S378=`IR:'41>C)+`Y`+AX%81`%?T`"5W`%EU`=W@%B
M;W!8VF$"?R,"-28A@LT(+LL.>%7,;>6R!<$D&_+N/J0&#[#PEKWPF+W`(/*:
M35N9H=VUE>KE\N`0"-)6%<)O647FB-,*-C!8K!PP)=^I/+!5V[G"RYNOWCD4
MP#VCX'G/R<O/=PF2K]=*/=B#F?20?%#$](DY*%$3;F=*=]:0^-)),;\3#'E9
M*C[12\'LS>&C%7"LJX*@I1M=9UR4F,>ZFK<]E\?>TX4]T'H8J4[?H?OJS0,L
MJGY-TF5YKXO3VA7@V8+K""!>P7%+9.G_NZF7QXQ,\TQ:%!;[/_^X%-4ND,3!
M;K\+^)SL*>-.EHK?A-S^XEC@\D51W"M^[L1'`'^P!$L0!5&`$7Z`W3MP4P;C
M,O@(!EF`R@;S'?-A#\H`0EP;.`&!9>/P[JH`J+9M\@I,8DQ+Y999"^XJJ5K.
M#L;(#V"B-GFSRQD`O@+R$"IF1BCW@4WGSF"0\C8@,-K))ZKE>II_[CB_R*15
MN)<3=BA!9_()D8[EU7X6D(DK''9K^(/^\SU1%*CU_K%T=U,/%3T`"&L+@X0+
M*`9%'E*+C(L<CY"0!Y-4!U275#X^`IQDGF0"*Y,KEYR8IY,<DP>/.:ZO#@YF
ML[0>L:I4'!ZV_PZNCY94`I_#Q)\2Q\C)RLO*'<X2SM'10D(]/0AB8B;;)GS>
MW^#AXN/DY>;GZ.GJZ^SM[NX[.^_S].1^?GQ&2U%12W]\9T;LN$)BQP0,`P9@
MN!*A@`H1&3+@P!$Q`X02:1A4`%&CQILW-@JH&5G`1D@U$6R(X3&GY8.7#QKR
ML($`P<>;-VLBZ-B1SH:?.CLV:``"!!PX%9+":0`G(8.G#)Q&%;$%FXT`!0I$
MV,JUJU<P/.+9X,&#!(&S]=*J7<NGC]L^!/ATV]%E@HDN&&+$\$-@6]\870Q.
M.!O8Q(0N@.7)+9?X;%S$BN/RT0MW<HQNWL[V^6;$B`D+>-@(&A1BT/^A1(H:
M,8H4Z91K39V("?`A"I@IUY58K8+T"I8L6F9BY<"52TJL7JJ`42GF20(Q9M"C
M2YLN38@/--:P:>.&F:WW[^##BV<7;[SY;R8V_UG"?LF(,WYV7(YWY<J$!B(P
M!(CPL(S$A"(,,-$`(B#P`P]810#32P6(88%6*4T@1@0IO"33&SN!,%0-/_W@
M(5`\%<41'37186(-&A[%`@,EE`%`!E,U@,&,&'AD4D@0;M62@A9Z%0$8`:@@
M9%GQ<.?'6VZ=IZ1W<>W05Q>!T5687-O(I]<.)A04@T$C1(G/8O8DQH<?>GT)
M#IDQ\$&"'XAYLYED^73VF1@LW(!"(8=,D5K_:JM%<L2?1^!V"6S",`=**)3<
MYMHJC++6FP-*!'><+\`<(<4N#OR"2:'/1>?I,L]`0UT'G#A#3379X;'-9DNV
MZNJKL'I37JQ,$M#%"".PARL))`0T@04!!&O#0<#R@`&,#8PPP'L!#K#%#UEI
M]4"%+Z70H!A9I50#`@&HX2&&-84(`HDDEL@3BD8=5=100P7XE%,)L;"%&"9E
MRU5+^"[XP(Y;@?'""T*JP&M?53K)S:RT)LR.'R:<)=@$$TB)EGQ18MF78%`&
MQ@Y@@'71<%SW@-,F'_+M@,^;WG1F!`$6(%`G(:?IR:=JD``:J*"9<,*IH:2.
MHC-NM5&Q0FV.NG+<_]&4!I,+IL0%P^FG4#,SZG0"G&K--6*HNDT^?V"A\-=@
MAUT.PF*S@_(9(N3ZAUXD\-!%?A9<8<,5!22!8``V8"""1QC@D':S"(PTQ[0I
M%%YA!`%L,6^XVWZTP4[BBHC&B9$;54$:%%Q4`8$;=F2320AFE>_@"RHX1U=@
M`!FDD&81\)8WV]Q3I&-\H%7V[=[@0T#)4L93F)57-KS-80:U"7+M;9G#,5_D
M$(`F7VBRREEG+&\A`YY%3*']S'UR`"C..NMLZ##.B%)*^`)<,K30EZ2"A"H<
M/-I+#L(-9TGZ'`A'7&S-10UU!\>8&JE,=:IJ9$-K5>A#9[#`0*_A[H$0-/\/
MV2*8CAB\IVM[4<$5ND"@'<R$;EM)0MX2(H8KC"`#N!J0@3S$P@WDI`8;TM"(
MSM61HASEAG!8%[N:)96G-,!&/+"7CD:G+]2E[E\JR$(6S,*=V!U)>N:@75N@
M2,%77>QW$-N2E&(P`2T*SP2]@U+#OF&[<C2)>;`#4V;0)*LMF2E.M;/`%F@`
M,T1LCWLU^QYNT+<SGD4#43D+GP^$-DA-$*U1O'E4TDS1&PZ<;QC^^]2HR%"=
M`EX-`5I;53Y<P,G.5/&3H)S'!$,)CKB<Y1]FZ0,)P*`"$XQ`!!.(%H_4\(8!
MU*$,-2C`&7"`JP$\)2D5H``%2O!+=K%+1,A,9HK_DI(&C"3%F#*:D1A`0A:M
M#`Y?I'M)OKAR1"2R[BS<J,(VJB#./J3G37`*Q_%(&383Z`6,=ME=E*`4/.YP
M#$I8RHQDTOD-E)VI=I(9(V;8Z#R](&^3GI$C'0UAQUW,S$^!^M,>Q3<^\DW'
M!XE"GR8V:DA&K>)]11N.(X,!B@.\`A?\(T,DI3/):5CM&MHQ@2=5QLE.3I&=
M.,WI-T:I4S5Q@00"`VJT>/"9',&D00*:@!HL@"MW0>`+&B""`HB0@"%0H`(Y
M5&:ZCD(4IK"@`E"!"E40,!:R8,6:^#(<-GO4+W_9876\:MT4S6F"!"+I=3T-
MI4'B43+A\>XP=N'.81`C_\;N4"D\\JD=F12S2;G(41"GR1X>\R@H]%7T$\Z@
M)'5JLPD^;G0VM5F%*'B3G).BE!,K0(+]2@')E4I-@!UX:0_F)8;$>C(SWG"@
MFZB8U][BCJ?L9!4!@!JP%^0(##E2T%8*@#>(B0&P&&``!!)`A#',H*H4H$$:
M<F@BRP$3K$J!YE!L`I($[6M?AE/K6ML:K("9Q0(6&*.;[G$RZ;&*M[Z%X.ZT
M^,YNV'-+D!'>8*.TI;C@]SMEBLN5PO%8AF9/3XW(X\U.$;[+6E2`&#W`"OCH
M65'49F@'`.E'*64;3ICTM,9P;3.H4\!38:<'&W@N8M83A7^0HXGYS?'M@!M*
MM_^@A0`J0*)6DGNOF-A+##/ZE4I*H`$KC,$*"?@"!=(`S*S"@450&<"&R`LZ
M>U4+FVN-25O]!3"!T:Z)JWKB376L4\SP-S!H`:-<^GH&C[DS8_,I</+.X\XT
MN8Z+W?C#'SZSA38X&,*.>(0>76/9BG;`$["-!F=U]D=AZ(PV(`8QHT#LBE4X
MS1,KB-_]GJ;B9+"X@`B@0T<@IJK![D6+><C#F,")9C;;6F$\!B4ZCT2"%T3@
M7V#P45>8FY5AB>&L*6$`$68`Y2A?%:PX8(`(V%65SP4Q1]E,;^%<PDW5L6Y@
M990+P]!\S@/?6FQ)(D=?2P8F_W)#BWB6TC:VU(V[FCO_+6SJ`O0@A@^O*=3!
MN^B>1">:4N9D-M+2R/"&!9!9S)**$X9<P48W/30D(&$4"X>T234<FU*;FH`N
MM@8=G/M<B-4%GECBZQ?);=ASN_P\N0[E6>X!Y(:H(-@1R&9#\)8-DU@`6Z?;
M2@`:H`$@:$#*6-60C*9Y%;2V1-OI+=V/F.M>6N>.OE@'!V:V]G)=\_:*6C19
M/_U",))%["XCX"*<Z=*P)R)I/,Z#$EP,LI>566`"%;!3$1+A@$0K&GSBZ^.%
M-8OP#F"TLPV'M#1F\UG::'AHF@CQXS/NC`QO(L4K/34U+EF3"9QA!WD@P5T*
M:X$=8"!B$,-2K;O.>B7%'*=9__)U@G)N."//)%AGG4-6@HU49-DH6-:L%M35
MRE;DEAG<+!=''XZD)'O?N_7J2'<X^FPE)\FE+^*<&,/H@B4\-^R=?;&WDMYY
M=\2LS`1B`,$:$&$&6TC!3X!O=#$0?JK8"L$9H4"\-!S^<(T.#?*.-WF7)VD<
MAWG^HWFH4A/98'+Q1!>7L0UY4#P1HW+<D&ZW!7T8J!:O5T7FE!G;H`([!P9/
M9SA:(&8QD3K+E3HJ.!-R,$3"EU9@UA*I8P=5)T5GPAWNH#(J$PZO@U?CX'S2
MEX'N$(2RPE?<MW5DUX'=T!<0<QA<%%@:LRIW=1Y_$0-X@`=6PC!BT`,R$`22
MDBF*=O\$!S!A%,9'!A=I+59_AJ=_T0`-A#=`<&A(M+$)CO=_`PA`H;!A!A@U
M+D4-;,`&V9$U=:4738AZH!=K>H$%?T!.5<!%JH<9G<%)0CB)HL18.K494/2!
M29`MA*-M)XB"*HB"M#<'4$>*@\--04(660!??C%7RP=%S]<J20*$L4A*]\9/
M/+A;X$"$ZT9O>Y8>FL%U5'(7:6)0=&$FSK=G]7!@\1%/?K`$,=`'/\<&,J`$
MR"%AN$$H%28,4_.&E51`&V4=L"$-`30UI0):$E<UZ/A9H6)XZ1@J!V@J/8`J
MBC,O[X8858)/7,<QJL0'^*1R;K*+E#B0Z["!$61?=,47*I#_!`RI(*68+=>4
M<_I21"'T`G`E5["C2;9&BV_G6VAQ8'#A.H:U?/M$=T98;SR(D-)S,AJ36`96
MBVR1)(;1!9N!!?P@C7C``M4H4DWS&MH8/OU'?VG(43[08N0H*N4X->P(6NSX
M:"H%#9#7AIXR*D*P+0NH;Y[4,1&C8'#&E?@H3RVY%RE)D&2)#@8)0;Q5)5D2
M9$EP+_S2B9ZX%67F7N!&:[,3%Q58EASX@[&(B62'&:P"1E="/&4'#V*Y)0$)
MD]]A3H?1!US@`M!H`GC0`RQP`I:I*?''890V'6G8F9UI?Z.2E`($E(Q7*D<)
M#9IP?P`TE7TX6_.2>FB!)H(1'T72_T;5YX#5-S*NJ)>\*0YG"4K^-3M"!2$P
M47O]DA7!P@.KB&;T!83*V)L49&XA$V[]Y!9D-R:U8TZX23PMIP[XT&=CLA>N
MHYCAL0U0@@5<@`61.9ELH`-(<`(7EYF:J5&>69_4\!/X20W3(9JPM9F$LI_(
MP'CP"!T@EX!;<'H6,QF%@7[T%`]<Z21@N0.8V#&,U9'0V9N_^4`6FI%^T39W
M$RW,I9RK&%]-5"0FP'SW0)X7&ER\A23<<#$&97;\I7KO<#*(*1]\082O<C"(
M@04NT`];\G,UT)XZH`/_)W%$28>-EZ2:@`8O=C50JA-2.J4(\!-74W]JV)\,
MUW_B(Y70,/\;6[IBST!`J5)R8D`";=$[3*B/^=B54G)08E*=.KJB`YFAN..#
M`#6,8/2(++=Z=`I]Z,1N*=F!<V9R6W(E[T1&Z6&8WA"CSWD>1'@PB?BCT.@'
M))`'8H``5_.'?\BD0L"IG\JI\QBE4YH-!P1?>&"JW)&J5S@!BJ.IUF"E&W"?
M/U&?7$IIFH4,#X>&FW<-$F(8@=6H>G$ELPE0#HBH"QJ>B+F+>/JG=6J)EQB$
MW;$96\,-X\:G8Z2BT:>,.HJ)Y#"%TC>GW)INWCJ)&YH['`.MO]BF6T0QZMH.
M9Z$7?Y8FR".NBRFM__4'+K`>2R")IIJIL`JE`CNP,*43VG"%?2K_4]R@3[0&
MK!+B7*`A!EL@(1^1J;$ZJRW664!)2<AP*%3Y4M@@F/JHK!)Z9R<'3HUALC$0
MFV6B?,WJK)-HI[<SA8_*E[M%5]*9.V83D/VDBP?%L\RW9CS+K%`4M&ZB&<SW
MDF!CM$*[%O@5KXA!H<AC)N!T&+@2,1D3A3V[,+43EOC`%^.Y)'A:HEVD6.S!
M28&)?O^:#=JQMFZ['>1F;T80#CK8%@?3162B;[9";VLZ`3H!I4.Y"5X*<O8G
M6XKS*WG@!V<`'R`#&&?`!WD`1B?[%V($M?HV1NS&3^<*LT(HLQIJ7RY[LZXH
MKDVBL_I$#H*F3IE!L_N$G<JXJ.GV8ZY[_R2Q^49Y.IV']36X^[+A$7>!T3%P
M9K>.`488@"LC@`&^$[PCR;7^V`TQ2KOV>AZW5240\WWF5U.>1*T+JZ?;FS)S
M.[<T.SU&8&,-5+X<N@/[8)/L$04,Y`)8H!>#!JP3FZD;<*59BH!"\#@Z48AV
M,1E+@`5S:QDQ<`;1B');(R6_TQA5**&<ZZR>>Z?:N@[+AUMG(IU;%S*K@I<,
MG*=D!";W@!D@$SL9R3`A,R9?HCL@HY()(W8O&<'G`$Y?@IME<F<0>GV&4;PT
MDGI[5:^@2QYI<A>*P7S1.QZ;$<#<4')5XD;FQP<VIH,7.`Y.K*).',!I]`<$
M_+[P\0T=LS)K@_^/Z`<Q4PJE^,D$3*"_-N&V@B$?!!P#?S"WLMD'4M)%!N.N
M)$.A!WPE03O$#9R!#SRSO(MO7Y+"HLNS<48P)[HU>&EU;W2BXS:,&3DF'T-V
M'[P8#$,R59*C/B:2"I.B@RP>^7@9(YNW$)J/KV07)C<")B</>FP.&L,F)[RY
M8IL/'.JP.U!Z6:NWG%%3+K`8L*P.LJ:,._@6"YNW`%97B%$%YM</4>!);/*K
M_WJ%T!S-F=2=`%&,9]#&;L$Q!*.F\_:5_@@E8-L[1KO*>]QZ?5PVY/P.P0G.
MU8D>TF,"D6LQVWO(#5NM\N9N+`<8?UG/:NF/::<9V:F[7Y+.[$#/\L3_5^DJ
M/(DQ%WAQO!&#9#-2%_%`T.+`)IM!%]_@=BZ\C+O81#J,3P<Q`>5`5TTDS#W8
ME[Q+;M5;B%B215%`KVW1L@E;TJSBQ`R$)AW3J&R:QK$SK`^(FPH=&.%*T>5\
M;N?\-5)(175[TLZYM0`U/&GS,7W1L%1R%B0P`:ALR,(XO'C9,#N0-EKM&%.]
M.[A"H_5,,.#T-B,`%T*,U/>UT>=PP)"!CPZ(N11Z&$DF&'J#H`0#UXGE3A7:
MRZXBS-S!T_S+=20]TSB(I_:&@^/`<JD7TC_W7`2<T0;UD<C#0./00)VD,HJ(
M!230!W--8/`$6-97?;0YK.&<8$0+UT6=7T>M_S!;0X1++7[H4*)Z,QCP%&!^
M)=%YH-;T5AZB=QF[<P9=1-Q?+0)Z&KD4^B1I\E>C#!B!%6MZTP7.DZ-?0ZZN
M70[L6F=^<<]R(=U0TH2&8;P8\!G".`]]<*-B2;2Q@I`I`PX[0,#Q4&>+2\!I
M6X&V+0X--*C6V;W3EY=^\`=H8BM=4*B!-3Q3TA;_@(O>\`?20]4A.7<//2.U
M++FHO+"`\9VC)P_CEK*C2]2OS6:Q34'9N]_FP!T$,`%P4Q!O(P(P'E@6!.,B
M<"L`(A!=HB:W$AAZ0^,>LP.X4J(OGC;Q@`$>T^,P+A!W0>.H''I?/0)/%+8)
MH]T2C(GF]M\R/-Z6R_^G"(QZQ7NU@65@]+!\EZ&@WYHPPNC$:Q,#[RO2%G3?
MC.78Z&"^K9W8-U:!X]O&1H`8LDEO>!!?J:??M3A.-$W2)&?DGW'/;2J6\M8D
M"UUOR3CB!%GB.M;8+YK;HE?:+"X"V_!*=0$E/9YZ47W5^2$8SP7CM07C#6.=
M>UT\\1#5@/5*&&`!>WWJ(]`P5:`L$Y#IJUYN+B=/E_%.N(F/@$8PB9%ZM[)@
M;$&;@OFN%$0F]AW928:/9K/=+FM.22(E\9$7F%%]'&U&=4R(6Q+HW6PR^/25
M!>6+DOZGE)YCELX-K\2G>-U!+'[KW,#BY_WJMWYW<`,Q,X+J3[[JYM3C)U?_
M>D0.7_7^&0%R>@@A`JKW-A,0N87N6RNY4Y`1IULT9U^YIUVTX_AD[;!S=MQ7
MLP>IQGAQ>@?QZ9#!/+8[M"[/%N0&/",?/6)N'K))3^XF)F")F.EN,NZV[A?:
M[N[NHK`#Y)Q>):_45")PZKL>7P8_Z^AW\/AN`D@>XT`^`KM%O#2>[P=O]+]B
M`@&B]$IN*["$R(+.9C&<&+W##3@ON0O:S5DK=MX!Q/)T,I\TP>AZ\@B:\OAD
MNN*0NDX]][66;_"DVC\;'BL);QYS15&H[8X>&)6<NT#/FT*?7^]N]*J7\$SE
M\/C.*Y_1^09_ZZ1^>EJ6#7KSZISN/.847W2Q\`&/__DD&N-JZ1>Y7:WE]L>D
MU+IJ3ZS![?:N+J\$0T]Z]AU'N*P@;_,9??*H7#PX;\(O[.!K06ZR,MI^AIW0
M3_SS-!^_"V\6`^PT^LB33_G.7I;V1G-47_:&$=7)C?JH!S$PGG*RKRPSHA`&
M/P"IGOK?R9T(@;Q$#@@8(B,[A28C(A@F)A.&!!@#$P2+BWV6EWR9FIN<G9Z?
MH*&BFGZ9.UTQ.S&IBUU=.R:3,:X3)B2GL)2S.Y.COINK)GXQ?`2_Q\C(?GY]
MIA,8$UTCKZXQB\;-R=J?E-W7IS'1I7S+V=N@YINJA:ZOB[-=M<:J,7[&FI3G
M^OO\_?[_`)$5"DBPX*]+R_\F34@4:P(B$1`)Y9'VL(L)08-V8(0HXM5#CH5&
MC,A4BA''C#M&8$@Y@*,BC2=73H+(:Q&?2Y8,ZO24$YR)72;XF/`Y="BJH*=<
M=9M%+*`?5\.ZV-M)L`\S9^U0%6*U+M2P<55QDLS4!Y>FG#>K?O+I2BB?I$&%
M[>J$B:K=NWCS\ANHMZ\^L900V1J*`9JA1=$,DV"$P2)C:(T(/(-<ZZ>UJX@+
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M(;-,X.<S,`I#DH7@[+@-EDK2D]1W9:4"UI1Z1BKI3DE.&ER$Y.S`3):<XBA*
MIYQN4@H!JO!DZ2=6C8,F.TI]<U1QUMRW"SL65L(40/3$__)44WE.:E4?Q;$C
MTC36,#AA*F;E9-6I_30*VRO-.7HBL]16NT^EUMZU3(.@=@LEHJ#>Y&F$8YX%
M);,$8`H7A4`A!5NQR5'RHZ9P&1-54^<F4^=;J#13;K6I_+F#0\-V84R-'MY6
M#TF]9AM*-E85,EN-ACIL\<6:8(LQ/W_\@>=5O^HEWC[D>NPIQC[&VPJ)L2Q:
M6[P'0V6G19K$<`9W^MBT72F%8FJM5H4-/+!(C:QR'[^OO+GEQL=L9S.03$<=
MM<92;^,Q60V+G.\Q?SPW<K;,&!/;*1-PU4Z'[=HF[ZU1005?<S?WLR8X/*_R
M7\7IJ9C4&2HU0K`T:?)[FVUX;_\\:EJ#VEWUXA=3S3C7.=(U2N&:=(P.Y;\8
M@0V8UJ+UHV/)D>B=34EYIV@N/CHZUY/.[5-4NHJWSJSFY/#K$#3Q$#P-+*P&
M]:YWCZ,J;G=^D%![\,A+ZGCRH%C>R;9;\W$U,AU/3U?TF4O?=9386YK-TQU*
MPTN"CB&E,CQPSOQ=4GW8^]LYP"9$:K\SWBFI$49DDC]F&$PSV@YG:(<U4M*%
M8@SE#&=@%>8<]@>P7&5XRV*>!(VTO`E:,'EHB=8.LK$=UP0P0O-K2NF4X[M7
MS0LYQ)#1H4P!E?K%X![P$9>4@C/#C%%$)(TI&^^J@:QXQ*9L0LG'!8=(1/-4
ML(A(Q-C_=7;VEF*$+@;-D0HIO(,L5@@C6!+STZ)*M3E^;"<3MR+'5"#%&B*9
M`SY)$8D/8Q&.6&6E(232RA632,<Z4NH[=LSCQ:[#NCM9Y7WU^T[;-$6^#?VD
M'7;"@#6`=Q.?Z:-U;_)9#?WR+;"THF\2@X=;"`@+-F5G?0_4HRA'Z8LCDO*4
M10IE5)C!,_O1S0_T.@K2@#04N`1K-XT,I38N08]FA'%3D^Q+)>,7E':4S3-O
MF@T)D=G#8A5B@:B,YA!-*<UJEG%;9-E%JK;#(MB,`Q?K4-3:PJ'#,)Y%ER+*
M!MW>HCA$J0<3%8)-)F&QJUF,PR@[5%@NK,E//5*SGP`M2`8=_[D+55FH.T!R
M39KP"2>DI<)^X(%.?<K20O1Q3TOER8DL+#(?H@A.C(%4:.^F$[F`FC1X_SRI
M2O4A23PICH52$5L+2_$F#[D#:<H45=:0P4%_M3`I$_U:1BV1KE;928<>JLG$
MA#2OI'!KI5"M6DJC2M7)K2:"W1%2(^U6.EH*SBAF8I4\QS*\9I%$G3_M%PR?
MA$Z1U2="55`9OW:HJ"`"18":FI4K_%6.JOHU6U/]JV`?IDIO#NHWW)37V6RJ
M3U6EPWD29>?"P!$CQ&7T)E4`7L)"HS2AX**A70IBRO"%U<&:-DR!/:UJR\HP
M;9+%;?4CD5`LA,;DO!13:(%L0"A+@/]('HZ&6"O&KAH**_-)!2G*[.0LUH1%
M:`G7D:N-[GA2*]W3UH5%K5V8AO!XJT.6R%X0JYYN_Q&Q5#2#LL>S;%]@.946
MU?)=K$(;*DSWJH2%<Q7M"UEU]^L7ZO+WK^R)BJ;L@2:[#4,5G)UO'*$(ICZ(
M=WL`45=%:[13JO14IM]\W[Q,X5X-*?85>3#**FK$VO^:^(XG3G%X-L'6SBX*
MIB3$*2/U2Y8'6X\@%NTL#<UASE.,8$,O1BAMBG-/1'IV0G%3;XJ7?!X\,GFP
M5PTE5KGYS=B=;;8*[F1=?F7C&S?+2NML48K^`YL]D;,1/BJ)PII)0F7.RD_O
MNADTGTSGM3C_N<[651$(L]I7-%5C45"9"S9)P0P;SYFP@W8JTDH!W1.UM1^K
M^MY-::2IF\S"L]LU+DT%",8_X_G3Y_`OJ$T:,GMY!ZUGZ(QGDH9?2SPJ121!
MH"]OAJD'#O30HM"DI9/C/BE:Q:*Q5=6575@S0([ZV*,0-;+YZ:!EM+-1\G!S
M/3"J'LJ28%<]%2.<J,V/*-Z**096ZZYO52@RO:B`,^).;);-[E`HN]W,GJ+]
M_(!FVWZ(K:B]D]+,L:U-$>1>E#8N%`^KG-]E&$B#K++1E`QO=K^[X=%TD+?K
M,R^M;*K1&<WPM-]$8QI'F**K""#%6VCI:<2PQUV(F_&J40XT5:=[_Q!_\L-C
MKL?P0,EI/DT:;7()O7<>+HS'&KB]'DTR7VKE0P4N-F(M_B2\"HZ#[XL0S&F>
MXIE3O8X29TYL>*@=5W.PPL+$R<X.>>Z&]C4@R[K7"/LC%R!I2*MI_M'`R?&^
MJ5]]R5:_.Q)3=<X';L?>O-!VY<"NM0BV"!P>%D8G!4KWHW>A?4VWGW,8+;YQ
M`-+E0]>[PS?HK<Y[_O.@#[WH1T_ZTIO^]*C/(([:=FIQV3KUL)<T+:)!C<L\
M,_4,0VA.8UL/6%(X9B1V,8Q`]*G8&__XR$^^\I?/_-+?OOG0C[[TIT]]V%\I
M/'XW;"YE6/W.9X(6$SO;/G$/4M@Y/CE.6_]X/0JJ<W6WD.]6[;[\YT__^ML_
M.L^_O_[WS__^GXSX$65JFH(0P.1_XK$J:,8W_E,LUE=^C;=4E$=A=)=`F]86
M,A53\!=_!KB!'-B!_I=_'AB"(CB"H;<>#&,.KG9VER!>!CA+N1,-:A0/RD%^
M&>A"D:1H0M84Z!.!4W%V&DB"0!B$0DAZ(#B$1GB$'(@._5:`$+."U:-_/4(+
M07,*J=8%T,!]I8<U_28AVC%?WA&!6R%@AQ53Z<)M/(&$:)B&:%B$:MB&;AA]
M8M)OU]$Q3DB']]<C?D(1A@$H9H*%J+>$JZ(AH[(J+)1DC9<:5X%QU_.&C-B(
M_,>&CAB)DDAZ>(+_@JHA29;`@G>()Q)3&/V3:A,00/'P'WZ((YW25Y@0(=ZE
M2>8G1;$E;\20*L)`=(LXB;9XB\H'B;BXB[P(>CU7BAR8$)^S._TS`=JF*IS0
M,=4!,IE(A[AE1GIE#8"'2P#D:RU7#KV8C=J8?+JXC=[XC4<(4MZ6%;0'"Y=6
M.\O2!U7@,>R%33BAB9?H!U=S+X<T0&2W,"[$+>"XC_PH>MW8CP`9D/S7;\,(
M"[3'<F+$5UV33'?3C'88CU(7B$8%%S!5#.DHD!B9D3CQCQK9D1Z)?*Q4#QME
M3(LP&KP6D8TG3]P"CQ#)05MG$62C'$650L#XD3:IC1QYDSJYDYZWA(U4_R>T
M((-9X766,`L)A%XU^37P)V"J$`VUD"FP)8^_PI-4>8LY6958F96IPE>69!0K
M07O#`D6<-R&OL3!,2$8,<W%W)45$)D/+T#5:&9=M>)5R69<>22YX*2M:`99A
M693TPT.*<Y;1X7?R>#S@AG#SU4B9:'-VV9A!2)>.&9G\:#E]IHKM,`U.*0V-
M,5\#R'KH,Y52.9C_X8P&U87MP&CAL3V2N9HA")FL^9J\R()RR$(X=!P4`3BD
MB'@*UGO_$9J<TG/<=)H)"9O$R8&N69S(V8@VUG.-X@HJ,3!^4C"Q0C<BMC.J
M(IA2@HI+A4=PF9S>:7_'^9WB>82&AHVI,@NU&?\2`G1`QR4,(O$NN-6=X&*>
MW.1@F2"?XYF?T1>>^MF?(=AE6G@5SX!#*4>2G[,R7(>/#M8I7?.+%_>6_AFA
MS,>?$EJA^P>@VJ91?"F*S80<M/%V"[.@OZF,SYBA26FA*/IY%)JB+%I]74:B
MV"@QFNF4\].>*:$(0B&1#`8JF-)`K*0B^-FB0NHM*SJD1JI\+^JCJ5(%.Z1&
M.X1^+^:A(S9MU^B0#3H.2KI]-Q&D1]JE^,=Y7AJF\\=*<I@N@YA7NRDXI"**
M,>5L-6)OO5<(9/J$6\DI#RFF>%H68)JG?-I\9+J$*5B4M^5;.^AL-^,^M%8C
M`[$M=,JE??JH&[FGD#K_J;`'B-##7BDY#H*(4V,H191&6;-8#EU#IY1:JGIJ
MJJAJ>I::@B'I*+"T=2,F1:U4#[NY*',Q@P5XIZG:IT6ZJZ:ZJB&S2N9FEJ?)
M:.A35#\&ABT"/;Z*JKW:K)-JJ>YX@X+(>MM2K87Z%+O#<N8)K9/ZK-[:IX!*
MD-[DIN?F5!'R+`KFBEVUF]T:KKPJJ?`ZKZR*EVZZ0;-:@=KAIO7P.8(4*+`*
M,N]*KT8*K@3KI2W7F:NBJ07::;(Z2$+6;^C#6&_BJ`<KI`9[L48:-LTQ8((F
M..SWL$P!%4A9.E34?BQGL1J+HAF[LBU:@&W#:`*V#*4CLX*VJ2G9>-J!0O*(
M_YTN6Z$M^[,I>JG".2/38$-G8+-'VXJ,]B,1&"L.U;.^*;0L*Z]4^ZO;LE3]
MBE>Q8:Q9X7LDYF<U$DE1>Y\0>K46&K1HZY^7&AL:HK,B^R$T`C4O1B.]1V0]
M*H\JN[;>J;9\FY\)R4XZ]WC,D*U/8ZS3T%>A]7V)NRV(56AON;=_6YQ^.[GB
MR:B%>S/E"B.O>C9@*Z=B:ZX,VR_*V$"D:KGY6;FHFYS5$YKVY`>:2V**9K<\
M8QN(9XCPP(Z2N[I]:[6\*Z:ENY6Q@4!QVK#(*A7E@'Y@ZXI,\0?VLKN_2[F^
M&[U>*I^;@D`E$A4BQR7#1X7Z!A7,P#X$8+I32[WCJ?^ZYEN<;FDSMOL[ARM&
MAVD;(1EUC)J^^HF^]MN8<-D)E99RL2I"73(J`)2T-^%CO7>(8N2CT)N_D8F_
M#"R73_@QL54BP0:5[V-1?P0D#E:Z)_K`DJD*21K"(CS")%S")GS"*)S"*KS"
M+-S"+OS",!S#,AS#\>AFCC=@`.>N,);`=3K#/OS#0!S$0CS$1%S$1JS"JW#$
M2KS$3-S$3OS$4&S$E^B7#T5AG]NYM":Z_1;%7-S%7OS%8!S&79;$8ES&9GS&
M:)S&1;S!XK4J;;*\QOI!?MFFTZ;&=GS'>)S'4$S&>MS'?OS'@`S%I9!R\36W
MP_!!/'B,>AO(C-S(CNS'?/S_R)(\R92,QVS<QHOLHTXU0FU#/X/$5JQ4R:(\
MRJ1LQ)%<RJB<RJKLPY?LHY';,0/A5+KF8ZY88-O$J*N<R[J\R^)URKS\R\"\
MRU:*RZ1IKO)[4%&[JL&\S,S<R+[<S-`<S9.LMYE\C+_SM0XKLX`HS=S<S67\
MS$!LJ6(LSD5,SMXLR-OLR']ZK\!FE,1@NJU[SO)LQN:<RN#\P_7LQ?D<Q/L\
MST?<SWYLJ;;Q)KF;P/Y\T&4,T*)\SSZLT$_LT#(,T0B-S^G<R-):8/#P03PW
MT1S=Q1(MR0P]PQ^]Q"/MPB7=T29=T8Q\T8>,"B-P!AX#SYF,TC3]SRJ-RB$=
MT3?M_]$['<X]7=,B_=-]S-)4&$#*88>O#-1*+<0GS<@Y'<--7<Y"'=1+N-3\
M/-5Z3,Q%N4'VI&U6_=5#'-6`_-0P+*U@;-9$?-%@K=-B/<Y:_152V=9K/=</
MIM:J;&`LG==ZO==\W==^_=>`'=B"/=B$7=B&?=B(G=B*S==)NLBWO-B0'=F2
M/=F47=F6?=F&_:*4C=>8W=F>_=F@'=JB/=J@;<*D?=JHG=JJO=J3K=F3S=FL
M'=NR/=NT7=ND;=JVG=NZO=N\7=BN+=FPW=O"/=S$7=RGC=O&G=S*O=RB_=N1
M'=S,'=W2/=W4/=,B7-W8G=W:;=?+^=J\N=W@'=[BW=S(/?_>YGW>O.W<D`W=
MZ-W>[OW>>GW"\#W?]$W>W0W<WUW?^KW?YEW"XET]40!+H$O--"NGKEP.6)#@
M"N[*57#15=#@C'W@E_T'6-"Z#W[A$`Z($D/,6.#7&6[.TGW?^,W?)%[B)E[=
M'1,%4>`"`H[#!+[A+-@Q"C[C?H#AVU)+-?[@$8[)EDWA%H[A'[X,#2XQ`R;C
M'9[7#I;C/7WB>\W>3/[D4![EGLW@%Y[)'5[E25W5))SC6$[8=3WA/*[E,)K.
M"1[?8W[34BZM3I[F;-[F;A[8)&KCU5/F6"[B22U>*AX%/JKC%<WE0)[/F/WE
M6]QE@+[D8G[F;^YL^9WHC-[HCG[_YR`.X3LPXQ7>NBT^8*T,HQ`^YS,NX;K-
MZ93>Z5<ZZ"2<X.K=Z&O^Z*J^ZB8NZ*3>CI,NZHA^YY9>XZ\\XU%PY.E=X:%N
MY*)^Z"S,ZJG.ZL1>[.]-X:9^Z41.L[!DZEB@YY8.Y'RNX2Z.YPFNXKUNZ@\6
MY+1.V;ZN[3:6ZY6^Y^OX[>`>PL8^[,:^[NR^W76-.MT`+#;!9:2:/MT@*MIF
M"#F>Z>9.Z8+^X79^V#C\[3"*Y]!.HH60XN(^[I@<TP?.[3T>\)GMZL^]Z.U^
M\1B/W7\0!4:@R5[I"HWAB5:H2'U@!#5.49Z8\B(_`9;`I-#I;%:QZ:,:Z@GN
M`A6.[5?*_S"G#M!:WHXS;03J*.V$+N`4CNVFGN2`"/32[NW^K=@[G]CJGO%2
M/_6]S?%_\$*'@`,9``%<W_5<GP%UD`$BL$&Y@`$X4`=UP/5HG_9U4`89@`,B
M4`LI`1&$2^3+/O1?KK`VENR'K8Q%7M</'B<8CC^8G/#BWL94*L"+\.=,O^5.
M/_0C3O62/_G#W;I"(0(`0`0:4`9E\`6>_P6<#P!N+P)B,#!B(`8-D`$```"?
M[_FB7P8`\`$:P`!^,@`X,`#'<1BG?_KZ01_P$2=$7@\/MN"([?>+K.(-5`6,
M(`83(`9X4/HFT.`Q@/R:[.-A'B<FP/O8'_U5O=CEW?>07_&4/__^Y&_;;[$#
M>8`!94`$)=``6_#^\/_^GE@+>*#\%B`&GAC_\%\8`P`(&AH#&"(XA#L3(@V,
MC8Z/#1B2$V*5>7D[.WY^,7^>6*!8?YNDI::GFYZJHZE_45&>?B:*CEMB%CM5
M?:^JJ:*QG%5\F2:SCB(88B:9K:RHS]"DJ]/4T=;/U,#7VZ@Q,=S@X>+CY.7F
MY^CIZNOL[>[O\/'NPSMB.!\96Q/[^A-;_?NZ2!*(@1_`??PH,2`"84LA$1-,
M8(`@J*+%BQH2)/@"H0V#`0UVY"G&IX\?5:%$<<N639HK6)M,-("@46.;!A,T
MG>3%JD\O/U6"[C!A02(.00D$X<"P3.?_3W8L6[9C*8_3MZI8LVK=RK6KUZ]@
MPV:M(FM"F0\-:C`H`X$MA+<0.+XMXW:N1KIPZ98I4:-&&0T-FEJPT```$"`*
M$BN&P1B&XL<*@!`!@$.$2'HH76AV9FK4*CY\C(`>/7K524^\9(D9,.,Q$`@0
M2[[45BHHV:$[1&0@PCCQZV3,3KK@?-KTRJA4BY^:M@UY<=KGO(F=3KVZ]>O8
MLVM'-TH7@2Y_^U(@HL&*^1GH9YA?KT']#,1`QA!9/X,(D3(-$%#0P,($GV*$
M`4#$84!D5-.!![:'6&0?E$&("29]H@H?RWE"5DS%9*)A3L048T(IL_5A@A@L
M>*&8&PH0D0`#_TQ1^)QIMBV#P0`"CF'C&)*U,0$NK<!BFH9.20.-B$T-]:$L
MQ1#IH8N;D/54<"YETZ&'IIBDTVFID.,-<EQVZ:54QWTIYIADEFGFF6BFJ>::
M;+;IIG%AOBEGE^#$8@1X`&RAGQ6">)&`%X#Z&>B@7M0WQ@R$EE=&,AGP=]I0
M#21`(!`#3-#%I9AB>L9#C1(Q!F-$9(`!`49$@<4.&#2"02:B8.%"J568@(<8
M_S3`0@4,Y)IK!2PT\`\>>!3S3:DN@&*""":ZT5AB##4@!AZVN>*J"[S$*D8#
M0Q"A`&,S0,$8$#J:(.$?FK@:QA]=V*I#KUVXT$<5KCACDA%!30#)O?^^_H-`
MAB;8%D488?B1*B-,!752*-2J,@&P6SRR3T'[?&.2B\0U$]66<Z999\8<=^SQ
MQR"'+'*9<8Z<\4KS3O!%GF*TP:<&?FI$Z,R&(AJH1E8L*D:C+/0A2JR1$DB$
M"*0:8?311A/PGP43T/AI8H/X800H&&0`@"`#^'<P3,5LP4(;0[0WH-!$(#I$
M&X@4([4+89C*![*-(3IV@0PLW*\?45!KJA$B-IW`M@I`D<`0RL(`[@1\_.&J
M)^5JYL<`?P*J`0XQO!NO'YIH8@10(B25D>2>(Z71$!"4@`PET%;!M@MG9/!G
M`I7V"V]*473B!QY;B$!1`@`X.,(((@0OP@C_E?O1Q_&H>(FQR5QNS/SST$<O
M_?0<ETR]QLV-8H19>2+0!J(PPPQHV?799[Y];MCHAAM0()I`SHSRY_,H,DD:
M&1$-6(!\E?W&0-0$#-"`8H"0`<3U@0\C*,."<&`\XY&E&$W[B[8D@Y&Y2:8,
M#'!6OUZ"A;=IH#$K:H,&"*0!!MA"=J\PG@5H%4`">:$-+*"!MPRGH\0MCEQX
M<Q4&R@`9``1F!XISAN;H)0)M*<!&AQF0?29%0@SB!`^-2Z!B2A"1H'SB5.\*
MRA9:*!D`L&@'70C>`,9XAC_$8`<E25Z7EG<]Z$2CC7",HQSG:#+KT?%+QY$:
M]_3DLCY%KC[K(]``_X&0OC&L#P;N:U#\>J:2^BUH:&+8Q/&.IXHLGM$"$QD@
M!%:U`\(H$`9C&,`W8B0&W8VP0&7(``."UP@1#(`!5OM`$AT4D>(00`0?=$P"
M_L$``2D1`I4JRC<@.(!LS;)28I#AMVHH(<SYH8,3P($2QT8$*HIK.*P`8G>*
M>!@-4"!7.`@G.#.0@;\(;441R841$J@L(#!@*$'IPS>,Q+0!0,`+72R!!F?Q
M.U<2CQXF42.7V-A&Y]WQH`A-J$+!9(V%XC%[>BP#R_H(,YF]YS!N,!\A`ZD^
M]B529SP+HBR"=C\1B.$;*<'"*V`A%`),H`W;PM$FAT(823%&E%F<!>2.6?\0
M``%H,"ML0"_'5L()$,`G1KBE!CX%@UUFH900D"5B2FB+H="*!B9*S`Q@8P(7
MQ$"9-(Q(,S7Q!T<6:#_=-"D?PJ"29\;B6$9,0`-F50P"9"@1A6@#/AW#'V7$
M:H>,&<,[-6&;H!0#`PRP0A)ALZ-E#,,;$?M#&J_4F35V0HX&=:AF-\M9YMFQ
MLV[$AO;VV+*7":I0&$V/:HE02/*!#WX[XX](S2H9$6QPI?]J&[4D28(N0,`W
M0+!F,;`%!,;@8`<$&`H><+E89PVF*3&(5:R(PC01*+";`U"&\8R`2Q#.M2@-
M.`J!/@`!9UUK-[XI(5-.L@,:-.9PXA+I4+97@@G_4J`&]3U,`?E@*L]4$JY0
MRY^'3'")*4V@!#-X6D/J"EA0OC,/0#'L+'27X,DL11E'2B-)?+(_T0[TLG',
M+&A'3.(2G^FSH,WC]B3*1_"=]CUEFUFATF<S+UC!"XI:)"CH%S0WU%9V``LR
MP#0#BDO@,C(*F$'6/!2IQ,!@`%A8!NX@0*`O:#!6$2YLC([:71L-8;U&ZRYC
MY-JO8JQ&4O!)``L8\#??J#DB/G'!#A@P0S>$:ZP[:,(6VJP!$1`FJS-H0!^*
M-8THR$($8PAP)3!WO#0BB584>%I?3="$!H=R!WW(1:PPV4)0`K.*!G/C'WR2
MI0I]>(XB-K&J5\WJIS24_]4J)JW+K/"Z/Y7/?0<JE*=PK9$<QY8%.Q[IWQ"#
MOZ+T032@0?8!1U)*!=YODP38!`$:P,-M0=FJ`P!T!<20"^/IY'A5B.Z%_,"'
M":3!4X>J&P'^P-U<*B`!!=NT(NYY&`442C%>T&<Q@F($.=,95.%ZIDJ,M)#$
M0/NE*%*`CGY!25<<.M$*``PNG!2O[JBF1,RB(A\(L,/BNC,3_C,&1;I)@Y#L
MVXJ>L%+R/(P<@EXOU:V.N<PWB^+.QIK%I?V<H-!7XT'5;%`X`RE_=@RTOZ$H
MT,K(A9DK(09^"!7-0)A!!AH@-5APO-H*&`"Y:`6!A`]A"R:(@1%6X9.HF&#/
M@/_[\KK;#3AXW\VP+$3S8Q)0@0GD87/P&C4`9P"J`D8[B)FP`-J3/`!-R"2K
M7A`!N2/L"7H="^*`2:XNQKY2OF$.#T$[C,8)<`9G?[S,B#TE>5D`:ML<3!2D
M/DGV3HW9FL_\];`/\>I5??.)EL?6Z,EH1E6[VD.EA];O$SH+@ECTQK2``F-\
MI:XJ@"L&M($FK1$<,-?+BSQT/#$,'%&3$],&L%?AAEV:10;PW0"E<?<#BO$A
MA"P4*SQ,@`40,"(1AF#2/$SKK7OO>RU5<48Q%/PW[S(BOY48!90)*!<%L8)H
M`39QBJ,9/$$NN#,$251`6,`%G;<@#'`+\S8V5E`"&`#_+,M@,*<1"A7S:JPG
M>[,7>RJX@B^7@B56>WPD.6/#+#Z&(O4V*1V%2'X"6R$U',47-S/P`1_`>[F7
M<(&3`$Z`$X,1&IY@?<X&`]DW`16`3XB1@1"2-U\2%`.@&$KF'^<'..HG<'\P
M796``4>Q(F#'!Z#`5C]3!?D'`T00<*!`)$U6((4W=E5@`=D&-28E.SMQ0`H8
M<?G3;0@#$U&&><-631/@*A>8&!6``%N4``/B31"Q;Y1U1<$F@M>@/"`&1S#'
M@J`8BA_C>C0'42O6/12E1$F441;$BO%A2,KR48OT!\,A;(UA.$L$&;JX+7[R
M39%@`F/G!R30<3<U%'M'(-E5_P53\PMD5W9D5P4#4%PP``4,X(5B]F[K18)"
MD2&+$!&)HQEL.(;AQ@!\!X?A$@,JD5PEX!B_41+TP@<3X7&;5!1.`@MO8T02
MUVW2,C5F)`MXL(>$!T1&T(C!50'&1`1?,`!@UR^9<R6*0X(E^$:6A6JD*(H6
M>9'8LXFP9HI[Y#TWI@'V41^1(1GG4S9+I#Y0T#XXQH-#5XOUTQA04#HX4`+D
M5`(V>9,9T!;MH1CD,74-A$D\5(RS0([WDUWDMF/4,$G[PP=5(`+EZ`;O%!K7
MN$L?DA+=H0EVE0<4@AH/V1,Q0([Z%W9O-0()X!A$4'@1X@DF,``"9(<8AC?%
M<H\+J/]I7)ER_X$M[%@&WF<$Q.@&2>%"VV8!T7(J#GE%H261)^B)%8F1C-F8
M=.*")(8R$=4]%/"1-@8H/B89,C8#A=1SOL8SH2!L"K`^,T!Z$>,-9P1R#],`
M(E`"7N`8D5$&EI&'6S`$BI&!34>.2612FQ`&P]%P4L%N3AE8U1AFN=14@?%,
M038<E3-V`),W>`@4I.`S<U:.H5)+H,`',9!MC`$!9U`L.Q$&\-AU`[))RQ!G
M'51$`:8")D`JFO&>Q1(#NC-#7D!Z_<)Q$-`8$$`!@$8!SD(`5?`*YU*8S!$.
MG$B1D.F8"KJ@#&HFIV@++B,H-<%:47<S%K5K,6,>@B!T(K#_.']E=*.9/\F&
M;*0Q&A#4.:`D'^5%%#MTFQ%QC+452?_B`JA@>M/9E%;P*5#9GN?7&V069Z:B
M$L>6-[K%?N.F.-7I&_OE(C)1!MJB9#OP"YM@:#N0;0-2FK@@+66EGA%'>EO0
M!0CQ,#-B-;QQ*#2``,%2!5?7&PQ0`Q4@B9(!.V*%!><2):YF,6GB<M7C#A@Y
M%0W*4.KPIW$D"@/)8G@P:Y&3%`EV*!;Z)U:08+@&?!J@ERW39^R'B(HQ!@V0
M!VP5#9,T#&P)2HA4-UEP?5DG$OXW-T9I!`!C&T#RJ@8(C:V19-6H-,RE2P7#
MCZ7@$S[")48P9T9$0!.@&56`.S1@_X/FJ0FDEFD2$7\H`@&(DQIPE42#`Q<4
M<*U#,`0)D&"1H0$08)^R(Q%8AYLS085>0`,+R8PI5PJO^B)HHJ<GPZ<7Z:>"
M"B?K4*]M1*B=-U'FL:TV8SZ(TG.%\BE0@&.W]R>4*D)PX*&8ZALBP*G8U!)!
M]`?X*:H*`*T6D$`+`F7_P1H$@@.15`6^63'?H`W%R@!(Y@59`X@CE!ANIXRT
MP:M>\JL%%QD9L`-L4ZS;-PAB8`-$`1H$0``6\%2A&G$/&R\).""&LR"[Z&0)
MD`&$P&VQ>G7%I0`96!1F*'_E)09;Z0F)HWJFMB;P.B?OT*=0@:]WF@YH^W+;
MLS(0VJ_E,_]-2T1(&D5(X)-K":L!"\M6L3)XD4$T`)-2H;!2T^)2)1!3"O!E
M0"F-UT9;^1!NBA.D0:I2K_">4=`'+Z48<G54'K0@9#8[6+"K%>>KP*JD,<`V
MF/M_:O8/&$`0K5L0N=-FKS$!4YJTH#(X0X`7;P&26N4$&+!"VG4:?/E)[I03
M$,1FQ":G:G@23.BN;S*V<E*V\WJV:RNO:QL])N%2;KLG-V9!Z/8T&S4V&34H
MM.8%>=NA(UL_/&E;1@.?[SDMQ0(*!+`%,*48\]A@4&AX+S4V<D6/W[>&[_F<
MN14&]8,CBL@W'J2Y@>$3*N4,=4FZ-1LJI^L"9H5(=T$7`-`[>E'_!I)X1##@
M!1FH:4W)&S`P"/XP"?O0`&V@+6.0`+;%;>*2-SI$O.\48<DU$TD$PAB@E1%V
M>H7H)M#[)M)KD?2*MM9[O<^3O2J#BC?F!>:#(H7T-(_!&"H).@@+H7TV9&5%
M4BG"OOWFOL5"9--24\!50$#9&`/@!W:U&E183;?0+Z'@F^#HFY7K`A-``Z_8
M9Y@&&D>&(C\:N0Z,E!`L?QD@=EAP8`2R+"/)1(*T+8:3`*571(PA<45A9H.Q
M!526(K0DF*HS9-?W<=UA+5M``[/*$"+`!R00+0\)OT#<B1XSQ*)8Q/AZQ$A<
M1VJ,`5>C)_R)8^B!6E3\J/2Q'N81,P9B_[Y8W*&.XTB^(6"%-4FNBFE*@P'C
ML;2#(!(M>E.C]E=4AEV4$$FH@#QYP`6Y`6@X,`$,[$&]`0!,P<"Q<"%B\JOG
MQH[A(A-MZ05P`1?DE,\Y"0$9\'RES`)O`!3<1<(2)SM5T"'41B!J)@8`RJHN
M0+6)43=XPPO$A&:3$3M^Z,.]*K:NW#&P'(JR7*^T7,LB@SE7!P`UX#T5A6.V
M9B/`AR`X`]-)<;ZN$KKJFQANL$\#MM,>L@,C@&`I2@048'=.Z&1:!Q2RPI;4
M2GIOB20=(A*Y46U`,`0BZC93R10-V,YXBAPT2\)V-@$D,&?P865-YQ`0$Z:3
M@`"1`IOWM5V27/_"1&/05E(/U,:_(L!OIG)UMZD,+Q$%2Y?0]C$Y3&'0F-C*
M)3W2+!C2@HK8)/W*6+E#*-TR1!`HXD--%F&P?2(Y%G$?$)IXQN,--PT#5E`!
M_U#:IEW:ML(`-&%$FKS`XKI`6)!3,$H>^H0ZP'+;LU(#X24@D;&BZ)G`CJ'.
M\45HTGDP,[L#%?`T7TW&*6*%/<W3Q,`TY+@^7K!M>3#"D]P`_Q$:8\<W!WU>
MGV*'[5D2'#<$;$H):K@9Y')8NW$86^5<(7A`:<DF0>PF'PV*BOVGC-W8'4,A
M+G46*;W"@C`#?3)!1/`!&"$^"<[98G!/=VT;'"<IRM+"0_`%7R#3O0;_DC=(
MVX.]<:;*0$P9;A,6?]3J$:LD/*]4`A1!5#>A7="I5+ZQ*(DCPQ;GO"Q!LXYA
M2&U0"0N!(HMBT-8`*;(+K1`F`A_`&.J,"1("$[*0!S-Q4;+)P^7]-+@I''MS
MT$.!6!:-3OYKIVI2WVURWXE-O4:<W_S=,?ZS`_%G4BQ0`C20!B60*S30!G1>
M`C-IYS;)`',>YS9)`S3``#8Y`+HM"($1(]OG&DT+&:#D!4-0VQ_2"?#H;`IP
M7"%.AEJNX239R^@Q(+YA!<!T0O#R"J)AY+X!`",0PYFXU5%!LX^A(PT@0,T-
MC!N]"CR!@`0@!B4`'Q^0-20@`@L"&$H.OU&P_SGD=BWQ%QD`$#MZG1@T0`GP
M$K\JP6Y&0")P*AFB4GH4Q]&';>:QQ^T+NM]GGC&5LY8-XBP(<.[HCNZ5$*;[
M4`EO@`!B`._QC@#O_@;XQ1"E9P(C0!$*GN`8,3@4$.=IX5?C-@*-@C4-M`GT
M4(8#8#5BX[T$7@8TP`*V4`D[,#6I85T5`0$C\$RF`A/N_"5&\)7A(]AL"3.;
M9#2\T%\HL6/#7@77\A>"H'&XM*$C(!MY$[]C=T;:Q^\:``"6\1V-@F-U$\/0
M7AQ1$.\-</`_GP$C4%C/V]%[ZNVO1_6.">[A3K:S<!1[\1',MWRX\B#_04RY
M,D:Z\A&O1!%;NPR;,/_R`^,(;P\)DG#624>7](,JD=``7=`,/H)&RS`!;^]*
MR;<(=-\4M)@P??/VJ^(S$!GR>&0O!+,JDM`P6[`#0V:5+0\*+S\,<Q\)QCCW
M!0$:*J7YA&HE?Z4JJ[(YBN\?>L-6Y!)=>6,M@!\)&$`\G"#MAATR8KZ"5M^8
M6)_U;0(+WV!]1Z&*)'G\U4PA_R$"AL'(DG$8^+!/0#3L6#`2U%4,6LG3VH\;
M.]`)8[?>RT`EOC#ZV)1I1K+34P)=03'C>Q.`1,%T_2*@O^#X7S+V6JDXF0:"
M=-HV$`D(?GY_A%A8A'Y\?'\$>3N/529YBB8F?7U_6"Z&6%%_ESN$?)65ET;_
M1J,F.R9&+F&O88)553$Q?WQ5JWF3?(:>FH>$PL/$Q<6UQLG*R\."SL_0T=+.
MS-76U]C9R=/<W8/:X.'BX]O>YM#DZ>KK[.U_4:=^)F\U#0PE]VDE)?K[.".9
M/O'!,&"?P8/X1&`04^D1%EAA_D0B4,7/)DX8#1'RY*GBNRA1L*RB%<./D3Z#
M.,$".6N6HF*7_@B26,5(IY"'6C84(V96%%@Y9VJ+XH?`NS`N8DPPX><A4D.R
M6@H5=M.%Q!@M^VAJ6243QHX57V'ITS)3&)!&JF""&`9+2:EN_QA!.]?%1:#L
MD+G;R[>OW[^``PL>3+BPX70AC<C<U7#"TD<[)CR*_Q$*)Y\^D!])7J7*Q*A'
MWP9UE>F5D&).A82!S`02I$9"*/WL,.F"[&69KW'Y07G(UZ'0HM[)-)G:)69(
M-GTANB6\4Z%@IYKYL>4BRB9YLW]&F=TTF,S1G38)?QY].%8_JP]Y*CD<T0[V
MOSSYJ=CZH?,_E'<O:E936'+O[8FCUV$$6G/.@=]<<V"!V2S(X(,0NN.@@0B>
M@TU&&MEUR&F;X*(6>O9]HM5%=I%8'4[5[3;+=#^I5]%%L"7XW"LA"7-)2M:Y
M,%]#6*'4!Q\EC9@C3IDHAE(>?VQ"%BW=52?2;/>]YM6&K!&)VB">>`;268?4
M@MY/?N`!Y4/B]6?()I[PYO_4*Q*%`B!IBNUV'&1O#C)31F@%M-]R?.PP"VB7
MH$0:-<-5.)TM$2:*B*'=-&BAHLI,".FDE)9C#C:,>K,76DO.@I$@LQGS32V8
M=#)?)*$D1PA]-L8F(T;"0(/).Q4%2IIJOUBEVBVH$`+?*9#U85-U,GF&17FS
M#M)+(?])EPA*C_`Q5S"Y#.+*?'Z>2=1\,YTH$VB^A"1;J-/)Q0>WF,B&;1^3
M$'+B;XO\,LRLPG2UVF6SN)KJ=`EF*LB`E1+H[S2.7AJPLYH>K#"EDC(S,,'D
MS'0C>N=&8LEIO[UGIY>+_&MG)N_%4,ESW\JXF[HQ9;1HK;LA4M%,Y2U1WUBQ
M!7C_:U,L<6:O(2>1>XN@,]TVE2?+S8=2+LB()\^YZ,6RHK:S_:D55*J$BE&P
M^+%WX\O.T`+91_)^`\\I1G@LRWP?W8+O,U02.C#`"P_V<#0%)[QPPW'G+?"C
M%,[]##C/<+>;*C%$05E#GNW7!RFGSK:DNFJ9D"5G8BP"U>%R3=>0X_0&]-V?
M@E.C"+TWM7+(*N^U%,./G6.QHQA^IO1M*62!:O2XB<0J2,>'DE)U4^Z!EN0?
M?J;VAPD,H3Z3/)7,(M<AJ8"NRBR>39\OM&+#(TJ<B_ZX"@$FN%3DZ"Y=]@TJ
MBP3Y-J)Z"^;WWYCRK3#>[=<?&/V6OB^CP]%0,EGQ\G!,_V2Z\(T^+84LA]-)
MR"0C+1,XQC$QZ((M##B;RRRN:N_9`4J"]+D_B8QI+VG*N?`3$.L<PH$C65&?
M0H$>ER%O>KU`R0-71P!!]`$K3+IA!`D8FTLP33,"5(3K#@>:IJ@K;#R9@!@<
MTY+(I/`T?7C@GS9#F<A(IHF9^9%<%(,?Q]F0#[MPC`1KA0G(A$\S&DR6(O3B
M+[C9CR_ZFTK?[#8_^;WQCGW!GZCBN+]E0$,S(AC``'`P@"X08'$$(>0`1-`%
MM4P@D$LQ01<4XJ<JC$"0@A1!23`0R$$*<@0QX,,C1W`)23PRD(0$Y>B<\0@'
MBD`$$P`?*2XY`DGX802:I`EF&O\P``PT)!*CC!=^7BD&"XCAE5WXQ"0SV07(
M<%*"JW@D,\\C$Y2(TI.OG,!E8H#+"5A@![BT!9:@MP,1,(`!.,"!"'9`@($(
M<BDOP\(9!+D%$\1`!/_PTPX(4LA9/!*=Z52(&/)0B7]B(#8.Y&4Z,P!+SG1A
M``R`I0,A.H`)5&$"(U#ES3+E1CRR@X]U:U3<].C1DHJ#I,3@8Q\CQ4I)XB`#
MBWPE!C183@BH4P2@-`(!,``!``R`G2.`*3NK,(`ZQ'0$NY%F!LJP2%#N-`,,
M*-LU,W!3A93DCZL0`0#*T`!2/&(``,@`!AR13@)2;P(]90!#+&H"#,!4$2>)
M`0ZX:@'_M_XT*0.`*3)1551?JB*O,>V")8YV.)[BP!X0$,&/_"`"AK:5JF?X
MQ#L,(<HR$$$#7["I(0G0@*WZ<D5Y&(%G[8F##S"`G2;0:AU\28`N0(`(886`
M!@`@`M@Y$`(?&`!*)#F`,FP5`A!@0#-'(8(/$(&KJ35N&410!7QJ\C;IXBC[
M3/K1.(:4&WE#*76W6PWMZLZZ%$+=(^:*`0N8UY@36%P#N/H&V_+AJ0!(K`5$
M8%3.,*`.WN2)($Q@WKP:<D=H'0`E1,!4_FZ.<\Q;8CKQ$<DJB*&W92B!-_>A
MQ%4\&`(#@$!Y)?/8`>2!+#]R*PXPP(`,3(`$?.@"5<OKB,/U_]:O$Z!J?BLA
M,9&U%0(LL$$-@CL)!^(``KP4JQ"=@X7*FK8&-=B,"3I;AAI,3Q(8`(`&MF"!
M"3#`M!9`7@,T4`8,@`^M1&`!'B90`M@V``]C?JT(]CN`#V@`EF+`P$Q7@0<&
M$&$&7AA`G8&@@3?CP9S/%4BA#-51[H8#I/$SV-WL:.A&=Y?1+`7OHSDC2:;R
M!`,-:,!,98.!,L!TD;/I<&\UG5A2]%:1&"!$*_.*`:9)$L.7V4%>=^"(5C)E
M.A7A3%X;0%\1D$(,Z&R`3<DLX276%<-N5>LW]PG3%I<D#VZUZ5A9UUB8SAE\
M+VX(/F':`$#MKA*=AFD)(#""/*RNK?\,L&E7+8<14>(6`FF(:"NCW.3I^0':
MLZ4RF;&L"A%PV<L['8(&Q&R!+20@S&A&JQ5$8`02Q,"R#+!`#>[12S\!6P,4
M2`"0(9!9/V\!`\ED6G0956A')_I]UX78HA5M\I;G3Z1S1'EX=1'E`1@3L25`
M;6=+\$I0RL.N$PBH8RO1VT7VTE>KZ*N')`E3:,VZUAB412O)O%RPGG86P"Y!
M/9B*@V(7T]\1S8"&EVW77=R0$;+VJ6<>@1).OK266<YV0P@R;E\_0AB/Z'0)
M[%&"G^[.`NME@`E(4"J,W/:R9<!P8;=:@RS3H@\8Z#.5Q5!:P5>BN%TVP4XA
MX`4QX\'@,_#_/%KSW/`)0/P-6\B`F_UN92]4H`U>@,`0*D`#(MA\B<1Q&\FG
MZ_*4#\SW=!LII'OO<N\N2M+5V&`B8FQB8V+@I=I,+9"O0-`*VK6N<UVNKL5J
M7A.XAP`O)D!)7CV`LO6AUXPYUWM<MHH&U.'3&:A#+1V8[L;G-<)*1-Y<%\D`
MM:NB['E00_M%8%U5$D!R;U?0:3B`6G+W"&%D4]RQ$:O`4R)@`V_@7P?8832&
M&J)@>AK```^$'TL&``#0`$M419WV`2P09[(U`*2`>;XD2E\0>F*P!:7U!2:8
M9K87!7U26D"&`,*66Y,P`6T0>BPP`S-``5O``$`0<;##.X.V>\0'_SC(]V@L
M=S#&-X4FE84JA0T=$TJW1%6:U@`EL(#$508,(&<@UP=/97.I18*^%G=,I88A
M018FH'0J(F**P`=G\%(*,0(@ESLE05.LYGQ"10"RQGU!%U;Y%U3KI`HO%0/@
MHV(C)F<A1P`$R!29P$UR1E\_A6VKU1"`B&E]IT&98!>[P5-IV`#I%`-&,'[/
MMTZ"P(''XX$V-PFNTU8`\`%0I4ZT%G0?@(8EH`$:IFW_)BVN10004`$E0((#
M4$Q5]EH#4&30E@%<%F]EH`$>YFXST``&9WO`1@2G%3M!,G)2J(4GYS?`AP["
M=X7H:')<B&C7$">)X`</E4Z$U%7@\WSX6/](M_!0784\YC1_)C`"^*A.UD$3
MEW0&UG11BU0VRX=/BI137;0;]Q2'?R51X%11E?!0Z^0GE[0#)P%M_Z!Y]YA.
M`S`"+H"(E^1+IG%/^*A)U$,0@F5/$JE.DF$M2B)*Z,0`[U0QB%1QQ+$1WS$!
M@[1N?Q`+;?52&="4FF0$$S5NUK8YSU=1:U008J=.-8DZ^*22^_5(/V93O;0(
M1CEBQ]1+QZ1.*Q(TWT5HO/>.D29S"C)\DY*%</E&\5B%RT`TP_%>D8$!C@$[
MX_)`$R!!H!(9U+-$?F)15@28$Y"0H,,==E@#8D!.801R$\`>,3(?M9`+J+,9
MLU!%B5`+CE,+N,#_+D_2$@\$F"(YF*O@#$:P`UT`F'EP*N-22;30!0^D"CBS
M&K+A&%N@1"H"*@(D"%PT'OXD0#L`)KE`F)EY*L@S`8"I>2BD&6?`'1?U0!I$
M`&F!%8@H&2`Q'^8%G)&T"*I081@T&<C2,5HD77?)/W9IA>Y8*0CRGO9Y1S.Q
M`^^UAT"3"`303DRC'_RB'^=R'GO83IXC$/3R+(HC&WLH+4RSF8D0H!.J+HH@
M.GLB%T"C1?@QH0_J#!=*#3_RGX3'':M#H8KPGX3"$7TY"HL5&@8X0BG%+?[#
M/@^ZA_0XH;MPH=RQ2C3ZH()"&OPI#..G>0\*&Z.CGR"4H<T0E]Q0<MFE_U)Y
MJ3]1*H_519?%T(7W.2D<T1K#T*4.DZ6%P@Q$\S>0MCSJP)?'=WP08R?`X0PL
MF@Q>JJ9.N@T;X:7$L!I92@W/H*?%$`QT"C9X2I1WF@[F`*7M**5T!)]4FJB-
MV@[U.9=ZN:5X9)=:*B%6>J6+RJ@P5T?=@*@KIZB=RJGJZ*ARJ:F;ZJ2E2JE;
MB*5[.JF&FJGK8*FNFBB'^I;U(ZKS^7*KZJFP.@Z1&G.]RJJ56JL(<ZJH.JRS
M:JQM.:H!<ZLEI:NIRJMS4Z6_>E)3BJS$BI?,RJ;:J@Z7"JG=&H789:K1`*J^
M*JW!)ZS5:J[M*J[=&J[;RJV[2JT/`T>R"J[C&O^?>_.IN-H^ZEJN['JO[DJP
M\%JOK_JH\TJOTVJOO[<7\KJL")NPSDJ?WH"N6!BPTI".RFJQ^1HQV=JQ"VNM
M%:NJ[WJPWQJK$SNC*QLAT.I1&KNQDJJP&?NQP!JR)SNR`+NO-GNSUXJM+=NL
M`INNTH"QSQJS[#BP#QNJ-*NO\=JS.GNT0>NM(@NR/WMH/#NU#/*RQ8JTA**T
M_D*R*>NS4QNQ4<NT0RN?8TNV:PNT#;M'6EL@7(N?7ONU:ENUD"*E$(NS!GNV
M8JMR8)LI^'JU5*BU_'H8<\NP7LNQ.2NUA+N.27NWC>NW-?NV%(NW;MNV6&NX
MXRJW%_NO>E.W=DNJD\O_,%"[N9;+LDU+N8Y;L@X;MIAZNH6;NL>:MJU;M%<E
MLRBKN7\ANBOUNO`3N[0KM*4+MZL+O,$KN;X+N,JKKO>YO(S+O(5!JW&[#%XB
MO2K[N'DDNM&[KKN+O2;;MZ0KOG[$M\OKO<TKK<_KN]V+OM.;M<-K#=>KN\F*
MN8#!OC/KNFQKN^6KO6:+O*/;O^>KOY>KL>O+O?E+P+T+OPJ,#?/KOME[O'*#
MP($;P$X;O^1:O`5,ON%+O^,[P,F;OKIZP'7;OI%K&-2+P<SPP"=\P1+L/A0L
MPA8<P?S;P;!;P89BPB$LP"#LP1^LOO8)O0E<PS#,N=6K#"R\PS1LOPM<PD/L
M_\,N3,3&R[M4J\&J&[\]W,#$&[`DO+A/#,43;,0J;+VY"\%6J[V#Z\4X_+MG
MK,55S,$`7"$Z/,-3G,5*;,,C',3XN\9L?#\,+,7:D,1TG+E4O+U.O,9I[,89
M#,=U;,6U"\B/;,=]O,'.J\<Q_,,M3!@IK,@K7,:9W,:%G,@Q.\>3C+J*_+^-
MS,B4;,:I;,>0*ZI=C+2D7,I^L<F0[,">?,?[R\2U?,D\?,O:8,N.O,5+*\.#
M?,62+$?&K+>6?,C+3,N&C,&'FPR"K,Q1S,O1+,M?_,F@#+YQ'*S/;+ZLO,H]
M_,J*&LNCO,W<[,=BS,ED#,RS#,Z(Z\MX?,RF#,^+7/_,F,PHLQS/]%S/Y]S,
M:OS,6_O'W@P.U0S-_MRYPJO-B+RW[8S-J$S.NDS1`VS.S/R>0LS'!1W1!QW(
MN6S/P3S1[#S0^VS-UPS&WRS.@JO.%8W,R8S1)%U\>TS0GNO1*HW0H`O1#(W"
MQB?'-OV]'TVL\OS+^'S3+\RJ0-VO1RRQ32T81@O02QW._[S2:"R[+3?3Q+S.
M>7O57IW,+WV_TVS47.S2*'T,.VW64WW2YRO36/W&-ZS1;SW6[YO4,*W/;+W1
M3#W&5&W76QW669/2>"W5>MW7H?S6CJ;5<,W5BH+8C@W6@-W+/9W7<VVL46W5
M90O9(OW7L+S0[LQ=BIW/C&UPJU]]V)I]UF'\U(1=V2U[V:T<UY1=U:^=QVI-
MU]'*VGP]SW[-V6L=V\ZLVZJ-V87L73%P!K5PW,B=W,J]W,S=W,[]W-`=W=(]
JW=1=W=9]W=B=W=J]W=S=W=[]W>`=WN(]WN1=WN9]WNB=WNIMW6<0"``[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
